Torsade	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
ventricular	B_Disease	O
tachycardia	I_Disease	O
during	O	O
low	O	O
dose	O	O
intermittent	O	O
dobutamine	B_Chemical	B_Chemical
treatment	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
dilated	B_Disease	B_Disease
cardiomyopathy	I_Disease	I_Disease
and	O	O
congestive	B_Disease	B_Disease
heart	I_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

The	O	O
authors	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
56-year-old	O	O
woman	O	O
with	O	O
chronic	O	O
,	O	O
severe	O	O
heart	B_Disease	B_Disease
failure	I_Disease	I_Disease
secondary	O	O
to	O	O
dilated	B_Disease	B_Disease
cardiomyopathy	I_Disease	I_Disease
and	O	O
absence	O	O
of	O	O
significant	O	O
ventricular	B_Disease	B_Disease
arrhythmias	I_Disease	I_Disease
who	O	O
developed	O	O
QT	B_Disease	O
prolongation	I_Disease	O
and	O	O
torsade	B_Disease	B_Disease
de	I_Disease	I_Disease
pointes	I_Disease	I_Disease
ventricular	B_Disease	I_Disease
tachycardia	I_Disease	I_Disease
during	O	O
one	O	O
cycle	O	O
of	O	O
intermittent	O	O
low	O	O
dose	O	O
(	O	O
2.5	O	O
mcg/kg	O	O
per	O	O
min	O	O
)	O	O
dobutamine	B_Chemical	B_Chemical
.	O	O

This	O	O
report	O	O
of	O	O
torsade	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
ventricular	B_Disease	O
tachycardia	I_Disease	O
during	O	O
intermittent	O	O
dobutamine	B_Chemical	B_Chemical
supports	O	O
the	O	O
hypothesis	O	O
that	O	O
unpredictable	O	O
fatal	O	O
arrhythmias	B_Disease	O
may	O	O
occur	O	O
even	O	O
with	O	O
low	O	O
doses	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
no	O	O
history	O	O
of	O	O
significant	O	O
rhythm	O	B_Disease
disturbances	O	I_Disease
.	O	O

The	O	O
mechanisms	O	O
of	O	O
proarrhythmic	O	O
effects	O	O
of	O	O
Dubutamine	B_Chemical	B_Chemical
are	O	O
discussed	O	O
.	O	O

Positive	O	O
skin	O	O
tests	O	O
in	O	O
late	O	O
reactions	O	O
to	O	O
radiographic	O	O
contrast	O	O
media	O	O
.	O	O

In	O	O
the	O	O
last	O	O
few	O	O
years	O	O
delayed	O	O
reactions	O	O
several	O	O
hours	O	O
after	O	O
the	O	O
injection	O	O
of	O	O
radiographic	O	O
and	O	O
contrast	B_Chemical	O
materials	I_Chemical	O
(	O	O
PRC	B_Chemical	O
)	O	O
have	O	O
been	O	O
described	O	O
with	O	O
increasing	O	O
frequency	O	O
.	O	O

The	O	O
authors	O	O
report	O	O
two	O	O
observations	O	O
on	O	O
patients	O	O
with	O	O
delayed	O	O
reactions	O	O
in	O	O
whom	O	O
intradermoreactions	O	O
(	O	O
IDR	O	O
)	O	O
and	O	O
patch	O	O
tests	O	O
to	O	O
a	O	O
series	O	O
of	O	O
ionic	O	O
and	O	O
non	O	O
ionic	O	O
PRC	B_Chemical	O
were	O	O
studied	O	O
.	O	O

After	O	O
angiography	O	O
by	O	O
the	O	O
venous	O	O
route	O	O
in	O	O
patient	O	O
n	O	O
degree	O	O
1	O	O
a	O	O
biphasic	O	O
reaction	O	O
with	O	O
an	O	O
immediate	O	O
reaction	O	O
(	O	O
dyspnea	B_Disease	O
,	O	O
loss	B_Disease	O
of	I_Disease	O
consciousness	I_Disease	O
)	O	O
and	O	O
delayed	O	O
macro-papular	B_Disease	B_Disease
rash	I_Disease	O
appeared	O	O
,	O	O
whilst	O	O
patient	O	O
n	O	O
degree	O	O
2	O	O
developed	O	O
a	O	O
generalised	O	O
sensation	O	O
of	O	O
heat	O	O
,	O	O
persistent	O	O
pain	B_Disease	O
at	O	O
the	O	O
site	O	O
of	O	O
injection	O	O
immediately	O	O
and	O	O
a	O	O
generalised	O	O
macro-papular	O	O
reaction	O	O
after	O	O
24	O	O
hours	O	O
.	O	O

The	O	O
skin	O	O
tests	O	O
revealed	O	O
positive	O	O
delayed	O	O
reactions	O	O
of	O	O
24	O	O
hours	O	O
and	O	O
48	O	O
hours	O	O
by	O	O
IDR	O	O
and	O	O
patch	O	O
tests	O	O
to	O	O
only	O	O
some	O	O
PRC	B_Chemical	O
with	O	O
common	O	O
chains	O	O
in	O	O
their	O	O
structures	O	O
.	O	O

The	O	O
positive	O	O
skin	O	O
tests	O	O
are	O	O
in	O	O
favour	O	O
of	O	O
immunological	O	O
reactions	O	O
and	O	O
may	O	O
help	O	O
in	O	O
diagnosis	O	O
of	O	O
allergy	B_Disease	O
in	O	O
the	O	O
patients	O	O
.	O	O

Risk	O	O
of	O	O
transient	O	O
hyperammonemic	B_Disease	B_Disease
encephalopathy	B_Disease	I_Disease
in	O	O
cancer	B_Disease	O
patients	O	O
who	O	O
received	O	O
continuous	O	O
infusion	O	O
of	O	O
5-fluorouracil	B_Chemical	B_Chemical
with	O	O
the	O	O
complication	O	O
of	O	O
dehydration	B_Disease	O
and	O	O
infection	B_Disease	O
.	O	O

From	O	O
1986	O	O
to	O	O
1998	O	O
,	O	O
29	O	O
cancer	B_Disease	O
patients	O	O
who	O	O
had	O	O
32	O	O
episodes	O	O
of	O	O
transient	O	O
hyperammonemic	B_Disease	B_Disease
encephalopathy	B_Disease	I_Disease
related	O	O
to	O	O
continuous	O	O
infusion	O	O
of	O	O
5-fluorouracil	B_Chemical	B_Chemical
(	O	O
5-FU	B_Chemical	B_Chemical
)	O	O
were	O	O
identified	O	O
.	O	O

None	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
decompensated	O	O
liver	B_Disease	O
disease	I_Disease	O
.	O	O

Onset	O	O
of	O	O
hyperammonemic	B_Disease	B_Disease
encephalopathy	B_Disease	I_Disease
varied	O	O
from	O	O
0.5	O	O
to	O	O
5	O	O
days	O	O
(	O	O
mean	O	O
:	O	O
2.6	O	O
+	O	O
/-	O	O

1.3	O	O
days	O	O
)	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
chemotherapy	O	O
.	O	O

Plasma	O	O
ammonium	B_Chemical	O
level	O	O
ranged	O	O
from	O	O
248	O	O
to	O	O
2387	O	O
microg%	O	O
(	O	O
mean	O	O
:	O	O
626	O	O
+	O	O
/-	O	O
431	O	O
microg%	O	O
)	O	O
.	O	O

Among	O	O
the	O	O
32	O	O
episodes	O	O
,	O	O
26	O	O
(	O	O
81	O	O
%	O	O
)	O	O
had	O	O
various	O	O
degrees	O	O
of	O	O
azotemia	B_Disease	O
,	O	O
18	O	O
(	O	O
56	O	O
%	O	O
)	O	O
occurred	O	O
during	O	O
bacterial	B_Disease	O
infections	I_Disease	O
and	O	O
14	O	O
(	O	O
44	O	O
%	O	O
)	O	O
without	O	O
infection	B_Disease	O
occurred	O	O
during	O	O
periods	O	O
of	O	O
dehydration	B_Disease	O
.	O	O

Higher	O	O
plasma	O	O
ammonium	B_Chemical	O
levels	O	O
and	O	O
more	O	O
rapid	O	O
onset	O	O
of	O	O
hyperammonemia	B_Disease	B_Disease
were	O	O
seen	O	O
in	O	O
18	O	O
patients	O	O
with	O	O
bacterial	B_Disease	O
infections	I_Disease	O
(	O	O
p=0.003	O	O
and	O	O
0.0006	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
in	O	O
nine	O	O
patients	O	O
receiving	O	O
high	O	O
daily	O	O
doses	O	O
(	O	O
2600	O	O
or	O	O
1800	O	O
mg/m2	O	O
)	O	O
of	O	O
5-FU	B_Chemical	O
(	O	O
p=0.0001	O	O
and	O	O
<	O	O
0.0001	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

In	O	O
25	O	O
out	O	O
of	O	O
32	O	O
episodes	O	O
(	O	O
78	O	O
%	O	O
)	O	O
,	O	O
plasma	O	O
ammonium	B_Chemical	O
levels	O	O
and	O	O
mental	O	O
status	O	O
returned	O	O
to	O	O
normal	O	O
within	O	O
2	O	O
days	O	O
after	O	O
adequate	O	O
management	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
hyperammonemic	B_Disease	B_Disease
encephalopathy	B_Disease	I_Disease
can	O	O
occur	O	O
in	O	O
patients	O	O
receiving	O	O
continuous	O	O
infusion	O	O
of	O	O
5-FU	B_Chemical	O
.	O	O

Azotemia	B_Disease	O
,	O	O
body	O	O
fluid	O	O
insufficiency	O	O
and	O	O
bacterial	B_Disease	O
infections	I_Disease	O
were	O	O
frequently	O	O
found	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

It	O	O
is	O	O
therefore	O	O
important	O	O
to	O	O
recognize	O	O
this	O	O
condition	O	O
in	O	O
patients	O	O
receiving	O	O
continuous	O	O
infusion	O	O
of	O	O
5-FU	B_Chemical	B_Chemical
.	O	O

The	O	O
effects	O	O
of	O	O
quinine	B_Chemical	O
and	O	O
4-aminopyridine	B_Chemical	B_Chemical
on	O	O
conditioned	O	O
place	O	O
preference	O	O
and	O	O
changes	O	O
in	O	O
motor	O	O
activity	O	O
induced	O	O
by	O	O
morphine	B_Chemical	O
in	O	O
rats.1	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
two	O	O
unselective	O	O
potassium	B_Chemical	O
(	O	O
K(+)-	O	O
)	O	O
channel	O	O
blockers	O	O
,	O	O
quinine	B_Chemical	O
(	O	O
12.5	O	O
,	O	O
25	O	O
and	O	O
50	O	O
mg/kg	O	O
)	O	O
and	O	O
4-aminopyridine	B_Chemical	B_Chemical
(	O	O
1	O	O
and	O	O
2	O	O
mg/kg	O	O
)	O	O
,	O	O
on	O	O
conditioned	O	O
place	O	O
preference	O	O
and	O	O
biphasic	O	O
changes	O	O
in	O	O
motor	O	O
activity	O	O
induced	O	O
by	O	O
morphine	B_Chemical	O
(	O	O
10	O	O
mg/kg	O	O
)	O	O
were	O	O
tested	O	O
in	O	O
Wistar	O	O
rats	O	O
.	O	O

Quinine	B_Chemical	O
is	O	O
known	O	O
to	O	O
block	O	O
voltage-	O	O
,	O	O
calcium-	O	O
and	O	O
ATP-sensitive	O	O
K(+)-channels	O	O
while	O	O
4-aminopyridine	B_Chemical	B_Chemical
is	O	O
known	O	O
to	O	O
block	O	O
voltage-sensitive	O	O
K(+)-channels	O	O
.	O	O

2	O	O
.	O	O
In	O	O
the	O	O
counterbalanced	O	O
method	O	O
,	O	O
quinine	B_Chemical	O
attenuated	O	O
morphine-induced	O	O
place	O	O
preference	O	O
,	O	O
whereas	O	O
4-aminopyridine	B_Chemical	B_Chemical
was	O	O
ineffective	O	O
.	O	O

In	O	O
the	O	O
motor	O	O
activity	O	O
test	O	O
measured	O	O
with	O	O
an	O	O
Animex-activity	O	O
meter	O	O
neither	O	O
of	O	O
the	O	O
K(+)-channel	O	O
blockers	O	O
affected	O	O
morphine-induced	O	O
hypoactivity	B_Disease	O
,	O	O
but	O	O
both	O	O
K(+)-channel	O	O
blockers	O	O
prevented	O	O
morphine-induced	O	O
secondary	O	O
hyperactivity	B_Disease	O
.	O	O

3	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
the	O	O
involvement	O	O
of	O	O
quinine-sensitive	O	O
but	O	O
not	O	O
4-aminopyridine-sensitive	O	O
K(+)-channels	O	O
in	O	O
morphine	B_Chemical	O
reward	O	O
.	O	O

It	O	O
is	O	O
also	O	O
suggested	O	O
that	O	O
the	O	O
blockade	O	O
of	O	O
K(+)-channels	O	O
sensitive	O	O
to	O	O
these	O	O
blockers	O	O
is	O	O
not	O	O
sufficient	O	O
to	O	O
prevent	O	O
morphine-induced	O	O
hypoactivity	B_Disease	O
whereas	O	O
morphine-induced	O	O
hyperactivity	B_Disease	O
seems	O	O
to	O	O
be	O	O
connected	O	O
to	O	O
both	O	O
quinine-	O	B_Chemical
and	O	O
4-aminopyridine-sensitive	O	O
K(+)-channels	O	O
.	O	O

Nociceptin/orphanin	O	O
FQ	O	O
and	O	O
nocistatin	B_Chemical	O
on	O	O
learning	B_Disease	O
and	I_Disease	O
memory	B_Disease	B_Disease
impairment	I_Disease	I_Disease
induced	O	O
by	O	O
scopolamine	B_Chemical	O
in	O	O
mice.1	O	O
.	O	O

Nociceptin	B_Chemical	O
,	O	O
also	O	O
known	O	O
as	O	O
orphanin	B_Chemical	O
FQ	I_Chemical	O
,	O	O
is	O	O
an	O	O
endogenous	O	O
ligand	O	O
for	O	O
the	O	O
orphan	O	O
opioid	O	O
receptor-like	O	O
receptor	O	O
1	O	O
(	O	O
ORL1	O	O
)	O	O
and	O	O
involves	O	O
in	O	O
various	O	O
functions	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
nocistatin	B_Chemical	O
is	O	O
recently	O	O
isolated	O	O
from	O	O
the	O	O
same	O	O
precursor	O	O
as	O	O
nociceptin	B_Chemical	O
and	O	O
blocks	O	O
nociceptin-induced	O	O
allodynia	B_Disease	O
and	O	O
hyperalgesia	B_Disease	B_Disease
.	O	O

2	O	O
.	O	O
Although	O	O
ORL1	O	O
receptors	O	O
which	O	O
display	O	O
a	O	O
high	O	O
degree	O	O
of	O	O
sequence	O	O
homology	O	O
with	O	O
classical	O	O
opioid	O	O
receptors	O	O
are	O	O
abundant	O	O
in	O	O
the	O	O
hippocampus	O	O
,	O	O
little	O	O
is	O	O
known	O	O
regarding	O	O
their	O	O
role	O	O
in	O	O
learning	O	O
and	O	O
memory	O	O
.	O	O

3	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
investigate	O	O
whether	O	O
nociceptin/orphanin	O	O
FQ	O	O
and	O	O
nocistatin	B_Chemical	O
could	O	O
modulate	O	O
impairment	B_Disease	O
of	I_Disease	O
learning	I_Disease	O
and	I_Disease	O
memory	I_Disease	O
induced	O	O
by	O	O
scopolamine	B_Chemical	O
,	O	O
a	O	O
muscarinic	O	O
cholinergic	O	O
receptor	O	O
antagonist	O	O
,	O	O
using	O	O
spontaneous	O	O
alternation	O	O
of	O	O
Y-maze	O	O
and	O	O
step-down	O	O
type	O	O
passive	O	O
avoidance	O	O
tasks	O	O
in	O	O
mice	O	O
.	O	O

4	O	O
.	O	O
While	O	O
nocistatin	B_Chemical	O
(	O	O
0.5	O	O
-	O	O
5.0	O	O
nmol	O	O
mouse-1	O	O
,	O	O
i.c.v	O	O
.	O	O
)	O	O
administered	O	O
30	O	O
min	O	O
before	O	O
spontaneous	O	O
alternation	O	O
performance	O	O
or	O	O
the	O	O
training	O	O
session	O	O
of	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
,	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
spontaneous	O	O
alternation	O	O
or	O	O
passive	O	O
avoidance	O	O
behaviours	O	O
,	O	O
a	O	O
lower	O	O
per	O	O
cent	O	O
alternation	O	O
and	O	O
shorter	O	O
median	O	O
step-down	O	O
latency	O	O
in	O	O
the	O	O
retention	O	O
test	O	O
were	O	O
obtained	O	O
in	O	O
nociceptin	B_Chemical	O
(	O	O
1.5	O	O
and/or	O	O
5.0	O	O
nmol	O	O
mouse-1	O	O
,	O	O
i.c.v.)-treated	O	O
normal	O	O
mice	O	O
.	O	O

5	O	O
.	O	O

Administration	O	O
of	O	O
nocistatin	B_Chemical	O
(	O	O
1.5	O	O
and/or	O	O
5.0	O	O
nmol	O	O
mouse-1	O	O
,	O	O
i.c.v	O	O
.	O	O
)	O	O
30	O	O
min	O	O
before	O	O
spontaneous	O	O
alternation	O	O
performance	O	O
or	O	O
the	O	O
training	O	O
session	O	O
of	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
,	O	O
attenuated	O	O
the	O	O
scopolamine-induced	O	O
impairment	O	O
of	O	O
spontaneous	O	O
alternation	O	O
and	O	O
passive	O	O
avoidance	O	O
behaviours	O	O
.	O	O

6	O	O
.	O	O

These	O	O
results	O	O
indicated	O	O
that	O	O
nocistatin	B_Chemical	O
,	O	O
a	O	O
new	O	O
biologically	O	O
active	O	O
peptide	O	O
,	O	O
ameliorates	O	O
impairments	O	O
of	O	O
spontaneous	O	O
alternation	O	O
and	O	O
passive	O	O
avoidance	O	O
induced	O	O
by	O	O
scopolamine	B_Chemical	O
,	O	O
and	O	O
suggested	O	O
that	O	O
these	O	O
peptides	O	O
play	O	O
opposite	O	O
roles	O	O
in	O	O
learning	O	O
and	O	O
memory	O	O
.	O	O

Meloxicam-induced	O	O
liver	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
rheumatoid	B_Disease	B_Disease
arthritis	I_Disease	I_Disease
who	O	O
developed	O	O
acute	O	O
cytolytic	O	O
hepatitis	B_Disease	O
due	O	O
to	O	O
meloxicam	B_Chemical	B_Chemical
.	O	O

Recently	O	O
introduced	O	O
in	O	O
Belgium	O	O
,	O	O
meloxicam	B_Chemical	B_Chemical
is	O	O
the	O	O
first	O	O
nonsteroidal	O	O
antiinflammatory	O	O
drug	O	O
with	O	O
selective	O	O
action	O	O
on	O	O
the	O	O
inducible	O	O
form	O	O
of	O	O
cyclooxygenase	O	O
2	O	O
.	O	O

The	O	O
acute	O	O
cytolytic	O	O
hepatitis	B_Disease	O
occurred	O	O
rapidly	O	O
after	O	O
meloxicam	B_Chemical	B_Chemical
administration	O	O
and	O	O
was	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
antinuclear	O	O
antibodies	O	O
suggesting	O	O
a	O	O
hypersensitivity	B_Disease	O
mechanism	O	O
.	O	O

This	O	O
first	O	O
case	O	O
of	O	O
meloxicam	B_Chemical	B_Chemical
related	O	O
liver	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
demonstrates	O	O
the	O	O
potential	O	O
of	O	O
this	O	O
drug	O	O
to	O	O
induce	O	O
hepatic	B_Disease	B_Disease
damage	I_Disease	I_Disease
.	O	O

Induction	O	O
of	O	O
apoptosis	O	O
by	O	O
remoxipride	B_Chemical	B_Chemical
metabolites	O	O
in	O	O
HL60	O	O
and	O	O
CD34+/CD19-	O	O
human	O	O
bone	O	O
marrow	O	O
progenitor	O	O
cells	O	O
:	O	O
potential	O	O
relevance	O	O
to	O	O
remoxipride-induced	O	O
aplastic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
.	O	O

The	O	O
antipsychotic	O	O
agent	O	O
,	O	O
remoxipride	B_Chemical	B_Chemical
[	O	O
(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz	B_Chemical	B_Chemical
amide	I_Chemical	I_Chemical
]	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
acquired	O	O
aplastic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
.	O	O

We	O	O
have	O	O
examined	O	O
the	O	O
ability	O	O
of	O	O
remoxipride	B_Chemical	B_Chemical
,	O	O
three	O	O
pyrrolidine	B_Chemical	B_Chemical
ring	O	O
metabolites	O	O
and	O	O
five	O	O
aromatic	O	O
ring	O	O
metabolites	O	O
of	O	O
the	O	O
parent	O	O
compound	O	O
to	O	O
induce	O	O
apoptosis	O	O
in	O	O
HL60	O	O
cells	O	O
and	O	O
human	O	O
bone	O	O
marrow	O	O
progenitor	O	O
(	O	O
HBMP	O	O
)	O	O
cells	O	O
.	O	O

Cells	O	O
were	O	O
treated	O	O
for	O	O
0	O	O
-	O	O
24	O	O
h	O	O
with	O	O
each	O	O
compound	O	O
(	O	O
0	O	O
-	O	O
200	O	O
microM	O	O
)	O	O
.	O	O

Apoptosis	O	O
was	O	O
assessed	O	O
by	O	O
fluorescence	O	O
microscopy	O	O
in	O	O
Hoechst	O	O
33342-	O	O
and	O	O
propidium	B_Chemical	O
iodide	I_Chemical	O
stained	O	O
cell	O	O
samples	O	O
.	O	O

Results	O	O
were	O	O
confirmed	O	O
by	O	O
determination	O	O
of	O	O
internucleosomal	O	O
DNA	O	O
fragmentation	O	O
using	O	O
gel	O	O
electrophoresis	O	O
for	O	O
HL60	O	O
cell	O	O
samples	O	O
and	O	O
terminal	O	O
deoxynucleotidyl	O	O
transferase	O	O
assay	O	O
in	O	O
HBMP	O	O
cells	O	O
.	O	O

The	O	O
catechol	B_Chemical	O
and	O	O
hydroquinone	B_Chemical	B_Chemical
metabolites	O	O
,	O	O
NCQ436	B_Chemical	O
and	O	O
NCQ344	B_Chemical	O
,	O	O
induced	O	O
apoptosis	O	O
in	O	O
HL60	O	O
and	O	O
HBMP	O	O
cells	O	O
in	O	O
a	O	O
time-	O	O
and	O	O
concentration	O	O
dependent	O	O
manner	O	O
,	O	O
while	O	O
the	O	O
phenols	B_Chemical	O
,	O	O
NCR181	O	O
,	O	O
FLA873	O	O
,	O	O
and	O	O
FLA797	B_Chemical	O
,	O	O
and	O	O
the	O	O
derivatives	O	O
formed	O	O
by	O	O
oxidation	O	O
of	O	O
the	O	O
pyrrolidine	B_Chemical	B_Chemical
ring	O	O
,	O	O
FLA838	O	O
,	O	O
NCM001	O	O
,	O	O
and	O	O
NCL118	O	O
,	O	O
had	O	O
no	O	O
effect	O	O
.	O	O

No	O	O
necrosis	B_Disease	O
was	O	O
observed	O	O
in	O	O
cells	O	O
treated	O	O
with	O	O
NCQ436	B_Chemical	O
but	O	O
NCQ344	B_Chemical	O
had	O	O
a	O	O
biphasic	O	O
effect	O	O
in	O	O
both	O	O
cell	O	O
types	O	O
,	O	O
inducing	O	O
apoptosis	O	O
at	O	O
lower	O	O
concentrations	O	O
and	O	O
necrosis	B_Disease	O
at	O	O
higher	O	O
concentrations	O	O
.	O	O

These	O	O
data	O	O
show	O	O
that	O	O
the	O	O
catechol	B_Chemical	B_Chemical
and	O	O
hydroquinone	B_Chemical	O
metabolites	O	O
of	O	O
remoxipride	B_Chemical	B_Chemical
have	O	O
direct	O	O
toxic	O	O
effects	O	O
in	O	O
HL60	O	O
and	O	O
HBMP	O	O
cells	O	O
,	O	O
leading	O	O
to	O	O
apoptosis	O	O
,	O	O
while	O	O
the	O	O
phenol	B_Chemical	O
metabolites	O	O
were	O	O
inactive	O	O
.	O	O

Similarly	O	O
,	O	O
benzene-derived	O	O
catechol	B_Chemical	B_Chemical
and	O	O
hydroquinone	B_Chemical	O
,	O	O
but	O	O
not	O	O
phenol	B_Chemical	O
,	O	O
induce	O	O
apoptosis	O	O
in	O	O
HBMP	O	O
cells	O	O
[	O	O
Moran	O	O
et	O	O
al.	O	O
,	O	O
Mol	O	O
.	O	O

Pharmacol	O	O
.	O	O
,	O	O
50	O	O
(	O	O
1996	O	O
)	O	O
610	O	O
-	O	O
615	O	O
]	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
remoxipride	B_Chemical	B_Chemical
and	O	O
benzene	B_Chemical	O
may	O	O
induce	O	O
aplastic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
via	O	O
production	O	O
of	O	O
similar	O	O
reactive	O	O
metabolites	O	O
and	O	O
that	O	O
the	O	O
ability	O	O
of	O	O
NCQ436	B_Chemical	O
and	O	O
NCQ344	B_Chemical	O
to	O	O
induce	O	O
apoptosis	O	O
in	O	O
HBMP	O	O
cells	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
mechanism	O	O
underlying	O	O
acquired	O	B_Disease
aplastic	B_Disease	I_Disease
anemia	I_Disease	I_Disease
that	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
remoxipride	B_Chemical	B_Chemical
.	O	O

Synthesis	O	O
and	O	O
preliminary	O	O
pharmacological	O	O
investigations	O	O
of	O	O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	O	B_Chemical
derivatives	O	O
as	O	O
potential	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
in	O	O
mice	O	O
.	O	O

In	O	O
research	O	O
towards	O	O
the	O	O
development	O	O
of	O	O
new	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
,	O	O
one	O	O
strategy	O	O
is	O	O
that	O	O
the	O	O
dopaminergic	O	O
system	O	O
can	O	O
be	O	O
modulated	O	O
through	O	O
manipulation	O	O
of	O	O
the	O	O
serotonergic	O	O
system	O	O
.	O	O

The	O	O
synthesis	O	O
and	O	O
preliminary	O	O
pharmacological	O	O
evaluation	O	O
of	O	O
a	O	O
series	O	O
of	O	O
potential	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
based	O	O
on	O	O
the	O	O
structure	O	O
of	O	O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	B_Chemical	B_Chemical
(	O	O
7	O	O
)	O	O
is	O	O
described	O	O
.	O	O

Compound	O	O
7e	O	B_Chemical
,	O	I_Chemical
5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy	B_Chemical	I_Chemical
dro-1H-	I_Chemical	I_Chemical
indol-2-one	I_Chemical	I_Chemical
,	O	O
from	O	O
this	O	O
series	O	O
showed	O	O
significant	O	O
affinities	O	O
at	O	O
the	O	O
5-HT1A	O	O
and	O	O
5-HT2A	O	O
receptors	O	O
and	O	O
moderate	O	O
affinity	O	O
at	O	O
the	O	O
D2	O	O
receptor	O	O
.	O	O

7e	O	B_Chemical
exhibits	O	O
a	O	O
high	O	O
reversal	O	O
of	O	O
catalepsy	B_Disease	O
induced	O	O
by	O	O
haloperidol	B_Chemical	O
indicating	O	O
its	O	O
atypical	O	O
antipsychotic	O	O
nature	O	O
.	O	O

Sub-chronic	O	O
inhibition	O	O
of	O	O
nitric-oxide	B_Chemical	O
synthesis	O	O
modifies	O	O
haloperidol-induced	O	O
catalepsy	B_Disease	O
and	O	O
the	O	O
number	O	O
of	O	O
NADPH-diaphorase	O	O
neurons	O	O
in	O	O
mice	O	O
.	O	O

RATIONALE	O	O
:	O	O
NG-nitro-L-arginine	B_Chemical	O
(	O	O
L-NOARG	B_Chemical	O
)	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
nitric-oxide	B_Chemical	O
synthase	O	O
(	O	O
NOS	O	O
)	O	O
,	O	O
induces	O	O
catalepsy	B_Disease	O
in	O	O
mice	O	O
.	O	O

This	O	O
effect	O	O
undergoes	O	O
rapid	O	O
tolerance	O	O
,	O	O
showing	O	O
a	O	O
significant	O	O
decrease	O	O
after	O	O
2	O	O
days	O	O
of	O	O
sub-chronic	O	O
L-NOARG	B_Chemical	O
treatment	O	O
.	O	O

Nitric	B_Chemical	O
oxide	I_Chemical	O
(	O	O
NO	B_Chemical	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
influence	O	O
dopaminergic	O	O
neurotransmission	O	O
in	O	O
the	O	O
striatum	O	O
.	O	O

Neuroleptic	O	O
drugs	O	O
such	O	O
as	O	O
haloperidol	B_Chemical	O
,	O	O
which	O	O
block	O	O
dopamine	B_Chemical	O
receptors	O	O
,	O	O
also	O	O
cause	O	O
catalepsy	B_Disease	O
in	O	O
rodents	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
subchronic	O	O
L-NOARG	B_Chemical	O
treatment	O	O
in	O	O
haloperidol-induced	O	O
catalepsy	B_Disease	O
and	O	O
the	O	O
number	O	O
of	O	O
NOS	O	O
neurons	O	O
in	O	O
areas	O	O
related	O	O
to	O	O
motor	O	O
control	O	O
.	O	O

METHODS	O	O
:	O	O
Male	O	O
albino	O	O
Swiss	O	O
mice	O	O
were	O	O
treated	O	O
sub-chronically	O	O
(	O	O
twice	O	O
a	O	O
day	O	O
for	O	O
4	O	O
days	O	O
)	O	O
with	O	O
L-NOARG	B_Chemical	O
(	O	O
40	O	O
mg/kg	O	O
i.p	O	O
.	O	O
)	O	O
or	O	O
haloperidol	B_Chemical	O
(	O	O
1	O	O
mg/kg	O	O
i.p	O	O
.	O	O
)	O	O
.	O	O

Catalepsy	B_Disease	O
was	O	O
evaluated	O	O
at	O	O
the	O	O
beginning	O	O
and	O	O
the	O	O
end	O	O
of	O	O
the	O	O
treatments	O	O
.	O	O

Reduced	O	O
nicotinamide	O	O
adenine	O	O
dinucleotide	O	O
phosphate-diaphorase	O	O
(	O	O
NADPH-d	O	O
)	O	O
histochemistry	O	O
was	O	O
also	O	O
employed	O	O
to	O	O
visualize	O	O
NOS	O	O
as	O	O
an	O	O
index	O	O
of	O	O
enzyme	O	O
expression	O	O
in	O	O
mice	O	O
brain	O	O
regions	O	O
related	O	O
to	O	O
motor	O	O
control	O	O
.	O	O

RESULTS	O	O
:	O	O
L-NOARG	B_Chemical	O
sub-chronic	O	O
administration	O	O
produced	O	O
tolerance	O	O
of	O	O
L-NOARG	B_Chemical	O
and	O	O
of	O	O
haloperidol-induced	O	O
catalepsy	B_Disease	O
.	O	O

It	O	O
also	O	O
induced	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
NADPH-d-positive	O	O
cells	O	O
in	O	O
the	O	O
dorsal	O	O
part	O	O
of	O	O
the	O	O
caudate	O	O
and	O	O
accumbens	O	O
nuclei	O	O
compared	O	O
with	O	O
haloperidol	B_Chemical	O
and	O	O
in	O	O
the	O	O
pedunculopontine	O	O
tegmental	O	O
nucleus	O	O
compared	O	O
with	O	O
saline	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
there	O	O
was	O	O
a	O	O
decrease	O	O
in	O	O
NADPH-d	O	O
neuron	O	O
number	O	O
in	O	O
the	O	O
substantia	O	O
nigra	O	O
,	O	O
pars	O	O
compacta	O	O
in	O	O
both	O	O
haloperidol-treated	O	O
and	O	O
L-NOARG-treated	O	O
animals	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
results	O	O
give	O	O
further	O	O
support	O	O
to	O	O
the	O	O
hypothesis	O	O
that	O	O
NO	B_Chemical	O
plays	O	O
a	O	O
role	O	O
in	O	O
motor	O	O
behavior	O	O
control	O	O
and	O	O
suggest	O	O
that	O	O
it	O	O
may	O	O
take	O	O
part	O	O
in	O	O
the	O	O
synaptic	O	O
changes	O	O
produced	O	O
by	O	O
antipsychotic	O	O
treatment	O	O
.	O	O

Prolonged	O	O
left	B_Disease	B_Disease
ventricular	I_Disease	I_Disease
dysfunction	I_Disease	I_Disease
occurs	O	O
in	O	O
patients	O	O
with	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
after	O	O
both	O	O
dobutamine	B_Chemical	B_Chemical
and	O	O
exercise	O	O
induced	O	O
myocardial	B_Disease	B_Disease
ischaemia	I_Disease	I_Disease
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
determine	O	O
whether	O	O
pharmacological	O	O
stress	O	O
leads	O	O
to	O	O
prolonged	O	O
but	O	O
reversible	O	O
left	B_Disease	B_Disease
ventricular	I_Disease	I_Disease
dysfunction	I_Disease	I_Disease
in	O	O
patients	O	O
with	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
,	O	O
similar	O	O
to	O	O
that	O	O
seen	O	O
after	O	O
exercise	O	O
.	O	O

DESIGN	O	O
:	O	O
A	O	O
randomised	O	O
crossover	O	O
study	O	O
of	O	O
recovery	O	O
time	O	O
of	O	O
systolic	O	O
and	O	O
diastolic	O	O
left	O	O
ventricular	O	O
function	O	O
after	O	O
exercise	O	O
and	O	O
dobutamine	B_Chemical	B_Chemical
induced	O	O
ischaemia	B_Disease	O
.	O	O

SUBJECTS	O	O
:	O	O
10	O	O
patients	O	O
with	O	O
stable	B_Disease	O
angina	I_Disease	O
,	O	O
angiographically	O	O
proven	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
,	O	O
and	O	O
normal	O	O
left	O	O
ventricular	O	O
function	O	O
.	O	O

INTERVENTIONS	O	O
:	O	O
Treadmill	O	O
exercise	O	O
and	O	O
dobutamine	B_Chemical	B_Chemical
stress	O	O
were	O	O
performed	O	O
on	O	O
different	O	O
days	O	O
.	O	O

Quantitative	O	O
assessment	O	O
of	O	O
systolic	O	O
and	O	O
diastolic	O	O
left	O	O
ventricular	O	O
function	O	O
was	O	O
performed	O	O
using	O	O
transthoracic	O	O
echocardiography	O	O
at	O	O
baseline	O	O
and	O	O
at	O	O
regular	O	O
intervals	O	O
after	O	O
each	O	O
test	O	O
.	O	O

RESULTS	O	O
:	O	O
Both	O	O
forms	O	O
of	O	O
stress	O	O
led	O	O
to	O	O
prolonged	O	O
but	O	O
reversible	O	O
systolic	O	O
and	O	O
diastolic	O	B_Disease
dysfunction	O	I_Disease
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
maximum	O	O
double	O	O
product	O	O
(	O	O
p	O	O
=	O	O
0.53	O	O
)	O	O
or	O	O
ST	O	O
depression	B_Disease	O
(	O	O
p	O	O
=	O	O
0.63	O	O
)	O	O
with	O	O
either	O	O
form	O	O
of	O	O
stress	O	O
.	O	O

After	O	O
exercise	O	O
,	O	O
ejection	O	O
fraction	O	O
was	O	O
reduced	O	O
at	O	O
15	O	O
and	O	O
30	O	O
minutes	O	O
compared	O	O
with	O	O
baseline	O	O
(	O	O
mean	O	O
(	O	O
SEM	O	O
)	O	O
,	O	O
-5.6	O	O
(1.5)%	O	O
,	O	O
p	O	O
<	O	O
0.05	O	O
;	O	O
and	O	O
-6.1	O	O
(2.2)%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
and	O	O
at	O	O
30	O	O
and	O	O
45	O	O
minutes	O	O
after	O	O
dobutamine	B_Chemical	B_Chemical
(	O	O
-10.8	O	O
(1.8)%	O	O
and	O	O
-5	O	O
.	O	O
5	O	O
(1.8)%	O	O
,	O	O
both	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Regional	O	O
analysis	O	O
showed	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
worst	O	O
affected	O	O
segment	O	O
15	O	O
and	O	O
30	O	O
minutes	O	O
after	O	O
exercise	O	O
(	O	O
-27.9	O	O
(7.2)%	O	O
and	O	O
-28.6	O	O
(5.7)%	O	O
,	O	O
both	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
,	O	O
and	O	O
at	O	O
30	O	O
minutes	O	O
after	O	O
dobutamine	B_Chemical	B_Chemical
(	O	O
-32	O	O
(5.3)%	O	O
,	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

The	O	O
isovolumic	O	O
relaxation	O	O
period	O	O
was	O	O
prolonged	O	O
45	O	O
minutes	O	O
after	O	O
each	O	O
form	O	O
of	O	O
stress	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
patients	O	O
with	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
,	O	O
dobutamine	B_Chemical	B_Chemical
induced	O	O
ischaemia	B_Disease	O
results	O	O
in	O	O
prolonged	O	O
reversible	O	O
left	B_Disease	B_Disease
ventricular	I_Disease	I_Disease
dysfunction	I_Disease	I_Disease
,	O	O
presumed	O	O
to	O	O
be	O	O
myocardial	B_Disease	O
stunning	I_Disease	O
,	O	O
similar	O	O
to	O	O
that	O	O
seen	O	O
after	O	O
exercise	O	O
.	O	O

Dobutamine	B_Chemical	B_Chemical
induced	O	O
ischaemia	B_Disease	O
could	O	O
therefore	O	O
be	O	O
used	O	O
to	O	O
study	O	O
the	O	O
pathophysiology	O	O
of	O	O
this	O	O
phenomenon	O	O
further	O	O
in	O	O
patients	O	O
with	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
.	O	O

Anorexigens	O	O
and	O	O
pulmonary	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
in	O	O
the	O	O
United	O	O
States	O	O
:	O	O
results	O	O
from	O	O
the	O	O
surveillance	O	O
of	O	O
North	O	O
American	O	O
pulmonary	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
use	O	O
of	O	O
appetite	O	B_Chemical
suppressants	O	I_Chemical
in	O	O
Europe	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
primary	B_Disease	B_Disease
pulmonary	I_Disease	I_Disease
hypertension	I_Disease	I_Disease
(	O	O
PPH	B_Disease	O
)	O	O
.	O	O

Recently	O	O
,	O	O
fenfluramine	B_Chemical	B_Chemical
appetite	O	I_Chemical
suppressants	O	I_Chemical
became	O	O
widely	O	O
used	O	O
in	O	O
the	O	O
United	O	O
States	O	O
but	O	O
were	O	O
withdrawn	O	O
in	O	O
September	O	O
1997	O	O
because	O	O
of	O	O
concerns	O	O
over	O	O
adverse	O	O
effects	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
We	O	O
conducted	O	O
a	O	O
prospective	O	O
surveillance	O	O
study	O	O
on	O	O
patients	O	O
diagnosed	O	O
with	O	O
pulmonary	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
at	O	O
12	O	O
large	O	O
referral	O	O
centers	O	O
in	O	O
North	O	O
America	O	O
.	O	O

Data	O	O
collected	O	O
on	O	O
patients	O	O
seen	O	O
from	O	O
September	O	O
1	O	O
,	O	O
1996	O	O
,	O	O
to	O	O
December	O	O
31	O	O
,	O	O
1997	O	O
,	O	O
included	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
pulmonary	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
and	O	O
its	O	O
severity	O	O
.	O	O

Patients	O	O
with	O	O
no	O	O
identifiable	O	O
cause	O	O
of	O	O
pulmonary	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
were	O	O
classed	O	O
as	O	O
PPH	B_Disease	O
.	O	O

A	O	O
history	O	O
of	O	O
drug	O	O
exposure	O	O
also	O	O
was	O	O
taken	O	O
with	O	O
special	O	O
attention	O	O
on	O	O
the	O	O
use	O	O
of	O	O
antidepressants	O	O
,	O	O
anorexigens	O	O
,	O	O
and	O	O
amphetamines	B_Chemical	O
.	O	O

RESULTS	O	O
:	O	O
Five	O	O
hundred	O	O
seventy-nine	O	O
patients	O	O
were	O	O
studied	O	O
,	O	O
205	O	O
with	O	O
PPH	B_Disease	O
and	O	O
374	O	O
with	O	O
pulmonary	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
from	O	O
other	O	O
causes	O	O
(	O	O
secondary	O	B_Disease
pulmonary	B_Disease	I_Disease
hypertension	I_Disease	I_Disease
[	O	O
SPH	O	O
]	O	O
)	O	O
.	O	O

The	O	O
use	O	O
of	O	O
anorexigens	O	O
was	O	O
common	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

However	O	O
,	O	O
of	O	O
the	O	O
medications	O	O
surveyed	O	O
,	O	O
only	O	O
the	O	O
fenfluramines	B_Chemical	O
had	O	O
a	O	O
significant	O	O
preferential	O	O
association	O	O
with	O	O
PPH	B_Disease	O
as	O	O
compared	O	O
with	O	O
SPH	O	O
(	O	O
adjusted	O	O
odds	O	O
ratio	O	O
for	O	O
use	O	O
>	O	O
6	O	O
months	O	O
,	O	O
7.5	O	O
;	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
1.7	O	O
to	O	O
32.4	O	O
)	O	O
.	O	O

The	O	O
association	O	O
was	O	O
stronger	O	O
with	O	O
longer	O	O
duration	O	O
of	O	O
use	O	O
when	O	O
compared	O	O
to	O	O
shorter	O	O
duration	O	O
of	O	O
use	O	O
and	O	O
was	O	O
more	O	O
pronounced	O	O
in	O	O
recent	O	O
users	O	O
than	O	O
in	O	O
remote	O	O
users	O	O
.	O	O

An	O	O
unexpectedly	O	O
high	O	O
(	O	O
11.4	O	O
%	O	O
)	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
SPH	O	O
had	O	O
used	O	O
anorexigens	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
magnitude	O	O
of	O	O
the	O	O
association	O	O
with	O	O
PPH	B_Disease	O
,	O	O
the	O	O
increase	O	O
of	O	O
association	O	O
with	O	O
increasing	O	O
duration	O	O
of	O	O
use	O	O
,	O	O
and	O	O
the	O	O
specificity	O	O
for	O	O
fenfluramines	B_Chemical	O
are	O	O
consistent	O	O
with	O	O
previous	O	O
studies	O	O
indicating	O	O
that	O	O
fenfluramines	B_Chemical	O
are	O	O
causally	O	O
related	O	O
to	O	O
PPH	B_Disease	O
.	O	O

The	O	O
high	O	O
prevalence	O	O
of	O	O
anorexigen	O	O
use	O	O
in	O	O
patients	O	O
with	O	O
SPH	O	O
also	O	O
raises	O	O
the	O	O
possibility	O	O
that	O	O
these	O	O
drugs	O	O
precipitate	O	O
pulmonary	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
in	O	O
patients	O	O
with	O	O
underlying	O	O
conditions	O	O
associated	O	O
with	O	O
SPH	O	O
.	O	O

Clinical	O	O
aspects	O	O
of	O	O
heparin-induced	O	O
thrombocytopenia	B_Disease	O
and	O	O
thrombosis	B_Disease	O
and	O	O
other	O	O
side	O	O
effects	O	O
of	O	O
heparin	B_Chemical	O
therapy	O	O
.	O	O

Heparin	B_Chemical	O
,	O	O
first	O	O
used	O	O
to	O	O
prevent	O	O
the	O	O
clotting	O	O
of	O	O
blood	O	O
in	O	O
vitro	O	O
,	O	O
has	O	O
been	O	O
clinically	O	O
used	O	O
to	O	O
treat	O	O
thrombosis	B_Disease	O
for	O	O
more	O	O
than	O	O
50	O	O
years	O	O
.	O	O

Although	O	O
several	O	O
new	O	O
anticoagulant	O	O
drugs	O	O
are	O	O
in	O	O
development	O	O
,	O	O
heparin	B_Chemical	O
remains	O	O
the	O	O
anticoagulant	O	O
of	O	O
choice	O	O
to	O	O
treat	O	O
acute	O	B_Disease
thrombotic	B_Disease	I_Disease
episodes	O	O
.	O	O

The	O	O
clinical	O	O
effects	O	O
of	O	O
heparin	B_Chemical	O
are	O	O
meritorious	O	O
,	O	O
but	O	O
side	O	O
effects	O	O
do	O	O
exist	O	O
.	O	O

Bleeding	B_Disease	O
is	O	O
the	O	O
primary	O	O
untoward	O	O
effect	O	O
of	O	O
heparin	B_Chemical	O
.	O	O

Major	O	O
bleeding	B_Disease	O
is	O	O
of	O	O
primary	O	O
concern	O	O
in	O	O
patients	O	O
receiving	O	O
heparin	B_Chemical	O
therapy	O	O
.	O	O

However	O	O
,	O	O
additional	O	O
important	O	O
untoward	O	O
effects	O	O
of	O	O
heparin	B_Chemical	O
therapy	O	O
include	O	O
heparin-induced	O	O
thrombocytopenia	B_Disease	O
,	O	O
heparin-associated	O	O
osteoporosis	B_Disease	O
,	O	O
eosinophilia	B_Disease	O
,	O	O
skin	B_Disease	B_Disease
reactions	I_Disease	I_Disease
,	O	O
allergic	B_Disease	B_Disease
reactions	I_Disease	I_Disease
other	O	O
than	O	O
thrombocytopenia	B_Disease	O
,	O	O
alopecia	B_Disease	O
,	O	O
transaminasemia	O	O
,	O	O
hyperkalemia	B_Disease	O
,	O	O
hypoaldosteronism	B_Disease	O
,	O	O
and	O	O
priapism	B_Disease	O
.	O	O

These	O	O
side	O	O
effects	O	O
are	O	O
relatively	O	O
rare	O	O
in	O	O
a	O	O
given	O	O
individual	O	O
,	O	O
but	O	O
given	O	O
the	O	O
extremely	O	O
widespread	O	O
use	O	O
of	O	O
heparin	B_Chemical	O
,	O	O
some	O	O
are	O	O
quite	O	O
common	O	O
,	O	O
particularly	O	O
HITT	B_Disease	O
and	O	O
osteoporosis	B_Disease	O
.	O	O

Although	O	O
reasonable	O	O
incidences	O	O
of	O	O
many	O	O
of	O	O
these	O	O
side	O	O
effects	O	O
can	O	O
be	O	O
"	O	O
softly	O	O
"	O	O
deduced	O	O
from	O	O
current	O	O
reports	O	O
dealing	O	O
with	O	O
unfractionated	O	O
heparin	B_Chemical	O
,	O	O
at	O	O
present	O	O
the	O	O
incidences	O	O
of	O	O
these	O	O
side	O	O
effects	O	O
with	O	O
newer	O	O
low	O	O
molecular	O	O
weight	O	O
heparins	B_Chemical	O
appear	O	O
to	O	O
be	O	O
much	O	O
less	O	O
common	O	O
.	O	O

However	O	O
,	O	O
only	O	O
longer	O	O
experience	O	O
will	O	O
more	O	O
clearly	O	O
define	O	O
the	O	O
incidence	O	O
of	O	O
each	O	O
side	O	O
effect	O	O
with	O	O
low	O	O
molecular	O	O
weight	O	O
preparations	O	O
.	O	O

A	O	O
case	O	O
of	O	O
bilateral	O	O
optic	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
in	O	O
a	O	O
patient	O	O
on	O	O
tacrolimus	B_Chemical	B_Chemical
(	O	O
FK506	B_Chemical	O
)	O	O
therapy	O	O
after	O	O
liver	O	O
transplantation	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
bilateral	O	O
optic	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
in	O	O
a	O	O
patient	O	O
receiving	O	O
tacrolimus	B_Chemical	B_Chemical
(	O	O
FK	B_Chemical	O
506	I_Chemical	O
,	O	O
Prograf	O	O
;	O	O
Fujisawa	O	O
USA	O	O
,	O	O
Inc	O	O
,	O	O
Deerfield	O	O
,	O	O
Illinois	O	O
)	O	O
for	O	O
immunosuppression	O	O
after	O	O
orthotropic	O	O
liver	O	O
transplantation	O	O
.	O	O

METHOD	O	O
:	O	O
Case	O	O
report	O	O
.	O	O

In	O	O
a	O	O
58-year-old	O	O
man	O	O
receiving	O	O
tacrolimus	B_Chemical	B_Chemical
after	O	O
orthotropic	O	O
liver	O	O
transplantation	O	O
,	O	O
serial	O	O
neuro-ophthalmologic	O	O
examinations	O	O
and	O	O
laboratory	O	O
studies	O	O
were	O	O
performed	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
patient	O	O
had	O	O
episodic	O	O
deterioration	O	O
of	O	O
vision	O	O
in	O	O
both	O	O
eyes	O	O
,	O	O
with	O	O
clinical	O	O
features	O	O
resembling	O	O
ischemic	B_Disease	O
optic	I_Disease	O
neuropathies	I_Disease	O
.	O	O

Deterioration	B_Disease	O
of	I_Disease	O
vision	I_Disease	O
occurred	O	O
despite	O	O
discontinuation	O	O
of	O	O
the	O	O
tacrolimus	B_Chemical	B_Chemical
.	O	O

CONCLUSION	O	O
:	O	O
Tacrolimus	B_Chemical	B_Chemical
and	O	O
other	O	O
immunosuppressive	O	O
agents	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
optic	B_Disease	O
nerve	I_Disease	O
toxicity	I_Disease	O
.	O	O

Hypercalcemia	B_Disease	O
,	O	O
arrhythmia	B_Disease	O
,	O	O
and	O	O
mood	O	O
stabilizers	O	O
.	O	O

Recent	O	O
findings	O	O
in	O	O
a	O	O
bipolar	B_Disease	O
patient	O	O
receiving	O	O
maintenance	O	O
lithium	B_Chemical	O
therapy	O	O
who	O	O
developed	O	O
hypercalcemia	B_Disease	O
and	O	O
severe	O	O
bradyarrhythmia	B_Disease	B_Disease
prompted	O	O
the	O	O
authors	O	O
to	O	O
conduct	O	O
a	O	O
retrospective	O	O
study	O	O
of	O	O
bipolar	B_Disease	O
patients	O	O
with	O	O
lithium-associated	O	O
hypercalcemia	B_Disease	O
.	O	O

A	O	O
printout	O	O
of	O	O
all	O	O
cases	O	O
of	O	O
hypercalcemia	B_Disease	O
that	O	O
presented	O	O
during	O	O
a	O	O
1-year	O	O
period	O	O
was	O	O
generated	O	O
.	O	O

After	O	O
eliminating	O	O
spurious	O	O
hypercalcemias	B_Disease	O
or	O	O
those	O	O
associated	O	O
with	O	O
intravenous	O	O
fluids	O	O
,	O	O
the	O	O
authors	O	O
identified	O	O
18	O	O
non-lithium-treated	O	O
patients	O	O
with	O	O
hypercalcemias	B_Disease	O
related	O	O
to	O	O
malignancies	B_Disease	O
and	O	O
other	O	O
medical	O	O
conditions	O	O
(	O	O
group	O	O
A	O	O
)	O	O
and	O	O
12	O	O
patients	O	O
with	O	O
lithium-associated	O	O
hypercalcemia	B_Disease	O
(	O	O
group	O	O
B	O	O
)	O	O
.	O	O

Patients	O	O
in	O	O
group	O	O
B	O	O
were	O	O
not	O	O
comparable	O	O
to	O	O
those	O	O
in	O	O
group	O	O
A	O	O
,	O	O
as	O	O
the	O	O
latter	O	O
were	O	O
medically	O	O
compromised	O	O
and	O	O
were	O	O
receiving	O	O
multiple	O	O
pharmacotherapies	O	O
.	O	O

Thus	O	O
,	O	O
two	O	O
control	O	O
groups	O	O
were	O	O
generated	O	O
:	O	O
group	O	O
C1	O	O
,	O	O
which	O	O
included	O	O
age-	O	O
and	O	O
sex-comparable	O	O
lithium-treated	O	O
bipolar	B_Disease	O
normocalcemic	O	O
patients	O	O
,	O	O
and	O	O
group	O	O
C2	O	O
,	O	O
which	O	O
included	O	O
bipolar	B_Disease	O
normocalcemic	O	O
patients	O	O
treated	O	O
with	O	O
anticonvulsant	O	O
mood	O	O
stabilizers	O	O
.	O	O

The	O	O
electrocardiographic	O	O
(	O	O
ECG	O	O
)	O	O
findings	O	O
for	O	O
patients	O	O
in	O	O
group	O	O
B	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
patients	O	O
in	O	O
groups	O	O
C1	O	O
and	O	O
C2	O	O
.	O	O

It	O	O
was	O	O
found	O	O
that	O	O
these	O	O
groups	O	O
did	O	O
not	O	O
differ	O	O
in	O	O
their	O	O
overall	O	O
frequency	O	O
of	O	O
ECG	O	O
abnormalities	O	O
;	O	O
however	O	O
,	O	O
there	O	O
were	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
frequency	O	O
of	O	O
conduction	O	B_Disease
defects	O	I_Disease
.	O	O

Patients	O	O
with	O	O
hypercalcemia	B_Disease	O
resulting	O	O
from	O	O
medical	O	O
diseases	O	O
and	O	O
bipolar	B_Disease	O
patients	O	O
with	O	O
lithium-associated	O	O
hypercalcemia	B_Disease	O
had	O	O
significantly	O	O
higher	O	O
frequencies	O	O
of	O	O
conduction	O	B_Disease
defects	O	I_Disease
.	O	O

Patients	O	O
in	O	O
group	O	O
A	O	O
had	O	O
significant	O	O
mortality	O	O
at	O	O
2-year	O	O
follow-up	O	O
(	O	O
28	O	O
%	O	O
)	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
zero	O	O
mortality	O	O
in	O	O
the	O	O
other	O	O
three	O	O
groups	O	O
.	O	O

The	O	O
clinical	O	O
implications	O	O
of	O	O
these	O	O
findings	O	O
are	O	O
discussed	O	O
.	O	O

Attenuation	O	O
of	O	O
nephrotoxicity	B_Disease	B_Disease
by	O	O
a	O	O
novel	O	O
lipid	O	O
nanosphere	O	O
(	O	O
NS-718	O	O
)	O	O
incorporating	O	O
amphotericin	O	O
B.NS-718	O	O
,	O	O
a	O	O
lipid	O	O
nanosphere	O	O
incorporating	O	O
amphotericin	B_Chemical	O
B	I_Chemical	O
,	O	O
is	O	O
effective	O	O
against	O	O
pathogenic	O	O
fungi	O	O
and	O	O
has	O	O
low	O	O
toxicity	B_Disease	O
.	O	O

We	O	O
compared	O	O
the	O	O
toxicity	B_Disease	O
of	O	O
NS-718	O	O
with	O	O
that	O	O
of	O	O
Fungizone	B_Chemical	O
(	O	O
amphotericin	B_Chemical	B_Chemical
B-sodium	I_Chemical	I_Chemical
deoxycholate	I_Chemical	I_Chemical
;	O	O
D-AmB	B_Chemical	O
)	O	O
in	O	O
vitro	O	O
using	O	O
renal	O	O
cell	O	O
cultures	O	O
and	O	O
in	O	O
vivo	O	O
by	O	O
biochemical	O	O
analysis	O	O
,	O	O
histopathological	O	O
study	O	O
of	O	O
the	O	O
kidney	O	O
and	O	O
pharmacokinetic	O	O
study	O	O
of	O	O
amphotericin	B_Chemical	O
B	I_Chemical	O
following	O	O
intravenous	O	O
infusion	O	O
of	O	O
the	O	O
formulation	O	O
in	O	O
rats	O	O
.	O	O

Incubation	O	O
with	O	O
NS-718	O	O
resulted	O	O
in	O	O
significantly	O	O
less	O	O
damage	O	O
of	O	O
cultured	O	O
human	O	O
renal	O	O
proximal	O	O
tubular	O	O
epithelial	O	O
cells	O	O
compared	O	O
with	O	O
D-AmB.	O	O
Serum	O	O
blood	O	B_Chemical
urea	B_Chemical	I_Chemical
and	O	O
creatinine	B_Chemical	B_Chemical
concentrations	O	O
increased	O	O
significantly	O	O
in	O	O
rats	O	O
given	O	O
an	O	O
iv	O	O
infusion	O	O
of	O	O
D-AmB	B_Chemical	O
3	O	O
mg/kg	O	O
but	O	O
not	O	O
in	O	O
those	O	O
given	O	O
the	O	O
same	O	O
dose	O	O
of	O	O
NS-718	O	O
.	O	O

Histopathological	O	O
examination	O	O
of	O	O
the	O	O
kidney	O	O
showed	O	O
tubular	B_Disease	B_Disease
necrosis	I_Disease	I_Disease
in	O	O
D-AmB-treated	O	O
rats	O	O
but	O	O
no	O	O
change	O	O
in	O	O
NS-718-treated	O	O
rats	O	O
.	O	O

Amphotericin	B_Chemical	O
B	I_Chemical	O
concentrations	O	O
in	O	O
the	O	O
kidney	O	O
in	O	O
NS-718-treated	O	O
rats	O	O
were	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
D-AmB-treated	O	O
rats	O	O
.	O	O

Our	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
results	O	O
suggest	O	O
that	O	O
incorporation	O	O
of	O	O
amphotericin	B_Chemical	O
B	I_Chemical	O
into	O	O
lipid	O	O
nanospheres	O	O
of	O	O
NS-718	O	O
attenuates	O	O
the	O	O
nephrotoxicity	B_Disease	B_Disease
of	O	O
amphotericin	O	O
B.	O	O

Patterns	O	O
of	O	O
sulfadiazine	B_Chemical	O
acute	B_Disease	O
nephrotoxicity	I_Disease	B_Disease
.	O	O

Sulfadiazine	B_Chemical	O
acute	B_Disease	O
nephrotoxicity	I_Disease	B_Disease
is	O	O
reviving	O	O
specially	O	O
because	O	O
of	O	O
its	O	O
use	O	O
in	O	O
toxoplasmosis	B_Disease	O
in	O	O
HIV-positive	O	O
patients	O	O
.	O	O

We	O	O
report	O	O
4	O	O
cases	O	O
,	O	O
one	O	O
of	O	O
them	O	O
in	O	O
a	O	O
previously	O	O
healthy	O	O
person	O	O
.	O	O

Under	O	O
treatment	O	O
with	O	O
sulfadiazine	B_Chemical	O
they	O	O
developed	O	O
oliguria	B_Disease	O
,	O	O
abdominal	B_Disease	B_Disease
pain	I_Disease	I_Disease
,	O	O
renal	B_Disease	B_Disease
failure	I_Disease	I_Disease
and	O	O
showed	O	O
multiple	O	O
radiolucent	O	O
renal	B_Disease	B_Disease
calculi	I_Disease	I_Disease
in	O	O
echography	O	O
.	O	O

All	O	O
patients	O	O
recovered	O	O
their	O	O
previous	O	O
normal	O	O
renal	O	O
function	O	O
after	O	O
adequate	O	O
hydration	O	O
and	O	O
alcalinization	O	O
.	O	O

A	O	O
nephrostomy	O	O
tube	O	O
had	O	O
to	O	O
be	O	O
placed	O	O
in	O	O
one	O	O
of	O	O
the	O	O
patients	O	O
for	O	O
ureteral	B_Disease	B_Disease
lithiasis	I_Disease	I_Disease
in	O	O
a	O	O
single	O	O
functional	O	O
kidney	O	O
.	O	O

None	O	O
of	O	O
them	O	O
needed	O	O
dialysis	O	O
or	O	O
a	O	O
renal	O	O
biopsy	O	O
because	O	O
of	O	O
a	O	O
typical	O	O
benign	O	O
course	O	O
.	O	O

Treatment	O	O
with	O	O
sulfadiazine	B_Chemical	O
requires	O	O
exquisite	O	O
control	O	O
of	O	O
renal	O	O
function	O	O
,	O	O
an	O	O
increase	O	O
in	O	O
water	O	O
ingestion	O	O
and	O	O
possibly	O	O
the	O	O
alcalinization	O	O
of	O	O
the	O	O
urine	O	O
.	O	O

We	O	O
communicate	O	O
a	O	O
case	O	O
in	O	O
a	O	O
previously	O	O
healthy	O	O
person	O	O
,	O	O
a	O	O
fact	O	O
not	O	O
found	O	O
in	O	O
the	O	O
recent	O	O
literature	O	O
.	O	O

Probably	O	O
many	O	O
more	O	O
cases	O	O
are	O	O
not	O	O
detected	O	O
.	O	O

We	O	O
think	O	O
that	O	O
a	O	O
prospective	O	O
study	O	O
would	O	O
be	O	O
useful	O	O
.	O	O

Downbeat	B_Disease	O
nystagmus	I_Disease	O
associated	O	O
with	O	O
intravenous	O	O
patient-controlled	O	O
administration	O	O
of	O	O
morphine	B_Chemical	O
.	O	O

IMPLICATIONS	O	O
:	O	O
This	O	O
case	O	O
documents	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
dizziness	B_Disease	O
with	O	O
downbeating	B_Disease	O
nystagmus	I_Disease	O
while	O	O
receiving	O	O
a	O	O
relatively	O	O
large	O	O
dose	O	O
of	O	O
IV	O	O
patient-controlled	O	O
analgesia	O	O
morphine	B_Chemical	O
.	O	O

Although	O	O
there	O	O
have	O	O
been	O	O
case	O	O
reports	O	O
of	O	O
epidural	O	O
morphine	B_Chemical	O
with	O	O
these	O	O
symptoms	O	O
and	O	O
signs	O	O
,	O	O
this	O	O
has	O	O
not	O	O
been	O	O
previously	O	O
documented	O	O
with	O	O
IV	O	O
or	O	O
patient-controlled	O	O
analgesia	O	O
morphine	B_Chemical	O
.	O	O

Hemodynamic	O	O
and	O	O
antiadrenergic	O	O
effects	O	O
of	O	O
dronedarone	B_Chemical	B_Chemical
and	O	O
amiodarone	B_Chemical	O
in	O	O
animals	O	O
with	O	O
a	O	O
healed	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
.	O	O

The	O	O
hemodynamic	O	O
and	O	O
antiadrenergic	O	O
effects	O	O
of	O	O
dronedarone	B_Chemical	B_Chemical
,	O	O
a	O	O
noniodinated	O	O
compound	O	O
structurally	O	O
related	O	O
to	O	O
amiodarone	B_Chemical	O
,	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
amiodarone	B_Chemical	O
after	O	O
prolonged	O	O
oral	O	O
administration	O	O
,	O	O
both	O	O
at	O	O
rest	O	O
and	O	O
during	O	O
sympathetic	O	O
stimulation	O	O
in	O	O
conscious	O	O
dogs	O	O
with	O	O
a	O	O
healed	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
.	O	O

All	O	O
dogs	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
randomly	O	O
received	O	O
orally	O	O
dronedarone	B_Chemical	B_Chemical
(	O	O
10	O	O
and	O	O
30	O	O
mg/kg	O	O
)	O	O
,	O	O
amiodarone	B_Chemical	O
(	O	O
10	O	O
and	O	O
30	O	O
mg/kg	O	O
)	O	O
,	O	O
and	O	O
placebo	O	O
twice	O	O
daily	O	O
for	O	O
7	O	O
days	O	O
,	O	O
with	O	O
a	O	O
3-week	O	O
washout	O	O
between	O	O
consecutive	O	O
treatments	O	O
.	O	O

Heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
(	O	O
MBP	O	O
)	O	O
,	O	O
positive	O	O
rate	O	O
of	O	O
increase	O	O
of	O	O
left	O	O
ventricular	O	O
pressure	O	O
(	O	O
+	O	O
LVdP/dt	O	O
)	O	O
,	O	O
echocardiographically	O	O
assessed	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
(	O	O
LVEF	O	O
)	O	O
,	O	O
and	O	O
fractional	O	O
shortening	O	O
(	O	O
FS	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
chronotropic	O	O
response	O	O
to	O	O
isoproterenol	B_Chemical	O
and	O	O
exercise-induced	O	O
sympathetic	O	O
stimulation	O	O
were	O	O
evaluated	O	O
under	O	O
baseline	O	O
and	O	O
posttreatment	O	O
conditions	O	O
.	O	O

Resting	O	O
values	O	O
of	O	O
LVEF	O	O
,	O	O
FS	O	O
,	O	O
+	O	O
LVdP/dt	O	O
,	O	O
and	O	O
MBP	O	O
remained	O	O
unchanged	O	O
whatever	O	O
the	O	O
drug	O	O
and	O	O
the	O	O
dosing	O	O
regimen	O	O
,	O	O
whereas	O	O
resting	O	O
HR	O	O
was	O	O
significantly	O	O
and	O	O
dose-dependently	O	O
lowered	O	O
after	O	O
dronedarone	B_Chemical	B_Chemical
and	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
after	O	O
amiodarone	B_Chemical	O
.	O	O

Both	O	O
dronedarone	B_Chemical	B_Chemical
and	O	O
amiodarone	B_Chemical	O
significantly	O	O
reduced	O	O
the	O	O
exercise-induced	O	O
tachycardia	B_Disease	O
and	O	O
,	O	O
at	O	O
the	O	O
highest	O	O
dose	O	O
,	O	O
decreased	O	O
the	O	O
isoproterenol-induced	O	O
tachycardia	B_Disease	O
.	O	O

Thus	O	O
,	O	O
dronedarone	B_Chemical	B_Chemical
and	O	O
amiodarone	B_Chemical	O
displayed	O	O
a	O	O
similar	O	O
level	O	O
of	O	O
antiadrenergic	O	O
effect	O	O
and	O	O
did	O	O
not	O	O
impair	O	O
the	O	O
resting	O	O
left	O	O
ventricular	O	O
function	O	O
.	O	O

Consequently	O	O
,	O	O
dronedarone	B_Chemical	B_Chemical
might	O	O
be	O	O
particularly	O	O
suitable	O	O
for	O	O
the	O	O
treatment	O	O
and	O	O
prevention	O	O
of	O	O
various	O	O
clinical	O	O
arrhythmias	B_Disease	O
,	O	O
without	O	O
compromising	O	O
the	O	O
left	O	O
ventricular	O	O
function	O	O
.	O	O

Phase	O	O
2	O	O
trial	O	O
of	O	O
liposomal	O	B_Chemical
doxorubicin	B_Chemical	I_Chemical
(	O	O
40	O	O
mg/m(2	O	O
)	O	O
)	O	O
in	O	O
platinum/paclitaxel-refractory	O	O
ovarian	B_Disease	O
and	I_Disease	O
fallopian	B_Disease	O
tube	I_Disease	O
cancers	I_Disease	O
and	O	O
primary	O	O
carcinoma	B_Disease	O
of	I_Disease	O
the	I_Disease	O
peritoneum	I_Disease	O
.	O	O

BACKGROUND	O	O
:	O	O
Several	O	O
studies	O	O
have	O	O
demonstrated	O	O
liposomal	O	B_Chemical
doxorubicin	B_Chemical	I_Chemical
(	O	O
Doxil	B_Chemical	B_Chemical
)	O	O
to	O	O
be	O	O
an	O	O
active	O	O
antineoplastic	O	O
agent	O	O
in	O	O
platinum-resistant	O	O
ovarian	B_Disease	B_Disease
cancer	I_Disease	I_Disease
,	O	O
with	O	O
dose	O	O
limiting	O	O
toxicity	B_Disease	O
of	O	O
the	O	O
standard	O	O
dosing	O	O
regimen	O	O
(	O	O
50	O	O
mg/m(2	O	O
)	O	O
q	O	O
4	O	O
weeks	O	O
)	O	O
being	O	O
severe	O	O
erythrodysesthesia	B_Disease	O
(	O	O
"	O	O
hand-foot	B_Disease	B_Disease
syndrome	I_Disease	I_Disease
"	O	O
)	O	O
and	O	O
stomatitis	B_Disease	O
.	O	O

We	O	O
wished	O	O
to	O	O
develop	O	O
a	O	O
more	O	O
tolerable	O	O
liposomal	O	B_Chemical
doxorubicin	B_Chemical	I_Chemical
treatment	O	O
regimen	O	O
and	O	O
document	O	O
its	O	O
level	O	O
of	O	O
activity	O	O
in	O	O
a	O	O
well-defined	O	O
patient	O	O
population	O	O
with	O	O
platinum/paclitaxel-refractory	O	O
disease	O	O
.	O	O

METHODS	O	O
AND	O	O
MATERIALS	O	O
:	O	O
Patients	O	O
with	O	O
ovarian	B_Disease	O
or	I_Disease	O
fallopian	B_Disease	O
tube	I_Disease	O
cancers	I_Disease	O
or	O	O
primary	O	O
peritoneal	B_Disease	O
carcinoma	I_Disease	O
with	O	O
platinum/paclitaxel-refractory	O	O
disease	O	O
(	O	O
stable	O	O
or	O	O
progressive	O	O
disease	O	O
following	O	O
treatment	O	O
with	O	O
these	O	O
agents	O	O
or	O	O
previous	O	O
objective	O	O
response	O	O
<3	O	O
months	O	O
in	O	O
duration	O	O
)	O	O
were	O	O
treated	O	O
with	O	O
liposomal	O	B_Chemical
doxorubicin	B_Chemical	I_Chemical
at	O	O
a	O	O
dose	O	O
of	O	O
40	O	O
mg/m(2	O	O
)	O	O
q	O	O
4	O	O
weeks	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
49	O	O
patients	O	O
(	O	O
median	O	O
age	O	O
:	O	O
60	O	O
;	O	O
range	O	O
41	O	O
-	O	O
81	O	O
)	O	O
entered	O	O
this	O	O
phase	O	O
2	O	O
trial	O	O
.	O	O

The	O	O
median	O	O
number	O	O
of	O	O
prior	O	O
regimens	O	O
was	O	O
2	O	O
(	O	O
range	O	O
:	O	O
1	O	O
-	O	O
6	O	O
)	O	O
.	O	O

Six	O	O
(	O	O
12	O	O
%	O	O
)	O	O
and	O	O
4	O	O
(	O	O
8	O	O
%	O	O
)	O	O
patients	O	O
experienced	O	O
grade	O	O
2	O	O
hand-foot	B_Disease	B_Disease
syndrome	I_Disease	I_Disease
and	O	O
stomatitis	B_Disease	O
,	O	O
respectively	O	O
(	O	O
no	O	O
episodes	O	O
of	O	O
grade	O	O
3	O	O
)	O	O
.	O	O

One	O	O
patient	O	O
developed	O	O
grade	O	O
3	O	O
diarrhea	B_Disease	O
requiring	O	O
hospitalization	O	O
for	O	O
hydration	O	O
.	O	O

Six	O	O
(	O	O
12	O	O
%	O	O
)	O	O
individuals	O	O
required	O	O
dose	O	O
reductions	O	O
.	O	O

The	O	O
median	O	O
number	O	O
of	O	O
courses	O	O
of	O	O
liposomal	O	B_Chemical
doxorubicin	B_Chemical	I_Chemical
administered	O	O
on	O	O
this	O	O
protocol	O	O
was	O	O
2	O	O
(	O	O
range	O	O
:	O	O
1	O	O
-	O	O
12	O	O
)	O	O
.	O	O

Four	O	O
of	O	O
44	O	O
patients	O	O
(	O	O
9	O	O
%	O	O
)	O	O
evaluable	O	O
for	O	O
response	O	O
exhibited	O	O
objective	O	O
and	O	O
subjective	O	O
evidence	O	O
of	O	O
an	O	O
antineoplastic	O	O
effect	O	O
of	O	O
therapy	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
modified	O	O
liposomal	O	B_Chemical
doxorubicin	B_Chemical	I_Chemical
regimen	O	O
results	O	O
in	O	O
less	O	O
toxicity	B_Disease	O
(	O	O
stomatitis	B_Disease	O
,	O	O
hand-foot	B_Disease	B_Disease
syndrome	I_Disease	I_Disease
)	O	O
than	O	O
the	O	O
standard	O	O
FDA-approved	O	O
dose	O	O
schedule	O	O
.	O	O

Definite	O	O
,	O	O
although	O	O
limited	O	O
,	O	O
antineoplastic	O	O
activity	O	O
is	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
well-defined	O	O
platinum-	O	O
and	O	O
paclitaxel-refractory	O	O
ovarian	B_Disease	B_Disease
cancer	I_Disease	I_Disease
.	O	O

Efficacy	O	O
of	O	O
olanzapine	B_Chemical	B_Chemical
in	O	O
acute	O	O
bipolar	B_Disease	B_Disease
mania	I_Disease	I_Disease
:	O	O
a	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
.	O	O

The	O	O
Olanzipine	B_Chemical	B_Chemical
HGGW	O	O
Study	O	O
Group	O	O
.	O	O

BACKGROUND	O	O
:	O	O
We	O	O
compared	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
olanzapine	B_Chemical	B_Chemical
vs	O	O
placebo	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
bipolar	B_Disease	B_Disease
mania	I_Disease	I_Disease
.	O	O

METHODS	O	O
:	O	O
Four-week	O	O
,	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
parallel	O	O
study	O	O
.	O	O

A	O	O
total	O	O
of	O	O
115	O	O
patients	O	O
with	O	O
a	O	O
DSM-IV	O	O
diagnosis	O	O
of	O	O
bipolar	B_Disease	B_Disease
disorder	I_Disease	I_Disease
,	O	O
manic	B_Disease	O
or	O	O
mixed	O	O
,	O	O
were	O	O
randomized	O	O
to	O	O
olanzapine	B_Chemical	B_Chemical
,	O	O
5	O	O
to	O	O
20	O	O
mg/d	O	O
(	O	O
n	O	O
=	O	O
55	O	O
)	O	O
,	O	O
or	O	O
placebo	O	O
(	O	O
n	O	O
=	O	O
60	O	O
)	O	O
.	O	O

The	O	O
primary	O	O
efficacy	O	O
measure	O	O
was	O	O
the	O	O
Young-Mania	O	O
Rating	O	O
Scale	O	O
(	O	O
Y-MRS	O	O
)	O	O
total	O	O
score	O	O
.	O	O

Response	O	O
and	O	O
euthymia	O	B_Disease
were	O	O
defined	O	O
,	O	O
a	O	O
priori	O	O
,	O	O
as	O	O
at	O	O
least	O	O
a	O	O
50	O	O
%	O	O
improvement	O	O
from	O	O
baseline	O	O
to	O	O
end	O	O
point	O	O
and	O	O
as	O	O
a	O	O
score	O	O
of	O	O
no	O	O
less	O	O
than	O	O
12	O	O
at	O	O
end	O	O
point	O	O
in	O	O
the	O	O
Y-MRS	O	O
total	O	O
score	O	O
,	O	O
respectively	O	O
.	O	O

Safety	O	O
was	O	O
assessed	O	O
using	O	O
adverse	O	O
events	O	O
,	O	O
Extrapyramidal	B_Disease	B_Disease
Symptom	I_Disease	O
(	O	O
EPS	B_Disease	O
)	O	O
rating	O	O
scales	O	O
,	O	O
laboratory	O	O
values	O	O
,	O	O
electrocardiograms	O	O
,	O	O
vital	O	O
signs	O	O
,	O	O
and	O	O
weight	O	O
change	O	O
.	O	O

RESULTS	O	O
:	O	O
Olanzapine-treated	O	O
patients	O	O
demonstrated	O	O
a	O	O
statistically	O	O
significant	O	O
greater	O	O
mean	O	O
(	O	O
+	O	O
/-	O	O
SD	O	O
)	O	O
improvement	O	O
in	O	O
Y-MRS	O	O
total	O	O
score	O	O
than	O	O
placebo-treated	O	O
patients	O	O
(	O	O
-14.8	O	O
+	O	O
/-	O	O
12.5	O	O
and	O	O
-8.1	O	O
+	O	O
/-	O	O
12.7	O	O
,	O	O
respectively	O	O
;	O	O
P<.001	O	O
)	O	O
,	O	O
which	O	O
was	O	O
evident	O	O
at	O	O
the	O	O
first	O	O
postbaseline	O	O
observation	O	O
1	O	O
week	O	O
after	O	O
randomization	O	O
and	O	O
was	O	O
maintained	O	O
throughout	O	O
the	O	O
study	O	O
(	O	O
last	O	O
observation	O	O
carried	O	O
forward	O	O
)	O	O
.	O	O

Olanzapine-treated	O	O
patients	O	O
demonstrated	O	O
a	O	O
higher	O	O
rate	O	O
of	O	O
response	O	O
(	O	O
65	O	O
%	O	O
vs	O	O
43	O	O
%	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
=	O	O
.02	O	O
)	O	O
and	O	O
euthymia	O	B_Disease
(	O	O
61	O	O
%	O	O
vs	O	O
36	O	O
%	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
=	O	O
.	O	O
01	O	O
)	O	O
than	O	O
placebo-treated	O	O
patients	O	O
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
in	O	O
EPSs	B_Disease	O
between	O	O
groups	O	O
.	O	O

However	O	O
,	O	O
olanzapine-treated	O	O
patients	O	O
had	O	O
a	O	O
statistically	O	O
significant	O	O
greater	O	O
mean	O	O
(	O	O
+	O	O
/-	O	O
SD	O	O
)	O	O
weight	B_Disease	O
gain	I_Disease	O
than	O	O
placebo-treated	O	O
patients	O	O
(	O	O
2.1	O	O
+	O	O
/-	O	O
2.8	O	O
vs	O	O
0.45	O	O
+	O	O
/-	O	O
2.3	O	O
kg	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
also	O	O
experienced	O	O
more	O	O
treatment-emergent	O	O
somnolence	B_Disease	O
(	O	O
21	O	O
patients	O	O
[	O	O
38.2	O	O
%	O	O
]	O	O
vs	O	O
5	O	O
[	O	O
8.3	O	O
%	O	O
]	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Olanzapine	B_Chemical	B_Chemical
demonstrated	O	O
greater	O	O
efficacy	O	O
than	O	O
placebo	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
bipolar	B_Disease	B_Disease
mania	I_Disease	I_Disease
and	O	O
was	O	O
generally	O	O
well	O	O
tolerated	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
pupil	B_Disease	O
dilation	I_Disease	O
with	O	O
tropicamide	B_Chemical	B_Chemical
on	O	O
vision	O	O
and	O	O
driving	O	O
simulator	O	O
performance	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
assess	O	O
the	O	O
effect	O	O
of	O	O
pupil	B_Disease	O
dilation	I_Disease	O
on	O	O
vision	O	O
and	O	O
driving	O	O
ability	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
series	O	O
of	O	O
tests	O	O
on	O	O
various	O	O
parameters	O	O
of	O	O
visual	O	O
function	O	O
and	O	O
driving	O	O
simulator	O	O
performance	O	O
were	O	O
performed	O	O
on	O	O
12	O	O
healthy	O	O
drivers	O	O
,	O	O
before	O	O
and	O	O
after	O	O
pupil	B_Disease	O
dilation	I_Disease	O
using	O	O
guttae	O	B_Chemical
tropicamide	B_Chemical	I_Chemical
1	O	O
%	O	O
.	O	O

A	O	O
driving	O	O
simulator	O	O
(	O	O
Transport	O	O
Research	O	O
Laboratory	O	O
)	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
reaction	O	O
time	O	O
(	O	O
RT	O	O
)	O	O
,	O	O
speed	O	O
maintenance	O	O
and	O	O
steering	O	O
accuracy	O	O
.	O	O

Tests	O	O
of	O	O
basic	O	O
visual	O	O
function	O	O
included	O	O
high-	O	O
and	O	O
low-contrast	O	O
visual	O	O
acuity	O	O
(	O	O
HCVA	O	O
and	O	O
LCVA	O	O
)	O	O
,	O	O
Pelli-Robson	O	O
contrast	O	O
threshold	O	O
(	O	O
CT	O	O
)	O	O
and	O	O
Goldmann	O	O
perimetry	O	O
(	O	O
FIELDS	O	O
)	O	O
.	O	O

Useful	O	O
Field	O	O
of	O	O
View	O	O
(	O	O
UFOV	O	O
--	O	O
a	O	O
test	O	O
of	O	O
visual	O	O
attention	O	O
)	O	O
was	O	O
also	O	O
undertaken	O	O
.	O	O

The	O	O
mean	O	O
differences	O	O
in	O	O
the	O	O
pre-	O	O
and	O	O
post-dilatation	O	O
measurements	O	O
were	O	O
tested	O	O
for	O	O
statistical	O	O
significance	O	O
at	O	O
the	O	O
95	O	O
%	O	O
level	O	O
using	O	O
one-tail	O	O
paired	O	O
t-tests	O	O
.	O	O

RESULTS	O	O
:	O	O
Pupillary	B_Disease	O
dilation	I_Disease	O
resulted	O	O
in	O	O
a	O	O
statistically	O	O
significant	O	O
deterioration	O	O
in	O	O
CT	O	O
and	O	O
HCVA	O	O
only	O	O
.	O	O

Five	O	O
of	O	O
12	O	O
drivers	O	O
also	O	O
exhibited	O	O
deterioration	O	O
in	O	O
LCVA	O	O
,	O	O
CT	O	O
and	O	O
RT	O	O
.	O	O

Little	O	O
evidence	O	O
emerged	O	O
for	O	O
deterioration	O	O
in	O	O
FIELDS	O	O
and	O	O
UFOV	O	O
.	O	O

Also	O	O
,	O	O
7	O	O
of	O	O
12	O	O
drivers	O	O
appeared	O	O
to	O	O
adjust	O	O
their	O	O
driving	O	O
behaviour	O	O
by	O	O
reducing	O	O
their	O	O
speed	O	O
on	O	O
the	O	O
driving	O	O
simulator	O	O
,	O	O
leading	O	O
to	O	O
improved	O	O
steering	O	O
accuracy	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Pupillary	B_Disease	O
dilation	I_Disease	O
may	O	O
lead	O	O
to	O	O
a	O	O
decrease	O	O
in	O	O
vision	O	O
and	O	O
daylight	O	O
driving	O	O
performance	O	O
in	O	O
young	O	O
people	O	O
.	O	O

A	O	O
larger	O	O
study	O	O
,	O	O
including	O	O
a	O	O
broader	O	O
spectrum	O	O
of	O	O
subjects	O	O
,	O	O
is	O	O
warranted	O	O
before	O	O
guidelines	O	O
can	O	O
be	O	O
recommended	O	O
.	O	O

A	O	O
case	O	O
of	O	O
isotretinoin	B_Disease	O
embryopathy	I_Disease	O
with	O	O
bilateral	O	O
anotia	B_Disease	O
and	O	O
Taussig-Bing	B_Disease	O
malformation	I_Disease	O
.	O	O

We	O	O
report	O	O
a	O	O
newborn	O	O
infant	O	O
with	O	O
multiple	O	O
congenital	O	O
anomalies	O	O
(	O	O
anotia	B_Disease	O
and	O	O
Taussig-Bing	B_Disease	O
malformation	I_Disease	O
)	O	O
due	O	O
to	O	O
exposure	O	O
to	O	O
isotretinoin	B_Chemical	O
within	O	O
the	O	O
first	O	O
trimester	O	O
.	O	O

In	O	O
this	O	O
paper	O	O
we	O	O
aim	O	O
to	O	O
draw	O	O
to	O	O
the	O	O
fact	O	O
that	O	O
caution	O	O
is	O	O
needed	O	O
when	O	O
prescribing	O	O
vitamin	O	O
A-containing	O	O
drugs	O	O
to	O	O
women	O	O
of	O	O
childbearing	O	O
years	O	O
.	O	O

Effect	O	O
of	O	O
methoxamine	B_Chemical	B_Chemical
on	O	O
maximum	O	O
urethral	O	O
pressure	O	O
in	O	O
women	O	O
with	O	O
genuine	O	O
stress	B_Disease	B_Disease
incontinence	I_Disease	I_Disease
:	O	O
a	O	O
placebo-controlled	O	O
,	O	O
double-blind	O	O
crossover	O	O
study	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
potential	O	O
role	O	O
for	O	O
a	O	O
selective	O	O
alpha1-adrenoceptor	O	O
agonist	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
urinary	B_Disease	B_Disease
stress	I_Disease	I_Disease
incontinence	I_Disease	I_Disease
.	O	O

A	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
,	O	O
crossover	O	O
study	O	O
design	O	O
was	O	O
employed	O	O
.	O	O

Half	O	O
log	O	O
incremental	O	O
doses	O	O
of	O	O
intravenous	O	O
methoxamine	B_Chemical	B_Chemical
or	O	O
placebo	O	O
(	O	O
saline	O	O
)	O	O
were	O	O
administered	O	O
to	O	O
a	O	O
group	O	O
of	O	O
women	O	O
with	O	O
genuine	O	O
stress	B_Disease	B_Disease
incontinence	I_Disease	I_Disease
while	O	O
measuring	O	O
maximum	O	O
urethral	O	O
pressure	O	O
(	O	O
MUP	O	O
)	O	O
,	O	O
blood	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
and	O	O
symptomatic	O	O
side	O	O
effects	O	O
.	O	O

Methoxamine	B_Chemical	B_Chemical
evoked	O	O
non-significant	O	O
increases	O	O
in	O	O
MUP	O	O
and	O	O
diastolic	O	O
blood	O	O
pressure	O	O
but	O	O
caused	O	O
a	B_Disease	O
significant	I_Disease	O
rise	I_Disease	O
in	I_Disease	O
systolic	I_Disease	O
blood	I_Disease	O
pressure	I_Disease	O
and	O	O
significant	O	O
fall	O	O
in	O	O
heart	O	O
rate	O	O
at	O	O
maximum	O	O
dosage	O	O
.	O	O

Systemic	O	O
side	O	O
effects	O	O
including	O	O
piloerection	O	O
,	O	O
headache	B_Disease	O
,	O	O
and	O	O
cold	O	O
extremities	O	O
were	O	O
experienced	O	O
in	O	O
all	O	O
subjects	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
clinical	O	O
usefulness	O	O
of	O	O
direct	O	O
,	O	O
peripherally	O	O
acting	O	O
sub-type-selective	O	O
alpha1-adrenoceptor	O	O
agonists	O	O
in	O	O
the	O	O
medical	O	O
treatment	O	O
of	O	O
stress	B_Disease	B_Disease
incontinence	I_Disease	I_Disease
may	O	O
be	O	O
limited	O	O
by	O	O
associated	O	O
piloerection	O	O
and	O	O
cardiovascular	O	O
side	O	O
effects	O	O
.	O	O

Hyperglycemic	B_Disease	O
effect	O	O
of	O	O
amino	B_Chemical	O
compounds	O	O
structurally	O	O
related	O	O
to	O	O
caproate	B_Chemical	B_Chemical
in	O	O
rats	O	O
.	O	O

The	O	O
chronic	O	O
feeding	O	O
of	O	O
small	O	O
amounts	O	O
(	O	O
0.3	O	O
-	O	O
3	O	O
%	O	O
of	O	O
diet	O	O
weight	O	O
)	O	O
of	O	O
certain	O	O
amino	B_Chemical	O
derivatives	O	O
of	O	O
caproate	B_Chemical	B_Chemical
resulted	O	O
in	O	O
hyperglycemia	B_Disease	O
,	O	O
an	O	O
elevated	O	O
glucose	B_Chemical	O
tolerance	O	O
curve	O	O
and	O	O
,	O	O
occasionally	O	O
,	O	O
glucosuria	B_Disease	O
.	O	O

Effective	O	O
compounds	O	O
included	O	O
norleucine	B_Chemical	B_Chemical
,	O	O
norvaline	B_Chemical	B_Chemical
,	O	O
glutamate	B_Chemical	O
,	O	O
epsilon-aminocaproate	B_Chemical	B_Chemical
,	O	O
methionine	B_Chemical	O
,	O	O
and	O	O
leucine	B_Chemical	O
.	O	O

Toleration	O	O
of	O	O
high	O	O
doses	O	O
of	O	O
angiotensin-converting	B_Chemical	O
enzyme	I_Chemical	O
inhibitors	I_Chemical	O
in	O	O
patients	O	O
with	O	O
chronic	O	B_Disease
heart	B_Disease	I_Disease
failure	I_Disease	I_Disease
:	O	O
results	O	O
from	O	O
the	O	O
ATLAS	O	O
trial	O	O
.	O	O

The	O	O
Assessment	O	O
of	O	O
Treatment	O	O
with	O	O
Lisinopril	B_Chemical	O
and	O	O
Survival	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Treatment	O	O
with	O	O
angiotensin-converting	B_Chemical	O
enzyme	I_Chemical	O
(	I_Chemical	O
ACE	I_Chemical	O
)	I_Chemical	O
inhibitors	I_Chemical	O
reduces	O	O
mortality	O	O
and	O	O
morbidity	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	B_Disease
heart	B_Disease	I_Disease
failure	I_Disease	I_Disease
(	O	O
CHF	B_Disease	O
)	O	O
,	O	O
but	O	O
most	O	O
affected	O	O
patients	O	O
are	O	O
not	O	O
receiving	O	O
these	O	O
agents	O	O
or	O	O
are	O	O
being	O	O
treated	O	O
with	O	O
doses	O	O
lower	O	O
than	O	O
those	O	O
found	O	O
to	O	O
be	O	O
efficacious	O	O
in	O	O
trials	O	O
,	O	O
primarily	O	O
because	O	O
of	O	O
concerns	O	O
about	O	O
the	O	O
safety	O	O
and	O	O
tolerability	O	O
of	O	O
these	O	O
agents	O	O
,	O	O
especially	O	O
at	O	O
the	O	O
recommended	O	O
doses	O	O
.	O	O

The	O	O
present	O	O
study	O	O
examines	O	O
the	O	O
safety	O	O
and	O	O
tolerability	O	O
of	O	O
high-	O	O
compared	O	O
with	O	O
low-dose	O	O
lisinopril	B_Chemical	O
in	O	O
CHF	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
Assessment	O	O
of	O	O
Lisinopril	B_Chemical	O
and	O	O
Survival	O	O
study	O	O
was	O	O
a	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
double-blind	O	O
trial	O	O
in	O	O
which	O	O
patients	O	O
with	O	O
or	O	O
without	O	O
previous	O	O
ACE	B_Chemical	O
inhibitor	I_Chemical	O
treatment	O	O
were	O	O
stabilized	O	O
receiving	O	O
medium-dose	O	O
lisinopril	B_Chemical	O
(	O	O
12.5	O	O
or	O	O
15.0	O	O
mg	O	O
once	O	O
daily	O	O
[	O	O
OD	O	O
]	O	O
)	O	O
for	O	O
2	O	O
to	O	O
4	O	O
weeks	O	O
and	O	O
then	O	O
randomized	O	O
to	O	O
high-	O	O
(	O	O
35.0	O	O
or	O	O
32.5	O	O
mg	O	O
OD	O	O
)	O	O
or	O	O
low-dose	O	O
(	O	O
5.0	O	O
or	O	O
2.5	O	O
mg	O	O
OD	O	O
)	O	O
groups	O	O
.	O	O

Patients	O	O
with	O	O
New	O	O
York	O	O
Heart	O	O
Association	O	O
classes	O	O
II	O	O
to	O	O
IV	O	O
CHF	B_Disease	O
and	O	O
left	O	O
ventricular	O	O
ejection	O	O
fractions	O	O
of	O	O
no	O	O
greater	O	O
than	O	O
0.30	O	O
(	O	O
n	O	O
=	O	O
3164	O	O
)	O	O
were	O	O
randomized	O	O
and	O	O
followed	O	O
up	O	O
for	O	O
a	O	O
median	O	O
of	O	O
46	O	O
months	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
occurrence	O	O
of	O	O
adverse	O	O
events	O	O
and	O	O
the	O	O
need	O	O
for	O	O
discontinuation	O	O
and	O	O
dose	O	O
reduction	O	O
during	O	O
treatment	O	O
,	O	O
with	O	O
a	O	O
focus	O	O
on	O	O
hypotension	B_Disease	O
and	O	O
renal	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
405	O	O
patients	O	O
not	O	O
previously	O	O
receiving	O	O
an	O	O
ACE	B_Chemical	O
inhibitor	I_Chemical	O
,	O	O
doses	O	O
in	O	O
only	O	O
4.2	O	O
%	O	O
could	O	O
not	O	O
be	O	O
titrated	O	O
to	O	O
the	O	O
medium	O	O
doses	O	O
required	O	O
for	O	O
randomization	O	O
because	O	O
of	O	O
symptoms	O	O
possibly	O	O
related	O	O
to	O	O
hypotension	B_Disease	O
(	O	O
2.0	O	O
%	O	O
)	O	O
or	O	O
because	O	O
of	O	O
renal	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
or	O	O
hyperkalemia	B_Disease	O
(	O	O
2.3	O	O
%	O	O
)	O	O
.	O	O

Doses	O	O
in	O	O
more	O	O
than	O	O
90	O	O
%	O	O
of	O	O
randomized	O	O
patients	O	O
in	O	O
the	O	O
high-	O	O
and	O	O
low-dose	O	O
groups	O	O
were	O	O
titrated	O	O
to	O	O
their	O	O
assigned	O	O
target	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
doses	O	O
of	O	O
blinded	O	O
medication	O	O
in	O	O
both	O	O
groups	O	O
remained	O	O
similar	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

Withdrawals	O	O
occurred	O	O
in	O	O
27.1	O	O
%	O	O
of	O	O
the	O	O
high-	O	O
and	O	O
30.7	O	O
%	O	O
of	O	O
the	O	O
low-dose	O	O
groups	O	O
.	O	O

Subgroups	O	O
presumed	O	O
to	O	O
be	O	O
at	O	O
higher	O	O
risk	O	O
for	O	O
ACE	B_Chemical	O
inhibitor	I_Chemical	O
intolerance	O	O
(	O	O
blood	O	O
pressure	O	O
,	O	O
<	O	O
120	O	O
mm	O	O
Hg	O	O
;	O	O
creatinine	B_Chemical	B_Chemical
,	O	O
>	O	O
or	O	O
=	O	O
132.6	O	O
micromol/L	O	O
[	O	O
>	O	O
or	O	O
=	O	O
1.5	O	O
mg/dL	O	O
]	O	O
;	O	O
age	O	O
,	O	O
>	O	O
or	O	O
=	O	O
70	O	O
years	O	O
;	O	O
and	O	O
patients	O	O
with	O	O
diabetes	B_Disease	O
)	O	O
generally	O	O
tolerated	O	O
the	O	O
high-dose	O	O
strategy	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
findings	O	O
demonstrate	O	O
that	O	O
ACE	B_Chemical	O
inhibitor	I_Chemical	O
therapy	O	O
in	O	O
most	O	O
patients	O	O
with	O	O
CHF	B_Disease	O
can	O	O
be	O	O
successfully	O	O
titrated	O	O
to	O	O
and	O	O
maintained	O	O
at	O	O
high	O	O
doses	O	O
,	O	O
and	O	O
that	O	O
more	O	O
aggressive	O	O
use	O	O
of	O	O
these	O	O
agents	O	O
is	O	O
warranted	O	O
.	O	O

Cocaine	B_Chemical	O
,	O	O
ethanol	B_Chemical	O
,	O	O
and	O	O
cocaethylene	B_Chemical	O
cardiotoxity	B_Disease	O
in	O	O
an	O	O
animal	O	O
model	O	O
of	O	O
cocaine	B_Disease	O
and	I_Disease	O
ethanol	B_Disease	O
abuse	I_Disease	O
.	O	O

OBJECTIVES	O	O
:	O	O
Simultaneous	O	O
abuse	B_Disease	O
of	I_Disease	O
cocaine	I_Disease	O
and	I_Disease	O
ethanol	I_Disease	O
affects	O	O
12	O	O
million	O	O
Americans	O	O
annually	O	O
.	O	O

In	O	O
combination	O	O
,	O	O
these	O	O
substances	O	O
are	O	O
substantially	O	O
more	O	O
toxic	O	O
than	O	O
either	O	O
drug	O	O
alone	O	O
.	O	O

Their	O	O
combined	O	O
cardiac	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
may	O	O
be	O	O
due	O	O
to	O	O
independent	O	O
effects	O	O
of	O	O
each	O	O
drug	O	O
;	O	O
however	O	O
,	O	O
they	O	O
may	O	O
also	O	O
be	O	O
due	O	O
to	O	O
cocaethylene	B_Chemical	B_Chemical
(	O	O
CE	B_Chemical	O
)	O	O
,	O	O
a	O	O
cocaine	B_Chemical	O
metabolite	O	O
formed	O	O
only	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
ethanol	B_Chemical	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
delineate	O	O
the	O	O
role	O	O
of	O	O
CE	B_Chemical	O
in	O	O
the	O	O
combined	O	O
cardiotoxicity	B_Disease	B_Disease
of	O	O
cocaine	B_Chemical	O
and	O	O
ethanol	B_Chemical	O
in	O	O
a	O	O
model	O	O
simulating	O	O
their	O	O
abuse	O	O
.	O	O

METHODS	O	O
:	O	O
Twenty-three	O	O
dogs	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
1	O	O
)	O	O
three	O	O
intravenous	O	O
(	O	O
IV	O	O
)	O	O
boluses	O	O
of	O	O
cocaine	B_Chemical	O
7.5	O	O
mg/kg	O	O
with	O	O
ethanol	B_Chemical	O
(	O	O
1	O	O
g/kg	O	O
)	O	O
as	O	O
an	O	O
IV	O	O
infusion	O	O
(	O	O
C+E	O	O
,	O	O
n	O	O
=	O	O
8)	O	O
,	O	O
2	O	O
)	O	O
three	O	O
cocaine	B_Chemical	O
boluses	O	O
only	O	O
(	O	O
C	O	O
,	O	O
n	O	O
=	O	O
6	O	O
)	O	O
,	O	O
3	O	O
)	O	O
ethanol	B_Chemical	O
infusion	O	O
only	O	O
(	O	O
E	O	O
,	O	O
n	O	O
=	O	O
5	O	O
)	O	O
,	O	O
or	O	O
4	O	O
)	O	O
placebo	O	O
boluses	O	O
and	O	O
infusion	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
.	O	O

Hemodynamic	O	O
measurements	O	O
,	O	O
electrocardiograms	O	O
,	O	O
and	O	O
serum	O	O
drug	O	O
concentrations	O	O
were	O	O
obtained	O	O
at	O	O
baseline	O	O
,	O	O
and	O	O
then	O	O
at	O	O
fixed	O	O
time	O	O
intervals	O	O
after	O	O
each	O	O
drug	O	O
was	O	O
administered	O	O
.	O	O

RESULTS	O	O
:	O	O
Two	O	O
of	O	O
eight	O	O
dogs	O	O
in	O	O
the	O	O
C+E	O	O
group	O	O
experienced	O	O
cardiovascular	B_Disease	O
collapse	I_Disease	O
.	O	O

The	O	O
most	O	O
dramatic	O	O
hemodynamic	O	O
changes	O	O
occurred	O	O
after	O	O
each	O	O
cocaine	B_Chemical	O
bolus	O	O
in	O	O
the	O	O
C+E	O	O
and	O	O
C	O	O
only	O	O
groups	O	O
;	O	O
however	O	O
,	O	O
persistent	O	O
hemodynamic	O	O
changes	O	O
occurred	O	O
in	O	O
the	O	O
C+E	O	O
group	O	O
.	O	O

Peak	O	O
CE	B_Chemical	O
levels	O	O
were	O	O
associated	O	O
with	O	O
a	O	O
45	O	O
%	O	O
(	O	O
SD	O	O
+	O	O
/-	O	O
22	O	O
%	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
=	O	O
22	O	O
%	O	O
to	O	O
69	O	O
%	O	O
)	O	O
decrease	B_Disease	O
in	I_Disease	O
cardiac	I_Disease	O
output	I_Disease	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
,	O	O
a	O	O
56	O	O
%	O	O
(	O	O
SD	O	O
+	O	O
/-	O	O
23	O	O
%	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
=	O	O
32	O	O
%	O	O
to	O	O
80	O	O
%	O	O
)	O	O
decrease	O	O
in	O	O
dP/dt(max	O	O
)	O	O
(	O	O
p	O	O
<	O	O
.006	O	O
)	O	O
,	O	O
and	O	O
a	O	O
23	O	O
%	O	O
(	O	O
SD	O	O
+	O	O
/-	O	O
15	O	O
%	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
=	O	O
7	O	O
%	O	O
to	O	O
49	O	O
%	O	O
)	O	O
decrease	O	O
in	O	O
SVO(2	O	O
)	O	O
(	O	O
p	O	O
<	O	O
0.025	O	O
)	O	O
.	O	O

Ventricular	B_Disease	B_Disease
arrhythmias	I_Disease	I_Disease
were	O	O
primarily	O	O
observed	O	O
in	O	O
the	O	O
C+E	O	O
group	O	O
,	O	O
in	O	O
which	O	O
four	O	O
of	O	O
eight	O	O
dogs	O	O
experienced	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
.	O	O

CONCLUSIONS	O	O
:	O	O
Cocaine	B_Chemical	O
and	O	O
ethanol	B_Chemical	O
in	O	O
combination	O	O
were	O	O
more	O	O
toxic	O	O
than	O	O
either	O	O
substance	O	O
alone	O	O
.	O	O

Co-administration	O	O
resulted	O	O
in	O	O
prolonged	O	O
cardiac	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
and	O	O
was	O	O
dysrhythmogenic	O	B_Disease
.	O	O

Peak	O	O
serum	O	O
cocaethylene	B_Chemical	B_Chemical
concentrations	O	O
were	O	O
associated	O	O
with	O	O
prolonged	O	O
myocardial	B_Disease	B_Disease
depression	I_Disease	I_Disease
.	O	O

Worsening	O	O
of	O	O
Parkinsonism	B_Disease	O
after	O	O
the	O	O
use	O	O
of	O	O
veralipride	B_Chemical	B_Chemical
for	O	O
treatment	O	O
of	O	O
menopause	O	O
:	O	O
case	O	O
report	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
stable	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
who	O	O
has	O	O
shown	O	O
a	O	O
marked	O	O
worsening	O	O
of	O	O
her	O	O
motor	O	O
functions	O	O
following	O	O
therapy	O	O
of	O	O
menopause	O	O
related	O	O
symptoms	O	O
with	O	O
veralipride	B_Chemical	B_Chemical
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
improvement	O	O
of	O	O
her	O	O
symptoms	O	O
back	O	O
to	O	O
baseline	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

We	O	O
emphasize	O	O
the	O	O
anti-dopaminergic	O	O
effect	O	O
of	O	O
veralipride	B_Chemical	B_Chemical
.	O	O

Viracept	B_Chemical	O
and	O	O
irregular	B_Disease	O
heartbeat	I_Disease	O
warning	O	O
.	O	O

A	O	O
group	O	O
of	O	O
doctors	O	O
in	O	O
Boston	O	O
warn	O	O
that	O	O
the	O	O
protease	O	O
inhibitor	O	O
Viracept	B_Chemical	O
may	O	O
cause	O	O
an	O	O
irregular	B_Disease	O
heart	I_Disease	B_Disease
beat	I_Disease	I_Disease
,	O	O
known	O	O
as	O	O
bradycardia	B_Disease	O
,	O	O
in	O	O
people	O	O
with	O	O
HIV	O	O
.	O	O

Bradycardia	B_Disease	O
occurred	O	O
in	O	O
a	O	O
45-year-old	O	O
male	O	O
patient	O	O
who	O	O
was	O	O
Viracept	B_Chemical	O
in	O	O
combination	O	O
with	O	O
other	O	O
anti-HIV	O	O
drugs	O	O
.	O	O

The	O	O
symptoms	O	O
ceased	O	O
after	O	O
switching	O	O
to	O	O
another	O	O
drug	O	O
combination	O	O
.	O	O

Frequency	O	O
of	O	O
appearance	O	O
of	O	O
myeloperoxidase-antineutrophil	O	O
cytoplasmic	O	O
antibody	O	O
(	O	O
MPO-ANCA	O	O
)	O	O
in	O	O
Graves	B_Disease	O
'	I_Disease	O
disease	I_Disease	O
patients	O	O
treated	O	O
with	O	O
propylthiouracil	B_Chemical	O
and	O	O
the	O	O
relationship	O	O
between	O	O
MPO-ANCA	O	O
and	O	O
clinical	O	O
manifestations	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
Myeloperoxidase	O	O
antineutrophil	O	O
cytoplasmic	O	O
antibody	O	O
(MPO-ANCA)-positive	O	O
vasculitis	B_Disease	O
has	O	O
been	O	O
reported	O	O
in	O	O
patients	O	O
with	O	O
Graves	B_Disease	O
'	I_Disease	O
disease	I_Disease	O
who	O	O
were	O	O
treated	O	O
with	O	O
propylthiouracil	B_Chemical	O
(	O	O
PTU	B_Chemical	O
)	O	O
.	O	O

The	O	O
appearance	O	O
of	O	O
MPO-ANCA	O	O
in	O	O
these	O	O
cases	O	O
was	O	O
suspected	O	O
of	O	O
being	O	O
related	O	O
to	O	O
PTU	B_Chemical	O
because	O	O
the	O	O
titres	O	O
of	O	O
MPO-ANCA	O	O
decreased	O	O
when	O	O
PTU	B_Chemical	O
was	O	O
stopped	O	O
.	O	O

Nevertheless	O	O
,	O	O
there	O	O
have	O	O
been	O	O
no	O	O
studies	O	O
on	O	O
the	O	O
temporal	O	O
relationship	O	O
between	O	O
the	O	O
appearance	O	O
of	O	O
MPO-ANCA	O	O
and	O	O
vasculitis	B_Disease	O
during	O	O
PTU	B_Chemical	O
therapy	O	O
,	O	O
or	O	O
on	O	O
the	O	O
incidence	O	O
of	O	O
MPO-ANCA	O	O
in	O	O
untreated	O	O
Graves	B_Disease	O
'	I_Disease	O
disease	I_Disease	O
patients	O	O
.	O	O

Therefore	O	O
,	O	O
we	O	O
sought	O	O
to	O	O
address	O	O
these	O	O
parameters	O	O
in	O	O
patients	O	O
with	O	O
Graves	B_Disease	O
'	I_Disease	O
disease	I_Disease	O
.	O	O

PATIENTS	O	O
:	O	O
We	O	O
investigated	O	O
102	O	O
untreated	O	O
patients	O	O
with	O	O
hyperthyroidism	B_Disease	O
due	O	O
to	O	O
Graves	B_Disease	O
'	I_Disease	O
disease	I_Disease	O
for	O	O
the	O	O
presence	O	O
of	O	O
MPO-ANCA	O	O
,	O	O
and	O	O
for	O	O
the	O	O
development	O	O
vasculitis	B_Disease	O
after	O	O
starting	O	O
PTU	B_Chemical	O
therapy	O	O
.	O	O

Twenty-nine	O	O
of	O	O
them	O	O
were	O	O
later	O	O
excluded	O	O
because	O	O
of	O	O
adverse	O	O
effects	O	O
of	O	O
PTU	B_Chemical	O
or	O	O
because	O	O
the	O	O
observation	O	O
period	O	O
was	O	O
less	O	O
than	O	O
3	O	O
months	O	O
.	O	O

The	O	O
remaining	O	O
73	O	O
patients	O	O
(	O	O
55	O	O
women	O	O
and	O	O
18	O	O
men	O	O
)	O	O
,	O	O
all	O	O
of	O	O
whom	O	O
were	O	O
examined	O	O
for	O	O
more	O	O
than	O	O
3	O	O
months	O	O
,	O	O
were	O	O
adopted	O	O
as	O	O
the	O	O
subjects	O	O
of	O	O
the	O	O
investigation	O	O
.	O	O

The	O	O
median	O	O
observation	O	O
period	O	O
was	O	O
23.6	O	O
months	O	O
(	O	O
range	O	O
:	O	O
3	O	O
-	O	O
37	O	O
months	O	O
)	O	O
.	O	O

MEASUREMENTS	O	O
:	O	O
MPO-ANCA	O	O
was	O	O
measured	O	O
at	O	O
intervals	O	O
of	O	O
2	O	O
-	O	O
6	O	O
months	O	O
.	O	O

RESULTS	O	O
:	O	O
Before	O	O
treatment	O	O
,	O	O
the	O	O
MPO-ANCA	O	O
titres	O	O
of	O	O
all	O	O
102	O	O
untreated	O	O
Graves	B_Disease	O
'	I_Disease	O
disease	I_Disease	O
patients	O	O
were	O	O
within	O	O
the	O	O
reference	O	O
range	O	O
(	O	O
below	O	O
10	O	O
U/ml	O	O
)	O	O
.	O	O

Three	O	O
(	O	O
4.1	O	O
%	O	O
)	O	O
of	O	O
the	O	O
73	O	O
patients	O	O
were	O	O
positive	O	O
for	O	O
MPO-ANCA	O	O
at	O	O
13	O	O
,	O	O
16	O	O
and	O	O
17	O	O
months	O	O
,	O	O
respectively	O	O
,	O	O
after	O	O
the	O	O
start	O	O
of	O	O
PTU	B_Chemical	O
therapy	O	O
.	O	O

In	O	O
two	O	O
of	O	O
them	O	O
,	O	O
the	O	O
MPO-ANCA	O	O
titres	O	O
transiently	O	O
increased	O	O
to	O	O
12.8	O	O
and	O	O
15.0	O	O
U/ml	O	O
,	O	O
respectively	O	O
,	O	O
despite	O	O
continued	O	O
PTU	B_Chemical	O
therapy	O	O
,	O	O
but	O	O
no	O	O
vasculitic	B_Disease	B_Disease
disorders	I_Disease	I_Disease
developed	O	O
.	O	O

In	O	O
the	O	O
third	O	O
patient	O	O
,	O	O
the	O	O
MPO-ANCA	O	O
titre	O	O
increased	O	O
to	O	O
204	O	O
U/ml	O	O
and	O	O
she	O	O
developed	O	O
a	O	O
higher	O	O
fever	B_Disease	O
,	O	O
oral	B_Disease	O
ulcers	I_Disease	O
and	O	O
polyarthralgia	B_Disease	B_Disease
,	O	O
but	O	O
the	O	O
symptoms	O	O
resolved	O	O
2	O	O
weeks	O	O
after	O	O
stopping	O	O
PTU	B_Chemical	O
therapy	O	O
,	O	O
and	O	O
the	O	O
MPO-ANCA	O	O
titre	O	O
decreased	O	O
to	O	O
20.7	O	O
U/ml	O	O
by	O	O
4	O	O
months	O	O
after	O	O
discontinuing	O	O
PTU	B_Chemical	O
.	O	O

CONCLUSIONS	O	O
:	O	O
PTU	B_Chemical	O
therapy	O	O
may	O	O
be	O	O
related	O	O
to	O	O
the	O	O
appearance	O	O
of	O	O
MPO-ANCA	O	O
,	O	O
but	O	O
MPO-ANCA	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
closely	O	O
related	O	O
to	O	O
vasculitis	B_Disease	O
.	O	O

Prevalence	O	O
of	O	O
heart	B_Disease	B_Disease
disease	I_Disease	I_Disease
in	O	O
asymptomatic	O	O
chronic	O	O
cocaine	B_Chemical	O
users	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
prevalence	O	O
of	O	O
heart	B_Disease	B_Disease
disease	I_Disease	I_Disease
in	O	O
outpatient	O	O
young	O	O
asymptomatic	O	O
chronic	O	O
cocaine	B_Chemical	O
users	O	O
,	O	O
35	O	O
cocaine	B_Chemical	O
users	O	O
and	O	O
32	O	O
age-matched	O	O
controls	O	O
underwent	O	O
resting	O	O
and	O	O
exercise	O	O
electrocardiography	O	O
(	O	O
ECG	O	O
)	O	O
and	O	O
Doppler	O	O
echocardiography	O	O
.	O	O

Findings	O	O
consistent	O	O
with	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
were	O	O
detected	O	O
in	O	O
12	O	O
(	O	O
34	O	O
%	O	O
)	O	O
patients	O	O
and	O	O
3	O	O
(	O	O
9	O	O
%	O	O
)	O	O
controls	O	O
(	O	O
p	O	O
=	O	O
0.01	O	O
)	O	O
.	O	O

Decreased	O	O
left	O	B_Disease
ventricular	O	I_Disease
systolic	O	I_Disease
function	O	O
was	O	O
demonstrated	O	O
in	O	O
5	O	O
(	O	O
14	O	O
%	O	O
)	O	O
patients	O	O
,	O	O
but	O	O
in	O	O
none	O	O
of	O	O
the	O	O
controls	O	O
(	O	O
p	O	O
=	O	O
0.055	O	O
)	O	O
.	O	O

Finally	O	O
,	O	O
resting	O	O
and	O	O
peak	O	O
exercise	O	O
abnormal	B_Disease	O
left	I_Disease	O
ventricular	I_Disease	O
filling	I_Disease	O
was	O	O
detected	O	O
in	O	O
38	O	O
and	O	O
35	O	O
%	O	O
of	O	O
patients	O	O
as	O	O
compared	O	O
to	O	O
19	O	O
and	O	O
9	O	O
%	O	O
of	O	O
controls	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
=	O	O
0.11	O	O
and	O	O
0.02	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
coronary	B_Disease	O
artery	I_Disease	O
or	I_Disease	O
myocardial	B_Disease	B_Disease
disease	I_Disease	I_Disease
is	O	O
common	O	O
(	O	O
38	O	O
%	O	O
)	O	O
in	O	O
young	O	O
asymptomatic	O	O
chronic	O	O
cocaine	B_Chemical	O
users	O	O
.	O	O

Therefore	O	O
,	O	O
screening	O	O
ECG	O	O
and	O	O
echocardiography	O	O
may	O	O
be	O	O
warranted	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

Cardioprotective	O	O
effects	O	O
of	O	O
Picrorrhiza	O	O
kurroa	O	O
against	O	O
isoproterenol-induced	O	O
myocardial	O	B_Disease
stress	O	I_Disease
in	O	O
rats	O	O
.	O	O

The	O	O
cardioprotective	O	O
effect	O	O
of	O	O
the	O	O
ethanol	B_Chemical	O
extract	O	O
of	O	O
Picrorrhiza	O	O
kurroa	O	O
rhizomes	O	O
and	O	O
roots	O	O
(	O	O
PK	O	O
)	O	O
on	O	O
isoproterenol-induced	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
in	O	O
rats	O	O
with	O	O
respect	O	O
to	O	O
lipid	O	O
metabolism	O	O
in	O	O
serum	O	O
and	O	O
heart	O	O
tissue	O	O
has	O	O
been	O	O
investigated	O	O
.	O	O

Oral	O	O
pre-treatment	O	O
with	O	O
PK	O	O
(	O	O
80	O	O
mg	O	O
kg(-1	O	O
)	O	O
day(-1	O	O
)	O	O
for	O	O
15	O	O
days	O	O
)	O	O
significantly	O	O
prevented	O	O
the	O	O
isoproterenol-induced	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
and	O	O
maintained	O	O
the	O	O
rats	O	O
at	O	O
near	O	O
normal	O	O
status	O	O
.	O	O

Phase	O	O
2	O	O
early	O	O
afterdepolarization	O	O
as	O	O
a	O	O
trigger	O	O
of	O	O
polymorphic	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
in	O	O
acquired	O	O
long-QT	B_Disease	O
syndrome	I_Disease	O
:	O	O
direct	O	O
evidence	O	O
from	O	O
intracellular	O	O
recordings	O	O
in	O	O
the	O	O
intact	O	O
left	O	O
ventricular	O	O
wall	O	O
.	O	O

BACKGROUND	O	O
:	O	O
This	O	O
study	O	O
examined	O	O
the	O	O
role	O	O
of	O	O
phase	O	O
2	O	O
early	O	O
afterdepolarization	O	O
(	O	O
EAD	O	O
)	O	O
in	O	O
producing	O	O
a	O	O
trigger	O	O
to	O	O
initiate	O	O
torsade	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
(	O	O
TdP	B_Disease	O
)	O	O
with	O	O
QT	B_Disease	O
prolongation	I_Disease	O
induced	O	O
by	O	O
dl-sotalol	O	B_Chemical
and	O	O
azimilide	B_Chemical	B_Chemical
.	O	O

The	O	O
contribution	O	O
of	O	O
transmural	O	O
dispersion	O	O
of	O	O
repolarization	O	O
(	O	O
TDR	O	O
)	O	O
to	O	O
transmural	O	O
propagation	O	O
of	O	O
EAD	O	O
and	O	O
the	O	O
maintenance	O	O
of	O	O
TdP	B_Disease	O
was	O	O
also	O	O
evaluated	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
Transmembrane	O	O
action	O	O
potentials	O	O
from	O	O
epicardium	O	O
,	O	O
midmyocardium	O	O
,	O	O
and	O	O
endocardium	O	O
were	O	O
recorded	O	O
simultaneously	O	O
,	O	O
together	O	O
with	O	O
a	O	O
transmural	O	O
ECG	O	O
,	O	O
in	O	O
arterially	O	O
perfused	O	O
canine	O	O
and	O	O
rabbit	O	O
left	O	O
ventricular	O	O
preparations	O	O
.	O	O

dl-Sotalol	O	B_Chemical
preferentially	O	O
prolonged	O	O
action	O	O
potential	O	O
duration	O	O
(	O	O
APD	O	O
)	O	O
in	O	O
M	O	O
cells	O	O
dose-dependently	O	O
(	O	O
1	O	O
to	O	O
100	O	O
micromol/L	O	O
)	O	O
,	O	O
leading	O	O
to	O	O
QT	B_Disease	O
prolongation	I_Disease	O
and	O	O
an	O	O
increase	O	O
in	O	O
TDR	O	O
.	O	O

Azimilide	B_Chemical	B_Chemical
,	O	O
however	O	O
,	O	O
significantly	O	O
prolonged	O	O
APD	O	O
and	O	O
QT	O	O
interval	O	O
at	O	O
concentrations	O	O
from	O	O
0.1	O	O
to	O	O
10	O	O
micromol/L	O	O
but	O	O
shortened	O	O
them	O	O
at	O	O
30	O	O
micromol/L.	O	O
Unlike	O	O
dl-sotalol	O	B_Chemical
,	O	O
azimilide	B_Chemical	B_Chemical
(	O	O
>	O	O
3	O	O
micromol/L	O	O
)	O	O
increased	O	O
epicardial	O	O
APD	O	O
markedly	O	O
,	O	O
causing	O	O
a	O	O
diminished	O	O
TDR	O	O
.	O	O

Although	O	O
both	O	O
dl-sotalol	O	B_Chemical
and	O	O
azimilide	B_Chemical	B_Chemical
rarely	O	O
induced	O	O
EADs	O	O
in	O	O
canine	O	O
left	O	O
ventricles	O	O
,	O	O
they	O	O
produced	O	O
frequent	O	O
EADs	O	O
in	O	O
rabbits	O	O
,	O	O
in	O	O
which	O	O
more	O	O
pronounced	O	O
QT	B_Disease	O
prolongation	I_Disease	O
was	O	O
seen	O	O
.	O	O

An	O	O
increase	O	O
in	O	O
TDR	O	O
by	O	O
dl-sotalol	O	O
facilitated	O	O
transmural	O	O
propagation	O	O
of	O	O
EADs	O	O
that	O	O
initiated	O	O
multiple	O	O
episodes	O	O
of	O	O
spontaneous	O	O
TdP	B_Disease	O
in	O	O
3	O	O
of	O	O
6	O	O
rabbit	O	O
left	O	O
ventricles	O	O
.	O	O

Of	O	O
note	O	O
,	O	O
although	O	O
azimilide	B_Chemical	B_Chemical
(	O	O
3	O	O
to	O	O
10	O	O
micromol/L	O	O
)	O	O
increased	O	O
APD	O	O
more	O	O
than	O	O
dl-sotalol	O	O
,	O	O
its	O	O
EADs	O	O
often	O	O
failed	O	O
to	O	O
propagate	O	O
transmurally	O	O
,	O	O
probably	O	O
because	O	O
of	O	O
a	O	O
diminished	O	O
TDR	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
This	O	O
study	O	O
provides	O	O
the	O	O
first	O	O
direct	O	O
evidence	O	O
from	O	O
intracellular	O	O
action	O	O
potential	O	O
recordings	O	O
that	O	O
phase	O	O
2	O	O
EAD	O	O
can	O	O
be	O	O
generated	O	O
from	O	O
intact	O	O
ventricular	O	O
wall	O	O
and	O	O
produce	O	O
a	O	O
trigger	O	O
to	O	O
initiate	O	O
the	O	O
onset	O	O
of	O	O
TdP	B_Disease	O
under	O	O
QT	B_Disease	O
prolongation	I_Disease	O
.	O	O

A	O	O
pilot	O	O
study	O	O
to	O	O
assess	O	O
the	O	O
safety	O	O
of	O	O
dobutamine	B_Chemical	B_Chemical
stress	O	O
echocardiography	O	O
in	O	O
the	O	O
emergency	O	O
department	O	O
evaluation	O	O
of	O	O
cocaine-associated	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
.	O	O

STUDY	O	O
OBJECTIVE	O	O
:	O	O
Chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
in	O	O
the	O	O
setting	O	O
of	O	O
cocaine	B_Chemical	O
use	O	O
poses	O	O
a	O	O
diagnostic	O	O
dilemma	O	O
.	O	O

Dobutamine	B_Chemical	B_Chemical
stress	O	O
echocardiography	O	O
(	O	O
DSE	O	O
)	O	O
is	O	O
a	O	O
widely	O	O
available	O	O
and	O	O
sensitive	O	O
test	O	O
for	O	O
evaluating	O	O
cardiac	O	B_Disease
ischemia	B_Disease	I_Disease
.	O	O

Because	O	O
of	O	O
the	O	O
theoretical	O	O
concern	O	O
regarding	O	O
administration	O	O
of	O	O
dobutamine	B_Chemical	B_Chemical
in	O	O
the	O	O
setting	O	O
of	O	O
cocaine	B_Chemical	O
use	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
pilot	O	O
study	O	O
to	O	O
assess	O	O
the	O	O
safety	O	O
of	O	O
DSE	O	O
in	O	O
emergency	O	O
department	O	O
patients	O	O
with	O	O
cocaine-associated	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
.	O	O

METHODS	O	O
:	O	O
A	O	O
prospective	O	O
case	O	O
series	O	O
was	O	O
conducted	O	O
in	O	O
the	O	O
intensive	O	O
diagnostic	O	O
and	O	O
treatment	O	O
unit	O	O
in	O	O
the	O	O
ED	O	O
of	O	O
an	O	O
urban	O	O
tertiary-care	O	O
teaching	O	O
hospital	O	O
.	O	O

Patients	O	O
were	O	O
eligible	O	O
for	O	O
DSE	O	O
if	O	O
they	O	O
had	O	O
used	O	O
cocaine	B_Chemical	O
within	O	O
24	O	O
hours	O	O
preceding	O	O
the	O	O
onset	O	O
of	O	O
chest	B_Disease	O
pain	I_Disease	O
and	O	O
had	O	O
a	O	O
normal	O	O
ECG	O	O
and	O	O
tropinin	O	O
I	O	O
level	O	O
.	O	O

Patients	O	O
exhibiting	O	O
signs	O	O
of	O	O
continuing	O	O
cocaine	B_Chemical	O
toxicity	B_Disease	O
were	O	O
excluded	O	O
from	O	O
the	O	O
study	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
serial	O	O
testing	O	O
after	O	O
the	O	O
DSE	O	O
testing	O	O
in	O	O
the	O	O
intensive	O	O
diagnostic	O	O
and	O	O
treatment	O	O
unit	O	O
.	O	O

RESULTS	O	O
:	O	O
Twenty-four	O	O
patients	O	O
were	O	O
enrolled	O	O
.	O	O

Two	O	O
patients	O	O
had	O	O
inadequate	O	O
resting	O	O
images	O	O
,	O	O
one	O	O
DSE	O	O
was	O	O
terminated	O	O
because	O	O
of	O	O
inferior	O	O
hypokinesis	B_Disease	O
,	O	O
another	O	O
DSE	O	O
was	O	O
terminated	O	O
because	O	O
of	O	O
a	O	O
rate-related	O	O
atrial	O	O
conduction	O	O
deficit	O	O
,	O	O
and	O	O
1	O	O
patient	O	O
did	O	O
not	O	O
reach	O	O
the	O	O
target	O	O
heart	O	O
rate	O	O
.	O	O

Thus	O	O
,	O	O
19	O	O
patients	O	O
completed	O	O
a	O	O
DSE	O	O
and	O	O
reached	O	O
their	O	O
target	O	O
heart	O	O
rates	O	O
.	O	O

None	O	O
of	O	O
the	O	O
patients	O	O
experienced	O	O
signs	O	O
of	O	O
exaggerated	O	O
adrenergic	O	O
response	O	O
,	O	O
which	O	O
was	O	O
defined	O	O
as	O	O
a	O	O
systolic	O	O
blood	O	O
pressure	O	O
of	O	O
greater	O	O
than	O	O
200	O	O
mm	O	O
Hg	O	O
or	O	O
the	O	O
occurrence	O	O
of	O	O
tachydysrhythmias	B_Disease	B_Disease
(	O	O
excluding	O	O
sinus	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
)	O	O
.	O	O

Further	O	O
suggesting	O	O
lack	O	O
of	O	O
exaggerated	O	O
adrenergic	O	O
response	O	O
,	O	O
13	O	O
(	O	O
65	O	O
%	O	O
)	O	O
of	O	O
20	O	O
patients	O	O
required	O	O
supplemental	O	O
atropine	B_Chemical	O
to	O	O
reach	O	O
their	O	O
target	O	O
heart	O	O
rates	O	O
.	O	O

CONCLUSION	O	O
:	O	O
No	O	O
exaggerated	O	O
adrenergic	O	O
response	O	O
was	O	O
detected	O	O
when	O	O
dobutamine	B_Chemical	B_Chemical
was	O	O
administered	O	O
to	O	O
patients	O	O
with	O	O
cocaine-related	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
.	O	O

Prenatal	O	O
cocaine	B_Chemical	O
exposure	O	O
and	O	O
cranial	O	O
sonographic	O	O
findings	O	O
in	O	O
preterm	B_Disease	O
infants	I_Disease	O
.	O	O

PURPOSE	O	O
:	O	O
Prenatal	O	O
cocaine	B_Chemical	O
exposure	O	O
has	O	O
been	O	O
linked	O	O
with	O	O
subependymal	O	O
hemorrhage	B_Disease	O
and	O	O
the	O	O
formation	O	O
of	O	O
cysts	B_Disease	O
that	O	O
are	O	O
detectable	O	O
on	O	O
cranial	O	O
sonography	O	O
in	O	O
neonates	O	O
born	O	O
at	O	O
term	O	O
.	O	O

We	O	O
sought	O	O
to	O	O
determine	O	O
if	O	O
prenatal	O	O
cocaine	B_Chemical	O
exposure	O	O
increases	O	O
the	O	O
incidence	O	O
of	O	O
subependymal	B_Disease	O
cysts	B_Disease	O
in	O	O
preterm	B_Disease	O
infants	I_Disease	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
retrospectively	O	O
reviewed	O	O
the	O	O
medical	O	O
records	O	O
and	O	O
cranial	O	O
sonograms	O	O
obtained	O	O
during	O	O
a	O	O
1-year	O	O
period	O	O
on	O	O
122	O	O
premature	B_Disease	O
(	I_Disease	O
<	I_Disease	O
36	I_Disease	O
weeks	I_Disease	O
of	I_Disease	O
gestation	I_Disease	O
)	I_Disease	O
infants	I_Disease	O
.	O	O

Infants	O	O
were	O	O
categorized	O	O
into	O	O
1	O	O
of	O	O
2	O	O
groups	O	O
:	O	O
those	O	O
exposed	O	O
to	O	O
cocaine	B_Chemical	O
and	O	O
those	O	O
not	O	O
exposed	O	O
to	O	O
cocaine	B_Chemical	O
.	O	O

Infants	O	O
were	O	O
assigned	O	O
to	O	O
the	O	O
cocaine-exposed	O	O
group	O	O
if	O	O
there	O	O
was	O	O
a	O	O
maternal	O	O
history	O	O
of	O	O
cocaine	B_Disease	B_Disease
abuse	I_Disease	I_Disease
during	O	O
pregnancy	O	O
or	O	O
if	O	O
maternal	O	O
or	O	O
neonatal	O	O
urine	O	O
toxicology	O	O
results	O	O
were	O	O
positive	O	O
at	O	O
the	O	O
time	O	O
of	O	O
delivery	O	O
.	O	O

RESULTS	O	O
:	O	O
Five	O	O
of	O	O
the	O	O
122	O	O
infants	O	O
were	O	O
excluded	O	O
from	O	O
the	O	O
study	O	O
because	O	O
of	O	O
insufficient	O	O
medical	O	O
and	O	O
drug	O	O
histories	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
subependymal	B_Disease	O
cysts	B_Disease	O
in	O	O
the	O	O
117	O	O
remaining	O	O
infants	O	O
was	O	O
14	O	O
%	O	O
(	O	O
16	O	O
of	O	O
117	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
subependymal	B_Disease	O
cysts	B_Disease	O
in	O	O
infants	O	O
exposed	O	O
to	O	O
cocaine	B_Chemical	O
prenatally	O	O
was	O	O
44	O	O
%	O	O
(	O	O
8	O	O
of	O	O
18	O	O
)	O	O
compared	O	O
with	O	O
8	O	O
%	O	O
(	O	O
8	O	O
of	O	O
99	O	O
)	O	O
in	O	O
the	O	O
unexposed	O	O
group	O	O
(	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
We	O	O
found	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
subependymal	B_Disease	O
cyst	B_Disease	O
formation	O	O
in	O	O
preterm	B_Disease	O
infants	I_Disease	O
who	O	O
were	O	O
exposed	O	O
to	O	O
cocaine	B_Chemical	O
prenatally	O	O
.	O	O

This	O	O
result	O	O
is	O	O
consistent	O	O
with	O	O
results	O	O
of	O	O
similar	O	O
studies	O	O
in	O	O
term	O	O
infants	O	O
.	O	O

Thalidomide	B_Chemical	O
neuropathy	B_Disease	O
in	O	O
patients	O	O
treated	O	O
for	O	O
metastatic	O	O
prostate	B_Disease	B_Disease
cancer	I_Disease	I_Disease
.	O	O

We	O	O
prospectively	O	O
evaluated	O	O
thalidomide-induced	O	O
neuropathy	B_Disease	O
using	O	O
electrodiagnostic	O	O
studies	O	O
.	O	O

Sixty-seven	O	O
men	O	O
with	O	O
metastatic	O	O
androgen-independent	O	O
prostate	B_Disease	B_Disease
cancer	I_Disease	I_Disease
in	O	O
an	O	O
open-label	O	O
trial	O	O
of	O	O
oral	O	O
thalidomide	B_Chemical	O
underwent	O	O
neurologic	O	O
examinations	O	O
and	O	O
nerve	O	O
conduction	O	O
studies	O	O
(	O	O
NCS	O	O
)	O	O
prior	O	O
to	O	O
and	O	O
at	O	O
3-month	O	O
intervals	O	O
during	O	O
treatment	O	O
.	O	O

NCS	O	O
included	O	O
recording	O	O
of	O	O
sensory	O	O
nerve	O	O
action	O	O
potentials	O	O
(	O	O
SNAPs	O	O
)	O	O
from	O	O
median	O	O
,	O	O
radial	O	O
,	O	O
ulnar	O	O
,	O	O
and	O	O
sural	O	O
nerves	O	O
.	O	O

SNAP	O	O
amplitudes	O	O
for	O	O
each	O	O
nerve	O	O
were	O	O
expressed	O	O
as	O	O
the	O	O
percentage	O	O
of	O	O
its	O	O
baseline	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
of	O	O
the	O	O
four	O	O
was	O	O
termed	O	O
the	O	O
SNAP	O	O
index	O	O
.	O	O

A	O	O
40	O	O
%	O	O
decline	O	O
in	O	O
the	O	O
SNAP	O	O
index	O	O
was	O	O
considered	O	O
clinically	O	O
significant	O	O
.	O	O

Thalidomide	B_Chemical	O
was	O	O
discontinued	O	O
in	O	O
55	O	O
patients	O	O
for	O	O
lack	O	O
of	O	O
therapeutic	O	O
response	O	O
.	O	O

Of	O	O
67	O	O
patients	O	O
initially	O	O
enrolled	O	O
,	O	O
24	O	O
remained	O	O
on	O	O
thalidomide	B_Chemical	O
for	O	O
3	O	O
months	O	O
,	O	O
8	O	O
remained	O	O
at	O	O
6	O	O
months	O	O
,	O	O
and	O	O
3	O	O
remained	O	O
at	O	O
9	O	O
months	O	O
.	O	O

Six	O	O
patients	O	O
developed	O	O
neuropathy	B_Disease	O
.	O	O

Clinical	O	O
symptoms	O	O
and	O	O
a	O	O
decline	O	O
in	O	O
the	O	O
SNAP	O	O
index	O	O
occurred	O	O
concurrently	O	O
.	O	O

Older	O	O
age	O	O
and	O	O
cumulative	O	O
dose	O	O
were	O	O
possible	O	O
contributing	O	O
factors	O	O
.	O	O

Neuropathy	B_Disease	O
may	O	O
thus	O	O
be	O	O
a	O	O
common	O	O
complication	O	O
of	O	O
thalidomide	B_Chemical	O
in	O	O
older	O	O
patients	O	O
.	O	O

The	O	O
SNAP	O	O
index	O	O
can	O	O
be	O	O
used	O	O
to	O	O
monitor	O	O
peripheral	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
,	O	O
but	O	O
not	O	O
for	O	O
early	O	O
detection	O	O
.	O	O

Overexpression	O	O
of	O	O
copper/zinc-superoxide	O	O
dismutase	O	O
protects	O	O
from	O	O
kanamycin-induced	O	O
hearing	B_Disease	B_Disease
loss	I_Disease	I_Disease
.	O	O

The	O	O
participation	O	O
of	O	O
reactive	O	O
oxygen	B_Chemical	O
species	O	O
in	O	O
aminoglycoside-induced	O	O
ototoxicity	B_Disease	B_Disease
has	O	O
been	O	O
deduced	O	O
from	O	O
observations	O	O
that	O	O
aminoglycoside-iron	O	O
complexes	O	O
catalyze	O	O
the	O	O
formation	O	O
of	O	O
superoxide	B_Chemical	O
radicals	O	O
in	O	O
vitro	O	O
and	O	O
that	O	O
antioxidants	O	O
attenuate	O	O
ototoxicity	B_Disease	B_Disease
in	O	O
vivo	O	O
.	O	O

We	O	O
therefore	O	O
hypothesized	O	O
that	O	O
overexpression	O	O
of	O	O
Cu/Zn-superoxide	O	O
dismutase	O	O
(	O	O
h-SOD1	O	O
)	O	O
should	O	O
protect	O	O
transgenic	O	O
mice	O	O
from	O	O
ototoxicity	B_Disease	B_Disease
.	O	O

Immunocytochemistry	O	O
confirmed	O	O
expression	O	O
of	O	O
h-SOD1	O	O
in	O	O
inner	O	O
ear	O	O
tissues	O	O
of	O	O
transgenic	O	O
C57BL/6-TgN[SOD1]3Cje	O	O
mice	O	O
.	O	O

Transgenic	O	O
and	O	O
nontransgenic	O	O
littermates	O	O
received	O	O
kanamycin	B_Chemical	O
(	O	O
400	O	O
mg/kg	O	O
body	O	O
weight/day	O	O
)	O	O
for	O	O
10	O	O
days	O	O
beginning	O	O
on	O	O
day	O	O
10	O	O
after	O	O
birth	O	O
.	O	O

Auditory	O	O
thresholds	O	O
were	O	O
tested	O	O
by	O	O
evoked	O	O
auditory	O	O
brain	O	O
stem	O	O
responses	O	O
at	O	O
1	O	O
month	O	O
after	O	O
birth	O	O
.	O	O

In	O	O
nontransgenic	O	O
animals	O	O
,	O	O
the	O	O
threshold	O	O
in	O	O
the	O	O
kanamycin-treated	O	O
group	O	O
was	O	O
45	O	O
-	O	O
50	O	O
dB	O	O
higher	O	O
than	O	O
in	O	O
saline-injected	O	O
controls	O	O
.	O	O

In	O	O
the	O	O
transgenic	O	O
group	O	O
,	O	O
kanamycin	B_Chemical	O
increased	O	O
the	O	O
threshold	O	O
by	O	O
only	O	O
15	O	O
dB	O	O
over	O	O
the	O	O
respective	O	O
controls	O	O
.	O	O

The	O	O
effects	O	O
were	O	O
similar	O	O
at	O	O
12	O	O
and	O	O
24	O	O
kHz	O	O
.	O	O

The	O	O
protection	O	O
by	O	O
overexpression	O	O
of	O	O
superoxide	B_Chemical	O
dismutase	O	O
supports	O	O
the	O	O
hypothesis	O	O
that	O	O
oxidant	O	O
stress	O	O
plays	O	O
a	O	O
significant	O	O
role	O	O
in	O	O
aminoglycoside-induced	O	O
ototoxicity	B_Disease	B_Disease
.	O	O

The	O	O
results	O	O
also	O	O
suggest	O	O
transgenic	O	O
animals	O	O
as	O	O
suitable	O	O
models	O	O
to	O	O
investigate	O	O
the	O	O
underlying	O	O
mechanisms	O	O
and	O	O
possible	O	O
strategies	O	O
for	O	O
prevention	O	O
.	O	O

Fatty	B_Disease	O
liver	I_Disease	O
induced	O	O
by	O	O
tetracycline	B_Chemical	O
in	O	O
the	O	O
rat	O	O
.	O	O

Dose-response	O	O
relationships	O	O
and	O	O
effect	O	O
of	O	O
sex	O	O
.	O	O

Dose-response	O	O
relationships	O	O
,	O	O
biochemical	O	O
mechanisms	O	O
,	O	O
and	O	O
sex	O	O
differences	O	O
in	O	O
the	O	O
experimental	O	O
fatty	B_Disease	O
liver	I_Disease	O
induced	O	O
by	O	O
tetracycline	B_Chemical	O
were	O	O
studied	O	O
in	O	O
the	O	O
intact	O	O
rat	O	O
and	O	O
with	O	O
the	O	O
isolated	O	O
perfused	O	O
rat	O	O
liver	O	O
in	O	O
vitro	O	O
.	O	O

In	O	O
the	O	O
intact	O	O
male	O	O
and	O	O
female	O	O
rat	O	O
,	O	O
no	O	O
direct	O	O
relationship	O	O
was	O	O
observed	O	O
between	O	O
dose	O	O
of	O	O
tetracycline	B_Chemical	O
and	O	O
hepatic	O	O
accumulation	O	O
of	O	O
triglyceride	B_Chemical	O
.	O	O

With	O	O
provision	O	O
of	O	O
adequate	O	O
oleic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
as	O	O
a	O	O
substrate	O	O
for	O	O
the	O	O
isolated	O	O
perfused	O	O
liver	O	O
,	O	O
a	O	O
direct	O	O
relationship	O	O
was	O	O
observed	O	O
between	O	O
dose	O	O
of	O	O
tetracycline	B_Chemical	O
and	O	O
both	O	O
accumulation	O	O
of	O	O
triglyceride	B_Chemical	O
in	O	O
the	O	O
liver	O	O
and	O	O
depression	B_Disease	O
of	O	O
output	O	O
of	O	O
triglyceride	B_Chemical	O
by	O	O
livers	O	O
from	O	O
male	O	O
and	O	O
female	O	O
rats	O	O
.	O	O

Marked	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
female	O	O
and	O	O
male	O	O
rats	O	O
with	O	O
regard	O	O
to	O	O
base	O	O
line	O	O
(	O	O
control	O	O
)	O	O
hepatic	O	O
concentration	O	O
of	O	O
triglyceride	B_Chemical	O
and	O	O
output	O	O
of	O	O
triglyceride	B_Chemical	O
.	O	O

Accumulation	O	O
of	O	O
hepatic	O	B_Chemical
triglyceride	B_Chemical	I_Chemical
,	O	O
as	O	O
a	O	O
per	O	O
cent	O	O
of	O	O
control	O	O
values	O	O
,	O	O
in	O	O
response	O	O
to	O	O
graded	O	O
doses	O	O
of	O	O
tetracycline	B_Chemical	O
,	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
male	O	O
,	O	O
female	O	O
and	O	O
pregnant	O	O
rat	O	O
livers	O	O
.	O	O

However	O	O
,	O	O
livers	O	O
from	O	O
female	O	O
,	O	O
and	O	O
especially	O	O
pregnant	O	O
female	O	O
rats	O	O
,	O	O
were	O	O
strikingly	O	O
resistant	O	O
to	O	O
the	O	O
effects	O	O
of	O	O
tetracycline	B_Chemical	O
on	O	O
depression	B_Disease	O
of	O	O
output	O	O
of	O	O
triglyceride	B_Chemical	O
under	O	O
these	O	O
experimental	O	O
conditions	O	O
.	O	O

These	O	O
differences	O	O
between	O	O
the	O	O
sexes	O	O
could	O	O
not	O	O
be	O	O
related	O	O
to	O	O
altered	O	O
disposition	O	O
of	O	O
tetracycline	B_Chemical	O
or	O	O
altered	O	O
uptake	O	O
of	O	O
oleic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
.	O	O

Depressed	O	O
hepatic	O	O
secretion	O	O
of	O	O
triglyceride	B_Chemical	O
accounted	O	O
only	O	O
for	O	O
30	O	O
to	O	O
50	O	O
%	O	O
of	O	O
accumulated	O	O
hepatic	O	O
triglyceride	B_Chemical	O
,	O	O
indicating	O	O
that	O	O
additional	O	O
mechanisms	O	O
must	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
production	O	O
of	O	O
the	O	O
triglyceride-rich	O	O
fatty	B_Disease	O
liver	I_Disease	O
in	O	O
response	O	O
to	O	O
tetracycline	B_Chemical	O
.	O	O

Prednisone	B_Chemical	O
induces	O	O
anxiety	B_Disease	O
and	O	O
glial	O	O
cerebral	O	O
changes	O	O
in	O	O
rats	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
assess	O	O
whether	O	O
prednisone	B_Chemical	O
(	O	O
PDN	B_Chemical	O
)	O	O
produces	O	O
anxiety	B_Disease	O
and/or	O	O
cerebral	O	O
glial	O	O
changes	O	O
in	O	O
rats	O	O
.	O	O

METHODS	O	O
:	O	O
Male	O	O
Wistar	O	O
rats	O	O
were	O	O
studied	O	O
and	O	O
3	O	O
groups	O	O
were	O	O
formed	O	O
(	O	O
8	O	O
rats	O	O
per	O	O
group	O	O
)	O	O
.	O	O

The	O	O
moderate-dose	O	O
group	O	O
received	O	O
5	O	O
mg/kg/day	O	O
PDN	B_Chemical	O
released	O	O
from	O	O
a	O	O
subcutaneous	O	O
implant	O	O
.	O	O

In	O	O
the	O	O
high-dose	O	O
group	O	O
,	O	O
implants	O	O
containing	O	O
PDN	B_Chemical	O
equivalent	O	O
to	O	O
60	O	O
mg/kg/day	O	O
were	O	O
applied	O	O
.	O	O

In	O	O
the	O	O
control	O	O
group	O	O
implants	O	O
contained	O	O
no	O	O
PDN	B_Chemical	O
.	O	O

Anxiety	B_Disease	O
was	O	O
assessed	O	O
using	O	O
an	O	O
open	O	O
field	O	O
and	O	O
elevated	O	O
plus-maze	O	O
devices	O	O
.	O	O

The	O	O
number	O	O
of	O	O
cells	O	O
and	O	O
cytoplasmic	O	O
transformation	O	O
of	O	O
astrocytes	O	O
and	O	O
microglia	O	O
cells	O	O
were	O	O
assessed	O	O
by	O	O
immunohistochemical	O	O
analyses	O	O
.	O	O

RESULTS	O	O
:	O	O
Anxiety	B_Disease	O
was	O	O
documented	O	O
in	O	O
both	O	O
groups	O	O
of	O	O
PDN	B_Chemical	O
treated	O	O
rats	O	O
compared	O	O
with	O	O
controls	O	O
.	O	O

The	O	O
magnitude	O	O
of	O	O
transformation	O	O
of	O	O
the	O	O
microglia	O	O
assessed	O	O
by	O	O
the	O	O
number	O	O
of	O	O
intersections	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
PDN	B_Chemical	O
groups	O	O
than	O	O
in	O	O
controls	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
(	O	O
moderate-dose	O	O
,	O	O
24.1	O	O
;	O	O
high-dose	O	O
,	O	O
23.6	O	O
;	O	O
controls	O	O
18.7	O	O
;	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
and	O	O
striatum	O	O
(	O	O
moderate-dose	O	O
25.6	O	O
;	O	O
high-dose	O	O
26.3	O	O
;	O	O
controls	O	O
18.9	O	O
;	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
,	O	O
but	O	O
not	O	O
in	O	O
hippocampus	O	O
.	O	O

The	O	O
number	O	O
of	O	O
stained	O	O
microglia	O	O
cells	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
PDN	B_Chemical	O
treated	O	O
groups	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
than	O	O
in	O	O
controls	O	O
(	O	O
moderate-dose	O	O
,	O	O
29.1	O	O
;	O	O
high-dose	O	O
,	O	O
28.4	O	O
;	O	O
control	O	O
,	O	O
17.7	O	O
cells	O	O
per	O	O
field	O	O
;	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Stained	O	O
microglia	O	O
cells	O	O
were	O	O
significantly	O	O
more	O	O
numerous	O	O
striatum	O	O
and	O	O
hippocampus	O	O
in	O	O
the	O	O
high-dose	O	O
group	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Subacute	O	O
exposure	O	O
to	O	O
PDN	B_Chemical	O
induced	O	O
anxiety	B_Disease	O
and	O	O
reactivity	O	O
of	O	O
microglia	O	O
.	O	O

The	O	O
relevance	O	O
of	O	O
these	O	O
features	O	O
for	O	O
patients	O	O
using	O	O
PDN	B_Chemical	O
remains	O	O
to	O	O
be	O	O
elucidated	O	O
.	O	O

Phase	O	O
II	O	O
study	O	O
of	O	O
carboplatin	B_Chemical	B_Chemical
and	O	O
liposomal	O	B_Chemical
doxorubicin	B_Chemical	I_Chemical
in	O	O
patients	O	O
with	O	O
recurrent	O	O
squamous	B_Disease	O
cell	I_Disease	O
carcinoma	B_Disease	O
of	I_Disease	O
the	I_Disease	O
cervix	I_Disease	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
activity	O	O
of	O	O
the	O	O
combination	O	O
of	O	O
carboplatin	B_Chemical	B_Chemical
and	O	O
liposomal	O	O
doxorubicin	B_Chemical	O
was	O	O
tested	O	O
in	O	O
a	O	O
Phase	O	O
II	O	O
study	O	O
of	O	O
patients	O	O
with	O	O
recurrent	O	O
cervical	B_Disease	O
carcinoma	I_Disease	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
combination	O	O
of	O	O
carboplatin	B_Chemical	B_Chemical
(	O	O
area	O	O
under	O	O
the	O	O
concentration	O	O
curve	O	O
[	O	O
AUC	O	O
]	O	O
,	O	O
5	O	O
)	O	O
and	O	O
liposomal	O	B_Chemical
doxorubicin	B_Chemical	I_Chemical
(	O	O
Doxil	B_Chemical	B_Chemical
;	O	O
starting	O	O
dose	O	O
,	O	O
40	O	O
mg/m(2	O	O
)	O	O
)	O	O
was	O	O
administered	O	O
intravenously	O	O
every	O	O
28	O	O
days	O	O
to	O	O
37	O	O
patients	O	O
with	O	O
recurrent	O	O
squamous	B_Disease	O
cell	I_Disease	O
cervical	B_Disease	B_Disease
carcinoma	I_Disease	I_Disease
to	O	O
determine	O	O
antitumor	O	O
activity	O	O
and	O	O
toxicity	B_Disease	O
profile	O	O
.	O	O

RESULTS	O	O
:	O	O
Twenty-nine	O	O
patients	O	O
were	O	O
assessable	O	O
for	O	O
response	O	O
,	O	O
and	O	O
35	O	O
patients	O	O
were	O	O
assessable	O	O
for	O	O
toxicity	B_Disease	O
.	O	O

The	O	O
overall	O	O
response	O	O
rate	O	O
was	O	O
38	O	O
%	O	O
,	O	O
the	O	O
median	O	O
time	O	O
to	O	O
response	O	O
was	O	O
10	O	O
weeks	O	O
,	O	O
the	O	O
median	O	O
duration	O	O
of	O	O
response	O	O
was	O	O
26	O	O
weeks	O	O
,	O	O
and	O	O
the	O	O
median	O	O
survival	O	O
was	O	O
37	O	O
weeks	O	O
.	O	O

The	O	O
main	O	O
toxic	O	O
effect	O	O
was	O	O
myelosuppression	B_Disease	B_Disease
,	O	O
with	O	O
Grade	O	O
3	O	O
and	O	O
4	O	O
neutropenia	B_Disease	O
in	O	O
16	O	O
patients	O	O
,	O	O
anemia	B_Disease	O
in	O	O
12	O	O
patients	O	O
,	O	O
thrombocytopenia	B_Disease	O
in	O	O
11	O	O
patients	O	O
,	O	O
and	O	O
neutropenic	B_Disease	B_Disease
fever	B_Disease	I_Disease
in	O	O
3	O	O
patients	O	O
.	O	O

Four	O	O
patients	O	O
had	O	O
five	O	O
infusion-related	O	O
reactions	O	O
during	O	O
the	O	O
infusion	O	O
of	O	O
liposomal	O	B_Chemical
doxorubicin	B_Chemical	I_Chemical
,	O	O
leading	O	O
to	O	O
treatment	O	O
discontinuation	O	O
in	O	O
three	O	O
patients	O	O
.	O	O

Grade	O	O
>	O	O
or	O	O
=	O	O
2	O	O
nonhematologic	O	O
toxicity	B_Disease	O
included	O	O
nausea	B_Disease	O
in	O	O
17	O	O
patients	O	O
,	O	O
emesis	B_Disease	O
in	O	O
14	O	O
patients	O	O
,	O	O
fatigue	B_Disease	O
in	O	O
9	O	O
patients	O	O
,	O	O
mucositis	B_Disease	B_Disease
and/or	O	O
stomatitis	B_Disease	O
in	O	O
8	O	O
patients	O	O
,	O	O
constipation	B_Disease	O
in	O	O
6	O	O
patients	O	O
,	O	O
weight	B_Disease	B_Disease
loss	I_Disease	I_Disease
in	O	O
5	O	O
patients	O	O
,	O	O
hand-foot	B_Disease	B_Disease
syndrome	I_Disease	I_Disease
in	O	O
2	O	O
patients	O	O
,	O	O
and	O	O
skin	B_Disease	O
reactions	I_Disease	O
in	O	O
3	O	O
patients	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
combination	O	O
of	O	O
carboplatin	B_Chemical	B_Chemical
and	O	O
liposomal	O	O
doxorubicin	B_Chemical	O
has	O	O
modest	O	O
activity	O	O
in	O	O
patients	O	O
with	O	O
recurrent	O	O
cervical	B_Disease	O
carcinoma	I_Disease	O
.	O	O

Antimicrobial-induced	O	O
mania	B_Disease	O
(	O	O
antibiomania	B_Disease	O
):	O	O
a	O	O
review	O	O
of	O	O
spontaneous	O	O
reports	O	O
.	O	O

The	O	O
authors	O	O
reviewed	O	O
reported	O	O
cases	O	O
of	O	O
antibiotic-induced	O	O
manic	B_Disease	O
episodes	O	O
by	O	O
means	O	O
of	O	O
a	O	O
MEDLINE	O	O
and	O	O
PsychLit	O	O
search	O	O
for	O	O
reports	O	O
of	O	O
antibiotic-induced	O	O
mania	B_Disease	O
.	O	O

Unpublished	O	O
reports	O	O
were	O	O
requested	O	O
from	O	O
the	O	O
World	O	O
Health	O	O
Organization	O	O
(	O	O
WHO	O	O
)	O	O
and	O	O
the	O	O
Food	O	O
and	O	O
Drug	O	O
Administration	O	O
(	O	O
FDA	O	O
)	O	O
.	O	O

Twenty-one	O	O
reports	O	O
of	O	O
antimicrobial-induced	O	O
mania	B_Disease	O
were	O	O
found	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

There	O	O
were	O	O
6	O	O
cases	O	O
implicating	O	O
clarithromycin	B_Chemical	B_Chemical
,	O	O
13	O	O
implicating	O	O
isoniazid	B_Chemical	O
,	O	O
and	O	O
1	O	O
case	O	O
each	O	O
implicating	O	O
erythromycin	B_Chemical	O
and	O	O
amoxicillin	B_Chemical	O
.	O	O

The	O	O
WHO	O	O
reported	O	O
82	O	O
cases	O	O
.	O	O

Of	O	O
these	O	O
,	O	O
clarithromycin	B_Chemical	B_Chemical
was	O	O
implicated	O	O
in	O	O
23	O	O
(	O	O
27.6	O	O
%	O	O
)	O	O
cases	O	O
,	O	O
ciprofloxacin	B_Chemical	O
in	O	O
12	O	O
(	O	O
14.4	O	O
%	O	O
)	O	O
cases	O	O
,	O	O
and	O	O
ofloxacin	B_Chemical	B_Chemical
in	O	O
10	O	O
(	O	O
12	O	O
%	O	O
)	O	O
cases	O	O
.	O	O

Cotrimoxazole	B_Chemical	B_Chemical
,	O	O
metronidazole	B_Chemical	O
,	O	O
and	O	O
erythromycin	B_Chemical	O
were	O	O
involved	O	O
in	O	O
15	O	O
reported	O	O
manic	B_Disease	O
episodes	O	O
.	O	O

Cases	O	O
reported	O	O
by	O	O
the	O	O
FDA	O	O
showed	O	O
clarithromycin	B_Chemical	B_Chemical
and	O	O
ciprofloxacin	B_Chemical	O
to	O	O
be	O	O
the	O	O
most	O	O
frequently	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
mania	B_Disease	O
.	O	O

Statistical	O	O
analysis	O	O
of	O	O
the	O	O
data	O	O
would	O	O
not	O	O
have	O	O
demonstrated	O	O
a	O	O
significant	O	O
statistical	O	O
correlative	O	O
risk	O	O
and	O	O
was	O	O
therefore	O	O
not	O	O
undertaken	O	O
.	O	O

Patients	O	O
have	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
developing	O	O
mania	B_Disease	O
while	O	O
being	O	O
treated	O	O
with	O	O
antimicrobials	O	O
.	O	O

Although	O	O
this	O	O
is	O	O
not	O	O
a	O	O
statistically	O	O
significant	O	O
risk	O	O
,	O	O
physicians	O	O
must	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
effect	O	O
and	O	O
reversibility	O	O
.	O	O

Further	O	O
research	O	O
clearly	O	O
is	O	O
required	O	O
to	O	O
determine	O	O
the	O	O
incidence	O	O
of	O	O
antimicrobial-induced	O	O
mania	B_Disease	O
,	O	O
the	O	O
relative	O	O
risk	O	O
factors	O	O
of	O	O
developing	O	O
an	O	O
antimicrobial-induced	O	O
manic	B_Disease	O
episode	O	O
among	O	O
various	O	O
demographic	O	O
populations	O	O
,	O	O
and	O	O
the	O	O
incidence	O	O
of	O	O
patients	O	O
who	O	O
continue	O	O
to	O	O
have	O	O
persistent	O	O
affective	O	O
disorders	O	O
once	O	O
the	O	O
initial	O	O
episode	O	O
,	O	O
which	O	O
occurs	O	O
while	O	O
the	O	O
patient	O	O
is	O	O
taking	O	O
antibiotics	O	O
,	O	O
subsides	O	O
.	O	O

The	O	O
authors	O	O
elected	O	O
to	O	O
name	O	O
this	O	O
syndrome	O	O
"	O	O
antibiomania	B_Disease	O
.	O	O
"	O	O

Levodopa-induced	O	O
ocular	B_Disease	B_Disease
dyskinesias	I_Disease	I_Disease
in	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
.	O	O

Levodopa-induced	O	O
ocular	B_Disease	B_Disease
dyskinesias	I_Disease	I_Disease
are	O	O
very	O	O
uncommon	O	O
.	O	O

Usually	O	O
they	O	O
occur	O	O
simultaneously	O	O
with	O	O
limb	O	O
peak-dose	O	O
choreatic	B_Disease	O
dyskinesias	I_Disease	O
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
patient	O	O
with	O	O
leftward	O	O
and	O	O
upward	O	O
deviations	O	O
of	O	O
gaze	O	O
during	O	O
the	O	O
peak	O	O
effect	O	O
of	O	O
levodopa	B_Chemical	O
,	O	O
and	O	O
hypothesize	O	O
that	O	O
a	O	O
severe	O	O
dopaminergic	O	O
denervation	O	O
in	O	O
the	O	O
caudate	O	O
nucleus	O	O
is	O	O
needed	O	O
for	O	O
the	O	O
appearance	O	O
of	O	O
these	O	O
levodopa-induce	O	O
ocular	B_Disease	B_Disease
dyskinesias	I_Disease	I_Disease
.	O	O

A	O	O
comparison	O	O
of	O	O
glyceryl	B_Chemical	B_Chemical
trinitrate	I_Chemical	I_Chemical
with	O	O
diclofenac	B_Chemical	B_Chemical
for	O	O
the	O	O
treatment	O	O
of	O	O
primary	O	B_Disease
dysmenorrhea	B_Disease	I_Disease
:	O	O
an	O	O
open	O	O
,	O	O
randomized	O	O
,	O	O
cross-over	O	O
trial	O	O
.	O	O

Primary	O	B_Disease
dysmenorrhea	B_Disease	I_Disease
is	O	O
a	O	O
syndrome	O	O
characterized	O	O
by	O	O
painful	O	O
uterine	O	O
contractility	O	O
caused	O	O
by	O	O
a	O	O
hypersecretion	O	O
of	O	O
endometrial	O	O
prostaglandins	B_Chemical	O
;	O	O
non-steroidal	O	O
anti-inflammatory	O	O
drugs	O	O
are	O	O
the	O	O
first	O	O
choice	O	O
for	O	O
its	O	O
treatment	O	O
.	O	O

However	O	O
,	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
studies	O	O
have	O	O
demonstrated	O	O
that	O	O
myometrial	O	O
cells	O	O
are	O	O
also	O	O
targets	O	O
of	O	O
the	O	O
relaxant	O	O
effects	O	O
of	O	O
nitric	B_Chemical	O
oxide	I_Chemical	O
(	O	O
NO	B_Chemical	O
)	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
efficacy	O	O
of	O	O
glyceryl	B_Chemical	B_Chemical
trinitrate	I_Chemical	I_Chemical
(	O	O
GTN	B_Chemical	O
)	O	O
,	O	O
an	O	O
NO	B_Chemical	O
donor	O	O
,	O	O
in	O	O
the	O	O
resolution	O	O
of	O	O
primary	O	O
dysmenorrhea	B_Disease	O
in	O	O
comparison	O	O
with	O	O
diclofenac	B_Chemical	B_Chemical
(	O	O
DCF	B_Chemical	O
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
24	O	O
patients	O	O
with	O	O
the	O	O
diagnosis	O	O
of	O	O
severe	O	O
primary	O	B_Disease
dysmenorrhea	B_Disease	I_Disease
were	O	O
studied	O	O
during	O	O
two	O	O
consecutive	O	O
menstrual	O	O
cycles	O	O
.	O	O

In	O	O
an	O	O
open	O	O
,	O	O
cross-over	O	O
,	O	O
controlled	O	O
design	O	O
,	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
DCF	B_Chemical	O
per	O	O
os	O	O
or	O	O
GTN	B_Chemical	O
patches	O	O
the	O	O
first	O	O
days	O	O
of	O	O
menses	O	O
,	O	O
when	O	O
menstrual	O	O
cramps	O	O
became	O	O
unendurable	O	O
.	O	O

In	O	O
the	O	O
subsequent	O	O
cycle	O	O
the	O	O
other	O	O
treatment	O	O
was	O	O
used	O	O
.	O	O

Patients	O	O
received	O	O
up	O	O
to	O	O
3	O	O
doses/day	O	O
of	O	O
50	O	O
mg	O	O
DCF	B_Chemical	O
or	O	O
2.5	O	O
mg/24	O	O
h	O	O
transdermal	O	O
GTN	B_Chemical	O
for	O	O
the	O	O
first	O	O
3	O	O
days	O	O
of	O	O
the	O	O
cycle	O	O
,	O	O
according	O	O
to	O	O
their	O	O
needs	O	O
.	O	O

The	O	O
participants	O	O
recorded	O	O
menstrual	O	B_Disease
symptoms	O	I_Disease
and	O	O
possible	O	O
side-effects	O	O
at	O	O
different	O	O
times	O	O
(	O	O
0	O	O
,	O	O
30	O	O
,	O	O
60	O	O
,	O	O
120	O	O
minutes	O	O
)	O	O
after	O	O
the	O	O
first	O	O
dose	O	O
of	O	O
medication	O	O
on	O	O
the	O	O
first	O	O
day	O	O
of	O	O
the	O	O
cycle	O	O
,	O	O
with	O	O
both	O	O
drugs	O	O
.	O	O

The	O	O
difference	O	O
in	O	O
pain	B_Disease	O
intensity	O	O
score	O	O
(	O	O
DPI	O	O
)	O	O
was	O	O
the	O	O
main	O	O
outcome	O	O
variable	O	O
.	O	O

Both	O	O
treatments	O	O
significantly	O	O
reduced	O	O
DPI	O	O
by	O	O
the	O	O
30th	O	O
minute	O	O
(	O	O
GTN	B_Chemical	O
,	O	O
-12.8	O	O
+	O	O
/-	O	O
17.9	O	O
;	O	O
DCF	B_Chemical	O
,	O	O
-18.9	O	O
+	O	O
/-	O	O
16.6	O	O
)	O	O
.	O	O

However	O	O
,	O	O
DCF	B_Chemical	O
continued	O	O
to	O	O
be	O	O
effective	O	O
in	O	O
reducing	O	O
pelvic	B_Disease	O
pain	I_Disease	O
for	O	O
two	O	O
hours	O	O
,	O	O
whereas	O	O
GTN	B_Chemical	O
scores	O	O
remained	O	O
more	O	O
or	O	O
less	O	O
stable	O	O
after	O	O
30	O	O
min	O	O
and	O	O
significantly	O	O
higher	O	O
than	O	O
those	O	O
for	O	O
DFC	O	O
(	O	O
after	O	O
one	O	O
hour	O	O
:	O	O
GTN	B_Chemical	O
,	O	O
-12.8	O	O
+	O	O
/-	O	O
17.9	O	O
;	O	O
DFC	O	O
,	O	O
-18.9	O	O
+	O	O
/-	O	O
16.6	O	O
and	O	O
after	O	O
two	O	O
hours	O	O
:	O	O
GTN	B_Chemical	O
,	O	O
-23.7	O	O
+	O	O
/-	O	O
20.5	O	O
;	O	O
DFC	O	O
,	O	O
-59.7	O	O
+	O	O
/-	O	O
17.9	O	O
,	O	O
p	O	O
=	O	O
0.0001	O	O
)	O	O
.	O	O

Low	B_Disease	B_Disease
back	I_Disease	I_Disease
pain	I_Disease	I_Disease
was	O	O
also	O	O
relieved	O	O
by	O	O
both	O	O
drugs	O	O
.	O	O

Headache	B_Disease	O
was	O	O
significantly	O	O
increased	O	O
by	O	O
GTN	B_Chemical	O
but	O	O
not	O	O
by	O	O
DCF	B_Chemical	O
.	O	O

Eight	O	O
patients	O	O
stopped	O	O
using	O	O
GTN	B_Chemical	O
because	O	O
headache	B_Disease	O
--	O	O
attributed	O	O
to	O	O
its	O	O
use	O	O
--	O	O
became	O	O
intolerable	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
GTN	B_Chemical	O
has	O	O
a	O	O
reduced	O	O
efficacy	O	O
and	O	O
tolerability	O	O
by	O	O
comparison	O	O
with	O	O
DCF	B_Chemical	O
in	O	O
the	O	O
treatment	O	O
of	O	O
primary	O	B_Disease
dysmenorrhea	B_Disease	I_Disease
.	O	O

Temocapril	B_Chemical	B_Chemical
,	O	O
a	O	O
long-acting	O	O
non-SH	O	O
group	O	O
angiotensin	B_Chemical	O
converting	O	O
enzyme	O	O
inhibitor	O	O
,	O	O
modulates	O	O
glomerular	B_Disease	B_Disease
injury	I_Disease	I_Disease
in	O	O
chronic	O	O
puromycin	B_Chemical	O
aminonucleoside	I_Chemical	O
nephrosis	B_Disease	O
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
chronic	O	O
administration	O	O
of	O	O
temocapril	B_Chemical	B_Chemical
,	O	O
a	O	O
long-acting	O	O
non-SH	O	O
group	O	O
angiotensin	B_Chemical	O
converting	O	O
enzyme	O	O
(	O	O
ACE	O	O
)	O	O
inhibitor	O	O
,	O	O
reduced	O	O
proteinuria	B_Disease	O
,	O	O
inhibited	O	O
glomerular	O	B_Disease
hypertrophy	B_Disease	I_Disease
and	O	O
prevented	O	O
glomerulosclerosis	B_Disease	B_Disease
in	O	O
chronic	O	O
puromycin	B_Chemical	O
aminonucleoside	I_Chemical	O
(	O	O
PAN	B_Chemical	O
)	O	O
-	O	O
induced	O	O
nephrotic	B_Disease	B_Disease
rats	O	O
.	O	O

Nephrosis	B_Disease	O
was	O	O
induced	O	O
by	O	O
injection	O	O
of	O	O
PAN	B_Chemical	O
(	O	O
15mg/100	O	O
g	O	O
body	O	O
weight	O	O
)	O	O
in	O	O
male	O	O
Sprague-Dawley	O	O
(	O	O
SD	O	O
)	O	O
rats	O	O
.	O	O

Four	O	O
groups	O	O
were	O	O
used	O	O
,	O	O
i	O	O
)	O	O
the	O	O
PAN	B_Chemical	O
group	O	O
(	O	O
14	O	O
)	O	O
,	O	O
ii	O	O
)	O	O
PAN/temocapril	O	B_Chemical
(	O	O
13	O	O
)	O	O
,	O	O
iii	O	O
)	O	O
temocapril	B_Chemical	B_Chemical
(	O	O
14	O	O
)	O	O
and	O	O
iv	O	O
)	O	O
untreated	O	O
controls	O	O
(	O	O
15	O	O
)	O	O
.	O	O

Temocapril	B_Chemical	B_Chemical
(	O	O
8	O	O
mg/kg/day	O	O
)	O	O
was	O	O
administered	O	O
to	O	O
the	O	O
rats	O	O
which	O	O
were	O	O
killed	O	O
at	O	O
weeks	O	O
4	O	O
,	O	O
14	O	O
or	O	O
20	O	O
.	O	O

At	O	O
each	O	O
time	O	O
point	O	O
,	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
,	O	O
urinary	O	O
protein	O	O
excretion	O	O
and	O	O
renal	O	O
histopathological	O	O
findings	O	O
were	O	O
evaluated	O	O
,	O	O
and	O	O
morphometric	O	O
image	O	O
analysis	O	O
was	O	O
done	O	O
.	O	O

Systolic	O	O
BP	O	O
in	O	O
the	O	O
PAN	B_Chemical	O
group	O	O
was	O	O
significantly	O	O
high	O	O
at	O	O
4	O	O
,	O	O
14	O	O
and	O	O
20	O	O
weeks	O	O
,	O	O
but	O	O
was	O	O
normal	O	O
in	O	O
the	O	O
PAN/temocapril	O	B_Chemical
group	O	O
.	O	O

Urinary	O	O
protein	O	O
excretion	O	O
in	O	O
the	O	O
PAN	B_Chemical	O
group	O	O
increased	O	O
significantly	O	O
,	O	O
peaking	O	O
at	O	O
8	O	O
days	O	O
,	O	O
then	O	O
decreased	O	O
at	O	O
4	O	O
weeks	O	O
,	O	O
but	O	O
rose	O	O
again	O	O
significantly	O	O
at	O	O
14	O	O
and	O	O
20	O	O
weeks	O	O
.	O	O

Temocapril	B_Chemical	B_Chemical
did	O	O
not	O	O
attenuate	O	O
proteinuria	B_Disease	O
at	O	O
8	O	O
days	O	O
,	O	O
but	O	O
it	O	O
did	O	O
markedly	O	O
lower	O	O
it	O	O
from	O	O
weeks	O	O
4	O	O
to	O	O
20	O	O
.	O	O

The	O	O
glomerulosclerosis	B_Disease	B_Disease
index	O	O
(	O	O
GSI	O	O
)	O	O
was	O	O
6.21	O	O
%	O	O
at	O	O
4	O	O
weeks	O	O
and	O	O
respectively	O	O
25.35	O	O
%	O	O
and	O	O
30.49	O	O
%	O	O
at	O	O
14	O	O
and	O	O
20	O	O
weeks	O	O
in	O	O
the	O	O
PAN	B_Chemical	O
group	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
correlation	O	O
between	O	O
urinary	O	O
protein	O	O
excretion	O	O
and	O	O
GSI	O	O
(	O	O
r	O	O
=	O	O
0.808	O	O
,	O	O
p	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

The	O	O
ratio	O	O
of	O	O
glomerular	O	O
tuft	O	O
area	O	O
to	O	O
the	O	O
area	O	O
of	O	O
Bowman	O	O
's	O	O
capsules	O	O
(	O	O
GT/BC	O	O
)	O	O
in	O	O
the	O	O
PAN	B_Chemical	O
group	O	O
was	O	O
significantly	O	O
increased	O	O
,	O	O
but	O	O
it	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
PAN/temocapril	O	B_Chemical
group	O	O
.	O	O

It	O	O
appears	O	O
that	O	O
temocapril	B_Chemical	B_Chemical
was	O	O
effective	O	O
in	O	O
retarding	O	O
renal	O	O
progression	O	O
and	O	O
protected	O	O
renal	O	O
function	O	O
in	O	O
PAN	B_Chemical	O
neprotic	B_Disease	O
rats	O	O
.	O	O

Pulmonary	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
after	O	O
ibuprofen	B_Chemical	O
prophylaxis	O	O
in	O	O
very	O	O
preterm	O	O
infants	O	O
.	O	O

We	O	O
report	O	O
three	O	O
cases	O	O
of	O	O
severe	O	O
hypoxaemia	B_Disease	B_Disease
after	O	O
ibuprofen	B_Chemical	O
administration	O	O
during	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
of	O	O
prophylactic	O	O
treatment	O	O
of	O	O
patent	B_Disease	O
ductus	I_Disease	O
arteriosus	I_Disease	O
with	O	O
ibuprofen	B_Chemical	O
in	O	O
premature	O	O
infants	O	O
born	O	O
at	O	O
less	O	O
than	O	O
28	O	O
weeks	O	O
of	O	O
gestation	O	O
.	O	O

Echocardiography	O	O
showed	O	O
severely	O	O
decreased	O	O
pulmonary	O	O
blood	O	O
flow	O	O
.	O	O

Hypoxaemia	B_Disease	B_Disease
resolved	O	O
quickly	O	O
on	O	O
inhaled	O	O
nitric	B_Chemical	O
oxide	I_Chemical	O
therapy	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
investigators	O	O
involved	O	O
in	O	O
similar	O	O
trials	O	O
pay	O	O
close	O	O
attention	O	O
to	O	O
pulmonary	O	O
pressure	O	O
if	O	O
hypoxaemia	B_Disease	O
occurs	O	O
after	O	O
prophylactic	O	O
administration	O	O
of	O	O
ibuprofen	B_Chemical	O
.	O	O

Hyponatremia	B_Disease	O
and	O	O
syndrome	B_Disease	O
of	I_Disease	O
inappropriate	I_Disease	O
anti-diuretic	I_Disease	O
hormone	I_Disease	O
reported	O	O
with	O	O
the	O	O
use	O	O
of	O	O
Vincristine	B_Chemical	O
:	O	O
an	O	O
over-representation	O	O
of	O	O
Asians?PURPOSE	O	O
:	O	O
This	O	O
retrospective	O	O
study	O	O
used	O	O
a	O	O
pharmaceutical	O	O
company	O	O
's	O	O
global	O	O
safety	O	O
database	O	O
to	O	O
determine	O	O
the	O	O
reporting	O	O
rate	O	O
of	O	O
hyponatremia	B_Disease	O
and/or	O	O
syndrome	B_Disease	O
of	I_Disease	O
inappropriate	I_Disease	O
secretion	I_Disease	O
of	I_Disease	O
anti-diuretic	I_Disease	O
hormone	I_Disease	O
(	O	O
SIADH	B_Disease	O
)	O	O
among	O	O
vincristine-treated	O	O
patients	O	O
and	O	O
to	O	O
explore	O	O
the	O	O
possibility	O	O
of	O	O
at-risk	O	O
population	O	O
subgroups	O	O
.	O	O

METHOD	O	O
:	O	O
We	O	O
searched	O	O
the	O	O
Eli	O	O
Lilly	O	O
and	O	O
Company	O	O
's	O	O
computerized	O	O
adverse	O	O
event	O	O
database	O	O
for	O	O
all	O	O
reported	O	O
cases	O	O
of	O	O
hyponatremia	B_Disease	O
and/or	O	O
SIADH	B_Disease	O
as	O	O
of	O	O
1	O	O
November	O	O
1999	O	O
that	O	O
had	O	O
been	O	O
reported	O	O
during	O	O
the	O	O
use	O	O
of	O	O
vincristine	B_Chemical	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
76	O	O
cases	O	O
of	O	O
hyponatremia	B_Disease	O
and/or	O	O
SIADH	B_Disease	O
associated	O	O
with	O	O
vincristine	B_Chemical	O
use	O	O
were	O	O
identified	O	O
.	O	O

The	O	O
overall	O	O
reporting	O	O
rate	O	O
was	O	O
estimated	O	O
to	O	O
be	O	O
1.3/100,000	O	O
treated	O	O
patients	O	O
.	O	O

The	O	O
average	O	O
age	O	O
of	O	O
patients	O	O
was	O	O
35.6	O	O
+	O	O
/-	O	O
28.3	O	O
years	O	O
,	O	O
and	O	O
62	O	O
%	O	O
were	O	O
males	O	O
.	O	O

Approximately	O	O
75	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
receiving	O	O
treatment	O	O
for	O	O
leukemia	B_Disease	O
or	O	O
lymphoma	B_Disease	O
.	O	O

Among	O	O
the	O	O
39	O	O
reports	O	O
that	O	O
included	O	O
information	O	O
on	O	O
race	O	O
,	O	O
the	O	O
racial	O	O
distribution	O	O
was	O	O
:	O	O
1	O	O
Black	O	O
,	O	O
3	O	O
Caucasian	O	O
,	O	O
and	O	O
35	O	O
Asian	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Our	O	O
data	O	O
suggest	O	O
that	O	O
Asian	O	O
patients	O	O
may	O	O
be	O	O
at	O	O
increased	O	O
risk	O	O
of	O	O
hyponatremia	B_Disease	O
and/or	O	O
SIADH	B_Disease	O
associated	O	O
with	O	O
vincristine	B_Chemical	O
use	O	O
.	O	O

Although	O	O
the	O	O
overall	O	O
reported	O	O
rate	O	O
of	O	O
SIADH	B_Disease	O
associated	O	O
with	O	O
vincristine	B_Chemical	O
is	O	O
very	O	O
low	O	O
,	O	O
physicians	O	O
caring	O	O
for	O	O
Asian	O	O
oncology	O	O
patients	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
potential	O	O
serious	O	O
but	O	O
reversible	O	O
adverse	O	O
event	O	O
.	O	O

Delayed	O	O
toxicity	B_Disease	O
of	O	O
cyclophosphamide	B_Chemical	B_Chemical
on	O	O
the	O	O
bladder	O	O
of	O	O
DBA/2	O	O
and	O	O
C57BL/6	O	O
female	O	O
mouse	O	O
.	O	O

The	O	O
present	O	O
study	O	O
describes	O	O
the	O	O
delayed	O	O
development	O	O
of	O	O
a	O	O
severe	O	O
bladder	O	B_Disease
pathology	O	I_Disease
in	O	O
a	O	O
susceptible	O	O
strain	O	O
of	O	O
mice	O	O
(	O	O
DBA/2	O	O
)	O	O
but	O	O
not	O	O
in	O	O
a	O	O
resistant	O	O
strain	O	O
(	O	O
C57BL/6	O	O
)	O	O
when	O	O
both	O	O
were	O	O
treated	O	O
with	O	O
a	O	O
single	O	O
300	O	O
mg/kg	O	O
dose	O	O
of	O	O
cyclophosphamide	B_Chemical	B_Chemical
(	O	O
CY	B_Chemical	B_Chemical
)	O	O
.	O	O

Inbred	O	O
DBA/2	O	O
and	O	O
C57BL/6	O	O
female	O	O
mice	O	O
were	O	O
injected	O	O
with	O	O
CY	B_Chemical	O
,	O	O
and	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
drug	O	O
on	O	O
the	O	O
bladder	O	O
was	O	O
assessed	O	O
during	O	O
100	O	O
days	O	O
by	O	O
light	O	O
microscopy	O	O
using	O	O
different	O	O
staining	O	O
procedures	O	O
,	O	O
and	O	O
after	O	O
30	O	O
days	O	O
by	O	O
conventional	O	O
electron	O	O
microscopy	O	O
.	O	O

Early	O	O
CY	B_Chemical	O
toxicity	B_Disease	O
caused	O	O
a	O	O
typical	O	O
haemorrhagic	B_Disease	O
cystitis	B_Disease	O
in	O	O
both	O	O
strains	O	O
that	O	O
was	O	O
completely	O	O
repaired	O	O
in	O	O
about	O	O
7	O	O
-	O	O
10	O	O
days	O	O
.	O	O

After	O	O
30	O	O
days	O	O
of	O	O
CY	B_Chemical	O
injection	O	O
ulcerous	O	O
and	O	O
non-ulcerous	O	O
forms	O	O
of	O	O
chronic	O	B_Disease
cystitis	B_Disease	I_Disease
appeared	O	O
in	O	O
86	O	O
%	O	O
of	O	O
DBA/2	O	O
mice	O	O
but	O	O
only	O	O
in	O	O
4	O	O
%	O	O
of	O	O
C57BL/6	O	O
mice	O	O
.	O	O

Delayed	O	O
cystitis	B_Disease	O
was	O	O
characterized	O	O
by	O	O
infiltration	O	O
and	O	O
transepithelial	O	O
passage	O	O
into	O	O
the	O	O
lumen	O	O
of	O	O
inflammatory	O	O
cells	O	O
and	O	O
by	O	O
frequent	O	O
exfoliation	O	O
of	O	O
the	O	O
urothelium	O	O
.	O	O

Mast	O	O
cells	O	O
appeared	O	O
in	O	O
the	O	O
connective	O	O
and	O	O
muscular	O	O
layers	O	O
of	O	O
the	O	O
bladder	O	O
at	O	O
a	O	O
much	O	O
higher	O	O
number	O	O
in	O	O
DBA/2	O	O
mice	O	O
than	O	O
in	O	O
C57BL/6	O	O
mice	O	O
or	O	O
untreated	O	O
controls	O	O
.	O	O

Electron	O	O
microscopy	O	O
disclosed	O	O
the	O	O
absence	O	O
of	O	O
the	O	O
typical	O	O
discoidal	O	O
vesicles	O	O
normally	O	O
present	O	O
in	O	O
the	O	O
cytoplasm	O	O
of	O	O
surface	O	O
cells	O	O
.	O	O

Instead	O	O
,	O	O
numerous	O	O
abnormal	O	O
vesicles	O	O
containing	O	O
one	O	O
or	O	O
several	O	O
dark	O	O
granules	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
cytoplasm	O	O
of	O	O
cells	O	O
from	O	O
all	O	O
the	O	O
epithelial	O	O
layers	O	O
.	O	O

Delayed	O	O
cystitis	B_Disease	O
still	O	O
persisted	O	O
in	O	O
DBA/2	O	O
mice	O	O
100	O	O
days	O	O
after	O	O
treatment	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
delayed	O	O
toxicity	B_Disease	O
of	O	O
CY	B_Chemical	O
in	O	O
female	O	O
DBA/2	O	O
mice	O	O
causes	O	O
a	O	O
bladder	O	B_Disease
pathology	O	I_Disease
that	O	O
is	O	O
not	O	O
observed	O	O
in	O	O
C57BL/6	O	O
mice	O	O
.	O	O

This	O	O
pathology	O	O
resembles	O	O
interstitial	B_Disease	B_Disease
cystitis	I_Disease	I_Disease
in	O	O
humans	O	O
and	O	O
could	O	O
perhaps	O	O
be	O	O
used	O	O
as	O	O
an	O	O
animal	O	O
model	O	O
for	O	O
studies	O	O
on	O	O
the	O	O
disease	O	O
.	O	O

High-dose	O	B_Chemical
5-fluorouracil	B_Chemical	I_Chemical
/	O	I_Chemical
folinic	B_Chemical	I_Chemical
acid	I_Chemical	I_Chemical
in	O	O
combination	O	O
with	O	O
three-weekly	O	O
mitomycin	B_Chemical	O
C	I_Chemical	O
in	O	O
the	O	O
treatment	O	O
of	O	O
advanced	O	O
gastric	B_Disease	B_Disease
cancer	I_Disease	I_Disease
.	O	O

A	O	O
phase	O	O
II	O	O
study	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
24-hour	O	O
continuous	O	O
infusion	O	O
of	O	O
5-fluorouracil	B_Chemical	B_Chemical
(	O	O
5-FU	B_Chemical	B_Chemical
)	O	O
and	O	O
folinic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(	O	O
FA	B_Chemical	O
)	O	O
as	O	O
part	O	O
of	O	O
several	O	O
new	O	O
multidrug	O	O
chemotherapy	O	O
regimens	O	O
in	O	O
advanced	O	O
gastric	B_Disease	B_Disease
cancer	I_Disease	I_Disease
(	O	O
AGC	B_Disease	O
)	O	O
has	O	O
shown	O	O
to	O	O
be	O	O
effective	O	O
,	O	O
with	O	O
low	O	O
toxicity	B_Disease	O
.	O	O

In	O	O
a	O	O
previous	O	O
phase	O	O
II	O	O
study	O	O
with	O	O
3-weekly	O	O
bolus	O	O
5-FU	B_Chemical	O
,	O	O
FA	B_Chemical	O
and	O	O
mitomycin	B_Chemical	O
C	I_Chemical	O
(	O	O
MMC	B_Chemical	O
)	O	O
we	O	O
found	O	O
a	O	O
low	O	O
toxicity	B_Disease	O
rate	O	O
and	O	O
response	O	O
rates	O	O
comparable	O	O
to	O	O
those	O	O
of	O	O
regimens	O	O
such	O	O
as	O	O
ELF	O	O
,	O	O
FAM	O	O
or	O	O
FAMTX	O	O
,	O	O
and	O	O
a	O	O
promising	O	O
median	O	O
overall	O	O
survival	O	O
.	O	O

In	O	O
order	O	O
to	O	O
improve	O	O
this	O	O
MMC-dependent	O	O
schedule	O	O
we	O	O
initiated	O	O
a	O	O
phase	O	O
II	O	O
study	O	O
with	O	O
high-dose	O	O
5-FU/FA	O	O
and	O	O
3-weekly	O	O
bolus	O	O
MMC	B_Chemical	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
From	O	O
February	O	O
,	O	O
1998	O	O
to	O	O
September	O	O
,	O	O
2000	O	O
we	O	O
recruited	O	O
33	O	O
patients	O	O
with	O	O
AGC	B_Disease	O
to	O	O
receive	O	O
weekly	O	O
24-hour	O	O
5-FU	B_Chemical	O
2,600	O	O
mg/m(2	O	O
)	O	O
preceded	O	O
by	O	O
2-hour	O	O
FA	B_Chemical	O
500	O	O
mg/m(2	O	O
)	O	O
for	O	O
6	O	O
weeks	O	O
,	O	O
followed	O	O
by	O	O
a	O	O
2-week	O	O
rest	O	O
period	O	O
.	O	O

Bolus	O	O
MMC	B_Chemical	O
10	O	O
mg/m(2	O	O
)	O	O
was	O	O
added	O	O
in	O	O
3-weekly	O	O
intervals	O	O
.	O	O

Treatment	O	O
given	O	O
on	O	O
an	O	O
outpatient	O	O
basis	O	O
,	O	O
using	O	O
portable	O	O
pump	O	O
systems	O	O
,	O	O
was	O	O
repeated	O	O
on	O	O
day	O	O
57	O	O
.	O	O

Patients	O	O
'	O	O
characteristics	O	O
were	O	O
:	O	O
male/female	O	O
ratio	O	O
20/13	O	O
;	O	O
median	O	O
age	O	O
57	O	O
(	O	O
27	O	O
-	O	O
75	O	O
)	O	O
years	O	O
;	O	O
median	O	O
WHO	O	O
status	O	O
1	O	O
(	O	O
0	O	O
-	O	O
2	O	O
)	O	O
.	O	O

18	O	O
patients	O	O
had	O	O
a	O	O
primary	O	O
AGC	B_Disease	O
,	O	O
and	O	O
15	O	O
showed	O	O
a	O	O
relapsed	O	O
AGC	B_Disease	O
.	O	O

Median	O	O
follow-up	O	O
was	O	O
11.8	O	O
months	O	O
(	O	O
range	O	O
of	O	O
those	O	O
surviving	O	O
:	O	O
2.7	O	O
-	O	O
11.8	O	O
months	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
32	O	O
patients	O	O
were	O	O
evaluable	O	O
for	O	O
response	O	O
-	O	O
complete	O	O
remission	O	O
9.1	O	O
%	O	O
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
,	O	O
partial	O	O
remission	O	O
45.5	O	O
%	O	O
(	O	O
n	O	O
=	O	O
15	O	O
)	O	O
,	O	O
no	O	O
change	O	O
27.3	O	O
%	O	O
(	O	O
n	O	O
=	O	O
9	O	O
)	O	O
,	O	O
progressive	O	B_Disease
disease	O	I_Disease
15.1	O	O
%	O	O
(	O	O
n	O	O
=	O	O
5	O	O
)	O	O
.	O	O

Median	O	O
overall	O	O
survival	O	O
time	O	O
was	O	O
10.2	O	O
months	O	O
[	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
):	O	O
8.7	O	O
-	O	O
11.6	O	O
]	O	O
,	O	O
and	O	O
median	O	O
progression-free	O	O
survival	O	O
time	O	O
was	O	O
7.6	O	O
months	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
4.4	O	O
-	O	O
10.9	O	O
)	O	O
.	O	O

The	O	O
worst	O	O
toxicities	B_Disease	O
(	O	O
%	O	O
)	O	O
observed	O	O
were	O	O
(	O	O
CTC-NCI	O	O
1/2/3	O	O
):	O	O
leukopenia	B_Disease	O
45.5/18.2/6.1	O	O
,	O	O
thrombocytopenia	B_Disease	O
33.3/9.1/6.1	O	O
,	O	O
vomitus	B_Disease	O
24.2/9.1/0	O	O
,	O	O
diarrhea	B_Disease	O
36.4/6.1/3.0	O	O
,	O	O
stomatitis	B_Disease	O
18.2/9.1/0	O	O
,	O	O
hand-foot	B_Disease	B_Disease
syndrome	I_Disease	I_Disease
12.1/0/0	O	O
.	O	O

Two	O	O
patients	O	O
developed	O	O
hemolytic-uremic	B_Disease	B_Disease
syndrome	I_Disease	I_Disease
(	O	O
HUS	B_Disease	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
High-dose	O	O
5-FU/FA/MMC	O	O
is	O	O
an	O	O
effective	O	O
and	O	O
well-tolerated	O	O
outpatient	O	O
regimen	O	O
for	O	O
AGC	B_Disease	O
(	O	O
objective	O	O
response	O	O
rate	O	O
54.6	O	O
%	O	O
)	O	O
.	O	O

It	O	O
may	O	O
serve	O	O
as	O	O
an	O	O
alternative	O	O
to	O	O
cisplatin-containing	O	O
regimens	O	O
;	O	O
however	O	O
,	O	O
it	O	O
has	O	O
to	O	O
be	O	O
considered	O	O
that	O	O
possibly	O	O
HUS	B_Disease	O
may	O	O
occur	O	O
.	O	O

Persistent	O	O
sterile	O	O
leukocyturia	B_Disease	O
is	O	O
associated	O	O
with	O	O
impaired	B_Disease	O
renal	I_Disease	O
function	I_Disease	O
in	O	O
human	B_Disease	O
immunodeficiency	I_Disease	O
virus	I_Disease	O
type	I_Disease	O
1-infected	I_Disease	O
children	O	O
treated	O	O
with	O	O
indinavir	B_Chemical	O
.	O	O

BACKGROUND	O	O
:	O	O
Prolonged	O	O
administration	O	O
of	O	O
indinavir	B_Chemical	O
is	O	O
associated	O	O
with	O	O
the	O	O
occurrence	O	O
of	O	O
a	O	O
variety	O	O
of	O	O
renal	O	B_Disease
complications	O	I_Disease
in	O	O
adults	O	O
.	O	O

These	O	O
well-documented	O	O
side	O	O
effects	O	O
have	O	O
restricted	O	O
the	O	O
use	O	O
of	O	O
this	O	O
potent	O	O
protease	O	O
inhibitor	O	O
in	O	O
children	O	O
.	O	O

DESIGN	O	O
:	O	O
A	O	O
prospective	O	O
study	O	O
to	O	O
monitor	O	O
indinavir-related	O	O
nephrotoxicity	B_Disease	B_Disease
in	O	O
a	O	O
cohort	O	O
of	O	O
30	O	O
human	B_Disease	O
immunodeficiency	I_Disease	O
virus	I_Disease	O
type	I_Disease	O
1-infected	I_Disease	O
children	O	O
treated	O	O
with	O	O
indinavir	B_Chemical	O
.	O	O

METHODS	O	O
:	O	O
Urinary	O	O
pH	O	O
,	O	O
albumin	O	O
,	O	O
creatinine	B_Chemical	B_Chemical
,	O	O
the	O	O
presence	O	O
of	O	O
erythrocytes	O	O
,	O	O
leukocytes	O	O
,	O	O
bacteria	O	O
and	O	O
crystals	O	O
,	O	O
and	O	O
culture	O	O
were	O	O
analyzed	O	O
every	O	O
3	O	O
months	O	O
for	O	O
96	O	O
weeks	O	O
.	O	O

Serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
levels	O	O
were	O	O
routinely	O	O
determined	O	O
at	O	O
the	O	O
same	O	O
time	O	O
points	O	O
.	O	O

Steady-state	O	O
pharmacokinetics	O	O
of	O	O
indinavir	B_Chemical	O
were	O	O
done	O	O
at	O	O
week	O	O
4	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
indinavir	B_Chemical	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
cumulative	O	O
incidence	O	O
of	O	O
persistent	O	O
sterile	O	O
leukocyturia	B_Disease	O
(	O	O
>	O	O
or	O	O
=	O	O
75	O	O
cells/	O	O
micro	O	O
L	O	O
in	O	O
at	O	O
least	O	O
2	O	O
consecutive	O	O
visits	O	O
)	O	O
after	O	O
96	O	O
weeks	O	O
was	O	O
53	O	O
%	O	O
.	O	O

Persistent	O	O
sterile	O	O
leukocyturia	B_Disease	O
was	O	O
frequently	O	O
associated	O	O
with	O	O
a	O	O
mild	O	O
increase	O	O
in	O	O
the	O	O
urine	O	O
albumin/creatinine	O	O
ratio	O	O
and	O	O
by	O	O
microscopic	O	O
hematuria	B_Disease	O
.	O	O

The	O	O
cumulative	O	O
incidence	O	O
of	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
levels	O	O
>	O	O
50	O	O
%	O	O
above	O	O
normal	O	O
was	O	O
33	O	O
%	O	O
after	O	O
96	O	O
weeks	O	O
.	O	O

Children	O	O
with	O	O
persistent	O	O
sterile	O	O
leukocyturia	B_Disease	O
more	O	O
frequently	O	O
had	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
levels	O	O
of	O	O
50	O	O
%	O	O
above	O	O
normal	O	O
than	O	O
those	O	O
children	O	O
without	O	O
persistent	O	O
sterile	O	O
leukocyturia	B_Disease	O
.	O	O

In	O	O
children	O	O
younger	O	O
than	O	O
5.6	O	O
years	O	O
,	O	O
persistent	O	O
sterile	O	O
leukocyturia	B_Disease	O
was	O	O
significantly	O	O
more	O	O
frequent	O	O
than	O	O
in	O	O
older	O	O
children	O	O
.	O	O

A	O	O
higher	O	O
cumulative	O	O
incidence	O	O
of	O	O
persistent	O	O
leukocyturia	B_Disease	O
was	O	O
found	O	O
in	O	O
children	O	O
with	O	O
an	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
>	O	O
19	O	O
mg/L	O	O
x	O	O
h	O	O
or	O	O
a	O	O
peak	O	O
serum	O	O
level	O	O
of	O	O
indinavir	B_Chemical	O
>	O	O
12	O	O
mg/L.	O	O
In	O	O
4	O	O
children	O	O
,	O	O
indinavir	B_Chemical	O
was	O	O
discontinued	O	O
because	O	O
of	O	O
nephrotoxicity	B_Disease	B_Disease
.	O	O

Subsequently	O	O
,	O	O
the	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
levels	O	O
decreased	O	O
,	O	O
the	O	O
urine	O	O
albumin/creatinine	O	O
ratios	O	O
returned	O	O
to	O	O
zero	O	O
,	O	O
and	O	O
the	O	O
leukocyturia	B_Disease	O
disappeared	O	O
within	O	O
3	O	O
months	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Children	O	O
treated	O	O
with	O	O
indinavir	B_Chemical	O
have	O	O
a	O	O
high	O	O
cumulative	O	O
incidence	O	O
of	O	O
persistent	O	O
sterile	O	O
leukocyturia	B_Disease	O
.	O	O

Children	O	O
with	O	O
persistent	O	O
sterile	O	O
leukocyturia	B_Disease	O
more	O	O
frequently	O	O
had	O	O
an	O	O
increase	O	O
in	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
levels	O	O
of	O	O
>	O	O
50	O	O
%	O	O
above	O	O
normal	O	O
.	O	O

Younger	O	O
children	O	O
have	O	O
an	O	O
additional	O	O
risk	O	O
for	O	O
renal	O	B_Disease
complications	O	I_Disease
.	O	O

The	O	O
impairment	B_Disease	O
of	I_Disease	O
the	I_Disease	O
renal	I_Disease	O
function	I_Disease	O
in	O	O
these	O	O
children	O	O
occurred	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
clinical	O	O
symptoms	O	O
of	O	O
nephrolithiasis	B_Disease	O
.	O	O

Indinavir-associated	O	O
nephrotoxicity	B_Disease	B_Disease
must	O	O
be	O	O
monitored	O	O
closely	O	O
,	O	O
especially	O	O
in	O	O
children	O	O
with	O	O
risk	O	O
factors	O	O
such	O	O
as	O	O
persistent	O	O
sterile	O	O
leukocyturia	B_Disease	O
,	O	O
age	O	O
<	O	O
5.6	O	O
years	O	O
,	O	O
an	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
of	O	O
indinavir	B_Chemical	O
>	O	O
19	O	O
mg/L	O	O
x	O	O
h	O	O
,	O	O
and	O	O
a	O	O
C(max	O	O
)	O	O
>	O	O
12	O	O
mg/L.	O	O

Utility	O	O
of	O	O
troponin	O	O
I	O	O
in	O	O
patients	O	O
with	O	O
cocaine-associated	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
.	O	O

Baseline	O	O
electrocardiogram	O	O
abnormalities	O	O
and	O	O
market	O	O
elevations	O	O
not	O	O
associated	O	O
with	O	O
myocardial	B_Disease	B_Disease
necrosis	I_Disease	I_Disease
make	O	O
accurate	O	O
diagnosis	O	O
of	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
(	O	O
MI	B_Disease	O
)	O	O
difficult	O	O
in	O	O
patients	O	O
with	O	O
cocaine-associated	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
.	O	O

Troponin	O	O
sampling	O	O
may	O	O
offer	O	O
greater	O	O
diagnostic	O	O
utility	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
assess	O	O
outcomes	O	O
based	O	O
on	O	O
troponin	O	O
positivity	O	O
in	O	O
patients	O	O
with	O	O
cocaine	B_Chemical	B_Disease
chest	B_Disease	I_Disease
pain	I_Disease	I_Disease
admitted	O	O
for	O	O
exclusion	O	O
of	O	O
MI	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
Outcomes	O	O
were	O	O
examined	O	O
in	O	O
patients	O	O
admitted	O	O
for	O	O
possible	O	O
MI	B_Disease	O
after	O	O
cocaine	B_Chemical	O
use	O	O
.	O	O

All	O	O
patients	O	O
underwent	O	O
a	O	O
rapid	O	O
rule-in	O	O
protocol	O	O
that	O	O
included	O	O
serial	O	O
sampling	O	O
of	O	O
creatine	B_Chemical	B_Chemical
kinase	O	I_Chemical
(	O	O
CK	O	O
)	O	O
,	O	O
CK-MB	O	O
,	O	O
and	O	O
cardiac	O	O
troponin	O	O
I	O	O
(	O	O
cTnI	O	O
)	O	O
over	O	O
eight	O	O
hours	O	O
.	O	O

Outcomes	O	O
included	O	O
CK-MB	O	O
MI	B_Disease	O
(	O	O
CK-MB	O	O
>	O	O
or=	O	O
8	O	O
ng/mL	O	O
with	O	O
a	O	O
relative	O	O
index	O	O
[	O	O
(	O	O
CK-MB	O	O
x	O	O
100)/total	O	O
CK	O	O
]	O	O
>	O	O
or=	O	O
4	O	O
,	O	O
cardiac	B_Disease	B_Disease
death	I_Disease	I_Disease
,	O	O
and	O	O
significant	O	O
coronary	B_Disease	B_Disease
disease	I_Disease	I_Disease
(	O	O
>	O	O
or=50	O	O
%	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
the	O	O
246	O	O
admitted	O	O
patients	O	O
,	O	O
34	O	O
(	O	O
14	O	O
%	O	O
)	O	O
met	O	O
CK-MB	O	O
criteria	O	O
for	O	O
MI	B_Disease	O
and	O	O
38	O	O
(	O	O
16	O	O
%	O	O
)	O	O
had	O	O
cTnI	O	O
elevations	O	O
.	O	O

Angiography	O	O
was	O	O
performed	O	O
in	O	O
29	O	O
of	O	O
38	O	O
patients	O	O
who	O	O
were	O	O
cTnI-positive	O	O
,	O	O
with	O	O
significant	O	O
disease	O	O
present	O	O
in	O	O
25	O	O
(	O	O
86	O	O
%	O	O
)	O	O
.	O	O

Three	O	O
of	O	O
the	O	O
four	O	O
patients	O	O
without	O	O
significant	O	O
disease	O	O
who	O	O
had	O	O
cTnI	O	O
elevations	O	O
met	O	O
CK-MB	O	O
criteria	O	O
for	O	O
MI	B_Disease	O
,	O	O
and	O	O
the	O	O
other	O	O
had	O	O
a	O	O
peak	O	O
CK-MB	O	O
level	O	O
of	O	O
13	O	O
ng/mL.	O	O
Sensitivities	O	O
,	O	O
specificities	O	O
,	O	O
and	O	O
positive	O	O
and	O	O
negative	O	O
likelihood	O	O
ratios	O	O
for	O	O
predicting	O	O
cardiac	B_Disease	B_Disease
death	I_Disease	I_Disease
or	O	O
significant	O	O
disease	O	O
were	O	O
high	O	O
for	O	O
both	O	O
CK-MB	O	O
MI	B_Disease	O
and	O	O
cTnI	O	O
and	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Most	O	O
patients	O	O
with	O	O
cTnI	O	O
elevations	O	O
meet	O	O
CK-MB	O	O
criteria	O	O
for	O	O
MI	B_Disease	O
,	O	O
as	O	O
well	O	O
as	O	O
have	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
underlying	O	O
significant	O	O
disease	O	O
.	O	O

Troponin	O	O
appears	O	O
to	O	O
have	O	O
an	O	O
equivalent	O	O
diagnostic	O	O
accuracy	O	O
compared	O	O
with	O	O
CK-MB	O	O
for	O	O
diagnosing	O	O
necrosis	B_Disease	O
in	O	O
patients	O	O
with	O	O
cocaine-associated	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
and	O	O
suspected	O	O
MI	B_Disease	O
.	O	O

Acute	O	B_Disease
interstitial	B_Disease	I_Disease
nephritis	I_Disease	I_Disease
due	O	O
to	O	O
nicergoline	B_Chemical	O
(Sermion).We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	O	B_Disease
interstitial	B_Disease	I_Disease
nephritis	I_Disease	I_Disease
(	O	O
AIN	B_Disease	O
)	O	O
due	O	O
to	O	O
nicergoline	B_Chemical	O
(	O	O
Sermion	B_Chemical	O
)	O	O
.	O	O

A	O	O
50-year-old	O	O
patient	O	O
admitted	O	O
to	O	O
our	O	O
hospital	O	O
for	O	O
fever	B_Disease	O
and	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

Before	O	O
admission	O	O
,	O	O
he	O	O
had	O	O
been	O	O
taking	O	O
nicergoline	B_Chemical	O
and	O	O
bendazac	B_Chemical	B_Chemical
lysine	I_Chemical	I_Chemical
due	O	O
to	O	O
retinal	B_Disease	O
vein	I_Disease	O
occlusion	I_Disease	O
at	O	O
ophthalmologic	O	O
department	O	O
.	O	O

Thereafter	O	O
,	O	O
he	O	O
experienced	O	O
intermittent	O	O
fever	B_Disease	O
and	O	O
skin	B_Disease	O
rash	I_Disease	O
.	O	O

On	O	O
admission	O	O
,	O	O
clinical	O	O
symptoms	O	O
(	O	O
i.e.	O	O
arthralgia	B_Disease	O
and	O	O
fever	B_Disease	O
)	O	O
and	O	O
laboratory	O	O
findings	O	O
(	O	O
i.e.	O	O
eosinophilia	B_Disease	O
and	O	O
renal	B_Disease	B_Disease
failure	I_Disease	I_Disease
)	O	O
suggested	O	O
AIN	B_Disease	O
,	O	O
and	O	O
which	O	O
was	O	O
confirmed	O	O
by	O	O
pathologic	O	O
findings	O	O
on	O	O
renal	O	O
biopsy	O	O
.	O	O

A	O	O
lymphocyte	O	O
transformation	O	O
test	O	O
demonstrated	O	O
a	O	O
positive	O	O
result	O	O
against	O	O
nicergoline	B_Chemical	O
.	O	O

Treatment	O	O
was	O	O
consisted	O	O
of	O	O
withdrawal	O	O
of	O	O
nicergoline	B_Chemical	O
and	O	O
intravenous	O	O
methylprednisolone	B_Chemical	B_Chemical
,	O	O
and	O	O
his	O	O
renal	O	O
function	O	O
was	O	O
completely	O	O
recovered	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
nicergoline-associated	O	O
AIN	B_Disease	O
.	O	O

Neuroleptic	B_Disease	O
malignant	I_Disease	O
syndrome	I_Disease	O
complicated	O	O
by	O	O
massive	O	O
intestinal	O	O
bleeding	B_Disease	O
in	O	O
a	O	O
patient	O	O
with	O	O
chronic	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

A	O	O
patient	O	O
with	O	O
chronic	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
(	O	O
CRF	B_Disease	O
)	O	O
developed	O	O
neuroleptic	B_Disease	O
malignant	I_Disease	O
syndrome	I_Disease	O
(	O	O
NMS	B_Disease	O
)	O	O
after	O	O
administration	O	O
of	O	O
risperidone	B_Chemical	B_Chemical
and	O	O
levomepromazine	B_Chemical	B_Chemical
.	O	O

In	O	O
addition	O	O
to	O	O
the	O	O
typical	O	O
symptoms	O	O
of	O	O
NMS	B_Disease	O
,	O	O
massive	O	O
intestinal	O	O
bleeding	B_Disease	O
was	O	O
observed	O	O
during	O	O
the	O	O
episode	O	O
.	O	O

This	O	O
report	O	O
suggests	O	O
that	O	O
NMS	B_Disease	O
in	O	O
a	O	O
patient	O	O
with	O	O
CRF	B_Disease	O
may	O	O
be	O	O
complicated	O	O
by	O	O
intestinal	O	O
bleeding	B_Disease	O
and	O	O
needs	O	O
special	O	O
caution	O	O
for	O	O
this	O	O
complication	O	O
.	O	O

Blood	O	O
brain	O	O
barrier	O	O
in	O	O
right-	O	O
and	O	O
left-pawed	O	O
female	O	O
rats	O	O
assessed	O	O
by	O	O
a	O	O
new	O	O
staining	O	O
method	O	O
.	O	O

The	O	O
asymmetrical	O	O
breakdown	O	O
of	O	O
the	O	O
blood-brain	O	O
barrier	O	O
(	O	O
BBB	O	O
)	O	O
was	O	O
studied	O	O
in	O	O
female	O	O
rats	O	O
.	O	O

Paw	O	O
preference	O	O
was	O	O
assessed	O	O
by	O	O
a	O	O
food	O	O
reaching	O	O
test	O	O
.	O	O

Adrenaline-induced	O	O
hypertension	B_Disease	O
was	O	O
used	O	O
to	O	O
destroy	O	O
the	O	O
BBB	O	O
,	O	O
which	O	O
was	O	O
evaluated	O	O
using	O	O
triphenyltetrazolium	B_Chemical	B_Chemical
(	O	O
TTC	B_Chemical	O
)	O	O
staining	O	O
of	O	O
the	O	O
brain	O	O
slices	O	O
just	O	O
after	O	O
giving	O	O
adrenaline	B_Chemical	O
for	O	O
30	O	O
s.	O	O
In	O	O
normal	O	O
rats	O	O
,	O	O
the	O	O
whole	O	O
brain	O	O
sections	O	O
exhibited	O	O
complete	O	O
staining	O	O
with	O	O
TTC	B_Chemical	O
.	O	O

After	O	O
adrenaline	B_Chemical	O
infusion	O	O
for	O	O
30	O	O
s	O	O
,	O	O
there	O	O
were	O	O
large	O	O
unstained	O	O
areas	O	O
in	O	O
the	O	O
left	O	O
brain	O	O
in	O	O
right-pawed	O	O
animals	O	O
,	O	O
and	O	O
vice	O	O
versa	O	O
in	O	O
left-pawed	O	O
animals	O	O
.	O	O

Similar	O	O
results	O	O
were	O	O
obtained	O	O
in	O	O
seizure-induced	O	O
breakdown	O	O
of	O	O
BBB	O	O
.	O	O

These	O	O
results	O	O
were	O	O
explained	O	O
by	O	O
an	O	O
asymmetric	O	O
cerebral	O	O
blood	O	O
flow	O	O
depending	O	O
upon	O	O
the	O	O
paw	O	O
preference	O	O
in	O	O
rats	O	O
.	O	O

It	O	O
was	O	O
suggested	O	O
that	O	O
this	O	O
new	O	O
method	O	O
and	O	O
the	O	O
results	O	O
are	O	O
consistent	O	O
with	O	O
contralateral	O	O
motor	O	O
control	O	O
that	O	O
may	O	O
be	O	O
important	O	O
in	O	O
determining	O	O
the	O	O
dominant	O	O
cerebral	O	O
hemisphere	O	O
in	O	O
animals	O	O
.	O	O

Carvedilol	B_Chemical	O
protects	O	O
against	O	O
doxorubicin-induced	O	O
mitochondrial	O	B_Disease
cardiomyopathy	B_Disease	I_Disease
.	O	O

Several	O	O
cytopathic	O	O
mechanisms	O	O
have	O	O
been	O	O
suggested	O	O
to	O	O
mediate	O	O
the	O	O
dose-limiting	O	O
cumulative	O	O
and	O	O
irreversible	O	O
cardiomyopathy	B_Disease	O
caused	O	O
by	O	O
doxorubicin	B_Chemical	O
.	O	O

Recent	O	O
evidence	O	O
indicates	O	O
that	O	O
oxidative	O	O
stress	O	O
and	O	O
mitochondrial	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
are	O	O
key	O	O
factors	O	O
in	O	O
the	O	O
pathogenic	O	O
process	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
test	O	O
the	O	O
hypothesis	O	O
that	O	O
carvedilol	B_Chemical	O
,	O	O
a	O	O
nonselective	O	O
beta-adrenergic	O	O
receptor	O	O
antagonist	O	O
with	O	O
potent	O	O
antioxidant	O	O
properties	O	O
,	O	O
protects	O	O
against	O	O
the	O	O
cardiac	O	O
and	O	O
hepatic	O	O
mitochondrial	O	B_Disease
bioenergetic	O	O
dysfunction	O	O
associated	O	O
with	O	O
subchronic	O	O
doxorubicin	B_Chemical	O
toxicity	B_Disease	O
.	O	O

Heart	O	O
and	O	O
liver	O	O
mitochondria	O	O
were	O	O
isolated	O	O
from	O	O
rats	O	O
treated	O	O
for	O	O
7	O	O
weeks	O	O
with	O	O
doxorubicin	B_Chemical	O
(	O	O
2	O	O
mg/kg	O	O
sc/week	O	O
)	O	O
,	O	O
carvedilol	B_Chemical	O
(	O	O
1	O	O
mg/kg	O	O
ip/week	O	O
)	O	O
,	O	O
or	O	O
the	O	O
combination	O	O
of	O	O
the	O	O
two	O	O
drugs	O	O
.	O	O

Heart	O	O
mitochondria	O	O
isolated	O	O
from	O	O
doxorubicin-treated	O	O
rats	O	O
exhibited	O	O
depressed	O	O
rates	O	O
for	O	O
state	O	O
3	O	O
respiration	O	O
(	O	O
336	O	O
+	O	O
/-	O	O
26	O	O
versus	O	O
425	O	O
+	O	O
/-	O	O
53	O	O
natom	O	O
O/min/mg	O	O
protein	O	O
)	O	O
and	O	O
a	O	O
lower	O	O
respiratory	O	O
control	O	O
ratio	O	O
(	O	O
RCR	O	O
)	O	O
(	O	O
4.3	O	O
+	O	O
/-	O	O
0.6	O	O
versus	O	O
5.8	O	O
+	O	O
/-	O	O
0.4	O	O
)	O	O
compared	O	O
with	O	O
cardiac	O	O
mitochondria	O	O
isolated	O	O
from	O	O
saline-treated	O	O
rats	O	O
.	O	O

Mitochondrial	O	O
calcium-loading	O	O
capacity	O	O
and	O	O
the	O	O
activity	O	O
of	O	O
NADH-dehydrogenase	O	O
were	O	O
also	O	O
suppressed	O	O
in	O	O
cardiac	O	O
mitochondria	O	O
from	O	O
doxorubicin-treated	O	O
rats	O	O
.	O	O

Doxorubicin	B_Chemical	O
treatment	O	O
also	O	O
caused	O	O
a	O	O
decrease	O	O
in	O	O
RCR	O	O
for	O	O
liver	O	O
mitochondria	O	O
(	O	O
3.9	O	O
+	O	O
/-	O	O
0.9	O	O
versus	O	O
5.6	O	O
+	O	O
/-	O	O
0.7	O	O
for	O	O
control	O	O
rats	O	O
)	O	O
and	O	O
inhibition	O	O
of	O	O
hepatic	O	O
cytochrome	O	O
oxidase	O	O
activity	O	O
.	O	O

Coadministration	O	O
of	O	O
carvedilol	B_Chemical	O
decreased	O	O
the	O	O
extent	O	O
of	O	O
cellular	O	O
vacuolization	O	O
in	O	O
cardiac	O	O
myocytes	O	O
and	O	O
prevented	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
doxorubicin	B_Chemical	O
on	O	O
mitochondrial	O	O
respiration	O	O
in	O	O
both	O	O
heart	O	O
and	O	O
liver	O	O
.	O	O

Carvedilol	B_Chemical	O
also	O	O
prevented	O	O
the	O	O
decrease	O	O
in	O	O
mitochondrial	O	O
Ca(2	O	O
+	O	O
)	O	O
loading	O	O
capacity	O	O
and	O	O
the	O	O
inhibition	O	O
of	O	O
the	O	O
respiratory	O	O
complexes	O	O
of	O	O
heart	O	O
mitochondria	O	O
caused	O	O
by	O	O
doxorubicin	B_Chemical	O
.	O	O

Carvedilol	B_Chemical	O
by	O	O
itself	O	O
did	O	O
not	O	O
affect	O	O
any	O	O
of	O	O
the	O	O
parameters	O	O
measured	O	O
for	O	O
heart	O	O
or	O	O
liver	O	O
mitochondria	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
this	O	O
protection	O	O
by	O	O
carvedilol	B_Chemical	O
against	O	O
both	O	O
the	O	O
structural	O	O
and	O	O
functional	O	O
cardiac	O	O
tissue	O	O
damage	O	O
may	O	O
afford	O	O
significant	O	O
clinical	O	O
advantage	O	O
in	O	O
minimizing	O	O
the	O	O
dose-limiting	O	O
mitochondrial	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
and	O	O
cardiomyopathy	B_Disease	O
that	O	O
accompanies	O	O
long-term	O	O
doxorubicin	B_Chemical	O
therapy	O	O
in	O	O
cancer	B_Disease	O
patients	O	O
.	O	O

Cocaine-induced	O	O
hyperactivity	B_Disease	O
is	O	O
more	O	O
influenced	O	O
by	O	O
adenosine	B_Chemical	O
receptor	O	O
agonists	O	O
than	O	O
amphetamine-induced	O	O
hyperactivity	B_Disease	O
.	O	O

The	O	O
influence	O	O
of	O	O
adenosine	B_Chemical	O
receptor	O	O
agonists	O	O
and	O	O
antagonists	O	O
on	O	O
cocaine-and	O	O
amphetamine-induced	O	O
hyperactivity	B_Disease	O
was	O	O
examined	O	O
in	O	O
mice	O	O
.	O	O

All	O	O
adenosine	B_Chemical	O
receptor	O	O
agonists	O	O
significantly	O	O
decreased	B_Disease	O
the	I_Disease	O
locomotor	I_Disease	O
activity	I_Disease	O
in	O	O
mice	O	O
,	O	O
and	O	O
the	O	O
effects	O	O
were	O	O
dose-dependent	O	O
.	O	O

It	O	O
seems	O	O
that	O	O
adenosine	B_Chemical	O
A1	O	O
and	O	O
A2	O	O
receptors	O	O
might	O	O
be	O	O
involved	O	O
in	O	O
this	O	O
reaction	O	O
.	O	O

Moreover	O	O
,	O	O
all	O	O
adenosine	B_Chemical	O
receptor	O	O
agonists	O	O
:	O	O
2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine	B_Chemical	B_Chemical
(	O	O
CGS	B_Chemical	O
21680	I_Chemical	O
)	O	O
,	O	O
A2A	O	O
receptor	O	O
agonist	O	O
,	O	O
N6-cyclopentyladenosine	B_Chemical	B_Chemical
(	O	O
CPA	B_Chemical	O
)	O	O
,	O	O
A1	O	O
receptor	O	O
agonist	O	O
,	O	O
and	O	O
5'-N-ethylcarboxamidoadenosine	B_Chemical	B_Chemical
(	O	O
NECA	B_Chemical	O
)	O	O
,	O	O
A2/A1	O	O
receptor	O	O
agonist	O	O
significantly	O	O
and	O	O
dose-dependently	O	O
decreased	O	O
cocaine-induced	O	O
locomotor	O	O
activity	O	O
.	O	O

CPA	B_Chemical	O
reduced	O	O
cocaine	B_Chemical	O
action	O	O
at	O	O
the	O	O
doses	O	O
which	O	O
,	O	O
given	O	O
alone	O	O
,	O	O
did	O	O
not	O	O
influence	O	O
motility	O	O
,	O	O
while	O	O
CGS	B_Chemical	O
21680	I_Chemical	O
and	O	O
NECA	B_Chemical	O
decreased	O	O
the	O	O
action	O	O
of	O	O
cocaine	B_Chemical	O
at	O	O
the	O	O
doses	O	O
which	O	O
,	O	O
given	O	O
alone	O	O
,	O	O
decreased	O	O
locomotor	O	O
activity	O	O
in	O	O
animals	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
the	O	O
involvement	O	O
of	O	O
both	O	O
adenosine	B_Chemical	O
receptors	O	O
in	O	O
the	O	O
action	O	O
of	O	O
cocaine	B_Chemical	O
although	O	O
agonists	O	O
of	O	O
A1	O	O
receptors	O	O
seem	O	O
to	O	O
have	O	O
stronger	O	O
influence	O	O
on	O	O
it	O	O
.	O	O

The	O	O
selective	O	O
blockade	O	O
of	O	O
A2	O	O
adenosine	B_Chemical	O
receptor	O	O
by	O	O
DMPX	B_Chemical	O
(	O	O
3,7-dimethyl-1-propargylxanthine	B_Chemical	B_Chemical
)	O	O
significantly	O	O
enhanced	O	O
cocaine-induced	O	O
locomotor	O	O
activity	O	O
of	O	O
animals	O	O
.	O	O

Caffeine	B_Chemical	O
had	O	O
similar	O	O
action	O	O
but	O	O
the	O	O
effect	O	O
was	O	O
not	O	O
significant	O	O
.	O	O

CPT	B_Chemical	O
(8-cyclopentyltheophylline)--A1	O	O
receptor	O	O
antagonist	O	O
,	O	O
did	O	O
not	O	O
show	O	O
any	O	O
influence	O	O
in	O	O
this	O	O
test	O	O
.	O	O

Similarly	O	O
,	O	O
all	O	O
adenosine	B_Chemical	O
receptor	O	O
agonists	O	O
decreased	O	O
amphetamine-induced	O	O
hyperactivity	B_Disease	O
,	O	O
but	O	O
at	O	O
the	O	O
higher	O	O
doses	O	O
than	O	O
those	O	O
which	O	O
were	O	O
active	O	O
in	O	O
cocaine-induced	O	O
hyperactivity	B_Disease	O
.	O	O

The	O	O
selective	O	O
blockade	O	O
of	O	O
A2	O	O
adenosine	B_Chemical	O
receptors	O	O
(	O	O
DMPX	B_Chemical	O
)	O	O
and	O	O
non-selective	O	O
blockade	O	O
of	O	O
adenosine	B_Chemical	O
receptors	O	O
(	O	O
caffeine	B_Chemical	O
)	O	O
significantly	O	O
increased	O	O
the	O	O
action	O	O
of	O	O
amphetamine	B_Chemical	O
in	O	O
the	O	O
locomotor	O	O
activity	O	O
test	O	O
.	O	O

Our	O	O
results	O	O
have	O	O
shown	O	O
that	O	O
all	O	O
adenosine	B_Chemical	O
receptor	O	O
agonists	O	O
(	O	O
A1	O	O
and	O	O
A2	O	O
)	O	O
reduce	O	O
cocaine-	O	B_Chemical
and	O	O
amphetamine-induced	O	O
locomotor	O	O
activity	O	O
and	O	O
indicate	O	O
that	O	O
cocaine-induced	O	O
hyperactivity	B_Disease	O
is	O	O
more	O	O
influenced	O	O
by	O	O
adenosine	B_Chemical	O
receptor	O	O
agonists	O	O
(	O	O
particularly	O	O
A1	O	O
receptors	O	O
)	O	O
than	O	O
amphetamine-induced	O	O
hyperactivity	B_Disease	O
.	O	O

Amiodarone	B_Chemical	O
and	O	O
the	O	O
risk	O	O
of	O	O
bradyarrhythmia	B_Disease	O
requiring	O	O
permanent	O	O
pacemaker	O	O
in	O	O
elderly	O	O
patients	O	O
with	O	O
atrial	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
and	O	O
prior	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
use	O	O
of	O	O
amiodarone	B_Chemical	O
in	O	O
patients	O	O
with	O	O
atrial	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
(	O	O
AF	B_Disease	O
)	O	O
increases	O	O
the	O	O
risk	O	O
of	O	O
bradyarrhythmia	B_Disease	B_Disease
requiring	O	O
a	O	O
permanent	O	O
pacemaker	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Reports	O	O
of	O	O
severe	O	O
bradyarrhythmia	B_Disease	B_Disease
during	O	O
amiodarone	B_Chemical	O
therapy	O	O
are	O	O
infrequent	O	O
and	O	O
limited	O	O
to	O	O
studies	O	O
assessing	O	O
the	O	O
therapy	O	O
's	O	O
use	O	O
in	O	O
the	O	O
management	O	O
of	O	O
patients	O	O
with	O	O
ventricular	B_Disease	B_Disease
arrhythmias	I_Disease	I_Disease
.	O	O

METHODS	O	O
:	O	O
A	O	O
study	O	O
cohort	O	O
of	O	O
8,770	O	O
patients	O	O
age	O	O
>	O	O
or	O	O
=	O	O
65	O	O
years	O	O
with	O	O
a	O	O
new	O	O
diagnosis	O	O
of	O	O
AF	B_Disease	O
was	O	O
identified	O	O
from	O	O
a	O	O
provincewide	O	O
database	O	O
of	O	O
Quebec	O	O
residents	O	O
with	O	O
a	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
(	O	O
MI	B_Disease	O
)	O	O
between	O	O
1991	O	O
and	O	O
1999	O	O
.	O	O

Using	O	O
a	O	O
nested	O	O
case-control	O	O
design	O	O
,	O	O
477	O	O
cases	O	O
of	O	O
bradyarrhythmia	B_Disease	B_Disease
requiring	O	O
a	O	O
permanent	O	O
pacemaker	O	O
were	O	O
matched	O	O
(	O	O
1:4	O	O
)	O	O
to	O	O
1,908	O	O
controls	O	O
.	O	O

Multivariable	O	O
logistic	O	O
regression	O	O
was	O	O
used	O	O
to	O	O
estimate	O	O
the	O	O
odds	O	O
ratio	O	O
(	O	O
OR	O	O
)	O	O
of	O	O
pacemaker	O	O
insertion	O	O
associated	O	O
with	O	O
amiodarone	B_Chemical	O
use	O	O
,	O	O
controlling	O	O
for	O	O
baseline	O	O
risk	O	O
factors	O	O
and	O	O
exposure	O	O
to	O	O
sotalol	B_Chemical	B_Chemical
,	O	O
Class	O	O
I	O	O
antiarrhythmic	O	O
agents	O	O
,	O	O
beta-blockers	O	B_Chemical
,	O	O
calcium	B_Chemical	B_Chemical
channel	O	I_Chemical
blockers	O	I_Chemical
,	O	O
and	O	O
digoxin	B_Chemical	O
.	O	O

RESULTS	O	O
:	O	O
amiodarone	B_Chemical	O
use	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
pacemaker	O	O
insertion	O	O
(	O	O
OR	O	O
:	O	O
2.14	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
:	O	O
1.30	O	O
to	O	O
3.54	O	O
)	O	O
.	O	O

This	O	O
effect	O	O
was	O	O
modified	O	O
by	O	O
gender	O	O
,	O	O
with	O	O
a	O	O
greater	O	O
risk	O	O
in	O	O
women	O	O
versus	O	O
men	O	O
(	O	O
OR	O	O
:	O	O
3.86	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
1.70	O	O
to	O	O
8.75	O	O
vs.	O	O
OR	O	O
:	O	O
1.52	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
0.80	O	O
to	O	O
2.89	O	O
)	O	O
.	O	O

Digoxin	B_Chemical	O
was	O	O
the	O	O
only	O	O
other	O	O
medication	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
pacemaker	O	O
insertion	O	O
(	O	O
OR	O	O
:	O	O
1.78	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
1.37	O	O
to	O	O
2.31	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
This	O	O
study	O	O
suggests	O	O
that	O	O
the	O	O
use	O	O
of	O	O
amiodarone	B_Chemical	O
in	O	O
elderly	O	O
patients	O	O
with	O	O
AF	B_Disease	O
and	O	O
a	O	O
previous	O	O
MI	B_Disease	O
increases	O	O
the	O	O
risk	O	O
of	O	O
bradyarrhythmia	B_Disease	B_Disease
requiring	O	O
a	O	O
permanent	O	O
pacemaker	O	O
.	O	O

The	O	O
finding	O	O
of	O	O
an	O	O
augmented	O	O
risk	O	O
of	O	O
pacemaker	O	O
insertion	O	O
in	O	O
elderly	O	O
women	O	O
receiving	O	O
amiodarone	B_Chemical	O
requires	O	O
further	O	O
investigation	O	O
.	O	O

Indomethacin-induced	O	O
morphologic	O	O
changes	O	O
in	O	O
the	O	O
rat	O	O
urinary	O	O
bladder	O	O
epithelium	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
morphologic	O	O
changes	O	O
in	O	O
rat	O	O
urothelium	O	O
induced	O	O
by	O	O
indomethacin	B_Chemical	O
.	O	O

Nonsteroidal	O	O
anti-inflammatory	O	O
drug-induced	O	O
cystitis	B_Disease	O
is	O	O
a	O	O
poorly	O	O
recognized	O	O
and	O	O
under-reported	O	O
condition	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
tiaprofenic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
,	O	O
indomethacin	B_Chemical	O
has	O	O
been	O	O
reported	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
this	O	O
condition	O	O
.	O	O

METHODS	O	O
:	O	O
Three	O	O
groups	O	O
were	O	O
established	O	O
:	O	O
a	O	O
control	O	O
group	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
,	O	O
a	O	O
high-dose	O	O
group	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
,	O	O
treated	O	O
with	O	O
one	O	O
intraperitoneal	O	O
injection	O	O
of	O	O
indomethacin	B_Chemical	O
20	O	O
mg/kg	O	O
,	O	O
and	O	O
a	O	O
therapeutic	O	O
dose	O	O
group	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
in	O	O
which	O	O
oral	O	O
indomethacin	B_Chemical	O
was	O	O
administered	O	O
3.25	O	O
mg/kg	O	O
body	O	O
weight	O	O
daily	O	O
for	O	O
3	O	O
weeks	O	O
.	O	O

The	O	O
animals	O	O
were	O	O
then	O	O
killed	O	O
and	O	O
the	O	O
bladders	O	O
removed	O	O
for	O	O
light	O	O
and	O	O
electron	O	O
microscopic	O	O
studies	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
light	O	O
microscopic	O	O
findings	O	O
showed	O	O
some	O	O
focal	O	O
epithelial	O	O
degeneration	O	O
that	O	O
was	O	O
more	O	O
prominent	O	O
in	O	O
the	O	O
high-dose	O	O
group	O	O
.	O	O

When	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
,	O	O
both	O	O
indomethacin	B_Chemical	O
groups	O	O
revealed	O	O
statistically	O	O
increased	O	O
numbers	O	O
of	O	O
mast	O	O
cells	O	O
in	O	O
the	O	O
mucosa	O	O
(	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
and	O	O
penetration	O	O
of	O	O
lanthanum	B_Chemical	O
nitrate	I_Chemical	O
through	O	O
intercellular	O	O
areas	O	O
of	O	O
the	O	O
epithelium	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
difference	O	O
in	O	O
mast	O	O
cell	O	O
counts	O	O
between	O	O
the	O	O
high	O	O
and	O	O
therapeutic	O	O
dose	O	O
groups	O	O
was	O	O
also	O	O
statistically	O	O
significant	O	O
(	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Indomethacin	B_Chemical	O
resulted	O	O
in	O	O
histopathologic	O	O
findings	O	O
typical	O	O
of	O	O
interstitial	B_Disease	B_Disease
cystitis	I_Disease	I_Disease
,	O	O
such	O	O
as	O	O
leaky	O	O
bladder	O	O
epithelium	O	O
and	O	O
mucosal	O	O
mastocytosis	B_Disease	B_Disease
.	O	O

The	O	O
true	O	O
incidence	O	O
of	O	O
nonsteroidal	O	O
anti-inflammatory	O	O
drug-induced	O	O
cystitis	B_Disease	O
in	O	O
humans	O	O
must	O	O
be	O	O
clarified	O	O
by	O	O
prospective	O	O
clinical	O	O
trials	O	O
.	O	O

An	O	O
open-label	O	O
phase	O	O
II	O	O
study	O	O
of	O	O
low-dose	O	O
thalidomide	B_Chemical	O
in	O	O
androgen-independent	O	O
prostate	B_Disease	B_Disease
cancer	I_Disease	I_Disease
.	O	O

The	O	O
antiangiogenic	O	O
effects	O	O
of	O	O
thalidomide	B_Chemical	O
have	O	O
been	O	O
assessed	O	O
in	O	O
clinical	O	O
trials	O	O
in	O	O
patients	O	O
with	O	O
various	O	O
solid	O	O
and	O	O
haematological	B_Disease	O
malignancies	I_Disease	O
.	O	O

Thalidomide	B_Chemical	O
blocks	O	O
the	O	O
activity	O	O
of	O	O
angiogenic	O	O
agents	O	O
including	O	O
bFGF	O	O
,	O	O
VEGF	O	O
and	O	O
IL-6	O	O
.	O	O

We	O	O
undertook	O	O
an	O	O
open-label	O	O
study	O	O
using	O	O
thalidomide	B_Chemical	O
100	O	O
mg	O	O
once	O	O
daily	O	O
for	O	O
up	O	O
to	O	O
6	O	O
months	O	O
in	O	O
20	O	O
men	O	O
with	O	O
androgen-independent	O	O
prostate	B_Disease	B_Disease
cancer	I_Disease	I_Disease
.	O	O

The	O	O
mean	O	O
time	O	O
of	O	O
study	O	O
was	O	O
109	O	O
days	O	O
(	O	O
median	O	O
107	O	O
,	O	O
range	O	O
4	O	O
-	O	O
184	O	O
days	O	O
)	O	O
.	O	O

Patients	O	O
underwent	O	O
regular	O	O
measurement	O	O
of	O	O
prostate-specific	O	O
antigen	O	O
(	O	O
PSA	O	O
)	O	O
,	O	O
urea	B_Chemical	O
and	O	O
electrolytes	O	O
,	O	O
serum	O	O
bFGF	O	O
and	O	O
VEGF	O	O
.	O	O

Three	O	O
men	O	O
(	O	O
15	O	O
%	O	O
)	O	O
showed	O	O
a	O	O
decline	O	O
in	O	O
serum	O	O
PSA	O	O
of	O	O
at	O	O
least	O	O
50	O	O
%	O	O
,	O	O
sustained	O	O
throughout	O	O
treatment	O	O
.	O	O

Of	O	O
16	O	O
men	O	O
treated	O	O
for	O	O
at	O	O
least	O	O
2	O	O
months	O	O
,	O	O
six	O	O
(	O	O
37.5	O	O
%	O	O
)	O	O
showed	O	O
a	O	O
fall	O	O
in	O	O
absolute	O	O
PSA	O	O
by	O	O
a	O	O
median	O	O
of	O	O
48	O	O
%	O	O
.	O	O

Increasing	O	O
levels	O	O
of	O	O
serum	O	O
bFGF	O	O
and	O	O
VEGF	O	O
were	O	O
associated	O	O
with	O	O
progressive	O	O
disease	O	O
;	O	O
five	O	O
of	O	O
six	O	O
men	O	O
who	O	O
demonstrated	O	O
a	O	O
fall	O	O
in	O	O
PSA	O	O
also	O	O
showed	O	O
a	O	O
decline	O	O
in	O	O
bFGF	O	O
and	O	O
VEGF	O	O
levels	O	O
,	O	O
and	O	O
three	O	O
of	O	O
four	O	O
men	O	O
with	O	O
a	O	O
rising	O	O
PSA	O	O
showed	O	O
an	O	O
increase	O	O
in	O	O
both	O	O
growth	O	O
factors	O	O
.	O	O

Adverse	O	O
effects	O	O
included	O	O
constipation	B_Disease	O
,	O	O
morning	O	O
drowsiness	B_Disease	O
,	O	O
dizziness	B_Disease	O
and	O	O
rash	B_Disease	O
,	O	O
and	O	O
resulted	O	O
in	O	O
withdrawal	O	O
from	O	O
the	O	O
study	O	O
by	O	O
three	O	O
men	O	O
.	O	O

Evidence	O	O
of	O	O
peripheral	B_Disease	B_Disease
sensory	I_Disease	I_Disease
neuropathy	I_Disease	I_Disease
was	O	O
found	O	O
in	O	O
nine	O	O
of	O	O
13	O	O
men	O	O
before	O	O
treatment	O	O
.	O	O

In	O	O
the	O	O
seven	O	O
men	O	O
who	O	O
completed	O	O
six	O	O
months	O	O
on	O	O
thalidomide	B_Chemical	O
,	O	O
subclinical	O	O
evidence	O	O
of	O	O
peripheral	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
was	O	O
found	O	O
in	O	O
four	O	O
before	O	O
treatment	O	O
,	O	O
but	O	O
in	O	O
all	O	O
seven	O	O
at	O	O
repeat	O	O
testing	O	O
.	O	O

The	O	O
findings	O	O
indicate	O	O
that	O	O
thalidomide	B_Chemical	O
may	O	O
be	O	O
an	O	O
option	O	O
for	O	O
patients	O	O
who	O	O
have	O	O
failed	O	O
other	O	O
forms	O	O
of	O	O
therapy	O	O
,	O	O
provided	O	O
close	O	O
follow-up	O	O
is	O	O
maintained	O	O
for	O	O
development	O	O
of	O	O
peripheral	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
.	O	O

Central	B_Disease	O
nervous	I_Disease	O
system	I_Disease	O
toxicity	I_Disease	O
following	O	O
the	O	O
administration	O	O
of	O	O
levobupivacaine	B_Chemical	B_Chemical
for	O	O
lumbar	O	O
plexus	O	O
block	O	O
:	O	O
A	O	O
report	O	O
of	O	O
two	O	O
cases	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVES	O	O
:	O	O
Central	B_Disease	O
nervous	I_Disease	O
system	I_Disease	O
and	I_Disease	O
cardiac	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
following	O	O
the	O	O
administration	O	O
of	O	O
local	O	O
anesthetics	O	O
is	O	O
a	O	O
recognized	O	O
complication	O	O
of	O	O
regional	O	O
anesthesia	O	O
.	O	O

Levobupivacaine	B_Chemical	B_Chemical
,	O	O
the	O	O
pure	O	O
S(-	O	O
)	O	O
enantiomer	O	O
of	O	O
bupivacaine	B_Chemical	B_Chemical
,	O	O
was	O	O
developed	O	O
to	O	O
improve	O	O
the	O	O
cardiac	O	O
safety	O	O
profile	O	O
of	O	O
bupivacaine	B_Chemical	B_Chemical
.	O	O

We	O	O
describe	O	O
2	O	O
cases	O	O
of	O	O
grand	B_Disease	O
mal	I_Disease	O
seizures	I_Disease	O
following	O	O
accidental	O	O
intravascular	O	O
injection	O	O
of	O	O
levobupivacaine	B_Chemical	B_Chemical
.	O	O

CASE	O	O
REPORT	O	O
:	O	O
Two	O	O
patients	O	O
presenting	O	O
for	O	O
elective	O	O
orthopedic	O	O
surgery	O	O
of	O	O
the	O	O
lower	O	O
limb	O	O
underwent	O	O
blockade	O	O
of	O	O
the	O	O
lumbar	O	O
plexus	O	O
via	O	O
the	O	O
posterior	O	O
approach	O	O
.	O	O

Immediately	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
levobupivacaine	B_Chemical	B_Chemical
0.5	O	O
%	O	O
with	O	O
epinephrine	B_Chemical	O
2.5	O	O
microgram/mL	O	O
,	O	O
the	O	O
patients	O	O
developed	O	O
grand	B_Disease	B_Disease
mal	I_Disease	I_Disease
seizures	I_Disease	I_Disease
,	O	O
despite	O	O
negative	O	O
aspiration	O	O
for	O	O
blood	O	O
and	O	O
no	O	O
clinical	O	O
signs	O	O
of	O	O
intravenous	O	O
epinephrine	B_Chemical	O
administration	O	O
.	O	O

The	O	O
seizures	B_Disease	O
were	O	O
successfully	O	O
treated	O	O
with	O	O
sodium	B_Chemical	O
thiopental	I_Chemical	O
in	O	O
addition	O	O
to	O	O
succinylcholine	B_Chemical	O
in	O	O
1	O	O
patient	O	O
.	O	O

Neither	O	O
patient	O	O
developed	O	O
signs	O	O
of	O	O
cardiovascular	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
.	O	O

Both	O	O
patients	O	O
were	O	O
treated	O	O
preoperatively	O	O
with	O	O
beta-adrenergic	O	O
antagonist	O	O
medications	O	O
,	O	O
which	O	O
may	O	O
have	O	O
masked	O	O
the	O	O
cardiovascular	O	O
signs	O	O
of	O	O
the	O	O
unintentional	O	O
intravascular	O	O
administration	O	O
of	O	O
levobupivacaine	B_Chemical	B_Chemical
with	O	O
epinephrine	B_Chemical	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Although	O	O
levobupivacaine	B_Chemical	B_Chemical
may	O	O
have	O	O
a	O	O
safer	O	O
cardiac	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
profile	O	O
than	O	O
racemic	O	O
bupivacaine	B_Chemical	B_Chemical
,	O	O
if	O	O
adequate	O	O
amounts	O	O
of	O	O
levobupivacaine	B_Chemical	B_Chemical
reach	O	O
the	O	O
circulation	O	O
,	O	O
it	O	O
will	O	O
result	O	O
in	O	O
convulsions	B_Disease	O
.	O	O

Plasma	O	O
concentrations	O	O
sufficient	O	O
to	O	O
result	O	O
in	O	O
central	B_Disease	O
nervous	I_Disease	O
system	I_Disease	O
toxicity	I_Disease	O
did	O	O
not	O	O
produce	O	O
manifestations	O	O
of	O	O
cardiac	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
in	O	O
these	O	O
2	O	O
patients	O	O
.	O	O

Amiodarone-induced	O	O
torsade	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
during	O	O
bladder	O	O
irrigation	O	O
:	O	O
an	O	O
unusual	O	O
presentation	O	O
--	O	O
a	O	O
case	O	O
report	O	O
.	O	O

The	O	O
authors	O	O
present	O	O
a	O	O
case	O	O
of	O	O
early	O	O
(	O	O
within	O	O
4	O	O
days	O	O
)	O	O
development	O	O
of	O	O
torsade	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
(	O	O
TdP	B_Disease	O
)	O	O
associated	O	O
with	O	O
oral	O	O
amiodarone	B_Chemical	O
therapy	O	O
.	O	O

Consistent	O	O
with	O	O
other	O	O
reports	O	O
this	O	O
case	O	O
of	O	O
TdP	B_Disease	O
occurred	O	O
in	O	O
the	O	O
context	O	O
of	O	O
multiple	O	O
exacerbating	O	O
factors	O	O
including	O	O
hypokalemia	B_Disease	O
and	O	O
digoxin	B_Chemical	O
excess	O	O
.	O	O

Transient	O	O
prolongation	O	O
of	O	O
the	O	O
QT	O	O
during	O	O
bladder	O	O
irrigation	O	O
prompted	O	O
the	O	O
episode	O	O
of	O	O
TdP.	O	O
It	O	O
is	O	O
well	O	O
known	O	O
that	O	O
bradycardia	B_Disease	O
exacerbates	O	O
acquired	O	O
TdP.	O	O
The	O	O
authors	O	O
speculate	O	O
that	O	O
the	O	O
increased	O	O
vagal	O	O
tone	O	O
during	O	O
bladder	O	O
irrigation	O	O
,	O	O
a	O	O
vagal	O	O
maneuver	O	O
,	O	O
in	O	O
the	O	O
context	O	O
of	O	O
amiodarone	B_Chemical	O
therapy	O	O
resulted	O	O
in	O	O
amiodarone-induced	O	O
proarrhythmia	B_Disease	O
.	O	O

In	O	O
the	O	O
absence	O	O
of	O	O
amiodarone	B_Chemical	O
therapy	O	O
,	O	O
a	O	O
second	O	O
bladder	O	O
irrigation	O	O
did	O	O
not	O	O
induce	O	O
TdP	B_Disease	O
despite	O	O
hypokalemia	B_Disease	O
and	O	O
hypomagnesemia	B_Disease	O
.	O	O

Anaesthetic	O	O
complications	O	O
associated	O	O
with	O	O
myotonia	B_Disease	B_Disease
congenita	I_Disease	I_Disease
:	O	O
case	O	O
study	O	O
and	O	O
comparison	O	O
with	O	O
other	O	O
myotonic	B_Disease	B_Disease
disorders	I_Disease	I_Disease
.	O	O

Myotonia	B_Disease	O
congenita	I_Disease	O
(	O	O
MC	B_Disease	O
)	O	O
is	O	O
caused	O	O
by	O	O
a	O	O
defect	O	O
in	O	O
the	O	O
skeletal	O	O
muscle	O	O
chloride	B_Chemical	O
channel	O	O
function	O	O
,	O	O
which	O	O
may	O	O
cause	O	O
sustained	B_Disease	O
membrane	I_Disease	O
depolarisation	I_Disease	O
.	O	O

We	O	O
describe	O	O
a	O	O
previously	O	O
healthy	O	O
32-year-old	O	O
woman	O	O
who	O	O
developed	O	O
a	O	O
life-threatening	O	O
muscle	B_Disease	B_Disease
spasm	I_Disease	I_Disease
and	O	O
secondary	O	O
ventilation	O	O
difficulties	O	O
following	O	O
a	O	O
preoperative	O	O
injection	O	O
of	O	O
suxamethonium	B_Chemical	B_Chemical
.	O	O

The	O	O
muscle	B_Disease	O
spasms	I_Disease	O
disappeared	O	O
spontaneously	O	O
and	O	O
the	O	O
surgery	O	O
proceeded	O	O
without	O	O
further	O	O
problems	O	O
.	O	O

When	O	O
subsequently	O	O
questioned	O	O
,	O	O
she	O	O
reported	O	O
minor	O	O
symptoms	O	O
suggesting	O	O
a	O	O
myotonic	B_Disease	B_Disease
condition	I_Disease	I_Disease
.	O	O

Myotonia	B_Disease	O
was	O	O
found	O	O
on	O	O
clinical	O	O
examination	O	O
and	O	O
EMG	O	O
.	O	O

The	O	O
diagnosis	O	O
MC	B_Disease	O
was	O	O
confirmed	O	O
genetically	O	O
.	O	O

Neither	O	O
the	O	O
patient	O	O
nor	O	O
the	O	O
anaesthetist	O	O
were	O	O
aware	O	O
of	O	O
the	O	O
diagnosis	O	O
before	O	O
this	O	O
potentially	O	O
lethal	O	O
complication	O	O
occurred	O	O
.	O	O

We	O	O
give	O	O
a	O	O
brief	O	O
overview	O	O
of	O	O
ion	B_Disease	O
channel	I_Disease	O
disorders	I_Disease	O
including	O	O
malignant	B_Disease	B_Disease
hyperthermia	I_Disease	I_Disease
and	O	O
their	O	O
anaesthetic	O	O
considerations	O	O
.	O	O

Respiratory	O	O
pattern	O	O
in	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
epilepsy	O	O
.	O	O

PURPOSE	O	O
:	O	O
Apnea	B_Disease	O
is	O	O
known	O	O
to	O	O
occur	O	O
during	O	O
seizures	B_Disease	O
,	O	O
but	O	O
systematic	O	O
studies	O	O
of	O	O
ictal	O	O
respiratory	O	O
changes	O	O
in	O	O
adults	O	O
are	O	O
few	O	O
.	O	O

Data	O	O
regarding	O	O
respiratory	O	O
pattern	O	O
defects	O	O
during	O	O
interictal	O	O
periods	O	O
also	O	O
are	O	O
scarce	O	O
.	O	O

Here	O	O
we	O	O
sought	O	O
to	O	O
generate	O	O
information	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
interictal	O	O
period	O	O
in	O	O
animals	O	O
with	O	O
pilocarpine-induced	O	O
epilepsy	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
Twelve	O	O
rats	O	O
(	O	O
six	O	O
chronically	O	O
epileptic	B_Disease	O
animals	O	O
and	O	O
six	O	O
controls	O	O
)	O	O
were	O	O
anesthetized	O	O
,	O	O
given	O	O
tracheotomies	O	O
,	O	O
and	O	O
subjected	O	O
to	O	O
hyperventilation	B_Disease	O
or	O	O
hypoventilation	O	O
conditions	O	O
.	O	O

Breathing	O	O
movements	O	O
caused	O	O
changes	O	O
in	O	O
thoracic	O	O
volume	O	O
and	O	O
forced	O	O
air	O	O
to	O	O
flow	O	O
tidally	O	O
through	O	O
a	O	O
pneumotachograph	O	O
.	O	O

This	O	O
flow	O	O
was	O	O
measured	O	O
by	O	O
using	O	O
a	O	O
differential	O	O
pressure	O	O
transducer	O	O
,	O	O
passed	O	O
through	O	O
a	O	O
polygraph	O	O
,	O	O
and	O	O
from	O	O
this	O	O
to	O	O
a	O	O
computer	O	O
with	O	O
custom	O	O
software	O	O
that	O	O
derived	O	O
ventilation	O	O
(	O	O
VE	O	O
)	O	O
,	O	O
tidal	O	O
volume	O	O
(	O	O
VT	O	O
)	O	O
,	O	O
inspiratory	O	O
time	O	O
(	O	O
TI	O	O
)	O	O
,	O	O
expiratory	O	O
time	O	O
(	O	O
TE	O	O
)	O	O
,	O	O
breathing	O	O
frequency	O	O
(	O	O
f	O	O
)	O	O
,	O	O
and	O	O
mean	O	O
inspiratory	O	O
flow	O	O
(	O	O
VT/TI	O	O
)	O	O
on	O	O
a	O	O
breath-by-breath	O	O
basis	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
hyperventilation	B_Disease	O
maneuver	O	O
caused	O	O
a	O	O
decrease	O	O
in	O	O
spontaneous	O	O
ventilation	O	O
in	O	O
pilocarpine-treated	O	O
and	O	O
control	O	O
rats	O	O
.	O	O

Although	O	O
VE	O	O
had	O	O
a	O	O
similar	O	O
decrease	O	O
in	O	O
both	O	O
groups	O	O
,	O	O
in	O	O
the	O	O
epileptic	B_Disease	O
group	O	O
,	O	O
the	O	O
decrease	O	O
in	O	O
VE	O	O
was	O	O
due	O	O
to	O	O
a	O	O
significant	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
increase	O	O
in	O	O
TE	O	O
peak	O	O
in	O	O
relation	O	O
to	O	O
that	O	O
of	O	O
the	O	O
control	O	O
animals	O	O
.	O	O

The	O	O
hypoventilation	O	O
maneuver	O	O
led	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
arterial	O	O
Paco2	O	O
,	O	O
followed	O	O
by	O	O
an	O	O
increase	O	O
in	O	O
VE	O	O
.	O	O

In	O	O
the	O	O
epileptic	B_Disease	O
group	O	O
,	O	O
the	O	O
increase	O	O
in	O	O
VE	O	O
was	O	O
mediated	O	O
by	O	O
a	O	O
significant	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
decrease	O	O
in	O	O
TE	O	O
peak	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Systemic	O	O
application	O	O
of	O	O
KCN	O	O
,	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
peripheral	O	O
chemoreception	O	O
activation	O	O
on	O	O
ventilation	O	O
,	O	O
led	O	O
to	O	O
a	O	O
similar	O	O
increase	O	O
in	O	O
VE	O	O
for	O	O
both	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
data	O	O
indicate	O	O
that	O	O
pilocarpine-treated	O	O
animals	O	O
have	O	O
an	O	O
altered	O	O
ability	O	O
to	O	O
react	O	O
to	O	O
(	O	O
or	O	O
compensate	O	O
for	O	O
)	O	O
blood	O	O
gas	O	O
changes	O	O
with	O	O
changes	O	O
in	O	O
ventilation	O	O
and	O	O
suggest	O	O
that	O	O
it	O	O
is	O	O
centrally	O	O
determined	O	O
.	O	O

We	O	O
speculate	O	O
on	O	O
the	O	O
possible	O	O
relation	O	O
of	O	O
the	O	O
current	O	O
findings	O	O
on	O	O
treating	O	O
different	O	O
epilepsy-associated	O	O
conditions	O	O
.	O	O

Fatal	O	O
myeloencephalopathy	B_Disease	B_Disease
due	O	O
to	O	O
intrathecal	O	O
vincristine	B_Chemical	O
administration	O	O
.	O	O

Vincristine	B_Chemical	O
was	O	O
accidentally	O	O
given	O	O
intrathecally	O	O
to	O	O
a	O	O
child	O	O
with	O	O
leukaemia	B_Disease	O
,	O	O
producing	O	O
sensory	B_Disease	O
and	I_Disease	O
motor	I_Disease	B_Disease
dysfunction	I_Disease	I_Disease
followed	O	O
by	O	O
encephalopathy	B_Disease	O
and	O	O
death	O	O
.	O	O

Separate	O	O
times	O	O
for	O	O
administering	O	O
vincristine	B_Chemical	O
and	O	O
intrathecal	O	O
therapy	O	O
is	O	O
recommended	O	O
.	O	O

Progesterone	B_Chemical	O
potentiation	O	O
of	O	O
bupivacaine	B_Chemical	O
arrhythmogenicity	O	O
in	O	O
pentobarbital-anesthetized	O	O
rats	O	O
and	O	O
beating	O	O
rat	O	O
heart	O	O
cell	O	O
cultures	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
progesterone	B_Chemical	O
treatment	O	O
on	O	O
bupivacaine	B_Chemical	O
arrhythmogenicity	O	O
in	O	O
beating	O	O
rat	O	O
heart	O	O
myocyte	O	O
cultures	O	O
and	O	O
on	O	O
anesthetized	O	O
rats	O	O
were	O	O
determined	O	O
.	O	O

After	O	O
determining	O	O
the	O	O
bupivacaine	B_Chemical	B_Chemical
AD50	O	O
(	O	O
the	O	O
concentration	O	O
of	O	O
bupivacaine	B_Chemical	B_Chemical
that	O	O
caused	O	O
50	O	O
%	O	O
of	O	O
all	O	O
beating	O	O
rat	O	O
heart	O	O
myocyte	O	O
cultures	O	O
to	O	O
become	O	O
arrhythmic	B_Disease	O
)	O	O
,	O	O
we	O	O
determined	O	O
the	O	O
effect	O	O
of	O	O
1-hour	O	O
progesterone	B_Chemical	O
HCl	B_Chemical	O
exposure	O	O
on	O	O
myocyte	O	O
contractile	O	O
rhythm	O	O
.	O	O

Each	O	O
concentration	O	O
of	O	O
progesterone	B_Chemical	O
(	O	O
6.25	O	O
,	O	O
12.5	O	O
,	O	O
25	O	O
,	O	O
and	O	O
50	O	O
micrograms/ml	O	O
)	O	O
caused	O	O
a	O	O
significant	O	O
and	O	O
concentration-dependent	O	O
reduction	O	O
in	O	O
the	O	O
AD50	O	O
for	O	O
bupivacaine	B_Chemical	B_Chemical
.	O	O

Estradiol	B_Chemical	O
treatment	O	O
also	O	O
increased	O	O
the	O	O
arrhythmogenicity	O	B_Disease
of	O	O
bupivacaine	B_Chemical	B_Chemical
in	O	O
myocyte	O	O
cultures	O	O
,	O	O
but	O	O
was	O	O
only	O	O
one	O	O
fourth	O	O
as	O	O
potent	O	O
as	O	O
progesterone	B_Chemical	O
.	O	O

Neither	O	O
progesterone	B_Chemical	O
nor	O	O
estradiol	B_Chemical	O
effects	O	O
on	O	O
bupivacaine	B_Chemical	O
arrhythmogenicity	O	O
were	O	O
potentiated	O	O
by	O	O
epinephrine	B_Chemical	O
.	O	O

Chronic	O	O
progesterone	B_Chemical	O
pretreatment	O	O
(	O	O
5	O	O
mg/kg/day	O	O
for	O	O
21	O	O
days	O	O
)	O	O
caused	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
bupivacaine	B_Chemical	O
arrhythmogenicity	O	O
in	O	O
intact	O	O
pentobarbital-anesthetized	O	O
rats	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
the	O	O
time	O	O
to	O	O
onset	O	O
of	O	O
arrhythmia	B_Disease	O
as	O	O
compared	O	O
with	O	O
control	O	O
nonprogesterone-treated	O	O
rats	O	O
(	O	O
6.2	O	O
+	O	O
/-	O	O
1.3	O	O
vs.	O	O
30.8	O	O
+	O	O
/-	O	O
2.5	O	O
min	O	O
,	O	O
mean	O	O
+	O	O
/-	O	O
SE	O	O
)	O	O
.	O	O

The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
indicate	O	O
that	O	O
progesterone	B_Chemical	O
can	O	O
potentiate	O	O
bupivacaine	B_Chemical	O
arrhythmogenicity	O	O
both	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
.	O	O

Potentiation	O	O
of	O	O
bupivacaine	B_Chemical	O
arrhythmia	B_Disease	O
in	O	O
myocyte	O	O
cultures	O	O
suggests	O	O
that	O	O
this	O	O
effect	O	O
is	O	O
at	O	O
least	O	O
partly	O	O
mediated	O	O
at	O	O
the	O	O
myocyte	O	O
level	O	O
.	O	O

Increased	O	O
serum	O	O
soluble	O	O
Fas	O	O
in	O	O
patients	O	O
with	O	O
acute	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
due	O	O
to	O	O
paracetamol	B_Chemical	O
overdose	B_Disease	O
.	O	O

BACKGROUND/AIMS	O	O
:	O	O
Experimental	O	O
studies	O	O
have	O	O
suggested	O	O
that	O	O
apoptosis	O	O
via	O	O
the	O	O
Fas/Fas	O	O
Ligand	O	O
signaling	O	O
system	O	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
development	O	O
of	O	O
acute	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
soluble	O	O
form	O	O
of	O	O
Fas	O	O
in	O	O
patients	O	O
with	O	O
acute	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

METHODOLOGY	O	O
:	O	O
Serum	O	O
levels	O	O
of	O	O
sFas	O	O
(	O	O
soluble	O	O
Fas	O	O
)	O	O
were	O	O
measured	O	O
by	O	O
ELISA	O	O
in	O	O
24	O	O
patients	O	O
with	O	O
acute	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
and	O	O
10	O	O
normal	O	O
control	O	O
subjects	O	O
.	O	O

Serum	O	O
levels	O	O
of	O	O
tumor	B_Disease	O
necrosis	B_Disease	O
factor-alpha	O	O
and	O	O
interferon-gamma	O	O
were	O	O
also	O	O
determined	O	O
by	O	O
ELISA	O	O
.	O	O

RESULTS	O	O
:	O	O
Serum	O	O
sFas	O	O
was	O	O
significantly	O	O
increased	O	O
in	O	O
patients	O	O
with	O	O
acute	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
(	O	O
median	O	O
,	O	O
26.8	O	O
U/mL	O	O
;	O	O
range	O	O
,	O	O
6.9	O	O
-	O	O
52.7	O	O
U/mL	O	O
)	O	O
compared	O	O
to	O	O
the	O	O
normal	O	O
controls	O	O
(	O	O
median	O	O
,	O	O
8.6	O	O
U/mL	O	O
;	O	O
range	O	O
,	O	O
6.5	O	O
-	O	O
12.0	O	O
U/mL	O	O
,	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Levels	O	O
were	O	O
significantly	O	O
greater	O	O
in	O	O
patients	O	O
with	O	O
acute	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
due	O	O
to	O	O
paracetamol	B_Chemical	O
overdose	B_Disease	O
(	O	O
median	O	O
,	O	O
28.7	O	O
U/mL	O	O
;	O	O
range	O	O
,	O	O
12.8	O	O
-	O	O
52.7	O	O
U/mL	O	O
,	O	O
n	O	O
=	O	O
17	O	O
)	O	O
than	O	O
those	O	O
due	O	O
to	O	O
non-A	O	O
to	O	O
E	O	O
hepatitis	B_Disease	O
(	O	O
median	O	O
,	O	O
12.5	O	O
U/mL	O	O
;	O	O
range	O	O
,	O	O
6.9	O	O
-	O	O
46.0	O	O
U/mL	O	O
,	O	O
n	O	O
=	O	O
7	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
relationship	O	O
of	O	O
sFas	O	O
to	O	O
eventual	O	O
outcome	O	O
in	O	O
the	O	O
patients	O	O
.	O	O

A	O	O
significant	O	O
correlation	O	O
was	O	O
observed	O	O
between	O	O
serum	O	O
sFas	O	O
levels	O	O
and	O	O
aspartate	B_Chemical	B_Chemical
aminotransferase	O	I_Chemical
(	O	O
r	O	O
=	O	O
0.613	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
increased	O	O
concentration	O	O
of	O	O
sFas	O	O
in	O	O
serum	O	O
of	O	O
patients	O	O
with	O	O
acute	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
may	O	O
reflect	O	O
activation	O	O
of	O	O
Fas-mediated	O	O
apoptosis	O	O
in	O	O
the	O	O
liver	O	O
and	O	O
this	O	O
together	O	O
with	O	O
increased	O	O
tumor	B_Disease	B_Disease
necrosis	B_Disease	I_Disease
factor-alpha	O	O
may	O	O
be	O	O
an	O	O
important	O	O
factor	O	O
in	O	O
liver	O	O
cell	O	O
loss	O	O
.	O	O

Bilateral	O	O
subthalamic	O	O
nucleus	O	O
stimulation	O	O
for	O	O
Parkinson	O	O
's	O	O
disease	O	O
.	O	O

High	O	O
frequency	O	O
stimulation	O	O
of	O	O
the	O	O
subthalamic	O	O
nucleus	O	O
(	O	O
STN	O	O
)	O	O
is	O	O
known	O	O
to	O	O
ameliorate	O	O
the	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
advanced	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
.	O	O

AIM	O	O
:	O	O
We	O	O
studied	O	O
the	O	O
effect	O	O
of	O	O
high	O	O
frequency	O	O
STN	O	O
stimulation	O	O
in	O	O
23	O	O
patients	O	O
.	O	O

METHOD	O	O
:	O	O
Twenty-three	O	O
patients	O	O
suffering	O	O
from	O	O
severe	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
(	O	O
Stages	O	O
III-V	O	O
on	O	O
Hoehn	O	O
and	O	O
Yahr	O	O
scale	O	O
)	O	O
and	O	O
,	O	O
particularly	O	O
bradykinesia	B_Disease	O
,	O	O
rigidity	B_Disease	O
,	O	O
and	O	O
levodopa-induced	O	O
dyskinesias	B_Disease	O
underwent	O	O
bilateral	O	O
implantation	O	O
of	O	O
electrodes	O	O
in	O	O
the	O	O
STN	O	O
.	O	O

Preoperative	O	O
and	O	O
postoperative	O	O
assessments	O	O
of	O	O
these	O	O
patients	O	O
at	O	O
1	O	O
,	O	O
3	O	O
,	O	O
6	O	O
and	O	O
12	O	O
months	O	O
follow-up	O	O
,	O	O
in	O	O
"	O	O
on	O	O
"	O	O
and	O	O
"	O	O
off	O	O
"	O	O
drug	O	O
conditions	O	O
,	O	O
was	O	O
carried	O	O
out	O	O
using	O	O
Unified	O	O
Parkinson	B_Disease	O
's	I_Disease	O
Disease	I_Disease	O
Rating	O	O
Scale	O	O
,	O	O
Hoehn	O	O
and	O	O
Yahr	O	O
staging	O	O
,	O	O
England	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
score	O	O
and	O	O
video	O	O
recordings	O	O
.	O	O

RESULTS	O	O
:	O	O
After	O	O
one	O	O
year	O	O
of	O	O
electrical	O	O
stimulation	O	O
of	O	O
the	O	O
STN	O	O
,	O	O
the	O	O
patients	O	O
'	O	O
scores	O	O
for	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
and	O	O
motor	O	O
examination	O	O
scores	O	O
(	O	O
Unified	O	O
Parkinson	B_Disease	O
's	I_Disease	O
Disease	I_Disease	O
Rating	O	O
Scale	O	O
parts	O	O
II	O	O
and	O	O
III	O	O
)	O	O
off	O	O
medication	O	O
improved	O	O
by	O	O
62	O	O
%	O	O
and	O	O
61	O	O
%	O	O
respectively	O	O
(	O	O
p<0.0005	O	O
)	O	O
.	O	O

The	O	O
subscores	O	O
for	O	O
the	O	O
akinesia	B_Disease	O
,	O	O
rigidity	B_Disease	O
,	O	O
tremor	B_Disease	O
and	O	O
gait	O	O
also	O	O
improved	O	O
.	O	O

(	O	O
p<0.0005	O	O
)	O	O
.	O	O

The	O	O
average	O	O
levodopa	B_Chemical	O
dose	O	O
decreased	O	O
from	O	O
813	O	O
mg	O	O
to	O	O
359	O	O
mg	O	O
.	O	O

The	O	O
cognitive	O	O
functions	O	O
remained	O	O
unchanged	O	O
.	O	O

Two	O	O
patients	O	O
developed	O	O
device-related	O	O
complications	O	O
and	O	O
two	O	O
patients	O	O
experienced	O	O
abnormal	O	O
weight	O	O
gain	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Bilateral	O	O
subthalamic	O	O
nucleus	O	O
stimulation	O	O
is	O	O
an	O	O
effective	O	O
treatment	O	O
for	O	O
advanced	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
.	O	O

It	O	O
reduces	O	O
the	O	O
severity	O	O
of	O	O
"	O	O
off	O	O
"	O	O
phase	O	O
symptoms	O	O
,	O	O
improves	O	O
the	O	O
axial	O	B_Disease
symptoms	O	I_Disease
and	O	O
reduces	O	O
levodopa	B_Chemical	O
requirements	O	O
.	O	O

The	O	O
reduction	O	O
in	O	O
the	O	O
levodopa	B_Chemical	O
dose	O	O
is	O	O
useful	O	O
in	O	O
controlling	O	O
drug-induced	B_Disease	O
dyskinesias	I_Disease	O
.	O	O

Acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
occurring	O	O
during	O	O
intravenous	O	O
desferrioxamine	B_Chemical	B_Chemical
therapy	O	O
:	O	O
recovery	O	O
after	O	O
haemodialysis	O	O
.	O	O

A	O	O
patient	O	O
with	O	O
transfusion-dependent	O	O
thalassemia	B_Disease	O
was	O	O
undergoing	O	O
home	O	O
intravenous	O	O
desferrioxamine	B_Chemical	B_Chemical
(	O	O
DFX	B_Chemical	B_Chemical
)	O	O
treatment	O	O
by	O	O
means	O	O
of	O	O
a	O	O
totally	O	O
implanted	O	O
system	O	O
because	O	O
of	O	O
his	O	O
poor	O	O
compliance	O	O
with	O	O
the	O	O
nightly	O	O
subcutaneous	O	O
therapy	O	O
.	O	O

Due	O	O
to	O	O
an	O	O
accidental	O	O
malfunctioning	O	O
of	O	O
the	O	O
infusion	O	O
pump	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
inadvertently	O	O
administered	O	O
a	O	O
toxic	O	O
dosage	O	O
of	O	O
the	O	O
drug	O	O
which	O	O
caused	O	O
renal	B_Disease	B_Disease
insufficiency	I_Disease	I_Disease
.	O	O

Given	O	O
the	O	O
progressive	O	O
deterioration	O	O
of	O	O
the	O	O
symptoms	O	O
and	O	O
of	O	O
the	O	O
laboratory	O	O
values	O	O
,	O	O
despite	O	O
adequate	O	O
medical	O	O
treatment	O	O
,	O	O
a	O	O
decision	O	O
was	O	O
made	O	O
to	O	O
introduce	O	O
haemodialytical	O	O
therapy	O	O
in	O	O
order	O	O
to	O	O
remove	O	O
the	O	O
drug	O	O
and	O	O
therapy	O	O
reduce	O	O
the	O	O
nephrotoxicity	B_Disease	B_Disease
.	O	O

From	O	O
the	O	O
results	O	O
obtained	O	O
,	O	O
haemodialysis	O	O
can	O	O
therefore	O	O
be	O	O
suggested	O	O
as	O	O
a	O	O
useful	O	O
therapy	O	O
in	O	O
rare	O	O
cases	O	O
of	O	O
progressive	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
caused	O	O
by	O	O
desferrioxamine	B_Chemical	B_Chemical
.	O	O

Ocular	O	O
motility	O	O
changes	O	O
after	O	O
subtenon	O	B_Chemical
carboplatin	B_Chemical	I_Chemical
chemotherapy	O	O
for	O	O
retinoblastoma	B_Disease	O
.	O	O

BACKGROUND	O	O
:	O	O
Focal	O	O
subtenon	O	B_Chemical
carboplatin	B_Chemical	I_Chemical
injections	O	O
have	O	O
recently	O	O
been	O	O
used	O	O
as	O	O
a	O	O
presumably	O	O
toxicity-free	O	O
adjunct	O	O
to	O	O
systemic	O	O
chemotherapy	O	O
for	O	O
intraocular	O	O
retinoblastoma	B_Disease	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
our	O	O
clinical	O	O
experience	O	O
with	O	O
abnormal	B_Disease	O
ocular	I_Disease	O
motility	I_Disease	O
in	O	O
patients	O	O
treated	O	O
with	O	O
subtenon	O	B_Chemical
carboplatin	B_Chemical	I_Chemical
chemotherapy	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
noted	O	O
abnormal	B_Disease	O
ocular	I_Disease	O
motility	I_Disease	O
in	O	O
10	O	O
consecutive	O	O
patients	O	O
with	O	O
retinoblastoma	B_Disease	O
who	O	O
had	O	O
received	O	O
subtenon	O	B_Chemical
carboplatin	B_Chemical	I_Chemical
.	O	O

During	O	O
ocular	O	O
manipulation	O	O
under	O	O
general	O	O
anesthesia	O	O
,	O	O
we	O	O
assessed	O	O
their	O	O
eyes	O	O
by	O	O
forced	O	O
duction	O	O
testing	O	O
,	O	O
comparing	O	O
ocular	O	O
motility	O	O
after	O	O
tumor	B_Disease	O
control	O	O
with	O	O
ocular	O	O
motility	O	O
at	O	O
diagnosis	O	O
.	O	O

Eyes	O	O
subsequently	O	O
enucleated	O	O
because	O	O
of	O	O
treatment	O	O
failure	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
were	O	O
examined	O	O
histologically	O	O
.	O	O

RESULTS	O	O
:	O	O
Limitation	O	O
of	O	O
ocular	O	O
motility	O	O
was	O	O
detected	O	O
in	O	O
all	O	O
12	O	O
eyes	O	O
of	O	O
10	O	O
patients	O	O
treated	O	O
for	O	O
intraocular	O	O
retinoblastoma	B_Disease	O
with	O	O
1	O	O
to	O	O
6	O	O
injections	O	O
of	O	O
subtenon	O	B_Chemical
carboplatin	B_Chemical	I_Chemical
as	O	O
part	O	O
of	O	O
multimodality	O	O
therapy	O	O
.	O	O

Histopathological	O	O
examination	O	O
revealed	O	O
many	O	O
lipophages	O	O
in	O	O
the	O	O
periorbital	O	O
fat	O	O
surrounding	O	O
the	O	O
optic	O	O
nerve	O	O
in	O	O
1	O	O
eye	O	O
,	O	O
indicative	O	O
of	O	O
phagocytosis	O	O
of	O	O
previously	O	O
existing	O	O
fat	O	O
cells	O	O
and	O	O
suggesting	O	O
prior	O	O
fat	O	O
necrosis	B_Disease	O
.	O	O

The	O	O
enucleations	O	O
were	O	O
technically	O	O
difficult	O	O
and	O	O
hazardous	O	O
for	O	O
globe	O	O
rupture	B_Disease	O
because	O	O
of	O	O
extensive	O	O
orbital	O	O
soft	O	O
tissue	O	O
adhesions	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Subtenon	O	B_Chemical
carboplatin	B_Chemical	I_Chemical
chemotherapy	O	O
is	O	O
associated	O	O
with	O	O
significant	O	O
fibrosis	B_Disease	O
of	O	O
orbital	O	O
soft	O	O
tissues	O	O
,	O	O
leading	O	O
to	O	O
mechanical	O	O
restriction	O	O
of	O	O
eye	O	O
movements	O	O
and	O	O
making	O	O
subsequent	O	O
enucleation	O	O
difficult	O	O
.	O	O

Subtenon	O	B_Chemical
carboplatin	B_Chemical	I_Chemical
is	O	O
not	O	O
free	O	O
of	O	O
toxicity	B_Disease	O
,	O	O
and	O	O
its	O	O
use	O	O
is	O	O
best	O	O
restricted	O	O
to	O	O
specific	O	O
indications	O	O
.	O	O

Ethambutol	B_Chemical	B_Chemical
and	O	O
optic	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
demonstrate	O	O
the	O	O
association	O	O
between	O	O
ethambutol	B_Chemical	B_Chemical
and	O	O
optic	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
.	O	O

METHOD	O	O
:	O	O
Thirteen	O	O
patients	O	O
who	O	O
developed	O	O
optic	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
after	O	O
being	O	O
treated	O	O
with	O	O
ethambutol	B_Chemical	B_Chemical
for	O	O
tuberculosis	B_Disease	O
of	I_Disease	O
the	I_Disease	O
lung	I_Disease	O
or	I_Disease	O
lymph	I_Disease	O
node	I_Disease	O
at	O	O
Siriraj	O	O
Hospital	O	O
between	O	O
1997	O	O
and	O	O
2001	O	O
were	O	O
retrospectively	O	O
reviewed	O	O
.	O	O

The	O	O
clinical	O	O
characteristics	O	O
and	O	O
initial	O	O
and	O	O
final	O	O
visual	O	O
acuity	O	O
were	O	O
analyzed	O	O
to	O	O
determine	O	O
visual	O	O
outcome	O	O
.	O	O

RESULTS	O	O
:	O	O
All	O	O
patients	O	O
had	O	O
optic	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
between	O	O
1	O	O
to	O	O
6	O	O
months	O	O
(	O	O
mean	O	O
=	O	O
2.9	O	O
months	O	O
)	O	O
after	O	O
starting	O	O
ethambutol	B_Chemical	B_Chemical
therapy	O	O
at	O	O
a	O	O
dosage	O	O
ranging	O	O
from	O	O
13	O	O
to	O	O
20	O	O
mg/kg/day	O	O
(	O	O
mean	O	O
=	O	O
17	O	O
mg/kg/day	O	O
)	O	O
.	O	O

Seven	O	O
(	O	O
54	O	O
%	O	O
)	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
experienced	O	O
visual	O	O
recovery	O	O
after	O	O
stopping	O	O
the	O	O
drug	O	O
.	O	O

Of	O	O
6	O	O
patients	O	O
with	O	O
irreversible	O	O
visual	B_Disease	B_Disease
impairment	I_Disease	I_Disease
,	O	O
4	O	O
patients	O	O
had	O	O
diabetes	B_Disease	O
mellitus	I_Disease	O
,	O	O
glaucoma	B_Disease	O
and	O	O
a	O	O
history	O	O
of	O	O
heavy	O	O
smoking	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Early	O	O
recognition	O	O
of	O	O
optic	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
with	O	O
ethambutol	B_Chemical	B_Chemical
therapy	O	O
.	O	O

A	O	O
low	O	O
dose	O	O
and	O	O
prompt	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
is	O	O
recommended	O	O
particularly	O	O
in	O	O
individuals	O	O
with	O	O
diabetes	B_Disease	O
mellitus	I_Disease	O
,	O	O
glaucoma	B_Disease	O
or	O	O
who	O	O
are	O	O
heavy	O	O
smokers	O	O
.	O	O

Treatment	O	O
of	O	O
compensatory	O	O
gustatory	B_Disease	O
hyperhidrosis	I_Disease	O
with	O	O
topical	O	O
glycopyrrolate	B_Chemical	B_Chemical
.	O	O

Gustatory	B_Disease	O
hyperhidrosis	I_Disease	O
is	O	O
facial	O	O
sweating	B_Disease	O
usually	O	O
associated	O	O
with	O	O
the	O	O
eating	O	O
of	O	O
hot	O	O
spicy	O	O
food	O	O
or	O	O
even	O	O
smelling	O	O
this	O	O
food	O	O
.	O	O

Current	O	O
options	O	O
of	O	O
treatment	O	O
include	O	O
oral	O	O
anticholinergic	O	O
drugs	O	O
,	O	O
the	O	O
topical	O	O
application	O	O
of	O	O
anticholinergics	O	O
or	O	O
aluminum	B_Chemical	B_Chemical
chloride	I_Chemical	I_Chemical
,	O	O
and	O	O
the	O	O
injection	O	O
of	O	O
botulinum	O	O
toxin	O	O
.	O	O

Thirteen	O	O
patients	O	O
have	O	O
been	O	O
treated	O	O
to	O	O
date	O	O
with	O	O
1.5	O	O
%	O	O
or	O	O
2	O	O
%	O	O
topical	O	O
glycopyrrolate	B_Chemical	B_Chemical
.	O	O

All	O	O
patients	O	O
had	O	O
gustatory	B_Disease	O
hyperhidrosis	I_Disease	O
,	O	O
which	O	O
interfered	O	O
with	O	O
their	O	O
social	O	O
activities	O	O
,	O	O
after	O	O
transthroacic	O	O
endoscopic	O	O
sympathectomy	O	O
,	O	O
and	O	O
which	O	O
was	O	O
associated	O	O
with	O	O
compensatory	O	O
focal	O	O
hyperhidrosis	B_Disease	O
.	O	O

After	O	O
applying	O	O
topical	O	O
glycopyrrolate	B_Chemical	B_Chemical
,	O	O
the	O	O
subjective	O	O
effect	O	O
was	O	O
excellent	O	O
(	O	O
no	O	O
sweating	B_Disease	O
after	O	O
eating	O	O
hot	O	O
spicy	O	O
food	O	O
)	O	O
in	O	O
10	O	O
patients	O	O
(	O	O
77	O	O
%	O	O
)	O	O
,	O	O
and	O	O
fair	O	O
(	O	O
clearly	O	O
reduced	O	O
sweating	B_Disease	O
)	O	O
in	O	O
3	O	O
patients	O	O
(	O	O
23	O	O
%	O	O
)	O	O
.	O	O

All	O	O
had	O	O
reported	O	O
incidents	O	O
of	O	O
being	O	O
very	O	O
embarrassed	O	O
whilst	O	O
eating	O	O
hot	O	O
spicy	O	O
foods	O	O
.	O	O

Adverse	O	O
effects	O	O
included	O	O
a	O	O
mildly	O	O
dry	B_Disease	B_Disease
mouth	I_Disease	I_Disease
and	O	O
a	O	O
sore	B_Disease	O
throat	I_Disease	O
in	O	O
2	O	O
patients	O	O
(	O	O
2	O	O
%	O	O
glycopyrrolate	B_Chemical	B_Chemical
)	O	O
,	O	O
a	O	O
light	O	O
headache	B_Disease	O
in	O	O
1	O	O
patient	O	O
(	O	O
1.5	O	O
%	O	O
glycopyrrolate	B_Chemical	B_Chemical
)	O	O
.	O	O

The	O	O
topical	O	O
application	O	O
of	O	O
a	O	O
glycopyrrolate	B_Chemical	B_Chemical
pad	O	O
appeared	O	O
to	O	O
be	O	O
safe	O	O
,	O	O
efficacious	O	O
,	O	O
well	O	O
tolerated	O	O
,	O	O
and	O	O
a	O	O
convenient	O	O
method	O	O
of	O	O
treatment	O	O
for	O	O
moderate	O	O
to	O	O
severe	O	O
symptoms	O	O
of	O	O
gustatory	B_Disease	O
hyperhidrosis	I_Disease	O
in	O	O
post	O	O
transthoracic	O	O
endoscopic	O	O
sympathectomy	O	O
or	O	O
sympathicotomy	O	O
patients	O	O
,	O	O
with	O	O
few	O	O
side	O	O
effects	O	O
.	O	O

Neuroleptic-associated	O	O
hyperprolactinemia	B_Disease	B_Disease
.	O	O
Can	O	O
it	O	O
be	O	O
treated	O	O
with	O	O
bromocriptine?Six	O	O
stable	O	O
psychiatric	O	O
outpatients	O	O
with	O	O
hyperprolactinemia	B_Disease	B_Disease
and	O	O
amenorrhea/oligomenorrhea	O	B_Disease
associated	O	O
with	O	O
their	O	O
neuroleptic	B_Chemical	O
medications	I_Chemical	O
were	O	O
treated	O	O
with	O	O
bromocriptine	B_Chemical	B_Chemical
.	O	O

Daily	O	O
dosages	O	O
of	O	O
5	O	O
-	O	O
10	O	O
mg	O	O
corrected	O	O
the	O	O
hyperprolactinemia	B_Disease	B_Disease
and	O	O
restored	O	O
menstruation	O	O
in	O	O
four	O	O
of	O	O
the	O	O
six	O	O
patients	O	O
.	O	O

One	O	O
woman	O	O
,	O	O
however	O	O
,	O	O
developed	O	O
worsened	O	O
psychiatric	B_Disease	B_Disease
symptoms	I_Disease	I_Disease
while	O	O
taking	O	O
bromocriptine	B_Chemical	B_Chemical
,	O	O
and	O	O
it	O	O
was	O	O
discontinued	O	O
.	O	O

Thus	O	O
,	O	O
three	O	O
of	O	O
six	O	O
patients	O	O
had	O	O
their	O	O
menstrual	O	B_Disease
irregularity	O	I_Disease
successfully	O	O
corrected	O	O
with	O	O
bromocriptine	B_Chemical	B_Chemical
.	O	O

This	O	O
suggests	O	O
that	O	O
bromocriptine	B_Chemical	B_Chemical
should	O	O
be	O	O
further	O	O
evaluated	O	O
as	O	O
potential	O	O
therapy	O	O
for	O	O
neuroleptic-associated	O	O
hyperprolactinemia	B_Disease	B_Disease
and	O	O
amenorrhea/galactorrhea	O	O
.	O	O

Ethacrynic	O	O
acid-induced	O	O
convulsions	B_Disease	O
and	O	O
brain	O	O
neurotransmitters	O	O
in	O	O
mice	O	O
.	O	O

Intracerebroventricular	O	O
injection	O	O
of	O	O
ethacrynic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(	O	O
50	O	O
%	O	O
convulsive	B_Disease	O
dose	O	O
;	O	O
50	O	O
micrograms/mouse	O	O
)	O	O
accelerated	O	O
the	O	O
synthesis/turnover	O	O
of	O	O
5-hydroxytryptamine	B_Chemical	O
(	O	O
5-HT	B_Chemical	O
)	O	O
but	O	O
suppressed	O	O
the	O	O
synthesis	O	O
of	O	O
gamma-aminobutyric	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
and	O	O
acetylcholine	B_Chemical	O
in	O	O
mouse	O	O
brain	O	O
.	O	O

These	O	O
effects	O	O
were	O	O
completely	O	O
antagonized	O	O
by	O	O
pretreatment	O	O
with	O	O
a	O	O
glutamate/N-methyl-D-aspartate	O	B_Chemical
antagonist	O	O
,	O	O
aminophosphonovaleric	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
.	O	O

In	O	O
ethacrynic	O	O
acid-induced	O	O
convulsions	B_Disease	O
,	O	O
these	O	O
neurotransmitter	O	O
systems	O	O
may	O	O
be	O	O
differentially	O	O
modulated	O	O
,	O	O
probably	O	O
through	O	O
activation	O	O
of	O	O
glutaminergic	O	O
neurons	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

Pharmacology	O	O
of	O	O
gamma-aminobutyric	O	O
acidA	O	O
receptor	O	O
complex	O	O
after	O	O
the	O	O
in	O	O
vivo	O	O
administration	O	O
of	O	O
the	O	O
anxioselective	O	O
and	O	O
anticonvulsant	O	O
beta-carboline	B_Chemical	B_Chemical
derivative	O	O
abecarnil	B_Chemical	O
.	O	O

In	O	O
rodents	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
beta-carboline	B_Chemical	B_Chemical
derivative	O	O
isopropyl-6-	B_Chemical	B_Chemical
benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate	I_Chemical	I_Chemical
(	O	O
abecarrnil	B_Chemical	O
)	O	O
,	O	O
a	O	O
new	O	O
ligand	O	O
for	O	O
benzodiazepine	B_Chemical	O
receptors	O	O
possessing	O	O
anxiolytic	O	O
and	O	O
anticonvulsant	O	O
properties	O	O
,	O	O
was	O	O
evaluated	O	O
on	O	O
the	O	O
function	O	O
of	O	O
central	O	O
gamma-aminobutyric	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(GABA)A	O	O
receptor	O	O
complex	O	O
,	O	O
both	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

Added	O	O
in	O	O
vitro	O	O
to	O	O
rat	O	O
cortical	O	O
membrane	O	O
preparation	O	O
,	O	O
abecarnil	B_Chemical	O
increased	O	O
[3H]GABA	O	O
binding	O	O
,	O	O
enhanced	O	O
muscimol-stimulated	O	O
36Cl-	O	O
uptake	O	O
and	O	O
reduced	O	O
the	O	O
binding	O	O
of	O	O
t-[35S]butylbicyclophosphorothionate	B_Chemical	B_Chemical
(	O	O
[35S]TBPS	B_Chemical	O
)	O	O
.	O	O

These	O	O
effects	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
induced	O	O
by	O	O
diazepam	B_Chemical	O
,	O	O
whereas	O	O
the	O	O
partial	O	O
agonist	O	O
Ro	B_Chemical	O
16	I_Chemical	O
-	I_Chemical	O
6028	I_Chemical	O
(	O	O
tert-butyl-(S)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-	B_Chemical	B_Chemical
imidazo[1,5-a]-pyrrolo-[2,1-c][1,4]benzodiazepine-1-carboxylate	I_Chemical	B_Chemical
)	O	O
showed	O	O
very	O	O
weak	O	O
efficacy	O	O
in	O	O
these	O	O
biochemical	O	O
tests	O	O
.	O	O

After	O	O
i.p	O	O
.	O	O

injection	O	O
to	O	O
rats	O	O
,	O	O
abecarnil	B_Chemical	O
and	O	O
diazepam	B_Chemical	O
decreased	O	O
in	O	O
a	O	O
time-dependent	O	O
and	O	O
dose-related	O	O
(	O	O
0.25	O	O
-	O	O
20	O	O
mg/kg	O	O
i.p	O	O
.	O	O
)	O	O
manner	O	O
[35S]TBPS	B_Chemical	O
binding	O	O
measured	O	O
ex	O	O
vivo	O	O
in	O	O
the	O	O
cerebral	O	O
cortex	O	O
.	O	O

Moreover	O	O
,	O	O
both	O	O
drugs	O	O
at	O	O
the	O	O
dose	O	O
of	O	O
0.5	O	O
mg/kg	O	O
antagonized	O	O
completely	O	O
the	O	O
convulsant	O	O
activity	O	O
and	O	O
the	O	O
increase	O	O
of	O	O
[35S]TBPS	B_Chemical	O
binding	O	O
induced	O	O
by	O	O
isoniazide	B_Chemical	B_Chemical
(	O	O
350	O	O
mg/kg	O	O
s.c	O	O
.	O	O
)	O	O
as	O	O
well	O	O
as	O	O
the	O	O
increase	O	O
of	O	O
[35S]TBPS	B_Chemical	O
binding	O	O
induced	O	O
by	O	O
foot-shock	O	O
stress	O	O
.	O	O

To	O	O
better	O	O
correlate	O	O
the	O	O
biochemical	O	O
and	O	O
the	O	O
pharmacological	O	O
effects	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
action	O	O
of	O	O
abecarnil	B_Chemical	O
on	O	O
[35S]TBPS	B_Chemical	O
binding	O	O
,	O	O
exploratory	O	O
motility	O	O
and	O	O
on	O	O
isoniazid-induced	O	O
biochemical	O	O
and	O	O
pharmacological	O	O
effects	O	O
in	O	O
mice	O	O
.	O	O

In	O	O
these	O	O
animals	O	O
,	O	O
abecarnil	B_Chemical	O
produced	O	O
a	O	O
paralleled	O	O
dose-dependent	O	O
(	O	O
0.05	O	O
-	O	O
1	O	O
mg/kg	O	O
i.p	O	O
.	O	O
)	O	O
reduction	O	O
of	O	O
both	O	O
motor	O	O
behavior	O	O
and	O	O
cortical	O	O
[35S]TBPS	O	O
binding	O	O
.	O	O

Moreover	O	O
,	O	O
0.05	O	O
mg/kg	O	O
of	O	O
this	O	O
beta-carboline	B_Chemical	B_Chemical
reduced	O	O
markedly	O	O
the	O	O
increase	O	O
of	O	O
[35S]TBPS	B_Chemical	O
binding	O	O
and	O	O
the	O	O
convulsions	B_Disease	O
induced	O	O
by	O	O
isoniazid	B_Chemical	O
(	O	O
200	O	O
mg/kg	O	O
s.c.).(ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O

Recurrent	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
in	O	O
a	O	O
postpartum	O	O
patient	O	O
receiving	O	O
bromocriptine	B_Chemical	B_Chemical
.	O	O

Myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
in	O	O
puerperium	O	O
is	O	O
infrequently	O	O
reported	O	O
.	O	O

Spasm	B_Disease	O
,	O	O
coronary	O	O
dissection	O	O
,	O	O
or	O	O
atheromatous	O	O
etiology	O	O
has	O	O
been	O	O
described	O	O
.	O	O

Bromocriptine	B_Chemical	B_Chemical
has	O	O
been	O	O
implicated	O	O
in	O	O
several	O	O
previous	O	O
case	O	O
reports	O	O
of	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
in	O	O
the	O	O
puerperium	O	O
.	O	O

Our	O	O
case	O	O
(	O	O
including	O	O
an	O	O
inadvertent	O	O
rechallenge	O	O
)	O	O
suggests	O	O
such	O	O
a	O	O
relationship	O	O
.	O	O

Although	O	O
generally	O	O
regarded	O	O
as	O	O
"	O	O
safe	O	O
,	O	O
"	O	O
possible	O	O
serious	O	O
cardiac	O	O
effects	O	O
of	O	O
bromocriptine	B_Chemical	B_Chemical
should	O	O
be	O	O
acknowledged	O	O
.	O	O

Asterixis	B_Disease	B_Disease
induced	O	O
by	O	O
carbamazepine	B_Chemical	B_Chemical
therapy	O	O
.	O	O

There	O	O
are	O	O
very	O	O
few	O	O
reports	O	O
about	O	O
asterixis	B_Disease	B_Disease
as	O	O
a	O	O
side	O	O
effect	O	O
of	O	O
treatment	O	O
with	O	O
psychopharmacologic	O	O
agents	O	O
.	O	O

In	O	O
this	O	O
report	O	O
we	O	O
present	O	O
four	O	O
patients	O	O
treated	O	O
with	O	O
a	O	O
combination	O	O
of	O	O
different	O	O
psychotropic	O	O
drugs	O	O
,	O	O
in	O	O
whom	O	O
asterixis	B_Disease	B_Disease
was	O	O
triggered	O	O
either	O	O
by	O	O
adding	O	O
carbamazepine	B_Chemical	B_Chemical
(	O	O
CBZ	B_Chemical	O
)	O	O
to	O	O
a	O	O
treatment	O	O
regimen	O	O
,	O	O
or	O	O
by	O	O
increasing	O	O
its	O	O
dosage	O	O
.	O	O

Neither	O	O
dosage	O	O
nor	O	O
serum	O	O
levels	O	O
of	O	O
CBZ	B_Chemical	O
were	O	O
in	O	O
a	O	O
higher	O	O
range	O	O
.	O	O

We	O	O
consider	O	O
asterixis	B_Disease	B_Disease
to	O	O
be	O	O
an	O	O
easily	O	O
overlooked	O	O
sign	O	O
of	O	O
neurotoxicity	B_Disease	B_Disease
,	O	O
which	O	O
may	O	O
occur	O	O
even	O	O
at	O	O
low	O	O
or	O	O
moderate	O	O
dosage	O	O
levels	O	O
,	O	O
if	O	O
certain	O	O
drugs	O	O
as	O	O
lithium	B_Chemical	O
or	O	O
clozapine	B_Chemical	O
are	O	O
used	O	O
in	O	O
combination	O	O
with	O	O
CBZ	B_Chemical	O
.	O	O

Pharmacodynamics	O	O
of	O	O
the	O	O
hypotensive	B_Disease	O
effect	O	O
of	O	O
levodopa	B_Chemical	O
in	O	O
parkinsonian	B_Disease	B_Disease
patients	O	O
.	O	O

Blood	O	O
pressure	O	O
effects	O	O
of	O	O
i.v	O	O
.	O	O

levodopa	B_Chemical	O
were	O	O
examined	O	O
in	O	O
parkinsonian	B_Disease	B_Disease
patients	O	O
with	O	O
stable	O	O
and	O	O
fluctuating	O	O
responses	O	O
to	O	O
levodopa	B_Chemical	O
.	O	O

The	O	O
magnitude	O	O
of	O	O
the	O	O
hypotensive	B_Disease	O
effect	O	O
of	O	O
levodopa	B_Chemical	O
was	O	O
concentration	O	O
dependent	O	O
and	O	O
was	O	O
fit	O	O
to	O	O
an	O	O
Emax	O	O
model	O	O
in	O	O
fluctuating	O	O
responders	O	O
.	O	O

Stable	O	O
responders	O	O
demonstrated	O	O
a	O	O
small	O	O
hypotensive	B_Disease	O
response	O	O
.	O	O

Baseline	O	O
blood	O	O
pressures	O	O
were	O	O
higher	O	O
in	O	O
fluctuating	O	O
patients	O	O
;	O	O
a	O	O
higher	O	O
baseline	O	O
blood	O	O
pressure	O	O
correlated	O	O
with	O	O
greater	O	O
hypotensive	B_Disease	O
effects	O	O
.	O	O

Antiparkinsonian	O	B_Disease
effects	O	O
of	O	O
levodopa	B_Chemical	O
temporally	O	O
correlated	O	O
with	O	O
blood	O	O
pressure	O	O
changes	O	O
.	O	O

Phenylalanine	B_Chemical	O
,	O	O
a	O	O
large	O	O
neutral	O	O
amino	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(	O	O
LNAA	O	O
)	O	O
competing	O	O
with	O	O
levodopa	B_Chemical	O
for	O	O
transport	O	O
across	O	O
the	O	O
blood-brain	O	O
barrier	O	O
,	O	O
reduced	O	O
the	O	O
hypotensive	B_Disease	O
and	O	O
antiparkinsonian	O	B_Disease
effects	O	O
of	O	O
levodopa	B_Chemical	O
.	O	O

We	O	O
conclude	O	O
that	O	O
levodopa	B_Chemical	O
has	O	O
a	O	O
central	O	O
hypotensive	B_Disease	O
action	O	O
that	O	O
parallels	O	O
the	O	O
motor	O	O
effects	O	O
in	O	O
fluctuating	O	O
patients	O	O
.	O	O

The	O	O
hypotensive	B_Disease	O
effect	O	O
appears	O	O
to	O	O
be	O	O
related	O	O
to	O	O
the	O	O
higher	O	O
baseline	O	O
blood	O	O
pressure	O	O
we	O	O
observed	O	O
in	O	O
fluctuating	O	O
patients	O	O
relative	O	O
to	O	O
stable	O	O
patients	O	O
.	O	O

Syndrome	B_Disease	O
of	I_Disease	O
inappropriate	I_Disease	O
secretion	I_Disease	O
of	I_Disease	O
antidiuretic	I_Disease	O
hormone	I_Disease	O
after	O	O
infusional	O	O
vincristine	B_Chemical	O
.	O	O

A	O	O
77-year-old	O	O
woman	O	O
with	O	O
refractory	O	O
multiple	B_Disease	B_Disease
myeloma	I_Disease	I_Disease
was	O	O
treated	O	O
with	O	O
a	O	O
4-day	O	O
continuous	O	O
intravenous	O	O
infusion	O	O
of	O	O
vincristine	B_Chemical	O
and	O	O
doxorubicin	B_Chemical	O
and	O	O
4	O	O
days	O	O
of	O	O
oral	O	O
dexamethasone	B_Chemical	O
.	O	O

Nine	O	O
days	O	O
after	O	O
her	O	O
second	O	O
cycle	O	O
she	O	O
presented	O	O
with	O	O
lethargy	B_Disease	O
and	O	O
weakness	B_Disease	O
associated	O	O
with	O	O
hyponatremia	B_Disease	O
.	O	O

Evaluation	O	O
revealed	O	O
the	O	O
syndrome	B_Disease	O
of	I_Disease	O
inappropriate	I_Disease	O
secretion	I_Disease	O
of	I_Disease	O
antidiuretic	I_Disease	O
hormone	I_Disease	O
,	O	O
which	O	O
was	O	O
attributed	O	O
to	O	O
the	O	O
vincristine	B_Chemical	O
infusion	O	O
.	O	O

After	O	O
normal	O	O
serum	O	O
sodium	B_Chemical	O
levels	O	O
returned	O	O
,	O	O
further	O	O
doxorubicin	B_Chemical	O
and	O	O
dexamethasone	B_Chemical	O
chemotherapy	O	O
without	O	O
vincristine	B_Chemical	O
did	O	O
not	O	O
produce	O	O
this	O	O
complication	O	O
.	O	O

Heart	O	B_Disease
failure	O	I_Disease
:	O	O
to	O	O
digitalise	O	O
or	O	O
not	O	O
?	O	O
The	O	O
view	O	O
against	O	O
.	O	O

Despite	O	O
extensive	O	O
clinical	O	O
experience	O	O
the	O	O
role	O	O
of	O	O
digoxin	B_Chemical	O
is	O	O
still	O	O
not	O	O
well	O	O
defined	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
atrial	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
digoxin	B_Chemical	O
is	O	O
beneficial	O	O
for	O	O
ventricular	O	O
rate	O	O
control	O	O
.	O	O

For	O	O
patients	O	O
in	O	O
sinus	O	B_Disease
rhythm	O	I_Disease
and	O	O
heart	B_Disease	B_Disease
failure	I_Disease	I_Disease
the	O	O
situation	O	O
is	O	O
less	O	O
clear	O	O
.	O	O

Digoxin	B_Chemical	O
has	O	O
a	O	O
narrow	O	O
therapeutic	O	O
:	O	O
toxic	O	O
ratio	O	O
and	O	O
concentrations	O	O
are	O	O
affected	O	O
by	O	O
a	O	O
number	O	O
of	O	O
drugs	O	O
.	O	O

Also	O	O
,	O	O
digoxin	B_Chemical	O
has	O	O
undesirable	O	O
effects	O	O
such	O	O
as	O	O
increasing	O	O
peripheral	O	O
resistance	O	O
and	O	O
myocardial	O	O
demands	O	O
,	O	O
and	O	O
causing	O	O
arrhythmias	B_Disease	O
.	O	O

There	O	O
is	O	O
a	O	O
paucity	O	O
of	O	O
data	O	O
from	O	O
well-designed	O	O
trials	O	O
.	O	O

The	O	O
trials	O	O
that	O	O
are	O	O
available	O	O
are	O	O
generally	O	O
small	O	O
with	O	O
limitations	O	O
in	O	O
design	O	O
and	O	O
these	O	O
show	O	O
variation	O	O
in	O	O
patient	O	O
benefit	O	O
.	O	O

More	O	O
convincing	O	O
evidence	O	O
is	O	O
required	O	O
showing	O	O
that	O	O
digoxin	B_Chemical	O
improves	O	O
symptoms	O	O
or	O	O
exercise	O	O
capacity	O	O
.	O	O

Furthermore	O	O
,	O	O
no	O	O
trial	O	O
has	O	O
had	O	O
sufficient	O	O
power	O	O
to	O	O
evaluate	O	O
mortality	O	O
.	O	O

Pooled	O	O
analysis	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
other	O	O
inotropic	O	O
drugs	O	O
shows	O	O
an	O	O
excess	O	O
mortality	O	O
and	O	O
there	O	O
is	O	O
a	O	O
possibility	O	O
that	O	O
digoxin	B_Chemical	O
may	O	O
increase	O	O
mortality	O	O
after	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
(	O	O
MI	B_Disease	O
)	O	O
.	O	O

Angiotensin-converting	O	O
enzyme	O	O
(	O	O
ACE	O	O
)	O	O
inhibitors	O	O
should	O	O
be	O	O
used	O	O
first	O	O
as	O	O
they	O	O
are	O	O
safer	O	O
,	O	O
do	O	O
not	O	O
require	O	O
blood	O	O
level	O	O
monitoring	O	O
,	O	O
modify	O	O
progression	O	O
of	O	O
disease	O	O
,	O	O
relieve	O	O
symptoms	O	O
,	O	O
improve	O	O
exercise	O	O
tolerance	O	O
and	O	O
reduce	O	O
mortality	O	O
.	O	O

Caution	O	O
should	O	O
be	O	O
exercised	O	O
in	O	O
using	O	O
digoxin	B_Chemical	O
until	O	O
large	O	O
mortality	O	O
trials	O	O
are	O	O
completed	O	O
showing	O	O
either	O	O
benefit	O	O
or	O	O
harm	O	O
.	O	O

Until	O	O
then	O	O
digoxin	B_Chemical	O
should	O	O
be	O	O
considered	O	O
a	O	O
third-line	O	O
therapy	O	O
.	O	O

Isradipine	B_Chemical	B_Chemical
treatment	O	O
for	O	O
hypertension	B_Disease	O
in	O	O
general	O	O
practice	O	O
in	O	O
Hong	O	O
Kong	O	O
.	O	O

A	O	O
6-week	O	O
open	O	O
study	O	O
of	O	O
the	O	O
introduction	O	O
of	O	O
isradipine	B_Chemical	B_Chemical
treatment	O	O
was	O	O
conducted	O	O
in	O	O
general	O	O
practice	O	O
in	O	O
Hong	O	O
Kong	O	O
.	O	O

303	O	O
Chinese	O	O
patients	O	O
with	O	O
mild	O	O
to	O	O
moderate	O	O
hypertension	B_Disease	O
entered	O	O
the	O	O
study	O	O
.	O	O

Side	O	O
effects	O	O
were	O	O
reported	O	O
in	O	O
21	O	O
%	O	O
of	O	O
patients	O	O
and	O	O
caused	O	O
withdrawal	O	O
from	O	O
the	O	O
study	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

The	O	O
main	O	O
side-effects	O	O
were	O	O
headache	B_Disease	O
,	O	O
dizziness	B_Disease	O
,	O	O
palpitation	B_Disease	O
and	O	O
flushing	B_Disease	O
and	O	O
these	O	O
were	O	O
not	O	O
more	O	O
frequent	O	O
than	O	O
reported	O	O
in	O	O
other	O	O
studies	O	O
with	O	O
isradipine	B_Chemical	B_Chemical
or	O	O
with	O	O
placebo	O	O
.	O	O

Supine	O	O
blood	O	O
pressure	O	O
was	O	O
reduced	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
from	O	O
170	O	O
+	O	O
/-	O	O
20/102	O	O
+	O	O
/-	O	O
6	O	O
mmHg	O	O
to	O	O
153	O	O
+	O	O
/-	O	O
19/92	O	O
+	O	O
/-	O	O
8	O	O
,	O	O
147	O	O
+	O	O
/-	O	O
18/88	O	O
+	O	O
/-	O	O
7	O	O
and	O	O
144	O	O
+	O	O
/-	O	O
14/87	O	O
+	O	O
/-	O	O
6	O	O
mmHg	O	O
at	O	O
2	O	O
,	O	O
4	O	O
and	O	O
6	O	O
weeks	O	O
respectively	O	O
in	O	O
evaluable	O	O
patients	O	O
.	O	O

Similar	O	O
reductions	O	O
occurred	O	O
in	O	O
standing	O	O
blood	O	O
pressure	O	O
and	O	O
there	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
postural	B_Disease	B_Disease
hypotension	I_Disease	I_Disease
.	O	O

Normalization	O	O
and	O	O
responder	O	O
rates	O	O
at	O	O
6	O	O
weeks	O	O
were	O	O
86	O	O
%	O	O
and	O	O
69	O	O
%	O	O
respectively	O	O
.	O	O

Dosage	O	O
was	O	O
increased	O	O
from	O	O
2.5	O	O
mg	O	O
b.d	O	O
.	O	O
to	O	O
5	O	O
mg	O	O
b.d	O	O
.	O	O

at	O	O
4	O	O
weeks	O	O
in	O	O
patients	O	O
with	O	O
diastolic	O	O
blood	O	O
pressure	O	O
greater	O	O
than	O	O
90	O	O
mmHg	O	O
and	O	O
their	O	O
further	O	O
response	O	O
was	O	O
greater	O	O
than	O	O
those	O	O
remaining	O	O
on	O	O
2.5	O	O
mg	O	O
b.d	O	O
.	O	O

Pharmacological	O	O
characteristics	O	O
and	O	O
side	O	O
effects	O	O
of	O	O
a	O	O
new	O	O
galenic	O	O
formulation	O	O
of	O	O
propofol	O	B_Chemical
without	O	O
soyabean	O	B_Chemical
oil	O	I_Chemical
.	O	O

We	O	O
compared	O	O
the	O	O
pharmacokinetics	O	O
,	O	O
pharmacodynamics	O	O
and	O	O
safety	O	O
profile	O	O
of	O	O
a	O	O
new	O	O
galenic	O	O
formulation	O	O
of	O	O
propofol	B_Chemical	B_Chemical
(	O	O
AM149	O	O
1	O	O
%	O	O
)	O	O
,	O	O
which	O	O
does	O	O
not	O	O
contain	O	O
soyabean	O	B_Chemical
oil	O	I_Chemical
,	O	O
with	O	O
a	O	O
standard	O	O
formulation	O	O
of	O	O
propofol	B_Chemical	B_Chemical
(	O	O
Disoprivan	B_Chemical	B_Chemical
1	O	O
%	O	O
)	O	O
.	O	O

In	O	O
a	O	O
randomised	O	O
,	O	O
double-blind	O	O
,	O	O
cross-over	O	O
study	O	O
,	O	O
30	O	O
healthy	O	O
volunteers	O	O
received	O	O
a	O	O
single	O	O
intravenous	O	O
bolus	O	O
injection	O	O
of	O	O
2.5	O	O
mg.kg-1	O	O
propofol	B_Chemical	B_Chemical
.	O	O

Plasma	O	O
propofol	B_Chemical	B_Chemical
levels	O	O
were	O	O
measured	O	O
for	O	O
48	O	O
h	O	O
following	O	O
drug	O	O
administration	O	O
and	O	O
evaluated	O	O
according	O	O
to	O	O
a	O	O
three-compartment	O	O
model	O	O
.	O	O

The	O	O
pharmacodynamic	O	O
parameters	O	O
assessed	O	O
included	O	O
induction	O	O
and	O	O
emergence	O	O
times	O	O
,	O	O
respiratory	O	O
and	O	O
cardiovascular	O	O
effects	O	O
,	O	O
and	O	O
pain	B_Disease	O
on	O	O
injection	O	O
.	O	O

Patients	O	O
were	O	O
monitored	O	O
for	O	O
side	O	O
effects	O	O
over	O	O
48	O	O
h.	O	O
Owing	O	O
to	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
thrombophlebitis	B_Disease	O
,	O	O
the	O	O
study	O	O
was	O	O
terminated	O	O
prematurely	O	O
and	O	O
only	O	O
the	O	O
data	O	O
of	O	O
the	O	O
two	O	O
parallel	O	O
treatment	O	O
groups	O	O
(	O	O
15	O	O
patients	O	O
in	O	O
each	O	O
group	O	O
)	O	O
were	O	O
analysed	O	O
.	O	O

Plasma	O	O
concentrations	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
two	O	O
formulations	O	O
.	O	O

Anaesthesia	O	O
induction	O	O
and	O	O
emergence	O	O
times	O	O
,	O	O
respiratory	O	O
and	O	O
cardiovascular	O	O
variables	O	O
showed	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
treatment	O	O
groups	O	O
.	O	O

Pain	B_Disease	O
on	O	O
injection	O	O
(	O	O
80	O	O
vs.	O	O
20	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
and	O	O
thrombophlebitis	B_Disease	O
(	O	O
93.3	O	O
vs.	O	O
6.6	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
occurred	O	O
more	O	O
frequently	O	O
with	O	O
AM149	O	O
than	O	O
with	O	O
Disoprivan	B_Chemical	B_Chemical
.	O	O
Although	O	O
both	O	O
formulations	O	O
had	O	O
similar	O	O
pharmacokinetic	O	O
and	O	O
pharmacodynamic	O	O
profiles	O	O
the	O	O
new	O	O
formulation	O	O
is	O	O
not	O	O
suitable	O	O
for	O	O
clinical	O	O
use	O	O
due	O	O
to	O	O
the	O	O
high	O	O
incidence	O	O
of	O	O
thrombophlebitis	B_Disease	O
produced	O	O
.	O	O

Pure	B_Disease	O
red	I_Disease	O
cell	I_Disease	O
aplasia	I_Disease	O
,	O	O
toxic	B_Disease	O
dermatitis	I_Disease	O
and	O	O
lymphadenopathy	B_Disease	O
in	O	O
a	O	O
patient	O	O
taking	O	O
diphenylhydantoin	B_Chemical	O
.	O	O

A	O	O
patient	O	O
taking	O	O
diphenylhydantoin	B_Chemical	O
for	O	O
3	O	O
weeks	O	O
developed	O	O
a	O	O
generalized	O	O
skin	B_Disease	O
rash	I_Disease	O
,	O	O
lymphadenopathy	B_Disease	O
and	O	O
pure	B_Disease	O
red	I_Disease	O
cell	I_Disease	O
aplasia	I_Disease	O
.	O	O

After	O	O
withdrawal	O	O
of	O	O
the	O	O
pharmacon	O	O
all	O	O
symptoms	O	O
disappeared	O	O
spontaneously	O	O
.	O	O

Skin	B_Disease	O
rash	I_Disease	O
is	O	O
a	O	O
well-known	O	O
complication	O	O
of	O	O
diphenylhydantoin	B_Chemical	O
treatment	O	O
as	O	O
is	O	O
benign	O	O
and	O	O
malignant	O	O
lymphadenopathy	B_Disease	O
.	O	O

Pure	B_Disease	O
red	I_Disease	O
cell	I_Disease	O
aplasia	I_Disease	O
associated	O	O
with	O	O
diphenylhydantoin	B_Chemical	O
medication	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

The	O	O
exact	O	O
mechanism	O	O
by	O	O
which	O	O
diphenylhydantoin	B_Chemical	O
exerts	O	O
its	O	O
toxic	O	O
effects	O	O
is	O	O
not	O	O
known	O	O
.	O	O

In	O	O
this	O	O
patient	O	O
the	O	O
time	O	O
relation	O	O
between	O	O
the	O	O
ingestion	O	O
of	O	O
diphenylhydantoin	B_Chemical	O
and	O	O
the	O	O
occurrence	O	O
of	O	O
the	O	O
skin	B_Disease	O
rash	I_Disease	O
,	O	O
lymphadenopathy	B_Disease	O
and	O	O
pure	B_Disease	O
red	I_Disease	O
cell	I_Disease	O
aplasia	I_Disease	O
is	O	O
very	O	O
suggestive	O	O
of	O	O
a	O	O
direct	O	O
connection	O	O
.	O	O

Vinorelbine-related	O	O
cardiac	O	O
events	O	O
:	O	O
a	O	O
meta-analysis	O	O
of	O	O
randomized	O	O
clinical	O	O
trials	O	O
.	O	O

Several	O	O
cases	O	O
of	O	O
cardiac	O	B_Disease
adverse	O	I_Disease
reactions	O	I_Disease
related	O	O
to	O	O
vinorelbine	B_Chemical	B_Chemical
(	O	O
VNR	B_Chemical	O
)	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

In	O	O
order	O	O
to	O	O
quantify	O	O
the	O	O
incidence	O	O
of	O	O
these	O	O
cardiac	O	B_Disease
events	O	I_Disease
,	O	O
we	O	O
performed	O	O
a	O	O
meta-analysis	O	O
of	O	O
clinical	O	O
trials	O	O
comparing	O	O
VNR	B_Chemical	O
with	O	O
other	O	O
chemotherapeutic	O	O
agents	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
various	O	O
malignancies	B_Disease	O
.	O	O

Randomized	O	O
clinical	O	O
trials	O	O
comparing	O	O
VNR	B_Chemical	O
with	O	O
other	O	O
drugs	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
cancer	B_Disease	O
were	O	O
searched	O	O
in	O	O
Medline	O	O
,	O	O
Embase	O	O
,	O	O
Evidence-based	O	O
Medicine	O	O
Reviews	O	O
databases	O	O
and	O	O
the	O	O
Cochrane	O	O
library	O	O
from	O	O
1987	O	O
to	O	O
2002	O	O
.	O	O

Outcomes	O	O
of	O	O
interest	O	O
were	O	O
severe	O	O
cardiac	O	O
events	O	O
,	O	O
toxic	O	B_Disease
deaths	O	I_Disease
and	O	O
cardiac	O	O
event-related	O	O
deaths	O	O
reported	O	O
in	O	O
each	O	O
publication	O	O
.	O	O

We	O	O
found	O	O
19	O	O
trials	O	O
,	O	O
involving	O	O
2441	O	O
patients	O	O
treated	O	O
by	O	O
VNR	B_Chemical	O
and	O	O
2050	O	O
control	O	O
patients	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
cardiac	O	B_Disease
events	O	I_Disease
with	O	O
VNR	B_Chemical	O
was	O	O
1.19	O	O
%	O	O
[	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
)	O	O
(	O	O
0.75	O	O
;	O	O
1.67	O	O
)	O	O
]	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
risk	O	O
of	O	O
cardiac	O	B_Disease
events	O	I_Disease
between	O	O
VNR	B_Chemical	O
and	O	O
other	O	O
drugs	O	O
[	O	O
odds	O	O
ratio	O	O
:	O	O
0.92	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
(	O	O
0.54	O	O
;	O	O
1.55	O	O
)	O	O
]	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
VNR	B_Chemical	O
cardiac	O	O
events	O	O
was	O	O
similar	O	O
to	O	O
vindesine	B_Chemical	B_Chemical
(	O	O
VDS	B_Chemical	O
)	O	O
and	O	O
other	O	O
cardiotoxic	B_Disease	B_Disease
drugs	O	O
[	O	O
fluorouracil	B_Chemical	O
,	O	O
anthracyclines	B_Chemical	B_Chemical
,	O	O
gemcitabine	B_Chemical	B_Chemical
(	O	O
GEM	B_Chemical	O
)	O	O
em	O	O
leader	O	O
]	O	O
.	O	O

Even	O	O
if	O	O
it	O	O
did	O	O
not	O	O
reach	O	O
statistical	O	O
significance	O	O
because	O	O
of	O	O
a	O	O
few	O	O
number	O	O
of	O	O
cases	O	O
,	O	O
the	O	O
risk	O	O
was	O	O
lower	O	O
in	O	O
trials	O	O
excluding	O	O
patients	O	O
with	O	O
cardiac	O	O
history	O	O
,	O	O
and	O	O
seemed	O	O
to	O	O
be	O	O
higher	O	O
in	O	O
trials	O	O
including	O	O
patients	O	O
with	O	O
pre-existing	O	O
cardiac	B_Disease	O
diseases	I_Disease	O
.	O	O

Vinorelbine-related	O	O
cardiac	O	O
events	O	O
concern	O	O
about	O	O
1	O	O
%	O	O
of	O	O
treated	O	O
patients	O	O
in	O	O
clinical	O	O
trials	O	O
.	O	O

However	O	O
,	O	O
the	O	O
risk	O	O
associated	O	O
with	O	O
VNR	B_Chemical	O
seems	O	O
to	O	O
be	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
other	O	O
chemotherapeutic	O	O
agents	O	O
in	O	O
the	O	O
same	O	O
indications	O	O
.	O	O

MRI	O	O
findings	O	O
of	O	O
hypoxic	O	O
cortical	O	O
laminar	O	O
necrosis	B_Disease	O
in	O	O
a	O	O
child	O	O
with	O	O
hemolytic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
crisis	O	O
.	O	O

We	O	O
present	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
findings	O	O
of	O	O
a	O	O
5-year-old	O	O
girl	O	O
who	O	O
had	O	O
a	O	O
rapidly	O	O
installing	O	O
hemolytic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
crisis	O	O
induced	O	O
by	O	O
trimethoprim-sulfomethoxazole	B_Chemical	B_Chemical
,	O	O
resulting	O	O
in	O	O
cerebral	B_Disease	O
anoxia	I_Disease	O
leading	O	O
to	O	O
permanent	O	O
damage	O	O
.	O	O

Magnetic	O	O
Resonance	O	O
imaging	O	O
revealed	O	O
cortical	O	O
laminar	O	O
necrosis	B_Disease	O
in	O	O
arterial	O	O
border	O	O
zones	O	O
in	O	O
both	O	O
cerebral	O	O
hemispheres	O	O
,	O	O
ischemic	O	O
changes	O	O
in	O	O
subcortical	O	O
white	O	O
matter	O	O
of	O	O
left	O	O
cerebral	O	O
hemisphere	O	O
,	O	O
and	O	O
in	O	O
the	O	O
left	O	O
putamen	O	O
.	O	O

Although	O	O
cortical	O	O
laminar	O	O
necrosis	B_Disease	O
is	O	O
a	O	O
classic	O	O
entity	O	O
in	O	O
adulthood	O	O
related	O	O
to	O	O
conditions	O	O
of	O	O
energy	O	O
depletions	O	O
,	O	O
there	O	O
are	O	O
few	O	O
reports	O	O
available	O	O
in	O	O
children	O	O
.	O	O

A	O	O
wide	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
is	O	O
also	O	O
presented	O	O
.	O	O

The	O	O
natural	O	O
history	O	O
of	O	O
Vigabatrin	B_Chemical	B_Chemical
associated	O	O
visual	B_Disease	B_Disease
field	I_Disease	I_Disease
defects	I_Disease	I_Disease
in	O	O
patients	O	O
electing	O	O
to	O	O
continue	O	O
their	O	O
medication	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
natural	O	O
history	O	O
of	O	O
visual	B_Disease	B_Disease
field	I_Disease	I_Disease
defects	I_Disease	I_Disease
in	O	O
a	O	O
group	O	O
of	O	O
patients	O	O
known	O	O
to	O	O
have	O	O
Vigabatrin-associated	O	O
changes	O	O
who	O	O
elected	O	O
to	O	O
continue	O	O
the	O	O
medication	O	O
because	O	O
of	O	O
good	O	O
seizure	B_Disease	O
control	O	O
.	O	O

METHODS	O	O
:	O	O
All	O	O
patients	O	O
taking	O	O
Vigabatrin	B_Chemical	B_Chemical
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
antiepileptic	O	O
drugs	O	O
for	O	O
at	O	O
least	O	O
5	O	O
years	O	O
(	O	O
range	O	O
5	O	O
-	O	O
12	O	O
years	O	O
)	O	O
were	O	O
entered	O	O
into	O	O
a	O	O
visual	O	O
surveillance	O	O
programme	O	O
.	O	O

Patients	O	O
were	O	O
followed	O	O
up	O	O
at	O	O
6-monthly	O	O
intervals	O	O
for	O	O
not	O	O
less	O	O
than	O	O
18	O	O
months	O	O
(	O	O
range	O	O
18	O	O
-	O	O
43	O	O
months	O	O
)	O	O
.	O	O

In	O	O
all	O	O
,	O	O
16	O	O
patients	O	O
with	O	O
unequivocal	O	O
defects	O	O
continued	O	O
the	O	O
medication	O	O
.	O	O

Following	O	O
already	O	O
published	O	O
methodology	O	O
(	O	O
Eye	O	O
2002	O	O
;	O	O
16;567	O	O
-	O	O
571	O	O
)	O	O
monocular	O	O
mean	O	O
radial	O	O
degrees	O	O
(	O	O
MRDs	O	O
)	O	O
to	O	O
the	O	O
I/4e	O	O
isopter	O	O
on	O	O
Goldmann	O	O
perimetry	O	O
was	O	O
calculated	O	O
for	O	O
the	O	O
right	O	O
eye	O	O
at	O	O
the	O	O
time	O	O
of	O	O
discovery	O	O
of	O	O
a	O	O
visual	B_Disease	B_Disease
field	I_Disease	I_Disease
defect	I_Disease	I_Disease
and	O	O
again	O	O
after	O	O
not	O	O
less	O	O
than	O	O
18	O	O
months	O	O
follow-up	O	O
.	O	O

RESULTS	O	O
:	O	O
Mean	O	O
right	O	O
eye	O	O
MRD	O	O
at	O	O
presentation	O	O
was	O	O
36.98	O	O
degrees	O	O
(	O	O
range	O	O
22.25	O	O
-	O	O
51.0	O	O
)	O	O
,	O	O
compared	O	O
to	O	O
38.40	O	O
degrees	O	O
(	O	O
range	O	O
22.5	O	O
-	O	O
49.75	O	O
)	O	O
after	O	O
follow-up	O	O
;	O	O
P=0.338	O	O
unpaired	O	O
t-test	O	O
.	O	O

Only	O	O
one	O	O
patient	O	O
demonstrated	O	O
a	O	O
deterioration	B_Disease	O
in	I_Disease	O
visual	I_Disease	O
field	I_Disease	O
during	O	O
the	O	O
study	O	O
period	O	O
and	O	O
discontinued	O	O
treatment	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Established	O	O
visual	B_Disease	B_Disease
field	I_Disease	I_Disease
defects	I_Disease	I_Disease
presumed	O	O
to	O	O
be	O	O
due	O	O
to	O	O
Vigabatrin	B_Chemical	B_Chemical
therapy	O	O
did	O	O
not	O	O
usually	O	O
progress	O	O
in	O	O
spite	O	O
of	O	O
continuing	O	O
use	O	O
of	O	O
the	O	O
medication	O	O
.	O	O

These	O	O
data	O	O
give	O	O
support	O	O
to	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
pathogenesis	O	O
of	O	O
Vigabatrin-associated	O	O
visual	B_Disease	B_Disease
field	I_Disease	I_Disease
defects	I_Disease	I_Disease
may	O	O
be	O	O
an	O	O
idiosyncratic	O	O
adverse	O	O
drug	O	O
reaction	O	O
rather	O	O
than	O	O
dose-dependent	O	O
toxicity	B_Disease	O
.	O	O

Induction	O	O
of	O	O
rosaceiform	O	O
dermatitis	B_Disease	O
during	O	O
treatment	O	O
of	O	O
facial	B_Disease	O
inflammatory	I_Disease	O
dermatoses	I_Disease	O
with	O	O
tacrolimus	B_Chemical	B_Chemical
ointment	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Tacrolimus	B_Chemical	B_Chemical
ointment	O	O
is	O	O
increasingly	O	O
used	O	O
for	O	O
anti-inflammatory	O	O
treatment	O	O
of	O	O
sensitive	O	O
areas	O	O
such	O	O
as	O	O
the	O	O
face	O	O
,	O	O
and	O	O
recent	O	O
observations	O	O
indicate	O	O
that	O	O
the	O	O
treatment	O	O
is	O	O
effective	O	O
in	O	O
steroid-aggravated	O	O
rosacea	B_Disease	O
and	O	O
perioral	B_Disease	O
dermatitis	I_Disease	O
.	O	O

We	O	O
report	O	O
on	O	O
rosaceiform	O	O
dermatitis	B_Disease	O
as	O	O
a	O	O
complication	O	O
of	O	O
treatment	O	O
with	O	O
tacrolimus	B_Chemical	B_Chemical
ointment	O	O
.	O	O

OBSERVATIONS	O	O
:	O	O
Six	O	O
adult	O	O
patients	O	O
with	O	O
inflammatory	B_Disease	B_Disease
facial	I_Disease	I_Disease
dermatoses	I_Disease	I_Disease
were	O	O
treated	O	O
with	O	O
tacrolimus	B_Chemical	B_Chemical
ointment	O	O
because	O	O
of	O	O
the	O	O
ineffectiveness	O	O
of	O	O
standard	O	O
treatments	O	O
.	O	O

Within	O	O
2	O	O
to	O	O
3	O	O
weeks	O	O
of	O	O
initially	O	O
effective	O	O
and	O	O
well-tolerated	O	O
treatment	O	O
,	O	O
3	O	O
patients	O	O
with	O	O
a	O	O
history	O	O
of	O	O
rosacea	B_Disease	O
and	O	O
1	O	O
with	O	O
a	O	O
history	O	O
of	O	O
acne	B_Disease	O
experienced	O	O
sudden	O	O
worsening	O	O
with	O	O
pustular	O	O
rosaceiform	O	O
lesions	O	O
.	O	O

Biopsy	O	O
revealed	O	O
an	O	O
abundance	O	O
of	O	O
Demodex	O	O
mites	O	O
in	O	O
2	O	O
of	O	O
these	O	O
patients	O	O
.	O	O

In	O	O
1	O	O
patient	O	O
with	O	O
eyelid	O	O
eczema	B_Disease	O
,	O	O
rosaceiform	O	O
periocular	B_Disease	B_Disease
dermatitis	I_Disease	I_Disease
gradually	O	O
appeared	O	O
after	O	O
3	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

In	O	O
1	O	O
patient	O	O
with	O	O
atopic	B_Disease	O
dermatitis	I_Disease	O
,	O	O
telangiectatic	O	O
and	O	O
papular	B_Disease	O
rosacea	I_Disease	O
insidiously	O	O
appeared	O	O
after	O	O
5	O	O
months	O	O
of	O	O
treatment	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Our	O	O
observations	O	O
suggest	O	O
that	O	O
the	O	O
spectrum	O	O
of	O	O
rosaceiform	O	O
dermatitis	B_Disease	O
as	O	O
a	O	O
complication	O	O
of	O	O
treatment	O	O
with	O	O
tacrolimus	B_Chemical	B_Chemical
ointment	O	O
is	O	O
heterogeneous	O	O
.	O	O

A	O	O
variety	O	O
of	O	O
factors	O	O
,	O	O
such	O	O
as	O	O
vasoactive	O	O
properties	O	O
of	O	O
tacrolimus	B_Chemical	B_Chemical
,	O	O
proliferation	O	O
of	O	O
Demodex	O	O
due	O	O
to	O	O
local	O	O
immunosuppression	O	O
,	O	O
and	O	O
the	O	O
occlusive	O	O
properties	O	O
of	O	O
the	O	O
ointment	O	O
,	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
observed	O	O
phenomena	O	O
.	O	O

Future	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
identify	O	O
individual	O	O
risk	O	O
factors	O	O
.	O	O

Intravascular	O	B_Disease
hemolysis	B_Disease	I_Disease
and	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
following	O	O
intermittent	O	O
rifampin	B_Chemical	O
therapy	O	O
.	O	O

Renal	B_Disease	B_Disease
failure	I_Disease	I_Disease
is	O	O
a	O	O
rare	O	O
complication	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
rifampin	B_Chemical	O
.	O	O

Intravascular	O	B_Disease
hemolysis	B_Disease	I_Disease
leading	O	O
to	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
following	O	O
rifampin	B_Chemical	O
therapy	O	O
is	O	O
extremely	O	O
rare	O	O
.	O	O

Two	O	O
patients	O	O
with	O	O
leprosy	B_Disease	O
who	O	O
developed	O	O
hemolysis	B_Disease	O
and	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
following	O	O
rifampin	B_Chemical	O
are	O	O
reported	O	O
.	O	O

Structural	O	O
abnormalities	O	O
in	O	O
the	O	O
brains	O	O
of	O	O
human	O	O
subjects	O	O
who	O	O
use	O	O
methamphetamine	O	O
.	O	O

We	O	O
visualize	O	O
,	O	O
for	O	O
the	O	O
first	O	O
time	O	O
,	O	O
the	O	O
profile	O	O
of	O	O
structural	B_Disease	O
deficits	I_Disease	O
in	I_Disease	O
the	I_Disease	O
human	I_Disease	O
brain	I_Disease	O
associated	O	O
with	O	O
chronic	O	O
methamphetamine	B_Chemical	O
(	O	O
MA	B_Chemical	O
)	O	O
abuse	O	O
.	O	O

Studies	O	O
of	O	O
human	O	O
subjects	O	O
who	O	O
have	O	O
used	O	O
MA	B_Chemical	O
chronically	O	O
have	O	O
revealed	O	O
deficits	O	O
in	O	O
dopaminergic	O	O
and	O	O
serotonergic	O	O
systems	O	O
and	O	O
cerebral	O	B_Disease
metabolic	B_Disease	I_Disease
abnormalities	I_Disease	I_Disease
.	O	O

Using	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
and	O	O
new	O	O
computational	O	O
brain-mapping	O	O
techniques	O	O
,	O	O
we	O	O
determined	O	O
the	O	O
pattern	O	O
of	O	O
structural	O	O
brain	O	O
alterations	O	O
associated	O	O
with	O	O
chronic	O	O
MA	B_Chemical	O
abuse	O	O
in	O	O
human	O	O
subjects	O	O
and	O	O
related	O	O
these	O	O
deficits	O	O
to	O	O
cognitive	B_Disease	B_Disease
impairment	I_Disease	I_Disease
.	O	O

We	O	O
used	O	O
high-resolution	O	O
MRI	O	O
and	O	O
surface-based	O	O
computational	O	O
image	O	O
analyses	O	O
to	O	O
map	O	O
regional	O	O
abnormalities	B_Disease	O
in	I_Disease	O
the	I_Disease	O
cortex	I_Disease	O
,	I_Disease	O
hippocampus	I_Disease	O
,	I_Disease	O
white	I_Disease	O
matter	I_Disease	O
,	I_Disease	O
and	I_Disease	O
ventricles	I_Disease	O
in	O	O
22	O	O
human	O	O
subjects	O	O
who	O	O
used	O	O
MA	B_Chemical	O
and	O	O
21	O	O
age-matched	O	O
,	O	O
healthy	O	O
controls	O	O
.	O	O

Cortical	O	O
maps	O	O
revealed	O	O
severe	O	O
gray-matter	O	O
deficits	O	O
in	O	O
the	O	O
cingulate	O	O
,	O	O
limbic	O	O
,	O	O
and	O	O
paralimbic	O	O
cortices	O	O
of	O	O
MA	B_Chemical	O
abusers	O	O
(	O	O
averaging	O	O
11.3	O	O
%	O	O
below	O	O
control	O	O
;	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

On	O	O
average	O	O
,	O	O
MA	B_Chemical	O
abusers	O	O
had	O	O
7.8	O	O
%	O	O
smaller	O	O
hippocampal	O	O
volumes	O	O
than	O	O
control	O	O
subjects	O	O
(	O	O
p	O	O
<	O	O
0.01	O	O
;	O	O
left	O	O
,	O	O
p	O	O
=	O	O
0.01	O	O
;	O	O
right	O	O
,	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
and	O	O
significant	O	O
white-matter	O	O
hypertrophy	B_Disease	O
(	O	O
7.0	O	O
%	O	O
;	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Hippocampal	O	O
deficits	O	O
were	O	O
mapped	O	O
and	O	O
correlated	O	O
with	O	O
memory	O	O
performance	O	O
on	O	O
a	O	O
word-recall	O	O
test	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

MRI-based	O	O
maps	O	O
suggest	O	O
that	O	O
chronic	O	O
methamphetamine	B_Chemical	O
abuse	O	O
causes	O	O
a	O	O
selective	O	O
pattern	O	O
of	O	O
cerebral	O	O
deterioration	O	O
that	O	O
contributes	O	O
to	O	O
impaired	B_Disease	O
memory	I_Disease	O
performance	I_Disease	O
.	O	O

MA	B_Chemical	O
may	O	O
selectively	O	O
damage	O	O
the	O	O
medial	O	O
temporal	O	O
lobe	O	O
and	O	O
,	O	O
consistent	O	O
with	O	O
metabolic	O	O
studies	O	O
,	O	O
the	O	O
cingulate-limbic	O	O
cortex	O	O
,	O	O
inducing	O	O
neuroadaptation	O	O
,	O	O
neuropil	O	O
reduction	O	O
,	O	O
or	O	O
cell	O	O
death	O	O
.	O	O

Prominent	O	O
white-matter	O	O
hypertrophy	B_Disease	O
may	O	O
result	O	O
from	O	O
altered	O	O
myelination	O	O
and	O	O
adaptive	O	O
glial	O	O
changes	O	O
,	O	O
including	O	O
gliosis	B_Disease	B_Disease
secondary	O	O
to	O	O
neuronal	B_Disease	B_Disease
damage	I_Disease	I_Disease
.	O	O

These	O	O
brain	O	O
substrates	O	O
may	O	O
help	O	O
account	O	O
for	O	O
the	O	O
symptoms	O	O
of	O	O
MA	B_Chemical	O
abuse	O	O
,	O	O
providing	O	O
therapeutic	O	O
targets	O	O
for	O	O
drug-induced	O	O
brain	B_Disease	B_Disease
injury	I_Disease	I_Disease
.	O	O

Disruption	O	O
of	O	O
hepatic	O	O
lipid	O	O
homeostasis	O	O
in	O	O
mice	O	O
after	O	O
amiodarone	O	O
treatment	O	O
is	O	O
associated	O	O
with	O	O
peroxisome	O	O
proliferator-activated	O	O
receptor-alpha	O	O
target	O	O
gene	O	O
activation	O	O
.	O	O

Amiodarone	B_Chemical	O
,	O	O
an	O	O
efficacious	O	O
and	O	O
widely	O	O
used	O	O
antiarrhythmic	O	O
agent	O	O
,	O	O
has	O	O
been	O	O
reported	O	O
to	O	O
cause	O	O
hepatotoxicity	B_Disease	B_Disease
in	O	O
some	O	O
patients	O	O
.	O	O

To	O	O
gain	O	O
insight	O	O
into	O	O
the	O	O
mechanism	O	O
of	O	O
this	O	O
unwanted	O	O
effect	O	O
,	O	O
mice	O	O
were	O	O
administered	O	O
various	O	O
doses	O	O
of	O	O
amiodarone	B_Chemical	O
and	O	O
examined	O	O
for	O	O
changes	O	O
in	O	O
hepatic	O	O
histology	O	O
and	O	O
gene	O	O
regulation	O	O
.	O	O

Amiodarone	B_Chemical	O
induced	O	O
hepatomegaly	B_Disease	O
,	O	O
hepatocyte	O	O
microvesicular	O	O
lipid	O	O
accumulation	O	O
,	O	O
and	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
serum	O	O
triglycerides	B_Chemical	O
and	O	O
glucose	B_Chemical	O
.	O	O

Northern	O	O
blot	O	O
analysis	O	O
of	O	O
hepatic	O	O
RNA	O	O
revealed	O	O
a	O	O
dose-dependent	O	O
increase	O	O
in	O	O
the	O	O
expression	O	O
of	O	O
a	O	O
number	O	O
of	O	O
genes	O	O
critical	O	O
for	O	O
fatty	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
oxidation	O	O
,	O	O
lipoprotein	O	O
assembly	O	O
,	O	O
and	O	O
lipid	O	O
transport	O	O
.	O	O

Many	O	O
of	O	O
these	O	O
genes	O	O
are	O	O
regulated	O	O
by	O	O
the	O	O
peroxisome	O	O
proliferator-activated	O	O
receptor-alpha	O	O
(	O	O
PPARalpha	O	O
)	O	O
,	O	O
a	O	O
ligand-activated	O	O
nuclear	O	O
hormone	O	O
receptor	O	O
transcription	O	O
factor	O	O
.	O	O

The	O	O
absence	O	O
of	O	O
induction	O	O
of	O	O
these	O	O
genes	O	O
as	O	O
well	O	O
as	O	O
hepatomegaly	B_Disease	O
in	O	O
PPARalpha	O	O
knockout	O	O
[	O	O
PPARalpha-/-	O	O
]	O	O
mice	O	O
indicated	O	O
that	O	O
the	O	O
effects	O	O
of	O	O
amiodarone	B_Chemical	O
were	O	O
dependent	O	O
upon	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
functional	O	O
PPARalpha	O	O
gene	O	O
.	O	O

Compared	O	O
to	O	O
wild-type	O	O
mice	O	O
,	O	O
treatment	O	O
of	O	O
PPARalpha-/-	O	O
mice	O	O
with	O	O
amiodarone	B_Chemical	O
resulted	O	O
in	O	O
an	O	O
increased	O	O
rate	O	O
and	O	O
extent	O	O
of	O	O
total	O	O
body	O	B_Disease
weight	B_Disease	I_Disease
loss	I_Disease	I_Disease
.	O	O

The	O	O
inability	O	O
of	O	O
amiodarone	B_Chemical	O
to	O	O
directly	O	O
activate	O	O
either	O	O
human	O	O
or	O	O
mouse	O	O
PPARalpha	O	O
transiently	O	O
expressed	O	O
in	O	O
human	O	O
HepG2	O	O
hepatoma	B_Disease	O
cells	O	O
indicates	O	O
that	O	O
the	O	O
effects	O	O
of	O	O
amiodarone	B_Chemical	O
on	O	O
the	O	O
function	O	O
of	O	O
this	O	O
receptor	O	O
were	O	O
indirect	O	O
.	O	O

Based	O	O
upon	O	O
these	O	O
results	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
amiodarone	B_Chemical	O
disrupts	O	O
hepatic	O	O
lipid	O	O
homeostasis	O	O
and	O	O
that	O	O
the	O	O
increased	O	O
expression	O	O
of	O	O
PPARalpha	O	O
target	O	O
genes	O	O
is	O	O
secondary	O	O
to	O	O
this	O	O
toxic	O	O
effect	O	O
.	O	O

These	O	O
results	O	O
provide	O	O
important	O	O
new	O	O
mechanistic	O	O
information	O	O
regarding	O	O
the	O	O
hepatotoxic	B_Disease	O
effects	O	O
of	O	O
amiodarone	B_Chemical	O
and	O	O
indicate	O	O
that	O	O
PPARalpha	O	B_Chemical
protects	O	O
against	O	O
amiodarone-induced	O	O
hepatotoxicity	B_Disease	B_Disease
.	O	O

Safety	O	O
and	O	O
compliance	O	O
with	O	O
once-daily	O	O
niacin	O	O
extended-release/lovastatin	O	O
as	O	O
initial	O	O
therapy	O	O
in	O	O
the	O	O
Impact	O	O
of	O	O
Medical	O	O
Subspecialty	O	O
on	O	O
Patient	O	O
Compliance	O	O
to	O	O
Treatment	O	O
(	O	O
IMPACT	O	O
)	O	O
study	O	O
.	O	O

Niacin	B_Chemical	O
extended-release/lovastatin	I_Chemical	O
is	O	O
a	O	O
new	O	O
combination	O	O
product	O	O
approved	O	O
for	O	O
treatment	O	O
of	O	O
primary	O	B_Disease
hypercholesterolemia	B_Disease	I_Disease
and	O	O
mixed	O	O
dyslipidemia	B_Disease	O
.	O	O

This	O	O
open-labeled	O	O
,	O	O
multicenter	O	O
study	O	O
evaluated	O	O
the	O	O
safety	O	O
of	O	O
bedtime	O	O
niacin	B_Chemical	O
extended-release/lovastatin	I_Chemical	O
when	O	O
dosed	O	O
as	O	O
initial	O	O
therapy	O	O
and	O	O
patient	O	O
compliance	O	O
to	O	O
treatment	O	O
in	O	O
various	O	O
clinical	O	O
practice	O	O
settings	O	O
.	O	O

A	O	O
total	O	O
of	O	O
4,499	O	O
patients	O	O
with	O	O
dyslipidemia	B_Disease	B_Disease
requiring	O	O
drug	O	O
intervention	O	O
was	O	O
enrolled	O	O
at	O	O
1,081	O	O
sites	O	O
.	O	O

Patients	O	O
were	O	O
treated	O	O
with	O	O
1	O	O
tablet	O	O
(	O	O
500	O	O
mg	O	O
of	O	O
niacin	B_Chemical	O
extended-release/20	O	O
mg	O	O
of	O	O
lovastatin	B_Chemical	O
)	O	O
once	O	O
nightly	O	O
for	O	O
4	O	O
weeks	O	O
and	O	O
then	O	O
2	O	O
tablets	O	O
for	O	O
8	O	O
weeks	O	O
.	O	O

Patients	O	O
also	O	O
received	O	O
dietary	O	O
counseling	O	O
,	O	O
educational	O	O
materials	O	O
,	O	O
and	O	O
reminders	O	O
to	O	O
call	O	O
a	O	O
toll-free	O	O
number	O	O
that	O	O
provided	O	O
further	O	O
education	O	O
about	O	O
dyslipidemia	B_Disease	O
and	O	O
niacin	B_Chemical	O
extended-release/lovastatin	I_Chemical	O
.	O	O

Primary	O	O
end	O	O
points	O	O
were	O	O
study	O	O
compliance	O	O
,	O	O
increases	O	O
in	O	O
liver	O	O
transaminases	O	O
to	O	O
>	O	O
3	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
,	O	O
and	O	O
clinical	O	O
myopathy	B_Disease	O
.	O	O

Final	O	O
study	O	O
status	O	O
was	O	O
available	O	O
for	O	O
4,217	O	O
patients	O	O
(	O	O
94	O	O
%	O	O
)	O	O
.	O	O

Compliance	O	O
to	O	O
niacin	B_Chemical	O
extended-release/lovastatin	I_Chemical	O
was	O	O
77	O	O
%	O	O
,	O	O
with	O	O
3,245	O	O
patients	O	O
completing	O	O
the	O	O
study	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
southeast	O	O
and	O	O
those	O	O
enrolled	O	O
by	O	O
endocrinologists	O	O
had	O	O
the	O	O
lowest	O	O
compliance	O	O
and	O	O
highest	O	O
adverse	O	O
event	O	O
rates	O	O
.	O	O

Flushing	B_Disease	O
was	O	O
the	O	O
most	O	O
common	O	O
adverse	O	O
event	O	O
,	O	O
reported	O	O
by	O	O
18	O	O
%	O	O
of	O	O
patients	O	O
and	O	O
leading	O	O
to	O	O
discontinuation	O	O
by	O	O
6	O	O
%	O	O
.	O	O

Incidence	O	O
of	O	O
increased	O	O
aspartate	B_Chemical	B_Chemical
aminotransferase	O	I_Chemical
and/or	O	O
alanine	B_Chemical	B_Chemical
aminotransferase	O	I_Chemical
>	O	O
3	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
was	O	O
<	O	O
0.3	O	O
%	O	O
.	O	O

An	O	O
increase	O	O
of	O	O
creatine	B_Chemical	O
phosphokinase	O	O
to	O	O
>	O	O
5	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
occurred	O	O
in	O	O
0.24	O	O
%	O	O
of	O	O
patients	O	O
,	O	O
and	O	O
no	O	O
cases	O	O
of	O	O
drug-induced	O	O
myopathy	B_Disease	O
were	O	O
observed	O	O
.	O	O

Niacin	B_Chemical	O
extended-release/lovastatin	I_Chemical	O
1,000/40	O	O
mg	O	O
,	O	O
dosed	O	O
as	O	O
initial	O	O
therapy	O	O
,	O	O
was	O	O
associated	O	O
with	O	O
good	O	O
compliance	O	O
and	O	O
safety	O	O
and	O	O
had	O	O
very	O	O
low	O	O
incidences	O	O
of	O	O
increased	O	O
liver	O	O
and	O	O
muscle	O	O
enzymes	O	O
.	O	O

Protective	O	O
effect	O	O
of	O	O
Terminalia	B_Chemical	O
chebula	I_Chemical	O
against	O	O
experimental	O	O
myocardial	B_Disease	B_Disease
injury	I_Disease	I_Disease
induced	O	O
by	O	O
isoproterenol	B_Chemical	O
.	O	O

Cardioprotective	O	O
effect	O	O
of	O	O
ethanolic	B_Chemical	O
extract	I_Chemical	O
of	I_Chemical	O
Terminalia	I_Chemical	O
chebula	I_Chemical	O
fruits	I_Chemical	O
(	O	O
500	O	O
mg/kg	O	O
body	O	O
wt	O	O
)	O	O
was	O	O
examined	O	O
in	O	O
isoproterenol	B_Chemical	O
(	O	O
200	O	O
mg/kg	O	O
body	O	O
wt	O	O
)	O	O
induced	O	O
myocardial	B_Disease	B_Disease
damage	I_Disease	I_Disease
in	O	O
rats	O	O
.	O	O

In	O	O
isoproterenol	B_Chemical	O
administered	O	O
rats	O	O
,	O	O
the	O	O
level	O	O
of	O	O
lipid	O	O
peroxides	B_Chemical	O
increased	O	O
significantly	O	O
in	O	O
the	O	O
serum	O	O
and	O	O
heart	O	O
.	O	O

A	O	O
significant	O	O
decrease	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
myocardial	O	O
marker	O	O
enzymes	O	O
with	O	O
a	O	O
concomitant	O	O
increase	O	O
in	O	O
their	O	O
activity	O	O
in	O	O
serum	O	O
.	O	O

Histopathological	O	O
examination	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
confirm	O	O
the	O	O
myocardial	O	B_Disease
necrosis	B_Disease	I_Disease
.	O	O

T.	B_Chemical	O
chebula	I_Chemical	O
extract	I_Chemical	O
pretreatment	O	O
was	O	O
found	O	O
to	O	O
ameliorate	O	O
the	O	O
effect	O	O
of	O	O
isoproterenol	B_Chemical	O
on	O	O
lipid	O	O
peroxide	B_Chemical	O
formation	O	O
and	O	O
retained	O	O
the	O	O
activities	O	O
of	O	O
the	O	O
diagnostic	O	O
marker	O	O
enzymes	O	O
.	O	O

A	O	O
case	O	O
of	O	O
postoperative	O	O
anxiety	B_Disease	O
due	O	O
to	O	O
low	O	O
dose	O	O
droperidol	B_Chemical	B_Chemical
used	O	O
with	O	O
patient-controlled	O	O
analgesia	O	O
.	O	O

A	O	O
multiparous	O	O
woman	O	O
in	O	O
good	O	O
psychological	O	O
health	O	O
underwent	O	O
urgent	O	O
caesarean	O	O
section	O	O
in	O	O
labour	O	O
.	O	O

Postoperatively	O	O
,	O	O
she	O	O
was	O	O
given	O	O
a	O	O
patient-controlled	O	O
analgesia	O	O
device	O	O
delivering	O	O
boluses	O	O
of	O	O
diamorphine	B_Chemical	B_Chemical
0.5	O	O
mg	O	O
and	O	O
droperidol	B_Chemical	B_Chemical
0.025	O	O
mg	O	O
.	O	O

Whilst	O	O
using	O	O
the	O	O
device	O	O
she	O	O
gradually	O	O
became	O	O
anxious	O	O
,	O	O
the	O	O
feeling	O	O
worsening	O	O
after	O	O
each	O	O
bolus	O	O
.	O	O

The	O	O
diagnosis	O	O
of	O	O
droperidol-induced	O	O
psychological	B_Disease	B_Disease
disturbance	I_Disease	I_Disease
was	O	O
not	O	O
made	O	O
straight	O	O
away	O	O
although	O	O
on	O	O
subsequent	O	O
close	O	O
questioning	O	O
the	O	O
patient	O	O
gave	O	O
a	O	O
very	O	O
clear	O	O
history	O	O
.	O	O

After	O	O
she	O	O
had	O	O
received	O	O
a	O	O
total	O	O
of	O	O
only	O	O
0.9	O	O
mg	O	O
droperidol	B_Chemical	B_Chemical
,	O	O
a	O	O
syringe	O	O
containing	O	O
diamorphine	B_Chemical	B_Chemical
only	O	O
was	O	O
substituted	O	O
and	O	O
her	O	O
unease	O	O
resolved	O	O
completely	O	O
.	O	O

We	O	O
feel	O	O
that	O	O
,	O	O
although	O	O
the	O	O
dramatic	O	O
extrapyramidal	O	O
side	O	O
effects	O	O
of	O	O
dopaminergic	O	O
antiemetics	O	O
are	O	O
well	O	O
known	O	O
,	O	O
more	O	O
subtle	O	O
manifestations	O	O
may	O	O
easily	O	O
be	O	O
overlooked	O	O
.	O	O

Accurate	O	O
patient	O	O
history	O	O
contributes	O	O
to	O	O
differentiating	O	O
diabetes	O	O
insipidus	O	O
:	O	O
a	O	O
case	O	O
study	O	O
.	O	O

This	O	O
case	O	O
study	O	O
highlights	O	O
the	O	O
important	O	O
contribution	O	O
of	O	O
nursing	O	O
in	O	O
obtaining	O	O
an	O	O
accurate	O	O
health	O	O
history	O	O
.	O	O

The	O	O
case	O	O
discussed	O	O
herein	O	O
initially	O	O
appeared	O	O
to	O	O
be	O	O
neurogenic	B_Disease	O
diabetes	I_Disease	O
insipidus	I_Disease	O
(	O	O
DI	B_Disease	O
)	O	O
secondary	O	O
to	O	O
a	O	O
traumatic	B_Disease	B_Disease
brain	I_Disease	I_Disease
injury	I_Disease	I_Disease
.	O	O

The	O	O
nursing	O	O
staff	O	O
,	O	O
by	O	O
reviewing	O	O
the	O	O
patient	O	O
's	O	O
health	O	O
history	O	O
with	O	O
his	O	O
family	O	O
,	O	O
discovered	O	O
a	O	O
history	O	O
of	O	O
polydipsia	B_Disease	O
and	O	O
long-standing	O	O
lithium	B_Chemical	O
use	O	O
.	O	O

Lithium	B_Chemical	O
is	O	O
implicated	O	O
in	O	O
drug-induced	O	O
nephrogenic	B_Disease	O
DI	I_Disease	O
,	O	O
and	O	O
because	O	O
the	O	O
patient	O	O
had	O	O
not	O	O
received	O	O
lithium	B_Chemical	O
since	O	O
being	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
,	O	O
his	O	O
treatment	O	O
changed	O	O
to	O	O
focus	O	O
on	O	O
nephrogenic	B_Disease	B_Disease
DI	I_Disease	I_Disease
.	O	O

By	O	O
combining	O	O
information	O	O
from	O	O
the	O	O
patient	O	O
history	O	O
,	O	O
the	O	O
physical	O	O
examination	O	O
,	O	O
and	O	O
radiologic	O	O
and	O	O
laboratory	O	O
studies	O	O
,	O	O
the	O	O
critical	O	O
care	O	O
team	O	O
demonstrated	O	O
that	O	O
the	O	O
patient	O	O
had	O	O
been	O	O
self-treating	O	O
his	O	O
lithium-induced	O	O
nephrogenic	B_Disease	B_Chemical
DI	I_Disease	I_Chemical
and	O	O
developed	O	O
neurogenic	B_Disease	O
DI	I_Disease	O
secondary	O	O
to	O	O
brain	B_Disease	B_Disease
trauma	I_Disease	I_Disease
.	O	O

Thus	O	O
successful	O	O
treatment	O	O
required	O	O
that	O	O
nephrogenic	O	O
and	O	O
neurogenic	B_Disease	O
DI	I_Disease	O
be	O	O
treated	O	O
concomitantly	O	O
.	O	O

Factors	O	O
contributing	O	O
to	O	O
ribavirin-induced	O	O
anemia	B_Disease	O
.	O	O

BACKGROUND	O	O
AND	O	O
AIM	O	O
:	O	O
Interferon	B_Chemical	O
and	O	O
ribavirin	B_Chemical	O
combination	O	O
therapy	O	O
for	O	O
chronic	B_Disease	O
hepatitis	I_Disease	O
C	I_Disease	O
produces	O	O
hemolytic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
.	O	O

This	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
identify	O	O
the	O	O
factors	O	O
contributing	O	O
to	O	O
ribavirin-induced	O	O
anemia	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
Eighty-eight	O	O
patients	O	O
with	O	O
chronic	B_Disease	O
hepatitis	I_Disease	O
C	I_Disease	O
who	O	O
received	O	O
interferon-alpha-2b	B_Chemical	O
at	O	O
a	O	O
dose	O	O
of	O	O
6	O	O
MU	O	O
administered	O	O
intramuscularly	O	O
for	O	O
24	O	O
weeks	O	O
in	O	O
combination	O	O
with	O	O
ribavirin	B_Chemical	O
administered	O	O
orally	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
600	O	O
mg	O	O
or	O	O
800	O	O
mg	O	O
participated	O	O
in	O	O
the	O	O
study	O	O
.	O	O

A	O	O
hemoglobin	O	O
concentration	O	O
of	O	O
<	O	O
10	O	O
g/dL	O	O
was	O	O
defined	O	O
as	O	O
ribavirin-induced	O	O
anemia	B_Disease	O
.	O	O

RESULTS	O	O
:	O	O
Ribavirin-induced	O	O
anemia	B_Disease	O
occurred	O	O
in	O	O
18	O	O
(	O	O
20.5	O	O
%	O	O
)	O	O
patients	O	O
during	O	O
treatment	O	O
.	O	O

A	O	O
2	O	O
g/dL	O	O
decrease	O	O
in	O	O
hemoglobin	O	O
concentrations	O	O
in	O	O
patients	O	O
with	O	O
anemia	B_Disease	O
was	O	O
observed	O	O
at	O	O
week	O	O
2	O	O
after	O	O
the	O	O
start	O	O
of	O	O
treatment	O	O
.	O	O

The	O	O
hemoglobin	O	O
concentration	O	O
in	O	O
patients	O	O
with	O	O
>	O	O
or	O	O
=	O	O
2	O	O
g/dL	O	O
decrease	O	O
at	O	O
week	O	O
2	O	O
was	O	O
observed	O	O
to	O	O
be	O	O
significantly	O	O
lower	O	O
even	O	O
after	O	O
week	O	O
2	O	O
than	O	O
in	O	O
patients	O	O
with	O	O
<	O	O
2	O	O
g/dL	O	O
decrease	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

A	O	O
significant	O	O
relationship	O	O
was	O	O
observed	O	O
between	O	O
the	O	O
rate	O	O
of	O	O
reduction	O	O
of	O	O
hemoglobin	O	O
concentrations	O	O
at	O	O
week	O	O
2	O	O
and	O	O
the	O	O
severity	O	O
of	O	O
anemia	B_Disease	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Such	O	O
factors	O	O
as	O	O
sex	O	O
(	O	O
female	O	O
)	O	O
,	O	O
age	O	O
(	O	O
>	O	O
or	O	O
=	O	O
60	O	O
years	O	O
old	O	O
)	O	O
,	O	O
and	O	O
the	O	O
ribavirin	B_Chemical	O
dose	O	O
by	O	O
body	O	O
weight	O	O
(	O	O
12	O	O
mg/kg	O	O
or	O	O
more	O	O
)	O	O
were	O	O
significant	O	O
by	O	O
univariate	O	O
analysis	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Careful	O	O
administration	O	O
is	O	O
necessary	O	O
in	O	O
patients	O	O
>	O	O
or	O	O
=	O	O
60	O	O
years	O	O
old	O	O
,	O	O
in	O	O
female	O	O
patients	O	O
,	O	O
and	O	O
in	O	O
patients	O	O
receiving	O	O
a	O	O
ribavirin	B_Chemical	O
dose	O	O
of	O	O
12	O	O
mg/kg	O	O
or	O	O
more	O	O
.	O	O

Patients	O	O
who	O	O
experience	O	O
a	O	O
fall	O	O
in	O	O
hemoglobin	O	O
concentrations	O	O
of	O	O
2	O	O
g/dL	O	O
or	O	O
more	O	O
at	O	O
week	O	O
2	O	O
after	O	O
the	O	O
start	O	O
of	O	O
treatment	O	O
should	O	O
be	O	O
monitored	O	O
with	O	O
particular	O	O
care	O	O
.	O	O

Zidovudine-induced	O	O
hepatitis	B_Disease	O
.	O	O

A	O	O
case	O	O
of	O	O
acute	O	O
hepatitis	B_Disease	O
induced	O	O
by	O	O
zidovudine	B_Chemical	O
in	O	O
a	O	O
38-year-old	O	O
patient	O	O
with	O	O
AIDS	B_Disease	O
is	O	O
presented	O	O
.	O	O

The	O	O
mechanism	O	O
whereby	O	O
the	O	O
hepatitis	B_Disease	O
was	O	O
induced	O	O
is	O	O
not	O	O
known	O	O
.	O	O

However	O	O
,	O	O
the	O	O
patient	O	O
tolerated	O	O
well	O	O
an	O	O
alternative	O	O
reverse	O	O
transcriptase	O	O
inhibitor	O	O
,	O	O
2'3	B_Chemical	B_Chemical
'	I_Chemical	I_Chemical
dideoxyinosine	I_Chemical	I_Chemical
.	O	O

Physicians	O	O
caring	O	O
for	O	O
patients	O	O
with	O	O
AIDS	B_Disease	O
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
hitherto	O	O
rarely	O	O
reported	O	O
complication	O	O
.	O	O

Oxidative	O	B_Disease
damage	O	I_Disease
precedes	O	O
nitrative	O	O
damage	O	O
in	O	O
adriamycin-induced	O	O
cardiac	O	B_Disease
mitochondrial	B_Disease	I_Disease
injury	I_Disease	I_Disease
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
elevated	O	O
reactive	O	O
oxygen	B_Chemical	O
(ROS)/nitrogen	O	O
species	O	O
(	O	O
RNS	O	O
)	O	O
reported	O	O
to	O	O
be	O	O
present	O	O
in	O	O
adriamycin	B_Chemical	B_Chemical
(ADR)-induced	O	O
cardiotoxicity	B_Disease	B_Disease
actually	O	O
resulted	O	O
in	O	O
cardiomyocyte	O	B_Disease
oxidative/nitrative	O	I_Disease
damage	O	I_Disease
,	O	O
and	O	O
to	O	O
quantitatively	O	O
determine	O	O
the	O	O
time	O	O
course	O	O
and	O	O
subcellular	O	O
localization	O	O
of	O	O
these	O	O
postulated	O	O
damage	O	O
products	O	O
using	O	O
an	O	O
in	O	O
vivo	O	O
approach	O	O
.	O	O

B6C3	O	O
mice	O	O
were	O	O
treated	O	O
with	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
20	O	O
mg/kg	O	O
ADR	B_Chemical	O
.	O	O

Ultrastructural	O	O
damage	O	O
and	O	O
levels	O	O
of	O	O
4-hydroxy-2-nonenal	B_Chemical	O
(4HNE)-protein	O	O
adducts	O	O
and	O	O
3-nitrotyrosine	B_Chemical	B_Chemical
(	O	O
3NT	B_Chemical	O
)	O	O
were	O	O
analyzed	O	O
.	O	O

Quantitative	O	O
ultrastructural	O	O
damage	O	O
using	O	O
computerized	O	O
image	O	O
techniques	O	O
showed	O	O
cardiomyocyte	O	O
injury	O	O
as	O	O
early	O	O
as	O	O
3	O	O
hours	O	O
,	O	O
with	O	O
mitochondria	O	O
being	O	O
the	O	O
most	O	O
extensively	O	O
and	O	O
progressively	O	O
injured	O	O
subcellular	O	O
organelle	O	O
.	O	O

Analysis	O	O
of	O	O
4HNE	B_Chemical	O
protein	O	O
adducts	O	O
by	O	O
immunogold	O	O
electron	O	O
microscopy	O	O
showed	O	O
appearance	O	O
of	O	O
4HNE	B_Chemical	O
protein	O	O
adducts	O	O
in	O	O
mitochondria	O	O
as	O	O
early	O	O
as	O	O
3	O	O
hours	O	O
,	O	O
with	O	O
a	O	O
peak	O	O
at	O	O
6	O	O
hours	O	O
and	O	O
subsequent	O	O
decline	O	O
at	O	O
24	O	O
hours	O	O
.	O	O

3NT	B_Chemical	O
levels	O	O
were	O	O
significantly	O	O
increased	O	O
in	O	O
all	O	O
subcellular	O	O
compartments	O	O
at	O	O
6	O	O
hours	O	O
and	O	O
subsequently	O	O
declined	O	O
at	O	O
24	O	O
hours	O	O
.	O	O

Our	O	O
data	O	O
showed	O	O
ADR	B_Chemical	O
induced	O	O
4HNE-protein	O	O
adducts	O	O
in	O	O
mitochondria	O	O
at	O	O
the	O	O
same	O	O
time	O	O
point	O	O
as	O	O
when	O	O
mitochondrial	B_Disease	O
injury	I_Disease	O
initially	O	O
appeared	O	O
.	O	O

These	O	O
results	O	O
document	O	O
for	O	O
the	O	O
first	O	O
time	O	O
in	O	O
vivo	O	O
that	O	O
mitochondrial	B_Disease	B_Disease
oxidative	I_Disease	I_Disease
damage	I_Disease	I_Disease
precedes	O	O
nitrative	O	B_Disease
damage	O	I_Disease
.	O	O

The	O	O
progressive	O	O
nature	O	O
of	O	O
mitochondrial	B_Disease	O
injury	I_Disease	O
suggests	O	O
that	O	O
mitochondria	O	O
,	O	O
not	O	O
other	O	O
subcellular	O	O
organelles	O	O
,	O	O
are	O	O
the	O	O
major	O	O
site	O	O
of	O	O
intracellular	O	O
injury	O	O
.	O	O

Sotalol-induced	O	O
coronary	B_Disease	B_Disease
spasm	I_Disease	I_Disease
in	O	O
a	O	O
patient	O	O
with	O	O
dilated	B_Disease	B_Disease
cardiomyopathy	I_Disease	I_Disease
associated	O	O
with	O	O
sustained	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
.	O	O

A	O	O
54-year-old	O	O
man	O	O
with	O	O
severe	O	O
left	O	B_Disease
ventricular	B_Disease	I_Disease
dysfunction	I_Disease	I_Disease
due	O	O
to	O	O
dilated	B_Disease	B_Disease
cardiomyopathy	I_Disease	I_Disease
was	O	O
referred	O	O
to	O	O
our	O	O
hospital	O	O
for	O	O
symptomatic	O	O
incessant	O	O
sustained	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
(	O	O
VT	B_Disease	O
)	O	O
.	O	O

After	O	O
the	O	O
administration	O	O
of	O	O
nifekalant	B_Chemical	B_Chemical
hydrochloride	I_Chemical	I_Chemical
,	O	O
sustained	O	O
VT	B_Disease	O
was	O	O
terminated	O	O
.	O	O

An	O	O
alternate	O	O
class	O	O
III	O	O
agent	O	O
,	O	O
sotalol	B_Chemical	O
,	O	O
was	O	O
also	O	O
effective	O	O
for	O	O
the	O	O
prevention	O	O
of	O	O
VT	B_Disease	O
.	O	O

However	O	O
,	O	O
one	O	O
month	O	O
after	O	O
switching	O	O
over	O	O
nifekalant	B_Chemical	B_Chemical
to	O	O
sotalol	B_Chemical	O
,	O	O
a	O	O
short	O	O
duration	O	O
of	O	O
ST	O	O
elevation	O	O
was	O	O
documented	O	O
in	O	O
ECG	O	O
monitoring	O	O
at	O	O
almost	O	O
the	O	O
same	O	O
time	O	O
for	O	O
three	O	O
consecutive	O	O
days	O	O
.	O	O

ST	O	O
elevation	O	O
with	O	O
chest	O	B_Disease
discomfort	O	I_Disease
disappeared	O	O
since	O	O
he	O	O
began	O	O
taking	O	O
long-acting	O	O
diltiazem	B_Chemical	O
.	O	O

Coronary	B_Disease	B_Disease
vasospasm	I_Disease	I_Disease
may	O	O
be	O	O
induced	O	O
by	O	O
the	O	O
non-selective	O	O
beta-blocking	O	O
properties	O	O
of	O	O
sotalol	B_Chemical	B_Chemical
.	O	O

Effects	O	O
of	O	O
the	O	O
antidepressant	O	O
trazodone	B_Chemical	O
,	O	O
a	O	O
5-HT	B_Chemical	O
2A/2C	O	O
receptor	O	O
antagonist	O	O
,	O	O
on	O	O
dopamine-dependent	O	O
behaviors	O	O
in	O	O
rats	O	O
.	O	O

RATIONALE	O	O
:	O	O
5-Hydroxytryptamine	B_Chemical	O
,	O	O
via	O	O
stimulation	O	O
of	O	O
5-HT	B_Chemical	O
2C	O	O
receptors	O	O
,	O	O
exerts	O	O
a	O	O
tonic	O	O
inhibitory	O	O
influence	O	O
on	O	O
dopaminergic	O	O
neurotransmission	O	O
,	O	O
whereas	O	O
activation	O	O
of	O	O
5-HT	B_Chemical	O
2A	O	O
receptors	O	O
enhances	O	O
stimulated	O	O
DAergic	O	O
neurotransmission	O	O
.	O	O

The	O	O
antidepressant	O	O
trazodone	B_Chemical	O
is	O	O
a	O	O
5-HT	B_Chemical	O
2A/2C	O	O
receptor	O	O
antagonist	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
trazodone	B_Chemical	O
treatment	O	O
on	O	O
behaviors	O	O
dependent	O	O
on	O	O
the	O	O
functional	O	O
status	O	O
of	O	O
the	O	O
nigrostriatal	O	O
DAergic	O	O
system	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
effect	O	O
of	O	O
pretreatment	O	O
with	O	O
trazodone	B_Chemical	O
on	O	O
dexamphetamine-	O	B_Chemical
and	O	O
apomorphine-induced	O	O
oral	B_Disease	O
stereotypies	I_Disease	O
,	O	O
on	O	O
catalepsy	B_Disease	O
induced	O	O
by	O	O
haloperidol	B_Chemical	O
and	O	O
apomorphine	B_Chemical	O
(	O	O
0.05	O	O
mg/kg	O	O
,	O	O
i.p	O	O
.	O	O
)	O	O
,	O	O
on	O	O
ergometrine-induced	O	O
wet	O	O
dog	O	O
shake	O	O
(	O	O
WDS	O	O
)	O	O
behavior	O	O
and	O	O
fluoxetine-induced	O	O
penile	O	O
erections	O	O
was	O	O
studied	O	O
in	O	O
rats	O	O
.	O	O

We	O	O
also	O	O
investigated	O	O
whether	O	O
trazodone	B_Chemical	O
induces	O	O
catalepsy	B_Disease	O
in	O	O
rats	O	O
.	O	O

RESULTS	O	O
:	O	O
Trazodone	B_Chemical	O
at	O	O
2.5	O	O
-	O	O
20	O	O
mg/kg	O	O
i.p	O	O
.	O	O
did	O	O
not	O	O
induce	O	O
catalepsy	B_Disease	O
,	O	O
and	O	O
did	O	O
not	O	O
antagonize	O	O
apomorphine	B_Chemical	O
(	O	O
1.5	O	O
and	O	O
3	O	O
mg/kg	O	O
)	O	O
stereotypy	O	O
and	O	O
apomorphine	B_Chemical	O
(	O	O
0.05	O	O
mg/kg)-induced	O	O
catalepsy	B_Disease	O
.	O	O

However	O	O
,	O	O
pretreatment	O	O
with	O	O
5	O	O
,	O	O
10	O	O
and	O	O
20	O	O
mg/kg	O	O
i.p	O	O
.	O	O

trazodone	B_Chemical	O
enhanced	O	O
dexamphetamine	B_Chemical	O
stereotypy	O	O
,	O	O
and	O	O
antagonized	O	O
haloperidol	B_Chemical	O
catalepsy	B_Disease	O
,	O	O
ergometrine-induced	O	O
WDS	O	O
behavior	O	O
and	O	O
fluoxetine-induced	O	O
penile	O	O
erections	O	O
.	O	O

Trazodone	B_Chemical	O
at	O	O
30	O	O
,	O	O
40	O	O
and	O	O
50	O	O
mg/kg	O	O
i.p	O	O
.	O	O
induced	O	O
catalepsy	B_Disease	O
and	O	O
antagonized	O	O
apomorphine	B_Chemical	O
and	O	O
dexamphetamine	B_Chemical	O
stereotypies	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Our	O	O
results	O	O
indicate	O	O
that	O	O
trazodone	B_Chemical	O
at	O	O
2.5	O	O
-	O	O
20	O	O
mg/kg	O	O
does	O	O
not	O	O
block	O	O
pre-	O	O
and	O	O
postsynaptic	O	O
striatal	O	O
D2	O	O
DA	O	O
receptors	O	O
,	O	O
while	O	O
at	O	O
30	O	O
,	O	O
40	O	O
and	O	O
50	O	O
mg/kg	O	O
it	O	O
blocks	O	O
postsynaptic	O	O
striatal	O	O
D2	O	O
DA	O	O
receptors	O	O
.	O	O

Furthermore	O	O
,	O	O
at	O	O
5	O	O
,	O	O
10	O	O
and	O	O
20	O	O
mg/kg	O	O
,	O	O
trazodone	B_Chemical	O
blocks	O	O
5-HT	B_Chemical	O
2A	O	O
and	O	O
5-HT	B_Chemical	O
2C	O	O
receptors	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
trazodone	B_Chemical	O
(	O	O
5	O	O
,	O	O
10	O	O
and	O	O
20	O	O
mg/kg	O	O
)	O	O
,	O	O
by	O	O
blocking	O	O
the	O	O
5-HT	B_Chemical	O
2C	O	O
receptors	O	O
,	O	O
releases	O	O
the	O	O
nigrostriatal	O	O
DAergic	O	O
neurons	O	O
from	O	O
tonic	O	O
inhibition	O	O
caused	O	O
by	O	O
5-HT	B_Chemical	O
,	O	O
and	O	O
thereby	O	O
potentiates	O	O
dexamphetamine	B_Chemical	O
stereotypy	O	O
and	O	O
antagonizes	O	O
haloperidol	B_Chemical	O
catalepsy	B_Disease	O
.	O	O

Swallowing	B_Disease	O
abnormalities	I_Disease	O
and	O	O
dyskinesia	B_Disease	O
in	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
.	O	O

Gastrointestinal	B_Disease	O
abnormalities	I_Disease	O
in	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
(	O	O
PD	B_Disease	O
)	O	O
have	O	O
been	O	O
known	O	O
for	O	O
almost	O	O
two	O	O
centuries	O	O
,	O	O
but	O	O
many	O	O
aspects	O	O
concerning	O	O
their	O	O
pathophysiology	O	O
have	O	O
not	O	O
been	O	O
completely	O	O
clarified	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
characterize	O	O
the	O	O
oropharyngeal	O	O
dynamics	O	O
in	O	O
PD	B_Disease	O
patients	O	O
with	O	O
and	O	O
without	O	O
levodopa-induced	O	O
dyskinesia	B_Disease	O
.	O	O

Fifteen	O	O
dyskinetic	B_Disease	O
,	O	O
12	O	O
nondyskinetic	O	O
patients	O	O
,	O	O
and	O	O
a	O	O
control	O	O
group	O	O
were	O	O
included	O	O
.	O	O

Patients	O	O
were	O	O
asked	O	O
about	O	O
dysphagia	B_Disease	O
and	O	O
evaluated	O	O
with	O	O
the	O	O
Unified	O	O
Parkinson	B_Disease	O
's	I_Disease	O
Disease	I_Disease	O
Rating	O	O
Scale	O	O
Parts	O	O
II	O	O
and	O	O
III	O	O
and	O	O
the	O	O
Hoehn	O	O
and	O	O
Yahr	O	O
scale	O	O
.	O	O

Deglutition	O	O
was	O	O
assessed	O	O
using	O	O
modified	O	O
barium	B_Chemical	O
swallow	O	O
with	O	O
videofluoroscopy	O	O
.	O	O

Nondyskinetic	O	O
patients	O	O
,	O	O
but	O	O
not	O	O
the	O	O
dyskinetic	B_Disease	O
ones	O	O
,	O	O
showed	O	O
less	O	O
oropharyngeal	O	O
swallowing	O	O
efficiency	O	O
(	O	O
OPSE	O	O
)	O	O
for	O	O
liquid	O	O
food	O	O
than	O	O
controls	O	O
(	O	O
Dunnett	O	O
,	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
.	O	O

Dyskinetic	B_Disease	O
patients	O	O
tended	O	O
to	O	O
have	O	O
a	O	O
greater	O	O
OPSE	O	O
than	O	O
nondyskinetic	O	O
(	O	O
Dunnett	O	O
,	O	O
P	O	O
=	O	O
0.06	O	O
)	O	O
.	O	O

Patients	O	O
who	O	O
were	O	O
using	O	O
a	O	O
higher	O	O
dose	O	O
of	O	O
levodopa	B_Chemical	O
had	O	O
a	O	O
greater	O	O
OPSE	O	O
and	O	O
a	O	O
trend	O	O
toward	O	O
a	O	O
smaller	O	O
oral	O	O
transit	O	O
time	O	O
(	O	O
Pearson	O	O
's	O	O
correlation	O	O
,	O	O
P	O	O
=	O	O
0.01	O	O
and	O	O
0.08	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Neither	O	O
the	O	O
report	O	O
of	O	O
dysphagia	B_Disease	O
nor	O	O
any	O	O
of	O	O
the	O	O
PD	B_Disease	O
severity	O	O
parameters	O	O
correlated	O	O
to	O	O
the	O	O
videofluoroscopic	O	O
variables	O	O
.	O	O

In	O	O
the	O	O
current	O	O
study	O	O
,	O	O
dyskinetic	B_Disease	O
patients	O	O
performed	O	O
better	O	O
in	O	O
swallowing	O	O
function	O	O
,	O	O
which	O	O
could	O	O
be	O	O
explained	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
a	O	O
greater	O	O
levodopa	B_Chemical	O
dose	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
a	O	O
role	O	O
for	O	O
levodopa	B_Chemical	O
in	O	O
the	O	O
oral	O	O
phase	O	O
of	O	O
deglutition	O	O
and	O	O
confirm	O	O
that	O	O
dysphagia	B_Disease	O
is	O	O
not	O	O
a	O	O
good	O	O
predictor	O	O
of	O	O
deglutition	O	O
alterations	O	O
in	O	O
PD	B_Disease	O
.	O	O

Inhibition	O	O
of	O	O
nuclear	O	O
factor-kappaB	O	O
activation	O	O
attenuates	O	O
tubulointerstitial	B_Disease	O
nephritis	I_Disease	O
induced	O	O
by	O	O
gentamicin	B_Chemical	O
.	O	O

BACKGROUND	O	O
:	O	O
Animals	O	O
treated	O	O
with	O	O
gentamicin	B_Chemical	O
can	O	O
show	O	O
residual	O	O
areas	O	O
of	O	O
interstitial	O	B_Disease
fibrosis	B_Disease	I_Disease
in	O	O
the	O	O
renal	O	O
cortex	O	O
.	O	O

This	O	O
study	O	O
investigated	O	O
the	O	O
expression	O	O
of	O	O
nuclear	O	O
factor-kappaB	O	O
(	O	O
NF-kappaB	O	O
)	O	O
,	O	O
mitogen-activated	O	O
protein	O	O
(	O	O
MAP	O	O
)	O	O
kinases	O	O
and	O	O
macrophages	O	O
in	O	O
the	O	O
renal	O	O
cortex	O	O
and	O	O
structural	O	O
and	O	O
functional	O	O
renal	O	O
changes	O	O
of	O	O
rats	O	O
treated	O	O
with	O	O
gentamicin	B_Chemical	O
or	O	O
gentamicin	B_Chemical	O
+	O	O
pyrrolidine	B_Chemical	B_Chemical
dithiocarbamate	I_Chemical	I_Chemical
(	O	O
PDTC	B_Chemical	O
)	O	O
,	O	O
an	O	O
NF-kappaB	O	O
inhibitor	O	O
.	O	O

METHODS	O	O
:	O	O
38	O	O
female	O	O
Wistar	O	O
rats	O	O
were	O	O
injected	O	O
with	O	O
gentamicin	B_Chemical	O
,	O	O
40	O	O
mg/kg	O	O
,	O	O
twice	O	O
a	O	O
day	O	O
for	O	O
9	O	O
days	O	O
,	O	O
38	O	O
with	O	O
gentamicin	B_Chemical	O
+	O	O
PDTC	B_Chemical	O
,	O	O
and	O	O
28	O	O
with	O	O
0.15	O	O
M	O	O
NaCl	B_Chemical	O
solution	O	O
.	O	O

The	O	O
animals	O	O
were	O	O
killed	O	O
5	O	O
and	O	O
30	O	O
days	O	O
after	O	O
these	O	O
injections	O	O
and	O	O
the	O	O
kidneys	O	O
were	O	O
removed	O	O
for	O	O
histological	O	O
and	O	O
immunohistochemical	O	O
studies	O	O
.	O	O

The	O	O
results	O	O
of	O	O
the	O	O
immunohistochemical	O	O
studies	O	O
were	O	O
scored	O	O
according	O	O
to	O	O
the	O	O
extent	O	O
of	O	O
staining	O	O
.	O	O

The	O	O
fractional	O	O
interstitial	O	O
area	O	O
was	O	O
determined	O	O
by	O	O
morphometry	O	O
.	O	O

RESULTS	O	O
:	O	O
Gentamicin-treated	O	O
rats	O	O
presented	O	O
a	O	O
transitory	O	O
increase	O	O
in	O	O
plasma	O	O
creatinine	B_Chemical	B_Chemical
levels	O	O
.	O	O

Increased	O	O
ED-1	O	O
,	O	O
MAP	O	O
kinases	O	O
and	O	O
NF-kappaB	O	O
staining	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
the	O	O
renal	O	O
cortex	O	O
from	O	O
all	O	O
gentamicin-treated	O	O
rats	O	O
compared	O	O
to	O	O
control	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
animals	O	O
killed	O	O
on	O	O
day	O	O
30	O	O
also	O	O
presented	O	O
fibrosis	B_Disease	O
in	O	O
the	O	O
renal	O	O
cortex	O	O
despite	O	O
the	O	O
recovery	O	O
of	O	O
renal	O	O
function	O	O
.	O	O

Treatment	O	O
with	O	O
PDTC	B_Chemical	O
reduced	O	O
the	O	O
functional	O	O
and	O	O
structural	O	O
changes	O	O
induced	O	O
by	O	O
gentamicin	B_Chemical	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
data	O	O
show	O	O
that	O	O
inhibition	O	O
of	O	O
NF-kappaB	O	O
activation	O	O
attenuates	O	O
tubulointerstitial	B_Disease	O
nephritis	I_Disease	O
induced	O	O
by	O	O
gentamicin	B_Chemical	O
.	O	O

Glucose	B_Chemical	O
metabolism	O	O
in	O	O
patients	O	O
with	O	O
schizophrenia	B_Disease	O
treated	O	O
with	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
:	O	O
a	O	O
frequently	O	O
sampled	O	O
intravenous	O	O
glucose	B_Chemical	O
tolerance	O	O
test	O	O
and	O	O
minimal	O	O
model	O	O
analysis	O	O
.	O	O

BACKGROUND	O	O
:	O	O
While	O	O
the	O	O
incidence	O	O
of	O	O
new-onset	O	O
diabetes	B_Disease	O
mellitus	I_Disease	O
may	O	O
be	O	O
increasing	O	O
in	O	O
patients	O	O
with	O	O
schizophrenia	B_Disease	O
treated	O	O
with	O	O
certain	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
,	O	O
it	O	O
remains	O	O
unclear	O	O
whether	O	O
atypical	O	O
agents	O	O
are	O	O
directly	O	O
affecting	O	O
glucose	B_Chemical	O
metabolism	O	O
or	O	O
simply	O	O
increasing	O	O
known	O	O
risk	O	O
factors	O	O
for	O	O
diabetes	B_Disease	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
study	O	O
the	O	O
2	O	O
drugs	O	O
most	O	O
clearly	O	O
implicated	O	O
(	O	O
clozapine	B_Chemical	O
and	O	O
olanzapine	B_Chemical	B_Chemical
)	O	O
and	O	O
risperidone	B_Chemical	B_Chemical
using	O	O
a	O	O
frequently	O	O
sampled	O	O
intravenous	O	O
glucose	B_Chemical	O
tolerance	O	O
test	O	O
.	O	O

DESIGN	O	O
:	O	O
A	O	O
cross-sectional	O	O
design	O	O
in	O	O
stable	O	O
,	O	O
treated	O	O
patients	O	O
with	O	O
schizophrenia	B_Disease	O
evaluated	O	O
using	O	O
a	O	O
frequently	O	O
sampled	O	O
intravenous	O	O
glucose	B_Chemical	O
tolerance	O	O
test	O	O
and	O	O
the	O	O
Bergman	O	O
minimal	O	O
model	O	O
analysis	O	O
.	O	O

SETTING	O	O
:	O	O
Subjects	O	O
were	O	O
recruited	O	O
from	O	O
an	O	O
urban	O	O
community	O	O
mental	O	O
health	O	O
clinic	O	O
and	O	O
were	O	O
studied	O	O
at	O	O
a	O	O
general	O	O
clinical	O	O
research	O	O
center	O	O
.	O	O

Patients	O	O
Fifty	O	O
subjects	O	O
signed	O	O
informed	O	O
consent	O	O
and	O	O
41	O	O
underwent	O	O
the	O	O
frequently	O	O
sampled	O	O
intravenous	O	O
glucose	B_Chemical	O
tolerance	O	O
test	O	O
.	O	O

Thirty-six	O	O
nonobese	O	O
subjects	O	O
with	O	O
schizophrenia	B_Disease	O
or	O	O
schizoaffective	B_Disease	O
disorder	I_Disease	O
,	O	O
matched	O	O
by	O	O
body	O	O
mass	O	O
index	O	O
and	O	O
treated	O	O
with	O	O
either	O	O
clozapine	B_Chemical	O
,	O	O
olanzapine	B_Chemical	B_Chemical
,	O	O
or	O	O
risperidone	B_Chemical	B_Chemical
,	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
:	O	O
Fasting	O	O
plasma	O	O
glucose	B_Chemical	O
and	O	O
fasting	O	O
serum	O	O
insulin	O	O
levels	O	O
,	O	O
insulin	B_Disease	O
sensitivity	I_Disease	O
index	O	O
,	O	O
homeostasis	O	O
model	O	O
assessment	O	O
of	O	O
insulin	B_Disease	O
resistance	I_Disease	O
,	O	O
and	O	O
glucose	B_Chemical	O
effectiveness	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
mean	O	O
+	O	O
/-	O	O
SD	O	O
duration	O	O
of	O	O
treatment	O	O
with	O	O
the	O	O
identified	O	O
atypical	O	O
antipsychotic	O	O
agent	O	O
was	O	O
68.3	O	O
+	O	O
/-	O	O
28.9	O	O
months	O	O
(	O	O
clozapine	B_Chemical	O
)	O	O
,	O	O
29.5	O	O
+	O	O
/-	O	O
17.5	O	O
months	O	O
(	O	O
olanzapine	B_Chemical	B_Chemical
)	O	O
,	O	O
and	O	O
40.9	O	O
+	O	O
/-	O	O
33.7	O	O
(	O	O
risperidone	B_Chemical	B_Chemical
)	O	O
.	O	O

Fasting	O	O
serum	O	O
insulin	O	O
concentrations	O	O
differed	O	O
among	O	O
groups	O	O
(	O	O
F(33	O	O
)	O	O
=	O	O
3.35	O	O
;	O	O
P	O	O
=	O	O
.047	O	O
)	O	O
(	O	O
clozapine	B_Chemical	O
>	O	O
olanzapine	B_Chemical	B_Chemical
>	O	O
risperidone	B_Chemical	B_Chemical
)	O	O
with	O	O
significant	O	O
differences	O	O
between	O	O
clozapine	B_Chemical	O
and	O	O
risperidone	B_Chemical	B_Chemical
(	O	O
t(33	O	O
)	O	O
=	O	O
2.32	O	O
;	O	O
P	O	O
=	O	O
.03	O	O
)	O	O
and	O	O
olanzapine	B_Chemical	B_Chemical
and	O	O
risperidone	B_Chemical	B_Chemical
(	O	O
t(33	O	O
)	O	O
=	O	O
2.15	O	O
;	O	O
P	O	O
=	O	O
.04	O	O
)	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
in	O	O
insulin	B_Disease	O
sensitivity	I_Disease	O
index	O	O
among	O	O
groups	O	O
(	O	O
F(33	O	O
)	O	O
=	O	O
10.66	O	O
;	O	O
P<.001	O	O
)	O	O
(	O	O
clozapine	B_Chemical	O
<	O	O
olanzapine	B_Chemical	B_Chemical
<	O	O
risperidone	B_Chemical	B_Chemical
)	O	O
,	O	O
with	O	O
subjects	O	O
who	O	O
received	O	O
clozapine	B_Chemical	O
and	O	O
olanzapine	B_Chemical	B_Chemical
exhibiting	O	O
significant	O	O
insulin	B_Disease	O
resistance	I_Disease	O
compared	O	O
with	O	O
subjects	O	O
who	O	O
were	O	O
treated	O	O
with	O	O
risperidone	B_Chemical	B_Chemical
(	O	O
clozapine	B_Chemical	O
vs	O	O
risperidone	B_Chemical	B_Chemical
,	O	O
t(33	O	O
)	O	O
=	O	O
-4.29	O	O
;	O	O
P<.001	O	O
;	O	O
olanzapine	B_Chemical	B_Chemical
vs	O	O
risperidone	B_Chemical	B_Chemical
,	O	O
t(33	O	O
)	O	O
=	O	O
-3.62	O	O
;	O	O
P	O	O
=	O	O
.001	O	O
[	O	O
P<.001	O	O
]	O	O
)	O	O
.	O	O

The	O	O
homeostasis	O	O
model	O	O
assessment	O	O
of	O	O
insulin	B_Disease	O
resistance	I_Disease	O
also	O	O
differed	O	O
significantly	O	O
among	O	O
groups	O	O
(	O	O
F(33	O	O
)	O	O
=	O	O
4.92	O	O
;	O	O
P	O	O
=	O	O
.01	O	O
)	O	O
(	O	O
clozapine	B_Chemical	O
>	O	O
olanzapine	B_Chemical	B_Chemical
>	O	O
risperidone	B_Chemical	B_Chemical
)	O	O
(	O	O
clozapine	B_Chemical	O
vs	O	O
risperidone	B_Chemical	B_Chemical
,	O	O
t(33	O	O
)	O	O
=	O	O
2.94	O	O
;	O	O
P	O	O
=	O	O
.006	O	O
;	O	O
olanzapine	B_Chemical	B_Chemical
vs	O	O
risperidone	B_Chemical	B_Chemical
,	O	O
t(33	O	O
)	O	O
=	O	O
2.42	O	O
;	O	O
P	O	O
=	O	O
.02	O	O
)	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
among	O	O
groups	O	O
in	O	O
glucose	B_Chemical	O
effectiveness	O	O
(	O	O
F(30	O	O
)	O	O
=	O	O
4.18	O	O
;	O	O
P	O	O
=	O	O
.02	O	O
)	O	O
(	O	O
clozapine	B_Chemical	O
<	O	O
olanzapine	B_Chemical	B_Chemical
<	O	O
risperidone	B_Chemical	B_Chemical
)	O	O
with	O	O
significant	O	O
differences	O	O
between	O	O
clozapine	B_Chemical	O
and	O	O
risperidone	B_Chemical	B_Chemical
(	O	O
t(30	O	O
)	O	O
=	O	O
-2.59	O	O
;	O	O
P	O	O
=	O	O
.02	O	O
)	O	O
and	O	O
olanzapine	B_Chemical	B_Chemical
and	O	O
risperidone	B_Chemical	B_Chemical
(	O	O
t(30	O	O
)	O	O
=	O	O
-2.34	O	O
,	O	O
P	O	O
=	O	O
.03	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Both	O	O
nonobese	O	O
clozapine-	O	B_Chemical
and	O	O
olanzapine-treated	O	O
groups	O	O
displayed	O	O
significant	O	O
insulin	B_Disease	O
resistance	I_Disease	O
and	O	O
impairment	O	O
of	O	O
glucose	B_Chemical	O
effectiveness	O	O
compared	O	O
with	O	O
risperidone-treated	O	O
subjects	O	O
.	O	O

Patients	O	O
taking	O	O
clozapine	B_Chemical	O
and	O	O
olanzapine	B_Chemical	B_Chemical
must	O	O
be	O	O
examined	O	O
for	O	O
insulin	B_Disease	O
resistance	I_Disease	O
and	O	O
its	O	O
consequences	O	O
.	O	O

Thoracic	B_Disease	B_Disease
hematomyelia	I_Disease	I_Disease
secondary	O	O
to	O	O
coumadin	B_Chemical	O
anticoagulant	O	O
therapy	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

A	O	O
case	O	O
of	O	O
thoracic	O	B_Disease
hematomyelia	O	I_Disease
secondary	O	O
to	O	O
anticoagulant	O	O
therapy	O	O
is	O	O
presented	O	O
.	O	O

Clinical	O	O
features	O	O
,	O	O
similar	O	O
to	O	O
2	O	O
other	O	O
previously	O	O
reported	O	O
cases	O	O
,	O	O
are	O	O
discussed	O	O
.	O	O

A	O	O
high	O	O
index	O	O
of	O	O
suspicion	O	O
may	O	O
lead	O	O
to	O	O
a	O	O
quick	O	O
diagnostic	O	O
procedure	O	O
and	O	O
successful	O	O
decompressive	O	O
surgery	O	O
.	O	O

Mania	B_Disease	O
associated	O	O
with	O	O
fluoxetine	B_Chemical	O
treatment	O	O
in	O	O
adolescents	O	O
.	O	O

Fluoxetine	B_Chemical	O
,	O	O
a	O	O
selective	O	O
serotonin	B_Chemical	O
reuptake	O	O
inhibitor	O	O
,	O	O
is	O	O
gaining	O	O
increased	O	O
acceptance	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
adolescent	O	O
depression	B_Disease	O
.	O	O

Generally	O	O
safe	O	O
and	O	O
well	O	O
tolerated	O	O
by	O	O
adults	O	O
,	O	O
fluoxetine	B_Chemical	O
has	O	O
been	O	O
reported	O	O
to	O	O
induce	O	O
mania	B_Disease	O
.	O	O

The	O	O
cases	O	O
of	O	O
five	O	O
depressed	B_Disease	O
adolescents	O	O
,	O	O
14	O	O
-	O	O
16	O	O
years	O	O
of	O	O
age	O	O
,	O	O
who	O	O
developed	O	O
mania	B_Disease	O
during	O	O
pharmacotherapy	O	O
with	O	O
fluoxetine	B_Chemical	O
,	O	O
are	O	O
reported	O	O
here	O	O
.	O	O

Apparent	O	O
risk	O	O
factors	O	O
for	O	O
the	O	O
development	O	O
of	O	O
mania	B_Disease	O
or	O	O
hypomania	B_Disease	O
during	O	O
fluoxetine	B_Chemical	O
pharmacotherapy	O	O
in	O	O
this	O	O
population	O	O
were	O	O
the	O	O
combination	O	O
of	O	O
attention-deficit	B_Disease	O
hyperactivity	I_Disease	O
disorder	I_Disease	O
and	O	O
affective	O	B_Disease
instability	O	I_Disease
;	O	O
major	O	B_Disease
depression	B_Disease	I_Disease
with	O	O
psychotic	B_Disease	O
features	O	O
;	O	O
a	O	O
family	O	O
history	O	O
of	O	O
affective	B_Disease	B_Disease
disorder	I_Disease	I_Disease
,	O	O
especially	O	O
bipolar	B_Disease	B_Disease
disorder	I_Disease	I_Disease
;	O	O
and	O	O
a	O	O
diagnosis	O	O
of	O	O
bipolar	B_Disease	O
disorder	I_Disease	O
.	O	O

Further	O	O
study	O	O
is	O	O
needed	O	O
to	O	O
determine	O	O
the	O	O
optimal	O	O
dosage	O	O
and	O	O
to	O	O
identify	O	O
risk	O	O
factors	O	O
that	O	O
increase	O	O
individual	O	O
vulnerability	O	O
to	O	O
fluoxetine	B_Chemical	O
induced	O	O
mania	B_Disease	O
in	O	O
adolescents	O	O
.	O	O

Acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
insufficiency	I_Disease	I_Disease
after	O	O
high-dose	O	B_Chemical
melphalan	B_Chemical	I_Chemical
in	O	O
patients	O	O
with	O	O
primary	B_Disease	O
systemic	I_Disease	B_Disease
amyloidosis	I_Disease	I_Disease
during	O	O
stem	O	O
cell	O	O
transplantation	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Patients	O	O
with	O	O
primary	B_Disease	O
systemic	I_Disease	O
amyloidosis	I_Disease	O
(	O	O
AL	B_Disease	O
)	O	O
have	O	O
a	O	O
poor	O	O
prognosis	O	O
.	O	O

Median	O	O
survival	O	O
time	O	O
from	O	O
standard	O	O
treatments	O	O
is	O	O
only	O	O
17	O	O
months	O	O
.	O	O

High-dose	O	O
intravenous	O	O
melphalan	B_Chemical	O
followed	O	O
by	O	O
peripheral	O	O
blood	O	O
stem	O	O
cell	O	O
transplant	O	O
(	O	O
PBSCT	O	O
)	O	O
appears	O	O
to	O	O
be	O	O
the	O	O
most	O	O
promising	O	O
therapy	O	O
,	O	O
but	O	O
treatment	O	O
mortality	O	O
can	O	O
be	O	O
high	O	O
.	O	O

The	O	O
authors	O	O
have	O	O
noted	O	O
the	O	O
development	O	O
of	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
insufficiency	I_Disease	I_Disease
immediately	O	O
after	O	O
melphalan	B_Chemical	O
conditioning	O	O
.	O	O

This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
further	O	O
examine	O	O
its	O	O
risk	O	O
factors	O	O
and	O	O
impact	O	O
on	O	O
posttransplant	O	O
mortality	O	O
.	O	O

METHODS	O	O
:	O	O
Consecutive	O	O
AL	B_Disease	O
patients	O	O
who	O	O
underwent	O	O
PBSCT	O	O
were	O	O
studied	O	O
retrospectively	O	O
.	O	O

Acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
insufficiency	I_Disease	I_Disease
(	O	O
ARI	B_Disease	O
)	O	O
after	O	O
high-dose	O	B_Chemical
melphalan	B_Chemical	I_Chemical
was	O	O
defined	O	O
by	O	O
a	O	O
minimum	O	O
increase	O	O
of	O	O
0.5	O	O
mg/dL	O	O
(	O	O
44	O	O
micromol/L	O	O
)	O	O
in	O	O
the	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
level	O	O
that	O	O
is	O	O
greater	O	O
than	O	O
50	O	O
%	O	O
of	O	O
baseline	O	O
immediately	O	O
after	O	O
conditioning	O	O
.	O	O

Urine	O	O
sediment	O	O
score	O	O
was	O	O
the	O	O
sum	O	O
of	O	O
the	O	O
individual	O	O
types	O	O
of	O	O
sediment	O	O
identified	O	O
on	O	O
urine	O	O
microscopy	O	O
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
the	O	O
80	O	O
patients	O	O
studied	O	O
,	O	O
ARI	B_Disease	O
developed	O	O
in	O	O
18.8	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
after	O	O
high-dose	O	B_Chemical
melphalan	B_Chemical	I_Chemical
.	O	O

Univariate	O	O
analysis	O	O
identified	O	O
age	O	O
,	O	O
hypoalbuminemia	B_Disease	B_Disease
,	O	O
heavy	O	O
proteinuria	B_Disease	O
,	O	O
diuretic	O	O
use	O	O
,	O	O
and	O	O
urine	O	O
sediment	O	O
score	O	O
(	O	O
>	O	O
3	O	O
)	O	O
as	O	O
risk	O	O
factors	O	O
.	O	O

Age	O	O
and	O	O
urine	O	O
sediment	O	O
score	O	O
remained	O	O
independently	O	O
significant	O	O
risk	O	O
factors	O	O
in	O	O
the	O	O
multivariate	O	O
analysis	O	O
.	O	O

Patients	O	O
who	O	O
had	O	O
ARI	B_Disease	O
after	O	O
high-dose	O	B_Chemical
melphalan	B_Chemical	I_Chemical
underwent	O	O
dialysis	O	O
more	O	O
often	O	O
(	O	O
P	O	O
=	O	O
0.007	O	O
)	O	O
,	O	O
and	O	O
had	O	O
a	O	O
worse	O	O
1-year	O	O
survival	O	O
(	O	O
P	O	O
=	O	O
0.03	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
timing	O	O
of	O	O
renal	B_Disease	B_Disease
injury	I_Disease	I_Disease
strongly	O	O
suggests	O	O
melphalan	B_Chemical	O
as	O	O
the	O	O
causative	O	O
agent	O	O
.	O	O

Ongoing	O	O
tubular	B_Disease	B_Disease
injury	I_Disease	I_Disease
may	O	O
be	O	O
a	O	O
prerequisite	O	O
for	O	O
renal	B_Disease	B_Disease
injury	I_Disease	I_Disease
by	O	O
melphalan	B_Chemical	O
as	O	O
evidenced	O	O
by	O	O
the	O	O
active	O	O
urinary	O	O
sediment	O	O
.	O	O

Development	O	O
of	O	O
ARI	B_Disease	O
adversely	O	O
affected	O	O
the	O	O
outcome	O	O
after	O	O
PBSCT	O	O
.	O	O

Effective	O	O
preventive	O	O
measures	O	O
may	O	O
help	O	O
decrease	O	O
the	O	O
treatment	O	O
mortality	O	O
of	O	O
PBSCT	O	O
in	O	O
AL	B_Disease	O
patients	O	O
.	O	O

Focal	O	O
cerebral	B_Disease	B_Disease
ischemia	I_Disease	I_Disease
in	O	O
rats	O	O
:	O	O
effect	O	O
of	O	O
phenylephrine-induced	O	O
hypertension	B_Disease	O
during	O	O
reperfusion	O	O
.	O	O

After	O	O
180	O	O
min	O	O
of	O	O
temporary	O	O
middle	B_Disease	O
cerebral	I_Disease	O
artery	I_Disease	O
occlusion	I_Disease	O
in	O	O
spontaneously	O	O
hypertensive	B_Disease	O
rats	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
phenylephrine-induced	O	O
hypertension	B_Disease	O
on	O	O
ischemic	B_Disease	B_Disease
brain	I_Disease	I_Disease
injury	I_Disease	I_Disease
and	O	O
blood-brain	O	O
barrier	O	O
permeability	O	O
was	O	O
determined	O	O
.	O	O

Blood	O	O
pressure	O	O
was	O	O
manipulated	O	O
by	O	O
one	O	O
of	O	O
the	O	O
following	O	O
schedules	O	O
during	O	O
120	O	O
min	O	O
of	O	O
reperfusion	O	O
:	O	O
Control	O	O
,	O	O
normotensive	O	O
reperfusion	O	O
;	O	O
90/hypertension	O	O
(	O	O
90/HTN	O	O
)	O	O
,	O	O
blood	O	O
pressure	O	O
was	O	O
increased	O	O
by	O	O
35	O	O
mm	O	O
Hg	O	O
during	O	O
the	O	O
initial	O	O
90	O	O
min	O	O
of	O	O
reperfusion	O	O
only	O	O
;	O	O
15/hypertension	O	O
(	O	O
15/HTN	O	O
)	O	O
,	O	O
normotensive	O	O
reperfusion	O	O
for	O	O
30	O	O
min	O	O
followed	O	O
by	O	O
15	O	O
min	O	O
of	O	O
hypertension	B_Disease	O
and	O	O
75	O	O
min	O	O
of	O	O
normotension	O	O
.	O	O

Part	O	O
A	O	O
,	O	O
for	O	O
eight	O	O
rats	O	O
in	O	O
each	O	O
group	O	O
brain	B_Disease	B_Disease
injury	I_Disease	I_Disease
was	O	O
evaluated	O	O
by	O	O
staining	O	O
tissue	O	O
using	O	O
2,3,5-triphenyltetrazolium	B_Chemical	B_Chemical
chloride	I_Chemical	I_Chemical
and	O	O
edema	B_Disease	O
was	O	O
evaluated	O	O
by	O	O
microgravimetry	O	O
.	O	O

Part	O	O
B	O	O
,	O	O
for	O	O
eight	O	O
different	O	O
rats	O	O
in	O	O
each	O	O
group	O	O
blood-brain	O	O
barrier	O	O
permeability	O	O
was	O	O
evaluated	O	O
by	O	O
measuring	O	O
the	O	O
amount	O	O
and	O	O
extent	O	O
of	O	O
extravasation	O	O
of	O	O
Evans	O	O
Blue	O	O
dye	O	O
.	O	O

Brain	B_Disease	B_Disease
injury	I_Disease	I_Disease
(	O	O
percentage	O	O
of	O	O
the	O	O
ischemic	B_Disease	O
hemisphere	I_Disease	O
)	O	O
was	O	O
less	O	O
in	O	O
the	O	O
15/HTN	O	O
group	O	O
(	O	O
16	O	O
+	O	O
/-	O	O
6	O	O
,	O	O
mean	O	O
+	O	O
/-	O	O
SD	O	O
)	O	O
versus	O	O
the	O	O
90/HTN	O	O
group	O	O
(	O	O
30	O	O
+	O	O
/-	O	O
6	O	O
)	O	O
,	O	O
which	O	O
was	O	O
in	O	O
turn	O	O
less	O	O
than	O	O
the	O	O
control	O	O
group	O	O
(	O	O
42	O	O
+	O	O
/-	O	O
5	O	O
)	O	O
.	O	O

Specific	O	O
gravity	O	O
was	O	O
greater	O	O
in	O	O
the	O	O
15/HTN	O	O
group	O	O
(	O	O
1.043	O	O
+	O	O
/-	O	O
0.002	O	O
)	O	O
versus	O	O
the	O	O
90/HTN	O	O
(	O	O
1.036	O	O
+	O	O
/-	O	O
0.003	O	O
)	O	O
and	O	O
control	O	O
(	O	O
1.037	O	O
+	O	O
/-	O	O
0.003	O	O
)	O	O
groups	O	O
.	O	O

Evans	B_Chemical	O
Blue	I_Chemical	O
(	O	O
mug	O	O
g-1	O	O
of	O	O
brain	O	O
tissue	O	O
)	O	O
was	O	O
greater	O	O
in	O	O
the	O	O
90/HTN	O	O
group	O	O
(	O	O
24.4	O	O
+	O	O
/-	O	O
6.0	O	O
)	O	O
versus	O	O
the	O	O
control	O	O
group	O	O
(	O	O
12.3	O	O
+	O	O
/-	O	O
4.1	O	O
)	O	O
,	O	O
which	O	O
was	O	O
in	O	O
turn	O	O
greater	O	O
than	O	O
the	O	O
15/HTN	O	O
group	O	O
(	O	O
7.3	O	O
+	O	O
/-	O	O
3.2	O	O
)	O	O
.	O	O

This	O	O
study	O	O
supports	O	O
a	O	O
hypothesis	O	O
that	O	O
during	O	O
reperfusion	O	O
,	O	O
a	O	O
short	O	O
interval	O	O
of	O	O
hypertension	B_Disease	O
decreases	O	O
brain	B_Disease	B_Disease
injury	I_Disease	I_Disease
and	O	O
edema	B_Disease	O
;	O	O
and	O	O
that	O	O
sustained	O	O
hypertension	B_Disease	O
increases	O	O
the	O	O
risk	O	O
of	O	O
vasogenic	B_Disease	B_Disease
edema	I_Disease	I_Disease
.	O	O

People	O	O
aged	O	O
over	O	O
75	O	O
in	O	O
atrial	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
on	O	O
warfarin	B_Chemical	O
:	O	O
the	O	O
rate	O	O
of	O	O
major	O	O
hemorrhage	B_Disease	O
and	O	O
stroke	B_Disease	O
in	O	O
more	O	O
than	O	O
500	O	O
patient-years	O	O
of	O	O
follow-up	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
incidence	O	O
of	O	O
major	O	O
hemorrhage	B_Disease	O
and	O	O
stroke	B_Disease	O
in	O	O
people	O	O
aged	O	O
76	O	O
and	O	O
older	O	O
with	O	O
atrial	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
on	O	O
adjusted-dose	O	O
warfarin	B_Chemical	O
who	O	O
had	O	O
been	O	O
recently	O	O
been	O	O
admitted	O	O
to	O	O
hospital	O	O
.	O	O

DESIGN	O	O
:	O	O
A	O	O
retrospective	O	O
observational	O	O
cohort	O	O
study	O	O
.	O	O

SETTING	O	O
:	O	O
A	O	O
major	O	O
healthcare	O	O
network	O	O
involving	O	O
four	O	O
tertiary	O	O
hospitals	O	O
.	O	O

PARTICIPANTS	O	O
:	O	O
Two	O	O
hundred	O	O
thirty-five	O	O
patients	O	O
aged	O	O
76	O	O
and	O	O
older	O	O
admitted	O	O
to	O	O
a	O	O
major	O	O
healthcare	O	O
network	O	O
between	O	O
July	O	O
1	O	O
,	O	O
2001	O	O
,	O	O
and	O	O
June	O	O
30	O	O
,	O	O
2002	O	O
,	O	O
with	O	O
atrial	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
on	O	O
warfarin	B_Chemical	O
were	O	O
enrolled	O	O
.	O	O

MEASUREMENTS	O	O
:	O	O
Information	O	O
regarding	O	O
major	O	O
bleeding	B_Disease	O
episodes	O	O
,	O	O
strokes	B_Disease	O
,	O	O
and	O	O
warfarin	B_Chemical	O
use	O	O
was	O	O
obtained	O	O
from	O	O
patients	O	O
,	O	O
relatives	O	O
,	O	O
primary	O	O
physicians	O	O
,	O	O
and	O	O
medical	O	O
records	O	O
.	O	O

RESULTS	O	O
:	O	O
Two	O	O
hundred	O	O
twenty-eight	O	O
patients	O	O
(	O	O
42	O	O
%	O	O
men	O	O
)	O	O
with	O	O
a	O	O
mean	O	O
age	O	O
of	O	O
81.1	O	O
(	O	O
range	O	O
76	O	O
-	O	O
94	O	O
)	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

Total	O	O
follow-up	O	O
on	O	O
warfarin	B_Chemical	O
was	O	O
530	O	O
years	O	O
(	O	O
mean	O	O
28	O	O
months	O	O
)	O	O
.	O	O

There	O	O
were	O	O
53	O	O
major	O	O
hemorrhages	B_Disease	O
,	O	O
for	O	O
an	O	O
annual	O	O
rate	O	O
of	O	O
10.0	O	O
%	O	O
,	O	O
including	O	O
24	O	O
(	O	O
45.3	O	O
%	O	O
)	O	O
life-threatening	O	O
and	O	O
five	O	O
(	O	O
9.4	O	O
%	O	O
)	O	O
fatal	O	O
bleeds	O	O
.	O	O

The	O	O
annual	O	O
stroke	B_Disease	O
rate	O	O
after	O	O
initiation	O	O
of	O	O
warfarin	B_Chemical	O
was	O	O
2.6	O	O
%	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
rate	O	O
of	O	O
major	O	O
hemorrhage	B_Disease	O
was	O	O
high	O	O
in	O	O
this	O	O
old	O	O
,	O	O
frail	O	O
group	O	O
,	O	O
but	O	O
excluding	O	O
fatalities	O	O
,	O	O
resulted	O	O
in	O	O
no	O	O
long-term	O	O
sequelae	O	O
,	O	O
and	O	O
the	O	O
stroke	B_Disease	O
rate	O	O
on	O	O
warfarin	B_Chemical	O
was	O	O
low	O	O
,	O	O
demonstrating	O	O
how	O	O
effective	O	O
warfarin	B_Chemical	O
treatment	O	O
is	O	O
.	O	O

Safety	O	O
of	O	O
celecoxib	B_Chemical	O
in	O	O
patients	O	O
with	O	O
adverse	O	B_Disease
skin	B_Disease	I_Disease
reactions	I_Disease	I_Disease
to	O	O
acetaminophen	B_Chemical	O
(	O	O
paracetamol	B_Chemical	B_Chemical
)	O	O
and	O	O
nimesulide	B_Chemical	B_Chemical
associated	O	O
or	O	O
not	O	O
with	O	O
common	O	O
non-steroidal	O	O
anti-inflammatory	O	O
drugs	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Acetaminophen	B_Chemical	O
(	O	O
paracetamol	B_Chemical	O
--	O	O
P	B_Chemical	O
)	O	O
and	O	O
Nimesulide	B_Chemical	B_Chemical
(	O	O
N	B_Chemical	O
)	O	O
are	O	O
widely	O	O
used	O	O
analgesic-antipyretic/anti-inflammatory	O	O
drugs	O	O
.	O	O

The	O	O
rate	O	O
of	O	O
adverse	O	B_Disease
hypersensitivity	B_Disease	I_Disease
reactions	O	O
to	O	O
these	O	O
agents	O	O
is	O	O
generally	O	O
low	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
non-steroidal	O	O
anti-inflammatory	O	O
drugs	O	O
(	O	O
NSAIDs	O	O
)	O	O
are	O	O
commonly	O	O
involved	O	O
in	O	O
such	O	O
reactions	O	O
.	O	O

Celecoxib	B_Chemical	O
(	O	O
CE	B_Chemical	O
)	O	O
is	O	O
a	O	O
novel	O	O
drug	O	O
,	O	O
with	O	O
high	O	O
selectivity	O	O
and	O	O
affinity	O	O
for	O	O
COX-2	O	O
enzyme	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
We	O	O
evaluated	O	O
the	O	O
tolerability	O	O
of	O	O
CE	B_Chemical	O
in	O	O
a	O	O
group	O	O
of	O	O
patients	O	O
with	O	O
documented	O	O
history	O	O
of	O	O
adverse	O	O
cutaneous	B_Disease	O
reactions	I_Disease	O
to	O	O
P	B_Chemical	O
and	O	O
N	B_Chemical	O
associated	O	O
or	O	O
not	O	O
to	O	O
classic	O	O
NSAIDs	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
studied	O	O
9	O	O
patients	O	O
with	O	O
hypersensitivity	B_Disease	O
to	O	O
P	B_Chemical	O
and	O	O
N	B_Chemical	O
with	O	O
or	O	O
without	O	O
associated	O	O
reactions	O	O
to	O	O
classic	O	O
NSAIDs	O	O
.	O	O

The	O	O
diagnosis	O	O
of	O	O
P	B_Chemical	O
and	O	O
N-induced	O	O
skin	B_Disease	O
reactions	I_Disease	O
was	O	O
based	O	O
in	O	O
vivo	O	O
challenge	O	O
.	O	O

The	O	O
placebo	O	O
was	O	O
blindly	O	O
administered	O	O
at	O	O
the	O	O
beginning	O	O
of	O	O
each	O	O
challenge	O	O
.	O	O

After	O	O
three	O	O
days	O	O
,	O	O
a	O	O
cumulative	O	O
dosage	O	O
of	O	O
200	O	O
mg	O	O
of	O	O
CE	B_Chemical	O
in	O	O
refracted	O	O
doses	O	O
were	O	O
given	O	O
.	O	O

After	O	O
2	O	O
-	O	O
3	O	O
days	O	O
,	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
200	O	O
mg	O	O
was	O	O
administered	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
observed	O	O
for	O	O
6	O	O
hours	O	O
after	O	O
each	O	O
challenge	O	O
,	O	O
and	O	O
controlled	O	O
again	O	O
after	O	O
24	O	O
hours	O	O
to	O	O
exclude	O	O
delayed	O	O
reactions	O	O
.	O	O

The	O	O
challenge	O	O
was	O	O
considered	O	O
positive	O	O
if	O	O
one	O	O
or	O	O
more	O	O
of	O	O
the	O	O
following	O	O
appeared	O	O
:	O	O
erythema	B_Disease	O
,	O	O
rush	O	O
or	O	O
urticaria-angioedema	O	O
.	O	O

RESULTS	O	O
:	O	O
No	O	O
reaction	O	O
was	O	O
observed	O	O
with	O	O
placebo	O	O
and	O	O
eight	O	O
patients	O	O
(	O	O
88.8	O	O
%	O	O
)	O	O
tolerated	O	O
CE	B_Chemical	O
.	O	O

Only	O	O
one	O	O
patient	O	O
developed	O	O
a	O	O
moderate	O	O
angioedema	B_Disease	O
of	O	O
the	O	O
lips	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Only	O	O
one	O	O
hypersensitivity	B_Disease	B_Disease
reaction	O	I_Disease
to	O	O
CE	B_Chemical	O
was	O	O
documented	O	O
among	O	O
9	O	O
P	B_Chemical	O
and	O	O
N-highly	O	O
NSAIDs	O	O
intolerant	O	O
patients	O	O
.	O	O

Thus	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
CE	B_Chemical	O
is	O	O
a	O	O
reasonably	O	O
safe	O	O
alternative	O	O
to	O	O
be	O	O
used	O	O
in	O	O
subjects	O	O
who	O	O
do	O	O
not	O	O
tolerate	O	O
P	B_Chemical	O
and	O	O
N.	O	O

Case-control	O	O
study	O	O
of	O	O
regular	O	O
analgesic	O	O
and	O	O
nonsteroidal	O	O
anti-inflammatory	O	O
use	O	O
and	O	O
end-stage	O	B_Disease
renal	O	I_Disease
disease	O	I_Disease
.	O	O

BACKGROUND	O	O
:	O	O
Studies	O	O
on	O	O
the	O	O
association	O	O
between	O	O
the	O	O
long-term	O	O
use	O	O
of	O	O
aspirin	B_Chemical	O
and	O	O
other	O	O
analgesic	O	O
and	O	O
nonsteroidal	O	O
anti-inflammatory	O	O
drugs	O	O
(	O	O
NSAIDs	O	O
)	O	O
and	O	O
end-stage	B_Disease	B_Disease
renal	I_Disease	I_Disease
disease	I_Disease	I_Disease
(	O	O
ESRD	B_Disease	O
)	O	O
have	O	O
given	O	O
conflicting	O	O
results	O	O
.	O	O

In	O	O
order	O	O
to	O	O
examine	O	O
this	O	O
association	O	O
,	O	O
a	O	O
case-control	O	O
study	O	O
with	O	O
incident	O	O
cases	O	O
of	O	O
ESRD	B_Disease	O
was	O	O
carried	O	O
out	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
cases	O	O
were	O	O
all	O	O
patients	O	O
entering	O	O
the	O	O
local	O	O
dialysis	O	O
program	O	O
because	O	O
of	O	O
ESRD	B_Disease	O
in	O	O
the	O	O
study	O	O
area	O	O
between	O	O
June	O	O
1	O	O
,	O	O
1995	O	O
and	O	O
November	O	O
30	O	O
,	O	O
1997	O	O
.	O	O
They	O	O
were	O	O
classified	O	O
according	O	O
to	O	O
the	O	O
underlying	O	O
disease	O	O
,	O	O
which	O	O
had	O	O
presumably	O	O
led	O	O
them	O	O
to	O	O
ESRD	B_Disease	O
.	O	O

Controls	O	O
were	O	O
patients	O	O
admitted	O	O
to	O	O
the	O	O
same	O	O
hospitals	O	O
from	O	O
where	O	O
the	O	O
cases	O	O
arose	O	O
,	O	O
also	O	O
matched	O	O
by	O	O
age	O	O
and	O	O
sex	O	O
.	O	O

Odds	O	O
ratios	O	O
were	O	O
calculated	O	O
using	O	O
a	O	O
conditional	O	O
logistic	O	O
model	O	O
,	O	O
including	O	O
potential	O	O
confounding	O	O
factors	O	O
,	O	O
both	O	O
for	O	O
the	O	O
whole	O	O
study	O	O
population	O	O
and	O	O
for	O	O
the	O	O
various	O	O
underlying	O	O
diseases	O	O
.	O	O

RESULTS	O	O
:	O	O
Five	O	O
hundred	O	O
and	O	O
eighty-three	O	O
cases	O	O
and	O	O
1190	O	O
controls	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

Long-term	O	O
use	O	O
of	O	O
any	O	O
analgesic	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
overall	O	O
odds	O	O
ratio	O	O
of	O	O
1.22	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.89	O	O
-	O	O
1.66	O	O
)	O	O
.	O	O

For	O	O
specific	O	O
groups	O	O
of	O	O
drugs	O	O
,	O	O
the	O	O
risks	O	O
were	O	O
1.56	O	O
(	O	O
1.05	O	O
-	O	O
2.30	O	O
)	O	O
for	O	O
aspirin	B_Chemical	O
,	O	O
1.03	O	O
(	O	O
0.60	O	O
-	O	O
1.76	O	O
)	O	O
for	O	O
pyrazolones	B_Chemical	B_Chemical
,	O	O
0.80	O	O
(	O	O
0.39	O	O
-	O	O
1.63	O	O
)	O	O
for	O	O
paracetamol	B_Chemical	B_Chemical
,	O	O
and	O	O
0.94	O	O
(	O	O
0.57	O	O
-	O	O
1.56	O	O
)	O	O
for	O	O
nonaspirin	O	B_Chemical
NSAIDs	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
ESRD	B_Disease	O
associated	O	O
with	O	O
aspirin	B_Chemical	O
was	O	O
related	O	O
to	O	O
the	O	O
cumulated	O	O
dose	O	O
and	O	O
duration	O	O
of	O	O
use	O	O
,	O	O
and	O	O
it	O	O
was	O	O
particularly	O	O
high	O	O
among	O	O
the	O	O
subset	O	O
of	O	O
patients	O	O
with	O	O
vascular	O	B_Disease
nephropathy	B_Disease	I_Disease
as	O	O
underlying	O	O
disease	O	O
[	O	O
2.35	O	O
(	O	O
1.17	O	O
-	O	O
4.72	O	O
)	O	O
]	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Our	O	O
data	O	O
indicate	O	O
that	O	O
long-term	O	O
use	O	O
of	O	O
nonaspirin	O	B_Chemical
analgesic	O	O
drugs	O	O
and	O	O
NSAIDs	O	O
is	O	O
not	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
ESRD	B_Disease	O
.	O	O

However	O	O
,	O	O
the	O	O
chronic	O	O
use	O	O
of	O	O
aspirin	B_Chemical	O
may	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
ESRD	B_Disease	O
.	O	O

Two	O	O
cases	O	O
of	O	O
amisulpride	B_Chemical	O
overdose	B_Disease	O
:	O	O
a	O	O
cause	O	O
for	O	O
prolonged	B_Disease	O
QT	I_Disease	O
syndrome	I_Disease	O
.	O	O

Two	O	O
cases	O	O
of	O	O
deliberate	O	O
self-poisoning	O	O
with	O	O
5	O	O
g	O	O
and	O	O
3.6	O	O
g	O	O
of	O	O
amisulpride	B_Chemical	B_Chemical
,	O	O
respectively	O	O
,	O	O
are	O	O
reported	O	O
.	O	O

In	O	O
both	O	O
cases	O	O
,	O	O
QT	B_Disease	O
prolongation	I_Disease	O
and	O	O
hypocalcaemia	B_Disease	O
were	O	O
noted	O	O
.	O	O

The	O	O
QT	B_Disease	O
prolongation	I_Disease	O
appeared	O	O
to	O	O
respond	O	O
to	O	O
administration	O	O
of	O	O
i.v	O	O
.	O	O
calcium	B_Chemical	B_Chemical
gluconate	I_Chemical	I_Chemical
.	O	O

Growth-associated	O	O
protein	O	O
43	O	O
expression	O	O
in	O	O
hippocampal	O	O
molecular	O	O
layer	O	O
of	O	O
chronic	O	O
epileptic	B_Disease	O
rats	O	O
treated	O	O
with	O	O
cycloheximide	B_Chemical	B_Chemical
.	O	O

PURPOSE	O	O
:	O	O
GAP43	O	O
has	O	O
been	O	O
thought	O	O
to	O	O
be	O	O
linked	O	O
with	O	O
mossy	O	O
fiber	O	O
sprouting	O	O
(	O	O
MFS	O	O
)	O	O
in	O	O
various	O	O
experimental	O	O
models	O	O
of	O	O
epilepsy	B_Disease	O
.	O	O

To	O	O
investigate	O	O
how	O	O
GAP43	O	O
expression	O	O
(	O	O
GAP43-ir	O	O
)	O	O
correlates	O	O
with	O	O
MFS	O	O
,	O	O
we	O	O
assessed	O	O
the	O	O
intensity	O	O
(	O	O
densitometry	O	O
)	O	O
and	O	O
extension	O	O
(	O	O
width	O	O
)	O	O
of	O	O
GAP43-ir	O	O
in	O	O
the	O	O
inner	O	O
molecular	O	O
layer	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
(	O	O
IML	O	O
)	O	O
of	O	O
rats	O	O
subject	O	O
to	O	O
status	B_Disease	O
epilepticus	I_Disease	O
induced	O	O
by	O	O
pilocarpine	B_Chemical	O
(	O	O
Pilo	B_Chemical	O
)	O	O
,	O	O
previously	O	O
injected	O	O
or	O	O
not	O	O
with	O	O
cycloheximide	B_Chemical	B_Chemical
(	O	O
CHX	B_Chemical	B_Chemical
)	O	O
,	O	O
which	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
inhibit	O	O
MFS	O	O
.	O	O

METHODS	O	O
:	O	O
CHX	B_Chemical	B_Chemical
was	O	O
injected	O	O
before	O	O
the	O	O
Pilo	B_Chemical	O
injection	O	O
in	O	O
adult	O	O
Wistar	O	O
rats	O	O
.	O	O

The	O	O
Pilo	B_Chemical	O
group	O	O
was	O	O
injected	O	O
with	O	O
the	O	O
same	O	O
drugs	O	O
,	O	O
except	O	O
for	O	O
CHX	B_Chemical	O
.	O	O

Animals	O	O
were	O	O
killed	O	O
between	O	O
30	O	O
and	O	O
60	O	O
days	O	O
later	O	O
,	O	O
and	O	O
brain	O	O
sections	O	O
were	O	O
processed	O	O
for	O	O
GAP43	O	O
immunohistochemistry	O	O
.	O	O

RESULTS	O	O
:	O	O
Densitometry	O	O
showed	O	O
no	O	O
significant	O	O
difference	O	O
regarding	O	O
GAP43-ir	O	O
in	O	O
the	O	O
IML	O	O
between	O	O
Pilo	B_Chemical	O
,	O	O
CHX+Pilo	O	O
,	O	O
and	O	O
control	O	O
groups	O	O
.	O	O

However	O	O
,	O	O
the	O	O
results	O	O
of	O	O
the	O	O
width	O	O
of	O	O
the	O	O
GAP43-ir	O	O
band	O	O
in	O	O
the	O	O
IML	O	O
showed	O	O
that	O	O
CHX+Pilo	O	O
and	O	O
control	O	O
animals	O	O
had	O	O
a	O	O
significantly	O	O
larger	O	O
band	O	O
(	O	O
p	O	O
=	O	O
0.03	O	O
)	O	O
as	O	O
compared	O	O
with	O	O
that	O	O
in	O	O
the	O	O
Pilo	B_Chemical	O
group	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Our	O	O
current	O	O
finding	O	O
that	O	O
animals	O	O
in	O	O
the	O	O
CHX+Pilo	O	O
group	O	O
have	O	O
a	O	O
GAP43-ir	O	O
band	O	O
in	O	O
the	O	O
IML	O	O
,	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
controls	O	O
,	O	O
reinforces	O	O
prior	O	O
data	O	O
on	O	O
the	O	O
blockade	O	O
of	O	O
MFS	O	O
in	O	O
these	O	O
animals	O	O
.	O	O

The	O	O
change	O	O
in	O	O
GAP43-ir	O	O
present	O	O
in	O	O
Pilo-treated	O	O
animals	O	O
was	O	O
a	O	O
thinning	O	O
of	O	O
the	O	O
band	O	O
to	O	O
a	O	O
very	O	O
narrow	O	O
layer	O	O
just	O	O
above	O	O
the	O	O
granule	O	O
cell	O	O
layer	O	O
that	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
loss	O	O
of	O	O
hilar	O	O
cell	O	O
projections	O	O
that	O	O
express	O	O
GAP-43	O	O
.	O	O

Nicotine	B_Chemical	O
antagonizes	O	O
caffeine-	O	O
but	O	O
not	O	O
pentylenetetrazole-induced	O	O
anxiogenic	O	O
effect	O	O
in	O	O
mice	O	O
.	O	O

RATIONALE	O	O
:	O	O
Nicotine	B_Chemical	O
and	O	O
caffeine	B_Chemical	O
are	O	O
widely	O	O
consumed	O	O
licit	O	O
psychoactive	O	O
drugs	O	O
worldwide	O	O
.	O	O

Epidemiological	O	O
studies	O	O
showed	O	O
that	O	O
they	O	O
were	O	O
generally	O	O
used	O	O
concurrently	O	O
.	O	O

Although	O	O
some	O	O
studies	O	O
in	O	O
experimental	O	O
animals	O	O
indicate	O	O
clear	O	O
pharmacological	O	O
interactions	O	O
between	O	O
them	O	O
,	O	O
no	O	O
studies	O	O
have	O	O
shown	O	O
a	O	O
specific	O	O
interaction	O	O
on	O	O
anxiety	B_Disease	O
responses	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
present	O	O
study	O	O
investigates	O	O
the	O	O
effects	O	O
of	O	O
nicotine	B_Chemical	O
on	O	O
anxiety	B_Disease	O
induced	O	O
by	O	O
caffeine	B_Chemical	O
and	O	O
another	O	O
anxiogenic	O	O
drug	O	O
,	O	O
pentylenetetrazole	B_Chemical	B_Chemical
,	O	O
in	O	O
mice	O	O
.	O	O

The	O	O
elevated	O	O
plus-maze	O	O
(	O	O
EPM	O	O
)	O	O
test	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
drugs	O	O
on	O	O
anxiety	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
Adult	O	O
male	O	O
Swiss	O	O
Webster	O	O
mice	O	O
(	O	O
25	O	O
-	O	O
32	O	O
g	O	O
)	O	O
were	O	O
given	O	O
nicotine	B_Chemical	O
(	O	O
0.05	O	O
-	O	O
0.25	O	O
mg/kg	O	O
s.c	O	O
.	O	O
)	O	O
or	O	O
saline	O	O
10	O	O
min	O	O
before	O	O
caffeine	B_Chemical	O
(	O	O
70	O	O
mg/kg	O	O
i.p	O	O
.	O	O
)	O	O
or	O	O
pentylenetetrazole	B_Chemical	B_Chemical
(	O	O
15	O	O
and	O	O
30	O	O
mg/kg	O	O
i.p	O	O
.	O	O
)	O	O
injections	O	O
.	O	O

After	O	O
15	O	O
min	O	O
,	O	O
mice	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
open-	O	O
and	O	O
closed-arm	O	O
time	O	O
and	O	O
entries	O	O
on	O	O
the	O	O
EPM	O	O
for	O	O
a	O	O
10-min	O	O
session	O	O
.	O	O

Locomotor	O	O
activity	O	O
was	O	O
recorded	O	O
for	O	O
individual	O	O
groups	O	O
by	O	O
using	O	O
the	O	O
same	O	O
treatment	O	O
protocol	O	O
with	O	O
the	O	O
EPM	O	O
test	O	O
.	O	O

RESULTS	O	O
:	O	O
Nicotine	B_Chemical	O
(	O	O
0.05	O	O
-	O	O
0.25	O	O
mg/kg	O	O
)	O	O
itself	O	O
did	O	O
not	O	O
produce	O	O
any	O	O
significant	O	O
effect	O	O
in	O	O
the	O	O
EPM	O	O
test	O	O
,	O	O
whereas	O	O
caffeine	B_Chemical	O
(	O	O
70	O	O
mg/kg	O	O
)	O	O
and	O	O
pentylenetetrazole	B_Chemical	O
(	O	O
30	O	O
mg/kg	O	O
)	O	O
produced	O	O
an	O	O
anxiogenic	O	O
effect	O	O
,	O	O
apparent	O	O
with	O	O
decreases	O	O
in	O	O
open-arm	O	O
time	O	O
and	O	O
entry	O	O
.	O	O

Nicotine	B_Chemical	O
(	O	O
0.25	O	O
mg/kg	O	O
)	O	O
pretreatment	O	O
blocked	O	O
the	O	O
caffeine-	O	O
but	O	O
not	O	O
pentylenetetrazole-induced	O	O
anxiety	B_Disease	O
.	O	O

Administration	O	O
of	O	O
each	O	O
drug	O	O
and	O	O
their	O	O
combinations	O	O
did	O	O
not	O	O
produce	O	O
any	O	O
effect	O	O
on	O	O
locomotor	O	O
activity	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Our	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
antagonistic	O	O
effect	O	O
of	O	O
nicotine	B_Chemical	O
on	O	O
caffeine-induced	O	O
anxiety	B_Disease	O
is	O	O
specific	O	O
to	O	O
caffeine	B_Chemical	O
,	O	O
instead	O	O
of	O	O
a	O	O
non-specific	O	O
anxiolytic	O	O
effect	O	O
.	O	O

Thus	O	O
,	O	O
it	O	O
may	O	O
extend	O	O
the	O	O
current	O	O
findings	O	O
on	O	O
the	O	O
interaction	O	O
between	O	O
nicotine	B_Chemical	O
and	O	O
caffeine	B_Chemical	O
.	O	O

Long	O	O
term	O	O
hormone	O	O
therapy	O	O
for	O	O
perimenopausal	O	O
and	O	O
postmenopausal	O	O
women	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Hormone	O	O
therapy	O	O
(	O	O
HT	O	O
)	O	O
is	O	O
widely	O	O
used	O	O
for	O	O
controlling	O	O
menopausal	B_Disease	O
symptoms	I_Disease	O
.	O	O

It	O	O
has	O	O
also	O	O
been	O	O
used	O	O
for	O	O
the	O	O
management	O	O
and	O	O
prevention	O	O
of	O	O
cardiovascular	B_Disease	B_Disease
disease	I_Disease	I_Disease
,	O	O
osteoporosis	B_Disease	O
and	O	O
dementia	B_Disease	O
in	O	O
older	O	O
women	O	O
but	O	O
the	O	O
evidence	O	O
supporting	O	O
its	O	O
use	O	O
for	O	O
these	O	O
indications	O	O
is	O	O
largely	O	O
observational	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
assess	O	O
the	O	O
effect	O	O
of	O	O
long-term	O	O
HT	O	O
on	O	O
mortality	O	O
,	O	O
heart	B_Disease	B_Disease
disease	I_Disease	I_Disease
,	O	O
venous	B_Disease	B_Disease
thromboembolism	I_Disease	I_Disease
,	O	O
stroke	B_Disease	O
,	O	O
transient	B_Disease	B_Disease
ischaemic	I_Disease	I_Disease
attacks	I_Disease	I_Disease
,	O	O
breast	B_Disease	B_Disease
cancer	I_Disease	I_Disease
,	O	O
colorectal	B_Disease	B_Disease
cancer	I_Disease	I_Disease
,	O	O
ovarian	B_Disease	B_Disease
cancer	I_Disease	I_Disease
,	O	O
endometrial	B_Disease	B_Disease
cancer	I_Disease	I_Disease
,	O	O
gallbladder	B_Disease	B_Disease
disease	I_Disease	I_Disease
,	O	O
cognitive	O	O
function	O	O
,	O	O
dementia	B_Disease	O
,	O	O
fractures	B_Disease	O
and	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

SEARCH	O	O
STRATEGY	O	O
:	O	O
We	O	O
searched	O	O
the	O	O
following	O	O
databases	O	O
up	O	O
to	O	O
November	O	O
2004	O	O
:	O	O
the	O	O
Cochrane	O	O
Menstrual	O	O
Disorders	O	O
and	O	O
Subfertility	O	O
Group	O	O
Trials	O	O
Register	O	O
,	O	O
Cochrane	O	O
Central	O	O
Register	O	O
of	O	O
Controlled	O	O
Trials	O	O
(	O	O
CENTRAL	O	O
)	O	O
,	O	O
MEDLINE	O	O
,	O	O
EMBASE	O	O
,	O	O
Biological	O	O
Abstracts	O	O
.	O	O

Relevant	O	O
non-indexed	O	O
journals	O	O
and	O	O
conference	O	O
abstracts	O	O
were	O	O
also	O	O
searched	O	O
.	O	O

SELECTION	O	O
CRITERIA	O	O
:	O	O
Randomised	O	O
double-blind	O	O
trials	O	O
of	O	O
HT	O	O
(	O	O
oestrogens	B_Chemical	O
with	O	O
or	O	O
without	O	O
progestogens	B_Chemical	O
)	O	O
versus	O	O
placebo	O	O
,	O	O
taken	O	O
for	O	O
at	O	O
least	O	O
one	O	O
year	O	O
by	O	O
perimenopausal	O	B_Disease
or	O	O
postmenopausal	O	O
women	O	O
.	O	O

DATA	O	O
COLLECTION	O	O
AND	O	O
ANALYSIS	O	O
:	O	O
Fifteen	O	O
RCTs	O	O
were	O	O
included	O	O
.	O	O

Trials	O	O
were	O	O
assessed	O	O
for	O	O
quality	O	O
and	O	O
two	O	O
review	O	O
authors	O	O
extracted	O	O
data	O	O
independently	O	O
.	O	O

They	O	O
calculated	O	O
risk	O	O
ratios	O	O
for	O	O
dichotomous	O	O
outcomes	O	O
and	O	O
weighted	O	O
mean	O	O
differences	O	O
for	O	O
continuous	O	O
outcomes	O	O
.	O	O

Clinical	O	O
heterogeneity	O	O
precluded	O	O
meta-analysis	O	O
for	O	O
most	O	O
outcomes	O	O
.	O	O

MAIN	O	O
RESULTS	O	O
:	O	O
All	O	O
the	O	O
statistically	O	O
significant	O	O
results	O	O
were	O	O
derived	O	O
from	O	O
the	O	O
two	O	O
biggest	O	O
trials	O	O
.	O	O

In	O	O
relatively	O	O
healthy	O	O
women	O	O
,	O	O
combined	O	O
continuous	O	O
HT	O	O
significantly	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
venous	B_Disease	B_Disease
thromboembolism	I_Disease	I_Disease
or	O	O
coronary	O	O
event	O	O
(	O	O
after	O	O
one	O	O
year	O	O
's	O	O
use	O	O
)	O	O
,	O	O
stroke	B_Disease	O
(	O	O
after	O	O
3	O	O
years	O	O
)	O	O
,	O	O
breast	B_Disease	B_Disease
cancer	I_Disease	I_Disease
(	O	O
after	O	O
5	O	O
years	O	O
)	O	O
and	O	O
gallbladder	B_Disease	B_Disease
disease	I_Disease	I_Disease
.	O	O

Long-term	O	O
oestrogen-only	O	O
HT	O	O
also	O	O
significantly	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
stroke	B_Disease	O
and	O	O
gallbladder	B_Disease	B_Disease
disease	I_Disease	I_Disease
.	O	O

Overall	O	O
,	O	O
the	O	O
only	O	O
statistically	O	O
significant	O	O
benefits	O	O
of	O	O
HT	O	O
were	O	O
a	O	O
decreased	O	O
incidence	O	O
of	O	O
fractures	B_Disease	O
and	O	O
colon	B_Disease	B_Disease
cancer	I_Disease	I_Disease
with	O	O
long-term	O	O
use	O	O
.	O	O

Among	O	O
relatively	O	O
healthy	O	O
women	O	O
over	O	O
65	O	O
years	O	O
taking	O	O
continuous	O	O
combined	O	O
HT	O	O
,	O	O
there	O	O
was	O	O
a	O	O
statistically	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
dementia	B_Disease	O
.	O	O

Among	O	O
women	O	O
with	O	O
cardiovascular	B_Disease	B_Disease
disease	I_Disease	I_Disease
,	O	O
long-term	O	O
use	O	O
of	O	O
combined	O	O
continuous	O	O
HT	O	O
significantly	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
venous	B_Disease	B_Disease
thromboembolism	I_Disease	I_Disease
.	O	O

No	O	O
trials	O	O
focussed	O	O
specifically	O	O
on	O	O
younger	O	O
women	O	O
.	O	O

However	O	O
,	O	O
one	O	O
trial	O	O
analysed	O	O
subgroups	O	O
of	O	O
2839	O	O
relatively	O	O
healthy	O	O
50	O	O
to	O	O
59	O	O
year-old	O	O
women	O	O
taking	O	O
combined	O	O
continuous	O	O
HT	O	O
and	O	O
1637	O	O
taking	O	O
oestrogen-only	O	O
HT	O	O
,	O	O
versus	O	O
similar-sized	O	O
placebo	O	O
groups	O	O
.	O	O

The	O	O
only	O	O
significantly	O	O
increased	O	O
risk	O	O
reported	O	O
was	O	O
for	O	O
venous	B_Disease	B_Disease
thromboembolism	I_Disease	I_Disease
in	O	O
women	O	O
taking	O	O
combined	O	O
continuous	O	O
HT	O	O
;	O	O
their	O	O
absolute	O	O
risk	O	O
remained	O	O
very	O	O
low	O	O
.	O	O
AUTHORS	O	O
'	O	O
CONCLUSIONS	O	O
:	O	O
HT	O	O
is	O	O
not	O	O
indicated	O	O
for	O	O
the	O	O
routine	O	O
management	O	O
of	O	O
chronic	B_Disease	B_Disease
disease	I_Disease	I_Disease
.	O	O

We	O	O
need	O	O
more	O	O
evidence	O	O
on	O	O
the	O	O
safety	O	O
of	O	O
HT	O	O
for	O	O
menopausal	O	O
symptom	O	O
control	O	O
,	O	O
though	O	O
short-term	O	O
use	O	O
appears	O	O
to	O	O
be	O	O
relatively	O	O
safe	O	O
for	O	O
healthy	O	O
younger	O	O
women	O	O
.	O	O

Drug-induced	O	O
liver	O	B_Disease
injury	O	I_Disease
:	O	O
an	O	O
analysis	O	O
of	O	O
461	O	O
incidences	O	O
submitted	O	O
to	O	O
the	O	O
Spanish	O	O
registry	O	O
over	O	O
a	O	O
10-year	O	O
period	O	O
.	O	O

BACKGROUND	O	O
&	O	O
AIMS	O	O
:	O	O
Progress	O	O
in	O	O
the	O	O
understanding	O	O
of	O	O
susceptibility	O	O
factors	O	O
to	O	O
drug-induced	B_Disease	O
liver	I_Disease	B_Disease
injury	I_Disease	I_Disease
(	O	O
DILI	B_Disease	O
)	O	O
and	O	O
outcome	O	O
predictability	O	O
are	O	O
hampered	O	O
by	O	O
the	O	O
lack	O	O
of	O	O
systematic	O	O
programs	O	O
to	O	O
detect	O	O
bona	O	O
fide	O	O
cases	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
cooperative	O	O
network	O	O
was	O	O
created	O	O
in	O	O
1994	O	O
in	O	O
Spain	O	O
to	O	O
identify	O	O
all	O	O
suspicions	O	O
of	O	O
DILI	B_Disease	O
following	O	O
a	O	O
prospective	O	O
structured	O	O
report	O	O
form	O	O
.	O	O

The	O	O
liver	B_Disease	B_Disease
damage	I_Disease	I_Disease
was	O	O
characterized	O	O
according	O	O
to	O	O
hepatocellular	O	B_Disease
,	O	O
cholestatic	B_Disease	B_Disease
,	O	O
and	O	O
mixed	O	O
laboratory	O	O
criteria	O	O
and	O	O
to	O	O
histologic	O	O
criteria	O	O
when	O	O
available	O	O
.	O	O

Further	O	O
evaluation	O	O
of	O	O
causality	O	O
assessment	O	O
was	O	O
centrally	O	O
performed	O	O
.	O	O

RESULTS	O	O
:	O	O
Since	O	O
April	O	O
1994	O	O
to	O	O
August	O	O
2004	O	O
,	O	O
461	O	O
out	O	O
of	O	O
570	O	O
submitted	O	O
cases	O	O
,	O	O
involving	O	O
505	O	O
drugs	O	O
,	O	O
were	O	O
deemed	O	O
to	O	O
be	O	O
related	O	O
to	O	O
DILI	B_Disease	O
.	O	O

The	O	O
antiinfective	O	O
group	O	O
of	O	O
drugs	O	O
was	O	O
the	O	O
more	O	O
frequently	O	O
incriminated	O	O
,	O	O
amoxicillin-clavulanate	B_Chemical	B_Chemical
accounting	O	O
for	O	O
the	O	O
12.8	O	O
%	O	O
of	O	O
the	O	O
whole	O	O
series	O	O
.	O	O

The	O	O
hepatocellular	O	O
pattern	O	O
of	O	O
damage	O	O
was	O	O
the	O	O
most	O	O
common	O	O
(	O	O
58	O	O
%	O	O
)	O	O
,	O	O
was	O	O
inversely	O	O
correlated	O	O
with	O	O
age	O	O
(	O	O
P	O	O
<	O	O
.0001	O	O
)	O	O
,	O	O
and	O	O
had	O	O
the	O	O
worst	O	O
outcome	O	O
(	O	O
Cox	O	O
regression	O	O
,	O	O
P	O	O
<	O	O
.034	O	O
)	O	O
.	O	O

Indeed	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
liver	O	O
transplantation	O	O
and	O	O
death	O	O
in	O	O
this	O	O
group	O	O
was	O	O
11.7	O	O
%	O	O
if	O	O
patients	O	O
had	O	O
jaundice	B_Disease	O
at	O	O
presentation	O	O
,	O	O
whereas	O	O
the	O	O
corresponding	O	O
figure	O	O
was	O	O
3.8	O	O
%	O	O
in	O	O
nonjaundiced	O	O
patients	O	O
(	O	O
P	O	O
<	O	O
.04	O	O
)	O	O
.	O	O

Factors	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
fulminant	B_Disease	B_Disease
hepatic	I_Disease	I_Disease
failure	I_Disease	I_Disease
were	O	O
female	O	O
sex	O	O
(	O	O
OR	O	O
=	O	O
25	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
4.1	O	O
-	O	O
151	O	O
;	O	O
P	O	O
<	O	O
.0001	O	O
)	O	O
,	O	O
hepatocellular	O	B_Disease
damage	O	I_Disease
(	O	O
OR	O	O
=	O	O
7.9	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
1.6	O	O
-	O	O
37	O	O
;	O	O
P	O	O
<	O	O
.009	O	O
)	O	O
,	O	O
and	O	O
higher	O	O
baseline	O	O
plasma	O	O
bilirubin	B_Chemical	O
value	O	O
(	O	O
OR	O	O
=	O	O
1.15	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
1.09	O	O
-	O	O
1.22	O	O
;	O	O
P	O	O
<	O	O
.0001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Patients	O	O
with	O	O
drug-induced	O	O
hepatocellular	O	B_Disease
jaundice	B_Disease	I_Disease
have	O	O
11.7	O	O
%	O	O
chance	O	O
of	O	O
progressing	O	O
to	O	O
death	O	O
or	O	O
transplantation	O	O
.	O	O

Amoxicillin-clavulanate	B_Chemical	B_Chemical
stands	O	O
out	O	O
as	O	O
the	O	O
most	O	O
common	O	O
drug	O	O
related	O	O
to	O	O
DILI	B_Disease	O
.	O	O

Morphological	O	O
evaluation	O	O
of	O	O
the	O	O
effect	O	O
of	O	O
d-ribose	B_Chemical	O
on	O	O
adriamycin-evoked	O	O
cardiotoxicity	B_Disease	B_Disease
in	O	O
rats	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
d-ribose	B_Chemical	O
on	O	O
adriamycin-induced	O	O
myocardiopathy	B_Disease	O
in	O	O
rats	O	O
was	O	O
studied	O	O
.	O	O

Adriamycin	B_Chemical	B_Chemical
in	O	O
the	O	O
cumulative	O	O
dose	O	O
of	O	O
25	O	O
mg/kg	O	O
evoked	O	O
fully	O	O
developed	O	O
cardiac	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
.	O	O

D-ribose	B_Chemical	O
in	O	O
the	O	O
multiple	O	O
doses	O	O
of	O	O
200	O	O
mg/kg	O	O
did	O	O
not	O	O
influence	O	O
ADR	B_Chemical	O
cardiotoxicity	B_Disease	O
.	O	O

In	O	O
vivo	O	O
evidences	O	O
suggesting	O	O
the	O	O
role	O	O
of	O	O
oxidative	O	O
stress	O	O
in	O	O
pathogenesis	O	O
of	O	O
vancomycin-induced	O	O
nephrotoxicity	B_Disease	B_Disease
:	O	O
protection	O	O
by	O	O
erdosteine	B_Chemical	B_Chemical
.	O	O

The	O	O
aims	O	O
of	O	O
this	O	O
study	O	O
were	O	O
to	O	O
examine	O	O
vancomycin	B_Chemical	O
(VCM)-induced	O	O
oxidative	O	O
stress	O	O
that	O	O
promotes	O	O
production	O	O
of	O	O
reactive	O	O
oxygen	B_Chemical	O
species	O	O
(	O	O
ROS	O	O
)	O	O
and	O	O
to	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
erdosteine	B_Chemical	B_Chemical
,	O	O
an	O	O
expectorant	O	O
agent	O	O
,	O	O
which	O	O
has	O	O
also	O	O
antioxidant	O	O
properties	O	O
,	O	O
on	O	O
kidney	O	O
tissue	O	O
against	O	O
the	O	O
possible	O	O
VCM-induced	O	O
renal	B_Disease	B_Disease
impairment	I_Disease	I_Disease
in	O	O
rats	O	O
.	O	O

Rats	O	O
were	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
:	O	O
sham	O	O
,	O	O
VCM	B_Chemical	O
and	O	O
VCM	B_Chemical	O
plus	O	O
erdosteine	B_Chemical	B_Chemical
.	O	O

VCM	B_Chemical	O
was	O	O
administrated	O	O
intraperitoneally	O	O
(	O	O
i.p	O	O
.	O	O
)	O	O
with	O	O
200mgkg(-1	O	O
)	O	O
twice	O	O
daily	O	O
for	O	O
7	O	O
days	O	O
.	O	O

Erdosteine	B_Chemical	B_Chemical
was	O	O
administered	O	O
orally	O	O
.	O	O

VCM	B_Chemical	O
administration	O	O
to	O	O
control	O	O
rats	O	O
significantly	O	O
increased	O	O
renal	O	B_Chemical
malondialdehyde	B_Chemical	I_Chemical
(	O	O
MDA	B_Chemical	O
)	O	O
and	O	O
urinary	O	O
N-acetyl-beta-d-glucosaminidase	O	B_Chemical
(	O	O
NAG	O	O
,	O	O
a	O	O
marker	O	O
of	O	O
renal	B_Disease	B_Disease
tubular	I_Disease	I_Disease
injury	I_Disease	I_Disease
)	O	O
excretion	O	O
but	O	O
decreased	O	O
superoxide	B_Chemical	O
dismutase	O	O
(	O	O
SOD	O	O
)	O	O
and	O	O
catalase	O	O
(	O	O
CAT	O	O
)	O	O
activities	O	O
.	O	O

Erdosteine	B_Chemical	B_Chemical
administration	O	O
with	O	O
VCM	B_Chemical	O
injections	O	O
caused	O	O
significantly	O	O
decreased	O	O
renal	O	O
MDA	B_Chemical	O
and	O	O
urinary	O	O
NAG	O	O
excretion	O	O
,	O	O
and	O	O
increased	O	O
SOD	O	O
activity	O	O
,	O	O
but	O	O
not	O	O
CAT	O	O
activity	O	O
in	O	O
renal	O	O
tissue	O	O
when	O	O
compared	O	O
with	O	O
VCM	B_Chemical	O
alone	O	O
.	O	O

Erdosteine	B_Chemical	B_Chemical
showed	O	O
histopathological	O	O
protection	O	O
against	O	O
VCM-induced	O	O
nephrotoxicity	B_Disease	B_Disease
.	O	O

There	O	O
were	O	O
a	O	O
significant	O	O
dilatation	O	O
of	O	O
tubular	O	O
lumens	O	O
,	O	O
extensive	O	O
epithelial	O	O
cell	O	O
vacuolization	O	O
,	O	O
atrophy	B_Disease	O
,	O	O
desquamation	B_Disease	O
,	O	O
and	O	O
necrosis	B_Disease	O
in	O	O
VCM-treated	O	O
rats	O	O
more	O	O
than	O	O
those	O	O
of	O	O
the	O	O
control	O	O
and	O	O
the	O	O
erdosteine	B_Chemical	B_Chemical
groups	O	O
.	O	O

Erdosteine	B_Chemical	B_Chemical
caused	O	O
a	O	O
marked	O	O
reduction	O	O
in	O	O
the	O	O
extent	O	O
of	O	O
tubular	O	B_Disease
damage	O	I_Disease
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
oxidative	O	B_Disease
tubular	O	I_Disease
damage	O	I_Disease
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
VCM-induced	O	O
nephrotoxicity	B_Disease	B_Disease
and	O	O
the	O	O
modulation	O	O
of	O	O
oxidative	O	O
stress	O	O
with	O	O
erdosteine	B_Chemical	B_Chemical
reduces	O	O
the	O	O
VCM-induced	O	O
kidney	B_Disease	B_Disease
damage	I_Disease	I_Disease
both	O	O
at	O	O
the	O	O
biochemical	O	O
and	O	O
histological	O	O
levels	O	O
.	O	O

Gemfibrozil-lovastatin	O	O
therapy	O	O
for	O	O
primary	O	O
hyperlipoproteinemias	B_Disease	O
.	O	O

The	O	O
specific	O	O
aim	O	O
of	O	O
this	O	O
retrospective	O	O
,	O	O
observational	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
long-term	O	O
(	O	O
21	O	O
months/patient	O	O
)	O	O
,	O	O
open-label	O	O
,	O	O
gemfibrozil-lovastatin	O	B_Chemical
treatment	O	O
in	O	O
80	O	O
patients	O	O
with	O	O
primary	O	O
mixed	O	O
hyperlipidemia	B_Disease	O
(	O	O
68	O	O
%	O	O
of	O	O
whom	O	O
had	O	O
atherosclerotic	B_Disease	B_Disease
vascular	I_Disease	I_Disease
disease	I_Disease	I_Disease
)	O	O
.	O	O

Because	O	O
ideal	O	O
lipid	O	O
targets	O	O
were	O	O
not	O	O
reached	O	O
(	O	O
low-density	O	O
lipoprotein	O	O
(	O	O
LDL	O	O
)	O	O
cholesterol	B_Chemical	O
less	O	O
than	O	O
130	O	O
mg/dl	O	O
,	O	O
high-density	O	O
lipoprotein	O	O
(	O	O
HDL	O	O
)	O	O
cholesterol	B_Chemical	O
greater	O	O
than	O	O
35	O	O
mg/dl	O	O
,	O	O
or	O	O
total	O	O
cholesterol/HDL	O	O
cholesterol	B_Chemical	O
less	O	O
than	O	O
4.5	O	O
mg/dl	O	O
)	O	O
with	O	O
diet	O	O
plus	O	O
a	O	O
single	O	O
drug	O	O
,	O	O
gemfibrozil	B_Chemical	O
(	O	O
1.2	O	O
g/day)-lovastatin	O	O
(	O	O
primarily	O	O
20	O	O
or	O	O
40	O	O
mg	O	O
)	O	O
treatment	O	O
was	O	O
given	O	O
.	O	O

Follow-up	O	O
visits	O	O
were	O	O
scheduled	O	O
with	O	O
2-drug	O	O
therapy	O	O
every	O	O
6	O	O
to	O	O
8	O	O
weeks	O	O
,	O	O
an	O	O
average	O	O
of	O	O
10.3	O	O
visits	O	O
per	O	O
patient	O	O
,	O	O
with	O	O
741	O	O
batteries	O	O
of	O	O
6	O	O
liver	O	O
function	O	O
tests	O	O
and	O	O
714	O	O
creatine	B_Chemical	O
phosphokinase	O	O
levels	O	O
measured	O	O
.	O	O

Only	O	O
1	O	O
of	O	O
the	O	O
4,446	O	O
liver	O	O
function	O	O
tests	O	O
(	O	O
0.02	O	O
%	O	O
)	O	O
,	O	O
a	O	O
gamma	O	O
glutamyl	O	O
transferase	O	O
,	O	O
was	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
3	O	O
times	O	O
the	O	O
upper	O	O
normal	O	O
limit	O	O
.	O	O

Of	O	O
the	O	O
714	O	O
creatine	B_Chemical	O
phosphokinase	O	O
levels	O	O
,	O	O
9	O	O
%	O	O
were	O	O
high	O	O
;	O	O
only	O	O
1	O	O
(	O	O
0.1	O	O
%	O	O
)	O	O
was	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
3	O	O
times	O	O
the	O	O
upper	O	O
normal	O	O
limit	O	O
.	O	O

With	O	O
2-drug	O	O
therapy	O	O
,	O	O
mean	O	O
total	O	O
cholesterol	B_Chemical	O
decreased	O	O
22	O	O
%	O	O
from	O	O
255	O	O
to	O	O
200	O	O
mg/dl	O	O
,	O	O
triglyceride	B_Chemical	O
levels	O	O
decreased	O	O
35	O	O
%	O	O
from	O	O
236	O	O
to	O	O
154	O	O
mg/dl	O	O
,	O	O
LDL	O	O
cholesterol	B_Chemical	O
decreased	O	O
26	O	O
%	O	O
from	O	O
176	O	O
to	O	O
131	O	O
mg/dl	O	O
,	O	O
and	O	O
the	O	O
total	O	O
cholesterol/HDL	O	O
cholesterol	B_Chemical	O
ratio	O	O
decreased	O	O
24	O	O
%	O	O
from	O	O
7.1	O	O
to	O	O
5.4	O	O
,	O	O
all	O	O
p	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
0.0001	O	O
.	O	O

Myositis	B_Disease	O
,	O	O
attributable	O	O
to	O	O
the	O	O
drug	O	O
combination	O	O
and	O	O
symptomatic	O	O
enough	O	O
to	O	O
discontinue	O	O
it	O	O
,	O	O
occurred	O	O
in	O	O
3	O	O
%	O	O
of	O	O
patients	O	O
,	O	O
and	O	O
in	O	O
1	O	O
%	O	O
with	O	O
concurrent	O	O
high	O	O
creatine	B_Chemical	O
phosphokinase	O	O
(	O	O
769	O	O
U/liter	O	O
)	O	O
;	O	O
no	O	O
patients	O	O
had	O	O
rhabdomyolysis	B_Disease	B_Disease
or	O	O
myoglobinuria.(ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O

Does	O	O
domperidone	B_Chemical	B_Chemical
potentiate	O	O
mirtazapine-associated	O	O
restless	O	O
legs	O	O
syndrome?There	O	O
is	O	O
now	O	O
evidence	O	O
to	O	O
suggest	O	O
a	O	O
central	O	O
role	O	O
for	O	O
the	O	O
dopaminergic	O	O
system	O	O
in	O	O
restless	B_Disease	O
legs	I_Disease	O
syndrome	I_Disease	O
(	O	O
RLS	B_Disease	O
)	O	O
.	O	O

For	O	O
example	O	O
,	O	O
the	O	O
symptoms	O	O
of	O	O
RLS	B_Disease	O
can	O	O
be	O	O
dramatically	O	O
improved	O	O
by	O	O
levodopa	B_Chemical	O
and	O	O
dopamine	B_Chemical	O
agonists	O	O
,	O	O
whereas	O	O
central	O	O
dopamine	B_Chemical	O
D2	O	O
receptor	O	O
antagonists	O	O
can	O	O
induce	O	O
or	O	O
aggravate	O	O
RLS	B_Disease	B_Disease
symptoms	O	I_Disease
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
there	O	O
is	O	O
no	O	O
previous	O	O
report	O	O
regarding	O	O
whether	O	O
domperidone	B_Chemical	B_Chemical
,	O	O
a	O	O
peripheral	O	O
dopamine	B_Chemical	O
D2	O	O
receptor	O	O
antagonist	O	O
,	O	O
can	O	O
also	O	O
induce	O	O
or	O	O
aggravate	O	O
symptoms	O	O
of	O	O
RLS	B_Disease	O
.	O	O

Mirtazapine	B_Chemical	B_Chemical
,	O	O
the	O	O
first	O	O
noradrenergic	O	O
and	O	O
specific	O	O
serotonergic	O	O
antidepressant	O	O
(	O	O
NaSSA	O	O
)	O	O
,	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
RLS	B_Disease	O
in	O	O
several	O	O
recent	O	O
publications	O	O
.	O	O

The	O	O
authors	O	O
report	O	O
here	O	O
a	O	O
depressed	O	O
patient	O	O
comorbid	O	O
with	O	O
postprandial	B_Disease	O
dyspepsia	I_Disease	O
who	O	O
developed	O	O
RLS	B_Disease	O
after	O	O
mirtazapine	B_Chemical	B_Chemical
had	O	O
been	O	O
added	O	O
to	O	O
his	O	O
domperidone	B_Chemical	B_Chemical
therapy	O	O
.	O	O

Our	O	O
patient	O	O
started	O	O
to	O	O
have	O	O
symptoms	O	O
of	O	O
RLS	B_Disease	O
only	O	O
after	O	O
he	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
mirtazapine	B_Chemical	B_Chemical
,	O	O
and	O	O
his	O	O
RLS	B_Disease	O
symptoms	O	O
resolved	O	O
completely	O	O
upon	O	O
discontinuation	O	O
of	O	O
his	O	O
mirtazapine	B_Chemical	B_Chemical
.	O	O

Such	O	O
a	O	O
temporal	O	O
relationship	O	O
between	O	O
the	O	O
use	O	O
of	O	O
mirtazapine	B_Chemical	B_Chemical
and	O	O
the	O	O
symptoms	O	O
of	O	O
RLS	B_Disease	O
in	O	O
our	O	O
patient	O	O
did	O	O
not	O	O
support	O	O
a	O	O
potentiating	O	O
effect	O	O
of	O	O
domperione	B_Chemical	B_Chemical
on	O	O
mirtazapine-associated	O	O
RLS	B_Disease	O
.	O	O

However	O	O
,	O	O
physicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
possibility	O	O
that	O	O
mirtazapine	B_Chemical	B_Chemical
can	O	O
be	O	O
associated	O	O
with	O	O
RLS	B_Disease	O
in	O	O
some	O	O
individuals	O	O
,	O	O
especially	O	O
those	O	O
receiving	O	O
concomitant	O	O
dopamine	B_Chemical	O
D2	O	O
receptor	O	O
antagonists	O	O
.	O	O

Antiandrogenic	O	O
therapy	O	O
can	O	O
cause	O	O
coronary	O	B_Disease
arterial	O	I_Disease
disease	O	I_Disease
.	O	O

AIM	O	O
:	O	O
To	O	O
study	O	O
the	O	O
change	O	O
of	O	O
lipid	O	O
metabolism	O	O
by	O	O
antiandrogen	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
prostate	B_Disease	B_Disease
cancer	I_Disease	I_Disease
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
We	O	O
studied	O	O
with	O	O
a	O	O
2.5	O	O
years	O	O
follow-up	O	O
the	O	O
changes	O	O
in	O	O
plasma	O	O
cholesterols	B_Chemical	O
(	O	O
C	B_Chemical	O
)	O	O
,	O	O
triglycerides	B_Chemical	O
(	O	O
TG	B_Chemical	O
)	O	O
,	O	O
lipoproteins	O	O
(	O	O
LP	O	O
)	O	O
,	O	O
and	O	O
apolipoproteins	O	O
(	O	O
Apo	O	O
)	O	O
B-100	O	O
,	O	O
A-I	O	O
,	O	O
and	O	O
A-II	O	O
pro	O	O
fi	O	O
les	O	O
in	O	O
24	O	O
patients	O	O
of	O	O
mean	O	O
age	O	O
60	O	O
years	O	O
with	O	O
low	O	B_Disease
risk	O	I_Disease
prostate	B_Disease	I_Disease
cancer	I_Disease	I_Disease
(	O	O
stage	O	O
:	O	O
T1cN0M0	O	O
,	O	O
Gleason	O	O
score	O	O
:	O	O
2	O	O
-	O	O
5	O	O
)	O	O
during	O	O
treatment	O	O
with	O	O
cyproterone	B_Chemical	B_Chemical
acetate	I_Chemical	I_Chemical
(	O	O
CPA	B_Chemical	O
)	O	O
without	O	O
surgical	O	O
management	O	O
or	O	O
radiation	O	O
therapy	O	O
.	O	O

RESULTS	O	O
:	O	O
Significant	O	O
decreases	O	O
of	O	O
HDL-C	O	O
,	O	O
Apo	O	O
A-I	O	O
and	O	O
Apo	O	O
A-II	O	O
and	O	O
an	O	O
increase	O	O
of	O	O
triglyceride	B_Chemical	O
levels	O	O
in	O	O
VLDL	O	O
were	O	O
induced	O	O
by	O	O
CPA	B_Chemical	O
.	O	O

After	O	O
a	O	O
period	O	O
of	O	O
2.5	O	O
years	O	O
on	O	O
CPA	B_Chemical	O
treatment	O	O
,	O	O
four	O	O
patients	O	O
out	O	O
of	O	O
twenty-four	O	O
were	O	O
found	O	O
to	O	O
be	O	O
affected	O	O
by	O	O
coronary	B_Disease	B_Disease
heart	I_Disease	I_Disease
disease	I_Disease	I_Disease
.	O	O

CONCLUSIONS	O	O
:	O	O
Ischaemic	O	B_Disease
coronary	B_Disease	I_Disease
arteriosclerosis	I_Disease	I_Disease
with	O	O
an	O	O
incidence	O	O
rate	O	O
of	O	O
16.6	O	O
%	O	O
as	O	O
caused	O	O
by	O	O
prolonged	O	O
CPA	B_Chemical	O
therapy	O	O
is	O	O
mediated	O	O
through	O	O
changes	O	O
in	O	O
HDL	O	O
cholesterol	B_Chemical	O
,	O	O
Apo	O	O
A-I	O	O
and	O	O
Apo	O	O
A-II	O	O
pro	O	O
fi	O	O
les	O	O
,	O	O
other	O	O
than	O	O
the	O	O
well-known	O	O
hyperglyceridemic	B_Disease	O
effect	I_Disease	O
caused	O	O
by	O	O
estrogen	B_Chemical	O
.	O	O

5-Fluorouracil	B_Chemical	O
cardiotoxicity	B_Disease	O
induced	O	O
by	O	O
alpha-fluoro-beta-alanine	B_Chemical	B_Chemical
.	O	O

Cardiotoxicity	B_Disease	B_Disease
is	O	O
a	O	O
rare	O	O
complication	O	O
occurring	O	O
during	O	O
5-fluorouracil	B_Chemical	B_Chemical
(	O	O
5-FU	B_Chemical	B_Chemical
)	O	O
treatment	O	O
for	O	O
malignancies	B_Disease	O
.	O	O

We	O	O
herein	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
70-year-old	O	O
man	O	O
with	O	O
5-FU-induced	O	O
cardiotoxicity	B_Disease	B_Disease
,	O	O
in	O	O
whom	O	O
a	O	O
high	O	O
serum	O	O
level	O	O
of	O	O
alpha-fluoro-beta-alanine	B_Chemical	B_Chemical
(	O	O
FBAL	B_Chemical	O
)	O	O
was	O	O
observed	O	O
.	O	O

The	O	O
patient	O	O
,	O	O
who	O	O
had	O	O
unresectable	O	O
colon	B_Disease	B_Disease
cancer	I_Disease	I_Disease
metastases	O	O
to	O	O
the	O	O
liver	O	O
and	O	O
lung	O	O
,	O	O
was	O	O
referred	O	O
to	O	O
us	O	O
for	O	O
chemotherapy	O	O
from	O	O
an	O	O
affiliated	O	O
hospital	O	O
;	O	O
he	O	O
had	O	O
no	O	O
cardiac	O	O
history	O	O
.	O	O

After	O	O
admission	O	O
,	O	O
the	O	O
patient	O	O
received	O	O
a	O	O
continuous	O	O
intravenous	O	O
infusion	O	O
of	O	O
5-FU	B_Chemical	B_Chemical
(	O	O
1000	O	O
mg/day	O	O
)	O	O
,	O	O
during	O	O
which	O	O
precordial	B_Disease	O
pain	I_Disease	O
with	O	O
right	B_Disease	O
bundle	I_Disease	O
branch	I_Disease	O
block	I_Disease	O
occurred	O	O
concomitantly	O	O
with	O	O
a	O	O
high	O	O
serum	O	O
FBAL	B_Chemical	O
concentration	O	O
of	O	O
1955	O	O
ng/ml	O	O
.	O	O

Both	O	O
the	O	O
precordial	B_Disease	O
pain	I_Disease	O
and	O	O
the	O	O
electrocardiographic	O	O
changes	O	O
disappeared	O	O
spontaneously	O	O
after	O	O
the	O	O
discontinuation	O	O
of	O	O
5-FU	B_Chemical	O
.	O	O

As	O	O
the	O	O
precordial	B_Disease	O
pain	I_Disease	O
in	O	O
this	O	O
patient	O	O
was	O	O
considered	O	O
to	O	O
have	O	O
been	O	O
due	O	O
to	O	O
5-FU-induced	O	O
cardiotoxicity	B_Disease	B_Disease
,	O	O
the	O	O
administration	O	O
of	O	O
5-FU	B_Chemical	O
was	O	O
abandoned	O	O
.	O	O

Instead	O	O
,	O	O
oral	O	O
administration	O	O
of	O	O
S-1	O	O
(	O	O
a	O	O
derivative	O	O
of	O	O
5-FU	B_Chemical	O
)	O	O
,	O	O
at	O	O
200	O	O
mg/day	O	O
twice	O	O
a	O	O
week	O	O
,	O	O
was	O	O
instituted	O	O
,	O	O
because	O	O
S-1	O	B_Chemical
has	O	O
a	O	O
strong	O	O
inhibitory	O	O
effect	O	O
on	O	O
dihydropyrimidine	B_Chemical	O
dehydrogenase	O	O
,	O	O
which	O	O
catalyzes	O	O
the	O	O
degradative	O	O
of	O	O
5-FU	B_Chemical	O
into	O	O
FBAL	B_Chemical	O
.	O	O

The	O	O
serum	O	O
FBAL	B_Chemical	O
concentration	O	O
subsequently	O	O
decreased	O	O
to	O	O
352	O	O
ng/ml	O	O
,	O	O
the	O	O
same	O	O
as	O	O
the	O	O
value	O	O
measured	O	O
on	O	O
the	O	O
first	O	O
day	O	O
of	O	O
S-1	O	O
administration	O	O
.	O	O

Thereafter	O	O
,	O	O
no	O	O
cardiac	B_Disease	B_Disease
symptoms	I_Disease	I_Disease
were	O	O
observed	O	O
.	O	O

The	O	O
patient	O	O
achieved	O	O
a	O	O
partial	O	O
response	O	O
6	O	O
months	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
the	O	O
S-1	O	O
treatment	O	O
.	O	O

The	O	O
experience	O	O
of	O	O
this	O	O
case	O	O
,	O	O
together	O	O
with	O	O
a	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
,	O	O
suggests	O	O
that	O	O
FBAL	B_Chemical	O
is	O	O
related	O	O
to	O	O
5-FU-induced	O	O
cardiotoxicity	B_Disease	B_Disease
.	O	O

S-1	O	O
may	O	O
be	O	O
administered	O	O
safely	O	O
to	O	O
patients	O	O
with	O	O
5-FU-induced	O	O
cardiotoxicity	B_Disease	B_Disease
.	O	O

Hepatocellular	B_Disease	B_Disease
carcinoma	I_Disease	I_Disease
in	O	O
Fanconi	B_Disease	O
's	I_Disease	O
anemia	I_Disease	O
treated	O	O
with	O	O
androgen	B_Chemical	O
and	O	O
corticosteroid	B_Chemical	O
.	O	O

The	O	O
case	O	O
of	O	O
an	O	O
11-year-old	O	O
boy	O	O
is	O	O
reported	O	O
who	O	O
was	O	O
known	O	O
to	O	O
have	O	O
Fanconi	B_Disease	O
's	I_Disease	O
anemia	I_Disease	O
for	O	O
3	O	O
years	O	O
and	O	O
was	O	O
treated	O	O
with	O	O
androgens	B_Chemical	O
,	O	O
corticosteroids	B_Chemical	O
and	O	O
transfusions	O	O
.	O	O

Two	O	O
weeks	O	O
before	O	O
his	O	O
death	O	O
he	O	O
was	O	O
readmitted	O	O
because	O	O
of	O	O
aplastic	O	B_Disease
crisis	O	O
with	O	O
septicemia	B_Disease	O
and	O	O
marked	O	O
abnormalities	O	O
in	O	O
liver	O	O
function	O	O
and	O	O
died	O	O
of	O	O
hemorrhagic	B_Disease	B_Disease
bronchopneumonia	I_Disease	I_Disease
.	O	O

At	O	O
autopsy	O	O
peliosis	B_Disease	O
and	O	O
multiple	O	O
hepatic	B_Disease	O
tumors	I_Disease	O
were	O	O
found	O	O
which	O	O
histologically	O	O
proved	O	O
to	O	O
be	O	O
well-differentiated	O	O
hepatocellular	B_Disease	B_Disease
carcinoma	I_Disease	I_Disease
.	O	O

This	O	O
case	O	O
contributes	O	O
to	O	O
the	O	O
previous	O	O
observations	O	O
that	O	O
non-metastasizing	O	O
hepatic	B_Disease	O
neoplasms	I_Disease	O
and	O	O
peliosis	B_Disease	O
can	O	O
develop	O	O
in	O	O
patients	O	O
with	O	O
androgen-	O	O
and	O	O
corticosteroid-treated	O	O
Fanconi	B_Disease	O
's	I_Disease	O
anemia	I_Disease	O
.	O	O

The	O	O
influence	O	O
of	O	O
the	O	O
time	O	O
interval	O	O
between	O	O
monoHER	B_Chemical	O
and	O	O
doxorubicin	B_Chemical	O
administration	O	O
on	O	O
the	O	O
protection	O	O
against	O	O
doxorubicin-induced	O	O
cardiotoxicity	B_Disease	B_Disease
in	O	O
mice	O	O
.	O	O

PURPOSE	O	O
:	O	O
Despite	O	O
its	O	O
well-known	O	O
cardiotoxicity	B_Disease	B_Disease
,	O	O
the	O	O
anthracyclin	O	B_Chemical
doxorubicin	B_Chemical	I_Chemical
(	O	O
DOX	B_Chemical	B_Chemical
)	O	O
continues	O	O
to	O	O
be	O	O
an	O	O
effective	O	O
and	O	O
widely	O	O
used	O	O
chemotherapeutic	O	O
agent	O	O
.	O	O

DOX-induced	O	O
cardiac	B_Disease	B_Disease
damage	I_Disease	I_Disease
presumably	O	O
results	O	O
from	O	O
the	O	O
formation	O	O
of	O	O
free	O	O
radicals	O	O
by	O	O
DOX	B_Chemical	B_Chemical
.	O	O

Reactive	O	O
oxygen	B_Chemical	O
species	O	O
particularly	O	O
affect	O	O
the	O	O
cardiac	O	O
myocytes	O	O
because	O	O
these	O	O
cells	O	O
seem	O	O
to	O	O
have	O	O
a	O	O
relatively	O	O
poor	O	O
antioxidant	O	O
defense	O	O
system	O	O
.	O	O

The	O	O
semisynthetic	O	O
flavonoid	B_Chemical	O
monohydroxyethylrutoside	B_Chemical	O
(	O	O
monoHER	B_Chemical	O
)	O	O
showed	O	O
cardioprotection	O	O
against	O	O
DOX-induced	O	O
cardiotoxicity	B_Disease	B_Disease
through	O	O
its	O	O
radical	O	O
scavenging	O	O
and	O	O
iron	B_Chemical	O
chelating	O	O
properties	O	O
.	O	O

Because	O	O
of	O	O
the	O	O
relatively	O	O
short	O	O
final	O	O
half-life	O	O
of	O	O
monoHER	B_Chemical	O
(	O	O
about	O	O
30	O	O
min	O	O
)	O	O
,	O	O
it	O	O
is	O	O
expected	O	O
that	O	O
the	O	O
time	O	O
interval	O	O
between	O	O
monoHER	B_Chemical	O
and	O	O
DOX	B_Chemical	B_Chemical
might	O	O
be	O	O
of	O	O
influence	O	O
on	O	O
the	O	O
cardioprotective	O	O
effect	O	O
of	O	O
monoHER	B_Chemical	O
.	O	O

Therefore	O	O
,	O	O
the	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
this	O	O
possible	O	O
effect	O	O
.	O	O

METHODS	O	O
:	O	O
Six	O	O
groups	O	O
of	O	O
6	O	O
BALB/c	O	O
mice	O	O
were	O	O
treated	O	O
with	O	O
saline	O	O
,	O	O
DOX	B_Chemical	B_Chemical
alone	O	O
or	O	O
DOX	B_Chemical	B_Chemical
(	O	O
4	O	O
mg/kg	O	O
i.v	O	O
.	O	O
)	O	O
preceded	O	O
by	O	O
monoHER	B_Chemical	O
(	O	O
500	O	O
mg/kg	O	O
i.p	O	O
.	O	O
)	O	O
with	O	O
an	O	O
interval	O	O
of	O	O
10	O	O
,	O	O
30	O	O
,	O	O
60	O	O
or	O	O
120	O	O
min	O	O
.	O	O

After	O	O
a	O	O
6-week	O	O
treatment	O	O
period	O	O
and	O	O
additional	O	O
observation	O	O
for	O	O
2	O	O
weeks	O	O
,	O	O
the	O	O
mice	O	O
were	O	O
sacrificed	O	O
.	O	O

Their	O	O
cardiac	O	O
tissues	O	O
were	O	O
processed	O	O
for	O	O
light	O	O
microscopy	O	O
,	O	O
after	O	O
which	O	O
cardiomyocyte	B_Disease	O
damage	I_Disease	O
was	O	O
evaluated	O	O
according	O	O
to	O	O
Billingham	O	O
(	O	O
in	O	O
Cancer	B_Disease	O
Treat	O	O
Rep	O	O
62(6):865	O	O
-	O	O
872	O	O
,	O	O
1978	O	O
)	O	O
.	O	O

Microscopic	O	O
evaluation	O	O
revealed	O	O
that	O	O
treatment	O	O
with	O	O
DOX	B_Chemical	B_Chemical
alone	O	O
induced	O	O
significant	O	O
cardiac	B_Disease	B_Disease
damage	I_Disease	I_Disease
in	O	O
comparison	O	O
to	O	O
the	O	O
saline	O	O
control	O	O
group	O	O
(	O	O
P<0.001	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
number	O	O
of	O	O
damaged	O	O
cardiomyocytes	O	O
was	O	O
9.6-fold	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
4.4	O	O
-	O	O
21.0	O	O
)	O	O
higher	O	O
in	O	O
mice	O	O
treated	O	O
with	O	O
DOX	B_Chemical	B_Chemical
alone	O	O
than	O	O
that	O	O
in	O	O
animals	O	O
of	O	O
the	O	O
control	O	O
group	O	O
.	O	O

The	O	O
ratio	O	O
of	O	O
aberrant	O	O
cardiomyocytes	O	O
in	O	O
mice	O	O
treated	O	O
with	O	O
DOX	B_Chemical	O
preceded	O	O
by	O	O
monoHER	B_Chemical	O
and	O	O
those	O	O
in	O	O
mice	O	O
treated	O	O
with	O	O
saline	O	O
ranged	O	O
from	O	O
1.6	O	O
to	O	O
2.8	O	O
(	O	O
mean	O	O
2.2	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
1.2	O	O
-	O	O
4.1	O	O
,	O	O
P=0.019	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
protective	O	O
effect	O	O
by	O	O
adding	O	O
monoHER	B_Chemical	O
before	O	O
DOX	B_Chemical	O
led	O	O
to	O	O
a	O	O
significant	O	O
4.4-fold	O	O
reduction	O	O
(	O	O
P<0.001	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
2.3	O	O
-	O	O
8.2	O	O
)	O	O
of	O	O
abnormal	O	O
cardiomyocytes	O	B_Disease
.	O	O

This	O	O
protective	O	O
effect	O	O
did	O	O
not	O	O
depend	O	O
on	O	O
the	O	O
time	O	O
interval	O	O
between	O	O
monoHER	B_Chemical	O
and	O	O
DOX	B_Chemical	O
administration	O	O
(	O	O
P=0.345	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
results	O	O
indicate	O	O
that	O	O
in	O	O
an	O	O
outpatient	O	O
clinical	O	O
setting	O	O
monoHER	B_Chemical	O
may	O	O
be	O	O
administered	O	O
shortly	O	O
before	O	O
DOX	B_Chemical	O
.	O	O

Clinical	O	O
evaluation	O	O
of	O	O
adverse	O	O
effects	O	O
during	O	O
bepridil	B_Chemical	B_Chemical
administration	O	O
for	O	O
atrial	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
and	I_Disease	O
flutter	I_Disease	O
.	O	O

BACKGROUND	O	O
:	O	O
Bepridil	B_Chemical	B_Chemical
hydrochloride	I_Chemical	I_Chemical
(	O	O
Bpd	B_Chemical	O
)	O	O
has	O	O
attracted	O	O
attention	O	O
as	O	O
an	O	O
effective	O	O
drug	O	O
for	O	O
atrial	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
(	O	O
AF	B_Disease	O
)	O	O
and	O	O
atrial	B_Disease	O
flutter	I_Disease	O
(	O	O
AFL	B_Disease	O
)	O	O
.	O	O

However	O	O
,	O	O
serious	O	O
adverse	O	O
effects	O	O
,	O	O
including	O	O
torsade	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
(	O	O
Tdp	B_Disease	O
)	O	O
,	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
Adverse	O	O
effects	O	O
of	O	O
Bpd	B_Chemical	O
requiring	O	O
discontinuation	O	O
of	O	O
treatment	O	O
were	O	O
evaluated	O	O
.	O	O

Bpd	B_Chemical	O
was	O	O
administered	O	O
to	O	O
459	O	O
patients	O	O
(	O	O
361	O	O
males	O	O
,	O	O
63+/-12	O	O
years	O	O
old	O	O
)	O	O
comprising	O	O
378	O	O
AF	B_Disease	O
and	O	O
81	O	O
AFL	B_Disease	O
cases	O	O
.	O	O

Mean	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
and	O	O
atrial	O	O
dimension	O	O
(	O	O
LAD	O	O
)	O	O
were	O	O
66+/-11	O	O
%	O	O
and	O	O
40+/-6	O	O
mm	O	O
,	O	O
respectively	O	O
.	O	O

Adverse	O	O
effects	O	O
were	O	O
observed	O	O
in	O	O
19	O	O
patients	O	O
(	O	O
4	O	O
%	O	O
)	O	O
during	O	O
an	O	O
average	O	O
follow-up	O	O
of	O	O
20	O	O
months	O	O
.	O	O

There	O	O
was	O	O
marked	O	O
QT	B_Disease	O
prolongation	I_Disease	O
greater	O	O
than	O	O
0.55	O	O
s	O	O
in	O	O
13	O	O
patients	O	O
,	O	O
bradycardia	B_Disease	O
less	O	O
than	O	O
40	O	O
beats/min	O	O
in	O	O
6	O	O
patients	O	O
,	O	O
dizziness	B_Disease	O
and	O	O
general	O	O
fatigue	B_Disease	O
in	O	O
1	O	O
patient	O	O
each	O	O
.	O	O

In	O	O
4	O	O
of	O	O
13	O	O
patients	O	O
with	O	O
QT	B_Disease	O
prolongation	I_Disease	O
,	O	O
Tdp	B_Disease	O
occurred	O	O
.	O	O

The	O	O
major	O	O
triggering	O	O
factors	O	O
of	O	O
Tdp	B_Disease	O
were	O	O
hypokalemia	B_Disease	O
and	O	O
sudden	O	O
decrease	O	O
in	O	O
heart	O	O
rate	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
the	O	O
clinical	O	O
backgrounds	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
and	O	O
without	O	O
Tdp	B_Disease	O
other	O	O
than	O	O
LAD	O	O
and	O	O
age	O	O
,	O	O
which	O	O
were	O	O
larger	O	O
and	O	O
older	O	O
in	O	O
the	O	O
patients	O	O
with	O	O
Tdp	B_Disease	O
.	O	O

CONCLUSION	O	O
:	O	O
Careful	O	O
observation	O	O
of	O	O
serum	O	O
potassium	B_Chemical	O
concentration	O	O
and	O	O
the	O	O
ECG	O	O
should	O	O
always	O	O
be	O	O
done	O	O
during	O	O
Bpd	B_Chemical	O
administration	O	O
,	O	O
particularly	O	O
in	O	O
elderly	O	O
patients	O	O
.	O	O

Enhanced	O	O
isoproterenol-induced	O	O
cardiac	B_Disease	B_Disease
hypertrophy	I_Disease	I_Disease
in	O	O
transgenic	O	O
rats	O	O
with	O	O
low	O	O
brain	O	O
angiotensinogen	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
shown	O	O
that	O	O
a	O	O
permanent	O	O
deficiency	O	O
in	O	O
the	O	O
brain	O	O
renin-angiotensin	O	B_Chemical
system	O	O
(	O	O
RAS	O	O
)	O	O
may	O	O
increase	O	O
the	O	O
sensitivity	O	O
of	O	O
the	O	O
baroreflex	O	O
control	O	O
of	O	O
heart	O	O
rate	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
aimed	O	O
at	O	O
studying	O	O
the	O	O
involvement	O	O
of	O	O
the	O	O
brain	O	O
RAS	O	O
in	O	O
the	O	O
cardiac	O	O
reactivity	O	O
to	O	O
the	O	O
beta-adrenoceptor	O	O
(	O	O
beta-AR	O	O
)	O	O
agonist	O	O
isoproterenol	B_Chemical	O
(	O	O
Iso	B_Chemical	O
)	O	O
.	O	O

Transgenic	O	O
rats	O	O
with	O	O
low	O	O
brain	O	O
angiotensinogen	O	O
(	O	O
TGR	O	O
)	O	O
were	O	O
used	O	O
.	O	O

In	O	O
isolated	O	O
hearts	O	O
,	O	O
Iso	B_Chemical	O
induced	O	O
a	O	O
significantly	O	O
greater	O	O
increase	O	O
in	O	O
left	O	O
ventricular	O	O
(	O	O
LV	O	O
)	O	O
pressure	O	O
and	O	O
maximal	O	O
contraction	O	O
(	O	O
+	O	O
dP/dt(max	O	O
)	O	O
)	O	O
in	O	O
the	O	O
TGR	O	O
than	O	O
in	O	O
the	O	O
Sprague-Dawley	O	O
(	O	O
SD	O	O
)	O	O
rats	O	O
.	O	O

LV	B_Disease	O
hypertrophy	I_Disease	O
induced	O	O
by	O	O
Iso	B_Chemical	O
treatment	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
TGR	O	O
than	O	O
in	O	O
SD	O	O
rats	O	O
(	O	O
in	O	O
g	O	O
LV	O	O
wt/100	O	O
g	O	O
body	O	O
wt	O	O
,	O	O
0.28	O	O
+	O	O
/-	O	O
0.004	O	O
vs.	O	O
0.24	O	O
+	O	O
/-	O	O
0.004	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
greater	O	O
LV	B_Disease	O
hypertrophy	I_Disease	O
in	O	O
TGR	O	O
rats	O	O
was	O	O
associated	O	O
with	O	O
more	O	O
pronounced	O	O
downregulation	O	O
of	O	O
beta-AR	O	O
and	O	O
upregulation	O	O
of	O	O
LV	O	O
beta-AR	O	O
kinase-1	O	O
mRNA	O	O
levels	O	O
compared	O	O
with	O	O
those	O	O
in	O	O
SD	O	O
rats	O	O
.	O	O

The	O	O
decrease	O	O
in	O	O
the	O	O
heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
induced	O	O
by	O	O
the	O	O
beta-AR	O	O
antagonist	O	O
metoprolol	B_Chemical	O
in	O	O
conscious	O	O
rats	O	O
was	O	O
significantly	O	O
attenuated	O	O
in	O	O
TGR	O	O
compared	O	O
with	O	O
SD	O	O
rats	O	O
(	O	O
-9.9	O	O
+	O	O
/-	O	O
1.7	O	O
%	O	O
vs.	O	O
-18.1	O	O
+	O	O
/-	O	O
1.5	O	O
%	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
effect	O	O
of	O	O
parasympathetic	O	O
blockade	O	O
by	O	O
atropine	B_Chemical	O
on	O	O
HR	O	O
was	O	O
similar	O	O
in	O	O
both	O	O
strains	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
TGR	O	O
are	O	O
more	O	O
sensitive	O	O
to	O	O
beta-AR	O	O
agonist-induced	O	O
cardiac	B_Disease	O
inotropic	I_Disease	O
response	O	O
and	O	O
hypertrophy	B_Disease	O
,	O	O
possibly	O	O
due	O	O
to	O	O
chronically	O	O
low	O	O
sympathetic	O	O
outflow	O	O
directed	O	O
to	O	O
the	O	O
heart	O	O
.	O	O

Drug-induced	O	O
long	B_Disease	O
QT	I_Disease	O
syndrome	I_Disease	O
in	O	O
injection	O	O
drug	O	O
users	O	O
receiving	O	O
methadone	B_Chemical	O
:	O	O
high	O	O
frequency	O	O
in	O	O
hospitalized	O	O
patients	O	O
and	O	O
risk	O	O
factors	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Drug-induced	O	O
long	B_Disease	O
QT	I_Disease	O
syndrome	I_Disease	O
is	O	O
a	O	O
serious	O	O
adverse	O	O
drug	O	O
reaction	O	O
.	O	O

Methadone	B_Chemical	O
prolongs	O	O
the	O	O
QT	O	O
interval	O	O
in	O	O
vitro	O	O
in	O	O
a	O	O
dose-dependent	O	O
manner	O	O
.	O	O

In	O	O
the	O	O
inpatient	O	O
setting	O	O
,	O	O
the	O	O
frequency	O	O
of	O	O
QT	B_Disease	O
interval	I_Disease	O
prolongation	I_Disease	O
with	O	O
methadone	B_Chemical	O
treatment	O	O
,	O	O
its	O	O
dose	O	O
dependence	O	O
,	O	O
and	O	O
the	O	O
importance	O	O
of	O	O
cofactors	O	O
such	O	O
as	O	O
drug-drug	O	O
interactions	O	O
remain	O	O
unknown	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
performed	O	O
a	O	O
systematic	O	O
,	O	O
retrospective	O	O
study	O	O
comparing	O	O
active	O	O
or	O	O
former	O	O
intravenous	O	O
drug	O	O
users	O	O
receiving	O	O
methadone	B_Chemical	O
and	O	O
those	O	O
not	O	O
receiving	O	O
methadone	B_Chemical	O
among	O	O
all	O	O
patients	O	O
hospitalized	O	O
over	O	O
a	O	O
5-year	O	O
period	O	O
in	O	O
a	O	O
tertiary	O	O
care	O	O
hospital	O	O
.	O	O

A	O	O
total	O	O
of	O	O
167	O	O
patients	O	O
receiving	O	O
methadone	B_Chemical	O
fulfilled	O	O
the	O	O
inclusion	O	O
criteria	O	O
and	O	O
were	O	O
compared	O	O
with	O	O
a	O	O
control	O	O
group	O	O
of	O	O
80	O	O
injection	O	O
drug	O	O
users	O	O
not	O	O
receiving	O	O
methadone	B_Chemical	O
.	O	O

In	O	O
addition	O	O
to	O	O
methadone	B_Chemical	O
dose	O	O
,	O	O
15	O	O
demographic	O	O
,	O	O
biological	O	O
,	O	O
and	O	O
pharmacological	O	O
variables	O	O
were	O	O
considered	O	O
as	O	O
potential	O	O
risk	O	O
factors	O	O
for	O	O
QT	B_Disease	O
prolongation	I_Disease	O
.	O	O

RESULTS	O	O
:	O	O
Among	O	O
167	O	O
methadone	B_Chemical	O
maintenance	O	O
patients	O	O
,	O	O
the	O	O
prevalence	O	O
of	O	O
QTc	O	O
prolongation	O	O
to	O	O
0.50	O	O
second((1/2	O	O
)	O	O
)	O	O
or	O	O
longer	O	O
was	O	O
16.2	O	O
%	O	O
compared	O	O
with	O	O
0	O	O
%	O	O
in	O	O
80	O	O
control	O	O
subjects	O	O
.	O	O

Six	O	O
patients	O	O
(	O	O
3.6	O	O
%	O	O
)	O	O
in	O	O
the	O	O
methadone	B_Chemical	O
group	O	O
presented	O	O
torsades	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
.	O	O

QTc	O	O
length	O	O
was	O	O
weakly	O	O
but	O	O
significantly	O	O
associated	O	O
with	O	O
methadone	B_Chemical	O
daily	O	O
dose	O	O
(	O	O
Spearman	O	O
rank	O	O
correlation	O	O
coefficient	O	O
,	O	O
0.20	O	O
;	O	O
P<.01	O	O
)	O	O
.	O	O

Multivariate	O	O
regression	O	O
analysis	O	O
allowed	O	O
attribution	O	O
of	O	O
31.8	O	O
%	O	O
of	O	O
QTc	O	O
variability	O	O
to	O	O
methadone	B_Chemical	O
dose	O	O
,	O	O
cytochrome	O	O
P-450	O	O
3A4	O	O
drug-drug	O	O
interactions	O	O
,	O	O
hypokalemia	B_Disease	O
,	O	O
and	O	O
altered	O	O
liver	O	O
function	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
QT	B_Disease	O
interval	I_Disease	O
prolongation	I_Disease	O
in	O	O
methadone	B_Chemical	O
maintenance	O	O
patients	O	O
hospitalized	O	O
in	O	O
a	O	O
tertiary	O	O
care	O	O
center	O	O
is	O	O
a	O	O
frequent	O	O
finding	O	O
.	O	O

Methadone	B_Chemical	O
dose	O	O
,	O	O
presence	O	O
of	O	O
cytochrome	O	O
P-450	O	O
3A4	O	O
inhibitors	O	O
,	O	O
potassium	B_Chemical	O
level	O	O
,	O	O
and	O	O
liver	O	O
function	O	O
contribute	O	O
to	O	O
QT	B_Disease	O
prolongation	I_Disease	O
.	O	O

Long	B_Disease	O
QT	I_Disease	O
syndrome	I_Disease	O
can	O	O
occur	O	O
with	O	O
low	O	O
doses	O	O
of	O	O
methadone	B_Chemical	O
.	O	O

Mechanisms	O	O
of	O	O
hypertension	B_Disease	O
induced	O	O
by	O	O
nitric	B_Chemical	O
oxide	I_Chemical	O
(	O	O
NO	B_Chemical	O
)	O	O
deficiency	O	O
:	O	O
focus	O	O
on	O	O
venous	O	O
function	O	O
.	O	O

Loss	O	O
of	O	O
endothelial	O	O
cell-derived	O	O
nitric	B_Chemical	O
oxide	I_Chemical	O
(	O	O
NO	B_Chemical	O
)	O	O
in	O	O
hypertension	B_Disease	O
is	O	O
a	O	O
hallmark	O	O
of	O	O
arterial	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
.	O	O

Experimental	O	O
hypertension	B_Disease	O
created	O	O
by	O	O
the	O	O
removal	O	O
of	O	O
NO	B_Chemical	O
,	O	O
however	O	O
,	O	O
involves	O	O
mechanisms	O	O
in	O	O
addition	O	O
to	O	O
decreased	O	O
arterial	O	O
vasodilator	O	O
activity	O	O
.	O	O

These	O	O
include	O	O
augmented	O	O
endothelin-1	O	O
(	O	O
ET-1	O	O
)	O	O
release	O	O
,	O	O
increased	O	O
sympathetic	O	O
nervous	O	O
system	O	O
activity	O	O
,	O	O
and	O	O
elevated	O	O
tissue	O	O
oxidative	O	O
stress	O	O
.	O	O

We	O	O
hypothesized	O	O
that	O	O
increased	O	O
venous	O	O
smooth	O	O
muscle	O	O
(	O	O
venomotor	O	O
)	O	O
tone	O	O
plays	O	O
a	O	O
role	O	O
in	O	O
Nomega-nitro-L-arginine	B_Chemical	O
(	O	O
LNNA	B_Chemical	O
)	O	O
hypertension	B_Disease	O
through	O	O
these	O	O
mechanisms	O	O
.	O	O

Rats	O	O
were	O	O
treated	O	O
with	O	O
the	O	O
NO	B_Chemical	O
synthase	O	O
inhibitor	O	O
LNNA	B_Chemical	B_Chemical
(	O	O
0.5	O	O
g/L	O	O
in	O	O
drinking	O	O
water	O	O
)	O	O
for	O	O
2	O	O
weeks	O	O
.	O	O

Mean	O	O
arterial	O	O
pressure	O	O
of	O	O
conscious	O	O
rats	O	O
was	O	O
119	O	O
+	O	O
/-	O	O
2	O	O
mm	O	O
Hg	O	O
in	O	O
control	O	O
and	O	O
194	O	O
+	O	O
/-	O	O
5	O	O
mm	O	O
Hg	O	O
in	O	O
LNNA	B_Chemical	O
rats	O	O
(	O	O
P<0.05	O	O
)	O	O
.	O	O

Carotid	O	O
arteries	O	O
and	O	O
vena	O	O
cava	O	O
were	O	O
removed	O	O
for	O	O
measurement	O	O
of	O	O
isometric	O	O
contraction	O	O
.	O	O

Maximal	O	O
contraction	O	O
to	O	O
norepinephrine	B_Chemical	O
was	O	O
modestly	O	O
reduced	O	O
in	O	O
arteries	O	O
from	O	O
LNNA	B_Chemical	O
compared	O	O
with	O	O
control	O	O
rats	O	O
whereas	O	O
the	O	O
maximum	O	O
contraction	O	O
to	O	O
ET-1	O	O
was	O	O
significantly	O	O
reduced	O	O
(	O	O
54	O	O
%	O	O
control	O	O
)	O	O
.	O	O

Maximum	O	O
contraction	O	O
of	O	O
vena	O	O
cava	O	O
to	O	O
norepinephrine	B_Chemical	O
(	O	O
37	O	O
%	O	O
control	O	O
)	O	O
also	O	O
was	O	O
reduced	O	O
but	O	O
no	O	O
change	O	O
in	O	O
response	O	O
to	O	O
ET-1	O	O
was	O	O
observed	O	O
.	O	O

Mean	O	O
circulatory	O	O
filling	O	O
pressure	O	O
,	O	O
an	O	O
in	O	O
vivo	O	O
measure	O	O
of	O	O
venomotor	O	O
tone	O	O
,	O	O
was	O	O
not	O	O
elevated	O	O
in	O	O
LNNA	B_Chemical	O
hypertension	B_Disease	O
at	O	O
1	O	O
or	O	O
2	O	O
weeks	O	O
after	O	O
LNNA	B_Chemical	O
.	O	O

The	O	O
superoxide	B_Chemical	O
scavenger	O	O
tempol	B_Chemical	O
(	O	O
30	O	O
,	O	O
100	O	O
,	O	O
and	O	O
300	O	O
micromol	O	O
kg(-1	O	O
)	O	O
,	O	O
IV	O	O
)	O	O
did	O	O
not	O	O
change	O	O
arterial	O	O
pressure	O	O
in	O	O
control	O	O
rats	O	O
but	O	O
caused	O	O
a	O	O
dose-dependent	O	O
decrease	O	O
in	O	O
LNNA	B_Chemical	O
rats	O	O
(	O	O
-18	O	O
+	O	O
/-	O	O
8	O	O
,	O	O
-26	O	O
+	O	O
/-	O	O
15	O	O
,	O	O
and	O	O
-54	O	O
+	O	O
/-	O	O
11	O	O
mm	O	O
Hg	O	O
)	O	O
.	O	O

Similarly	O	O
,	O	O
ganglionic	O	O
blockade	O	O
with	O	O
hexamethonium	B_Chemical	B_Chemical
caused	O	O
a	O	O
significantly	O	O
greater	O	O
fall	O	O
in	O	O
LNNA	B_Chemical	O
hypertensive	B_Disease	O
rats	O	O
(	O	O
76	O	O
+	O	O
/-	O	O
9	O	O
mm	O	O
Hg	O	O
)	O	O
compared	O	O
with	O	O
control	O	O
rats	O	O
(	O	O
35	O	O
+	O	O
/-	O	O
10	O	O
mm	O	O
Hg	O	O
)	O	O
.	O	O

Carotid	O	O
arteries	O	O
,	O	O
vena	O	O
cava	O	O
,	O	O
and	O	O
sympathetic	O	O
ganglia	O	O
from	O	O
LNNA	B_Chemical	O
rats	O	O
had	O	O
higher	O	O
basal	O	O
levels	O	O
of	O	O
superoxide	B_Chemical	O
compared	O	O
with	O	O
those	O	O
from	O	O
control	O	O
rats	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
while	O	O
NO	B_Chemical	O
deficiency	O	O
increases	O	O
oxidative	O	O
stress	O	O
and	O	O
sympathetic	O	O
activity	O	O
in	O	O
both	O	O
arterial	O	O
and	O	O
venous	O	O
vessels	O	O
,	O	O
the	O	O
impact	O	O
on	O	O
veins	O	O
does	O	O
not	O	O
make	O	O
a	O	O
major	O	O
contribution	O	O
to	O	O
this	O	O
form	O	O
of	O	O
hypertension	B_Disease	O
.	O	O

Association	O	O
of	O	O
DRD2	O	O
polymorphisms	O	O
and	O	O
chlorpromazine-induced	O	O
extrapyramidal	B_Disease	B_Disease
syndrome	I_Disease	I_Disease
in	O	O
Chinese	O	O
schizophrenic	B_Disease	O
patients	O	O
.	O	O

AIM	O	O
:	O	O
Extrapyramidal	B_Disease	B_Disease
syndrome	I_Disease	I_Disease
(	O	O
EPS	B_Disease	O
)	O	O
is	O	O
most	O	O
commonly	O	O
affected	O	O
by	O	O
typical	O	O
antipsychotic	O	O
drugs	O	O
that	O	O
have	O	O
a	O	O
high	O	O
affinity	O	O
with	O	O
the	O	O
D2	O	O
receptor	O	O
.	O	O

Recently	O	O
,	O	O
many	O	O
research	O	O
groups	O	O
have	O	O
reported	O	O
on	O	O
the	O	O
positive	O	O
relationship	O	O
between	O	O
the	O	O
genetic	O	O
variations	O	O
in	O	O
the	O	O
DRD2	O	O
gene	O	O
and	O	O
the	O	O
therapeutic	O	O
response	O	O
in	O	O
schizophrenia	B_Disease	O
patients	O	O
as	O	O
a	O	O
result	O	O
of	O	O
the	O	O
role	O	O
of	O	O
variations	O	O
in	O	O
the	O	O
receptor	O	O
in	O	O
modulating	O	O
receptor	O	O
expression	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
evaluate	O	O
the	O	O
role	O	O
DRD2	O	O
plays	O	O
in	O	O
chlorpromazine-induced	O	O
EPS	B_Disease	O
in	O	O
schizophrenic	B_Disease	O
patients	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
identified	O	O
seven	O	O
SNP(single	O	O
nucleotide	O	O
polymorphism	O	O
)	O	O
(	O	O
-141Cins	O	O
>	O	O
del	O	O
,	O	O
TaqIB	O	O
,	O	O
TaqID	O	O
,	O	O
Ser311Cys	O	O
,	O	O
rs6275	O	O
,	O	O
rs6277	O	O
and	O	O
TaqIA	O	O
)	O	O
in	O	O
the	O	O
DRD2	O	O
gene	O	O
in	O	O
146	O	O
schizophrenic	B_Disease	O
inpatients	O	O
(	O	O
59	O	O
with	O	O
EPS	B_Disease	O
and	O	O
87	O	O
without	O	O
EPS	B_Disease	O
according	O	O
to	O	O
the	O	O
Simpson-Angus	O	O
Scale	O	O
)	O	O
treated	O	O
with	O	O
chlorpromazine	B_Chemical	O
after	O	O
8	O	O
weeks	O	O
.	O	O

The	O	O
alleles	O	O
of	O	O
all	O	O
loci	O	O
were	O	O
determined	O	O
by	O	O
PCR	O	O
(	O	O
polymerase	O	O
chain	O	O
reaction	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Polymorphisms	O	O
TaqID	O	O
,	O	O
Ser311Cys	O	O
and	O	O
rs6277	O	O
were	O	O
not	O	O
polymorphic	O	O
in	O	O
the	O	O
population	O	O
recruited	O	O
in	O	O
the	O	O
present	O	O
study	O	O
.	O	O

No	O	O
statistical	O	O
significance	O	O
was	O	O
found	O	O
in	O	O
the	O	O
allele	O	O
distribution	O	O
of	O	O
-141Cins	O	O
>	O	O
del	O	O
,	O	O
TaqIB	O	O
,	O	O
rs6275	O	O
and	O	O
TaqIA	O	O
or	O	O
in	O	O
the	O	O
estimated	O	O
haplotypes	O	O
(	O	O
constituted	O	O
by	O	O
TaqIB	O	O
,	O	O
rs6275	O	O
and	O	O
TaqIA	O	O
)	O	O
in	O	O
linkage	O	O
disequilibrium	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Our	O	O
results	O	O
did	O	O
not	O	O
lend	O	O
strong	O	O
support	O	O
to	O	O
the	O	O
view	O	O
that	O	O
the	O	O
genetic	O	O
variation	O	O
of	O	O
the	O	O
DRD2	O	O
gene	O	O
plays	O	O
a	O	O
major	O	O
role	O	O
in	O	O
the	O	O
individually	O	O
variable	O	O
adverse	O	O
effect	O	O
induced	O	O
by	O	O
chlorpromazine	B_Chemical	O
,	O	O
at	O	O
least	O	O
in	O	O
Chinese	O	O
patients	O	O
with	O	O
schizophrenia	B_Disease	O
.	O	O

Our	O	O
results	O	O
confirmed	O	O
a	O	O
previous	O	O
study	O	O
on	O	O
the	O	O
relationship	O	O
between	O	O
DRD2	O	O
and	O	O
EPS	B_Disease	O
in	O	O
Caucasians	O	O
.	O	O

Physical	O	O
training	O	O
decreases	O	O
susceptibility	O	O
to	O	O
subsequent	O	O
pilocarpine-induced	O	O
seizures	B_Disease	O
in	O	O
the	O	O
rat	O	O
.	O	O

Regular	O	O
motor	O	O
activity	O	O
has	O	O
many	O	O
benefits	O	O
for	O	O
mental	O	O
and	O	O
physical	O	O
condition	O	O
but	O	O
its	O	O
implications	O	O
for	O	O
epilepsy	B_Disease	O
are	O	O
still	O	O
controversial	O	O
.	O	O

In	O	O
order	O	O
to	O	O
elucidate	O	O
this	O	O
problem	O	O
,	O	O
we	O	O
have	O	O
studied	O	O
the	O	O
effect	O	O
of	O	O
long-term	O	O
physical	O	O
activity	O	O
on	O	O
susceptibility	O	O
to	O	O
subsequent	O	O
seizures	B_Disease	O
.	O	O

Male	O	O
Wistar	O	O
rats	O	O
were	O	O
subjected	O	O
to	O	O
repeated	O	O
training	O	O
sessions	O	O
in	O	O
a	O	O
treadmill	O	O
and	O	O
swimming	O	O
pool	O	O
.	O	O

Thereafter	O	O
,	O	O
seizures	B_Disease	O
were	O	O
induced	O	O
by	O	O
pilocarpine	B_Chemical	O
injections	O	O
in	O	O
trained	O	O
and	O	O
non-trained	O	O
control	O	O
groups	O	O
.	O	O

During	O	O
the	O	O
acute	O	O
period	O	O
of	O	O
status	B_Disease	O
epilepticus	I_Disease	O
,	O	O
we	O	O
measured	O	O
:	O	O
(	O	O
1	O	O
)	O	O
the	O	O
latency	O	O
of	O	O
the	O	O
first	O	O
motor	O	O
sign	O	O
,	O	O
(	O	O
2	O	O
)	O	O
the	O	O
intensity	O	O
of	O	O
seizures	B_Disease	O
,	O	O
(	O	O
3	O	O
)	O	O
the	O	O
time	O	O
when	O	O
it	O	O
occurred	O	O
within	O	O
the	O	O
6-h	O	O
observation	O	O
period	O	O
,	O	O
and	O	O
(	O	O
4	O	O
)	O	O
the	O	O
time	O	O
when	O	O
the	O	O
acute	O	O
period	O	O
ended	O	O
.	O	O

All	O	O
these	O	O
behavioral	O	O
parameters	O	O
showed	O	O
statistically	O	O
significant	O	O
changes	O	O
suggesting	O	O
that	O	O
regular	O	O
physical	O	O
exercises	O	O
decrease	O	O
susceptibility	O	O
to	O	O
subsequently	O	O
induced	O	O
seizures	B_Disease	O
and	O	O
ameliorate	O	O
the	O	O
course	O	O
of	O	O
experimentally	O	O
induced	O	O
status	B_Disease	O
epilepticus	I_Disease	O
.	O	O

Tonic	O	O
dopaminergic	O	O
stimulation	O	O
impairs	O	O
associative	O	O
learning	O	O
in	O	O
healthy	O	O
subjects	O	O
.	O	O

Endogenous	O	O
dopamine	B_Chemical	O
plays	O	O
a	O	O
central	O	O
role	O	O
in	O	O
salience	O	O
coding	O	O
during	O	O
associative	O	O
learning	O	O
.	O	O

Administration	O	O
of	O	O
the	O	O
dopamine	B_Chemical	O
precursor	O	O
levodopa	B_Chemical	O
enhances	O	O
learning	O	O
in	O	O
healthy	O	O
subjects	O	O
and	O	O
stroke	B_Disease	O
patients	O	O
.	O	O

Because	O	O
levodopa	B_Chemical	O
increases	O	O
both	O	O
phasic	O	O
and	O	O
tonic	O	O
dopaminergic	O	O
neurotransmission	O	O
,	O	O
the	O	O
critical	O	O
mechanism	O	O
mediating	O	O
the	O	O
enhancement	O	O
of	O	O
learning	O	O
is	O	O
unresolved	O	O
.	O	O

We	O	O
here	O	O
probed	O	O
how	O	O
selective	O	O
tonic	O	O
dopaminergic	O	O
stimulation	O	O
affects	O	O
associative	O	O
learning	O	O
.	O	O

Forty	O	O
healthy	O	O
subjects	O	O
were	O	O
trained	O	O
in	O	O
a	O	O
novel	O	O
vocabulary	O	O
of	O	O
45	O	O
concrete	O	O
nouns	O	O
over	O	O
the	O	O
course	O	O
of	O	O
5	O	O
consecutive	O	O
training	O	O
days	O	O
in	O	O
a	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
design	O	O
.	O	O

Subjects	O	O
received	O	O
the	O	O
tonically	O	O
stimulating	O	O
dopamine-receptor	O	O
agonist	O	O
pergolide	B_Chemical	B_Chemical
(	O	O
0.1	O	O
mg	O	O
)	O	O
vs	O	O
placebo	O	O
120	O	O
min	O	O
before	O	O
training	O	O
on	O	O
each	O	O
training	O	O
day	O	O
.	O	O

The	O	O
dopamine	B_Chemical	O
agonist	O	O
significantly	O	O
impaired	B_Disease	O
novel	I_Disease	O
word	I_Disease	O
learning	I_Disease	O
compared	O	O
to	O	O
placebo	O	O
.	O	O

This	O	O
learning	O	O
decrement	O	O
persisted	O	O
up	O	O
to	O	O
the	O	O
last	O	O
follow-up	O	O
4	O	O
weeks	O	O
post-training	O	O
.	O	O

Subjects	O	O
treated	O	O
with	O	O
pergolide	B_Chemical	B_Chemical
also	O	O
showed	O	O
restricted	O	O
emotional	O	O
responses	O	O
compared	O	O
to	O	O
the	O	O
PLACEBO	O	O
group	O	O
.	O	O

The	O	O
extent	O	O
of	O	O
'	O	O
flattened	O	O
'	O	O
affect	O	O
with	O	O
pergolide	B_Chemical	B_Chemical
was	O	O
related	O	O
to	O	O
the	O	O
degree	O	O
of	O	O
learning	O	O
inhibition	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
tonic	O	O
occupation	O	O
of	O	O
dopamine	B_Chemical	O
receptors	O	O
impairs	O	O
learning	O	O
by	O	O
competition	O	O
with	O	O
phasic	O	O
dopamine	B_Chemical	O
signals	O	O
.	O	O

Thus	O	O
,	O	O
phasic	O	O
signaling	O	O
seems	O	O
to	O	O
be	O	O
the	O	O
critical	O	O
mechanism	O	O
by	O	O
which	O	O
dopamine	B_Chemical	O
enhances	O	O
associative	O	O
learning	O	O
in	O	O
healthy	O	O
subjects	O	O
and	O	O
stroke	B_Disease	O
patients	O	O
.	O	O

Minocycline-induced	O	O
vasculitis	B_Disease	O
fulfilling	O	O
the	O	O
criteria	O	O
of	O	O
polyarteritis	B_Disease	O
nodosa	I_Disease	O
.	O	O

A	O	O
47-year-old	O	O
man	O	O
who	O	O
had	O	O
been	O	O
taking	O	O
minocycline	B_Chemical	O
for	O	O
palmoplantar	B_Disease	O
pustulosis	I_Disease	O
developed	O	O
fever	B_Disease	O
,	O	O
myalgias	B_Disease	O
,	O	O
polyneuropathy	B_Disease	B_Disease
,	O	O
and	O	O
testicular	B_Disease	B_Disease
pain	I_Disease	I_Disease
,	O	O
with	O	O
elevated	O	O
C-reactive	O	O
protein	O	O
(	O	O
CRP	O	O
)	O	O
.	O	O

Neither	O	O
myeloperoxidase-	O	B_Chemical
nor	O	O
proteinase-3-antineutrophil	O	O
cytoplasmic	O	O
antibody	O	O
was	O	O
positive	O	O
.	O	O

These	O	O
manifestations	O	O
met	O	O
the	O	O
American	O	O
College	O	O
of	O	O
Rheumatology	O	O
1990	O	O
criteria	O	O
for	O	O
the	O	O
classification	O	O
of	O	O
polyarteritis	B_Disease	O
nodosa	I_Disease	O
.	O	O

Stopping	O	O
minocycline	B_Chemical	O
led	O	O
to	O	O
amelioration	O	O
of	O	O
symptoms	O	O
and	O	O
normalization	O	O
of	O	O
CRP	O	O
level	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
second	O	O
case	O	O
of	O	O
minocycline-induced	O	O
vasculitis	B_Disease	O
satisfying	O	O
the	O	O
criteria	O	O
.	O	O

Differential	O	O
diagnosis	O	O
for	O	O
drug-induced	O	O
disease	O	O
is	O	O
invaluable	O	O
even	O	O
for	O	O
patients	O	O
with	O	O
classical	O	O
polyarteritis	B_Disease	O
nodosa	I_Disease	O
.	O	O

Intramuscular	O	O
hepatitis	B_Disease	O
B	I_Disease	O
immune	O	O
globulin	O	O
combined	O	O
with	O	O
lamivudine	B_Chemical	O
in	O	O
prevention	O	O
of	O	O
hepatitis	B_Disease	O
B	I_Disease	O
recurrence	O	O
after	O	O
liver	O	O
transplantation	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Combined	O	O
hepatitis	B_Disease	O
B	I_Disease	O
immune	O	O
globulin	O	O
(	O	O
HBIg	O	O
)	O	O
and	O	O
lamivudine	B_Chemical	O
in	O	O
prophylaxis	O	O
of	O	O
the	O	O
recurrence	O	O
of	O	O
hepatitis	B_Disease	O
B	I_Disease	O
after	O	O
liver	O	O
transplantation	O	O
has	O	O
significantly	O	O
improved	O	O
the	O	O
survival	O	O
of	O	O
HBsAg	B_Chemical	O
positive	O	O
patients	O	O
.	O	O

This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
evaluate	O	O
the	O	O
outcomes	O	O
of	O	O
liver	O	O
transplantation	O	O
for	O	O
patients	O	O
with	O	O
hepatitis	B_Disease	O
B	I_Disease	O
virus	O	O
(	O	O
HBV	O	O
)	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
retrospective	O	O
chart	O	O
analysis	O	O
and	O	O
a	O	O
review	O	O
of	O	O
the	O	O
organ	O	O
transplant	O	O
database	O	O
identified	O	O
51	O	O
patients	O	O
(	O	O
43	O	O
men	O	O
and	O	O
8	O	O
women	O	O
)	O	O
transplanted	O	O
for	O	O
benign	O	O
HBV-related	O	O
cirrhotic	B_Disease	B_Disease
diseases	I_Disease	I_Disease
between	O	O
June	O	O
2002	O	O
and	O	O
December	O	O
2004	O	O
who	O	O
had	O	O
survived	O	O
more	O	O
than	O	O
3	O	O
months	O	O
.	O	O

HBIg	O	O
was	O	O
administered	O	O
intravenously	O	O
during	O	O
the	O	O
first	O	O
week	O	O
and	O	O
intramuscularly	O	O
thereafter	O	O
.	O	O

RESULTS	O	O
:	O	O
At	O	O
a	O	O
median	O	O
follow-up	O	O
of	O	O
14.1	O	O
months	O	O
,	O	O
the	O	O
overall	O	O
recurrence	O	O
rate	O	O
in	O	O
the	O	O
51	O	O
patients	O	O
was	O	O
3.9	O	O
%	O	O
(	O	O
2/51	O	O
)	O	O
.	O	O

The	O	O
overall	O	O
patient	O	O
survival	O	O
was	O	O
88.3	O	O
%	O	O
,	O	O
and	O	O
82.4	O	O
%	O	O
after	O	O
1	O	O
and	O	O
2	O	O
years	O	O
,	O	O
respectively	O	O
.	O	O

A	O	O
daily	O	O
oral	O	O
dose	O	O
of	O	O
100	O	O
mg	O	O
lamivudine	B_Chemical	O
for	O	O
2	O	O
weeks	O	O
before	O	O
transplantation	O	O
for	O	O
10	O	O
patients	O	O
enabled	O	O
57.1	O	O
%	O	O
(	O	O
4/7	O	O
)	O	O
and	O	O
62.5	O	O
%	O	O
(	O	O
5/8	O	O
)	O	O
of	O	O
HBV-DNA	O	O
and	O	O
HBeAg	B_Chemical	O
positive	O	O
patients	O	O
respectively	O	O
to	O	O
convert	O	O
to	O	O
be	O	O
negative	O	O
.	O	O

Intramuscular	O	O
HBIg	O	O
was	O	O
well	O	O
tolerated	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Lamivudine	B_Chemical	O
combined	O	O
with	O	O
intramuscular	O	O
HBIg	O	O
can	O	O
effectively	O	O
prevent	O	O
allograft	O	O
from	O	O
the	O	O
recurrence	O	O
of	O	O
HBV	O	O
after	O	O
liver	O	O
transplantation	O	O
.	O	O

Anticonvulsant	O	O
effect	O	O
of	O	O
eslicarbazepine	B_Chemical	B_Chemical
acetate	I_Chemical	I_Chemical
(	O	O
BIA	B_Chemical	O
2	I_Chemical	O
-	I_Chemical	O
093	I_Chemical	O
)	O	O
on	O	O
seizures	B_Disease	O
induced	O	O
by	O	O
microperfusion	O	O
of	O	O
picrotoxin	B_Chemical	B_Chemical
in	O	O
the	O	O
hippocampus	O	O
of	O	O
freely	O	O
moving	O	O
rats	O	O
.	O	O

Eslicarbazepine	B_Chemical	B_Chemical
acetate	I_Chemical	I_Chemical
(	O	O
BIA	B_Chemical	O
2	I_Chemical	O
-	I_Chemical	O
093	I_Chemical	O
,	O	O
S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b	B_Chemical	B_Chemical
,	I_Chemical	O
f/azepine-5-carboxamide	I_Chemical	B_Chemical
)	O	O
is	O	O
a	O	O
novel	O	O
antiepileptic	O	O
drug	O	O
,	O	O
now	O	O
in	O	O
Phase	O	O
III	O	O
clinical	O	O
trials	O	O
,	O	O
designed	O	O
with	O	O
the	O	O
aim	O	O
of	O	O
improving	O	O
efficacy	O	O
and	O	O
safety	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
structurally	O	O
related	O	O
drugs	O	O
carbamazepine	B_Chemical	B_Chemical
(	O	O
CBZ	B_Chemical	O
)	O	O
and	O	O
oxcarbazepine	B_Chemical	B_Chemical
(	O	O
OXC	B_Chemical	O
)	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
the	O	O
effects	O	O
of	O	O
oral	O	O
treatment	O	O
with	O	O
eslicarbazepine	B_Chemical	B_Chemical
acetate	I_Chemical	I_Chemical
on	O	O
a	O	O
whole-animal	O	O
model	O	O
in	O	O
which	O	O
partial	O	O
seizures	B_Disease	O
can	O	O
be	O	O
elicited	O	O
repeatedly	O	O
on	O	O
different	O	O
days	O	O
without	O	O
changes	O	O
in	O	O
threshold	O	O
or	O	O
seizure	B_Disease	O
patterns	O	O
.	O	O

In	O	O
the	O	O
animals	O	O
treated	O	O
with	O	O
threshold	O	O
doses	O	O
of	O	O
picrotoxin	B_Chemical	B_Chemical
,	O	O
the	O	O
average	O	O
number	O	O
of	O	O
seizures	B_Disease	O
was	O	O
2.3+/-1.2	O	O
,	O	O
and	O	O
average	O	O
seizure	B_Disease	O
duration	O	O
was	O	O
39.5+/-8.4s	O	O
.	O	O
Pre-treatment	O	O
with	O	O
a	O	O
dose	O	O
of	O	O
30	O	O
mg/kg	O	O
2h	O	O
before	O	O
picrotoxin	B_Chemical	B_Chemical
microperfusion	O	O
prevented	O	O
seizures	B_Disease	O
in	O	O
the	O	O
75	O	O
%	O	O
of	O	O
the	O	O
rats	O	O
.	O	O

Lower	O	O
doses	O	O
(	O	O
3	O	O
and	O	O
10mg/kg	O	O
)	O	O
did	O	O
not	O	O
suppress	O	O
seizures	B_Disease	O
,	O	O
however	O	O
,	O	O
after	O	O
administration	O	O
of	O	O
10mg/kg	O	O
,	O	O
significant	O	O
reductions	O	O
in	O	O
seizures	B_Disease	O
duration	O	O
(	O	O
24.3+/-6.8s	O	O
)	O	O
and	O	O
seizure	B_Disease	O
number	O	O
(	O	O
1.6+/-0.34	O	O
)	O	O
were	O	O
found	O	O
.	O	O

No	O	O
adverse	O	O
effects	O	O
of	O	O
eslicarbazepine	B_Chemical	B_Chemical
acetate	I_Chemical	I_Chemical
were	O	O
observed	O	O
in	O	O
the	O	O
behavioral/EEG	O	O
patterns	O	O
studied	O	O
,	O	O
including	O	O
sleep/wakefulness	O	O
cycle	O	O
,	O	O
at	O	O
the	O	O
doses	O	O
studied	O	O
.	O	O

Acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
associated	O	O
with	O	O
prolonged	O	O
intake	O	O
of	O	O
slimming	O	O
pills	O	O
containing	O	O
anthraquinones	B_Chemical	O
.	O	O

Chinese	B_Chemical	O
herbal	I_Chemical	O
medicine	O	O
preparations	O	O
are	O	O
widely	O	O
available	O	O
and	O	O
often	O	O
regarded	O	O
by	O	O
the	O	O
public	O	O
as	O	O
natural	O	O
and	O	O
safe	O	O
remedies	O	O
for	O	O
a	O	O
variety	O	O
of	O	O
medical	O	O
conditions	O	O
.	O	O

Nephropathy	B_Disease	O
caused	O	O
by	O	O
Chinese	B_Chemical	O
herbs	I_Chemical	O
has	O	O
previously	O	O
been	O	O
reported	O	O
,	O	O
usually	O	O
involving	O	O
the	O	O
use	O	O
of	O	O
aristolochic	B_Chemical	B_Chemical
acids	I_Chemical	I_Chemical
.	O	O

We	O	O
report	O	O
a	O	O
23-year-old	O	O
woman	O	O
who	O	O
developed	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
following	O	O
prolonged	O	O
use	O	O
of	O	O
a	O	O
proprietary	O	O
Chinese	B_Chemical	O
herbal	I_Chemical	O
slimming	O	O
pill	O	O
that	O	O
contained	O	O
anthraquinone	B_Chemical	B_Chemical
derivatives	O	O
,	O	O
extracted	O	O
from	O	O
Rhizoma	O	O
Rhei	O	O
(	O	O
rhubarb	O	O
)	O	O
.	O	O

The	O	O
renal	B_Disease	B_Disease
injury	I_Disease	I_Disease
was	O	O
probably	O	O
aggravated	O	O
by	O	O
the	O	O
concomitant	O	O
intake	O	O
of	O	O
a	O	O
non-steroidal	O	O
anti-inflammatory	O	O
drug	O	O
,	O	O
diclofenac	B_Chemical	B_Chemical
.	O	O

Renal	O	B_Disease
pathology	O	I_Disease
was	O	O
that	O	O
of	O	O
hypocellular	O	O
interstitial	O	B_Disease
fibrosis	B_Disease	I_Disease
.	O	O

Spontaneous	O	O
renal	O	O
recovery	O	O
occurred	O	O
upon	O	O
cessation	O	O
of	O	O
the	O	O
slimming	O	O
pills	O	O
,	O	O
but	O	O
mild	O	O
interstitial	O	B_Disease
fibrosis	B_Disease	I_Disease
and	O	O
tubular	O	B_Disease
atrophy	B_Disease	I_Disease
was	O	O
still	O	O
evident	O	O
histologically	O	O
4	O	O
months	O	O
later	O	O
.	O	O

Although	O	O
a	O	O
causal	O	O
relationship	O	O
between	O	O
the	O	O
use	O	O
of	O	O
an	O	O
anthraquinone-containing	O	O
herbal	O	O
agent	O	O
and	O	O
renal	B_Disease	B_Disease
injury	I_Disease	I_Disease
remains	O	O
to	O	O
be	O	O
proven	O	O
,	O	O
phytotherapy-associated	O	O
interstitial	O	B_Disease
nephropathy	B_Disease	I_Disease
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
who	O	O
present	O	O
with	O	O
unexplained	O	B_Disease
renal	B_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

Chloroacetaldehyde	B_Chemical	B_Chemical
as	O	O
a	O	O
sulfhydryl	B_Chemical	O
reagent	O	O
:	O	O
the	O	O
role	O	O
of	O	O
critical	O	O
thiol	B_Chemical	O
groups	O	O
in	O	O
ifosfamide	B_Chemical	O
nephropathy	B_Disease	O
.	O	O

Chloroacetaldehyde	B_Chemical	B_Chemical
(	O	O
CAA	B_Chemical	O
)	O	O
is	O	O
a	O	O
metabolite	O	O
of	O	O
the	O	O
alkylating	O	O
agent	O	O
ifosfamide	B_Chemical	B_Chemical
(	O	O
IFO	B_Chemical	B_Chemical
)	O	O
and	O	O
putatively	O	O
responsible	O	O
for	O	O
renal	B_Disease	B_Disease
damage	I_Disease	I_Disease
following	O	O
anti-tumor	O	O
therapy	O	O
with	O	O
IFO	B_Chemical	B_Chemical
.	O	O

Depletion	O	O
of	O	O
sulfhydryl	B_Chemical	O
(	O	O
SH	B_Chemical	O
)	O	O
groups	O	O
has	O	O
been	O	O
reported	O	O
from	O	O
cell	O	O
culture	O	O
,	O	O
animal	O	O
and	O	O
clinical	O	O
studies	O	O
.	O	O

In	O	O
this	O	O
work	O	O
the	O	O
effect	O	O
of	O	O
CAA	B_Chemical	O
on	O	O
human	O	O
proximal	O	O
tubule	O	O
cells	O	O
in	O	O
primary	O	O
culture	O	O
(	O	O
hRPTEC	O	O
)	O	O
was	O	O
investigated	O	O
.	O	O

Toxicity	B_Disease	O
of	O	O
CAA	B_Chemical	O
was	O	O
determined	O	O
by	O	O
protein	O	O
content	O	O
,	O	O
cell	O	O
number	O	O
,	O	O
LDH	O	O
release	O	O
,	O	O
trypan	B_Chemical	O
blue	I_Chemical	O
exclusion	O	O
assay	O	O
and	O	O
caspase-3	O	O
activity	O	O
.	O	O

Free	O	O
thiols	B_Chemical	O
were	O	O
measured	O	O
by	O	O
the	O	O
method	O	O
of	O	O
Ellman	O	O
.	O	O

CAA	B_Chemical	O
reduced	O	O
hRPTEC	O	O
cell	O	O
number	O	O
and	O	O
protein	O	O
,	O	O
induced	O	O
a	O	O
loss	O	O
in	O	O
free	O	O
intracellular	O	O
thiols	B_Chemical	O
and	O	O
an	O	O
increase	O	O
in	O	O
necrosis	B_Disease	O
markers	O	O
.	O	O

CAA	B_Chemical	O
but	O	O
not	O	O
acrolein	B_Chemical	O
inhibited	O	O
the	O	O
cysteine	B_Chemical	O
proteases	O	O
caspase-3	O	O
,	O	O
caspase-8	O	O
and	O	O
cathepsin	O	O
B.	O	O
Caspase	O	O
activation	O	O
by	O	O
cisplatin	B_Chemical	B_Chemical
was	O	O
inhibited	O	O
by	O	O
CAA	B_Chemical	O
.	O	O

In	O	O
cells	O	O
stained	O	O
with	O	O
fluorescent	O	O
dyes	O	O
targeting	O	O
lysosomes	O	O
,	O	O
CAA	B_Chemical	O
induced	O	O
an	O	O
increase	O	O
in	O	O
lysosomal	O	O
size	O	O
and	O	O
lysosomal	O	O
leakage	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
CAA	B_Chemical	O
on	O	O
cysteine	B_Chemical	O
protease	O	O
activities	O	O
and	O	O
thiols	B_Chemical	O
could	O	O
be	O	O
reproduced	O	O
in	O	O
cell	O	O
lysate	O	O
.	O	O

Acidification	O	O
,	O	O
which	O	O
slowed	O	O
the	O	O
reaction	O	O
of	O	O
CAA	B_Chemical	O
with	O	O
thiol	B_Chemical	O
donors	O	O
,	O	O
could	O	O
also	O	O
attenuate	O	O
effects	O	O
of	O	O
CAA	B_Chemical	O
on	O	O
necrosis	B_Disease	O
markers	O	O
,	O	O
thiol	B_Chemical	O
depletion	O	O
and	O	O
cysteine	B_Chemical	O
protease	O	O
inhibition	O	O
in	O	O
living	O	O
cells	O	O
.	O	O

Thus	O	O
,	O	O
CAA	B_Chemical	O
directly	O	O
reacts	O	O
with	O	O
cellular	O	O
protein	O	O
and	O	O
non-protein	O	O
thiols	B_Chemical	O
,	O	O
mediating	O	O
its	O	O
toxicity	B_Disease	O
on	O	O
hRPTEC	O	O
.	O	O

This	O	O
effect	O	O
can	O	O
be	O	O
reduced	O	O
by	O	O
acidification	O	O
.	O	O

Therefore	O	O
,	O	O
urinary	O	O
acidification	O	O
could	O	O
be	O	O
an	O	O
option	O	O
to	O	O
prevent	O	O
IFO	B_Chemical	O
nephropathy	B_Disease	O
in	O	O
patients	O	O
.	O	O

Stereological	O	O
methods	O	O
reveal	O	O
the	O	O
robust	O	O
size	O	O
and	O	O
stability	O	O
of	O	O
ectopic	O	O
hilar	O	O
granule	O	O
cells	O	O
after	O	O
pilocarpine-induced	O	O
status	B_Disease	O
epilepticus	I_Disease	O
in	O	O
the	O	O
adult	O	O
rat	O	O
.	O	O

Following	O	O
status	B_Disease	O
epilepticus	I_Disease	O
in	O	O
the	O	O
rat	O	O
,	O	O
dentate	O	O
granule	O	O
cell	O	O
neurogenesis	O	O
increases	O	O
greatly	O	O
,	O	O
and	O	O
many	O	O
of	O	O
the	O	O
new	O	O
neurons	O	O
appear	O	O
to	O	O
develop	O	O
ectopically	O	O
,	O	O
in	O	O
the	O	O
hilar	O	O
region	O	O
of	O	O
the	O	O
hippocampal	O	O
formation	O	O
.	O	O

It	O	O
has	O	O
been	O	O
suggested	O	O
that	O	O
the	O	O
ectopic	O	O
hilar	O	O
granule	O	O
cells	O	O
could	O	O
contribute	O	O
to	O	O
the	O	O
spontaneous	O	O
seizures	B_Disease	O
that	O	O
ultimately	O	O
develop	O	O
after	O	O
status	B_Disease	O
epilepticus	I_Disease	O
.	O	O

However	O	O
,	O	O
the	O	O
population	O	O
has	O	O
never	O	O
been	O	O
quantified	O	O
,	O	O
so	O	O
it	O	O
is	O	O
unclear	O	O
whether	O	O
it	O	O
is	O	O
substantial	O	O
enough	O	O
to	O	O
have	O	O
a	O	O
strong	O	O
influence	O	O
on	O	O
epileptogenesis	O	O
.	O	O

To	O	O
quantify	O	O
this	O	O
population	O	O
,	O	O
the	O	O
total	O	O
number	O	O
of	O	O
ectopic	O	O
hilar	O	O
granule	O	O
cells	O	O
was	O	O
estimated	O	O
using	O	O
unbiased	O	O
stereology	O	O
at	O	O
different	O	O
times	O	O
after	O	O
pilocarpine-induced	O	O
status	B_Disease	O
epilepticus	I_Disease	O
.	O	O

The	O	O
number	O	O
of	O	O
hilar	O	O
neurons	O	O
immunoreactive	O	O
for	O	O
Prox-1	O	O
,	O	O
a	O	O
granule-cell-specific	O	O
marker	O	O
,	O	O
was	O	O
estimated	O	O
using	O	O
the	O	O
optical	O	O
fractionator	O	O
method	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
size	O	O
of	O	O
the	O	O
hilar	O	O
ectopic	O	O
granule	O	O
cell	O	O
population	O	O
after	O	O
status	B_Disease	O
epilepticus	I_Disease	O
is	O	O
substantial	O	O
,	O	O
and	O	O
stable	O	O
over	O	O
time	O	O
.	O	O

Interestingly	O	O
,	O	O
the	O	O
size	O	O
of	O	O
the	O	O
population	O	O
appears	O	O
to	O	O
be	O	O
correlated	O	O
with	O	O
the	O	O
frequency	O	O
of	O	O
behavioral	O	O
seizures	B_Disease	O
,	O	O
because	O	O
animals	O	O
with	O	O
more	O	O
ectopic	O	O
granule	O	O
cells	O	O
in	O	O
the	O	O
hilus	O	O
have	O	O
more	O	O
frequent	O	O
behavioral	O	O
seizures	B_Disease	O
.	O	O

The	O	O
hilar	O	O
ectopic	O	O
granule	O	O
cell	O	O
population	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
vary	O	O
systematically	O	O
across	O	O
the	O	O
septotemporal	O	O
axis	O	O
,	O	O
although	O	O
it	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
volume	O	O
of	O	O
the	O	O
hilus	O	O
.	O	O

The	O	O
results	O	O
provide	O	O
new	O	O
insight	O	O
into	O	O
the	O	O
potential	O	O
role	O	O
of	O	O
ectopic	O	O
hilar	O	O
granule	O	O
cells	O	O
in	O	O
the	O	O
pilocarpine	B_Chemical	O
model	O	O
of	O	O
temporal	B_Disease	B_Disease
lobe	I_Disease	I_Disease
epilepsy	I_Disease	I_Disease
.	O	O

A	O	O
prospective	O	O
,	O	O
open-label	O	O
trial	O	O
of	O	O
galantamine	B_Chemical	B_Chemical
in	O	O
autistic	B_Disease	O
disorder	I_Disease	O
.	O	O

OBJECTIVE	O	O
:	O	O
Post-mortem	O	O
studies	O	O
have	O	O
reported	O	O
abnormalities	O	O
of	O	O
the	O	O
cholinergic	O	O
system	O	O
in	O	O
autism	B_Disease	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
use	O	O
of	O	O
galantamine	B_Chemical	B_Chemical
,	O	O
an	O	O
acetylcholinesterase	O	O
inhibitor	O	O
and	O	O
nicotinic	O	O
receptor	O	O
modulator	O	O
,	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
interfering	O	O
behaviors	O	O
in	O	O
children	O	O
with	O	O
autism	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
Thirteen	O	O
medication-free	O	O
children	O	O
with	O	O
autism	B_Disease	O
(	O	O
mean	O	O
age	O	O
,	O	O
8.8	O	O
+	O	O
/-	O	O
3.5	O	O
years	O	O
)	O	O
participated	O	O
in	O	O
a	O	O
12-week	O	O
,	O	O
open-label	O	O
trial	O	O
of	O	O
galantamine	B_Chemical	B_Chemical
.	O	O

Patients	O	O
were	O	O
rated	O	O
monthly	O	O
by	O	O
parents	O	O
on	O	O
the	O	O
Aberrant	O	O
Behavior	O	O
Checklist	O	O
(	O	O
ABC	O	O
)	O	O
and	O	O
the	O	O
Conners	O	O
'	O	O
Parent	O	O
Rating	O	O
Scale-Revised	O	O
,	O	O
and	O	O
by	O	O
a	O	O
physician	O	O
using	O	O
the	O	O
Children	O	O
's	O	O
Psychiatric	O	O
Rating	O	O
Scale	O	O
and	O	O
the	O	O
Clinical	O	O
Global	O	O
Impressions	O	O
scale	O	O
.	O	O

RESULTS	O	O
:	O	O
Patients	O	O
showed	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
parent-rated	O	O
irritability	B_Disease	O
and	O	O
social	O	O
withdrawal	O	O
on	O	O
the	O	O
ABC	O	O
as	O	O
well	O	O
as	O	O
significant	O	O
improvements	O	O
in	O	O
emotional	O	O
lability	O	O
and	O	O
inattention	O	O
on	O	O
the	O	O
Conners	O	O
'	O	O
Parent	O	O
Rating	O	O
Scale	O	O
--	O	O
Revised	O	O
.	O	O

Similarly	O	O
,	O	O
clinician	O	O
ratings	O	O
showed	O	O
reductions	O	O
in	O	O
the	O	O
anger	O	O
subscale	O	O
of	O	O
the	O	O
Children	O	O
's	O	O
Psychiatric	O	O
Rating	O	O
Scale	O	O
.	O	O

Eight	O	O
of	O	O
13	O	O
participants	O	O
were	O	O
rated	O	O
as	O	O
responders	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
their	O	O
improvement	O	O
scores	O	O
on	O	O
the	O	O
Clinical	O	O
Global	O	O
Impressions	O	O
scale	O	O
.	O	O

Overall	O	O
,	O	O
galantamine	B_Chemical	B_Chemical
was	O	O
well-tolerated	O	O
,	O	O
with	O	O
no	O	O
significant	O	O
adverse	O	O
effects	O	O
apart	O	O
from	O	O
headaches	B_Disease	O
in	O	O
one	O	O
patient	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
this	O	O
open	O	O
trial	O	O
,	O	O
galantamine	B_Chemical	B_Chemical
was	O	O
well-tolerated	O	O
and	O	O
appeared	O	O
to	O	O
be	O	O
beneficial	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
interfering	O	O
behaviors	O	O
in	O	O
children	O	O
with	O	O
autism	B_Disease	O
,	O	O
particularly	O	O
aggression	B_Disease	O
,	O	O
behavioral	B_Disease	O
dyscontrol	I_Disease	O
,	O	O
and	O	O
inattention	B_Disease	O
.	O	O

Further	O	O
controlled	O	O
trials	O	O
are	O	O
warranted	O	O
.	O	O

Randomized	O	O
comparison	O	O
of	O	O
olanzapine	B_Chemical	B_Chemical
versus	O	O
risperidone	B_Chemical	B_Chemical
for	O	O
the	O	O
treatment	O	O
of	O	O
first-episode	O	O
schizophrenia	B_Disease	O
:	O	O
4-month	O	O
outcomes	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
authors	O	O
compared	O	O
4-month	O	O
treatment	O	O
outcomes	O	O
for	O	O
olanzapine	B_Chemical	B_Chemical
versus	O	O
risperidone	B_Chemical	B_Chemical
in	O	O
patients	O	O
with	O	O
first-episode	O	O
schizophrenia	B_Disease	B_Disease
spectrum	O	I_Disease
disorders	O	I_Disease
.	O	O

METHOD	O	O
:	O	O
One	O	O
hundred	O	O
twelve	O	O
subjects	O	O
(	O	O
70	O	O
%	O	O
male	O	O
;	O	O
mean	O	O
age=23.3	O	O
years	O	O
[	O	O
SD	O	O
=	O	O
5.1	O	O
]	O	O
)	O	O
with	O	O
first-episode	O	O
schizophrenia	B_Disease	O
(	O	O
75	O	O
%	O	O
)	O	O
,	O	O
schizophreniform	B_Disease	B_Disease
disorder	I_Disease	I_Disease
(	O	O
17	O	O
%	O	O
)	O	O
,	O	O
or	O	O
schizoaffective	B_Disease	O
disorder	I_Disease	O
(	O	O
8	O	O
%	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
treatment	O	O
with	O	O
olanzapine	B_Chemical	B_Chemical
(	O	O
2.5	O	O
-	O	O
20	O	O
mg/day	O	O
)	O	O
or	O	O
risperidone	B_Chemical	B_Chemical
(	O	O
1	O	O
-	O	O
6	O	O
mg/day	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Response	O	O
rates	O	O
did	O	O
not	O	O
significantly	O	O
differ	O	O
between	O	O
olanzapine	B_Chemical	B_Chemical
(	O	O
43.7	O	O
%	O	O
,	O	O
95	O	O
%	O	O
CI=28.8%-58.6	O	O
%	O	O
)	O	O
and	O	O
risperidone	B_Chemical	B_Chemical
(	O	O
54.3	O	O
%	O	O
,	O	O
95	O	O
%	O	O
CI=39.9%-68.7	O	O
%	O	O
)	O	O
.	O	O

Among	O	O
those	O	O
responding	O	O
to	O	O
treatment	O	O
,	O	O
more	O	O
subjects	O	O
in	O	O
the	O	O
olanzapine	B_Chemical	B_Chemical
group	O	O
(	O	O
40.9	O	O
%	O	O
,	O	O
95	O	O
%	O	O
CI=16.8%-65.0	O	O
%	O	O
)	O	O
than	O	O
in	O	O
the	O	O
risperidone	B_Chemical	B_Chemical
group	O	O
(	O	O
18.9	O	O
%	O	O
,	O	O
95	O	O
%	O	O
CI=0%-39.2	O	O
%	O	O
)	O	O
had	O	O
subsequent	O	O
ratings	O	O
not	O	O
meeting	O	O
response	O	O
criteria	O	O
.	O	O

Negative	O	O
symptom	O	O
outcomes	O	O
and	O	O
measures	O	O
of	O	O
parkinsonism	B_Disease	O
and	O	O
akathisia	B_Disease	O
did	O	O
not	O	O
differ	O	O
between	O	O
medications	O	O
.	O	O

Extrapyramidal	B_Disease	B_Disease
symptom	I_Disease	I_Disease
severity	O	I_Disease
scores	O	O
were	O	O
1.4	O	O
(	O	O
95	O	O
%	O	O
CI=1.2	O	O
-	O	O
1.6	O	O
)	O	O
with	O	O
risperidone	B_Chemical	B_Chemical
and	O	O
1.2	O	O
(	O	O
95	O	O
%	O	O
CI=1.0	O	O
-	O	O
1.4	O	O
)	O	O
with	O	O
olanzapine	B_Chemical	B_Chemical
.	O	O

Significantly	O	O
more	O	O
weight	B_Disease	O
gain	I_Disease	O
occurred	O	O
with	O	O
olanzapine	B_Chemical	B_Chemical
than	O	O
with	O	O
risperidone	B_Chemical	B_Chemical
:	O	O
the	O	O
increase	O	O
in	O	O
weight	O	O
at	O	O
4	O	O
months	O	O
relative	O	O
to	O	O
baseline	O	O
weight	O	O
was	O	O
17.3	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI=14.2%-20.5	O	O
%	O	O
)	O	O
with	O	O
olanzapine	B_Chemical	B_Chemical
and	O	O
11.3	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI=8.4%-14.3	O	O
%	O	O
)	O	O
with	O	O
risperidone	B_Chemical	B_Chemical
.	O	O

Body	O	O
mass	O	O
index	O	O
at	O	O
baseline	O	O
and	O	O
at	O	O
4	O	O
months	O	O
was	O	O
24.3	O	O
(	O	O
95	O	O
%	O	O
CI=22.8	O	O
-	O	O
25.7	O	O
)	O	O
versus	O	O
28.2	O	O
(	O	O
95	O	O
%	O	O
CI=26.7	O	O
-	O	O
29.7	O	O
)	O	O
with	O	O
olanzapine	B_Chemical	B_Chemical
and	O	O
23.9	O	O
(	O	O
95	O	O
%	O	O
CI=22.5	O	O
-	O	O
25.3	O	O
)	O	O
versus	O	O
26.7	O	O
(	O	O
95	O	O
%	O	O
CI=25.2	O	O
-	O	O
28.2	O	O
)	O	O
with	O	O
risperidone	B_Chemical	B_Chemical
.	O	O

CONCLUSIONS	O	O
:	O	O
Clinical	O	O
outcomes	O	O
with	O	O
risperidone	B_Chemical	B_Chemical
were	O	O
equal	O	O
to	O	O
those	O	O
with	O	O
olanzapine	B_Chemical	B_Chemical
,	O	O
and	O	O
response	O	O
may	O	O
be	O	O
more	O	O
stable	O	O
.	O	O

Olanzapine	B_Chemical	B_Chemical
may	O	O
have	O	O
an	O	O
advantage	O	O
for	O	O
motor	O	O
side	O	O
effects	O	O
.	O	O

Both	O	O
medications	O	O
caused	O	O
substantial	O	O
rapid	O	O
weight	B_Disease	O
gain	I_Disease	O
,	O	O
but	O	O
weight	B_Disease	O
gain	I_Disease	O
was	O	O
greater	O	O
with	O	O
olanzapine	B_Chemical	B_Chemical
.	O	O

Early	O	O
paracentral	O	O
visual	B_Disease	O
field	I_Disease	O
loss	I_Disease	O
in	O	O
patients	O	O
taking	O	O
hydroxychloroquine	B_Chemical	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
review	O	O
the	O	O
natural	O	O
history	O	O
and	O	O
ocular	O	O
and	O	O
systemic	O	O
adverse	O	O
effects	O	O
of	O	O
patients	O	O
taking	O	O
hydroxychloroquine	B_Chemical	B_Chemical
sulfate	I_Chemical	I_Chemical
who	O	O
attended	O	O
an	O	O
ophthalmic	O	O
screening	O	O
program	O	O
.	O	O

DESIGN	O	O
:	O	O
Retrospective	O	O
study	O	O
.	O	O

RESULTS	O	O
:	O	O
Records	O	O
of	O	O
262	O	O
patients	O	O
who	O	O
were	O	O
taking	O	O
hydroxychloroquine	B_Chemical	O
and	O	O
screened	O	O
in	O	O
the	O	O
Department	O	O
of	O	O
Ophthalmology	O	O
were	O	O
reviewed	O	O
.	O	O

Of	O	O
the	O	O
262	O	O
patients	O	O
,	O	O
14	O	O
(	O	O
18	O	O
%	O	O
)	O	O
of	O	O
76	O	O
who	O	O
had	O	O
stopped	O	O
treatment	O	O
at	O	O
the	O	O
time	O	O
of	O	O
the	O	O
study	O	O
experienced	O	O
documented	O	O
adverse	O	O
effects	O	O
.	O	O

Systemic	O	O
adverse	O	O
effects	O	O
occurred	O	O
in	O	O
8	O	O
patients	O	O
(	O	O
10.5	O	O
%	O	O
)	O	O
and	O	O
ocular	O	O
adverse	O	O
effects	O	O
,	O	O
in	O	O
5	O	O
(	O	O
6.5	O	O
%	O	O
)	O	O
.	O	O

Thirty-five	O	O
patients	O	O
(	O	O
13.4	O	O
%	O	O
)	O	O
had	O	O
visual	B_Disease	O
field	I_Disease	O
abnormalities	I_Disease	O
,	O	O
which	O	O
were	O	O
attributed	O	O
to	O	O
hydroxychloroquine	B_Chemical	O
treatment	O	O
in	O	O
4	O	O
patients	O	O
(	O	O
1.5	O	O
%	O	O
)	O	O
.	O	O

Three	O	O
of	O	O
the	O	O
4	O	O
patients	O	O
were	O	O
taking	O	O
less	O	O
than	O	O
6.5	O	O
mg/kg	O	O
per	O	O
day	O	O
and	O	O
all	O	O
patients	O	O
had	O	O
normal	O	O
renal	O	O
and	O	O
liver	O	O
function	O	O
test	O	O
results	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
current	O	O
study	O	O
used	O	O
a	O	O
protocol	O	O
of	O	O
visual	O	O
acuity	O	O
and	O	O
color	O	O
vision	O	O
assessment	O	O
,	O	O
funduscopy	O	O
,	O	O
and	O	O
Humphrey	O	O
10	O	O
-	O	O
2	O	O
visual	O	O
field	O	O
testing	O	O
and	O	O
shows	O	O
that	O	O
visual	B_Disease	B_Disease
field	I_Disease	I_Disease
defects	I_Disease	I_Disease
appeared	O	O
before	O	O
any	O	O
corresponding	O	O
changes	O	O
in	O	O
any	O	O
other	O	O
tested	O	O
clinical	O	O
parameters	O	O
;	O	O
the	O	O
defects	O	O
were	O	O
reproducible	O	O
and	O	O
the	O	O
test	O	O
parameters	O	O
were	O	O
reliable	O	O
.	O	O

Patients	O	O
taking	O	O
hydroxychloroquine	B_Chemical	O
can	O	O
demonstrate	O	O
a	O	O
toxic	O	O
reaction	O	O
in	O	O
the	O	O
retina	O	O
despite	O	O
the	O	O
absence	O	O
of	O	O
known	O	O
risk	O	O
factors	O	O
.	O	O

Screening	O	O
,	O	O
including	O	O
Humphrey	O	O
10	O	O
-	O	O
2	O	O
visual	O	O
field	O	O
assessment	O	O
,	O	O
is	O	O
recommended	O	O
2	O	O
years	O	O
after	O	O
the	O	O
initial	O	O
baseline	O	O
and	O	O
yearly	O	O
thereafter	O	O
.	O	O

Peri-operative	O	O
atrioventricular	B_Disease	O
block	I_Disease	O
as	O	O
a	O	O
result	O	O
of	O	O
chemotherapy	O	O
with	O	O
epirubicin	B_Chemical	B_Chemical
and	O	O
paclitaxel	B_Chemical	B_Chemical
.	O	O

A	O	O
47-year-old	O	O
woman	O	O
presented	O	O
for	O	O
mastectomy	O	O
and	O	O
immediate	O	O
latissimus	O	O
dorsi	O	O
flap	O	O
reconstruction	O	O
having	O	O
been	O	O
diagnosed	O	O
with	O	O
carcinoma	B_Disease	O
of	I_Disease	O
the	I_Disease	O
breast	I_Disease	O
6	O	O
months	O	O
previously	O	O
.	O	O

In	O	O
the	O	O
preceding	O	O
months	O	O
she	O	O
had	O	O
received	O	O
neo-adjuvant	O	O
chemotherapy	O	O
with	O	O
epirubicin	B_Chemical	B_Chemical
,	O	O
paclitaxel	B_Chemical	B_Chemical
(	O	O
Taxol	B_Chemical	B_Chemical
)	O	O
and	O	O
cyclophosphamide	B_Chemical	B_Chemical
.	O	O

This	O	O
had	O	O
been	O	O
apparently	O	O
uncomplicated	O	O
and	O	O
she	O	O
had	O	O
maintained	O	O
a	O	O
remarkably	O	O
high	O	O
level	O	O
of	O	O
physical	O	O
activity	O	O
.	O	O

She	O	O
was	O	O
found	O	O
to	O	O
be	O	O
bradycardic	B_Disease	O
at	O	O
pre-operative	O	O
assessment	O	O
but	O	O
had	O	O
no	O	O
cardiac	O	B_Disease
symptoms	O	I_Disease
.	O	O

Second	O	O
degree	O	O
Mobitz	O	O
type	O	O
II	O	O
atrioventricular	B_Disease	O
block	I_Disease	O
was	O	O
diagnosed	O	O
on	O	O
electrocardiogram	O	O
,	O	O
and	O	O
temporary	O	O
transvenous	O	O
ventricular	O	O
pacing	O	O
instituted	O	O
in	O	O
the	O	O
peri-operative	O	O
period	O	O
.	O	O

We	O	O
discuss	O	O
how	O	O
evidence-based	O	O
guidelines	O	O
would	O	O
not	O	O
have	O	O
been	O	O
helpful	O	O
in	O	O
this	O	O
case	O	O
,	O	O
and	O	O
how	O	O
chemotherapy	O	O
can	O	O
exhibit	O	O
substantial	O	O
cardiotoxicity	B_Disease	B_Disease
that	O	O
may	O	O
develop	O	O
over	O	O
many	O	O
years	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
patients	O	O
who	O	O
have	O	O
received	O	O
chemotherapy	O	O
at	O	O
any	O	O
time	O	O
should	O	O
have	O	O
a	O	O
pre-operative	O	O
electrocardiogram	O	O
even	O	O
if	O	O
they	O	O
are	O	O
asymptomatic	O	O
.	O	O

Risks	O	O
and	O	O
benefits	O	O
of	O	O
COX-2	O	O
inhibitors	O	O
vs	O	O
non-selective	O	O
NSAIDs	O	O
:	O	O
does	O	O
their	O	O
cardiovascular	O	O
risk	O	O
exceed	O	O
their	O	O
gastrointestinal	O	O
benefit	O	O
?	O	O
A	O	O
retrospective	O	O
cohort	O	O
study	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
risk	O	O
of	O	O
acute	B_Disease	B_Disease
myocardial	I_Disease	I_Disease
infarction	I_Disease	I_Disease
(	O	O
AMI	B_Disease	O
)	O	O
with	O	O
COX-2	B_Chemical	O
inhibitors	I_Chemical	O
may	O	O
offset	O	O
their	O	O
gastrointestinal	O	O
(	O	O
GI	O	O
)	O	O
benefit	O	O
compared	O	O
with	O	O
non-selective	O	O
(	O	O
NS	O	O
)	O	O
non-steroidal	B_Chemical	O
anti-inflammatory	I_Chemical	O
drugs	I_Chemical	O
(	O	O
NSAIDs	O	O
)	O	O
.	O	O

We	O	O
aimed	O	O
to	O	O
compare	O	O
the	O	O
risks	O	O
of	O	O
hospitalization	O	O
for	O	O
AMI	B_Disease	O
and	O	O
GI	B_Disease	O
bleeding	I_Disease	O
among	O	O
elderly	O	O
patients	O	O
using	O	O
COX-2	B_Chemical	O
inhibitors	I_Chemical	O
,	O	O
NS-NSAIDs	O	O
and	O	O
acetaminophen	B_Chemical	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
conducted	O	O
a	O	O
retrospective	O	O
cohort	O	O
study	O	O
using	O	O
administrative	O	O
data	O	O
of	O	O
patients	O	O
>	O	O
or	O	O
=	O	O
65	O	O
years	O	O
of	O	O
age	O	O
who	O	O
filled	O	O
a	O	O
prescription	O	O
for	O	O
NSAID	O	O
or	O	O
acetaminophen	B_Chemical	O
during	O	O
1999	O	O
-	O	O
2002	O	O
.	O	O

Outcomes	O	O
were	O	O
compared	O	O
using	O	O
Cox	O	O
regression	O	O
models	O	O
with	O	O
time-dependent	O	O
exposures	O	O
.	O	O

RESULTS	O	O
:	O	O
Person-years	O	O
of	O	O
exposure	O	O
among	O	O
non-users	O	O
of	O	O
aspirin	B_Chemical	O
were	O	O
:	O	O
75,761	O	O
to	O	O
acetaminophen	B_Chemical	O
,	O	O
42,671	O	O
to	O	O
rofecoxib	B_Chemical	O
65,860	O	O
to	O	O
celecoxib	B_Chemical	O
,	O	O
and	O	O
37,495	O	O
to	O	O
NS-NSAIDs	O	O
.	O	O

Among	O	O
users	O	O
of	O	O
aspirin	B_Chemical	O
,	O	O
they	O	O
were	O	O
:	O	O
14,671	O	O
to	O	O
rofecoxib	B_Chemical	O
,	O	O
22,875	O	O
to	O	O
celecoxib	B_Chemical	O
,	O	O
9,832	O	O
to	O	O
NS-NSAIDs	O	O
and	O	O
38,048	O	O
to	O	O
acetaminophen	B_Chemical	O
.	O	O

Among	O	O
non-users	O	O
of	O	O
aspirin	B_Chemical	O
,	O	O
the	O	O
adjusted	O	O
hazard	O	O
ratios	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
)	O	O
of	O	O
hospitalization	O	O
for	O	O
AMI/GI	O	O
vs	O	O
the	O	O
acetaminophen	B_Chemical	O
(	O	O
with	O	O
no	O	O
aspirin	B_Chemical	O
)	O	O
group	O	O
were	O	O
:	O	O
rofecoxib	B_Chemical	O
1.27	O	O
(	O	O
1.13	O	O
,	O	O
1.42	O	O
)	O	O
,	O	O
celecoxib	B_Chemical	O
0.93	O	O
(	O	O
0.83	O	O
,	O	O
1.03	O	O
)	O	O
,	O	O
naproxen	B_Chemical	O
1.59	O	O
(	O	O
1.31	O	O
,	O	O
1.93	O	O
)	O	O
,	O	O
diclofenac	B_Chemical	B_Chemical
1.17	O	O
(	O	O
0.99	O	O
,	O	O
1.38	O	O
)	O	O
and	O	O
ibuprofen	B_Chemical	O
1.05	O	O
(	O	O
0.74	O	O
,	O	O
1.51	O	O
)	O	O
.	O	O

Among	O	O
users	O	O
of	O	O
aspirin	B_Chemical	O
,	O	O
they	O	O
were	O	O
:	O	O
rofecoxib	B_Chemical	O
1.73	O	O
(	O	O
1.52	O	O
,	O	O
1.98	O	O
)	O	O
,	O	O
celecoxib	B_Chemical	O
1.34	O	O
(	O	O
1.19	O	O
,	O	O
1.52	O	O
)	O	O
,	O	O
ibuprofen	B_Chemical	O
1.51	O	O
(	O	O
0.95	O	O
,	O	O
2.41	O	O
)	O	O
,	O	O
diclofenac	B_Chemical	B_Chemical
1.69	O	O
(	O	O
1.35	O	O
,	O	O
2.10	O	O
)	O	O
,	O	O
naproxen	B_Chemical	O
1.35	O	O
(	O	O
0.97	O	O
,	O	O
1.88	O	O
)	O	O
and	O	O
acetaminophen	B_Chemical	O
1.29	O	O
(	O	O
1.17	O	O
,	O	O
1.42	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Among	O	O
non-users	O	O
of	O	O
aspirin	B_Chemical	O
,	O	O
naproxen	B_Chemical	O
seemed	O	O
to	O	O
carry	O	O
the	O	O
highest	O	O
risk	O	O
for	O	O
AMI/GI	O	O
bleeding	O	O
.	O	O

The	O	O
AMI/GI	O	O
toxicity	B_Disease	O
of	O	O
celecoxib	B_Chemical	O
was	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
acetaminophen	B_Chemical	O
and	O	O
seemed	O	O
to	O	O
be	O	O
better	O	O
than	O	O
those	O	O
of	O	O
rofecoxib	B_Chemical	O
and	O	O
NS-NSAIDs	O	O
.	O	O

Among	O	O
users	O	O
of	O	O
aspirin	B_Chemical	O
,	O	O
both	O	O
celecoxib	B_Chemical	O
and	O	O
naproxen	B_Chemical	O
seemed	O	O
to	O	O
be	O	O
the	O	O
least	O	O
toxic	O	O
.	O	O

Quinine-induced	O	O
arrhythmia	B_Disease	O
in	O	O
a	O	O
patient	O	O
with	O	O
severe	B_Disease	O
malaria	I_Disease	O
.	O	O

It	O	O
was	O	O
reported	O	O
that	O	O
there	O	O
was	O	O
a	O	O
case	O	O
of	O	O
severe	B_Disease	O
malaria	I_Disease	O
patient	O	O
with	O	O
jaundice	B_Disease	O
who	O	O
presented	O	O
with	O	O
arrhythmia	B_Disease	O
(	O	O
premature	B_Disease	B_Disease
ventricular	I_Disease	I_Disease
contraction	I_Disease	I_Disease
)	O	O
while	O	O
getting	O	O
quinine	B_Chemical	O
infusion	O	O
was	O	O
reported	O	O
.	O	O

A	O	O
man	O	O
,	O	O
25	O	O
years	O	O
old	O	O
,	O	O
was	O	O
admitted	O	O
to	O	O
hospital	O	O
with	O	O
high	O	B_Disease
fever	B_Disease	I_Disease
,	O	O
chill	B_Disease	O
,	O	O
vomiting	B_Disease	O
,	O	O
jaundice	B_Disease	O
.	O	O

The	O	O
patient	O	O
was	O	O
fully	O	O
conscious	O	O
,	O	O
blood	O	O
pressure	O	O
120/80	O	O
mmHg	O	O
,	O	O
pulse	O	O
rate	O	O
100	O	O
x/minute	O	O
,	O	O
regular	O	O
.	O	O

On	O	O
admission	O	O
,	O	O
laboratory	O	O
examination	O	O
showed	O	O
Plasmodium	O	O
falciparum	O	O
(	O	O
+	O	O
+	O	O
+	O	O
+	O	O
)	O	O
,	O	O
total	O	O
bilirubin	B_Chemical	O
8.25	O	O
mg/dL	O	O
,	O	O
conjugated	O	O
bilirubin	B_Chemical	O
4.36	O	O
mg/dL	O	O
,	O	O
unconjugated	O	O
bilirubin	B_Chemical	O
3.89	O	O
mg/dL	O	O
,	O	O
potassium	B_Chemical	O
3.52	O	O
meq/L	O	O
Patient	O	O
was	O	O
diagnosed	O	O
as	O	O
severe	B_Disease	O
malaria	I_Disease	B_Chemical
with	O	I_Chemical
jaundice	B_Disease	I_Chemical
and	O	O
got	O	O
quinine	B_Chemical	O
infusion	O	O
in	O	O
dextrose	B_Chemical	O
5	O	O
%	O	O
500	O	O
mg/8	O	O
hour	O	O
.	O	O

On	O	O
the	O	O
second	O	O
day	O	O
the	O	O
patient	O	O
had	O	O
vomitus	B_Disease	O
,	O	O
diarrhea	B_Disease	O
,	O	O
tinnitus	B_Disease	O
,	O	O
loss	B_Disease	O
of	I_Disease	O
hearing	I_Disease	O
.	O	O

After	O	O
30	O	O
hours	O	O
of	O	O
quinine	B_Chemical	O
infusion	O	O
the	O	O
patient	O	O
felt	O	O
palpitation	B_Disease	O
and	O	O
electrocardiography	O	O
(	O	O
ECG	O	O
)	O	O
recording	O	O
showed	O	O
premature	B_Disease	B_Disease
ventricular	I_Disease	I_Disease
contraction	I_Disease	I_Disease
(	O	O
PVC	B_Disease	O
)	O	O
>	O	O
5	O	O
x/minute	O	O
,	O	O
trigemini	O	O
,	O	O
constant	O	O
type	O	O
--	O	O
sinoatrial	B_Disease	O
block	I_Disease	O
,	O	O
positive	O	O
U	O	O
wave	O	O
.	O	O

He	O	O
was	O	O
treated	O	O
with	O	O
lidocaine	B_Chemical	O
50	O	O
mg	O	O
intravenously	O	O
followed	O	O
by	O	O
infusion	O	O
1500	O	O
mg	O	O
in	O	O
dextrose	B_Chemical	O
5%/24	O	O
hour	O	O
and	O	O
potassium	B_Chemical	B_Chemical
aspartate	I_Chemical	I_Chemical
tablet	O	O
.	O	O

Quinine	B_Chemical	O
infusion	O	O
was	O	O
discontinued	O	O
and	O	O
changed	O	O
with	O	O
sulfate	O	B_Chemical
quinine	B_Chemical	I_Chemical
tablets	O	O
.	O	O

Three	O	O
hours	O	O
later	O	O
the	O	O
patient	O	O
felt	O	O
better	O	O
,	O	O
the	O	O
frequency	O	O
of	O	O
PVC	B_Disease	O
reduced	O	O
to	O	O
4	O	O
-	O	O
5	O	O
x/minute	O	O
and	O	O
on	O	O
the	O	O
third	O	O
day	O	O
ECG	O	O
was	O	O
normal	O	O
,	O	O
potassium	B_Chemical	O
level	O	O
was	O	O
3.34	O	O
meq/L.	O	O
He	O	O
was	O	O
discharged	O	O
on	O	O
7th	O	O
day	O	O
in	O	O
good	O	O
condition	O	O
.	O	O

Quinine	B_Chemical	O
,	O	O
like	O	O
quinidine	B_Chemical	O
,	O	O
is	O	O
a	O	O
chincona	O	O
alkaloid	O	O
that	O	O
has	O	O
anti-arrhythmic	O	O
property	O	O
,	O	O
although	O	O
it	O	O
also	O	O
pro-arrhythmic	O	O
that	O	O
can	O	O
cause	O	O
various	O	O
arrhythmias	B_Disease	O
,	O	O
including	O	O
severe	O	O
arrhythmia	B_Disease	O
such	O	O
as	O	O
multiple	O	O
PVC	B_Disease	O
.	O	O

Administration	O	O
of	O	O
parenteral	O	O
quinine	B_Chemical	O
must	O	O
be	O	O
done	O	O
carefully	O	O
and	O	O
with	O	O
good	O	O
observation	O	O
because	O	O
of	O	O
its	O	O
pro-arrhythmic	O	O
effect	O	O
,	O	O
especially	O	O
in	O	O
older	O	O
patients	O	O
who	O	O
have	O	O
heart	B_Disease	B_Disease
diseases	I_Disease	I_Disease
or	O	O
patients	O	O
with	O	O
electrolyte	B_Disease	B_Disease
disorder	I_Disease	I_Disease
(	O	O
hypokalemia	B_Disease	O
)	O	O
which	O	O
frequently	O	O
occurs	O	O
due	O	O
to	O	O
vomiting	B_Disease	O
and	O	O
or	O	O
diarrhea	B_Disease	O
in	O	O
malaria	B_Disease	O
cases	O	O
.	O	O

Penicillamine-related	O	O
lichenoid	B_Disease	O
dermatitis	I_Disease	O
and	O	O
utility	O	O
of	O	O
zinc	B_Chemical	B_Chemical
acetate	I_Chemical	I_Chemical
in	O	O
a	O	O
Wilson	B_Disease	O
disease	I_Disease	O
patient	O	O
with	O	O
hepatic	O	O
presentation	O	O
,	O	O
anxiety	B_Disease	O
and	O	O
SPECT	O	O
abnormalities	O	O
.	O	O

Wilson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
is	O	O
an	O	O
autosomal	O	O
recessive	O	O
disorder	O	O
of	O	O
hepatic	O	O
copper	B_Chemical	O
metabolism	O	O
with	O	O
consequent	O	O
copper	B_Chemical	O
accumulation	O	O
and	O	O
toxicity	B_Disease	O
in	O	O
many	O	O
tissues	O	O
and	O	O
consequent	O	O
hepatic	B_Disease	O
,	I_Disease	O
neurologic	I_Disease	O
and	I_Disease	O
psychiatric	B_Disease	B_Disease
disorders	I_Disease	I_Disease
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
Wilson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
with	O	O
chronic	B_Disease	B_Disease
liver	I_Disease	I_Disease
disease	I_Disease	I_Disease
;	O	O
moreover	O	O
,	O	O
in	O	O
our	O	O
patient	O	O
,	O	O
presenting	O	O
also	O	O
with	O	O
high	O	O
levels	O	O
of	O	O
state	O	O
anxiety	B_Disease	O
without	O	O
depression	B_Disease	O
,	O	O
99mTc-ECD-SPECT	O	O
showed	O	O
cortical	O	O
hypoperfusion	O	O
in	O	O
frontal	O	O
lobes	O	O
,	O	O
more	O	O
marked	O	O
on	O	O
the	O	O
left	O	O
frontal	O	O
lobe	O	O
.	O	O

During	O	O
the	O	O
follow-up	O	O
of	O	O
our	O	O
patient	O	O
,	O	O
penicillamine	B_Chemical	O
was	O	O
interrupted	O	O
after	O	O
the	O	O
appearance	O	O
of	O	O
a	O	O
lichenoid	B_Disease	B_Disease
dermatitis	I_Disease	I_Disease
,	O	O
and	O	O
zinc	B_Chemical	B_Chemical
acetate	I_Chemical	I_Chemical
permitted	O	O
to	O	O
continue	O	O
the	O	O
successful	O	O
treatment	O	O
of	O	O
the	O	O
patient	O	O
without	O	O
side-effects	O	O
.	O	O

In	O	O
our	O	O
case	O	O
the	O	O
therapy	O	O
with	O	O
zinc	B_Chemical	B_Chemical
acetate	I_Chemical	I_Chemical
represented	O	O
an	O	O
effective	O	O
treatment	O	O
for	O	O
a	O	O
Wilson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
patient	O	O
in	O	O
which	O	O
penicillamine-related	O	O
side	O	O
effects	O	O
appeared	O	O
.	O	O

The	O	O
safety	O	O
of	O	O
the	O	O
zinc	B_Chemical	B_Chemical
acetate	I_Chemical	I_Chemical
allowed	O	O
us	O	O
to	O	O
avoid	O	O
other	O	O
potentially	O	O
toxic	O	O
chelating	O	O
drugs	O	O
;	O	O
this	O	O
observation	O	O
is	O	O
in	O	O
line	O	O
with	O	O
the	O	O
growing	O	O
evidence	O	O
on	O	O
the	O	O
efficacy	O	O
of	O	O
the	O	O
drug	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
Wilson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
.	O	O

Since	O	O
most	O	O
of	O	O
Wilson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
penicillamine-treated	O	O
patients	O	O
do	O	O
not	O	O
seem	O	O
to	O	O
develop	O	O
this	O	O
skin	B_Disease	O
lesion	I_Disease	O
,	O	O
it	O	O
could	O	O
be	O	O
conceivable	O	O
that	O	O
a	O	O
specific	O	O
genetic	O	O
factor	O	O
is	O	O
involved	O	O
in	O	O
drug	O	O
response	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
needed	O	O
for	O	O
a	O	O
better	O	O
clarification	O	O
of	O	O
Wilson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
therapy	O	O
,	O	O
and	O	O
in	O	O
particular	O	O
to	O	O
differentiate	O	O
specific	O	O
therapies	O	O
for	O	O
different	O	O
Wilson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
phenotypes	O	O
.	O	O

A	O	O
dramatic	O	O
drop	B_Disease	O
in	I_Disease	O
blood	I_Disease	O
pressure	I_Disease	O
following	O	O
prehospital	O	O
GTN	B_Chemical	O
administration	O	O
.	O	O

A	O	O
male	O	O
in	O	O
his	O	O
sixties	O	O
with	O	O
no	O	O
history	O	O
of	O	O
cardiac	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
awoke	O	O
with	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
following	O	O
an	O	O
afternoon	O	O
sleep	O	O
.	O	O

The	O	O
patient	O	O
did	O	O
not	O	O
self	O	O
medicate	O	O
.	O	O

The	O	O
patient	O	O
's	O	O
observations	O	O
were	O	O
within	O	O
normal	O	O
limits	O	O
,	O	O
he	O	O
was	O	O
administered	O	O
oxygen	B_Chemical	O
via	O	O
a	O	O
face	O	O
mask	O	O
and	O	O
glyceryl	B_Chemical	O
trinitrate	I_Chemical	O
(	O	O
GTN	B_Chemical	O
)	O	O
.	O	O

Several	O	O
minutes	O	O
after	O	O
the	O	O
GTN	B_Chemical	O
the	O	O
patient	O	O
experienced	O	O
a	O	O
sudden	O	O
drop	B_Disease	O
in	I_Disease	O
blood	I_Disease	O
pressure	I_Disease	O
and	O	O
heart	O	O
rate	O	O
,	O	O
this	O	O
was	O	O
rectified	O	O
by	O	O
atropine	B_Chemical	B_Chemical
sulphate	I_Chemical	I_Chemical
and	O	O
a	O	O
fluid	O	O
challenge	O	O
.	O	O

There	O	O
was	O	O
no	O	O
further	O	O
deterioration	O	O
in	O	O
the	O	O
patient	O	O
's	O	O
condition	O	O
during	O	O
transport	O	O
to	O	O
hospital	O	O
.	O	O

There	O	O
are	O	O
very	O	O
few	O	O
documented	O	O
case	O	O
like	O	O
this	O	O
in	O	O
the	O	O
prehospital	O	O
scientific	O	O
literature	O	O
.	O	O

The	O	O
cause	O	O
appears	O	O
to	O	O
be	O	O
the	O	O
Bezold-Jarish	O	O
reflex	O	O
,	O	O
stimulation	O	O
of	O	O
the	O	O
ventricular	O	O
walls	O	O
which	O	O
in	O	O
turn	O	O
decreases	O	O
sympathetic	O	O
outflow	O	O
from	O	O
the	O	O
vasomotor	O	O
centre	O	O
.	O	O

Prehospital	O	O
care	O	O
providers	O	O
who	O	O
are	O	O
managing	O	O
any	O	O
patient	O	O
with	O	O
a	O	O
syncopal	B_Disease	B_Disease
episode	I_Disease	O
that	O	O
fails	O	O
to	O	O
recover	O	O
within	O	O
a	O	O
reasonable	O	O
time	O	O
frame	O	O
should	O	O
consider	O	O
the	O	O
Bezold-Jarisch	O	O
reflex	O	O
as	O	O
the	O	O
cause	O	O
and	O	O
manage	O	O
the	O	O
patient	O	O
accordingly	O	O
.	O	O

Chronic	O	O
lesion	O	O
of	O	O
rostral	O	O
ventrolateral	O	O
medulla	O	O
in	O	O
spontaneously	O	O
hypertensive	O	O
rats	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
effects	O	O
of	O	O
chronic	O	O
selective	O	O
neuronal	O	O
lesion	O	O
of	O	O
rostral	O	O
ventrolateral	O	O
medulla	O	O
on	O	O
mean	O	O
arterial	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
and	O	O
neurogenic	O	O
tone	O	O
in	O	O
conscious	O	O
,	O	O
unrestrained	O	O
spontaneously	O	O
hypertensive	B_Disease	O
rats	O	O
.	O	O

The	O	O
lesions	O	O
were	O	O
placed	O	O
via	O	O
bilateral	O	O
microinjections	O	O
of	O	O
30	O	O
nmol/200	O	O
nl	O	O
N-methyl-D-aspartic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
.	O	O

The	O	O
restimulation	O	O
of	O	O
this	O	O
area	O	O
with	O	O
N-methyl-D-aspartic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
15	O	O
days	O	O
postlesion	O	O
failed	O	O
to	O	O
produce	O	O
a	O	O
pressor	O	O
response	O	O
.	O	O

One	O	O
day	O	O
postlesion	O	O
,	O	O
the	O	O
resting	O	O
mean	O	O
arterial	O	O
pressure	O	O
was	O	O
significantly	O	O
decreased	O	O
in	O	O
lesioned	O	O
rats	O	O
when	O	O
compared	O	O
with	O	O
sham	O	O
rats	O	O
(	O	O
100	O	O
+	O	O
/-	O	O
7	O	O
versus	O	O
173	O	O
+	O	O
/-	O	O
4	O	O
mm	O	O
Hg	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

Fifteen	O	O
days	O	O
later	O	O
,	O	O
the	O	O
lesioned	O	O
group	O	O
still	O	O
showed	O	O
values	O	O
significantly	O	O
lower	O	O
than	O	O
the	O	O
sham	O	O
group	O	O
(	O	O
150	O	O
+	O	O
/-	O	O
6	O	O
versus	O	O
167	O	O
+	O	O
/-	O	O
5	O	O
mm	O	O
Hg	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
heart	O	O
rate	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
the	O	O
sham	O	O
and	O	O
lesioned	O	O
groups	O	O
.	O	O

The	O	O
ganglionic	O	O
blocker	O	O
trimethaphan	B_Chemical	B_Chemical
(	O	O
5	O	O
mg/kg	O	O
i.v	O	O
.	O	O
)	O	O
caused	O	O
similar	O	O
reductions	O	O
in	O	O
mean	O	O
arterial	O	O
pressure	O	O
in	O	O
both	O	O
lesioned	O	O
and	O	O
sham	O	O
groups	O	O
.	O	O

The	O	O
trimethaphan-induced	O	O
hypotension	B_Disease	O
was	O	O
accompanied	O	O
by	O	O
a	O	O
significant	O	O
bradycardia	B_Disease	O
in	O	O
lesioned	O	O
rats	O	O
(	O	O
-32	O	O
+	O	O
/-	O	O
13	O	O
beats	O	O
per	O	O
minute	O	O
)	O	O
but	O	O
a	O	O
tachycardia	B_Disease	O
in	O	O
sham	O	O
rats	O	O
(	O	O
+	O	O
33	O	O
+	O	O
/-	O	O
12	O	O
beats	O	O
per	O	O
minute	O	O
)	O	O
1	O	O
day	O	O
postlesion	O	O
.	O	O

Therefore	O	O
,	O	O
rostral	O	O
ventrolateral	O	O
medulla	O	O
neurons	O	O
appear	O	O
to	O	O
play	O	O
a	O	O
significant	O	O
role	O	O
in	O	O
maintaining	O	O
hypertension	B_Disease	O
in	O	O
conscious	O	O
spontaneously	O	O
hypertensive	B_Disease	O
rats	O	O
.	O	O

Spinal	O	O
or	O	O
suprabulbar	O	O
structures	O	O
could	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
gradual	O	O
recovery	O	O
of	O	O
the	O	O
hypertension	B_Disease	O
in	O	O
the	O	O
lesioned	O	O
rats	O	O
.	O	O

Acute	B_Disease	B_Disease
encephalopathy	I_Disease	I_Disease
and	O	O
cerebral	B_Disease	B_Disease
vasospasm	I_Disease	I_Disease
after	O	O
multiagent	O	O
chemotherapy	O	O
including	O	O
PEG-asparaginase	B_Chemical	O
and	O	O
intrathecal	O	O
cytarabine	B_Chemical	B_Chemical
for	O	O
the	O	O
treatment	O	O
of	O	O
acute	B_Disease	B_Disease
lymphoblastic	I_Disease	I_Disease
leukemia	I_Disease	I_Disease
.	O	O

A	O	O
7-year-old	O	O
girl	O	O
with	O	O
an	O	O
unusual	O	O
reaction	O	O
to	O	O
induction	O	O
chemotherapy	O	O
for	O	O
precursor	O	O
B-cell	O	O
acute	B_Disease	B_Disease
lymphoblastic	I_Disease	I_Disease
leukemia	I_Disease	I_Disease
(	O	O
ALL	B_Disease	O
)	O	O
is	O	O
described	O	O
.	O	O

The	O	O
patient	O	O
developed	O	O
acute	B_Disease	O
encephalopathy	I_Disease	O
evidenced	O	O
by	O	O
behavioral	O	O
changes	O	O
,	O	O
aphasia	B_Disease	O
,	O	O
incontinence	B_Disease	O
,	O	O
visual	B_Disease	B_Disease
hallucinations	I_Disease	I_Disease
,	O	O
and	O	O
right-sided	O	O
weakness	B_Disease	O
with	O	O
diffuse	O	O
cerebral	B_Disease	B_Disease
vasospasm	I_Disease	I_Disease
on	O	O
magnetic	O	O
resonance	O	O
angiography	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
intrathecal	O	O
cytarabine	B_Chemical	B_Chemical
.	O	O

Vincristine	B_Chemical	O
,	O	O
dexamethasone	B_Chemical	O
,	O	O
and	O	O
polyethylene	B_Chemical	B_Chemical
glycol-asparaginase	I_Chemical	I_Chemical
were	O	O
also	O	O
administered	O	O
before	O	O
the	O	O
episode	O	O
as	O	O
part	O	O
of	O	O
induction	O	O
therapy	O	O
.	O	O

Neurologic	O	O
status	O	O
returned	O	O
to	O	O
baseline	O	O
within	O	O
10	O	O
days	O	O
of	O	O
the	O	O
acute	O	O
event	O	O
,	O	O
and	O	O
magnetic	O	O
resonance	O	O
angiography	O	O
findings	O	O
returned	O	O
to	O	O
normal	O	O
4	O	O
months	O	O
later	O	O
.	O	O

Comparison	O	O
of	O	O
valsartan/hydrochlorothiazide	O	B_Chemical
combination	O	O
therapy	O	O
at	O	O
doses	O	O
up	O	O
to	O	O
320/25	O	O
mg	O	O
versus	O	O
monotherapy	O	O
:	O	O
a	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
followed	O	O
by	O	O
long-term	O	O
combination	O	O
therapy	O	O
in	O	O
hypertensive	B_Disease	O
adults	O	O
.	O	O

BACKGROUND	O	O
:	O	O
One	O	O
third	O	O
of	O	O
patients	O	O
treated	O	O
for	O	O
hypertension	B_Disease	O
attain	O	O
adequate	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
control	O	O
,	O	O
and	O	O
multidrug	O	O
regimens	O	O
are	O	O
often	O	O
required	O	O
.	O	O

Given	O	O
the	O	O
lifelong	O	O
nature	O	O
of	O	O
hypertension	B_Disease	O
,	O	O
there	O	O
is	O	O
a	O	O
need	O	O
to	O	O
evaluate	O	O
the	O	O
long-term	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
higher	O	O
doses	O	O
of	O	O
combination	O	O
anti-hypertensive	O	O
therapies	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
This	O	O
study	O	O
investigated	O	O
the	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
valsartan	B_Chemical	O
(	O	O
VAL	B_Chemical	O
)	O	O
or	O	O
hydrochlorothiazide	B_Chemical	O
(HCTZ)-monotherapy	O	O
and	O	O
higher-dose	O	O
combinations	O	O
in	O	O
patients	O	O
with	O	O
essential	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
.	O	O

METHODS	O	O
:	O	O
The	O	O
first	O	O
part	O	O
of	O	O
this	O	O
study	O	O
was	O	O
an	O	O
8-week	O	O
,	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
double-blind	O	O
,	O	O
placebo	O	O
controlled	O	O
,	O	O
parallel-group	O	O
trial	O	O
.	O	O

Patients	O	O
with	O	O
essential	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
(	O	O
mean	O	O
sitting	O	O
diastolic	O	O
BP	O	O
[	O	O
MSDBP	O	O
]	O	O
,	O	O
>	O	O
or	O	O
=	O	O
95	O	O
mm	O	O
Hg	O	O
and	O	O
<	O	O
110	O	O
mm	O	O
Hg	O	O
)	O	O
were	O	O
randomized	O	O
to	O	O
1	O	O
of	O	O
8	O	O
treatment	O	O
groups	O	O
:	O	O
VAL	B_Chemical	O
160	O	O
or	O	O
320	O	O
mg	O	O
;	O	O
HCTZ	B_Chemical	O
12.5	O	O
or	O	O
25	O	O
mg	O	O
;	O	O
VAL/HCTZ	O	O
160/12.5	O	O
,	O	O
320/12.5	O	O
,	O	O
or	O	O
320/25	O	O
mg	O	O
;	O	O
or	O	O
placebo	O	O
.	O	O

Mean	O	O
changes	O	O
in	O	O
MSDBP	O	O
and	O	O
mean	O	O
sitting	O	O
systolic	O	O
BP	O	O
(	O	O
MSSBP	O	O
)	O	O
were	O	O
analyzed	O	O
at	O	O
the	O	O
8-week	O	O
core	O	O
study	O	O
end	O	O
point	O	O
.	O	O

VAL/HCTZ	O	O
320/12.5	O	O
and	O	O
320/25	O	O
mg	O	O
were	O	O
further	O	O
investigated	O	O
in	O	O
a	O	O
54-week	O	O
,	O	O
open-label	O	O
extension	O	O
.	O	O

Response	O	O
was	O	O
defined	O	O
as	O	O
MSDBP	O	O
<	O	O
90	O	O
mm	O	O
Hg	O	O
or	O	O
a	O	O
>	O	O
or	O	O
=	O	O
10	O	O
mm	O	O
Hg	O	O
decrease	O	O
compared	O	O
to	O	O
baseline	O	O
.	O	O

Control	O	O
was	O	O
defined	O	O
as	O	O
MSDBP	O	O
<	O	O
90	O	O
mm	O	O
Hg	O	O
compared	O	O
with	O	O
baseline	O	O
.	O	O

Tolerability	O	O
was	O	O
assessed	O	O
by	O	O
monitoring	O	O
adverse	O	O
events	O	O
at	O	O
randomization	O	O
and	O	O
all	O	O
subsequent	O	O
study	O	O
visits	O	O
and	O	O
regular	O	O
evaluation	O	O
of	O	O
hematology	O	O
and	O	O
blood	O	O
chemistry	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
1346	O	O
patients	O	O
were	O	O
randomized	O	O
into	O	O
the	O	O
8-week	O	O
core	O	O
study	O	O
(	O	O
734	O	O
men	O	O
,	O	O
612	O	O
women	O	O
;	O	O
924	O	O
white	O	O
,	O	O
291	O	O
black	O	O
,	O	O
23	O	O
Asian	O	O
,	O	O
108	O	O
other	O	O
;	O	O
mean	O	O
age	O	O
,	O	O
52.7	O	O
years	O	O
;	O	O
mean	O	O
weight	O	O
,	O	O
92.6	O	O
kg	O	O
)	O	O
.	O	O

All	O	O
active	O	O
treatments	O	O
were	O	O
associated	O	O
with	O	O
significantly	O	O
reduced	O	O
MSSBP	O	O
and	O	O
MSDBP	O	O
during	O	O
the	O	O
core	O	O
8-week	O	O
study	O	O
,	O	O
with	O	O
each	O	O
monotherapy	O	O
significantly	O	O
contributing	O	O
to	O	O
the	O	O
overall	O	O
effect	O	O
of	O	O
combination	O	O
therapy	O	O
(	O	O
VAL	B_Chemical	O
and	O	O
HCTZ	B_Chemical	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Each	O	O
combination	O	O
was	O	O
associated	O	O
with	O	O
significantly	O	O
greater	O	O
reductions	O	O
in	O	O
MSSBP	O	O
and	O	O
MSDBP	O	O
compared	O	O
with	O	O
the	O	O
monotherapies	O	O
and	O	O
placebo	O	O
(	O	O
all	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
reduction	O	O
in	O	O
MSSBP/MSDBP	O	O
with	O	O
VAL/HCTZ	O	O
320/25	O	O
mg	O	O
was	O	O
24.7/16.6	O	O
mm	O	O
Hg	O	O
,	O	O
compared	O	O
with	O	O
5.9/7.0	O	O
mm	O	O
Hg	O	O
with	O	O
placebo	O	O
.	O	O

The	O	O
reduction	O	O
in	O	O
MSSBP	O	O
was	O	O
significantly	O	O
greater	O	O
with	O	O
VAL/HCTZ	O	O
320/25	O	O
mg	O	O
compared	O	O
with	O	O
VAL/HCTZ	O	O
160/12.5	O	O
mg	O	O
(	O	O
P	O	O
<	O	O
0.002	O	O
)	O	O
.	O	O

Rates	O	O
of	O	O
response	O	O
and	O	O
BP	O	O
control	O	O
were	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
groups	O	O
that	O	O
received	O	O
combination	O	O
treatment	O	O
compared	O	O
with	O	O
those	O	O
that	O	O
received	O	O
monotherapy	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
hypokalemia	B_Disease	O
was	O	O
lower	O	O
with	O	O
VAL/HCTZ	O	O
combinations	O	O
(	O	O
1.8%-6.1	O	O
%	O	O
)	O	O
than	O	O
with	O	O
HCTZ	B_Chemical	O
monotherapies	O	O
(	O	O
7.1%-13.3	O	O
%	O	O
)	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
adverse	O	O
events	O	O
in	O	O
the	O	O
core	O	O
study	O	O
were	O	O
of	O	O
mild	O	O
to	O	O
moderate	O	O
severity	O	O
.	O	O

The	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
VAL/HCTZ	O	O
combinations	O	O
were	O	O
maintained	O	O
during	O	O
the	O	O
extension	O	O
(	O	O
797	O	O
patients	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
this	O	O
study	O	O
population	O	O
,	O	O
combination	O	O
therapies	O	O
with	O	O
VAL/HCTZ	O	O
were	O	O
associated	O	O
with	O	O
significantly	O	O
greater	O	O
BP	O	O
reductions	O	O
compared	O	O
with	O	O
either	O	O
monotherapy	O	O
,	O	O
were	O	O
well	O	O
tolerated	O	O
,	O	O
and	O	O
were	O	O
associated	O	O
with	O	O
less	O	O
hypokalemia	B_Disease	O
than	O	O
HCTZ	B_Chemical	O
alone	O	O
.	O	O

Succimer	B_Chemical	B_Chemical
chelation	O	O
improves	O	O
learning	O	O
,	O	O
attention	O	O
,	O	O
and	O	O
arousal	O	O
regulation	O	O
in	O	O
lead-exposed	O	O
rats	O	O
but	O	O
produces	O	O
lasting	O	O
cognitive	B_Disease	B_Disease
impairment	I_Disease	I_Disease
in	O	O
the	O	O
absence	O	O
of	O	O
lead	B_Chemical	O
exposure	O	O
.	O	O

BACKGROUND	O	O
:	O	O
There	O	O
is	O	O
growing	O	O
pressure	O	O
for	O	O
clinicians	O	O
to	O	O
prescribe	O	O
chelation	O	O
therapy	O	O
at	O	O
only	O	O
slightly	O	O
elevated	O	O
blood	O	O
lead	B_Chemical	O
levels	O	O
.	O	O

However	O	O
,	O	O
very	O	O
few	O	O
studies	O	O
have	O	O
evaluated	O	O
whether	O	O
chelation	O	O
improves	O	O
cognitive	O	O
outcomes	O	O
in	O	O
Pb-exposed	O	O
children	O	O
,	O	O
or	O	O
whether	O	O
these	O	O
agents	O	O
have	O	O
adverse	O	O
effects	O	O
that	O	O
may	O	O
affect	O	O
brain	O	O
development	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
Pb	B_Chemical	O
exposure	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
answer	O	O
these	O	O
questions	O	O
,	O	O
using	O	O
a	O	O
rodent	O	O
model	O	O
of	O	O
early	O	O
childhood	O	O
Pb	B_Chemical	O
exposure	O	O
and	O	O
treatment	O	O
with	O	O
succimer	B_Chemical	B_Chemical
,	O	O
a	O	O
widely	O	O
used	O	O
chelating	O	O
agent	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
Pb	B_Disease	O
poisoning	I_Disease	O
.	O	O

RESULTS	O	O
:	O	O
Pb	B_Chemical	O
exposure	O	O
produced	O	O
lasting	O	O
impairments	B_Disease	O
in	I_Disease	O
learning	I_Disease	O
,	I_Disease	O
attention	I_Disease	O
,	I_Disease	O
inhibitory	I_Disease	O
control	I_Disease	O
,	I_Disease	O
and	I_Disease	O
arousal	I_Disease	O
regulation	I_Disease	O
,	O	O
paralleling	O	O
the	O	O
areas	O	O
of	O	O
dysfunction	O	O
seen	O	O
in	O	O
Pb-exposed	O	O
children	O	O
.	O	O

Succimer	B_Chemical	B_Chemical
treatment	O	O
of	O	O
the	O	O
Pb-exposed	O	O
rats	O	O
significantly	O	O
improved	O	O
learning	O	O
,	O	O
attention	O	O
,	O	O
and	O	O
arousal	O	O
regulation	O	O
,	O	O
although	O	O
the	O	O
efficacy	O	O
of	O	O
the	O	O
treatment	O	O
varied	O	O
as	O	O
a	O	O
function	O	O
of	O	O
the	O	O
Pb	B_Chemical	O
exposure	O	O
level	O	O
and	O	O
the	O	O
specific	O	O
functional	O	O
deficit	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
succimer	B_Chemical	B_Chemical
treatment	O	O
of	O	O
rats	O	O
not	O	O
previously	O	O
exposed	O	O
to	O	O
Pb	B_Chemical	O
produced	O	O
lasting	O	O
and	O	O
pervasive	O	O
cognitive	B_Disease	O
and	I_Disease	O
affective	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
comparable	O	O
in	O	O
magnitude	O	O
to	O	O
that	O	O
produced	O	O
by	O	O
the	O	O
higher	O	O
Pb	B_Chemical	O
exposure	O	O
regimen	O	O
.	O	O
CONCLUSIONS	O	O
:	O	O
These	O	O
are	O	O
the	O	O
first	O	O
data	O	O
,	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
to	O	O
show	O	O
that	O	O
treatment	O	O
with	O	O
any	O	O
chelating	O	O
agent	O	O
can	O	O
alleviate	O	O
cognitive	B_Disease	B_Disease
deficits	I_Disease	I_Disease
due	O	O
to	O	O
Pb	B_Chemical	O
exposure	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
it	O	O
may	O	O
be	O	O
possible	O	O
to	O	O
identify	O	O
a	O	O
succimer	B_Chemical	B_Chemical
treatment	O	O
protocol	O	O
that	O	O
improves	O	O
cognitive	O	O
outcomes	O	O
in	O	O
Pb-exposed	O	O
children	O	O
.	O	O

However	O	O
,	O	O
they	O	O
also	O	O
suggest	O	O
that	O	O
succimer	B_Chemical	B_Chemical
treatment	O	O
should	O	O
be	O	O
strongly	O	O
discouraged	O	O
for	O	O
children	O	O
who	O	O
do	O	O
not	O	O
have	O	O
elevated	O	O
tissue	O	O
levels	O	O
of	O	O
Pb	B_Chemical	O
or	O	O
other	O	O
heavy	O	O
metals	O	O
.	O	O

Caffeine	B_Chemical	O
challenge	O	O
test	O	O
in	O	O
panic	B_Disease	O
disorder	I_Disease	O
and	O	O
depression	B_Disease	O
with	O	O
panic	B_Disease	O
attacks	I_Disease	O
.	O	O

Our	O	O
aim	O	O
was	O	O
to	O	O
observe	O	O
if	O	O
patients	O	O
with	O	O
panic	B_Disease	B_Disease
disorder	I_Disease	I_Disease
(	O	O
PD	B_Disease	O
)	O	O
and	O	O
patients	O	O
with	O	O
major	B_Disease	B_Disease
depression	I_Disease	I_Disease
with	O	O
panic	B_Disease	O
attacks	I_Disease	O
(	O	O
MDP	B_Disease	O
)	O	O
(	O	O
Diagnostic	O	O
and	O	O
Statistical	O	O
Manual	O	O
of	O	O
Mental	B_Disease	B_Disease
Disorders	I_Disease	I_Disease
,	O	O
Fourth	O	O
Edition	O	O
criteria	O	O
)	O	O
respond	O	O
in	O	O
a	O	O
similar	O	O
way	O	O
to	O	O
the	O	O
induction	O	O
of	O	O
panic	B_Disease	B_Disease
attacks	I_Disease	I_Disease
by	O	O
an	O	O
oral	O	O
caffeine	B_Chemical	O
challenge	O	O
test	O	O
.	O	O

We	O	O
randomly	O	O
selected	O	O
29	O	O
patients	O	O
with	O	O
PD	B_Disease	O
,	O	O
27	O	O
with	O	O
MDP	B_Disease	O
,	O	O
25	O	O
with	O	O
major	B_Disease	B_Disease
depression	I_Disease	I_Disease
without	O	O
panic	B_Disease	O
attacks	I_Disease	O
(	O	O
MD	B_Disease	O
)	O	O
,	O	O
and	O	O
28	O	O
healthy	O	O
volunteers	O	O
.	O	O

The	O	O
patients	O	O
had	O	O
no	O	O
psychotropic	O	O
drug	O	O
for	O	O
at	O	O
least	O	O
a	O	O
4-week	O	O
period	O	O
.	O	O

In	O	O
a	O	O
randomized	O	O
double-blind	O	O
experiment	O	O
performed	O	O
in	O	O
2	O	O
occasions	O	O
7	O	O
days	O	O
apart	O	O
,	O	O
480	O	O
mg	O	O
caffeine	B_Chemical	O
and	O	O
a	O	O
caffeine-free	O	O
(	O	O
placebo	O	O
)	O	O
solution	O	O
were	O	O
administered	O	O
in	O	O
a	O	O
coffee	O	O
form	O	O
and	O	O
anxiety	B_Disease	O
scales	O	O
were	O	O
applied	O	O
before	O	O
and	O	O
after	O	O
each	O	O
test	O	O
.	O	O

A	O	O
total	O	O
of	O	O
58.6	O	O
%	O	O
(	O	O
n	O	O
=	O	O
17	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
PD	B_Disease	O
,	O	O
44.4	O	O
%	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
MDP	B_Disease	O
,	O	O
12.0	O	O
%	O	O
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
MD	B_Disease	O
,	O	O
and	O	O
7.1	O	O
%	O	O
(	O	O
n=	O	O
2	O	O
)	O	O
of	O	O
control	O	O
subjects	O	O
had	O	O
a	O	O
panic	B_Disease	O
attack	I_Disease	O
after	O	O
the	O	O
480-mg	O	O
caffeine	B_Chemical	O
challenge	O	O
test	O	O
(	O	O
chi(2)(3	O	O
)	O	O
=	O	O
16.22	O	O
,	O	O
P	O	O
=	O	O
.001	O	O
)	O	O
.	O	O

The	O	O
patients	O	O
with	O	O
PD	B_Disease	O
and	O	O
MDP	B_Disease	O
were	O	O
more	O	O
sensitive	O	O
to	O	O
caffeine	B_Chemical	O
than	O	O
were	O	O
patients	O	O
with	O	O
MD	B_Disease	O
and	O	O
healthy	O	O
volunteers	O	O
.	O	O

No	O	O
panic	B_Disease	O
attack	I_Disease	O
was	O	O
observed	O	O
after	O	O
the	O	O
caffeine-free	O	O
solution	O	O
intake	O	O
.	O	O

The	O	O
patients	O	O
with	O	O
MD	B_Disease	O
had	O	O
a	O	O
lower	O	O
heart	O	O
rate	O	O
response	O	O
to	O	O
the	O	O
test	O	O
than	O	O
all	O	O
the	O	O
other	O	O
groups	O	O
(	O	O
2-way	O	O
analysis	O	O
of	O	O
variance	O	O
,	O	O
group	O	O
by	O	O
time	O	O
interaction	O	O
with	O	O
Greenhouse-Geisser	O	O
correction	O	O
:	O	O
F(3,762	O	O
)	O	O
=	O	O
2.85	O	O
,	O	O
P	O	O
=	O	O
.026	O	O
)	O	O
.	O	O

Our	O	O
data	O	O
suggest	O	O
that	O	O
there	O	O
is	O	O
an	O	O
association	O	O
between	O	O
panic	B_Disease	O
attacks	I_Disease	O
,	O	O
no	O	O
matter	O	O
if	O	O
associated	O	O
with	O	O
PD	B_Disease	O
or	O	O
MDP	B_Disease	O
,	O	O
and	O	O
hyperreactivity	O	O
to	O	O
an	O	O
oral	O	O
caffeine	B_Chemical	O
challenge	O	O
test	O	O
.	O	O

Mitral	O	B_Disease
annuloplasty	O	I_Disease
as	O	O
a	O	O
ventricular	O	O
restoration	O	O
method	O	O
for	O	O
the	O	O
failing	O	O
left	O	O
ventricle	O	O
:	O	O
a	O	O
pilot	O	O
study	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
AIM	O	O
OF	O	O
THE	O	O
STUDY	O	O
:	O	O
Undersized	O	O
mitral	O	O
annuloplasty	O	O
(	O	O
MAP	O	O
)	O	O
is	O	O
effective	O	O
in	O	O
patients	O	O
with	O	O
dilated	B_Disease	B_Disease
cardiomyopathy	I_Disease	I_Disease
and	O	O
functional	O	B_Disease
mitral	B_Disease	I_Disease
regurgitation	I_Disease	I_Disease
(	O	O
MR	B_Disease	O
)	O	O
since	O	O
,	O	O
as	O	O
well	O	O
as	O	O
addressing	O	O
the	O	O
MR	B_Disease	O
,	O	O
the	O	O
MAP	O	O
may	O	O
also	O	O
reshape	O	O
the	O	O
dilated	O	O
left	O	O
ventricular	O	O
(	O	O
LV	O	O
)	O	O
base	O	O
.	O	O

However	O	O
,	O	O
the	O	O
direct	O	O
benefits	O	O
of	O	O
this	O	O
possible	O	O
reshaping	O	O
on	O	O
LV	O	O
function	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
underlying	O	O
MR	B_Disease	O
remain	O	O
incompletely	O	O
understood	O	O
.	O	O

The	O	O
study	O	O
aim	O	O
was	O	O
to	O	O
identify	O	O
these	O	O
benefits	O	O
in	O	O
a	O	O
canine	O	O
model	O	O
of	O	O
acute	O	B_Disease
heart	B_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

METHODS	O	O
:	O	O
Six	O	O
dogs	O	O
underwent	O	O
MAP	O	O
with	O	O
a	O	O
prosthetic	O	O
band	O	O
on	O	O
the	O	O
posterior	O	O
mitral	O	O
annulus	O	O
,	O	O
using	O	O
four	O	O
mattress	O	O
sutures	O	O
.	O	O

The	O	O
sutures	O	O
were	O	O
passed	O	O
individually	O	O
through	O	O
four	O	O
tourniquets	O	O
and	O	O
exteriorized	O	O
untied	O	O
via	O	O
the	O	O
left	O	O
atriotomy	O	O
.	O	O

Sonomicrometry	O	O
crystals	O	O
were	O	O
implanted	O	O
around	O	O
the	O	O
mitral	O	O
annulus	O	O
and	O	O
left	O	O
ventricle	O	O
to	O	O
measure	O	O
geometry	O	O
and	O	O
regional	O	O
function	O	O
.	O	O

Acute	O	B_Disease
heart	B_Disease	I_Disease
failure	I_Disease	I_Disease
was	O	O
induced	O	O
by	O	O
propranolol	B_Chemical	B_Chemical
and	O	O
volume	O	O
loading	O	O
after	O	O
weaning	O	O
from	O	O
cardiopulmonary	O	O
bypass	O	O
;	O	O
an	O	O
absence	O	O
of	O	O
MR	B_Disease	O
was	O	O
confirmed	O	O
by	O	O
echocardiography	O	O
.	O	O

MAP	O	O
was	O	O
accomplished	O	O
by	O	O
cinching	O	O
the	O	O
tourniquets	O	O
.	O	O

Data	O	O
were	O	O
acquired	O	O
at	O	O
baseline	O	O
,	O	O
after	O	O
induction	O	O
of	O	O
acute	O	B_Disease
heart	B_Disease	I_Disease
failure	I_Disease	I_Disease
,	O	O
and	O	O
after	O	O
MAP	O	O
.	O	O

RESULTS	O	O
:	O	O
MAP	O	O
decreased	O	O
mitral	O	O
annular	O	O
dimensions	O	O
in	O	O
both	O	O
commissure-commissure	O	O
and	O	O
septal-lateral	O	O
directions	O	O
.	O	O

Concomitantly	O	O
,	O	O
the	O	O
diastolic	O	O
diameter	O	O
of	O	O
the	O	O
LV	O	O
base	O	O
and	O	O
LV	O	O
sphericity	O	O
decreased	O	O
(	O	O
i.e.	O	O
,	O	O
improved	O	O
)	O	O
from	O	O
37.4	O	O
+	O	O
/-	O	O
9.3	O	O
to	O	O
35.9	O	O
+	O	O
/-	O	O
10	O	O
mm	O	O
(	O	O
p	O	O
=	O	O
0.063	O	O
)	O	O
,	O	O
and	O	O
from	O	O
67.9	O	O
+	O	O
/-	O	O
18.6	O	O
%	O	O
to	O	O
65.3	O	O
+	O	O
/-	O	O
18.9	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0.016	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

Decreases	O	O
were	O	O
evident	O	O
in	O	O
both	O	O
LV	O	O
end-diastolic	O	O
pressure	O	O
(	O	O
from	O	O
17	O	O
+	O	O
/-	O	O
7	O	O
to	O	O
15	O	O
+	O	O
/-	O	O
6	O	O
mmHg	O	O
,	O	O
p	O	O
=	O	O
0.0480	O	O
and	O	O
Tau	O	O
(	O	O
from	O	O
48	O	O
+	O	O
/-	O	O
8	O	O
to	O	O
45	O	O
+	O	O
/-	O	O
8	O	O
ms	O	O
,	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
,	O	O
while	O	O
fractional	O	O
shortening	O	O
at	O	O
the	O	O
LV	O	O
base	O	O
increased	O	O
from	O	O
7.7	O	O
+	O	O
/-	O	O
4.5	O	O
%	O	O
to	O	O
9.4	O	O
+	O	O
/-	O	O
4.5	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0.045	O	O
)	O	O
.	O	O

After	O	O
MAP	O	O
,	O	O
increases	O	O
were	O	O
identified	O	O
in	O	O
both	O	O
cardiac	O	O
output	O	O
(	O	O
from	O	O
1.54	O	O
+	O	O
/-	O	O
0.57	O	O
to	O	O
1.65	O	O
+	O	O
/-	O	O
0.57	O	O
1/min	O	O
)	O	O
and	O	O
Emax	O	O
(	O	O
from	O	O
1.86	O	O
+	O	O
/-	O	O
0.9	O	O
to	O	O
2.41	O	O
+	O	O
/-	O	O
1.31	O	O
mmHg/ml	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
data	O	O
acquired	O	O
suggest	O	O
that	O	O
isolated	O	O
MAP	O	O
may	O	O
have	O	O
certain	O	O
benefits	O	O
on	O	O
LV	O	O
dimension/function	O	O
in	O	O
acute	O	B_Disease
heart	B_Disease	I_Disease
failure	I_Disease	I_Disease
,	O	O
even	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
MR	B_Disease	O
.	O	O

However	O	O
,	O	O
further	O	O
investigations	O	O
are	O	O
warranted	O	O
in	O	O
a	O	O
model	O	O
of	O	O
chronic	O	B_Disease
heart	B_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

Piperacillin/tazobactam-induced	O	O
seizure	B_Disease	O
rapidly	O	O
reversed	O	O
by	O	O
high	O	O
flux	O	O
hemodialysis	O	O
in	O	O
a	O	O
patient	O	O
on	O	O
peritoneal	O	O
dialysis	O	O
.	O	O

Despite	O	O
popular	O	O
use	O	O
of	O	O
piperacillin	B_Chemical	O
,	O	O
the	O	O
dire	O	O
neurotoxicity	B_Disease	B_Disease
associated	O	O
with	O	O
piperacillin	B_Chemical	O
still	O	O
goes	O	O
unrecognized	O	O
,	O	O
leading	O	O
to	O	O
a	O	O
delay	O	O
in	O	O
appropriate	O	O
management	O	O
.	O	O

We	O	O
report	O	O
a	O	O
57-year-old	O	O
woman	O	O
with	O	O
end-stage	B_Disease	B_Disease
renal	I_Disease	I_Disease
disease	I_Disease	I_Disease
receiving	O	O
continuous	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
(	O	O
CAPD	O	O
)	O	O
,	O	O
who	O	O
developed	O	O
slurred	O	O
speech	O	O
,	O	O
tremor	B_Disease	O
,	O	O
bizarre	O	O
behavior	O	O
,	O	O
progressive	O	O
mental	O	B_Disease
confusion	B_Disease	I_Disease
,	O	O
and	O	O
2	O	O
episodes	O	O
of	O	O
generalized	O	O
tonic-clonic	B_Disease	O
seizure	I_Disease	O
(	O	O
GTCS	B_Disease	O
)	O	O
after	O	O
5	O	O
doses	O	O
of	O	O
piperacillin/tazobactam	B_Chemical	B_Chemical
(	O	O
2	O	O
g/250	O	O
mg	O	O
)	O	O
were	O	O
given	O	O
for	O	O
bronchiectasis	B_Disease	O
with	O	O
secondary	B_Disease	O
infection	I_Disease	O
.	O	O

The	O	O
laboratory	O	O
data	O	O
revealed	O	O
normal	O	O
plasma	O	O
electrolyte	O	O
and	O	O
ammonia	B_Chemical	O
levels	O	O
but	O	O
leukocytosis	B_Disease	O
.	O	O

Neurologic	O	O
examinations	O	O
showed	O	O
dysarthria	B_Disease	O
and	O	O
bilateral	O	O
Babinski	O	O
sign	O	O
.	O	O

Computed	O	O
tomography	O	O
of	O	O
brain	O	O
and	O	O
electroencephalogram	O	O
were	O	O
unremarkable	O	O
.	O	O

Despite	O	O
the	O	O
use	O	O
of	O	O
antiepileptic	O	O
agents	O	O
,	O	O
another	O	O
GTCS	B_Disease	O
episode	O	O
recurred	O	O
after	O	O
the	O	O
sixth	O	O
dose	O	O
of	O	O
piperacillin/tazobactam	B_Chemical	O
.	O	O

Brain	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
did	O	O
not	O	O
demonstrate	O	O
acute	O	B_Disease
infarction	B_Disease	I_Disease
and	O	O
organic	B_Disease	O
brain	I_Disease	O
lesions	I_Disease	O
.	O	O

Initiation	O	O
of	O	O
high-flux	O	O
hemodialysis	O	O
rapidly	O	O
reversed	O	O
the	O	O
neurologic	O	B_Disease
symptoms	O	I_Disease
within	O	O
4	O	O
hours	O	O
.	O	O

Piperacillin-induced	O	O
encephalopathy	B_Disease	O
should	O	O
be	O	O
considered	O	O
in	O	O
any	O	O
uremic	B_Disease	O
patients	O	O
with	O	O
unexplained	O	O
neurological	O	O
manifestations	O	O
.	O	O

CAPD	O	O
is	O	O
inefficient	O	O
in	O	O
removing	O	O
piperacillin	B_Chemical	O
,	O	O
whereas	O	O
hemodialysis	O	O
can	O	O
rapidly	O	O
terminate	O	O
the	O	O
piperacillin-induced	O	O
encephalopathy	B_Disease	O
.	O	O

Frequency	O	O
of	O	O
transient	O	O
ipsilateral	O	O
vocal	O	O
cord	O	O
paralysis	O	O
in	O	O
patients	O	O
undergoing	O	O
carotid	O	O
endarterectomy	O	O
under	O	O
local	O	O
anesthesia	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Especially	O	O
because	O	O
of	O	O
improvements	O	O
in	O	O
clinical	O	O
neurologic	O	O
monitoring	O	O
,	O	O
carotid	O	O
endarterectomy	O	O
done	O	O
under	O	O
local	O	O
anesthesia	O	O
has	O	O
become	O	O
the	O	O
technique	O	O
of	O	O
choice	O	O
in	O	O
several	O	O
centers	O	O
.	O	O

Temporary	O	O
ipsilateral	O	O
vocal	B_Disease	O
nerve	I_Disease	O
palsies	I_Disease	O
due	O	O
to	O	O
local	O	O
anesthetics	O	O
have	O	O
been	O	O
described	O	O
,	O	O
however	O	O
.	O	O

Such	O	O
complications	O	O
are	O	O
most	O	O
important	O	O
in	O	O
situations	O	O
where	O	O
there	O	O
is	O	O
a	O	O
pre-existing	O	O
contralateral	O	O
paralysis	B_Disease	O
.	O	O

We	O	O
therefore	O	O
examined	O	O
the	O	O
effect	O	O
of	O	O
local	O	O
anesthesia	O	O
on	O	O
vocal	O	O
cord	O	O
function	O	O
to	O	O
better	O	O
understand	O	O
its	O	O
possible	O	O
consequences	O	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
prospective	O	O
study	O	O
included	O	O
28	O	O
patients	O	O
undergoing	O	O
carotid	O	O
endarterectomy	O	O
under	O	O
local	O	O
anesthesia	O	O
.	O	O

Vocal	O	O
cord	O	O
function	O	O
was	O	O
evaluated	O	O
before	O	O
,	O	O
during	O	O
,	O	O
and	O	O
after	O	O
surgery	O	O
(	O	O
postoperative	O	O
day	O	O
1	O	O
)	O	O
using	O	O
flexible	O	O
laryngoscopy	O	O
.	O	O

Anesthesia	O	O
was	O	O
performed	O	O
by	O	O
injecting	O	O
20	O	O
to	O	O
40	O	O
mL	O	O
of	O	O
a	O	O
mixture	O	O
of	O	O
long-acting	O	O
(	O	O
ropivacaine	B_Chemical	B_Chemical
)	O	O
and	O	O
short-acting	O	O
(	O	O
prilocaine	B_Chemical	B_Chemical
)	O	O
anesthetic	O	O
.	O	O

RESULTS	O	O
:	O	O
All	O	O
patients	O	O
had	O	O
normal	O	O
vocal	O	O
cord	O	O
function	O	O
preoperatively	O	O
.	O	O

Twelve	O	O
patients	O	O
(	O	O
43	O	O
%	O	O
)	O	O
were	O	O
found	O	O
to	O	O
have	O	O
intraoperative	O	O
ipsilateral	O	O
vocal	B_Disease	O
cord	I_Disease	O
paralysis	I_Disease	O
.	O	O

It	O	O
resolved	O	O
in	O	O
all	O	O
cases	O	O
<	O	O
or	O	O
=	O	O
24	O	O
hours	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
operating	O	O
time	O	O
or	O	O
volume	O	O
or	O	O
frequency	O	O
of	O	O
anesthetic	O	O
administration	O	O
in	O	O
patients	O	O
with	O	O
temporary	O	O
vocal	B_Disease	O
cord	I_Disease	O
paralysis	I_Disease	O
compared	O	O
with	O	O
those	O	O
without	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Local	O	O
anesthesia	O	O
led	O	O
to	O	O
temporary	O	O
ipsilateral	O	O
vocal	B_Disease	O
cord	I_Disease	O
paralysis	I_Disease	O
in	O	O
almost	O	O
half	O	O
of	O	O
these	O	O
patients	O	O
.	O	O

Because	O	O
pre-existing	O	O
paralysis	B_Disease	O
is	O	O
of	O	O
a	O	O
relevant	O	O
frequency	O	O
(	O	O
up	O	O
to	O	O
3	O	O
%	O	O
)	O	O
,	O	O
a	O	O
preoperative	O	O
evaluation	O	O
of	O	O
vocal	O	O
cord	O	O
function	O	O
before	O	O
carotid	O	O
endarterectomy	O	O
under	O	O
local	O	O
anesthesia	O	O
is	O	O
recommended	O	O
to	O	O
avoid	O	O
intraoperative	O	O
bilateral	O	O
paralysis	B_Disease	O
.	O	O

In	O	O
patients	O	O
with	O	O
preoperative	O	O
contralateral	O	O
vocal	B_Disease	O
cord	I_Disease	O
paralysis	I_Disease	O
,	O	O
surgery	O	O
under	O	O
general	O	O
anesthesia	O	O
should	O	O
be	O	O
considered	O	O
.	O	O

Impaired	B_Disease	O
fear	I_Disease	O
recognition	I_Disease	O
in	O	O
regular	O	O
recreational	O	O
cocaine	B_Chemical	O
users	O	O
.	O	O

INTRODUCTION	O	O
:	O	O
The	O	O
ability	O	O
to	O	O
read	O	O
facial	O	O
expressions	O	O
is	O	O
essential	O	O
for	O	O
normal	O	O
human	O	O
social	O	O
interaction	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
conduct	O	O
the	O	O
first	O	O
investigation	O	O
of	O	O
facial	O	O
expression	O	O
recognition	O	O
performance	O	O
in	O	O
recreational	O	O
cocaine	B_Chemical	O
users	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
Three	O	O
groups	O	O
,	O	O
comprised	O	O
of	O	O
21	O	O
cocaine	B_Chemical	O
naive	O	O
participants	O	O
(	O	O
CN	O	O
)	O	O
,	O	O
 	O	O
30	O	O
occasional	O	O
cocaine	B_Chemical	O
(	O	O
OC	O	O
)	O	O
,	O	O
and	O	O
48	O	O
regular	O	O
recreational	O	O
cocaine	B_Chemical	O
(	O	O
RC	O	O
)	O	O
users	O	O
,	O	O
were	O	O
compared	O	O
.	O	O

An	O	O
emotional	O	O
facial	O	O
expression	O	O
(	O	O
EFE	O	O
)	O	O
task	O	O
consisting	O	O
of	O	O
a	O	O
male	O	O
and	O	O
female	O	O
face	O	O
expressing	O	O
six	O	O
basic	O	O
emotions	O	O
(	O	O
happiness	O	O
,	O	O
surprise	O	O
,	O	O
sadness	O	O
,	O	O
anger	O	O
,	O	O
fear	O	O
,	O	O
and	O	O
disgust	O	O
)	O	O
was	O	O
administered	O	O
.	O	O

Mean	O	O
percent	O	O
accuracy	O	O
and	O	O
latencies	O	O
for	O	O
correct	O	O
responses	O	O
across	O	O
eight	O	O
presentations	O	O
of	O	O
each	O	O
basic	O	O
emotion	O	O
were	O	O
derived	O	O
.	O	O

Participants	O	O
were	O	O
also	O	O
assessed	O	O
with	O	O
the	O	O
"	O	O
Eyes	O	O
task	O	O
"	O	O
to	O	O
investigate	O	O
their	O	O
ability	O	O
to	O	O
recognize	O	O
more	O	O
complex	O	O
emotional	O	O
states	O	O
and	O	O
the	O	O
Symptom	O	O
CheckList-90-Revised	O	O
to	O	O
measure	O	O
psychopathology	O	O
.	O	O

RESULTS	O	O
:	O	O
There	O	O
were	O	O
no	O	O
group	O	O
differences	O	O
in	O	O
psychopathology	O	O
or	O	O
"	O	O
eyes	O	O
task	O	O
"	O	O
performance	O	O
,	O	O
but	O	O
the	O	O
RC	O	O
group	O	O
,	O	O
who	O	O
otherwise	O	O
had	O	O
similar	O	O
illicit	O	O
substance	O	O
use	O	O
histories	O	O
to	O	O
the	O	O
OC	O	O
group	O	O
,	O	O
exhibited	O	O
impaired	B_Disease	O
fear	I_Disease	O
recognition	I_Disease	O
accuracy	O	O
compared	O	O
to	O	O
the	O	O
OC	O	O
and	O	O
CN	O	O
groups	O	O
.	O	O

The	O	O
RC	O	O
group	O	O
also	O	O
correctly	O	O
identified	O	O
anger	O	O
,	O	O
fear	O	O
,	O	O
happiness	O	O
,	O	O
and	O	O
surprise	O	O
,	O	O
more	O	O
slowly	O	O
than	O	O
CN	O	O
,	O	O
but	O	O
not	O	O
OC	O	O
participants	O	O
.	O	O

The	O	O
OC	O	O
group	O	O
was	O	O
slower	O	O
than	O	O
CN	O	O
when	O	O
correctly	O	O
identifying	O	O
disgust	O	O
.	O	O

The	O	O
selective	O	O
deficit	B_Disease	O
in	I_Disease	O
fear	I_Disease	O
recognition	I_Disease	O
accuracy	O	O
manifested	O	O
by	O	O
the	O	O
RC	O	O
group	O	O
can	O	O
not	O	O
be	O	O
explained	O	O
by	O	O
the	O	O
subacute	O	O
effects	O	O
of	O	O
cocaine	B_Chemical	O
,	O	O
or	O	O
ecstasy	B_Chemical	O
,	O	O
because	O	O
recent	O	O
and	O	O
less	O	O
recent	O	O
users	O	O
of	O	O
these	O	O
drugs	O	O
within	O	O
this	O	O
group	O	O
were	O	O
similarly	O	O
impaired	O	O
.	O	O

Possible	O	O
parallels	O	O
between	O	O
RC	O	O
users	O	O
and	O	O
psychopaths	B_Disease	O
with	O	O
respect	O	O
to	O	O
impaired	B_Disease	O
fear	I_Disease	O
recognition	I_Disease	O
,	O	O
amygdala	B_Disease	O
dysfunction	I_Disease	O
,	O	O
and	O	O
etiology	O	O
are	O	O
discussed	O	O
.	O	O

Damage	B_Disease	O
of	I_Disease	O
substantia	I_Disease	O
nigra	I_Disease	O
pars	I_Disease	O
reticulata	I_Disease	O
during	O	O
pilocarpine-induced	O	O
status	B_Disease	O
epilepticus	I_Disease	O
in	O	O
the	O	O
rat	O	O
:	O	O
immunohistochemical	O	O
study	O	O
of	O	O
neurons	O	O
,	O	O
astrocytes	O	O
and	O	O
serum-protein	O	O
extravasation	O	O
.	O	O

The	O	O
substantia	O	O
nigra	O	O
has	O	O
a	O	O
gating	O	O
function	O	O
controlling	O	O
the	O	O
spread	O	O
of	O	O
epileptic	B_Disease	O
seizure	I_Disease	O
activity	O	O
.	O	O

Additionally	O	O
,	O	O
in	O	O
models	O	O
of	O	O
prolonged	B_Disease	O
status	I_Disease	O
epilepticus	I_Disease	O
the	O	O
pars	O	O
reticulata	O	O
of	O	O
substantia	O	O
nigra	O	O
(	O	O
SNR	O	O
)	O	O
suffers	O	O
from	O	O
a	O	O
massive	O	O
lesion	O	O
which	O	O
may	O	O
arise	O	O
from	O	O
a	O	O
massive	O	O
metabolic	B_Disease	O
derangement	I_Disease	O
and	O	O
hyperexcitation	O	B_Disease
developing	O	O
in	O	O
the	O	O
activated	O	O
SNR	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
status	B_Disease	O
epilepticus	I_Disease	O
was	O	O
induced	O	O
by	O	O
systemic	O	O
injection	O	O
of	O	O
pilocarpine	B_Chemical	O
in	O	O
rats	O	O
.	O	O

The	O	O
neuropathology	O	O
of	O	O
SNR	O	O
was	O	O
investigated	O	O
using	O	O
immunohistochemical	O	O
techniques	O	O
with	O	O
the	O	O
major	O	O
emphasis	O	O
on	O	O
the	O	O
time-course	O	O
of	O	O
changes	O	O
in	O	O
neurons	O	O
and	O	O
astrocytes	O	O
.	O	O

Animals	O	O
surviving	O	O
20	O	O
,	O	O
30	O	O
,	O	O
40	O	O
,	O	O
60	O	O
min	O	O
,	O	O
2	O	O
,	O	O
3	O	O
,	O	O
6	O	O
hours	O	O
,	O	O
1	O	O
,	O	O
2	O	O
,	O	O
and	O	O
3	O	O
days	O	O
after	O	O
induction	O	O
of	O	O
status	B_Disease	O
epilepticus	I_Disease	O
were	O	O
perfusion-fixed	O	O
,	O	O
and	O	O
brains	O	O
processed	O	O
for	O	O
immunohistochemical	O	O
staining	O	O
of	O	O
SNR	O	O
.	O	O

Nissl-staining	O	O
and	O	O
antibodies	O	O
against	O	O
the	O	O
neuron-specific	O	O
calcium-binding	O	O
protein	O	O
,	O	O
parvalbumin	O	O
,	O	O
served	O	O
to	O	O
detect	O	O
neuronal	B_Disease	B_Disease
damage	I_Disease	I_Disease
in	O	O
SNR	O	O
.	O	O

Antibodies	O	O
against	O	O
the	O	O
astroglia-specific	O	O
cytoskeletal	O	O
protein	O	O
,	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
(	O	O
GFAP	O	O
)	O	O
,	O	O
and	O	O
against	O	O
the	O	O
glial	O	O
calcium-binding	O	O
protein	O	O
,	O	O
S-100	O	O
protein	O	O
,	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
the	O	O
status	O	O
of	O	O
astrocytes	O	O
.	O	O

Immunohistochemical	O	O
staining	O	O
for	O	O
serum-albumin	O	O
and	O	O
immunoglobulins	O	O
in	O	O
brain	O	O
tissue	O	O
was	O	O
taken	O	O
as	O	O
indicator	O	O
of	O	O
blood-brain	O	O
barrier	O	O
disturbances	O	O
and	O	O
vasogenic	B_Disease	B_Disease
edema	I_Disease	I_Disease
formation	O	O
.	O	O

Immunohistochemical	O	O
staining	O	O
indicated	O	O
loss	O	O
of	O	O
GFAP-staining	O	O
already	O	O
at	O	O
30	O	O
min	O	O
after	O	O
induction	O	O
of	O	O
seizures	B_Disease	O
in	O	O
an	O	O
oval	O	O
focus	O	O
situated	O	O
in	O	O
the	O	O
center	O	O
of	O	O
SNR	O	O
while	O	O
sparing	O	O
medial	O	O
and	O	O
lateral	O	O
aspects	O	O
.	O	O

At	O	O
1	O	O
h	O	O
there	O	O
was	O	O
additional	O	O
vacuolation	O	O
in	O	O
S-100	O	O
protein	O	O
staining	O	O
.	O	O

By	O	O
2	O	O
hours	O	O
,	O	O
parvalbumin-staining	O	O
changed	O	O
in	O	O
the	O	O
central	O	O
SNR	O	O
indicating	O	O
neuronal	B_Disease	B_Disease
damage	I_Disease	I_Disease
,	O	O
and	O	O
Nissl-staining	O	O
visualized	O	O
some	O	O
neuronal	O	B_Disease
distortion	O	I_Disease
.	O	O

Staining	O	O
for	O	O
serum-proteins	O	O
occurred	O	O
in	O	O
a	O	O
patchy	O	O
manner	O	O
throughout	O	O
the	O	O
forebrain	O	O
during	O	O
the	O	O
first	O	O
hours	O	O
.	O	O

By	O	O
6	O	O
h	O	O
,	O	O
vasogenic	B_Disease	B_Disease
edema	I_Disease	I_Disease
covered	O	O
the	O	O
lesioned	B_Disease	O
SNR	I_Disease	O
.	O	O

By	O	O
24	O	O
h	O	O
,	O	O
glial	O	O
and	O	O
neuronal	O	O
markers	O	O
indicated	O	O
a	O	O
massive	O	O
lesion	O	O
in	O	O
the	O	O
center	O	O
of	O	O
SNR	O	O
.	O	O

By	O	O
48	O	O
-	O	O
72	O	O
h	O	O
,	O	O
astrocytes	O	O
surrounding	O	O
the	O	O
lesion	O	O
increased	O	O
in	O	O
size	O	O
,	O	O
and	O	O
polymorphic	O	O
phagocytotic	O	O
cells	O	O
invaded	O	O
the	O	O
damaged	O	O
area	O	O
.	O	O

In	O	O
a	O	O
further	O	O
group	O	O
of	O	O
animals	O	O
surviving	O	O
1	O	O
to	O	O
5	O	O
days	O	O
,	O	O
conventional	O	O
paraffin-sections	O	O
confirmed	O	O
the	O	O
neuronal	O	O
and	O	O
glial	O	B_Disease
damage	B_Disease	I_Disease
of	I_Disease	O
SNR	I_Disease	O
.	O	O

Additional	O	O
pathology	O	O
of	O	O
similar	O	O
quality	O	O
was	O	O
found	O	O
in	O	O
the	O	O
globus	O	O
pallidus	O	O
.	O	O

Since	O	O
astrocytes	O	O
were	O	O
always	O	O
damaged	O	O
in	O	O
parallel	O	O
with	O	O
neurons	O	O
in	O	O
SNR	O	O
it	O	O
is	O	O
proposed	O	O
that	O	O
the	O	O
anatomical	O	O
and	O	O
functional	O	O
interrelationship	O	O
between	O	O
neurons	O	O
and	O	O
astrocytes	O	O
is	O	O
particularly	O	O
tight	O	O
in	O	O
SNR	O	O
.	O	O

Both	O	O
cell	O	O
elements	O	O
may	O	O
suffer	O	O
in	O	O
common	O	O
from	O	O
metabolic	O	B_Disease
disturbance	O	I_Disease
and	O	O
neurotransmitter	B_Disease	O
dysfunction	I_Disease	O
as	O	O
occur	O	O
during	O	O
massive	O	O
status	B_Disease	O
epilepticus	I_Disease	O
.	O	O

Neuroprotective	O	O
effects	O	O
of	O	O
melatonin	B_Chemical	O
upon	O	O
the	O	O
offspring	O	O
cerebellar	O	O
cortex	O	O
in	O	O
the	O	O
rat	O	O
model	O	O
of	O	O
BCNU-induced	O	O
cortical	B_Disease	B_Disease
dysplasia	I_Disease	I_Disease
.	O	O

Cortical	B_Disease	B_Disease
dysplasia	I_Disease	I_Disease
is	O	O
a	O	O
malformation	O	O
characterized	O	O
by	O	O
defects	O	O
in	O	O
proliferation	O	O
,	O	O
migration	O	O
and	O	O
maturation	O	O
.	O	O

This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
evaluate	O	O
the	O	O
alterations	O	O
in	O	O
offspring	O	O
rat	O	O
cerebellum	O	O
induced	O	O
by	O	O
maternal	O	O
exposure	O	O
to	O	O
carmustine-[1,3-bis	O	O
(2-chloroethyl)-1-nitrosoure	O	O
]	O	O
(	O	O
BCNU	B_Chemical	O
)	O	O
and	O	O
to	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
exogenous	O	O
melatonin	B_Chemical	O
upon	O	O
cerebellar	O	O
BCNU-induced	O	O
cortical	B_Disease	B_Disease
dysplasia	I_Disease	I_Disease
,	O	O
using	O	O
histological	O	O
and	O	O
biochemical	O	O
analyses	O	O
.	O	O

Pregnant	O	O
Wistar	O	O
rats	O	O
were	O	O
assigned	O	O
to	O	O
five	O	O
groups	O	O
:	O	O
intact-control	O	O
,	O	O
saline-control	O	O
,	O	O
melatonin-treated	O	O
,	O	O
BCNU-exposed	O	O
and	O	O
BCNU-exposed	O	O
plus	O	O
melatonin	B_Chemical	O
.	O	O

Rats	O	O
were	O	O
exposed	O	O
to	O	O
BCNU	B_Chemical	O
on	O	O
embryonic	O	O
day	O	O
15	O	O
and	O	O
melatonin	B_Chemical	O
was	O	O
given	O	O
until	O	O
delivery	O	O
.	O	O

Immuno/histochemistry	O	O
and	O	O
electron	O	O
microscopy	O	O
were	O	O
carried	O	O
out	O	O
on	O	O
the	O	O
offspring	O	O
cerebellum	O	O
,	O	O
and	O	O
levels	O	O
of	O	O
malondialdehyde	B_Chemical	B_Chemical
and	O	O
superoxide	B_Chemical	O
dismutase	O	O
were	O	O
determined	O	O
.	O	O

Histopathologically	O	O
,	O	O
typical	O	O
findings	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
cerebella	O	O
from	O	O
the	O	O
control	O	O
groups	O	O
,	O	O
but	O	O
the	O	O
findings	O	O
consistent	O	O
with	O	O
early	O	O
embryonic	O	O
development	O	O
were	O	O
noted	O	O
in	O	O
BCNU-exposed	O	O
cortical	B_Disease	B_Disease
dysplasia	I_Disease	I_Disease
group	O	O
.	O	O

There	O	O
was	O	O
a	O	O
marked	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
TUNEL	O	O
positive	O	O
cells	O	O
and	O	O
nestin	O	O
positive	O	O
cells	O	O
in	O	O
BCNU-exposed	O	O
group	O	O
,	O	O
but	O	O
a	O	O
decreased	O	O
immunoreactivity	O	O
to	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
,	O	O
synaptophysin	O	O
and	O	O
transforming	O	O
growth	O	O
factor	O	O
beta1	O	O
was	O	O
observed	O	O
,	O	O
indicating	O	O
a	O	O
delayed	O	O
maturation	O	O
,	O	O
and	O	O
melatonin	B_Chemical	O
significantly	O	O
reversed	O	O
these	O	O
changes	O	O
.	O	O

Malondialdehyde	B_Chemical	B_Chemical
level	O	O
in	O	O
BCNU-exposed	O	O
group	O	O
was	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
control	O	O
groups	O	O
and	O	O
melatonin	B_Chemical	O
decreased	O	O
malondialdehyde	B_Chemical	B_Chemical
levels	O	O
in	O	O
BCNU	B_Chemical	O
group	O	O
(	O	O
P<0.01	O	O
)	O	O
,	O	O
while	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
superoxide	B_Chemical	O
dismutase	O	O
levels	O	O
between	O	O
these	O	O
groups	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
exposure	O	O
of	O	O
animals	O	O
to	O	O
BCNU	B_Chemical	O
during	O	O
pregnancy	O	O
leads	O	O
to	O	O
delayed	O	O
maturation	O	O
of	O	O
offspring	O	O
cerebellum	O	O
and	O	O
melatonin	B_Chemical	O
protects	O	O
the	O	O
cerebellum	O	O
against	O	O
the	O	O
effects	O	O
of	O	O
BCNU	B_Chemical	O
.	O	O

Reduced	O	O
cardiotoxicity	B_Disease	B_Disease
of	O	O
doxorubicin	B_Chemical	O
given	O	O
in	O	O
the	O	O
form	O	O
of	O	O
N-(2-hydroxypropyl)methacrylamide	B_Chemical	B_Chemical
conjugates	O	O
:	O	O
and	O	O
experimental	O	O
study	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

A	O	O
rat	O	O
model	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
general	O	O
acute	O	B_Disease
toxicity	B_Disease	I_Disease
and	O	O
the	O	O
late	O	O
cardiotoxicity	B_Disease	B_Disease
of	O	O
4	O	O
mg/kg	O	O
doxorubicin	B_Chemical	O
(	O	O
DOX	B_Chemical	B_Chemical
)	O	O
given	O	O
either	O	O
as	O	O
free	O	O
drug	O	O
or	O	O
in	O	O
the	O	O
form	O	O
of	O	O
three	O	O
N-(2-hydroxypropyl)methacrylamide	B_Chemical	B_Chemical
(	O	O
HPMA	B_Chemical	O
)	O	O
copolymer	O	O
conjugates	O	O
.	O	O

In	O	O
these	O	O
HPMA	B_Chemical	O
copolymers	O	O
,	O	O
DOX	B_Chemical	O
was	O	O
covalently	O	O
bound	O	O
via	O	O
peptide	O	O
linkages	O	O
that	O	O
were	O	O
either	O	O
non-biodegradable	O	O
(	O	O
Gly-Gly	O	O
)	O	O
or	O	O
degradable	O	O
by	O	O
lysosomal	O	O
proteinases	O	O
(	O	O
Gly-Phe-Leu-Gly	B_Chemical	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
one	O	O
biodegradable	O	O
conjugate	O	O
containing	O	O
galactosamine	B_Chemical	B_Chemical
was	O	O
used	O	O
;	O	O
this	O	O
residue	O	O
was	O	O
targeted	O	O
to	O	O
the	O	O
liver	O	O
.	O	O

Over	O	O
the	O	O
first	O	O
3	O	O
weeks	O	O
after	O	O
the	O	O
i.v	O	O
.	O	O

administration	O	O
of	O	O
free	O	O
and	O	O
polymer-bound	O	O
DOX	B_Chemical	O
,	O	O
all	O	O
animals	O	O
showed	O	O
a	O	O
transient	O	O
reduction	O	O
in	O	O
body	O	O
weight	O	O
.	O	O

However	O	O
,	O	O
the	O	O
maximal	O	O
reduction	O	O
in	O	O
body	O	O
weight	O	O
seen	O	O
in	O	O
animals	O	O
that	O	O
received	O	O
polymer-bound	O	O
DOX	B_Chemical	B_Chemical
(	O	O
4	O	O
mg/kg	O	O
)	O	O
was	O	O
significantly	O	O
lower	O	O
than	O	O
that	O	O
observed	O	O
in	O	O
those	O	O
that	O	O
received	O	O
free	O	O
DOX	B_Chemical	B_Chemical
(	O	O
4	O	O
mg/kg	O	O
)	O	O
or	O	O
a	O	O
mixture	O	O
of	O	O
the	O	O
unmodified	O	O
parent	O	O
HPMA	B_Chemical	O
copolymer	O	O
and	O	O
free	O	O
DOX	B_Chemical	B_Chemical
(	O	O
4	O	O
mg/kg	O	O
;	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
.	O	O

Throughout	O	O
the	O	O
study	O	O
(	O	O
20	O	O
weeks	O	O
)	O	O
,	O	O
deaths	O	O
related	O	O
to	O	O
cardiotoxicity	B_Disease	B_Disease
were	O	O
observed	O	O
only	O	O
in	O	O
animals	O	O
that	O	O
received	O	O
either	O	O
free	O	O
DOX	B_Chemical	O
or	O	O
the	O	O
mixture	O	O
of	O	O
HPMA	B_Chemical	O
copolymer	O	O
and	O	O
free	O	O
DOX	B_Chemical	O
;	O	O
in	O	O
these	O	O
cases	O	O
,	O	O
histological	O	O
investigations	O	O
revealed	O	O
marked	O	O
changes	O	O
in	O	O
the	O	O
heart	O	O
that	O	O
were	O	O
consistent	O	O
with	O	O
DOX-induced	O	O
cardiotoxicity	B_Disease	B_Disease
.	O	O

Sequential	O	O
measurements	O	O
of	O	O
cardiac	O	O
output	O	O
in	O	O
surviving	O	O
animals	O	O
that	O	O
received	O	O
either	O	O
free	O	O
DOX	B_Chemical	B_Chemical
or	O	O
the	O	O
mixture	O	O
of	O	O
HPMA	B_Chemical	O
copolymer	O	O
and	O	O
free	O	O
DOX	B_Chemical	B_Chemical
showed	O	O
a	O	O
reduction	O	O
of	O	O
approximately	O	O
30	O	O
%	O	O
in	O	O
function	O	O
beginning	O	O
at	O	O
the	O	O
4th	O	O
week	O	O
after	O	O
drug	O	O
administration	O	O
.	O	O

The	O	O
heart	O	O
rate	O	O
in	O	O
these	O	O
animals	O	O
was	O	O
approximately	O	O
12	O	O
%	O	O
lower	O	O
than	O	O
that	O	O
measured	O	O
in	O	O
age-matched	O	O
control	O	O
rats	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

Animals	O	O
that	O	O
were	O	O
given	O	O
the	O	O
HPMA	B_Chemical	O
copolymer	O	O
conjugates	O	O
containing	O	O
DOX	B_Chemical	B_Chemical
exhibited	O	O
no	O	O
significant	O	O
change	O	O
in	O	O
cardiac	O	O
output	O	O
throughout	O	O
the	O	O
study	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
no	O	O
significant	O	O
histological	O	O
change	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
heart	O	O
of	O	O
animals	O	O
that	O	O
received	O	O
DOX	B_Chemical	O
in	O	O
the	O	O
form	O	O
of	O	O
HPMA	B_Chemical	O
copolymer	O	O
conjugates	O	O
and	O	O
were	O	O
killed	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
study	O	O
.	O	O

However	O	O
,	O	O
these	O	O
animals	O	O
had	O	O
shown	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
beginning	O	O
at	O	O
8	O	O
weeks	O	O
after	O	O
drug	O	O
administration	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01).(ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
400	O	O
WORDS	O	O
)	O	O

Corneal	B_Disease	O
ulcers	I_Disease	O
associated	O	O
with	O	O
aerosolized	O	O
crack	B_Chemical	O
cocaine	I_Chemical	O
use	O	O
.	O	O

PURPOSE	O	O
:	O	O
We	O	O
report	O	O
4	O	O
cases	O	O
of	O	O
corneal	B_Disease	O
ulcers	I_Disease	O
associated	O	O
with	O	O
drug	B_Disease	B_Disease
abuse	I_Disease	I_Disease
.	O	O

The	O	O
pathogenesis	O	O
of	O	O
these	O	O
ulcers	B_Disease	O
and	O	O
management	O	O
of	O	O
these	O	O
patients	O	O
are	O	O
also	O	O
reviewed	O	O
.	O	O

METHODS	O	O
:	O	O
Review	O	O
of	O	O
all	O	O
cases	O	O
of	O	O
corneal	B_Disease	O
ulcers	I_Disease	O
associated	O	O
with	O	O
drug	B_Disease	B_Disease
abuse	I_Disease	I_Disease
seen	O	O
at	O	O
our	O	O
institution	O	O
from	O	O
July	O	O
2006	O	O
to	O	O
December	O	O
2006	O	O
.	O	O

RESULTS	O	O
:	O	O
Four	O	O
patients	O	O
with	O	O
corneal	B_Disease	O
ulcers	I_Disease	O
associated	O	O
with	O	O
crack	B_Chemical	O
cocaine	I_Chemical	O
use	O	O
were	O	O
reviewed	O	O
.	O	O

All	O	O
corneal	B_Disease	O
ulcers	I_Disease	O
were	O	O
cultured	O	O
,	O	O
and	O	O
the	O	O
patients	O	O
were	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
intensive	O	O
topical	O	O
antibiotic	O	O
treatment	O	O
.	O	O

Each	O	O
patient	O	O
received	O	O
comprehensive	O	O
health	O	O
care	O	O
,	O	O
including	O	O
medical	O	O
and	O	O
substance	B_Disease	O
abuse	I_Disease	O
consultations	O	O
.	O	O

Streptococcal	O	O
organisms	O	O
were	O	O
found	O	O
in	O	O
3	O	O
cases	O	O
and	O	O
Capnocytophaga	O	O
and	O	O
Brevibacterium	O	O
casei	O	O
in	O	O
1	O	O
patient	O	O
.	O	O

The	O	O
infections	B_Disease	O
responded	O	O
to	O	O
antibiotic	O	O
treatment	O	O
.	O	O

Two	O	O
patients	O	O
needed	O	O
a	O	O
lateral	O	O
tarsorrhaphy	O	O
for	O	O
persistent	O	O
epithelial	B_Disease	B_Disease
defects	I_Disease	I_Disease
.	O	O

CONCLUSIONS	O	O
:	O	O
Aerosolized	O	O
crack	B_Chemical	O
cocaine	I_Chemical	O
use	O	O
can	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
corneal	B_Disease	O
ulcers	I_Disease	O
.	O	O

Drug	B_Disease	B_Disease
abuse	I_Disease	I_Disease
provides	O	O
additional	O	O
challenges	O	O
for	O	O
management	O	O
.	O	O

Not	O	O
only	O	O
treatment	O	O
of	O	O
their	O	O
infections	B_Disease	O
but	O	O
also	O	O
the	O	O
overall	O	O
poor	O	O
health	O	O
of	O	O
the	O	O
patients	O	O
and	O	O
increased	O	O
risk	O	O
of	O	O
noncompliance	O	O
need	O	O
to	O	O
be	O	O
addressed	O	O
.	O	O

Comprehensive	O	O
care	O	O
may	O	O
provide	O	O
the	O	O
patient	O	O
the	O	O
opportunity	O	O
to	O	O
discontinue	O	O
their	O	O
substance	B_Disease	O
abuse	I_Disease	O
,	O	O
improve	O	O
their	O	O
overall	O	O
health	O	O
,	O	O
and	O	O
prevent	O	O
future	O	O
corneal	O	O
complications	O	O
.	O	O

Topical	O	O
0.025	O	O
%	O	O
capsaicin	B_Chemical	O
in	O	O
chronic	O	O
post-herpetic	B_Disease	O
neuralgia	I_Disease	O
:	O	O
efficacy	O	O
,	O	O
predictors	O	O
of	O	O
response	O	O
and	O	O
long-term	O	O
course	O	O
.	O	O

In	O	O
order	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
,	O	O
time-course	O	O
of	O	O
action	O	O
and	O	O
predictors	O	O
of	O	O
response	O	O
to	O	O
topical	O	O
capsaicin	B_Chemical	O
,	O	O
39	O	O
patients	O	O
with	O	O
chronic	O	O
post-herpetic	B_Disease	O
neuralgia	I_Disease	O
(	O	O
PHN	B_Disease	O
)	O	O
,	O	O
median	O	O
duration	O	O
24	O	O
months	O	O
,	O	O
were	O	O
treated	O	O
with	O	O
0.025	O	O
%	O	O
capsaicin	B_Chemical	O
cream	O	O
for	O	O
8	O	O
weeks	O	O
.	O	O

During	O	O
therapy	O	O
the	O	O
patients	O	O
rated	O	O
their	O	O
pain	B_Disease	O
on	O	O
a	O	O
visual	O	O
analogue	O	O
scale	O	O
(	O	O
VAS	O	O
)	O	O
and	O	O
a	O	O
verbal	O	O
outcome	O	O
scale	O	O
.	O	O

A	O	O
follow-up	O	O
investigation	O	O
was	O	O
performed	O	O
10	O	O
-	O	O
12	O	O
months	O	O
after	O	O
study	O	O
onset	O	O
on	O	O
the	O	O
patients	O	O
who	O	O
had	O	O
improved	O	O
.	O	O

Nineteen	O	O
patients	O	O
(	O	O
48.7	O	O
%	O	O
)	O	O
substantially	O	O
improved	O	O
after	O	O
the	O	O
8-week	O	O
trial	O	O
;	O	O
5	O	O
(	O	O
12.8	O	O
%	O	O
)	O	O
discontinued	O	O
therapy	O	O
due	O	O
to	O	O
side-effects	O	O
such	O	O
as	O	O
intolerable	O	O
capsaicin-induced	O	O
burning	O	O
sensations	O	O
(	O	O
4	O	O
)	O	O
or	O	O
mastitis	B_Disease	O
(	O	O
1	O	O
)	O	O
;	O	O
15	O	O
(	O	O
38.5	O	O
%	O	O
)	O	O
reported	O	O
no	O	O
benefit	O	O
.	O	O

The	O	O
decrease	O	O
in	O	O
VAS	O	O
ratings	O	O
was	O	O
significant	O	O
after	O	O
2	O	O
weeks	O	O
of	O	O
continuous	O	O
application	O	O
.	O	O

Of	O	O
the	O	O
responders	O	O
72.2	O	O
%	O	O
were	O	O
still	O	O
improved	O	O
at	O	O
the	O	O
follow-up	O	O
;	O	O
only	O	O
one-third	O	O
of	O	O
them	O	O
had	O	O
continued	O	O
application	O	O
irregularly	O	O
.	O	O

Treatment	O	O
effect	O	O
was	O	O
not	O	O
dependent	O	O
on	O	O
patient	O	O
's	O	O
age	O	O
,	O	O
duration	O	O
or	O	O
localization	O	O
of	O	O
PHN	B_Disease	O
(	O	O
trigeminal	O	O
involvement	O	O
was	O	O
excluded	O	O
)	O	O
,	O	O
sensory	B_Disease	B_Disease
disturbance	I_Disease	I_Disease
or	O	O
pain	B_Disease	O
character	O	O
.	O	O

Treatment	O	O
response	O	O
was	O	O
not	O	O
correlated	O	O
with	O	O
the	O	O
incidence	O	O
,	O	O
time-course	O	O
or	O	O
severity	O	O
of	O	O
capsaicin-induced	O	O
burning	O	O
.	O	O

If	O	O
confirmed	O	O
in	O	O
controlled	O	O
trials	O	O
,	O	O
the	O	O
long-term	O	O
results	O	O
of	O	O
this	O	O
open	O	O
,	O	O
non-randomized	O	O
study	O	O
might	O	O
indicate	O	O
that	O	O
the	O	O
analgesic	O	O
effect	O	O
of	O	O
capsaicin	B_Chemical	O
in	O	O
PHN	B_Disease	O
is	O	O
mediated	O	O
by	O	O
both	O	O
interference	O	O
with	O	O
neuropeptide	O	O
metabolism	O	O
and	O	O
morphological	O	O
changes	O	O
(	O	O
perhaps	O	O
degeneration	O	O
)	O	O
of	O	O
nociceptive	O	O
afferents	O	O
.	O	O

Myo-inositol-1-phosphate	B_Chemical	B_Chemical
(	O	O
MIP	B_Chemical	O
)	O	O
synthase	O	O
inhibition	O	O
:	O	O
in-vivo	O	O
study	O	O
in	O	O
rats	O	O
.	O	O

Lithium	B_Chemical	O
and	O	O
valproate	B_Chemical	B_Chemical
are	O	O
the	O	O
prototypic	O	O
mood	O	O
stabilizers	O	O
and	O	O
have	O	O
diverse	O	O
structures	O	O
and	O	O
targets	O	O
.	O	O

Both	O	O
drugs	O	O
influence	O	O
inositol	B_Chemical	O
metabolism	O	O
.	O	O

Lithium	B_Chemical	O
inhibits	O	O
IMPase	O	O
and	O	O
valproate	B_Chemical	B_Chemical
inhibits	O	O
MIP	B_Chemical	O
synthase	O	O
.	O	O

This	O	O
study	O	O
shows	O	O
that	O	O
MIP	B_Chemical	O
synthase	O	O
inhibition	O	O
does	O	O
not	O	O
replicate	O	O
or	O	O
augment	O	O
the	O	O
effects	O	O
of	O	O
lithium	B_Chemical	O
in	O	O
the	O	O
inositol	B_Chemical	O
sensitive	O	O
pilocarpine-induced	O	O
seizures	B_Disease	O
model	O	O
.	O	O

This	O	O
lack	O	O
of	O	O
effects	O	O
may	O	O
stem	O	O
from	O	O
the	O	O
low	O	O
contribution	O	O
of	O	O
de-novo	O	O
synthesis	O	O
to	O	O
cellular	O	O
inositol	B_Chemical	O
supply	O	O
or	O	O
to	O	O
the	O	O
inhibition	O	O
of	O	O
the	O	O
de-novo	O	O
synthesis	O	O
by	O	O
lithium	B_Chemical	O
itself	O	O
.	O	O

Non-steroidal	O	O
anti-inflammatory	O	O
drugs-associated	O	O
acute	O	B_Disease
interstitial	O	I_Disease
nephritis	O	I_Disease
with	O	O
granular	O	O
tubular	O	O
basement	O	O
membrane	O	O
deposits	O	O
.	O	O

Acute	B_Disease	O
tubulo-interstitial	I_Disease	B_Disease
nephritis	I_Disease	I_Disease
(	O	O
ATIN	B_Disease	O
)	O	O
is	O	O
an	O	O
important	O	O
cause	O	O
of	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
resulting	O	O
from	O	O
a	O	O
variety	O	O
of	O	O
insults	O	O
,	O	O
including	O	O
immune	O	O
complex-mediated	O	O
tubulo-interstitial	B_Disease	B_Disease
injury	I_Disease	I_Disease
,	O	O
but	O	O
drugs	O	O
such	O	O
as	O	O
non-steroidal	O	O
anti-inflammatory	O	O
drugs	O	O
(	O	O
NSAIDs	O	O
)	O	O
are	O	O
a	O	O
far	O	O
more	O	O
frequent	O	O
cause	O	O
.	O	O

Overall	O	O
,	O	O
as	O	O
an	O	O
entity	O	O
,	O	O
ATIN	B_Disease	O
remains	O	O
under-diagnosed	O	O
,	O	O
as	O	O
symptoms	O	O
resolve	O	O
spontaneously	O	O
if	O	O
the	O	O
medication	O	O
is	O	O
stopped	O	O
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
14-year-old	O	O
boy	O	O
who	O	O
developed	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
2	O	O
weeks	O	O
after	O	O
aortic	O	B_Disease
valve	O	I_Disease
surgery	O	O
.	O	O

He	O	O
was	O	O
put	O	O
on	O	O
aspirin	B_Chemical	O
following	O	O
surgery	O	O
and	O	O
took	O	O
ibuprofen	B_Chemical	O
for	O	O
fever	B_Disease	O
for	O	O
nearly	O	O
a	O	O
week	O	O
prior	O	O
to	O	O
presentation	O	O
.	O	O

He	O	O
then	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
feeling	O	O
quite	O	O
ill	O	O
and	O	O
was	O	O
found	O	O
to	O	O
have	O	O
a	O	O
blood	B_Chemical	B_Chemical
urea	I_Chemical	I_Chemical
nitrogen	I_Chemical	I_Chemical
(	O	O
BUN	B_Chemical	O
)	O	O
concentration	O	O
of	O	O
of	O	O
147	O	O
mg/dl	O	O
,	O	O
creatinine	B_Chemical	B_Chemical
of	O	O
15.3	O	O
mg/dl	O	O
and	O	O
serum	O	O
potassium	B_Chemical	O
of	O	O
8.7	O	O
mEq/l	O	O
.	O	O

Dialysis	O	O
was	O	O
immediately	O	O
initiated	O	O
.	O	O

A	O	O
kidney	O	O
biopsy	O	O
showed	O	O
inflammatory	O	O
infiltrate	O	O
consistent	O	O
with	O	O
ATIN	B_Disease	B_Chemical
.	O	O

However	O	O
,	O	O
in	O	O
the	O	O
tubular	O	O
basement	O	O
membrane	O	O
(	O	O
TBM	O	O
)	O	O
,	O	O
very	O	O
intense	O	O
granular	O	O
deposits	O	O
of	O	O
polyclonal	O	O
IgG	O	O
and	O	O
C3	O	O
were	O	O
noted	O	O
.	O	O

He	O	O
needed	O	O
dialysis	O	O
for	O	O
2	O	O
weeks	O	O
and	O	O
was	O	O
treated	O	O
successfully	O	O
with	O	O
steroids	B_Chemical	O
for	O	O
6	O	O
months	O	O
.	O	O

His	O	O
renal	O	O
recovery	O	O
and	O	O
disappearance	O	O
of	O	O
proteinuria	B_Disease	O
took	O	O
a	O	O
year	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
this	O	O
is	O	O
a	O	O
first	O	O
report	O	O
of	O	O
NSAIDs-associated	O	O
ATIN	B_Disease	O
,	O	O
showing	O	O
deposits	O	O
of	O	O
granular	O	O
immune	O	O
complex	O	O
present	O	O
only	O	O
in	O	O
the	O	O
TBM	O	O
and	O	O
not	O	O
in	O	O
the	O	O
glomeruli	O	O
.	O	O

Rifampicin-associated	O	O
segmental	O	O
necrotizing	O	O
glomerulonephritis	B_Disease	O
in	O	O
staphylococcal	B_Disease	O
endocarditis	B_Disease	O
.	O	O

Segmental	O	O
necrotising	O	O
glomerulonephritis	B_Disease	O
has	O	O
been	O	O
reported	O	O
as	O	O
complication	O	O
of	O	O
rifampicin	B_Chemical	B_Chemical
therapy	O	O
in	O	O
patients	O	O
receiving	O	O
treatment	O	O
for	O	O
tuberculosis	B_Disease	O
.	O	O

Changing	O	O
epidemiology	O	O
of	O	O
infections	B_Disease	O
such	O	O
as	O	O
infective	B_Disease	O
endocarditis	I_Disease	O
(	O	O
IE	B_Disease	O
)	O	O
has	O	O
led	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
use	O	O
of	O	O
rifampicin	B_Chemical	B_Chemical
for	O	O
Staphylococcal	B_Disease	O
infections	I_Disease	O
.	O	O

We	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
Staphylococcal	B_Disease	O
IE	B_Disease	O
who	O	O
developed	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
secondary	O	O
to	O	O
a	O	O
segmental	O	O
necrotising	O	O
glomerulonephritis	B_Disease	O
while	O	O
being	O	O
treated	O	O
with	O	O
rifampicin	B_Chemical	B_Chemical
,	O	O
and	O	O
review	O	O
the	O	O
literature	O	O
regarding	O	O
this	O	O
complication	O	O
of	O	O
rifampicin	B_Chemical	B_Chemical
therapy	O	O
.	O	O

Rate	O	O
of	O	O
YMDD	O	O
motif	O	O
mutants	O	O
in	O	O
lamivudine-untreated	O	O
Iranian	O	O
patients	O	O
with	O	O
chronic	B_Disease	O
hepatitis	I_Disease	O
B	I_Disease	O
virus	I_Disease	O
infection	I_Disease	O
.	O	O

BACKGROUND	O	O
:	O	O
Lamivudine	B_Chemical	O
is	O	O
used	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
chronic	B_Disease	O
hepatitis	I_Disease	O
B	I_Disease	O
patients	O	O
.	O	O

Recent	O	O
studies	O	O
show	O	O
that	O	O
the	O	O
YMDD	O	O
motif	O	O
mutants	O	O
(	O	O
resistant	O	O
hepatitis	B_Disease	O
B	I_Disease	O
virus	O	O
)	O	O
occur	O	O
as	O	O
natural	O	O
genome	O	O
variability	O	O
in	O	O
lamivudine-untreated	O	O
chronic	B_Disease	O
hepatitis	I_Disease	O
B	I_Disease	O
patients	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
aimed	O	O
to	O	O
determine	O	O
the	O	O
rate	O	O
of	O	O
YMDD	O	O
motif	O	O
mutants	O	O
in	O	O
lamivudine-untreated	O	O
chronic	B_Disease	O
hepatitis	I_Disease	O
B	I_Disease	O
patients	O	O
in	O	O
Iran	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
77	O	O
chronic	B_Disease	O
hepatitis	I_Disease	O
B	I_Disease	O
patients	O	O
who	O	O
had	O	O
not	O	O
been	O	O
treated	O	O
with	O	O
lamivudine	B_Chemical	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Serum	O	O
samples	O	O
from	O	O
patients	O	O
were	O	O
tested	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction-restriction	O	O
fragment	O	O
length	O	O
polymorphism	O	O
(	O	O
PCR-RFLP	O	O
)	O	O
for	O	O
detection	O	O
of	O	O
YMDD	O	O
motif	O	O
mutants	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
also	O	O
tested	O	O
for	O	O
liver	O	O
enzymes	O	O
,	O	O
anti-HCV	O	O
,	O	O
HBeAg	B_Chemical	O
,	O	O
and	O	O
anti-HBe	O	O
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
the	O	O
77	O	O
patients	O	O
enrolled	O	O
in	O	O
the	O	O
study	O	O
,	O	O
73	O	O
%	O	O
were	O	O
male	O	O
and	O	O
27	O	O
%	O	O
were	O	O
female	O	O
.	O	O

Mean	O	O
ALT	O	O
and	O	O
AST	O	O
levels	O	O
were	O	O
124.4+/-73.4	O	O
and	O	O
103.1+/-81	O	O
IU/l	O	O
,	O	O
respectively	O	O
.	O	O

HBeAg	B_Chemical	O
was	O	O
positive	O	O
in	O	O
40	O	O
%	O	O
and	O	O
anti-HBe	O	O
in	O	O
60	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
.	O	O

Anti-HCV	O	O
was	O	O
negative	O	O
in	O	O
all	O	O
of	O	O
them	O	O
.	O	O

YMDD	O	O
motif	O	O
mutants	O	O
were	O	O
not	O	O
detected	O	O
in	O	O
any	O	O
of	O	O
the	O	O
patients	O	O
despite	O	O
the	O	O
liver	O	O
enzyme	O	O
levels	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
HBeAg	B_Chemical	O
or	O	O
anti-HBe	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Although	O	O
the	O	O
natural	O	O
occurrence	O	O
of	O	O
YMDD	O	O
motif	O	O
mutants	O	O
in	O	O
lamivudine-untreated	O	O
patients	O	O
with	O	O
chronic	B_Disease	O
hepatitis	I_Disease	O
B	I_Disease	O
has	O	O
been	O	O
reported	O	O
,	O	O
these	O	O
mutants	O	O
were	O	O
not	O	O
detected	O	O
in	O	O
Iranian	O	O
lamivudine-untreated	O	O
chronic	B_Disease	O
hepatitis	I_Disease	O
B	I_Disease	O
patients	O	O
.	O	O

Branch	O	O
retinal	B_Disease	O
vein	I_Disease	O
occlusion	I_Disease	O
and	O	O
fluoxetine	B_Chemical	O
.	O	O

A	O	O
case	O	O
of	O	O
branch	O	O
retinal	B_Disease	O
vein	I_Disease	O
occlusion	I_Disease	O
associated	O	O
with	O	O
fluoxetine-induced	O	O
secondary	O	B_Disease
hypertension	B_Disease	I_Disease
is	O	O
described	O	O
.	O	O

Although	O	O
an	O	O
infrequent	O	O
complication	O	O
of	O	O
selective	O	O
serotonin	B_Chemical	O
reuptake	O	O
inhibitor	O	O
therapy	O	O
,	O	O
it	O	O
is	O	O
important	O	O
that	O	O
ophthalmologists	O	O
are	O	O
aware	O	O
that	O	O
these	O	O
agents	O	O
can	O	O
cause	O	O
hypertension	B_Disease	O
because	O	O
this	O	O
class	O	O
of	O	O
drugs	O	O
is	O	O
widely	O	O
prescribed	O	O
.	O	O

The	O	O
differential	O	O
effects	O	O
of	O	O
bupivacaine	B_Chemical	B_Chemical
and	O	O
lidocaine	B_Chemical	O
on	O	O
prostaglandin	B_Chemical	O
E2	I_Chemical	O
release	O	O
,	O	O
cyclooxygenase	O	O
gene	O	O
expression	O	O
and	O	O
pain	B_Disease	O
in	O	O
a	O	O
clinical	O	O
pain	B_Disease	O
model	O	O
.	O	O

BACKGROUND	O	O
:	O	O
In	O	O
addition	O	O
to	O	O
blocking	O	O
nociceptive	O	O
input	O	O
from	O	O
surgical	O	O
sites	O	O
,	O	O
long-acting	O	O
local	O	O
anesthetics	O	O
might	O	O
directly	O	O
modulate	O	O
inflammation	B_Disease	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
proinflammatory	O	O
effects	O	O
of	O	O
bupivacaine	B_Chemical	B_Chemical
on	O	O
local	O	O
prostaglandin	B_Chemical	O
E2	I_Chemical	O
(	O	O
PGE2	B_Chemical	O
)	O	O
production	O	O
and	O	O
cyclooxygenase	O	O
(	O	O
COX	O	O
)	O	O
gene	O	O
expression	O	O
that	O	O
increases	O	O
postoperative	B_Disease	O
pain	I_Disease	O
in	O	O
human	O	O
subjects	O	O
.	O	O

METHODS	O	O
:	O	O
Subjects	O	O
(	O	O
n	O	O
=	O	O
114	O	O
)	O	O
undergoing	O	O
extraction	O	O
of	O	O
impacted	O	O
third	O	O
molars	O	O
received	O	O
either	O	O
2	O	O
%	O	O
lidocaine	B_Chemical	O
or	O	O
0.5	O	O
%	O	O
bupivacaine	B_Chemical	B_Chemical
before	O	O
surgery	O	O
and	O	O
either	O	O
rofecoxib	B_Chemical	O
50	O	O
mg	O	O
or	O	O
placebo	O	O
orally	O	O
90	O	O
min	O	O
before	O	O
surgery	O	O
and	O	O
for	O	O
the	O	O
following	O	O
48	O	O
h.	O	O
Oral	O	O
mucosal	O	O
biopsies	O	O
were	O	O
taken	O	O
before	O	O
surgery	O	O
and	O	O
48	O	O
h	O	O
after	O	O
surgery	O	O
.	O	O

After	O	O
extraction	O	O
,	O	O
a	O	O
microdialysis	O	O
probe	O	O
was	O	O
placed	O	O
at	O	O
the	O	O
surgical	O	O
site	O	O
for	O	O
PGE2	B_Chemical	O
and	O	O
thromboxane	B_Chemical	B_Chemical
B2	I_Chemical	O
(	O	O
TXB2	B_Chemical	O
)	O	O
measurements	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
bupivacaine/rofecoxib	O	O
group	O	O
reported	O	O
significantly	O	O
less	O	O
pain	B_Disease	O
,	O	O
as	O	O
assessed	O	O
by	O	O
a	O	O
visual	O	O
analog	O	O
scale	O	O
,	O	O
compared	O	O
with	O	O
the	O	O
other	O	O
three	O	O
treatment	O	O
groups	O	O
over	O	O
the	O	O
first	O	O
4	O	O
h.	O	O
However	O	O
,	O	O
the	O	O
bupivacaine/placebo	O	B_Chemical
group	O	O
reported	O	O
significantly	O	O
more	O	O
pain	B_Disease	O
at	O	O
24	O	O
h	O	O
and	O	O
PGE2	B_Chemical	O
levels	O	O
during	O	O
the	O	O
first	O	O
4	O	O
h	O	O
were	O	O
significantly	O	O
higher	O	O
than	O	O
the	O	O
other	O	O
three	O	O
treatment	O	O
groups	O	O
.	O	O

Moreover	O	O
,	O	O
bupivacaine	B_Chemical	B_Chemical
significantly	O	O
increased	O	O
COX-2	O	O
gene	O	O
expression	O	O
at	O	O
48	O	O
h	O	O
as	O	O
compared	O	O
with	O	O
the	O	O
lidocaine/placebo	O	O
group	O	O
.	O	O

Thromboxane	B_Chemical	B_Chemical
levels	O	O
were	O	O
not	O	O
significantly	O	O
affected	O	O
by	O	O
any	O	O
of	O	O
the	O	O
treatments	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
effects	O	O
seen	O	O
were	O	O
attributable	O	O
to	O	O
inhibition	O	O
of	O	O
COX-2	O	O
,	O	O
but	O	O
not	O	O
COX-1	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
results	O	O
suggest	O	O
that	O	O
bupivacaine	B_Chemical	B_Chemical
stimulates	O	O
COX-2	O	O
gene	O	O
expression	O	O
after	O	O
tissue	B_Disease	O
injury	I_Disease	O
,	O	O
which	O	O
is	O	O
associated	O	O
with	O	O
higher	O	O
PGE2	B_Chemical	O
production	O	O
and	O	O
pain	B_Disease	O
after	O	O
the	O	O
local	O	O
anesthetic	O	O
effect	O	O
dissipates	O	O
.	O	O

p75NTR	O	O
expression	O	O
in	O	O
rat	O	O
urinary	O	O
bladder	O	O
sensory	O	O
neurons	O	O
and	O	O
spinal	O	O
cord	O	O
with	O	O
cyclophosphamide-induced	O	O
cystitis	B_Disease	O
.	O	O

A	O	O
role	O	O
for	O	O
nerve	O	O
growth	O	O
factor	O	O
(	O	O
NGF	O	O
)	O	O
in	O	O
contributing	O	O
to	O	O
increased	O	O
voiding	O	O
frequency	O	O
and	O	O
altered	O	O
sensation	O	O
from	O	O
the	O	O
urinary	O	O
bladder	O	O
has	O	O
been	O	O
suggested	O	O
.	O	O

Previous	O	O
studies	O	O
have	O	O
examined	O	O
the	O	O
expression	O	O
and	O	O
regulation	O	O
of	O	O
tyrosine	B_Chemical	O
kinase	O	O
receptors	O	O
(	O	O
Trks	O	O
)	O	O
in	O	O
micturition	O	O
reflexes	O	O
with	O	O
urinary	B_Disease	O
bladder	I_Disease	B_Disease
inflammation	I_Disease	I_Disease
.	O	O

The	O	O
present	O	O
studies	O	O
examine	O	O
the	O	O
expression	O	O
and	O	O
regulation	O	O
of	O	O
another	O	O
receptor	O	O
known	O	O
to	O	O
bind	O	O
NGF	O	O
,	O	O
p75(NTR	O	O
)	O	O
,	O	O
after	O	O
various	O	O
durations	O	O
of	O	O
bladder	B_Disease	B_Disease
inflammation	I_Disease	I_Disease
induced	O	O
by	O	O
cyclophosphamide	B_Chemical	B_Chemical
(	O	O
CYP	B_Chemical	O
)	O	O
.	O	O

CYP-induced	O	O
cystitis	B_Disease	O
increased	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
0.001	O	O
)	O	O
p75(NTR	O	O
)	O	O
expression	O	O
in	O	O
the	O	O
superficial	O	O
lateral	O	O
and	O	O
medial	O	O
dorsal	O	O
horn	O	O
in	O	O
L1-L2	O	O
and	O	O
L6-S1	O	O
spinal	O	O
segments	O	O
.	O	O

The	O	O
number	O	O
of	O	O
p75(NTR)-immunoreactive	O	O
(	O	O
-IR	O	O
)	O	O
cells	O	O
in	O	O
the	O	O
lumbosacral	O	O
dorsal	O	O
root	O	O
ganglia	O	O
(	O	O
DRG	O	O
)	O	O
also	O	O
increased	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
0.05	O	O
)	O	O
with	O	O
CYP-induced	O	O
cystitis	B_Disease	O
(	O	O
acute	O	O
,	O	O
intermediate	O	O
,	O	O
and	O	O
chronic	O	O
)	O	O
.	O	O

Quantitative	O	O
,	O	O
real-time	O	O
polymerase	O	O
chain	O	O
reaction	O	O
also	O	O
demonstrated	O	O
significant	O	O
increases	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
0.01	O	O
)	O	O
in	O	O
p75(NTR	O	O
)	O	O
mRNA	O	O
in	O	O
DRG	O	O
with	O	O
intermediate	O	O
and	O	O
chronic	O	O
CYP-induced	O	O
cystitis	B_Disease	O
.	O	O

Retrograde	O	O
dye-tracing	O	O
techniques	O	O
with	O	O
Fastblue	O	O
were	O	O
used	O	O
to	O	O
identify	O	O
presumptive	O	O
bladder	O	O
afferent	O	O
cells	O	O
in	O	O
the	O	O
lumbosacral	O	O
DRG	O	O
.	O	O

In	O	O
bladder	O	O
afferent	O	O
cells	O	O
in	O	O
DRG	O	O
,	O	O
p75(NTR)-IR	O	O
was	O	O
also	O	O
increased	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
0.01	O	O
)	O	O
with	O	O
cystitis	B_Disease	O
.	O	O

In	O	O
addition	O	O
to	O	O
increases	O	O
in	O	O
p75(NTR)-IR	O	O
in	O	O
DRG	O	O
cell	O	O
bodies	O	O
,	O	O
increases	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
0.001	O	O
)	O	O
in	O	O
pericellular	O	O
(	O	O
encircling	O	O
DRG	O	O
cells	O	O
)	O	O
p75(NTR)-IR	O	O
in	O	O
DRG	O	O
also	O	O
increased	O	O
.	O	O

Confocal	O	O
analyses	O	O
demonstrated	O	O
that	O	O
pericellular	O	O
p75(NTR)-IR	O	O
was	O	O
not	O	O
colocalized	O	O
with	O	O
the	O	O
glial	O	O
marker	O	O
,	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
(	O	O
GFAP	O	O
)	O	O
.	O	O

These	O	O
studies	O	O
demonstrate	O	O
that	O	O
p75(NTR	O	O
)	O	O
expression	O	O
in	O	O
micturition	O	O
reflexes	O	O
is	O	O
present	O	O
constitutively	O	O
and	O	O
modified	O	O
by	O	O
bladder	B_Disease	O
inflammation	I_Disease	O
.	O	O

The	O	O
functional	O	O
significance	O	O
of	O	O
p75(NTR	O	O
)	O	O
expression	O	O
in	O	O
micturition	O	O
reflexes	O	O
remains	O	O
to	O	O
be	O	O
determined	O	O
.	O	O

Azathioprine-induced	O	O
suicidal	O	B_Disease
erythrocyte	O	I_Disease
death	O	I_Disease
.	O	O

BACKGROUND	O	O
:	O	O
Azathioprine	B_Chemical	O
is	O	O
widely	O	O
used	O	O
as	O	O
an	O	O
immunosuppressive	O	O
drug	O	O
.	O	O

The	O	O
side	O	O
effects	O	O
of	O	O
azathioprine	B_Chemical	O
include	O	O
anemia	B_Disease	O
,	O	O
which	O	O
has	O	O
been	O	O
attributed	O	O
to	O	O
bone	O	B_Disease
marrow	O	I_Disease
suppression	O	I_Disease
.	O	O

Alternatively	O	O
,	O	O
anemia	B_Disease	O
could	O	O
result	O	O
from	O	O
accelerated	O	O
suicidal	O	B_Disease
erythrocyte	O	I_Disease
death	O	I_Disease
or	O	O
eryptosis	O	B_Disease
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
exposure	O	O
of	O	O
phosphatidylserine	B_Chemical	O
(	O	O
PS	B_Chemical	O
)	O	O
at	O	O
the	O	O
erythrocyte	O	O
surface	O	O
and	O	O
by	O	O
cell	O	O
shrinkage	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
present	O	O
experiments	O	O
explored	O	O
whether	O	O
azathioprine	B_Chemical	O
influences	O	O
eryptosis	O	O
.	O	O

According	O	O
to	O	O
annexin	O	O
V	O	O
binding	O	O
,	O	O
erythrocytes	O	O
from	O	O
patients	O	O
indeed	O	O
showed	O	O
a	O	O
significant	O	O
increase	O	O
of	O	O
PS	B_Chemical	O
exposure	O	O
within	O	O
1	O	O
week	O	O
of	O	O
treatment	O	O
with	O	O
azathioprine	B_Chemical	O
.	O	O

In	O	O
a	O	O
second	O	O
series	O	O
,	O	O
cytosolic	O	O
Ca2	O	O
+	O	O
activity	O	O
(	O	O
Fluo3	B_Chemical	O
fluorescence	O	O
)	O	O
,	O	O
cell	O	O
volume	O	O
(	O	O
forward	O	O
scatter	O	O
)	O	O
,	O	O
and	O	O
PS-exposure	O	O
(	O	O
annexin	O	O
V	O	O
binding	O	O
)	O	O
were	O	O
determined	O	O
by	O	O
FACS	O	O
analysis	O	O
in	O	O
erythrocytes	O	O
from	O	O
healthy	O	O
volunteers	O	O
.	O	O

RESULTS	O	O
:	O	O
Exposure	O	O
to	O	O
azathioprine	B_Chemical	O
(	O	O
>	O	O
or	O	O
=	O	O
2	O	O
microg/mL	O	O
)	O	O
for	O	O
48	O	O
hours	O	O
increased	O	O
cytosolic	O	O
Ca2	O	O
+	O	O
activity	O	O
and	O	O
annexin	O	O
V	O	O
binding	O	O
and	O	O
decreased	O	O
forward	O	O
scatter	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
azathioprine	B_Chemical	O
on	O	O
both	O	O
annexin	O	O
V	O	O
binding	O	O
and	O	O
forward	O	O
scatter	O	O
was	O	O
significantly	O	O
blunted	O	O
in	O	O
the	O	O
nominal	O	O
absence	O	O
of	O	O
extracellular	O	O
Ca2	O	O
+	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Azathioprine	B_Chemical	O
triggers	O	O
suicidal	O	O
erythrocyte	O	B_Disease
death	O	I_Disease
,	O	O
an	O	O
effect	O	O
presumably	O	O
contributing	O	O
to	O	O
azathioprine-induced	O	O
anemia	B_Disease	O
.	O	O

Levetiracetam	B_Chemical	B_Chemical
as	O	O
an	O	O
adjunct	O	O
to	O	O
phenobarbital	B_Chemical	O
treatment	O	O
in	O	O
cats	O	O
with	O	O
suspected	O	O
idiopathic	B_Disease	B_Disease
epilepsy	I_Disease	I_Disease
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
assess	O	O
pharmacokinetics	O	O
,	O	O
efficacy	O	O
,	O	O
and	O	O
tolerability	O	O
of	O	O
oral	O	O
levetiracetam	B_Chemical	B_Chemical
administered	O	O
as	O	O
an	O	O
adjunct	O	O
to	O	O
phenobarbital	B_Chemical	O
treatment	O	O
in	O	O
cats	O	O
with	O	O
poorly	O	O
controlled	O	O
suspected	O	O
idiopathic	B_Disease	B_Disease
epilepsy	I_Disease	I_Disease
.	O	O

DESIGN-Open-label	O	O
,	O	O
noncomparative	O	O
clinical	O	O
trial	O	O
.	O	O

ANIMALS	O	O
:	O	O
12	O	O
cats	O	O
suspected	O	O
to	O	O
have	O	O
idiopathic	B_Disease	B_Disease
epilepsy	I_Disease	I_Disease
that	O	O
was	O	O
poorly	O	O
controlled	O	O
with	O	O
phenobarbital	B_Chemical	O
or	O	O
that	O	O
had	O	O
unacceptable	O	O
adverse	O	O
effects	O	O
when	O	O
treated	O	O
with	O	O
phenobarbital	B_Chemical	O
.	O	O

PROCEDURES	O	O
:	O	O
Cats	O	O
were	O	O
treated	O	O
with	O	O
levetiracetam	B_Chemical	B_Chemical
(	O	O
20	O	O
mg/kg	O	O
[	O	O
9.1	O	O
mg/lb	O	O
]	O	O
,	O	O
PO	O	O
,	O	O
q	O	O
8	O	O
h	O	O
)	O	O
.	O	O

After	O	O
a	O	O
minimum	O	O
of	O	O
1	O	O
week	O	O
of	O	O
treatment	O	O
,	O	O
serum	O	O
levetiracetam	B_Chemical	B_Chemical
concentrations	O	O
were	O	O
measured	O	O
before	O	O
and	O	O
2	O	O
,	O	O
4	O	O
,	O	O
and	O	O
6	O	O
hours	O	O
after	O	O
drug	O	O
administration	O	O
,	O	O
and	O	O
maximum	O	O
and	O	O
minimum	O	O
serum	O	O
concentrations	O	O
and	O	O
elimination	O	O
half-life	O	O
were	O	O
calculated	O	O
.	O	O

Seizure	B_Disease	O
frequencies	O	O
before	O	O
and	O	O
after	O	O
initiation	O	O
of	O	O
levetiracetam	B_Chemical	B_Chemical
treatment	O	O
were	O	O
compared	O	O
,	O	O
and	O	O
adverse	O	O
effects	O	O
were	O	O
recorded	O	O
.	O	O

RESULTS	O	O
:	O	O
Median	O	O
maximum	O	O
serum	O	O
levetiracetam	B_Chemical	B_Chemical
concentration	O	O
was	O	O
25.5	O	O
microg/mL	O	O
,	O	O
median	O	O
minimum	O	O
serum	O	O
levetiracetam	B_Chemical	B_Chemical
concentration	O	O
was	O	O
8.3	O	O
microg/mL	O	O
,	O	O
and	O	O
median	O	O
elimination	O	O
half-life	O	O
was	O	O
2.9	O	O
hours	O	O
.	O	O

Median	O	O
seizure	B_Disease	O
frequency	O	O
prior	O	O
to	O	O
treatment	O	O
with	O	O
levetiracetam	B_Chemical	B_Chemical
(	O	O
2.1	O	O
seizures/mo	O	O
)	O	O
was	O	O
significantly	O	O
higher	O	O
than	O	O
median	O	O
seizure	B_Disease	O
frequency	O	O
after	O	O
initiation	O	O
of	O	O
levetiracetam	B_Chemical	B_Chemical
treatment	O	O
(	O	O
0.42	O	O
seizures/mo	O	O
)	O	O
,	O	O
and	O	O
7	O	O
of	O	O
10	O	O
cats	O	O
were	O	O
classified	O	O
as	O	O
having	O	O
responded	O	O
to	O	O
levetiracetam	B_Chemical	B_Chemical
treatment	O	O
(	O	O
ie	O	O
,	O	O
reduction	O	O
in	O	O
seizure	B_Disease	O
frequency	O	O
of	O	O
>	O	O
or=50	O	O
%	O	O
)	O	O
.	O	O

Two	O	O
cats	O	O
had	O	O
transient	O	O
lethargy	B_Disease	O
and	O	O
inappetence	B_Disease	B_Chemical
.	O	O

CONCLUSIONS	O	O
AND	O	O
CLINICAL	O	O
RELEVANCE	O	O
:	O	O
Results	O	O
suggested	O	O
that	O	O
levetiracetam	B_Chemical	B_Chemical
is	O	O
well	O	O
tolerated	O	O
in	O	O
cats	O	O
and	O	O
may	O	O
be	O	O
useful	O	O
as	O	O
an	O	O
adjunct	O	O
to	O	O
phenobarbital	B_Chemical	O
treatment	O	O
in	O	O
cats	O	O
with	O	O
idiopathic	B_Disease	B_Disease
epilepsy	I_Disease	I_Disease
.	O	O

Serotonin	B_Chemical	O
reuptake	O	O
inhibitors	O	O
,	O	O
paranoia	B_Disease	O
,	O	O
and	O	O
the	O	O
ventral	O	O
basal	O	O
ganglia	O	O
.	O	O

Antidepressants	O	O
have	O	O
previously	O	O
been	O	O
associated	O	O
with	O	O
paranoid	B_Disease	O
reactions	O	O
in	O	O
psychiatric	O	O
patients	O	O
.	O	O

Five	O	O
cases	O	O
of	O	O
paranoid	B_Disease	O
exacerbation	O	O
with	O	O
the	O	O
serotonin	B_Chemical	O
reuptake	O	O
inhibitors	O	O
fluoxetine	B_Chemical	O
and	O	O
amitriptyline	B_Chemical	O
are	O	O
reported	O	O
here	O	O
.	O	O

Elements	O	O
common	O	O
to	O	O
these	O	O
cases	O	O
included	O	O
a	O	O
history	O	O
of	O	O
paranoid	B_Disease	O
symptomatology	O	O
and	O	O
the	O	O
concomitant	O	O
occurrence	O	O
of	O	O
depressive	B_Disease	O
and	I_Disease	O
psychotic	B_Disease	B_Disease
symptoms	I_Disease	I_Disease
.	O	O

Complicated	O	O
depressive	B_Disease	B_Disease
disorders	I_Disease	I_Disease
(	O	O
including	O	O
atypicality	O	O
of	O	O
course	O	O
and	O	O
symptomatology	O	O
,	O	O
chronicity	O	O
,	O	O
psychosis	B_Disease	O
,	O	O
bipolarity	O	O
,	O	O
and	O	O
secondary	O	O
onset	O	O
in	O	O
the	O	O
course	O	O
of	O	O
a	O	O
primary	O	O
psychosis	B_Disease	O
)	O	O
may	O	O
present	O	O
particular	O	O
vulnerability	O	O
to	O	O
paranoid	B_Disease	O
exacerbations	O	O
associated	O	O
with	O	O
serotonin	B_Chemical	O
reuptake	O	O
inhibitors	O	O
.	O	O

Although	O	O
the	O	O
pharmacology	O	O
and	O	O
neurobiology	O	O
of	O	O
paranoia	B_Disease	O
remain	O	O
cryptic	O	O
,	O	O
several	O	O
mechanisms	O	O
,	O	O
including	O	O
5HT3	O	O
receptor-mediated	O	O
dopamine	B_Chemical	O
release	O	O
,	O	O
beta-noradrenergic	O	O
receptor	O	O
downregulation	O	O
,	O	O
or	O	O
GABAB	O	O
receptor	O	O
upregulation	O	O
acting	O	O
in	O	O
the	O	O
vicinity	O	O
of	O	O
the	O	O
ventral	O	O
basal	O	O
ganglia	O	O
(	O	O
possibly	O	O
in	O	O
lateral	O	O
orbitofrontal	O	O
or	O	O
anterior	O	O
cingulate	O	O
circuits	O	O
)	O	O
,	O	O
might	O	O
apply	O	O
to	O	O
this	O	O
phenomenon	O	O
.	O	O

These	O	O
cases	O	O
call	O	O
attention	O	O
to	O	O
possible	O	O
paranoid	B_Disease	O
exacerbations	O	O
with	O	O
serotonin	B_Chemical	O
reuptake	O	O
blockers	O	O
in	O	O
select	O	O
patients	O	O
and	O	O
raise	O	O
neurobiological	O	O
considerations	O	O
regarding	O	O
paranoia	B_Disease	O
.	O	O

Clinical	O	O
comparison	O	O
of	O	O
cardiorespiratory	O	O
effects	O	O
during	O	O
unilateral	O	O
and	O	O
conventional	O	O
spinal	O	O
anaesthesia	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Spinal	O	O
anaesthesia	O	O
is	O	O
widely	O	O
employed	O	O
in	O	O
clinical	O	O
practice	O	O
but	O	O
has	O	O
the	O	O
main	O	O
drawback	O	O
of	O	O
post-spinal	O	O
block	O	O
hypotension	B_Disease	O
.	O	O

Efforts	O	O
must	O	O
therefore	O	O
continue	O	O
to	O	O
be	O	O
made	O	O
to	O	O
obviate	O	O
this	O	O
setback	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
cardiovascular	O	O
and	O	O
respiratory	O	O
changes	O	O
during	O	O
unilateral	O	O
and	O	O
conventional	O	O
spinal	O	O
anaesthesia	O	O
.	O	O

METHODS	O	O
:	O	O
With	O	O
ethical	O	O
approval	O	O
,	O	O
we	O	O
studied	O	O
74	O	O
American	O	O
Society	O	O
of	O	O
Anesthesiologists	O	O
(	O	O
ASA	O	O
)	O	O
,	O	O
physical	O	O
status	O	O
class	O	O
1	O	O
and	O	O
2	O	O
patients	O	O
scheduled	O	O
for	O	O
elective	O	O
unilateral	O	O
lower	O	O
limb	O	O
surgery	O	O
.	O	O

Patients	O	O
were	O	O
randomly	O	O
allocated	O	O
into	O	O
one	O	O
of	O	O
two	O	O
groups	O	O
:	O	O
lateral	O	O
and	O	O
conventional	O	O
spinal	O	O
anaesthesia	O	O
groups	O	O
.	O	O

In	O	O
the	O	O
lateral	O	O
position	O	O
with	O	O
operative	O	O
side	O	O
down	O	O
,	O	O
patients	O	O
recived	O	O
10	O	O
mg	O	O
(	O	O
2mls	O	O
)	O	O
of	O	O
0.5	O	O
%	O	O
hyperbaric	O	O
bupivacaine	B_Chemical	B_Chemical
through	O	O
a	O	O
25-gauge	O	O
spinal	O	O
needle	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
unilateral	O	O
group	O	O
were	O	O
maintained	O	O
in	O	O
the	O	O
lateral	O	O
position	O	O
for	O	O
15	O	O
minutes	O	O
following	O	O
spinal	O	O
injection	O	O
while	O	O
those	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
were	O	O
turned	O	O
supine	O	O
immediately	O	O
after	O	O
injection	O	O
.	O	O

Blood	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
respiratory	O	O
rate	O	O
and	O	O
oxygen	B_Chemical	O
saturation	O	O
were	O	O
monitored	O	O
over	O	O
1	O	O
hour	O	O
.	O	O

RESULTS	O	O
:	O	O
Three	O	O
patients	O	O
(	O	O
8.1	O	O
%	O	O
)	O	O
in	O	O
the	O	O
unilateral	O	O
group	O	O
and	O	O
5	O	O
(	O	O
13.5	O	O
%	O	O
)	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
developed	O	O
hypotension	B_Disease	O
,	O	O
P=	O	O
0.71	O	O
.	O	O

Four	O	O
(	O	O
10.8	O	O
%	O	O
)	O	O
patients	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
and	O	O
1	O	O
(	O	O
2.7	O	O
%	O	O
)	O	O
in	O	O
the	O	O
unilateral	O	O
group	O	O
,	O	O
P=	O	O
0.17	O	O
required	O	O
epinephrine	B_Chemical	O
infusion	O	O
to	O	O
treat	O	O
hypotension	B_Disease	O
.	O	O

Patients	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
had	O	O
statistically	O	O
significant	O	O
greater	O	O
fall	O	O
in	O	O
the	O	O
systolic	O	O
blood	O	O
pressures	O	O
at	O	O
15	O	O
,	O	O
30	O	O
and	O	O
45	O	O
minutes	O	O
when	O	O
compared	O	O
to	O	O
the	O	O
baseline	O	O
(	O	O
P=	O	O
0.003	O	O
,	O	O
0.001	O	O
and	O	O
0.004	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
respiratory	O	O
rate	O	O
and	O	O
oxygen	B_Chemical	O
saturations	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
were	O	O
similar	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Compared	O	O
to	O	O
conventional	O	O
spinal	O	O
anaesthesia	O	O
,	O	O
unilateral	O	O
spinal	O	O
anaesthesia	O	O
was	O	O
associated	O	O
with	O	O
fewer	O	O
cardiovascular	O	O
perturbations	O	O
.	O	O

Also	O	O
,	O	O
the	O	O
type	O	O
of	O	O
spinal	O	O
block	O	O
instituted	O	O
affected	O	O
neither	O	O
the	O	O
respiratory	O	O
rate	O	O
nor	O	O
the	O	O
arterial	O	O
oxygen	B_Chemical	O
saturation	O	O
.	O	O

Spectrum	O	O
of	O	O
adverse	O	O
events	O	O
after	O	O
generic	O	O
HAART	O	O
in	O	O
southern	O	O
Indian	O	O
HIV-infected	O	O
patients	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
incidence	O	O
of	O	O
clinically	O	O
significant	O	O
adverse	O	O
events	O	O
after	O	O
long-term	O	O
,	O	O
fixed-dose	O	O
,	O	O
generic	O	O
highly	O	O
active	O	O
antiretroviral	O	O
therapy	O	O
(	O	O
HAART	O	O
)	O	O
use	O	O
among	O	O
HIV-infected	B_Disease	O
individuals	O	O
in	O	O
South	O	O
India	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
experiences	O	O
of	O	O
3154	O	O
HIV-infected	B_Disease	O
individuals	O	O
who	O	O
received	O	O
a	O	O
minimum	O	O
of	O	O
3	O	O
months	O	O
of	O	O
generic	O	O
HAART	O	O
between	O	O
February	O	O
1996	O	O
and	O	O
December	O	O
2006	O	O
at	O	O
a	O	O
tertiary	O	O
HIV	O	O
care	O	O
referral	O	O
center	O	O
in	O	O
South	O	O
India	O	O
.	O	O

The	O	O
most	O	O
common	O	O
regimens	O	O
were	O	O
3TC	B_Chemical	O
+	O	O
d4	B_Chemical	O
T	I_Chemical	O
+	O	O
nevirapine	B_Chemical	O
(	O	O
NVP	B_Chemical	O
)	O	O
(	O	O
54.8	O	O
%	O	O
)	O	O
,	O	O
zidovudine	B_Chemical	O
(	O	O
AZT	B_Chemical	O
)	O	O
+	O	O
3TC	B_Chemical	O
+	O	O
NVP	B_Chemical	O
(	O	O
14.5	O	O
%	O	O
)	O	O
,	O	O
3TC	B_Chemical	O
+	O	O
d4	B_Chemical	O
T	I_Chemical	O
+	O	O
efavirenz	B_Chemical	B_Chemical
(	O	O
EFV	B_Chemical	O
)	O	O
(	O	O
20.1	O	O
%	O	O
)	O	O
,	O	O
and	O	O
AZT	B_Chemical	O
+	O	O
3TC	B_Chemical	O
+	O	O
EFV	B_Chemical	O
(	O	O
5.4	O	O
%	O	O
)	O	O
.	O	O

The	O	O
most	O	O
common	O	O
adverse	O	O
events	O	O
and	O	O
median	O	O
CD4	O	O
at	O	O
time	O	O
of	O	O
event	O	O
were	O	O
rash	B_Disease	O
(	O	O
15.2	O	O
%	O	O
;	O	O
CD4	O	O
,	O	O
285	O	O
cells/microL	O	O
)	O	O
and	O	O
peripheral	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
(	O	O
9.0	O	O
%	O	O
and	O	O
348	O	O
cells/microL	O	O
)	O	O
.	O	O

Clinically	O	O
significant	O	O
anemia	B_Disease	O
(	O	O
hemoglobin	O	O
<	O	O
7	O	O
g/dL	O	O
)	O	O
was	O	O
observed	O	O
in	O	O
5.4	O	O
%	O	O
of	O	O
patients	O	O
(	O	O
CD4	O	O
,	O	O
165	O	O
cells/microL	O	O
)	O	O
and	O	O
hepatitis	B_Disease	O
(	O	O
clinical	O	O
jaundice	B_Disease	O
with	O	O
alanine	B_Chemical	B_Chemical
aminotransferase	O	I_Chemical
>	O	O
5	O	O
times	O	O
upper	O	O
limits	O	O
of	O	O
normal	O	O
)	O	O
in	O	O
3.5	O	O
%	O	O
of	O	O
patients	O	O
(	O	O
CD4	O	O
,	O	O
260	O	O
cells/microL	O	O
)	O	O
.	O	O

Women	O	O
were	O	O
significantly	O	O
more	O	O
likely	O	O
to	O	O
experience	O	O
lactic	B_Disease	B_Disease
acidosis	I_Disease	I_Disease
,	O	O
while	O	O
men	O	O
were	O	O
significantly	O	O
more	O	O
likely	O	O
to	O	O
experience	O	O
immune	B_Disease	O
reconstitution	I_Disease	O
syndrome	I_Disease	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

Among	O	O
the	O	O
patients	O	O
with	O	O
1	O	O
year	O	O
of	O	O
follow-up	O	O
,	O	O
NVP	B_Chemical	O
therapy	O	O
was	O	O
significantly	O	O
associated	O	O
with	O	O
developing	O	O
rash	B_Disease	O
and	O	O
d4	B_Chemical	O
T	I_Chemical	O
therapy	O	O
with	O	O
developing	O	O
peripheral	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

Anemia	B_Disease	O
and	O	O
hepatitis	B_Disease	O
often	O	O
occur	O	O
within	O	O
12	O	O
weeks	O	O
of	O	O
initiating	O	O
generic	O	O
HAART	O	O
.	O	O

Frequent	O	O
and	O	O
early	O	O
monitoring	O	O
for	O	O
these	O	O
toxicities	B_Disease	O
is	O	O
warranted	O	O
in	O	O
developing	O	O
countries	O	O
where	O	O
generic	O	O
HAART	O	O
is	O	O
increasingly	O	O
available	O	O
.	O	O

Thalidomide	B_Chemical	O
and	O	O
sensory	B_Disease	B_Disease
neurotoxicity	I_Disease	I_Disease
:	O	O
a	O	O
neurophysiological	O	O
study	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Recent	O	O
studies	O	O
confirmed	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
sensory	B_Disease	B_Disease
axonal	I_Disease	I_Disease
neuropathy	I_Disease	I_Disease
in	O	O
patients	O	O
treated	O	O
with	O	O
different	O	O
doses	O	O
of	O	O
thalidomide	B_Chemical	O
.	O	O

The	O	O
study	O	O
's	O	O
aims	O	O
were	O	O
to	O	O
measure	O	O
variations	O	O
in	O	O
sural	O	O
nerve	O	O
sensory	O	O
action	O	O
potential	O	O
(	O	O
SAP	O	O
)	O	O
amplitude	O	O
in	O	O
patients	O	O
with	O	O
refractory	O	O
cutaneous	B_Disease	O
lupus	I_Disease	O
erythematosus	I_Disease	O
(	O	O
CLE	B_Disease	O
)	O	O
treated	O	O
with	O	O
thalidomide	B_Chemical	O
and	O	O
use	O	O
these	O	O
findings	O	O
to	O	O
identify	O	O
the	O	O
neurotoxic	B_Disease	O
potential	O	O
of	O	O
thalidomide	B_Chemical	O
and	O	O
the	O	O
recovery	O	O
capacity	O	O
of	O	O
sensory	O	O
fibres	O	O
after	O	O
discontinuation	O	O
of	O	O
treatment	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
Clinical	O	O
and	O	O
electrophysiological	O	O
data	O	O
in	O	O
12	O	O
female	O	O
patients	O	O
with	O	O
CLE	B_Disease	O
during	O	O
treatment	O	O
with	O	O
thalidomide	B_Chemical	O
and	O	O
up	O	O
to	O	O
47	O	O
months	O	O
after	O	O
discontinuation	O	O
of	O	O
treatment	O	O
were	O	O
analysed	O	O
.	O	O

Sural	O	O
nerve	O	O
SAP	O	O
amplitude	O	O
reduction	O	O
>	O	O
or	O	O
=	O	O
40	O	O
%	O	O
was	O	O
the	O	O
criteria	O	O
for	O	O
discontinuing	O	O
therapy	O	O
.	O	O

RESULTS	O	O
:	O	O
During	O	O
treatment	O	O
,	O	O
11	O	O
patients	O	O
showed	O	O
a	O	O
reduction	O	O
in	O	O
sural	O	O
nerve	O	O
SAP	O	O
amplitude	O	O
compared	O	O
to	O	O
baseline	O	O
values	O	O
(	O	O
9	O	O
with	O	O
a	O	O
reduction	O	O
>	O	O
or	O	O
=	O	O
50	O	O
%	O	O
and	O	O
2	O	O
<	O	O
50	O	O
%	O	O
)	O	O
.	O	O

One	O	O
patient	O	O
showed	O	O
no	O	O
changes	O	O
in	O	O
SAP	O	O
amplitude	O	O
.	O	O

Five	O	O
patients	O	O
complained	O	O
of	O	O
paresthesias	B_Disease	O
and	O	O
leg	O	O
cramps	B_Disease	O
.	O	O

After	O	O
thalidomide	B_Chemical	O
treatment	O	O
,	O	O
sural	O	O
SAP	O	O
amplitude	O	O
recovered	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

At	O	O
detection	O	O
of	O	O
reduction	O	O
in	O	O
sural	O	O
nerve	O	O
SAP	O	O
amplitude	O	O
,	O	O
the	O	O
median	O	O
thalidomide	B_Chemical	O
cumulative	O	O
dose	O	O
was	O	O
21.4	O	O
g.	O	O
The	O	O
threshold	O	O
neurotoxic	B_Disease	O
dosage	O	O
is	O	O
lower	O	O
than	O	O
previously	O	O
reported	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Sural	O	O
nerve	O	O
SAP	O	O
amplitude	O	O
reduction	O	O
is	O	O
a	O	O
reliable	O	O
and	O	O
sensitive	O	O
marker	O	O
of	O	O
degeneration	O	O
and	O	O
recovery	O	O
of	O	O
sensory	O	O
fibres	O	O
.	O	O

This	O	O
electrophysiological	O	O
parameter	O	O
provides	O	O
information	O	O
about	O	O
subclinical	O	O
neurotoxic	B_Disease	O
potential	O	O
of	O	O
thalidomide	B_Chemical	O
but	O	O
is	O	O
not	O	O
helpful	O	O
in	O	O
predicting	O	O
the	O	O
appearance	O	O
of	O	O
sensory	O	B_Disease
symptoms	O	I_Disease
.	O	O

Five	O	O
cases	O	O
of	O	O
encephalitis	B_Disease	O
during	O	O
treatment	O	O
of	O	O
loiasis	B_Disease	O
with	O	O
diethylcarbamazine	B_Chemical	B_Chemical
.	O	O

Five	O	O
cases	O	O
of	O	O
encephalitis	B_Disease	O
following	O	O
treatment	O	O
with	O	O
diethylcarbamazine	B_Chemical	B_Chemical
(	O	O
DEC	B_Chemical	O
)	O	O
were	O	O
observed	O	O
in	O	O
Congolese	O	O
patients	O	O
with	O	O
Loa	O	O
loa	O	O
filariasis	B_Disease	O
.	O	O

Two	O	O
cases	O	O
had	O	O
a	O	O
fatal	O	O
outcome	O	O
and	O	O
one	O	O
resulted	O	O
in	O	O
severe	O	O
sequelae	O	O
.	O	O

The	O	O
notable	O	O
fact	O	O
was	O	O
that	O	O
this	O	O
complication	O	O
occurred	O	O
in	O	O
three	O	O
patients	O	O
hospitalized	O	O
before	O	O
treatment	O	O
began	O	O
,	O	O
with	O	O
whom	O	O
particularly	O	O
strict	O	O
therapeutic	O	O
precautions	O	O
were	O	O
taken	O	O
,	O	O
i.e.	O	O
,	O	O
initial	O	O
dose	O	O
less	O	O
than	O	O
10	O	O
mg	O	O
of	O	O
DEC	B_Chemical	O
,	O	O
very	O	O
gradual	O	O
dose	O	O
increases	O	O
,	O	O
and	O	O
associated	O	O
anti-allergic	O	O
treatment	O	O
.	O	O

This	O	O
type	O	O
of	O	O
drug-induced	O	O
complication	O	O
may	O	O
not	O	O
be	O	O
that	O	O
uncommon	O	O
in	O	O
highly	O	O
endemic	O	O
regions	O	O
.	O	O

It	O	O
occurs	O	O
primarily	O	O
,	O	O
but	O	O
not	O	O
exclusively	O	O
,	O	O
in	O	O
subjects	O	O
presenting	O	O
with	O	O
a	O	O
high	O	O
microfilarial	O	O
load	O	O
.	O	O

The	O	O
relationship	O	O
between	O	O
the	O	O
occurrence	O	O
of	O	O
encephalitis	B_Disease	O
and	O	O
the	O	O
decrease	O	O
in	O	O
microfilaremia	B_Disease	O
is	O	O
evident	O	O
.	O	O

The	O	O
pathophysiological	O	O
mechanisms	O	O
are	O	O
discussed	O	O
in	O	O
the	O	O
light	O	O
of	O	O
these	O	O
observations	O	O
and	O	O
the	O	O
few	O	O
other	O	O
comments	O	O
on	O	O
this	O	O
subject	O	O
published	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

Amiodarone-related	O	O
pulmonary	B_Disease	O
mass	I_Disease	O
and	O	O
unique	O	O
membranous	B_Disease	O
glomerulonephritis	I_Disease	O
in	O	O
a	O	O
patient	O	O
with	O	O
valvular	B_Disease	B_Disease
heart	I_Disease	I_Disease
disease	I_Disease	I_Disease
:	O	O
Diagnostic	O	O
pitfall	O	O
and	O	O
new	O	O
findings	O	O
.	O	O

Amiodarone	B_Chemical	O
is	O	O
an	O	O
anti-arrhythmic	O	O
drug	O	O
for	O	O
life-threatening	O	O
tachycardia	B_Disease	O
,	O	O
but	O	O
various	O	O
adverse	O	O
effects	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

Reported	O	O
herein	O	O
is	O	O
an	O	O
autopsy	O	O
case	O	O
of	O	O
valvular	B_Disease	B_Disease
heart	I_Disease	I_Disease
disease	I_Disease	I_Disease
,	O	O
in	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
a	O	O
lung	B_Disease	O
mass	I_Disease	O
(	O	O
1.5	O	O
cm	O	O
in	O	O
diameter	O	O
)	O	O
and	O	O
proteinuria	B_Disease	O
(	O	O
2.76	O	O
g/day	O	O
)	O	O
after	O	O
treatment	O	O
with	O	O
amiodarone	B_Chemical	O
for	O	O
a	O	O
long	O	O
time	O	O
.	O	O

The	O	O
lung	B_Disease	O
mass	I_Disease	O
was	O	O
highly	O	O
suspected	O	O
to	O	O
be	O	O
lung	B_Disease	B_Disease
cancer	I_Disease	I_Disease
on	O	O
CT	O	O
and	O	O
positron	O	O
emission	O	O
tomography	O	O
,	O	O
but	O	O
histologically	O	O
the	O	O
lesion	O	O
was	O	O
composed	O	O
of	O	O
lymphoplasmacytic	O	O
infiltrates	O	O
in	O	O
alveolar	O	O
walls	O	O
and	O	O
intra-alveolar	O	O
accumulation	O	O
of	O	O
foamy	O	O
macrophages	O	O
containing	O	O
characteristic	O	O
myelinoid	O	O
bodies	O	O
,	O	O
indicating	O	O
that	O	O
it	O	O
was	O	O
an	O	O
amiodarone-related	O	O
lesion	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
lung	O	O
tissue	O	O
had	O	O
unevenly	O	O
distributed	O	O
hemosiderin	B_Disease	O
deposition	O	O
,	O	O
and	O	O
abnormally	O	O
tortuous	O	O
capillaries	O	O
were	O	O
seen	O	O
in	O	O
the	O	O
mass	O	O
and	O	O
in	O	O
heavily	O	O
hemosiderotic	B_Disease	O
lung	O	O
portions	O	O
outside	O	O
the	O	O
mass	O	O
.	O	O

In	O	O
the	O	O
kidneys	O	O
,	O	O
glomeruli	O	O
had	O	O
membrane	O	O
spikes	O	O
,	O	O
prominent	O	O
swelling	O	O
of	O	O
podocytes	O	O
and	O	O
subepithelial	O	O
deposits	O	O
,	O	O
which	O	O
were	O	O
sometimes	O	O
large	O	O
and	O	O
hump-like	O	O
.	O	O

Autoimmune	B_Disease	O
diseases	I_Disease	O
,	O	O
viral	B_Disease	O
hepatitis	I_Disease	O
,	O	O
malignant	O	O
neoplasms	B_Disease	O
or	O	O
other	O	O
diseases	O	O
with	O	O
a	O	O
known	O	O
relationship	O	O
to	O	O
membranous	B_Disease	O
glomerulonephritis	I_Disease	O
were	O	O
not	O	O
found	O	O
.	O	O

The	O	O
present	O	O
case	O	O
highlights	O	O
the	O	O
possibility	O	O
that	O	O
differential	O	O
diagnosis	O	O
between	O	O
an	O	O
amiodarone-related	O	O
pulmonary	B_Disease	O
lesion	I_Disease	O
and	O	O
a	O	O
neoplasm	B_Disease	O
can	O	O
be	O	O
very	O	O
difficult	O	O
radiologically	O	O
,	O	O
and	O	O
suggests	O	O
that	O	O
membranous	B_Disease	O
glomerulonephritis	I_Disease	O
might	O	O
be	O	O
another	O	O
possible	O	O
complication	O	O
of	O	O
amiodarone	B_Chemical	O
treatment	O	O
.	O	O

Risk	O	O
of	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
associated	O	O
with	O	O
initial	O	O
sulphonylurea	B_Chemical	B_Chemical
treatment	O	O
of	O	O
patients	O	O
with	O	O
type	B_Disease	O
2	I_Disease	O
diabetes	I_Disease	O
:	O	O
a	O	O
matched	O	O
case-control	O	O
study	O	O
.	O	O

AIMS	O	O
:	O	O
This	O	O
study	O	O
sought	O	O
to	O	O
assess	O	O
the	O	O
risk	O	O
of	O	O
developing	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
(	O	O
CAD	B_Disease	O
)	O	O
associated	O	O
with	O	O
initial	O	O
treatment	O	O
of	O	O
type	B_Disease	O
2	I_Disease	O
diabetes	I_Disease	O
with	O	O
different	O	O
sulphonylureas	B_Chemical	O
.	O	O

METHODS	O	O
:	O	O
In	O	O
type	B_Disease	O
2	I_Disease	O
diabetic	I_Disease	O
patients	O	O
,	O	O
cases	O	O
who	O	O
developed	O	O
CAD	B_Disease	O
were	O	O
compared	O	O
retrospectively	O	O
with	O	O
controls	O	O
that	O	O
did	O	O
not	O	O
.	O	O

The	O	O
20-year	O	O
risk	O	O
of	O	O
CAD	B_Disease	O
at	O	O
diagnosis	O	O
of	O	O
diabetes	B_Disease	O
,	O	O
using	O	O
the	O	O
UKPDS	O	O
risk	O	O
engine	O	O
,	O	O
was	O	O
used	O	O
to	O	O
match	O	O
cases	O	O
with	O	O
controls	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
76	O	O
cases	O	O
of	O	O
CAD	B_Disease	O
were	O	O
compared	O	O
with	O	O
152	O	O
controls	O	O
.	O	O

The	O	O
hazard	O	O
of	O	O
developing	O	O
CAD	B_Disease	O
(	O	O
95	O	O
%	O	O
CI	O	O
)	O	O
associated	O	O
with	O	O
initial	O	O
treatment	O	O
increased	O	O
by	O	O
2.4-fold	O	O
(	O	O
1.3	O	O
-	O	O
4.3	O	O
,	O	O
P=0.004	O	O
)	O	O
with	O	O
glibenclamide	B_Chemical	B_Chemical
;	O	O
2-fold	O	O
(	O	O
0.9	O	O
-	O	O
4.6	O	O
,	O	O
P=0.099	O	O
)	O	O
with	O	O
glipizide	B_Chemical	O
;	O	O
2.9-fold	O	O
(	O	O
1.6	O	O
-	O	O
5.1	O	O
,	O	O
P=0.000	O	O
)	O	O
with	O	O
either	O	O
,	O	O
and	O	O
was	O	O
unchanged	O	O
with	O	O
metformin	B_Chemical	O
.	O	O

The	O	O
hazard	O	O
decreased	O	O
0.3-fold	O	O
(	O	O
0.7	O	O
-	O	O
1.7	O	O
,	O	O
P=0.385	O	O
)	O	O
with	O	O
glimepiride	B_Chemical	B_Chemical
,	O	O
0.4-fold	O	O
(	O	O
0.7	O	O
-	O	O
1.3	O	O
,	O	O
P=0.192	O	O
)	O	O
with	O	O
gliclazide	B_Chemical	B_Chemical
,	O	O
and	O	O
0.4-fold	O	O
(	O	O
0.7	O	O
-	O	O
1.1	O	O
,	O	O
P=0.09	O	O
)	O	O
with	O	O
either	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Initiating	O	O
treatment	O	O
of	O	O
type	B_Disease	O
2	I_Disease	O
diabetes	I_Disease	O
with	O	O
glibenclamide	B_Chemical	B_Chemical
or	O	O
glipizide	B_Chemical	O
is	O	O
associated	O	O
with	O	O
increased	O	O
risk	O	O
of	O	O
CAD	B_Disease	O
in	O	O
comparison	O	O
to	O	O
gliclazide	B_Chemical	B_Chemical
or	O	O
glimepiride	B_Chemical	B_Chemical
.	O	O

If	O	O
confirmed	O	O
,	O	O
this	O	O
may	O	O
be	O	O
important	O	O
because	O	O
most	O	O
Indian	O	O
patients	O	O
receive	O	O
the	O	O
cheaper	O	O
older	O	O
sulphonylureas	B_Chemical	O
,	O	O
and	O	O
present	O	O
guidelines	O	O
do	O	O
not	O	O
distinguish	O	O
between	O	O
individual	O	O
agents	O	O
.	O	O

Reduced	O	O
progression	O	O
of	O	O
adriamycin	B_Chemical	O
nephropathy	B_Disease	O
in	O	O
spontaneously	O	O
hypertensive	B_Disease	O
rats	O	O
treated	O	O
by	O	O
losartan	B_Chemical	B_Chemical
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
antihypertensive	O	O
effects	O	O
of	O	O
angiotensin	B_Chemical	O
II	I_Chemical	O
type-1	O	O
receptor	O	O
blocker	O	O
,	O	O
losartan	B_Chemical	B_Chemical
,	O	O
and	O	O
its	O	O
potential	O	O
in	O	O
slowing	O	O
down	O	O
renal	B_Disease	B_Disease
disease	I_Disease	I_Disease
progression	O	I_Disease
in	O	O
spontaneously	O	O
hypertensive	B_Disease	O
rats	O	O
(	O	O
SHR	O	O
)	O	O
with	O	O
adriamycin	B_Chemical	B_Chemical
(	O	O
ADR	B_Chemical	O
)	O	O
nephropathy	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
Six-month-old	O	O
female	O	O
SHR	O	O
were	O	O
randomly	O	O
selected	O	O
in	O	O
six	O	O
groups	O	O
.	O	O

Two	O	O
control	O	O
groups	O	O
(	O	O
SH(6	O	O
)	O	O
,	O	O
SH(12	O	O
)	O	O
)	O	O
received	O	O
vehicle	O	O
.	O	O

Groups	O	O
ADR(6	O	O
)	O	O
,	O	O
ADR+LOS(6	O	O
)	O	O
and	O	O
ADR(12	O	O
)	O	O
,	O	O
and	O	O
ADR+LOS(12	O	O
)	O	O
received	O	O
ADR	B_Chemical	O
(	O	O
2	O	O
mg/kg/b.w	O	O
.	O	O

i.v	O	O
.	O	O
)	O	O
twice	O	O
in	O	O
a	O	O
3-week	O	O
interval	O	O
.	O	O

Group	O	O
ADR+LOS(6	O	O
)	O	O
received	O	O
losartan	B_Chemical	B_Chemical
(	O	O
10	O	O
mg/kg/b.w./day	O	O
by	O	O
gavages	O	O
)	O	O
for	O	O
6	O	O
weeks	O	O
and	O	O
group	O	O
ADR+LOS(12	O	O
)	O	O
for	O	O
12	O	O
weeks	O	O
after	O	O
second	O	O
injection	O	O
of	O	O
ADR	B_Chemical	O
.	O	O

Animals	O	O
were	O	O
killed	O	O
after	O	O
6	O	O
or	O	O
12	O	O
weeks	O	O
,	O	O
respectively	O	O
.	O	O

Haemodynamic	O	O
measurements	O	O
were	O	O
performed	O	O
on	O	O
anaesthetized	O	O
animals	O	O
,	O	O
blood	O	O
and	O	O
urine	O	O
samples	O	O
were	O	O
taken	O	O
for	O	O
biochemical	O	O
analysis	O	O
and	O	O
the	O	O
left	O	O
kidney	O	O
was	O	O
processed	O	O
for	O	O
morphological	O	O
studies	O	O
.	O	O

RESULTS	O	O
:	O	O
Short-term	O	O
losartan	B_Chemical	B_Chemical
treatment	O	O
,	O	O
besides	O	O
antihypertensive	O	O
effect	O	O
,	O	O
improved	O	O
glomerular	O	O
filtration	O	O
rate	O	O
and	O	O
ameliorated	O	O
glomerulosclerosis	B_Disease	B_Disease
resulting	O	O
in	O	O
decreased	O	O
proteinuria	B_Disease	O
.	O	O

Prolonged	O	O
treatment	O	O
with	O	O
losartan	B_Chemical	B_Chemical
showed	O	O
further	O	O
reduction	O	O
of	O	O
glomerulosclerosis	B_Disease	B_Disease
associated	O	O
with	O	O
reduced	O	O
progression	O	O
of	O	O
tubular	O	O
atrophy	B_Disease	O
and	O	O
interstitial	B_Disease	B_Disease
fibrosis	I_Disease	I_Disease
,	O	O
thus	O	O
preventing	O	O
heavy	O	O
proteinuria	B_Disease	O
and	O	O
chronic	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

Losartan	B_Chemical	B_Chemical
reduced	O	O
uraemia	B_Disease	O
and	O	O
increased	O	O
urea	B_Chemical	O
clearance	O	O
in	O	O
advanced	O	O
ADR	B_Chemical	O
nephropathy	B_Disease	O
in	O	O
SHR	O	O
.	O	O

Histological	O	O
examination	O	O
showed	O	O
that	O	O
losartan	B_Chemical	B_Chemical
could	O	O
prevent	O	O
tubular	O	B_Disease
atrophy	B_Disease	I_Disease
,	O	O
interstitial	O	O
infiltration	O	O
and	O	O
fibrosis	B_Disease	O
in	O	O
ADR	B_Chemical	O
nephropathy	B_Disease	O
.	O	O

CONCLUSION	O	O
:	O	O
Losartan	B_Chemical	B_Chemical
reduces	O	O
the	O	O
rate	O	O
of	O	O
progression	O	O
of	O	O
ADR-induced	O	O
focal	B_Disease	O
segmental	I_Disease	O
glomerulosclerosis	I_Disease	O
to	O	O
end-stage	B_Disease	B_Disease
renal	I_Disease	I_Disease
disease	I_Disease	I_Disease
in	O	O
SHR	O	O
.	O	O

The	O	O
risks	O	O
of	O	O
aprotinin	O	B_Chemical
and	O	O
tranexamic	O	B_Chemical
acid	O	I_Chemical
in	O	O
cardiac	O	O
surgery	O	O
:	O	O
a	O	O
one-year	O	O
follow-up	O	O
of	O	O
1188	O	O
consecutive	O	O
patients	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Our	O	O
aim	O	O
was	O	O
to	O	O
investigate	O	O
postoperative	O	O
complications	O	O
and	O	O
mortality	O	O
after	O	O
administration	O	O
of	O	O
aprotinin	O	B_Chemical
compared	O	O
to	O	O
tranexamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
in	O	O
an	O	O
unselected	O	O
,	O	O
consecutive	O	O
cohort	O	O
.	O	O

METHODS	O	O
:	O	O
Perioperative	O	O
data	O	O
from	O	O
consecutive	O	O
cardiac	O	O
surgery	O	O
patients	O	O
were	O	O
prospectively	O	O
collected	O	O
between	O	O
September	O	O
2005	O	O
and	O	O
June	O	O
2006	O	O
in	O	O
a	O	O
university-affiliated	O	O
clinic	O	O
(	O	O
n	O	O
=	O	O
1188	O	O
)	O	O
.	O	O

During	O	O
the	O	O
first	O	O
5	O	O
mo	O	O
,	O	O
596	O	O
patients	O	O
received	O	O
aprotinin	O	B_Chemical
(	O	O
Group	O	O
A	O	O
)	O	O
;	O	O
in	O	O
the	O	O
next	O	O
5	O	O
mo	O	O
,	O	O
592	O	O
patients	O	O
were	O	O
treated	O	O
with	O	O
tranexamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(	O	O
Group	O	O
T	O	O
)	O	O
.	O	O

Except	O	O
for	O	O
antifibrinolytic	O	O
therapy	O	O
,	O	O
the	O	O
anesthetic	O	O
and	O	O
surgical	O	O
protocols	O	O
remained	O	O
unchanged	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
pre-	O	O
and	O	O
intraoperative	O	O
variables	O	O
were	O	O
comparable	O	O
between	O	O
the	O	O
treatment	O	O
groups	O	O
.	O	O

Postoperatively	O	O
,	O	O
a	O	O
significantly	O	O
higher	O	O
incidence	O	O
of	O	O
seizures	B_Disease	O
was	O	O
found	O	O
in	O	O
Group	O	O
T	O	O
(	O	O
4.6	O	O
%	O	O
vs	O	O
1.2	O	O
%	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

This	O	O
difference	O	O
was	O	O
also	O	O
significant	O	O
in	O	O
the	O	O
primary	O	O
valve	O	O
surgery	O	O
and	O	O
the	O	O
high	O	O
risk	O	O
surgery	O	O
subgroups	O	O
(	O	O
7.9	O	O
%	O	O
vs	O	O
1.2	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.003	O	O
;	O	O
7.3	O	O
%	O	O
vs	O	O
2.4	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.035	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Persistent	O	O
atrial	O	B_Disease
fibrillation	O	I_Disease
(	O	O
7.9	O	O
%	O	O
vs	O	O
2.3	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.020	O	O
)	O	O
and	O	O
renal	B_Disease	B_Disease
failure	I_Disease	I_Disease
(	O	O
9.7	O	O
%	O	O
vs	O	O
1.7	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.002	O	O
)	O	O
were	O	O
also	O	O
more	O	O
common	O	O
in	O	O
Group	O	O
T	O	O
,	O	O
in	O	O
the	O	O
primary	O	O
valve	O	O
surgery	O	O
subgroup	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
among	O	O
primary	O	O
coronary	O	O
artery	O	O
bypass	O	O
surgery	O	O
patients	O	O
,	O	O
there	O	O
were	O	O
more	O	O
acute	O	B_Disease
myocardial	B_Disease	I_Disease
infarctions	I_Disease	I_Disease
and	O	O
renal	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
in	O	O
Group	O	O
A	O	O
(	O	O
5.8	O	O
%	O	O
vs	O	O
2.0	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.027	O	O
;	O	O
22.5	O	O
%	O	O
vs	O	O
15.2	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.036	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
1-yr	O	O
mortality	O	O
was	O	O
significantly	O	O
higher	O	O
after	O	O
aprotinin	O	B_Chemical
treatment	O	O
in	O	O
the	O	O
high	O	O
risk	O	O
surgery	O	O
group	O	O
(	O	O
17.7	O	O
%	O	O
vs	O	O
9.8	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0.034	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Both	O	O
antifibrinolytic	O	O
drugs	O	O
bear	O	O
the	O	O
risk	O	O
of	O	O
adverse	O	O
outcome	O	O
depending	O	O
on	O	O
the	O	O
type	O	O
of	O	O
cardiac	O	O
surgery	O	O
.	O	O

Administration	O	O
of	O	O
aprotinin	O	B_Chemical
should	O	O
be	O	O
avoided	O	O
in	O	O
coronary	O	O
artery	O	O
bypass	O	O
graft	O	O
and	O	O
high	O	O
risk	O	O
patients	O	O
,	O	O
whereas	O	O
administration	O	O
of	O	O
tranexamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
is	O	O
not	O	O
recommended	O	O
in	O	O
valve	O	O
surgery	O	O
.	O	O

Delirium	B_Disease	O
in	O	O
an	O	O
elderly	O	O
woman	O	O
possibly	O	O
associated	O	O
with	O	O
administration	O	O
of	O	O
misoprostol	B_Chemical	B_Chemical
.	O	O

Misoprostol	B_Chemical	B_Chemical
has	O	O
been	O	O
associated	O	O
with	O	O
adverse	O	O
reactions	O	O
,	O	O
including	O	O
gastrointestinal	O	B_Disease
symptoms	O	I_Disease
,	O	O
gynecologic	O	O
problems	O	O
,	O	O
and	O	O
headache	B_Disease	O
.	O	O

Changes	O	O
in	O	O
mental	O	O
status	O	O
,	O	O
however	O	O
,	O	O
have	O	O
not	O	O
been	O	O
reported	O	O
.	O	O

We	O	O
present	O	O
a	O	O
case	O	O
in	O	O
which	O	O
an	O	O
89-year-old	O	O
woman	O	O
in	O	O
a	O	O
long-term	O	O
care	O	O
facility	O	O
became	O	O
confused	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
misoprostol	B_Chemical	B_Chemical
therapy	O	O
.	O	O

The	O	O
patient	O	O
's	O	O
change	O	O
in	O	O
mental	O	O
status	O	O
was	O	O
first	O	O
reported	O	O
nine	O	O
days	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
therapy	O	O
.	O	O

Her	O	O
delirium	B_Disease	O
significantly	O	O
improved	O	O
after	O	O
misoprostol	B_Chemical	B_Chemical
was	O	O
discontinued	O	O
and	O	O
her	O	O
mental	O	O
status	O	O
returned	O	O
to	O	O
normal	O	O
within	O	O
a	O	O
week	O	O
.	O	O
Because	O	O
no	O	O
other	O	O
factors	O	O
related	O	O
to	O	O
this	O	O
patient	O	O
changed	O	O
significantly	O	O
,	O	O
the	O	O
delirium	B_Disease	O
experienced	O	O
by	O	O
this	O	O
patient	O	O
possibly	O	O
resulted	O	O
from	O	O
misoprostol	B_Chemical	B_Chemical
therapy	O	O
.	O	O

The	O	O
biological	O	O
properties	O	O
of	O	O
the	O	O
optical	O	O
isomers	O	O
of	O	O
propranolol	B_Chemical	B_Chemical
and	O	O
their	O	O
effects	O	O
on	O	O
cardiac	O	O
arrhythmias.1	O	O
.	O	O

The	O	O
optical	O	O
isomers	O	O
of	O	O
propranolol	B_Chemical	B_Chemical
have	O	O
been	O	O
compared	O	O
for	O	O
their	O	O
beta-blocking	O	O
and	O	O
antiarrhythmic	O	O
activities.2	O	O
.	O	O

In	O	O
blocking	O	O
the	O	O
positive	O	O
inotropic	O	O
and	O	O
chronotropic	O	O
responses	O	O
to	O	O
isoprenaline	B_Chemical	O
,	O	O
(+)-propranolol	O	B_Chemical
had	O	O
less	O	O
than	O	O
one	O	O
hundredth	O	O
the	O	O
potency	O	O
of	O	O
(-)-propranolol	O	B_Chemical
.	O	O

At	O	O
dose	O	O
levels	O	O
of	O	O
(+)-propranolol	O	B_Chemical
which	O	O
attenuated	O	O
the	O	O
responses	O	O
to	O	O
isoprenaline	B_Chemical	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
prolongation	O	O
of	O	O
the	O	O
PR	O	O
interval	O	O
of	O	O
the	O	O
electrocardiogram.3	O	O
.	O	O

The	O	O
metabolic	O	O
responses	O	O
to	O	O
isoprenaline	B_Chemical	O
in	O	O
dogs	O	O
(	O	O
an	O	O
increase	O	O
in	O	O
circulating	O	O
glucose	B_Chemical	O
,	O	O
lactate	B_Chemical	O
and	O	O
free	O	O
fatty	B_Chemical	B_Chemical
acids	I_Chemical	I_Chemical
)	O	O
were	O	O
all	O	O
blocked	O	O
by	O	O
(-)-propranolol	O	B_Chemical
.	O	O

(+)-Propranolol	O	B_Chemical
had	O	O
no	O	O
effect	O	O
on	O	O
fatty	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
mobilization	O	O
but	O	O
significantly	O	O
reduced	O	O
the	O	O
increments	O	O
in	O	O
both	O	O
lactate	B_Chemical	O
and	O	O
glucose.4	O	B_Chemical
.	O	O

Both	O	O
isomers	O	O
of	O	O
propranolol	B_Chemical	B_Chemical
possessed	O	O
similar	O	O
depressant	O	O
potency	O	O
on	O	O
isolated	O	O
atrial	O	O
muscle	O	O
taken	O	O
from	O	O
guinea-pigs.5	O	O
.	O	O

The	O	O
isomers	O	O
of	O	O
propranolol	B_Chemical	B_Chemical
exhibited	O	O
similar	O	O
local	O	O
anaesthetic	O	O
potencies	O	O
on	O	O
an	O	O
isolated	O	O
frog	O	O
nerve	O	O
preparation	O	O
at	O	O
a	O	O
level	O	O
approximately	O	O
three	O	O
times	O	O
that	O	O
of	O	O
procaine	B_Chemical	O
.	O	O

The	O	O
racemic	O	O
compound	O	O
was	O	O
significantly	O	O
less	O	O
potent	O	O
than	O	O
either	O	O
isomer.6	O	O
.	O	O

Both	O	O
isomers	O	O
of	O	O
propranolol	B_Chemical	B_Chemical
were	O	O
capable	O	O
of	O	O
preventing	O	O
adrenaline-induced	O	O
cardiac	B_Disease	B_Disease
arrhythmias	I_Disease	I_Disease
in	O	O
cats	O	O
anaesthetized	O	O
with	O	O
halothane	B_Chemical	O
,	O	O
but	O	O
the	O	O
mean	O	O
dose	O	O
of	O	O
(-)-propranolol	O	B_Chemical
was	O	O
0.09+/-0.02	O	O
mg/kg	O	O
whereas	O	O
that	O	O
of	O	O
(+)-propranolol	O	B_Chemical
was	O	O
4.2+/-1.2	O	B_Chemical
mg/kg	O	O
.	O	O

At	O	O
the	O	O
effective	O	O
dose	O	O
level	O	O
of	O	O
(+)-propranolol	O	B_Chemical
there	O	O
was	O	O
a	O	O
significant	O	O
prolongation	O	O
of	O	O
the	O	O
PR	O	O
interval	O	O
of	O	O
the	O	O
electrocardiogram	O	O
.	O	O

Blockade	O	O
of	O	O
arrhythmias	B_Disease	O
with	O	O
both	O	O
isomers	O	O
was	O	O
surmountable	O	O
by	O	O
increasing	O	O
the	O	O
dose	O	O
of	O	O
adrenaline.7	O	O
.	O	O

Both	O	O
isomers	O	O
of	O	O
propranolol	B_Chemical	B_Chemical
were	O	O
also	O	O
capable	O	O
of	O	O
reversing	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
caused	O	O
by	O	O
ouabain	B_Chemical	B_Chemical
in	O	O
anaesthetized	O	O
cats	O	O
and	O	O
dogs	O	O
.	O	O

The	O	O
dose	O	O
of	O	O
(-)-propranolol	O	B_Chemical
was	O	O
significantly	O	O
smaller	O	O
than	O	O
that	O	O
of	O	O
(+)-propranolol	O	B_Chemical
in	O	O
both	O	O
species	O	O
but	O	O
much	O	O
higher	O	O
than	O	O
that	O	O
required	O	O
to	O	O
produce	O	O
evidence	O	O
of	O	O
beta-blockade.8	O	O
.	O	O

The	O	O
implications	O	O
of	O	O
these	O	O
results	O	O
are	O	O
discussed	O	O
.	O	O

Topotecan	B_Chemical	O
in	O	O
combination	O	O
with	O	O
radiotherapy	O	O
in	O	O
unresectable	O	O
glioblastoma	B_Disease	O
:	O	O
a	O	O
phase	O	O
2	O	O
study	O	O
.	O	O

Improving	O	O
glioblastoma	B_Disease	O
multiforme	I_Disease	O
(	O	O
GBM	B_Disease	O
)	O	O
treatment	O	O
with	O	O
radio-chemotherapy	O	O
remains	O	O
a	O	O
challenge	O	O
.	O	O

Topotecan	B_Chemical	O
is	O	O
an	O	O
attractive	O	O
option	O	O
as	O	O
it	O	O
exhibits	O	O
growth	O	O
inhibition	O	O
of	O	O
human	O	O
glioma	B_Disease	O
as	O	O
well	O	O
as	O	O
brain	O	O
penetration	O	O
.	O	O

The	O	O
present	O	O
study	O	O
assessed	O	O
the	O	O
combination	O	O
of	O	O
radiotherapy	O	O
(	O	O
60	O	O
Gy/30	O	O
fractions/40	O	O
days	O	O
)	O	O
and	O	O
topotecan	B_Chemical	O
(	O	O
0.9	O	O
mg/m(2)/day	O	O
on	O	O
days	O	O
1	O	O
-	O	O
5	O	O
on	O	O
weeks	O	O
1	O	O
,	O	O
3	O	O
and	O	O
5	O	O
)	O	O
in	O	O
50	O	O
adults	O	O
with	O	O
histologically	O	O
proven	O	O
and	O	O
untreated	O	O
GBM	B_Disease	O
.	O	O

The	O	O
incidence	O	O
of	O	O
non-hematological	O	O
toxicities	B_Disease	O
was	O	O
low	O	O
and	O	O
grade	O	O
3	O	O
-	O	O
4	O	O
hematological	O	O
toxicities	B_Disease	O
were	O	O
reported	O	O
in	O	O
20	O	O
patients	O	O
(	O	O
mainly	O	O
lymphopenia	B_Disease	O
and	O	O
neutropenia	B_Disease	O
)	O	O
.	O	O

Partial	O	O
response	O	O
and	O	O
stabilization	O	O
rates	O	O
were	O	O
2	O	O
%	O	O
and	O	O
32	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
with	O	O
an	O	O
overall	O	O
time	O	O
to	O	O
progression	O	O
of	O	O
12	O	O
weeks	O	O
.	O	O

One-year	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
rate	O	O
was	O	O
42	O	O
%	O	O
,	O	O
with	O	O
a	O	O
median	O	O
OS	O	O
of	O	O
40	O	O
weeks	O	O
.	O	O

Topotecan	B_Chemical	O
in	O	O
combination	O	O
with	O	O
radiotherapy	O	O
was	O	O
well	O	O
tolerated	O	O
.	O	O

However	O	O
,	O	O
while	O	O
response	O	O
and	O	O
stabilization	O	O
concerned	O	O
one-third	O	O
of	O	O
the	O	O
patients	O	O
,	O	O
the	O	O
study	O	O
did	O	O
not	O	O
show	O	O
increased	O	O
benefits	O	O
in	O	O
terms	O	O
of	O	O
survival	O	O
in	O	O
patients	O	O
with	O	O
unresectable	O	O
GBM	B_Disease	O
.	O	O

Long-term	O	O
lithium	B_Chemical	O
therapy	O	O
leading	O	O
to	O	O
hyperparathyroidism	B_Disease	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

PURPOSE	O	O
:	O	O
This	O	O
paper	O	O
reviews	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
lithium	B_Chemical	O
therapy	O	O
on	O	O
serum	O	O
calcium	B_Chemical	O
level	O	O
and	O	O
parathyroid	O	O
glands	O	O
,	O	O
its	O	O
pathogenesis	O	O
,	O	O
and	O	O
treatment	O	O
options	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
case	O	O
of	O	O
a	O	O
lithium-treated	O	O
patient	O	O
who	O	O
had	O	O
recurrent	O	O
hypercalcemia	B_Disease	O
to	O	O
better	O	O
understand	O	O
the	O	O
disease	O	O
process	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Primary	B_Disease	O
hyperparathyroidism	I_Disease	O
is	O	O
a	O	O
rare	O	O
but	O	O
potentially	O	O
life-threatening	O	O
side	O	O
effect	O	O
of	O	O
long-term	O	O
lithium	B_Chemical	O
therapy	O	O
.	O	O

Careful	O	O
patient	O	O
selection	O	O
and	O	O
long-term	O	O
follow-up	O	O
can	O	O
reduce	O	O
morbidity	O	O
.	O	O

PRACTICAL	O	O
IMPLICATIONS	O	O
:	O	O
As	O	O
much	O	O
as	O	O
15	O	O
%	O	O
of	O	O
lithium-treated	O	O
patients	O	O
become	O	O
hypercalcemic	B_Disease	B_Disease
.	O	O

By	O	O
routinely	O	O
monitoring	O	O
serum	O	O
calcium	B_Chemical	O
levels	O	O
,	O	O
healthcare	O	O
providers	O	O
can	O	O
improve	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
of	O	O
this	O	O
patient	O	O
group	O	O
.	O	O

Comparison	O	O
of	O	O
laryngeal	O	O
mask	O	O
with	O	O
endotracheal	O	O
tube	O	O
for	O	O
anesthesia	O	O
in	O	O
endoscopic	O	O
sinus	O	O
surgery	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
surgical	O	O
conditions	O	O
,	O	O
including	O	O
the	O	O
amount	O	O
of	O	O
intraoperative	O	O
bleeding	B_Disease	O
as	O	O
well	O	O
as	O	O
intraoperative	O	O
blood	O	O
pressure	O	O
,	O	O
during	O	O
functional	O	O
endoscopic	O	O
sinus	O	O
surgery	O	O
(	O	O
FESS	O	O
)	O	O
using	O	O
flexible	O	O
reinforced	O	O
laryngeal	O	O
mask	O	O
airway	O	O
(	O	O
FRLMA	O	O
)	O	O
versus	O	O
endotracheal	O	O
tube	O	O
(	O	O
ETT	O	O
)	O	O
in	O	O
maintaining	O	O
controlled	O	O
hypotension	B_Disease	O
anesthesia	O	O
induced	O	O
by	O	O
propofol-remifentanil	O	B_Chemical
total	O	O
i.v	O	O
.	O	O
anesthesia	O	O
(	O	O
TIVA	O	O
)	O	O
.	O	O

METHODS	O	O
:	O	O
Sixty	O	O
normotensive	O	O
American	O	O
Society	O	O
of	O	O
Anesthesiologists	O	O
I-II	O	O
adult	O	O
patients	O	O
undergoing	O	O
FESS	O	O
under	O	O
controlled	O	O
hypotension	B_Disease	O
anesthesia	O	O
caused	O	O
by	O	O
propofol-remifentanil-TIVA	O	O
were	O	O
randomly	O	O
assigned	O	O
into	O	O
two	O	O
groups	O	O
:	O	O
group	O	O
I	O	O
,	O	O
FRLMA	O	O
;	O	O
group	O	O
II	O	O
,	O	O
ETT	O	O
.	O	O

Hemorrhage	B_Disease	O
was	O	O
measured	O	O
and	O	O
the	O	O
visibility	O	O
of	O	O
the	O	O
operative	O	O
field	O	O
was	O	O
evaluated	O	O
according	O	O
to	O	O
a	O	O
six-point	O	O
scale	O	O
.	O	O

RESULTS	O	O
:	O	O
Controlled	O	O
hypotension	B_Disease	O
was	O	O
achieved	O	O
within	O	O
a	O	O
shorter	O	O
period	O	O
using	O	O
laryngeal	O	O
mask	O	O
using	O	O
lower	O	O
rates	O	O
of	O	O
remifentanil	B_Chemical	B_Chemical
infusion	O	O
and	O	O
lower	O	O
total	O	O
dose	O	O
of	O	O
remifentanil	B_Chemical	B_Chemical
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
summary	O	O
,	O	O
our	O	O
results	O	O
indicate	O	O
that	O	O
airway	O	O
management	O	O
using	O	O
FRLMA	O	O
during	O	O
controlled	O	O
hypotension	B_Disease	O
anesthesia	O	O
provided	O	O
better	O	O
surgical	O	O
conditions	O	O
in	O	O
terms	O	O
of	O	O
quality	O	O
of	O	O
operative	O	O
field	O	O
and	O	O
blood	O	B_Disease
loss	O	I_Disease
and	O	O
allowed	O	O
for	O	O
convenient	O	O
induced	O	O
hypotension	B_Disease	O
with	O	O
low	O	O
doses	O	O
of	O	O
remifentanil	B_Chemical	B_Chemical
during	O	O
TIVA	O	O
in	O	O
patients	O	O
undergoing	O	O
FESS	O	O
.	O	O

Nonalcoholic	B_Disease	O
fatty	I_Disease	O
liver	I_Disease	O
disease	I_Disease	O
during	O	O
valproate	B_Chemical	B_Chemical
therapy	O	O
.	O	O

Valproic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(	O	O
VPA	B_Chemical	B_Chemical
)	O	O
is	O	O
effective	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
many	O	O
types	O	O
of	O	O
epilepsy	B_Disease	O
,	O	O
but	O	O
its	O	O
use	O	O
can	O	O
be	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
body	O	O
weight	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
nonalcoholic	B_Disease	O
fatty	I_Disease	O
liver	I_Disease	O
disease	I_Disease	O
(	O	O
NAFLD	B_Disease	O
)	O	O
arising	O	O
in	O	O
a	O	O
child	O	O
who	O	O
developed	O	O
obesity	B_Disease	O
during	O	O
VPA	B_Chemical	O
treatment	O	O
.	O	O

Laboratory	O	O
data	O	O
revealed	O	O
hyperinsulinemia	B_Disease	B_Disease
with	O	O
insulin	B_Disease	O
resistance	I_Disease	O
.	O	O

After	O	O
the	O	O
withdrawal	O	O
of	O	O
VPA	B_Chemical	B_Chemical
therapy	O	O
,	O	O
our	O	O
patient	O	O
showed	O	O
a	O	O
significant	O	O
weight	B_Disease	O
loss	I_Disease	O
,	O	O
a	O	O
decrease	O	O
of	O	O
body	O	O
mass	O	O
index	O	O
,	O	O
and	O	O
normalization	O	O
of	O	O
metabolic	O	O
and	O	O
endocrine	O	O
parameters	O	O
;	O	O
moreover	O	O
,	O	O
ultrasound	O	O
measurements	O	O
showed	O	O
a	O	O
complete	O	O
normalization	O	O
.	O	O

The	O	O
present	O	O
case	O	O
suggests	O	O
that	O	O
obesity	B_Disease	O
,	O	O
hyperinsulinemia	B_Disease	B_Disease
,	O	O
insulin	B_Disease	O
resistance	I_Disease	O
,	O	O
and	O	O
long-term	O	O
treatment	O	O
with	O	O
VPA	B_Chemical	B_Chemical
may	O	O
be	O	O
all	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
NAFLD	B_Disease	B_Chemical
;	O	O
this	O	O
side	O	O
effect	O	O
is	O	O
reversible	O	O
after	O	O
VPA	B_Chemical	B_Chemical
withdrawal	O	O
.	O	O

Carbimazole	B_Chemical	B_Chemical
induced	O	O
ANCA	B_Disease	O
positive	I_Disease	O
vasculitis	I_Disease	O
.	O	O

Anti-thyroid	B_Chemical	O
drugs	I_Chemical	O
,	O	O
like	O	O
carbimazole	B_Chemical	B_Chemical
and	O	O
propylthiouracil	B_Chemical	O
(	O	O
PTU	B_Chemical	O
)	O	O
are	O	O
commonly	O	O
prescribed	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
hyperthyroidism	B_Disease	O
.	O	O

One	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
side	O	O
effects	O	O
of	O	O
antithyroid	B_Chemical	O
medications	I_Chemical	O
.	O	O

Antineutrophil	B_Disease	O
cytoplasmic	I_Disease	O
antibody	I_Disease	O
(ANCA)--associated	I_Disease	O
vasculitis	I_Disease	O
is	O	O
a	O	O
potentially	O	O
life-threatening	O	O
adverse	O	O
effect	O	O
of	O	O
antithyroidmedications	B_Chemical	O
.	O	O

We	O	O
report	O	O
a	O	O
patient	O	O
with	O	O
Graves	B_Disease	O
'	I_Disease	O
disease	I_Disease	O
who	O	O
developed	O	O
ANCA	O	O
positive	O	O
carbimazole	B_Chemical	B_Chemical
induced	O	O
vasculitis	B_Disease	O
.	O	O

The	O	O
episode	O	O
was	O	O
characterized	O	O
by	O	O
a	O	O
vasculitic	B_Disease	O
skin	B_Disease	O
rash	I_Disease	O
associated	O	O
with	O	O
large	O	O
joint	O	O
arthritis	B_Disease	O
,	O	O
pyrexia	B_Disease	O
and	O	O
parotiditis	B_Disease	O
but	O	O
no	O	O
renal	O	O
or	O	O
pulmonary	O	O
involvement	O	O
.	O	O

He	O	O
was	O	O
referred	O	O
to	O	O
us	O	O
for	O	O
neurological	O	O
evaluation	O	O
because	O	O
he	O	O
had	O	O
difficulty	O	O
in	O	O
getting	O	O
up	O	O
from	O	O
squatting	O	O
position	O	O
and	O	O
was	O	O
suspected	O	O
to	O	O
have	O	O
myositis	B_Disease	O
.	O	O

Carbimazole	B_Chemical	B_Chemical
and	O	O
methimazole	B_Chemical	B_Chemical
have	O	O
a	O	O
lower	O	O
incidence	O	O
of	O	O
reported	O	O
ANCA	O	O
positive	O	O
side	O	O
effects	O	O
than	O	O
PUT	O	O
.	O	O

To	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
this	O	O
is	O	O
the	O	O
first	O	O
ANCA	O	O
positive	O	O
carbimazole	B_Chemical	B_Chemical
induced	O	O
vasculitis	B_Disease	O
case	O	O
reported	O	O
from	O	O
India	O	O
.	O	O

Aspirin	O	O
for	O	O
the	O	O
primary	O	O
prevention	O	O
of	O	O
cardiovascular	O	O
events	O	O
:	O	O
an	O	O
update	O	O
of	O	O
the	O	O
evidence	O	O
for	O	O
the	O	O
U.S.	O	O
Preventive	O	O
Services	O	O
Task	O	O
Force	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Coronary	B_Disease	B_Disease
heart	I_Disease	I_Disease
disease	I_Disease	I_Disease
and	O	O
cerebrovascular	B_Disease	B_Disease
disease	I_Disease	I_Disease
are	O	O
leading	O	O
causes	O	O
of	O	O
death	O	O
in	O	O
the	O	O
United	O	O
States	O	O
.	O	O

In	O	O
2002	O	O
,	O	O
the	O	O
U.S.	O	O
Preventive	O	O
Services	O	O
Task	O	O
Force	O	O
(	O	O
USPSTF	O	O
)	O	O
strongly	O	O
recommended	O	O
that	O	O
clinicians	O	O
discuss	O	O
aspirin	B_Chemical	O
with	O	O
adults	O	O
who	O	O
are	O	O
at	O	O
increased	O	O
risk	O	O
for	O	O
coronary	B_Disease	B_Disease
heart	I_Disease	I_Disease
disease	I_Disease	I_Disease
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
benefits	O	O
and	O	O
harms	O	O
of	O	O
taking	O	O
aspirin	B_Chemical	O
for	O	O
the	O	O
primary	O	O
prevention	O	O
of	O	O
myocardial	B_Disease	B_Disease
infarctions	I_Disease	I_Disease
,	O	O
strokes	B_Disease	O
,	O	O
and	O	O
death	O	O
.	O	O

DATA	O	O
SOURCES	O	O
:	O	O
MEDLINE	O	O
and	O	O
Cochrane	O	O
Library	O	O
(	O	O
search	O	O
dates	O	O
,	O	O
1	O	O
January	O	O
2001	O	O
to	O	O
28	O	O
August	O	O
2008	O	O
)	O	O
,	O	O
recent	O	O
systematic	O	O
reviews	O	O
,	O	O
reference	O	O
lists	O	O
of	O	O
retrieved	O	O
articles	O	O
,	O	O
and	O	O
suggestions	O	O
from	O	O
experts	O	O
.	O	O

STUDY	O	O
SELECTION	O	O
:	O	O
English-language	O	O
randomized	O	O
,	O	O
controlled	O	O
trials	O	O
(	O	O
RCTs	O	O
)	O	O
;	O	O
case-control	O	O
studies	O	O
;	O	O
meta-analyses	O	O
;	O	O
and	O	O
systematic	O	O
reviews	O	O
of	O	O
aspirin	B_Chemical	O
versus	O	O
control	O	O
for	O	O
the	O	O
primary	O	O
prevention	O	O
of	O	O
cardiovascular	B_Disease	B_Disease
disease	I_Disease	I_Disease
(	O	O
CVD	B_Disease	O
)	O	O
were	O	O
selected	O	O
to	O	O
answer	O	O
the	O	O
following	O	O
questions	O	O
:	O	O
Does	O	O
aspirin	B_Chemical	O
decrease	O	O
coronary	O	B_Disease
heart	O	I_Disease
events	O	I_Disease
,	O	O
strokes	B_Disease	O
,	O	O
death	O	O
from	O	O
coronary	O	B_Disease
heart	O	I_Disease
events	O	I_Disease
or	O	O
stroke	B_Disease	O
,	O	O
or	O	O
all-cause	O	O
mortality	O	O
in	O	O
adults	O	O
without	O	O
known	O	O
CVD	B_Disease	O
?	O	O
Does	O	O
aspirin	B_Chemical	O
increase	O	O
gastrointestinal	B_Disease	B_Disease
bleeding	I_Disease	I_Disease
or	O	O
hemorrhagic	B_Disease	O
strokes	B_Disease	O
?	O	O
DATA	O	O
EXTRACTION	O	O
:	O	O
All	O	O
studies	O	O
were	O	O
reviewed	O	O
,	O	O
abstracted	O	O
,	O	O
and	O	O
rated	O	O
for	O	O
quality	O	O
by	O	O
using	O	O
predefined	O	O
USPSTF	O	O
criteria	O	O
.	O	O

DATA	O	O
SYNTHESIS	O	O
:	O	O
New	O	O
evidence	O	O
from	O	O
1	O	O
good-quality	O	O
RCT	O	O
,	O	O
1	O	O
good-quality	O	O
meta-analysis	O	O
,	O	O
and	O	O
2	O	O
fair-quality	O	O
subanalyses	O	O
of	O	O
RCTs	O	O
demonstrates	O	O
that	O	O
aspirin	B_Chemical	O
use	O	O
reduces	O	O
the	O	O
number	O	O
of	O	O
CVD	B_Disease	O
events	O	O
in	O	O
patients	O	O
without	O	O
known	O	O
CVD	B_Disease	O
.	O	O

Men	O	O
in	O	O
these	O	O
studies	O	O
experienced	O	O
fewer	O	O
myocardial	B_Disease	B_Disease
infarctions	I_Disease	I_Disease
and	O	O
women	O	O
experienced	O	O
fewer	O	O
ischemic	O	O
strokes	B_Disease	O
.	O	O

Aspirin	B_Chemical	O
does	O	O
not	O	O
seem	O	O
to	O	O
affect	O	O
CVD	B_Disease	O
mortality	O	O
or	O	O
all-cause	O	O
mortality	O	O
in	O	O
either	O	O
men	O	O
or	O	O
women	O	O
.	O	O

The	O	O
use	O	O
of	O	O
aspirin	B_Chemical	O
for	O	O
primary	O	O
prevention	O	O
increases	O	O
the	O	O
risk	O	O
for	O	O
major	O	O
bleeding	B_Disease	O
events	O	O
,	O	O
primarily	O	O
gastrointestinal	B_Disease	O
bleeding	I_Disease	O
events	O	O
,	O	O
in	O	O
both	O	O
men	O	O
and	O	O
women	O	O
.	O	O

Men	O	O
have	O	O
an	O	O
increased	O	O
risk	O	O
for	O	O
hemorrhagic	B_Disease	O
strokes	B_Disease	O
with	O	O
aspirin	B_Chemical	O
use	O	O
.	O	O

A	O	O
new	O	O
RCT	O	O
and	O	O
meta-analysis	O	O
suggest	O	O
that	O	O
the	O	O
risk	O	O
for	O	O
hemorrhagic	B_Disease	O
strokes	B_Disease	O
in	O	O
women	O	O
is	O	O
not	O	O
statistically	O	O
significantly	O	O
increased	O	O
.	O	O

LIMITATIONS	O	O
:	O	O
New	O	O
evidence	O	O
on	O	O
aspirin	B_Chemical	O
for	O	O
the	O	O
primary	O	O
prevention	O	O
of	O	O
CVD	B_Disease	O
is	O	O
limited	O	O
.	O	O

The	O	O
dose	O	O
of	O	O
aspirin	B_Chemical	O
used	O	O
in	O	O
the	O	O
RCTs	O	O
varied	O	O
,	O	O
which	O	O
prevented	O	O
the	O	O
estimation	O	O
of	O	O
the	O	O
most	O	O
appropriate	O	O
dose	O	O
for	O	O
primary	O	O
prevention	O	O
.	O	O

Several	O	O
of	O	O
the	O	O
RCTs	O	O
were	O	O
conducted	O	O
within	O	O
populations	O	O
of	O	O
health	O	O
professionals	O	O
,	O	O
which	O	O
potentially	O	O
limits	O	O
generalizability	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Aspirin	B_Chemical	O
reduces	O	O
the	O	O
risk	O	O
for	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
in	O	O
men	O	O
and	O	O
strokes	B_Disease	O
in	O	O
women	O	O
.	O	O

Aspirin	B_Chemical	O
use	O	O
increases	O	O
the	O	O
risk	O	O
for	O	O
serious	O	O
bleeding	B_Disease	B_Disease
events	O	I_Disease
.	O	O

Reducing	O	O
harm	O	O
associated	O	O
with	O	O
anticoagulation	O	O
:	O	O
practical	O	O
considerations	O	O
of	O	O
argatroban	B_Chemical	B_Chemical
therapy	O	O
in	O	O
heparin-induced	O	O
thrombocytopenia	B_Disease	O
.	O	O

Argatroban	B_Chemical	B_Chemical
is	O	O
a	O	O
hepatically	O	O
metabolized	O	O
,	O	O
direct	O	O
thrombin	O	O
inhibitor	O	O
used	O	O
for	O	O
prophylaxis	O	O
or	O	O
treatment	O	O
of	O	O
thrombosis	B_Disease	O
in	O	O
heparin-induced	O	O
thrombocytopenia	B_Disease	O
(	O	O
HIT	B_Disease	O
)	O	O
and	O	O
for	O	O
patients	O	O
with	O	O
or	O	O
at	O	O
risk	O	O
of	O	O
HIT	B_Disease	O
undergoing	O	O
percutaneous	O	O
coronary	O	O
intervention	O	O
(	O	O
PCI	O	O
)	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
review	O	O
is	O	O
to	O	O
summarize	O	O
practical	O	O
considerations	O	O
of	O	O
argatroban	B_Chemical	B_Chemical
therapy	O	O
in	O	O
HIT	B_Disease	O
.	O	O

The	O	O
US	O	O
FDA-recommended	O	O
argatroban	B_Chemical	B_Chemical
dose	O	O
in	O	O
HIT	B_Disease	O
is	O	O
2	O	O
microg/kg/min	O	O
(	O	O
reduced	O	O
in	O	O
patients	O	O
with	O	O
hepatic	B_Disease	B_Disease
impairment	I_Disease	I_Disease
and	O	O
in	O	O
paediatric	O	O
patients	O	O
)	O	O
,	O	O
adjusted	O	O
to	O	O
achieve	O	O
activated	O	O
partial	O	O
thromboplastin	O	O
times	O	O
(	O	O
aPTTs	O	O
)	O	O
1.5	O	O
-	O	O
3	O	O
times	O	O
baseline	O	O
(	O	O
not	O	O
>	O	O
100	O	O
seconds	O	O
)	O	O
.	O	O

Contemporary	O	O
experiences	O	O
indicate	O	O
that	O	O
reduced	O	O
doses	O	O
are	O	O
also	O	O
needed	O	O
in	O	O
patients	O	O
with	O	O
conditions	O	O
associated	O	O
with	O	O
hepatic	O	O
hypoperfusion	O	O
,	O	O
e.g.	O	O
heart	B_Disease	B_Disease
failure	I_Disease	I_Disease
,	O	O
yet	O	O
are	O	O
unnecessary	O	O
for	O	O
renal	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
,	O	O
adult	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
race/ethnicity	O	O
or	O	O
obesity	B_Disease	O
.	O	O

Argatroban	B_Chemical	B_Chemical
0.5	O	O
-	O	O
1.2	O	O
microg/kg/min	O	O
typically	O	O
supports	O	O
therapeutic	O	O
aPTTs	O	O
.	O	O

The	O	O
FDA-recommended	O	O
dose	O	O
during	O	O
PCI	O	O
is	O	O
25	O	O
microg/kg/min	O	O
(	O	O
350	O	O
microg/kg	O	O
initial	O	O
bolus	O	O
)	O	O
,	O	O
adjusted	O	O
to	O	O
achieve	O	O
activated	O	O
clotting	O	O
times	O	O
(	O	O
ACTs	O	O
)	O	O
of	O	O
300	O	O
-	O	O
450	O	O
sec.	O	O
For	O	O
PCI	O	O
,	O	O
argatroban	B_Chemical	B_Chemical
has	O	O
not	O	O
been	O	O
investigated	O	O
in	O	O
hepatically	O	O
impaired	O	O
patients	O	O
;	O	O
dose	O	O
adjustment	O	O
is	O	O
unnecessary	O	O
for	O	O
adult	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
race/ethnicity	O	O
or	O	O
obesity	B_Disease	O
,	O	O
and	O	O
lesser	O	O
doses	O	O
may	O	O
be	O	O
adequate	O	O
with	O	O
concurrent	O	O
glycoprotein	O	O
IIb/IIIa	O	O
inhibition	O	O
.	O	O

Argatroban	B_Chemical	B_Chemical
prolongs	O	O
the	O	O
International	O	O
Normalized	O	O
Ratio	O	O
,	O	O
and	O	O
published	O	O
approaches	O	O
for	O	O
monitoring	O	O
the	O	O
argatroban-to-warfarin	O	B_Chemical
transition	O	O
should	O	O
be	O	O
followed	O	O
.	O	O

Major	O	O
bleeding	B_Disease	O
with	O	O
argatroban	B_Chemical	B_Chemical
is	O	O
0	O	O
-	O	O
10	O	O
%	O	O
in	O	O
the	O	O
non-interventional	O	O
setting	O	O
and	O	O
0	O	O
-	O	O
5.8	O	O
%	O	O
periprocedurally	O	O
.	O	O

Argatroban	B_Chemical	B_Chemical
has	O	O
no	O	O
specific	O	O
antidote	O	O
,	O	O
and	O	O
if	O	O
excessive	O	O
anticoagulation	O	O
occurs	O	O
,	O	O
argatroban	B_Chemical	B_Chemical
infusion	O	O
should	O	O
be	O	O
stopped	O	O
or	O	O
reduced	O	O
.	O	O

Improved	O	O
familiarity	O	O
of	O	O
healthcare	O	O
professionals	O	O
with	O	O
argatroban	B_Chemical	B_Chemical
therapy	O	O
in	O	O
HIT	B_Disease	O
,	O	O
including	O	O
in	O	O
special	O	O
populations	O	O
and	O	O
during	O	O
PCI	O	O
,	O	O
may	O	O
facilitate	O	O
reduction	O	O
of	O	O
harm	O	O
associated	O	O
with	O	O
HIT	B_Disease	O
(	O	O
e.g.	O	O
fewer	O	O
thromboses	O	O
)	O	O
or	O	O
its	O	O
treatment	O	O
(	O	O
e.g.	O	O
fewer	O	O
argatroban	B_Chemical	O
medication	O	O
errors	O	O
)	O	O
.	O	O

Rhabdomyolysis	B_Disease	B_Disease
and	O	O
brain	O	B_Disease
ischemic	B_Disease	I_Disease
stroke	I_Disease	I_Disease
in	O	O
a	O	O
heroin-dependent	O	O
male	O	O
under	O	O
methadone	B_Chemical	O
maintenance	O	O
therapy	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
There	O	O
are	O	O
several	O	O
complications	O	O
associated	O	O
with	O	O
heroin	B_Disease	O
abuse	I_Disease	O
,	O	O
some	O	O
of	O	O
which	O	O
are	O	O
life-threatening	O	O
.	O	O

Methadone	B_Chemical	O
may	O	O
aggravate	O	O
this	O	O
problem	O	O
.	O	O

METHOD	O	O
:	O	O
A	O	O
clinical	O	O
case	O	O
description	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
33-year-old	O	O
man	O	O
presented	O	O
with	O	O
rhabdomyolysis	B_Disease	B_Disease
and	O	O
cerebral	O	B_Disease
ischemic	B_Disease	I_Disease
stroke	I_Disease	I_Disease
after	O	O
intravenous	O	O
heroin	B_Chemical	O
.	O	O

He	O	O
had	O	O
used	O	O
heroin	B_Chemical	O
since	O	O
age	O	O
20	O	O
,	O	O
and	O	O
had	O	O
used	O	O
150	O	O
mg	O	O
methadone	B_Chemical	O
daily	O	O
for	O	O
6	O	O
months	O	O
.	O	O

He	O	O
was	O	O
found	O	O
unconsciousness	B_Disease	O
at	O	O
home	O	O
and	O	O
was	O	O
sent	O	O
to	O	O
our	O	O
hospital	O	O
.	O	O

In	O	O
the	O	O
ER	O	O
,	O	O
his	O	O
opiate	O	O
level	O	O
was	O	O
4497	O	O
ng/ml	O	O
.	O	O

In	O	O
the	O	O
ICU	O	O
,	O	O
we	O	O
found	O	O
rhabdomyolysis	B_Disease	B_Disease
,	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
and	O	O
acute	O	B_Disease
respiratory	B_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

After	O	O
transfer	O	O
to	O	O
an	O	O
internal	O	O
ward	O	O
,	O	O
we	O	O
noted	O	O
aphasia	B_Disease	O
and	O	O
weakness	B_Disease	O
of	O	O
his	O	O
left	O	O
limbs	O	O
.	O	O

After	O	O
MRI	O	O
,	O	O
we	O	O
found	O	O
cerebral	B_Disease	B_Disease
ischemic	I_Disease	I_Disease
infarction	I_Disease	I_Disease
.	O	O

CONCLUSION	O	O
:	O	O
Those	O	O
using	O	O
methadone	B_Chemical	O
and	O	O
heroin	B_Chemical	O
simultaneously	O	O
may	O	O
increase	O	O
risk	O	O
of	O	O
rhabdomyolysis	B_Disease	B_Disease
and	O	O
ischemic	B_Disease	B_Disease
stroke	I_Disease	I_Disease
.	O	O

Patients	O	O
under	O	O
methadone	B_Chemical	O
maintenance	O	O
therapy	O	O
should	O	O
be	O	O
warned	O	O
regarding	O	O
these	O	O
serious	O	O
adverse	O	O
events	O	O
.	O	O

Hypotheses	O	O
of	O	O
heroin-related	O	O
rhabdomyolysis	B_Disease	B_Disease
and	O	O
stroke	B_Disease	O
in	O	O
heroin	B_Chemical	O
abusers	O	O
are	O	O
discussed	O	O
.	O	O

Increased	O	O
vulnerability	O	O
to	O	O
6-hydroxydopamine	B_Chemical	B_Chemical
lesion	O	O
and	O	O
reduced	O	O
development	O	O
of	O	O
dyskinesias	B_Disease	O
in	O	O
mice	O	O
lacking	O	O
CB1	O	O
cannabinoid	O	O
receptors	O	O
.	O	O

Motor	O	B_Disease
impairment	O	I_Disease
,	O	O
dopamine	B_Chemical	O
(	O	O
DA	B_Chemical	O
)	O	O
neuronal	O	O
activity	O	O
and	O	O
proenkephalin	B_Chemical	O
(	O	O
PENK	B_Chemical	O
)	O	O
gene	O	O
expression	O	O
in	O	O
the	O	O
caudate-putamen	O	O
(	O	O
CPu	O	O
)	O	O
were	O	O
measured	O	O
in	O	O
6-OHDA-lesioned	O	O
and	O	O
treated	O	O
(	O	O
L-DOPA+benserazide	B_Chemical	B_Chemical
)	O	O
CB1	O	O
KO	O	O
and	O	O
WT	O	O
mice	O	O
.	O	O

A	O	O
lesion	O	O
induced	O	O
by	O	O
6-OHDA	B_Chemical	O
produced	O	O
more	O	O
severe	O	O
motor	O	O
deterioration	O	O
in	O	O
CB1	O	O
KO	O	O
mice	O	O
accompanied	O	O
by	O	O
more	O	O
loss	O	O
of	O	O
DA	B_Chemical	O
neurons	O	O
and	O	O
increased	O	O
PENK	B_Chemical	O
gene	O	O
expression	O	O
in	O	O
the	O	O
CPu	O	O
.	O	O

Oxidative/nitrosative	O	O
and	O	O
neuroinflammatory	O	O
parameters	O	O
were	O	O
estimated	O	O
in	O	O
the	O	O
CPu	O	O
and	O	O
cingulate	O	O
cortex	O	O
(	O	O
Cg	O	O
)	O	O
.	O	O

CB1	O	O
KO	O	O
mice	O	O
exhibited	O	O
higher	O	O
MDA	B_Chemical	O
levels	O	O
and	O	O
iNOS	O	O
protein	O	O
expression	O	O
in	O	O
the	O	O
CPu	O	O
and	O	O
Cg	O	O
compared	O	O
to	O	O
WT	O	O
mice	O	O
.	O	O

Treatment	O	O
with	O	O
L-DOPA+benserazide	B_Chemical	B_Chemical
(	O	O
12	O	O
weeks	O	O
)	O	O
resulted	O	O
in	O	O
less	O	O
severe	O	O
dyskinesias	B_Disease	O
in	O	O
CB1	O	O
KO	O	O
than	O	O
in	O	O
WT	O	O
mice	O	O
.	O	O

The	O	O
results	O	O
revealed	O	O
that	O	O
the	O	O
lack	O	O
of	O	O
cannabinoid	O	O
CB1	O	O
receptors	O	O
increased	O	O
the	O	O
severity	O	O
of	O	O
motor	O	B_Disease
impairment	O	I_Disease
and	O	O
DA	B_Chemical	O
lesion	O	O
,	O	O
and	O	O
reduced	O	O
L-DOPA-induced	O	O
dyskinesias	B_Disease	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
activation	O	O
of	O	O
CB1	O	O
receptors	O	O
offers	O	O
neuroprotection	O	O
against	O	O
dopaminergic	O	O
lesion	O	O
and	O	O
the	O	O
development	O	O
of	O	O
L-DOPA-induced	O	O
dyskinesias	B_Disease	O
.	O	O

Hepatocellular	O	O
oxidant	O	O
stress	O	O
following	O	O
intestinal	O	O
ischemia-reperfusion	O	O
injury	O	O
.	O	O

Reperfusion	O	O
of	O	O
ischemic	B_Disease	O
intestine	O	O
results	O	O
in	O	O
acute	O	B_Disease
liver	B_Disease	I_Disease
dysfunction	I_Disease	I_Disease
characterized	O	O
by	O	O
hepatocellular	O	O
enzyme	O	O
release	O	O
into	O	O
plasma	O	O
,	O	O
reduction	O	O
in	O	O
bile	O	O
flow	O	O
rate	O	O
,	O	O
and	O	O
neutrophil	O	O
sequestration	O	O
within	O	O
the	O	O
liver	O	O
.	O	O

The	O	O
pathophysiology	O	O
underlying	O	O
this	O	O
acute	O	B_Disease
hepatic	B_Disease	I_Disease
injury	I_Disease	I_Disease
is	O	O
unknown	O	O
.	O	O

This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
determine	O	O
whether	O	O
oxidants	O	O
are	O	O
associated	O	O
with	O	O
the	O	O
hepatic	B_Disease	B_Disease
injury	I_Disease	I_Disease
and	O	O
to	O	O
determine	O	O
the	O	O
relative	O	O
value	O	O
of	O	O
several	O	O
indirect	O	O
methods	O	O
of	O	O
assessing	O	O
oxidant	O	O
exposure	O	O
in	O	O
vivo	O	O
.	O	O

Rats	O	O
were	O	O
subjected	O	O
to	O	O
a	O	O
standardized	O	O
intestinal	O	O
ischemia-reperfusion	O	O
injury	O	O
.	O	O

Hepatic	O	O
tissue	O	O
was	O	O
assayed	O	O
for	O	O
lipid	O	O
peroxidation	O	O
products	O	O
and	O	O
oxidized	B_Chemical	O
and	I_Chemical	O
reduced	B_Chemical	O
glutathione	I_Chemical	B_Chemical
.	O	O

There	O	O
was	O	O
no	O	O
change	O	O
in	O	O
hepatic	O	O
tissue	O	O
total	O	O
glutathione	B_Chemical	B_Chemical
following	O	O
intestinal	O	O
ischemia-reperfusion	O	O
injury	O	O
.	O	O

Oxidized	B_Chemical	O
glutathione	I_Chemical	B_Chemical
(	O	O
GSSG	B_Chemical	O
)	O	O
increased	O	O
significantly	O	O
following	O	O
30	O	O
and	O	O
60	O	O
min	O	O
of	O	O
reperfusion	O	O
.	O	O

There	O	O
was	O	O
no	O	O
increase	O	O
in	O	O
any	O	O
of	O	O
the	O	O
products	O	O
of	O	O
lipid	O	O
peroxidation	O	O
associated	O	O
with	O	O
this	O	O
injury	O	O
.	O	O

An	O	O
increase	O	O
in	O	O
GSSG	B_Chemical	O
within	O	O
hepatic	O	O
tissue	O	O
during	O	O
intestinal	O	O
reperfusion	O	O
suggests	O	O
exposure	O	O
of	O	O
hepatocytes	O	O
to	O	O
an	O	O
oxidant	O	O
stress	O	O
.	O	O

The	O	O
lack	O	O
of	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
products	O	O
of	O	O
lipid	O	O
peroxidation	O	O
suggests	O	O
that	O	O
the	O	O
oxidant	O	O
stress	O	O
is	O	O
of	O	O
insufficient	O	O
magnitude	O	O
to	O	O
result	O	O
in	O	O
irreversible	O	O
injury	O	O
to	O	O
hepatocyte	O	O
cell	O	O
membranes	O	O
.	O	O

These	O	O
data	O	O
also	O	O
suggest	O	O
that	O	O
the	O	O
measurement	O	O
of	O	O
tissue	O	O
GSSG	B_Chemical	O
may	O	O
be	O	O
a	O	O
more	O	O
sensitive	O	O
indicator	O	O
of	O	O
oxidant	O	O
stress	O	O
than	O	O
measurement	O	O
of	O	O
products	O	O
of	O	O
lipid	O	O
peroxidation	O	O
.	O	O

Animal	O	O
model	O	O
of	O	O
mania	B_Disease	O
induced	O	O
by	O	O
ouabain	B_Chemical	B_Chemical
:	O	O
Evidence	O	O
of	O	O
oxidative	O	O
stress	O	O
in	O	O
submitochondrial	O	O
particles	O	O
of	O	O
the	O	O
rat	O	O
brain	O	O
.	O	O

The	O	O
intracerebroventricular	O	O
(	O	O
ICV	O	O
)	O	O
administration	O	O
of	O	O
ouabain	B_Chemical	B_Chemical
(	O	O
a	O	O
Na(+)/K(+)-ATPase	O	O
inhibitor	O	O
)	O	O
in	O	O
rats	O	O
has	O	O
been	O	O
suggested	O	O
to	O	O
mimic	O	O
some	O	O
symptoms	O	O
of	O	O
human	O	O
bipolar	B_Disease	B_Disease
mania	I_Disease	I_Disease
.	O	O

Clinical	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
bipolar	B_Disease	O
disorder	I_Disease	O
may	O	O
be	O	O
related	O	O
to	O	O
mitochondrial	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
.	O	O

Herein	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
behavioral	O	O
and	O	O
biochemical	O	O
effects	O	O
induced	O	O
by	O	O
the	O	O
ICV	O	O
administration	O	O
of	O	O
ouabain	B_Chemical	B_Chemical
in	O	O
rats	O	O
.	O	O

To	O	O
achieve	O	O
this	O	O
aim	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
ouabain	B_Chemical	B_Chemical
injection	O	O
immediately	O	O
after	O	O
and	O	O
7	O	O
days	O	O
following	O	O
a	O	O
single	O	O
ICV	O	O
administration	O	O
(	O	O
at	O	O
concentrations	O	O
of	O	O
10(-2	O	O
)	O	O
and	O	O
10(-3)M	O	O
)	O	O
on	O	O
locomotion	O	O
was	O	O
measured	O	O
using	O	O
the	O	O
open-field	O	O
test	O	O
.	O	O

Additionally	O	O
,	O	O
thiobarbituric	B_Chemical	O
acid	I_Chemical	O
reactive	O	O
substances	O	O
(	O	O
TBARSs	O	O
)	O	O
and	O	O
superoxide	B_Chemical	O
production	O	O
were	O	O
measured	O	O
in	O	O
submitochondrial	O	O
particles	O	O
of	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
hippocampus	O	O
,	O	O
striatum	O	O
and	O	O
amygdala	O	O
.	O	O

Our	O	O
findings	O	O
demonstrated	O	O
that	O	O
ouabain	B_Chemical	B_Chemical
at	O	O
10(-2	O	O
)	O	O
and	O	O
10(-3)M	O	O
induced	O	O
hyperlocomotion	B_Disease	B_Disease
in	O	O
rats	O	O
,	O	O
and	O	O
this	O	O
response	O	O
remained	O	O
up	O	O
to	O	O
7	O	O
days	O	O
following	O	O
a	O	O
single	O	O
ICV	O	O
injection	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
observed	O	O
that	O	O
the	O	O
persistent	O	O
increase	O	O
in	O	O
the	O	O
rat	O	O
spontaneous	O	O
locomotion	O	O
is	O	O
associated	O	O
with	O	O
increased	O	O
TBARS	O	O
levels	O	O
and	O	O
superoxide	B_Chemical	O
generation	O	O
in	O	O
submitochondrial	O	O
particles	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
striatum	O	O
and	O	O
amygdala	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
ouabain-induced	O	O
mania-like	O	O
behavior	O	O
may	O	O
provide	O	O
a	O	O
useful	O	O
animal	O	O
model	O	O
to	O	O
test	O	O
the	O	O
hypothesis	O	O
of	O	O
the	O	O
involvement	O	O
of	O	O
oxidative	O	O
stress	O	O
in	O	O
bipolar	B_Disease	B_Disease
disorder	I_Disease	I_Disease
.	O	O

Intraoperative	O	O
dialysis	O	O
during	O	O
liver	O	O
transplantation	O	O
with	O	O
citrate	O	B_Chemical
dialysate	O	I_Chemical
.	O	O

Liver	O	O
transplantation	O	O
for	O	O
acutely	O	O
ill	O	O
patients	O	O
with	O	O
fulminant	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
carries	O	O
high	O	O
intraoperative	O	O
and	O	O
immediate	O	O
postoperative	O	O
risks	O	O
.	O	O

These	O	O
are	O	O
increased	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
concomitant	O	O
acute	B_Disease	B_Disease
kidney	I_Disease	I_Disease
injury	I_Disease	I_Disease
(	O	O
AKI	B_Disease	O
)	O	O
and	O	O
intraoperative	O	O
dialysis	O	O
is	O	O
sometimes	O	O
required	O	O
to	O	O
allow	O	O
the	O	O
transplant	O	O
to	O	O
proceed	O	O
.	O	O

The	O	O
derangements	O	O
in	O	O
the	O	O
procoagulant	O	O
and	O	O
anticoagulant	O	O
pathways	O	O
during	O	O
fulminant	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
can	O	O
lead	O	O
to	O	O
difficulties	O	O
with	O	O
anticoagulation	O	O
during	O	O
dialysis	O	O
,	O	O
especially	O	O
when	O	O
continued	O	O
in	O	O
the	O	O
operating	O	O
room	O	O
.	O	O

Systemic	O	O
anticoagulation	O	O
is	O	O
unsafe	O	O
and	O	O
regional	O	O
citrate	B_Chemical	O
anticoagulation	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
functional	O	O
liver	O	O
carries	O	O
the	O	O
risk	O	O
of	O	O
citrate	B_Chemical	O
toxicity	B_Disease	O
.	O	O

Citrate	B_Chemical	B_Chemical
dialysate	O	I_Chemical
,	O	O
a	O	O
new	O	O
dialysate	O	B_Chemical
with	O	O
citric	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
can	O	O
be	O	O
used	O	O
for	O	O
anticoagulation	O	O
in	O	O
patients	O	O
who	O	O
can	O	O
not	O	O
tolerate	O	O
heparin	B_Chemical	O
or	O	O
regional	O	O
citrate	B_Chemical	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
40-year-old	O	O
female	O	O
with	O	O
acetaminophen-induced	O	O
fulminant	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
with	O	O
associated	O	O
AKI	B_Disease	O
who	O	O
underwent	O	O
intraoperative	O	O
dialytic	O	O
support	O	O
during	O	O
liver	O	O
transplantation	O	O
anticoagulated	O	O
with	O	O
citrate	B_Chemical	B_Chemical
dialysate	O	I_Chemical
during	O	O
the	O	O
entire	O	O
procedure	O	O
.	O	O

The	O	O
patient	O	O
tolerated	O	O
the	O	O
procedure	O	O
well	O	O
without	O	O
any	O	O
signs	O	O
of	O	O
citrate	B_Chemical	O
toxicity	B_Disease	O
and	O	O
maintained	O	O
adequate	O	O
anticoagulation	O	O
for	O	O
patency	O	O
of	O	O
the	O	O
dialysis	O	O
circuit	O	O
.	O	O

Citrate	B_Chemical	B_Chemical
dialysate	O	I_Chemical
is	O	O
a	O	O
safe	O	O
alternative	O	O
for	O	O
intradialytic	O	O
support	O	O
of	O	O
liver	O	O
transplantation	O	O
in	O	O
fulminant	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

Delirium	B_Disease	O
in	O	O
a	O	O
patient	O	O
with	O	O
toxic	O	O
flecainide	B_Chemical	O
plasma	O	O
concentrations	O	O
:	O	O
the	O	O
role	O	O
of	O	O
a	O	O
pharmacokinetic	O	O
drug	O	O
interaction	O	O
with	O	O
paroxetine	B_Chemical	B_Chemical
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
flecainide-induced	O	O
delirium	B_Disease	O
associated	O	O
with	O	O
a	O	O
pharmacokinetic	O	O
drug	O	O
interaction	O	O
with	O	O
paroxetine	B_Chemical	B_Chemical
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
69-year-old	O	O
white	O	O
female	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
with	O	O
a	O	O
history	O	O
of	O	O
confusion	B_Disease	O
and	O	O
paranoia	B_Disease	O
over	O	O
the	O	O
past	O	O
several	O	O
days	O	O
.	O	O

On	O	O
admission	O	O
the	O	O
patient	O	O
was	O	O
taking	O	O
carvedilol	B_Chemical	O
12	O	O
mg	O	O
twice	O	O
daily	O	O
,	O	O
warfarin	B_Chemical	O
2	O	O
mg/day	O	O
,	O	O
folic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
1	O	O
mg/day	O	O
,	O	O
levothyroxine	B_Chemical	B_Chemical
100	O	O
microg/day	O	O
,	O	O
pantoprazole	B_Chemical	B_Chemical
40	O	O
mg/day	O	O
,	O	O
paroxetine	B_Chemical	B_Chemical
40	O	O
mg/day	O	O
,	O	O
and	O	O
flecainide	B_Chemical	O
100	O	O
mg	O	O
twice	O	O
daily	O	O
.	O	O

Flecainide	B_Chemical	O
had	O	O
been	O	O
started	O	O
2	O	O
weeks	O	O
prior	O	O
for	O	O
atrial	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
.	O	O

Laboratory	O	O
test	O	O
findings	O	O
on	O	O
admission	O	O
were	O	O
notable	O	O
only	O	O
for	O	O
a	O	O
flecainide	B_Chemical	O
plasma	O	O
concentration	O	O
of	O	O
1360	O	O
microg/L	O	O
(	O	O
reference	O	O
range	O	O
200	O	O
-	O	O
1000	O	O
)	O	O
.	O	O

A	O	O
metabolic	O	O
drug	O	O
interaction	O	O
between	O	O
flecainide	B_Chemical	O
and	O	O
paroxetine	B_Chemical	B_Chemical
,	O	O
which	O	O
the	O	O
patient	O	O
had	O	O
been	O	O
taking	O	O
for	O	O
more	O	O
than	O	O
5	O	O
years	O	O
,	O	O
was	O	O
considered	O	O
.	O	O

Paroxetine	B_Chemical	B_Chemical
was	O	O
discontinued	O	O
and	O	O
the	O	O
dose	O	O
of	O	O
flecainide	B_Chemical	O
was	O	O
reduced	O	O
to	O	O
50	O	O
mg	O	O
twice	O	O
daily	O	O
.	O	O

Her	O	O
delirium	B_Disease	O
resolved	O	O
3	O	O
days	O	O
later	O	O
.	O	O

DISCUSSION	O	O
:	O	O
Flecainide	B_Chemical	O
and	O	O
pharmacologically	O	O
similar	O	O
agents	O	O
that	O	O
interact	O	O
with	O	O
sodium	B_Chemical	O
channels	O	O
may	O	O
cause	O	O
delirium	B_Disease	O
in	O	O
susceptible	O	O
patients	O	O
.	O	O

A	O	O
MEDLINE	O	O
search	O	O
(	O	O
1966-January	O	O
2009	O	O
)	O	O
revealed	O	O
one	O	O
in	O	O
vivo	O	O
pharmacokinetic	O	O
study	O	O
on	O	O
the	O	O
interaction	O	O
between	O	O
flecainide	B_Chemical	O
,	O	O
a	O	O
CYP2D6	O	O
substrate	O	O
,	O	O
and	O	O
paroxetine	B_Chemical	B_Chemical
,	O	O
a	O	O
CYP2D6	O	O
inhibitor	O	O
,	O	O
as	O	O
well	O	O
as	O	O
3	O	O
case	O	O
reports	O	O
of	O	O
flecainide-induced	O	O
delirium	B_Disease	O
.	O	O

According	O	O
to	O	O
the	O	O
Naranjo	O	O
probability	O	O
scale	O	O
,	O	O
flecainide	B_Chemical	O
was	O	O
the	O	O
probable	O	O
cause	O	O
of	O	O
the	O	O
patient	O	O
's	O	O
delirium	B_Disease	O
;	O	O
the	O	O
Horn	O	O
Drug	O	O
Interaction	O	O
Probability	O	O
Scale	O	O
indicates	O	O
a	O	O
possible	O	O
pharmacokinetic	O	O
drug	O	O
interaction	O	O
between	O	O
flecainide	B_Chemical	O
and	O	O
paroxetine	B_Chemical	B_Chemical
.	O	O

CONCLUSIONS	O	O
:	O	O
Supratherapeutic	O	O
flecainide	B_Chemical	O
plasma	O	O
concentrations	O	O
may	O	O
cause	O	O
delirium	B_Disease	O
.	O	O

Because	O	O
toxicity	B_Disease	O
may	O	O
occur	O	O
when	O	O
flecainide	B_Chemical	O
is	O	O
prescribed	O	O
with	O	O
paroxetine	B_Chemical	B_Chemical
and	O	O
other	O	O
potent	O	O
CYP2D6	O	O
inhibitors	O	O
,	O	O
flecainide	B_Chemical	O
plasma	O	O
concentrations	O	O
should	O	O
be	O	O
monitored	O	O
closely	O	O
with	O	O
commencement	O	O
of	O	O
CYP2D6	O	O
inhibitors	O	O
.	O	O

Efficacy	O	O
of	O	O
everolimus	B_Chemical	B_Chemical
(	O	O
RAD001	B_Chemical	O
)	O	O
in	O	O
patients	O	O
with	O	O
advanced	O	O
NSCLC	B_Disease	O
previously	O	O
treated	O	O
with	O	O
chemotherapy	O	O
alone	O	O
or	O	O
with	O	O
chemotherapy	O	O
and	O	O
EGFR	O	O
inhibitors	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Treatment	O	O
options	O	O
are	O	O
scarce	O	O
in	O	O
pretreated	O	O
advanced	O	O
non-small-cell	B_Disease	O
lung	I_Disease	B_Disease
cancer	I_Disease	I_Disease
(	O	O
NSCLC	B_Disease	O
)	O	O
patients	O	O
.	O	O

RAD001	B_Chemical	O
,	O	O
an	O	O
oral	O	O
inhibitor	O	O
of	O	O
the	O	O
mammalian	O	O
target	O	O
of	O	O
rapamycin	B_Chemical	B_Chemical
(	O	O
mTOR	O	O
)	O	O
,	O	O
has	O	O
shown	O	O
phase	O	O
I	O	O
efficacy	O	O
in	O	O
NSCLC	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
Stage	O	O
IIIb	O	O
or	O	O
IV	O	O
NSCLC	B_Disease	O
patients	O	O
,	O	O
with	O	O
two	O	O
or	O	O
fewer	O	O
prior	O	O
chemotherapy	O	O
regimens	O	O
,	O	O
one	O	O
platinum	B_Chemical	O
based	O	O
(	O	O
stratum	O	O
1	O	O
)	O	O
or	O	O
both	O	O
chemotherapy	O	O
and	O	O
epidermal	O	O
growth	O	O
factor	O	O
receptor	O	O
tyrosine	B_Chemical	O
kinase	O	O
inhibitors	O	O
(	O	O
stratum	O	O
2	O	O
)	O	O
,	O	O
received	O	O
RAD001	B_Chemical	O
10	O	O
mg/day	O	O
until	O	O
progression	O	O
or	O	O
unacceptable	O	O
toxicity	B_Disease	O
.	O	O

Primary	O	O
objective	O	O
was	O	O
overall	O	O
response	O	O
rate	O	O
(	O	O
ORR	O	O
)	O	O
.	O	O

Analyses	O	O
of	O	O
markers	O	O
associated	O	O
with	O	O
the	O	O
mTOR	O	O
pathway	O	O
were	O	O
carried	O	O
out	O	O
on	O	O
archival	O	O
tumor	B_Disease	O
from	O	O
a	O	O
subgroup	O	O
using	O	O
immunohistochemistry	O	O
(	O	O
IHC	O	O
)	O	O
and	O	O
direct	O	O
mutation	O	O
sequencing	O	O
.	O	O

RESULTS	O	O
:	O	O
Eighty-five	O	O
patients	O	O
were	O	O
enrolled	O	O
,	O	O
42	O	O
in	O	O
stratum	O	O
1	O	O
and	O	O
43	O	O
in	O	O
stratum	O	O
.	O	O

ORR	O	O
was	O	O
4.7	O	O
%	O	O
(	O	O
7.1	O	O
%	O	O
stratum	O	O
1	O	O
;	O	O
2.3	O	O
%	O	O
stratum	O	O
2	O	O
)	O	O
.	O	O

Overall	O	O
disease	O	O
control	O	O
rate	O	O
was	O	O
47.1	O	O
%	O	O
.	O	O

Median	O	O
progression-free	O	O
survivals	O	O
(	O	O
PFSs	O	O
)	O	O
were	O	O
2.6	O	O
(	O	O
stratum	O	O
1	O	O
)	O	O
and	O	O
2.7	O	O
months	O	O
(	O	O
stratum	O	O
2	O	O
)	O	O
.	O	O

Common	O	O
>	O	O
or	O	O
=	O	O
grade	O	O
3	O	O
events	O	O
were	O	O
fatigue	B_Disease	O
,	O	O
dyspnea	B_Disease	O
,	O	O
stomatitis	B_Disease	O
,	O	O
anemia	B_Disease	O
,	O	O
and	O	O
thrombocytopenia	B_Disease	O
.	O	O

Pneumonitis	B_Disease	O
,	O	O
probably	O	O
or	O	O
possibly	O	O
related	O	O
,	O	O
mainly	O	O
grade	O	O
1/2	O	O
,	O	O
occurred	O	O
in	O	O
25	O	O
%	O	O
.	O	O

Cox	O	O
regression	O	O
analysis	O	O
of	O	O
IHC	O	O
scores	O	O
found	O	O
that	O	O
only	O	O
phospho	O	O
AKT	O	O
(	O	O
pAKT	O	O
)	O	O
was	O	O
a	O	O
significant	O	O
independent	O	O
predictor	O	O
of	O	O
worse	O	O
PFS	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
RAD001	B_Chemical	O
10	O	O
mg/day	O	O
was	O	O
well	O	O
tolerated	O	O
,	O	O
showing	O	O
modest	O	O
clinical	O	O
activity	O	O
in	O	O
pretreated	O	O
NSCLC	B_Disease	O
.	O	O

Evaluation	O	O
of	O	O
RAD001	B_Chemical	O
plus	O	O
standard	O	O
therapy	O	O
for	O	O
metastatic	O	O
NSCLC	B_Disease	O
continues	O	O
.	O	O

Posttransplant	O	O
anemia	B_Disease	O
:	O	O
the	O	O
role	O	O
of	O	O
sirolimus	B_Chemical	B_Chemical
.	O	O

Posttransplant	O	O
anemia	B_Disease	O
is	O	O
a	O	O
common	O	O
problem	O	O
that	O	O
may	O	O
hinder	O	O
patients	O	O
'	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

It	O	O
occurs	O	O
in	O	O
12	O	O
to	O	O
76	O	O
%	O	O
of	O	O
patients	O	O
,	O	O
and	O	O
is	O	O
most	O	O
common	O	O
in	O	O
the	O	O
immediate	O	O
posttransplant	O	O
period	O	O
.	O	O

A	O	O
variety	O	O
of	O	O
factors	O	O
have	O	O
been	O	O
identified	O	O
that	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
posttransplant	O	O
anemia	B_Disease	O
,	O	O
of	O	O
which	O	O
the	O	O
level	O	O
of	O	O
renal	O	O
function	O	O
is	O	O
most	O	O
important	O	O
.	O	O

Sirolimus	B_Chemical	B_Chemical
,	O	O
a	O	O
mammalian	O	O
target	O	O
of	O	O
rapamycin	B_Chemical	B_Chemical
inhibitor	O	O
,	O	O
has	O	O
been	O	O
implicated	O	O
as	O	O
playing	O	O
a	O	O
special	O	O
role	O	O
in	O	O
posttransplant	O	O
anemia	B_Disease	O
.	O	O

This	O	O
review	O	O
considers	O	O
anemia	B_Disease	O
associated	O	O
with	O	O
sirolimus	B_Chemical	B_Chemical
,	O	O
including	O	O
its	O	O
presentation	O	O
,	O	O
mechanisms	O	O
,	O	O
and	O	O
management	O	O
.	O	O

Coronary	O	O
computerized	O	O
tomography	O	O
angiography	O	O
for	O	O
rapid	O	O
discharge	O	O
of	O	O
low-risk	O	O
patients	O	O
with	O	O
cocaine-associated	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
.	O	O

BACKGROUND	O	O
:	O	O
Most	O	O
patients	O	O
presenting	O	O
to	O	O
emergency	O	O
departments	O	O
(	O	O
EDs	O	O
)	O	O
with	O	O
cocaine-associated	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
are	O	O
admitted	O	O
for	O	O
at	O	O
least	O	O
12	O	O
hours	O	O
and	O	O
receive	O	O
a	O	O
"	O	O
rule	O	O
out	O	O
acute	B_Disease	B_Disease
coronary	I_Disease	I_Disease
syndrome	I_Disease	I_Disease
"	O	O
protocol	O	O
,	O	O
often	O	O
with	O	O
noninvasive	O	O
testing	O	O
prior	O	O
to	O	O
discharge	O	O
.	O	O

In	O	O
patients	O	O
without	O	O
cocaine	B_Chemical	O
use	O	O
,	O	O
coronary	O	O
computerized	O	O
tomography	O	O
angiography	O	O
(	O	O
CTA	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
useful	O	O
for	O	O
identifying	O	O
a	O	O
group	O	O
of	O	O
patients	O	O
at	O	O
low	O	B_Disease
risk	O	I_Disease
for	O	O
cardiac	O	B_Disease
events	O	I_Disease
who	O	O
can	O	O
be	O	O
safely	O	O
discharged	O	O
.	O	O

It	O	O
is	O	O
unclear	O	O
whether	O	O
a	O	O
coronary	O	O
CTA	O	O
strategy	O	O
would	O	O
be	O	O
efficacious	O	O
in	O	O
cocaine-associated	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
,	O	O
as	O	O
coronary	B_Disease	B_Disease
vasospasm	I_Disease	I_Disease
may	O	O
account	O	O
for	O	O
some	O	O
of	O	O
the	O	O
ischemia	B_Disease	O
.	O	O

We	O	O
studied	O	O
whether	O	O
a	O	O
negative	O	O
coronary	O	O
CTA	O	O
in	O	O
patients	O	O
with	O	O
cocaine-associated	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
could	O	O
identify	O	O
a	O	O
subset	O	O
safe	O	O
for	O	O
discharge	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
prospectively	O	O
evaluated	O	O
the	O	O
safety	O	O
of	O	O
coronary	O	O
CTA	O	O
for	O	O
low-risk	O	O
patients	O	O
who	O	O
presented	O	O
to	O	O
the	O	O
ED	O	O
with	O	O
cocaineassociated	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
(	O	O
self-reported	O	O
or	O	O
positive	O	O
urine	O	O
test	O	O
)	O	O
.	O	O

Consecutive	O	O
patients	O	O
received	O	O
either	O	O
immediate	O	O
coronary	O	O
CTA	O	O
in	O	O
the	O	O
ED	O	O
(	O	O
without	O	O
serial	O	O
markers	O	O
)	O	O
or	O	O
underwent	O	O
coronary	O	O
CTA	O	O
after	O	O
a	O	O
brief	O	O
observation	O	O
period	O	O
with	O	O
serial	O	O
cardiac	O	O
marker	O	O
measurements	O	O
.	O	O

Patients	O	O
with	O	O
negative	O	O
coronary	O	O
CTA	O	O
(	O	O
maximal	O	O
stenosis	B_Disease	O
less	O	O
than	O	O
50	O	O
%	O	O
)	O	O
were	O	O
discharged	O	O
.	O	O

The	O	O
main	O	O
outcome	O	O
was	O	O
30-day	O	O
cardiovascular	O	B_Disease
death	O	I_Disease
or	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
.	O	O

RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
59	O	O
patients	O	O
with	O	O
cocaine-associated	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
were	O	O
evaluated	O	O
.	O	O

Patients	O	O
had	O	O
a	O	O
mean	O	O
age	O	O
of	O	O
45.6	O	O
+	O	O
/-	O	O
6.6	O	O
yrs	O	O
and	O	O
were	O	O
86	O	O
%	O	O
black	O	O
,	O	O
66	O	O
%	O	O
male	O	O
.	O	O

Seventy-nine	O	O
percent	O	O
had	O	O
a	O	O
normal	O	O
or	O	O
nonspecific	O	O
ECG	O	O
and	O	O
85	O	O
%	O	O
had	O	O
a	O	O
TIMI	O	O
score	O	O
<	O	O
2	O	O
.	O	O

Twenty	O	O
patients	O	O
received	O	O
coronary	O	O
CTA	O	O
immediately	O	O
in	O	O
the	O	O
ED	O	O
,	O	O
18	O	O
of	O	O
whom	O	O
were	O	O
discharged	O	O
following	O	O
CTA	O	O
(	O	O
90	O	O
%	O	O
)	O	O
.	O	O

Thirty-nine	O	O
received	O	O
coronary	O	O
CTA	O	O
after	O	O
a	O	O
brief	O	O
observation	O	O
period	O	O
,	O	O
with	O	O
37	O	O
discharged	O	O
home	O	O
following	O	O
CTA	O	O
(	O	O
95	O	O
%	O	O
)	O	O
.	O	O

Six	O	O
patients	O	O
had	O	O
coronary	B_Disease	B_Disease
stenosis	I_Disease	I_Disease
>	O	O
or=50	O	O
%	O	O
.	O	O

During	O	O
the	O	O
30-day	O	O
follow-up	O	O
period	O	O
,	O	O
no	O	O
patients	O	O
died	O	O
of	O	O
a	O	O
cardiovascular	O	O
event	O	O
(	O	O
0	O	O
%	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0	O	O
-	O	O
6.1	O	O
%	O	O
)	O	O
and	O	O
no	O	O
patient	O	O
sustained	O	O
a	O	O
nonfatal	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
(	O	O
0	O	O
%	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0	O	O
-	O	O
6.1	O	O
%	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Although	O	O
cocaine-associated	O	O
myocardial	B_Disease	O
ischemia	I_Disease	O
can	O	O
result	O	O
from	O	O
coronary	O	O
vasoconstriction	O	O
,	O	O
patients	O	O
with	O	O
cocaine	B_Chemical	O
associated	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
,	O	O
a	O	O
non-ischemic	O	O
ECG	O	O
,	O	O
and	O	O
a	O	O
TIMI	O	O
risk	O	O
score	O	O
<	O	O
2	O	O
may	O	O
be	O	O
safely	O	O
discharged	O	O
from	O	O
the	O	O
ED	O	O
after	O	O
a	O	O
negative	O	O
coronary	O	O
CTA	O	O
with	O	O
a	O	O
low	O	B_Disease
risk	O	I_Disease
of	O	O
30-day	O	O
adverse	O	O
events	O	O
.	O	O

Bilateral	O	O
haemorrhagic	B_Disease	O
infarction	B_Disease	O
of	I_Disease	O
the	I_Disease	O
globus	I_Disease	O
pallidus	I_Disease	O
after	O	O
cocaine	B_Chemical	O
and	O	O
alcohol	B_Chemical	O
intoxication	O	O
.	O	O

Cocaine	B_Chemical	O
is	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
both	O	O
ischemic	B_Disease	O
and	I_Disease	O
haemorrhagic	B_Disease	B_Disease
stroke	I_Disease	I_Disease
.	O	O

We	O	O
present	O	O
the	O	O
case	O	O
of	O	O
a	O	O
31-year-old	O	O
man	O	O
with	O	O
bilateral	O	O
ischemia	B_Disease	O
of	I_Disease	O
the	I_Disease	O
globus	I_Disease	O
pallidus	I_Disease	O
after	O	O
excessive	O	O
alcohol	B_Chemical	O
and	O	O
intranasal	O	O
cocaine	B_Chemical	O
use	O	O
.	O	O

Drug-related	O	O
globus	B_Disease	O
pallidus	I_Disease	O
infarctions	I_Disease	O
are	O	O
most	O	O
often	O	O
associated	O	O
with	O	O
heroin	B_Chemical	O
.	O	O

Bilateral	O	O
basal	B_Disease	O
ganglia	I_Disease	O
infarcts	I_Disease	O
after	O	O
the	O	O
use	O	O
of	O	O
cocaine	B_Chemical	O
,	O	O
without	O	O
concurrent	O	O
heroin	B_Chemical	O
use	O	O
,	O	O
have	O	O
never	O	O
been	O	O
reported	O	O
.	O	O

In	O	O
our	O	O
patient	O	O
,	O	O
transient	O	O
cardiac	B_Disease	B_Disease
arrhythmia	I_Disease	I_Disease
or	O	O
respiratory	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
related	O	O
to	O	O
cocaine	B_Chemical	O
and/or	O	O
ethanol	B_Chemical	O
use	O	O
were	O	O
the	O	O
most	O	O
likely	O	O
causes	O	O
of	O	O
cerebral	B_Disease	O
hypoperfusion	I_Disease	O
.	O	O

Late	O	O
fulminant	O	O
posterior	O	O
reversible	O	O
encephalopathy	O	B_Disease
syndrome	O	I_Disease
after	O	O
liver	O	O
transplant	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
Posterior	B_Disease	O
leukoencephalopathy	I_Disease	B_Disease
due	O	O
to	O	O
calcineurin-inhibitor-related	O	O
neurotoxicity	B_Disease	B_Disease
is	O	O
a	O	O
rare	O	O
but	O	O
severe	O	O
complication	O	O
that	O	O
results	O	O
from	O	O
treatment	O	O
with	O	O
immunosuppressive	O	O
agents	O	O
(	O	O
primarily	O	O
those	O	O
administered	O	O
after	O	O
a	O	O
liver	O	O
or	O	O
kidney	O	O
transplant	O	O
)	O	O
.	O	O

The	O	O
pathophysiologic	O	O
mechanisms	O	O
of	O	O
that	O	O
disorder	O	O
remain	O	O
unknown	O	O
.	O	O

CASE	O	O
:	O	O
We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
46-year-old	O	O
woman	O	O
who	O	O
received	O	O
a	O	O
liver	O	O
transplant	O	O
in	O	O
our	O	O
center	O	O
as	O	O
treatment	O	O
for	O	O
alcoholic	B_Disease	O
cirrhosis	I_Disease	O
and	O	O
in	O	O
whom	O	O
either	O	O
a	O	O
fulminant	O	O
course	O	O
of	O	O
posterior	B_Disease	O
leukoencephalopathy	I_Disease	B_Disease
or	O	O
posterior	B_Disease	O
reversible	I_Disease	O
encephalopathy	I_Disease	B_Disease
syndrome	I_Disease	I_Disease
developed	O	O
110	O	O
days	O	O
after	O	O
transplant	O	O
.	O	O

After	O	O
an	O	O
initially	O	O
uneventful	O	O
course	O	O
after	O	O
the	O	O
transplant	O	O
,	O	O
the	O	O
patient	O	O
rapidly	O	O
fell	O	O
into	O	O
deep	O	O
coma	O	O
.	O	O

RESULTS	O	O
:	O	O
Cerebral	O	O
MRI	O	O
scan	O	O
showed	O	O
typical	O	O
signs	O	O
of	O	O
enhancement	O	O
in	O	O
the	O	O
pontine	O	O
and	O	O
posterior	O	O
regions	O	O
.	O	O

Switching	O	O
the	O	O
immunosuppressive	O	O
regimen	O	O
from	O	O
tacrolimus	B_Chemical	B_Chemical
to	O	O
cyclosporine	B_Chemical	B_Chemical
did	O	O
not	O	O
improve	O	O
the	O	O
clinical	O	O
situation	O	O
.	O	O

The	O	O
termination	O	O
of	O	O
treatment	O	O
with	O	O
any	O	O
calcineurin	O	B_Chemical
inhibitor	O	O
resulted	O	O
in	O	O
a	O	O
complete	O	O
resolution	O	O
of	O	O
that	O	O
complication	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Posterior	B_Disease	O
reversible	I_Disease	O
encephalopathy	I_Disease	B_Disease
syndrome	I_Disease	I_Disease
after	O	O
liver	O	O
transplant	O	O
is	O	O
rare	O	O
.	O	O

We	O	O
recommend	O	O
a	O	O
complete	O	O
cessation	O	O
of	O	O
any	O	O
calcineurin	O	B_Chemical
inhibitor	O	O
rather	O	O
than	O	O
a	O	O
dose	O	O
reduction	O	O
.	O	O

Prolonged	O	O
hypothermia	B_Disease	O
as	O	O
a	O	O
bridge	O	O
to	O	O
recovery	O	O
for	O	O
cerebral	B_Disease	B_Disease
edema	I_Disease	I_Disease
and	O	O
intracranial	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
associated	O	I_Disease
with	O	O
fulminant	B_Disease	B_Disease
hepatic	I_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

BACKGROUND	O	O
:	O	O
To	O	O
review	O	O
evidence-based	O	O
treatment	O	O
options	O	O
in	O	O
patients	O	O
with	O	O
cerebral	B_Disease	B_Disease
edema	I_Disease	I_Disease
complicating	O	O
fulminant	B_Disease	B_Disease
hepatic	I_Disease	I_Disease
failure	I_Disease	I_Disease
(	O	O
FHF	B_Disease	O
)	O	O
and	O	O
discuss	O	O
the	O	O
potential	O	O
applications	O	O
of	O	O
hypothermia	B_Disease	O
.	O	O

METHOD	O	O
:	O	O
Case-based	O	O
observations	O	O
from	O	O
a	O	O
medical	O	O
intensive	O	O
care	O	O
unit	O	O
(	O	O
MICU	O	O
)	O	O
in	O	O
a	O	O
tertiary	O	O
care	O	O
facility	O	O
in	O	O
a	O	O
27-year-old	O	O
female	O	O
with	O	O
FHF	B_Disease	O
from	O	O
acetaminophen	B_Chemical	O
and	O	O
resultant	O	O
cerebral	B_Disease	B_Disease
edema	I_Disease	I_Disease
.	O	O

RESULTS	O	O
:	O	O
Our	O	O
patient	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
MICU	O	O
after	O	O
being	O	O
found	O	O
unresponsive	O	O
with	O	O
presumed	O	O
toxicity	B_Disease	O
from	O	O
acetaminophen	B_Chemical	O
which	O	O
was	O	O
ingested	O	O
over	O	O
a	O	O
2-day	O	O
period	O	O
.	O	O

The	O	O
patient	O	O
had	O	O
depressed	O	O
of	O	O
mental	O	O
status	O	O
lasting	O	O
at	O	O
least	O	O
24	O	O
h	O	O
prior	O	O
to	O	O
admission	O	O
.	O	O

Initial	O	O
evaluation	O	O
confirmed	O	O
FHF	B_Disease	O
from	O	O
acetaminophen	B_Chemical	O
and	O	O
cerebral	B_Disease	B_Disease
edema	I_Disease	I_Disease
.	O	O

The	O	O
patient	O	O
was	O	O
treated	O	O
with	O	O
hyperosmolar	O	O
therapy	O	O
,	O	O
hyperventilation	B_Disease	O
,	O	O
sedation	O	O
,	O	O
and	O	O
chemical	O	O
paralysis	B_Disease	O
.	O	O

Her	O	O
intracranial	O	O
pressure	O	O
remained	O	O
elevated	O	O
despite	O	O
maximal	O	O
medical	O	O
therapy	O	O
.	O	O

We	O	O
then	O	O
initiated	O	O
therapeutic	O	O
hypothermia	B_Disease	O
which	O	O
was	O	O
continued	O	O
for	O	O
5	O	O
days	O	O
.	O	O

At	O	O
re-warming	O	O
,	O	O
patient	O	O
had	O	O
resolution	O	O
of	O	O
her	O	O
cerebral	B_Disease	B_Disease
edema	I_Disease	I_Disease
and	O	O
intracranial	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
.	O	O

At	O	O
discharge	O	O
,	O	O
she	O	O
had	O	O
complete	O	O
recovery	O	O
of	O	O
neurological	O	O
and	O	O
hepatic	O	O
functions	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
patients	O	O
with	O	O
FHF	B_Disease	O
and	O	O
cerebral	B_Disease	B_Disease
edema	I_Disease	I_Disease
from	O	O
acetaminophen	B_Chemical	O
overdose	B_Disease	O
,	O	O
prolonged	O	O
therapeutic	O	O
hypothermia	B_Disease	O
could	O	O
potentially	O	O
be	O	O
used	O	O
as	O	O
a	O	O
life	O	O
saving	O	O
therapy	O	O
and	O	O
a	O	O
bridge	O	O
to	O	O
hepatic	O	O
and	O	O
neurological	O	O
recovery	O	O
.	O	O

A	O	O
clinical	O	O
trial	O	O
of	O	O
hypothermia	B_Disease	O
in	O	O
patients	O	O
with	O	O
this	O	O
condition	O	O
is	O	O
warranted	O	O
.	O	O

Binasal	B_Disease	O
visual	I_Disease	B_Disease
field	I_Disease	I_Disease
defects	I_Disease	I_Disease
are	O	O
not	O	O
specific	O	O
to	O	O
vigabatrin	B_Chemical	B_Chemical
.	O	O

This	O	O
study	O	O
investigated	O	O
the	O	O
visual	B_Disease	B_Disease
defects	I_Disease	I_Disease
associated	O	O
with	O	O
the	O	O
antiepileptic	O	O
drug	O	O
vigabatrin	B_Chemical	B_Chemical
(	O	O
VGB	B_Chemical	O
)	O	O
.	O	O

Two	O	O
hundred	O	O
four	O	O
people	O	O
with	O	O
epilepsy	B_Disease	O
were	O	O
grouped	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
antiepileptic	O	O
drug	O	O
therapy	O	O
(	O	O
current	O	O
,	O	O
previous	O	O
,	O	O
or	O	O
no	O	O
exposure	O	O
to	O	O
VGB	B_Chemical	O
)	O	O
.	O	O

Groups	O	O
were	O	O
matched	O	O
with	O	O
respect	O	O
to	O	O
age	O	O
,	O	O
gender	O	O
,	O	O
and	O	O
seizure	B_Disease	O
frequency	O	O
.	O	O

All	O	O
patients	O	O
underwent	O	O
objective	O	O
assessment	O	O
of	O	O
electrophysiological	O	O
function	O	O
(	O	O
wide-field	O	O
multifocal	O	O
electroretinography	O	O
)	O	O
and	O	O
conventional	O	O
visual	O	O
field	O	O
testing	O	O
(	O	O
static	O	O
perimetry	O	O
)	O	O
.	O	O

Bilateral	O	O
visual	O	O
field	O	O
constriction	O	O
was	O	O
observed	O	O
in	O	O
59	O	O
%	O	O
of	O	O
patients	O	O
currently	O	O
taking	O	O
VGB	B_Chemical	O
,	O	O
43	O	O
%	O	O
of	O	O
patients	O	O
who	O	O
previously	O	O
took	O	O
VGB	B_Chemical	O
,	O	O
and	O	O
24	O	O
%	O	O
of	O	O
patients	O	O
with	O	O
no	O	O
exposure	O	O
to	O	O
VGB	B_Chemical	O
.	O	O

Assessment	O	O
of	O	O
retinal	O	O
function	O	O
revealed	O	O
abnormal	O	O
responses	O	O
in	O	O
48	O	O
%	O	O
of	O	O
current	O	O
VGB	B_Chemical	O
users	O	O
and	O	O
22	O	O
%	O	O
of	O	O
prior	O	O
VGB	B_Chemical	O
users	O	O
,	O	O
but	O	O
in	O	O
none	O	O
of	O	O
the	O	O
patients	O	O
without	O	O
previous	O	O
exposure	O	O
to	O	O
VGB	B_Chemical	O
.	O	O

Bilateral	B_Disease	O
visual	I_Disease	O
field	I_Disease	O
abnormalities	I_Disease	O
are	O	O
common	O	O
in	O	O
the	O	O
treated	O	O
epilepsy	B_Disease	O
population	O	O
,	O	O
irrespective	O	O
of	O	O
drug	O	O
history	O	O
.	O	O

Assessment	O	O
by	O	O
conventional	O	O
static	O	O
perimetry	O	O
may	O	O
neither	O	O
be	O	O
sufficiently	O	O
sensitive	O	O
nor	O	O
specific	O	O
to	O	O
reliably	O	O
identify	O	O
retinal	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
associated	O	O
with	O	O
VGB	B_Chemical	O
.	O	O

Smoking	O	O
of	O	O
crack	B_Chemical	O
cocaine	I_Chemical	O
as	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
HIV	B_Disease	O
infection	I_Disease	O
among	O	O
people	O	O
who	O	O
use	O	O
injection	O	O
drugs	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
possible	O	O
role	O	O
that	O	O
smoking	O	O
crack	B_Chemical	O
cocaine	I_Chemical	O
has	O	O
on	O	O
the	O	O
incidence	O	O
of	O	O
HIV	B_Disease	O
infection	I_Disease	O
.	O	O

Given	O	O
the	O	O
increasing	O	O
use	O	O
of	O	O
crack	B_Chemical	O
cocaine	I_Chemical	O
,	O	O
we	O	O
sought	O	O
to	O	O
examine	O	O
whether	O	O
use	O	O
of	O	O
this	O	O
illicit	O	O
drug	O	O
has	O	O
become	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
HIV	B_Disease	O
infection	I_Disease	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
included	O	O
data	O	O
from	O	O
people	O	O
participating	O	O
in	O	O
the	O	O
Vancouver	O	O
Injection	O	O
Drug	O	O
Users	O	O
Study	O	O
who	O	O
reported	O	O
injecting	O	O
illicit	O	O
drugs	O	O
at	O	O
least	O	O
once	O	O
in	O	O
the	O	O
month	O	O
before	O	O
enrolment	O	O
,	O	O
lived	O	O
in	O	O
the	O	O
greater	O	O
Vancouver	O	O
area	O	O
,	O	O
were	O	O
HIV-negative	O	O
at	O	O
enrolment	O	O
and	O	O
completed	O	O
at	O	O
least	O	O
1	O	O
follow-up	O	O
study	O	O
visit	O	O
.	O	O

To	O	O
determine	O	O
whether	O	O
the	O	O
risk	O	O
of	O	O
HIV	B_Disease	O
seroconversion	I_Disease	O
among	O	O
daily	O	O
smokers	O	O
of	O	O
crack	B_Chemical	O
cocaine	I_Chemical	O
changed	O	O
over	O	O
time	O	O
,	O	O
we	O	O
used	O	O
Cox	O	O
proportional	O	O
hazards	O	O
regression	O	O
and	O	O
divided	O	O
the	O	O
study	O	O
into	O	O
3	O	O
periods	O	O
:	O	O
May	O	O
1	O	O
,	O	O
1996-Nov	O	O
.	O	O

30	O	O
,	O	O
1999	O	O
(	O	O
period	O	O
1	O	O
)	O	O
,	O	O
Dec.	O	O
1	O	O
,	O	O
1999-Nov	O	O
.	O	O

30	O	O
,	O	O
2002	O	O
(	O	O
period	O	O
2	O	O
)	O	O
,	O	O
and	O	O
Dec.	O	O
1	O	O
,	O	O
2002-Dec	O	O
.	O	O
30	O	O
,	O	O
2005	O	O
(	O	O
period	O	O
3	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Overall	O	O
,	O	O
1048	O	O
eligible	O	O
injection	O	O
drug	O	O
users	O	O
were	O	O
included	O	O
in	O	O
our	O	O
study	O	O
.	O	O

Of	O	O
these	O	O
,	O	O
137	O	O
acquired	O	O
HIV	B_Disease	O
infection	I_Disease	O
during	O	O
follow-up	O	O
.	O	O

The	O	O
mean	O	O
proportion	O	O
of	O	O
participants	O	O
who	O	O
reported	O	O
daily	O	O
smoking	O	O
of	O	O
crack	B_Chemical	O
cocaine	I_Chemical	O
increased	O	O
from	O	O
11.6	O	O
%	O	O
in	O	O
period	O	O
1	O	O
to	O	O
39.7	O	O
%	O	O
in	O	O
period	O	O
3	O	O
.	O	O

After	O	O
adjusting	O	O
for	O	O
potential	O	O
confounders	O	O
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
risk	O	O
of	O	O
HIV	B_Disease	O
seroconversion	I_Disease	O
among	O	O
participants	O	O
who	O	O
were	O	O
daily	O	O
smokers	O	O
of	O	O
crack	B_Chemical	O
cocaine	I_Chemical	O
increased	O	O
over	O	O
time	O	O
(	O	O
period	O	O
1	O	O
:	O	O
hazard	O	O
ratio	O	O
[	O	O
HR	O	O
]	O	O
1.03	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
0.57	O	O
-	O	O
1.85	O	O
;	O	O
period	O	O
2	O	O
:	O	O
HR	O	O
1.68	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
1.01	O	O
-	O	O
2.80	O	O
;	O	O
and	O	O
period	O	O
3	O	O
:	O	O
HR	O	O
2.74	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
1.06	O	O
-	O	O
7.11	O	O
)	O	O
.	O	O

INTERPRETATION	O	O
:	O	O
Smoking	O	O
of	O	O
crack	B_Chemical	O
cocaine	I_Chemical	O
was	O	O
found	O	O
to	O	O
be	O	O
an	O	O
independent	O	O
risk	O	O
factor	O	O
for	O	O
HIV	B_Disease	O
seroconversion	I_Disease	O
among	O	O
people	O	O
who	O	O
were	O	O
injection	O	O
drug	O	O
users	O	O
.	O	O

This	O	O
finding	O	O
points	O	O
to	O	O
the	O	O
urgent	O	O
need	O	O
for	O	O
evidence-based	O	O
public	O	O
health	O	O
initiatives	O	O
targeted	O	O
at	O	O
people	O	O
who	O	O
smoke	O	O
crack	B_Chemical	O
cocaine	I_Chemical	O
.	O	O

Fluoxetine	B_Chemical	O
improves	O	O
the	O	O
memory	B_Disease	B_Disease
deficits	I_Disease	I_Disease
caused	O	O
by	O	O
the	O	O
chemotherapy	O	O
agent	O	O
5-fluorouracil	B_Chemical	B_Chemical
.	O	O

Cancer	B_Disease	O
patients	O	O
who	O	O
have	O	O
been	O	O
treated	O	O
with	O	O
systemic	O	O
adjuvant	O	O
chemotherapy	O	O
have	O	O
described	O	O
experiencing	O	O
deteriorations	O	O
in	O	O
cognition	O	O
.	O	O

A	O	O
widely	O	O
used	O	O
chemotherapeutic	O	O
agent	O	O
,	O	O
5-fluorouracil	B_Chemical	B_Chemical
(	O	O
5-FU	B_Chemical	O
)	O	O
,	O	O
readily	O	O
crosses	O	O
the	O	O
blood-brain	O	O
barrier	O	O
and	O	O
so	O	O
could	O	O
have	O	O
a	O	O
direct	O	O
effect	O	O
on	O	O
brain	O	O
function	O	O
.	O	O

In	O	O
particular	O	O
this	O	O
anti	O	O
mitotic	O	O
drug	O	O
could	O	O
reduce	O	O
cell	O	O
proliferation	O	O
in	O	O
the	O	O
neurogenic	O	O
regions	O	O
of	O	O
the	O	O
adult	O	O
brain	O	O
.	O	O

In	O	O
contrast	O	O
reports	O	O
indicate	O	O
that	O	O
hippocampal	O	O
dependent	O	O
neurogenesis	O	O
and	O	O
cognition	O	O
are	O	O
enhanced	O	O
by	O	O
the	O	O
SSRI	B_Chemical	O
antidepressant	O	B_Chemical
Fluoxetine	B_Chemical	I_Chemical
.	O	O

In	O	O
this	O	O
investigation	O	O
the	O	O
behavioural	O	O
effects	O	O
of	O	O
chronic	O	O
(	O	O
two	O	O
week	O	O
)	O	O
treatment	O	O
with	O	O
5-FU	B_Chemical	O
and	O	O
(	O	O
three	O	O
weeks	O	O
)	O	O
with	O	O
Fluoxetine	B_Chemical	O
either	O	O
separately	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
5-FU	B_Chemical	O
were	O	O
tested	O	O
on	O	O
adult	O	O
Lister	O	O
hooded	O	O
rats	O	O
.	O	O

Behavioural	O	O
effects	O	O
were	O	O
tested	O	O
using	O	O
a	O	O
context	O	O
dependent	O	O
conditioned	O	O
emotional	O	O
response	O	O
test	O	O
(	O	O
CER	O	O
)	O	O
which	O	O
showed	O	O
that	O	O
animals	O	O
treated	O	O
with	O	O
5-FU	B_Chemical	O
had	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
freezing	O	O
time	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

A	O	O
separate	O	O
group	O	O
of	O	O
animals	O	O
was	O	O
tested	O	O
using	O	O
a	O	O
hippocampal	O	O
dependent	O	O
spatial	O	O
working	O	O
memory	O	O
test	O	O
,	O	O
the	O	O
object	O	O
location	O	O
recognition	O	O
test	O	O
(	O	O
OLR	O	O
)	O	O
.	O	O

Animals	O	O
treated	O	O
only	O	O
with	O	O
5-FU	B_Chemical	O
showed	O	O
significant	O	O
deficits	O	O
in	O	O
their	O	O
ability	O	O
to	O	O
carry	O	O
out	O	O
the	O	O
OLR	O	O
task	O	O
but	O	O
co	O	O
administration	O	O
of	O	O
Fluoxetine	B_Chemical	O
improved	O	O
their	O	O
performance	O	O
.	O	O

5-FU	B_Chemical	O
chemotherapy	O	O
caused	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
number	O	O
of	O	O
proliferating	O	O
cells	O	O
in	O	O
the	O	O
sub	O	O
granular	O	O
zone	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

This	O	O
reduction	O	O
was	O	O
eliminated	O	O
when	O	O
Fluoxetine	B_Chemical	O
was	O	O
co	O	O
administered	O	O
with	O	O
5-FU	B_Chemical	B_Chemical
.	O	O

Fluoxetine	B_Chemical	O
on	O	O
its	O	O
own	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
proliferating	O	O
cell	O	O
number	O	O
or	O	O
behaviour	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
5-FU	B_Chemical	O
can	O	O
negatively	O	O
affect	O	O
both	O	O
cell	O	O
proliferation	O	O
and	O	O
hippocampal	O	O
dependent	O	O
working	O	O
memory	O	O
and	O	O
that	O	O
these	O	O
deficits	O	O
can	O	O
be	O	O
reversed	O	O
by	O	O
the	O	O
simultaneous	O	O
administration	O	O
of	O	O
the	O	O
antidepressant	O	B_Chemical
Fluoxetine	B_Chemical	I_Chemical
.	O	O

Liver-specific	O	O
ablation	O	O
of	O	O
integrin-linked	O	O
kinase	O	O
in	O	O
mice	O	O
results	O	O
in	O	O
enhanced	O	O
and	O	O
prolonged	O	O
cell	O	O
proliferation	O	O
and	O	O
hepatomegaly	B_Disease	O
after	O	O
phenobarbital	B_Chemical	O
administration	O	O
.	O	O

We	O	O
have	O	O
recently	O	O
demonstrated	O	O
that	O	O
disruption	O	O
of	O	O
extracellular	O	O
matrix	O	O
(ECM)/integrin	O	O
signaling	O	O
via	O	O
elimination	O	O
of	O	O
integrin-linked	O	O
kinase	O	O
(	O	O
ILK	O	O
)	O	O
in	O	O
hepatocytes	O	O
interferes	O	O
with	O	O
signals	O	O
leading	O	O
to	O	O
termination	O	O
of	O	O
liver	O	O
regeneration	O	O
.	O	O

This	O	O
study	O	O
investigates	O	O
the	O	O
role	O	O
of	O	O
ILK	O	O
in	O	O
liver	O	B_Disease
enlargement	O	I_Disease
induced	O	O
by	O	O
phenobarbital	B_Chemical	O
(	O	O
PB	B_Chemical	O
)	O	O
.	O	O

Wild-type	O	O
(	O	O
WT	O	O
)	O	O
and	O	O
ILK	O	O
:	O	O
liver-/-	O	O
mice	O	O
were	O	O
given	O	O
PB	B_Chemical	O
(	O	O
0.1	O	O
%	O	O
in	O	O
drinking	O	O
water	O	O
)	O	O
for	O	O
10	O	O
days	O	O
.	O	O

Livers	O	O
were	O	O
harvested	O	O
on	O	O
2	O	O
,	O	O
5	O	O
,	O	O
and	O	O
10	O	O
days	O	O
during	O	O
PB	B_Chemical	O
administration	O	O
.	O	O

In	O	O
the	O	O
hepatocyte-specific	O	O
ILK/liver-/-	O	O
mice	O	O
,	O	O
the	O	O
liver	O	O
:	O	O
body	O	O
weight	O	O
ratio	O	O
was	O	O
more	O	O
than	O	O
double	O	O
as	O	O
compared	O	O
to	O	O
0	O	O
h	O	O
at	O	O
day	O	O
2	O	O
(	O	O
2.5	O	O
times	O	O
)	O	O
,	O	O
while	O	O
at	O	O
days	O	O
5	O	O
and	O	O
10	O	O
,	O	O
it	O	O
was	O	O
enlarged	O	O
three	O	O
times	O	O
.	O	O

In	O	O
the	O	O
WT	O	O
mice	O	O
,	O	O
the	O	O
increase	O	O
was	O	O
as	O	O
expected	O	O
from	O	O
previous	O	O
literature	O	O
(	O	O
1.8	O	O
times	O	O
)	O	O
and	O	O
seems	O	O
to	O	O
have	O	O
leveled	O	O
off	O	O
after	O	O
day	O	O
2	O	O
.	O	O

There	O	O
were	O	O
slightly	O	O
increased	O	O
proliferating	O	O
cell	O	O
nuclear	O	O
antigen-positive	O	O
cells	O	O
in	O	O
the	O	O
ILK/liver-/-	O	O
animals	O	O
at	O	O
day	O	O
2	O	O
as	O	O
compared	O	O
to	O	O
WT	O	O
after	O	O
PB	B_Chemical	O
administration	O	O
.	O	O

In	O	O
the	O	O
WT	O	O
animals	O	O
,	O	O
the	O	O
proliferative	O	O
response	O	O
had	O	O
come	O	O
back	O	O
to	O	O
normal	O	O
by	O	O
days	O	O
5	O	O
and	O	O
10	O	O
.	O	O

Hepatocytes	O	O
of	O	O
the	O	O
ILK/liver-/-	O	O
mice	O	O
continued	O	O
to	O	O
proliferate	O	O
up	O	O
until	O	O
day	O	O
10	O	O
.	O	O

ILK/liver-/-	O	O
mice	O	O
also	O	O
showed	O	O
increased	O	O
expression	O	O
of	O	O
key	O	O
genes	O	O
involved	O	O
in	O	O
hepatocyte	O	O
proliferation	O	O
at	O	O
different	O	O
time	O	O
points	O	O
during	O	O
PB	B_Chemical	O
administration	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
ECM	O	O
proteins	O	O
communicate	O	O
with	O	O
the	O	O
signaling	O	O
machinery	O	O
of	O	O
dividing	O	O
cells	O	O
via	O	O
ILK	O	O
to	O	O
regulate	O	O
hepatocyte	O	O
proliferation	O	O
and	O	O
termination	O	O
of	O	O
the	O	O
proliferative	O	O
response	O	O
.	O	O

Lack	O	O
of	O	O
ILK	O	O
in	O	O
the	O	O
hepatocytes	O	O
imparts	O	O
prolonged	O	O
proliferative	O	O
response	O	O
not	O	O
only	O	O
to	O	O
stimuli	O	O
related	O	O
to	O	O
liver	O	O
regeneration	O	O
but	O	O
also	O	O
to	O	O
xenobiotic	O	O
chemical	O	O
mitogens	O	O
,	O	O
such	O	O
as	O	O
PB	B_Chemical	O
.	O	O

Decreased	O	O
Expression	O	O
of	O	O
Na/K-ATPase	O	O
,	O	O
NHE3	O	O
,	O	O
NBC1	O	O
,	O	O
AQP1	O	O
and	O	O
OAT	O	O
in	O	O
Gentamicin-induced	O	O
Nephropathy	B_Disease	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
aimed	O	O
to	O	O
determine	O	O
whether	O	O
there	O	O
is	O	O
an	O	O
altered	O	O
regulation	O	O
of	O	O
tubular	O	O
transporters	O	O
in	O	O
gentamicin-induced	O	O
nephropathy	B_Disease	O
.	O	O

Sprague-Dawley	O	O
male	O	O
rats	O	O
(	O	O
200~250	O	O
g	O	O
)	O	O
were	O	O
subcutaneously	O	O
injected	O	O
with	O	O
gentamicin	B_Chemical	O
(	O	O
100	O	O
mg/kg	O	O
per	O	O
day	O	O
)	O	O
for	O	O
7	O	O
days	O	O
,	O	O
and	O	O
the	O	O
expression	O	O
of	O	O
tubular	O	O
transporters	O	O
was	O	O
determined	O	O
by	O	O
immunoblotting	O	O
and	O	O
immunohistochemistry	O	O
.	O	O

The	O	O
mRNA	O	O
and	O	O
protein	O	O
expression	O	O
of	O	O
OAT	O	O
was	O	O
also	O	O
determined	O	O
.	O	O

Gentamicin-treated	O	O
rats	O	O
exhibited	O	O
significantly	O	O
decreased	O	O
creatinine	B_Chemical	B_Chemical
clearance	O	O
along	O	O
with	O	O
increased	O	O
plasma	O	O
creatinine	B_Chemical	B_Chemical
levels	O	O
.	O	O

Accordingly	O	O
,	O	O
the	O	O
fractional	O	O
excretion	O	O
of	O	O
sodium	B_Chemical	O
increased	O	O
.	O	O

Urine	O	O
volume	O	O
was	O	O
increased	O	O
,	O	O
while	O	O
urine	O	O
osmolality	O	O
and	O	O
free	O	O
water	O	O
reabsorption	O	O
were	O	O
decreased	O	O
.	O	O

Immunoblotting	O	O
and	O	O
immunohistochemistry	O	O
revealed	O	O
decreased	O	O
expression	O	O
of	O	O
Na(+)/K(+)-ATPase	O	O
,	O	O
NHE3	O	O
,	O	O
NBC1	O	O
,	O	O
and	O	O
AQP1	O	O
in	O	O
the	O	O
kidney	O	O
of	O	O
gentamicin-treated	O	O
rats	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
OAT1	O	O
and	O	O
OAT3	O	O
was	O	O
also	O	O
decreased	O	O
.	O	O

Gentamicin-induced	O	O
nephropathy	B_Disease	O
may	O	O
at	O	O
least	O	O
in	O	O
part	O	O
be	O	O
causally	O	O
related	O	O
with	O	O
a	O	O
decreased	O	O
expression	O	O
of	O	O
Na(+)/K(+)-ATPase	O	O
,	O	O
NHE3	O	O
,	O	O
NBC1	O	O
,	O	O
AQP1	O	O
and	O	O
OAT	O	O
.	O	O

Acute	B_Disease	O
renal	I_Disease	O
failure	I_Disease	O
after	O	O
high-dose	O	B_Chemical
methotrexate	B_Chemical	I_Chemical
therapy	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
ileostomy	O	O
.	O	O

High-dose	O	B_Chemical
methotrexate	B_Chemical	I_Chemical
(	O	O
HD-MTX	O	O
)	O	O
is	O	O
an	O	O
important	O	O
treatment	O	O
for	O	O
Burkitt	B_Disease	O
lymphoma	I_Disease	O
,	O	O
but	O	O
can	O	O
cause	O	O
hepatic	B_Disease	O
and	I_Disease	O
renal	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
when	O	O
its	O	O
clearance	O	O
is	O	O
delayed	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
after	O	O
HD-MTX	O	O
therapy	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
ileostomy	O	O
,	O	O
The	O	O
patient	O	O
was	O	O
a	O	O
3-year-old	O	O
boy	O	O
who	O	O
had	O	O
received	O	O
a	O	O
living-related	O	O
liver	O	O
transplantation	O	O
for	O	O
congenital	O	O
biliary	B_Disease	B_Disease
atresia	I_Disease	I_Disease
.	O	O

At	O	O
day	O	O
833	O	O
after	O	O
the	O	O
transplantation	O	O
,	O	O
he	O	O
was	O	O
diagnosed	O	O
with	O	O
PTLD	B_Disease	O
(	O	O
post-transplantation	B_Disease	O
lymphoproliferative	I_Disease	O
disorder	I_Disease	O
,	O	O
Burkitt-type	B_Disease	O
malignant	I_Disease	O
lymphoma	I_Disease	O
)	O	O
.	O	O

During	O	O
induction	O	O
therapy	O	O
,	O	O
he	O	O
suffered	O	O
ileal	O	B_Disease
perforation	O	I_Disease
and	O	O
ileostomy	O	O
was	O	O
performed	O	O
.	O	O

Subsequent	O	O
HD-MTX	O	O
therapy	O	O
caused	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
that	O	O
required	O	O
continuous	O	O
hemodialysis	O	O
.	O	O

We	O	O
supposed	O	O
that	O	O
intravascular	O	B_Disease
hypovolemia	B_Disease	I_Disease
due	O	O
to	O	O
substantial	O	O
drainage	O	O
from	O	O
the	O	O
ileostoma	O	B_Disease
caused	O	O
acute	B_Disease	B_Disease
prerenal	I_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

After	O	O
recovery	O	O
of	O	O
his	O	O
renal	O	O
function	O	O
,	O	O
we	O	O
could	O	O
safely	O	O
treat	O	O
the	O	O
patient	O	O
with	O	O
HD-MTX	O	O
therapy	O	O
by	O	O
controlling	O	O
drainage	O	O
from	O	O
ileostoma	O	B_Disease
with	O	O
total	O	O
parenteral	O	O
nutrition	O	O
.	O	O

Longitudinal	O	O
association	O	O
of	O	O
alcohol	B_Chemical	O
use	O	O
with	O	O
HIV	B_Disease	O
disease	I_Disease	O
progression	O	O
and	O	O
psychological	O	O
health	O	O
of	O	O
women	O	O
with	O	O
HIV.We	O	O
evaluated	O	O
the	O	O
association	O	O
of	O	O
alcohol	B_Chemical	O
consumption	O	O
and	O	O
depression	B_Disease	O
,	O	O
and	O	O
their	O	O
effects	O	O
on	O	O
HIV	B_Disease	O
disease	I_Disease	O
progression	O	O
among	O	O
women	O	O
with	O	O
HIV	O	O
.	O	O

The	O	O
study	O	O
included	O	O
871	O	O
women	O	O
with	O	O
HIV	O	O
who	O	O
were	O	O
recruited	O	O
from	O	O
1993	O	O
-	O	O
1995	O	O
in	O	O
four	O	O
US	O	O
cities	O	O
.	O	O

The	O	O
participants	O	O
had	O	O
physical	O	O
examination	O	O
,	O	O
medical	O	O
record	O	O
extraction	O	O
,	O	O
and	O	O
venipuncture	O	O
,	O	O
CD4+T-cell	O	O
counts	O	O
determination	O	O
,	O	O
measurement	O	O
of	O	O
depression	B_Disease	O
symptoms	O	O
(	O	O
using	O	O
the	O	O
self-report	O	O
Center	O	O
for	O	O
Epidemiological	O	O
Studies-Depression	O	O
Scale	O	O
)	O	O
,	O	O
and	O	O
alcohol	B_Chemical	O
use	O	O
assessment	O	O
at	O	O
enrollment	O	O
,	O	O
and	O	O
semiannually	O	O
until	O	O
March	O	O
2000	O	O
.	O	O

Multilevel	O	O
random	O	O
coefficient	O	O
ordinal	O	O
models	O	O
as	O	O
well	O	O
as	O	O
multilevel	O	O
models	O	O
with	O	O
joint	O	O
responses	O	O
were	O	O
used	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
association	O	O
between	O	O
level	O	O
of	O	O
alcohol	B_Chemical	O
use	O	O
and	O	O
CD4	O	O
+	O	O
T-cell	O	O
counts	O	O
.	O	O

When	O	O
participants	O	O
were	O	O
stratified	O	O
by	O	O
antiretroviral	O	O
therapy	O	O
(	O	O
ART	O	O
)	O	O
use	O	O
,	O	O
the	O	O
association	O	O
between	O	O
alcohol	B_Chemical	O
and	O	O
CD4	O	O
+	O	O
T-cell	O	O
did	O	O
not	O	O
reach	O	O
statistical	O	O
significance	O	O
.	O	O

The	O	O
association	O	O
between	O	O
alcohol	B_Chemical	O
consumption	O	O
and	O	O
depression	B_Disease	O
was	O	O
significant	O	O
(	O	O
p<0.001	O	O
)	O	O
.	O	O

Depression	B_Disease	O
had	O	O
a	O	O
significant	O	O
negative	O	O
effect	O	O
on	O	O
CD4	O	O
+	O	O
T-cell	O	O
counts	O	O
over	O	O
time	O	O
regardless	O	O
of	O	O
ART	O	O
use	O	O
.	O	O

Our	O	O
findings	O	O
suggest	O	O
that	O	O
alcohol	B_Chemical	O
consumption	O	O
has	O	O
a	O	O
direct	O	O
association	O	O
with	O	O
depression	B_Disease	O
.	O	O

Moreover	O	O
,	O	O
depression	B_Disease	O
is	O	O
associated	O	O
with	O	O
HIV	B_Disease	O
disease	I_Disease	O
progression	O	O
.	O	O

Our	O	O
findings	O	O
have	O	O
implications	O	O
for	O	O
the	O	O
provision	O	O
of	O	O
alcohol	B_Chemical	O
use	O	O
interventions	O	O
and	O	O
psychological	O	O
resources	O	O
to	O	O
improve	O	O
the	O	O
health	O	O
of	O	O
women	O	O
with	O	O
HIV	O	O
.	O	O

Chemokine	O	O
CCL2	O	O
and	O	O
its	O	O
receptor	O	O
CCR2	O	O
are	O	O
increased	O	O
in	O	O
the	O	O
hippocampus	O	O
following	O	O
pilocarpine-induced	O	O
status	B_Disease	O
epilepticus	I_Disease	O
.	O	O

BACKGROUND	O	O
:	O	O
Neuroinflammation	B_Disease	O
occurs	O	O
after	O	O
seizures	B_Disease	O
and	O	O
is	O	O
implicated	O	O
in	O	O
epileptogenesis	O	O
.	O	O

CCR2	O	O
is	O	O
a	O	O
chemokine	O	O
receptor	O	O
for	O	O
CCL2	O	O
and	O	O
their	O	O
interaction	O	O
mediates	O	O
monocyte	O	O
infiltration	O	O
in	O	O
the	O	O
neuroinflammatory	B_Disease	O
cascade	O	O
triggered	O	O
in	O	O
different	O	O
brain	O	O
pathologies	O	O
.	O	O

In	O	O
this	O	O
work	O	O
CCR2	O	O
and	O	O
CCL2	O	O
expression	O	O
were	O	O
examined	O	O
following	O	O
status	B_Disease	O
epilepticus	I_Disease	O
(	O	O
SE	B_Disease	O
)	O	O
induced	O	O
by	O	O
pilocarpine	B_Chemical	O
injection	O	O
.	O	O

METHODS	O	O
:	O	O
SE	B_Disease	O
was	O	O
induced	O	O
by	O	O
pilocarpine	B_Chemical	O
injection	O	O
.	O	O

Control	O	O
rats	O	O
were	O	O
injected	O	O
with	O	O
saline	O	O
instead	O	O
of	O	O
pilocarpine	B_Chemical	O
.	O	O

Five	O	O
days	O	O
after	O	O
SE	B_Disease	O
,	O	O
CCR2	O	O
staining	O	O
in	O	O
neurons	O	O
and	O	O
glial	O	O
cells	O	O
was	O	O
examined	O	O
using	O	O
imunohistochemical	O	O
analyses	O	O
.	O	O

The	O	O
number	O	O
of	O	O
CCR2	O	O
positive	O	O
cells	O	O
was	O	O
determined	O	O
using	O	O
stereology	O	O
probes	O	O
in	O	O
the	O	O
hippocampus	O	O
.	O	O

CCL2	O	O
expression	O	O
in	O	O
the	O	O
hippocampus	O	O
was	O	O
examined	O	O
by	O	O
molecular	O	O
assay	O	O
.	O	O

RESULTS	O	O
:	O	O
Increased	O	O
CCR2	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
hippocampus	O	O
after	O	O
SE	B_Disease	O
.	O	O

Seizures	B_Disease	O
also	O	O
resulted	O	O
in	O	O
alterations	O	O
to	O	O
the	O	O
cell	O	O
types	O	O
expressing	O	O
CCR2	O	O
.	O	O

Increased	O	O
numbers	O	O
of	O	O
neurons	O	O
that	O	O
expressed	O	O
CCR2	O	O
was	O	O
observed	O	O
following	O	O
SE	B_Disease	O
.	O	O

Microglial	O	O
cells	O	O
were	O	O
more	O	O
closely	O	O
apposed	O	O
to	O	O
the	O	O
CCR2-labeled	O	O
cells	O	O
in	O	O
SE	B_Disease	O
rats	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
rats	O	O
that	O	O
experienced	O	O
SE	B_Disease	O
exhibited	O	O
CCR2-labeling	O	O
in	O	O
populations	O	O
of	O	O
hypertrophied	B_Disease	O
astrocytes	O	O
,	O	O
especially	O	O
in	O	O
CA1	O	O
and	O	O
dentate	O	O
gyrus	O	O
.	O	O

These	O	O
CCR2	O	O
+	O	O
astroctytes	O	O
were	O	O
not	O	O
observed	O	O
in	O	O
control	O	O
rats	O	O
.	O	O

Examination	O	O
of	O	O
CCL2	O	O
expression	O	O
showed	O	O
that	O	O
it	O	O
was	O	O
elevated	O	O
in	O	O
the	O	O
hippocampus	O	O
following	O	O
SE	B_Disease	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
data	O	O
show	O	O
that	O	O
CCR2	O	O
and	O	O
CCL2	O	O
are	O	O
up-regulated	O	O
in	O	O
the	O	O
hippocampus	O	O
after	O	O
pilocarpine-induced	O	O
SE	B_Disease	O
.	O	O

Seizures	B_Disease	O
also	O	O
result	O	O
in	O	O
changes	O	O
to	O	O
CCR2	O	O
receptor	O	O
expression	O	O
in	O	O
neurons	O	O
and	O	O
astrocytes	O	O
.	O	O

These	O	O
changes	O	O
might	O	O
be	O	O
involved	O	O
in	O	O
detrimental	O	O
neuroplasticity	O	O
and	O	O
neuroinflammatory	B_Disease	O
changes	O	O
that	O	O
occur	O	O
following	O	O
seizures	B_Disease	O
.	O	O

Metallothionein	B_Chemical	B_Chemical
induction	O	O
reduces	O	O
caspase-3	O	O
activity	O	O
and	O	O
TNFalpha	O	O
levels	O	O
with	O	O
preservation	O	O
of	O	O
cognitive	O	O
function	O	O
and	O	O
intact	O	O
hippocampal	O	O
neurons	O	O
in	O	O
carmustine-treated	O	O
rats	O	O
.	O	O

Hippocampal	O	O
integrity	O	O
is	O	O
essential	O	O
for	O	O
cognitive	O	O
functions	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
induction	O	O
of	O	O
metallothionein	B_Chemical	B_Chemical
(	O	O
MT	B_Chemical	O
)	O	O
by	O	O
ZnSO(4	B_Chemical	O
)	I_Chemical	O
and	O	O
its	O	O
role	O	O
in	O	O
neuroprotection	O	O
has	O	O
been	O	O
documented	O	O
.	O	O

The	O	O
present	O	O
study	O	O
aimed	O	O
to	O	O
explore	O	O
the	O	O
effect	O	O
of	O	O
MT	B_Chemical	O
induction	O	O
on	O	O
carmustine	B_Chemical	O
(BCNU)-induced	O	O
hippocampal	O	B_Disease
cognitive	B_Disease	I_Disease
dysfunction	I_Disease	I_Disease
in	O	O
rats	O	O
.	O	O

A	O	O
total	O	O
of	O	O
60	O	O
male	O	O
Wistar	O	O
albino	O	O
rats	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
four	O	O
groups	O	O
(	O	O
15/group	O	O
):	O	O
The	O	O
control	O	O
group	O	O
injected	O	O
with	O	O
single	O	O
doses	O	O
of	O	O
normal	O	O
saline	O	O
(	O	O
i.c.v	O	O
)	O	O
followed	O	O
24	O	O
h	O	O
later	O	O
by	O	O
BCNU	B_Chemical	O
solvent	O	O
(	O	O
i.v	O	O
)	O	O
.	O	O

The	O	O
second	O	O
group	O	O
administered	O	O
ZnSO(4	B_Chemical	O
)	I_Chemical	O
(	O	O
0.1	O	O
micromol/10	O	O
microl	O	O
normal	O	O
saline	O	O
,	O	O
i.c.v	O	O
,	O	O
once	O	O
)	O	O
then	O	O
BCNU	B_Chemical	O
solvent	O	O
(	O	O
i.v	O	O
)	O	O
after	O	O
24	O	O
h.	O	O
Third	O	O
group	O	O
received	O	O
BCNU	B_Chemical	B_Chemical
(	O	O
20	O	O
mg/kg	O	O
,	O	O
i.v	O	O
,	O	O
once	O	O
)	O	O
24	O	O
h	O	O
after	O	O
injection	O	O
with	O	O
normal	O	O
saline	O	O
(	O	O
i.c.v	O	O
)	O	O
.	O	O

Fourth	O	O
group	O	O
received	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
ZnSO(4	B_Chemical	O
)	I_Chemical	O
(	O	O
0.1	O	O
micromol/10	O	O
microl	O	O
normal	O	O
saline	O	O
,	O	O
i.c.v	O	O
)	O	O
then	O	O
BCNU	B_Chemical	O
(	O	O
20	O	O
mg/kg	O	O
,	O	O
i.v	O	O
,	O	O
once	O	O
)	O	O
after	O	O
24	O	O
h.	O	O
The	O	O
obtained	O	O
data	O	O
revealed	O	O
that	O	O
BCNU	B_Chemical	O
administration	O	O
resulted	O	O
in	O	O
deterioration	B_Disease	O
of	I_Disease	O
learning	I_Disease	O
and	I_Disease	O
short-term	I_Disease	O
memory	I_Disease	O
(	O	O
STM	O	O
)	O	O
,	O	O
as	O	O
measured	O	O
by	O	O
using	O	O
radial	O	O
arm	O	O
water	O	O
maze	O	O
,	O	O
accompanied	O	O
with	O	O
decreased	O	O
hippocampal	O	O
glutathione	B_Chemical	O
reductase	O	O
(	O	O
GR	O	O
)	O	O
activity	O	O
and	O	O
reduced	O	O
glutathione	B_Chemical	B_Chemical
(	O	O
GSH	B_Chemical	O
)	O	O
content	O	O
.	O	O

Also	O	O
,	O	O
BCNU	B_Chemical	O
administration	O	O
increased	O	O
serum	O	O
tumor	B_Disease	O
necrosis	B_Disease	O
factor-alpha	O	O
(	O	O
TNFalpha	O	O
)	O	O
,	O	O
hippocampal	O	O
MT	B_Chemical	O
and	O	O
malondialdehyde	B_Chemical	B_Chemical
(	O	O
MDA	B_Chemical	O
)	O	O
contents	O	O
as	O	O
well	O	O
as	O	O
caspase-3	O	O
activity	O	O
in	O	O
addition	O	O
to	O	O
histological	O	O
alterations	O	O
.	O	O

ZnSO(4	B_Chemical	O
)	I_Chemical	O
pretreatment	O	O
counteracted	O	O
BCNU-induced	O	O
inhibition	O	O
of	O	O
GR	O	O
and	O	O
depletion	O	O
of	O	O
GSH	B_Chemical	O
and	O	O
resulted	O	O
in	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
MDA	B_Chemical	O
and	O	O
TNFalpha	O	O
as	O	O
well	O	O
as	O	O
the	O	O
activity	O	O
of	O	O
caspase-3	O	O
.	O	O

The	O	O
histological	O	O
features	O	O
were	O	O
improved	O	O
in	O	O
hippocampus	O	O
of	O	O
rats	O	O
treated	O	O
with	O	O
ZnSO(4	B_Chemical	O
)	I_Chemical	O
+	O	O
BCNU	B_Chemical	O
compared	O	O
to	O	O
only	O	O
BCNU-treated	O	O
animals	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
MT	B_Chemical	O
induction	O	O
halts	O	O
BCNU-induced	O	O
hippocampal	O	O
toxicity	B_Disease	O
as	O	O
it	O	O
prevented	O	O
GR	O	O
inhibition	O	O
and	O	O
GSH	B_Chemical	O
depletion	O	O
and	O	O
counteracted	O	O
the	O	O
increased	O	O
levels	O	O
of	O	O
TNFalpha	O	O
,	O	O
MDA	B_Chemical	O
and	O	O
caspase-3	O	O
activity	O	O
with	O	O
subsequent	O	O
preservation	O	O
of	O	O
cognition	O	O
.	O	O

Fatal	O	O
carbamazepine	B_Chemical	B_Chemical
induced	O	O
fulminant	B_Disease	O
eosinophilic	I_Disease	O
(	O	O
hypersensitivity	B_Disease	O
)	O	O
myocarditis	B_Disease	O
:	O	O
emphasis	O	O
on	O	O
anatomical	O	O
and	O	O
histological	O	O
characteristics	O	O
,	O	O
mechanisms	O	O
and	O	O
genetics	O	O
of	O	O
drug	B_Disease	O
hypersensitivity	I_Disease	O
and	O	O
differential	O	O
diagnosis	O	O
.	O	O

The	O	O
most	O	O
severe	O	O
adverse	O	O
reactions	O	O
to	O	O
carbamazepine	B_Chemical	B_Chemical
have	O	O
been	O	O
observed	O	O
in	O	O
the	O	O
haemopoietic	O	O
system	O	O
,	O	O
the	O	O
liver	O	O
and	O	O
the	O	O
cardiovascular	O	O
system	O	O
.	O	O

A	O	O
frequently	O	O
fatal	O	O
,	O	O
although	O	O
exceptionally	O	O
rare	O	O
side	O	O
effect	O	O
of	O	O
carbamazepine	B_Chemical	B_Chemical
is	O	O
necrotizing	O	O
eosinophilic	O	O
(	O	O
hypersensitivity	B_Disease	O
)	O	O
myocarditis	B_Disease	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
hypersensitivity	B_Disease	B_Disease
myocarditis	B_Disease	I_Disease
secondary	O	O
to	O	O
administration	O	O
of	O	O
carbamazepine	B_Chemical	B_Chemical
.	O	O

Acute	O	O
hypersensitivity	B_Disease	B_Disease
myocarditis	B_Disease	I_Disease
was	O	O
not	O	O
suspected	O	O
clinically	O	O
,	O	O
and	O	O
the	O	O
diagnosis	O	O
was	O	O
made	O	O
post-mortem	O	O
.	O	O

Histology	O	O
revealed	O	O
diffuse	O	O
infiltration	O	O
of	O	O
the	O	O
myocardium	O	O
by	O	O
eosinophils	O	O
and	O	O
lymphocytes	O	O
with	O	O
myocyte	O	O
damage	O	O
.	O	O

Clinically	O	O
,	O	O
death	O	O
was	O	O
due	O	O
to	O	O
cardiogenic	B_Disease	B_Disease
shock	I_Disease	I_Disease
.	O	O

To	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
this	O	O
is	O	O
the	O	O
second	O	O
case	O	O
of	O	O
fatal	O	O
carbamazepine	B_Chemical	B_Chemical
induced	O	O
myocarditis	B_Disease	O
reported	O	O
in	O	O
English	O	O
literature	O	O
.	O	O

Neuropsychiatric	O	O
behaviors	O	O
in	O	O
the	O	O
MPTP	B_Chemical	O
marmoset	O	O
model	O	O
of	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
.	O	O

OBJECTIVES	O	O
:	O	O
Neuropsychiatric	O	B_Disease
symptoms	O	I_Disease
are	O	O
increasingly	O	O
recognised	O	O
as	O	O
a	O	O
significant	O	O
problem	O	O
in	O	O
patients	O	O
with	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
(	O	O
PD	B_Disease	O
)	O	O
.	O	O

These	O	O
symptoms	O	O
may	O	O
be	O	O
due	O	O
to	O	O
'	O	O
sensitisation	O	O
'	O	O
following	O	O
repeated	O	O
levodopa	B_Chemical	O
treatment	O	O
or	O	O
a	O	O
direct	O	O
effect	O	O
of	O	O
dopamine	B_Chemical	O
on	O	O
the	O	O
disease	O	O
state	O	O
.	O	O

The	O	O
levodopa-treated	O	O
MPTP-lesioned	O	O
marmoset	O	O
was	O	O
used	O	O
as	O	O
a	O	O
model	O	O
of	O	O
neuropsychiatric	B_Disease	B_Disease
symptoms	I_Disease	I_Disease
in	O	O
PD	B_Disease	O
patients	O	O
.	O	O

Here	O	O
we	O	O
compare	O	O
the	O	O
time	O	O
course	O	O
of	O	O
levodopa-induced	O	O
motor	O	O
fluctuations	O	O
and	O	O
neuropsychiatric-like	B_Disease	O
behaviors	I_Disease	O
to	O	O
determine	O	O
the	O	O
relationship	O	O
between	O	O
duration	O	O
of	O	O
treatment	O	O
and	O	O
onset	O	O
of	O	O
symptoms	O	O
.	O	O

METHODS	O	O
:	O	O
Marmosets	O	O
were	O	O
administered	O	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	B_Chemical	B_Chemical
(	O	O
2.0	O	O
mg/kg	O	O
s.c	O	O
.	O	O
)	O	O
for	O	O
five	O	O
days	O	O
,	O	O
resulting	O	O
in	O	O
stable	O	O
parkinsonism	B_Disease	O
.	O	O

Levodopa	B_Chemical	O
(	O	O
15	O	O
mg/kg	O	O
and	O	O
benserazide	B_Chemical	B_Chemical
,	O	O
3.75	O	O
mg/kg	O	O
)	O	O
p.o	O	O
.	O	O

b.i.d	O	O
,	O	O
was	O	O
administered	O	O
for	O	O
30	O	O
days	O	O
.	O	O

Animals	O	O
were	O	O
evaluated	O	O
for	O	O
parkinsonian	B_Disease	B_Disease
disability	I_Disease	I_Disease
,	O	O
dyskinesia	B_Disease	O
and	O	O
on-time	O	O
(	O	O
motor	O	O
fluctuations	O	O
)	O	O
and	O	O
neuropsychiatric-like	B_Disease	O
behaviors	I_Disease	O
on	O	O
Day	O	O
0	O	O
(	O	O
prior	O	O
to	O	O
levodopa	B_Chemical	O
)	O	O
and	O	O
on	O	O
Days	O	O
1	O	O
,	O	O
7	O	O
,	O	O
13	O	O
,	O	O
27	O	O
and	O	O
30	O	O
of	O	O
treatment	O	O
using	O	O
post	O	O
hoc	O	O
DVD	O	O
analysis	O	O
by	O	O
a	O	O
trained	O	O
rater	O	O
,	O	O
blind	O	O
to	O	O
the	O	O
treatment	O	O
day	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
neuropsychiatric-like	B_Disease	O
behavior	I_Disease	O
rating	O	O
scale	O	O
demonstrated	O	O
high	O	O
interrater	O	O
reliability	O	O
between	O	O
three	O	O
trained	O	O
raters	O	O
of	O	O
differing	O	O
professional	O	O
backgrounds	O	O
.	O	O

As	O	O
anticipated	O	O
,	O	O
animals	O	O
exhibited	O	O
a	O	O
progressive	O	O
increase	O	O
in	O	O
levodopa-induced	O	O
motor	O	O
fluctuations	O	O
,	O	O
dyskinesia	B_Disease	O
and	O	O
wearing-off	O	O
,	O	O
that	O	O
correlated	O	O
with	O	O
the	O	O
duration	O	O
of	O	O
levodopa	B_Chemical	O
therapy	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
levodopa-induced	O	O
neuropsychiatric-like	B_Disease	O
behaviors	I_Disease	O
were	O	O
present	O	O
on	O	O
Day	O	O
1	O	O
of	O	O
levodopa	B_Chemical	O
treatment	O	O
and	O	O
their	O	O
severity	O	O
did	O	O
not	O	O
correlate	O	O
with	O	O
duration	O	O
of	O	O
treatment	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
data	O	O
suggest	O	O
that	O	O
neuropsychiatric	B_Disease	B_Disease
disorders	I_Disease	I_Disease
in	O	O
PD	B_Disease	O
are	O	O
more	O	O
likely	O	O
an	O	O
interaction	O	O
between	O	O
levodopa	B_Chemical	O
and	O	O
the	O	O
disease	O	O
state	O	O
than	O	O
a	O	O
consequence	O	O
of	O	O
sensitisation	O	O
to	O	O
repeated	O	O
dopaminergic	O	O
therapy	O	O
.	O	O

Contrast	B_Chemical	O
medium	I_Chemical	O
nephrotoxicity	B_Disease	B_Disease
after	O	O
renal	O	O
artery	O	O
and	O	O
coronary	O	O
angioplasty	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Renal	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
induced	O	O
by	O	O
iodinated	O	O
contrast	B_Chemical	O
medium	I_Chemical	O
(	O	O
CM	B_Chemical	O
)	O	O
administration	O	O
can	O	O
minimize	O	O
the	O	O
benefit	O	O
of	O	O
the	O	O
interventional	O	O
procedure	O	O
in	O	O
patients	O	O
undergoing	O	O
renal	O	O
angioplasty	O	O
(	O	O
PTRA	O	O
)	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
compare	O	O
the	O	O
susceptibility	O	O
to	O	O
nephrotoxic	B_Disease	O
effect	O	O
of	O	O
CM	B_Chemical	O
in	O	O
patients	O	O
undergoing	O	O
PTRA	O	O
with	O	O
that	O	O
of	O	O
patients	O	O
submitted	O	O
to	O	O
percutaneous	O	O
coronary	O	O
intervention	O	O
(	O	O
PCI	O	O
)	O	O
.	O	O

MATERIAL	O	O
AND	O	O
METHODS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
33	O	O
patients	O	O
successfully	O	O
treated	O	O
with	O	O
PTRA	O	O
(	O	O
PTRA	O	O
group	O	O
,	O	O
mean	O	O
age	O	O
70+/-12	O	O
years	O	O
,	O	O
23	O	O
female	O	O
,	O	O
basal	O	O
creatinine	B_Chemical	B_Chemical
1.46+/-0.79	O	O
,	O	O
range	O	O
0.7	O	O
-	O	O
4.9	O	O
mg/dl	O	O
)	O	O
were	O	O
compared	O	O
with	O	O
33	O	O
patients	O	O
undergoing	O	O
successful	O	O
PCI	O	O
(	O	O
PCI	O	O
group	O	O
)	O	O
,	O	O
matched	O	O
for	O	O
basal	O	B_Chemical
creatinine	B_Chemical	I_Chemical
(	O	O
1.44+/-0.6	O	O
,	O	O
range	O	O
0.7	O	O
-	O	O
3.4	O	O
mg/dl	O	O
)	O	O
,	O	O
gender	O	O
,	O	O
and	O	O
age	O	O
.	O	O

In	O	O
both	O	O
groups	O	O
postprocedural	O	O
(	O	O
48	O	O
h	O	O
)	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
was	O	O
measured	O	O
.	O	O

RESULTS	O	O
:	O	O
Postprocedural	O	O
creatinine	B_Chemical	B_Chemical
level	O	O
decreased	O	O
nonsignificantly	O	O
in	O	O
the	O	O
PTRA	O	O
group	O	O
(	O	O
1.46+/-0.8	O	O
vs.	O	O
1.34+/-0.5	O	O
mg/dl	O	O
,	O	O
P	O	O
=	O	O
NS	O	O
)	O	O
and	O	O
increased	O	O
significantly	O	O
in	O	O
the	O	O
PCI	O	O
group	O	O
(	O	O
1.44+/-0.6	O	O
vs.	O	O
1.57+/-0.7	O	O
mg/dl	O	O
,	O	O
P<0.02	O	O
)	O	O
.	O	O

Changes	O	O
in	O	O
serum	O	O
creatinine	B_Chemical	O
after	O	O
intervention	O	O
(	O	O
after-before	O	O
)	O	O
were	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
PTRA	O	O
and	O	O
PCI	O	O
groups	O	O
(	O	O
-0.12+/-0.5	O	O
vs.	O	O
0.13+/-0.3	O	O
,	O	O
P=0.014	O	O
)	O	O
.	O	O

This	O	O
difference	O	O
was	O	O
not	O	O
related	O	O
to	O	O
either	O	O
a	O	O
different	O	O
clinical	O	O
risk	O	O
profile	O	O
or	O	O
to	O	O
the	O	O
volume	O	O
of	O	O
CM	B_Chemical	O
administered	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
this	O	O
preliminary	O	O
study	O	O
patients	O	O
submitted	O	O
to	O	O
PTRA	O	O
showed	O	O
a	O	O
lower	O	O
susceptibility	O	O
to	O	O
renal	B_Disease	B_Disease
damage	I_Disease	I_Disease
induced	O	O
by	O	O
CM	B_Chemical	O
administration	O	O
than	O	O
PCI	O	O
patients	O	O
.	O	O

The	O	O
effectiveness	O	O
of	O	O
PTRA	O	O
on	O	O
renal	O	O
function	O	O
seems	O	O
to	O	O
be	O	O
barely	O	O
influenced	O	O
by	O	O
CM	B_Chemical	O
toxicity	B_Disease	O
.	O	O

Diphenhydramine	B_Chemical	O
prevents	O	O
the	O	O
haemodynamic	O	B_Disease
changes	O	O
of	O	O
cimetidine	B_Chemical	O
in	O	O
ICU	O	O
patients	O	O
.	O	O

Cimetidine	B_Chemical	O
,	O	O
a	O	O
histamine	B_Chemical	O
2	O	O
(	O	O
H2	O	O
)	O	O
antagonist	O	O
,	O	O
produces	O	O
a	O	O
decrease	O	O
in	O	O
arterial	O	O
pressure	O	O
due	O	O
to	O	O
vasodilatation	O	O
,	O	O
especially	O	O
in	O	O
critically	O	O
ill	O	O
patients	O	O
.	O	O

This	O	O
may	O	O
be	O	O
because	O	O
cimetidine	B_Chemical	O
acts	O	O
as	O	O
a	O	O
histamine	B_Chemical	O
agonist	O	O
.	O	O

We	O	O
,	O	O
therefore	O	O
,	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
histamine	B_Chemical	O
1(H1	O	O
)	O	O
receptor	O	O
antagonist	O	O
,	O	O
diphenhydramine	B_Chemical	O
,	O	O
on	O	O
the	O	O
haemodynamic	O	O
changes	O	O
observed	O	O
after	O	O
cimetidine	B_Chemical	O
in	O	O
ICU	O	O
patients	O	O
.	O	O

Each	O	O
patient	O	O
was	O	O
studied	O	O
on	O	O
two	O	O
separate	O	O
days	O	O
.	O	O

In	O	O
a	O	O
random	O	O
fashion	O	O
,	O	O
they	O	O
received	O	O
cimetidine	B_Chemical	O
200	O	O
mg	O	O
iv	O	O
on	O	O
one	O	O
day	O	O
,	O	O
and	O	O
on	O	O
the	O	O
other	O	O
,	O	O
a	O	O
pretreatment	O	O
of	O	O
diphenhydramine	B_Chemical	O
40	O	O
mg	O	O
iv	O	O
with	O	O
cimetidine	B_Chemical	O
200	O	O
mg	O	O
iv	O	O
.	O	O

In	O	O
the	O	O
non-pretreatment	O	O
group	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
(	O	O
MAP	O	O
)	O	O
decreased	O	O
from	O	O
107.4	O	O
+	O	O
/-	O	O
8.4	O	O
mmHg	O	O
to	O	O
86.7	O	O
+	O	O
/-	O	O
11.4	O	O
mmHg	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
two	O	O
minutes	O	O
after	O	O
cimetidine	B_Chemical	O
.	O	O

Also	O	O
,	O	O
systemic	O	O
vascular	O	O
resistance	O	O
(	O	O
SVR	O	O
)	O	O
decreased	O	O
during	O	O
the	O	O
eight-minute	O	O
observation	O	O
period	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
in	O	O
the	O	O
pretreatment	O	O
group	O	O
,	O	O
little	O	O
haemodynamic	O	O
change	O	O
was	O	O
seen	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
an	O	O
H1	O	O
antagonist	O	O
may	O	O
be	O	O
useful	O	O
in	O	O
preventing	O	O
hypotension	B_Disease	O
caused	O	O
by	O	O
iv	O	O
cimetidine	B_Chemical	O
,	O	O
since	O	O
the	O	O
vasodilating	O	O
activity	O	O
of	O	O
cimetidine	B_Chemical	O
is	O	O
mediated	O	O
,	O	O
in	O	O
part	O	O
,	O	O
through	O	O
the	O	O
H1	O	O
receptor	O	O
.	O	O

Medical	O	O
and	O	O
psychiatric	O	O
outcomes	O	O
for	O	O
patients	O	O
transplanted	O	O
for	O	O
acetaminophen-induced	O	O
acute	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
:	O	O
a	O	O
case-control	O	O
study	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Acetaminophen-induced	O	O
hepatotoxicity	B_Disease	B_Disease
is	O	O
the	O	O
most	O	O
common	O	O
cause	O	O
of	O	O
acute	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
(	O	O
ALF	B_Disease	O
)	O	O
in	O	O
the	O	O
UK	O	O
.	O	O

Patients	O	O
often	O	O
consume	O	O
the	O	O
drug	O	O
with	O	O
suicidal	O	B_Disease
intent	O	I_Disease
or	O	O
with	O	O
a	O	O
background	O	O
of	O	O
substance	O	O
dependence	O	O
.	O	O

AIMS	O	O
AND	O	O
METHODS	O	O
:	O	O
We	O	O
compared	O	O
the	O	O
severity	O	O
of	O	O
pretransplant	O	O
illness	O	O
,	O	O
psychiatric	O	O
co-morbidity	O	O
,	O	O
medical	O	O
and	O	O
psychosocial	O	O
outcomes	O	O
of	O	O
all	O	O
patients	O	O
who	O	O
had	O	O
undergone	O	O
liver	O	O
transplantation	O	O
(	O	O
LT	O	O
)	O	O
emergently	O	O
between	O	O
1999	O	O
-	O	O
2004	O	O
for	O	O
acetaminophen-induced	O	O
ALF	B_Disease	B_Chemical
(	O	O
n=36	O	O
)	O	O
with	O	O
age-	O	O
and	O	O
sex-matched	O	O
patients	O	O
undergoing	O	O
emergent	O	O
LT	O	O
for	O	O
non-acetaminophen-induced	O	O
ALF	B_Disease	B_Chemical
(	O	O
n=35	O	O
)	O	O
and	O	O
elective	O	O
LT	O	O
for	O	O
chronic	B_Disease	B_Disease
liver	I_Disease	I_Disease
disease	I_Disease	I_Disease
(	O	O
CLD	B_Disease	O
,	O	O
n=34	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Acetaminophen-induced	O	O
ALF	B_Disease	O
patients	O	O
undergoing	O	O
LT	O	O
had	O	O
a	O	O
greater	O	O
severity	O	O
of	O	O
pre-LT	O	O
illness	O	O
reflected	O	O
by	O	O
higher	O	O
Acute	O	O
Physiology	O	O
and	O	O
Chronic	O	O
Health	O	O
Evaluation	O	O
II	O	O
scores	O	O
and	O	O
requirement	O	O
for	O	O
organ	O	O
support	O	O
compared	O	O
with	O	O
the	O	O
other	O	O
two	O	O
groups	O	O
.	O	O

Twenty	O	O
(	O	O
56	O	O
%	O	O
)	O	O
acetaminophen-induced	O	O
ALF	B_Disease	O
patients	O	O
had	O	O
a	O	O
formal	O	O
psychiatric	O	O
diagnosis	O	O
before	O	O
LT	O	O
(	O	O
non-acetaminophen-induced	O	O
ALF=0/35	O	O
,	O	O
CLD=2/34	O	O
;	O	O
P<0.01	O	O
for	O	O
all	O	O
)	O	O
and	O	O
nine	O	O
(	O	O
25	O	O
%	O	O
)	O	O
had	O	O
a	O	O
previous	O	O
suicide	O	O
attempt	O	O
.	O	O

During	O	O
follow-up	O	O
(	O	O
median	O	O
5	O	O
years	O	O
)	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
rejection	O	O
(	O	O
acute	O	O
and	O	O
chronic	O	O
)	O	O
,	O	O
graft	O	B_Disease
failure	O	I_Disease
or	O	O
survival	O	O
between	O	O
the	O	O
groups	O	O
(	O	O
acetaminophen-induced	O	O
ALF	B_Disease	O
1	O	O
year	O	O
87	O	O
%	O	O
,	O	O
5	O	O
years	O	O
75	O	O
%	O	O
;	O	O
non-acetaminophen-induced	O	O
ALF	B_Disease	O
88	O	O
%	O	O
,	O	O
78	O	O
%	O	O
;	O	O
CLD	B_Disease	O
93	O	O
%	O	O
,	O	O
82	O	O
%	O	O
:	O	O
P>0.6	O	O
log	O	O
rank	O	O
)	O	O
.	O	O

Two	O	O
acetaminophen-induced	O	O
ALF	B_Disease	O
patients	O	O
reattempted	O	O
suicide	O	O
post-LT	O	O
(	O	O
one	O	O
died	O	O
8	O	O
years	O	O
post-LT	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Despite	O	O
a	O	O
high	O	O
prevalence	O	O
of	O	O
psychiatric	O	O
disturbance	O	O
,	O	O
outcomes	O	O
for	O	O
patients	O	O
transplanted	O	O
emergently	O	O
for	O	O
acetaminophen-induced	O	O
ALF	B_Disease	O
were	O	O
comparable	O	O
to	O	O
those	O	O
transplanted	O	O
for	O	O
non-acetaminophen-induced	O	O
ALF	B_Disease	O
and	O	O
electively	O	O
for	O	O
CLD	B_Disease	O
.	O	O

Multidisciplinary	O	O
approaches	O	O
with	O	O
long-term	O	O
psychiatric	O	O
follow-up	O	O
may	O	O
contribute	O	O
to	O	O
low	O	O
post-transplant	O	O
suicide	O	O
rates	O	O
seen	O	O
and	O	O
low	O	O
rates	O	O
of	O	O
graft	O	B_Disease
loss	O	I_Disease
because	O	O
of	O	O
non-compliance	O	O
.	O	O

Antithrombotic	O	O
drug	O	O
use	O	O
,	O	O
cerebral	B_Disease	O
microbleeds	I_Disease	O
,	O	O
and	O	O
intracerebral	B_Disease	O
hemorrhage	I_Disease	O
:	O	O
a	O	O
systematic	O	O
review	O	O
of	O	O
published	O	O
and	O	O
unpublished	O	O
studies	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
PURPOSE	O	O
:	O	O
Cerebral	B_Disease	O
microbleeds	I_Disease	O
(	O	O
MB	B_Disease	O
)	O	O
are	O	O
potential	O	O
risk	O	O
factors	O	O
for	O	O
intracerebral	B_Disease	O
hemorrhage	I_Disease	O
(	O	O
ICH	B_Disease	O
)	O	O
,	O	O
but	O	O
it	O	O
is	O	O
unclear	O	O
if	O	O
they	O	O
are	O	O
a	O	O
contraindication	O	O
to	O	O
using	O	O
antithrombotic	O	O
drugs	O	O
.	O	O

Insights	O	O
could	O	O
be	O	O
gained	O	O
by	O	O
pooling	O	O
data	O	O
on	O	O
MB	B_Disease	O
frequency	O	O
stratified	O	O
by	O	O
antithrombotic	O	O
use	O	O
in	O	O
cohorts	O	O
with	O	O
ICH	B_Disease	O
and	O	O
ischemic	B_Disease	B_Disease
stroke	I_Disease	I_Disease
(IS)/transient	O	O
ischemic	O	O
attack	O	O
(	O	O
TIA	B_Disease	O
)	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
performed	O	O
a	O	O
systematic	O	O
review	O	O
of	O	O
published	O	O
and	O	O
unpublished	O	O
data	O	O
from	O	O
cohorts	O	O
with	O	O
stroke	B_Disease	O
or	O	O
TIA	B_Disease	O
to	O	O
compare	O	O
the	O	O
presence	O	O
of	O	O
MB	B_Disease	O
in	O	O
:	O	O
(	O	O
1	O	O
)	O	O
antithrombotic	O	O
users	O	O
vs	O	O
nonantithrombotic	O	O
users	O	O
with	O	O
ICH	B_Disease	O
;	O	O
(	O	O
2	O	O
)	O	O
antithrombotic	O	O
users	O	O
vs	O	O
nonusers	O	O
with	O	O
IS/TIA	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
ICH	B_Disease	O
vs	O	O
ischemic	B_Disease	O
events	O	O
stratified	O	O
by	O	O
antithrombotic	O	O
use	O	O
.	O	O

We	O	O
also	O	O
analyzed	O	O
published	O	O
and	O	O
unpublished	O	O
follow-up	O	O
data	O	O
to	O	O
determine	O	O
the	O	O
risk	O	O
of	O	O
ICH	B_Disease	O
in	O	O
antithrombotic	O	O
users	O	O
with	O	O
MB	B_Disease	O
.	O	O

RESULTS	O	O
:	O	O
In	O	O
a	O	O
pooled	O	O
analysis	O	O
of	O	O
1460	O	O
ICH	B_Disease	O
and	O	O
3817	O	O
IS/TIA	O	O
,	O	O
MB	B_Disease	O
were	O	O
more	O	O
frequent	O	O
in	O	O
ICH	B_Disease	O
vs	O	O
IS/TIA	O	O
in	O	O
all	O	O
treatment	O	O
groups	O	O
,	O	O
but	O	O
the	O	O
excess	O	O
increased	O	O
from	O	O
2.8	O	O
(	O	O
odds	O	O
ratio	O	O
;	O	O
range	O	O
,	O	O
2.3	O	O
-	O	O
3.5	O	O
)	O	O
in	O	O
nonantithrombotic	O	O
users	O	O
to	O	O
5.7	O	O
(	O	O
range	O	O
,	O	O
3.4	O	O
-	O	O
9.7	O	O
)	O	O
in	O	O
antiplatelet	O	O
users	O	O
and	O	O
8.0	O	O
(	O	O
range	O	O
,	O	O
3.5	O	O
-	O	O
17.8	O	O
)	O	O
in	O	O
warfarin	B_Chemical	O
users	O	O
(	O	O
P	O	O
difference=0.01	O	O
)	O	O
.	O	O

There	O	O
was	O	O
also	O	O
an	O	O
excess	O	O
of	O	O
MB	B_Disease	O
in	O	O
warfarin	B_Chemical	O
users	O	O
vs	O	O
nonusers	O	O
with	O	O
ICH	B_Disease	O
(	O	O
OR	O	O
,	O	O
2.7	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.6	O	O
-	O	O
4.4	O	O
;	O	O
P<0.001	O	O
)	O	O
but	O	O
none	O	O
in	O	O
warfarin	B_Chemical	O
users	O	O
with	O	O
IS/TIA	O	O
(	O	O
OR	O	O
,	O	O
1.3	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.9	O	O
-	O	O
1.7	O	O
;	O	O
P=0.33	O	O
;	O	O
P	O	O
difference=0.01	O	O
)	O	O
.	O	O

There	O	O
was	O	O
a	O	O
smaller	O	O
excess	O	O
of	O	O
MB	B_Disease	O
in	O	O
antiplatelet	O	O
users	O	O
vs	O	O
nonusers	O	O
with	O	O
ICH	B_Disease	O
(	O	O
OR	O	O
,	O	O
1.7	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.3	O	O
-	O	O
2.3	O	O
;	O	O
P<0.001	O	O
)	O	O
,	O	O
but	O	O
findings	O	O
were	O	O
similar	O	O
for	O	O
antiplatelet	O	O
users	O	O
with	O	O
IS/TIA	O	O
(	O	O
OR	O	O
,	O	O
1.4	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
1.2	O	O
-	O	O
1.7	O	O
;	O	O
P<0.001	O	O
;	O	O
P	O	O
difference=0.25	O	O
)	O	O
.	O	O

In	O	O
pooled	O	O
follow-up	O	O
data	O	O
for	O	O
768	O	O
antithrombotic	O	O
users	O	O
,	O	O
presence	O	O
of	O	O
MB	B_Disease	O
at	O	O
baseline	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
substantially	O	O
increased	O	O
risk	O	O
of	O	O
subsequent	O	O
ICH	B_Disease	O
(	O	O
OR	O	O
,	O	O
12.1	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
3.4	O	O
-	O	O
42.5	O	O
;	O	O
P<0.001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
excess	O	O
of	O	O
MB	B_Disease	O
in	O	O
warfarin	B_Chemical	O
users	O	O
with	O	O
ICH	B_Disease	O
compared	O	O
to	O	O
other	O	O
groups	O	O
suggests	O	O
that	O	O
MB	B_Disease	O
increase	O	O
the	O	O
risk	O	O
of	O	O
warfarin-associated	O	O
ICH	B_Disease	O
.	O	O

Limited	O	O
prospective	O	O
data	O	O
corroborate	O	O
these	O	O
findings	O	O
,	O	O
but	O	O
larger	O	O
prospective	O	O
studies	O	O
are	O	O
urgently	O	O
required	O	O
.	O	O

Studies	O	O
of	O	O
synergy	O	O
between	O	O
morphine	B_Chemical	O
and	O	O
a	O	O
novel	O	O
sodium	B_Chemical	O
channel	O	O
blocker	O	O
,	O	O
CNSB002	B_Chemical	O
,	O	O
in	O	O
rat	O	O
models	O	O
of	O	O
inflammatory	O	O
and	O	O
neuropathic	B_Disease	B_Disease
pain	I_Disease	I_Disease
.	O	O

OBJECTIVE	O	O
:	O	O
This	O	O
study	O	O
determined	O	O
the	O	O
antihyperalgesic	O	O
effect	O	O
of	O	O
CNSB002	B_Chemical	O
,	O	O
a	O	O
sodium	B_Chemical	O
channel	O	O
blocker	O	O
with	O	O
antioxidant	O	O
properties	O	O
given	O	O
alone	O	O
and	O	O
in	O	O
combinations	O	O
with	O	O
morphine	B_Chemical	O
in	O	O
rat	O	O
models	O	O
of	O	O
inflammatory	O	O
and	O	O
neuropathic	B_Disease	B_Disease
pain	I_Disease	I_Disease
.	O	O

DESIGN	O	O
:	O	O
Dose	O	O
response	O	O
curves	O	O
for	O	O
nonsedating	O	O
doses	O	O
of	O	O
morphine	B_Chemical	O
and	O	O
CNSB002	B_Chemical	O
given	O	O
intraperitoneally	O	O
alone	O	O
and	O	O
together	O	O
in	O	O
combinations	O	O
were	O	O
constructed	O	O
for	O	O
antihyperalgesic	O	O
effect	O	O
using	O	O
paw	O	O
withdrawal	O	O
from	O	O
noxious	O	O
heat	O	O
in	O	O
two	O	O
rat	O	O
pain	B_Disease	O
models	O	O
:	O	O
carrageenan-induced	O	O
paw	O	O
inflammation	B_Disease	O
and	O	O
streptozotocin	B_Chemical	B_Chemical
(STZ)-induced	O	O
diabetic	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
.	O	O

RESULTS	O	O
:	O	O
The	O	O
maximum	O	O
nonsedating	O	O
doses	O	O
were	O	O
:	O	O
morphine	B_Chemical	O
,	O	O
3.2	O	O
mg/kg	O	O
;	O	O
CNSB002	B_Chemical	O
10.0	O	O
mg/kg	O	O
;	O	O
5.0	O	O
mg/kg	O	O
CNSB002	B_Chemical	O
with	O	O
morphine	B_Chemical	O
3.2	O	O
mg/kg	O	O
in	O	O
combination	O	O
.	O	O

The	O	O
doses	O	O
calculated	O	O
to	O	O
cause	O	O
50	O	O
%	O	O
reversal	O	O
of	O	O
hyperalgesia	B_Disease	B_Disease
(	O	O
ED50	O	O
)	O	O
were	O	O
7.54	O	O
(	O	O
1.81	O	O
)	O	O
and	O	O
4.83	O	O
(	O	O
1.54	O	O
)	O	O
in	O	O
the	O	O
carrageenan	B_Chemical	O
model	O	O
and	O	O
44.18	O	O
(	O	O
1.37	O	O
)	O	O
and	O	O
9.14	O	O
(	O	O
1.24	O	O
)	O	O
in	O	O
the	O	O
STZ-induced	O	O
neuropathy	B_Disease	O
model	O	O
for	O	O
CNSB002	B_Chemical	O
and	O	O
morphine	B_Chemical	O
,	O	O
respectively	O	O
(	O	O
mg/kg	O	O
;	O	O
mean	O	O
,	O	O
SEM	O	O
)	O	O
.	O	O

These	O	O
values	O	O
were	O	O
greater	O	O
than	O	O
the	O	O
maximum	O	O
nonsedating	O	O
doses	O	O
.	O	O

The	O	O
ED50	O	O
values	O	O
for	O	O
morphine	B_Chemical	O
when	O	O
given	O	O
in	O	O
combination	O	O
with	O	O
CNSB002	B_Chemical	O
(	O	O
5	O	O
mg/kg	O	O
)	O	O
were	O	O
less	O	O
than	O	O
the	O	O
maximum	O	O
nonsedating	O	O
dose	O	O
:	O	O
0.56	O	O
(	O	O
1.55	O	O
)	O	O
in	O	O
the	O	O
carrageenan	B_Chemical	O
model	O	O
and	O	O
1.37	O	O
(	O	O
1.23	O	O
)	O	O
in	O	O
the	O	O
neuropathy	B_Disease	O
model	O	O
(	O	O
mg/kg	O	O
;	O	O
mean	O	O
,	O	O
SEM	O	O
)	O	O
.	O	O

The	O	O
antinociception	O	O
after	O	O
morphine	B_Chemical	O
(	O	O
3.2	O	O
mg/kg	O	O
)	O	O
was	O	O
increased	O	O
by	O	O
co-administration	O	O
with	O	O
CNSB002	B_Chemical	O
from	O	O
28.0	O	O
and	O	O
31.7	O	O
%	O	O
to	O	O
114.6	O	O
and	O	O
56.9	O	O
%	O	O
reversal	O	O
of	O	O
hyperalgesia	B_Disease	B_Disease
in	O	O
the	O	O
inflammatory	O	O
and	O	O
neuropathic	B_Disease	B_Disease
models	O	O
,	O	O
respectively	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
;	O	O
one-way	O	O
analysis	O	O
of	O	O
variance-significantly	O	O
greater	O	O
than	O	O
either	O	O
drug	O	O
given	O	O
alone	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
maximum	O	O
antihyperalgesic	O	O
effect	O	O
achievable	O	O
with	O	O
nonsedating	O	O
doses	O	O
of	O	O
morphine	B_Chemical	O
may	O	O
be	O	O
increased	O	O
significantly	O	O
when	O	O
the	O	O
drug	O	O
is	O	O
used	O	O
in	O	O
combination	O	O
with	O	O
CNSB002	B_Chemical	O
.	O	O

Heparin-induced	O	O
thrombocytopenia	B_Disease	O
:	O	O
a	O	O
practical	O	O
review	O	O
.	O	O

Heparin-induced	O	O
thrombocytopenia	B_Disease	O
(	O	O
HIT	B_Disease	O
)	O	O
remains	O	O
under-recognized	O	O
despite	O	O
its	O	O
potentially	O	O
devastating	O	O
outcomes	O	O
.	O	O

It	O	O
begins	O	O
when	O	O
heparin	B_Chemical	O
exposure	O	O
stimulates	O	O
the	O	O
formation	O	O
of	O	O
heparin-platelet	O	O
factor	O	O
4	O	O
antibodies	O	O
,	O	O
which	O	O
in	O	O
turn	O	O
triggers	O	O
the	O	O
release	O	O
of	O	O
procoagulant	O	O
platelet	O	O
particles	O	O
.	O	O

Thrombosis	B_Disease	O
and	O	O
thrombocytopenia	B_Disease	O
that	O	O
follow	O	O
comprise	O	O
the	O	O
2	O	O
hallmark	O	O
traits	O	O
of	O	O
HIT	B_Disease	O
,	O	O
with	O	O
the	O	O
former	O	O
largely	O	O
responsible	O	O
for	O	O
significant	O	O
vascular	O	B_Disease
complications	O	I_Disease
.	O	O

The	O	O
prevalence	O	O
of	O	O
HIT	B_Disease	O
varies	O	O
among	O	O
several	O	O
subgroups	O	O
,	O	O
with	O	O
greater	O	O
incidence	O	O
in	O	O
surgical	O	O
as	O	O
compared	O	O
with	O	O
medical	O	O
populations	O	O
.	O	O

HIT	B_Disease	O
must	O	O
be	O	O
acknowledged	O	O
for	O	O
its	O	O
intense	O	O
predilection	O	O
for	O	O
thrombosis	B_Disease	O
and	O	O
suspected	O	O
whenever	O	O
thrombosis	B_Disease	O
occurs	O	O
after	O	O
heparin	B_Chemical	O
exposure	O	O
.	O	O

Early	O	O
recognition	O	O
that	O	O
incorporates	O	O
the	O	O
clinical	O	O
and	O	O
serologic	O	O
clues	O	O
is	O	O
paramount	O	O
to	O	O
timely	O	O
institution	O	O
of	O	O
treatment	O	O
,	O	O
as	O	O
its	O	O
delay	O	O
may	O	O
result	O	O
in	O	O
catastrophic	O	O
outcomes	O	O
.	O	O

The	O	O
treatment	O	O
of	O	O
HIT	B_Disease	O
mandates	O	O
an	O	O
immediate	O	O
cessation	O	O
of	O	O
all	O	O
heparin	B_Chemical	O
exposure	O	O
and	O	O
the	O	O
institution	O	O
of	O	O
an	O	O
antithrombotic	O	O
therapy	O	O
,	O	O
most	O	O
commonly	O	O
using	O	O
a	O	O
direct	B_Chemical	O
thrombin	I_Chemical	O
inhibitor	I_Chemical	O
.	O	O

Current	O	O
"	O	O
diagnostic	O	O
"	O	O
tests	O	O
,	O	O
which	O	O
primarily	O	O
include	O	O
functional	O	O
and	O	O
antigenic	O	O
assays	O	O
,	O	O
have	O	O
more	O	O
of	O	O
a	O	O
confirmatory	O	O
than	O	O
diagnostic	O	O
role	O	O
in	O	O
the	O	O
management	O	O
of	O	O
HIT	B_Disease	O
.	O	O

Special	O	O
attention	O	O
must	O	O
be	O	O
paid	O	O
to	O	O
cardiac	O	O
patients	O	O
who	O	O
are	O	O
often	O	O
exposed	O	O
to	O	O
heparin	B_Chemical	O
multiple	O	O
times	O	O
during	O	O
their	O	O
course	O	O
of	O	O
treatment	O	O
.	O	O

Direct	B_Chemical	O
thrombin	I_Chemical	O
inhibitors	I_Chemical	O
are	O	O
appropriate	O	O
,	O	O
evidence-based	O	O
alternatives	O	O
to	O	O
heparin	B_Chemical	O
in	O	O
patients	O	O
with	O	O
a	O	O
history	O	O
of	O	O
HIT	B_Disease	O
,	O	O
who	O	O
need	O	O
to	O	O
undergo	O	O
percutaneous	O	O
coronary	O	O
intervention	O	O
.	O	O

As	O	O
heparin	B_Chemical	O
remains	O	O
one	O	O
of	O	O
the	O	O
most	O	O
frequently	O	O
used	O	O
medications	O	O
today	O	O
with	O	O
potential	O	O
for	O	O
HIT	B_Disease	O
with	O	O
every	O	O
heparin	B_Chemical	O
exposure	O	O
,	O	O
a	O	O
close	O	O
vigilance	O	O
of	O	O
platelet	O	O
counts	O	O
must	O	O
be	O	O
practiced	O	O
whenever	O	O
heparin	B_Chemical	O
is	O	O
initiated	O	O
.	O	O

Abductor	O	O
paralysis	B_Disease	O
after	O	O
botox	B_Chemical	O
injection	O	O
for	O	O
adductor	B_Disease	O
spasmodic	I_Disease	O
dysphonia	I_Disease	O
.	O	O

OBJECTIVES/HYPOTHESIS	O	O
:	O	O
Botulinum	O	O
toxin	O	O
(	O	O
Botox	B_Chemical	O
)	O	O
injections	O	O
into	O	O
the	O	O
thyroarytenoid	O	O
muscles	O	O
are	O	O
the	O	O
current	O	O
standard	O	O
of	O	O
care	O	O
for	O	O
adductor	B_Disease	O
spasmodic	I_Disease	O
dysphonia	I_Disease	O
(	O	O
ADSD	B_Disease	O
)	O	O
.	O	O

Reported	O	O
adverse	O	O
effects	O	O
include	O	O
a	O	O
period	O	O
of	O	O
breathiness	O	B_Disease
,	O	O
throat	B_Disease	O
pain	I_Disease	O
,	O	O
and	O	O
difficulty	O	O
with	O	O
swallowing	O	O
liquids	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
multiple	O	O
cases	O	O
of	O	O
bilateral	O	O
abductor	O	O
paralysis	B_Disease	O
following	O	O
Botox	B_Chemical	O
injections	O	O
for	O	O
ADSD	B_Disease	O
,	O	O
a	O	O
complication	O	O
previously	O	O
unreported	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
:	O	O
Retrospective	O	O
case	O	O
series	O	O
.	O	O

METHODS	O	O
:	O	O
Patients	O	O
that	O	O
received	O	O
Botox	B_Chemical	O
injections	O	O
for	O	O
spasmodic	B_Disease	O
dysphonia	I_Disease	O
between	O	O
January	O	O
2000	O	O
and	O	O
October	O	O
2009	O	O
were	O	O
evaluated	O	O
.	O	O

Patients	O	O
with	O	O
ADSD	B_Disease	O
were	O	O
identified	O	O
.	O	O

The	O	O
number	O	O
of	O	O
treatments	O	O
received	O	O
and	O	O
adverse	O	O
effects	O	O
were	O	O
noted	O	O
.	O	O

For	O	O
patients	O	O
with	O	O
bilateral	O	O
abductor	O	O
paralysis	B_Disease	O
,	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
paralytic	O	O
Botox	B_Chemical	O
dose	O	O
,	O	O
prior	O	O
Botox	B_Chemical	O
dose	O	O
,	O	O
and	O	O
course	O	O
following	O	O
paralysis	B_Disease	O
were	O	O
noted	O	O
.	O	O

RESULTS	O	O
:	O	O
From	O	O
a	O	O
database	O	O
of	O	O
452	O	O
patients	O	O
receiving	O	O
Botox	B_Chemical	O
,	O	O
352	O	O
patients	O	O
had	O	O
been	O	O
diagnosed	O	O
with	O	O
ADSD	B_Disease	O
.	O	O

Of	O	O
these	O	O
352	O	O
patients	O	O
,	O	O
eight	O	O
patients	O	O
suffered	O	O
bilateral	O	O
abductor	O	O
paralysis	B_Disease	O
,	O	O
and	O	O
two	O	O
suffered	O	O
this	O	O
complication	O	O
twice	O	O
.	O	O

All	O	O
affected	O	O
patients	O	O
were	O	O
females	O	O
over	O	O
the	O	O
age	O	O
of	O	O
50	O	O
years	O	O
.	O	O

Most	O	O
patients	O	O
had	O	O
received	O	O
treatments	O	O
prior	O	O
to	O	O
abductor	O	O
paralysis	B_Disease	O
and	O	O
continued	O	O
receiving	O	O
after	O	O
paralysis	B_Disease	O
.	O	O

Seven	O	O
patients	O	O
recovered	O	O
after	O	O
a	O	O
brief	O	O
period	O	O
of	O	O
activity	O	O
restrictions	O	O
,	O	O
and	O	O
one	O	O
underwent	O	O
a	O	O
tracheotomy	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
abductor	O	O
paralysis	B_Disease	O
after	O	O
Botox	B_Chemical	O
injection	O	O
for	O	O
ADSD	B_Disease	O
was	O	O
0.34	O	O
%	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Bilateral	O	O
abductor	O	O
paralysis	B_Disease	O
is	O	O
a	O	O
rare	O	O
complication	O	O
of	O	O
Botox	B_Chemical	O
injections	O	O
for	O	O
ADSD	B_Disease	O
,	O	O
causing	O	O
difficulty	O	O
with	O	O
breathing	O	O
upon	O	O
exertion	O	O
.	O	O

The	O	O
likely	O	O
mechanism	O	O
of	O	O
paralysis	B_Disease	O
is	O	O
diffusion	O	O
of	O	O
Botox	B_Chemical	O
around	O	O
the	O	O
muscular	O	O
process	O	O
of	O	O
the	O	O
arytenoid	O	O
to	O	O
the	O	O
posterior	O	O
cricoarytenoid	O	O
muscles	O	O
.	O	O

The	O	O
paralysis	B_Disease	O
is	O	O
temporary	O	O
,	O	O
and	O	O
watchful	O	O
waiting	O	O
with	O	O
restriction	O	O
of	O	O
activity	O	O
is	O	O
the	O	O
recommended	O	O
management	O	O
.	O	O

Mitochondrial	B_Disease	B_Disease
impairment	I_Disease	I_Disease
contributes	O	O
to	O	O
cocaine-induced	O	O
cardiac	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
:	O	O
Prevention	O	O
by	O	O
the	O	O
targeted	O	O
antioxidant	O	O
MitoQ.The	O	O
goal	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
mitochondrial	O	O
function	O	O
and	O	O
ROS	O	O
production	O	O
in	O	O
an	O	O
experimental	O	O
model	O	O
of	O	O
cocaine-induced	O	O
cardiac	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
.	O	O

We	O	O
hypothesized	O	O
that	O	O
cocaine	B_Disease	B_Disease
abuse	I_Disease	I_Disease
may	O	O
lead	O	O
to	O	O
altered	O	O
mitochondrial	O	O
function	O	O
that	O	O
in	O	O
turn	O	O
may	O	O
cause	O	O
left	B_Disease	B_Disease
ventricular	I_Disease	I_Disease
dysfunction	I_Disease	I_Disease
.	O	O

Seven	O	O
days	O	O
of	O	O
cocaine	B_Chemical	O
administration	O	O
to	O	O
rats	O	O
led	O	O
to	O	O
an	O	O
increased	O	O
oxygen	B_Chemical	O
consumption	O	O
detected	O	O
in	O	O
cardiac	O	O
fibers	O	O
,	O	O
specifically	O	O
through	O	O
complex	O	O
I	O	O
and	O	O
complex	O	O
III	O	O
.	O	O

ROS	O	O
levels	O	O
were	O	O
increased	O	O
,	O	O
specifically	O	O
in	O	O
interfibrillar	O	O
mitochondria	O	O
.	O	O

In	O	O
parallel	O	O
there	O	O
was	O	O
a	O	O
decrease	O	O
in	O	O
ATP	B_Chemical	O
synthesis	O	O
,	O	O
whereas	O	O
no	O	O
difference	O	O
was	O	O
observed	O	O
in	O	O
subsarcolemmal	O	O
mitochondria	O	O
.	O	O

This	O	O
uncoupling	O	O
effect	O	O
on	O	O
oxidative	O	O
phosphorylation	O	O
was	O	O
not	O	O
detectable	O	O
after	O	O
short-term	O	O
exposure	O	O
to	O	O
cocaine	B_Chemical	O
,	O	O
suggesting	O	O
that	O	O
these	O	O
mitochondrial	B_Disease	O
abnormalities	I_Disease	O
were	O	O
a	O	O
late	O	O
rather	O	O
than	O	O
a	O	O
primary	O	O
event	O	O
in	O	O
the	O	O
pathological	O	O
response	O	O
to	O	O
cocaine	B_Chemical	O
.	O	O

MitoQ	B_Chemical	O
,	O	O
a	O	O
mitochondrial-targeted	O	O
antioxidant	O	O
,	O	O
was	O	O
shown	O	O
to	O	O
completely	O	O
prevent	O	O
these	O	O
mitochondrial	B_Disease	O
abnormalities	I_Disease	O
as	O	O
well	O	O
as	O	O
cardiac	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
characterized	O	O
here	O	O
by	O	O
a	O	O
diastolic	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
studied	O	O
with	O	O
a	O	O
conductance	O	O
catheter	O	O
to	O	O
obtain	O	O
pressure-volume	O	O
data	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
these	O	O
results	O	O
extend	O	O
previous	O	O
studies	O	O
and	O	O
demonstrate	O	O
that	O	O
cocaine-induced	O	O
cardiac	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
may	O	O
be	O	O
due	O	O
to	O	O
a	O	O
mitochondrial	B_Disease	B_Disease
defect	I_Disease	O
.	O	O

Trimethoprim-induced	O	O
immune	O	B_Disease
hemolytic	B_Disease	I_Disease
anemia	I_Disease	I_Disease
in	O	O
a	O	O
pediatric	O	O
oncology	O	O
patient	O	O
presenting	O	O
as	O	O
an	O	O
acute	O	B_Disease
hemolytic	O	I_Disease
transfusion	O	I_Disease
reaction	O	I_Disease
.	O	O

A	O	O
10-year-old	O	O
male	O	O
with	O	O
acute	B_Disease	B_Disease
leukemia	I_Disease	I_Disease
presented	O	O
with	O	O
post-chemotherapy	O	O
anemia	B_Disease	O
.	O	O

During	O	O
red	O	O
cell	O	O
transfusion	O	O
,	O	O
he	O	O
developed	O	O
hemoglobinuria	B_Disease	O
.	O	O

Transfusion	O	O
reaction	O	O
workup	O	O
was	O	O
negative	O	O
.	O	O

Drug-induced	O	O
immune	O	B_Disease
hemolytic	B_Disease	I_Disease
anemia	I_Disease	I_Disease
was	O	O
suspected	O	O
because	O	O
of	O	O
positive	O	O
direct	O	O
antiglobulin	O	O
test	O	O
,	O	O
negative	O	O
eluate	O	O
,	O	O
and	O	O
microspherocytes	O	O
on	O	O
smear	O	O
pre-	O	O
and	O	O
post-transfusion	O	O
.	O	O

Drug	O	O
studies	O	O
using	O	O
the	O	O
indirect	O	O
antiglobulin	O	O
test	O	O
were	O	O
strongly	O	O
positive	O	O
with	O	O
trimethoprim	B_Chemical	B_Chemical
and	O	O
trimethoprim-sulfamethoxazole	B_Chemical	B_Chemical
but	O	O
negative	O	O
with	O	O
sulfamethoxazole	B_Chemical	O
.	O	O

The	O	O
patient	O	O
recovered	O	O
after	O	O
discontinuing	O	O
the	O	O
drug	O	O
,	O	O
with	O	O
no	O	O
recurrence	O	O
in	O	O
2	O	O
years	O	O
.	O	O

Other	O	O
causes	O	O
of	O	O
anemia	B_Disease	O
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
with	O	O
worse-than-expected	O	O
anemia	B_Disease	O
after	O	O
chemotherapy	O	O
.	O	O

Furthermore	O	O
,	O	O
hemolysis	B_Disease	O
during	O	O
transfusion	O	O
is	O	O
not	O	O
always	O	O
a	O	O
transfusion	O	O
reaction	O	O
.	O	O

Verapamil	B_Chemical	O
stimulation	O	O
test	O	O
in	O	O
hyperprolactinemia	B_Disease	B_Disease
:	O	O
loss	O	O
of	O	O
prolactin	O	O
response	O	O
in	O	O
anatomic	O	O
or	O	O
functional	O	O
stalk	O	O
effect	O	O
.	O	O

AIM	O	O
:	O	O
Verapamil	B_Chemical	O
stimulation	O	O
test	O	O
was	O	O
previously	O	O
investigated	O	O
as	O	O
a	O	O
tool	O	O
for	O	O
differential	O	O
diagnosis	O	O
of	O	O
hyperprolactinemia	B_Disease	B_Disease
,	O	O
but	O	O
with	O	O
conflicting	O	O
results	O	O
.	O	O

Macroprolactinemia	B_Disease	B_Disease
was	O	O
never	O	O
considered	O	O
in	O	O
those	O	O
previous	O	O
studies	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
aimed	O	O
to	O	O
re-investigate	O	O
the	O	O
diagnostic	O	O
value	O	O
of	O	O
verapamil	B_Chemical	O
in	O	O
a	O	O
population	O	O
who	O	O
were	O	O
all	O	O
screened	O	O
for	O	O
macroprolactinemia	B_Disease	B_Disease
.	O	O

Prolactin	O	O
responses	O	O
to	O	O
verapamil	B_Chemical	O
in	O	O
65	O	O
female	O	O
patients	O	O
(	O	O
age	O	O
:	O	O
29.9	O	O
+	O	O
/-	O	O
8.1	O	O
years	O	O
)	O	O
with	O	O
hyperprolactinemia	B_Disease	B_Disease
were	O	O
tested	O	O
in	O	O
a	O	O
descriptive	O	O
,	O	O
matched	O	O
case-control	O	O
study	O	O
.	O	O

METHODS	O	O
:	O	O
Verapamil	B_Chemical	O
80	O	O
mg	O	O
,	O	O
p.o	O	O
.	O	O
was	O	O
administered	O	O
,	O	O
and	O	O
then	O	O
PRL	O	O
levels	O	O
were	O	O
measured	O	O
at	O	O
8th	O	O
and	O	O
16th	O	O
hours	O	O
,	O	O
by	O	O
immunometric	O	O
chemiluminescence	O	O
.	O	O

Verapamil	B_Chemical	O
responsiveness	O	O
was	O	O
determined	O	O
by	O	O
peak	O	O
percent	O	O
change	O	O
in	O	O
basal	O	O
prolactin	O	O
levels	O	O
(	O	O
PRL	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Verapamil	B_Chemical	O
significantly	O	O
increased	O	O
PRL	O	O
levels	O	O
in	O	O
healthy	O	O
controls	O	O
(	O	O
N.	O	O
8	O	O
,	O	O
PRL	O	O
:	O	O
183	O	O
%	O	O
)	O	O
,	O	O
macroprolactinoma	B_Disease	B_Disease
(	O	O
N.	O	O
8	O	O
,	O	O
PRL	O	O
:	O	O
7	O	O
%	O	O
)	O	O
,	O	O
microprolactinoma	B_Disease	B_Disease
(	O	O
N.	O	O
19	O	O
,	O	O
PRL	O	O
:	O	O
21	O	O
%	O	O
)	O	O
,	O	O
macroprolactinemia	B_Disease	B_Disease
(	O	O
N.	O	O
23	O	O
,	O	O
PRL	O	O
:	O	O
126	O	O
%	O	O
)	O	O
,	O	O
but	O	O
not	O	O
in	O	O
pseudoprolactinoma	B_Disease	B_Disease
(	O	O
N.	O	O
8	O	O
,	O	O
PRL	O	B_Chemical
:	O	O
0.8	O	O
%	O	O
)	O	O
,	O	O
and	O	O
risperidone-induced	O	O
hyperprolactinemia	B_Disease	B_Disease
(	O	O
N.	O	O
7	O	O
,	O	O
PRL	O	O
:	O	O
3	O	O
%	O	O
)	O	O
.	O	O

ROC	O	O
curve	O	O
analysis	O	O
revealed	O	O
that	O	O
unresponsiveness	O	O
to	O	O
verapamil	B_Chemical	O
defined	O	O
as	O	O
PRL	O	O
<	O	O
7	O	O
%	O	O
,	O	O
discriminated	O	O
anatomical	O	O
or	O	O
functional	O	O
stalk	O	O
effect	O	O
(	O	O
sensitivity	O	O
:	O	O
74	O	O
%	O	O
,	O	O
specificity	O	O
:	O	O
73	O	O
%	O	O
,	O	O
AUC	O	O
:	O	O
0.855+/-0.04	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
,	O	O
CI	O	O
:	O	O
0.768	O	O
-	O	O
0.942	O	O
)	O	O
associated	O	O
with	O	O
pseudoprolactinoma	B_Disease	O
or	O	O
risperidone-induced	O	O
hyperprolactinemia	B_Disease	B_Disease
,	O	O
respectively	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Verapamil	B_Chemical	O
responsiveness	O	O
is	O	O
not	O	O
a	O	O
reliable	O	O
finding	O	O
for	O	O
the	O	O
differential	O	O
diagnosis	O	O
of	O	O
hyperprolactinemia	B_Disease	B_Disease
.	O	O

However	O	O
,	O	O
verapamil	B_Chemical	O
unresponsiveness	O	O
discriminates	O	O
stalk	O	O
effect	O	O
(	O	O
i.e.	O	O
,	O	O
anatomically	O	O
or	O	O
functionally	O	O
inhibited	O	O
dopaminergic	O	O
tonus	O	O
)	O	O
from	O	O
other	O	O
causes	O	O
of	O	O
hyperprolactinemia	B_Disease	B_Disease
with	O	O
varying	O	O
degrees	O	O
of	O	O
responsiveness	O	O
.	O	O

Blockade	O	O
of	O	O
endothelial-mesenchymal	O	O
transition	O	O
by	O	O
a	O	O
Smad3	O	O
inhibitor	O	O
delays	O	O
the	O	O
early	O	O
development	O	O
of	O	O
streptozotocin-induced	O	O
diabetic	B_Disease	B_Disease
nephropathy	I_Disease	I_Disease
.	O	O

OBJECTIVE	O	O
:	O	O
A	O	O
multicenter	O	O
,	O	O
controlled	O	O
trial	O	O
showed	O	O
that	O	O
early	O	O
blockade	O	O
of	O	O
the	O	O
renin-angiotensin	O	O
system	O	O
in	O	O
patients	O	O
with	O	O
type	B_Disease	O
1	I_Disease	O
diabetes	I_Disease	O
and	O	O
normoalbuminuria	O	O
did	O	O
not	O	O
retard	O	O
the	O	O
progression	O	O
of	O	O
nephropathy	B_Disease	O
,	O	O
suggesting	O	O
that	O	O
other	O	O
mechanism(s	O	O
)	O	O
are	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
early	O	O
diabetic	B_Disease	B_Disease
nephropathy	I_Disease	I_Disease
(	O	O
diabetic	B_Disease	B_Disease
nephropathy	I_Disease	I_Disease
)	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
demonstrated	O	O
that	O	O
endothelial-mesenchymal-transition	O	O
(	O	O
EndoMT	O	O
)	O	O
contributes	O	O
to	O	O
the	O	O
early	O	O
development	O	O
of	O	O
renal	O	B_Disease
interstitial	O	I_Disease
fibrosis	B_Disease	I_Disease
independently	O	O
of	O	O
microalbuminuria	O	O
in	O	O
mice	O	O
with	O	O
streptozotocin	B_Chemical	B_Chemical
(STZ)-induced	O	O
diabetes	B_Disease	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
hypothesized	O	O
that	O	O
blocking	O	O
EndoMT	O	O
reduces	O	O
the	O	O
early	O	O
development	O	O
of	O	O
diabetic	B_Disease	B_Disease
nephropathy	I_Disease	I_Disease
.	O	O

RESEARCH	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
:	O	O
EndoMT	O	O
was	O	O
induced	O	O
in	O	O
a	O	O
mouse	O	O
pancreatic	O	O
microvascular	O	O
endothelial	O	O
cell	O	O
line	O	O
(	O	O
MMEC	O	O
)	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
advanced	O	O
glycation	O	O
end	O	O
products	O	O
(	O	O
AGEs	O	O
)	O	O
and	O	O
in	O	O
the	O	O
endothelial	O	O
lineage-traceble	O	O
mouse	O	O
line	O	O
Tie2-Cre;Loxp-EGFP	O	O
by	O	O
administration	O	O
of	O	O
AGEs	O	O
,	O	O
with	O	O
nonglycated	O	O
mouse	O	O
albumin	O	O
serving	O	O
as	O	O
a	O	O
control	O	O
.	O	O

Phosphorylated	O	O
Smad3	O	O
was	O	O
detected	O	O
by	O	O
immunoprecipitation/Western	O	O
blotting	O	O
and	O	O
confocal	O	O
microscopy	O	O
.	O	O

Blocking	O	O
studies	O	O
using	O	O
receptor	O	O
for	O	O
AGE	O	O
siRNA	O	O
and	O	O
a	O	O
specific	O	O
inhibitor	O	O
of	O	O
Smad3	O	O
(	O	O
SIS3	O	O
)	O	O
were	O	O
performed	O	O
in	O	O
MMECs	O	O
and	O	O
in	O	O
STZ-induced	O	O
diabetic	B_Disease	B_Disease
nephropathy	I_Disease	I_Disease
in	O	O
Tie2-Cre;Loxp-EGFP	O	O
mice	O	O
.	O	O

RESULTS	O	O
:	O	O
Confocal	O	O
microscopy	O	O
and	O	O
real-time	O	O
PCR	O	O
demonstrated	O	O
that	O	O
AGEs	O	O
induced	O	O
EndoMT	O	O
in	O	O
MMECs	O	O
and	O	O
in	O	O
Tie2-Cre;Loxp-EGFP	O	O
mice	O	O
.	O	O

Immunoprecipitation/Western	O	O
blotting	O	O
showed	O	O
that	O	O
Smad3	O	O
was	O	O
activated	O	O
by	O	O
AGEs	O	O
but	O	O
was	O	O
inhibited	O	O
by	O	O
SIS3	O	O
in	O	O
MMECs	O	O
and	O	O
in	O	O
STZ-induced	O	O
diabetic	B_Disease	B_Disease
nephropathy	I_Disease	I_Disease
.	O	O

Confocal	O	O
microscopy	O	O
and	O	O
real-time	O	O
PCR	O	O
further	O	O
demonstrated	O	O
that	O	O
SIS3	O	O
abrogated	O	O
EndoMT	O	O
,	O	O
reduced	O	O
renal	O	B_Disease
fibrosis	B_Disease	I_Disease
,	O	O
and	O	O
retarded	O	O
progression	O	O
of	O	O
nephropathy	B_Disease	O
.	O	O

CONCLUSIONS	O	O
:	O	O
EndoMT	O	O
is	O	O
a	O	O
novel	O	O
pathway	O	O
leading	O	O
to	O	O
early	O	O
development	O	O
of	O	O
diabetic	B_Disease	B_Disease
nephropathy	I_Disease	I_Disease
.	O	O

Blockade	O	O
of	O	O
EndoMT	O	O
by	O	O
SIS3	O	O
may	O	O
provide	O	O
a	O	O
new	O	O
strategy	O	O
to	O	O
retard	O	O
the	O	O
progression	O	O
of	O	O
diabetic	B_Disease	B_Disease
nephropathy	I_Disease	I_Disease
and	O	O
other	O	O
diabetes	B_Disease	O
complications	I_Disease	O
.	O	O

Cytostatic	O	O
and	O	O
anti-angiogenic	O	O
effects	O	O
of	O	O
temsirolimus	B_Chemical	B_Chemical
in	O	O
refractory	O	O
mantle	B_Disease	O
cell	I_Disease	O
lymphoma	I_Disease	O
.	O	O

Mantle	B_Disease	O
cell	I_Disease	O
lymphoma	I_Disease	O
(	O	O
MCL	B_Disease	O
)	O	O
is	O	O
a	O	O
rare	O	O
and	O	O
aggressive	O	O
type	O	O
of	O	O
B-cell	B_Disease	O
non-Hodgkin	I_Disease	O
's	I_Disease	O
lymphoma	I_Disease	O
.	O	O

Patients	O	O
become	O	O
progressively	O	O
refractory	O	O
to	O	O
conventional	O	O
chemotherapy	O	O
,	O	O
and	O	O
their	O	O
prognosis	O	O
is	O	O
poor	O	O
.	O	O

However	O	O
,	O	O
a	O	O
38	O	O
%	O	O
remission	O	O
rate	O	O
has	O	O
been	O	O
recently	O	O
reported	O	O
in	O	O
refractory	O	O
MCL	B_Disease	O
treated	O	O
with	O	O
temsirolimus	B_Chemical	B_Chemical
,	O	O
a	O	O
mTOR	O	O
inhibitor	O	O
.	O	O

Here	O	O
we	O	O
had	O	O
the	O	O
opportunity	O	O
to	O	O
study	O	O
a	O	O
case	O	O
of	O	O
refractory	O	O
MCL	B_Disease	O
who	O	O
had	O	O
tumor	B_Disease	O
regression	O	O
two	O	O
months	O	O
after	O	O
temsirolimus	B_Chemical	B_Chemical
treatment	O	O
,	O	O
and	O	O
a	O	O
progression-free	O	O
survival	O	O
of	O	O
10	O	O
months	O	O
.	O	O

In	O	O
this	O	O
case	O	O
,	O	O
lymph	O	O
node	O	O
biopsies	O	O
were	O	O
performed	O	O
before	O	O
and	O	O
six	O	O
months	O	O
after	O	O
temsirolimus	B_Chemical	B_Chemical
therapy	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
two	O	O
biopsies	O	O
showed	O	O
that	O	O
temsirolimus	B_Chemical	O
inhibited	O	O
tumor	B_Disease	O
cell	O	O
proliferation	O	O
through	O	O
cell	O	O
cycle	O	O
arrest	O	O
,	O	O
but	O	O
did	O	O
not	O	O
induce	O	O
any	O	O
change	O	O
in	O	O
the	O	O
number	O	O
of	O	O
apoptotic	O	O
tumor	B_Disease	O
cells	O	O
.	O	O

Apart	O	O
from	O	O
this	O	O
cytostatic	O	O
effect	O	O
,	O	O
temsirolimus	B_Chemical	B_Chemical
had	O	O
an	O	O
antiangiogenic	O	O
effect	O	O
with	O	O
decrease	O	O
of	O	O
tumor	B_Disease	O
microvessel	O	O
density	O	O
and	O	O
of	O	O
VEGF	O	O
expression	O	O
.	O	O

Moreover	O	O
,	O	O
numerous	O	O
patchy	O	O
,	O	O
well-limited	O	O
fibrotic	O	O
areas	O	O
,	O	O
compatible	O	O
with	O	O
post-necrotic	O	O
tissue	O	O
repair	O	O
,	O	O
were	O	O
found	O	O
after	O	O
6-month	O	O
temsirolimus	B_Chemical	B_Chemical
therapy	O	O
.	O	O

Thus	O	O
,	O	O
temsirolimus	B_Chemical	B_Chemical
reduced	O	O
tumor	B_Disease	O
burden	O	O
through	O	O
associated	O	O
cytostatic	O	O
and	O	O
anti-angiogenic	O	O
effects	O	O
.	O	O

This	O	O
dual	O	O
effect	O	O
of	O	O
temsirolimus	B_Chemical	B_Chemical
on	O	O
tumor	B_Disease	O
tissue	O	O
could	O	O
contribute	O	O
to	O	O
its	O	O
recently	O	O
reported	O	O
efficiency	O	O
in	O	O
refractory	O	O
MCL	B_Disease	O
resistant	O	O
to	O	O
conventional	O	O
chemotherapy	O	O
.	O	O

Acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
due	O	O
to	O	O
rifampicin	B_Chemical	B_Chemical
.	O	O

A	O	O
23-year-old	O	O
male	O	O
patient	O	O
with	O	O
bacteriologically	O	O
proven	O	O
pulmonary	B_Disease	O
tuberculosis	I_Disease	O
was	O	O
treated	O	O
with	O	O
the	O	O
various	O	O
regimens	O	O
of	O	O
antituberculosis	O	O
drugs	O	O
for	O	O
nearly	O	O
15	O	O
months	O	O
.	O	O

Rifampicin	B_Chemical	B_Chemical
was	O	O
administered	O	O
thrice	O	O
as	O	O
one	O	O
of	O	O
the	O	O
3	O	O
-	O	O
4	O	O
drug	O	O
regimen	O	O
and	O	O
each	O	O
time	O	O
he	O	O
developed	O	O
untoward	O	O
side	O	O
effects	O	O
like	O	O
nausea	B_Disease	O
,	O	O
vomiting	B_Disease	O
and	O	O
fever	B_Disease	O
with	O	O
chills	O	O
and	O	O
rigors	O	O
.	O	O

The	O	O
last	O	O
such	O	O
episode	O	O
was	O	O
of	O	O
acute	O	B_Disease
renal	O	I_Disease
failure	O	I_Disease
at	O	O
which	O	O
stage	O	O
the	O	O
patient	O	O
was	O	O
seen	O	O
by	O	O
the	O	O
authors	O	O
of	O	O
this	O	O
report	O	O
.	O	O

The	O	O
patient	O	O
,	O	O
however	O	O
,	O	O
made	O	O
a	O	O
full	O	O
recovery	O	O
.	O	O

Syncope	B_Disease	O
caused	O	O
by	O	O
hyperkalemia	B_Disease	O
during	O	O
use	O	O
of	O	O
a	O	O
combined	O	O
therapy	O	O
with	O	O
the	O	O
angiotensin-converting	O	O
enzyme	O	O
inhibitor	O	O
and	O	O
spironolactone	B_Chemical	O
.	O	O

A	O	O
76	O	O
year-old	O	O
woman	O	O
with	O	O
a	O	O
history	O	O
of	O	O
coronary	O	O
artery	O	O
bypass	O	O
grafting	O	O
and	O	O
prior	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
was	O	O
transferred	O	O
to	O	O
the	O	O
emergency	O	O
room	O	O
with	O	O
loss	B_Disease	O
of	I_Disease	O
consciousness	I_Disease	O
due	O	O
to	O	O
marked	O	O
bradycardia	B_Disease	O
caused	O	O
by	O	O
hyperkalemia	B_Disease	O
.	O	O

The	O	O
concentration	O	O
of	O	O
serum	O	O
potassium	B_Chemical	O
was	O	O
high	O	O
,	O	O
and	O	O
normal	O	O
sinus	O	O
rhythm	O	O
was	O	O
restored	O	O
after	O	O
correction	O	O
of	O	O
the	O	O
serum	O	O
potassium	B_Chemical	O
level	O	O
.	O	O

The	O	O
cause	O	O
of	O	O
hyperkalemia	B_Disease	O
was	O	O
considered	O	O
to	O	O
be	O	O
several	O	O
doses	O	O
of	O	O
spiranolactone	B_Chemical	B_Chemical
,	O	O
an	O	O
aldosterone	B_Chemical	O
antagonist	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
the	O	O
long-term	O	O
intake	O	O
of	O	O
ramipril	B_Chemical	O
,	O	O
an	O	O
ACE	O	O
inhibitor	O	O
.	O	O

This	O	O
case	O	O
is	O	O
a	O	O
good	O	O
example	O	O
of	O	O
electrolyte	O	O
imbalance	O	O
causing	O	O
acute	O	O
life-threatening	O	O
cardiac	O	B_Disease
events	O	I_Disease
.	O	O

Clinicians	O	O
should	O	O
be	O	O
alert	O	O
to	O	O
the	O	O
possibility	O	O
of	O	O
hyperkalemia	B_Disease	O
,	O	O
especially	O	O
in	O	O
elderly	O	O
patients	O	O
using	O	O
ACE/ARB	O	O
in	O	O
combination	O	O
with	O	O
potassium	B_Chemical	O
sparing	O	O
agents	O	O
and	O	O
who	O	O
have	O	O
mild	O	B_Disease
renal	B_Disease	I_Disease
disturbance	I_Disease	I_Disease
.	O	O

Diffuse	O	O
skeletal	O	B_Disease
pain	B_Disease	I_Disease
after	O	O
administration	O	O
of	O	O
alendronate	B_Chemical	O
.	O	O

BACKGROUND	O	O
:	O	O
Osteoporosis	B_Disease	O
is	O	O
caused	O	O
by	O	O
bone	O	B_Disease
resorption	O	I_Disease
in	O	O
excess	O	O
of	O	O
bone	O	O
formation	O	O
,	O	O
and	O	O
bisphosphonates	B_Chemical	O
,	O	O
are	O	O
used	O	O
to	O	O
inhibit	O	O
bone	O	B_Disease
resorption	O	I_Disease
.	O	O

Alendronate	B_Chemical	O
,	O	O
a	O	O
biphosphonate	B_Chemical	B_Chemical
,	O	O
is	O	O
effective	O	O
for	O	O
both	O	O
the	O	O
treatment	O	O
and	O	O
prevention	O	O
of	O	O
osteoporosis	B_Disease	O
in	O	O
postmenopausal	O	O
women	O	O
.	O	O

Side	O	O
effects	O	O
are	O	O
relatively	O	O
few	O	O
and	O	O
prominently	O	O
gastrointestinal	O	O
.	O	O

Musculoskeletal	B_Disease	B_Disease
pain	I_Disease	I_Disease
may	O	O
be	O	O
an	O	O
important	O	O
side	O	O
effect	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

We	O	O
presented	O	O
a	O	O
patient	O	O
admitted	O	O
to	O	O
our	O	O
out-patient	O	O
clinic	O	O
with	O	O
diffuse	O	O
skeletal	O	B_Disease
pain	B_Disease	I_Disease
after	O	O
three	O	O
consecutive	O	O
administration	O	O
of	O	O
alendronate	B_Chemical	O
.	O	O

CONCLUSION	O	O
:	O	O
We	O	O
conclude	O	O
that	O	O
patients	O	O
with	O	O
osteoporosis	B_Disease	O
can	O	O
report	O	O
pain	B_Disease	O
,	O	O
and	O	O
bisphosphonate-related	O	O
pain	B_Disease	O
should	O	O
also	O	O
be	O	O
considered	O	O
before	O	O
ascribing	O	O
this	O	O
complaint	O	O
to	O	O
osteoporosis	B_Disease	O
.	O	O

Cerebrospinal	O	O
fluid	O	O
penetration	O	O
of	O	O
high-dose	O	O
daptomycin	B_Chemical	O
in	O	O
suspected	O	O
Staphylococcus	O	O
aureus	O	O
meningitis	B_Disease	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
methicillin-sensitive	O	O
Staphylococcus	O	O
aureus	O	O
(	O	O
MSSA	O	O
)	O	O
bacteremia	B_Disease	O
with	O	O
suspected	O	O
MSSA	O	O
meningitis	B_Disease	O
treated	O	O
with	O	O
high-dose	O	B_Chemical
daptomycin	B_Chemical	I_Chemical
assessed	O	O
with	O	O
concurrent	O	O
serum	O	O
and	O	O
cerebrospinal	O	O
fluid	O	O
(	O	O
CSF	O	O
)	O	O
concentrations	O	O
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
54-year-old	O	O
male	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
with	O	O
generalized	O	O
weakness	B_Disease	O
and	O	O
presumed	O	O
health-care-associated	O	O
pneumonia	B_Disease	O
shown	O	O
on	O	O
chest	O	O
radiograph	O	O
.	O	O

Treatment	O	O
was	O	O
empirically	O	O
initiated	O	O
with	O	O
vancomycin	B_Chemical	O
,	O	O
levofloxacin	B_Chemical	B_Chemical
,	O	O
and	O	O
piperacillin/tazobactam	O	O
.	O	O

Blood	O	O
cultures	O	O
revealed	O	O
S.	O	O
aureus	O	O
susceptible	O	O
to	O	O
oxacillin	B_Chemical	O
.	O	O

Empiric	O	O
antibiotic	O	O
treatment	O	O
was	O	O
narrowed	O	O
to	O	O
nafcillin	B_Chemical	O
on	O	O
day	O	O
4	O	O
.	O	O

On	O	O
day	O	O
8	O	O
,	O	O
the	O	O
patient	O	O
developed	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
(	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
1.9	O	O
mg/dL	O	O
,	O	O
increased	O	O
from	O	O
1.2	O	O
mg/dL	O	O
the	O	O
previous	O	O
day	O	O
and	O	O
0.8	O	O
mg/dL	O	O
on	O	O
admission	O	O
)	O	O
.	O	O

The	O	O
patient	O	O
's	O	O
Glasgow	O	O
Coma	O	O
Score	O	O
was	O	O
3	O	O
,	O	O
with	O	O
normal	O	O
findings	O	O
shown	O	O
on	O	O
computed	O	O
tomography	O	O
scan	O	O
of	O	O
the	O	O
head	O	O
72	O	O
hours	O	O
following	O	O
an	O	O
episode	O	O
of	O	O
cardiac	B_Disease	B_Disease
arrest	I_Disease	I_Disease
on	O	O
day	O	O
10	O	O
.	O	O

The	O	O
patient	O	O
experienced	O	O
relapsing	O	O
MSSA	O	O
bacteremia	B_Disease	O
on	O	O
day	O	O
9	O	O
,	O	O
increasing	O	O
the	O	O
suspicion	O	O
for	O	O
a	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
infection	B_Disease	O
.	O	O

Nafcillin	B_Chemical	O
was	O	O
discontinued	O	O
and	O	O
daptomycin	B_Chemical	B_Chemical
9	O	O
mg/kg	O	O
daily	O	O
was	O	O
initiated	O	O
for	O	O
suspected	O	O
meningitis	B_Disease	O
and	O	O
was	O	O
continued	O	O
until	O	O
the	O	O
patient	O	O
's	O	O
death	O	O
on	O	O
day	O	O
16	O	O
.	O	O

Daptomycin	B_Chemical	B_Chemical
serum	O	O
and	O	O
CSF	O	O
trough	O	O
concentrations	O	O
were	O	O
11.21	O	O
ug/mL	O	O
and	O	O
0.52	O	O
ug/mL	O	O
,	O	O
respectively	O	O
,	O	O
prior	O	O
to	O	O
the	O	O
third	O	O
dose	O	O
.	O	O

Lumbar	O	O
puncture	O	O
results	O	O
were	O	O
inconclusive	O	O
and	O	O
no	O	O
further	O	O
blood	O	O
cultures	O	O
were	O	O
positive	O	O
for	O	O
MSSA	O	O
.	O	O

Creatine	B_Chemical	B_Chemical
kinase	O	I_Chemical
levels	O	O
were	O	O
normal	O	O
prior	O	O
to	O	O
daptomycin	B_Chemical	B_Chemical
therapy	O	O
and	O	O
were	O	O
not	O	O
reassessed	O	O
.	O	O

DISCUSSION	O	O
:	O	O
Daptomycin	B_Chemical	B_Chemical
was	O	O
initiated	O	O
in	O	O
our	O	O
patient	O	O
secondary	O	O
to	O	O
possible	O	O
nafcillin-induced	O	O
acute	O	B_Disease
interstitial	B_Disease	I_Disease
nephritis	I_Disease	I_Disease
and	O	O
relapsing	O	O
bacteremia	B_Disease	O
.	O	O

At	O	O
a	O	O
dose	O	O
of	O	O
9	O	O
mg/kg	O	O
,	O	O
resultant	O	O
penetration	O	O
of	O	O
5	O	O
%	O	O
was	O	O
higher	O	O
than	O	O
in	O	O
previous	O	O
reports	O	O
,	O	O
more	O	O
consistent	O	O
with	O	O
inflamed	O	O
meninges	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
High-dose	O	B_Chemical
daptomycin	B_Chemical	I_Chemical
may	O	O
be	O	O
an	O	O
alternative	O	O
option	O	O
for	O	O
MSSA	O	O
bacteremia	B_Disease	O
with	O	O
or	O	O
without	O	O
a	O	O
CNS	O	O
source	O	O
in	O	O
patients	O	O
who	O	O
have	O	O
failed	O	O
or	O	O
can	O	O
not	O	O
tolerate	O	O
standard	O	O
therapy	O	O
.	O	O

Further	O	O
clinical	O	O
evaluation	O	O
in	O	O
patients	O	O
with	O	O
confirmed	O	O
meningitis	B_Disease	O
is	O	O
warranted	O	O
.	O	O

The	O	O
role	O	O
of	O	O
nitric	B_Chemical	O
oxide	I_Chemical	O
in	O	O
convulsions	B_Disease	O
induced	O	O
by	O	O
lindane	B_Chemical	O
in	O	O
rats	O	O
.	O	O

Lindane	B_Chemical	O
is	O	O
an	O	O
organochloride	O	B_Chemical
pesticide	O	O
and	O	O
scabicide	O	O
.	O	O

It	O	O
evokes	O	O
convulsions	B_Disease	O
mainly	O	O
trough	O	O
the	O	O
blockage	O	O
of	O	O
GABA(A	O	O
)	O	O
receptors	O	O
.	O	O

Nitric	B_Chemical	O
oxide	I_Chemical	O
(	O	O
NO	B_Chemical	O
)	O	O
,	O	O
gaseous	O	O
neurotransmitter	O	O
,	O	O
has	O	O
contradictor	O	O
role	O	O
in	O	O
epileptogenesis	O	O
due	O	O
to	O	O
opposite	O	O
effects	O	O
of	O	O
L-arginine	B_Chemical	B_Chemical
,	O	O
precursor	O	O
of	O	O
NO	B_Chemical	O
syntheses	O	O
(	O	O
NOS	O	O
)	O	O
,	O	O
and	O	O
L-NAME	B_Chemical	O
(	O	O
NOS	O	O
inhibitor	O	O
)	O	O
observed	O	O
in	O	O
different	O	O
epilepsy	B_Disease	O
models	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
current	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
effects	O	O
of	O	O
NO	B_Chemical	O
on	O	O
the	O	O
behavioral	O	O
and	O	O
EEG	O	O
characteristics	O	O
of	O	O
lindane-induced	O	O
epilepsy	B_Disease	O
in	O	O
male	O	O
Wistar	O	O
albino	O	O
rats	O	O
.	O	O

The	O	O
administration	O	O
of	O	O
L-arginine	B_Chemical	B_Chemical
(	O	O
600	O	O
,	O	O
800	O	O
and	O	O
1000	O	O
mg/kg	O	O
,	O	O
i.p	O	O
.	O	O
)	O	O
in	O	O
dose-dependent	O	O
manner	O	O
significantly	O	O
increased	O	O
convulsion	B_Disease	O
incidence	O	O
and	O	O
severity	O	O
and	O	O
shortened	O	O
latency	O	O
time	O	O
to	O	O
first	O	O
convulsion	B_Disease	O
elicited	O	O
by	O	O
lower	O	O
lindane	B_Chemical	O
dose	O	O
(	O	O
4	O	O
mg/kg	O	O
,	O	O
i.p	O	O
.	O	O
)	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
pretreatment	O	O
with	O	O
L-NAME	B_Chemical	O
(	O	O
500	O	O
,	O	O
700	O	O
and	O	O
900	O	O
mg/kg	O	O
,	O	O
i.p	O	O
.	O	O
)	O	O
decreased	O	O
convulsion	B_Disease	O
incidence	O	O
and	O	O
severity	O	O
and	O	O
prolonged	O	O
latency	O	O
time	O	O
to	O	O
convulsion	B_Disease	O
following	O	O
injection	O	O
with	O	O
a	O	O
convulsive	B_Disease	O
dose	O	O
of	O	O
lindane	B_Chemical	O
(	O	O
8	O	O
mg/kg	O	O
,	O	O
i.p	O	O
.	O	O
)	O	O
.	O	O

EEG	O	O
analyses	O	O
showed	O	O
increase	O	O
of	O	O
number	O	O
and	O	O
duration	O	O
of	O	O
ictal	O	O
periods	O	O
in	O	O
EEG	O	O
of	O	O
rats	O	O
receiving	O	O
l-arginine	B_Chemical	B_Chemical
prior	O	O
to	O	O
lindane	B_Chemical	O
and	O	O
decrease	O	O
of	O	O
this	O	O
number	O	O
in	O	O
rats	O	O
pretreated	O	O
with	O	O
L-NAME	B_Chemical	O
.	O	O

These	O	O
results	O	O
support	O	O
the	O	O
conclusion	O	O
that	O	O
NO	B_Chemical	O
plays	O	O
a	O	O
role	O	O
of	O	O
endogenous	O	O
convulsant	O	O
in	O	O
rat	O	O
model	O	O
of	O	O
lindane	B_Chemical	O
seizures	B_Disease	O
.	O	O

Severe	O	O
polyneuropathy	B_Disease	B_Disease
and	O	O
motor	O	B_Disease
loss	O	I_Disease
after	O	O
intrathecal	O	O
thiotepa	B_Chemical	O
combination	O	O
chemotherapy	O	O
:	O	O
description	O	O
of	O	O
two	O	O
cases	O	O
.	O	O

Two	O	O
cases	O	O
of	O	O
severe	O	O
delayed	O	O
neurologic	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
related	O	O
to	O	O
the	O	O
administration	O	O
of	O	O
intrathecal	O	O
(	O	O
IT	O	O
)	O	O
combination	O	O
chemotherapy	O	O
including	O	O
thiotepa	B_Chemical	O
(	O	O
TSPA	B_Chemical	O
)	O	O
are	O	O
presented	O	O
.	O	O

Both	O	O
cases	O	O
developed	O	O
axonal	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
with	O	O
motor	O	O
predominance	O	O
in	O	O
the	O	O
lower	O	O
extremities	O	O
1	O	O
and	O	O
6	O	O
months	O	O
after	O	O
IT	O	O
chemotherapy	O	O
was	O	O
administered	O	O
.	O	O

Neurologic	B_Disease	B_Disease
toxicities	I_Disease	I_Disease
have	O	O
been	O	O
described	O	O
with	O	O
IT-methotrexate	O	B_Chemical
,	O	O
IT-cytosine	O	O
arabinoside	O	O
and	O	O
IT-TSPA	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
however	O	O
,	O	O
axonal	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
following	O	O
administration	O	O
of	O	O
these	O	O
three	O	O
agents	O	O
has	O	O
not	O	O
been	O	O
previously	O	O
described	O	O
.	O	O

In	O	O
spite	O	O
of	O	O
the	O	O
fact	O	O
that	O	O
TSPA	B_Chemical	O
is	O	O
a	O	O
useful	O	O
IT	O	O
agent	O	O
,	O	O
its	O	O
combination	O	O
with	O	O
MTX	B_Chemical	O
,	O	O
ara-C	B_Chemical	O
and	O	O
radiotherapy	O	O
could	O	O
cause	O	O
severe	O	O
neurotoxicity	B_Disease	B_Disease
.	O	O

This	O	O
unexpected	O	O
complication	O	O
indicates	O	O
the	O	O
need	O	O
for	O	O
further	O	O
toxicology	O	O
research	O	O
on	O	O
IT-TSPA	O	O
.	O	O

Effects	O	O
of	O	O
cromakalim	B_Chemical	B_Chemical
and	O	O
pinacidil	B_Chemical	O
on	O	O
large	O	O
epicardial	O	O
and	O	O
small	O	O
coronary	O	O
arteries	O	O
in	O	O
conscious	O	O
dogs	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
i.v	O	O
.	O	O

bolus	O	O
administration	O	O
of	O	O
cromakalim	B_Chemical	B_Chemical
(	O	O
1	O	O
-	O	O
10	O	O
micrograms/kg	O	O
)	O	O
and	O	O
pinacidil	B_Chemical	O
(	O	O
3	O	O
-	O	O
100	O	O
micrograms/kg	O	O
)	O	O
on	O	O
large	O	O
(	O	O
circumflex	O	O
artery	O	O
)	O	O
and	O	O
small	O	O
coronary	O	O
arteries	O	O
and	O	O
on	O	O
systemic	O	O
hemodynamics	O	O
were	O	O
investigated	O	O
in	O	O
chronically	O	O
instrumented	O	O
conscious	O	O
dogs	O	O
and	O	O
compared	O	O
to	O	O
those	O	O
of	O	O
nitroglycerin	B_Chemical	O
(	O	O
0.03	O	O
-	O	O
10	O	O
micrograms/kg	O	O
)	O	O
.	O	O

Nitroglycerin	B_Chemical	O
,	O	O
up	O	O
to	O	O
0.3	O	O
micrograms/kg	O	O
,	O	O
selectively	O	O
increased	O	O
circumflex	O	O
artery	O	O
diameter	O	O
(	O	O
CxAD	O	O
)	O	O
without	O	O
simultaneously	O	O
affecting	O	O
any	O	O
other	O	O
cardiac	O	O
or	O	O
systemic	O	O
hemodynamic	O	O
parameter	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
cromakalim	B_Chemical	B_Chemical
and	O	O
pinacidil	B_Chemical	O
at	O	O
all	O	O
doses	O	O
and	O	O
nitroglycerin	B_Chemical	O
at	O	O
doses	O	O
higher	O	O
than	O	O
0.3	O	O
micrograms/kg	O	O
simultaneously	O	O
and	O	O
dose-dependently	O	O
increased	O	O
CxAD	O	O
,	O	O
coronary	O	O
blood	O	O
flow	O	O
and	O	O
heart	O	O
rate	O	O
and	O	O
decreased	O	O
coronary	O	O
vascular	O	O
resistance	O	O
and	O	O
aortic	O	O
pressure	O	O
.	O	O

Cromakalim	B_Chemical	B_Chemical
was	O	O
approximately	O	O
8-	O	O
to	O	O
9.5-fold	O	O
more	O	O
potent	O	O
than	O	O
pinacidil	B_Chemical	O
in	O	O
increasing	O	O
CxAD	O	O
.	O	O

Vasodilation	O	O
of	O	O
large	O	O
and	O	O
small	O	O
coronary	O	O
vessels	O	O
and	O	O
hypotension	B_Disease	O
induced	O	O
by	O	O
cromakalim	B_Chemical	B_Chemical
and	O	O
pinacidil	B_Chemical	O
were	O	O
not	O	O
affected	O	O
by	O	O
prior	O	O
combined	O	O
beta	B_Chemical	O
adrenergic	I_Chemical	O
and	I_Chemical	O
muscarinic	B_Chemical	O
receptors	I_Chemical	O
blockade	I_Chemical	O
but	O	O
drug-induced	O	O
tachycardia	B_Disease	O
was	O	O
abolished	O	O
.	O	O

When	O	O
circumflex	O	O
artery	O	O
blood	O	O
flow	O	O
was	O	O
maintained	O	O
constant	O	O
,	O	O
the	O	O
increases	O	O
in	O	O
CxAD	O	O
induced	O	O
by	O	O
cromakalim	B_Chemical	O
(	O	O
10	O	O
micrograms/kg	O	O
)	O	O
,	O	O
pinacidil	B_Chemical	O
(	O	O
30	O	O
micrograms/kg	O	O
)	O	O
and	O	O
nitroglycerin	B_Chemical	O
(	O	O
10	O	O
micrograms/kg	O	O
)	O	O
were	O	O
reduced	O	O
by	O	O
68	O	O
+	O	O
/-	O	O
7	O	O
,	O	O
54	O	O
+	O	O
/-	O	O
9	O	O
and	O	O
1	O	O
+	O	O
/-	O	O
1	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

Thus	O	O
,	O	O
whereas	O	O
nitroglycerin	B_Chemical	O
preferentially	O	O
and	O	O
flow-independently	O	O
dilates	O	O
large	O	O
coronary	O	O
arteries	O	O
,	O	O
cromakalim	B_Chemical	O
and	O	O
pinacidil	B_Chemical	O
dilate	O	O
both	O	O
large	O	O
and	O	O
small	O	O
coronary	O	O
arteries	O	O
and	O	O
this	O	O
effect	O	O
is	O	O
not	O	O
dependent	O	O
upon	O	O
the	O	O
simultaneous	O	O
beta	O	O
adrenoceptors-mediated	O	O
rise	O	O
in	O	O
myocardial	O	O
metabolic	O	O
demand	O	O
.	O	O

Finally	O	O
,	O	O
two	O	O
mechanisms	O	O
at	O	O
least	O	O
,	O	O
direct	O	O
vasodilation	O	O
and	O	O
flow	O	O
dependency	O	O
,	O	O
are	O	O
involved	O	O
in	O	O
the	O	O
cromakalim-	O	O
and	O	O
pinacidil-induced	O	O
increase	O	O
in	O	O
CxAD	O	O
.	O	O

Mefenamic	O	O
acid-induced	O	O
neutropenia	B_Disease	O
and	O	O
renal	B_Disease	B_Disease
failure	I_Disease	I_Disease
in	O	O
elderly	O	O
females	O	O
with	O	O
hypothyroidism	B_Disease	O
.	O	O

We	O	O
report	O	O
mefenamic	O	O
acid-induced	O	O
non-oliguric	O	O
renal	B_Disease	B_Disease
failure	I_Disease	I_Disease
and	O	O
severe	O	O
neutropenia	B_Disease	O
occurring	O	O
simultaneously	O	O
in	O	O
two	O	O
elderly	O	O
females	O	O
.	O	O

The	O	O
neutropenia	B_Disease	O
was	O	O
due	O	O
to	O	O
maturation	O	O
arrest	O	O
of	O	O
the	O	O
myeloid	O	O
series	O	O
in	O	O
one	O	O
patient	O	O
.	O	O

Both	O	O
patients	O	O
were	O	O
also	O	O
hypothyroid	B_Disease	B_Disease
,	O	O
but	O	O
it	O	O
is	O	O
not	O	O
clear	O	O
whether	O	O
this	O	O
was	O	O
a	O	O
predisposing	O	O
factor	O	O
to	O	O
the	O	O
development	O	O
of	O	O
these	O	O
adverse	O	O
reactions	O	O
.	O	O

However	O	O
,	O	O
it	O	O
would	O	O
seem	O	O
prudent	O	O
not	O	O
to	O	O
use	O	O
mefenamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
in	O	O
hypothyroid	B_Disease	B_Disease
patients	O	O
until	O	O
the	O	O
hypothyroidism	B_Disease	O
has	O	O
been	O	O
corrected	O	O
.	O	O

Etiology	O	O
of	O	O
hypercalcemia	B_Disease	O
in	O	O
hemodialysis	O	O
patients	O	O
on	O	O
calcium	B_Chemical	B_Chemical
carbonate	I_Chemical	I_Chemical
therapy	O	O
.	O	O

Fourteen	O	O
of	O	O
39	O	O
dialysis	O	O
patients	O	O
(	O	O
36	O	O
%	O	O
)	O	O
became	O	O
hypercalcemic	B_Disease	B_Disease
after	O	O
switching	O	O
to	O	O
calcium	B_Chemical	O
carbonate	I_Chemical	O
as	O	O
their	O	O
principal	O	O
phosphate	B_Chemical	O
binder	O	O
.	O	O

In	O	O
order	O	O
to	O	O
identify	O	O
risk	O	O
factors	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
hypercalcemia	B_Disease	O
,	O	O
indirect	O	O
parameters	O	O
of	O	O
intestinal	O	O
calcium	B_Chemical	O
reabsorption	O	O
and	O	O
bone	O	O
turnover	O	O
rate	O	O
in	O	O
these	O	O
14	O	O
patients	O	O
were	O	O
compared	O	O
with	O	O
results	O	O
in	O	O
14	O	O
eucalcemic	O	O
patients	O	O
matched	O	O
for	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
length	O	O
of	O	O
time	O	O
on	O	O
dialysis	O	O
,	O	O
and	O	O
etiology	O	O
of	O	O
renal	B_Disease	B_Disease
disease	I_Disease	I_Disease
.	O	O

In	O	O
addition	O	O
to	O	O
experiencing	O	O
hypercalcemic	B_Disease	B_Disease
episodes	O	O
with	O	O
peak	O	O
calcium	B_Chemical	O
values	O	O
of	O	O
2.7	O	O
to	O	O
3.8	O	O
mmol/L	O	O
(	O	O
10.7	O	O
to	O	O
15.0	O	O
mg/dL	O	O
)	O	O
,	O	O
patients	O	O
in	O	O
the	O	O
hypercalcemic	B_Disease	B_Disease
group	O	O
exhibited	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
mean	O	O
calcium	B_Chemical	O
concentration	O	O
obtained	O	O
during	O	O
6	O	O
months	O	O
before	O	O
the	O	O
switch	O	O
,	O	O
compared	O	O
with	O	O
the	O	O
mean	O	O
value	O	O
obtained	O	O
during	O	O
the	O	O
7	O	O
months	O	O
of	O	O
observation	O	O
after	O	O
the	O	O
switch	O	O
(	O	O
2.4	O	O
+	O	O
/-	O	O
0.03	O	O
to	O	O
2.5	O	O
+	O	O
/-	O	O
0.03	O	O
mmol/L	O	O
[	O	O
9.7	O	O
+	O	O
/-	O	O
0.2	O	O
to	O	O
10.2	O	O
+	O	O
/-	O	O
0.1	O	O
mg/dL	O	O
]	O	O
,	O	O
P	O	O
=	O	O
0.006	O	O
)	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
eucalcemic	O	B_Disease
patients	O	O
exhibited	O	O
no	O	O
change	O	O
in	O	O
mean	O	O
calcium	B_Chemical	O
values	O	O
over	O	O
the	O	O
same	O	O
time	O	O
period	O	O
(	O	O
2.3	O	O
+	O	O
/-	O	O
0.05	O	O
to	O	O
2.3	O	O
+	O	O
/-	O	O
0.05	O	O
mmol/L	O	O
[	O	O
9.2	O	O
+	O	O
/-	O	O
0.2	O	O
to	O	O
9.2	O	O
+	O	O
/-	O	O
0.2	O	O
mg/dL	O	O
]	O	O
)	O	O
.	O	O

CaCO3	B_Chemical	O
dosage	O	O
,	O	O
calculated	O	O
dietary	O	O
calcium	B_Chemical	O
intake	O	O
,	O	O
and	O	O
circulating	O	O
levels	O	O
of	O	O
vitamin	B_Chemical	B_Chemical
D	I_Chemical	I_Chemical
metabolites	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Physical	O	O
activity	O	O
index	O	O
and	O	O
predialysis	O	O
serum	O	O
bicarbonate	B_Chemical	O
levels	O	O
also	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

However	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
in	O	O
parameters	O	O
reflecting	O	O
bone	O	O
turnover	O	O
rates	O	O
between	O	O
groups.(ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O

Late-onset	O	O
scleroderma	B_Disease	B_Disease
renal	I_Disease	I_Disease
crisis	I_Disease	I_Disease
induced	O	O
by	O	O
tacrolimus	B_Chemical	B_Chemical
and	O	O
prednisolone	B_Chemical	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

Scleroderma	B_Disease	B_Disease
renal	I_Disease	I_Disease
crisis	I_Disease	I_Disease
(	O	O
SRC	B_Disease	O
)	O	O
is	O	O
a	O	O
rare	O	O
complication	O	O
of	O	O
systemic	B_Disease	O
sclerosis	I_Disease	O
(	O	O
SSc	B_Disease	O
)	O	O
but	O	O
can	O	O
be	O	O
severe	O	O
enough	O	O
to	O	O
require	O	O
temporary	O	O
or	O	O
permanent	O	O
renal	O	O
replacement	O	O
therapy	O	O
.	O	O

Moderate	O	O
to	O	O
high	O	O
dose	O	O
corticosteroid	B_Chemical	O
use	O	O
is	O	O
recognized	O	O
as	O	O
a	O	O
major	O	O
risk	O	O
factor	O	O
for	O	O
SRC	B_Disease	O
.	O	O

Furthermore	O	O
,	O	O
there	O	O
have	O	O
been	O	O
reports	O	O
of	O	O
thrombotic	B_Disease	B_Disease
microangiopathy	I_Disease	I_Disease
precipitated	O	O
by	O	O
cyclosporine	B_Chemical	B_Chemical
in	O	O
patients	O	O
with	O	O
SSc	B_Disease	O
.	O	O

In	O	O
this	O	O
article	O	O
,	O	O
we	O	O
report	O	O
a	O	O
patient	O	O
with	O	O
SRC	B_Disease	O
induced	O	O
by	O	O
tacrolimus	B_Chemical	B_Chemical
and	O	O
corticosteroids	B_Chemical	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
work	O	O
is	O	O
to	O	O
call	O	O
attention	O	O
to	O	O
the	O	O
risk	O	O
of	O	O
tacrolimus	B_Chemical	B_Chemical
use	O	O
in	O	O
patients	O	O
with	O	O
SSc	B_Disease	O
.	O	O

Methyldopa-induced	O	O
hemolytic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
in	O	O
a	O	O
15	O	O
year	O	O
old	O	O
presenting	O	O
as	O	O
near-syncope	O	O
.	O	O

Methyldopa	B_Chemical	O
is	O	O
an	O	O
antihypertensive	O	O
medication	O	O
which	O	O
is	O	O
available	O	O
generically	O	O
and	O	O
under	O	O
the	O	O
trade	O	O
name	O	O
Aldomet	B_Chemical	O
that	O	O
is	O	O
widely	O	O
prescribed	O	O
in	O	O
the	O	O
adult	O	O
population	O	O
and	O	O
infrequently	O	O
used	O	O
in	O	O
children	O	O
.	O	O

Methyldopa	B_Chemical	O
causes	O	O
an	O	O
autoimmune	B_Disease	B_Disease
hemolytic	I_Disease	I_Disease
anemia	I_Disease	I_Disease
in	O	O
a	O	O
small	O	O
percentage	O	O
of	O	O
patients	O	O
who	O	O
take	O	O
the	O	O
drug	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
methyldopa-induced	O	O
hemolytic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
in	O	O
a	O	O
15-year-old	O	O
boy	O	O
who	O	O
presented	O	O
to	O	O
the	O	O
emergency	B_Disease	O
department	I_Disease	O
with	O	O
near-syncope	O	O
.	O	O

The	O	O
boy	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
intravenous	O	O
methyldopa	B_Chemical	O
during	O	O
a	O	O
trauma	B_Disease	O
admission	O	O
seven	O	O
weeks	O	O
prior	O	O
to	O	O
presentation	O	O
.	O	O

Evaluation	O	O
revealed	O	O
a	O	O
hemoglobin	O	O
of	O	O
three	O	O
grams	O	O
,	O	O
3	O	O
+	O	O
Coombs	O	O
'	O	O
test	O	O
with	O	O
polyspecific	O	O
anti-human	O	O
globulin	O	O
and	O	O
monospecific	O	O
IgG	O	O
reagents	O	O
,	O	O
and	O	O
a	O	O
warm	O	O
reacting	O	O
autoantibody	O	O
.	O	O

Transfusion	O	O
and	O	O
corticosteroid	B_Chemical	O
therapy	O	O
resulted	O	O
in	O	O
a	O	O
complete	O	O
recovery	O	O
of	O	O
the	O	O
patient	O	O
.	O	O

Emergency	O	O
physicians	O	O
treating	O	O
children	O	O
must	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
syndrome	O	O
in	O	O
order	O	O
to	O	O
diagnose	O	O
and	O	O
treat	O	O
it	O	O
correctly	O	O
.	O	O

A	O	O
brief	O	O
review	O	O
of	O	O
autoimmune	O	O
and	O	O
drug-induced	O	O
hemolytic	B_Disease	B_Disease
anemias	I_Disease	I_Disease
is	O	O
provided	O	O
.	O	O

The	O	O
risk	O	O
and	O	O
associated	O	O
factors	O	O
of	O	O
methamphetamine	B_Chemical	O
psychosis	B_Disease	O
in	O	O
methamphetamine-dependent	O	O
patients	O	O
in	O	O
Malaysia	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
risk	O	O
of	O	O
lifetime	O	O
and	O	O
current	O	O
methamphetamine-induced	O	O
psychosis	B_Disease	O
in	O	O
patients	O	O
with	O	O
methamphetamine	B_Chemical	O
dependence	O	O
.	O	O

The	O	O
association	O	O
between	O	O
psychiatric	O	O
co-morbidity	O	O
and	O	O
methamphetamine-induced	O	O
psychosis	B_Disease	O
was	O	O
also	O	O
studied	O	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
was	O	O
a	O	O
cross-sectional	O	O
study	O	O
conducted	O	O
concurrently	O	O
at	O	O
a	O	O
teaching	O	O
hospital	O	O
and	O	O
a	O	O
drug	O	O
rehabilitation	O	O
center	O	O
in	O	O
Malaysia	O	O
.	O	O

Patients	O	O
with	O	O
the	O	O
diagnosis	O	O
of	O	O
methamphetamine	B_Chemical	O
based	O	O
on	O	O
DSM-IV	O	O
were	O	O
interviewed	O	O
using	O	O
the	O	O
Mini	O	O
International	O	O
Neuropsychiatric	O	O
Interview	O	O
(	O	O
M.I.N.I.	O	O
)	O	O
for	O	O
methamphetamine-induced	O	O
psychosis	B_Disease	O
and	O	O
other	O	O
Axis	O	O
I	O	O
psychiatric	B_Disease	B_Disease
disorders	I_Disease	I_Disease
.	O	O

The	O	O
information	O	O
on	O	O
sociodemographic	O	O
background	O	O
and	O	O
drug	O	O
use	O	O
history	O	O
was	O	O
obtained	O	O
from	O	O
interview	O	O
or	O	O
medical	O	O
records	O	O
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
292	O	O
subjects	O	O
,	O	O
47.9	O	O
%	O	O
of	O	O
the	O	O
subjects	O	O
had	O	O
a	O	O
past	O	O
history	O	O
of	O	O
psychotic	B_Disease	B_Disease
symptoms	I_Disease	I_Disease
and	O	O
13.0	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
having	O	O
current	O	O
psychotic	B_Disease	B_Disease
symptoms	I_Disease	I_Disease
.	O	O

Co-morbid	O	O
major	O	O
depressive	B_Disease	B_Disease
disorder	I_Disease	I_Disease
(	O	O
OR=7.18	O	O
,	O	O
95	O	O
CI=2.612	O	O
-	O	O
19.708	O	O
)	O	O
,	O	O
bipolar	B_Disease	B_Disease
disorder	I_Disease	I_Disease
(	O	O
OR=13.807	O	O
,	O	O
95	O	O
CI=5.194	O	O
-	O	O
36.706	O	O
)	O	O
,	O	O
antisocial	B_Disease	B_Disease
personality	I_Disease	I_Disease
disorder	I_Disease	I_Disease
(	O	O
OR=12.619	O	O
,	O	O
95	O	O
CI=6.702	O	O
-	O	O
23.759	O	O
)	O	O
and	O	O
heavy	O	O
methamphetamine	B_Chemical	O
uses	O	O
were	O	O
significantly	O	O
associated	O	O
with	O	O
lifetime	O	O
methamphetamine-induced	O	O
psychosis	B_Disease	O
after	O	O
adjusted	O	O
for	O	O
other	O	O
factors	O	O
.	O	O

Major	B_Disease	B_Disease
depressive	I_Disease	I_Disease
disorder	I_Disease	I_Disease
(	O	O
OR=2.870	O	O
,	O	O
CI=1.154	O	O
-	O	O
7.142	O	O
)	O	O
and	O	O
antisocial	B_Disease	B_Disease
personality	I_Disease	I_Disease
disorder	I_Disease	I_Disease
(	O	O
OR=3.299	O	O
,	O	O
95	O	O
CI=1.375	O	O
-	O	O
7.914	O	O
)	O	O
were	O	O
the	O	O
only	O	O
factors	O	O
associated	O	O
with	O	O
current	O	O
psychosis	B_Disease	O
.	O	O

CONCLUSION	O	O
:	O	O
There	O	O
was	O	O
a	O	O
high	O	O
risk	O	O
of	O	O
psychosis	B_Disease	O
in	O	O
patients	O	O
with	O	O
methamphetamine	B_Chemical	O
dependence	O	O
.	O	O

It	O	O
was	O	O
associated	O	O
with	O	O
co-morbid	O	O
affective	B_Disease	O
disorder	I_Disease	O
,	O	O
antisocial	B_Disease	O
personality	I_Disease	O
,	O	O
and	O	O
heavy	O	O
methamphetamine	B_Chemical	O
use	O	O
.	O	O

It	O	O
is	O	O
recommended	O	O
that	O	O
all	O	O
cases	O	O
of	O	O
methamphetamine	B_Chemical	O
dependence	O	O
should	O	O
be	O	O
screened	O	O
for	O	O
psychotic	B_Disease	B_Disease
symptoms	I_Disease	I_Disease
.	O	O

Cerebellar	O	O
sensory	O	O
processing	O	O
alterations	O	O
impact	O	O
motor	O	O
cortical	O	O
plasticity	O	O
in	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
:	O	O
clues	O	O
from	O	O
dyskinetic	B_Disease	O
patients	O	O
.	O	O

The	O	O
plasticity	O	O
of	O	O
primary	O	O
motor	O	O
cortex	O	O
(	O	O
M1	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
(	O	O
PD	B_Disease	O
)	O	O
and	O	O
levodopa-induced	O	O
dyskinesias	B_Disease	O
(	O	O
LIDs	B_Disease	O
)	O	O
is	O	O
severely	O	B_Disease
impaired	O	I_Disease
.	O	O

We	O	O
recently	O	O
reported	O	O
in	O	O
young	O	O
healthy	O	O
subjects	O	O
that	O	O
inhibitory	O	O
cerebellar	O	O
stimulation	O	O
enhanced	O	O
the	O	O
sensorimotor	O	O
plasticity	O	O
of	O	O
M1	O	O
that	O	O
was	O	O
induced	O	O
by	O	O
paired	O	O
associative	O	O
stimulation	O	O
(	O	O
PAS	O	O
)	O	O
.	O	O

This	O	O
study	O	O
demonstrates	O	O
that	O	O
the	O	O
deficient	O	O
sensorimotor	O	O
M1	O	O
plasticity	O	O
in	O	O
16	O	O
patients	O	O
with	O	O
LIDs	B_Disease	O
could	O	O
be	O	O
reinstated	O	O
by	O	O
a	O	O
single	O	O
session	O	O
of	O	O
real	O	O
inhibitory	O	O
cerebellar	O	O
stimulation	O	O
but	O	O
not	O	O
sham	O	O
stimulation	O	O
.	O	O

This	O	O
was	O	O
evident	O	O
only	O	O
when	O	O
a	O	O
sensory	O	O
component	O	O
was	O	O
involved	O	O
in	O	O
the	O	O
induction	O	O
of	O	O
plasticity	O	O
,	O	O
indicating	O	O
that	O	O
cerebellar	O	O
sensory	O	O
processing	O	O
function	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
resurgence	O	O
of	O	O
M1	O	O
plasticity	O	O
.	O	O

The	O	O
benefit	O	O
of	O	O
inhibitory	O	O
cerebellar	O	O
stimulation	O	O
on	O	O
LIDs	B_Disease	O
is	O	O
known	O	O
.	O	O

To	O	O
explore	O	O
whether	O	O
this	O	O
benefit	O	O
is	O	O
linked	O	O
to	O	O
the	O	O
restoration	O	O
of	O	O
sensorimotor	O	O
plasticity	O	O
of	O	O
M1	O	O
,	O	O
we	O	O
conducted	O	O
an	O	O
additional	O	O
study	O	O
looking	O	O
at	O	O
changes	O	O
in	O	O
LIDs	B_Disease	O
and	O	O
PAS-induced	O	O
plasticity	O	O
after	O	O
10	O	O
sessions	O	O
of	O	O
either	O	O
bilateral	O	O
,	O	O
real	O	O
inhibitory	O	O
cerebellar	O	O
stimulation	O	O
or	O	O
sham	O	O
stimulation	O	O
.	O	O

Only	O	O
real	O	O
and	O	O
not	O	O
sham	O	O
stimulation	O	O
had	O	O
an	O	O
antidyskinetic	O	O
effect	O	O
and	O	O
it	O	O
was	O	O
paralleled	O	O
by	O	O
a	O	O
resurgence	O	O
in	O	O
the	O	O
sensorimotor	O	O
plasticity	O	O
of	O	O
M1	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
alterations	O	O
in	O	O
cerebellar	O	O
sensory	O	O
processing	O	O
function	O	O
,	O	O
occurring	O	O
secondary	O	O
to	O	O
abnormal	O	O
basal	O	O
ganglia	O	O
signals	O	O
reaching	O	O
it	O	O
,	O	O
may	O	O
be	O	O
an	O	O
important	O	O
element	O	O
contributing	O	O
to	O	O
the	O	O
maladaptive	O	B_Disease
sensorimotor	O	I_Disease
plasticity	O	I_Disease
of	O	O
M1	O	O
and	O	O
the	O	O
emergence	O	O
of	O	O
abnormal	B_Disease	O
involuntary	I_Disease	O
movements	I_Disease	O
.	O	O

The	O	O
long-term	O	O
safety	O	O
of	O	O
danazol	B_Chemical	B_Chemical
in	O	O
women	O	O
with	O	O
hereditary	B_Disease	O
angioedema	I_Disease	O
.	O	O

Although	O	O
the	O	O
short-term	O	O
safety	O	O
(	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
6	O	O
months	O	O
)	O	O
of	O	O
danazol	B_Chemical	B_Chemical
has	O	O
been	O	O
established	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
settings	O	O
,	O	O
no	O	O
information	O	O
exists	O	O
as	O	O
to	O	O
its	O	O
long-term	O	O
safety	O	O
.	O	O

We	O	O
therefore	O	O
investigated	O	O
the	O	O
long-term	O	O
safety	O	O
of	O	O
danazol	B_Chemical	B_Chemical
by	O	O
performing	O	O
a	O	O
retrospective	O	O
chart	O	O
review	O	O
of	O	O
60	O	O
female	O	O
patients	O	O
with	O	O
hereditary	B_Disease	O
angioedema	I_Disease	O
treated	O	O
with	O	O
danazol	B_Chemical	B_Chemical
for	O	O
a	O	O
continuous	O	O
period	O	O
of	O	O
6	O	O
months	O	O
or	O	O
longer	O	O
.	O	O

The	O	O
mean	O	O
age	O	O
of	O	O
the	O	O
patients	O	O
was	O	O
35.2	O	O
years	O	O
and	O	O
the	O	O
mean	O	O
duration	O	O
of	O	O
therapy	O	O
was	O	O
59.7	O	O
months	O	O
.	O	O

Virtually	O	O
all	O	O
patients	O	O
experienced	O	O
one	O	O
or	O	O
more	O	O
adverse	O	O
reactions	O	O
.	O	O

Menstrual	B_Disease	O
abnormalities	I_Disease	O
(	O	O
79	O	O
%	O	O
)	O	O
,	O	O
weight	B_Disease	O
gain	I_Disease	O
(	O	O
60	O	O
%	O	O
)	O	O
,	O	O
muscle	O	O
cramps/myalgias	O	O
(	O	O
40	O	O
%	O	O
)	O	O
,	O	O
and	O	O
transaminase	O	O
elevations	O	O
(	O	O
40	O	O
%	O	O
)	O	O
were	O	O
the	O	O
most	O	O
common	O	O
adverse	O	B_Disease
reactions	O	I_Disease
.	O	O

The	O	O
drug	O	O
was	O	O
discontinued	O	O
due	O	O
to	O	O
adverse	O	O
reactions	O	O
in	O	O
8	O	O
patients	O	O
.	O	O

No	O	O
patient	O	O
has	O	O
died	O	O
or	O	O
suffered	O	O
any	O	O
apparent	O	O
long-term	O	O
sequelae	O	O
that	O	O
were	O	O
directly	O	O
attributable	O	O
to	O	O
the	O	O
drug	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
,	O	O
despite	O	O
a	O	O
relatively	O	O
high	O	O
incidence	O	O
of	O	O
adverse	O	O
reactions	O	O
,	O	O
danazol	B_Chemical	B_Chemical
has	O	O
proven	O	O
to	O	O
be	O	O
remarkably	O	O
safe	O	O
over	O	O
the	O	O
long-term	O	O
in	O	O
this	O	O
group	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
function	O	O
of	O	O
P2X3	O	O
receptor	O	O
and	O	O
NK1	O	O
receptor	O	O
antagonists	O	O
on	O	O
cyclophosphamide-induced	O	O
cystitis	B_Disease	O
in	O	O
rats	O	O
.	O	O

PURPOSE	O	O
:	O	O
The	O	O
purpose	O	O
of	O	O
the	O	O
study	O	O
is	O	O
to	O	O
explore	O	O
the	O	O
function	O	O
of	O	O
P2X3	O	O
and	O	O
NK1	O	O
receptors	O	O
antagonists	O	O
on	O	O
cyclophosphamide	B_Chemical	B_Chemical
(CYP)-induced	O	O
cystitis	B_Disease	O
in	O	O
rats	O	O
.	O	O

METHODS	O	O
:	O	O
Sixty	O	O
female	O	O
Sprague-Dawley	O	O
(	O	O
SD	O	O
)	O	O
rats	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
.	O	O

The	O	O
rats	O	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
intraperitoneally	O	O
(	O	O
i.p	O	O
.	O	O
)	O	O
injected	O	O
with	O	O
0.9	O	O
%	O	O
saline	O	O
(	O	O
4	O	O
ml/kg	O	O
)	O	O
;	O	O
the	O	O
rats	O	O
in	O	O
the	O	O
model	O	O
group	O	O
were	O	O
i.p	O	O
.	O	O
injected	O	O
with	O	O
CYP	B_Chemical	O
(	O	O
150	O	O
mg/kg	O	O
)	O	O
;	O	O
and	O	O
the	O	O
rats	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
were	O	O
i.p	O	O
.	O	O
injected	O	O
with	O	O
CYP	B_Chemical	O
with	O	O
subsequently	O	O
perfusion	O	O
of	O	O
bladder	O	O
with	O	O
P2X3	O	O
and	O	O
NK1	O	O
receptors	O	O
'	O	O
antagonists	O	O
,	O	O
Suramin	B_Chemical	O
and	O	O
GR	B_Chemical	O
82334	I_Chemical	O
.	O	O

Spontaneous	O	O
pain	B_Disease	O
behaviors	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
CYP	B_Chemical	O
were	O	O
observed	O	O
.	O	O

Urodynamic	O	O
parameters	O	O
,	O	O
bladder	O	O
pressure-volume	O	O
curve	O	O
,	O	O
maximum	O	O
voiding	O	O
pressure	O	O
(	O	O
MVP	O	O
)	O	O
,	O	O
and	O	O
maximum	O	O
cystometric	O	O
capacity	O	O
(	O	O
MCC	O	O
)	O	O
,	O	O
were	O	O
recorded	O	O
.	O	O

Pathological	O	O
changes	O	O
in	O	O
bladder	O	O
tissue	O	O
were	O	O
observed	O	O
.	O	O

Immunofluorescence	O	O
was	O	O
used	O	O
to	O	O
detect	O	O
the	O	O
expression	O	O
of	O	O
P2X3	O	O
and	O	O
NK1	O	O
receptors	O	O
in	O	O
bladder	O	O
.	O	O

RESULTS	O	O
:	O	O
Cyclophosphamide	B_Chemical	B_Chemical
treatment	O	O
increased	O	O
the	O	O
spontaneous	O	O
pain	B_Disease	O
behaviors	O	O
scores	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
bladder	O	B_Disease
instability	O	I_Disease
during	O	O
urine	O	O
storage	O	O
period	O	O
of	O	O
model	O	O
group	O	O
was	O	O
significantly	O	O
higher	O	O
than	O	O
intervention	O	O
group	O	O
(	O	O
X(2	O	O
)	O	O
=	O	O
7.619	O	O
,	O	O
P	O	O
=	O	O
0.007	O	O
)	O	O
and	O	O
control	O	O
group	O	O
(	O	O
X(2	O	O
)	O	O
=	O	O
13.755	O	O
,	O	O
P	O	O
=	O	O
0.000	O	O
)	O	O
.	O	O

MCC	O	O
in	O	O
the	O	O
model	O	O
group	O	O
was	O	O
lower	O	O
than	O	O
the	O	O
control	O	O
and	O	O
intervention	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Histological	O	O
changes	O	O
evident	O	O
in	O	O
model	O	O
and	O	O
intervention	O	O
groups	O	O
rats	O	O
'	O	O
bladder	O	O
included	O	O
edema	B_Disease	O
,	O	O
vasodilation	O	O
,	O	O
and	O	O
infiltration	O	O
of	O	O
inflammatory	O	O
cells	O	O
.	O	O

In	O	O
model	O	O
group	O	O
,	O	O
the	O	O
expression	O	O
of	O	O
P2X3	O	O
receptor	O	O
increased	O	O
in	O	O
urothelium	O	O
and	O	O
suburothelium	O	O
,	O	O
and	O	O
NK1	O	O
receptor	O	O
increased	O	O
in	O	O
suburothelium	O	O
,	O	O
while	O	O
the	O	O
expression	O	O
of	O	O
them	O	O
in	O	O
intervention	O	O
group	O	O
was	O	O
lower	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
CYP-induced	O	O
cystitis	B_Disease	O
,	O	O
the	O	O
expression	O	O
of	O	O
P2X3	O	O
and	O	O
NK1	O	O
receptors	O	O
increased	O	O
in	O	O
urothelium	O	O
and/or	O	O
suburothelium	O	O
.	O	O

Perfusion	O	O
of	O	O
bladder	O	O
with	O	O
P2X3	O	O
and	O	O
NK1	O	O
receptors	O	O
antagonists	O	O
ameliorated	O	O
the	O	O
bladder	O	O
function	O	O
.	O	O

Patient	O	O
tolerance	O	O
study	O	O
of	O	O
topical	O	O
chlorhexidine	B_Chemical	B_Chemical
diphosphanilate	I_Chemical	I_Chemical
:	O	O
a	O	O
new	O	O
topical	O	O
agent	O	O
for	O	O
burns	B_Disease	O
.	O	O

Effective	O	O
topical	O	O
antimicrobial	O	O
agents	O	O
decrease	O	O
infection	B_Disease	O
and	O	O
mortality	O	O
in	O	O
burn	B_Disease	O
patients	O	O
.	O	O

Chlorhexidine	B_Chemical	B_Chemical
phosphanilate	I_Chemical	I_Chemical
(	O	O
CHP	B_Chemical	O
)	O	O
,	O	O
a	O	O
new	O	O
broad-spectrum	O	O
antimicrobial	O	O
agent	O	O
,	O	O
has	O	O
been	O	O
evaluated	O	O
as	O	O
a	O	O
topical	O	O
burn	B_Disease	O
wound	O	O
dressing	O	O
in	O	O
cream	O	O
form	O	O
,	O	O
but	O	O
preliminary	O	O
clinical	O	O
trials	O	O
reported	O	O
that	O	O
it	O	O
was	O	O
painful	O	O
upon	O	O
application	O	O
.	O	O

This	O	O
study	O	O
compared	O	O
various	O	O
concentrations	O	O
of	O	O
CHP	B_Chemical	O
to	O	O
determine	O	O
if	O	O
a	O	O
tolerable	O	O
concentration	O	O
could	O	O
be	O	O
identified	O	O
with	O	O
retention	O	O
of	O	O
antimicrobial	O	O
efficacy	O	O
.	O	O

Twenty-nine	O	O
burn	B_Disease	O
patients	O	O
,	O	O
each	O	O
with	O	O
two	O	O
similar	O	O
burns	B_Disease	O
which	O	O
could	O	O
be	O	O
separately	O	O
treated	O	O
,	O	O
were	O	O
given	O	O
pairs	O	O
of	O	O
treatments	O	O
at	O	O
successive	O	O
12-h	O	O
intervals	O	O
over	O	O
a	O	O
3-day	O	O
period	O	O
.	O	O

One	O	O
burn	B_Disease	O
site	O	O
was	O	O
treated	O	O
with	O	O
each	O	O
of	O	O
four	O	O
different	O	O
CHP	B_Chemical	O
concentrations	O	O
,	O	O
from	O	O
0.25	O	O
per	O	O
cent	O	O
to	O	O
2	O	O
per	O	O
cent	O	O
,	O	O
their	O	O
vehicle	O	O
,	O	O
and	O	O
1	O	O
per	O	O
cent	O	O
silver	B_Chemical	B_Chemical
sulphadiazine	I_Chemical	I_Chemical
(	O	O
AgSD	B_Chemical	O
)	O	O
cream	O	O
,	O	O
an	O	O
antimicrobial	O	O
agent	O	O
frequently	O	O
used	O	O
for	O	O
topical	O	O
treatment	O	O
of	O	O
burn	B_Disease	O
wounds	O	O
.	O	O

The	O	O
other	O	O
site	O	O
was	O	O
always	O	O
treated	O	O
with	O	O
AgSD	B_Chemical	O
cream	O	O
.	O	O

There	O	O
was	O	O
a	O	O
direct	O	O
relationship	O	O
between	O	O
CHP	B_Chemical	O
concentration	O	O
and	O	O
patients	O	O
'	O	O
ratings	O	O
of	O	O
pain	B_Disease	O
on	O	O
an	O	O
analogue	O	O
scale	O	O
.	O	O

The	O	O
0.25	O	O
per	O	O
cent	O	O
CHP	B_Chemical	O
cream	O	O
was	O	O
closest	O	O
to	O	O
AgSD	B_Chemical	O
in	O	O
pain	B_Disease	O
tolerance	O	O
;	O	O
however	O	O
,	O	O
none	O	O
of	O	O
the	O	O
treatments	O	O
differed	O	O
statistically	O	O
from	O	O
AgSD	B_Chemical	O
or	O	O
from	O	O
each	O	O
other	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
ease	O	O
of	O	O
application	O	O
of	O	O
CHP	B_Chemical	O
creams	O	O
was	O	O
less	O	O
satisfactory	O	O
than	O	O
that	O	O
of	O	O
AgSD	B_Chemical	O
.	O	O

It	O	O
was	O	O
concluded	O	O
that	O	O
formulations	O	O
at	O	O
or	O	O
below	O	O
0.5	O	O
per	O	O
cent	O	O
CHP	B_Chemical	O
may	O	O
prove	O	O
acceptable	O	O
for	O	O
wound	O	O
care	O	O
,	O	O
but	O	O
the	O	O
vehicle	O	O
system	O	O
needs	O	O
pharmaceutical	O	O
improvement	O	O
to	O	O
render	O	O
it	O	O
more	O	O
tolerable	O	O
and	O	O
easier	O	O
to	O	O
use	O	O
.	O	O

Acute	O	O
hepatitis	B_Disease	O
associated	O	O
with	O	O
clopidogrel	B_Chemical	B_Chemical
:	O	O
a	O	O
case	O	O
report	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O

Drug-induced	O	O
hepatotoxicity	B_Disease	B_Disease
is	O	O
a	O	O
common	O	O
cause	O	O
of	O	O
acute	O	O
hepatitis	B_Disease	O
,	O	O
and	O	O
the	O	O
recognition	O	O
of	O	O
the	O	O
responsible	O	O
drug	O	O
may	O	O
be	O	O
difficult	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
clopidogrel-related	O	O
acute	O	O
hepatitis	B_Disease	O
.	O	O

The	O	O
diagnosis	O	O
is	O	O
strongly	O	O
suggested	O	O
by	O	O
an	O	O
accurate	O	O
medical	O	O
history	O	O
and	O	O
liver	O	O
biopsy	O	O
.	O	O

Reports	O	O
about	O	O
cases	O	O
of	O	O
hepatotoxicity	B_Disease	B_Disease
due	O	O
to	O	O
clopidogrel	B_Chemical	B_Chemical
are	O	O
increasing	O	O
in	O	O
the	O	O
last	O	O
few	O	O
years	O	O
,	O	O
after	O	O
the	O	O
increased	O	O
use	O	O
of	O	O
this	O	O
drug	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
we	O	O
believe	O	O
that	O	O
physicians	O	O
should	O	O
carefully	O	O
consider	O	O
the	O	O
risk	O	O
of	O	O
drug-induced	O	O
hepatic	B_Disease	B_Disease
injury	I_Disease	I_Disease
when	O	O
clopidogrel	B_Chemical	B_Chemical
is	O	O
prescribed	O	O
.	O	O

Bortezomib	B_Chemical	O
and	O	O
dexamethasone	B_Chemical	O
as	O	O
salvage	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
relapsed/refractory	O	O
multiple	B_Disease	O
myeloma	I_Disease	O
:	O	O
analysis	O	O
of	O	O
long-term	O	O
clinical	O	O
outcomes	O	O
.	O	O

Bortezomib	B_Chemical	O
(bort)-dexamethasone	O	O
(	O	O
dex	B_Chemical	B_Chemical
)	O	O
is	O	O
an	O	O
effective	O	O
therapy	O	O
for	O	O
relapsed/refractory	O	O
(	O	O
R/R	O	O
)	O	O
multiple	B_Disease	B_Disease
myeloma	I_Disease	I_Disease
(	O	O
MM	B_Disease	O
)	O	O
.	O	O

This	O	O
retrospective	O	O
study	O	O
investigated	O	O
the	O	O
combination	O	O
of	O	O
bort	B_Chemical	O
(	O	O
1.3	O	O
mg/m(2	O	O
)	O	O
on	O	O
days	O	O
1	O	O
,	O	O
4	O	O
,	O	O
8	O	O
,	O	O
and	O	O
11	O	O
every	O	O
3	O	O
weeks	O	O
)	O	O
and	O	O
dex	B_Chemical	B_Chemical
(	O	O
20	O	O
mg	O	O
on	O	O
the	O	O
day	O	O
of	O	O
and	O	O
the	O	O
day	O	O
after	O	O
bort	B_Chemical	O
)	O	O
as	O	O
salvage	O	O
treatment	O	O
in	O	O
85	O	O
patients	O	O
with	O	O
R/R	O	O
MM	B_Disease	O
after	O	O
prior	O	O
autologous	O	O
stem	O	O
cell	O	O
transplantation	O	O
or	O	O
conventional	O	O
chemotherapy	O	O
.	O	O

The	O	O
median	O	O
number	O	O
of	O	O
prior	O	O
lines	O	O
of	O	O
therapy	O	O
was	O	O
2	O	O
.	O	O

Eighty-seven	O	O
percent	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
received	O	O
immunomodulatory	O	O
drugs	O	O
included	O	O
in	O	O
some	O	O
line	O	O
of	O	O
therapy	O	O
before	O	O
bort-dex	O	O
.	O	O

The	O	O
median	O	O
number	O	O
of	O	O
bort-dex	O	O
cycles	O	O
was	O	O
6	O	O
,	O	O
up	O	O
to	O	O
a	O	O
maximum	O	O
of	O	O
12	O	O
cycles	O	O
.	O	O

On	O	O
an	O	O
intention-to-treat	O	O
basis	O	O
,	O	O
55	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
achieved	O	O
at	O	O
least	O	O
partial	O	O
response	O	O
,	O	O
including	O	O
19	O	O
%	O	O
CR	O	O
and	O	O
35	O	O
%	O	O
achieved	O	O
at	O	O
least	O	O
very	O	O
good	O	O
partial	O	O
response	O	O
.	O	O

Median	O	O
durations	O	O
of	O	O
response	O	O
,	O	O
time	O	O
to	O	O
next	O	O
therapy	O	O
and	O	O
treatment-free	O	O
interval	O	O
were	O	O
8	O	O
,	O	O
11.2	O	O
,	O	O
and	O	O
5.1	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
most	O	O
relevant	O	O
adverse	O	O
event	O	O
was	O	O
peripheral	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
,	O	O
which	O	O
occurred	O	O
in	O	O
78	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
(	O	O
grade	O	O
II	O	O
,	O	O
38	O	O
%	O	O
;	O	O
grade	O	O
III	O	O
,	O	O
21	O	O
%	O	O
)	O	O
and	O	O
led	O	O
to	O	O
treatment	O	O
discontinuation	O	O
in	O	O
6	O	O
%	O	O
.	O	O

With	O	O
a	O	O
median	O	O
follow	O	O
up	O	O
of	O	O
22	O	O
months	O	O
,	O	O
median	O	O
time	O	O
to	O	O
progression	O	O
,	O	O
progression-free	O	O
survival	O	O
(	O	O
PFS	O	O
)	O	O
and	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
were	O	O
8.9	O	O
,	O	O
8.7	O	O
,	O	O
and	O	O
22	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O

Prolonged	O	O
PFS	O	O
and	O	O
OS	O	O
were	O	O
observed	O	O
in	O	O
patients	O	O
achieving	O	O
CR	O	O
and	O	O
receiving	O	O
bort-dex	O	B_Chemical
a	O	O
single	O	O
line	O	O
of	O	O
prior	O	O
therapy	O	O
.	O	O

Bort-dex	O	B_Chemical
was	O	O
an	O	O
effective	O	O
salvage	O	O
treatment	O	O
for	O	O
MM	B_Disease	O
patients	O	O
,	O	O
particularly	O	O
for	O	O
those	O	O
in	O	O
first	O	O
relapse	O	O
.	O	O

Pubertal	O	O
exposure	O	O
to	O	O
Bisphenol	B_Chemical	B_Chemical
A	I_Chemical	O
increases	O	O
anxiety-like	O	O
behavior	O	O
and	O	O
decreases	O	O
acetylcholinesterase	O	O
activity	O	O
of	O	O
hippocampus	O	O
in	O	O
adult	O	O
male	O	O
mice	O	O
.	O	O

The	O	O
negative	O	O
effects	O	O
of	O	O
Bisphenol	B_Chemical	B_Chemical
A	I_Chemical	O
(	O	O
BPA	B_Chemical	O
)	O	O
on	O	O
neurodevelopment	O	O
and	O	O
behaviors	O	O
have	O	O
been	O	O
well	O	O
established	O	O
.	O	O

Acetylcholinesterase	O	O
(	O	O
AChE	O	O
)	O	O
is	O	O
a	O	O
regulatory	O	O
enzyme	O	O
which	O	O
is	O	O
involved	O	O
in	O	O
anxiety-like	O	O
behavior	O	O
.	O	O

This	O	O
study	O	O
investigated	O	O
behavioral	O	O
phenotypes	O	O
and	O	O
AChE	O	O
activity	O	O
in	O	O
male	O	O
mice	O	O
following	O	O
BPA	B_Chemical	O
exposure	O	O
during	O	O
puberty	O	O
.	O	O

On	O	O
postnatal	O	O
day	O	O
(	O	O
PND	O	O
)	O	O
35	O	O
,	O	O
male	O	O
mice	O	O
were	O	O
exposed	O	O
to	O	O
50	O	O
mg	O	O
BPA/kg	O	O
diet	O	O
per	O	O
day	O	O
for	O	O
a	O	O
period	O	O
of	O	O
35	O	O
days	O	O
.	O	O

On	O	O
PND71	O	O
,	O	O
a	O	O
behavioral	O	O
assay	O	O
was	O	O
performed	O	O
using	O	O
the	O	O
elevated	O	O
plus	O	O
maze	O	O
(	O	O
EPM	O	O
)	O	O
and	O	O
the	O	O
light/dark	O	O
test	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
AChE	O	O
activity	O	O
was	O	O
measured	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
hypothalamus	O	O
,	O	O
cerebellum	O	O
and	O	O
hippocampus	O	O
.	O	O

Results	O	O
from	O	O
our	O	O
behavioral	O	O
phenotyping	O	O
indicated	O	O
that	O	O
anxiety-like	O	O
behavior	O	O
was	O	O
increased	O	O
in	O	O
mice	O	O
exposed	O	O
to	O	O
BPA	B_Chemical	O
.	O	O

AChE	O	O
activity	O	O
was	O	O
significantly	O	O
decreased	O	O
in	O	O
the	O	O
hippocampus	O	O
of	O	O
mice	O	O
with	O	O
BPA	B_Chemical	O
compared	O	O
to	O	O
control	O	O
mice	O	O
,	O	O
whereas	O	O
no	O	O
difference	O	O
was	O	O
found	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
hypothalamus	O	O
and	O	O
cerebellum	O	O
.	O	O

Our	O	O
findings	O	O
showed	O	O
that	O	O
pubertal	O	O
BPA	B_Chemical	O
exposure	O	O
increased	O	O
anxiety-like	O	O
behavior	O	O
,	O	O
which	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
decreased	O	O
AChE	O	O
activity	O	O
of	O	O
the	O	O
hippocampus	O	O
in	O	O
adult	O	O
male	O	O
mice	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
necessary	O	O
to	O	O
investigate	O	O
the	O	O
cholinergic	O	O
signaling	O	O
of	O	O
the	O	O
hippocampus	O	O
in	O	O
PBE	O	O
induced	O	O
anxiety-like	O	O
behaviors	O	O
.	O	O

Biochemical	O	O
effects	O	O
of	O	O
Solidago	O	B_Chemical
virgaurea	O	I_Chemical
extract	O	O
on	O	O
experimental	O	O
cardiotoxicity	O	B_Disease
.	O	O

Cardiovascular	B_Disease	O
diseases	I_Disease	O
(	O	O
CVDs	B_Disease	O
)	O	O
are	O	O
the	O	O
major	O	O
health	O	O
problem	O	O
of	O	O
advanced	O	O
as	O	O
well	O	O
as	O	O
developing	O	O
countries	O	O
of	O	O
the	O	O
world	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
protective	O	O
effect	O	O
of	O	O
the	O	O
Solidago	O	O
virgaurea	O	O
extract	O	O
on	O	O
isoproterenol-induced	O	O
cardiotoxicity	B_Disease	B_Disease
in	O	O
rats	O	O
.	O	O

The	O	O
subcutaneous	O	O
injection	O	O
of	O	O
isoproterenol	B_Chemical	O
(	O	O
30	O	O
mg/kg	O	O
)	O	O
into	O	O
rats	O	O
twice	O	O
at	O	O
an	O	O
interval	O	O
of	O	O
24	O	O
h	O	O
,	O	O
for	O	O
two	O	O
consecutive	O	O
days	O	O
,	O	O
led	O	O
to	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
serum	O	O
lactate	B_Chemical	B_Chemical
dehydrogenase	O	I_Chemical
,	O	O
creatine	B_Chemical	O
phosphokinase	O	O
,	O	O
alanine	B_Chemical	B_Chemical
transaminase	O	I_Chemical
,	O	O
aspartate	B_Chemical	B_Chemical
transaminase	O	O
,	O	O
and	O	O
angiotensin-converting	O	O
enzyme	O	O
activities	O	O
,	O	O
total	O	B_Chemical
cholesterol	B_Chemical	I_Chemical
,	O	O
triglycerides	B_Chemical	O
,	O	O
free	O	O
serum	O	B_Chemical
fatty	B_Chemical	I_Chemical
acid	I_Chemical	I_Chemical
,	O	O
cardiac	O	O
tissue	O	O
malondialdehyde	B_Chemical	B_Chemical
(	O	O
MDA	B_Chemical	O
)	O	O
,	O	O
and	O	O
nitric	B_Chemical	O
oxide	I_Chemical	O
levels	O	O
and	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
levels	O	O
of	O	O
glutathione	B_Chemical	B_Chemical
and	O	O
superoxide	B_Chemical	O
dismutase	O	O
in	O	O
cardiac	O	O
tissue	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
normal	O	O
control	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

Pretreatment	O	O
with	O	O
S.	O	O
virgaurea	O	O
extract	O	O
for	O	O
5	O	O
weeks	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
250	O	O
mg/kg	O	O
followed	O	O
by	O	O
isoproterenol	B_Chemical	O
injection	O	O
significantly	O	O
prevented	O	O
the	O	O
observed	O	O
alterations	O	O
.	O	O

Captopril	B_Chemical	O
(	O	O
50	O	O
mg/kg/day	O	O
,	O	O
given	O	O
orally	O	O
)	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
angiotensin-converting	O	O
enzyme	O	O
used	O	O
as	O	O
a	O	O
standard	O	O
cardioprotective	O	O
drug	O	O
,	O	O
was	O	O
used	O	O
as	O	O
a	O	O
positive	O	O
control	O	O
in	O	O
this	O	O
study	O	O
.	O	O

The	O	O
data	O	O
of	O	O
the	O	O
present	O	O
study	O	O
suggest	O	O
that	O	O
S.	O	O
virgaurea	O	O
extract	O	O
exerts	O	O
its	O	O
protective	O	O
effect	O	O
by	O	O
decreasing	O	O
MDA	B_Chemical	O
level	O	O
and	O	O
increasing	O	O
the	O	O
antioxidant	O	O
status	O	O
in	O	O
isoproterenol-treated	O	O
rats	O	O
.	O	O

The	O	O
study	O	O
emphasizes	O	O
the	O	O
beneficial	O	O
action	O	O
of	O	O
S.	O	O
virgaurea	O	B_Chemical
extract	O	O
as	O	O
a	O	O
cardioprotective	O	O
agent	O	O
.	O	O

"	O	O
Real-world	O	O
"	O	O
data	O	O
on	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
lenalidomide	B_Chemical	B_Chemical
and	O	O
dexamethasone	B_Chemical	O
in	O	O
patients	O	O
with	O	O
relapsed/refractory	O	O
multiple	B_Disease	B_Disease
myeloma	I_Disease	I_Disease
who	O	O
were	O	O
treated	O	O
according	O	O
to	O	O
the	O	O
standard	O	O
clinical	O	O
practice	O	O
:	O	O
a	O	O
study	O	O
of	O	O
the	O	O
Greek	O	O
Myeloma	B_Disease	O
Study	O	O
Group	O	O
.	O	O

Lenalidomide	B_Chemical	B_Chemical
and	O	O
dexamethasone	B_Chemical	O
(	O	O
RD	B_Chemical	O
)	O	O
is	O	O
a	O	O
standard	O	O
of	O	O
care	O	O
for	O	O
relapsed/refractory	O	O
multiple	B_Disease	O
myeloma	I_Disease	O
(	O	O
RRMM	B_Disease	O
)	O	O
,	O	O
but	O	O
there	O	O
is	O	O
limited	O	O
published	O	O
data	O	O
on	O	O
its	O	O
efficacy	O	O
and	O	O
safety	O	O
in	O	O
the	O	O
"	O	O
real	O	O
world	O	O
"	O	O
(	O	O
RW	O	O
)	O	O
,	O	O
according	O	O
to	O	O
the	O	O
International	O	O
Society	O	O
of	O	O
Pharmacoeconomics	O	O
and	O	O
Outcomes	O	O
Research	O	O
definition	O	O
.	O	O

We	O	O
studied	O	O
212	O	O
RRMM	B_Disease	O
patients	O	O
who	O	O
received	O	O
RD	B_Chemical	O
in	O	O
RW	O	O
.	O	O

Objective	O	O
response	O	O
(	O	O
>	O	O
PR	O	O
(	O	O
partial	O	O
response	O	O
)	O	O
)	O	O
rate	O	O
was	O	O
77.4	O	O
%	O	O
(	O	O
complete	O	O
response	O	O
(	O	O
CR	O	O
)	O	O
,	O	O
20.2	O	O
%	O	O
)	O	O
.	O	O

Median	O	O
time	O	O
to	O	O
first	O	O
and	O	O
best	O	O
response	O	O
was	O	O
2	O	O
and	O	O
5	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O

Median	O	O
time	O	O
to	O	O
CR	O	O
when	O	O
RD	B_Chemical	O
was	O	O
given	O	O
as	O	O
2nd	O	O
or	O	O
>	O	O
2(nd)-line	O	O
treatment	O	O
at	O	O
4	O	O
and	O	O
11	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O

Quality	O	O
of	O	O
response	O	O
was	O	O
independent	O	O
of	O	O
previous	O	O
lines	O	O
of	O	O
therapies	O	O
or	O	O
previous	O	O
exposure	O	O
to	O	O
thalidomide	B_Chemical	O
or	O	O
bortezomib	B_Chemical	O
.	O	O

Median	O	O
duration	O	O
of	O	O
response	O	O
was	O	O
34.4	O	O
months	O	O
,	O	O
and	O	O
it	O	O
was	O	O
higher	O	O
in	O	O
patients	O	O
who	O	O
received	O	O
RD	B_Chemical	O
until	O	O
progression	O	O
(	O	O
not	O	O
reached	O	O
versus	O	O
19	O	O
months	O	O
,	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Improvement	O	O
of	O	O
humoral	O	O
immunity	O	O
occurred	O	O
in	O	O
60	O	O
%	O	O
of	O	O
responders	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
and	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
patients	O	O
who	O	O
achieved	O	O
stable	O	O
disease	O	O
.	O	O

Adverse	O	O
events	O	O
were	O	O
reported	O	O
in	O	O
68.9	O	O
%	O	O
of	O	O
patients	O	O
(	O	O
myelosuppression	B_Disease	B_Disease
in	O	O
49.4	O	O
%	O	O
)	O	O
and	O	O
12.7	O	O
%	O	O
of	O	O
patients	O	O
needed	O	O
hospitalization	O	O
.	O	O

Peripheral	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
was	O	O
observed	O	O
only	O	O
in	O	O
2.5	O	O
%	O	O
of	O	O
patients	O	O
and	O	O
deep	B_Disease	O
vein	I_Disease	O
thrombosis	I_Disease	O
in	O	O
5.7	O	O
%	O	O
.	O	O

Dose	O	O
reductions	O	O
were	O	O
needed	O	O
in	O	O
31	O	O
%	O	O
of	O	O
patients	O	O
and	O	O
permanent	O	O
discontinuation	O	O
in	O	O
38.9	O	O
%	O	O
.	O	O

Median	O	O
time	O	O
to	O	O
treatment	O	O
discontinuation	O	O
was	O	O
16.8	O	O
months	O	O
.	O	O

Performance	O	O
status	O	O
(	O	O
PS	O	O
)	O	O
and	O	O
initial	O	O
lenalidomide	B_Chemical	B_Chemical
dose	O	O
predicted	O	O
for	O	O
treatment	O	O
discontinuation	O	O
.	O	O

Extra-medullary	O	O
relapses	O	O
occurred	O	O
in	O	O
3.8	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

Our	O	O
study	O	O
confirms	O	O
that	O	O
RD	B_Chemical	O
is	O	O
effective	O	O
and	O	O
safe	O	O
in	O	O
RRMM	B_Disease	O
in	O	O
the	O	O
RW	O	O
;	O	O
it	O	O
produces	O	O
durable	O	O
responses	O	O
especially	O	O
in	O	O
patients	O	O
who	O	O
continue	O	O
on	O	O
treatment	O	O
till	O	O
progression	O	O
and	O	O
improves	O	O
humoral	O	O
immunity	O	O
even	O	O
in	O	O
patients	O	O
with	O	O
stable	O	O
disease	O	O
.	O	O

The	O	O
cytogenetic	O	O
action	O	O
of	O	O
ifosfamide	B_Chemical	B_Chemical
,	O	O
mesna	B_Chemical	B_Chemical
,	O	O
and	O	O
their	O	O
combination	O	O
on	O	O
peripheral	O	O
rabbit	O	O
lymphocytes	O	O
:	O	O
an	O	O
in	O	O
vivo/in	O	O
vitro	O	O
cytogenetic	O	O
study	O	O
.	O	O

Ifosfamide	B_Chemical	B_Chemical
(	O	O
IFO	B_Chemical	B_Chemical
)	O	O
is	O	O
an	O	O
alkylating	O	O
nitrogen	B_Chemical	O
mustard	O	O
,	O	O
administrated	O	O
as	O	O
an	O	O
antineoplasmic	O	O
agent	O	O
.	O	O

It	O	O
is	O	O
characterized	O	O
by	O	O
its	O	O
intense	O	O
urotoxic	O	O
action	O	O
,	O	O
leading	O	O
to	O	O
hemorrhagic	B_Disease	B_Disease
cystitis	B_Disease	I_Disease
.	O	O

This	O	O
side	O	O
effect	O	O
of	O	O
IFO	B_Chemical	O
raises	O	O
the	O	O
requirement	O	O
for	O	O
the	O	O
co-administration	O	O
with	O	O
sodium	B_Chemical	B_Chemical
2-sulfanylethanesulfonate	I_Chemical	I_Chemical
(	O	O
Mesna	B_Chemical	B_Chemical
)	O	O
aiming	O	O
to	O	O
avoid	O	O
or	O	O
minimize	O	O
this	O	O
effect	O	O
.	O	O

IFO	B_Chemical	O
and	O	O
Mesna	B_Chemical	B_Chemical
were	O	O
administrated	O	O
separately	O	O
on	O	O
rabbit	O	O
's	O	O
lymphocytes	O	O
in	O	O
vivo	O	O
,	O	O
which	O	O
were	O	O
later	O	O
developed	O	O
in	O	O
vitro	O	O
.	O	O

Cytogenetic	O	O
markers	O	O
for	O	O
sister	O	O
chromatid	O	O
exchanges	O	O
(	O	O
SCEs	O	O
)	O	O
,	O	O
proliferation	O	O
rate	O	O
index	O	O
(	O	O
PRI	O	O
)	O	O
and	O	O
Mitotic	O	O
Index	O	O
were	O	O
recorded	O	O
.	O	O

Mesna	B_Chemical	B_Chemical
's	O	O
action	O	O
,	O	O
in	O	O
conjunction	O	O
with	O	O
IFO	B_Chemical	O
reduces	O	O
the	O	O
frequency	O	O
of	O	O
SCEs	O	O
,	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
SCEs	O	O
recordings	O	O
obtained	O	O
when	O	O
IFO	B_Chemical	O
is	O	O
administered	O	O
alone	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
this	O	O
,	O	O
when	O	O
high	O	O
concentrations	O	O
of	O	O
Mesna	B_Chemical	B_Chemical
were	O	O
administered	O	O
alone	O	O
significant	O	O
reductions	O	O
of	O	O
the	O	O
PRI	O	O
were	O	O
noted	O	O
,	O	O
than	O	O
with	O	O
IFO	B_Chemical	B_Chemical
acting	O	O
at	O	O
the	O	O
same	O	O
concentration	O	O
on	O	O
the	O	O
lymphocytes	O	O
.	O	O

Mesna	B_Chemical	B_Chemical
significantly	O	O
reduces	O	O
IFO	B_Chemical	O
's	O	O
genotoxicity	B_Disease	B_Disease
,	O	O
while	O	O
when	O	O
administered	O	O
in	O	O
high	O	O
concentrations	O	O
it	O	O
acts	O	O
in	O	O
an	O	O
inhibitory	O	O
fashion	O	O
on	O	O
the	O	O
cytostatic	O	O
action	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

Risk	O	O
factors	O	O
and	O	O
predictors	O	O
of	O	O
levodopa-induced	O	O
dyskinesia	B_Disease	O
among	O	O
multiethnic	O	O
Malaysians	O	O
with	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
.	O	O

Chronic	O	O
pulsatile	O	O
levodopa	B_Chemical	O
therapy	O	O
for	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
(	O	O
PD	B_Disease	O
)	O	O
leads	O	O
to	O	O
the	O	O
development	O	O
of	O	O
motor	O	O
fluctuations	O	O
and	O	O
dyskinesia	B_Disease	O
.	O	O

We	O	O
studied	O	O
the	O	O
prevalence	O	O
and	O	O
predictors	O	O
of	O	O
levodopa-induced	O	O
dyskinesia	B_Disease	O
among	O	O
multiethnic	O	O
Malaysian	O	O
patients	O	O
with	O	O
PD	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
is	O	O
a	O	O
cross-sectional	O	O
study	O	O
involving	O	O
95	O	O
patients	O	O
with	O	O
PD	B_Disease	O
on	O	O
uninterrupted	O	O
levodopa	B_Chemical	O
therapy	O	O
for	O	O
at	O	O
least	O	O
6	O	O
months	O	O
.	O	O

The	O	O
instrument	O	O
used	O	O
was	O	O
the	O	O
UPDRS	O	O
questionnaires	O	O
.	O	O

The	O	O
predictors	O	O
of	O	O
dyskinesia	B_Disease	O
were	O	O
determined	O	O
using	O	O
multivariate	O	O
logistic	O	O
regression	O	O
analysis	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
mean	O	O
age	O	O
was	O	O
65.6	O	O
+	O	O
8.5	O	O
years	O	O
.	O	O

The	O	O
mean	O	O
onset	O	O
age	O	O
was	O	O
58.5	O	O
+	O	O
9.8	O	O
years	O	O
.	O	O

The	O	O
median	O	O
disease	O	O
duration	O	O
was	O	O
6	O	O
(	O	O
7	O	O
)	O	O
years	O	O
.	O	O

Dyskinesia	B_Disease	O
was	O	O
present	O	O
in	O	O
44	O	O
%	O	O
(	O	O
n	O	O
=	O	O
42	O	O
)	O	O
with	O	O
median	O	O
levodopa	B_Chemical	O
therapy	O	O
of	O	O
3	O	O
years	O	O
.	O	O

There	O	O
were	O	O
64.3	O	O
%	O	O
Chinese	O	O
,	O	O
31	O	O
%	O	O
Malays	O	O
,	O	O
and	O	O
3.7	O	O
%	O	O
Indians	O	O
and	O	O
other	O	O
ethnic	O	O
groups	O	O
.	O	O

Eighty-one	O	O
percent	O	O
of	O	O
patients	O	O
with	O	O
dyskinesia	B_Disease	O
had	O	O
clinical	O	O
fluctuations	O	O
.	O	O

Patients	O	O
with	O	O
dyskinesia	B_Disease	O
had	O	O
lower	O	O
onset	O	O
age	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
longer	O	O
duration	O	O
of	O	O
levodopa	B_Chemical	O
therapy	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
longer	O	O
disease	O	O
duration	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
higher	O	O
total	O	O
daily	O	O
levodopa	B_Chemical	O
dose	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
and	O	O
higher	O	O
total	O	O
UPDRS	O	O
scores	O	O
(	O	O
p	O	O
=	O	O
0.005	O	O
)	O	O
than	O	O
patients	O	O
without	O	O
dyskinesia	B_Disease	O
.	O	O

The	O	O
three	O	O
significant	O	O
predictors	O	O
of	O	O
dyskinesia	B_Disease	O
were	O	O
duration	O	O
of	O	O
levodopa	B_Chemical	O
therapy	O	O
,	O	O
onset	O	O
age	O	O
,	O	O
and	O	O
total	O	O
daily	O	O
levodopa	B_Chemical	O
dose	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
prevalence	O	O
of	O	O
levodopa-induced	O	O
dyskinesia	B_Disease	O
in	O	O
our	O	O
patients	O	O
was	O	O
44	O	O
%	O	O
.	O	O

The	O	O
most	O	O
significant	O	O
predictors	O	O
were	O	O
duration	O	O
of	O	O
levodopa	B_Chemical	O
therapy	O	O
,	O	O
total	O	O
daily	O	O
levodopa	B_Chemical	O
dose	O	O
,	O	O
and	O	O
onset	O	O
age	O	O
.	O	O

Dose-dependent	O	O
neurotoxicity	B_Disease	B_Disease
of	O	O
high-dose	O	B_Chemical
busulfan	B_Chemical	I_Chemical
in	O	O
children	O	O
:	O	O
a	O	O
clinical	O	O
and	O	O
pharmacological	O	O
study	O	O
.	O	O

Busulfan	B_Chemical	B_Chemical
is	O	O
known	O	O
to	O	O
be	O	O
neurotoxic	B_Disease	O
in	O	O
animals	O	O
and	O	O
humans	O	O
,	O	O
but	O	O
its	O	O
acute	O	O
neurotoxicity	B_Disease	B_Disease
remains	O	O
poorly	O	O
characterized	O	O
in	O	O
children	O	O
.	O	O

We	O	O
report	O	O
here	O	O
a	O	O
retrospective	O	O
study	O	O
of	O	O
123	O	O
children	O	O
(	O	O
median	O	O
age	O	O
,	O	O
6.5	O	O
years	O	O
)	O	O
receiving	O	O
high-dose	O	O
busulfan	B_Chemical	O
in	O	O
combined	O	O
chemotherapy	O	O
before	O	O
bone	O	O
marrow	O	O
transplantation	O	O
for	O	O
malignant	O	O
solid	O	O
tumors	B_Disease	O
,	O	O
brain	B_Disease	O
tumors	I_Disease	O
excluded	O	O
.	O	O

Busulfan	B_Chemical	B_Chemical
was	O	O
given	O	O
p.o	O	O
.	O	O
,	O	O
every	O	O
6	O	O
hours	O	O
for	O	O
16	O	O
doses	O	O
over	O	O
4	O	O
days	O	O
.	O	O

Two	O	O
total	O	O
doses	O	O
were	O	O
consecutively	O	O
used	O	O
:	O	O
16	O	O
mg/kg	O	O
,	O	O
then	O	O
600	O	O
mg/m2	O	O
.	O	O

The	O	O
dose	O	O
calculation	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
body	O	O
surface	O	O
area	O	O
results	O	O
in	O	O
higher	O	O
doses	O	O
in	O	O
young	O	O
children	O	O
than	O	O
in	O	O
older	O	O
patients	O	O
(	O	O
16	O	O
to	O	O
28	O	O
mg/kg	O	O
)	O	O
.	O	O

Ninety-six	O	O
patients	O	O
were	O	O
not	O	O
given	O	O
anticonvulsive	O	O
prophylaxis	O	O
;	O	O
7	O	O
(	O	O
7.5	O	O
%	O	O
)	O	O
developed	O	O
seizures	B_Disease	O
during	O	O
the	O	O
4	O	O
days	O	O
of	O	O
the	O	O
busulfan	B_Chemical	B_Chemical
course	O	O
or	O	O
within	O	O
24	O	O
h	O	O
after	O	O
the	O	O
last	O	O
dosing	O	O
.	O	O

When	O	O
the	O	O
total	O	O
busulfan	B_Chemical	B_Chemical
dose	O	O
was	O	O
taken	O	O
into	O	O
account	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
in	O	O
terms	O	O
of	O	O
neurotoxicity	B_Disease	B_Disease
incidence	O	O
among	O	O
patients	O	O
under	O	O
16	O	O
mg/kg	O	O
(	O	O
1	O	O
of	O	O
57	O	O
,	O	O
1.7	O	O
%	O	O
)	O	O
and	O	O
patients	O	O
under	O	O
600	O	O
mg/m2	O	O
(	O	O
6	O	O
of	O	O
39	O	O
,	O	O
15.4	O	O
%	O	O
)	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.02	O	O
)	O	O
.	O	O

Twenty-seven	O	O
patients	O	O
were	O	O
given	O	O
a	O	O
600-mg/m2	O	O
busulfan	B_Chemical	B_Chemical
total	O	O
dose	O	O
with	O	O
continuous	O	O
i.v	O	O
.	O	O

infusion	O	O
of	O	O
clonazepam	B_Chemical	B_Chemical
;	O	O
none	O	O
had	O	O
any	O	O
neurological	B_Disease	B_Disease
symptoms	I_Disease	I_Disease
.	O	O

Busulfan	B_Chemical	B_Chemical
levels	O	O
were	O	O
measured	O	O
by	O	O
a	O	O
gas	O	O
chromatographic-mass	O	O
spectrometry	O	O
assay	O	O
in	O	O
the	O	O
plasma	O	O
and	O	O
cerebrospinal	O	O
fluid	O	O
of	O	O
9	O	O
children	O	O
without	O	O
central	B_Disease	O
nervous	I_Disease	O
system	I_Disease	O
disease	I_Disease	O
under	O	O
600	O	O
mg/m2	O	O
busulfan	B_Chemical	B_Chemical
with	O	O
clonazepam	B_Chemical	B_Chemical
:	O	O
busulfan	B_Chemical	B_Chemical
cerebrospinal	O	O
fluid	O	O
:	O	O
plasma	O	O
ratio	O	O
was	O	O
1.39	O	O
.	O	O

This	O	O
was	O	O
significantly	O	O
different	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.02	O	O
)	O	O
from	O	O
the	O	O
cerebrospinal	O	O
fluid	O	O
:	O	O
plasma	O	O
ratio	O	O
previously	O	O
defined	O	O
in	O	O
children	O	O
receiving	O	O
a	O	O
16-mg/kg	O	O
total	O	O
dose	O	O
of	O	O
busulfan	B_Chemical	B_Chemical
.	O	O

This	O	O
study	O	O
shows	O	O
that	O	O
busulfan	B_Chemical	O
neurotoxicity	B_Disease	O
is	O	O
dose-dependent	O	O
in	O	O
children	O	O
and	O	O
efficiently	O	O
prevented	O	O
by	O	O
clonazepam	B_Chemical	B_Chemical
.	O	O

A	O	O
busulfan	B_Chemical	B_Chemical
dose	O	O
calculated	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
body	O	O
surface	O	O
area	O	O
,	O	O
resulting	O	O
in	O	O
higher	O	O
doses	O	O
in	O	O
young	O	O
children	O	O
,	O	O
was	O	O
followed	O	O
by	O	O
increased	O	O
neurotoxicity	B_Disease	B_Disease
,	O	O
close	O	O
to	O	O
neurotoxicity	B_Disease	B_Disease
incidence	O	O
observed	O	O
in	O	O
adults	O	O
.	O	O

Since	O	O
plasma	O	O
pharmacokinetic	O	O
studies	O	O
showed	O	O
a	O	O
faster	O	O
busulfan	B_Chemical	B_Chemical
clearance	O	O
in	O	O
children	O	O
than	O	O
in	O	O
adults	O	O
,	O	O
this	O	O
new	O	O
dose	O	O
may	O	O
approximate	O	O
more	O	O
closely	O	O
the	O	O
adult	O	O
systemic	O	O
exposure	O	O
obtained	O	O
after	O	O
the	O	O
usual	O	O
16-mg/kg	O	O
total	O	O
dose	O	O
,	O	O
with	O	O
potential	O	O
inferences	O	O
in	O	O
terms	O	O
of	O	O
anticancer	O	O
or	O	O
myeloablative	O	O
effects	O	O
.	O	O

The	O	O
busulfan	B_Chemical	B_Chemical
dose	O	O
in	O	O
children	O	O
and	O	O
infants	O	O
undergoing	O	O
bone	O	O
marrow	O	O
transplantation	O	O
should	O	O
be	O	O
reconsidered	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
pharmacokinetic	O	O
studies	O	O
.	O	O

An	O	O
unexpected	O	O
diagnosis	O	O
in	O	O
a	O	O
renal-transplant	O	O
patient	O	O
with	O	O
proteinuria	B_Disease	O
treated	O	O
with	O	O
everolimus	B_Chemical	B_Chemical
:	O	O
AL	B_Disease	O
amyloidosis	B_Disease	O
.	O	O

Proteinuria	B_Disease	O
is	O	O
an	O	O
expected	O	O
complication	O	O
in	O	O
transplant	O	O
patients	O	O
treated	O	O
with	O	O
mammalian	O	O
target	O	O
of	O	O
rapamycin	B_Chemical	B_Chemical
inhibitors	O	O
(	O	O
mTOR-i	O	O
)	O	O
.	O	O

However	O	O
,	O	O
clinical	O	O
suspicion	O	O
should	O	O
always	O	O
be	O	O
supported	O	O
by	O	O
histological	O	O
evidence	O	O
in	O	O
order	O	O
to	O	O
investigate	O	O
potential	O	O
alternate	O	O
diagnoses	O	O
such	O	O
as	O	O
acute	O	O
or	O	O
chronic	O	O
rejection	O	O
,	O	O
interstitial	O	B_Disease
fibrosis	B_Disease	I_Disease
and	O	O
tubular	O	O
atrophy	B_Disease	O
,	O	O
or	O	O
recurrent	O	O
or	O	O
de	O	O
novo	O	O
glomerulopathy	B_Disease	B_Disease
.	O	O

In	O	O
this	O	O
case	O	O
we	O	O
report	O	O
the	O	O
unexpected	O	O
diagnosis	O	O
of	O	O
amyloidosis	B_Disease	O
in	O	O
a	O	O
renal-transplant	O	O
patient	O	O
with	O	O
pre-transplant	O	O
monoclonal	O	O
gammapathy	O	O
of	O	O
undetermined	O	O
significance	O	O
who	O	O
developed	O	O
proteinuria	B_Disease	O
after	O	O
conversion	O	O
from	O	O
tacrolimus	B_Chemical	B_Chemical
to	O	O
everolimus	B_Chemical	B_Chemical
.	O	O

Long-term	O	O
oral	O	O
galactose	B_Chemical	O
treatment	O	O
prevents	O	O
cognitive	B_Disease	B_Disease
deficits	I_Disease	I_Disease
in	O	O
male	O	O
Wistar	O	O
rats	O	O
treated	O	O
intracerebroventricularly	O	O
with	O	O
streptozotocin	B_Chemical	B_Chemical
.	O	O

Basic	O	O
and	O	O
clinical	O	O
research	O	O
has	O	O
demonstrated	O	O
that	O	O
dementia	B_Disease	O
of	O	O
sporadic	O	O
Alzheimer	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
(	O	O
sAD	O	O
)	O	O
type	O	O
is	O	O
associated	O	O
with	O	O
dysfunction	O	O
of	O	O
the	O	O
insulin-receptor	O	O
(	O	O
IR	O	O
)	O	O
system	O	O
followed	O	O
by	O	O
decreased	O	O
glucose	B_Chemical	O
transport	O	O
via	O	O
glucose	B_Chemical	O
transporter	O	O
GLUT4	O	O
and	O	O
decreased	O	O
glucose	B_Chemical	O
metabolism	O	O
in	O	O
brain	O	O
cells	O	O
.	O	O

An	O	O
alternative	O	O
source	O	O
of	O	O
energy	O	O
is	O	O
d-galactose	B_Chemical	B_Chemical
(	O	O
the	O	O
C-4-epimer	O	O
of	O	O
d-glucose	B_Chemical	B_Chemical
)	O	O
which	O	O
is	O	O
transported	O	O
into	O	O
the	O	O
brain	O	O
by	O	O
insulin-independent	O	O
GLUT3	O	O
transporter	O	O
where	O	O
it	O	O
might	O	O
be	O	O
metabolized	O	O
to	O	O
glucose	B_Chemical	O
via	O	O
the	O	O
Leloir	O	O
pathway	O	O
.	O	O

Exclusively	O	O
parenteral	O	O
daily	O	O
injections	O	O
of	O	O
galactose	B_Chemical	O
induce	O	O
memory	B_Disease	B_Disease
deterioration	I_Disease	I_Disease
in	O	O
rodents	O	O
and	O	O
are	O	O
used	O	O
to	O	O
generate	O	O
animal	O	O
aging	O	O
model	O	O
,	O	O
but	O	O
the	O	O
effects	O	O
of	O	O
oral	O	O
galactose	B_Chemical	O
treatment	O	O
on	O	O
cognitive	O	O
functions	O	O
have	O	O
never	O	O
been	O	O
tested	O	O
.	O	O

We	O	O
have	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
continuous	O	O
daily	O	O
oral	O	O
galactose	B_Chemical	O
(	O	O
200	O	O
mg/kg/day	O	O
)	O	O
treatment	O	O
on	O	O
cognitive	B_Disease	B_Disease
deficits	I_Disease	I_Disease
in	O	O
streptozotocin-induced	O	O
(	O	O
STZ-icv	O	O
)	O	O
rat	O	O
model	O	O
of	O	O
sAD	O	O
,	O	O
tested	O	O
by	O	O
Morris	O	O
Water	O	O
Maze	O	O
and	O	O
Passive	O	O
Avoidance	O	O
test	O	O
,	O	O
respectively	O	O
.	O	O

One	O	O
month	O	O
of	O	O
oral	O	O
galactose	B_Chemical	O
treatment	O	O
initiated	O	O
immediately	O	O
after	O	O
the	O	O
STZ-icv	O	O
administration	O	O
,	O	O
successfully	O	O
prevented	O	O
development	O	O
of	O	O
the	O	O
STZ-icv-induced	O	O
cognitive	B_Disease	B_Disease
deficits	I_Disease	I_Disease
.	O	O

Beneficial	O	O
effect	O	O
of	O	O
oral	O	O
galactose	B_Chemical	O
was	O	O
independent	O	O
of	O	O
the	O	O
rat	O	O
age	O	O
and	O	O
of	O	O
the	O	O
galactose	B_Chemical	O
dose	O	O
ranging	O	O
from	O	O
100	O	O
to	O	O
300	O	O
mg/kg/day	O	O
.	O	O

Additionally	O	O
,	O	O
oral	O	O
galactose	B_Chemical	O
administration	O	O
led	O	O
to	O	O
the	O	O
appearance	O	O
of	O	O
galactose	B_Chemical	O
in	O	O
the	O	O
blood	O	O
.	O	O

The	O	O
increase	O	O
of	O	O
galactose	B_Chemical	O
concentration	O	O
in	O	O
the	O	O
cerebrospinal	O	O
fluid	O	O
was	O	O
several	O	O
times	O	O
lower	O	O
after	O	O
oral	O	O
than	O	O
after	O	O
parenteral	O	O
administration	O	O
of	O	O
the	O	O
same	O	O
galactose	B_Chemical	O
dose	O	O
.	O	O

Oral	O	O
galactose	B_Chemical	O
exposure	O	O
might	O	O
have	O	O
beneficial	O	O
effects	O	O
on	O	O
learning	O	O
and	O	O
memory	O	O
ability	O	O
and	O	O
could	O	O
be	O	O
worth	O	O
investigating	O	O
for	O	O
improvement	O	O
of	O	O
cognitive	B_Disease	B_Disease
deficits	I_Disease	I_Disease
associated	O	O
with	O	O
glucose	B_Disease	O
hypometabolism	I_Disease	O
in	O	O
AD	B_Disease	O
.	O	O

An	O	O
investigation	O	O
of	O	O
the	O	O
pattern	O	O
of	O	O
kidney	B_Disease	B_Disease
injury	I_Disease	I_Disease
in	O	O
HIV-positive	O	O
persons	O	O
exposed	O	O
to	O	O
tenofovir	B_Chemical	B_Chemical
disoproxil	I_Chemical	I_Chemical
fumarate	I_Chemical	I_Chemical
:	O	O
an	O	O
examination	O	O
of	O	O
a	O	O
large	O	O
population	O	O
database	O	O
(	O	O
MHRA	O	O
database).The	O	O
potential	O	O
for	O	O
tenofovir	B_Chemical	B_Chemical
to	O	O
cause	O	O
a	O	O
range	O	O
of	O	O
kidney	O	O
syndromes	O	O
has	O	O
been	O	O
established	O	O
from	O	O
mechanistic	O	O
and	O	O
randomised	O	O
clinical	O	O
trials	O	O
.	O	O

However	O	O
,	O	O
the	O	O
exact	O	O
pattern	O	O
of	O	O
kidney	O	O
involvement	O	O
is	O	O
still	O	O
uncertain	O	O
.	O	O

We	O	O
undertook	O	O
a	O	O
descriptive	O	O
analysis	O	O
of	O	O
Yellow	O	O
Card	O	O
records	O	O
of	O	O
407	O	O
HIV-positive	O	O
persons	O	O
taking	O	O
tenofovir	B_Chemical	B_Chemical
disoproxil	I_Chemical	I_Chemical
fumarate	I_Chemical	I_Chemical
(	O	O
TDF	B_Chemical	O
)	O	O
as	O	O
part	O	O
of	O	O
their	O	O
antiretroviral	O	O
therapy	O	O
regimen	O	O
and	O	O
submitted	O	O
to	O	O
the	O	O
Medicines	O	O
and	O	O
Healthcare	O	O
Products	O	O
Regulatory	O	O
Agency	O	O
(	O	O
MHRA	O	O
)	O	O
with	O	O
suspected	O	O
kidney	O	O
adverse	O	O
effects	O	O
.	O	O

Reports	O	O
that	O	O
satisfy	O	O
defined	O	O
criteria	O	O
were	O	O
classified	O	O
as	O	O
acute	B_Disease	B_Disease
kidney	I_Disease	I_Disease
injury	I_Disease	I_Disease
,	O	O
kidney	B_Disease	B_Disease
tubular	I_Disease	I_Disease
dysfunction	I_Disease	I_Disease
and	O	O
Fanconi	B_Disease	O
syndrome	I_Disease	O
.	O	O

Of	O	O
the	O	O
407	O	O
Yellow	O	O
Card	O	O
records	O	O
analysed	O	O
,	O	O
106	O	O
satisfied	O	O
criteria	O	O
for	O	O
TDF-related	O	O
kidney	B_Disease	B_Disease
disease	I_Disease	I_Disease
,	O	O
of	O	O
which	O	O
53	O	O
(	O	O
50	O	O
%	O	O
)	O	O
had	O	O
features	O	O
of	O	O
kidney	B_Disease	B_Disease
tubular	I_Disease	I_Disease
dysfunction	I_Disease	I_Disease
,	O	O
35	O	O
(	O	O
33	O	O
%	O	O
)	O	O
were	O	O
found	O	O
to	O	O
have	O	O
features	O	O
of	O	O
glomerular	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
and	O	O
18	O	O
(	O	O
17	O	O
%	O	O
)	O	O
had	O	O
Fanconi	B_Disease	O
syndrome	I_Disease	O
.	O	O

The	O	O
median	O	O
TDF	B_Chemical	O
exposure	O	O
was	O	O
316	O	O
days	O	O
(	O	O
interquartile	O	O
range	O	O
120	O	O
-	O	O
740	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
hospitalisation	O	O
for	O	O
TDF	B_Chemical	O
kidney	O	O
adverse	O	O
effects	O	O
was	O	O
high	O	O
,	O	O
particularly	O	O
amongst	O	O
patients	O	O
with	O	O
features	O	O
of	O	O
Fanconi	B_Disease	O
syndrome	I_Disease	O
.	O	O

The	O	O
pattern	O	O
of	O	O
kidney	O	O
syndromes	O	O
in	O	O
this	O	O
population	O	O
series	O	O
mirrors	O	O
that	O	O
reported	O	O
in	O	O
randomised	O	O
clinical	O	O
trials	O	O
.	O	O

Cessation	O	O
of	O	O
TDF	B_Chemical	O
was	O	O
associated	O	O
with	O	O
complete	O	O
restoration	O	O
of	O	O
kidney	O	O
function	O	O
in	O	O
up	O	O
half	O	O
of	O	O
the	O	O
patients	O	O
in	O	O
this	O	O
report	O	O
.	O	O

Incidence	O	O
of	O	O
postoperative	O	O
delirium	O	O
is	O	O
high	O	O
even	O	O
in	O	O
a	O	O
population	O	O
without	O	O
known	O	O
risk	O	O
factors	O	O
.	O	O

PURPOSE	O	O
:	O	O
Postoperative	B_Disease	O
delirium	I_Disease	O
is	O	O
a	O	O
recognized	O	O
complication	O	O
in	O	O
populations	O	O
at	O	O
risk	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
assess	O	O
the	O	O
prevalence	O	O
of	O	O
early	O	O
postoperative	B_Disease	O
delirium	I_Disease	O
in	O	O
a	O	O
population	O	O
without	O	O
known	O	O
risk	O	O
factors	O	O
admitted	O	O
to	O	O
the	O	O
ICU	O	O
for	O	O
postoperative	O	O
monitoring	O	O
after	O	O
elective	O	O
major	O	O
surgery	O	O
.	O	O

The	O	O
secondary	O	O
outcome	O	O
investigated	O	O
is	O	O
to	O	O
identify	O	O
eventual	O	O
independent	O	O
risk	O	O
factors	O	O
among	O	O
demographic	O	O
data	O	O
and	O	O
anesthetic	O	O
drugs	O	O
used	O	O
.	O	O

METHODS	O	O
:	O	O
An	O	O
observational	O	O
,	O	O
prospective	O	O
study	O	O
was	O	O
conducted	O	O
on	O	O
a	O	O
consecutive	O	O
cohort	O	O
of	O	O
patients	O	O
admitted	O	O
to	O	O
our	O	O
ICU	O	O
within	O	O
and	O	O
for	O	O
at	O	O
least	O	O
24	O	O
h	O	O
after	O	O
major	O	O
surgical	O	O
procedures	O	O
.	O	O

Exclusion	O	O
criteria	O	O
were	O	O
any	O	O
preexisting	O	O
predisposing	O	O
factor	O	O
for	O	O
delirium	B_Disease	O
or	O	O
other	O	O
potentially	O	O
confounding	O	O
neurological	B_Disease	O
dysfunctions	I_Disease	O
.	O	O

Patients	O	O
were	O	O
assessed	O	O
daily	O	O
using	O	O
the	O	O
confusion	B_Disease	O
assessment	O	O
method	O	O
for	O	O
the	O	O
ICU	O	O
scale	O	O
for	O	O
3	O	O
days	O	O
after	O	O
the	O	O
surgical	O	O
procedure	O	O
.	O	O

Early	O	O
postoperative	B_Disease	O
delirium	I_Disease	O
incidence	O	O
risk	O	O
factors	O	O
were	O	O
then	O	O
assessed	O	O
through	O	O
three	O	O
different	O	O
multiple	O	O
regression	O	O
models	O	O
.	O	O

RESULTS	O	O
:	O	O
According	O	O
to	O	O
the	O	O
confusion	O	O
assessment	O	O
method	O	O
for	O	O
the	O	O
ICU	O	O
scale	O	O
,	O	O
28	O	O
%	O	O
of	O	O
patients	O	O
were	O	O
diagnosed	O	O
with	O	O
early	O	O
postoperative	B_Disease	O
delirium	I_Disease	O
.	O	O

The	O	O
use	O	O
of	O	O
thiopentone	B_Chemical	B_Chemical
was	O	O
significantly	O	O
associated	O	O
with	O	O
an	O	O
eight-fold-higher	O	O
risk	O	O
for	O	O
delirium	B_Disease	O
compared	O	O
to	O	O
propofol	B_Chemical	B_Chemical
(	O	O
57.1	O	O
%	O	O
vs.	O	O
7.1	O	O
%	O	O
,	O	O
RR	O	O
=	O	O
8.0	O	O
,	O	O
X2	O	O
=	O	O
4.256	O	O
;	O	O
df	O	O
=	O	O
1	O	O
;	O	O
0.05	O	O
<	O	O
p	O	O
<	O	O
0.02	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
this	O	O
study	O	O
early	O	O
postoperative	B_Disease	O
delirium	I_Disease	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
very	O	O
common	O	O
complication	O	O
after	O	O
major	O	O
surgery	O	O
,	O	O
even	O	O
in	O	O
a	O	O
population	O	O
without	O	O
known	O	O
risk	O	O
factors	O	O
.	O	O

Thiopentone	B_Chemical	B_Chemical
was	O	O
independently	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
its	O	O
relative	O	O
risk	O	O
.	O	O

A	O	O
single	O	O
neurotoxic	B_Disease	O
dose	O	O
of	O	O
methamphetamine	B_Chemical	O
induces	O	O
a	O	O
long-lasting	O	O
depressive-like	O	O
behaviour	O	O
in	O	O
mice	O	O
.	O	O

Methamphetamine	B_Chemical	O
(	O	O
METH	B_Chemical	O
)	O	O
triggers	O	O
a	O	O
disruption	O	O
of	O	O
the	O	O
monoaminergic	O	O
system	O	O
and	O	O
METH	B_Chemical	O
abuse	O	O
leads	O	O
to	O	O
negative	O	O
emotional	O	O
states	O	O
including	O	O
depressive	B_Disease	B_Disease
symptoms	I_Disease	I_Disease
during	O	O
drug	O	O
withdrawal	O	O
.	O	O

However	O	O
,	O	O
it	O	O
is	O	O
currently	O	O
unknown	O	O
if	O	O
the	O	O
acute	O	O
toxic	O	O
dosage	O	O
of	O	O
METH	B_Chemical	O
also	O	O
causes	O	O
a	O	O
long-lasting	O	O
depressive	B_Disease	O
phenotype	O	O
and	O	O
persistent	O	O
monoaminergic	O	B_Disease
deficits	O	I_Disease
.	O	O

Thus	O	O
,	O	O
we	O	O
now	O	O
assessed	O	O
the	O	O
depressive-like	O	O
behaviour	O	O
in	O	O
mice	O	O
at	O	O
early	O	O
and	O	O
long-term	O	O
periods	O	O
following	O	O
a	O	O
single	O	O
high	O	O
METH	B_Chemical	O
dose	O	O
(	O	O
30	O	O
mg/kg	O	O
,	O	O
i.p	O	O
.	O	O
)	O	O
.	O	O

METH	B_Chemical	O
did	O	O
not	O	O
alter	O	O
the	O	O
motor	O	O
function	O	O
and	O	O
procedural	O	O
memory	O	O
of	O	O
mice	O	O
as	O	O
assessed	O	O
by	O	O
swimming	O	O
speed	O	O
and	O	O
escape	O	O
latency	O	O
to	O	O
find	O	O
the	O	O
platform	O	O
in	O	O
a	O	O
cued	O	O
version	O	O
of	O	O
the	O	O
water	O	O
maze	O	O
task	O	O
.	O	O

However	O	O
,	O	O
METH	B_Chemical	O
significantly	O	O
increased	O	O
the	O	O
immobility	O	O
time	O	O
in	O	O
the	O	O
tail	O	O
suspension	O	O
test	O	O
at	O	O
3	O	O
and	O	O
49	O	O
days	O	O
post-administration	O	O
.	O	O

This	O	O
depressive-like	O	O
profile	O	O
induced	O	O
by	O	O
METH	B_Chemical	O
was	O	O
accompanied	O	O
by	O	O
a	O	O
marked	O	O
depletion	O	O
of	O	O
frontostriatal	O	O
dopaminergic	O	O
and	O	O
serotonergic	O	O
neurotransmission	O	O
,	O	O
indicated	O	O
by	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
dopamine	B_Chemical	O
,	O	O
DOPAC	B_Chemical	B_Chemical
and	O	O
HVA	B_Chemical	O
,	O	O
tyrosine	B_Chemical	O
hydroxylase	O	O
and	O	O
serotonin	B_Chemical	O
,	O	O
observed	O	O
at	O	O
both	O	O
3	O	O
and	O	O
49	O	O
days	O	O
post-administration	O	O
.	O	O

In	O	O
parallel	O	O
,	O	O
another	O	O
neurochemical	O	O
feature	O	O
of	O	O
depression	B_Disease	O
--	O	O
astroglial	O	O
dysfunction	O	O
--	O	O
was	O	O
unaffected	O	O
in	O	O
the	O	O
cortex	O	O
and	O	O
the	O	O
striatal	O	O
levels	O	O
of	O	O
the	O	O
astrocytic	O	O
protein	O	O
marker	O	O
,	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
,	O	O
were	O	O
only	O	O
transiently	O	O
increased	O	O
at	O	O
3	O	O
days	O	O
.	O	O

These	O	O
findings	O	O
demonstrate	O	O
for	O	O
the	O	O
first	O	O
time	O	O
that	O	O
a	O	O
single	O	O
high	O	O
dose	O	O
of	O	O
METH	B_Chemical	O
induces	O	O
long-lasting	O	O
depressive-like	O	O
behaviour	O	O
in	O	O
mice	O	O
associated	O	O
with	O	O
a	O	O
persistent	O	O
disruption	O	O
of	O	O
frontostriatal	O	O
dopaminergic	O	O
and	O	O
serotonergic	O	O
homoeostasis	O	O
.	O	O

Linezolid-induced	O	O
optic	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
.	O	O

Many	O	O
systemic	O	O
antimicrobials	O	O
have	O	O
been	O	O
implicated	O	O
to	O	O
cause	O	O
ocular	O	O
adverse	O	O
effects	O	O
.	O	O

This	O	O
is	O	O
especially	O	O
relevant	O	O
in	O	O
multidrug	O	O
therapy	O	O
where	O	O
more	O	O
than	O	O
one	O	O
drug	O	O
can	O	O
cause	O	O
a	O	O
similar	O	O
ocular	O	O
adverse	O	O
effect	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
progressive	O	O
loss	B_Disease	O
of	I_Disease	O
vision	I_Disease	O
associated	O	O
with	O	O
linezolid	B_Chemical	B_Chemical
therapy	O	O
.	O	O

A	O	O
45-year-old	O	O
male	O	O
patient	O	O
who	O	O
was	O	O
on	O	O
treatment	O	O
with	O	O
multiple	O	O
second-line	O	O
anti-tuberculous	O	O
drugs	O	O
including	O	O
linezolid	B_Chemical	B_Chemical
and	O	O
ethambutol	B_Chemical	B_Chemical
for	O	O
extensively	B_Disease	O
drug-resistant	I_Disease	O
tuberculosis	I_Disease	O
(	O	O
XDR-TB	B_Disease	O
)	O	O
presented	O	O
to	O	O
us	O	O
with	O	O
painless	O	O
progressive	O	O
loss	B_Disease	O
of	I_Disease	O
vision	I_Disease	O
in	O	O
both	O	O
eyes	O	O
.	O	O

Color	O	O
vision	O	O
was	O	O
defective	O	O
and	O	O
fundus	O	O
examination	O	O
revealed	O	O
optic	B_Disease	O
disc	I_Disease	O
edema	I_Disease	O
in	O	O
both	O	O
eyes	O	O
.	O	O

Ethambutol-induced	O	O
toxic	B_Disease	B_Disease
optic	I_Disease	I_Disease
neuropathy	I_Disease	I_Disease
was	O	O
suspected	O	O
and	O	O
tablet	O	O
ethambutol	B_Chemical	B_Chemical
was	O	O
withdrawn	O	O
.	O	O

Deterioration	B_Disease	O
of	I_Disease	O
vision	I_Disease	O
occurred	O	O
despite	O	O
withdrawal	O	O
of	O	O
ethambutol	B_Chemical	B_Chemical
.	O	O

Discontinuation	O	O
of	O	O
linezolid	B_Chemical	B_Chemical
resulted	O	O
in	O	O
marked	O	O
improvement	O	O
of	O	O
vision	O	O
.	O	O

Our	O	O
report	O	O
emphasizes	O	O
the	O	O
need	O	O
for	O	O
monitoring	O	O
of	O	O
visual	O	O
function	O	O
in	O	O
patients	O	O
on	O	O
long-term	O	O
linezolid	B_Chemical	B_Chemical
treatment	O	O
.	O	O

Resuscitation	O	O
with	O	O
lipid	O	O
,	O	O
epinephrine	B_Chemical	O
,	O	O
or	O	O
both	O	O
in	O	O
levobupivacaine-induced	O	O
cardiac	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
in	O	O
newborn	O	O
piglets	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
optimal	O	O
dosing	O	O
regimens	O	O
of	O	O
lipid	O	O
emulsion	O	O
,	O	O
epinephrine	B_Chemical	O
,	O	O
or	O	O
both	O	O
are	O	O
not	O	O
yet	O	O
determined	O	O
in	O	O
neonates	O	O
in	O	O
cases	O	O
of	O	O
local	O	O
anaesthetic	O	O
systemic	O	O
toxicity	B_Disease	O
(	O	O
LAST	O	O
)	O	O
.	O	O

METHODS	O	O
:	O	O
Newborn	O	O
piglets	O	O
received	O	O
levobupivacaine	B_Chemical	B_Chemical
until	O	O
cardiovascular	B_Disease	B_Disease
collapse	I_Disease	I_Disease
occurred	O	O
.	O	O

Standard	O	O
cardiopulmonary	O	O
resuscitation	O	O
was	O	O
started	O	O
and	O	O
electrocardiogram	O	O
(	O	O
ECG	O	O
)	O	O
was	O	O
monitored	O	O
for	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
,	O	O
fibrillation	B_Disease	O
,	O	O
or	O	O
QRS	O	O
prolongation	O	O
.	O	O

Piglets	O	O
were	O	O
then	O	O
randomly	O	O
allocated	O	O
to	O	O
four	O	O
groups	O	O
:	O	O
control	O	O
(	O	O
saline	O	O
)	O	O
,	O	O
Intralipid	O	O
(	O	O
)	O	O
alone	O	O
,	O	O
epinephrine	B_Chemical	O
alone	O	O
,	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
Intralipd	O	O
plus	O	O
epinephrine	B_Chemical	O
.	O	O

Resuscitation	O	O
continued	O	O
for	O	O
30	O	O
min	O	O
or	O	O
until	O	O
there	O	O
was	O	O
a	O	O
return	O	O
of	O	O
spontaneous	O	O
circulation	O	O
(	O	O
ROSC	O	O
)	O	O
accompanied	O	O
by	O	O
a	O	O
mean	O	O
arterial	O	O
pressure	O	O
at	O	O
or	O	O
superior	O	O
to	O	O
the	O	O
baseline	O	O
pressure	O	O
and	O	O
normal	O	O
sinus	O	O
rhythm	O	O
for	O	O
a	O	O
period	O	O
of	O	O
30	O	O
min	O	O
.	O	O

RESULTS	O	O
:	O	O
ROSC	O	O
was	O	O
achieved	O	O
in	O	O
only	O	O
one	O	O
of	O	O
the	O	O
control	O	O
piglets	O	O
compared	O	O
with	O	O
most	O	O
of	O	O
the	O	O
treated	O	O
piglets	O	O
.	O	O

Mortality	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
three	O	O
treatment	O	O
groups	O	O
,	O	O
but	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
all	O	O
the	O	O
treatment	O	O
groups	O	O
compared	O	O
with	O	O
control	O	O
.	O	O

The	O	O
number	O	O
of	O	O
ECG	O	O
abnormalities	O	O
was	O	O
zero	O	O
in	O	O
the	O	O
Intralipid	O	O
only	O	O
group	O	O
,	O	O
but	O	O
14	O	O
and	O	O
17	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
epinephrine	B_Chemical	O
and	O	O
epinephrine	B_Chemical	O
plus	O	O
lipid	O	O
groups	O	O
(	O	O
P<0.05	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Lipid	O	O
emulsion	O	O
with	O	O
or	O	O
without	O	O
epinephrine	B_Chemical	O
,	O	O
or	O	O
epinephrine	B_Chemical	O
alone	O	O
were	O	O
equally	O	O
effective	O	O
in	O	O
achieving	O	O
a	O	O
return	O	O
to	O	O
spontaneous	O	O
circulation	O	O
in	O	O
this	O	O
model	O	O
of	O	O
LAST	O	O
.	O	O

Epinephrine	B_Chemical	O
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
lipid	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
number	O	O
of	O	O
ECG	O	O
abnormalities	O	O
compared	O	O
with	O	O
lipid	O	O
emulsion	O	O
alone	O	O
.	O	O

Incidence	O	O
of	O	O
heparin-induced	O	O
thrombocytopenia	B_Disease	O
type	I_Disease	O
II	I_Disease	O
and	O	O
postoperative	O	O
recovery	O	O
of	O	O
platelet	O	O
count	O	O
in	O	O
liver	O	O
graft	O	O
recipients	O	O
:	O	O
a	O	O
retrospective	O	O
cohort	O	O
analysis	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Thrombocytopenia	B_Disease	O
in	O	O
patients	O	O
with	O	O
end-stage	B_Disease	B_Disease
liver	I_Disease	I_Disease
disease	I_Disease	I_Disease
is	O	O
a	O	O
common	O	O
disorder	O	O
caused	O	O
mainly	O	O
by	O	O
portal	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
,	O	O
low	O	O
levels	O	O
of	O	O
thrombopoetin	O	O
,	O	O
and	O	O
endotoxemia	B_Disease	B_Disease
.	O	O

The	O	O
impact	O	O
of	O	O
immune-mediated	O	O
heparin-induced	O	O
thrombocytopenia	B_Disease	O
type	I_Disease	O
II	I_Disease	O
(	O	O
HIT	B_Disease	O
type	I_Disease	O
II	I_Disease	O
)	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
thrombocytopenia	B_Disease	O
after	O	O
liver	O	O
transplantation	O	O
is	O	O
not	O	O
yet	O	O
understood	O	O
,	O	O
with	O	O
few	O	O
literature	O	O
citations	O	O
reporting	O	O
contradictory	O	O
results	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
our	O	O
study	O	O
was	O	O
to	O	O
demonstrate	O	O
the	O	O
perioperative	O	O
course	O	O
of	O	O
thrombocytopenia	B_Disease	O
after	O	O
liver	O	O
transplantation	O	O
and	O	O
determine	O	O
the	O	O
occurrence	O	O
of	O	O
clinical	O	O
HIT	B_Disease	O
type	I_Disease	O
II	I_Disease	O
.	O	O

METHOD	O	O
:	O	O
We	O	O
retrospectively	O	O
evaluated	O	O
the	O	O
medical	O	O
records	O	O
of	O	O
205	O	O
consecutive	O	O
adult	O	O
patients	O	O
who	O	O
underwent	O	O
full-size	O	O
liver	O	O
transplantation	O	O
between	O	O
January	O	O
2006	O	O
and	O	O
December	O	O
2010	O	O
due	O	O
to	O	O
end-stage	B_Disease	O
or	I_Disease	O
malignant	B_Disease	O
liver	I_Disease	B_Disease
disease	I_Disease	I_Disease
.	O	O

Preoperative	O	O
platelet	O	O
count	O	O
,	O	O
postoperative	O	O
course	O	O
of	O	O
platelets	O	O
,	O	O
and	O	O
clinical	O	O
signs	O	O
of	O	O
HIT	B_Disease	O
type	I_Disease	O
II	I_Disease	O
were	O	O
analyzed	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
155	O	O
(	O	O
75.6	O	O
%	O	O
)	O	O
of	O	O
205	O	O
patients	O	O
had	O	O
thrombocytopenia	B_Disease	O
before	O	O
transplantation	O	O
,	O	O
significantly	O	O
influenced	O	O
by	O	O
Model	O	O
of	O	O
End-Stage	B_Disease	B_Disease
Liver	I_Disease	I_Disease
Disease	I_Disease	I_Disease
score	O	O
and	O	O
liver	B_Disease	B_Disease
cirrhosis	I_Disease	I_Disease
.	O	O

The	O	O
platelet	O	O
count	O	O
exceeded	O	O
100,000/uL	O	O
in	O	O
most	O	O
of	O	O
the	O	O
patients	O	O
(	O	O
n	O	O
=	O	O
193	O	O
)	O	O
at	O	O
a	O	O
medium	O	O
of	O	O
7	O	O
d.	O	O
Regarding	O	O
HIT	B_Disease	O
II	I_Disease	O
,	O	O
there	O	O
were	O	O
four	O	O
(	O	O
1.95	O	O
%	O	O
)	O	O
patients	O	O
with	O	O
a	O	O
background	O	O
of	O	O
HIT	B_Disease	O
type	I_Disease	O
II	I_Disease	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
incidence	O	O
of	O	O
HIT	B_Disease	O
in	O	O
patients	O	O
with	O	O
end-stage	B_Disease	B_Disease
hepatic	I_Disease	I_Disease
failure	I_Disease	I_Disease
is	O	O
,	O	O
with	O	O
about	O	O
1.95	O	O
%	O	O
,	O	O
rare	O	O
.	O	O

For	O	O
further	O	O
reduction	O	O
of	O	O
HIT	B_Disease	O
type	I_Disease	O
II	I_Disease	O
,	O	O
the	O	O
use	O	O
of	O	O
intravenous	O	O
heparin	B_Chemical	O
should	O	O
be	O	O
avoided	O	O
and	O	O
the	O	O
prophylactic	O	O
anticoagulation	O	O
should	O	O
be	O	O
performed	O	O
with	O	O
low-molecular-weight	O	O
heparin	B_Chemical	O
after	O	O
normalization	O	O
of	O	O
platelet	O	O
count	O	O
.	O	O

Takotsubo	B_Disease	O
syndrome	I_Disease	O
(	O	O
or	O	O
apical	B_Disease	O
ballooning	I_Disease	O
syndrome	I_Disease	O
)	O	O
secondary	O	O
to	O	O
Zolmitriptan	B_Chemical	B_Chemical
.	O	O

Takotsubo	B_Disease	O
syndrome	I_Disease	O
(	O	O
TS	B_Disease	O
)	O	O
,	O	O
also	O	O
known	O	O
as	O	O
broken	B_Disease	O
heart	I_Disease	O
syndrome	I_Disease	O
,	O	O
is	O	O
characterized	O	O
by	O	O
left	O	O
ventricle	O	O
apical	O	O
ballooning	O	O
with	O	O
elevated	O	O
cardiac	O	O
biomarkers	O	O
and	O	O
electrocardiographic	O	O
changes	O	O
suggestive	O	O
of	O	O
an	O	O
acute	B_Disease	B_Disease
coronary	I_Disease	I_Disease
syndrome	I_Disease	I_Disease
(	O	O
ie	O	O
,	O	O
ST-segment	O	O
elevation	O	O
,	O	O
T	O	O
wave	O	O
inversions	O	O
,	O	O
and	O	O
pathologic	O	O
Q	O	O
waves	O	O
)	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
54-year-old	O	O
woman	O	O
with	O	O
medical	O	O
history	O	O
of	O	O
mitral	B_Disease	B_Disease
valve	I_Disease	I_Disease
prolapse	I_Disease	I_Disease
and	O	O
migraines	B_Disease	O
,	O	O
who	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
substernal	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
and	O	O
electrocardiogram	O	O
demonstrated	O	O
1/2	O	O
mm	O	O
ST-segment	O	O
elevation	O	O
in	O	O
leads	O	O
II	O	O
,	O	O
III	O	O
,	O	O
aVF	O	O
,	O	O
V5	O	O
,	O	O
and	O	O
V6	O	O
and	O	O
positive	O	O
troponin	O	O
I.	O	O
Emergent	O	O
coronary	O	O
angiogram	O	O
revealed	O	O
normal	O	O
coronary	O	O
arteries	O	O
with	O	O
moderately	O	O
reduced	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
with	O	O
wall	O	O
motion	O	O
abnormalities	O	O
consistent	O	O
with	O	O
TS	B_Disease	O
.	O	O

Detailed	O	O
history	O	O
obtained	O	O
retrospectively	O	O
revealed	O	O
that	O	O
the	O	O
patient	O	O
took	O	O
zolmitriptan	B_Chemical	B_Chemical
sparingly	O	O
only	O	O
when	O	O
she	O	O
had	O	O
migraines	B_Disease	O
.	O	O

But	O	O
before	O	O
this	O	O
event	O	O
,	O	O
she	O	O
was	O	O
taking	O	O
zolmitriptan	B_Chemical	B_Chemical
2	O	O
-	O	O
3	O	O
times	O	O
daily	O	O
for	O	O
several	O	O
days	O	O
because	O	O
of	O	O
a	O	O
persistent	O	O
migraine	B_Disease	O
headache	I_Disease	O
.	O	O

She	O	O
otherwise	O	O
reported	O	O
that	O	O
she	O	O
is	O	O
quite	O	O
active	O	O
,	O	O
rides	O	O
horses	O	O
,	O	O
and	O	O
does	O	O
show	O	O
jumping	O	O
without	O	O
any	O	O
limitations	O	O
in	O	O
her	O	O
physical	O	O
activity	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
any	O	O
recent	O	O
stress	O	O
or	O	O
status	B_Disease	O
migrainosus	I_Disease	O
.	O	O

Extensive	O	O
literature	O	O
search	O	O
revealed	O	O
multiple	O	O
cases	O	O
of	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
vasospasm	I_Disease	I_Disease
secondary	O	O
to	O	O
zolmitriptan	B_Chemical	B_Chemical
,	O	O
but	O	O
none	O	O
of	O	O
the	O	O
cases	O	O
were	O	O
associated	O	O
with	O	O
TS	B_Disease	O
.	O	O

Depression	B_Disease	O
,	O	O
impulsiveness	B_Disease	O
,	O	O
sleep	O	O
,	O	O
and	O	O
memory	O	O
in	O	O
past	O	O
and	O	O
present	O	O
polydrug	O	O
users	O	O
of	O	O
3,4-methylenedioxymethamphetamine	B_Chemical	B_Chemical
(	O	O
MDMA	B_Chemical	O
,	O	O
ecstasy).RATIONALE	O	O
:	O	O
Ecstasy	B_Chemical	O
(	O	O
3,4-methylenedioxymethamphetamine	B_Chemical	B_Chemical
,	O	O
MDMA	B_Chemical	O
)	O	O
is	O	O
a	O	O
worldwide	O	O
recreational	O	O
drug	O	O
of	O	O
abuse	O	O
.	O	O

Unfortunately	O	O
,	O	O
the	O	O
results	O	O
from	O	O
human	O	O
research	O	O
investigating	O	O
its	O	O
psychological	O	O
effects	O	O
have	O	O
been	O	O
inconsistent	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
present	O	O
study	O	O
aimed	O	O
to	O	O
be	O	O
the	O	O
largest	O	O
to	O	O
date	O	O
in	O	O
sample	O	O
size	O	O
and	O	O
5HT-related	O	O
behaviors	O	O
;	O	O
the	O	O
first	O	O
to	O	O
compare	O	O
present	O	O
ecstasy	B_Chemical	O
users	O	O
with	O	O
past	O	O
users	O	O
after	O	O
an	O	O
abstinence	O	O
of	O	O
4	O	O
or	O	O
more	O	O
years	O	O
,	O	O
and	O	O
the	O	O
first	O	O
to	O	O
include	O	O
robust	O	O
controls	O	O
for	O	O
other	O	O
recreational	O	O
substances	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
sample	O	O
of	O	O
997	O	O
participants	O	O
(	O	O
52	O	O
%	O	O
male	O	O
)	O	O
was	O	O
recruited	O	O
to	O	O
four	O	O
control	O	O
groups	O	O
(	O	O
non-drug	O	O
(	O	O
ND	O	O
)	O	O
,	O	O
alcohol/nicotine	O	O
(	O	O
AN	B_Chemical	O
)	O	O
,	O	O
cannabis/alcohol/nicotine	O	O
(	O	O
CAN	B_Chemical	O
)	O	O
,	O	O
non-ecstasy	O	O
polydrug	O	O
(	O	O
PD	O	O
)	O	O
)	O	O
,	O	O
and	O	O
two	O	O
ecstasy	B_Chemical	O
polydrug	O	O
groups	O	O
(	O	O
present	O	O
(	O	O
MDMA	B_Chemical	O
)	O	O
and	O	O
past	O	O
users	O	O
(	O	O
EX-MDMA	O	O
)	O	O
.	O	O

Participants	O	O
completed	O	O
a	O	O
drug	O	O
history	O	O
questionnaire	O	O
,	O	O
Beck	O	O
Depression	B_Disease	O
Inventory	O	O
,	O	O
Barratt	O	O
Impulsiveness	B_Disease	O
Scale	O	O
,	O	O
Pittsburgh	O	O
Sleep	O	O
Quality	O	O
Index	O	O
,	O	O
and	O	O
Wechsler	O	O
Memory	O	O
Scale-Revised	O	O
which	O	O
,	O	O
in	O	O
total	O	O
,	O	O
provided	O	O
13	O	O
psychometric	O	O
measures	O	O
.	O	O

RESULTS	O	O
:	O	O
While	O	O
the	O	O
CAN	B_Chemical	O
and	O	O
PD	O	O
groups	O	O
tended	O	O
to	O	O
record	O	O
greater	O	O
deficits	O	O
than	O	O
the	O	O
non-drug	O	O
controls	O	O
,	O	O
the	O	O
MDMA	B_Chemical	O
and	O	O
EX-MDMA	O	O
groups	O	O
recorded	O	O
greater	O	O
deficits	O	O
than	O	O
all	O	O
the	O	O
control	O	O
groups	O	O
on	O	O
ten	O	O
of	O	O
the	O	O
13	O	O
psychometric	O	O
measures	O	O
.	O	O

Strikingly	O	O
,	O	O
despite	O	O
prolonged	O	O
abstinence	O	O
(	O	O
mean	O	O
,	O	O
4.98	O	O
;	O	O
range	O	O
,	O	O
4	O	O
-	O	O
9	O	O
years	O	O
)	O	O
,	O	O
past	O	O
ecstasy	B_Chemical	O
users	O	O
showed	O	O
few	O	O
signs	O	O
of	O	O
recovery	O	O
.	O	O

Compared	O	O
with	O	O
present	O	O
ecstasy	B_Chemical	O
users	O	O
,	O	O
the	O	O
past	O	O
users	O	O
showed	O	O
no	O	O
change	O	O
for	O	O
ten	O	O
measures	O	O
,	O	O
increased	O	O
impairment	O	O
for	O	O
two	O	O
measures	O	O
,	O	O
and	O	O
improvement	O	O
on	O	O
just	O	O
one	O	O
measure	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Given	O	O
this	O	O
record	O	O
of	O	O
impaired	B_Disease	O
memory	I_Disease	O
and	O	O
clinically	O	O
significant	O	O
levels	O	O
of	O	O
depression	B_Disease	O
,	O	O
impulsiveness	B_Disease	O
,	O	O
and	O	O
sleep	B_Disease	O
disturbance	I_Disease	O
,	O	O
the	O	O
prognosis	O	O
for	O	O
the	O	O
current	O	O
generation	O	O
of	O	O
ecstasy	B_Chemical	O
users	O	O
is	O	O
a	O	O
major	O	O
cause	O	O
for	O	O
concern	O	O
.	O	O

Association	O	O
of	O	O
common	O	O
genetic	O	O
variants	O	O
of	O	O
HOMER1	O	O
gene	O	O
with	O	O
levodopa	B_Chemical	O
adverse	O	O
effects	O	O
in	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
patients	O	O
.	O	O

Levodopa	B_Chemical	O
is	O	O
the	O	O
most	O	O
effective	O	O
symptomatic	O	O
therapy	O	O
for	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
,	O	O
but	O	O
its	O	O
chronic	O	O
use	O	O
could	O	O
lead	O	O
to	O	O
chronic	O	O
adverse	O	O
outcomes	O	O
,	O	O
such	O	O
as	O	O
motor	O	O
fluctuations	O	O
,	O	O
dyskinesia	B_Disease	O
and	O	O
visual	B_Disease	B_Disease
hallucinations	I_Disease	I_Disease
.	O	O

HOMER1	O	O
is	O	O
a	O	O
protein	O	O
with	O	O
pivotal	O	O
function	O	O
in	O	O
glutamate	B_Chemical	O
transmission	O	O
,	O	O
which	O	O
has	O	O
been	O	O
related	O	O
to	O	O
the	O	O
pathogenesis	O	O
of	O	O
these	O	O
complications	O	O
.	O	O

This	O	O
study	O	O
investigates	O	O
whether	O	O
polymorphisms	O	O
in	O	O
the	O	O
HOMER1	O	O
gene	O	O
promoter	O	O
region	O	O
are	O	O
associated	O	O
with	O	O
the	O	O
occurrence	O	O
of	O	O
the	O	O
chronic	O	O
complications	O	O
of	O	O
levodopa	B_Chemical	O
therapy	O	O
.	O	O

A	O	O
total	O	O
of	O	O
205	O	O
patients	O	O
with	O	O
idiopathic	B_Disease	O
Parkinson	I_Disease	O
's	I_Disease	O
disease	I_Disease	O
were	O	O
investigated	O	O
.	O	O

Patients	O	O
were	O	O
genotyped	O	O
for	O	O
rs4704559	O	O
,	O	O
rs10942891	O	O
and	O	O
rs4704560	O	O
by	O	O
allelic	O	O
discrimination	O	O
with	O	O
Taqman	O	O
assays	O	O
.	O	O

The	O	O
rs4704559	O	O
G	O	O
allele	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
lower	O	O
prevalence	O	O
of	O	O
dyskinesia	B_Disease	O
(	O	O
prevalence	O	O
ratio	O	O
(PR)=0.615	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
)	O	O
0.426	O	O
-	O	O
0.887	O	O
,	O	O
P=0.009	O	O
)	O	O
and	O	O
visual	B_Disease	B_Disease
hallucinations	I_Disease	I_Disease
(	O	O
PR=0.515	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
0.295	O	O
-	O	O
0.899	O	O
,	O	O
P=0.020	O	O
)	O	O
.	O	O

Our	O	O
data	O	O
suggest	O	O
that	O	O
HOMER1	O	O
rs4704559	O	O
G	O	O
allele	O	O
has	O	O
a	O	O
protective	O	O
role	O	O
for	O	O
the	O	O
development	O	O
of	O	O
levodopa	B_Chemical	O
adverse	O	O
effects	O	O
.	O	O

Crocin	B_Chemical	B_Chemical
improves	O	O
lipid	O	O
dysregulation	O	O
in	O	O
subacute	O	O
diazinon	B_Chemical	B_Chemical
exposure	O	O
through	O	O
ERK1/2	O	O
pathway	O	O
in	O	O
rat	O	O
liver	O	O
.	O	O

INTRODUCTION	O	O
:	O	O
Diazinon	B_Chemical	B_Chemical
Yis	O	O
one	O	O
of	O	O
the	O	O
most	O	O
broadly	O	O
used	O	O
organophosphorus	B_Chemical	O
insecticides	O	O
in	O	O
agriculture	O	O
.	O	O

It	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
exposure	O	O
to	O	O
diazinon	B_Chemical	B_Chemical
may	O	O
interfere	O	O
with	O	O
lipid	O	O
metabolism	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
hypolipidemic	O	O
effect	O	O
of	O	O
crocin	B_Chemical	B_Chemical
has	O	O
been	O	O
established	O	O
.	O	O

Earlier	O	O
studies	O	O
revealed	O	O
the	O	O
major	O	O
role	O	O
of	O	O
Extracellular	O	O
signal-regulated	O	O
kinase	O	O
(	O	O
ERK	O	O
)	O	O
pathways	O	O
in	O	O
low-density	O	O
lipoprotein	O	O
receptor	O	O
(	O	O
LDLr	O	O
)	O	O
expression	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
changes	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
lipid	O	O
metabolism	O	O
,	O	O
ERK	O	O
and	O	O
LDLr	O	O
expression	O	O
in	O	O
the	O	O
liver	O	O
of	O	O
rats	O	O
exposed	O	O
to	O	O
subacute	O	O
diazinon	B_Chemical	B_Chemical
.	O	O

Furthermore	O	O
ameliorating	O	O
effect	O	O
of	O	O
crocin	B_Chemical	B_Chemical
on	O	O
diazinon	B_Chemical	O
induced	O	O
disturbed	O	O
cholesterol	B_Chemical	O
homeostasis	O	O
was	O	O
studied	O	O
.	O	O

METHODS	O	O
:	O	O
24	O	O
Rats	O	O
were	O	O
divided	O	O
into	O	O
4	O	O
groups	O	O
and	O	O
received	O	O
following	O	O
treatments	O	O
for	O	O
4	O	O
weeks	O	O
;	O	O
Corn	O	O
oil	O	O
(	O	O
control	O	O
)	O	O
,	O	O
diazinon	B_Chemical	B_Chemical
(	O	O
15mg/kg	O	O
per	O	O
day	O	O
,	O	O
orally	O	O
)	O	O
and	O	O
crocin	B_Chemical	B_Chemical
(	O	O
12.5	O	O
and	O	O
25mg/kg	O	O
per	O	O
day	O	O
,	O	O
intraperitoneally	O	O
)	O	O
in	O	O
combination	O	O
with	O	O
diazinon	B_Chemical	B_Chemical
(	O	O
15	O	O
mg/kg	O	O
)	O	O
.	O	O

The	O	O
levels	O	O
of	O	O
cholesterol	B_Chemical	O
,	O	O
triglyceride	B_Chemical	O
and	O	O
LDL	O	O
in	O	O
blood	O	O
of	O	O
rats	O	O
were	O	O
analyzed	O	O
.	O	O

Moreover	O	O
mRNA	O	O
levels	O	O
of	O	O
LDLr	O	O
and	O	O
ERK1/2	O	O
as	O	O
well	O	O
as	O	O
protein	O	O
levels	O	O
of	O	O
total	O	O
and	O	O
activated	O	O
forms	O	O
of	O	O
ERK1/2	O	O
in	O	O
rat	O	O
liver	O	O
were	O	O
evaluated	O	O
by	O	O
Western	O	O
blotting	O	O
and	O	O
quantitative	O	O
real	O	O
time	O	O
polymerase	O	O
chain	O	O
reaction	O	O
analysis	O	O
.	O	O

RESULTS	O	O
:	O	O
Our	O	O
data	O	O
showed	O	O
that	O	O
subacute	O	O
exposure	O	O
to	O	O
diazinon	B_Chemical	B_Chemical
significantly	O	O
increased	O	O
concentrations	O	O
of	O	O
cholesterol	B_Chemical	O
,	O	O
triglyceride	B_Chemical	O
and	O	O
LDL	O	O
.	O	O

Moreover	O	O
diazinon	B_Chemical	B_Chemical
decreased	O	O
ERK1/2	O	O
protein	O	O
phosphorylation	O	O
and	O	O
LDLr	O	O
transcript	O	O
.	O	O

Crocin	B_Chemical	B_Chemical
reduced	O	O
inhibition	O	O
of	O	O
ERK	O	O
activation	O	O
and	O	O
diazinon-induced	O	O
hyperlipemia	B_Disease	O
and	O	O
increased	O	O
levels	O	O
of	O	O
LDLr	O	O
transcript	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Crocin	B_Chemical	B_Chemical
may	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
novel	O	O
protective	O	O
agent	O	O
in	O	O
diazinon-induced	O	O
hyperlipemia	B_Disease	O
through	O	O
modulating	O	O
of	O	O
ERK	O	O
pathway	O	O
and	O	O
increase	O	O
of	O	O
LDLr	O	O
expression	O	O
.	O	O

GEM-P	O	O
chemotherapy	O	O
is	O	O
active	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
relapsed	O	O
Hodgkin	B_Disease	O
lymphoma	I_Disease	O
.	O	O

Hodgkin	B_Disease	O
lymphoma	I_Disease	O
(	O	O
HL	B_Disease	O
)	O	O
is	O	O
a	O	O
relatively	O	O
chemosensitive	O	O
malignancy	B_Disease	O
.	O	O

However	O	O
,	O	O
for	O	O
those	O	O
who	O	O
relapse	O	O
,	O	O
high-dose	O	O
chemotherapy	O	O
with	O	O
autologous	O	O
stem	O	O
cell	O	O
transplant	O	O
is	O	O
the	O	O
treatment	O	O
of	O	O
choice	O	O
which	O	O
relies	O	O
on	O	O
adequate	O	O
disease	O	O
control	O	O
with	O	O
salvage	O	O
chemotherapy	O	O
.	O	O

Regimens	O	O
commonly	O	O
used	O	O
often	O	O
require	O	O
inpatient	O	O
administration	O	O
and	O	O
can	O	O
be	O	O
difficult	O	O
to	O	O
deliver	O	O
due	O	O
to	O	O
toxicity	B_Disease	O
.	O	O

Gemcitabine	B_Chemical	B_Chemical
and	O	O
cisplatin	B_Chemical	B_Chemical
have	O	O
activity	O	O
in	O	O
HL	B_Disease	O
,	O	O
non-overlapping	O	O
toxicity	B_Disease	O
with	O	O
first-line	O	O
chemotherapeutics	O	O
,	O	O
and	O	O
may	O	O
be	O	O
delivered	O	O
in	O	O
an	O	O
outpatient	O	O
setting	O	O
.	O	O

In	O	O
this	O	O
retrospective	O	O
single-centre	O	O
analysis	O	O
,	O	O
patients	O	O
with	O	O
relapsed	O	O
or	O	O
refractory	O	O
HL	B_Disease	O
treated	O	O
with	O	O
gemcitabine	B_Chemical	B_Chemical
1,000	O	O
mg/m(2	O	O
)	O	O
day	O	O
(D)1	O	O
,	O	O
D8	O	O
and	O	O
D15	O	O
;	O	O
methylprednisolone	B_Chemical	B_Chemical
1,000	O	O
mg	O	O
D1	O	O
-	O	O
5	O	O
;	O	O
and	O	O
cisplatin	B_Chemical	B_Chemical
100	O	O
mg/m(2	O	O
)	O	O
D15	O	O
,	O	O
every	O	O
28	O	O
days	O	O
(	O	O
GEM-P	O	O
)	O	O
were	O	O
included	O	O
.	O	O

Demographic	O	O
,	O	O
survival	O	O
,	O	O
response	O	O
and	O	O
toxicity	B_Disease	O
data	O	O
were	O	O
recorded	O	O
.	O	O

Forty-one	O	O
eligible	O	O
patients	O	O
were	O	O
identified	O	O
:	O	O
median	O	O
age	O	O
27	O	O
.	O	O

One	O	O
hundred	O	O
and	O	O
twenty-two	O	O
cycles	O	O
of	O	O
GEM-P	O	O
were	O	O
administered	O	O
in	O	O
total	O	O
(	O	O
median	O	O
3	O	O
cycles	O	O
;	O	O
range	O	O
1	O	O
-	O	O
6	O	O
)	O	O
.	O	O

Twenty	O	O
of	O	O
41	O	O
(	O	O
48	O	O
%	O	O
)	O	O
patients	O	O
received	O	O
GEM-P	O	O
as	O	O
second-line	O	O
treatment	O	O
and	O	O
11/41	O	O
(	O	O
27	O	O
%	O	O
)	O	O
as	O	O
third-line	O	O
therapy	O	O
.	O	O

Overall	O	O
response	O	O
rate	O	O
(	O	O
ORR	O	O
)	O	O
to	O	O
GEM-P	O	O
in	O	O
the	O	O
entire	O	O
cohort	O	O
was	O	O
80	O	O
%	O	O
(	O	O
complete	O	O
response	O	O
(	O	O
CR	O	O
)	O	O
37	O	O
%	O	O
,	O	O
partial	O	O
response	O	O
44	O	O
%	O	O
)	O	O
with	O	O
14/15	O	O
CR	O	O
confirmed	O	O
as	O	O
a	O	O
metabolic	O	O
CR	O	O
on	O	O
PET	O	O
and	O	O
ORR	O	O
of	O	O
85	O	O
%	O	O
in	O	O
the	O	O
20	O	O
second-line	O	O
patients	O	O
.	O	O

The	O	O
most	O	O
common	O	O
grade	O	O
3/4	O	O
toxicities	B_Disease	O
were	O	O
haematological	O	O
:	O	O
neutropenia	B_Disease	O
54	O	O
%	O	O
and	O	O
thrombocytopenia	B_Disease	O
51	O	O
%	O	O
.	O	O

Median	O	O
follow-up	O	O
from	O	O
the	O	O
start	O	O
of	O	O
GEM-P	O	O
was	O	O
4.5	O	O
years	O	O
.	O	O

Following	O	O
GEM-P	O	O
,	O	O
5-year	O	O
progression-free	O	O
survival	O	O
was	O	O
46	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
)	O	O
,	O	O
30	O	O
-	O	O
62	O	O
%	O	O
)	O	O
and	O	O
5-year	O	O
overall	O	O
survival	O	O
was	O	O
59	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
43	O	O
-	O	O
74	O	O
%	O	O
)	O	O
.	O	O

Fourteen	O	O
of	O	O
41	O	O
patients	O	O
proceeded	O	O
directly	O	O
to	O	O
autologous	O	O
transplant	O	O
.	O	O

GEM-P	O	O
is	O	O
a	O	O
salvage	O	O
chemotherapy	O	O
with	O	O
relatively	O	O
high	O	O
response	O	O
rates	O	O
,	O	O
leading	O	O
to	O	O
successful	O	O
transplantation	O	O
in	O	O
appropriate	O	O
patients	O	O
,	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
relapsed	O	O
or	O	O
refractory	O	O
HL	B_Disease	O
.	O	O

Basal	O	O
functioning	O	O
of	O	O
the	O	O
hypothalamic-pituitary-adrenal	O	O
(	O	O
HPA	O	O
)	O	O
axis	O	O
and	O	O
psychological	O	B_Disease
distress	O	I_Disease
in	O	O
recreational	O	O
ecstasy	O	O
polydrug	O	O
users	O	O
.	O	O

RATIONALE	O	O
:	O	O
Ecstasy	B_Chemical	O
(	O	O
MDMA	B_Chemical	O
)	O	O
is	O	O
a	O	O
psychostimulant	O	O
drug	O	O
which	O	O
is	O	O
increasingly	O	O
associated	O	O
with	O	O
psychobiological	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
.	O	O

While	O	O
some	O	O
recent	O	O
studies	O	O
suggest	O	O
acute	O	O
changes	O	O
in	O	O
neuroendocrine	O	O
function	O	O
,	O	O
less	O	O
is	O	O
known	O	O
about	O	O
long-term	O	O
changes	O	O
in	O	O
HPA	O	O
functionality	O	O
in	O	O
recreational	O	O
users	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
current	O	O
study	O	O
is	O	O
the	O	O
first	O	O
to	O	O
explore	O	O
the	O	O
effects	O	O
of	O	O
ecstasy-polydrug	O	O
use	O	O
on	O	O
psychological	O	B_Disease
distress	O	I_Disease
and	O	O
basal	O	O
functioning	O	O
of	O	O
the	O	O
HPA	O	O
axis	O	O
through	O	O
assessing	O	O
the	O	O
secretion	O	O
of	O	O
cortisol	B_Chemical	O
across	O	O
the	O	O
diurnal	O	O
period	O	O
.	O	O

METHOD	O	O
:	O	O
Seventy-six	O	O
participants	O	O
(	O	O
21	O	O
nonusers	O	O
,	O	O
29	O	O
light	O	O
ecstasy-polydrug	O	O
users	O	O
,	O	O
26	O	O
heavy	O	O
ecstasy-polydrug	O	O
users	O	O
)	O	O
completed	O	O
a	O	O
substance	O	O
use	O	O
inventory	O	O
and	O	O
measures	O	O
of	O	O
psychological	O	B_Disease
distress	O	I_Disease
at	O	O
baseline	O	O
,	O	O
then	O	O
two	O	O
consecutive	O	O
days	O	O
of	O	O
cortisol	B_Chemical	O
sampling	O	O
(	O	O
on	O	O
awakening	O	O
,	O	O
30	O	O
min	O	O
post	O	O
awakening	O	O
,	O	O
between	O	O
1400	O	O
and	O	O
1600	O	O
hours	O	O
and	O	O
pre	O	O
bedtime	O	O
)	O	O
.	O	O

On	O	O
day	O	O
2	O	O
,	O	O
participants	O	O
also	O	O
attended	O	O
the	O	O
laboratory	O	O
to	O	O
complete	O	O
a	O	O
20-min	O	O
multitasking	O	O
stressor	O	O
.	O	O

RESULTS	O	O
:	O	O
Both	O	O
user	O	O
groups	O	O
exhibited	O	O
significantly	O	O
greater	O	O
levels	O	O
of	O	O
anxiety	B_Disease	O
and	O	O
depression	B_Disease	O
than	O	O
nonusers	O	O
.	O	O

On	O	O
day	O	O
1	O	O
,	O	O
all	O	O
participants	O	O
exhibited	O	O
a	O	O
typical	O	O
cortisol	B_Chemical	O
profile	O	O
,	O	O
though	O	O
light	O	O
users	O	O
had	O	O
significantly	O	O
elevated	O	O
levels	O	O
pre-bed	O	O
.	O	O

On	O	O
day	O	O
2	O	O
,	O	O
heavy	O	O
users	O	O
demonstrated	O	O
elevated	O	O
levels	O	O
upon	O	O
awakening	O	O
and	O	O
all	O	O
ecstasy-polydrug	O	O
users	O	O
demonstrated	O	O
elevated	O	O
pre-bed	O	O
levels	O	O
compared	O	O
to	O	O
non-users	O	O
.	O	O

Significant	O	O
between	O	O
group	O	O
differences	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
afternoon	O	O
cortisol	B_Chemical	O
levels	O	O
and	O	O
in	O	O
overall	O	O
cortisol	B_Chemical	O
secretion	O	O
across	O	O
the	O	O
day	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
increases	O	O
in	O	O
anxiety	B_Disease	O
and	O	O
depression	B_Disease	O
are	O	O
in	O	O
line	O	O
with	O	O
previous	O	O
observations	O	O
in	O	O
recreational	O	O
ecstasy-polydrug	O	O
users	O	O
.	O	O

Dysregulated	O	O
diurnal	O	O
cortisol	B_Chemical	O
may	O	O
be	O	O
indicative	O	O
of	O	O
inappropriate	O	O
anticipation	O	O
of	O	O
forthcoming	O	O
demands	O	O
and	O	O
hypersecretion	O	O
may	O	O
lead	O	O
to	O	O
the	O	O
increased	O	O
psychological	O	O
and	O	O
physical	O	O
morbidity	O	O
associated	O	O
with	O	O
heavy	O	O
recreational	O	O
use	O	O
of	O	O
ecstasy	B_Chemical	O
.	O	O

Ifosfamide	B_Chemical	B_Chemical
related	O	O
encephalopathy	B_Disease	O
:	O	O
the	O	O
need	O	O
for	O	O
a	O	O
timely	O	O
EEG	O	O
evaluation	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Ifosfamide	B_Chemical	B_Chemical
is	O	O
an	O	O
alkylating	O	O
agent	O	O
useful	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
cancers	B_Disease	O
including	O	O
sarcomas	B_Disease	O
,	O	O
lymphoma	B_Disease	O
,	O	O
gynecologic	B_Disease	O
and	I_Disease	O
testicular	I_Disease	O
cancers	I_Disease	O
.	O	O

Encephalopathy	B_Disease	O
has	O	O
been	O	O
reported	O	O
in	O	O
10	O	O
-	O	O
40	O	O
%	O	O
of	O	O
patients	O	O
receiving	O	O
high-dose	O	O
IV	O	O
ifosfamide	B_Chemical	B_Chemical
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
highlight	O	O
the	O	O
role	O	O
of	O	O
electroencephalogram	O	O
(	O	O
EEG	O	O
)	O	O
in	O	O
the	O	O
early	O	O
detection	O	O
and	O	O
management	O	O
of	O	O
ifosfamide	B_Chemical	B_Chemical
related	O	O
encephalopathy	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
Retrospective	O	O
chart	O	O
review	O	O
including	O	O
clinical	O	O
data	O	O
and	O	O
EEG	O	O
recordings	O	O
was	O	O
done	O	O
on	O	O
five	O	O
patients	O	O
,	O	O
admitted	O	O
to	O	O
MD	O	O
Anderson	O	O
Cancer	B_Disease	O
Center	O	O
between	O	O
years	O	O
2009	O	O
and	O	O
2012	O	O
,	O	O
who	O	O
developed	O	O
ifosfamide	B_Chemical	B_Chemical
related	O	O
acute	O	B_Disease
encephalopathy	B_Disease	I_Disease
.	O	O

RESULTS	O	O
:	O	O
All	O	O
five	O	O
patients	O	O
experienced	O	O
symptoms	O	O
of	O	O
encephalopathy	B_Disease	O
soon	O	O
after	O	O
(	O	O
within	O	O
12	O	O
h-2	O	O
days	O	O
)	O	O
receiving	O	O
ifosfamide	B_Chemical	B_Chemical
.	O	O

Two	O	O
patients	O	O
developed	O	O
generalized	O	O
convulsions	B_Disease	O
while	O	O
one	O	O
patient	O	O
developed	O	O
continuous	O	O
non-convulsive	B_Disease	O
status	I_Disease	O
epilepticus	I_Disease	O
(	O	O
NCSE	B_Disease	O
)	O	O
that	O	O
required	O	O
ICU	O	O
admission	O	O
and	O	O
intubation	O	O
.	O	O

Initial	O	O
EEG	O	O
showed	O	O
epileptiform	O	O
discharges	O	O
in	O	O
three	O	O
patients	O	O
;	O	O
run	O	O
of	O	O
triphasic	O	O
waves	O	O
in	O	O
one	O	O
patient	O	O
and	O	O
moderate	O	O
degree	O	O
diffuse	O	O
generalized	O	O
slowing	O	O
.	O	O

Mixed	O	O
pattern	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
both	O	O
sharps	O	O
and	O	O
triphasic	O	O
waves	O	O
were	O	O
also	O	O
noted	O	O
.	O	O

Repeat	O	O
EEGs	O	O
within	O	O
24_h	O	O
of	O	O
symptom	O	O
onset	O	O
showed	O	O
marked	O	O
improvement	O	O
that	O	O
was	O	O
correlated	O	O
with	O	O
clinical	O	O
improvement	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Severity	O	O
of	O	O
ifosfamide	B_Chemical	B_Chemical
related	O	O
encephalopathy	B_Disease	O
correlates	O	O
with	O	O
EEG	O	O
changes	O	O
.	O	O

We	O	O
suggest	O	O
a	O	O
timely	O	O
EEG	O	O
evaluation	O	O
for	O	O
patients	O	O
receiving	O	O
ifosfamide	B_Chemical	B_Chemical
who	O	O
develop	O	O
features	O	O
of	O	O
encephalopathy	B_Disease	O
.	O	O

Incidence	O	O
of	O	O
contrast-induced	O	O
nephropathy	B_Disease	O
in	O	O
hospitalised	O	O
patients	O	O
with	O	O
cancer	B_Disease	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
frequency	O	O
of	O	O
and	O	O
possible	O	O
factors	O	O
related	O	O
to	O	O
contrast-induced	O	O
nephropathy	B_Disease	O
(	O	O
CIN	O	O
)	O	O
in	O	O
hospitalised	O	O
patients	O	O
with	O	O
cancer	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
Ninety	O	O
adult	O	O
patients	O	O
were	O	O
enrolled	O	O
.	O	O

Patients	O	O
with	O	O
risk	O	O
factors	O	O
for	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
were	O	O
excluded	O	O
.	O	O

Blood	O	O
samples	O	O
were	O	O
examined	O	O
the	O	O
day	O	O
before	O	O
contrast-enhanced	O	O
computed	O	O
tomography	O	O
(	O	O
CT	O	O
)	O	O
and	O	O
serially	O	O
for	O	O
3	O	O
days	O	O
thereafter	O	O
.	O	O

CIN	O	O
was	O	O
defined	O	O
as	O	O
an	O	O
increase	O	O
in	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
(	O	O
Cr	B_Chemical	O
)	O	O
of	O	O
0.5	O	O
mg/dl	O	O
or	O	O
more	O	O
,	O	O
or	O	O
elevation	O	O
of	O	O
Cr	B_Chemical	O
to	O	O
25	O	O
%	O	O
over	O	O
baseline	O	O
.	O	O

Relationships	O	O
between	O	O
CIN	O	O
and	O	O
possible	O	O
risk	O	O
factors	O	O
were	O	O
investigated	O	O
.	O	O

RESULTS	O	O
:	O	O
CIN	O	O
was	O	O
detected	O	O
in	O	O
18/90	O	O
(	O	O
20	O	O
%	O	O
)	O	O
patients	O	O
.	O	O

CIN	O	O
developed	O	O
in	O	O
25.5	O	O
%	O	O
patients	O	O
who	O	O
underwent	O	O
chemotherapy	O	O
and	O	O
in	O	O
11	O	O
%	O	O
patients	O	O
who	O	O
did	O	O
not	O	O
(	O	O
P	O	O
=	O	O
0.1	O	O
)	O	O
.	O	O

CIN	O	O
more	O	O
frequently	O	O
developed	O	O
in	O	O
patients	O	O
who	O	O
had	O	O
undergone	O	O
CT	O	O
within	O	O
45	O	O
days	O	O
after	O	O
the	O	O
last	O	O
chemotherapy	O	O
(	O	O
P	O	O
=	O	O
0.005	O	O
)	O	O
;	O	O
it	O	O
was	O	O
also	O	O
an	O	O
independent	O	O
risk	O	O
factor	O	O
(	O	O
P	O	O
=	O	O
0.017	O	O
)	O	O
.	O	O

CIN	O	O
was	O	O
significantly	O	O
more	O	O
after	O	O
treatment	O	O
with	O	O
bevacizumab/irinotecan	O	O
(	O	O
P	O	O
=	O	O
0.021	O	O
)	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
hypertension	B_Disease	O
(	O	O
P	O	O
=	O	O
0.044	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
incidence	O	O
of	O	O
CIN	O	O
after	O	O
CT	O	O
in	O	O
hospitalised	O	O
oncological	O	O
patients	O	O
was	O	O
20	O	O
%	O	O
.	O	O

CIN	O	O
developed	O	O
4.5-times	O	O
more	O	O
frequently	O	O
in	O	O
patients	O	O
with	O	O
cancer	B_Disease	O
who	O	O
had	O	O
undergone	O	O
recent	O	O
chemotherapy	O	O
.	O	O

Hypertension	B_Disease	O
and	O	O
the	O	O
combination	O	O
of	O	O
bevacizumab/irinotecan	O	O
may	O	O
be	O	O
additional	O	O
risk	O	O
factors	O	O
for	O	O
CIN	O	O
development	O	O
.	O	O

KEY	O	O
POINTS	O	O
:	O	O
.	O	O

Contrast-induced	O	O
nephropathy	B_Disease	O
(	O	O
CIN	O	O
)	O	O
is	O	O
a	O	O
concern	O	O
for	O	O
oncological	O	O
patients	O	O
undergoing	O	O
CT	O	O
.	O	O
.	O	O

CIN	O	O
occurs	O	O
more	O	O
often	O	O
when	O	O
CT	O	O
is	O	O
performed	O	O
<	O	O
45	O	O
days	O	O
after	O	O
chemotherapy	O	O
.	O	O
.	O	O

Hypertension	B_Disease	O
and	O	O
treatment	O	O
with	O	O
bevacizumab	B_Chemical	B_Chemical
appear	O	O
to	O	O
be	O	O
additional	O	O
risk	O	O
factors	O	O
.	O	O

Syndrome	B_Disease	O
of	I_Disease	O
inappropriate	I_Disease	O
antidiuretic	I_Disease	O
hormone	I_Disease	O
secretion	O	O
associated	O	O
with	O	O
desvenlafaxine	B_Chemical	B_Chemical
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
syndrome	B_Disease	O
of	I_Disease	O
inappropriate	I_Disease	O
anti-diuretic	I_Disease	O
hormone	I_Disease	O
(	O	O
SIADH	B_Disease	O
)	O	O
secretion	O	O
associated	O	O
with	O	O
desvenlafaxine	B_Chemical	B_Chemical
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
57-year	O	O
old	O	O
female	O	O
with	O	O
hyponatraemia	B_Disease	O
.	O	O

Her	O	O
medications	O	O
included	O	O
desvenlafaxine	B_Chemical	B_Chemical
,	O	O
and	O	O
symptoms	O	O
included	O	O
nausea	B_Disease	O
,	O	O
anxiety	B_Disease	O
and	O	O
confusion	B_Disease	O
.	O	O

The	O	O
serum	O	O
sodium	B_Chemical	O
at	O	O
this	O	O
time	O	O
was	O	O
120	O	O
mmol/L	O	O
,	O	O
serum	O	O
osmolality	O	O
was	O	O
263	O	O
mosmol/kg	O	O
,	O	O
urine	O	O
osmolality	O	O
410	O	O
mosmol/kg	O	O
and	O	O
urine	O	O
sodium	B_Chemical	O
63	O	O
mmol/L	O	O
,	O	O
consistent	O	O
with	O	O
a	O	O
diagnosis	O	O
of	O	O
SIADH	B_Disease	O
.	O	O

Desvenlafaxine	B_Chemical	B_Chemical
was	O	O
ceased	O	O
and	O	O
fluid	O	O
restriction	O	O
implemented	O	O
.	O	O

After	O	O
4	O	O
days	O	O
the	O	O
sodium	B_Chemical	O
increased	O	O
to	O	O
128	O	O
mmol/L	O	O
and	O	O
fluid	O	O
restriction	O	O
was	O	O
relaxed	O	O
.	O	O

During	O	O
her	O	O
further	O	O
3	O	O
weeks	O	O
inpatient	O	O
admission	O	O
the	O	O
serum	O	O
sodium	B_Chemical	O
ranged	O	O
from	O	O
134	O	O
to	O	O
137	O	O
mmol/L	O	O
during	O	O
treatment	O	O
with	O	O
mirtazapine	B_Chemical	B_Chemical
.	O	O

DISCUSSION	O	O
:	O	O
SIADH	B_Disease	O
has	O	O
been	O	O
widely	O	O
reported	O	O
with	O	O
a	O	O
range	O	O
of	O	O
antidepressants	O	O
.	O	O

This	O	O
case	O	O
report	O	O
suggests	O	O
that	O	O
desvenlafaxine	B_Chemical	B_Chemical
might	O	O
cause	O	O
clinically	O	O
significant	O	O
hyponatremia	B_Disease	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Clinicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
potential	O	O
for	O	O
antidepressants	O	O
to	O	O
cause	O	O
hyponatremia	B_Disease	O
,	O	O
and	O	O
take	O	O
appropriate	O	O
corrective	O	O
action	O	O
where	O	O
necessary	O	O
.	O	O

Oxidative	O	B_Disease
stress	O	I_Disease
on	O	O
cardiotoxicity	B_Disease	B_Disease
after	O	O
treatment	O	O
with	O	O
single	O	O
and	O	O
multiple	O	O
doses	O	O
of	O	O
doxorubicin	B_Chemical	O
.	O	O

The	O	O
mechanism	O	O
of	O	O
doxorubicin	B_Chemical	O
(DOX)-induced	O	O
cardiotoxicity	B_Disease	B_Disease
remains	O	O
controversial	O	O
.	O	O

Wistar	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
66	O	O
)	O	O
received	O	O
DOX	B_Chemical	B_Chemical
injections	O	O
intraperitoneally	O	O
and	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
2	O	O
experimental	O	O
protocols	O	O
:	O	O
(	O	O
1	O	O
)	O	O
rats	O	O
were	O	O
killed	O	O
before	O	O
(	O	O
-24	O	O
h	O	O
,	O	O
n	O	O
=	O	O
8)	O	O
and	O	O
24	O	O
h	O	O
after	O	O
(	O	O
+	O	O
24	O	O
h	O	O
,	O	O
n	O	O
=	O	O
8)	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
DOX	B_Chemical	B_Chemical
(	O	O
4	O	O
mg/kg	O	O
body	O	O
weight	O	O
)	O	O
to	O	O
determine	O	O
the	O	O
DOX	B_Chemical	B_Chemical
acute	O	O
effect	O	O
and	O	O
(	O	O
2	O	O
)	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
58	O	O
)	O	O
received	O	O
4	O	O
injections	O	O
of	O	O
DOX	B_Chemical	B_Chemical
(	O	O
4	O	O
mg/kg	O	O
body	O	O
weight/week	O	O
)	O	O
and	O	O
were	O	O
killed	O	O
before	O	O
the	O	O
first	O	O
injection	O	O
(	O	O
M0	O	O
)	O	O
and	O	O
1	O	O
week	O	O
after	O	O
each	O	O
injection	O	O
(	O	O
M1	O	O
,	O	O
M2	O	O
,	O	O
M3	O	O
,	O	O
and	O	O
M4	O	O
)	O	O
to	O	O
determine	O	O
the	O	O
chronological	O	O
effects	O	O
.	O	O

Animals	O	O
used	O	O
at	O	O
M0	O	O
(	O	O
n	O	O
=	O	O
8)	O	O
were	O	O
also	O	O
used	O	O
at	O	O
moment	O	O
-24	O	O
h	O	O
of	O	O
acute	O	O
study	O	O
.	O	O

Cardiac	O	O
total	O	O
antioxidant	O	O
performance	O	O
(	O	O
TAP	O	O
)	O	O
,	O	O
DNA	O	O
damage	O	O
,	O	O
and	O	O
morphology	O	O
analyses	O	O
were	O	O
carried	O	O
out	O	O
at	O	O
each	O	O
time	O	O
point	O	O
.	O	O

Single	O	O
dose	O	O
of	O	O
DOX	B_Chemical	O
was	O	O
associated	O	O
with	O	O
increased	O	O
cardiac	B_Disease	O
disarrangement	I_Disease	O
,	O	O
necrosis	B_Disease	O
,	O	O
and	O	O
DNA	O	O
damage	O	O
(	O	O
strand	O	O
breaks	O	O
(	O	O
SBs	O	O
)	O	O
and	O	O
oxidized	O	O
pyrimidines	O	O
)	O	O
and	O	O
decreased	O	O
TAP	O	O
.	O	O

The	O	O
chronological	O	O
study	O	O
showed	O	O
an	O	O
effect	O	O
of	O	O
a	O	O
cumulative	O	O
dose	O	O
on	O	O
body	O	O
weight	O	O
(	O	O
R	O	O
=	O	O
-0.99	O	O
,	O	O
p	O	O
=	O	O
0.011	O	O
)	O	O
,	O	O
necrosis	B_Disease	O
(	O	O
R	O	O
=	O	O
1.00	O	O
,	O	O
p	O	O
=	O	O
0.004	O	O
)	O	O
,	O	O
TAP	O	O
(	O	O
R	O	O
=	O	O
0.95	O	O
,	O	O
p	O	O
=	O	O
0.049	O	O
)	O	O
,	O	O
and	O	O
DNA	O	O
SBs	O	O
(	O	O
R	O	O
=	O	O
-0.95	O	O
,	O	O
p	O	O
=	O	O
0.049	O	O
)	O	O
.	O	O

DNA	O	O
SBs	O	O
damage	O	O
was	O	O
negatively	O	O
associated	O	O
with	O	O
TAP	O	O
(	O	O
R	O	O
=	O	O
-0.98	O	O
,	O	O
p	O	O
=	O	O
0.018	O	O
)	O	O
,	O	O
and	O	O
necrosis	B_Disease	O
(	O	O
R	O	O
=	O	O
-0.97	O	O
,	O	O
p	O	O
=	O	O
0.027	O	O
)	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
oxidative	O	B_Disease
damage	O	I_Disease
is	O	O
associated	O	O
with	O	O
acute	O	O
cardiotoxicity	B_Disease	O
induced	O	O
by	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
DOX	B_Chemical	O
only	O	O
.	O	O

Increased	O	O
resistance	O	O
to	O	O
the	O	O
oxidative	O	O
stress	O	O
is	O	O
plausible	O	O
for	O	O
the	O	O
multiple	O	O
dose	O	O
of	O	O
DOX	B_Chemical	B_Chemical
.	O	O

Thus	O	O
,	O	O
different	O	O
mechanisms	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
acute	O	B_Disease
toxicity	B_Disease	I_Disease
versus	O	O
chronic	O	O
toxicity	B_Disease	O
.	O	O

Tacrolimus-related	O	O
seizure	B_Disease	O
after	O	O
pediatric	O	O
liver	O	O
transplantation	O	O
--	O	O
a	O	O
single-center	O	O
experience	O	O
.	O	O

To	O	O
identify	O	O
the	O	O
risk	O	O
factors	O	O
for	O	O
new-onset	O	O
seizures	B_Disease	O
after	O	O
pediatric	O	O
LT	O	O
and	O	O
to	O	O
assess	O	O
their	O	O
clinical	O	O
implications	O	O
and	O	O
long-term	O	O
prognosis	O	O
.	O	O

The	O	O
clinical	O	O
and	O	O
laboratory	O	O
data	O	O
of	O	O
27	O	O
consecutive	O	O
children	O	O
who	O	O
underwent	O	O
LT	O	O
from	O	O
January	O	O
2007	O	O
to	O	O
December	O	O
2010	O	O
in	O	O
our	O	O
center	O	O
were	O	O
analyzed	O	O
retrospectively	O	O
.	O	O

Patients	O	O
were	O	O
divided	O	O
into	O	O
seizures	B_Disease	O
group	O	O
and	O	O
a	O	O
non-seizures	O	O
group	O	O
.	O	O

Pre-operative	O	O
,	O	O
intra-operative	O	O
,	O	O
and	O	O
post-operative	O	O
data	O	O
were	O	O
collected	O	O
.	O	O

Seizures	B_Disease	O
occurred	O	O
in	O	O
four	O	O
children	O	O
,	O	O
an	O	O
incidence	O	O
of	O	O
14.8	O	O
%	O	O
.	O	O

All	O	O
exhibited	O	O
generalized	O	O
tonic-clonic	B_Disease	O
seizures	I_Disease	O
within	O	O
the	O	O
first	O	O
two	O	O
wk	O	O
after	O	O
LT	O	O
.	O	O

Univariate	O	O
analysis	O	O
showed	O	O
that	O	O
the	O	O
risk	O	O
factors	O	O
associated	O	O
with	O	O
seizures	B_Disease	O
after	O	O
pediatric	O	O
LT	O	O
included	O	O
gender	O	O
,	O	O
pediatric	O	O
end-stage	B_Disease	B_Disease
liver	I_Disease	I_Disease
disease	I_Disease	I_Disease
score	O	O
before	O	O
surgery	O	O
,	O	O
Child-Pugh	O	O
score	O	O
before	O	O
surgery	O	O
,	O	O
serum	O	O
total	O	O
bilirubin	B_Chemical	O
after	O	O
surgery	O	O
,	O	O
and	O	O
trough	O	O
TAC	B_Chemical	O
level	O	O
.	O	O

Multivariate	O	O
analysis	O	O
showed	O	O
that	O	O
trough	O	O
TAC	B_Chemical	O
level	O	O
was	O	O
the	O	O
only	O	O
independent	O	O
risk	O	O
factor	O	O
associated	O	O
with	O	O
the	O	O
seizures	B_Disease	O
.	O	O

All	O	O
children	O	O
who	O	O
experienced	O	O
seizures	B_Disease	O
survived	O	O
with	O	O
good	O	O
graft	O	O
function	O	O
and	O	O
remained	O	O
seizure-free	O	O
without	O	O
anti-epileptic	O	O
drugs	O	O
over	O	O
a	O	O
mean	O	O
follow-up	O	O
period	O	O
of	O	O
33.7	O	O
+	O	O
14.6	O	O
months	O	O
.	O	O

High	O	O
trough	O	O
TAC	B_Chemical	O
level	O	O
was	O	O
the	O	O
predominant	O	O
factor	O	O
that	O	O
contributed	O	O
to	O	O
seizures	B_Disease	O
in	O	O
the	O	O
early	O	O
post-operative	O	O
period	O	O
after	O	O
pediatric	O	O
LT	O	O
.	O	O

High	O	O
PELD	O	O
and	O	O
Child-Pugh	O	O
scores	O	O
before	O	O
LT	O	O
and	O	O
high	O	O
post-operative	O	O
serum	O	O
Tbil	O	O
may	O	O
be	O	O
contributory	O	O
risk	O	O
factors	O	O
for	O	O
TAC-related	O	O
seizures	B_Disease	O
.	O	O

The	O	O
flavonoid	B_Chemical	B_Chemical
apigenin	B_Chemical	I_Chemical
delays	O	O
forgetting	O	O
of	O	O
passive	O	O
avoidance	O	O
conditioning	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
present	O	O
experiments	O	O
were	O	O
performed	O	O
to	O	O
study	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
flavonoid	B_Chemical	O
apigenin	B_Chemical	B_Chemical
(	O	O
20	O	O
mg/kg	O	O
intraperitoneally	O	O
(	O	O
i.p	O	O
.	O	O
)	O	O
,	O	O
1	O	O
h	O	O
before	O	O
acquisition	O	O
)	O	O
,	O	O
on	O	O
24	O	O
h	O	O
retention	O	O
performance	O	O
and	O	O
forgetting	O	O
of	O	O
a	O	O
step-through	O	O
passive	O	O
avoidance	O	O
task	O	O
,	O	O
in	O	O
young	O	O
male	O	O
Wistar	O	O
rats	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
between	O	O
saline-	O	O
and	O	O
apigenin-treated	O	O
groups	O	O
in	O	O
the	O	O
24	O	O
h	O	O
retention	O	O
trial	O	O
.	O	O

Furthermore	O	O
,	O	O
apigenin	B_Chemical	B_Chemical
did	O	O
not	O	O
prevent	O	O
the	O	O
amnesia	B_Disease	O
induced	O	O
by	O	O
scopolamine	B_Chemical	O
(	O	O
1mg/kg	O	O
,	O	O
i.p	O	O
.	O	O
,	O	O
30	O	O
min	O	O
before	O	O
the	O	O
acquisition	O	O
)	O	O
.	O	O

The	O	O
saline-	O	O
and	O	O
apigenin-treated	O	O
rats	O	O
that	O	O
did	O	O
not	O	O
step	O	O
through	O	O
into	O	O
the	O	O
dark	O	O
compartment	O	O
during	O	O
the	O	O
cut-off	O	O
time	O	O
(	O	O
540	O	O
s	O	O
)	O	O
were	O	O
retested	O	O
weekly	O	O
for	O	O
up	O	O
to	O	O
eight	O	O
weeks	O	O
.	O	O

In	O	O
the	O	O
saline	O	O
treated	O	O
group	O	O
,	O	O
the	O	O
first	O	O
significant	O	O
decline	O	O
in	O	O
passive	O	O
avoidance	O	O
response	O	O
was	O	O
observed	O	O
at	O	O
four	O	O
weeks	O	O
,	O	O
and	O	O
complete	O	O
memory	B_Disease	B_Disease
loss	I_Disease	I_Disease
was	O	O
found	O	O
five	O	O
weeks	O	O
after	O	O
the	O	O
acquisition	O	O
of	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
.	O	O

At	O	O
the	O	O
end	O	O
of	O	O
the	O	O
experimental	O	O
period	O	O
,	O	O
60	O	O
%	O	O
of	O	O
the	O	O
animals	O	O
treated	O	O
with	O	O
apigenin	B_Chemical	B_Chemical
still	O	O
did	O	O
not	O	O
step	O	O
through	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
1	O	O
)	O	O
apigenin	B_Chemical	B_Chemical
delays	O	O
the	O	O
long-term	O	O
forgetting	O	O
but	O	O
did	O	O
not	O	O
modulate	O	O
the	O	O
24	O	O
h	O	O
retention	O	O
of	O	O
fear	O	O
memory	O	O
and	O	O
2	O	O
)	O	O
the	O	O
obtained	O	O
beneficial	O	O
effect	O	O
of	O	O
apigenin	B_Chemical	B_Chemical
on	O	O
the	O	O
passive	O	O
avoidance	O	O
conditioning	O	O
is	O	O
mediated	O	O
by	O	O
mechanisms	O	O
that	O	O
do	O	O
not	O	O
implicate	O	O
its	O	O
action	O	O
on	O	O
the	O	O
muscarinic	O	O
cholinergic	O	O
system	O	O
.	O	O

Histamine	B_Chemical	O
antagonists	O	O
and	O	O
d-tubocurarine-induced	O	O
hypotension	B_Disease	O
in	O	O
cardiac	O	O
surgical	O	O
patients	O	O
.	O	O

Hemodynamic	O	O
effects	O	O
and	O	O
histamine	B_Chemical	O
release	O	O
by	O	O
bolus	O	O
injection	O	O
of	O	O
0.35	O	O
mg/kg	O	O
of	O	O
d-tubocurarine	B_Chemical	O
were	O	O
studied	O	O
in	O	O
24	O	O
patients	O	O
.	O	O

H1-	O	O
and	O	O
H2-histamine	O	O
antagonists	O	O
or	O	O
placebo	O	O
were	O	O
given	O	O
before	O	O
dosing	O	O
with	O	O
d-tubocurarine	B_Chemical	O
in	O	O
a	O	O
randomized	O	O
double-blind	O	O
fashion	O	O
to	O	O
four	O	O
groups	O	O
:	O	O
group	O	O
1	O	O
-	O	O
-placebo	O	O
;	O	O
group	O	O
2	O	B_Chemical
-	O	I_Chemical
-cimetidine	O	I_Chemical
,	O	O
4	O	O
mg/kg	O	O
,	O	O
plus	O	O
placebo	O	O
;	O	O
group	O	O
3	O	B_Chemical
-	O	I_Chemical
-chlorpheniramine	O	I_Chemical
,	O	O
0.1	O	O
mg/kg	O	O
,	O	O
plus	O	O
placebo	O	O
;	O	O
and	O	O
group	O	O
4	O	B_Chemical
-	O	I_Chemical
-cimetidine	O	I_Chemical
plus	O	O
chlorpheniramine	B_Chemical	B_Chemical
.	O	O

Histamine	B_Chemical	O
release	O	O
occurred	O	O
in	O	O
most	O	O
patients	O	O
,	O	O
the	O	O
highest	O	O
level	O	O
2	O	O
minutes	O	O
after	O	O
d-tubocurarine	B_Chemical	O
dosing	O	O
.	O	O

Group	O	O
1	O	O
had	O	O
a	O	O
moderate	O	O
negative	O	O
correlation	O	O
between	O	O
plasma	O	O
histamine	B_Chemical	O
change	O	O
and	O	O
systemic	O	O
vascular	O	O
resistance	O	O
(	O	O
r	O	O
=	O	O
0.58	O	O
;	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
not	O	O
present	O	O
in	O	O
group	O	O
4	O	O
.	O	O

Prior	O	O
dosing	O	O
with	O	O
antagonists	O	O
partially	O	O
prevented	O	O
the	O	O
fall	O	O
in	O	O
systemic	O	O
vascular	O	O
resistance	O	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
that	O	O
the	O	O
hemodynamic	O	O
changes	O	O
associated	O	O
with	O	O
d-tubocurarine	B_Chemical	B_Chemical
dosing	O	O
are	O	O
only	O	O
partially	O	O
explained	O	O
by	O	O
histamine	B_Chemical	O
release	O	O
.	O	O

Thus	O	O
prior	O	O
dosing	O	O
with	O	O
H1-	O	O
and	O	O
H2-antagonists	O	O
provides	O	O
only	O	O
partial	O	O
protection	O	O
.	O	O

Cholecystokinin-octapeptide	B_Chemical	B_Chemical
restored	O	O
morphine-induced	O	O
hippocampal	O	O
long-term	O	O
potentiation	O	O
impairment	O	O
in	O	O
rats	O	O
.	O	O

Cholecystokinin-octapeptide	B_Chemical	B_Chemical
(	O	O
CCK-8	B_Chemical	O
)	O	O
,	O	O
which	O	O
is	O	O
a	O	O
typical	O	O
brain-gut	O	O
peptide	O	O
,	O	O
exerts	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
biological	O	O
activities	O	O
on	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
reported	O	O
that	O	O
CCK-8	B_Chemical	O
significantly	O	O
alleviated	O	O
morphine-induced	O	O
amnesia	B_Disease	O
and	O	O
reversed	O	O
spine	O	O
density	O	O
decreases	O	O
in	O	O
the	O	O
CA1	O	O
region	O	O
of	O	O
the	O	O
hippocampus	O	O
in	O	O
morphine-treated	O	O
animals	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
CCK-8	B_Chemical	O
on	O	O
long-term	O	O
potentiation	O	O
(	O	O
LTP	O	O
)	O	O
in	O	O
the	O	O
lateral	O	O
perforant	O	O
path	O	O
(LPP)-granule	O	O
cell	O	O
synapse	O	O
of	O	O
rat	O	O
dentate	O	O
gyrus	O	O
(	O	O
DG	O	O
)	O	O
in	O	O
acute	O	O
saline	O	O
or	O	O
morphine-treated	O	O
rats	O	O
.	O	O

Population	O	O
spikes	O	O
(	O	O
PS	O	O
)	O	O
,	O	O
which	O	O
were	O	O
evoked	O	O
by	O	O
stimulation	O	O
of	O	O
the	O	O
LPP	O	O
,	O	O
were	O	O
recorded	O	O
in	O	O
the	O	O
DG	O	O
region	O	O
.	O	O

Acute	O	O
morphine	B_Chemical	O
(	O	O
30mg/kg	O	O
,	O	O
s.c	O	O
.	O	O
)	O	O
treatment	O	O
significantly	O	O
attenuated	O	O
hippocampal	O	O
LTP	O	O
and	O	O
CCK-8	B_Chemical	O
(	O	O
1ug	O	O
,	O	O
i.c.v	O	O
.	O	O
)	O	O
restored	O	O
the	O	O
amplitude	O	O
of	O	O
PS	O	O
that	O	O
was	O	O
attenuated	O	O
by	O	O
morphine	B_Chemical	O
injection	O	O
.	O	O

Furthermore	O	O
,	O	O
microinjection	O	O
of	O	O
CCK-8	B_Chemical	O
(	O	O
0.1	O	O
and	O	O
1ug	O	O
,	O	O
i.c.v	O	O
.	O	O
)	O	O
also	O	O
significantly	O	O
augmented	O	O
hippocampal	O	O
LTP	O	O
in	O	O
saline-treated	O	O
(	O	O
1ml/kg	O	O
,	O	O
s.c	O	O
.	O	O
)	O	O
rats	O	O
.	O	O

Pre-treatment	O	O
of	O	O
the	O	O
CCK2	O	O
receptor	O	O
antagonist	O	O
L-365,260	O	O
(	O	O
10ug	O	O
,	O	O
i.c.v	O	O
)	O	O
reversed	O	O
the	O	O
effects	O	O
of	O	O
CCK-8	B_Chemical	O
,	O	O
but	O	O
the	O	O
CCK1	O	O
receptor	O	O
antagonist	O	O
L-364,718	O	O
(	O	O
10ug	O	O
,	O	O
i.c.v	O	O
)	O	O
did	O	O
not	O	O
.	O	O

The	O	O
present	O	O
results	O	O
demonstrate	O	O
that	O	O
CCK-8	B_Chemical	O
attenuates	O	O
the	O	O
effect	O	O
of	O	O
morphine	B_Chemical	O
on	O	O
hippocampal	O	O
LTP	O	O
through	O	O
CCK2	O	O
receptors	O	O
and	O	O
suggest	O	O
an	O	O
ameliorative	O	O
function	O	O
of	O	O
CCK-8	B_Chemical	O
on	O	O
morphine-induced	O	O
memory	B_Disease	B_Disease
impairment	I_Disease	I_Disease
.	O	O

Glial	O	O
activation	O	O
and	O	O
post-synaptic	O	O
neurotoxicity	B_Disease	B_Disease
:	O	O
the	O	O
key	O	O
events	O	O
in	O	O
Streptozotocin	B_Chemical	B_Chemical
(	O	O
ICV	O	O
)	O	O
induced	O	O
memory	B_Disease	B_Disease
impairment	I_Disease	I_Disease
in	O	O
rats	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
the	O	O
role	O	O
of	O	O
glial	O	O
activation	O	O
and	O	O
post	O	O
synaptic	O	O
toxicity	B_Disease	O
in	O	O
ICV	O	O
Streptozotocin	B_Chemical	B_Chemical
(	O	O
STZ	B_Chemical	O
)	O	O
induced	O	O
memory	B_Disease	B_Disease
impaired	I_Disease	I_Disease
rats	O	O
was	O	O
explored	O	O
.	O	O

In	O	O
experiment	O	O
set	O	O
up	O	O
1	O	O
:	O	O
Memory	B_Disease	O
deficit	I_Disease	O
was	O	O
found	O	O
in	O	O
Morris	O	O
water	O	O
maze	O	O
test	O	O
on	O	O
14	O	O
-	O	O
16	O	O
days	O	O
after	O	O
STZ	B_Chemical	O
(	O	O
ICV	O	O
;	O	O
3mg/Kg	O	O
)	O	O
administration	O	O
.	O	O

STZ	B_Chemical	O
causes	O	O
increased	O	O
expression	O	O
of	O	O
GFAP	O	O
,	O	O
CD11b	O	O
and	O	O
TNF-a	O	O
indicating	O	O
glial	O	O
activation	O	O
and	O	O
neuroinflammation	B_Disease	O
.	O	O

STZ	B_Chemical	O
also	O	O
significantly	O	O
increased	O	O
the	O	O
level	O	O
of	O	O
ROS	O	O
,	O	O
nitrite	B_Chemical	O
,	O	O
Ca(2	O	O
+	O	O
)	O	O
and	O	O
reduced	O	O
the	O	O
mitochondrial	O	O
activity	O	O
in	O	O
synaptosomal	O	O
preparation	O	O
illustrating	O	O
free	O	O
radical	O	O
generation	O	O
and	O	O
excitotoxicity	B_Disease	B_Disease
.	O	O

Increased	O	O
expression	O	O
and	O	O
activity	O	O
of	O	O
Caspase-3	O	O
was	O	O
also	O	O
observed	O	O
in	O	O
STZ	B_Chemical	O
treated	O	O
rat	O	O
which	O	O
specify	O	O
apoptotic	O	O
cell	O	O
death	O	O
in	O	O
hippocampus	O	O
and	O	O
cortex	O	O
.	O	O

STZ	B_Chemical	O
treatment	O	O
showed	O	O
decrease	O	O
expression	O	O
of	O	O
post	O	O
synaptic	O	O
markers	O	O
CaMKIIa	O	O
and	O	O
PSD-95	O	O
,	O	O
while	O	O
,	O	O
expression	O	O
of	O	O
pre	O	O
synaptic	O	O
markers	O	O
(	O	O
synaptophysin	O	O
and	O	O
SNAP-25	O	O
)	O	O
remains	O	O
unaltered	O	O
indicating	O	O
selective	O	O
post	O	O
synaptic	O	O
neurotoxicity	B_Disease	B_Disease
.	O	O

Oral	O	O
treatment	O	O
with	O	O
Memantine	B_Chemical	B_Chemical
(	O	O
10mg/kg	O	O
)	O	O
and	O	O
Ibuprofen	B_Chemical	O
(	O	O
50	O	O
mg/kg	O	O
)	O	O
daily	O	O
for	O	O
13	O	O
days	O	O
attenuated	O	O
STZ	B_Chemical	O
induced	O	O
glial	O	O
activation	O	O
,	O	O
apoptotic	O	O
cell	O	O
death	O	O
and	O	O
post	O	O
synaptic	O	O
neurotoxicity	B_Disease	B_Disease
in	O	O
rat	O	O
brain	O	O
.	O	O

Further	O	O
,	O	O
in	O	O
experiment	O	O
set	O	O
up	O	O
2	O	O
:	O	O
where	O	O
memory	O	O
function	O	O
was	O	O
not	O	O
affected	O	O
i.e.	O	O
7	O	O
-	O	O
9	O	O
days	O	O
after	O	O
STZ	B_Chemical	O
treatment	O	O
.	O	O

The	O	O
level	O	O
of	O	O
GFAP	O	O
,	O	O
CD11b	O	O
,	O	O
TNF-a	O	O
,	O	O
ROS	O	O
and	O	O
nitrite	B_Chemical	O
levels	O	O
were	O	O
increased	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
apoptotic	O	O
marker	O	O
,	O	O
synaptic	O	O
markers	O	O
,	O	O
mitochondrial	O	O
activity	O	O
and	O	O
Ca(2	O	O
+	O	O
)	O	O
levels	O	O
remained	O	O
unaffected	O	O
.	O	O

Collective	O	O
data	O	O
indicates	O	O
that	O	O
neuroinflammatory	B_Disease	O
process	O	O
and	O	O
oxidative	O	O
stress	O	O
occurs	O	O
earlier	O	O
to	O	O
apoptosis	O	O
and	O	O
does	O	O
not	O	O
affect	O	O
memory	O	O
function	O	O
.	O	O

Present	O	O
study	O	O
clearly	O	O
suggests	O	O
that	O	O
glial	O	O
activation	O	O
and	O	O
post	O	O
synaptic	O	O
neurotoxicity	B_Disease	B_Disease
are	O	O
the	O	O
key	O	O
factors	O	O
in	O	O
STZ	B_Chemical	O
induced	O	O
memory	B_Disease	B_Disease
impairment	I_Disease	I_Disease
and	O	O
neuronal	O	O
cell	O	O
death	O	O
.	O	O

Comparison	O	O
of	O	O
effects	O	O
of	O	O
isotonic	O	O
sodium	B_Chemical	B_Chemical
chloride	I_Chemical	I_Chemical
with	O	O
diltiazem	B_Chemical	O
in	O	O
prevention	O	O
of	O	O
contrast-induced	O	O
nephropathy	B_Disease	O
.	O	O

INTRODUCTION	O	O
AND	O	O
OBJECTIVE	O	O
:	O	O
Contrast-induced	O	O
nephropathy	B_Disease	O
(	O	O
CIN	O	O
)	O	O
significantly	O	O
increases	O	O
the	O	O
morbidity	O	O
and	O	O
mortality	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
investigate	O	O
and	O	O
compare	O	O
the	O	O
protective	O	O
effects	O	O
of	O	O
isotonic	O	O
sodium	B_Chemical	B_Chemical
chloride	I_Chemical	I_Chemical
with	O	O
sodium	B_Chemical	O
bicarbonate	I_Chemical	O
infusion	O	O
and	O	O
isotonic	O	O
sodium	B_Chemical	B_Chemical
chloride	I_Chemical	I_Chemical
infusion	O	O
with	O	O
diltiazem	B_Chemical	O
,	O	O
a	O	O
calcium	B_Chemical	O
channel	O	O
blocker	O	O
,	O	O
in	O	O
preventing	O	O
CIN	O	B_Chemical
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
Our	O	O
study	O	O
included	O	O
patients	O	O
who	O	O
were	O	O
administered	O	O
30	O	O
-	O	O
60	O	O
mL	O	O
of	O	O
iodinated	O	O
contrast	B_Chemical	O
agent	O	O
for	O	O
percutaneous	O	O
coronary	O	O
angiography	O	O
(	O	O
PCAG	O	O
)	O	O
,	O	O
all	O	O
with	O	O
creatinine	B_Chemical	B_Chemical
values	O	O
between	O	O
1.1	O	O
and	O	O
3.1	O	O
mg/dL.	O	O
Patients	O	O
were	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
and	O	O
each	O	O
group	O	O
had	O	O
20	O	O
patients	O	O
.	O	O

The	O	O
first	O	O
group	O	O
of	O	O
patients	O	O
was	O	O
administered	O	O
isotonic	O	O
sodium	B_Chemical	B_Chemical
chloride	I_Chemical	I_Chemical
;	O	O
the	O	O
second	O	O
group	O	O
was	O	O
administered	O	O
a	O	O
solution	O	O
that	O	O
of	O	O
5	O	O
%	O	O
dextrose	B_Chemical	O
and	O	O
sodium	B_Chemical	O
bicarbonate	I_Chemical	O
,	O	O
while	O	O
the	O	O
third	O	O
group	O	O
was	O	O
administered	O	O
isotonic	O	O
sodium	B_Chemical	B_Chemical
chloride	I_Chemical	I_Chemical
before	O	O
and	O	O
after	O	O
the	O	O
contrast	B_Chemical	O
injection	O	O
.	O	O

The	O	O
third	O	O
group	O	O
received	O	O
an	O	O
additional	O	O
injection	O	O
of	O	O
diltiazem	B_Chemical	O
the	O	O
day	O	O
before	O	O
and	O	O
first	O	O
2	O	O
days	O	O
after	O	O
the	O	O
contrast	B_Chemical	O
injection	O	O
.	O	O

All	O	O
of	O	O
the	O	O
patients	O	O
'	O	O
plasma	O	O
blood	B_Chemical	B_Chemical
urea	I_Chemical	I_Chemical
nitrogen	I_Chemical	I_Chemical
(	O	O
BUN	B_Chemical	O
)	O	O
and	O	O
creatinine	B_Chemical	B_Chemical
levels	O	O
were	O	O
measured	O	O
on	O	O
the	O	O
second	O	O
and	O	O
seventh	O	O
day	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
intravenous	O	O
contrast	B_Chemical	O
material	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
basal	O	O
creatinine	B_Chemical	B_Chemical
levels	O	O
were	O	O
similar	O	O
for	O	O
all	O	O
three	O	O
groups	O	O
(	O	O
p	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

Among	O	O
a	O	O
total	O	O
of	O	O
60	O	O
patients	O	O
included	O	O
in	O	O
the	O	O
study	O	O
,	O	O
16	O	O
patients	O	O
developed	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
(	O	O
ARF	B_Disease	O
)	O	O
on	O	O
the	O	O
second	O	O
day	O	O
after	O	O
contrast	B_Chemical	O
material	O	O
was	O	O
injected	O	O
(	O	O
26.6	O	O
%	O	O
)	O	O
.	O	O

The	O	O
number	O	O
of	O	O
patients	O	O
who	O	O
developed	O	O
ARF	B_Disease	O
on	O	O
the	O	O
second	O	O
day	O	O
after	O	O
the	O	O
injection	O	O
in	O	O
the	O	O
first	O	O
group	O	O
was	O	O
five	O	O
(	O	O
25	O	O
%	O	O
)	O	O
,	O	O
in	O	O
the	O	O
second	O	O
group	O	O
was	O	O
six	O	O
(	O	O
30	O	O
%	O	O
)	O	O
and	O	O
the	O	O
third	O	O
group	O	O
was	O	O
five	O	O
(	O	O
25	O	O
%	O	O
)	O	O
(	O	O
p	O	O
>	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
isotonic	O	O
sodium	B_Chemical	B_Chemical
chloride	I_Chemical	I_Chemical
,	O	O
sodium	B_Chemical	B_Chemical
bicarbonate	I_Chemical	I_Chemical
and	O	O
isotonic	O	O
sodium	B_Chemical	B_Chemical
chloride	I_Chemical	I_Chemical
with	O	O
diltiazem	B_Chemical	O
application	O	O
in	O	O
prevention	O	O
of	O	O
CIN	O	B_Chemical
.	O	O

Neurocognitive	O	O
and	O	O
neuroradiologic	O	O
central	O	O
nervous	O	O
system	O	O
late	O	O
effects	O	O
in	O	O
children	O	O
treated	O	O
on	O	O
Pediatric	O	O
Oncology	O	O
Group	O	O
(	O	O
POG	O	O
)	O	O
P9605	O	O
(	O	O
standard	O	O
risk	O	O
)	O	O
and	O	O
P9201	O	O
(	O	O
lesser	O	O
risk	O	O
)	O	O
acute	B_Disease	B_Disease
lymphoblastic	I_Disease	I_Disease
leukemia	I_Disease	I_Disease
protocols	O	O
(	O	O
ACCL0131	O	O
):	O	O
a	O	O
methotrexate	B_Chemical	O
consequence	O	O
?	O	O

A	O	O
report	O	O
from	O	O
the	O	O
Children	O	O
's	O	O
Oncology	O	O
Group	O	O
.	O	O

Concerns	O	O
about	O	O
long-term	O	O
methotrexate	B_Chemical	O
(	O	O
MTX	B_Chemical	B_Chemical
)	O	O
neurotoxicity	B_Disease	B_Disease
in	O	O
the	O	O
1990s	O	O
led	O	O
to	O	O
modifications	O	O
in	O	O
intrathecal	O	O
(	O	O
IT	O	O
)	O	O
therapy	O	O
,	O	O
leucovorin	O	B_Chemical
rescue	O	O
,	O	O
and	O	O
frequency	O	O
of	O	O
systemic	O	O
MTX	B_Chemical	B_Chemical
administration	O	O
in	O	O
children	O	O
with	O	O
acute	B_Disease	B_Disease
lymphoblastic	I_Disease	I_Disease
leukemia	I_Disease	I_Disease
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
neurocognitive	O	O
outcomes	O	O
and	O	O
neuroradiologic	O	O
evidence	O	O
of	O	O
leukoencephalopathy	B_Disease	B_Disease
were	O	O
compared	O	O
in	O	O
children	O	O
treated	O	O
with	O	O
intense	O	O
central	O	O
nervous	O	O
system	O	O
(CNS)-directed	O	O
therapy	O	O
(	O	O
P9605	O	O
)	O	O
versus	O	O
those	O	O
receiving	O	O
fewer	O	O
CNS-directed	O	O
treatment	O	O
days	O	O
during	O	O
intensive	O	O
consolidation	O	O
(	O	O
P9201	O	O
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
66	O	O
children	O	O
from	O	O
16	O	O
Pediatric	O	O
Oncology	O	O
Group	O	O
institutions	O	O
with	O	O
"	O	O
standard-risk	O	O
"	O	O
acute	B_Disease	B_Disease
lymphoblastic	I_Disease	I_Disease
leukemia	I_Disease	I_Disease
,	O	O
1.00	O	O
to	O	O
9.99	O	O
years	O	O
at	O	O
diagnosis	O	O
,	O	O
without	O	O
evidence	O	O
of	O	O
CNS	O	O
leukemia	B_Disease	O
at	O	O
diagnosis	O	O
were	O	O
enrolled	O	O
on	O	O
ACCL0131	O	O
:	O	O
28	O	O
from	O	O
P9201	O	O
and	O	O
38	O	O
from	O	O
P9605	O	O
.	O	O

Magnetic	O	O
resonance	O	O
imaging	O	O
scans	O	O
and	O	O
standard	O	O
neuropsychological	O	O
tests	O	O
were	O	O
performed	O	O
>	O	O
2.6	O	O
years	O	O
after	O	O
the	O	O
end	O	O
of	O	O
treatment	O	O
.	O	O

Significantly	O	O
more	O	O
P9605	O	O
patients	O	O
developed	O	O
leukoencephalopathy	B_Disease	B_Disease
compared	O	O
with	O	O
P9201	O	O
patients	O	O
(	O	O
68	O	O
%	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
49%-83	O	O
%	O	O
vs.	O	O
22	O	O
%	O	O
,	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
5%-44	O	O
%	O	O
;	O	O
P=0.001	O	O
)	O	O
identified	O	O
as	O	O
late	O	O
as	O	O
7.7	O	O
years	O	O
after	O	O
the	O	O
end	O	O
of	O	O
treatment	O	O
.	O	O

Overall	O	O
,	O	O
40	O	O
%	O	O
of	O	O
patients	O	O
scored	O	O
<	O	O
85	O	O
on	O	O
either	O	O
Verbal	O	O
or	O	O
Performance	O	O
IQ	O	O
.	O	O

Children	O	O
on	O	O
both	O	O
studies	O	O
had	O	O
significant	O	O
attention	B_Disease	O
problems	I_Disease	O
,	O	O
but	O	O
P9605	O	O
children	O	O
scored	O	O
below	O	O
average	O	O
on	O	O
more	O	O
neurocognitive	O	O
measures	O	O
than	O	O
those	O	O
treated	O	O
on	O	O
P9201	O	O
(	O	O
82	O	O
%	O	O
,	O	O
14/17	O	O
measures	O	O
vs.	O	O
24	O	O
%	O	O
,	O	O
4/17	O	O
measures	O	O
)	O	O
.	O	O

This	O	O
supports	O	O
ongoing	O	O
concerns	O	O
about	O	O
intensive	O	O
MTX	B_Chemical	B_Chemical
exposure	O	O
as	O	O
a	O	O
major	O	O
contributor	O	O
to	O	O
CNS	O	O
late	O	O
effects	O	O
.	O	O

Tranexamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
overdosage-induced	O	O
generalized	O	O
seizure	B_Disease	O
in	O	O
renal	B_Disease	B_Disease
failure	I_Disease	I_Disease
.	O	O

We	O	O
report	O	O
a	O	O
45-year-old	O	O
lady	O	O
with	O	O
chronic	B_Disease	B_Disease
kidney	I_Disease	I_Disease
disease	I_Disease	I_Disease
stage	O	O
4	O	O
due	O	O
to	O	O
chronic	O	O
tubulointerstial	B_Disease	O
disease	I_Disease	O
.	O	O

She	O	O
was	O	O
admitted	O	O
to	O	O
our	O	O
center	O	O
for	O	O
severe	O	O
anemia	B_Disease	O
due	O	O
to	O	O
menorrhagia	B_Disease	O
and	O	O
deterioration	B_Disease	O
of	I_Disease	O
renal	I_Disease	O
function	I_Disease	O
.	O	O

She	O	O
was	O	O
infused	O	O
three	O	O
units	O	O
of	O	O
packed	O	O
cells	O	O
during	O	O
a	O	O
session	O	O
of	O	O
hemodialysis	O	O
.	O	O

Tranexamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(	O	O
TNA	B_Chemical	O
)	O	O
1	O	O
g	O	O
8-hourly	O	O
was	O	O
administered	O	O
to	O	O
her	O	O
to	O	O
control	O	O
bleeding	B_Disease	O
per	O	O
vaginum	O	O
.	O	O

Two	O	O
hours	O	O
after	O	O
the	O	O
sixth	O	O
dose	O	O
of	O	O
TNA	B_Chemical	O
,	O	O
she	O	O
had	O	O
an	O	O
episode	O	O
of	O	O
generalized	O	O
tonic	B_Disease	O
clonic	I_Disease	O
convulsions	I_Disease	O
.	O	O

TNA	B_Chemical	O
was	O	O
discontinued	O	O
.	O	O

Investigations	O	O
of	O	O
the	O	O
patient	O	O
revealed	O	O
no	O	O
biochemical	O	O
or	O	O
structural	O	O
central	O	O
nervous	B_Disease	O
system	I_Disease	O
abnormalities	I_Disease	O
that	O	O
could	O	O
have	O	O
provoked	O	O
the	O	O
convulsions	B_Disease	O
.	O	O

She	O	O
did	O	O
not	O	O
require	O	O
any	O	O
further	O	O
dialytic	O	O
support	O	O
.	O	O

She	O	O
had	O	O
no	O	O
further	O	O
episodes	O	O
of	O	O
convulsion	B_Disease	O
till	O	O
dis-charge	O	O
and	O	O
during	O	O
the	O	O
two	O	O
months	O	O
of	O	O
follow-up	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
precipitating	O	O
cause	O	O
of	O	O
convulsions	B_Disease	O
was	O	O
believed	O	O
to	O	O
be	O	O
an	O	O
overdose	B_Disease	O
of	O	O
TNA	B_Chemical	O
.	O	O

Pre-treatment	O	O
of	O	O
bupivacaine-induced	O	O
cardiovascular	B_Disease	B_Disease
depression	I_Disease	I_Disease
using	O	O
different	O	O
lipid	O	O
formulations	O	O
of	O	O
propofol	B_Chemical	B_Chemical
.	O	O

BACKGROUND	O	O
:	O	O
Pre-treatment	O	O
with	O	O
lipid	O	O
emulsions	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
increase	O	O
lethal	O	O
doses	O	O
of	O	O
bupivacaine	B_Chemical	B_Chemical
,	O	O
and	O	O
the	O	O
lipid	O	O
content	O	O
of	O	O
propofol	B_Chemical	B_Chemical
may	O	O
alleviate	O	O
bupivacaine-induced	O	O
cardiotoxicity	B_Disease	B_Disease
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
propofol	B_Chemical	B_Chemical
in	O	O
intralipid	O	O
or	O	O
medialipid	O	O
emulsions	O	O
on	O	O
bupivacaine-induced	O	O
cardiotoxicity	B_Disease	B_Disease
.	O	O

METHODS	O	O
:	O	O
Rats	O	O
were	O	O
anaesthetised	O	O
with	O	O
ketamine	B_Chemical	O
and	O	O
were	O	O
given	O	O
0.5	O	O
mg/kg/min	O	O
propofol	B_Chemical	B_Chemical
in	O	O
intralipid	O	O
(	O	O
Group	O	O
P	O	O
)	O	O
,	O	O
propofol	B_Chemical	B_Chemical
in	O	O
medialipid	O	B_Chemical
(	O	O
Group	O	O
L	O	O
)	O	O
,	O	O
or	O	O
saline	O	O
(	O	O
Group	O	O
C	O	O
)	O	O
over	O	O
20	O	O
min	O	O
.	O	O

Thereafter	O	O
,	O	O
2	O	O
mg/kg/min	O	O
bupivacaine	B_Chemical	B_Chemical
0.5	O	O
%	O	O
was	O	O
infused	O	O
.	O	O

We	O	O
recorded	O	O
time	O	O
to	O	O
first	O	O
dysrhythmia	B_Disease	B_Disease
occurrence	O	O
,	O	O
respective	O	O
times	O	O
to	O	O
25	O	O
%	O	O
and	O	O
50	O	O
%	O	O
reduction	O	O
of	O	O
the	O	O
heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
and	O	O
mean	O	O
arterial	O	O
pressure	O	O
,	O	O
and	O	O
time	O	O
to	O	O
asystole	B_Disease	O
and	O	O
total	O	O
amount	O	O
of	O	O
bupivacaine	B_Chemical	B_Chemical
consumption	O	O
.	O	O

Blood	O	O
and	O	O
tissue	O	O
samples	O	O
were	O	O
collected	O	O
following	O	O
asystole	B_Disease	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
time	O	O
to	O	O
first	O	O
dysrhythmia	B_Disease	B_Disease
occurrence	O	O
,	O	O
time	O	O
to	O	O
25	O	O
%	O	O
and	O	O
50	O	O
%	O	O
reductions	O	O
in	O	O
HR	O	O
,	O	O
and	O	O
time	O	O
to	O	O
asystole	B_Disease	O
were	O	O
longer	O	O
in	O	O
Group	O	O
P	O	O
than	O	O
the	O	O
other	O	O
groups	O	O
.	O	O

The	O	O
cumulative	O	O
bupivacaine	B_Chemical	B_Chemical
dose	O	O
given	O	O
at	O	O
those	O	O
time	O	O
points	O	O
was	O	O
higher	O	O
in	O	O
Group	O	O
P.	O	O
Plasma	O	O
bupivacaine	B_Chemical	B_Chemical
levels	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
Group	O	O
P	O	O
than	O	O
in	O	O
Group	O	O
C.	O	O
Bupivacaine	B_Chemical	B_Chemical
levels	O	O
in	O	O
the	O	O
brain	O	O
and	O	O
heart	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
Group	O	O
P	O	O
and	O	O
Group	O	O
L	O	O
than	O	O
in	O	O
Group	O	O
C.	O	O
CONCLUSION	O	O
:	O	O
We	O	O
conclude	O	O
that	O	O
pre-treatment	O	O
with	O	O
propofol	B_Chemical	B_Chemical
in	O	O
intralipid	O	O
,	O	O
compared	O	O
with	O	O
propofol	B_Chemical	B_Chemical
in	O	O
medialipid	O	B_Chemical
or	O	O
saline	O	O
,	O	O
delayed	O	O
the	O	O
onset	O	O
of	O	O
bupivacaine-induced	O	O
cardiotoxic	B_Disease	B_Disease
effects	O	O
as	O	O
well	O	O
as	O	O
reduced	O	O
plasma	O	O
bupivacaine	B_Chemical	B_Chemical
levels	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
explore	O	O
tissue	O	O
bupivacaine	B_Chemical	B_Chemical
levels	O	O
of	O	O
propofol	B_Chemical	B_Chemical
in	O	O
medialipid	O	O
and	O	O
adapt	O	O
these	O	O
results	O	O
to	O	O
clinical	O	O
practice	O	O
.	O	O

Drug-Induced	B_Disease	O
Acute	I_Disease	B_Disease
Liver	I_Disease	I_Disease
Injury	I_Disease	I_Disease
Within	O	O
12	O	O
Hours	O	O
After	O	O
Fluvastatin	B_Chemical	O
Therapy	O	O
.	O	O

Although	O	O
statins	B_Chemical	O
are	O	O
generally	O	O
well-tolerated	O	O
drugs	O	O
,	O	O
recent	O	O
cases	O	O
of	O	O
drug-induced	B_Disease	O
liver	I_Disease	B_Disease
injury	I_Disease	I_Disease
associated	O	O
with	O	O
their	O	O
use	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

A	O	O
52-year-old	O	O
Chinese	O	O
man	O	O
reported	O	O
with	O	O
liver	B_Disease	B_Disease
damage	I_Disease	I_Disease
,	O	O
which	O	O
appeared	O	O
12	O	O
hours	O	O
after	O	O
beginning	O	O
treatment	O	O
with	O	O
fluvastatin	B_Chemical	O
.	O	O

Patient	O	O
presented	O	O
with	O	O
complaints	O	O
of	O	O
increasing	O	O
nausea	B_Disease	O
,	O	O
anorexia	B_Disease	O
,	O	O
and	O	O
upper	O	O
abdominal	B_Disease	B_Disease
pain	I_Disease	I_Disease
.	O	O

His	O	O
laboratory	O	O
values	O	O
showed	O	O
elevated	O	O
creatine	B_Chemical	B_Chemical
kinase	O	I_Chemical
and	O	O
transaminases	O	O
.	O	O

Testing	O	O
for	O	O
autoantibodies	O	O
was	O	O
also	O	O
negative	O	O
.	O	O

The	O	O
liver	O	O
biochemistries	O	O
eventually	O	O
normalized	O	O
within	O	O
3	O	O
weeks	O	O
of	O	O
stopping	O	O
the	O	O
fluvastatin	B_Chemical	O
.	O	O

Therefore	O	O
,	O	O
when	O	O
prescribing	O	O
statins	O	O
,	O	O
the	O	O
possibility	O	O
of	O	O
hepatic	B_Disease	B_Disease
damage	I_Disease	I_Disease
should	O	O
be	O	O
taken	O	O
into	O	O
account	O	O
.	O	O

Fluconazole	B_Chemical	B_Chemical
associated	O	O
agranulocytosis	B_Disease	O
and	O	O
thrombocytopenia	B_Disease	O
.	O	O

CASE	O	O
:	O	O
We	O	O
describe	O	O
a	O	O
second	O	O
case	O	O
of	O	O
fluconazole	B_Chemical	B_Chemical
associated	O	O
agranulocytosis	B_Disease	O
with	O	O
thrombocytopenia	B_Disease	O
and	O	O
recovery	O	O
upon	O	O
discontinuation	O	O
of	O	O
therapy	O	O
.	O	O

The	O	O
patient	O	O
began	O	O
to	O	O
have	O	O
changes	O	O
in	O	O
white	O	O
blood	O	O
cells	O	O
and	O	O
platelets	O	O
within	O	O
48	O	O
h	O	O
of	O	O
administration	O	O
of	O	O
fluconazole	B_Chemical	B_Chemical
and	O	O
began	O	O
to	O	O
recover	O	O
with	O	O
48	O	O
h	O	O
of	O	O
discontinuation	O	O
.	O	O

This	O	O
case	O	O
highlights	O	O
that	O	O
drug-induced	O	O
blood	B_Disease	O
dyscrasias	I_Disease	O
can	O	O
occur	O	O
unexpectedly	O	O
as	O	O
a	O	O
result	O	O
of	O	O
treatment	O	O
with	O	O
a	O	O
commonly	O	O
used	O	O
drug	O	O
thought	O	O
to	O	O
be	O	O
"	O	O
safe	O	O
"	O	O
.	O	O

CONCLUSION	O	O
:	O	O
According	O	O
to	O	O
Naranjo	O	O
's	O	O
algorithm	O	O
the	O	O
likelihood	O	O
that	O	O
our	O	O
patient	O	O
's	O	O
agranulocytosis	B_Disease	O
and	O	O
thrombocytopenia	B_Disease	O
occurred	O	O
as	O	O
a	O	O
result	O	O
of	O	O
therapy	O	O
with	O	O
fluconazole	B_Chemical	B_Chemical
is	O	O
probable	O	O
,	O	O
with	O	O
a	O	O
total	O	O
of	O	O
six	O	O
points	O	O
.	O	O

We	O	O
feel	O	O
that	O	O
the	O	O
weight	O	O
of	O	O
the	O	O
overall	O	O
evidence	O	O
of	O	O
this	O	O
evidence	O	O
is	O	O
strong	O	O
.	O	O

In	O	O
particular	O	O
the	O	O
temporal	O	O
relationship	O	O
of	O	O
bone	B_Disease	B_Disease
marrow	I_Disease	I_Disease
suppression	I_Disease	I_Disease
to	O	O
the	O	O
initiation	O	O
of	O	O
fluconazole	B_Chemical	B_Chemical
and	O	O
the	O	O
abatement	O	O
of	O	O
symptoms	O	O
that	O	O
rapidly	O	O
reversed	O	O
immediately	O	O
following	O	O
discontinuation	O	O
.	O	O

Two-dimensional	O	O
speckle	O	O
tracking	O	O
echocardiography	O	O
combined	O	O
with	O	O
high-sensitive	O	O
cardiac	O	O
troponin	O	O
T	O	O
in	O	O
early	O	O
detection	O	O
and	O	O
prediction	O	O
of	O	O
cardiotoxicity	B_Disease	B_Disease
during	O	O
epirubicine-based	O	O
chemotherapy	O	O
.	O	O

AIMS	O	O
:	O	O
To	O	O
investigate	O	O
whether	O	O
alterations	O	O
of	O	O
myocardial	B_Disease	O
strain	I_Disease	O
and	O	O
high-sensitive	O	O
cardiac	O	O
troponin	O	O
T	O	O
(	O	O
cTnT	O	O
)	O	O
could	O	O
predict	O	O
future	O	O
cardiac	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
in	O	O
patients	O	O
after	O	O
epirubicin	B_Chemical	B_Chemical
exposure	O	O
.	O	O

METHODS	O	O
:	O	O
Seventy-five	O	O
patients	O	O
with	O	O
non-Hodgkin	B_Disease	O
lymphoma	I_Disease	O
treated	O	O
with	O	O
epirubicin	B_Chemical	B_Chemical
were	O	O
studied	O	O
.	O	O

Blood	O	O
collection	O	O
and	O	O
echocardiography	O	O
were	O	O
performed	O	O
at	O	O
baseline	O	O
,	O	O
1	O	O
day	O	O
after	O	O
the	O	O
third	O	O
cycle	O	O
,	O	O
and	O	O
1	O	O
day	O	O
after	O	O
completion	O	O
of	O	O
chemotherapy	O	O
.	O	O

Patients	O	O
were	O	O
studied	O	O
using	O	O
echocardiography	O	O
during	O	O
follow-up	O	O
.	O	O

Global	O	O
longitudinal	O	O
(	O	O
GLS	O	O
)	O	O
,	O	O
circumferential	O	O
(	O	O
GCS	O	O
)	O	O
,	O	O
and	O	O
radial	O	O
strain	O	O
(	O	O
GRS	O	O
)	O	O
were	O	O
calculated	O	O
using	O	O
speckle	O	O
tracking	O	O
echocardiography	O	O
.	O	O

Left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
was	O	O
analysed	O	O
by	O	O
real-time	O	O
3D	O	O
echocardiography	O	O
.	O	O

Cardiotoxicity	B_Disease	B_Disease
was	O	O
defined	O	O
as	O	O
a	O	O
reduction	O	O
of	O	O
the	O	O
LVEF	O	O
of	O	O
>	O	O
5	O	O
%	O	O
to	O	O
<	O	O
55	O	O
%	O	O
with	O	O
symptoms	O	O
of	O	O
heart	B_Disease	B_Disease
failure	I_Disease	I_Disease
or	O	O
an	O	O
asymptomatic	O	O
reduction	O	O
of	O	O
the	O	O
LVEF	O	O
of	O	O
>	O	O
10	O	O
%	O	O
to	O	O
<	O	O
55	O	O
%	O	O
.	O	O

RESULTS	O	O
:	O	O
Fourteen	O	O
patients	O	O
(	O	O
18.67	O	O
%	O	O
)	O	O
developed	O	O
cardiotoxicity	B_Disease	B_Disease
after	O	O
treatment	O	O
.	O	O

GLS	O	O
(	O	O
-18.48	O	O
+	O	O
1.72	O	O
%	O	O
vs.	O	O
-15.96	O	O
+	O	O
1.6	O	O
%	O	O
)	O	O
,	O	O
GCS	O	O
(	O	O
-20.93	O	O
+	O	O
2.86	O	O
%	O	O
vs.	O	O
-19.20	O	O
+	O	O
3.21	O	O
%	O	O
)	O	O
,	O	O
and	O	O
GRS	O	O
(	O	O
39.23	O	O
+	O	O
6.44	O	O
%	O	O
vs.	O	O
34.98	O	O
+	O	O
6.2	O	O
%	O	O
)	O	O
were	O	O
markedly	O	O
reduced	O	O
and	O	O
cTnT	O	O
was	O	O
elevated	O	O
from	O	O
0.0010	O	O
+	O	O
0.0020	O	O
to	O	O
0.0073	O	O
+	O	O
0.0038	O	O
ng/mL	O	O
(	O	O
P	O	O
all	O	O
<	O	O
0.01	O	O
)	O	O
at	O	O
the	O	O
completion	O	O
of	O	O
chemotherapy	O	O
compared	O	O
with	O	O
baseline	O	O
values	O	O
.	O	O

A	O	O
>	O	O
15.9	O	O
%	O	O
decrease	O	O
in	O	O
GLS	O	O
[	O	O
sensitivity	O	O
,	O	O
86	O	O
%	O	O
;	O	O
specificity	O	O
,	O	O
75	O	O
%	O	O
;	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
(	O	O
AUC	O	O
)	O	O
=	O	O
0.815	O	O
;	O	O
P	O	O
=	O	O
0.001	O	O
]	O	O
and	O	O
a	O	O
>	O	O
0.004	O	O
ng/mL	O	O
elevation	O	O
in	O	O
cTnT	O	O
(	O	O
sensitivity	O	O
,	O	O
79	O	O
%	O	O
;	O	O
specificity	O	O
,	O	O
64	O	O
%	O	O
;	O	O
AUC	O	O
=	O	O
0.757	O	O
;	O	O
P	O	O
=	O	O
0.005	O	O
)	O	O
from	O	O
baseline	O	O
to	O	O
the	O	O
third	O	O
cycle	O	O
of	O	O
chemotherapy	O	O
predicted	O	O
later	O	O
cardiotoxicity	B_Disease	B_Disease
.	O	O

The	O	O
decrease	O	O
in	O	O
GLS	O	O
remained	O	O
the	O	O
only	O	O
independent	O	O
predictor	O	O
of	O	O
cardiotoxicity	B_Disease	B_Disease
(	O	O
P	O	O
=	O	O
0.000	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
GLS	O	O
combined	O	O
with	O	O
cTnT	O	O
may	O	O
provide	O	O
a	O	O
reliable	O	O
and	O	O
non-invasive	O	O
method	O	O
to	O	O
predict	O	O
cardiac	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
in	O	O
patients	O	O
receiving	O	O
anthracycline-based	O	O
chemotherapy	O	O
.	O	O

Prevention	O	O
of	O	O
etomidate-induced	O	O
myoclonus	B_Disease	O
:	O	O
which	O	O
is	O	O
superior	O	O
:	O	O
Fentanyl	B_Chemical	O
,	O	O
midazolam	B_Chemical	O
,	O	O
or	O	O
a	O	O
combination	O	O
?	O	O
A	O	O
Retrospective	O	O
comparative	O	O
study	O	O
.	O	O

BACKGROUND	O	O
:	O	O
In	O	O
this	O	O
retrospective	O	O
comparative	O	O
study	O	O
,	O	O
we	O	O
aimed	O	O
to	O	O
compare	O	O
the	O	O
effectiveness	O	O
of	O	O
fentanyl	B_Chemical	O
,	O	O
midazolam	B_Chemical	O
,	O	O
and	O	O
a	O	O
combination	O	O
of	O	O
fentanyl	B_Chemical	O
and	O	O
midazolam	B_Chemical	O
to	O	O
prevent	O	O
etomidate-induced	O	O
myoclonus	B_Disease	O
.	O	O

MATERIAL	O	O
AND	O	O
METHODS	O	O
:	O	O
This	O	O
study	O	O
was	O	O
performed	O	O
based	O	O
on	O	O
anesthesia	O	O
records	O	O
.	O	O

Depending	O	O
on	O	O
the	O	O
drugs	O	O
that	O	O
would	O	O
be	O	O
given	O	O
before	O	O
the	O	O
induction	O	O
of	O	O
anesthesia	O	O
with	O	O
etomidate	B_Chemical	B_Chemical
,	O	O
the	O	O
patients	O	O
were	O	O
separated	O	O
into	O	O
4	O	O
groups	O	O
:	O	O
no	O	O
pretreatment	O	O
(	O	O
Group	O	O
NP	O	O
)	O	O
,	O	O
fentanyl	B_Chemical	O
1	O	O
ug.kg-1	O	O
(	O	O
Group	O	O
F	O	O
)	O	O
,	O	O
midazolam	B_Chemical	O
0.03	O	O
mg.kg-1	O	O
(	O	O
Group	O	O
M	O	O
)	O	O
,	O	O
and	O	O
midazolam	B_Chemical	O
0.015	O	O
mg.kg-1	O	O
+	O	O
fentanyl	B_Chemical	O
0.5	O	O
ug.kg-1	O	O
(	O	O
Group	O	O
FM	O	O
)	O	O
.	O	O

Patients	O	O
who	O	O
received	O	O
the	O	O
same	O	O
anesthetic	O	O
procedure	O	O
were	O	O
selected	O	O
:	O	O
2	O	O
minutes	O	O
after	O	O
intravenous	O	O
injections	O	O
of	O	O
the	O	O
pretreatment	O	O
drugs	O	O
,	O	O
anesthesia	O	O
is	O	O
induced	O	O
with	O	O
0.3	O	O
mg.kg-1	O	O
etomidate	B_Chemical	B_Chemical
injected	O	O
intravenously	O	O
over	O	O
a	O	O
period	O	O
of	O	O
20	O	O
-	O	O
30	O	O
seconds	O	O
.	O	O

Myoclonic	B_Disease	B_Disease
movements	I_Disease	O
are	O	O
evaluated	O	O
,	O	O
which	O	O
were	O	O
observed	O	O
and	O	O
graded	O	O
according	O	O
to	O	O
clinical	O	O
severity	O	O
during	O	O
the	O	O
2	O	O
minutes	O	O
after	O	O
etomidate	B_Chemical	O
injection	O	O
.	O	O

The	O	O
severity	O	O
of	O	O
pain	B_Disease	O
due	O	O
to	O	O
etomidate	B_Chemical	B_Chemical
injection	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
and	O	O
adverse	O	O
effects	O	O
were	O	O
also	O	O
evaluated	O	O
.	O	O

RESULTS	O	O
:	O	O
Study	O	O
results	O	O
showed	O	O
that	O	O
myoclonus	B_Disease	O
incidence	O	O
was	O	O
85	O	O
%	O	O
,	O	O
40	O	O
%	O	O
,	O	O
70	O	O
%	O	O
,	O	O
and	O	O
25	O	O
%	O	O
in	O	O
Group	O	O
NP	O	O
,	O	O
Group	O	O
F	O	O
,	O	O
Group	O	O
M	O	O
,	O	O
and	O	O
Group	O	O
FM	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
Group	O	O
F	O	O
and	O	O
Group	O	O
FM	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
We	O	O
conclude	O	O
that	O	O
pretreatment	O	O
with	O	O
fentanyl	B_Chemical	O
or	O	O
combination	O	O
of	O	O
fentanyl	B_Chemical	O
and	O	O
midazolam	B_Chemical	O
was	O	O
effective	O	O
in	O	O
preventing	O	O
etomidate-induced	O	O
myoclonus	B_Disease	O
.	O	O

Convulsant	O	O
effect	O	O
of	O	O
lindane	B_Chemical	O
and	O	O
regional	O	O
brain	O	O
concentration	O	O
of	O	O
GABA	B_Chemical	O
and	O	O
dopamine	B_Chemical	O
.	O	O

Lindane	B_Chemical	O
(	O	O
gamma-hexachlorocyclohexane	B_Chemical	B_Chemical
)	O	O
is	O	O
an	O	O
organochlorine	O	O
insecticide	O	O
with	O	O
known	O	O
neurotoxic	B_Disease	O
effects	O	O
.	O	O

Its	O	O
mechanism	O	O
of	O	O
action	O	O
is	O	O
not	O	O
well	O	O
understood	O	O
although	O	O
it	O	O
has	O	O
been	O	O
proposed	O	O
that	O	O
lindane	B_Chemical	O
acts	O	O
as	O	O
a	O	O
non-competitive	O	O
antagonist	O	O
at	O	O
the	O	O
gamma-aminobutyric	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(GABA)-A	O	O
receptor	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
effect	O	O
of	O	O
lindane	B_Chemical	O
(	O	O
150	O	O
mg/kg	O	O
)	O	O
on	O	O
the	O	O
GABAergic	O	O
and	O	O
dopaminergic	O	O
systems	O	O
by	O	O
measuring	O	O
the	O	O
concentration	O	O
of	O	O
GABA	B_Chemical	O
,	O	O
dopamine	B_Chemical	O
and	O	O
its	O	O
metabolites	O	O
in	O	O
7	O	O
brain	O	O
areas	O	O
at	O	O
the	O	O
onset	O	O
of	O	O
seizures	B_Disease	O
.	O	O

All	O	O
animals	O	O
suffered	O	O
tonic	O	O
convulsions	B_Disease	O
at	O	O
18.3	O	O
+	O	O
/-	O	O
1.4	O	O
min	O	O
after	O	O
lindane	B_Chemical	O
administration	O	O
.	O	O

The	O	O
concentration	O	O
of	O	O
GABA	B_Chemical	O
was	O	O
only	O	O
slightly	O	O
but	O	O
significantly	O	O
decreased	O	O
in	O	O
the	O	O
colliculi	O	O
without	O	O
modifications	O	O
in	O	O
the	O	O
other	O	O
areas	O	O
.	O	O

The	O	O
concentration	O	O
of	O	O
dopamine	B_Chemical	O
was	O	O
increased	O	O
in	O	O
the	O	O
mesencephalon	O	O
and	O	O
that	O	O
of	O	O
its	O	O
metabolite	O	O
DOPAC	B_Chemical	B_Chemical
was	O	O
also	O	O
increased	O	O
in	O	O
the	O	O
mesencephalon	O	O
and	O	O
the	O	O
striatum	O	O
.	O	O

Cholestatic	B_Disease	B_Disease
presentation	O	O
of	O	O
yellow	O	O
phosphorus	B_Chemical	O
poisoning	B_Disease	O
.	O	O

Yellow	O	B_Chemical
phosphorus	B_Chemical	I_Chemical
,	O	O
a	O	O
component	O	O
of	O	O
certain	O	O
pesticide	O	O
pastes	O	O
and	O	O
fireworks	O	O
,	O	O
is	O	O
well	O	O
known	O	O
to	O	O
cause	O	O
hepatotoxicity	B_Disease	B_Disease
.	O	O

Poisoning	B_Disease	O
with	O	O
yellow	O	O
phosphorus	B_Chemical	O
classically	O	O
manifests	O	O
with	O	O
acute	B_Disease	O
hepatitis	I_Disease	O
leading	O	O
to	O	O
acute	B_Disease	B_Disease
liver	I_Disease	I_Disease
failure	I_Disease	I_Disease
which	O	O
may	O	O
need	O	O
liver	O	O
transplantation	O	O
.	O	O

We	O	O
present	O	O
a	O	O
case	O	O
of	O	O
yellow	O	O
phosphorus	B_Chemical	O
poisoning	B_Disease	O
in	O	O
which	O	O
a	O	O
patient	O	O
presented	O	O
with	O	O
florid	O	O
clinical	O	O
features	O	O
of	O	O
cholestasis	B_Disease	O
highlighting	O	O
the	O	O
fact	O	O
that	O	O
cholestasis	B_Disease	O
can	O	O
rarely	O	O
be	O	O
a	O	O
presenting	O	O
feature	O	O
of	O	O
yellow	O	O
phosphorus	B_Chemical	O
hepatotoxicity	B_Disease	O
.	O	O

Vasovagal	B_Disease	B_Disease
syncope	I_Disease	I_Disease
and	O	O
severe	O	O
bradycardia	B_Disease	O
following	O	O
intranasal	O	O
dexmedetomidine	B_Chemical	B_Chemical
for	O	O
pediatric	O	O
procedural	O	O
sedation	O	O
.	O	O

We	O	O
report	O	O
syncope	B_Disease	O
and	O	O
bradycardia	B_Disease	O
in	O	O
an	O	O
11-year-old	O	O
girl	O	O
following	O	O
administration	O	O
of	O	O
intranasal	O	O
dexmedetomidine	B_Chemical	B_Chemical
for	O	O
sedation	O	O
for	O	O
a	O	O
voiding	O	O
cystourethrogram	O	O
.	O	O

Following	O	O
successful	O	O
completion	O	O
of	O	O
VCUG	O	O
and	O	O
a	O	O
60-min	O	O
recovery	O	O
period	O	O
,	O	O
the	O	O
patient	O	O
's	O	O
level	O	O
of	O	O
consciousness	O	O
and	O	O
vital	O	O
signs	O	O
returned	O	O
to	O	O
presedation	O	O
levels	O	O
.	O	O

Upon	O	O
leaving	O	O
the	O	O
sedation	O	O
area	O	O
,	O	O
the	O	O
patient	O	O
collapsed	O	O
,	O	O
with	O	O
no	O	O
apparent	O	O
inciting	O	O
event	O	O
.	O	O

The	O	O
patient	O	O
quickly	O	O
regained	O	O
consciousness	O	O
and	O	O
no	O	O
injury	O	O
occurred	O	O
.	O	O

The	O	O
primary	O	O
abnormality	O	O
found	O	O
was	O	O
persistent	O	O
bradycardia	B_Disease	O
,	O	O
and	O	O
she	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
telemetric	O	O
observation	O	O
.	O	O

The	O	O
bradycardia	B_Disease	O
lasted	O	O
~2	O	O
h	O	O
,	O	O
and	O	O
further	O	O
cardiac	O	O
workup	O	O
revealed	O	O
no	O	O
underlying	O	O
abnormality	O	O
.	O	O

Unanticipated	O	O
and	O	O
previously	O	O
unreported	O	O
outcomes	O	O
may	O	O
be	O	O
witnessed	O	O
as	O	O
we	O	O
expand	O	O
the	O	O
use	O	O
of	O	O
certain	O	O
sedatives	O	O
to	O	O
alternative	O	O
routes	O	O
of	O	O
administration	O	O
.	O	O

Paradoxical	O	O
severe	O	O
agitation	B_Disease	O
induced	O	O
by	O	O
add-on	O	O
high-doses	O	B_Chemical
quetiapine	B_Chemical	I_Chemical
in	O	O
schizo-affective	B_Disease	O
disorder	I_Disease	O
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
35-year-old	O	O
patient	O	O
suffering	O	O
from	O	O
schizo-affective	B_Disease	O
disorder	I_Disease	O
since	O	O
the	O	O
age	O	O
of	O	O
19	O	O
years	O	O
,	O	O
treated	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
first-generation	O	O
antipsychotics	O	O
,	O	O
zuclopenthixol	B_Chemical	B_Chemical
(	O	O
100	O	O
mg/day	O	O
)	O	O
and	O	O
lithium	B_Chemical	O
(	O	O
1200	O	O
mg/day	O	O
)	O	O
(	O	O
serum	O	O
lithium=0.85	O	O
mEq/l	O	O
)	O	O
.	O	O

This	O	O
patient	O	O
had	O	O
no	O	O
associated	O	O
personality	B_Disease	B_Disease
disorder	I_Disease	I_Disease
(	O	O
particularly	O	O
no	O	O
antisocial	B_Disease	O
disorder	I_Disease	O
)	O	O
and	O	O
no	O	O
substance	B_Disease	O
abuse	I_Disease	O
disorder	I_Disease	O
.	O	O

Within	O	O
the	O	O
48	O	O
h	O	O
following	O	O
the	O	O
gradual	O	O
introduction	O	O
of	O	O
quetiapine	B_Chemical	B_Chemical
(	O	O
up	O	O
to	O	O
600	O	O
mg/day	O	O
)	O	O
,	O	O
the	O	O
patient	O	O
presented	O	O
severe	O	O
agitation	B_Disease	O
without	O	O
an	O	O
environmental	O	O
explanation	O	O
,	O	O
contrasting	O	O
with	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
history	O	O
of	O	O
aggressiveness	B_Disease	O
or	O	O
personality	B_Disease	B_Disease
disorder	I_Disease	I_Disease
.	O	O

The	O	O
diagnoses	O	O
of	O	O
manic	B_Disease	O
shift	O	O
and	O	O
akathisia	B_Disease	O
were	O	O
dismissed	O	O
.	O	O

The	O	O
withdrawal	O	O
and	O	O
the	O	O
gradual	O	O
reintroduction	O	O
of	O	O
quetiapine	B_Chemical	B_Chemical
2	O	O
weeks	O	O
later	O	O
,	O	O
which	O	O
led	O	O
to	O	O
another	O	O
severe	O	O
agitation	B_Disease	O
,	O	O
enabled	O	O
us	O	O
to	O	O
attribute	O	O
the	O	O
agitation	B_Disease	O
specifically	O	O
to	O	O
quetiapine	B_Chemical	B_Chemical
.	O	O

Antioxidant	O	O
effects	O	O
of	O	O
bovine	O	O
lactoferrin	O	B_Chemical
on	O	O
dexamethasone-induced	O	O
hypertension	B_Disease	O
in	O	O
rat	O	O
.	O	O

Dexamethasone-	O	B_Chemical
(	O	O
Dex-	O	O
)	O	O
induced	O	O
hypertension	B_Disease	O
is	O	O
associated	O	O
with	O	O
enhanced	O	O
oxidative	O	O
stress	O	O
.	O	O

Lactoferrin	O	B_Chemical
(	O	O
LF	O	O
)	O	O
is	O	O
an	O	O
iron-binding	O	O
glycoprotein	O	O
with	O	O
antihypertensive	O	O
properties	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
administration	O	O
of	O	O
LF	O	O
on	O	O
oxidative	O	O
stress	O	O
and	O	O
hypertension	B_Disease	O
upon	O	O
Dex	B_Chemical	B_Chemical
administration	O	O
.	O	O

Male	O	O
Wistar	O	O
rats	O	O
were	O	O
treated	O	O
by	O	O
Dex	B_Chemical	B_Chemical
(	O	O
30	O	O
 	O	O
u	O	O
g/kg/day	O	O
subcutaneously	O	O
)	O	O
or	O	O
saline	O	O
for	O	O
14	O	O
days	O	O
.	O	O

Oral	O	O
bovine	O	O
LF	O	O
(	O	O
30	O	O
,	O	O
100	O	O
,	O	O
300	O	O
mg/kg	O	O
)	O	O
was	O	O
given	O	O
from	O	O
day	O	O
8	O	O
to	O	O
14	O	O
in	O	O
a	O	O
reversal	O	O
study	O	O
.	O	O

In	O	O
a	O	O
prevention	O	O
study	O	O
,	O	O
rats	O	O
received	O	O
4	O	O
days	O	O
of	O	O
LF	O	O
treatment	O	O
followed	O	O
by	O	O
Dex	B_Chemical	B_Chemical
and	O	O
continued	O	O
during	O	O
the	O	O
test	O	O
period	O	O
.	O	O

Systolic	O	O
blood	O	O
pressure	O	O
(	O	O
SBP	O	O
)	O	O
was	O	O
measured	O	O
using	O	O
tail-cuff	O	O
method	O	O
.	O	O

Thymus	O	O
weight	O	O
was	O	O
used	O	O
as	O	O
a	O	O
marker	O	O
of	O	O
glucocorticoid	O	O
activity	O	O
.	O	O

Plasma	O	O
hydrogen	B_Chemical	O
peroxide	I_Chemical	O
(	O	O
H2O2	B_Chemical	O
)	O	O
concentration	O	O
and	O	O
ferric	O	O
reducing	O	O
antioxidant	O	O
power	O	O
(	O	O
FRAP	O	O
)	O	O
value	O	O
were	O	O
determined	O	O
.	O	O

Dexamethasone	B_Chemical	O
significantly	O	O
increased	O	O
SBP	O	O
and	O	O
plasma	O	O
H2O2	B_Chemical	O
level	O	O
and	O	O
decreased	O	O
thymus	O	O
and	O	O
body	O	O
weights	O	O
.	O	O

LF	O	O
lowered	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
and	O	O
dose	O	O
dependently	O	O
prevented	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
Dex-induced	O	O
hypertension	B_Disease	O
.	O	O

LF	O	O
prevented	O	O
body	O	B_Disease
weight	B_Disease	I_Disease
loss	I_Disease	I_Disease
and	O	O
significantly	O	O
reduced	O	O
the	O	O
elevated	O	O
plasma	O	O
H2O2	B_Chemical	O
and	O	O
increased	O	O
FRAP	O	O
values	O	O
.	O	O

Chronic	O	O
administration	O	O
of	O	O
LF	O	O
strongly	O	O
reduced	O	O
the	O	O
blood	O	O
pressure	O	O
and	O	O
production	O	O
of	O	O
ROS	O	O
and	O	O
improved	O	O
antioxidant	O	O
capacity	O	O
in	O	O
Dex-induced	O	O
hypertension	B_Disease	O
,	O	O
suggesting	O	O
the	O	O
role	O	O
of	O	O
inhibition	O	O
of	O	O
oxidative	O	O
stress	O	O
as	O	O
another	O	O
mechanism	O	O
of	O	O
antihypertensive	O	O
action	O	O
of	O	O
LF	O	O
.	O	O

The	O	O
association	O	O
between	O	O
tranexamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
and	O	O
convulsive	B_Disease	B_Disease
seizures	B_Disease	I_Disease
after	O	O
cardiac	O	O
surgery	O	O
:	O	O
a	O	O
multivariate	O	O
analysis	O	O
in	O	O
11	O	O
529	O	O
patients	O	O
.	O	O

Because	O	O
of	O	O
a	O	O
lack	O	O
of	O	O
contemporary	O	O
data	O	O
regarding	O	O
seizures	B_Disease	O
after	O	O
cardiac	O	O
surgery	O	O
,	O	O
we	O	O
undertook	O	O
a	O	O
retrospective	O	O
analysis	O	O
of	O	O
prospectively	O	O
collected	O	O
data	O	O
from	O	O
11	O	O
529	O	O
patients	O	O
in	O	O
whom	O	O
cardiopulmonary	O	O
bypass	O	O
was	O	O
used	O	O
from	O	O
January	O	O
2004	O	O
to	O	O
December	O	O
2010	O	O
.	O	O

A	O	O
convulsive	B_Disease	B_Disease
seizure	B_Disease	I_Disease
was	O	O
defined	O	O
as	O	O
a	O	O
transient	O	O
episode	O	O
of	O	O
disturbed	O	O
brain	O	O
function	O	O
characterised	O	O
by	O	O
abnormal	B_Disease	O
involuntary	I_Disease	O
motor	I_Disease	O
movements	I_Disease	O
.	O	O

Multivariate	O	O
regression	O	O
analysis	O	O
was	O	O
performed	O	O
to	O	O
identify	O	O
independent	O	O
predictors	O	O
of	O	O
postoperative	O	O
seizures	B_Disease	O
.	O	O

A	O	O
total	O	O
of	O	O
100	O	O
(	O	O
0.9	O	O
%	O	O
)	O	O
patients	O	O
developed	O	O
postoperative	O	O
convulsive	B_Disease	O
seizures	B_Disease	O
.	O	O

Generalised	B_Disease	O
and	I_Disease	O
focal	I_Disease	O
seizures	I_Disease	O
were	O	O
identified	O	O
in	O	O
68	O	O
and	O	O
32	O	O
patients	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
median	O	O
(	O	O
IQR	O	O
[	O	O
range	O	O
]	O	O
)	O	O
time	O	O
after	O	O
surgery	O	O
when	O	O
the	O	O
seizure	B_Disease	O
occurred	O	O
was	O	O
7	O	O
(	O	O
6	O	O
-	O	O
12	O	O
[	O	O
1	O	O
-	O	O
216	O	O
]	O	O
)	O	O
h	O	O
and	O	O
8	O	O
(	O	O
6	O	O
-	O	O
11	O	O
[	O	O
4	O	O
-	O	O
18	O	O
]	O	O
)	O	O
h	O	O
,	O	O
respectively	O	O
.	O	O

Epileptiform	O	O
findings	O	O
on	O	O
electroencephalography	O	O
were	O	O
seen	O	O
in	O	O
19	O	O
patients	O	O
.	O	O

Independent	O	O
predictors	O	O
of	O	O
postoperative	O	O
seizures	B_Disease	O
included	O	O
age	O	O
,	O	O
female	O	O
sex	O	O
,	O	O
redo	O	O
cardiac	O	O
surgery	O	O
,	O	O
calcification	O	O
of	O	O
ascending	O	O
aorta	O	O
,	O	O
congestive	B_Disease	B_Disease
heart	I_Disease	I_Disease
failure	I_Disease	I_Disease
,	O	O
deep	O	O
hypothermic	B_Disease	O
circulatory	O	O
arrest	O	O
,	O	O
duration	O	O
of	O	O
aortic	O	O
cross-clamp	O	O
and	O	O
tranexamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
.	O	O

When	O	O
tested	O	O
in	O	O
a	O	O
multivariate	O	O
regression	O	O
analysis	O	O
,	O	O
tranexamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
was	O	O
a	O	O
strong	O	O
independent	O	O
predictor	O	O
of	O	O
seizures	B_Disease	O
(	O	O
OR	O	O
14.3	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
5.5	O	O
-	O	O
36.7	O	O
;	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Patients	O	O
with	O	O
convulsive	B_Disease	B_Disease
seizures	B_Disease	I_Disease
had	O	O
2.5	O	O
times	O	O
higher	O	O
in-hospital	O	O
mortality	O	O
rates	O	O
and	O	O
twice	O	O
the	O	O
length	O	O
of	O	O
hospital	O	O
stay	O	O
compared	O	O
with	O	O
patients	O	O
without	O	O
convulsive	B_Disease	B_Disease
seizures	B_Disease	I_Disease
.	O	O

Mean	O	O
(	O	O
IQR	O	O
[	O	O
range	O	O
]	O	O
)	O	O
length	O	O
of	O	O
stay	O	O
in	O	O
the	O	O
intensive	O	O
care	O	O
unit	O	O
was	O	O
115	O	O
(	O	O
49	O	O
-	O	O
228	O	O
[	O	O
32	O	O
-	O	O
481	O	O
]	O	O
)	O	O
h	O	O
in	O	O
patients	O	O
with	O	O
convulsive	B_Disease	B_Disease
seizures	B_Disease	I_Disease
compared	O	O
with	O	O
26	O	O
(	O	O
22	O	O
-	O	O
69	O	O
[	O	O
14	O	O
-	O	O
1080	O	O
]	O	O
)	O	O
h	O	O
in	O	O
patients	O	O
without	O	O
seizures	B_Disease	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Convulsive	B_Disease	O
seizures	B_Disease	O
are	O	O
a	O	O
serious	O	O
postoperative	B_Disease	O
complication	I_Disease	O
after	O	O
cardiac	O	O
surgery	O	O
.	O	O

As	O	O
tranexamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
is	O	O
the	O	O
only	O	O
modifiable	O	O
factor	O	O
,	O	O
its	O	O
administration	O	O
,	O	O
particularly	O	O
in	O	O
doses	O	O
exceeding	O	O
80	O	O
mg.kg(-1	O	O
)	O	O
,	O	O
should	O	O
be	O	O
weighed	O	O
against	O	O
the	O	O
risk	O	O
of	O	O
postoperative	O	O
seizures	B_Disease	O
.	O	O

Dysfunctional	B_Disease	O
overnight	I_Disease	O
memory	I_Disease	O
consolidation	O	O
in	O	O
ecstasy	B_Chemical	O
users	O	O
.	O	O

Sleep	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
consolidation	O	O
and	O	O
integration	O	O
of	O	O
memory	O	O
in	O	O
a	O	O
process	O	O
called	O	O
overnight	O	O
memory	O	O
consolidation	O	O
.	O	O

Previous	O	O
studies	O	O
indicate	O	O
that	O	O
ecstasy	B_Chemical	O
users	O	O
have	O	O
marked	O	O
and	O	O
persistent	O	O
neurocognitive	O	O
and	O	O
sleep-related	B_Disease	O
impairments	I_Disease	O
.	O	O

We	O	O
extend	O	O
past	O	O
research	O	O
by	O	O
examining	O	O
overnight	O	O
memory	O	O
consolidation	O	O
among	O	O
regular	O	O
ecstasy	B_Chemical	O
users	O	O
(	O	O
n=12	O	O
)	O	O
and	O	O
drug	O	O
naive	O	O
healthy	O	O
controls	O	O
(	O	O
n=26	O	O
)	O	O
.	O	O

Memory	O	O
recall	O	O
of	O	O
word	O	O
pairs	O	O
was	O	O
evaluated	O	O
before	O	O
and	O	O
after	O	O
a	O	O
period	O	O
of	O	O
sleep	O	O
,	O	O
with	O	O
and	O	O
without	O	O
interference	O	O
prior	O	O
to	O	O
testing	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
assessed	O	O
neurocognitive	O	O
performances	O	O
across	O	O
tasks	O	O
of	O	O
learning	O	O
,	O	O
memory	O	O
and	O	O
executive	O	O
functioning	O	O
.	O	O

Ecstasy	B_Chemical	O
users	O	O
demonstrated	O	O
impaired	B_Disease	O
overnight	I_Disease	O
memory	I_Disease	O
consolidation	O	O
,	O	O
a	O	O
finding	O	O
that	O	O
was	O	O
more	O	O
pronounced	O	O
following	O	O
associative	O	O
interference	O	O
.	O	O

Additionally	O	O
,	O	O
ecstasy	B_Chemical	O
users	O	O
demonstrated	O	O
impairments	O	O
on	O	O
tasks	O	O
recruiting	O	O
frontostriatal	O	O
and	O	O
hippocampal	O	O
neural	O	O
circuitry	O	O
,	O	O
in	O	O
the	O	O
domains	O	O
of	O	O
proactive	O	O
interference	O	O
memory	O	O
,	O	O
long-term	O	O
memory	O	O
,	O	O
encoding	O	O
,	O	O
working	O	O
memory	O	O
and	O	O
complex	O	O
planning	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
ecstasy-associated	O	O
dysfunction	O	O
in	O	O
fronto-temporal	O	O
circuitry	O	O
may	O	O
underlie	O	O
overnight	O	O
consolidation	O	O
memory	B_Disease	O
impairments	I_Disease	O
in	O	O
regular	O	O
ecstasy	B_Chemical	O
users	O	O
.	O	O

Normoammonemic	O	O
encephalopathy	B_Disease	O
:	O	O
solely	O	O
valproate	B_Chemical	B_Chemical
induced	O	O
or	O	O
multiple	O	O
mechanisms?A	O	O
77-year-old	O	O
woman	O	O
presented	O	O
with	O	O
subacute	O	O
onset	O	O
progressive	O	O
confusion	B_Disease	O
,	O	O
aggression	B_Disease	O
,	O	O
auditory	B_Disease	O
hallucinations	I_Disease	O
and	O	O
delusions	B_Disease	O
.	O	O

In	O	O
the	O	O
preceding	O	O
months	O	O
,	O	O
the	O	O
patient	O	O
had	O	O
a	O	O
number	O	O
of	O	O
admissions	O	O
with	O	O
transient	O	O
unilateral	O	O
hemiparesis	B_Disease	O
with	O	O
facial	O	O
droop	O	O
,	O	O
and	O	O
had	O	O
been	O	O
started	O	O
on	O	O
valproate	B_Chemical	B_Chemical
for	O	O
presumed	O	O
hemiplegic	B_Disease	B_Disease
migraine	I_Disease	I_Disease
.	O	O

Valproate	B_Chemical	B_Chemical
was	O	O
withdrawn	O	O
soon	O	O
after	O	O
admission	O	O
and	O	O
her	O	O
cognitive	O	O
abilities	O	O
have	O	O
gradually	O	O
improved	O	O
over	O	O
3	O	O
months	O	O
of	O	O
follow-up	O	O
.	O	O

Valproate	B_Chemical	B_Chemical
levels	O	O
taken	O	O
prior	O	O
to	O	O
withdrawal	O	O
were	O	O
subtherapeutic	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
normoammonaemic	O	O
.	O	O

EEG	O	O
undertaken	O	O
during	O	O
inpatient	O	O
stay	O	O
showed	O	O
changes	O	O
consistent	O	O
with	O	O
encephalopathy	B_Disease	O
,	O	O
and	O	O
low	O	O
titre	O	O
N-methyl-D-aspartate	B_Chemical	B_Chemical
(	O	O
NMDA	B_Chemical	O
)	O	O
receptor	O	O
antibodies	O	O
were	O	O
present	O	O
in	O	O
this	O	O
patient	O	O
.	O	O

The	O	O
possible	O	O
aetiologies	O	O
of	O	O
valproate-induced	O	O
encephalopathy	B_Disease	O
and	O	O
NMDA	B_Chemical	O
receptor-associated	O	O
encephalitis	B_Disease	O
present	O	O
a	O	O
diagnostic	O	O
dilemma	O	O
.	O	O

We	O	O
present	O	O
a	O	O
putative	O	O
combinatorial	O	O
hypothesis	O	O
to	O	O
explain	O	O
this	O	O
patient	O	O
's	O	O
symptoms	O	O
.	O	O

Cerebellar	B_Disease	O
and	I_Disease	O
oculomotor	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
induced	O	O
by	O	O
rapid	O	O
infusion	O	O
of	O	O
pethidine	B_Chemical	B_Chemical
.	O	O

Pethidine	B_Chemical	B_Chemical
is	O	O
an	O	O
opioid	O	O
that	O	O
gains	O	O
its	O	O
popularity	O	O
for	O	O
the	O	O
effective	O	O
pain	B_Disease	O
control	O	O
through	O	O
acting	O	O
on	O	O
the	O	O
opioid-receptors	O	O
.	O	O

However	O	O
,	O	O
rapid	O	O
pain	B_Disease	O
relief	O	O
sometimes	O	O
brings	O	O
about	O	O
unfavourable	O	O
side	O	O
effects	O	O
that	O	O
largely	O	O
limit	O	O
its	O	O
clinical	O	O
utility	O	O
.	O	O

Common	O	O
side	O	O
effects	O	O
include	O	O
nausea	B_Disease	O
,	O	O
vomiting	B_Disease	O
and	O	O
hypotension	B_Disease	O
.	O	O

In	O	O
patients	O	O
with	O	O
impaired	B_Disease	O
renal	I_Disease	O
and	I_Disease	O
liver	I_Disease	O
function	I_Disease	O
,	O	O
and	O	O
those	O	O
who	O	O
need	O	O
long-term	O	O
pain	B_Disease	O
control	O	O
,	O	O
pethidine	B_Chemical	B_Chemical
may	O	O
cause	O	O
excitatory	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
effects	O	O
through	O	O
its	O	O
neurotoxic	B_Disease	O
metabolite	O	O
,	O	O
norpethidine	B_Chemical	B_Chemical
,	O	O
resulting	O	O
in	O	O
irritability	B_Disease	O
and	O	O
seizure	B_Disease	B_Disease
attack	O	I_Disease
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
though	O	O
not	O	O
clinically	O	O
apparent	O	O
,	O	O
pethidine	B_Chemical	B_Chemical
potentially	O	O
causes	O	O
inhibitory	O	O
impacts	O	O
on	O	O
the	O	O
CNS	O	O
and	O	O
impairs	O	O
normal	O	O
cerebellar	O	O
and	O	O
oculomotor	O	O
function	O	O
in	O	O
the	O	O
short	O	O
term	O	O
.	O	O

In	O	O
this	O	O
case	O	O
report	O	O
,	O	O
we	O	O
highlight	O	O
opioid	O	O
's	O	O
inhibitory	O	O
side	O	O
effects	O	O
on	O	O
the	O	O
cerebellar	O	O
structure	O	O
that	O	O
causes	O	O
dysmetria	B_Disease	B_Disease
,	O	O
dysarthria	B_Disease	O
,	O	O
reduced	O	O
smooth	O	O
pursuit	O	O
gain	O	O
and	O	O
decreased	O	O
saccadic	O	O
velocity	O	O
.	O	O

Baboon	B_Disease	O
syndrome	I_Disease	O
induced	O	O
by	O	O
ketoconazole	B_Chemical	B_Chemical
.	O	O

A	O	O
27-year-old	O	O
male	O	O
patient	O	O
presented	O	O
with	O	O
a	O	O
maculopapular	B_Disease	O
eruption	I_Disease	O
on	O	O
the	O	O
flexural	O	O
areas	O	O
and	O	O
buttocks	O	O
after	O	O
using	O	O
oral	O	O
ketoconazole	B_Chemical	B_Chemical
.	O	O

The	O	O
patient	O	O
was	O	O
diagnosed	O	O
with	O	O
drug-induced	O	O
baboon	B_Disease	O
syndrome	I_Disease	O
based	O	O
on	O	O
his	O	O
history	O	O
,	O	O
which	O	O
included	O	O
prior	O	O
sensitivity	O	O
to	O	O
topical	O	O
ketoconazole	B_Chemical	B_Chemical
,	O	O
a	O	O
physical	O	O
examination	O	O
,	O	O
and	O	O
histopathological	O	O
findings	O	O
.	O	O

Baboon	B_Disease	O
syndrome	I_Disease	O
is	O	O
a	O	O
drug-	O	O
or	O	O
contact	O	O
allergen-related	O	O
maculopapular	B_Disease	O
eruption	I_Disease	O
that	O	O
typically	O	O
involves	O	O
the	O	O
flexural	O	O
and	O	O
gluteal	O	O
areas	O	O
.	O	O

To	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
ketoconazole-induced	O	O
baboon	B_Disease	O
syndrome	I_Disease	O
in	O	O
the	O	O
English	O	O
literature	O	O
.	O	O

A	O	O
Case	O	O
of	O	O
Sudden	B_Disease	B_Disease
Cardiac	I_Disease	I_Disease
Death	I_Disease	I_Disease
due	O	O
to	O	O
Pilsicainide-Induced	O	O
Torsades	B_Disease	O
de	I_Disease	O
Pointes	I_Disease	O
.	O	O

An	O	O
84-year-old	O	O
male	O	O
received	O	O
oral	O	O
pilsicainide	B_Chemical	O
,	O	O
a	O	O
pure	O	O
sodium	B_Chemical	O
channel	O	O
blocker	O	O
with	O	O
slow	O	O
recovery	O	O
kinetics	O	O
,	O	O
to	O	O
convert	O	O
his	O	O
paroxysmal	O	O
atrial	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
to	O	O
a	O	O
sinus	O	B_Disease
rhythm	O	I_Disease
;	O	O
the	O	O
patient	O	O
developed	O	O
sudden	B_Disease	B_Disease
cardiac	I_Disease	I_Disease
death	I_Disease	I_Disease
two	O	O
days	O	O
later	O	O
.	O	O

The	O	O
Holter	O	O
electrocardiogram	O	O
,	O	O
which	O	O
was	O	O
worn	O	O
by	O	O
chance	O	O
,	O	O
revealed	O	O
torsade	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
with	O	O
gradually	O	O
prolonged	O	O
QT	O	O
intervals	O	O
.	O	O

This	O	O
drug	O	O
is	O	O
rapidly	O	O
absorbed	O	O
from	O	O
the	O	O
gastrointestinal	O	O
tract	O	O
,	O	O
and	O	O
most	O	O
of	O	O
it	O	O
is	O	O
excreted	O	O
from	O	O
the	O	O
kidney	O	O
.	O	O

Although	O	O
the	O	O
patient	O	O
's	O	O
renal	O	O
function	O	O
was	O	O
not	O	O
highly	O	O
impaired	O	O
and	O	O
the	O	O
dose	O	O
of	O	O
pilsicainide	B_Chemical	O
was	O	O
low	O	O
,	O	O
the	O	O
plasma	O	O
concentration	O	O
of	O	O
pilsicainide	B_Chemical	O
may	O	O
have	O	O
been	O	O
high	O	O
,	O	O
which	O	O
can	O	O
produce	O	O
torsades	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
in	O	O
the	O	O
octogenarian	O	O
.	O	O

Although	O	O
the	O	O
oral	O	O
administration	O	O
of	O	O
class	O	O
IC	O	O
drugs	O	O
,	O	O
including	O	O
pilsicainide	B_Chemical	O
,	O	O
is	O	O
effective	O	O
to	O	O
terminate	O	O
atrial	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
,	O	O
careful	O	O
consideration	O	O
must	O	O
be	O	O
taken	O	O
before	O	O
giving	O	O
these	O	O
drugs	O	O
to	O	O
octogenarians	O	O
.	O	O

All-trans	O	O
retinoic	O	O
acid-induced	O	O
inflammatory	O	O
myositis	B_Disease	O
in	O	O
a	O	O
patient	O	O
with	O	O
acute	B_Disease	B_Disease
promyelocytic	I_Disease	I_Disease
leukemia	I_Disease	I_Disease
.	O	O

All-trans	B_Chemical	O
retinoic	I_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(	O	O
ATRA	B_Chemical	O
)	O	O
,	O	O
a	O	O
component	O	O
of	O	O
standard	O	O
therapy	O	O
for	O	O
acute	B_Disease	B_Disease
promyelocytic	I_Disease	I_Disease
leukemia	I_Disease	I_Disease
(	O	O
APL	B_Disease	O
)	O	O
,	O	O
is	O	O
associated	O	O
with	O	O
potentially	O	O
serious	O	O
but	O	O
treatable	O	O
adverse	O	O
effects	O	O
involving	O	O
numerous	O	O
organ	O	O
systems	O	O
,	O	O
including	O	O
rare	O	O
skeletal	O	O
muscle	O	O
involvement	O	O
.	O	O

Only	O	O
a	O	O
handful	O	O
of	O	O
cases	O	O
of	O	O
ATRA-induced	O	O
myositis	B_Disease	O
in	O	O
children	O	O
have	O	O
been	O	O
reported	O	O
,	O	O
and	O	O
none	O	O
in	O	O
the	O	O
radiology	O	O
literature	O	O
.	O	O

We	O	O
present	O	O
such	O	O
a	O	O
case	O	O
in	O	O
a	O	O
15-year-old	O	O
boy	O	O
with	O	O
APL	B_Disease	B_Chemical
,	O	O
where	O	O
recognition	O	O
of	O	O
imaging	O	O
findings	O	O
played	O	O
a	O	O
crucial	O	O
role	O	O
in	O	O
making	O	O
the	O	O
diagnosis	O	O
and	O	O
facilitated	O	O
prompt	O	O
,	O	O
effective	O	O
treatment	O	O
.	O	O

Tolerability	O	O
of	O	O
lomustine	B_Chemical	O
in	O	O
combination	O	O
with	O	O
cyclophosphamide	B_Chemical	B_Chemical
in	O	O
dogs	O	O
with	O	O
lymphoma	B_Disease	O
.	O	O

This	O	O
retrospective	O	O
study	O	O
describes	O	O
toxicity	B_Disease	O
associated	O	O
with	O	O
a	O	O
protocol	O	O
of	O	O
lomustine	B_Chemical	O
(	O	O
CCNU	B_Chemical	O
)	O	O
and	O	O
cyclophosphamide	B_Chemical	B_Chemical
(	O	O
CTX	B_Chemical	O
)	O	O
in	O	O
dogs	O	O
with	O	O
lymphoma	B_Disease	O
.	O	O

CCNU	B_Chemical	O
was	O	O
administered	O	O
per	O	O
os	O	O
(	O	O
PO	O	O
)	O	O
at	O	O
a	O	O
targeted	O	O
dosage	O	O
of	O	O
60	O	O
mg/m(2	O	O
)	O	O
body	O	O
surface	O	O
area	O	O
on	O	O
day	O	O
0	O	O
,	O	O
CTX	B_Chemical	O
was	O	O
administered	O	O
PO	O	O
at	O	O
a	O	O
targeted	O	O
dosage	O	O
of	O	O
250	O	O
mg/m(2	O	O
)	O	O
divided	O	O
over	O	O
days	O	O
0	O	O
through	O	O
4	O	O
,	O	O
and	O	O
all	O	O
dogs	O	O
received	O	O
prophylactic	O	O
antibiotics	O	O
.	O	O

Ninety	O	O
treatments	O	O
were	O	O
given	O	O
to	O	O
the	O	O
57	O	O
dogs	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Neutropenia	B_Disease	O
was	O	O
the	O	O
principal	O	O
toxic	O	O
effect	O	O
,	O	O
and	O	O
the	O	O
overall	O	O
frequency	O	O
of	O	O
grade	O	O
4	O	O
neutropenia	B_Disease	O
after	O	O
the	O	O
first	O	O
treatment	O	O
of	O	O
CCNU/CTX	O	O
was	O	O
30	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
19	O	O
-	O	O
43	O	O
%	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
body	O	O
weight	O	O
of	O	O
dogs	O	O
with	O	O
grade	O	O
4	O	O
neutropenia	B_Disease	O
(	O	O
19.7	O	O
kg	O	O
+	O	O
13.4	O	O
kg	O	O
)	O	O
was	O	O
significantly	O	O
less	O	O
than	O	O
the	O	O
mean	O	O
body	O	O
weight	O	O
of	O	O
dogs	O	O
that	O	O
did	O	O
not	O	O
develop	O	O
grade	O	O
4	O	O
neutropenia	B_Disease	O
(	O	O
31.7	O	O
kg	O	O
+	O	O
12.4	O	O
kg	O	O
;	O	O
P	O	O
=	O	O
.005	O	O
)	O	O
.	O	O

One	O	O
dog	O	O
(	O	O
3	O	O
%	O	O
)	O	O
developed	O	O
hematologic	O	O
changes	O	O
suggestive	O	O
of	O	O
hepatotoxicity	B_Disease	B_Disease
.	O	O

No	O	O
dogs	O	O
had	O	O
evidence	O	O
of	O	O
either	O	O
renal	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
or	O	O
hemorrhagic	B_Disease	B_Disease
cystitis	B_Disease	I_Disease
.	O	O

Adverse	O	O
gastrointestinal	O	O
effects	O	O
were	O	O
uncommon	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
findings	O	O
reported	O	O
herein	O	O
,	O	O
a	O	O
dose	O	O
of	O	O
60	O	O
mg/m(2	O	O
)	O	O
of	O	O
CCNU	B_Chemical	O
combined	O	O
with	O	O
250	O	O
mg/m(2	O	O
)	O	O
of	O	O
CTX	B_Chemical	O
(	O	O
divided	O	O
over	O	O
5	O	O
days	O	O
)	O	O
q	O	O
4	O	O
wk	O	O
is	O	O
tolerable	O	O
in	O	O
tumor-bearing	O	O
dogs	O	O
.	O	O

Nelarabine	B_Chemical	O
neurotoxicity	B_Disease	O
with	O	O
concurrent	O	O
intrathecal	O	O
chemotherapy	O	O
:	O	O
Case	O	O
report	O	O
and	O	O
review	O	O
of	O	O
literature	O	O
.	O	O

Severe	O	O
nelarabine	B_Chemical	O
neurotoxicity	B_Disease	O
in	O	O
a	O	O
patient	O	O
who	O	O
received	O	O
concurrent	O	O
intrathecal	O	O
(	O	O
IT	O	O
)	O	O
chemotherapy	O	O
is	O	O
reported	O	O
.	O	O

A	O	O
37-year-old	O	O
Caucasian	O	O
woman	O	O
with	O	O
a	O	O
history	O	O
of	O	O
T-cell	B_Disease	O
lymphoblastic	I_Disease	O
lymphoma	I_Disease	O
was	O	O
admitted	O	O
for	O	O
relapsed	O	O
disease	O	O
.	O	O

She	O	O
was	O	O
originally	O	O
treated	O	O
with	O	O
induction	O	O
chemotherapy	O	O
followed	O	O
by	O	O
an	O	O
autologous	O	O
transplant	O	O
.	O	O

She	O	O
developed	O	O
relapsed	O	O
disease	O	O
10	O	O
months	O	O
later	O	O
with	O	O
leukemic	B_Disease	B_Disease
involvement	O	I_Disease
.	O	O

She	O	O
was	O	O
re-induced	O	O
with	O	O
nelarabine	B_Chemical	B_Chemical
1500	O	O
mg/m(2	O	O
)	O	O
on	O	O
days	O	O
1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
5	O	O
with	O	O
1	O	O
dose	O	O
of	O	O
IT	O	O
cytarabine	B_Chemical	B_Chemical
100	O	O
mg	O	O
on	O	O
day	O	O
2	O	O
as	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
prophylaxis	O	O
.	O	O

At	O	O
the	O	O
time	O	O
of	O	O
treatment	O	O
,	O	O
she	O	O
was	O	O
on	O	O
continuous	O	O
renal	O	O
replacement	O	O
therapy	O	O
due	O	O
to	O	O
sequelae	O	O
of	O	O
tumor	B_Disease	O
lysis	I_Disease	O
syndrome	I_Disease	O
(	O	O
TLS	B_Disease	O
)	O	O
.	O	O

She	O	O
tolerated	O	O
therapy	O	O
well	O	O
,	O	O
entered	O	O
a	O	O
complete	O	O
remission	O	O
,	O	O
and	O	O
recovered	O	O
her	O	O
renal	O	O
function	O	O
.	O	O

She	O	O
received	O	O
a	O	O
second	O	O
cycle	O	O
of	O	O
nelarabine	B_Chemical	B_Chemical
without	O	O
additional	O	O
IT	O	O
prophylaxis	O	O
one	O	O
month	O	O
later	O	O
.	O	O

A	O	O
week	O	O
after	O	O
this	O	O
second	O	O
cycle	O	O
,	O	O
she	O	O
noted	O	O
numbness	O	O
in	O	O
her	O	O
lower	O	O
extremities	O	O
.	O	O

Predominantly	O	O
sensory	O	O
,	O	O
though	O	O
also	O	O
motor	O	O
and	O	O
autonomic	O	O
,	O	O
peripheral	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
started	O	O
in	O	O
her	O	O
feet	O	O
,	O	O
ascended	O	O
proximally	O	O
to	O	O
the	O	O
mid-thoracic	O	O
region	O	O
,	O	O
and	O	O
eventually	O	O
included	O	O
her	O	O
distal	O	O
upper	O	O
extremities	O	O
.	O	O

A	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
of	O	O
her	O	O
spine	O	O
demonstrated	O	O
changes	O	O
from	O	O
C2	O	O
to	O	O
C6	O	O
consistent	O	O
with	O	O
subacute	O	O
combined	O	O
degeneration	O	O
.	O	O

Nelarabine	B_Chemical	B_Chemical
was	O	O
felt	O	O
to	O	O
be	O	O
the	O	O
cause	O	O
of	O	O
her	O	O
symptoms	O	O
.	O	O

Her	O	O
neuropathy	B_Disease	O
stabilized	O	O
and	O	O
showed	O	O
slight	O	O
improvement	O	O
and	O	O
ultimately	O	O
received	O	O
an	O	O
unrelated	O	O
,	O	O
reduced-intensity	O	O
allogeneic	O	O
transplant	O	O
while	O	O
in	O	O
complete	O	O
remission	O	O
,	O	O
but	O	O
relapsed	O	O
disease	O	O
10	O	O
weeks	O	O
later	O	O
.	O	O

She	O	O
is	O	O
currently	O	O
being	O	O
treated	O	O
with	O	O
best	O	O
supportive	O	O
care	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
published	O	O
case	O	O
report	O	O
of	O	O
severe	O	O
neurotoxicity	B_Disease	B_Disease
caused	O	O
by	O	O
nelarabine	B_Chemical	B_Chemical
in	O	O
a	O	O
patient	O	O
who	O	O
received	O	O
concurrent	O	O
IT	O	O
chemotherapy	O	O
.	O	O

Valproate-induced	O	O
hyperammonemic	B_Disease	B_Disease
encephalopathy	B_Disease	I_Disease
in	O	O
a	O	O
renal	O	O
transplanted	O	O
patient	O	O
.	O	O

Neurological	B_Disease	O
complications	I_Disease	O
after	O	O
renal	O	O
transplantation	O	O
constitute	O	O
an	O	O
important	O	O
cause	O	O
of	O	O
morbidity	O	O
and	O	O
mortality	O	O
.	O	O

Their	O	O
differential	O	O
diagnosis	O	O
is	O	O
difficult	O	O
and	O	O
essential	O	O
for	O	O
subsequent	O	O
patient	O	O
's	O	O
management	O	O
.	O	O

Valproate-induced	O	O
hyperammonemic	B_Disease	B_Disease
encephalopathy	B_Disease	I_Disease
is	O	O
an	O	O
uncommon	O	O
but	O	O
serious	O	O
effect	O	O
of	O	O
valproate	B_Chemical	B_Chemical
treatment	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
15-year-old	O	O
girl	O	O
who	O	O
was	O	O
on	O	O
a	O	O
long-term	O	O
therapy	O	O
with	O	O
valproate	B_Chemical	B_Chemical
due	O	O
to	O	O
epilepsy	B_Disease	O
and	O	O
revealed	O	O
impaired	B_Disease	O
consciousness	I_Disease	O
with	O	O
hyperammonemia	B_Disease	B_Disease
12	O	O
days	O	O
after	O	O
renal	O	O
transplantation	O	O
.	O	O

After	O	O
withdraw	O	O
of	O	O
valproate	B_Chemical	B_Chemical
,	O	O
patients	O	O
'	O	O
symptoms	O	O
resolved	O	O
within	O	O
24	O	O
h.	O	O
Clinicians	O	O
should	O	O
increase	O	O
their	O	O
awareness	O	O
for	O	O
potential	O	O
complication	O	O
of	O	O
valproate	B_Chemical	B_Chemical
,	O	O
especially	O	O
in	O	O
transplanted	O	O
patients	O	O
.	O	O

Necrotising	B_Disease	O
fasciitis	I_Disease	O
after	O	O
bortezomib	B_Chemical	O
and	O	O
dexamethasone-containing	O	O
regimen	O	O
in	O	O
an	O	O
elderly	O	O
patient	O	O
of	O	O
Waldenstrom	B_Disease	O
macroglobulinaemia	I_Disease	O
.	O	O

Bortezomib	B_Chemical	O
and	O	O
high-dose	O	O
dexamethasone-containing	O	O
regimens	O	O
are	O	O
considered	O	O
to	O	O
be	O	O
generally	O	O
tolerable	O	O
with	O	O
few	O	O
severe	O	O
bacterial	B_Disease	O
infections	I_Disease	O
in	O	O
patients	O	O
with	O	O
B-cell	O	O
malignancies	B_Disease	O
.	O	O

However	O	O
,	O	O
information	O	O
is	O	O
limited	O	O
concerning	O	O
the	O	O
safety	O	O
of	O	O
the	O	O
regimen	O	O
in	O	O
elderly	O	O
patients	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
76-year-old	O	O
man	O	O
with	O	O
Waldenstrom	B_Disease	O
macroglobulinaemia	I_Disease	O
who	O	O
suffered	O	O
necrotising	B_Disease	O
fasciitis	I_Disease	O
without	O	O
neutropenia	B_Disease	O
after	O	O
the	O	O
combination	O	O
treatment	O	O
with	O	O
bortezomib	B_Chemical	B_Chemical
,	O	O
high-dose	O	O
dexamethasone	B_Chemical	O
and	O	O
rituximab	O	O
.	O	O

Despite	O	O
immediate	O	O
intravenous	O	O
antimicrobial	O	O
therapy	O	O
,	O	O
he	O	O
succumbed	O	O
23	O	O
h	O	O
after	O	O
the	O	O
onset	O	O
.	O	O

Physicians	O	O
should	O	O
recognise	O	O
the	O	O
possibility	O	O
of	O	O
fatal	O	O
bacterial	B_Disease	O
infections	I_Disease	O
related	O	O
to	O	O
bortezomib	B_Chemical	O
plus	O	O
high-dose	O	O
dexamethasone	B_Chemical	O
in	O	O
elderly	O	O
patients	O	O
,	O	O
and	O	O
we	O	O
believe	O	O
this	O	O
case	O	O
warrants	O	O
further	O	O
investigation	O	O
.	O	O

An	O	O
integrated	O	O
characterization	O	O
of	O	O
serological	O	O
,	O	O
pathological	O	O
,	O	O
and	O	O
functional	O	O
events	O	O
in	O	O
doxorubicin-induced	O	O
cardiotoxicity	B_Disease	B_Disease
.	O	O

Many	O	O
efficacious	O	O
cancer	B_Disease	O
treatments	O	O
cause	O	O
significant	O	O
cardiac	O	O
morbidity	O	O
,	O	O
yet	O	O
biomarkers	O	O
or	O	O
functional	O	O
indices	O	O
of	O	O
early	O	O
damage	O	O
,	O	O
which	O	O
would	O	O
allow	O	O
monitoring	O	O
and	O	O
intervention	O	O
,	O	O
are	O	O
lacking	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
have	O	O
utilized	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
progressive	O	O
doxorubicin	B_Chemical	O
(DOX)-induced	O	O
cardiomyopathy	B_Disease	O
,	O	O
applying	O	O
multiple	O	O
approaches	O	O
,	O	O
including	O	O
cardiac	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
,	O	O
to	O	O
provide	O	O
the	O	O
most	O	O
comprehensive	O	O
characterization	O	O
to	O	O
date	O	O
of	O	O
the	O	O
timecourse	O	O
of	O	O
serological	O	O
,	O	O
pathological	O	O
,	O	O
and	O	O
functional	O	O
events	O	O
underlying	O	O
this	O	O
toxicity	B_Disease	O
.	O	O

Hannover	O	O
Wistar	O	O
rats	O	O
were	O	O
dosed	O	O
with	O	O
1.25	O	O
mg/kg	O	O
DOX	B_Chemical	B_Chemical
weekly	O	O
for	O	O
8	O	O
weeks	O	O
followed	O	O
by	O	O
a	O	O
4	O	O
week	O	O
off-dosing	O	O
"	O	O
recovery	O	O
"	O	O
period	O	O
.	O	O

Electron	O	O
microscopy	O	O
of	O	O
the	O	O
myocardium	O	O
revealed	O	O
subcellular	B_Disease	O
degeneration	I_Disease	O
and	O	O
marked	O	O
mitochondrial	O	O
changes	O	O
after	O	O
a	O	O
single	O	O
dose	O	O
.	O	O

Histopathological	O	O
analysis	O	O
revealed	O	O
progressive	O	O
cardiomyocyte	B_Disease	O
degeneration	I_Disease	O
,	O	O
hypertrophy/cytomegaly	O	O
,	O	O
and	O	O
extensive	O	O
vacuolation	O	O
after	O	O
two	O	O
doses	O	O
.	O	O

Extensive	O	O
replacement	O	O
fibrosis	B_Disease	O
(	O	O
quantified	O	O
by	O	O
Sirius	O	O
red	O	O
staining	O	O
)	O	O
developed	O	O
during	O	O
the	O	O
off-dosing	O	O
period	O	O
.	O	O

Functional	O	O
indices	O	O
assessed	O	O
by	O	O
cardiac	O	O
MRI	O	O
(	O	O
including	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
(	O	O
LVEF	O	O
)	O	O
,	O	O
cardiac	O	O
output	O	O
,	O	O
and	O	O
E/A	O	O
ratio	O	O
)	O	O
declined	O	O
progressively	O	O
,	O	O
reaching	O	O
statistical	O	O
significance	O	O
after	O	O
two	O	O
doses	O	O
and	O	O
culminating	O	O
in	O	O
"	O	O
clinical	O	O
"	O	O
LV	B_Disease	O
dysfunction	I_Disease	O
by	O	O
12	O	O
weeks	O	O
.	O	O

Significant	O	O
increases	O	O
in	O	O
peak	O	O
myocardial	O	O
contrast	O	O
enhancement	O	O
and	O	O
serological	O	O
cardiac	O	O
troponin	O	O
I	O	O
(	O	O
cTnI	O	O
)	O	O
emerged	O	O
after	O	O
eight	O	O
doses	O	O
,	O	O
importantly	O	O
preceding	O	O
the	O	O
LVEF	O	O
decline	O	O
to	O	O
<	O	O
50	O	O
%	O	O
.	O	O

Troponin	O	O
I	O	O
levels	O	O
positively	O	O
correlated	O	O
with	O	O
delayed	O	O
and	O	O
peak	O	O
gadolinium	B_Chemical	O
contrast	O	O
enhancement	O	O
,	O	O
histopathological	O	O
grading	O	O
,	O	O
and	O	O
diastolic	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
.	O	O

In	O	O
summary	O	O
,	O	O
subcellular	O	O
cardiomyocyte	B_Disease	O
degeneration	I_Disease	O
was	O	O
the	O	O
earliest	O	O
marker	O	O
,	O	O
followed	O	O
by	O	O
progressive	O	O
functional	O	O
decline	O	O
and	O	O
histopathological	O	O
manifestations	O	O
.	O	O

Myocardial	O	O
contrast	O	O
enhancement	O	O
and	O	O
elevations	O	O
in	O	O
cTnI	O	O
occurred	O	O
later	O	O
.	O	O

However	O	O
,	O	O
all	O	O
indices	O	O
predated	O	O
"	O	O
clinical	O	O
"	O	O
LV	B_Disease	O
dysfunction	I_Disease	O
and	O	O
thus	O	O
warrant	O	O
further	O	O
evaluation	O	O
as	O	O
predictive	O	O
biomarkers	O	O
.	O	O

Intradermal	O	O
glutamate	B_Chemical	O
and	O	O
capsaicin	B_Chemical	O
injections	O	O
:	O	O
intra-	O	O
and	O	O
interindividual	O	O
variability	O	O
of	O	O
provoked	O	O
hyperalgesia	B_Disease	B_Disease
and	O	O
allodynia	B_Disease	B_Disease
.	O	O

Intradermal	O	O
injections	O	O
of	O	O
glutamate	B_Chemical	O
and	O	O
capsaicin	B_Chemical	O
are	O	O
attractive	O	O
to	O	O
use	O	O
in	O	O
human	O	O
experimental	O	O
pain	B_Disease	O
models	O	O
because	O	O
hyperalgesia	B_Disease	B_Disease
and	O	O
allodynia	B_Disease	B_Disease
mimic	O	O
isolated	O	O
aspects	O	O
of	O	O
clinical	O	B_Disease
pain	B_Disease	I_Disease
disorders	I_Disease	I_Disease
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
reproducibility	O	O
of	O	O
these	O	O
models	O	O
.	O	O

Twenty	O	O
healthy	O	O
male	O	O
volunteers	O	O
(	O	O
mean	O	O
age	O	O
24	O	O
years	O	O
;	O	O
range	O	O
18	O	O
-	O	O
38	O	O
years	O	O
)	O	O
received	O	O
intradermal	O	O
injections	O	O
of	O	O
glutamate	B_Chemical	O
and	O	O
capsaicin	B_Chemical	O
in	O	O
the	O	O
volar	O	O
forearm	O	O
.	O	O

Magnitudes	O	O
of	O	O
secondary	O	O
pinprick	O	O
hyperalgesia	B_Disease	B_Disease
and	O	O
brush-evoked	O	O
allodynia	B_Disease	O
were	O	O
investigated	O	O
using	O	O
von	O	O
Frey	O	O
filaments	O	O
(	O	O
gauges	O	O
10	O	O
,	O	O
15	O	O
,	O	O
60	O	O
and	O	O
100	O	O
g	O	O
)	O	O
and	O	O
brush	O	O
strokes	O	O
.	O	O

Areas	O	O
of	O	O
secondary	B_Disease	B_Disease
hyperalgesia	I_Disease	I_Disease
and	O	O
allodynia	B_Disease	O
were	O	O
quantified	O	O
immediately	O	O
after	O	O
injection	O	O
and	O	O
after	O	O
15	O	O
,	O	O
30	O	O
and	O	O
60	O	O
min	O	O
.	O	O

Two	O	O
identical	O	O
experiments	O	O
separated	O	O
by	O	O
at	O	O
least	O	O
7	O	O
days	O	O
were	O	O
performed	O	O
.	O	O

Reproducibility	O	O
across	O	O
and	O	O
within	O	O
volunteers	O	O
(	O	O
inter-	O	O
and	O	O
intra-individual	O	O
variation	O	O
,	O	O
respectively	O	O
)	O	O
was	O	O
assessed	O	O
using	O	O
intraclass	O	O
correlation	O	O
coefficient	O	O
(	O	O
ICC	O	O
)	O	O
and	O	O
coefficient	O	O
of	O	O
variation	O	O
(	O	O
CV	O	O
)	O	O
.	O	O

Secondary	O	O
pinprick	O	O
hyperalgesia	B_Disease	B_Disease
was	O	O
observed	O	O
as	O	O
a	O	O
marked	O	O
increase	O	O
in	O	O
the	O	O
visual	O	O
analogue	O	O
scale	O	O
(	O	O
VAS	O	O
)	O	O
response	O	O
to	O	O
von	O	O
Frey	O	O
gauges	O	O
60	O	O
and	O	O
100	O	O
g	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
after	O	O
glutamate	B_Chemical	O
injection	O	O
.	O	O

For	O	O
capsaicin	B_Chemical	O
,	O	O
secondary	O	O
pinprick	O	O
hyperalgesia	B_Disease	B_Disease
was	O	O
detected	O	O
with	O	O
all	O	O
von	O	O
Frey	O	O
gauges	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Glutamate	B_Chemical	O
evoked	O	O
reproducible	O	O
VAS	O	O
response	O	O
to	O	O
all	O	O
von	O	O
Frey	O	O
gauges	O	O
(	O	O
ICC	O	O
>	O	O
0.60	O	O
)	O	O
and	O	O
brush	O	O
strokes	O	O
(	O	O
ICC	O	O
>	O	O
0.83	O	O
)	O	O
.	O	O

Capsaicin	B_Chemical	O
injection	O	O
was	O	O
reproducible	O	O
for	O	O
secondary	B_Disease	B_Disease
hyperalgesia	I_Disease	I_Disease
(	O	O
ICC	O	O
>	O	O
0.70	O	O
)	O	O
and	O	O
allodynia	B_Disease	B_Disease
(	O	O
ICC	O	O
>	O	O
0.71	O	O
)	O	O
.	O	O

Intra-individual	O	O
variability	O	O
was	O	O
generally	O	O
lower	O	O
for	O	O
the	O	O
VAS	O	O
response	O	O
to	O	O
von	O	O
Frey	O	O
and	O	O
brush	O	O
compared	O	O
with	O	O
areas	O	O
of	O	O
secondary	B_Disease	B_Disease
hyperalgesia	I_Disease	I_Disease
and	O	O
allodynia	B_Disease	B_Disease
.	O	O

In	O	O
conclusion	O	O
,	O	O
glutamate	B_Chemical	O
and	O	O
capsaicin	B_Chemical	O
yield	O	O
reproducible	O	O
hyperalgesic	B_Disease	O
and	O	O
allodynic	B_Disease	O
responses	O	O
,	O	O
and	O	O
the	O	O
present	O	O
model	O	O
is	O	O
well	O	O
suited	O	O
for	O	O
basic	O	O
research	O	O
,	O	O
as	O	O
well	O	O
as	O	O
for	O	O
assessing	O	O
the	O	O
modulation	O	O
of	O	O
central	O	O
phenomena	O	O
.	O	O

Ocular-specific	O	O
ER	O	O
stress	O	O
reduction	O	O
rescues	O	O
glaucoma	B_Disease	O
in	O	O
murine	O	O
glucocorticoid-induced	O	O
glaucoma	B_Disease	O
.	O	O

Administration	O	O
of	O	O
glucocorticoids	O	O
induces	O	O
ocular	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
in	O	O
some	O	O
patients	O	O
.	O	O

If	O	O
untreated	O	O
,	O	O
these	O	O
patients	O	O
can	O	O
develop	O	O
a	O	O
secondary	O	O
glaucoma	B_Disease	O
that	O	O
resembles	O	O
primary	B_Disease	O
open-angle	I_Disease	O
glaucoma	I_Disease	O
(	O	O
POAG	B_Disease	O
)	O	O
.	O	O

The	O	O
underlying	O	O
pathology	O	O
of	O	O
glucocorticoid-induced	O	O
glaucoma	B_Disease	O
is	O	O
not	O	O
fully	O	O
understood	O	O
,	O	O
due	O	O
in	O	O
part	O	O
to	O	O
lack	O	O
of	O	O
an	O	O
appropriate	O	O
animal	O	O
model	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
developed	O	O
a	O	O
murine	O	O
model	O	O
of	O	O
glucocorticoid-induced	O	O
glaucoma	B_Disease	O
that	O	O
exhibits	O	O
glaucoma	B_Disease	O
features	O	O
that	O	O
are	O	O
observed	O	O
in	O	O
patients	O	O
.	O	O

Treatment	O	O
of	O	O
WT	O	O
mice	O	O
with	O	O
topical	O	O
ocular	O	O
0.1	O	O
%	O	O
dexamethasone	B_Chemical	O
led	O	O
to	O	O
elevation	O	O
of	O	O
intraocular	O	O
pressure	O	O
(	O	O
IOP	O	O
)	O	O
,	O	O
functional	O	O
and	O	O
structural	O	O
loss	O	O
of	O	O
retinal	B_Disease	O
ganglion	I_Disease	O
cells	O	O
,	O	O
and	O	O
axonal	B_Disease	O
degeneration	I_Disease	O
,	O	O
resembling	O	O
glucocorticoid-induced	O	O
glaucoma	B_Disease	O
in	O	O
human	O	O
patients	O	O
.	O	O

Furthermore	O	O
,	O	O
dexamethasone-induced	O	O
ocular	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
was	O	O
associated	O	O
with	O	O
chronic	O	O
ER	O	O
stress	O	O
of	O	O
the	O	O
trabecular	O	O
meshwork	O	O
(	O	O
TM	O	O
)	O	O
.	O	O

Similar	O	O
to	O	O
patients	O	O
,	O	O
withdrawal	O	O
of	O	O
dexamethasone	B_Chemical	O
treatment	O	O
reduced	O	O
elevated	O	O
IOP	O	O
and	O	O
ER	O	O
stress	O	O
in	O	O
this	O	O
animal	O	O
model	O	O
.	O	O

Dexamethasone	B_Chemical	O
induced	O	O
the	O	O
transcriptional	O	O
factor	O	O
CHOP	O	O
,	O	O
a	O	O
marker	O	O
for	O	O
chronic	O	O
ER	O	O
stress	O	O
,	O	O
in	O	O
the	O	O
anterior	O	O
segment	O	O
tissues	O	O
,	O	O
and	O	O
Chop	O	O
deletion	O	O
reduced	O	O
ER	O	O
stress	O	O
in	O	O
these	O	O
tissues	O	O
and	O	O
prevented	O	O
dexamethasone-induced	O	O
ocular	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
.	O	O

Furthermore	O	O
,	O	O
reduction	O	O
of	O	O
ER	O	O
stress	O	O
in	O	O
the	O	O
TM	O	O
with	O	O
sodium	B_Chemical	B_Chemical
4-phenylbutyrate	I_Chemical	I_Chemical
prevented	O	O
dexamethasone-induced	O	O
ocular	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
in	O	O
WT	O	O
mice	O	O
.	O	O

Our	O	O
data	O	O
indicate	O	O
that	O	O
ER	O	O
stress	O	O
contributes	O	O
to	O	O
glucocorticoid-induced	O	O
ocular	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
and	O	O
suggest	O	O
that	O	O
reducing	O	O
ER	O	O
stress	O	O
has	O	O
potential	O	O
as	O	O
a	O	O
therapeutic	O	O
strategy	O	O
for	O	O
treating	O	O
glucocorticoid-induced	O	O
glaucoma	B_Disease	O
.	O	O

Effects	O	O
of	O	O
ginsenosides	B_Chemical	B_Chemical
on	O	O
opioid-induced	O	O
hyperalgesia	B_Disease	B_Disease
in	O	O
mice	O	O
.	O	O

Opioid-induced	O	O
hyperalgesia	B_Disease	B_Disease
(	O	O
OIH	B_Disease	O
)	O	O
is	O	O
characterized	O	O
by	O	O
nociceptive	O	O
sensitization	O	O
caused	O	O
by	O	O
the	O	O
cessation	O	O
of	O	O
chronic	O	O
opioid	O	O
use	O	O
.	O	O

OIH	B_Disease	O
can	O	O
limit	O	O
the	O	O
clinical	O	O
use	O	O
of	O	O
opioid	O	O
analgesics	O	O
and	O	O
complicate	O	O
withdrawal	O	O
from	O	O
opioid	B_Disease	O
addiction	I_Disease	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
Re	B_Chemical	O
,	I_Chemical	O
Rg1	I_Chemical	O
,	I_Chemical	O
and	I_Chemical	O
Rb1	B_Chemical	O
ginsenosides	I_Chemical	O
,	O	O
the	O	O
bioactive	O	O
components	O	O
of	O	O
ginseng	O	O
,	O	O
on	O	O
OIH	B_Disease	O
.	O	O

OIH	B_Disease	O
was	O	O
achieved	O	O
in	O	O
mice	O	O
after	O	O
subcutaneous	O	O
administration	O	O
of	O	O
morphine	B_Chemical	O
for	O	O
7	O	O
consecutive	O	O
days	O	O
three	O	O
times	O	O
per	O	O
day	O	O
.	O	O

During	O	O
withdrawal	O	O
(	O	O
days	O	O
8	O	O
and	O	O
9	O	O
)	O	O
,	O	O
these	O	O
mice	O	O
were	O	O
administered	O	O
Re	B_Chemical	O
,	O	O
Rg1	B_Chemical	O
,	O	O
or	O	O
Rb1	B_Chemical	O
intragastrically	O	O
two	O	O
times	O	O
per	O	O
day	O	O
.	O	O

On	O	O
the	O	O
test	O	O
day	O	O
(	O	O
day	O	O
10	O	O
)	O	O
,	O	O
mice	O	O
were	O	O
subjected	O	O
to	O	O
the	O	O
thermal	O	O
sensitivity	O	O
test	O	O
and	O	O
the	O	O
acetic	O	O
acid-induced	O	O
writhing	O	O
test	O	O
.	O	O

Re	B_Chemical	O
(	O	O
300	O	O
mg/kg	O	O
)	O	O
inhibited	O	O
OIH	B_Disease	O
in	O	O
both	O	O
the	O	O
thermal	O	O
sensitivity	O	O
test	O	O
and	O	O
the	O	O
acetic	O	O
acid-induced	O	O
writhing	O	O
test	O	O
.	O	O

However	O	O
,	O	O
the	O	O
Rg1	B_Chemical	O
and	I_Chemical	O
Rb1	B_Chemical	O
ginsenosides	I_Chemical	O
failed	O	O
to	O	O
prevent	O	O
OIH	B_Disease	O
in	O	O
either	O	O
test	O	O
.	O	O

Furthermore	O	O
,	O	O
Rg1	B_Chemical	O
showed	O	O
a	O	O
tendency	O	O
to	O	O
aggravate	O	O
OIH	B_Disease	O
in	O	O
the	O	O
acetic	O	O
acid-induced	O	O
writhing	O	O
test	O	O
.	O	O

Our	O	O
data	O	O
suggested	O	O
that	O	O
the	O	O
ginsenoside	B_Chemical	B_Chemical
Re	I_Chemical	O
,	O	O
but	O	O
not	O	O
Rg1	B_Chemical	O
or	O	O
Rb1	B_Chemical	O
,	O	O
may	O	O
contribute	O	O
toward	O	O
reversal	O	O
of	O	O
OIH	B_Disease	O
.	O	O

A	O	O
comparison	O	O
of	O	O
severe	O	O
hemodynamic	O	B_Disease
disturbances	O	I_Disease
between	O	O
dexmedetomidine	B_Chemical	B_Chemical
and	O	O
propofol	B_Chemical	B_Chemical
for	O	O
sedation	O	O
in	O	O
neurocritical	O	O
care	O	O
patients	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
Dexmedetomidine	B_Chemical	B_Chemical
and	O	O
propofol	B_Chemical	B_Chemical
are	O	O
commonly	O	O
used	O	O
sedatives	O	O
in	O	O
neurocritical	O	O
care	O	O
as	O	O
they	O	O
allow	O	O
for	O	O
frequent	O	O
neurologic	O	O
examinations	O	O
.	O	O

However	O	O
,	O	O
both	O	O
agents	O	O
are	O	O
associated	O	O
with	O	O
significant	O	O
hemodynamic	O	O
side	O	O
effects	O	O
.	O	O

The	O	O
primary	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
compare	O	O
the	O	O
prevalence	O	O
of	O	O
severe	O	O
hemodynamic	O	O
effects	O	O
in	O	O
neurocritical	O	O
care	O	O
patients	O	O
receiving	O	O
dexmedetomidine	B_Chemical	B_Chemical
and	O	O
propofol	B_Chemical	B_Chemical
.	O	O

DESIGN	O	O
:	O	O
Multicenter	O	O
,	O	O
retrospective	O	O
,	O	O
propensity-matched	O	O
cohort	O	O
study	O	O
.	O	O

SETTING	O	O
:	O	O
Neurocritical	O	O
care	O	O
units	O	O
at	O	O
two	O	O
academic	O	O
medical	O	O
centers	O	O
with	O	O
dedicated	O	O
neurocritical	O	O
care	O	O
teams	O	O
and	O	O
board-certified	O	O
neurointensivists	O	O
.	O	O

PATIENTS	O	O
:	O	O
Neurocritical	O	O
care	O	O
patients	O	O
admitted	O	O
between	O	O
July	O	O
2009	O	O
and	O	O
September	O	O
2012	O	O
were	O	O
evaluated	O	O
and	O	O
then	O	O
matched	O	O
1:1	O	O
based	O	O
on	O	O
propensity	O	O
scoring	O	O
of	O	O
baseline	O	O
characteristics	O	O
.	O	O

INTERVENTIONS	O	O
:	O	O
Continuous	O	O
sedation	O	O
with	O	O
dexmedetomidine	B_Chemical	B_Chemical
or	O	O
propofol	B_Chemical	B_Chemical
.	O	O

MEASUREMENTS	O	O
AND	O	O
MAIN	O	O
RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
342	O	O
patients	O	O
(	O	O
105	O	O
dexmedetomidine	B_Chemical	B_Chemical
and	O	O
237	O	O
propofol	B_Chemical	B_Chemical
)	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
,	O	O
with	O	O
190	O	O
matched	O	O
(	O	O
95	O	O
in	O	O
each	O	O
group	O	O
)	O	O
by	O	O
propensity	O	O
score	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
of	O	O
this	O	O
study	O	O
was	O	O
a	O	O
composite	O	O
of	O	O
severe	O	O
hypotension	B_Disease	O
(	O	O
mean	O	O
arterial	O	O
pressure	O	O
<	O	O
60	O	O
mm	O	O
Hg	O	O
)	O	O
and	O	O
bradycardia	B_Disease	O
(	O	O
heart	O	O
rate	O	O
<	O	O
50	O	O
beats/min	O	O
)	O	O
during	O	O
sedative	O	O
infusion	O	O
.	O	O

No	O	O
difference	O	O
in	O	O
the	O	O
primary	O	O
composite	O	O
outcome	O	O
in	O	O
both	O	O
the	O	O
unmatched	O	O
(	O	O
30	O	O
%	O	O
vs	O	O
30	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.94	O	O
)	O	O
or	O	O
matched	O	O
cohorts	O	O
(	O	O
28	O	O
%	O	O
vs	O	O
34	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.35	O	O
)	O	O
could	O	O
be	O	O
found	O	O
.	O	O

When	O	O
analyzed	O	O
separately	O	O
,	O	O
no	O	O
differences	O	O
could	O	O
be	O	O
found	O	O
in	O	O
the	O	O
prevalence	O	O
of	O	O
severe	O	O
hypotension	B_Disease	O
or	O	O
bradycardia	B_Disease	O
in	O	O
either	O	O
the	O	O
unmatched	O	O
or	O	O
matched	O	O
cohorts	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Severe	O	O
hypotension	B_Disease	O
and	O	O
bradycardia	B_Disease	O
occur	O	O
at	O	O
similar	O	O
prevalence	O	O
in	O	O
neurocritical	O	O
care	O	O
patients	O	O
who	O	O
receive	O	O
dexmedetomidine	B_Chemical	B_Chemical
or	O	O
propofol	B_Chemical	B_Chemical
.	O	O

Providers	O	O
should	O	O
similarly	O	O
consider	O	O
the	O	O
likelihood	O	O
of	O	O
hypotension	B_Disease	O
or	O	O
bradycardia	B_Disease	O
before	O	O
starting	O	O
either	O	O
sedative	O	O
.	O	O

Hydroxytyrosol	B_Chemical	B_Chemical
ameliorates	O	O
oxidative	O	O
stress	O	O
and	O	O
mitochondrial	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
in	O	O
doxorubicin-induced	O	O
cardiotoxicity	B_Disease	B_Disease
in	O	O
rats	O	O
with	O	O
breast	B_Disease	B_Disease
cancer	I_Disease	I_Disease
.	O	O

Oxidative	O	O
stress	O	O
is	O	O
involved	O	O
in	O	O
several	O	O
processes	O	O
including	O	O
cancer	B_Disease	O
,	O	O
aging	O	O
and	O	O
cardiovascular	B_Disease	B_Disease
disease	I_Disease	I_Disease
,	O	O
and	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
potentiate	O	O
the	O	O
therapeutic	O	O
effect	O	O
of	O	O
drugs	O	O
such	O	O
as	O	O
doxorubicin	B_Chemical	O
.	O	O

Doxorubicin	B_Chemical	O
causes	O	O
significant	O	O
cardiotoxicity	B_Disease	B_Disease
characterized	O	O
by	O	O
marked	O	O
increases	O	O
in	O	O
oxidative	O	O
stress	O	O
and	O	O
mitochondrial	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
.	O	O

Herein	O	O
,	O	O
we	O	O
investigate	O	O
whether	O	O
doxorubicin-associated	O	O
chronic	O	O
cardiac	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
can	O	O
be	O	O
ameliorated	O	O
with	O	O
the	O	O
antioxidant	O	B_Chemical
hydroxytyrosol	B_Chemical	I_Chemical
in	O	O
rats	O	O
with	O	O
breast	B_Disease	B_Disease
cancer	I_Disease	I_Disease
.	O	O

Thirty-six	O	O
rats	O	O
bearing	O	O
breast	B_Disease	O
tumors	I_Disease	O
induced	O	O
chemically	O	O
were	O	O
divided	O	O
into	O	O
4	O	O
groups	O	O
:	O	O
control	O	O
,	O	O
hydroxytyrosol	B_Chemical	B_Chemical
(	O	O
0.5mg/kg	O	O
,	O	O
5days/week	O	O
)	O	O
,	O	O
doxorubicin	B_Chemical	O
(	O	O
1mg/kg/week	O	O
)	O	O
,	O	O
and	O	O
doxorubicin	B_Chemical	O
plus	O	O
hydroxytyrosol	B_Chemical	B_Chemical
.	O	O

Cardiac	B_Disease	O
disturbances	I_Disease	O
at	O	O
the	O	O
cellular	O	O
and	O	O
mitochondrial	O	O
level	O	O
,	O	O
mitochondrial	O	O
electron	O	O
transport	O	O
chain	O	O
complexes	O	O
I-IV	O	O
and	O	O
apoptosis-inducing	O	O
factor	O	O
,	O	O
and	O	O
oxidative	O	O
stress	O	O
markers	O	O
have	O	O
been	O	O
analyzed	O	O
.	O	O

Hydroxytyrosol	B_Chemical	B_Chemical
improved	O	O
the	O	O
cardiac	B_Disease	B_Disease
disturbances	I_Disease	I_Disease
enhanced	O	O
by	O	O
doxorubicin	B_Chemical	O
by	O	O
significantly	O	O
reducing	O	O
the	O	O
percentage	O	O
of	O	O
altered	O	O
mitochondria	O	O
and	O	O
oxidative	O	B_Disease
damage	O	I_Disease
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
hydroxytyrosol	B_Chemical	B_Chemical
improve	O	O
the	O	O
mitochondrial	O	O
electron	O	O
transport	O	O
chain	O	O
.	O	O

This	O	O
study	O	O
demonstrates	O	O
that	O	O
hydroxytyrosol	B_Chemical	B_Chemical
protect	O	O
rat	O	O
heart	B_Disease	B_Disease
damage	I_Disease	I_Disease
provoked	O	O
by	O	O
doxorubicin	B_Chemical	O
decreasing	O	O
oxidative	O	B_Disease
damage	O	I_Disease
and	O	O
mitochondrial	O	O
alterations	O	O
.	O	O

Amiodarone-induced	O	O
myxoedema	B_Disease	O
coma	B_Disease	O
.	O	O

A	O	O
62-year-old	O	O
man	O	O
was	O	O
found	O	O
to	O	O
have	O	O
bradycardia	B_Disease	O
,	O	O
hypothermia	B_Disease	O
and	O	O
respiratory	B_Disease	B_Disease
failure	I_Disease	I_Disease
3	O	O
weeks	O	O
after	O	O
initiation	O	O
of	O	O
amiodarone	B_Chemical	O
therapy	O	O
for	O	O
atrial	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
.	O	O

Thyroid-stimulating	O	O
hormone	O	O
was	O	O
found	O	O
to	O	O
be	O	O
168	O	O
uIU/mL	O	O
(	O	O
nl	O	O
.	O	O
0.3	O	O
-	O	O
5	O	O
uIU/mL	O	O
)	O	O
and	O	O
free	O	O
thyroxine	B_Chemical	O
(	O	O
FT4	O	O
)	O	O
was	O	O
<	O	O
0.2	O	O
ng/dL	O	O
(	O	O
nl	O	O
.	O	O
0.8	O	O
-	O	O
1.8	O	O
ng/dL	O	O
)	O	O
.	O	O

He	O	O
received	O	O
intravenous	O	O
fluids	O	O
,	O	O
vasopressor	O	O
therapy	O	O
and	O	O
stress	O	O
dose	O	O
steroids	B_Chemical	O
;	O	O
he	O	O
was	O	O
intubated	O	O
and	O	O
admitted	O	O
to	O	O
the	O	O
intensive	O	O
care	O	O
unit	O	O
.	O	O

He	O	O
received	O	O
500	O	O
ug	O	O
of	O	O
intravenous	O	O
levothyroxine	B_Chemical	B_Chemical
in	O	O
the	O	O
first	O	O
18	O	O
h	O	O
of	O	O
therapy	O	O
,	O	O
and	O	O
150	O	O
ug	O	O
intravenous	O	O
daily	O	O
thereafter	O	O
.	O	O

Haemodynamic	O	O
improvement	O	O
,	O	O
along	O	O
with	O	O
complete	O	O
recovery	O	O
of	O	O
mental	O	O
status	O	O
,	O	O
occurred	O	O
after	O	O
48	O	O
h.	O	O
Twelve	O	O
hours	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
therapy	O	O
,	O	O
FT4	O	O
was	O	O
0.96	O	O
ng/dL.	O	O
The	O	O
patient	O	O
was	O	O
maintained	O	O
on	O	O
levothyroxine	B_Chemical	B_Chemical
175	O	O
(	O	O
g	O	O
POorally	O	O
daily	O	O
.	O	O

A	O	O
thyroid	O	O
ultrasound	O	O
showed	O	O
diffuse	O	O
heterogeneity	O	O
.	O	O

The	O	O
24	O	O
hour	O	O
excretion	O	O
of	O	O
iodine	B_Chemical	O
was	O	O
3657	O	O
(	O	O
mcg	O	O
(	O	O
25	O	O
-	O	O
756	O	O
(	O	O
mcg	O	O
)	O	O
.	O	O

The	O	O
only	O	O
two	O	O
cases	O	O
of	O	O
amiodarone-induced	O	O
myxoedema	B_Disease	O
coma	B_Disease	O
in	O	O
the	O	O
literature	O	O
report	O	O
patient	O	O
death	O	O
despite	O	O
supportive	O	O
therapy	O	O
and	O	O
thyroid	O	O
hormone	O	O
replacement	O	O
.	O	O

This	O	O
case	O	O
represents	O	O
the	O	O
most	O	O
thoroughly	O	O
investigated	O	O
case	O	O
of	O	O
amiodarone-induced	O	O
myxoedema	B_Disease	O
coma	B_Disease	O
with	O	O
a	O	O
history	O	O
significant	O	O
for	O	O
subclinical	O	O
thyroid	B_Disease	B_Disease
disease	I_Disease	I_Disease
.	O	O

Use	O	O
of	O	O
argatroban	B_Chemical	B_Chemical
and	O	O
catheter-directed	O	O
thrombolysis	B_Disease	O
with	O	O
alteplase	O	O
in	O	O
an	O	O
oncology	O	O
patient	O	O
with	O	O
heparin-induced	O	O
thrombocytopenia	B_Disease	O
with	O	O
thrombosis	B_Disease	O
.	O	O

PURPOSE	O	O
:	O	O
The	O	O
case	O	O
of	O	O
an	O	O
oncology	O	O
patient	O	O
who	O	O
developed	O	O
heparin-induced	O	O
thrombocytopenia	B_Disease	O
with	O	O
thrombosis	B_Disease	O
(	O	O
HITT	B_Disease	O
)	O	O
and	O	O
was	O	O
treated	O	O
with	O	O
argatroban	B_Chemical	B_Chemical
plus	O	O
catheter-directed	O	O
thrombolysis	B_Disease	O
(	O	O
CDT	O	O
)	O	O
with	O	O
alteplase	O	O
is	O	O
presented	O	O
.	O	O

SUMMARY	O	O
:	O	O
A	O	O
63-year-old	O	O
Caucasian	O	O
man	O	O
with	O	O
renal	O	B_Disease
amyloidosis	B_Disease	I_Disease
undergoing	O	O
peripheral	O	O
blood	O	O
stem	O	O
cell	O	O
collection	O	O
for	O	O
an	O	O
autologous	O	O
stem	O	O
cell	O	O
transplant	O	O
developed	O	O
extensive	O	O
bilateral	O	O
upper-extremity	B_Disease	O
deep	I_Disease	B_Disease
venous	I_Disease	I_Disease
thrombosis	I_Disease	I_Disease
(	O	O
DVT	B_Disease	O
)	O	O
and	O	O
pulmonary	B_Disease	B_Disease
embolism	I_Disease	I_Disease
secondary	O	O
to	O	O
heparin-induced	O	O
thrombocytopenia	B_Disease	O
.	O	O

A	O	O
continuous	O	O
i.v	O	O
.	O	O

infusion	O	O
of	O	O
argatroban	B_Chemical	B_Chemical
was	O	O
initiated	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
managed	O	O
on	O	O
the	O	O
general	O	O
medical	O	O
floor	O	O
.	O	O

After	O	O
one	O	O
week	O	O
of	O	O
therapy	O	O
,	O	O
he	O	O
was	O	O
transferred	O	O
to	O	O
the	O	O
intensive	O	O
care	O	O
unit	O	O
with	O	O
cardiopulmonary	O	O
compromise	O	O
related	O	O
to	O	O
superior	B_Disease	O
vena	I_Disease	O
cava	I_Disease	O
(	I_Disease	O
SVC	I_Disease	O
)	I_Disease	O
syndrome	I_Disease	O
.	O	O

A	O	O
percutaneous	O	O
mechanical	O	O
thrombectomy	O	O
and	O	O
CDT	O	O
with	O	O
alteplase	O	O
were	O	O
attempted	O	O
,	O	O
but	O	O
the	O	O
procedure	O	O
was	O	O
aborted	O	O
due	O	O
to	O	O
epistaxis	B_Disease	O
.	O	O

The	O	O
epistaxis	B_Disease	O
resolved	O	O
the	O	O
next	O	O
day	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
restarted	O	O
on	O	O
argatroban	B_Chemical	B_Chemical
.	O	O

A	O	O
second	O	O
percutaneous	O	O
mechanical	O	O
thrombectomy	O	O
was	O	O
performed	O	O
six	O	O
days	O	O
later	O	O
and	O	O
resulted	O	O
in	O	O
partial	O	O
revascularization	O	O
of	O	O
the	O	O
SVC	O	O
and	O	O
central	O	O
veins	O	O
.	O	O

Postthrombectomy	O	O
continuous	O	O
CDT	O	O
with	O	O
alteplase	O	O
was	O	O
commenced	O	O
while	O	O
argatroban	B_Chemical	B_Chemical
was	O	O
withheld	O	O
,	O	O
and	O	O
complete	O	O
patency	O	O
of	O	O
the	O	O
SVC	O	O
and	O	O
central	O	O
veins	O	O
was	O	O
achieved	O	O
after	O	O
three	O	O
days	O	O
of	O	O
therapy	O	O
.	O	O

Alteplase	O	B_Chemical
was	O	O
discontinued	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
reinitiated	O	O
on	O	O
argatroban	B_Chemical	B_Chemical
;	O	O
ultimately	O	O
,	O	O
he	O	O
was	O	O
transitioned	O	O
to	O	O
warfarin	B_Chemical	O
for	O	O
long-term	O	O
anticoagulation	O	O
.	O	O

Although	O	O
the	O	O
patient	O	O
recovered	O	O
,	O	O
he	O	O
experienced	O	O
permanent	O	O
vision	B_Disease	O
and	I_Disease	O
hearing	B_Disease	B_Disease
loss	I_Disease	I_Disease
,	O	O
as	O	O
well	O	O
as	O	O
end-stage	B_Disease	B_Disease
renal	I_Disease	I_Disease
disease	I_Disease	I_Disease
.	O	O

CONCLUSION	O	O
:	O	O
A	O	O
63-year-old	O	O
man	O	O
with	O	O
renal	O	B_Disease
amyloidosis	B_Disease	I_Disease
and	O	O
SVC	B_Disease	O
syndrome	I_Disease	O
secondary	O	O
to	O	O
HITT	B_Disease	O
was	O	O
successfully	O	O
treated	O	O
with	O	O
argatroban	B_Chemical	B_Chemical
and	O	O
CDT	O	O
with	O	O
alteplase	O	B_Chemical
.	O	O

Effects	O	O
of	O	O
dehydroepiandrosterone	B_Chemical	B_Chemical
in	O	O
amphetamine-induced	O	O
schizophrenia	B_Disease	O
models	O	O
in	O	O
mice	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
examine	O	O
the	O	O
effects	O	O
of	O	O
dehydroepiandrosterone	B_Chemical	B_Chemical
(	O	O
DHEA	B_Chemical	O
)	O	O
on	O	O
animal	O	O
models	O	O
of	O	O
schizophrenia	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
Seventy	O	O
Swiss	O	O
albino	O	O
female	O	O
mice	O	O
(	O	O
25	O	O
-	O	O
35	O	O
g	O	O
)	O	O
were	O	O
divided	O	O
into	O	O
4	O	O
groups	O	O
:	O	O
amphetamine-free	O	O
(	O	O
control	O	O
)	O	O
,	O	O
amphetamine	B_Chemical	O
,	O	O
50	O	O
,	O	O
and	O	O
100	O	O
mg/kg	O	O
DHEA	B_Chemical	O
.	O	O

The	O	O
DHEA	B_Chemical	O
was	O	O
administered	O	O
intraperitoneally	O	O
(	O	O
ip	O	O
)	O	O
for	O	O
5	O	O
days	O	O
.	O	O

Amphetamine	B_Chemical	O
(	O	O
3	O	O
mg/kg	O	O
ip	O	O
)	O	O
induced	O	O
hyper	B_Disease	O
locomotion	O	O
,	O	O
apomorphine	B_Chemical	O
(	O	O
1.5	O	O
mg/kg	O	O
subcutaneously	O	O
[	O	O
sc	O	O
]	O	O
)	O	O
induced	O	O
climbing	O	O
,	O	O
and	O	O
haloperidol	B_Chemical	O
(	O	O
1.5	O	O
mg/kg	O	O
sc	O	O
)	O	O
induced	O	O
catalepsy	B_Disease	O
tests	O	O
were	O	O
used	O	O
as	O	O
animal	O	O
models	O	O
of	O	O
schizophrenia	B_Disease	O
.	O	O

The	O	O
study	O	O
was	O	O
conducted	O	O
at	O	O
the	O	O
Animal	O	O
Experiment	O	O
Laboratories	O	O
,	O	O
Department	O	O
of	O	O
Pharmacology	O	O
,	O	O
Medical	O	O
School	O	O
,	O	O
Eskisehir	O	O
Osmangazi	O	O
University	O	O
,	O	O
Eskisehir	O	O
,	O	O
Turkey	O	O
between	O	O
March	O	O
and	O	O
May	O	O
2012	O	O
.	O	O

Statistical	O	O
analysis	O	O
was	O	O
carried	O	O
out	O	O
using	O	O
Kruskal-Wallis	O	O
test	O	O
for	O	O
hyper	B_Disease	O
locomotion	O	O
,	O	O
and	O	O
one-way	O	O
ANOVA	O	O
for	O	O
climbing	O	O
and	O	O
catalepsy	B_Disease	O
tests	O	O
.	O	O

RESULTS	O	O
:	O	O
In	O	O
the	O	O
amphetamine-induced	O	O
locomotion	O	O
test	O	O
,	O	O
there	O	O
were	O	O
significant	O	O
increases	O	O
in	O	O
all	O	O
movements	O	O
compared	O	O
with	O	O
the	O	O
amphetamine-free	O	O
group	O	O
.	O	O

Both	O	O
DHEA	B_Chemical	O
50	O	O
mg/kg	O	O
(	O	O
p<0.05	O	O
)	O	O
,	O	O
and	O	O
100	O	O
mg/kg	O	O
(	O	O
p<0.01	O	O
)	O	O
significantly	O	O
decreased	O	O
all	O	O
movements	O	O
compared	O	O
with	O	O
the	O	O
amphetamine-induced	O	O
locomotion	O	O
group	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
between	O	O
groups	O	O
in	O	O
the	O	O
haloperidol-induced	O	O
catalepsy	B_Disease	O
test	O	O
(	O	O
p<0.05	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
groups	O	O
in	O	O
terms	O	O
of	O	O
total	O	O
climbing	O	O
time	O	O
in	O	O
the	O	O
apomorphine-induced	O	O
climbing	O	O
test	O	O
(	O	O
p>0.05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
We	O	O
observed	O	O
that	O	O
DHEA	B_Chemical	O
reduced	O	O
locomotor	O	O
activity	O	O
and	O	O
increased	O	O
catalepsy	B_Disease	O
at	O	O
both	O	O
doses	O	O
,	O	O
while	O	O
it	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
climbing	O	O
behavior	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
DHEA	B_Chemical	O
displays	O	O
typical	O	O
neuroleptic-like	O	O
effects	O	O
,	O	O
and	O	O
may	O	O
be	O	O
used	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
schizophrenia	B_Disease	O
.	O	O

Availability	O	O
of	O	O
human	O	O
induced	O	O
pluripotent	O	O
stem	O	O
cell-derived	O	O
cardiomyocytes	O	O
in	O	O
assessment	O	O
of	O	O
drug	O	O
potential	O	O
for	O	O
QT	O	O
prolongation	O	O
.	O	O

Field	O	O
potential	O	O
duration	O	O
(	O	O
FPD	O	O
)	O	O
in	O	O
human-induced	O	O
pluripotent	O	O
stem	O	O
cell-derived	O	O
cardiomyocytes	O	O
(	O	O
hiPS-CMs	O	O
)	O	O
,	O	O
which	O	O
can	O	O
express	O	O
QT	O	O
interval	O	O
in	O	O
an	O	O
electrocardiogram	O	O
,	O	O
is	O	O
reported	O	O
to	O	O
be	O	O
a	O	O
useful	O	O
tool	O	O
to	O	O
predict	O	O
K(+	O	O
)	O	O
channel	O	O
and	O	O
Ca(2	O	O
+	O	O
)	O	O
channel	O	O
blocker	O	O
effects	O	O
on	O	O
QT	O	O
interval	O	O
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
no	O	O
report	O	O
showing	O	O
that	O	O
this	O	O
technique	O	O
can	O	O
be	O	O
used	O	O
to	O	O
predict	O	O
multichannel	O	O
blocker	O	O
potential	O	O
for	O	O
QT	B_Disease	O
prolongation	I_Disease	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
show	O	O
that	O	O
FPD	O	O
from	O	O
MEA	O	O
(	O	O
Multielectrode	O	O
array	O	O
)	O	O
of	O	O
hiPS-CMs	O	O
can	O	O
detect	O	O
QT	B_Disease	O
prolongation	I_Disease	O
induced	O	O
by	O	O
multichannel	O	O
blockers	O	O
.	O	O

hiPS-CMs	O	O
were	O	O
seeded	O	O
onto	O	O
MEA	O	O
and	O	O
FPD	O	O
was	O	O
measured	O	O
for	O	O
2min	O	O
every	O	O
10min	O	O
for	O	O
30min	O	O
after	O	O
drug	O	O
exposure	O	O
for	O	O
the	O	O
vehicle	O	O
and	O	O
each	O	O
drug	O	O
concentration	O	O
.	O	O

IKr	O	O
and	O	O
IKs	O	O
blockers	O	O
concentration-dependently	O	O
prolonged	O	O
corrected	O	O
FPD	O	O
(	O	O
FPDc	O	O
)	O	O
,	O	O
whereas	O	O
Ca(2	O	O
+	O	O
)	O	O
channel	O	O
blockers	O	O
concentration-dependently	O	O
shortened	O	O
FPDc	O	O
.	O	O

Also	O	O
,	O	O
the	O	O
multichannel	O	O
blockers	O	O
Amiodarone	B_Chemical	O
,	O	O
Paroxetine	B_Chemical	B_Chemical
,	O	O
Terfenadine	B_Chemical	B_Chemical
and	O	O
Citalopram	B_Chemical	B_Chemical
prolonged	O	O
FPDc	O	O
in	O	O
a	O	O
concentration	O	O
dependent	O	O
manner	O	O
.	O	O

Finally	O	O
,	O	O
the	O	O
IKr	O	O
blockers	O	O
,	O	O
Terfenadine	B_Chemical	B_Chemical
and	O	O
Citalopram	B_Chemical	B_Chemical
,	O	O
which	O	O
are	O	O
reported	O	O
to	O	O
cause	O	O
Torsade	B_Disease	O
de	I_Disease	O
Pointes	I_Disease	O
(	O	O
TdP	B_Disease	O
)	O	O
in	O	O
clinical	O	O
practice	O	O
,	O	O
produced	O	O
early	O	O
afterdepolarization	O	O
(	O	O
EAD	O	O
)	O	O
.	O	O

hiPS-CMs	O	O
using	O	O
MEA	O	O
system	O	O
and	O	O
FPDc	O	O
can	O	O
predict	O	O
the	O	O
effects	O	O
of	O	O
drug	O	O
candidates	O	O
on	O	O
QT	O	O
interval	O	O
.	O	O

This	O	O
study	O	O
also	O	O
shows	O	O
that	O	O
this	O	O
assay	O	O
can	O	O
help	O	O
detect	O	O
EAD	O	O
for	O	O
drugs	O	O
with	O	O
TdP	B_Disease	O
potential	O	O
.	O	O

Dermal	O	O
developmental	O	B_Disease
toxicity	O	I_Disease
of	O	O
N-phenylimide	O	O
herbicides	O	O
in	O	O
rats	O	O
.	O	O

BACKGROUND	O	O
:	O	O
S-53482	B_Chemical	O
and	O	O
S-23121	B_Chemical	O
are	O	O
N-phenylimide	O	O
herbicides	O	O
and	O	O
produced	O	O
embryolethality	B_Disease	O
,	O	O
teratogenicity	B_Disease	O
(	O	O
mainly	O	O
ventricular	B_Disease	B_Disease
septal	I_Disease	I_Disease
defects	I_Disease	I_Disease
and	O	O
wavy	O	O
ribs	O	O
)	O	O
,	O	O
and	O	O
growth	B_Disease	O
retardation	I_Disease	O
in	O	O
rats	O	O
in	O	O
conventional	O	O
oral	O	O
developmental	O	O
toxicity	B_Disease	O
studies	O	O
.	O	O

Our	O	O
objective	O	O
in	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
the	O	O
compounds	O	O
induce	O	O
developmental	O	O
toxicity	B_Disease	O
via	O	O
the	O	O
dermal	O	O
route	O	O
,	O	O
which	O	O
is	O	O
more	O	O
relevant	O	O
to	O	O
occupational	O	O
exposure	O	O
,	O	O
hence	O	O
better	O	O
addressing	O	O
human	O	O
health	O	O
risks	O	O
.	O	O

METHODS	O	O
:	O	O
S-53482	B_Chemical	O
was	O	O
administered	O	O
dermally	O	O
to	O	O
rats	O	O
at	O	O
30	O	O
,	O	O
100	O	O
,	O	O
and	O	O
300	O	O
mg/kg	O	O
during	O	O
organogenesis	O	O
,	O	O
and	O	O
S-23121	B_Chemical	O
was	O	O
administered	O	O
at	O	O
200	O	O
,	O	O
400	O	O
,	O	O
and	O	O
800	O	O
mg/kg	O	O
(	O	O
the	O	O
maximum	O	O
applicable	O	O
dose	O	O
level	O	O
)	O	O
.	O	O

Fetuses	O	O
were	O	O
obtained	O	O
by	O	O
a	O	O
Cesarean	O	O
section	O	O
and	O	O
examined	O	O
for	O	O
external	O	O
,	O	O
visceral	O	O
,	O	O
and	O	O
skeletal	O	O
alterations	O	O
.	O	O

RESULTS	O	O
:	O	O
Dermal	O	O
exposure	O	O
of	O	O
rats	O	O
to	O	O
S-53482	B_Chemical	O
at	O	O
300	O	O
mg/kg	O	O
produced	O	O
patterns	O	O
of	O	O
developmental	O	B_Disease
toxicity	B_Disease	I_Disease
similar	O	O
to	O	O
those	O	O
resulting	O	O
from	O	O
oral	O	O
exposure	O	O
.	O	O

Toxicity	B_Disease	O
included	O	O
embryolethality	B_Disease	O
,	O	O
teratogenicity	B_Disease	O
,	O	O
and	O	O
growth	B_Disease	O
retardation	I_Disease	O
.	O	O

Dermal	O	O
administration	O	O
of	O	O
S-23121	B_Chemical	O
at	O	O
800	O	O
mg/kg	O	O
resulted	O	O
in	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
embryonic	B_Disease	O
death	I_Disease	O
and	O	O
ventricular	B_Disease	B_Disease
septal	I_Disease	I_Disease
defect	I_Disease	I_Disease
,	O	O
but	O	O
retarded	O	O
fetal	O	O
growth	O	O
was	O	O
not	O	O
observed	O	O
as	O	O
it	O	O
was	O	O
following	O	O
oral	O	O
exposure	O	O
to	O	O
S-23121	B_Chemical	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Based	O	O
on	O	O
the	O	O
results	O	O
,	O	O
S-53482	B_Chemical	O
and	O	O
S-23121	B_Chemical	O
were	O	O
teratogenic	B_Disease	O
when	O	O
administered	O	O
dermally	O	O
to	O	O
pregnant	O	O
rats	O	O
as	O	O
were	O	O
the	O	O
compounds	O	O
administered	O	O
orally	O	O
.	O	O

Thus	O	O
,	O	O
investigation	O	O
of	O	O
the	O	O
mechanism	O	O
and	O	O
its	O	O
human	O	O
relevancy	O	O
become	O	O
more	O	O
important	O	O
.	O	O

Rates	O	O
of	O	O
Renal	B_Disease	B_Disease
Toxicity	I_Disease	I_Disease
in	O	O
Cancer	B_Disease	O
Patients	O	O
Receiving	O	O
Cisplatin	B_Chemical	B_Chemical
With	O	O
and	O	O
Without	O	O
Mannitol	B_Chemical	O
.	O	O

BACKGROUND	O	O
:	O	O
Cisplatin	B_Chemical	B_Chemical
is	O	O
a	O	O
widely	O	O
used	O	O
antineoplastic	O	O
.	O	O

One	O	O
of	O	O
the	O	O
major	O	O
complications	O	O
of	O	O
cisplatin	B_Chemical	B_Chemical
use	O	O
is	O	O
dose-limiting	O	O
nephrotoxicity	B_Disease	B_Disease
.	O	O

There	O	O
are	O	O
many	O	O
strategies	O	O
to	O	O
prevent	O	O
this	O	O
toxicity	B_Disease	O
,	O	O
including	O	O
the	O	O
use	O	O
of	O	O
mannitol	B_Chemical	O
as	O	O
a	O	O
nephroprotectant	O	O
in	O	O
combination	O	O
with	O	O
hydration	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
We	O	O
aimed	O	O
to	O	O
evaluate	O	O
the	O	O
rates	O	O
of	O	O
cisplatin-induced	O	O
nephrotoxicity	B_Disease	B_Disease
in	O	O
cancer	B_Disease	O
patients	O	O
receiving	O	O
single-agent	O	O
cisplatin	B_Chemical	B_Chemical
with	O	O
and	O	O
without	O	O
mannitol	B_Chemical	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
single-center	O	O
retrospective	O	O
analysis	O	O
was	O	O
a	O	O
quasi	O	O
experiment	O	O
created	O	O
by	O	O
the	O	O
national	O	O
mannitol	B_Chemical	O
shortage	O	O
.	O	O

Data	O	O
were	O	O
collected	O	O
on	O	O
adult	O	O
cancer	B_Disease	O
patients	O	O
receiving	O	O
single-agent	O	O
cisplatin	B_Chemical	B_Chemical
as	O	O
an	O	O
outpatient	O	O
from	O	O
January	O	O
2011	O	O
to	O	O
September	O	O
2012	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
was	O	O
acute	B_Disease	B_Disease
kidney	I_Disease	I_Disease
injury	I_Disease	I_Disease
(	O	O
AKI	B_Disease	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
evaluated	O	O
143	O	O
patients	O	O
who	O	O
received	O	O
single-agent	O	O
cisplatin	B_Chemical	B_Chemical
;	O	O
97.2	O	O
%	O	O
of	O	O
patients	O	O
had	O	O
head	B_Disease	O
and	I_Disease	O
neck	I_Disease	O
cancer	I_Disease	O
as	O	O
their	O	O
primary	O	O
malignancy	B_Disease	O
.	O	O

Patients	O	O
who	O	O
did	O	O
not	O	O
receive	O	O
mannitol	B_Chemical	O
were	O	O
more	O	O
likely	O	O
to	O	O
develop	O	O
nephrotoxicity	B_Disease	B_Disease
:	O	O
odds	O	O
ratio	O	O
[	O	O
OR	O	O
]	O	O
=	O	O
2.646	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
=	O	O
1.008	O	O
,	O	O
6.944	O	O
;	O	O
P	O	O
=	O	O
0.048	O	O
)	O	O
.	O	O

Patients	O	O
who	O	O
received	O	O
the	O	O
100	O	O
mg/m(2	O	O
)	O	O
dosing	O	O
and	O	O
patients	O	O
who	O	O
had	O	O
a	O	O
history	O	O
of	O	O
hypertension	B_Disease	O
also	O	O
had	O	O
a	O	O
higher	O	O
likelihood	O	O
of	O	O
developing	O	O
nephrotoxicity	B_Disease	B_Disease
:	O	O
OR	O	O
=	O	O
11.494	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
=	O	O
4.149	O	O
,	O	O
32.258	O	O
;	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
and	O	O
OR	O	O
=	O	O
3.219	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
=	O	O
1.228	O	O
,	O	O
8.439	O	O
;	O	O
P	O	O
=	O	O
0.017	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
When	O	O
limited	O	O
quantities	O	O
of	O	O
mannitol	B_Chemical	O
are	O	O
available	O	O
,	O	O
it	O	O
should	O	O
preferentially	O	O
be	O	O
given	O	O
to	O	O
patients	O	O
at	O	O
particularly	O	O
high	O	O
risk	O	O
of	O	O
nephrotoxicity	B_Disease	B_Disease
.	O	O

Our	O	O
analysis	O	O
suggests	O	O
that	O	O
those	O	O
patients	O	O
receiving	O	O
the	O	O
dosing	O	O
schedule	O	O
of	O	O
100	O	O
mg/m(2	O	O
)	O	O
cisplatin	B_Chemical	B_Chemical
every	O	O
3	O	O
weeks	O	O
and	O	O
those	O	O
with	O	O
hypertension	B_Disease	O
are	O	O
at	O	O
the	O	O
greatest	O	O
risk	O	O
of	O	O
nephrotoxicity	B_Disease	B_Disease
and	O	O
would	O	O
benefit	O	O
from	O	O
the	O	O
addition	O	O
of	O	O
mannitol	B_Chemical	O
.	O	O

Metformin	B_Chemical	O
protects	O	O
against	O	O
seizures	B_Disease	O
,	O	O
learning	B_Disease	O
and	I_Disease	O
memory	B_Disease	O
impairments	I_Disease	O
and	O	O
oxidative	O	B_Disease
damage	O	I_Disease
induced	O	O
by	O	O
pentylenetetrazole-induced	O	O
kindling	O	O
in	O	O
mice	O	O
.	O	O

Cognitive	B_Disease	B_Disease
impairment	I_Disease	I_Disease
,	O	O
the	O	O
most	O	O
common	O	O
and	O	O
severe	O	O
comorbidity	O	O
of	O	O
epilepsy	B_Disease	O
,	O	O
greatly	O	O
diminishes	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

However	O	O
,	O	O
current	O	O
therapeutic	O	O
interventions	O	O
for	O	O
epilepsy	B_Disease	O
can	O	O
also	O	O
cause	O	O
untoward	O	O
cognitive	O	O
effects	O	O
.	O	O

Thus	O	O
,	O	O
there	O	O
is	O	O
an	O	O
urgent	O	O
need	O	O
for	O	O
new	O	O
kinds	O	O
of	O	O
agents	O	O
targeting	O	O
both	O	O
seizures	B_Disease	O
and	O	O
cognition	B_Disease	B_Disease
deficits	I_Disease	I_Disease
.	O	O

Oxidative	O	O
stress	O	O
is	O	O
considered	O	O
to	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
epileptogenesis	O	O
and	O	O
cognitive	B_Disease	B_Disease
deficits	I_Disease	I_Disease
,	O	O
and	O	O
antioxidants	O	O
have	O	O
a	O	O
putative	O	O
antiepileptic	O	O
potential	O	O
.	O	O

Metformin	B_Chemical	O
,	O	O
the	O	O
most	O	O
commonly	O	O
prescribed	O	O
antidiabetic	O	O
oral	O	O
drug	O	O
,	O	O
has	O	O
antioxidant	O	O
properties	O	O
.	O	O

This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
evaluate	O	O
the	O	O
ameliorative	O	O
effects	O	O
of	O	O
metformin	B_Chemical	O
on	O	O
seizures	B_Disease	O
,	O	O
cognitive	B_Disease	B_Disease
impairment	I_Disease	I_Disease
and	O	O
brain	O	O
oxidative	O	O
stress	O	O
markers	O	O
observed	O	O
in	O	O
pentylenetetrazole-induced	O	O
kindling	O	O
animals	O	O
.	O	O

Male	O	O
C57BL/6	O	O
mice	O	O
were	O	O
administered	O	O
with	O	O
subconvulsive	O	O
dose	O	O
of	O	O
pentylenetetrazole	B_Chemical	B_Chemical
(	O	O
37	O	O
mg/kg	O	O
,	O	O
i.p	O	O
.	O	O
)	O	O
every	O	O
other	O	O
day	O	O
for	O	O
14	O	O
injections	O	O
.	O	O

Metformin	B_Chemical	O
was	O	O
injected	O	O
intraperitoneally	O	O
in	O	O
dose	O	O
of	O	O
200mg/kg	O	O
along	O	O
with	O	O
alternate-day	O	O
PTZ	B_Chemical	O
.	O	O

We	O	O
found	O	O
that	O	O
metformin	B_Chemical	O
suppressed	O	O
the	O	O
progression	O	O
of	O	O
kindling	O	O
,	O	O
ameliorated	O	O
the	O	O
cognitive	B_Disease	B_Disease
impairment	I_Disease	I_Disease
and	O	O
decreased	O	O
brain	O	O
oxidative	O	B_Disease
stress	O	I_Disease
.	O	O

Thus	O	O
the	O	O
present	O	O
study	O	O
concluded	O	O
that	O	O
metformin	B_Chemical	O
may	O	O
be	O	O
a	O	O
potential	O	O
agent	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
epilepsy	B_Disease	O
as	O	O
well	O	O
as	O	O
a	O	O
protective	O	O
medicine	O	O
against	O	O
cognitive	B_Disease	B_Disease
impairment	I_Disease	I_Disease
induced	O	O
by	O	O
seizures	B_Disease	O
.	O	O

P53	O	O
inhibition	O	O
exacerbates	O	O
late-stage	O	O
anthracycline	B_Chemical	O
cardiotoxicity	B_Disease	O
.	O	O

AIMS	O	O
:	O	O
Doxorubicin	B_Chemical	O
(	O	O
DOX	B_Chemical	O
)	O	O
is	O	O
an	O	O
effective	O	O
anti-cancer	O	O
therapeutic	O	O
,	O	O
but	O	O
is	O	O
associated	O	O
with	O	O
both	O	O
acute	O	O
and	O	O
late-stage	O	O
cardiotoxicity	B_Disease	B_Disease
.	O	O

Children	O	O
are	O	O
particularly	O	O
sensitive	O	O
to	O	O
DOX-induced	O	O
heart	B_Disease	B_Disease
failure	I_Disease	I_Disease
.	O	O

Here	O	O
,	O	O
the	O	O
impact	O	O
of	O	O
p53	O	O
inhibition	O	O
on	O	O
acute	O	O
vs.	O	O
late-stage	O	O
DOX	B_Chemical	B_Disease
cardiotoxicity	B_Disease	I_Disease
was	O	O
examined	O	O
in	O	O
a	O	O
juvenile	O	O
model	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
Two-week-old	O	O
MHC-CB7	O	O
mice	O	O
(	O	O
which	O	O
express	O	O
dominant-interfering	O	O
p53	O	O
in	O	O
cardiomyocytes	O	O
)	O	O
and	O	O
their	O	O
non-transgenic	O	O
(	O	O
NON-TXG	O	O
)	O	O
littermates	O	O
received	O	O
weekly	O	O
DOX	B_Chemical	B_Chemical
injections	O	O
for	O	O
5	O	O
weeks	O	O
(	O	O
25	O	O
mg/kg	O	O
cumulative	O	O
dose	O	O
)	O	O
.	O	O

One	O	O
week	O	O
after	O	O
the	O	O
last	O	O
DOX	B_Chemical	O
treatment	O	O
(	O	O
acute	O	O
stage	O	O
)	O	O
,	O	O
MHC-CB7	O	O
mice	O	O
exhibited	O	O
improved	O	O
cardiac	O	O
function	O	O
and	O	O
lower	O	O
levels	O	O
of	O	O
cardiomyocyte	O	O
apoptosis	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
NON-TXG	O	O
mice	O	O
.	O	O

Surprisingly	O	O
,	O	O
by	O	O
13	O	O
weeks	O	O
following	O	O
the	O	O
last	O	O
DOX	B_Chemical	O
treatment	O	O
(	O	O
late	O	O
stage	O	O
)	O	O
,	O	O
MHC-CB7	O	O
exhibited	O	O
a	O	O
progressive	O	O
decrease	O	O
in	O	O
cardiac	O	O
function	O	O
and	O	O
higher	O	O
rates	O	O
of	O	O
cardiomyocyte	O	O
apoptosis	O	O
when	O	O
compared	O	O
with	O	O
NON-TXG	O	O
mice	O	O
.	O	O

p53	O	O
inhibition	O	O
blocked	O	O
transient	O	O
DOX-induced	O	O
STAT3	O	O
activation	O	O
in	O	O
MHC-CB7	O	O
mice	O	O
,	O	O
which	O	O
was	O	O
associated	O	O
with	O	O
enhanced	O	O
induction	O	O
of	O	O
the	O	O
DNA	O	O
repair	O	O
proteins	O	O
Ku70	O	O
and	O	O
Ku80	O	O
.	O	O

Mice	O	O
with	O	O
cardiomyocyte-restricted	O	O
deletion	O	O
of	O	O
STAT3	O	O
exhibited	O	O
worse	O	O
cardiac	O	O
function	O	O
,	O	O
higher	O	O
levels	O	O
of	O	O
cardiomyocyte	O	O
apoptosis	O	O
,	O	O
and	O	O
a	O	O
greater	O	O
induction	O	O
of	O	O
Ku70	O	O
and	O	O
Ku80	O	O
in	O	O
response	O	O
to	O	O
DOX	B_Chemical	O
treatment	O	O
during	O	O
the	O	O
acute	O	O
stage	O	O
when	O	O
compared	O	O
with	O	O
control	O	O
animals	O	O
.	O	O

CONCLUSION	O	O
:	O	O
These	O	O
data	O	O
support	O	O
a	O	O
model	O	O
wherein	O	O
a	O	O
p53-dependent	O	O
cardioprotective	O	O
pathway	O	O
,	O	O
mediated	O	O
via	O	O
STAT3	O	O
activation	O	O
,	O	O
mitigates	O	O
DOX-induced	O	O
myocardial	O	B_Disease
stress	O	I_Disease
during	O	O
drug	O	O
delivery	O	O
.	O	O

Furthermore	O	O
,	O	O
these	O	O
data	O	O
suggest	O	O
an	O	O
explanation	O	O
as	O	O
to	O	O
how	O	O
p53	O	O
inhibition	O	O
can	O	O
result	O	O
in	O	O
cardioprotection	O	O
during	O	O
drug	O	O
treatment	O	O
and	O	O
,	O	O
paradoxically	O	O
,	O	O
enhanced	O	O
cardiotoxicity	B_Disease	B_Disease
long	O	O
after	O	O
the	O	O
cessation	O	O
of	O	O
drug	O	O
treatment	O	O
.	O	O

Metronidazole-induced	O	O
encephalopathy	B_Disease	O
:	O	O
an	O	O
uncommon	O	O
scenario	O	O
.	O	O

Metronidazole	B_Chemical	O
can	O	O
produce	O	O
neurological	O	B_Disease
complications	O	I_Disease
although	O	O
it	O	O
is	O	O
not	O	O
a	O	O
common	O	O
scenario	O	O
.	O	O

We	O	O
present	O	O
a	O	O
case	O	O
where	O	O
a	O	O
patient	O	O
developed	O	O
features	O	O
of	O	O
encephalopathy	B_Disease	O
following	O	O
prolonged	O	O
metronidazole	B_Chemical	O
intake	O	O
.	O	O

Magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
brain	O	O
showed	O	O
abnormal	O	O
signal	O	O
intensity	O	O
involving	O	O
both	O	O
dentate	O	O
nuclei	O	O
of	O	O
cerebellum	O	O
and	O	O
splenium	O	O
of	O	O
corpus	O	O
callosum	O	O
.	O	O

The	O	O
diagnosis	O	O
of	O	O
metronidazole	B_Chemical	O
toxicity	B_Disease	O
was	O	O
made	O	O
by	O	O
the	O	O
MRI	O	O
findings	O	O
and	O	O
supported	O	O
clinically	O	O
.	O	O

Aconitine-induced	O	O
Ca2	O	O
+	O	O
overload	O	O
causes	O	O
arrhythmia	B_Disease	O
and	O	O
triggers	O	O
apoptosis	O	O
through	O	O
p38	O	O
MAPK	O	O
signaling	O	O
pathway	O	O
in	O	O
rats	O	O
.	O	O

Aconitine	B_Chemical	B_Chemical
is	O	O
a	O	O
major	O	O
bioactive	O	O
diterpenoid	O	O
alkaloid	O	O
with	O	O
high	O	O
content	O	O
derived	O	O
from	O	O
herbal	O	O
aconitum	O	O
plants	O	O
.	O	O

Emerging	O	O
evidence	O	O
indicates	O	O
that	O	O
voltage-dependent	O	O
Na(+	O	O
)	O	O
channels	O	O
have	O	O
pivotal	O	O
roles	O	O
in	O	O
the	O	O
cardiotoxicity	B_Disease	B_Disease
of	O	O
aconitine	B_Chemical	B_Chemical
.	O	O

However	O	O
,	O	O
no	O	O
reports	O	O
are	O	O
available	O	O
on	O	O
the	O	O
role	O	O
of	O	O
Ca(2	O	O
+	O	O
)	O	O
in	O	O
aconitine	B_Chemical	O
poisoning	B_Disease	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
explored	O	O
the	O	O
importance	O	O
of	O	O
pathological	O	O
Ca(2	O	O
+	O	O
)	O	O
signaling	O	O
in	O	O
aconitine	B_Chemical	O
poisoning	B_Disease	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

We	O	O
found	O	O
that	O	O
Ca(2	O	O
+	O	O
)	O	O
overload	O	O
lead	O	O
to	O	O
accelerated	O	O
beating	O	O
rhythm	O	O
in	O	O
adult	O	O
rat	O	O
ventricular	O	B_Disease
myocytes	O	I_Disease
and	O	O
caused	O	O
arrhythmia	B_Disease	O
in	O	O
conscious	O	O
freely	O	O
moving	O	O
rats	O	O
.	O	O

To	O	O
investigate	O	O
effects	O	O
of	O	O
aconitine	B_Chemical	O
on	O	O
myocardial	B_Disease	B_Disease
injury	I_Disease	I_Disease
,	O	O
we	O	O
performed	O	O
cytotoxicity	B_Disease	O
assay	O	O
in	O	O
neonatal	O	O
rat	O	O
ventricular	O	O
myocytes	O	O
(	O	O
NRVMs	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
measured	O	O
lactate	B_Chemical	O
dehydrogenase	O	O
level	O	O
in	O	O
the	O	O
culture	O	O
medium	O	O
of	O	O
NRVMs	O	O
and	O	O
activities	O	O
of	O	O
serum	O	O
cardiac	O	O
enzymes	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
aconitine	B_Chemical	O
resulted	O	O
in	O	O
myocardial	B_Disease	B_Disease
injury	I_Disease	I_Disease
and	O	O
reduced	O	O
NRVMs	O	O
viability	O	O
dose-dependently	O	O
.	O	O

To	O	O
confirm	O	O
the	O	O
pro-apoptotic	O	O
effects	O	O
,	O	O
we	O	O
performed	O	O
flow	O	O
cytometric	O	O
detection	O	O
,	O	O
cardiac	O	O
histology	O	O
,	O	O
transmission	O	O
electron	O	O
microscopy	O	O
and	O	O
terminal	O	O
deoxynucleotidyl	O	O
transferase-mediated	O	O
dUTP-biotin	O	O
nick	O	O
end	O	O
labeling	O	O
assay	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
aconitine	B_Chemical	O
stimulated	O	O
apoptosis	O	O
time-dependently	O	O
.	O	O

The	O	O
expression	O	O
analysis	O	O
of	O	O
Ca(2	O	O
+	O	O
)	O	O
handling	O	O
proteins	O	O
demonstrated	O	O
that	O	O
aconitine	B_Chemical	O
promoted	O	O
Ca(2	O	O
+	O	O
)	O	O
overload	O	O
through	O	O
the	O	O
expression	O	O
regulation	O	O
of	O	O
Ca(2	O	O
+	O	O
)	O	O
handling	O	O
proteins	O	O
.	O	O

The	O	O
expression	O	O
analysis	O	O
of	O	O
apoptosis-related	O	O
proteins	O	O
revealed	O	O
that	O	O
pro-apoptotic	O	O
protein	O	O
expression	O	O
was	O	O
upregulated	O	O
,	O	O
and	O	O
anti-apoptotic	O	O
protein	O	O
BCL-2	O	O
expression	O	O
was	O	O
downregulated	O	O
.	O	O

Furthermore	O	O
,	O	O
increased	O	O
phosphorylation	O	O
of	O	O
MAPK	O	O
family	O	O
members	O	O
,	O	O
especially	O	O
the	O	O
P-P38/P38	O	O
ratio	O	O
was	O	O
found	O	O
in	O	O
cardiac	O	O
tissues	O	O
.	O	O

Hence	O	O
,	O	O
our	O	O
results	O	O
suggest	O	O
that	O	O
aconitine	B_Chemical	B_Chemical
significantly	O	O
aggravates	O	O
Ca(2	O	O
+	O	O
)	O	O
overload	O	O
and	O	O
causes	O	O
arrhythmia	B_Disease	O
and	O	O
finally	O	O
promotes	O	O
apoptotic	O	O
development	O	O
via	O	O
phosphorylation	O	O
of	O	O
P38	O	O
mitogen-activated	O	O
protein	O	O
kinase	O	O
.	O	O

Chronic	O	O
treatment	O	O
with	O	O
metformin	B_Chemical	O
suppresses	O	O
toll-like	O	O
receptor	O	O
4	O	O
signaling	O	O
and	O	O
attenuates	O	O
left	B_Disease	B_Disease
ventricular	I_Disease	I_Disease
dysfunction	I_Disease	I_Disease
following	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
.	O	O

Acute	O	O
treatment	O	O
with	O	O
metformin	B_Chemical	O
has	O	O
a	O	O
protective	O	O
effect	O	O
in	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
by	O	O
suppression	O	O
of	O	O
inflammatory	O	O
responses	O	O
due	O	O
to	O	O
activation	O	O
of	O	O
AMP-activated	O	O
protein	O	O
kinase	O	O
(	O	O
AMPK	O	O
)	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
pre-treatment	O	O
with	O	O
metformin	B_Chemical	O
on	O	O
cardiac	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
and	O	O
toll-like	O	O
receptor	O	O
4	O	O
(	O	O
TLR4	O	O
)	O	O
activities	O	O
following	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
and	O	O
their	O	O
relation	O	O
with	O	O
AMPK	O	O
were	O	O
assessed	O	O
.	O	O

Male	O	O
Wistar	O	O
rats	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
5	O	O
groups	O	O
(	O	O
n=6	O	O
):	O	O
normal	O	O
control	O	O
and	O	O
groups	O	O
were	O	O
injected	O	O
isoproterenol	B_Chemical	O
after	O	O
chronic	O	O
pre-treatment	O	O
with	O	O
0	O	O
,	O	O
25	O	O
,	O	O
50	O	O
,	O	O
or	O	O
100mg/kg	O	O
of	O	O
metformin	B_Chemical	O
twice	O	O
daily	O	O
for	O	O
14	O	O
days	O	O
.	O	O

Isoproterenol	B_Chemical	O
(	O	O
100mg/kg	O	O
)	O	O
was	O	O
injected	O	O
subcutaneously	O	O
on	O	O
the	O	O
13th	O	O
and	O	O
14th	O	O
days	O	O
to	O	O
induce	O	O
acute	B_Disease	B_Disease
myocardial	I_Disease	I_Disease
infarction	I_Disease	I_Disease
.	O	O

Isoproterenol	B_Chemical	O
alone	O	O
decreased	O	O
left	O	B_Disease
ventricular	O	I_Disease
systolic	O	I_Disease
pressure	O	O
and	O	O
myocardial	O	O
contractility	O	O
indexed	O	O
as	O	O
LVdp/dtmax	O	O
and	O	O
LVdp/dtmin	O	O
.	O	O

The	O	O
left	B_Disease	B_Disease
ventricular	I_Disease	I_Disease
dysfunction	I_Disease	I_Disease
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
groups	O	O
treated	O	O
with	O	O
25	O	O
and	O	O
50mg/kg	O	O
of	O	O
metformin	B_Chemical	O
.	O	O

Metfromin	O	B_Chemical
markedly	O	O
lowered	O	O
isoproterenol-induced	O	O
elevation	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
TLR4	O	O
mRNA	O	O
,	O	O
myeloid	O	O
differentiation	O	O
protein	O	O
88	O	O
(	O	O
MyD88	O	O
)	O	O
,	O	O
tumor	B_Disease	O
necrosis	B_Disease	O
factor-alpha	O	O
(	O	O
TNF-a	O	O
)	O	O
,	O	O
and	O	O
interleukin	O	O
6	O	O
(	O	O
IL-6	O	O
)	O	O
in	O	O
the	O	O
heart	O	O
tissues	O	O
.	O	O

Similar	O	O
changes	O	O
were	O	O
also	O	O
seen	O	O
in	O	O
the	O	O
serum	O	O
levels	O	O
of	O	O
TNF-a	O	O
and	O	O
IL-6	O	O
.	O	O

However	O	O
,	O	O
the	O	O
lower	O	O
doses	O	O
of	O	O
25	O	O
and	O	O
50mg/kg	O	O
were	O	O
more	O	O
effective	O	O
than	O	O
100mg/kg	O	O
.	O	O

Phosphorylated	O	O
AMPKa	O	B_Chemical
(	O	O
p-AMPK	O	O
)	O	O
in	O	O
the	O	O
myocardium	O	O
was	O	O
significantly	O	O
elevated	O	O
by	O	O
25mg/kg	O	O
of	O	O
metformin	B_Chemical	O
,	O	O
slightly	O	O
by	O	O
50mg/kg	O	O
,	O	O
but	O	O
not	O	O
by	O	O
100mg/kg	O	O
.	O	O

Chronic	O	O
pre-treatment	O	O
with	O	O
metformin	B_Chemical	O
reduces	O	O
post-myocardial	O	O
infarction	O	O
cardiac	O	O
dysfunction	O	O
and	O	O
suppresses	O	O
inflammatory	O	O
responses	O	O
,	O	O
possibly	O	O
through	O	O
inhibition	O	O
of	O	O
TLR4	O	O
activities	O	O
.	O	O

This	O	O
mechanism	O	O
can	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
target	O	O
to	O	O
protect	O	O
infarcted	O	O
myocardium	O	O
.	O	O

Unusual	O	O
complications	O	O
of	O	O
antithyroid	O	O
drug	O	O
therapy	O	O
:	O	O
four	O	O
case	O	O
reports	O	O
and	O	O
review	O	O
of	O	O
literature	O	O
.	O	O

Two	O	O
cases	O	O
of	O	O
propylthiouracil-associated	O	O
acute	O	O
hepatitis	B_Disease	O
,	O	O
one	O	O
case	O	O
of	O	O
fatal	O	O
methimazole-associated	O	O
hepatocellular	B_Disease	B_Disease
necrosis	I_Disease	I_Disease
and	O	O
one	O	O
case	O	O
of	O	O
propylthiouracil-associated	O	O
lupus-like	B_Disease	O
syndrome	I_Disease	O
are	O	O
described	O	O
.	O	O

The	O	O
literature	O	O
related	O	O
to	O	O
antithyroid	O	O
drug	O	O
side	O	O
effects	O	O
and	O	O
the	O	O
mechanisms	O	O
for	O	O
their	O	O
occurrence	O	O
are	O	O
reviewed	O	O
and	O	O
the	O	O
efficacy	O	O
and	O	O
complications	O	O
of	O	O
thyroidectomy	O	O
and	O	O
radioiodine	O	O
compared	O	O
to	O	O
those	O	O
of	O	O
antithyroid	O	O
drugs	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
in	O	O
most	O	O
circumstances	O	O
131I	O	O
is	O	O
the	O	O
therapy	O	O
of	O	O
choice	O	O
for	O	O
hyperthyroidism	B_Disease	O
.	O	O

Neuroleptic	B_Disease	O
malignant	I_Disease	O
syndrome	I_Disease	O
induced	O	O
by	O	O
combination	O	O
therapy	O	O
with	O	O
tetrabenazine	B_Chemical	B_Chemical
and	O	O
tiapride	B_Chemical	B_Chemical
in	O	O
a	O	O
Japanese	O	O
patient	O	O
with	O	O
Huntington	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
at	O	O
the	O	O
terminal	O	O
stage	O	O
of	O	O
recurrent	O	O
breast	B_Disease	B_Disease
cancer	I_Disease	I_Disease
.	O	O

We	O	O
herein	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
an	O	O
81-year-old	O	O
Japanese	O	O
woman	O	O
with	O	O
neuroleptic	B_Disease	O
malignant	I_Disease	O
syndrome	I_Disease	O
that	O	O
occurred	O	O
36	O	O
days	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
combination	O	O
therapy	O	O
with	O	O
tiapride	B_Chemical	B_Chemical
(	O	O
75	O	O
mg/day	O	O
)	O	O
and	O	O
tetrabenazine	B_Chemical	B_Chemical
(	O	O
12.5	O	O
mg/day	O	O
)	O	O
for	O	O
Huntington	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
.	O	O

The	O	O
patient	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
tiapride	B_Chemical	B_Chemical
or	O	O
tetrabenazine	B_Chemical	B_Chemical
alone	O	O
without	O	O
any	O	O
adverse	O	O
effects	O	O
before	O	O
the	O	O
administration	O	O
of	O	O
the	O	O
combination	O	O
therapy	O	O
.	O	O

She	O	O
also	O	O
had	O	O
advanced	O	O
breast	B_Disease	B_Disease
cancer	I_Disease	I_Disease
when	O	O
the	O	O
combination	O	O
therapy	O	O
was	O	O
initiated	O	O
.	O	O

To	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
,	O	O
the	O	O
occurrence	O	O
of	O	O
neuroleptic	B_Disease	O
malignant	I_Disease	O
syndrome	I_Disease	O
due	O	O
to	O	O
combination	O	O
therapy	O	O
with	O	O
tetrabenazine	B_Chemical	B_Chemical
and	O	O
tiapride	B_Chemical	B_Chemical
has	O	O
not	O	O
been	O	O
previously	O	O
reported	O	O
.	O	O

Tetrabenazine	B_Chemical	B_Chemical
should	O	O
be	O	O
administered	O	O
very	O	O
carefully	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
neuroleptic	B_Chemical	O
drugs	I_Chemical	O
,	O	O
particularly	O	O
in	O	O
patients	O	O
with	O	O
a	O	O
worsening	O	O
general	O	O
condition	O	O
.	O	O

A	O	O
metoprolol-terbinafine	O	B_Chemical
combination	O	O
induced	O	O
bradycardia	B_Disease	O
.	O	O

To	O	O
report	O	O
a	O	O
sinus	B_Disease	B_Disease
bradycardia	I_Disease	I_Disease
induced	O	O
by	O	O
metoprolol	B_Chemical	O
and	O	O
terbinafine	B_Chemical	O
drug-drug	O	O
interaction	O	O
and	O	O
its	O	O
management	O	O
.	O	O

A	O	O
63	O	O
year-old	O	O
Caucasian	O	O
man	O	O
on	O	O
metoprolol	B_Chemical	O
200	O	O
mg/day	O	O
for	O	O
stable	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
was	O	O
prescribed	O	O
a	O	O
90-day	O	O
course	O	O
of	O	O
oral	O	O
terbinafine	B_Chemical	O
250	O	O
mg/day	O	O
for	O	O
onychomycosis	B_Disease	O
.	O	O

On	O	O
the	O	O
49th	O	O
day	O	O
of	O	O
terbinafine	B_Chemical	O
therapy	O	O
,	O	O
he	O	O
was	O	O
brought	O	O
to	O	O
the	O	O
emergency	O	O
room	O	O
for	O	O
a	O	O
decrease	O	O
of	O	O
his	O	O
global	O	O
health	O	O
status	O	O
,	O	O
confusion	B_Disease	O
and	O	O
falls	O	O
.	O	O

The	O	O
electrocardiogram	O	O
revealed	O	O
a	O	O
37	O	O
beats/min	O	O
sinus	B_Disease	B_Disease
bradycardia	I_Disease	I_Disease
.	O	O

A	O	O
score	O	O
of	O	O
7	O	O
on	O	O
the	O	O
Naranjo	O	O
adverse	B_Disease	O
drug	I_Disease	O
reaction	I_Disease	O
probability	O	O
scale	O	O
indicates	O	O
a	O	O
probable	O	O
relationship	O	O
between	O	O
the	O	O
patient	O	O
's	O	O
sinus	B_Disease	B_Disease
bradycardia	I_Disease	I_Disease
and	O	O
the	O	O
drug	O	O
interaction	O	O
between	O	O
metoprolol	B_Chemical	O
and	O	O
terbinafine	B_Chemical	O
.	O	O

The	O	O
heart	O	O
rate	O	O
ameliorated	O	O
first	O	O
with	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
dose	O	O
of	O	O
metoprolol	B_Chemical	O
.	O	O

It	O	O
was	O	O
subsequently	O	O
changed	O	O
to	O	O
bisoprolol	B_Chemical	B_Chemical
and	O	O
the	O	O
heart	O	O
rate	O	O
remained	O	O
normal	O	O
.	O	O

By	O	O
inhibiting	O	O
the	O	O
cytochrome	O	O
P450	O	O
2D6	O	O
,	O	O
terbinafine	B_Chemical	O
had	O	O
decreased	O	O
metoprolol	B_Chemical	O
's	O	O
clearance	O	O
,	O	O
leading	O	O
in	O	O
metoprolol	B_Chemical	O
accumulation	O	O
which	O	O
has	O	O
resulted	O	O
in	O	O
clinically	O	O
significant	O	O
sinus	B_Disease	B_Disease
bradycardia	I_Disease	I_Disease
.	O	O

Optochiasmatic	O	B_Disease
and	O	O
peripheral	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
due	O	O
to	O	O
ethambutol	B_Chemical	B_Chemical
overtreatment	O	O
.	O	O

Ethambutol	B_Chemical	B_Chemical
is	O	O
known	O	O
to	O	O
cause	O	O
optic	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
and	O	O
,	O	O
more	O	O
rarely	O	O
,	O	O
axonal	O	B_Disease
polyneuropathy	B_Disease	I_Disease
.	O	O

We	O	O
characterize	O	O
the	O	O
clinical	O	O
,	O	O
neurophysiological	O	O
,	O	O
and	O	O
neuroimaging	O	O
findings	O	O
in	O	O
a	O	O
72-year-old	O	O
man	O	O
who	O	O
developed	O	O
visual	B_Disease	B_Disease
loss	I_Disease	I_Disease
and	O	O
paresthesias	B_Disease	O
after	O	O
11	O	O
weeks	O	O
of	O	O
exposure	O	O
to	O	O
a	O	O
supratherapeutic	O	O
dose	O	O
of	O	O
ethambutol	B_Chemical	B_Chemical
.	O	O

This	O	O
case	O	O
demonstrates	O	O
the	O	O
selective	O	O
vulnerability	O	O
of	O	O
the	O	O
anterior	O	O
visual	O	O
pathways	O	O
and	O	O
peripheral	O	O
nerves	O	O
to	O	O
ethambutol	B_Chemical	O
toxicity	B_Disease	O
.	O	O

Testosterone	B_Chemical	O
ameliorates	O	O
streptozotocin-induced	O	O
memory	B_Disease	B_Disease
impairment	I_Disease	I_Disease
in	O	O
male	O	O
rats	O	O
.	O	O

AIM	O	O
:	O	O
To	O	O
study	O	O
the	O	O
effects	O	O
of	O	O
testosterone	B_Chemical	O
on	O	O
streptozotocin	B_Chemical	B_Chemical
(STZ)-induced	O	O
memory	B_Disease	B_Disease
impairment	I_Disease	I_Disease
in	O	O
male	O	O
rats	O	O
.	O	O

METHODS	O	O
:	O	O
Adult	O	O
male	O	O
Wistar	O	O
rats	O	O
were	O	O
intracerebroventricularly	O	O
(	O	O
icv	O	O
)	O	O
infused	O	O
with	O	O
STZ	B_Chemical	O
(	O	O
750	O	O
ug	O	O
)	O	O
on	O	O
d	O	O
1	O	O
and	O	O
d	O	O
3	O	O
,	O	O
and	O	O
a	O	O
passive	O	O
avoidance	O	O
task	O	O
was	O	O
assessed	O	O
2	O	O
weeks	O	O
after	O	O
the	O	O
first	O	O
injection	O	O
of	O	O
STZ	B_Chemical	O
.	O	O

Castration	O	O
surgery	O	O
was	O	O
performed	O	O
in	O	O
another	O	O
group	O	O
of	O	O
rats	O	O
,	O	O
and	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
was	O	O
assessed	O	O
4	O	O
weeks	O	O
after	O	O
the	O	O
operation	O	O
.	O	O

Testosterone	B_Chemical	O
(	O	O
1	O	O
mg.kg(-1).d(-1	O	O
)	O	O
,	O	O
sc	O	O
)	O	O
,	O	O
the	O	O
androgen	B_Chemical	O
receptor	O	O
antagonist	O	O
flutamide	B_Chemical	B_Chemical
(	O	O
10	O	O
mg.kg(-1).d(-1	O	O
)	O	O
,	O	O
ip	O	O
)	O	O
,	O	O
the	O	O
estrogen	B_Chemical	O
receptor	O	O
antagonist	O	O
tamoxifen	B_Chemical	O
(	O	O
1	O	O
mg.kg(-1).d(-1	O	O
)	O	O
,	O	O
ip	O	O
)	O	O
or	O	O
the	O	O
aromatase	O	B_Chemical
inhibitor	O	O
letrozole	B_Chemical	B_Chemical
(	O	O
4	O	O
mg.kg(-1).d(-1	O	O
)	O	O
,	O	O
ip	O	O
)	O	O
were	O	O
administered	O	O
for	O	O
6	O	O
d	O	O
after	O	O
the	O	O
first	O	O
injection	O	O
of	O	O
STZ	B_Chemical	O
.	O	O

RESULTS	O	O
:	O	O
STZ	B_Chemical	O
administration	O	O
and	O	O
castration	O	O
markedly	O	O
decreased	O	O
both	O	O
STL1	O	O
(	O	O
the	O	O
short	O	O
memory	O	O
)	O	O
and	O	O
STL2	O	O
(	O	O
the	O	O
long	O	O
memory	O	O
)	O	O
in	O	O
passive	O	O
avoidance	O	O
tests	O	O
.	O	O

Testosterone	B_Chemical	O
replacement	O	O
almost	O	O
restored	O	O
the	O	O
STL1	O	O
and	O	O
STL2	O	O
in	O	O
castrated	O	O
rats	O	O
,	O	O
and	O	O
significantly	O	O
prolonged	O	O
the	O	O
STL1	O	O
and	O	O
STL2	O	O
in	O	O
STZ-treated	O	O
rats	O	O
.	O	O

Administration	O	O
of	O	O
flutamide	B_Chemical	B_Chemical
,	O	O
letrozole	B_Chemical	B_Chemical
or	O	O
tamoxifen	B_Chemical	O
significantly	O	O
impaired	B_Disease	O
the	I_Disease	O
memory	I_Disease	O
in	O	O
intact	O	O
rats	O	O
,	O	O
and	O	O
significantly	O	O
attenuated	O	O
the	O	O
testosterone	B_Chemical	O
replacement	O	O
in	O	O
improving	O	O
STZ-	O	O
and	O	O
castration-induced	O	O
memory	B_Disease	B_Disease
impairment	I_Disease	I_Disease
.	O	O

CONCLUSION	O	O
:	O	O
Testosterone	B_Chemical	O
administration	O	O
ameliorates	O	O
STZ-	O	O
and	O	O
castration-induced	O	O
memory	B_Disease	B_Disease
impairment	I_Disease	I_Disease
in	O	O
male	O	O
Wistar	O	O
rats	O	O
.	O	O

Behavioral	O	O
and	O	O
neurochemical	O	O
studies	O	O
in	O	O
mice	O	O
pretreated	O	O
with	O	O
garcinielliptone	B_Chemical	O
FC	I_Chemical	O
in	O	O
pilocarpine-induced	O	O
seizures	B_Disease	O
.	O	O

Garcinielliptone	B_Chemical	B_Chemical
FC	I_Chemical	O
(	O	O
GFC	B_Chemical	O
)	O	O
isolated	O	O
from	O	O
hexanic	O	O
fraction	O	O
seed	O	O
extract	O	O
of	O	O
species	O	O
Platonia	O	O
insignis	O	O
Mart	O	O
.	O	O
It	O	O
is	O	O
widely	O	O
used	O	O
in	O	O
folk	O	O
medicine	O	O
to	O	O
treat	O	O
skin	B_Disease	O
diseases	I_Disease	O
in	O	O
both	O	O
humans	O	O
and	O	O
animals	O	O
as	O	O
well	O	O
as	O	O
the	O	O
seed	O	O
decoction	O	O
has	O	O
been	O	O
used	O	O
to	O	O
treat	O	O
diarrheas	B_Disease	O
and	O	O
inflammatory	B_Disease	O
diseases	I_Disease	O
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
no	O	O
research	O	O
on	O	O
GFC	B_Chemical	O
effects	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
of	O	O
rodents	O	O
.	O	O

The	O	O
present	O	O
study	O	O
aimed	O	O
to	O	O
evaluate	O	O
the	O	O
GFC	B_Chemical	O
effects	O	O
at	O	O
doses	O	O
of	O	O
25	O	O
,	O	O
50	O	O
or	O	O
75	O	O
mg/kg	O	O
on	O	O
seizure	B_Disease	O
parameters	O	O
to	O	O
determine	O	O
their	O	O
anticonvulsant	O	O
activity	O	O
and	O	O
its	O	O
effects	O	O
on	O	O
amino	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(	O	O
r-aminobutyric	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(	O	O
GABA	B_Chemical	O
)	O	O
,	O	O
glutamine	B_Chemical	O
,	O	O
aspartate	B_Chemical	B_Chemical
and	O	O
glutathione	B_Chemical	B_Chemical
)	O	O
levels	O	O
as	O	O
well	O	O
as	O	O
on	O	O
acetylcholinesterase	O	O
(	O	O
AChE	O	O
)	O	O
activity	O	O
in	O	O
mice	O	O
hippocampus	O	O
after	O	O
seizures	B_Disease	O
.	O	O

GFC	B_Chemical	O
produced	O	O
an	O	O
increased	O	O
latency	O	O
to	O	O
first	O	O
seizure	B_Disease	O
,	O	O
at	O	O
doses	O	O
25mg/kg	O	O
(	O	O
20.12	O	O
+	O	O
2.20	O	O
min	O	O
)	O	O
,	O	O
50mg/kg	O	O
(	O	O
20.95	O	O
+	O	O
2.21	O	O
min	O	O
)	O	O
or	O	O
75	O	O
mg/kg	O	O
(	O	O
23.43	O	O
+	O	O
1.99	O	O
min	O	O
)	O	O
when	O	O
compared	O	O
with	O	O
seized	O	O
mice	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
GABA	B_Chemical	O
content	O	O
of	O	O
mice	O	O
hippocampus	O	O
treated	O	O
with	O	O
GFC75	O	O
plus	O	O
P400	O	O
showed	O	O
an	O	O
increase	O	O
of	O	O
46.90	O	O
%	O	O
when	O	O
compared	O	O
with	O	O
seized	O	O
mice	O	O
.	O	O

In	O	O
aspartate	B_Chemical	B_Chemical
,	O	O
glutamine	B_Chemical	O
and	O	O
glutamate	B_Chemical	O
levels	O	O
detected	O	O
a	O	O
decrease	O	O
of	O	O
5.21	O	O
%	O	O
,	O	O
13.55	O	O
%	O	O
and	O	O
21.80	O	O
%	O	O
,	O	O
respectively	O	O
in	O	O
mice	O	O
hippocampus	O	O
treated	O	O
with	O	O
GFC75	O	O
plus	O	O
P400	O	O
when	O	O
compared	O	O
with	O	O
seized	O	O
mice	O	O
.	O	O

Hippocampus	O	O
mice	O	O
treated	O	O
with	O	O
GFC75	O	O
plus	O	O
P400	O	O
showed	O	O
an	O	O
increase	O	O
in	O	O
AChE	O	O
activity	O	O
(	O	O
63.30	O	O
%	O	O
)	O	O
when	O	O
compared	O	O
with	O	O
seized	O	O
mice	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
GFC	B_Chemical	O
can	O	O
exert	O	O
anticonvulsant	O	O
activity	O	O
and	O	O
reduce	O	O
the	O	O
frequency	O	O
of	O	O
installation	O	O
of	O	O
pilocarpine-induced	O	O
status	B_Disease	O
epilepticus	I_Disease	O
,	O	O
as	O	O
demonstrated	O	O
by	O	O
increase	O	O
in	O	O
latency	O	O
to	O	O
first	O	O
seizure	B_Disease	O
and	O	O
decrease	O	O
in	O	O
mortality	O	O
rate	O	O
of	O	O
animals	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
our	O	O
data	O	O
suggest	O	O
that	O	O
GFC	B_Chemical	O
may	O	O
influence	O	O
in	O	O
epileptogenesis	O	O
and	O	O
promote	O	O
anticonvulsant	O	O
actions	O	O
in	O	O
pilocarpine	B_Chemical	O
model	O	O
by	O	O
modulating	O	O
the	O	O
GABA	B_Chemical	O
and	O	O
glutamate	B_Chemical	O
contents	O	O
and	O	O
of	O	O
AChE	O	O
activity	O	O
in	O	O
seized	O	O
mice	O	O
hippocampus	O	O
.	O	O

This	O	O
compound	O	O
may	O	O
be	O	O
useful	O	O
to	O	O
produce	O	O
neuronal	O	O
protection	O	O
and	O	O
it	O	O
can	O	O
be	O	O
considered	O	O
as	O	O
an	O	O
anticonvulsant	O	O
agent	O	O
.	O	O

Standard	O	O
operating	O	O
procedures	O	O
for	O	O
antibiotic	O	O
therapy	O	O
and	O	O
the	O	O
occurrence	O	O
of	O	O
acute	O	B_Disease
kidney	O	I_Disease
injury	O	I_Disease
:	O	O
a	O	O
prospective	O	O
,	O	O
clinical	O	O
,	O	O
non-interventional	O	O
,	O	O
observational	O	O
study	O	O
.	O	O

INTRODUCTION	O	O
:	O	O
Acute	B_Disease	B_Disease
kidney	I_Disease	I_Disease
injury	I_Disease	I_Disease
(	O	O
AKI	B_Disease	O
)	O	O
occurs	O	O
in	O	O
7	O	O
%	O	O
of	O	O
hospitalized	O	O
and	O	O
66	O	O
%	O	O
of	O	O
Intensive	O	O
Care	O	O
Unit	O	O
(	O	O
ICU	O	O
)	O	O
patients	O	O
.	O	O

It	O	O
increases	O	O
mortality	O	O
,	O	O
hospital	O	O
length	O	O
of	O	O
stay	O	O
,	O	O
and	O	O
costs	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
,	O	O
whether	O	O
there	O	O
is	O	O
an	O	O
association	O	O
between	O	O
adherence	O	O
to	O	O
guidelines	O	O
(	O	O
standard	O	O
operating	O	O
procedures	O	O
(	O	O
SOP	O	O
)	O	O
)	O	O
for	O	O
potentially	O	O
nephrotoxic	B_Disease	O
antibiotics	O	O
and	O	O
the	O	O
occurrence	O	O
of	O	O
AKI	B_Disease	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
study	O	O
was	O	O
carried	O	O
out	O	O
as	O	O
a	O	O
prospective	O	O
,	O	O
clinical	O	O
,	O	O
non-interventional	O	O
,	O	O
observational	O	O
study	O	O
.	O	O

Data	O	O
collection	O	O
was	O	O
performed	O	O
over	O	O
a	O	O
total	O	O
of	O	O
170	O	O
days	O	O
in	O	O
three	O	O
ICUs	O	O
at	O	O
Charite	O	O
-	O	O
Universitaetsmedizin	O	O
Berlin	O	O
.	O	O

A	O	O
total	O	O
of	O	O
675	O	O
patients	O	O
were	O	O
included	O	O
;	O	O
163	O	O
of	O	O
these	O	O
had	O	O
therapy	O	O
with	O	O
vancomycin	B_Chemical	O
,	O	O
gentamicin	B_Chemical	O
,	O	O
or	O	O
tobramycin	B_Chemical	O
;	O	O
were	O	O
>	O	O
18	O	O
years	O	O
;	O	O
and	O	O
treated	O	O
in	O	O
the	O	O
ICU	O	O
for	O	O
>	O	O
24	O	O
hours	O	O
.	O	O

Patients	O	O
with	O	O
an	O	O
adherence	O	O
to	O	O
SOP	O	O
>	O	O
70	O	O
%	O	O
were	O	O
classified	O	O
into	O	O
the	O	O
high	O	O
adherence	O	O
group	O	O
(	O	O
HAG	O	O
)	O	O
and	O	O
patients	O	O
with	O	O
an	O	O
adherence	O	O
of	O	O
<	O	O
70	O	O
%	O	O
into	O	O
the	O	O
low	O	O
adherence	O	O
group	O	O
(	O	O
LAG	O	O
)	O	O
.	O	O

AKI	B_Disease	O
was	O	O
defined	O	O
according	O	O
to	O	O
RIFLE	O	O
criteria	O	O
.	O	O

Adherence	O	O
to	O	O
SOPs	O	O
was	O	O
evaluated	O	O
by	O	O
retrospective	O	O
expert	O	O
audit	O	O
.	O	O

Development	O	O
of	O	O
AKI	B_Disease	O
was	O	O
compared	O	O
between	O	O
groups	O	O
with	O	O
exact	O	O
Chi2-test	O	O
and	O	O
multivariate	O	O
logistic	O	O
regression	O	O
analysis	O	O
(	O	O
two-sided	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
LAG	O	O
consisted	O	O
of	O	O
75	O	O
patients	O	O
(	O	O
46	O	O
%	O	O
)	O	O
versus	O	O
88	O	O
HAG	O	O
patients	O	O
(	O	O
54	O	O
%	O	O
)	O	O
.	O	O

AKI	B_Disease	O
occurred	O	O
significantly	O	O
more	O	O
often	O	O
in	O	O
LAG	O	O
with	O	O
36	O	O
%	O	O
versus	O	O
21	O	O
%	O	O
in	O	O
HAG	O	O
(	O	O
P	O	O
=	O	O
0.035	O	O
)	O	O
.	O	O

Basic	O	O
characteristics	O	O
were	O	O
comparable	O	O
,	O	O
except	O	O
an	O	O
increased	O	O
rate	O	O
of	O	O
soft	O	O
tissue	O	O
infections	B_Disease	O
in	O	O
LAG	O	O
.	O	O

Multivariate	O	O
analysis	O	O
revealed	O	O
an	O	O
odds	O	O
ratio	O	O
of	O	O
2.5-fold	O	O
for	O	O
LAG	O	O
to	O	O
develop	O	O
AKI	B_Disease	O
compared	O	O
with	O	O
HAG	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
1.195	O	O
to	O	O
5.124	O	O
,	O	O
P	O	O
=	O	O
0.039	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Low	O	O
adherence	O	O
to	O	O
SOPs	O	O
for	O	O
potentially	O	O
nephrotoxic	B_Disease	O
antibiotics	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
higher	O	O
occurrence	O	O
of	O	O
AKI	B_Disease	O
.	O	O

TRIAL	O	O
REGISTRATION	O	O
:	O	O
Current	O	O
Controlled	O	O
Trials	O	O
ISRCTN54598675	O	O
.	O	O

Registered	O	O
17	O	O
August	O	O
2007	O	O
.	O	O

Rhabdomyolysis	B_Disease	B_Disease
in	O	O
a	O	O
hepatitis	B_Disease	O
C	I_Disease	O
virus	I_Disease	O
infected	I_Disease	O
patient	O	O
treated	O	O
with	O	O
telaprevir	B_Chemical	O
and	O	O
simvastatin	B_Chemical	O
.	O	O

A	O	O
46-year	O	O
old	O	O
man	O	O
with	O	O
a	O	O
chronic	O	O
hepatitis	B_Disease	O
C	I_Disease	O
virus	I_Disease	O
infection	I_Disease	O
received	O	O
triple	O	O
therapy	O	O
with	O	O
ribavirin	B_Chemical	O
,	O	O
pegylated	B_Chemical	O
interferon	I_Chemical	O
and	O	O
telaprevir	B_Chemical	O
.	O	O

The	O	O
patient	O	O
also	O	O
received	O	O
simvastatin	B_Chemical	O
.	O	O

One	O	O
month	O	O
after	O	O
starting	O	O
the	O	O
antiviral	O	O
therapy	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
because	O	O
he	O	O
developed	O	O
rhabdomyolysis	B_Disease	B_Disease
.	O	O

At	O	O
admission	O	O
simvastatin	B_Chemical	O
and	O	O
all	O	O
antiviral	O	O
drugs	O	O
were	O	O
discontinued	O	O
because	O	O
toxicity	B_Disease	O
due	O	O
to	O	O
a	O	O
drug-drug	O	O
interaction	O	O
was	O	O
suspected	O	O
.	O	O

The	O	O
creatine	B_Chemical	B_Chemical
kinase	O	I_Chemical
peaked	O	O
at	O	O
62,246	O	O
IU/L	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
treated	O	O
with	O	O
intravenous	O	O
normal	O	O
saline	O	O
.	O	O

The	O	O
patient	O	O
's	O	O
renal	O	O
function	O	O
remained	O	O
unaffected	O	O
.	O	O

Fourteen	O	O
days	O	O
after	O	O
hospitalization	O	O
,	O	O
creatine	B_Chemical	B_Chemical
kinase	O	I_Chemical
level	O	O
had	O	O
returned	O	O
to	O	O
230	O	O
IU/L	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
discharged	O	O
.	O	O

Telaprevir	B_Chemical	O
was	O	O
considered	O	O
the	O	O
probable	O	O
causative	O	O
agent	O	O
of	O	O
an	O	O
interaction	O	O
with	O	O
simvastatin	B_Chemical	O
according	O	O
to	O	O
the	O	O
Drug	O	O
Interaction	O	O
Probability	O	O
Scale	O	O
.	O	O

The	O	O
interaction	O	O
is	O	O
due	O	O
to	O	O
inhibition	O	O
of	O	O
CYP3A4-mediated	O	O
simvastatin	B_Chemical	O
clearance	O	O
.	O	O

Simvastatin	B_Chemical	O
plasma	O	O
concentration	O	O
increased	O	O
30	O	O
times	O	O
in	O	O
this	O	O
patient	O	O
and	O	O
statin	B_Chemical	O
induced	O	O
muscle	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
is	O	O
related	O	O
to	O	O
the	O	O
concentration	O	O
of	O	O
the	O	O
statin	B_Chemical	O
in	O	O
blood	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
with	O	O
this	O	O
case	O	O
we	O	O
illustrate	O	O
that	O	O
telaprevir	B_Chemical	O
as	O	O
well	O	O
as	O	O
statins	B_Chemical	O
are	O	O
susceptible	O	O
to	O	O
clinical	O	O
relevant	O	O
drug-drug	O	O
interactions	O	O
.	O	O

Combination	O	O
of	O	O
bortezomib	B_Chemical	O
,	O	O
thalidomide	B_Chemical	O
,	O	O
and	O	O
dexamethasone	B_Chemical	O
(	O	O
VTD	O	O
)	O	O
as	O	O
a	O	O
consolidation	O	O
therapy	O	O
after	O	O
autologous	O	O
stem	O	O
cell	O	O
transplantation	O	O
for	O	O
symptomatic	O	O
multiple	B_Disease	B_Disease
myeloma	I_Disease	I_Disease
in	O	O
Japanese	O	O
patients	O	O
.	O	O

Consolidation	O	O
therapy	O	O
for	O	O
patients	O	O
with	O	O
multiple	B_Disease	O
myeloma	I_Disease	O
(	O	O
MM	B_Disease	O
)	O	O
has	O	O
been	O	O
widely	O	O
adopted	O	O
to	O	O
improve	O	O
treatment	O	O
response	O	O
following	O	O
autologous	O	O
stem	O	O
cell	O	O
transplantation	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
retrospectively	O	O
analyzed	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
combination	O	O
regimen	O	O
of	O	O
bortezomib	B_Chemical	O
,	O	O
thalidomide	B_Chemical	O
,	O	O
and	O	O
dexamethasone	B_Chemical	O
(	O	O
VTD	O	O
)	O	O
as	O	O
consolidation	O	O
therapy	O	O
in	O	O
24	O	O
Japanese	O	O
patients	O	O
with	O	O
newly	O	O
diagnosed	O	O
MM	B_Disease	O
.	O	O

VTD	O	O
consisted	O	O
of	O	O
bortezomib	B_Chemical	O
at	O	O
a	O	O
dose	O	O
of	O	O
1.3	O	O
mg/m(2	O	O
)	O	O
and	O	O
dexamethasone	B_Chemical	O
at	O	O
a	O	O
dose	O	O
of	O	O
40	O	O
mg/day	O	O
on	O	O
days	O	O
1	O	O
,	O	O
8	O	O
,	O	O
15	O	O
,	O	O
and	O	O
22	O	O
of	O	O
a	O	O
35-day	O	O
cycle	O	O
,	O	O
with	O	O
daily	O	O
oral	O	O
thalidomide	B_Chemical	O
at	O	O
a	O	O
dose	O	O
of	O	O
100	O	O
mg/day	O	O
.	O	O

Grade	O	O
3	O	O
-	O	O
4	O	O
neutropenia	B_Disease	O
and	O	O
thrombocytopenia	B_Disease	O
were	O	O
documented	O	O
in	O	O
four	O	O
and	O	O
three	O	O
patients	O	O
(	O	O
17	O	O
and	O	O
13	O	O
%	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
but	O	O
drug	O	O
dose	O	O
reduction	O	O
due	O	O
to	O	O
cytopenia	B_Disease	O
was	O	O
not	O	O
required	O	O
in	O	O
any	O	O
case	O	O
.	O	O

Peripheral	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
was	O	O
common	O	O
(	O	O
63	O	O
%	O	O
)	O	O
,	O	O
but	O	O
severe	O	O
grade	O	O
3	O	O
-	O	O
4	O	O
peripheral	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
was	O	O
not	O	O
observed	O	O
.	O	O

Very	O	O
good	O	O
partial	O	O
response	O	O
or	O	O
better	O	O
response	O	O
(	O	O
>	O	O
VGPR	O	O
)	O	O
rates	O	O
before	O	O
and	O	O
after	O	O
consolidation	O	O
therapy	O	O
were	O	O
54	O	O
and	O	O
79	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

Patients	O	O
had	O	O
a	O	O
significant	O	O
probability	O	O
of	O	O
improving	O	O
from	O	O
<	O	O
VGPR	O	O
before	O	O
consolidation	O	O
therapy	O	O
to	O	O
>	O	O
VGPR	O	O
after	O	O
consolidation	O	O
therapy	O	O
(	O	O
p	O	O
=	O	O
0.041	O	O
)	O	O
.	O	O

The	O	O
VTD	O	O
regimen	O	O
may	O	O
be	O	O
safe	O	O
and	O	O
effective	O	O
as	O	O
a	O	O
consolidation	O	O
therapy	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
MM	O	O
in	O	O
Japanese	O	O
population	O	O
.	O	O

Conversion	O	O
to	O	O
sirolimus	B_Chemical	B_Chemical
ameliorates	O	O
cyclosporine-induced	O	O
nephropathy	B_Disease	O
in	O	O
the	O	O
rat	O	O
:	O	O
focus	O	O
on	O	O
serum	O	O
,	O	O
urine	O	O
,	O	O
gene	O	O
,	O	O
and	O	O
protein	O	O
renal	O	O
expression	O	O
biomarkers	O	O
.	O	O

Protocols	O	O
of	O	O
conversion	O	O
from	O	O
cyclosporin	B_Chemical	O
A	I_Chemical	O
(	O	O
CsA	B_Chemical	O
)	O	O
to	O	O
sirolimus	B_Chemical	B_Chemical
(	O	O
SRL	B_Chemical	O
)	O	O
have	O	O
been	O	O
widely	O	O
used	O	O
in	O	O
immunotherapy	O	O
after	O	O
transplantation	O	O
to	O	O
prevent	O	O
CsA-induced	O	O
nephropathy	B_Disease	O
,	O	O
but	O	O
the	O	O
molecular	O	O
mechanisms	O	O
underlying	O	O
these	O	O
protocols	O	O
remain	O	O
nuclear	O	O
.	O	O

This	O	O
study	O	O
aimed	O	O
to	O	O
identify	O	O
the	O	O
molecular	O	O
pathways	O	O
and	O	O
putative	O	O
biomarkers	O	O
of	O	O
CsA-to-SRL	O	O
conversion	O	O
in	O	O
a	O	O
rat	O	O
model	O	O
.	O	O

Four	O	O
animal	O	O
groups	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
were	O	O
tested	O	O
during	O	O
9	O	O
weeks	O	O
:	O	O
control	O	O
,	O	O
CsA	B_Chemical	O
,	O	O
SRL	B_Chemical	O
,	O	O
and	O	O
conversion	O	O
(	O	O
CsA	B_Chemical	O
for	O	O
3	O	O
weeks	O	O
followed	O	O
by	O	O
SRL	B_Chemical	O
for	O	O
6	O	O
weeks	O	O
)	O	O
.	O	O

Classical	O	O
and	O	O
emergent	O	O
serum	O	O
,	O	O
urinary	O	O
,	O	O
and	O	O
kidney	O	O
tissue	O	O
(	O	O
gene	O	O
and	O	O
protein	O	O
expression	O	O
)	O	O
markers	O	O
were	O	O
assessed	O	O
.	O	O

Renal	B_Disease	O
lesions	I_Disease	O
were	O	O
analyzed	O	O
in	O	O
hematoxylin	B_Chemical	O
and	O	O
eosin	B_Chemical	O
,	O	O
periodic	O	O
acid-Schiff	O	O
,	O	O
and	O	O
Masson	O	O
's	O	O
trichrome	O	O
stains	O	O
.	O	O

SRL-treated	O	O
rats	O	O
presented	O	O
proteinuria	B_Disease	O
and	O	O
NGAL	O	O
(	O	O
serum	O	O
and	O	O
urinary	O	O
)	O	O
as	O	O
the	O	O
best	O	O
markers	O	O
of	O	O
renal	B_Disease	B_Disease
impairment	I_Disease	I_Disease
.	O	O

Short	O	O
CsA	B_Chemical	O
treatment	O	O
presented	O	O
slight	O	O
or	O	O
even	O	O
absent	O	O
kidney	B_Disease	O
lesions	I_Disease	O
and	O	O
TGF-b	O	O
,	O	O
NF-	O	O
kb	O	O
,	O	O
mTOR	O	O
,	O	O
PCNA	O	O
,	O	O
TP53	O	O
,	O	O
KIM-1	O	O
,	O	O
and	O	O
CTGF	O	O
as	O	O
relevant	O	O
gene	O	O
and	O	O
protein	O	O
changes	O	O
.	O	O

Prolonged	O	O
CsA	B_Chemical	O
exposure	O	O
aggravated	O	O
renal	B_Disease	B_Disease
damage	I_Disease	I_Disease
,	O	O
without	O	O
clear	O	O
changes	O	O
on	O	O
the	O	O
traditional	O	O
markers	O	O
,	O	O
but	O	O
with	O	O
changes	O	O
in	O	O
serums	O	O
TGF-	O	O
b	O	O
and	O	O
IL-7	O	O
,	O	O
TBARs	O	O
clearance	O	O
,	O	O
and	O	O
kidney	O	O
TGF-b	O	O
and	O	O
mTOR	O	O
.	O	O

Conversion	O	O
to	O	O
SRL	B_Chemical	O
prevented	O	O
CsA-induced	O	O
renal	B_Disease	B_Disease
damage	I_Disease	I_Disease
evolution	O	O
(	O	O
absent/mild	O	O
grade	O	O
lesions	O	O
)	O	O
,	O	O
while	O	O
NGAL	O	O
(	O	O
serum	O	O
versus	O	O
urine	O	O
)	O	O
seems	O	O
to	O	O
be	O	O
a	O	O
feasible	O	O
biomarker	O	O
of	O	O
CsA	B_Chemical	O
replacement	O	O
to	O	O
SRL	B_Chemical	B_Chemical
.	O	O

Kinin	O	O
B2	O	O
receptor	O	O
deletion	O	O
and	O	O
blockage	O	O
ameliorates	O	O
cisplatin-induced	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
injury	I_Disease	I_Disease
.	O	O

Cisplatin	B_Chemical	B_Chemical
treatment	O	O
has	O	O
been	O	O
adopted	O	O
in	O	O
some	O	O
chemotherapies	O	O
;	O	O
however	O	O
,	O	O
this	O	O
drug	O	O
can	O	O
induce	O	O
acute	B_Disease	B_Disease
kidney	I_Disease	I_Disease
injury	I_Disease	I_Disease
due	O	O
its	O	O
ability	O	O
to	O	O
negatively	O	O
affect	O	O
renal	O	O
function	O	O
,	O	O
augment	O	O
serum	O	O
levels	O	O
of	O	O
creatinine	B_Chemical	B_Chemical
and	O	O
urea	B_Chemical	O
,	O	O
increase	O	O
the	O	O
acute	B_Disease	B_Disease
tubular	I_Disease	I_Disease
necrosis	I_Disease	I_Disease
score	O	O
and	O	O
up-regulate	O	O
cytokines	O	O
(	O	O
e.g.	O	O
,	O	O
IL-1b	O	O
and	O	O
TNF-a	O	O
)	O	O
.	O	O

The	O	O
kinin	O	O
B2	O	O
receptor	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
the	O	O
inflammation	B_Disease	O
process	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
regulation	O	O
of	O	O
cytokine	O	O
expression	O	O
,	O	O
and	O	O
its	O	O
deletion	O	O
resulted	O	O
in	O	O
an	O	O
improvement	O	O
in	O	O
the	O	O
diabetic	B_Disease	B_Disease
nephropathy	I_Disease	I_Disease
status	O	O
.	O	O

To	O	O
examine	O	O
the	O	O
role	O	O
of	O	O
the	O	O
kinin	O	O
B2	O	O
receptor	O	O
in	O	O
cisplatin-induced	O	O
acute	B_Disease	B_Disease
kidney	I_Disease	I_Disease
injury	I_Disease	I_Disease
,	O	O
kinin	O	O
B2	O	O
receptor	O	O
knockout	O	O
mice	O	O
were	O	O
challenged	O	O
with	O	O
cisplatin	B_Chemical	B_Chemical
.	O	O

Additionally	O	O
,	O	O
WT	O	O
mice	O	O
were	O	O
treated	O	O
with	O	O
a	O	O
B2	O	O
receptor	O	O
antagonist	O	O
after	O	O
cisplatin	B_Chemical	B_Chemical
administration	O	O
.	O	O

B2	O	O
receptor-deficient	O	O
mice	O	O
were	O	O
less	O	O
sensitive	O	O
to	O	O
this	O	O
drug	O	O
than	O	O
the	O	O
WT	O	O
mice	O	O
,	O	O
as	O	O
shown	O	O
by	O	O
reduced	O	O
weight	B_Disease	O
loss	I_Disease	O
,	O	O
better	O	O
preservation	O	O
of	O	O
kidney	O	O
function	O	O
,	O	O
down	O	O
regulation	O	O
of	O	O
inflammatory	O	O
cytokines	O	O
and	O	O
less	O	O
acute	B_Disease	B_Disease
tubular	I_Disease	I_Disease
necrosis	I_Disease	I_Disease
.	O	O

Moreover	O	O
,	O	O
treatment	O	O
with	O	O
the	O	O
kinin	O	O
B2	O	O
receptor	O	O
antagonist	O	O
effectively	O	O
reduced	O	O
the	O	O
levels	O	O
of	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
and	O	O
blood	O	B_Chemical
urea	B_Chemical	I_Chemical
after	O	O
cisplatin	B_Chemical	B_Chemical
administration	O	O
.	O	O

Thus	O	O
,	O	O
our	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
kinin	O	O
B2	O	O
receptor	O	O
is	O	O
involved	O	O
in	O	O
cisplatin-induced	O	O
acute	B_Disease	B_Disease
kidney	I_Disease	I_Disease
injury	I_Disease	I_Disease
by	O	O
mediating	O	O
the	O	O
necrotic	B_Disease	O
process	O	O
and	O	O
the	O	O
expression	O	O
of	O	O
inflammatory	O	O
cytokines	O	O
,	O	O
thus	O	O
resulting	O	O
in	O	O
declined	O	O
renal	O	O
function	O	O
.	O	O

These	O	O
results	O	O
highlight	O	O
the	O	O
kinin	O	O
B2	O	O
receptor	O	O
antagonist	O	O
treatment	O	O
in	O	O
amelioration	O	O
of	O	O
nephrotoxicity	B_Disease	B_Disease
induced	O	O
by	O	O
cisplatin	B_Chemical	B_Chemical
therapy	O	O
.	O	O

Safety	O	O
and	O	O
efficacy	O	O
of	O	O
fluocinolone	B_Chemical	O
acetonide	I_Chemical	O
intravitreal	O	O
implant	O	O
(	O	O
0.59	O	O
mg	O	O
)	O	O
in	O	O
birdshot	B_Disease	O
retinochoroidopathy	I_Disease	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
report	O	O
the	O	O
treatment	O	O
outcomes	O	O
of	O	O
the	O	O
fluocinolone	B_Chemical	O
acetonide	I_Chemical	O
intravitreal	O	O
implant	O	O
(	O	O
0.59	O	O
mg	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
birdshot	B_Disease	O
retinochoroidopathy	I_Disease	O
whose	O	O
disease	O	O
is	O	O
refractory	O	O
or	O	O
intolerant	O	O
to	O	O
conventional	O	O
immunomodulatory	O	O
therapy	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
retrospective	O	O
case	O	O
series	O	O
involving	O	O
11	O	O
birdshot	B_Disease	O
retinochoroidopathy	I_Disease	O
patients	O	O
(	O	O
11	O	O
eyes	O	O
)	O	O
.	O	O

Eleven	O	O
patients	O	O
(	O	O
11	O	O
eyes	O	O
)	O	O
underwent	O	O
surgery	O	O
for	O	O
fluocinolone	B_Chemical	B_Chemical
acetonide	I_Chemical	I_Chemical
implant	O	O
(	O	O
0.59	O	O
mg	O	O
)	O	O
.	O	O

Treatment	O	O
outcomes	O	O
of	O	O
interest	O	O
were	O	O
noted	O	O
at	O	O
baseline	O	O
,	O	O
before	O	O
fluocinolone	B_Chemical	B_Chemical
acetonide	I_Chemical	I_Chemical
implant	O	O
,	O	O
and	O	O
then	O	O
at	O	O
6	O	O
months	O	O
,	O	O
1	O	O
year	O	O
,	O	O
2	O	O
years	O	O
,	O	O
3	O	O
years	O	O
,	O	O
and	O	O
beyond	O	O
3	O	O
years	O	O
.	O	O

Disease	O	O
activity	O	O
markers	O	O
,	O	O
including	O	O
signs	O	O
of	O	O
ocular	O	O
inflammation	B_Disease	O
,	O	O
evidence	O	O
of	O	O
retinal	B_Disease	O
vasculitis	I_Disease	O
,	O	O
Swedish	O	O
interactive	O	O
threshold	O	O
algorithm-short	O	O
wavelength	O	O
automated	O	O
perimetry	O	O
Humphrey	O	O
visual	O	O
field	O	O
analysis	O	O
,	O	O
electroretinographic	O	O
parameters	O	O
,	O	O
and	O	O
optical	O	O
coherence	O	O
tomography	O	O
were	O	O
recorded	O	O
.	O	O

Data	O	O
on	O	O
occurrence	O	O
of	O	O
cataract	B_Disease	O
and	O	O
raised	B_Disease	O
intraocular	I_Disease	O
pressure	I_Disease	O
were	O	O
collected	O	O
in	O	O
all	O	O
eyes	O	O
.	O	O

RESULTS	O	O
:	O	O
Intraocular	O	O
inflammation	B_Disease	O
was	O	O
present	O	O
in	O	O
54.5	O	O
,	O	O
9.9	O	O
,	O	O
11.1	O	O
,	O	O
and	O	O
0	O	O
%	O	O
of	O	O
patients	O	O
at	O	O
baseline	O	O
,	O	O
6	O	O
months	O	O
,	O	O
1	O	O
year	O	O
,	O	O
2	O	O
years	O	O
,	O	O
3	O	O
years	O	O
,	O	O
and	O	O
beyond	O	O
3	O	O
years	O	O
after	O	O
receiving	O	O
the	O	O
implant	O	O
,	O	O
respectively	O	O
.	O	O

Active	O	O
vasculitis	B_Disease	O
was	O	O
noted	O	O
in	O	O
36.3	O	O
%	O	O
patients	O	O
at	O	O
baseline	O	O
and	O	O
0	O	O
%	O	O
at	O	O
3	O	O
years	O	O
of	O	O
follow-up	O	O
.	O	O

More	O	O
than	O	O
20	O	O
%	O	O
(	O	O
47.61	O	O
-	O	O
67.2	O	O
%	O	O
)	O	O
reduction	O	O
in	O	O
central	O	O
retinal	O	O
thickness	O	O
was	O	O
noted	O	O
in	O	O
all	O	O
patients	O	O
with	O	O
cystoid	B_Disease	O
macular	I_Disease	O
edema	I_Disease	O
at	O	O
6	O	O
months	O	O
,	O	O
1	O	O
year	O	O
,	O	O
2	O	O
years	O	O
,	O	O
and	O	O
3	O	O
years	O	O
postimplant	O	O
.	O	O

At	O	O
baseline	O	O
,	O	O
54.5	O	O
%	O	O
patients	O	O
were	O	O
on	O	O
immunomodulatory	O	O
agents	O	O
.	O	O

This	O	O
percentage	O	O
decreased	O	O
to	O	O
45.45	O	O
,	O	O
44.4	O	O
,	O	O
and	O	O
14.28	O	O
%	O	O
at	O	O
1	O	O
year	O	O
,	O	O
2	O	O
years	O	O
,	O	O
and	O	O
3	O	O
years	O	O
postimplant	O	O
,	O	O
respectively	O	O
.	O	O

Adverse	O	O
events	O	O
included	O	O
increased	B_Disease	O
intraocular	I_Disease	O
pressure	I_Disease	O
(	O	O
54.5	O	O
%	O	O
)	O	O
and	O	O
cataract	B_Disease	O
formation	O	O
(	O	O
100	O	O
%	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
data	O	O
suggest	O	O
that	O	O
fluocinolone	B_Chemical	B_Chemical
acetonide	I_Chemical	I_Chemical
implant	O	O
(	O	O
0.59	O	O
mg	O	O
)	O	O
helps	O	O
to	O	O
control	O	O
inflammation	B_Disease	O
in	O	O
otherwise	O	O
treatment-refractory	O	O
cases	O	O
of	O	O
birdshot	B_Disease	B_Disease
retinochoroidopathy	I_Disease	I_Disease
.	O	O

It	O	O
is	O	O
associated	O	O
with	O	O
significant	O	O
side	O	O
effects	O	O
of	O	O
cataract	B_Disease	O
and	O	O
ocular	B_Disease	B_Disease
hypertension	I_Disease	I_Disease
requiring	O	O
treatment	O	O
.	O	O

Optimal	O	O
precurarizing	O	O
dose	O	O
of	O	O
rocuronium	B_Chemical	B_Chemical
to	O	O
decrease	O	O
fasciculation	B_Disease	O
and	O	O
myalgia	B_Disease	O
following	O	O
succinylcholine	B_Chemical	O
administration	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Succinylcholine	B_Chemical	O
commonly	O	O
produces	O	O
frequent	O	O
adverse	O	O
effects	O	O
,	O	O
including	O	O
muscle	B_Disease	O
fasciculation	I_Disease	O
and	O	O
myalgia	B_Disease	O
.	O	O

The	O	O
current	O	O
study	O	O
identified	O	O
the	O	O
optimal	O	O
dose	O	O
of	O	O
rocuronium	B_Chemical	B_Chemical
to	O	O
prevent	O	O
succinylcholine-induced	O	O
fasciculation	B_Disease	O
and	O	O
myalgia	B_Disease	O
and	O	O
evaluated	O	O
the	O	O
influence	O	O
of	O	O
rocuronium	B_Chemical	B_Chemical
on	O	O
the	O	O
speed	O	O
of	O	O
onset	O	O
produced	O	O
by	O	O
succinylcholine	B_Chemical	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
randomized	O	O
,	O	O
double-blinded	O	O
study	O	O
was	O	O
conducted	O	O
in	O	O
100	O	O
patients	O	O
randomly	O	O
allocated	O	O
into	O	O
five	O	O
groups	O	O
of	O	O
20	O	O
patients	O	O
each	O	O
.	O	O

Patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
0.02	O	O
,	O	O
0.03	O	O
,	O	O
0.04	O	O
,	O	O
0.05	O	O
and	O	O
0.06	O	O
mg/kg	O	O
rocuronium	B_Chemical	B_Chemical
as	O	O
a	O	O
precurarizing	O	O
dose	O	O
.	O	O

Neuromuscular	O	O
monitoring	O	O
after	O	O
each	O	O
precurarizing	O	O
dose	O	O
was	O	O
recorded	O	O
from	O	O
the	O	O
adductor	O	O
pollicis	O	O
muscle	O	O
using	O	O
acceleromyography	O	O
with	O	O
train-of-four	O	O
stimulation	O	O
of	O	O
the	O	O
ulnar	O	O
nerve	O	O
.	O	O

All	O	O
patients	O	O
received	O	O
succinylcholine	B_Chemical	O
1.5	O	O
mg/kg	O	O
at	O	O
2	O	O
minutes	O	O
after	O	O
the	O	O
precurarization	O	O
,	O	O
and	O	O
were	O	O
assessed	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
fasciculations	B_Disease	O
,	O	O
while	O	O
myalgia	B_Disease	O
was	O	O
assessed	O	O
at	O	O
24	O	O
hours	O	O
after	O	O
surgery	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
visible	O	O
muscle	B_Disease	O
fasciculation	I_Disease	O
was	O	O
significantly	O	O
less	O	O
with	O	O
increasing	O	O
the	O	O
amount	O	O
of	O	O
precurarizing	O	O
dose	O	O
of	O	O
rocuronium	B_Chemical	B_Chemical
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Those	O	O
of	O	O
myalgia	B_Disease	O
tend	O	O
to	O	O
decrease	O	O
according	O	O
to	O	O
increasing	O	O
the	O	O
amount	O	O
of	O	O
precurarizing	O	O
dose	O	O
of	O	O
rocuronium	B_Chemical	B_Chemical
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
significance	O	O
(	O	O
P	O	O
=	O	O
0.072	O	O
)	O	O
.	O	O

The	O	O
onset	O	O
time	O	O
of	O	O
succinylcholine	B_Chemical	O
was	O	O
significantly	O	O
longer	O	O
with	O	O
increasing	O	O
the	O	O
amount	O	O
of	O	O
precurarizing	O	O
dose	O	O
of	O	O
rocuronium	B_Chemical	B_Chemical
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Precurarization	O	O
with	O	O
0.04	O	O
mg/kg	O	O
rocuronium	B_Chemical	B_Chemical
was	O	O
the	O	O
optimal	O	O
dose	O	O
considering	O	O
the	O	O
reduction	O	O
in	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
fasciculation	B_Disease	O
and	O	O
myalgia	B_Disease	O
with	O	O
acceptable	O	O
onset	O	O
time	O	O
,	O	O
and	O	O
the	O	O
safe	O	O
and	O	O
effective	O	O
precurarization	O	O
.	O	O

Absence	O	O
of	O	O
PKC-alpha	O	O
attenuates	O	O
lithium-induced	O	O
nephrogenic	B_Disease	O
diabetes	I_Disease	O
insipidus	I_Disease	O
.	O	O

Lithium	B_Chemical	O
,	O	O
an	O	O
effective	O	O
antipsychotic	O	O
,	O	O
induces	O	O
nephrogenic	B_Disease	O
diabetes	I_Disease	O
insipidus	I_Disease	O
(	O	O
NDI	B_Disease	O
)	O	O
in	O	O
 	O	O
40	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
decreased	O	O
capacity	O	O
to	O	O
concentrate	O	O
urine	O	O
is	O	O
likely	O	O
due	O	O
to	O	O
lithium	B_Chemical	O
acutely	O	O
disrupting	O	O
the	O	O
cAMP	B_Chemical	O
pathway	O	O
and	O	O
chronically	O	O
reducing	O	O
urea	B_Chemical	O
transporter	O	O
(	O	O
UT-A1	O	O
)	O	O
and	O	O
water	O	O
channel	O	O
(	O	O
AQP2	O	O
)	O	O
expression	O	O
in	O	O
the	O	O
inner	O	O
medulla	O	O
.	O	O

Targeting	O	O
an	O	O
alternative	O	O
signaling	O	O
pathway	O	O
,	O	O
such	O	O
as	O	O
PKC-mediated	O	O
signaling	O	O
,	O	O
may	O	O
be	O	O
an	O	O
effective	O	O
method	O	O
of	O	O
treating	O	O
lithium-induced	O	O
polyuria	B_Disease	O
.	O	O

PKC-alpha	O	O
null	O	O
mice	O	O
(	O	O
PKCa	O	O
KO	O	O
)	O	O
and	O	O
strain-matched	O	O
wild	O	O
type	O	O
(	O	O
WT	O	O
)	O	O
controls	O	O
were	O	O
treated	O	O
with	O	O
lithium	B_Chemical	O
for	O	O
0	O	O
,	O	O
3	O	O
or	O	O
5	O	O
days	O	O
.	O	O

WT	O	O
mice	O	O
had	O	O
increased	O	O
urine	O	O
output	O	O
and	O	O
lowered	O	O
urine	O	O
osmolality	O	O
after	O	O
3	O	O
and	O	O
5	O	O
days	O	O
of	O	O
treatment	O	O
whereas	O	O
PKCa	O	O
KO	O	O
mice	O	O
had	O	O
no	O	O
change	O	O
in	O	O
urine	O	O
output	O	O
or	O	O
concentration	O	O
.	O	O

Western	O	O
blot	O	O
analysis	O	O
revealed	O	O
that	O	O
AQP2	O	O
expression	O	O
in	O	O
medullary	O	O
tissues	O	O
was	O	O
lowered	O	O
after	O	O
3	O	O
and	O	O
5	O	O
days	O	O
in	O	O
WT	O	O
mice	O	O
;	O	O
however	O	O
,	O	O
AQP2	O	O
was	O	O
unchanged	O	O
in	O	O
PKCa	O	O
KO	O	O
.	O	O

Similar	O	O
results	O	O
were	O	O
observed	O	O
with	O	O
UT-A1	O	O
expression	O	O
.	O	O

Animals	O	O
were	O	O
also	O	O
treated	O	O
with	O	O
lithium	B_Chemical	O
for	O	O
6	O	O
weeks	O	O
.	O	O

Lithium-treated	O	O
WT	O	O
mice	O	O
had	O	O
19-fold	O	O
increased	O	O
urine	O	O
output	O	O
whereas	O	O
treated	O	O
PKCa	O	O
KO	O	O
animals	O	O
had	O	O
a	O	O
4-fold	O	O
increase	O	O
in	O	O
output	O	O
.	O	O

AQP2	O	O
and	O	O
UT-A1	O	O
expression	O	O
was	O	O
lowered	O	O
in	O	O
6	O	O
week	O	O
lithium-treated	O	O
WT	O	O
animals	O	O
whereas	O	O
in	O	O
treated	O	O
PKCa	O	O
KO	O	O
mice	O	O
,	O	O
AQP2	O	O
was	O	O
only	O	O
reduced	O	O
by	O	O
2-fold	O	O
and	O	O
UT-A1	O	O
expression	O	O
was	O	O
unaffected	O	O
.	O	O

Urinary	O	O
sodium	B_Chemical	O
,	O	O
potassium	B_Chemical	O
and	O	O
calcium	B_Chemical	O
were	O	O
elevated	O	O
in	O	O
lithium-fed	O	O
WT	O	O
but	O	O
not	O	O
in	O	O
lithium-fed	O	O
PKCa	O	O
KO	O	O
mice	O	O
.	O	O

Our	O	O
data	O	O
show	O	O
that	O	O
ablation	O	O
of	O	O
PKCa	O	O
preserves	O	O
AQP2	O	O
and	O	O
UT-A1	O	O
protein	O	O
expression	O	O
and	O	O
localization	O	O
in	O	O
lithium-induced	O	O
NDI	B_Disease	O
,	O	O
and	O	O
prevents	O	O
the	O	O
development	O	O
of	O	O
the	O	O
severe	O	O
polyuria	B_Disease	O
associated	O	O
with	O	O
lithium	B_Chemical	O
therapy	O	O
.	O	O

Is	O	O
Dysguesia	B_Disease	O
Going	O	O
to	O	O
be	O	O
a	O	O
Rare	O	O
or	O	O
a	O	O
Common	O	O
Side-effect	O	O
of	O	O
Amlodipine?A	O	O
very	O	O
rare	O	O
side-effect	O	O
of	O	O
amlodipine	B_Chemical	B_Chemical
is	O	O
dysguesia	B_Disease	B_Disease
.	O	O

A	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
produced	O	O
only	O	O
one	O	O
case	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
about	O	O
a	O	O
female	O	O
with	O	O
essential	O	B_Disease
hypertension	B_Disease	I_Disease
on	O	O
drug	O	O
treatment	O	O
with	O	O
amlodipine	B_Chemical	B_Chemical
developed	O	O
loss	B_Disease	O
of	I_Disease	O
taste	I_Disease	O
sensation	I_Disease	O
.	O	O

Condition	O	O
moderately	O	O
improved	O	O
on	O	O
stoppage	O	O
of	O	O
the	O	O
drug	O	O
for	O	O
25	O	O
days	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
amlodipine	B_Chemical	B_Chemical
can	O	O
cause	O	O
dysguesia	B_Disease	B_Disease
.	O	O

Here	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
clinical	O	O
presentation	O	O
and	O	O
review	O	O
the	O	O
relevant	O	O
literature	O	O
on	O	O
amlodipine	B_Chemical	B_Chemical
and	O	O
dysguesia	B_Disease	O
.	O	O

Rhabdomyolysis	B_Disease	B_Disease
in	O	O
association	O	O
with	O	O
simvastatin	B_Chemical	O
and	O	O
dosage	O	O
increment	O	O
in	O	O
clarithromycin	B_Chemical	B_Chemical
.	O	O

Clarithromycin	B_Chemical	B_Chemical
is	O	O
the	O	O
most	O	O
documented	O	O
cytochrome	O	O
P450	O	O
3A4	O	O
(	O	O
CYP3A4	O	O
)	O	O
inhibitor	O	O
to	O	O
cause	O	O
an	O	O
adverse	O	O
interaction	O	O
with	O	O
simvastatin	B_Chemical	O
.	O	O

This	O	O
particular	O	O
case	O	O
is	O	O
of	O	O
interest	O	O
as	O	O
rhabdomyolysis	B_Disease	B_Disease
only	O	O
occurred	O	O
after	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
dose	O	O
of	O	O
clarithromycin	B_Chemical	B_Chemical
.	O	O

The	O	O
patient	O	O
developed	O	O
raised	O	O
cardiac	O	O
biomarkers	O	O
without	O	O
any	O	O
obvious	O	O
cardiac	O	O
issues	O	O
,	O	O
a	O	O
phenomenon	O	O
that	O	O
has	O	O
been	O	O
linked	O	O
to	O	O
rhabdomyolysis	B_Disease	B_Disease
previously	O	O
.	O	O

To	O	O
date	O	O
,	O	O
there	O	O
has	O	O
been	O	O
no	O	O
reported	O	O
effect	O	O
of	O	O
rhabdomyolysis	B_Disease	B_Disease
on	O	O
the	O	O
structure	O	O
and	O	O
function	O	O
of	O	O
cardiac	O	O
muscle	O	O
.	O	O

Clinicians	O	O
need	O	O
to	O	O
be	O	O
aware	O	O
of	O	O
prescribing	O	O
concomitant	O	O
medications	O	O
that	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
myopathy	B_Disease	O
or	O	O
inhibit	O	O
the	O	O
CYP3A4	O	O
enzyme	O	O
.	O	O

Our	O	O
case	O	O
suggests	O	O
that	O	O
troponin	O	O
elevation	O	O
could	O	O
be	O	O
associated	O	O
with	O	O
statin	B_Chemical	O
induced	O	O
rhabdomyolysis	B_Disease	B_Disease
,	O	O
which	O	O
may	O	O
warrant	O	O
further	O	O
studies	O	O
.	O	O

Characterization	O	O
of	O	O
a	O	O
novel	O	O
BCHE	O	O
"	O	O
silent	O	O
"	O	O
allele	O	O
:	O	O
point	O	O
mutation	O	O
(	O	O
p.	O	O
Val204Asp	O	O
)	O	O
causes	O	O
loss	O	O
of	O	O
activity	O	O
and	O	O
prolonged	O	O
apnea	B_Disease	O
with	O	O
suxamethonium	B_Chemical	B_Chemical
.	O	O

Butyrylcholinesterase	B_Disease	O
deficiency	I_Disease	O
is	O	O
characterized	O	O
by	O	O
prolonged	O	O
apnea	B_Disease	O
after	O	O
the	O	O
use	O	O
of	O	O
muscle	O	O
relaxants	O	O
(	O	O
suxamethonium	B_Chemical	B_Chemical
or	O	O
mivacurium	B_Chemical	O
)	O	O
in	O	O
patients	O	O
who	O	O
have	O	O
mutations	O	O
in	O	O
the	O	O
BCHE	O	O
gene	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
prolonged	O	O
neuromuscular	O	O
block	O	O
after	O	O
administration	O	O
of	O	O
suxamethonium	B_Chemical	B_Chemical
leading	O	O
to	O	O
the	O	O
discovery	O	O
of	O	O
a	O	O
novel	O	O
BCHE	O	O
variant	O	O
(	O	O
c.695T	O	O
>	O	O
A	O	O
,	O	O
p.	O	O
Val204Asp	O	O
)	O	O
.	O	O

Inhibition	O	O
studies	O	O
,	O	O
kinetic	O	O
analysis	O	O
and	O	O
molecular	O	O
dynamics	O	O
were	O	O
undertaken	O	O
to	O	O
understand	O	O
how	O	O
this	O	O
mutation	O	O
disrupts	O	O
the	O	O
catalytic	O	O
triad	O	O
and	O	O
determines	O	O
a	O	O
"	O	O
silent	O	O
"	O	O
phenotype	O	O
.	O	O

Low	O	O
activity	O	O
of	O	O
patient	O	O
plasma	O	O
butyrylcholinesterase	O	O
with	O	O
butyrylthiocholine	B_Chemical	B_Chemical
(	O	O
BTC	B_Chemical	O
)	O	O
and	O	O
benzoylcholine	B_Chemical	B_Chemical
,	O	O
and	O	O
values	O	O
of	O	O
dibucaine	B_Chemical	O
and	O	O
fluoride	B_Chemical	O
numbers	O	O
fit	O	O
with	O	O
heterozygous	O	O
atypical	O	O
silent	O	O
genotype	O	O
.	O	O

Electrophoretic	O	O
analysis	O	O
of	O	O
plasma	O	O
BChE	O	O
of	O	O
the	O	O
proband	O	O
and	O	O
his	O	O
mother	O	O
showed	O	O
that	O	O
patient	O	O
has	O	O
a	O	O
reduced	O	O
amount	O	O
of	O	O
tetrameric	O	O
enzyme	O	O
in	O	O
plasma	O	O
and	O	O
that	O	O
minor	O	O
fast-moving	O	O
BChE	O	O
components	O	O
:	O	O
monomer	O	O
,	O	O
dimer	O	O
,	O	O
and	O	O
monomer-albumin	O	O
conjugate	O	O
are	O	O
missing	O	O
.	O	O

Kinetic	O	O
analysis	O	O
showed	O	O
that	O	O
the	O	O
p.	O	O
Val204Asp/p	O	O
.	O	O

Asp70Gly-p	O	O
.	O	O

Ala539Thr	O	O
BChE	O	O
displays	O	O
a	O	O
pure	O	O
Michaelian	O	O
behavior	O	O
with	O	O
BTC	B_Chemical	O
as	O	O
the	O	O
substrate	O	O
.	O	O

Both	O	O
catalytic	O	O
parameters	O	O
Km	O	O
=	O	O
265	O	O
uM	O	O
for	O	O
BTC	B_Chemical	O
,	O	O
two	O	O
times	O	O
higher	O	O
than	O	O
that	O	O
of	O	O
the	O	O
atypical	O	O
enzyme	O	O
,	O	O
and	O	O
a	O	O
low	O	O
Vmax	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
absence	O	O
of	O	O
activity	O	O
against	O	O
suxamethonium	B_Chemical	B_Chemical
.	O	O

Molecular	O	O
dynamic	O	O
(	O	O
MD	O	O
)	O	O
simulations	O	O
showed	O	O
that	O	O
the	O	O
overall	O	O
effect	O	O
of	O	O
the	O	O
mutation	O	O
p.	O	O
Val204Asp	O	O
is	O	O
disruption	O	O
of	O	O
hydrogen	B_Chemical	O
bonding	O	O
between	O	O
Gln223	O	O
and	O	O
Glu441	O	O
,	O	O
leading	O	O
Ser198	O	O
and	O	O
His438	O	O
to	O	O
move	O	O
away	O	O
from	O	O
each	O	O
other	O	O
with	O	O
subsequent	O	O
disruption	O	O
of	O	O
the	O	O
catalytic	O	O
triad	O	O
functionality	O	O
regardless	O	O
of	O	O
the	O	O
type	O	O
of	O	O
substrate	O	O
.	O	O

MD	O	O
also	O	O
showed	O	O
that	O	O
the	O	O
enzyme	O	O
volume	O	O
is	O	O
increased	O	O
,	O	O
suggesting	O	O
a	O	O
pre-denaturation	O	O
state	O	O
.	O	O

This	O	O
fits	O	O
with	O	O
the	O	O
reduced	O	O
concentration	O	O
of	O	O
p.	O	O
Ala204Asp/p	O	O
.	O	O

Asp70Gly-p	O	O
.	O	O

Ala539Thr	O	O
tetrameric	O	O
enzyme	O	O
in	O	O
the	O	O
plasma	O	O
and	O	O
non-detectable	O	O
fast	O	O
moving-bands	O	O
on	O	O
electrophoresis	O	O
gels	O	O
.	O	O

Delayed	O	O
anemia	B_Disease	O
after	O	O
treatment	O	O
with	O	O
injectable	O	O
artesunate	B_Chemical	B_Chemical
in	O	O
the	O	O
Democratic	O	O
Republic	O	O
of	O	O
the	O	O
Congo	O	O
:	O	O
a	O	O
manageable	O	O
issue	O	O
.	O	O

Cases	O	O
of	O	O
delayed	O	O
hemolytic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
have	O	O
been	O	O
described	O	O
after	O	O
treatment	O	O
with	O	O
injectable	O	O
artesunate	B_Chemical	B_Chemical
,	O	O
the	O	O
current	O	O
World	O	O
Health	O	O
Organization	O	O
(WHO)-recommended	O	O
first-line	O	O
drug	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
severe	O	O
malaria	B_Disease	O
.	O	O

A	O	O
total	O	O
of	O	O
350	O	O
patients	O	O
(	O	O
215	O	O
[	O	O
61.4	O	O
%	O	O
]	O	O
<	O	O
5	O	O
years	O	O
of	O	O
age	O	O
and	O	O
135	O	O
[	O	O
38.6	O	O
%	O	O
]	O	O
>	O	O
5	O	O
years	O	O
of	O	O
age	O	O
)	O	O
were	O	O
followed-up	O	O
after	O	O
treatment	O	O
with	O	O
injectable	O	O
artesunate	B_Chemical	B_Chemical
for	O	O
severe	O	O
malaria	B_Disease	O
in	O	O
hospitals	O	O
and	O	O
health	O	O
centers	O	O
of	O	O
the	O	O
Democratic	O	O
Republic	O	O
of	O	O
the	O	O
Congo	O	O
.	O	O

Complete	O	O
series	O	O
of	O	O
hemoglobin	O	O
(	O	O
Hb	O	O
)	O	O
measurements	O	O
were	O	O
available	O	O
for	O	O
201	O	O
patients	O	O
.	O	O

A	O	O
decrease	O	O
in	O	O
Hb	O	O
levels	O	O
between	O	O
2	O	O
and	O	O
5	O	O
g/dL	O	O
was	O	O
detected	O	O
in	O	O
23	O	O
(	O	O
11.4	O	O
%	O	O
)	O	O
patients	O	O
during	O	O
the	O	O
follow-up	O	O
period	O	O
.	O	O

For	O	O
five	O	O
patients	O	O
,	O	O
Hb	O	O
levels	O	O
decreased	O	O
below	O	O
5	O	O
g/dL	O	O
during	O	O
at	O	O
least	O	O
one	O	O
follow-up	O	O
visit	O	O
.	O	O

All	O	O
cases	O	O
of	O	O
delayed	O	O
anemia	B_Disease	O
were	O	O
clinically	O	O
manageable	O	O
and	O	O
resolved	O	O
within	O	O
one	O	O
month	O	O
.	O	O

Regulation	O	O
of	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	O	O
3	O	O
and	O	O
apoptotic	O	O
pathways	O	O
by	O	O
betaine	B_Chemical	O
attenuates	O	O
isoproterenol-induced	O	O
acute	O	B_Disease
myocardial	B_Disease	I_Disease
injury	I_Disease	I_Disease
in	O	O
rats	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
investigate	O	O
the	O	O
cardioprotective	O	O
effects	O	O
of	O	O
betaine	B_Chemical	O
on	O	O
acute	O	O
myocardial	B_Disease	O
ischemia	I_Disease	O
induced	O	O
experimentally	O	O
in	O	O
rats	O	O
focusing	O	O
on	O	O
regulation	O	O
of	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	O	O
3	O	O
(	O	O
STAT3	O	O
)	O	O
and	O	O
apoptotic	O	O
pathways	O	O
as	O	O
the	O	O
potential	O	O
mechanism	O	O
underlying	O	O
the	O	O
drug	O	O
effect	O	O
.	O	O

Male	O	O
Sprague	O	O
Dawley	O	O
rats	O	O
were	O	O
treated	O	O
with	O	O
betaine	B_Chemical	O
(	O	O
100	O	O
,	O	O
200	O	O
,	O	O
and	O	O
400	O	O
mg/kg	O	O
)	O	O
orally	O	O
for	O	O
40	O	O
days	O	O
.	O	O

Acute	O	B_Disease
myocardial	B_Disease	I_Disease
ischemic	I_Disease	I_Disease
injury	I_Disease	I_Disease
was	O	O
induced	O	O
in	O	O
rats	O	O
by	O	O
subcutaneous	O	O
injection	O	O
of	O	O
isoproterenol	B_Chemical	O
(	O	O
85	O	O
mg/kg	O	O
)	O	O
,	O	O
for	O	O
two	O	O
consecutive	O	O
days	O	O
.	O	O

Serum	O	O
cardiac	O	O
marker	O	O
enzyme	O	O
,	O	O
histopathological	O	O
variables	O	O
and	O	O
expression	O	O
of	O	O
protein	O	O
levels	O	O
were	O	O
analyzed	O	O
.	O	O

Oral	O	O
administration	O	O
of	O	O
betaine	B_Chemical	O
(	O	O
200	O	O
and	O	O
400	O	O
mg/kg	O	O
)	O	O
significantly	O	O
reduced	O	O
the	O	O
level	O	O
of	O	O
cardiac	O	O
marker	O	O
enzyme	O	O
in	O	O
the	O	O
serum	O	O
and	O	O
prevented	O	O
left	O	O
ventricular	B_Disease	O
remodeling	I_Disease	O
.	O	O

Western	O	O
blot	O	O
analysis	O	O
showed	O	O
that	O	O
isoproterenol-induced	O	O
phosphorylation	O	O
of	O	O
STAT3	O	O
was	O	O
maintained	O	O
or	O	O
further	O	O
enhanced	O	O
by	O	O
betaine	B_Chemical	O
treatment	O	O
in	O	O
myocardium	O	O
.	O	O

Furthermore	O	O
,	O	O
betaine	B_Chemical	O
(	O	O
200	O	O
and	O	O
400	O	O
mg/kg	O	O
)	O	O
treatment	O	O
increased	O	O
the	O	O
ventricular	O	O
expression	O	O
of	O	O
Bcl-2	O	O
and	O	O
reduced	O	O
the	O	O
level	O	O
of	O	O
Bax	O	O
,	O	O
therefore	O	O
causing	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
ratio	O	O
of	O	O
Bcl-2/Bax	O	O
.	O	O

The	O	O
protective	O	O
role	O	O
of	O	O
betaine	B_Chemical	O
on	O	O
myocardial	B_Disease	B_Disease
damage	I_Disease	I_Disease
was	O	O
further	O	O
confirmed	O	O
by	O	O
histopathological	O	O
examination	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
our	O	O
results	O	O
showed	O	O
that	O	O
betaine	B_Chemical	O
pretreatment	O	O
attenuated	O	O
isoproterenol-induced	O	O
acute	O	O
myocardial	B_Disease	O
ischemia	I_Disease	O
via	O	O
the	O	O
regulation	O	O
of	O	O
STAT3	O	O
and	O	O
apoptotic	O	O
pathways	O	O
.	O	O

Quetiapine-induced	O	O
neutropenia	B_Disease	O
in	O	O
a	O	O
bipolar	B_Disease	O
patient	O	O
with	O	O
hepatocellular	B_Disease	B_Disease
carcinoma	I_Disease	I_Disease
.	O	O

OBJECTIVE	O	O
:	O	O
Quetiapine	B_Chemical	B_Chemical
is	O	O
a	O	O
dibenzothiazepine	O	B_Chemical
derivative	O	O
,	O	O
similar	O	O
to	O	O
clozapine	B_Chemical	O
,	O	O
which	O	O
has	O	O
the	O	O
highest	O	O
risk	O	O
of	O	O
causing	O	O
blood	B_Disease	O
dyscrasias	I_Disease	O
,	O	O
especially	O	O
neutropenia	B_Disease	O
.	O	O

There	O	O
are	O	O
some	O	O
case	O	O
reports	O	O
about	O	O
this	O	O
side	O	O
effect	O	O
of	O	O
quetiapine	B_Chemical	B_Chemical
,	O	O
but	O	O
possible	O	O
risk	O	O
factors	O	O
are	O	O
seldom	O	O
discussed	O	O
and	O	O
identified	O	O
.	O	O

A	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
hepatocellular	B_Disease	B_Disease
carcinoma	I_Disease	I_Disease
that	O	O
developed	O	O
neutropenia	B_Disease	O
after	O	O
treatment	O	O
with	O	O
quetiapine	B_Chemical	B_Chemical
is	O	O
described	O	O
here	O	O
.	O	O

CASE	O	O
REPORT	O	O
:	O	O
A	O	O
62-year-old	O	O
Taiwanese	O	O
widow	O	O
with	O	O
bipolar	B_Disease	B_Disease
disorder	I_Disease	I_Disease
was	O	O
diagnosed	O	O
with	O	O
hepatocellular	B_Disease	B_Disease
carcinoma	I_Disease	I_Disease
at	O	O
age	O	O
60	O	O
.	O	O

She	O	O
developed	O	O
leucopenia	B_Disease	O
after	O	O
being	O	O
treated	O	O
with	O	O
quetiapine	B_Chemical	B_Chemical
.	O	O
After	O	O
quetiapine	B_Chemical	B_Chemical
was	O	O
discontinued	O	O
,	O	O
her	O	O
white	O	O
blood	O	O
cell	O	O
count	O	O
returned	O	O
to	O	O
normal	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Although	O	O
neutropenia	B_Disease	O
is	O	O
not	O	O
a	O	O
common	O	O
side	O	O
effect	O	O
of	O	O
quetiapine	B_Chemical	B_Chemical
,	O	O
physicians	O	O
should	O	O
be	O	O
cautious	O	O
about	O	O
its	O	O
presentation	O	O
and	O	O
associated	O	O
risk	O	O
factors	O	O
.	O	O

Hepatic	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
may	O	O
be	O	O
one	O	O
of	O	O
the	O	O
possible	O	O
risk	O	O
factors	O	O
,	O	O
and	O	O
concomitant	O	O
fever	B_Disease	O
may	O	O
be	O	O
a	O	O
diagnostic	O	O
marker	O	O
for	O	O
adverse	O	B_Disease
reaction	O	I_Disease
to	O	O
quetiapine	B_Chemical	B_Chemical
.	O	O

Lateral	O	O
antebrachial	O	O
cutaneous	O	O
neuropathy	B_Disease	O
after	O	O
steroid	B_Chemical	O
injection	O	O
at	O	O
lateral	O	O
epicondyle	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVES	O	O
:	O	O
This	O	O
report	O	O
aimed	O	O
to	O	O
present	O	O
a	O	O
case	O	O
of	O	O
lateral	O	O
antebrachial	O	O
cutaneous	O	O
neuropathy	B_Disease	O
(	O	O
LACNP	O	O
)	O	O
that	O	O
occurred	O	O
after	O	O
a	O	O
steroid	B_Chemical	O
injection	O	O
in	O	O
the	O	O
lateral	O	O
epicondyle	O	O
to	O	O
treat	O	O
lateral	B_Disease	O
epicondylitis	I_Disease	O
in	O	O
a	O	O
40-year-old	O	O
woman	O	O
.	O	O

MATERIAL	O	O
AND	O	O
METHOD	O	O
:	O	O
A	O	O
40-year-old	O	O
woman	O	O
presented	O	O
with	O	O
decreased	O	O
sensation	O	O
and	O	O
paresthesia	B_Disease	O
over	O	O
her	O	O
right	O	O
lateral	O	O
forearm	O	O
;	O	O
the	O	O
paresthesia	B_Disease	O
had	O	O
occurred	O	O
after	O	O
a	O	O
steroid	B_Chemical	O
injection	O	O
in	O	O
the	O	O
right	O	O
lateral	O	O
epicondyle	O	O
3	O	O
months	O	O
before	O	O
.	O	O

Her	O	O
sensation	O	O
of	O	O
light	O	O
touch	O	O
and	O	O
pain	B_Disease	O
was	O	O
diminished	O	O
over	O	O
the	O	O
lateral	O	O
side	O	O
of	O	O
the	O	O
right	O	O
forearm	O	O
and	O	O
wrist	O	O
area	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
sensory	O	O
action	O	O
potential	O	O
amplitude	O	O
of	O	O
the	O	O
right	O	O
lateral	O	O
antebrachial	O	O
cutaneous	O	O
nerve	O	O
(	O	O
LACN	O	O
)	O	O
(	O	O
6.2	O	O
uV	O	O
)	O	O
was	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
the	O	O
left	O	O
(	O	O
13.1	O	O
uV	O	O
)	O	O
.	O	O

The	O	O
difference	O	O
of	O	O
amplitude	O	O
between	O	O
both	O	O
sides	O	O
was	O	O
significant	O	O
because	O	O
there	O	O
was	O	O
more	O	O
than	O	O
a	O	O
50	O	O
%	O	O
reduction	O	O
.	O	O

She	O	O
was	O	O
diagnosed	O	O
with	O	O
right	O	O
LACNP	O	O
(	O	O
mainly	O	O
axonal	O	O
involvement	O	O
)	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
clinical	O	O
manifestation	O	O
and	O	O
the	O	O
electrodiagnostic	O	O
findings	O	O
.	O	O

Her	O	O
symptoms	O	O
improved	O	O
through	O	O
physical	O	O
therapy	O	O
but	O	O
persisted	O	O
to	O	O
some	O	O
degree	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
report	O	O
describes	O	O
the	O	O
case	O	O
of	O	O
a	O	O
woman	O	O
with	O	O
LACNP	O	O
that	O	O
developed	O	O
after	O	O
a	O	O
steroid	B_Chemical	O
injection	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
lateral	B_Disease	O
epicondylitis	I_Disease	O
.	O	O

An	O	O
electrodiagnostic	O	O
study	O	O
,	O	O
including	O	O
a	O	O
nerve	O	O
conduction	O	O
study	O	O
of	O	O
the	O	O
LACN	O	O
,	O	O
was	O	O
helpful	O	O
to	O	O
diagnose	O	O
right	O	O
LACNP	O	O
and	O	O
to	O	O
find	O	O
the	O	O
passage	O	O
of	O	O
the	O	O
LACN	O	O
on	O	O
the	O	O
lateral	O	O
epicondyle	O	O
.	O	O

Curcumin	B_Chemical	B_Chemical
prevents	O	O
maleate-induced	O	O
nephrotoxicity	B_Disease	B_Disease
:	O	O
relation	O	O
to	O	O
hemodynamic	O	O
alterations	O	O
,	O	O
oxidative	O	O
stress	O	O
,	O	O
mitochondrial	O	O
oxygen	B_Chemical	O
consumption	O	O
and	O	O
activity	O	O
of	O	O
respiratory	O	O
complex	O	O
I.The	O	O
potential	O	O
protective	O	O
effect	O	O
of	O	O
the	O	O
dietary	O	O
antioxidant	O	O
curcumin	B_Chemical	B_Chemical
(	O	O
120	O	O
mg/Kg/day	O	O
for	O	O
6	O	O
days	O	O
)	O	O
against	O	O
the	O	O
renal	B_Disease	B_Disease
injury	I_Disease	I_Disease
induced	O	O
by	O	O
maleate	B_Chemical	O
was	O	O
evaluated	O	O
.	O	O

Tubular	O	O
proteinuria	B_Disease	O
and	O	O
oxidative	O	O
stress	O	O
were	O	O
induced	O	O
by	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
maleate	B_Chemical	O
(	O	O
400	O	O
mg/kg	O	O
)	O	O
in	O	O
rats	O	O
.	O	O

Maleate-induced	O	O
renal	B_Disease	B_Disease
injury	I_Disease	I_Disease
included	O	O
increase	O	O
in	O	O
renal	O	O
vascular	O	O
resistance	O	O
and	O	O
in	O	O
the	O	O
urinary	O	O
excretion	O	O
of	O	O
total	O	O
protein	O	O
,	O	O
glucose	B_Chemical	O
,	O	O
sodium	B_Chemical	O
,	O	O
neutrophil	O	O
gelatinase-associated	O	O
lipocalin	O	O
(	O	O
NGAL	O	O
)	O	O
and	O	O
N-acetyl	O	B_Chemical
b-D-glucosaminidase	O	I_Chemical
(	O	O
NAG	O	O
)	O	O
,	O	O
upregulation	O	O
of	O	O
kidney	B_Disease	B_Disease
injury	I_Disease	I_Disease
molecule	O	O
(KIM)-1	O	O
,	O	O
decrease	O	O
in	O	O
renal	O	O
blood	O	O
flow	O	O
and	O	O
claudin-2	O	O
expression	O	O
besides	O	O
of	O	O
necrosis	B_Disease	O
and	O	O
apoptosis	O	O
of	O	O
tubular	O	O
cells	O	O
on	O	O
24	O	O
h.	O	O
Oxidative	O	O
stress	O	O
was	O	O
determined	O	O
by	O	O
measuring	O	O
the	O	O
oxidation	O	O
of	O	O
lipids	O	O
and	O	O
proteins	O	O
and	O	O
diminution	O	O
in	O	O
renal	O	O
Nrf2	O	O
levels	O	O
.	O	O

Studies	O	O
were	O	O
also	O	O
conducted	O	O
in	O	O
renal	O	O
epithelial	O	O
LLC-PK1	O	O
cells	O	O
and	O	O
in	O	O
mitochondria	O	O
isolated	O	O
from	O	O
kidneys	O	O
of	O	O
all	O	O
the	O	O
experimental	O	O
groups	O	O
.	O	O

Maleate	B_Chemical	O
induced	O	O
cell	O	B_Disease
damage	O	I_Disease
and	O	O
reactive	O	O
oxygen	B_Chemical	O
species	O	O
(	O	O
ROS	O	O
)	O	O
production	O	O
in	O	O
LLC-PK1	O	O
cells	O	O
in	O	O
culture	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
maleate	B_Chemical	O
treatment	O	O
reduced	O	O
oxygen	B_Chemical	O
consumption	O	O
in	O	O
ADP-stimulated	O	O
mitochondria	O	O
and	O	O
diminished	O	O
respiratory	O	O
control	O	O
index	O	O
when	O	O
using	O	O
malate/glutamate	O	B_Chemical
as	O	O
substrate	O	O
.	O	O

The	O	O
activities	O	O
of	O	O
both	O	O
complex	O	O
I	O	O
and	O	O
aconitase	O	O
were	O	O
also	O	O
diminished	O	O
.	O	O

All	O	O
the	O	O
above-described	O	O
alterations	O	O
were	O	O
prevented	O	O
by	O	O
curcumin	B_Chemical	B_Chemical
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
curcumin	B_Chemical	B_Chemical
is	O	O
able	O	O
to	O	O
attenuate	O	O
in	O	O
vivo	O	O
maleate-induced	O	O
nephropathy	B_Disease	O
and	O	O
in	O	O
vitro	O	O
cell	O	B_Disease
damage	O	I_Disease
.	O	O

The	O	O
in	O	O
vivo	O	O
protection	O	O
was	O	O
associated	O	O
to	O	O
the	O	O
prevention	O	O
of	O	O
oxidative	O	O
stress	O	O
and	O	O
preservation	O	O
of	O	O
mitochondrial	O	O
oxygen	B_Chemical	O
consumption	O	O
and	O	O
activity	O	O
of	O	O
respiratory	O	O
complex	O	O
I	O	O
,	O	O
and	O	O
the	O	O
in	O	O
vitro	O	O
protection	O	O
was	O	O
associated	O	O
to	O	O
the	O	O
prevention	O	O
of	O	O
ROS	O	O
production	O	O
.	O	O

Anticonvulsant	O	O
actions	O	O
of	O	O
MK-801	B_Chemical	O
on	O	O
the	O	O
lithium-pilocarpine	O	B_Chemical
model	O	O
of	O	O
status	B_Disease	O
epilepticus	I_Disease	O
in	O	O
rats	O	O
.	O	O

MK-801	B_Chemical	O
,	O	O
a	O	O
noncompetitive	O	O
N-methyl-D-aspartate	B_Chemical	B_Chemical
(	O	O
NMDA	B_Chemical	O
)	O	O
receptor	O	O
antagonist	O	O
,	O	O
was	O	O
tested	O	O
for	O	O
anticonvulsant	O	O
effects	O	O
in	O	O
rats	O	O
using	O	O
two	O	O
seizure	B_Disease	O
models	O	O
,	O	O
coadministration	O	O
of	O	O
lithium	B_Chemical	O
and	O	O
pilocarpine	B_Chemical	O
and	O	O
administration	O	O
of	O	O
a	O	O
high	O	O
dose	O	O
of	O	O
pilocarpine	B_Chemical	O
alone	O	O
.	O	O

Three	O	O
major	O	O
results	O	O
are	O	O
reported	O	O
.	O	O

First	O	O
,	O	O
pretreatment	O	O
with	O	O
MK-801	B_Chemical	O
produced	O	O
an	O	O
effective	O	O
and	O	O
dose-dependent	O	O
anticonvulsant	O	O
action	O	O
with	O	O
the	O	O
lithium-pilocarpine	O	B_Chemical
model	O	O
but	O	O
not	O	O
with	O	O
rats	O	O
treated	O	O
with	O	O
pilocarpine	B_Chemical	O
alone	O	O
,	O	O
suggesting	O	O
that	O	O
different	O	O
biochemical	O	O
mechanisms	O	O
control	O	O
seizures	B_Disease	O
in	O	O
these	O	O
two	O	O
models	O	O
.	O	O

Second	O	O
,	O	O
the	O	O
anticonvulsant	O	O
effect	O	O
of	O	O
MK-801	B_Chemical	O
in	O	O
the	O	O
lithium-pilocarpine	O	B_Chemical
model	O	O
only	O	O
occurred	O	O
after	O	O
initial	O	O
periods	O	O
of	O	O
seizure	B_Disease	O
activity	O	O
.	O	O

This	O	O
observation	O	O
is	O	O
suggested	O	O
to	O	O
be	O	O
an	O	O
in	O	O
vivo	O	O
demonstration	O	O
of	O	O
the	O	O
conclusion	O	O
derived	O	O
from	O	O
in	O	O
vitro	O	O
experiments	O	O
that	O	O
MK-801	B_Chemical	O
binding	O	O
requires	O	O
agonist-induced	O	O
opening	O	O
of	O	O
the	O	O
channel	O	O
sites	O	O
of	O	O
the	O	O
NMDA	B_Chemical	O
receptor	O	O
.	O	O

Third	O	O
,	O	O
although	O	O
it	O	O
is	O	O
relatively	O	O
easy	O	O
to	O	O
block	O	O
seizures	B_Disease	O
induced	O	O
by	O	O
lithium	B_Chemical	O
and	O	O
pilocarpine	B_Chemical	O
by	O	O
administration	O	O
of	O	O
anticonvulsants	O	O
prior	O	O
to	O	O
pilocarpine	B_Chemical	O
,	O	O
it	O	O
is	O	O
more	O	O
difficult	O	O
to	O	O
terminate	O	O
ongoing	O	O
status	B_Disease	O
epilepticus	I_Disease	O
and	O	O
block	O	O
the	O	O
lethality	O	O
of	O	O
the	O	O
seizures	B_Disease	O
.	O	O

Administration	O	O
of	O	O
MK-801	B_Chemical	O
30	O	O
or	O	O
60	O	O
min	O	O
after	O	O
pilocarpine	B_Chemical	O
,	O	O
i.e.	O	O
,	O	O
during	O	O
status	B_Disease	O
epilepticus	I_Disease	O
,	O	O
gradually	O	O
reduced	O	O
electrical	O	O
and	O	O
behavioral	O	O
seizure	B_Disease	O
activity	O	O
and	O	O
greatly	O	O
enhanced	O	O
the	O	O
survival	O	O
rate	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
activation	O	O
of	O	O
NMDA	B_Chemical	O
receptors	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
status	B_Disease	O
epilepticus	I_Disease	O
and	O	O
brain	B_Disease	B_Disease
damage	I_Disease	I_Disease
in	O	O
the	O	O
lithium-pilocarpine	O	B_Chemical
model	O	O
.	O	O

This	O	O
was	O	O
further	O	O
supported	O	O
by	O	O
results	O	O
showing	O	O
that	O	O
nonconvulsive	O	O
doses	O	O
of	O	O
NMDA	B_Chemical	O
and	O	O
pilocarpine	B_Chemical	O
were	O	O
synergistic	O	O
,	O	O
resulting	O	O
in	O	O
status	B_Disease	O
epilepticus	I_Disease	O
and	O	O
subsequent	O	O
mortality	O	O
.	O	O

Continuous	O	O
infusion	O	O
tobramycin	B_Chemical	O
combined	O	O
with	O	O
carbenicillin	B_Chemical	B_Chemical
for	O	O
infections	B_Disease	O
in	O	O
cancer	B_Disease	O
patients	O	O
.	O	O

The	O	O
cure	O	O
rate	O	O
of	O	O
infections	B_Disease	O
in	O	O
cancer	B_Disease	O
patients	O	O
is	O	O
adversely	O	O
affected	O	O
by	O	O
neutropenia	B_Disease	O
(	O	O
less	O	O
than	O	O
1,000/mm3	O	O
)	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
patients	O	O
with	O	O
severe	O	O
neutropenia	B_Disease	O
(	O	O
less	O	O
than	O	O
100/mm3	O	O
)	O	O
have	O	O
shown	O	O
a	O	O
poor	O	O
response	O	O
to	O	O
antibiotics	O	O
.	O	O

To	O	O
overcome	O	O
the	O	O
adverse	O	O
effects	O	O
of	O	O
neutropenia	B_Disease	O
,	O	O
tobramycin	B_Chemical	O
was	O	O
given	O	O
by	O	O
continuous	O	O
infusion	O	O
and	O	O
combined	O	O
with	O	O
intermittent	O	O
carbenicillin	B_Chemical	B_Chemical
.	O	O

Tobramycin	B_Chemical	O
was	O	O
given	O	O
to	O	O
a	O	O
total	O	O
daily	O	O
dose	O	O
of	O	O
300	O	O
mg/m2	O	O
and	O	O
carbenicillin	B_Chemical	B_Chemical
was	O	O
given	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
5	O	O
gm	O	O
every	O	O
four	O	O
hours	O	O
.	O	O

There	O	O
were	O	O
125	O	O
infectious	O	O
episodes	O	O
in	O	O
116	O	O
cancer	B_Disease	O
patients	O	O
receiving	O	O
myelosuppressive	O	B_Disease
chemotherapy	O	O
.	O	O

The	O	O
overall	O	O
cure	O	O
rate	O	O
was	O	O
70	O	O
%	O	O
.	O	O

Pneumonia	B_Disease	O
was	O	O
the	O	O
most	O	O
common	O	O
infection	B_Disease	O
and	O	O
61	O	O
%	O	O
of	O	O
59	O	O
episodes	O	O
were	O	O
cured	O	O
.	O	O

Gram-negative	O	O
bacilli	O	O
were	O	O
the	O	O
most	O	O
common	O	O
causative	O	O
organisms	O	O
and	O	O
69	O	O
%	O	O
of	O	O
these	O	O
infections	B_Disease	O
were	O	O
cured	O	O
.	O	O

The	O	O
most	O	O
common	O	O
pathogen	O	O
was	O	O
Klebsiella	O	O
pneumoniae	B_Disease	O
and	O	O
this	O	O
,	O	O
together	O	O
with	O	O
Escherichia	O	O
coli	O	O
and	O	O
Pseudomonas	O	O
aeruginosa	O	O
,	O	O
accounted	O	O
for	O	O
74	O	O
%	O	O
of	O	O
all	O	O
gram-negative	B_Disease	O
bacillary	I_Disease	O
infections	I_Disease	O
.	O	O

Response	O	O
was	O	O
not	O	O
influenced	O	O
by	O	O
the	O	O
initial	O	O
neutrophil	O	O
count	O	O
,	O	O
with	O	O
a	O	O
62	O	O
%	O	O
cure	O	O
rate	O	O
for	O	O
39	O	O
episodes	O	O
associated	O	O
with	O	O
severe	O	O
neutropenia	B_Disease	O
.	O	O

However	O	O
,	O	O
failure	O	O
of	O	O
the	O	O
neutrophil	O	O
count	O	O
to	O	O
increase	O	O
during	O	O
therapy	O	O
adversely	O	O
affected	O	O
response	O	O
.	O	O

Azotemia	B_Disease	O
was	O	O
the	O	O
major	O	O
side	O	O
effect	O	O
recognized	O	O
,	O	O
and	O	O
it	O	O
occurred	O	O
in	O	O
11	O	O
%	O	O
of	O	O
episodes	O	O
.	O	O

Major	O	O
azotemia	B_Disease	O
(	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
greater	O	O
than	O	O
2.5	O	O
mg/dl	O	O
or	O	O
BUN	O	O
greater	O	O
than	O	O
50	O	O
mg/dl	O	O
)	O	O
occurred	O	O
in	O	O
only	O	O
2	O	O
%	O	O
.	O	O

Azotemia	B_Disease	O
was	O	O
not	O	O
related	O	O
to	O	O
duration	O	O
of	O	O
therapy	O	O
or	O	O
serum	O	O
tobramycin	B_Chemical	O
concentration	O	O
.	O	O

This	O	O
antibiotic	O	O
regimen	O	O
showed	O	O
both	O	O
therapeutic	O	O
efficacy	O	O
and	O	O
acceptable	O	O
renal	B_Disease	B_Disease
toxicity	I_Disease	I_Disease
for	O	O
these	O	O
patients	O	O
.	O	O

Incidence	O	O
of	O	O
solid	O	O
tumours	B_Disease	O
among	O	O
pesticide	O	O
applicators	O	O
exposed	O	O
to	O	O
the	O	O
organophosphate	B_Chemical	O
insecticide	O	O
diazinon	B_Chemical	B_Chemical
in	O	O
the	O	O
Agricultural	O	O
Health	O	O
Study	O	O
:	O	O
an	O	O
updated	O	O
analysis	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
Diazinon	B_Chemical	B_Chemical
,	O	O
a	O	O
common	O	O
organophosphate	B_Chemical	O
insecticide	O	O
with	O	O
genotoxic	O	O
properties	O	O
,	O	O
was	O	O
previously	O	O
associated	O	O
with	O	O
lung	B_Disease	B_Disease
cancer	I_Disease	I_Disease
in	O	O
the	O	O
Agricultural	O	O
Health	O	O
Study	O	O
(	O	O
AHS	O	O
)	O	O
cohort	O	O
,	O	O
but	O	O
few	O	O
other	O	O
epidemiological	O	O
studies	O	O
have	O	O
examined	O	O
diazinon-associated	O	O
cancer	B_Disease	O
risk	O	O
.	O	O

We	O	O
used	O	O
updated	O	O
diazinon	B_Chemical	B_Chemical
exposure	O	O
and	O	O
cancer	B_Disease	O
incidence	O	O
information	O	O
to	O	O
evaluate	O	O
solid	O	O
tumour	B_Disease	O
risk	O	O
in	O	O
the	O	O
AHS	O	O
.	O	O

METHODS	O	O
:	O	O
Male	O	O
pesticide	O	O
applicators	O	O
in	O	O
Iowa	O	O
and	O	O
North	O	O
Carolina	O	O
reported	O	O
lifetime	O	O
diazinon	B_Chemical	B_Chemical
use	O	O
at	O	O
enrolment	O	O
(	O	O
1993	O	O
-	O	O
1997	O	O
)	O	O
and	O	O
follow-up	O	O
(	O	O
1998	O	O
-	O	O
2005	O	O
)	O	O
;	O	O
cancer	B_Disease	O
incidence	O	O
was	O	O
assessed	O	O
through	O	O
2010(North	O	O
Carolina)/2011(Iowa	O	O
)	O	O
.	O	O

Among	O	O
applicators	O	O
with	O	O
usage	O	O
information	O	O
sufficient	O	O
to	O	O
evaluate	O	O
exposure-response	O	O
patterns	O	O
,	O	O
we	O	O
used	O	O
Poisson	O	O
regression	O	O
to	O	O
estimate	O	O
adjusted	O	O
rate	O	O
ratios	O	O
(	O	O
RRs	O	O
)	O	O
and	O	O
95	O	O
%	O	O
CI	O	O
for	O	O
cancer	B_Disease	O
sites	O	O
with	O	O
>	O	O
10	O	O
exposed	O	O
cases	O	O
for	O	O
both	O	O
lifetime	O	O
(	O	O
LT	O	O
)	O	O
exposure	O	O
days	O	O
and	O	O
intensity-weighted	O	O
(	O	O
IW	O	O
)	O	O
lifetime	O	O
exposure	O	O
days	O	O
(	O	O
accounting	O	O
for	O	O
factors	O	O
impacting	O	O
exposure	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
observed	O	O
elevated	O	O
lung	B_Disease	B_Disease
cancer	I_Disease	I_Disease
risks	O	O
(	O	O
N=283	O	O
)	O	O
among	O	O
applicators	O	O
with	O	O
the	O	O
greatest	O	O
number	O	O
of	O	O
LT	O	O
(	O	O
RR=1.60	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
1.11	O	O
to	O	O
2.31	O	O
;	O	O
Ptrend=0.02	O	O
)	O	O
and	O	O
IW	O	O
days	O	O
of	O	O
diazinon	B_Chemical	B_Chemical
use	O	O
(	O	O
RR=1.41	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
0.98	O	O
to	O	O
2.04	O	O
;	O	O
Ptrend=0.08	O	O
)	O	O
.	O	O

Kidney	B_Disease	B_Disease
cancer	I_Disease	I_Disease
(	O	O
N=94	O	O
)	O	O
risks	O	O
were	O	O
non-significantly	O	O
elevated	O	O
(	O	O
RRLT	O	O
days=1.77	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
0.90	O	O
to	O	O
3.51	O	O
;	O	O
Ptrend=0.09	O	O
;	O	O
RRIW	O	O
days	O	O
1.37	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
0.64	O	O
to	O	O
2.92	O	O
;	O	O
Ptrend=0.50	O	O
)	O	O
,	O	O
as	O	O
were	O	O
risks	O	O
for	O	O
aggressive	O	B_Disease
prostate	B_Disease	I_Disease
cancer	I_Disease	I_Disease
(	O	O
N=656	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Our	O	O
updated	O	O
evaluation	O	O
of	O	O
diazinon	B_Chemical	B_Chemical
provides	O	O
additional	O	O
evidence	O	O
of	O	O
an	O	O
association	O	O
with	O	O
lung	B_Disease	B_Disease
cancer	I_Disease	I_Disease
risk	O	O
.	O	O

Newly	O	O
identified	O	O
links	O	O
to	O	O
kidney	B_Disease	B_Disease
cancer	I_Disease	I_Disease
and	O	O
associations	O	O
with	O	O
aggressive	O	O
prostate	B_Disease	B_Disease
cancer	I_Disease	I_Disease
require	O	O
further	O	O
evaluation	O	O
.	O	O

Associations	O	O
of	O	O
Ozone	B_Chemical	O
and	O	O
PM2.5	O	O
Concentrations	O	O
With	O	O
Parkinson	B_Disease	O
's	I_Disease	O
Disease	I_Disease	O
Among	O	O
Participants	O	O
in	O	O
the	O	O
Agricultural	O	O
Health	O	O
Study	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
This	O	O
study	O	O
describes	O	O
associations	O	O
of	O	O
ozone	B_Chemical	O
and	O	O
fine	O	O
particulate	B_Chemical	O
matter	I_Chemical	O
with	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
observed	O	O
among	O	O
farmers	O	O
in	O	O
North	O	O
Carolina	O	O
and	O	O
Iowa	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
used	O	O
logistic	O	O
regression	O	O
to	O	O
determine	O	O
the	O	O
associations	O	O
of	O	O
these	O	O
pollutants	O	O
with	O	O
self-reported	O	O
,	O	O
doctor-diagnosed	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
.	O	O

Daily	O	O
predicted	O	O
pollutant	O	O
concentrations	O	O
were	O	O
used	O	O
to	O	O
derive	O	O
surrogates	O	O
of	O	O
long-term	O	O
exposure	O	O
and	O	O
link	O	O
them	O	O
to	O	O
study	O	O
participants	O	O
'	O	O
geocoded	O	O
addresses	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
observed	O	O
positive	O	O
associations	O	O
of	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
with	O	O
ozone	B_Chemical	O
(	O	O
odds	O	O
ratio	O	O
=	O	O
1.39	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
0.98	O	O
to	O	O
1.98	O	O
)	O	O
and	O	O
fine	O	O
particulate	B_Chemical	O
matter	I_Chemical	O
(	O	O
odds	O	O
ratio	O	O
=	O	O
1.34	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
0.93	O	O
to	O	O
1.93	O	O
)	O	O
in	O	O
North	O	O
Carolina	O	O
but	O	O
not	O	O
in	O	O
Iowa	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
plausibility	O	O
of	O	O
an	O	O
effect	O	O
of	O	O
ambient	O	O
concentrations	O	O
of	O	O
these	O	O
pollutants	O	O
on	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
risk	O	O
is	O	O
supported	O	O
by	O	O
experimental	O	O
data	O	O
demonstrating	O	O
damage	O	O
to	O	O
dopaminergic	O	O
neurons	O	O
at	O	O
relevant	O	O
concentrations	O	O
.	O	O

Additional	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
address	O	O
uncertainties	O	O
related	O	O
to	O	O
confounding	O	O
and	O	O
to	O	O
examine	O	O
temporal	O	O
aspects	O	O
of	O	O
the	O	O
associations	O	O
we	O	O
observed	O	O
.	O	O

Low	O	O
functional	O	O
programming	O	O
of	O	O
renal	O	O
AT2R	O	O
mediates	O	O
the	O	O
developmental	O	O
origin	O	O
of	O	O
glomerulosclerosis	B_Disease	B_Disease
in	O	O
adult	O	O
offspring	O	O
induced	O	O
by	O	O
prenatal	O	O
caffeine	B_Chemical	O
exposure	O	O
.	O	O

UNASSIGNED	O	O
:	O	O
Our	O	O
previous	O	O
study	O	O
has	O	O
indicated	O	O
that	O	O
prenatal	O	O
caffeine	B_Chemical	O
exposure	O	O
(	O	O
PCE	O	O
)	O	O
could	O	O
induce	O	O
intrauterine	B_Disease	O
growth	I_Disease	O
retardation	I_Disease	O
(	O	O
IUGR	B_Disease	O
)	O	O
of	O	O
offspring	O	O
.	O	O

Recent	O	O
research	O	O
suggested	O	O
that	O	O
IUGR	B_Disease	O
is	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
glomerulosclerosis	B_Disease	B_Disease
.	O	O

However	O	O
,	O	O
whether	O	O
PCE	O	O
could	O	O
induce	O	O
glomerulosclerosis	B_Disease	B_Disease
and	O	O
its	O	O
underlying	O	O
mechanisms	O	O
remain	O	O
unknown	O	O
.	O	O

This	O	O
study	O	O
aimed	O	O
to	O	O
demonstrate	O	O
the	O	O
induction	O	O
to	O	O
glomerulosclerosis	B_Disease	B_Disease
in	O	O
adult	O	O
offspring	O	O
by	O	O
PCE	O	O
and	O	O
its	O	O
intrauterine	O	O
programming	O	O
mechanisms	O	O
.	O	O

A	O	O
rat	O	O
model	O	O
of	O	O
IUGR	B_Disease	O
was	O	O
established	O	O
by	O	O
PCE	O	O
,	O	O
male	O	O
fetuses	O	O
and	O	O
adult	O	O
offspring	O	O
at	O	O
the	O	O
age	O	O
of	O	O
postnatal	O	O
week	O	O
24	O	O
were	O	O
euthanized	O	O
.	O	O

The	O	O
results	O	O
revealed	O	O
that	O	O
the	O	O
adult	O	O
offspring	O	O
kidneys	O	O
in	O	O
the	O	O
PCE	O	O
group	O	O
exhibited	O	O
glomerulosclerosis	B_Disease	B_Disease
as	O	O
well	O	O
as	O	O
interstitial	B_Disease	B_Disease
fibrosis	I_Disease	I_Disease
,	O	O
accompanied	O	O
by	O	O
elevated	O	O
levels	O	O
of	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
and	O	O
urine	O	O
protein	O	O
.	O	O

Renal	O	O
angiotensin	B_Chemical	O
II	I_Chemical	O
receptor	O	O
type	O	O
2	O	O
(	O	O
AT2R	O	O
)	O	O
gene	O	O
expression	O	O
in	O	O
adult	O	O
offspring	O	O
was	O	O
reduced	O	O
by	O	O
PCE	O	O
,	O	O
whereas	O	O
the	O	O
renal	O	O
angiotensin	B_Chemical	O
II	I_Chemical	O
receptor	O	O
type	O	O
1a	O	O
(AT1aR)/AT2R	O	O
expression	O	O
ratio	O	O
was	O	O
increased	O	O
.	O	O

The	O	O
fetal	O	O
kidneys	O	O
in	O	O
the	O	O
PCE	O	O
group	O	O
displayed	O	O
an	O	O
enlarged	O	O
Bowman	O	O
's	O	O
space	O	O
and	O	O
a	O	O
shrunken	O	O
glomerular	O	O
tuft	O	O
,	O	O
accompanied	O	O
by	O	O
a	O	O
reduced	O	O
cortex	O	O
width	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
nephrogenic	O	O
zone/cortical	O	O
zone	O	O
ratio	O	O
.	O	O

Observation	O	O
by	O	O
electronic	O	O
microscope	O	O
revealed	O	O
structural	O	O
damage	O	O
of	O	O
podocytes	O	O
;	O	O
the	O	O
reduced	O	O
expression	O	O
level	O	O
of	O	O
podocyte	O	O
marker	O	O
genes	O	O
,	O	O
nephrin	O	O
and	O	O
podocin	O	O
,	O	O
was	O	O
also	O	O
detected	O	O
by	O	O
q-PCR	O	O
.	O	O

Moreover	O	O
,	O	O
AT2R	O	O
gene	O	O
and	O	O
protein	O	O
expressions	O	O
in	O	O
fetal	O	O
kidneys	O	O
were	O	O
inhibited	O	O
by	O	O
PCE	O	O
,	O	O
associated	O	O
with	O	O
the	O	O
repression	O	O
of	O	O
the	O	O
gene	O	O
expression	O	O
of	O	O
glial-cell-line-derived	O	O
neurotrophic	O	O
factor	O	O
(GDNF)/tyrosine	O	O
kinase	O	O
receptor	O	O
(	O	O
c-Ret	O	O
)	O	O
signaling	O	O
pathway	O	O
.	O	O

These	O	O
results	O	O
demonstrated	O	O
that	O	O
PCE	O	O
could	O	O
induce	O	O
dysplasia	B_Disease	O
of	I_Disease	O
fetal	I_Disease	O
kidneys	I_Disease	O
as	O	O
well	O	O
as	O	O
glomerulosclerosis	B_Disease	B_Disease
of	O	O
adult	O	O
offspring	O	O
,	O	O
and	O	O
the	O	O
low	O	O
functional	O	O
programming	O	O
of	O	O
renal	O	O
AT2R	O	O
might	O	O
mediate	O	O
the	O	O
developmental	O	O
origin	O	O
of	O	O
adult	O	O
glomerulosclerosis	B_Disease	B_Disease
.	O	O

1,3-Butadiene	B_Chemical	B_Chemical
,	O	O
CML	B_Disease	O
and	O	O
the	O	O
t(9:22	O	O
)	O	O
translocation	O	O
:	O	O
A	O	O
reality	O	O
check	O	O
.	O	O

UNASSIGNED	O	O
:	O	O
Epidemiological	O	O
studies	O	O
of	O	O
1,3-butadiene	B_Chemical	B_Chemical
have	O	O
suggest	O	O
that	O	O
exposures	O	O
to	O	O
humans	O	O
are	O	O
associated	O	O
with	O	O
chronic	B_Disease	O
myeloid	I_Disease	O
leukemia	I_Disease	O
(	O	O
CML	B_Disease	O
)	O	O
.	O	O

CML	B_Disease	O
has	O	O
a	O	O
well-documented	O	O
association	O	O
with	O	O
ionizing	O	O
radiation	O	O
,	O	O
but	O	O
reports	O	O
of	O	O
associations	O	O
with	O	O
chemical	O	O
exposures	O	O
have	O	O
been	O	O
questioned	O	O
.	O	O

Ionizing	O	O
radiation	O	O
is	O	O
capable	O	O
of	O	O
inducing	O	O
the	O	O
requisite	O	O
CML-associated	O	O
t(9:22	O	O
)	O	O
translocation	O	O
(	O	O
Philadelphia	B_Disease	O
chromosome	I_Disease	O
)	O	O
in	O	O
appropriate	O	O
cells	O	O
in	O	O
vitro	O	O
but	O	O
,	O	O
thus	O	O
far	O	O
,	O	O
chemicals	O	O
have	O	O
not	O	O
shown	O	O
this	O	O
capacity	O	O
.	O	O

We	O	O
have	O	O
proposed	O	O
that	O	O
1,3-butadiene	B_Chemical	B_Chemical
metabolites	O	O
be	O	O
so	O	O
tested	O	O
as	O	O
a	O	O
reality	O	O
check	O	O
on	O	O
the	O	O
epidemiological	O	O
reports	O	O
.	O	O

In	O	O
order	O	O
to	O	O
conduct	O	O
reliable	O	O
testing	O	O
in	O	O
this	O	O
regard	O	O
,	O	O
it	O	O
is	O	O
essential	O	O
that	O	O
a	O	O
positive	O	O
control	O	O
for	O	O
induction	O	O
be	O	O
available	O	O
.	O	O

We	O	O
have	O	O
used	O	O
ionizing	O	O
radiation	O	O
to	O	O
develop	O	O
such	O	O
a	O	O
control	O	O
.	O	O

Results	O	O
described	O	O
here	O	O
demonstrate	O	O
that	O	O
this	O	O
agent	O	O
does	O	O
in	O	O
fact	O	O
induce	O	O
pathogenic	O	O
t(9:22	O	O
)	O	O
translocations	O	O
in	O	O
a	O	O
human	O	O
myeloid	O	O
cell	O	O
line	O	O
in	O	O
vitro	O	O
,	O	O
but	O	O
does	O	O
so	O	O
at	O	O
low	O	O
frequencies	O	O
.	O	O

Conditions	O	O
that	O	O
will	O	O
be	O	O
required	O	O
for	O	O
studies	O	O
of	O	O
1,3-butadiene	B_Chemical	B_Chemical
are	O	O
discussed	O	O
.	O	O

Cancer	B_Disease	O
incidence	O	O
and	O	O
metolachlor	B_Chemical	B_Chemical
use	O	O
in	O	O
the	O	O
Agricultural	O	O
Health	O	O
Study	O	O
:	O	O
An	O	O
update	O	O
.	O	O

UNASSIGNED	O	O
:	O	O
Metolachlor	B_Chemical	O
,	O	O
a	O	O
widely	O	O
used	O	O
herbicide	O	O
,	O	O
is	O	O
classified	O	O
as	O	O
a	O	O
Group	O	O
C	O	O
carcinogen	O	O
by	O	O
the	O	O
U.S.	O	O
Environmental	O	O
Protection	O	O
Agency	O	O
based	O	O
on	O	O
increased	O	O
liver	B_Disease	B_Disease
neoplasms	I_Disease	I_Disease
in	O	O
female	O	O
rats	O	O
.	O	O

Epidemiologic	O	O
studies	O	O
of	O	O
the	O	O
health	O	O
effects	O	O
of	O	O
metolachlor	B_Chemical	B_Chemical
have	O	O
been	O	O
limited	O	O
.	O	O

The	O	O
Agricultural	O	O
Health	O	O
Study	O	O
(	O	O
AHS	O	O
)	O	O
is	O	O
a	O	O
prospective	O	O
cohort	O	O
study	O	O
including	O	O
licensed	O	O
private	O	O
and	O	O
commercial	O	O
pesticide	O	O
applicators	O	O
in	O	O
Iowa	O	O
and	O	O
North	O	O
Carolina	O	O
enrolled	O	O
1993	O	O
-	O	O
1997	O	O
.	O	O

We	O	O
evaluated	O	O
cancer	B_Disease	O
incidence	O	O
through	O	O
2010/2011	O	O
(	O	O
NC/IA	O	O
)	O	O
for	O	O
49,616	O	O
applicators	O	O
,	O	O
53	O	O
%	O	O
of	O	O
whom	O	O
reported	O	O
ever	O	O
using	O	O
metolachlor	B_Chemical	B_Chemical
.	O	O

We	O	O
used	O	O
Poisson	O	O
regression	O	O
to	O	O
evaluate	O	O
relations	O	O
between	O	O
two	O	O
metrics	O	O
of	O	O
metolachlor	B_Chemical	O
use	O	O
(	O	O
lifetime	O	O
days	O	O
,	O	O
intensity-weighted	O	O
lifetime	O	O
days	O	O
)	O	O
and	O	O
cancer	B_Disease	O
incidence	O	O
.	O	O

We	O	O
saw	O	O
no	O	O
association	O	O
between	O	O
metolachlor	B_Chemical	O
use	O	O
and	O	O
incidence	O	O
of	O	O
all	O	O
cancers	B_Disease	O
combined	O	O
(	O	O
n	O	O
=	O	O
5,701	O	O
with	O	O
a	O	O
5-year	O	O
lag	O	O
)	O	O
or	O	O
most	O	O
site-specific	O	O
cancers	B_Disease	O
.	O	O

For	O	O
liver	B_Disease	B_Disease
cancer	I_Disease	I_Disease
,	O	O
in	O	O
analyses	O	O
restricted	O	O
to	O	O
exposed	O	O
workers	O	O
,	O	O
elevations	O	O
observed	O	O
at	O	O
higher	O	O
categories	O	O
of	O	O
use	O	O
were	O	O
not	O	O
statistically	O	O
significant	O	O
.	O	O

However	O	O
,	O	O
trends	O	O
for	O	O
both	O	O
lifetime	O	O
and	O	O
intensity-weighted	O	O
lifetime	O	O
days	O	O
of	O	O
metolachor	B_Chemical	O
use	O	O
were	O	O
positive	O	O
and	O	O
statistically	O	O
significant	O	O
with	O	O
an	O	O
unexposed	O	O
reference	O	O
group	O	O
.	O	O

A	O	O
similar	O	O
pattern	O	O
was	O	O
observed	O	O
for	O	O
follicular	B_Disease	O
cell	I_Disease	O
lymphoma	I_Disease	O
,	O	O
but	O	O
no	O	O
other	O	O
lymphoma	B_Disease	O
subtypes	O	O
.	O	O

An	O	O
earlier	O	O
suggestion	O	O
of	O	O
increased	O	O
lung	B_Disease	B_Disease
cancer	I_Disease	I_Disease
risk	O	O
at	O	O
high	O	O
levels	O	O
of	O	O
metolachlor	B_Chemical	O
use	O	O
in	O	O
this	O	O
cohort	O	O
was	O	O
not	O	O
confirmed	O	O
in	O	O
this	O	O
update	O	O
.	O	O

This	O	O
suggestion	O	O
of	O	O
an	O	O
association	O	O
between	O	O
metolachlor	B_Chemical	O
and	O	O
liver	B_Disease	B_Disease
cancer	I_Disease	I_Disease
among	O	O
pesticide	O	O
applicators	O	O
is	O	O
a	O	O
novel	O	O
finding	O	O
and	O	O
echoes	O	O
observation	O	O
of	O	O
increased	O	O
liver	B_Disease	O
neoplasms	I_Disease	O
in	O	O
some	O	O
animal	O	O
studies	O	O
.	O	O

However	O	O
,	O	O
our	O	O
findings	O	O
for	O	O
both	O	O
liver	B_Disease	B_Disease
cancer	I_Disease	I_Disease
and	O	O
follicular	O	O
cell	O	O
lymphoma	B_Disease	O
warrant	O	O
follow-up	O	O
to	O	O
better	O	O
differentiate	O	O
effects	O	O
of	O	O
metolachlor	B_Chemical	B_Chemical
use	O	O
from	O	O
other	O	O
factors	O	O
.	O	O

Mechanisms	O	O
Underlying	O	O
Latent	O	O
Disease	O	O
Risk	O	O
Associated	O	O
with	O	O
Early-Life	O	O
Arsenic	O	O
Exposure	O	O
:	O	O
Current	O	O
Research	O	O
Trends	O	O
and	O	O
Scientific	O	O
Gaps	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Millions	O	O
of	O	O
individuals	O	O
worldwide	O	O
,	O	O
particularly	O	O
those	O	O
living	O	O
in	O	O
rural	O	O
and	O	O
developing	O	O
areas	O	O
,	O	O
are	O	O
exposed	O	O
to	O	O
harmful	O	O
levels	O	O
of	O	O
inorganic	B_Chemical	O
arsenic	I_Chemical	O
(	O	O
iAs	B_Chemical	O
)	O	O
in	O	O
their	O	O
drinking	O	O
water	O	O
.	O	O

Inorganic	B_Chemical	O
As	I_Chemical	O
exposure	O	O
during	O	O
key	O	O
developmental	O	O
periods	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
variety	O	O
of	O	O
adverse	O	O
health	O	O
effects	O	O
including	O	O
those	O	O
that	O	O
are	O	O
evident	O	O
in	O	O
adulthood	O	O
.	O	O

There	O	O
is	O	O
considerable	O	O
interest	O	O
in	O	O
identifying	O	O
the	O	O
molecular	O	O
mechanisms	O	O
that	O	O
relate	O	O
early-life	O	O
iAs	B_Chemical	O
exposure	O	O
to	O	O
the	O	O
development	O	O
of	O	O
these	O	O
latent	O	O
diseases	O	O
,	O	O
particularly	O	O
in	O	O
relationship	O	O
to	O	O
cancer	B_Disease	O
.	O	O

OBJECTIVES	O	O
:	O	O
This	O	O
work	O	O
summarizes	O	O
research	O	O
on	O	O
the	O	O
molecular	O	O
mechanisms	O	O
that	O	O
underlie	O	O
the	O	O
increased	O	O
risk	O	O
of	O	O
cancer	B_Disease	O
development	O	O
in	O	O
adulthood	O	O
that	O	O
is	O	O
associated	O	O
with	O	O
early-life	O	O
iAs	B_Chemical	O
exposure	O	O
.	O	O

DISCUSSION	O	O
:	O	O
Epigenetic	O	O
reprogramming	O	O
that	O	O
imparts	O	O
functional	O	O
changes	O	O
in	O	O
gene	O	O
expression	O	O
,	O	O
the	O	O
development	O	O
of	O	O
cancer	B_Disease	O
stem	O	O
cells	O	O
,	O	O
and	O	O
immunomodulation	O	O
are	O	O
plausible	O	O
underlying	O	O
mechanisms	O	O
by	O	O
which	O	O
early-life	O	O
iAs	B_Chemical	O
exposure	O	O
elicits	O	O
latent	O	O
carcinogenic	O	O
effects	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Evidence	O	O
is	O	O
mounting	O	O
that	O	O
relates	O	O
early-life	O	O
iAs	B_Chemical	O
exposure	O	O
and	O	O
cancer	B_Disease	O
development	O	O
later	O	O
in	O	O
life	O	O
.	O	O

Future	O	O
research	O	O
should	O	O
include	O	O
animal	O	O
studies	O	O
that	O	O
address	O	O
mechanistic	O	O
hypotheses	O	O
and	O	O
studies	O	O
of	O	O
human	O	O
populations	O	O
that	O	O
integrate	O	O
early-life	O	O
exposure	O	O
,	O	O
molecular	O	O
alterations	O	O
,	O	O
and	O	O
latent	O	O
disease	O	O
outcomes	O	O
.	O	O

Nifedipine	B_Chemical	O
induced	O	O
bradycardia	B_Disease	O
in	O	O
a	O	O
patient	O	O
with	O	O
autonomic	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
.	O	O

An	O	O
80	O	O
year	O	O
old	O	O
diabetic	B_Disease	O
male	O	O
with	O	O
evidence	O	O
of	O	O
peripheral	B_Disease	O
and	I_Disease	O
autonomic	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
was	O	O
admitted	O	O
with	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
.	O	O

He	O	O
was	O	O
found	O	O
to	O	O
have	O	O
atrial	B_Disease	O
flutter	I_Disease	O
at	O	O
a	O	O
ventricular	O	O
rate	O	O
of	O	O
70/min	O	O
which	O	O
slowed	O	O
down	O	O
to	O	O
30	O	O
-	O	O
40/min	O	O
when	O	O
nifedipine	B_Chemical	O
(	O	O
60	O	O
mg	O	O
)	O	O
in	O	O
3	O	O
divided	O	O
doses	O	O
,	O	O
during	O	O
which	O	O
he	O	O
was	O	O
paced	O	O
at	O	O
a	O	O
rate	O	O
of	O	O
70/min	O	O
.	O	O

This	O	O
is	O	O
inconsistent	O	O
with	O	O
the	O	O
well-established	O	O
finding	O	O
that	O	O
nifedipine	B_Chemical	O
induces	O	O
tachycardia	B_Disease	O
in	O	O
normally	O	O
innervated	O	O
hearts	O	O
.	O	O

However	O	O
,	O	O
in	O	O
hearts	O	O
deprived	O	O
of	O	O
compensatory	O	O
sympathetic	O	O
drive	O	O
,	O	O
it	O	O
may	O	O
lead	O	O
to	O	O
bradycardia	B_Disease	O
.	O	O

The	O	O
effect	O	O
of	O	O
haloperidol	B_Chemical	O
in	O	O
cocaine	B_Chemical	O
and	O	O
amphetamine	B_Chemical	O
intoxication	O	O
.	O	O

The	O	O
effectiveness	O	O
of	O	O
haloperidol	B_Chemical	O
pretreatment	O	O
in	O	O
preventing	O	O
the	O	O
toxic	O	O
effects	O	O
of	O	O
high	O	O
doses	O	O
of	O	O
amphetamine	B_Chemical	O
and	O	O
cocaine	B_Chemical	O
was	O	O
studied	O	O
in	O	O
rats	O	O
.	O	O

In	O	O
this	O	O
model	O	O
,	O	O
toxic	O	O
effects	O	O
were	O	O
induced	O	O
by	O	O
intraperitoneal	O	O
(	O	O
i.p	O	O
.	O	O
)	O	O
injection	O	O
of	O	O
amphetamine	B_Chemical	O
75	O	O
mg/kg	O	O
(	O	O
100	O	O
%	O	O
death	O	O
rate	O	O
)	O	O
or	O	O
cocaine	B_Chemical	O
70	O	O
mg/kg	O	O
(	O	O
82	O	O
%	O	O
death	O	O
rate	O	O
)	O	O
.	O	O

Haloperidol	B_Chemical	O
failed	O	O
to	O	O
prevent	O	O
amphetamine-induced	O	O
seizures	B_Disease	O
,	O	O
but	O	O
did	O	O
lower	O	O
the	O	O
mortality	O	O
rate	O	O
at	O	O
most	O	O
doses	O	O
tested	O	O
.	O	O

Haloperidol	B_Chemical	O
decreased	O	O
the	O	O
incidence	O	O
of	O	O
cocaine-induced	O	O
seizures	B_Disease	O
at	O	O
the	O	O
two	O	O
highest	O	O
doses	O	O
,	O	O
but	O	O
the	O	O
lowering	O	O
of	O	O
the	O	O
mortality	O	O
rate	O	O
did	O	O
not	O	O
reach	O	O
statistical	O	O
significance	O	O
at	O	O
any	O	O
dose	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
a	O	O
protective	O	O
role	O	O
for	O	O
the	O	O
central	O	O
dopamine	B_Chemical	O
blocker	O	O
haloperidol	B_Chemical	O
against	O	O
death	O	O
from	O	O
high-dose	O	O
amphetamine	B_Chemical	O
exposure	O	O
without	O	O
reducing	O	O
the	O	O
incidence	O	O
of	O	O
seizures	B_Disease	O
.	O	O

In	O	O
contrast	O	O
,	O	O
haloperidol	B_Chemical	O
demonstrated	O	O
an	O	O
ability	O	O
to	O	O
reduce	O	O
cocaine-induced	O	O
seizures	B_Disease	O
without	O	O
significantly	O	O
reducing	O	O
mortality	O	O
.	O	O

Autoradiographic	O	O
evidence	O	O
of	O	O
estrogen	B_Chemical	O
binding	O	O
sites	O	O
in	O	O
nuclei	O	O
of	O	O
diethylstilbesterol	B_Chemical	O
induced	O	O
hamster	O	O
renal	B_Disease	O
carcinomas	I_Disease	O
.	O	O

Estrogen	B_Chemical	O
binding	O	O
sites	O	O
were	O	O
demonstrated	O	O
by	O	O
autoradiography	O	O
in	O	O
one	O	O
transplantable	O	O
and	O	O
five	O	O
primary	O	O
diethylstilbesterol	B_Chemical	O
induced	O	O
renal	B_Disease	B_Disease
carcinomas	I_Disease	I_Disease
in	O	O
three	O	O
hamsters	O	O
.	O	O

Radiolabelling	O	O
,	O	O
following	O	O
the	O	O
in	O	O
vivo	O	O
injection	O	O
of	O	O
3H-17	O	B_Chemical
beta	O	I_Chemical
estradiol	B_Chemical	I_Chemical
,	O	O
was	O	O
increased	O	O
only	O	O
over	O	O
the	O	O
nuclei	O	O
of	O	O
tumor	B_Disease	O
cells	O	O
;	O	O
stereologic	O	O
analysis	O	O
revealed	O	O
a	O	O
4.5-	O	O
to	O	O
6.7-times	O	O
higher	O	O
concentration	O	O
of	O	O
reduced	O	O
silver	B_Chemical	O
grains	O	O
over	O	O
nuclei	O	O
than	O	O
cytoplasm	O	O
of	O	O
these	O	O
cells	O	O
.	O	O

Despite	O	O
rapid	O	O
tubular	O	O
excretion	O	O
of	O	O
estradiol	B_Chemical	O
which	O	O
peaked	O	O
in	O	O
less	O	O
than	O	O
1	O	O
h	O	O
,	O	O
the	O	O
normal	O	O
cells	O	O
did	O	O
not	O	O
appear	O	O
to	O	O
bind	O	O
the	O	O
ligand	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
published	O	O
report	O	O
documenting	O	O
the	O	O
preferential	O	O
in	O	O
vivo	O	O
binding	O	O
of	O	O
estrogen	B_Chemical	O
to	O	O
nuclei	O	O
of	O	O
cells	O	O
in	O	O
estrogen	B_Chemical	O
induced	O	O
hamster	O	O
renal	B_Disease	O
carcinomas	I_Disease	O
.	O	O

Bradycardia	B_Disease	O
due	O	O
to	O	O
biperiden	B_Chemical	O
.	O	O

In	O	O
a	O	O
38-year-old	O	O
male	O	O
patient	O	O
suffering	O	O
from	O	O
a	O	O
severe	O	O
postzosteric	B_Disease	O
trigeminal	B_Disease	O
neuralgia	I_Disease	O
,	O	O
intravenous	O	O
application	O	O
of	O	O
10	O	O
mg	O	O
biperiden	B_Chemical	O
lactate	I_Chemical	O
led	O	O
to	O	O
a	O	O
long-lasting	O	O
paradoxical	O	O
reaction	O	O
characterized	O	O
by	O	O
considerable	O	O
bradycardia	B_Disease	O
,	O	O
dysarthria	B_Disease	O
,	O	O
and	O	O
dysphagia	B_Disease	O
.	O	O

The	O	O
heart	O	O
rate	O	O
was	O	O
back	O	O
to	O	O
normal	O	O
within	O	O
12	O	O
hours	O	O
upon	O	O
administration	O	O
of	O	O
orciprenaline	B_Chemical	B_Chemical
under	O	O
cardiac	O	O
monitoring	O	O
in	O	O
an	O	O
intensive	O	O
care	O	O
unit	O	O
.	O	O

Bradycardia	B_Disease	O
induced	O	O
by	O	O
biperiden	B_Chemical	O
is	O	O
attributed	O	O
to	O	O
the	O	O
speed	O	O
of	O	O
injection	O	O
and	O	O
to	O	O
a	O	O
dose-related	O	O
dual	O	O
effect	O	O
of	O	O
atropine-like	O	O
drugs	O	O
on	O	O
muscarine	B_Chemical	O
receptors	O	O
.	O	O

Deliberate	O	O
hypotension	B_Disease	O
induced	O	O
by	O	O
labetalol	B_Chemical	O
with	O	O
halothane	B_Chemical	O
,	O	O
enflurane	B_Chemical	O
or	O	O
isoflurane	B_Chemical	O
for	O	O
middle-ear	O	O
surgery	O	O
.	O	O

The	O	O
feasibility	O	O
of	O	O
using	O	O
labetalol	B_Chemical	O
,	O	O
an	O	O
alpha-	O	B_Chemical
and	O	O
beta-adrenergic	O	O
blocking	O	O
agent	O	O
,	O	O
as	O	O
a	O	O
hypotensive	B_Disease	O
agent	O	O
in	O	O
combination	O	O
with	O	O
inhalation	O	O
anaesthetics	O	O
(	O	O
halothane	B_Chemical	O
,	O	O
enflurane	B_Chemical	O
or	O	O
isoflurane	B_Chemical	O
)	O	O
was	O	O
studied	O	O
in	O	O
23	O	O
adult	O	O
patients	O	O
undergoing	O	O
middle-ear	O	O
surgery	O	O
.	O	O

The	O	O
mean	O	O
arterial	O	O
pressure	O	O
was	O	O
decreased	O	O
from	O	O
86	O	O
+	O	O
/-	O	O
5	O	O
(	O	O
s.e	O	O
.	O	O
mean	O	O
)	O	O
mmHg	O	O
to	O	O
52	O	O
+	O	O
/-	O	O
1	O	O
mmHg	O	O
(	O	O
11.5	O	O
+	O	O
/-	O	O
0.7	O	O
to	O	O
6.9	O	O
+	O	O
/-	O	O
0.1	O	O
kPa	O	O
)	O	O
for	O	O
98	O	O
+	O	O
/-	O	O
10	O	O
min	O	O
in	O	O
the	O	O
halothane	B_Chemical	O
(	O	O
H	B_Chemical	O
)	O	O
group	O	O
,	O	O
from	O	O
79	O	O
+	O	O
/-	O	O
5	O	O
to	O	O
53	O	O
+	O	O
/-	O	O
1	O	O
mmHg	O	O
(	O	O
10.5	O	O
+	O	O
/-	O	O
0.7	O	O
to	O	O
7.1	O	O
+	O	O
/-	O	O
0.1	O	O
kPa	O	O
)	O	O
for	O	O
129	O	O
+	O	O
/-	O	O
11	O	O
min	O	O
in	O	O
the	O	O
enflurane	B_Chemical	O
(	O	O
E	B_Chemical	O
)	O	O
group	O	O
,	O	O
and	O	O
from	O	O
80	O	O
+	O	O
/-	O	O
4	O	O
to	O	O
49	O	O
+	O	O
/-	O	O
1	O	O
mmHg	O	O
(	O	O
10.7	O	O
+	O	O
/-	O	O
0.5	O	O
to	O	O
6.5	O	O
+	O	O
/-	O	O
0.1	O	O
kPa	O	O
)	O	O
for	O	O
135	O	O
+	O	O
/-	O	O
15	O	O
min	O	O
in	O	O
the	O	O
isoflurane	B_Chemical	O
(	O	O
I	B_Chemical	O
)	O	O
group	O	O
.	O	O

The	O	O
mean	O	O
H	B_Chemical	O
concentration	O	O
during	O	O
hypotension	B_Disease	O
in	O	O
the	O	O
inspiratory	O	O
gas	O	O
was	O	O
0.7	O	O
+	O	O
/-	O	O
0.1	O	O
vol%	O	O
,	O	O
the	O	O
mean	O	O
E	B_Chemical	O
concentration	O	O
1.6	O	O
+	O	O
/-	O	O
0.2	O	O
vol%	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
I	B_Chemical	O
concentration	O	O
1.0	O	O
+	O	O
/-	O	O
0.1	O	O
vol%	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
patients	O	O
received	O	O
fentanyl	B_Chemical	O
and	O	O
d-tubocurarine	B_Chemical	B_Chemical
.	O	O

The	O	O
initial	O	O
dose	O	O
of	O	O
labetalol	B_Chemical	O
for	O	O
lowering	O	O
blood	O	O
pressure	O	O
was	O	O
similar	O	O
,	O	O
0.52	O	O
-	O	O
0.59	O	O
mg/kg	O	O
,	O	O
in	O	O
all	O	O
the	O	O
groups	O	O
.	O	O

During	O	O
hypotension	B_Disease	O
,	O	O
the	O	O
heart	O	O
rate	O	O
was	O	O
stable	O	O
without	O	O
tachy-	B_Disease	O
or	I_Disease	O
bradycardia	I_Disease	O
.	O	O

The	O	O
operating	O	O
conditions	O	O
regarding	O	O
bleeding	B_Disease	O
were	O	O
estimated	O	O
in	O	O
a	O	O
double-blind	O	O
manner	O	O
,	O	O
and	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
groups	O	O
.	O	O

During	O	O
hypotension	B_Disease	O
,	O	O
the	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
concentration	O	O
rose	O	O
significantly	O	O
in	O	O
all	O	O
groups	O	O
from	O	O
the	O	O
values	O	O
before	O	O
hypotension	B_Disease	O
and	O	O
returned	O	O
postoperatively	O	O
to	O	O
the	O	O
initial	O	O
level	O	O
in	O	O
the	O	O
other	O	O
groups	O	O
,	O	O
except	O	O
the	O	O
isoflurane	B_Chemical	O
group	O	O
.	O	O

After	O	O
hypotension	B_Disease	O
there	O	O
was	O	O
no	O	O
rebound	O	O
phenomenon	O	O
in	O	O
either	O	O
blood	O	O
pressure	O	O
or	O	O
heart	O	O
rate	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
labetalol	B_Chemical	O
induces	O	O
easily	O	O
adjustable	O	O
hypotension	B_Disease	O
without	O	O
compensatory	O	B_Disease
tachycardia	B_Disease	I_Disease
and	O	O
rebound	O	O
hypertension	B_Disease	O
.	O	O

Convulsion	B_Disease	O
following	O	O
intravenous	O	O
fluorescein	B_Chemical	O
angiography	O	O
.	O	O

Tonic-clonic	B_Disease	O
seizures	I_Disease	O
followed	O	O
intravenous	O	O
fluorescein	B_Chemical	O
injection	O	O
for	O	O
fundus	O	O
angiography	O	O
in	O	O
a	O	O
47-year-old	O	O
male	O	O
.	O	O

Despite	O	O
precautions	O	O
this	O	O
adverse	O	B_Disease
reaction	O	I_Disease
recurred	O	O
on	O	O
re-exposure	O	O
to	O	O
intravenous	O	O
fluorescein	B_Chemical	O
.	O	O

Pharmacology	O	O
of	O	O
ACC-9653	B_Chemical	O
(	O	O
phenytoin	B_Chemical	O
prodrug).ACC-9653	O	O
,	O	O
the	O	O
disodium	B_Chemical	B_Chemical
phosphate	I_Chemical	I_Chemical
ester	I_Chemical	I_Chemical
of	O	O
3-hydroxymethyl-5,5-diphenylhydantoin	B_Chemical	B_Chemical
,	O	O
is	O	O
a	O	O
prodrug	O	O
of	O	O
phenytoin	B_Chemical	O
with	O	O
advantageous	O	O
physicochemical	O	O
properties	O	O
.	O	O

ACC-9653	B_Chemical	O
is	O	O
rapidly	O	O
converted	O	O
enzymatically	O	O
to	O	O
phenytoin	B_Chemical	O
in	O	O
vivo	O	O
.	O	O

ACC-9653	B_Chemical	O
and	O	O
phenytoin	B_Chemical	B_Chemical
sodium	I_Chemical	I_Chemical
have	O	O
equivalent	O	O
anticonvulsant	O	O
activity	O	O
against	O	O
seizures	B_Disease	O
induced	O	O
by	O	O
maximal	O	O
electroshock	O	O
(	O	O
MES	O	O
)	O	O
in	O	O
mice	O	O
following	O	O
i.p	O	O
.	O	O
,	O	O
oral	O	O
,	O	O
or	O	O
i.v	O	O
.	O	O
administration	O	O
.	O	O

The	O	O
ED50	O	O
doses	O	O
were	O	O
16	O	O
mg/kg	O	O
for	O	O
i.v	O	O
.	O	O

ACC-9653	B_Chemical	O
and	O	O
8	O	O
mg/kg	O	O
for	O	O
i.v	O	O
.	O	O

phenytoin	B_Chemical	B_Chemical
sodium	I_Chemical	I_Chemical
.	O	O

ACC-9653	B_Chemical	O
and	O	O
phenytoin	B_Chemical	B_Chemical
sodium	I_Chemical	I_Chemical
have	O	O
similar	O	O
antiarrhythmic	O	O
activity	O	O
against	O	O
ouabain-induced	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
in	O	O
anesthetized	O	O
dogs	O	O
.	O	O

The	O	O
total	O	O
doses	O	O
of	O	O
ACC-9653	B_Chemical	O
or	O	O
phenytoin	B_Chemical	B_Chemical
sodium	I_Chemical	I_Chemical
necessary	O	O
to	O	O
convert	O	O
the	O	O
arrhythmia	B_Disease	O
to	O	O
a	O	O
normal	O	O
sinus	O	B_Disease
rhythm	O	I_Disease
were	O	O
24	O	O
+	O	O
/-	O	O
6	O	O
and	O	O
14	O	O
+	O	O
/-	O	O
3	O	O
mg/kg	O	O
,	O	O
respectively	O	O
.	O	O

Only	O	O
phenytoin	B_Chemical	O
sodium	I_Chemical	O
displayed	O	O
in	O	O
vitro	O	O
antiarrhythmic	O	O
activity	O	O
against	O	O
strophanthidin-induced	O	O
arrhythmias	B_Disease	O
in	O	O
guinea	O	O
pig	O	O
right	O	O
atria	O	O
.	O	O

In	O	O
anesthetized	O	O
dogs	O	O
,	O	O
a	O	O
high	O	O
dose	O	O
of	O	O
ACC-9653	B_Chemical	O
(	O	O
31	O	O
mg/kg	O	O
)	O	O
was	O	O
infused	O	O
over	O	O
15	O	O
,	O	O
20	O	O
,	O	O
and	O	O
30	O	O
min	O	O
and	O	O
the	O	O
responses	O	O
were	O	O
compared	O	O
to	O	O
an	O	O
equimolar	O	O
dose	O	O
of	O	O
phenytoin	B_Chemical	B_Chemical
sodium	I_Chemical	I_Chemical
(	O	O
21	O	O
mg/kg	O	O
)	O	O
.	O	O

The	O	O
ACC-9653	B_Chemical	O
and	O	O
phenytoin	B_Chemical	B_Chemical
sodium	I_Chemical	I_Chemical
treatments	O	O
produced	O	O
similar	O	O
marked	O	O
reductions	O	O
in	O	O
diastolic	O	O
blood	O	O
pressure	O	O
and	O	O
contractile	O	O
force	O	O
(	O	O
LVdP/dt	O	O
)	O	O
.	O	O

The	O	O
maximum	O	O
effects	O	O
of	O	O
each	O	O
treatment	O	O
occurred	O	O
at	O	O
the	O	O
time	O	O
of	O	O
maximum	O	O
phenytoin	B_Chemical	B_Chemical
sodium	I_Chemical	I_Chemical
levels	O	O
.	O	O

Acute	O	O
toxicity	B_Disease	O
studies	O	O
of	O	O
ACC-9653	B_Chemical	O
and	O	O
phenytoin	B_Chemical	B_Chemical
sodium	I_Chemical	I_Chemical
were	O	O
carried	O	O
out	O	O
in	O	O
mice	O	O
,	O	O
rats	O	O
,	O	O
rabbits	O	O
,	O	O
and	O	O
dogs	O	O
by	O	O
i.v	O	O
.	O	O
,	O	O
i.m	O	O
.	O	O
,	O	O
and	O	O
i.p	O	O
.	O	O

routes	O	O
of	O	O
administration	O	O
.	O	O

The	O	O
systemic	O	O
toxic	O	O
signs	O	O
of	O	O
both	O	O
agents	O	O
were	O	O
similar	O	O
and	O	O
occurred	O	O
at	O	O
approximately	O	O
equivalent	O	O
doses	O	O
.	O	O

Importantly	O	O
,	O	O
the	O	O
local	O	O
irritation	O	O
of	O	O
ACC-9653	B_Chemical	O
was	O	O
markedly	O	O
less	O	O
than	O	O
phenytoin	B_Chemical	B_Chemical
sodium	I_Chemical	I_Chemical
following	O	O
i.m	O	O
.	O	O

administration.(ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O

Tachyphylaxis	O	B_Chemical
to	O	O
systemic	O	O
but	O	O
not	O	O
to	O	O
airway	O	O
responses	O	O
during	O	O
prolonged	O	O
therapy	O	O
with	O	O
high	O	O
dose	O	O
inhaled	O	O
salbutamol	B_Chemical	B_Chemical
in	O	O
asthmatics	B_Disease	O
.	O	O

High	O	O
doses	O	O
of	O	O
inhaled	O	O
salbutamol	B_Chemical	B_Chemical
produce	O	O
substantial	O	O
improvements	O	O
in	O	O
airway	O	O
response	O	O
in	O	O
patients	O	O
with	O	O
asthma	B_Disease	O
,	O	O
and	O	O
are	O	O
associated	O	O
with	O	O
dose-dependent	O	O
systemic	O	O
beta-adrenoceptor	O	O
responses	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
tachyphylaxis	O	O
occurs	O	O
during	O	O
prolonged	O	O
treatment	O	O
with	O	O
high	O	O
dose	O	O
inhaled	O	O
salbutamol	B_Chemical	B_Chemical
.	O	O

Twelve	O	O
asthmatic	B_Disease	O
patients	O	O
(	O	O
FEV1	O	O
,	O	O
81	O	O
+	O	O
/-	O	O
4	O	O
%	O	O
predicted	O	O
)	O	O
,	O	O
requiring	O	O
only	O	O
occasional	O	O
inhaled	O	O
beta-agonists	O	O
as	O	O
their	O	O
sole	O	O
therapy	O	O
,	O	O
were	O	O
given	O	O
a	O	O
14-day	O	O
treatment	O	O
with	O	O
high	O	O
dose	O	O
inhaled	O	O
salbutamol	B_Chemical	B_Chemical
(	O	O
HDS	O	O
)	O	O
,	O	O
4,000	O	O
micrograms	O	O
daily	O	O
,	O	O
low	O	O
dose	O	O
inhaled	O	O
salbutamol	B_Chemical	B_Chemical
(	O	O
LDS	O	O
)	O	O
,	O	O
800	O	O
micrograms	O	O
daily	O	O
,	O	O
or	O	O
placebo	O	O
(	O	O
PI	O	O
)	O	O
by	O	O
metered-dose	O	O
inhaler	O	O
in	O	O
a	O	O
double-blind	O	O
,	O	O
randomized	O	O
crossover	O	O
design	O	O
.	O	O

During	O	O
the	O	O
14-day	O	O
run-in	O	O
and	O	O
during	O	O
washout	O	O
periods	O	O
,	O	O
inhaled	O	O
beta-agonists	O	O
were	O	O
withheld	O	O
and	O	O
ipratropium	B_Chemical	B_Chemical
bromide	I_Chemical	I_Chemical
was	O	O
substituted	O	O
for	O	O
rescue	O	O
purposes	O	O
.	O	O

At	O	O
the	O	O
end	O	O
of	O	O
each	O	O
14-day	O	O
treatment	O	O
,	O	O
a	O	O
dose-response	O	O
curve	O	O
(	O	O
DRC	O	O
)	O	O
was	O	O
performed	O	O
,	O	O
and	O	O
airway	O	O
(	O	O
FEV1	O	O
,	O	O
FEF25	O	O
-	O	O
75	O	O
)	O	O
chronotropic	O	O
(	O	O
HR	O	O
)	O	O
,	O	O
tremor	B_Disease	O
,	O	O
and	O	O
metabolic	O	O
(	O	O
K	B_Chemical	O
,	O	O
Glu	B_Chemical	O
)	O	O
responses	O	O
were	O	O
measured	O	O
at	O	O
each	O	O
step	O	O
(	O	O
from	O	O
100	O	O
to	O	O
4,000	O	O
micrograms	O	O
)	O	O
.	O	O

Treatment	O	O
had	O	O
no	O	O
significant	O	O
effect	O	O
on	O	O
baseline	O	O
values	O	O
.	O	O

There	O	O
were	O	O
dose-dependent	O	O
increases	O	O
in	O	O
FEV1	O	O
and	O	O
FEF25	O	O
-	O	O
75	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
,	O	O
and	O	O
pretreatment	O	O
with	O	O
HDS	O	O
did	O	O
not	O	O
displace	O	O
the	O	O
DRC	O	O
to	O	O
the	O	O
right	O	O
.	O	O

DRC	O	O
for	O	O
HR	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
,	O	O
K	B_Chemical	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
,	O	O
and	O	O
Glu	B_Chemical	O
(	O	O
p	O	O
less	O	O
than	O	O
0.005	O	O
)	O	O
were	O	O
attenuated	O	O
after	O	O
treatment	O	O
with	O	O
HDS	O	O
compared	O	O
with	O	O
PI	O	O
.	O	O

There	O	O
were	O	O
also	O	O
differences	O	O
between	O	O
HDS	O	O
and	O	O
LDS	O	O
for	O	O
HR	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
and	O	O
Glu	B_Chemical	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
responses	O	O
.	O	O

Frequency	O	O
and	O	O
severity	O	O
of	O	O
subjective	O	O
adverse	O	O
effects	O	O
were	O	O
also	O	O
reduced	O	O
after	O	O
HDS	O	O
:	O	O
tremor	B_Disease	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
,	O	O
palpitations	B_Disease	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001).(ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O

Phenytoin	B_Chemical	O
induced	O	O
fatal	O	O
hepatic	B_Disease	B_Disease
injury	I_Disease	I_Disease
.	O	O

A	O	O
61	O	O
year	O	O
old	O	O
female	O	O
developed	O	O
fatal	O	O
hepatic	B_Disease	B_Disease
failure	I_Disease	I_Disease
after	O	O
phenytoin	B_Chemical	O
administration	O	O
.	O	O

A	O	O
typical	O	O
multisystem	O	O
clinical	O	O
pattern	O	O
precedes	O	O
the	O	O
manifestations	O	O
of	O	O
hepatic	B_Disease	B_Disease
injury	I_Disease	I_Disease
.	O	O

The	O	O
hematologic	O	O
,	O	O
biochemical	O	O
and	O	O
pathologic	O	O
features	O	O
indicate	O	O
a	O	O
mixed	O	O
hepatocellular	B_Disease	B_Disease
damage	I_Disease	I_Disease
due	O	O
to	O	O
drug	B_Disease	O
hypersensitivity	I_Disease	O
.	O	O

In	O	O
a	O	O
patient	O	O
receiving	O	O
phenytoin	B_Chemical	O
who	O	O
presents	O	O
a	O	O
viral-like	O	O
illness	O	O
,	O	O
early	O	O
recognition	O	O
and	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
are	O	O
mandatory	O	O
.	O	O

Treatment	O	O
of	O	O
lethal	O	O
pertussis	B_Chemical	O
vaccine	I_Chemical	O
reaction	O	O
with	O	O
histamine	B_Chemical	O
H1	O	O
antagonists	O	O
.	O	O

We	O	O
studied	O	O
mortality	O	O
after	O	O
pertussis	B_Disease	O
immunization	O	O
in	O	O
the	O	O
mouse	O	O
.	O	O

Without	O	O
treatment	O	O
,	O	O
73	O	O
of	O	O
92	O	O
animals	O	O
(	O	O
80	O	O
%	O	O
)	O	O
died	O	O
after	O	O
injection	O	O
of	O	O
bovine	O	O
serum	O	O
albumin	O	O
(	O	O
BSA	O	O
)	O	O
on	O	O
day	O	O
+	O	O
7	O	O
of	O	O
pertussis	B_Disease	O
immunization	O	O
.	O	O

After	O	O
pretreatment	O	O
with	O	O
3	O	O
mg	O	O
of	O	O
cyproheptadine	B_Chemical	O
,	O	O
2	O	O
mg	O	O
mianserin	B_Chemical	B_Chemical
,	O	O
or	O	O
2	O	O
mg	O	O
chlorpheniramine	B_Chemical	B_Chemical
,	O	O
only	O	O
5	O	O
of	O	O
105	O	O
animals	O	O
(	O	O
5	O	O
%	O	O
)	O	O
died	O	O
after	O	O
receiving	O	O
BSA	O	O
on	O	O
day	O	O
+	O	O
7	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

Blockade	O	O
of	O	O
histamine	B_Chemical	O
H1	O	O
receptors	O	O
may	O	O
reduce	O	O
mortality	O	O
in	O	O
pertussis	B_Disease	O
immunization-induced	O	O
encephalopathy	B_Disease	O
in	O	O
mice	O	O
.	O	O

Support	O	O
for	O	O
adrenaline-hypertension	O	O
hypothesis	O	O
:	O	O
18	O	O
hour	O	O
pressor	O	O
effect	O	O
after	O	O
6	O	O
hours	O	O
adrenaline	B_Chemical	O
infusion	O	O
.	O	O

In	O	O
a	O	O
double	O	O
blind	O	O
,	O	O
crossover	O	O
study	O	O
6	O	O
h	O	O
infusions	O	O
of	O	O
adrenaline	B_Chemical	O
(	O	O
15	O	O
ng/kg/min	O	O
;	O	O
1	O	O
ng	O	O
=	O	O
5.458	O	O
pmol	O	O
)	O	O
,	O	O
noradrenaline	B_Chemical	O
(	O	O
30	O	O
ng/kg/min	O	O
;	O	O
1	O	O
ng	O	O
=	O	O
5.911	O	O
pmol	O	O
)	O	O
,	O	O
and	O	O
a	O	O
5	O	O
%	O	O
dextrose	B_Chemical	O
solution	O	O
(	O	O
5.4	O	O
ml/h	O	O
)	O	O
,	O	O
were	O	O
given	O	O
to	O	O
ten	O	O
healthy	O	O
volunteers	O	O
in	O	O
random	O	O
order	O	O
2	O	O
weeks	O	O
apart	O	O
.	O	O

By	O	O
means	O	O
of	O	O
intra-arterial	O	O
ambulatory	O	O
monitoring	O	O
the	O	O
haemodynamic	O	O
effects	O	O
were	O	O
followed	O	O
for	O	O
18	O	O
h	O	O
after	O	O
the	O	O
infusions	O	O
were	O	O
stopped	O	O
.	O	O

Adrenaline	B_Chemical	O
,	O	O
but	O	O
not	O	O
noradrenaline	B_Chemical	O
,	O	O
caused	O	O
a	O	O
delayed	O	O
and	O	O
protracted	O	O
pressor	O	O
effect	O	O
.	O	O

Over	O	O
the	O	O
total	O	O
postinfusion	O	O
period	O	O
systolic	O	O
and	O	O
diastolic	O	O
arterial	O	O
pressure	O	O
were	O	O
6	O	O
(	O	O
SEM	O	O
2)%	O	O
and	O	O
7	O	O
(2)%	O	O
,	O	O
respectively	O	O
,	O	O
higher	O	O
than	O	O
after	O	O
dextrose	B_Chemical	O
infusion	O	O
(	O	O
ANOVA	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
.	O	O

Thus	O	O
,	O	O
"	O	O
stress	O	O
"	O	O
levels	O	O
of	O	O
adrenaline	B_Chemical	O
(	O	O
230	O	O
pg/ml	O	O
)	O	O
for	O	O
6	O	O
h	O	O
cause	O	O
a	O	O
delayed	O	O
and	O	O
protracted	O	O
pressor	O	O
effect	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
strong	O	O
support	O	O
for	O	O
the	O	O
adrenaline-hypertension	O	O
hypothesis	O	O
in	O	O
man	O	O
.	O	O

Effect	O	O
of	O	O
alkylxanthines	B_Chemical	B_Chemical
on	O	O
gentamicin-induced	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
in	O	O
the	O	O
rat	O	O
.	O	O

Adenosine	B_Chemical	O
antagonists	O	O
have	O	O
been	O	O
previously	O	O
shown	O	O
to	O	O
be	O	O
of	O	O
benefit	O	O
in	O	O
some	O	O
ischaemic	B_Disease	O
and	O	O
nephrotoxic	B_Disease	O
models	O	O
of	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
(	O	O
ARF	B_Disease	O
)	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
three	O	O
alkylxanthines	B_Chemical	O
with	O	O
different	O	O
potencies	O	O
as	O	O
adenosine	B_Chemical	O
antagonists	O	O
8-phenyltheophylline	B_Chemical	B_Chemical
,	O	O
theophylline	B_Chemical	O
and	O	O
enprofylline	B_Chemical	B_Chemical
,	O	O
were	O	O
examined	O	O
in	O	O
rats	O	O
developing	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
after	O	O
4	O	O
daily	O	O
injections	O	O
of	O	O
gentamicin	B_Chemical	O
(	O	O
200	O	O
mg	O	O
kg-1	O	O
)	O	O
.	O	O

Renal	O	O
function	O	O
was	O	O
assessed	O	O
by	O	O
biochemical	O	O
(	O	O
plasma	O	O
urea	B_Chemical	O
and	O	O
creatinine	B_Chemical	B_Chemical
)	O	O
,	O	O
functional	O	O
(	O	O
urine	O	O
analysis	O	O
and	O	O
[3H]inulin	O	O
and	O	O
[14C]p-aminohippuric	O	B_Chemical
acid	O	I_Chemical
clearances	O	O
)	O	O
and	O	O
morphological	O	O
(	O	O
degree	O	O
of	O	O
necrosis	B_Disease	O
)	O	O
indices	O	O
.	O	O

The	O	O
various	O	O
drug	O	O
treatments	O	O
produced	O	O
improvements	O	O
in	O	O
some	O	O
,	O	O
but	O	O
not	O	O
all	O	O
,	O	O
measurements	O	O
of	O	O
renal	O	O
function	O	O
.	O	O

However	O	O
,	O	O
any	O	O
improvement	O	O
produced	O	O
by	O	O
drug	O	O
treatment	O	O
was	O	O
largely	O	O
a	O	O
result	O	O
of	O	O
a	O	O
beneficial	O	O
effect	O	O
exerted	O	O
by	O	O
its	O	O
vehicle	O	O
(	O	O
polyethylene	B_Chemical	B_Chemical
glycol	I_Chemical	I_Chemical
and	O	O
NaOH	B_Chemical	O
)	O	O
.	O	O

The	O	O
lack	O	O
of	O	O
any	O	O
consistent	O	O
protective	O	O
effect	O	O
noted	O	O
with	O	O
the	O	O
alkylxanthines	B_Chemical	O
tested	O	O
in	O	O
the	O	O
present	O	O
study	O	O
indicates	O	O
that	O	O
adenosine	B_Chemical	O
plays	O	O
little	O	O
,	O	O
if	O	O
any	O	O
,	O	O
pathophysiological	O	O
role	O	O
in	O	O
gentamicin-induced	O	O
ARF	B_Disease	O
.	O	O

Adverse	O	B_Disease
ocular	O	I_Disease
reactions	O	I_Disease
possibly	O	O
associated	O	O
with	O	O
isotretinoin	O	O
.	O	O

A	O	O
total	O	O
of	O	O
261	O	O
adverse	O	O
ocular	O	O
reactions	O	O
occurred	O	O
in	O	O
237	O	O
patients	O	O
who	O	O
received	O	O
isotretinoin	B_Chemical	O
,	O	O
a	O	O
commonly	O	O
used	O	O
drug	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
severe	O	O
cystic	O	O
acne	B_Disease	O
.	O	O

Blepharoconjunctivitis	B_Disease	O
,	O	O
subjective	O	B_Disease
complaints	O	I_Disease
of	O	O
dry	B_Disease	O
eyes	I_Disease	O
,	O	O
blurred	B_Disease	O
vision	I_Disease	O
,	O	O
contact	O	O
lens	O	O
intolerance	O	O
,	O	O
and	O	O
photodermatitis	B_Disease	O
are	O	O
reversible	O	O
side	O	O
effects	O	O
.	O	O

More	O	O
serious	O	O
ocular	O	O
adverse	O	O
reactions	O	O
include	O	O
papilledema	B_Disease	O
,	O	O
pseudotumor	B_Disease	O
cerebri	I_Disease	O
,	O	O
and	O	O
white	O	O
or	O	O
gray	O	O
subepithelial	O	O
corneal	B_Disease	O
opacities	I_Disease	O
;	O	O
all	O	O
of	O	O
these	O	O
are	O	O
reversible	O	O
if	O	O
the	O	O
drug	O	O
is	O	O
discontinued	O	O
.	O	O

Reported	O	O
cases	O	O
of	O	O
decreased	O	O
dark	O	O
adaptation	O	O
are	O	O
under	O	O
investigation	O	O
.	O	O

Isotretinoin	B_Chemical	O
is	O	O
contraindicated	O	O
in	O	O
pregnancy	O	O
because	O	O
of	O	O
the	O	O
many	O	O
reported	O	O
congenital	B_Disease	O
abnormalities	I_Disease	O
after	O	O
maternal	O	O
use	O	O
(	O	O
including	O	O
microphthalmos	B_Disease	O
,	O	O
orbital	O	O
hypertelorism	B_Disease	O
,	O	O
and	O	O
optic	B_Disease	O
nerve	I_Disease	O
hypoplasia	I_Disease	O
)	O	O
.	O	O

Procaterol	B_Chemical	B_Chemical
and	O	O
terbutaline	B_Chemical	B_Chemical
in	O	O
bronchial	B_Disease	B_Disease
asthma	I_Disease	I_Disease
.	O	O

A	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
,	O	O
cross-over	O	O
study	O	O
.	O	O

Procaterol	B_Chemical	B_Chemical
,	O	O
a	O	O
new	O	O
beta-2	O	O
adrenoceptor	O	O
stimulant	O	O
,	O	O
was	O	O
studied	O	O
in	O	O
a	O	O
double-blind	O	O
,	O	O
placebo-controlled	O	O
,	O	O
cross-over	O	O
trial	O	O
in	O	O
patients	O	O
with	O	O
bronchial	B_Disease	B_Disease
asthma	I_Disease	I_Disease
.	O	O

Oral	O	O
procaterol	B_Chemical	B_Chemical
50	O	O
micrograms	O	O
b.d	O	O
.	O	O
,	O	O
procaterol	B_Chemical	O
100	O	O
micrograms	O	O
b.d	O	O
.	O	O
,	O	O
and	O	O
terbutaline	B_Chemical	B_Chemical
5	O	O
mg	O	O
t.i.d	O	O
.	O	O
,	O	O
were	O	O
compared	O	O
when	O	O
given	O	O
randomly	O	O
in	O	O
1-week	O	O
treatment	O	O
periods	O	O
.	O	O

The	O	O
best	O	O
clinical	O	O
effect	O	O
was	O	O
found	O	O
with	O	O
terbutaline	B_Chemical	B_Chemical
.	O	O

Both	O	O
anti-asthmatic	O	O
and	O	O
tremorgenic	B_Disease	O
effects	O	O
of	O	O
procaterol	B_Chemical	B_Chemical
were	O	O
dose-related	O	O
.	O	O

Procaterol	B_Chemical	B_Chemical
appeared	O	O
effective	O	O
in	O	O
the	O	O
doses	O	O
tested	O	O
,	O	O
and	O	O
a	O	O
twice	O	O
daily	O	O
regimen	O	O
would	O	O
appear	O	O
to	O	O
be	O	O
suitable	O	O
with	O	O
this	O	O
drug	O	O
.	O	O

Subacute	O	O
effects	O	O
of	O	O
propranolol	B_Chemical	B_Chemical
and	O	O
B	O	O
24/76	O	O
on	O	O
isoproterenol-induced	O	O
rat	O	O
heart	B_Disease	B_Disease
hypertrophy	I_Disease	I_Disease
in	O	O
correlation	O	O
with	O	O
blood	O	O
pressure	O	O
.	O	O

We	O	O
compared	O	O
the	O	O
potential	O	O
beta-receptor	O	O
blocker	O	O
,	O	O
B	O	O
24/76	O	O
i.e.	O	O
1-(2,4-dichlorophenoxy)-3[2	O	B_Chemical
-	O	I_Chemical
3,4-dimethoxyphenyl)ethanolamino]-prop	O	I_Chemical
an-2-ol	O	I_Chemical
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
beta	O	O
1-adrenoceptor	O	O
blocking	O	O
and	O	O
beta	O	O
2-adrenoceptor	O	O
stimulating	O	O
properties	O	O
with	O	O
propranolol	B_Chemical	B_Chemical
.	O	O

The	O	O
studies	O	O
were	O	O
performed	O	O
using	O	O
an	O	O
experimental	O	O
model	O	O
of	O	O
isoproterenol-induced	O	O
heart	B_Disease	B_Disease
hypertrophy	I_Disease	I_Disease
in	O	O
rats	O	O
.	O	O

A	O	O
correlation	O	O
of	O	O
the	O	O
blood	O	O
pressure	O	O
was	O	O
neither	O	O
found	O	O
in	O	O
the	O	O
development	O	O
nor	O	O
in	O	O
the	O	O
attempt	O	O
to	O	O
suppress	O	O
the	O	O
development	O	O
of	O	O
heart	B_Disease	B_Disease
hypertrophy	I_Disease	I_Disease
with	O	O
the	O	O
two	O	O
beta-receptor	O	O
blockers	O	O
.	O	O

Both	O	O
beta-blockers	O	O
influenced	O	O
the	O	O
development	O	O
of	O	O
hypertrophy	B_Disease	O
to	O	O
a	O	O
different	O	O
,	O	O
but	O	O
not	O	O
reproducible	O	O
extent	O	O
.	O	O

It	O	O
was	O	O
possible	O	O
to	O	O
suppress	O	O
the	O	O
increased	O	O
ornithine	B_Chemical	O
decarboxylase	O	O
activity	O	O
with	O	O
both	O	O
beta-blockers	O	O
in	O	O
hypertrophied	B_Disease	O
hearts	I_Disease	O
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
heart	O	O
mass	O	O
.	O	O

Neither	O	O
propranolol	B_Chemical	B_Chemical
nor	O	O
B	O	O
24/76	O	O
could	O	O
stop	O	O
the	O	O
changes	O	O
in	O	O
the	O	O
characteristic	O	O
myosin	O	O
isoenzyme	O	O
pattern	O	O
of	O	O
the	O	O
hypertrophied	B_Disease	O
rat	O	O
heart	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
investigations	O	O
did	O	O
not	O	O
provide	O	O
any	O	O
evidence	O	O
that	O	O
the	O	O
beta-receptor	O	O
blockers	O	O
propranolol	B_Chemical	B_Chemical
and	O	O
B	O	O
24/76	O	O
have	O	O
the	O	O
potency	O	O
to	O	O
prevent	O	O
isoproterenol	B_Chemical	O
from	O	O
producing	O	O
heart	B_Disease	B_Disease
hypertrophy	I_Disease	I_Disease
.	O	O

Increased	O	O
anxiogenic	O	O
effects	O	O
of	O	O
caffeine	B_Chemical	O
in	O	O
panic	B_Disease	B_Disease
disorders	I_Disease	I_Disease
.	O	O

The	O	O
effects	O	O
of	O	O
oral	O	O
administration	O	O
of	O	O
caffeine	B_Chemical	O
(	O	O
10	O	O
mg/kg	O	O
)	O	O
on	O	O
behavioral	O	O
ratings	O	O
,	O	O
somatic	O	O
symptoms	O	O
,	O	O
blood	O	O
pressure	O	O
and	O	O
plasma	O	O
levels	O	O
of	O	O
3-methoxy-4-hydroxyphenethyleneglycol	B_Chemical	B_Chemical
(	O	O
MHPG	B_Chemical	O
)	O	O
and	O	O
cortisol	B_Chemical	O
were	O	O
determined	O	O
in	O	O
17	O	O
healthy	O	O
subjects	O	O
and	O	O
21	O	O
patients	O	O
meeting	O	O
DSM-III	O	O
criteria	O	O
for	O	O
agoraphobia	B_Disease	O
with	O	O
panic	B_Disease	B_Disease
attacks	I_Disease	I_Disease
or	O	O
panic	B_Disease	O
disorder	I_Disease	O
.	O	O

Caffeine	B_Chemical	O
produced	O	O
significantly	O	O
greater	O	O
increases	O	O
in	O	O
subject-rated	O	O
anxiety	B_Disease	O
,	O	O
nervousness	O	O
,	O	O
fear	O	O
,	O	O
nausea	B_Disease	O
,	O	O
palpitations	B_Disease	O
,	O	O
restlessness	B_Disease	O
,	O	O
and	O	O
tremors	B_Disease	O
in	O	O
the	O	O
patients	O	O
compared	O	O
with	O	O
healthy	O	O
subjects	O	O
.	O	O

In	O	O
the	O	O
patients	O	O
,	O	O
but	O	O
not	O	O
the	O	O
healthy	O	O
subjects	O	O
,	O	O
these	O	O
symptoms	O	O
were	O	O
significantly	O	O
correlated	O	O
with	O	O
plasma	O	O
caffeine	B_Chemical	O
levels	O	O
.	O	O

Seventy-one	O	O
percent	O	O
of	O	O
the	O	O
patients	O	O
reported	O	O
that	O	O
the	O	O
behavioral	O	O
effects	O	O
of	O	O
caffeine	B_Chemical	O
were	O	O
similar	O	O
to	O	O
those	O	O
experienced	O	O
during	O	O
panic	B_Disease	O
attacks	I_Disease	O
.	O	O

Caffeine	B_Chemical	O
did	O	O
not	O	O
alter	O	O
plasma	O	O
MHPG	B_Chemical	O
levels	O	O
in	O	O
either	O	O
the	O	O
healthy	O	O
subjects	O	O
or	O	O
patients	O	O
.	O	O

Caffeine	B_Chemical	O
increased	O	O
plasma	O	O
cortisol	B_Chemical	O
levels	O	O
equally	O	O
in	O	O
the	O	O
patient	O	O
and	O	O
healthy	O	O
groups	O	O
.	O	O

Because	O	O
caffeine	B_Chemical	O
is	O	O
an	O	O
adenosine	B_Chemical	O
receptor	O	O
antagonist	O	O
,	O	O
these	O	O
results	O	O
suggest	O	O
that	O	O
some	O	O
panic	B_Disease	O
disorder	I_Disease	O
patients	O	O
may	O	O
have	O	O
abnormalities	B_Disease	O
in	I_Disease	O
neuronal	I_Disease	O
systems	I_Disease	O
involving	O	O
adenosine	B_Chemical	O
.	O	O

Patients	O	O
with	O	O
anxiety	B_Disease	B_Disease
disorders	I_Disease	I_Disease
may	O	O
benefit	O	O
by	O	O
avoiding	O	O
caffeine-containing	O	O
foods	O	O
and	O	O
beverages	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
effect	O	O
of	O	O
oxitropium	B_Chemical	B_Chemical
bromide	I_Chemical	I_Chemical
and	O	O
of	O	O
slow-release	O	O
theophylline	B_Chemical	O
on	O	O
nocturnal	O	O
asthma	B_Disease	O
.	O	O

The	O	O
effects	O	O
of	O	O
a	O	O
new	O	O
inhaled	O	O
antimuscarinic	O	O
drug	O	O
,	O	O
oxitropium	B_Chemical	B_Chemical
bromide	I_Chemical	I_Chemical
,	O	O
and	O	O
of	O	O
a	O	O
slow-release	O	O
theophylline	B_Chemical	O
preparation	O	O
upon	O	O
nocturnal	O	O
asthma	B_Disease	O
were	O	O
compared	O	O
in	O	O
a	O	O
placebo-controlled	O	O
double-blind	O	O
study	O	O
.	O	O

Two	O	O
samples	O	O
were	O	O
studied	O	O
:	O	O
12	O	O
patients	O	O
received	O	O
oxitropium	B_Chemical	O
at	O	O
600	O	O
micrograms	O	O
(	O	O
6	O	O
subjects	O	O
)	O	O
or	O	O
at	O	O
400	O	O
micrograms	O	O
t.i.d	O	O
.	O	O
(	O	O
6	O	O
subjects	O	O
)	O	O
whereas	O	O
11	O	O
received	O	O
theophylline	B_Chemical	O
at	O	O
300	O	O
mg	O	O
b.i.d	O	O
.	O	O

Morning	O	O
dipping	O	O
,	O	O
assessed	O	O
by	O	O
the	O	O
fall	O	O
in	O	O
peak	O	O
flow	O	O
overnight	O	O
,	O	O
was	O	O
significantly	O	O
reduced	O	O
in	O	O
the	O	O
periods	O	O
when	O	O
either	O	O
active	O	O
drug	O	O
was	O	O
taken	O	O
,	O	O
whereas	O	O
no	O	O
difference	O	O
was	O	O
noticed	O	O
during	O	O
the	O	O
placebo	O	O
administration	O	O
.	O	O

No	O	O
significant	O	O
difference	O	O
was	O	O
noticed	O	O
between	O	O
results	O	O
obtained	O	O
with	O	O
either	O	O
active	O	O
drug	O	O
,	O	O
as	O	O
well	O	O
as	O	O
with	O	O
either	O	O
dosage	O	O
of	O	O
oxitropium	B_Chemical	O
.	O	O

No	O	O
subject	O	O
reported	O	O
side	O	O
effects	O	O
of	O	O
oxitropium	B_Chemical	B_Chemical
,	O	O
as	O	O
compared	O	O
to	O	O
three	O	O
subjects	O	O
reporting	O	O
nausea	B_Disease	O
,	O	O
vomiting	B_Disease	O
and	O	O
tremors	B_Disease	O
after	O	O
theophylline	B_Chemical	O
.	O	O

Oxitropium	B_Chemical	B_Chemical
proves	O	O
to	O	O
be	O	O
a	O	O
valuable	O	O
alternative	O	O
to	O	O
theophylline	B_Chemical	O
in	O	O
nocturnal	O	O
asthma	B_Disease	O
,	O	O
since	O	O
it	O	O
is	O	O
equally	O	O
potent	O	O
,	O	O
safer	O	O
and	O	O
does	O	O
not	O	O
require	O	O
the	O	O
titration	O	O
of	O	O
dosage	O	O
.	O	O

Penicillin	B_Chemical	O
anaphylaxis	B_Disease	O
.	O	O

A	O	O
case	O	O
of	O	O
oral	O	O
penicillin	B_Chemical	O
anaphylaxis	B_Disease	O
is	O	O
described	O	O
,	O	O
and	O	O
the	O	O
terminology	O	O
,	O	O
occurrence	O	O
,	O	O
clinical	O	O
manifestations	O	O
,	O	O
pathogenesis	O	O
,	O	O
prevention	O	O
,	O	O
and	O	O
treatment	O	O
of	O	O
anaphylaxis	B_Disease	O
are	O	O
reviewed	O	O
.	O	O

Emergency	O	O
physicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
oral	O	O
penicillin	B_Chemical	O
anaphylaxis	B_Disease	O
in	O	O
order	O	O
to	O	O
prevent	O	O
its	O	O
occurrence	O	O
by	O	O
prescribing	O	O
the	O	O
antibiotic	O	O
judiciously	O	O
and	O	O
knowledgeably	O	O
and	O	O
to	O	O
offer	O	O
optimal	O	O
medical	O	O
therapy	O	O
once	O	O
this	O	O
life-threatening	O	O
reaction	O	O
has	O	O
begun	O	O
.	O	O

Reversible	O	O
valproic	O	O
acid-induced	O	O
dementia	B_Disease	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

Reversible	O	O
valproic	O	O
acid-induced	O	O
dementia	B_Disease	O
was	O	O
documented	O	O
in	O	O
a	O	O
21-year-old	O	O
man	O	O
with	O	O
epilepsy	B_Disease	O
who	O	O
had	O	O
a	O	O
3-year	O	O
history	O	O
of	O	O
insidious	O	O
progressive	O	O
decline	O	O
in	O	O
global	O	O
cognitive	O	O
abilities	O	O
documented	O	O
by	O	O
serial	O	O
neuropsychological	O	O
studies	O	O
.	O	O

Repeat	O	O
neuropsychological	O	O
testing	O	O
7	O	O
weeks	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
revealed	O	O
dramatic	O	O
improvement	O	O
in	O	O
IQ	O	O
,	O	O
memory	O	O
,	O	O
naming	O	O
,	O	O
and	O	O
other	O	O
tasks	O	O
commensurate	O	O
with	O	O
clinical	O	O
recovery	O	O
in	O	O
his	O	O
intellectual	O	O
capacity	O	O
.	O	O

Possible	O	O
pathophysiological	O	O
mechanisms	O	O
which	O	O
may	O	O
have	O	O
been	O	O
operative	O	O
in	O	O
this	O	O
case	O	O
include	O	O
:	O	O
a	O	O
direct	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
toxic	O	O
effect	O	O
of	O	O
valproic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
;	O	O
a	O	O
paradoxical	O	O
epileptogenic	O	O
effect	O	O
secondary	O	O
to	O	O
the	O	O
drug	O	O
;	O	O
and	O	O
an	O	O
indirect	O	O
CNS	O	O
toxic	O	O
effect	O	O
mediated	O	O
through	O	O
valproic	O	O
acid-induced	O	O
hyperammonemia	B_Disease	B_Disease
.	O	O

Reversal	O	O
of	O	O
scopolamine-induced	O	O
amnesia	B_Disease	O
of	O	O
passive	O	O
avoidance	O	O
by	O	O
pre-	O	O
and	O	O
post-training	O	O
naloxone	B_Chemical	O
.	O	O

In	O	O
a	O	O
series	O	O
of	O	O
five	O	O
experiments	O	O
,	O	O
the	O	O
modulating	O	O
role	O	O
of	O	O
naloxone	B_Chemical	O
on	O	O
a	O	O
scopolamine-induced	O	O
retention	B_Disease	O
deficit	I_Disease	O
in	O	O
a	O	O
passive	O	O
avoidance	O	O
paradigm	O	O
was	O	O
investigated	O	O
in	O	O
mice	O	O
.	O	O

Scopolamine	B_Chemical	O
,	O	O
but	O	O
not	O	O
methyl	B_Chemical	B_Chemical
scopolamine	I_Chemical	I_Chemical
(	O	O
1	O	O
and	O	O
3	O	O
mg/kg	O	O
)	O	O
,	O	O
induced	O	O
an	O	O
amnesia	B_Disease	O
as	O	O
measured	O	O
by	O	O
latency	O	O
and	O	O
duration	O	O
parameters	O	O
.	O	O

Naloxone	B_Chemical	O
(	O	O
0.3	O	O
,	O	O
1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
10	O	O
mg/kg	O	O
)	O	O
injected	O	O
prior	O	O
to	O	O
training	O	O
attenuated	O	O
the	O	O
retention	B_Disease	O
deficit	I_Disease	O
with	O	O
a	O	O
peak	O	O
of	O	O
activity	O	O
at	O	O
3	O	O
mg/kg	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
naloxone	B_Chemical	O
could	O	O
be	O	O
antagonized	O	O
with	O	O
morphine	B_Chemical	O
(	O	O
1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
10	O	O
mg/kg	O	O
)	O	O
,	O	O
demonstrating	O	O
the	O	O
opioid	O	B_Chemical
specificity	O	O
of	O	O
the	O	O
naloxone	B_Chemical	O
effect	O	O
.	O	O

Post-training	O	O
administration	O	O
of	O	O
naloxone	B_Chemical	O
(	O	O
3	O	O
mg/kg	O	O
)	O	O
as	O	O
a	O	O
single	O	O
or	O	O
as	O	O
a	O	O
split	O	O
dose	O	O
also	O	O
attenuated	O	O
the	O	O
scopolamine-induced	O	O
amnesia	B_Disease	O
.	O	O

Control	O	O
experiments	O	O
indicated	O	O
that	O	O
neither	O	O
an	O	O
increase	O	O
in	O	O
pain	B_Disease	O
sensitivity	O	O
(	O	O
pre-training	O	O
naloxone	B_Chemical	O
)	O	O
nor	O	O
an	O	O
induced	O	O
aversive	O	O
state	O	O
(	O	O
post-training	O	O
naloxone	B_Chemical	O
)	O	O
appear	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
influence	O	O
of	O	O
naloxone	B_Chemical	O
on	O	O
the	O	O
scopolamine-induced	O	O
retention	B_Disease	O
deficit	I_Disease	O
.	O	O

These	O	O
results	O	O
extend	O	O
previous	O	O
findings	O	O
implicating	O	O
a	O	O
cholinergic-opioid	O	O
interaction	O	O
in	O	O
memory	O	O
processes	O	O
.	O	O

A	O	O
possible	O	O
mechanism	O	O
for	O	O
this	O	O
interaction	O	O
involving	O	O
the	O	O
septo-hippocampal	O	O
cholinergic	O	O
pathway	O	O
is	O	O
discussed	O	O
.	O	O

Electron	O	O
microscopic	O	O
investigations	O	O
of	O	O
the	O	O
cyclophosphamide-induced	O	O
lesions	B_Disease	O
of	I_Disease	O
the	I_Disease	O
urinary	I_Disease	O
bladder	I_Disease	O
of	O	O
the	O	O
rat	O	O
and	O	O
their	O	O
prevention	O	O
by	O	O
mesna	B_Chemical	B_Chemical
.	O	O

Fully	O	O
developed	O	O
cyclophosphamide-induced	O	O
cystitis	B_Disease	O
is	O	O
characterized	O	O
by	O	O
nearly	O	O
complete	O	O
detachment	O	O
of	O	O
the	O	O
urothelium	O	O
,	O	O
severe	O	O
submucosal	O	O
edema	B_Disease	O
owing	O	O
to	O	O
damage	O	O
to	O	O
the	O	O
microvascular	O	O
bed	O	O
and	O	O
focal	O	O
muscle	O	O
necroses	B_Disease	O
.	O	O

The	O	O
initial	O	O
response	O	O
to	O	O
the	O	O
primary	O	O
attack	O	O
by	O	O
the	O	O
cyclophosphamide	B_Chemical	B_Chemical
metabolites	O	O
seems	O	O
to	O	O
be	O	O
fragmentation	O	O
of	O	O
the	O	O
luminal	B_Chemical	O
membrane	O	O
.	O	O

This	O	O
damages	O	O
the	O	O
cellular	O	O
barrier	O	O
against	O	O
the	O	O
hypertonic	O	O
urine	O	O
.	O	O

Subsequent	O	O
breaks	O	O
in	O	O
the	O	O
lateral	O	O
cell	O	O
membranes	O	O
of	O	O
the	O	O
superficial	O	O
cells	O	O
and	O	O
in	O	O
all	O	O
the	O	O
plasma	O	O
membranes	O	O
of	O	O
the	O	O
intermediate	O	O
and	O	O
basal	O	O
cells	O	O
,	O	O
intercellular	O	O
and	O	O
intracellular	O	O
edema	B_Disease	O
and	O	O
disintegration	O	O
of	O	O
the	O	O
desmosomes	O	O
and	O	O
hemidesmosomes	O	O
lead	O	O
to	O	O
progressive	O	O
degeneration	O	O
and	O	O
detachment	O	O
of	O	O
the	O	O
epithelial	O	O
cells	O	O
with	O	O
exposure	O	O
and	O	O
splitting	O	O
of	O	O
the	O	O
basal	O	O
membrane	O	O
.	O	O

The	O	O
morphological	O	O
changes	O	O
of	O	O
the	O	O
endothelial	O	O
cells	O	O
,	O	O
which	O	O
become	O	O
more	O	O
pronounced	O	O
in	O	O
the	O	O
later	O	O
stages	O	O
of	O	O
the	O	O
experiment	O	O
,	O	O
the	O	O
involvement	O	O
of	O	O
blood	O	O
vessels	O	O
regardless	O	O
of	O	O
their	O	O
diameter	O	O
and	O	O
the	O	O
location-dependent	O	O
extent	O	O
of	O	O
the	O	O
damage	O	O
indicate	O	O
a	O	O
direct	O	O
type	O	O
of	O	O
damage	O	O
which	O	O
is	O	O
preceded	O	O
by	O	O
a	O	O
mediator-induced	O	O
increase	O	O
in	O	O
permeability	O	O
,	O	O
the	O	O
morphological	O	O
correlate	O	O
of	O	O
which	O	O
is	O	O
the	O	O
formation	O	O
of	O	O
gaps	O	O
in	O	O
the	O	O
interendothelial	O	O
cell	O	O
connections	O	O
on	O	O
the	O	O
venules	O	O
.	O	O

These	O	O
changes	O	O
can	O	O
be	O	O
effectively	O	O
prevented	O	O
by	O	O
mesna	B_Chemical	B_Chemical
.	O	O

The	O	O
only	O	O
sign	O	O
of	O	O
a	O	O
possible	O	O
involvement	O	O
is	O	O
the	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
specific	O	O
granules	O	O
with	O	O
a	O	O
presumed	O	O
lysosomal	O	O
function	O	O
in	O	O
the	O	O
superficial	O	O
cells	O	O
.	O	O

Increase	O	O
in	O	O
intragastric	O	O
pressure	O	O
during	O	O
suxamethonium-induced	O	O
muscle	B_Disease	O
fasciculations	I_Disease	O
in	O	O
children	O	O
:	O	O
inhibition	O	O
by	O	O
alfentanil	B_Chemical	B_Chemical
.	O	O

Changes	O	O
in	O	O
intragastric	O	O
pressure	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
suxamethonium	B_Chemical	B_Chemical
1.5	O	O
mg	O	O
kg-1	O	O
i.v	O	O
.	O	O
were	O	O
studied	O	O
in	O	O
32	O	O
children	O	O
(	O	O
mean	O	O
age	O	O
6.9	O	O
yr	O	O
)	O	O
pretreated	O	O
with	O	O
either	O	O
physiological	O	O
saline	O	O
or	O	O
alfentanil	B_Chemical	B_Chemical
50	O	O
micrograms	O	O
kg-1	O	O
.	O	O

Anaesthesia	O	O
was	O	O
induced	O	O
with	O	O
thiopentone	B_Chemical	B_Chemical
5	O	O
mg	O	O
kg-1	O	O
.	O	O

The	O	O
incidence	O	O
and	O	O
intensity	O	O
of	O	O
muscle	B_Disease	O
fasciculations	I_Disease	O
caused	O	O
by	O	O
suxamethonium	B_Chemical	B_Chemical
were	O	O
significantly	O	O
greater	O	O
in	O	O
the	O	O
control	O	O
than	O	O
in	O	O
the	O	O
alfentanil	B_Chemical	B_Chemical
group	O	O
.	O	O

The	O	O
intragastric	O	O
pressure	O	O
during	O	O
muscle	B_Disease	O
fasciculations	I_Disease	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
control	O	O
group	O	O
(	O	O
16	O	O
+	O	O
/-	O	O
0.7	O	O
(	O	O
SEM	O	O
)	O	O
cm	O	O
H2O	B_Chemical	O
)	O	O
than	O	O
in	O	O
the	O	O
alfentanil	B_Chemical	B_Chemical
group	O	O
(	O	O
7.7	O	O
+	O	O
/-	O	O
1.5	O	O
(	O	O
SEM	O	O
)	O	O
cm	O	O
H2O	B_Chemical	O
)	O	O
.	O	O

The	O	O
increase	O	O
in	O	O
intragastric	O	O
pressure	O	O
was	O	O
directly	O	O
related	O	O
to	O	O
the	O	O
intensity	O	O
of	O	O
muscle	B_Disease	O
fasciculations	I_Disease	O
(	O	O
regression	O	O
line	O	O
:	O	O
y	O	O
=	O	O
0.5	O	O
+	O	O
4.78x	O	O
with	O	O
r	O	O
of	O	O
0.78	O	O
)	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
intragastric	O	O
pressure	O	O
increases	O	O
significantly	O	O
during	O	O
muscle	B_Disease	O
fasciculations	I_Disease	O
caused	O	O
by	O	O
suxamethonium	B_Chemical	B_Chemical
in	O	O
healthy	O	O
children	O	O
.	O	O

Alfentanil	B_Chemical	B_Chemical
50	O	O
micrograms	O	O
kg-1	O	O
effectively	O	O
inhibits	O	O
the	O	O
incidence	O	O
and	O	O
intensity	O	O
of	O	O
suxamethonium-induced	O	O
muscle	B_Disease	O
fasciculations	I_Disease	O
;	O	O
moreover	O	O
,	O	O
intragastric	O	O
pressure	O	O
remains	O	O
at	O	O
its	O	O
control	O	O
value	O	O
.	O	O

Acute	O	O
insulin	O	O
treatment	O	O
normalizes	O	O
the	O	O
resistance	O	O
to	O	O
the	O	O
cardiotoxic	B_Disease	B_Disease
effect	O	O
of	O	O
isoproterenol	B_Chemical	O
in	O	O
streptozotocin	B_Chemical	O
diabetic	B_Disease	O
rats	O	O
.	O	O

A	O	O
morphometric	O	O
study	O	O
of	O	O
isoproterenol	B_Chemical	O
induced	O	O
myocardial	O	B_Disease
fibrosis	B_Disease	I_Disease
.	O	O

The	O	O
acute	O	O
effect	O	O
of	O	O
insulin	O	O
treatment	O	O
on	O	O
the	O	O
earlier	O	O
reported	O	O
protective	O	O
effect	O	O
of	O	O
streptozotocin	B_Chemical	O
diabetes	B_Disease	O
against	O	O
the	O	O
cardiotoxic	B_Disease	B_Disease
effect	O	O
of	O	O
high	O	O
doses	O	O
of	O	O
isoproterenol	B_Chemical	O
(	O	O
ISO	B_Chemical	O
)	O	O
was	O	O
investigated	O	O
in	O	O
rats	O	O
.	O	O

Thirty	O	O
to	O	O
135	O	O
min	O	O
after	O	O
the	O	O
injection	O	O
of	O	O
crystalline	O	O
insulin	O	O
,	O	O
ISO	B_Chemical	O
was	O	O
given	O	O
subcutaneously	O	O
and	O	O
when	O	O
ISO	B_Chemical	O
induced	O	O
fibrosis	B_Disease	O
in	O	O
the	O	O
myocardium	O	O
was	O	O
morphometrically	O	O
analyzed	O	O
7	O	O
days	O	O
later	O	O
,	O	O
a	O	O
highly	O	O
significant	O	O
correlation	O	O
(	O	O
r	O	O
=	O	O
0.83	O	O
,	O	O
2	O	O
p	O	O
=	O	O
0.006	O	O
)	O	O
to	O	O
the	O	O
slope	O	O
of	O	O
the	O	O
fall	O	O
in	O	O
blood	O	O
glucose	B_Chemical	O
after	O	O
insulin	O	O
treatment	O	O
appeared	O	O
.	O	O

The	O	O
myocardial	O	O
content	O	O
of	O	O
catecholamines	B_Chemical	O
was	O	O
estimated	O	O
in	O	O
these	O	O
8	O	O
day	O	O
diabetic	B_Disease	O
rats	O	O
.	O	O

The	O	O
norepinephrine	B_Chemical	O
content	O	O
was	O	O
significantly	O	O
increased	O	O
while	O	O
epinephrine	B_Chemical	O
remained	O	O
unchanged	O	O
.	O	O

An	O	O
enhanced	O	O
sympathetic	O	O
nervous	O	O
system	O	O
activity	O	O
with	O	O
a	O	O
consequent	O	O
down	O	O
regulation	O	O
of	O	O
the	O	O
myocardial	O	O
beta-adrenergic	O	O
receptors	O	O
could	O	O
,	O	O
therefore	O	O
,	O	O
explain	O	O
this	O	O
catecholamine	B_Chemical	O
resistance	O	O
.	O	O

The	O	O
rapid	O	O
reversion	O	O
after	O	O
insulin	O	O
treatment	O	O
excludes	O	O
the	O	O
possibility	O	O
that	O	O
streptozotocin	B_Chemical	B_Chemical
in	O	O
itself	O	O
causes	O	O
the	O	O
ISO	B_Chemical	O
resistance	O	O
and	O	O
points	O	O
towards	O	O
a	O	O
direct	O	O
insulin	O	O
effect	O	O
on	O	O
myocardial	O	O
catecholamine	B_Chemical	O
sensitivity	O	O
in	O	O
diabetic	B_Disease	O
rats	O	O
.	O	O

The	O	O
phenomenon	O	O
described	O	O
might	O	O
elucidate	O	O
pathogenetic	O	O
mechanisms	O	O
behind	O	O
toxic	O	O
myocardial	O	O
cell	O	O
degeneration	O	O
and	O	O
may	O	O
possibly	O	O
have	O	O
relevance	O	O
for	O	O
acute	O	B_Disease
cardiovascular	O	I_Disease
complications	O	I_Disease
in	O	O
diabetic	B_Disease	O
patients	O	O
.	O	O

Differential	O	O
effects	O	O
of	O	O
non-steroidal	O	O
anti-inflammatory	O	O
drugs	O	O
on	O	O
seizures	B_Disease	O
produced	O	O
by	O	O
pilocarpine	B_Chemical	O
in	O	O
rats	O	O
.	O	O

The	O	O
muscarinic	O	O
cholinergic	O	O
agonist	O	O
pilocarpine	B_Chemical	O
induces	O	O
in	O	O
rats	O	O
seizures	B_Disease	O
and	O	O
status	B_Disease	O
epilepticus	I_Disease	O
followed	O	O
by	O	O
widespread	O	O
damage	O	O
to	O	O
the	O	O
forebrain	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
5	O	O
non-steroidal	O	O
anti-inflammatory	O	O
drugs	O	O
,	O	O
sodium	B_Chemical	B_Chemical
salicylate	I_Chemical	I_Chemical
,	O	O
phenylbutazone	B_Chemical	O
,	O	O
indomethacin	B_Chemical	O
,	O	O
ibuprofen	B_Chemical	O
and	O	O
mefenamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
,	O	O
on	O	O
seizures	B_Disease	O
produced	O	O
by	O	O
pilocarpine	B_Chemical	O
.	O	O

Pretreatment	O	O
of	O	O
rats	O	O
with	O	O
sodium	B_Chemical	B_Chemical
salicylate	I_Chemical	I_Chemical
,	O	O
ED50	O	O
103	O	O
mg/kg	O	O
(	O	O
60	O	O
-	O	O
174	O	O
)	O	O
,	O	O
and	O	O
phenylbutazone	B_Chemical	O
,	O	O
59	O	O
mg/kg	O	O
(	O	O
50	O	O
-	O	O
70	O	O
)	O	O
converted	O	O
the	O	O
non-convulsant	O	O
dose	O	O
of	O	O
pilocarpine	B_Chemical	O
,	O	O
200	O	O
mg/kg	O	O
,	O	O
to	O	O
a	O	O
convulsant	O	O
one	O	O
.	O	O

Indomethacin	B_Chemical	O
,	O	O
1	O	O
-	O	O
10	O	O
mg/kg	O	O
,	O	O
and	O	O
ibuprofen	B_Chemical	O
,	O	O
10	O	O
-	O	O
100	O	O
mg/kg	O	O
,	O	O
failed	O	O
to	O	O
modulate	O	O
seizures	B_Disease	O
produced	O	O
by	O	O
pilocarpine	B_Chemical	O
.	O	O

Mefenamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
,	O	O
26	O	O
(	O	O
22	O	O
-	O	O
30	O	O
)	O	O
mg/kg	O	O
,	O	O
prevented	O	O
seizures	B_Disease	O
and	O	O
protected	O	O
rats	O	O
from	O	O
seizure-related	O	O
brain	B_Disease	B_Disease
damage	I_Disease	I_Disease
induced	O	O
by	O	O
pilocarpine	B_Chemical	O
,	O	O
380	O	O
mg/kg	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
non-steroidal	O	O
anti-inflammatory	O	O
drugs	O	O
differentially	O	O
modulate	O	O
the	O	O
threshold	O	O
for	O	O
pilocarpine-induced	O	O
seizures	B_Disease	O
.	O	O

Acute	B_Disease	O
neurologic	I_Disease	B_Disease
dysfunction	I_Disease	I_Disease
after	O	O
high-dose	O	B_Chemical
etoposide	B_Chemical	I_Chemical
therapy	O	O
for	O	O
malignant	B_Disease	O
glioma	I_Disease	O
.	O	O

Etoposide	B_Chemical	B_Chemical
(	O	O
VP-16	B_Chemical	O
-	I_Chemical	O
213	I_Chemical	O
)	O	O
has	O	O
been	O	O
used	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
many	O	O
solid	O	O
tumors	B_Disease	O
and	O	O
hematologic	B_Disease	O
malignancies	I_Disease	O
.	O	O

When	O	O
used	O	O
in	O	O
high	O	O
doses	O	O
and	O	O
in	O	O
conjunction	O	O
with	O	O
autologous	O	O
bone	O	O
marrow	O	O
transplantation	O	O
,	O	O
this	O	O
agent	O	O
has	O	O
activity	O	O
against	O	O
several	O	O
treatment-resistant	O	O
cancers	B_Disease	O
including	O	O
malignant	B_Disease	O
glioma	I_Disease	O
.	O	O

In	O	O
six	O	O
of	O	O
eight	O	O
patients	O	O
(	O	O
75	O	O
%	O	O
)	O	O
who	O	O
we	O	O
treated	O	O
for	O	O
recurrent	O	O
or	O	O
resistant	O	O
glioma	B_Disease	O
,	O	O
sudden	O	O
severe	O	O
neurologic	B_Disease	B_Disease
deterioration	I_Disease	I_Disease
occurred	O	O
.	O	O

This	O	O
developed	O	O
a	O	O
median	O	O
of	O	O
9	O	O
days	O	O
after	O	O
initiation	O	O
of	O	O
high-dose	O	B_Chemical
etoposide	B_Chemical	I_Chemical
therapy	O	O
.	O	O

Significant	O	O
clinical	O	O
manifestations	O	O
have	O	O
included	O	O
confusion	B_Disease	O
,	O	O
papilledema	B_Disease	O
,	O	O
somnolence	B_Disease	O
,	O	O
exacerbation	O	O
of	O	O
motor	B_Disease	B_Disease
deficits	I_Disease	I_Disease
,	O	O
and	O	O
sharp	O	O
increase	O	O
in	O	O
seizure	B_Disease	O
activity	O	O
.	O	O

These	O	O
abnormalities	O	O
resolved	O	O
rapidly	O	O
after	O	O
initiation	O	O
of	O	O
high-dose	O	O
intravenous	O	O
dexamethasone	B_Chemical	O
therapy	O	O
.	O	O

In	O	O
all	O	O
patients	O	O
,	O	O
computerized	O	O
tomographic	O	O
(	O	O
CT	O	O
)	O	O
brain	O	O
scans	O	O
demonstrated	O	O
stability	O	O
in	O	O
tumor	B_Disease	O
size	O	O
and	O	O
peritumor	O	O
edema	B_Disease	O
when	O	O
compared	O	O
with	O	O
pretransplant	O	O
scans	O	O
.	O	O

This	O	O
complication	O	O
appears	O	O
to	O	O
represent	O	O
a	O	O
significant	O	O
new	O	O
toxicity	B_Disease	O
of	O	O
high-dose	O	B_Chemical
etoposide	B_Chemical	I_Chemical
therapy	O	O
for	O	O
malignant	B_Disease	O
glioma	I_Disease	O
.	O	O

Progressive	O	O
bile	B_Disease	B_Disease
duct	I_Disease	I_Disease
injury	I_Disease	I_Disease
after	O	O
thiabendazole	B_Chemical	O
administration	O	O
.	O	O

A	O	O
27-yr-old	O	O
man	O	O
developed	O	O
jaundice	B_Disease	O
2	O	O
wk	O	O
after	O	O
exposure	O	O
to	O	O
thiabendazole	B_Chemical	O
.	O	O

Cholestasis	B_Disease	O
persisted	O	O
for	O	O
3	O	O
yr	O	O
,	O	O
at	O	O
which	O	O
time	O	O
a	O	O
liver	O	O
transplant	O	O
was	O	O
performed	O	O
.	O	O

Two	O	O
liver	O	O
biopsy	O	O
specimens	O	O
and	O	O
the	O	O
hepatectomy	O	O
specimen	O	O
were	O	O
remarkable	O	O
for	O	O
almost	O	O
complete	O	O
disappearance	O	O
of	O	O
interlobular	O	O
bile	O	O
ducts	O	O
.	O	O

Prominent	O	O
fibrosis	B_Disease	O
and	O	O
hepatocellular	O	O
regeneration	O	O
were	O	O
also	O	O
present	O	O
;	O	O
however	O	O
,	O	O
the	O	O
lobular	O	O
architecture	O	O
was	O	O
preserved	O	O
.	O	O

This	O	O
case	O	O
represents	O	O
an	O	O
example	O	O
of	O	O
"	O	O
idiosyncratic	O	O
"	O	O
drug-induced	B_Disease	O
liver	I_Disease	B_Disease
damage	I_Disease	I_Disease
in	O	O
which	O	O
the	O	O
primary	O	O
target	O	O
of	O	O
injury	O	O
is	O	O
the	O	O
bile	O	O
duct	O	O
.	O	O

An	O	O
autoimmune	O	O
pathogenesis	O	O
of	O	O
the	O	O
bile	B_Disease	O
duct	I_Disease	O
destruction	I_Disease	O
is	O	O
suggested	O	O
.	O	O

Differential	O	O
effects	O	O
of	O	O
1,4-dihydropyridine	B_Chemical	O
calcium	B_Chemical	O
channel	I_Chemical	O
blockers	I_Chemical	O
:	O	O
therapeutic	O	O
implications	O	O
.	O	O

Increasing	O	O
recognition	O	O
of	O	O
the	O	O
importance	O	O
of	O	O
calcium	B_Chemical	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
cardiovascular	B_Disease	O
disease	I_Disease	O
has	O	O
stimulated	O	O
research	O	O
into	O	O
the	O	O
use	O	O
of	O	O
calcium	B_Chemical	O
channel	I_Chemical	O
blocking	I_Chemical	O
agents	I_Chemical	O
for	O	O
treatment	O	O
of	O	O
a	O	O
variety	O	O
of	O	O
cardiovascular	B_Disease	O
diseases	I_Disease	O
.	O	O

The	O	O
favorable	O	O
efficacy	O	O
and	O	O
tolerability	O	O
profiles	O	O
of	O	O
these	O	O
agents	O	O
make	O	O
them	O	O
attractive	O	O
therapeutic	O	O
modalities	O	O
.	O	O

Clinical	O	O
applications	O	O
of	O	O
calcium	B_Chemical	O
channel	I_Chemical	O
blockers	I_Chemical	O
parallel	O	O
their	O	O
tissue	O	O
selectivity	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
verapamil	B_Chemical	O
and	O	O
diltiazem	B_Chemical	O
,	O	O
which	O	O
are	O	O
roughly	O	O
equipotent	O	O
in	O	O
their	O	O
actions	O	O
on	O	O
the	O	O
heart	O	O
and	O	O
vascular	O	O
smooth	O	O
muscle	O	O
,	O	O
the	O	O
dihydropyridine	B_Chemical	O
calcium	B_Chemical	O
channel	I_Chemical	O
blockers	I_Chemical	O
are	O	O
a	O	O
group	O	O
of	O	O
potent	O	O
peripheral	O	O
vasodilator	O	O
agents	O	O
that	O	O
exert	O	O
minimal	O	O
electrophysiologic	O	O
effects	O	O
on	O	O
cardiac	O	O
nodal	O	O
or	O	O
conduction	O	O
tissue	O	O
.	O	O

As	O	O
the	O	O
first	O	O
dihydropyridine	B_Chemical	B_Chemical
available	O	O
for	O	O
use	O	O
in	O	O
the	O	O
United	O	O
States	O	O
,	O	O
nifedipine	B_Chemical	O
controls	O	O
angina	B_Disease	O
and	O	O
hypertension	B_Disease	O
with	O	O
minimal	O	O
depression	O	O
of	O	O
cardiac	O	O
function	O	O
.	O	O

Additional	O	O
members	O	O
of	O	O
this	O	O
group	O	O
of	O	O
calcium	B_Chemical	O
channel	I_Chemical	O
blockers	I_Chemical	O
have	O	O
been	O	O
studied	O	O
for	O	O
a	O	O
variety	O	O
of	O	O
indications	O	O
for	O	O
which	O	O
they	O	O
may	O	O
offer	O	O
advantages	O	O
over	O	O
current	O	O
therapy	O	O
.	O	O

Once	O	O
or	O	O
twice	O	O
daily	O	O
dosage	O	O
possible	O	O
with	O	O
nitrendipine	B_Chemical	B_Chemical
and	O	O
nisoldipine	B_Chemical	B_Chemical
offers	O	O
a	O	O
convenient	O	O
administration	O	O
schedule	O	O
,	O	O
which	O	O
encourages	O	O
patient	O	O
compliance	O	O
in	O	O
long-term	O	O
therapy	O	O
of	O	O
hypertension	B_Disease	O
.	O	O

The	O	O
coronary	O	O
vasodilating	O	O
properties	O	O
of	O	O
nisoldipine	B_Chemical	B_Chemical
have	O	O
led	O	O
to	O	O
the	O	O
investigation	O	O
of	O	O
this	O	O
agent	O	O
for	O	O
use	O	O
in	O	O
angina	B_Disease	O
.	O	O

Selectivity	O	O
for	O	O
the	O	O
cerebrovascular	O	O
bed	O	O
makes	O	O
nimodipine	B_Chemical	B_Chemical
potentially	O	O
useful	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
subarachnoid	B_Disease	O
hemorrhage	I_Disease	O
,	O	O
migraine	B_Disease	O
headache	I_Disease	O
,	O	O
dementia	B_Disease	O
,	O	O
and	O	O
stroke	B_Disease	O
.	O	O

In	O	O
general	O	O
,	O	O
the	O	O
dihydropyridine	B_Chemical	O
calcium	B_Chemical	O
channel	I_Chemical	O
blockers	I_Chemical	O
are	O	O
usually	O	O
well	O	O
tolerated	O	O
,	O	O
with	O	O
headache	B_Disease	O
,	O	O
facial	O	O
flushing	B_Disease	O
,	O	O
palpitations	B_Disease	O
,	O	O
edema	B_Disease	O
,	O	O
nausea	B_Disease	O
,	O	O
anorexia	B_Disease	O
,	O	O
and	O	O
dizziness	B_Disease	O
being	O	O
the	O	O
more	O	O
common	O	O
adverse	O	O
effects	O	O
.	O	O

The	O	O
enhancement	O	O
of	O	O
aminonucleoside	B_Chemical	O
nephrosis	B_Disease	O
by	O	O
the	O	O
co-administration	O	O
of	O	O
protamine	O	O
.	O	O

An	O	O
experimental	O	O
model	O	O
of	O	O
focal	B_Disease	O
segmental	I_Disease	O
glomerular	I_Disease	O
sclerosis	I_Disease	O
(	O	O
FSGS	B_Disease	O
)	O	O
was	O	O
developed	O	O
in	O	O
rats	O	O
by	O	O
the	O	O
combined	O	O
administration	O	O
of	O	O
puromycin-aminonucleoside	B_Chemical	O
(	O	O
AMNS	B_Chemical	O
)	O	O
and	O	O
protamine	B_Chemical	B_Chemical
sulfate	I_Chemical	I_Chemical
(	O	O
PS	B_Chemical	O
)	O	O
.	O	O

Male	O	O
Sprague-Dawley	O	O
rats	O	O
,	O	O
uninephrectomized	O	O
three	O	O
weeks	O	O
before	O	O
,	O	O
received	O	O
daily	O	O
injections	O	O
of	O	O
subcutaneous	O	O
AMNS	B_Chemical	O
(	O	O
1	O	O
mg/100	O	O
g	O	O
body	O	O
wt	O	O
)	O	O
and	O	O
intravenous	O	O
PS	B_Chemical	O
(	O	O
2	O	O
separated	O	O
doses	O	O
of	O	O
2.5	O	O
mg/100	O	O
g	O	O
body	O	O
wt	O	O
)	O	O
for	O	O
four	O	O
days	O	O
.	O	O

The	O	O
series	O	O
of	O	O
injections	O	O
were	O	O
repeated	O	O
another	O	O
three	O	O
times	O	O
at	O	O
10	O	O
day	O	O
intervals	O	O
.	O	O

The	O	O
animals	O	O
were	O	O
sacrificed	O	O
on	O	O
days	O	O
24	O	O
,	O	O
52	O	O
,	O	O
and	O	O
80	O	O
.	O	O

They	O	O
developed	O	O
nephrotic	B_Disease	B_Disease
syndrome	I_Disease	I_Disease
and	O	O
finally	O	O
renal	B_Disease	B_Disease
failure	I_Disease	I_Disease
.	O	O

The	O	O
time-course	O	O
curve	O	O
of	O	O
creatinine	B_Chemical	B_Chemical
clearance	O	O
dropped	O	O
and	O	O
showed	O	O
significant	O	O
difference	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
from	O	O
that	O	O
of	O	O
each	O	O
control	O	O
group	O	O
,	O	O
such	O	O
as	O	O
,	O	O
AMNS	B_Chemical	O
alone	O	O
,	O	O
PS	B_Chemical	O
alone	O	O
or	O	O
saline	O	O
injected	O	O
.	O	O

Their	O	O
glomeruli	O	O
showed	O	O
changes	O	O
of	O	O
progressive	O	O
FSGS	B_Disease	O
.	O	O

The	O	O
ultrastructural	O	O
studies	O	O
in	O	O
the	O	O
initial	O	O
stage	O	O
revealed	O	O
significant	O	O
lack	O	O
of	O	O
particles	O	O
of	O	O
perfused	O	O
ruthenium	B_Chemical	O
red	O	O
on	O	O
the	O	O
lamina	O	O
rara	O	O
externa	O	O
and	O	O
marked	O	O
changes	O	O
in	O	O
epithelial	O	O
cell	O	O
cytoplasm	O	O
.	O	O

Therefore	O	O
,	O	O
it	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
administration	O	O
of	O	O
PS	B_Chemical	O
enhances	O	O
the	O	O
toxicity	B_Disease	O
of	O	O
AMNS	B_Chemical	O
on	O	O
the	O	O
glomerulus	O	O
and	O	O
readily	O	O
produces	O	O
progressive	O	O
FSGS	B_Disease	O
in	O	O
rats	O	O
resulting	O	O
in	O	O
the	O	O
end-stage	B_Disease	B_Disease
renal	I_Disease	I_Disease
disease	I_Disease	I_Disease
.	O	O

Theophylline	B_Chemical	O
neurotoxicity	B_Disease	O
in	O	O
pregnant	O	O
rats	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
neurotoxicity	B_Disease	B_Disease
of	O	O
theophylline	B_Chemical	O
is	O	O
altered	O	O
in	O	O
advanced	O	O
pregnancy	O	O
.	O	O

Sprague-Dawley	O	O
rats	O	O
that	O	O
were	O	O
20	O	O
days	O	O
pregnant	O	O
and	O	O
nonpregnant	O	O
rats	O	O
of	O	O
the	O	O
same	O	O
age	O	O
and	O	O
strain	O	O
received	O	O
infusions	O	O
of	O	O
aminophylline	B_Chemical	O
until	O	O
onset	O	O
of	O	O
maximal	O	O
seizures	B_Disease	O
which	O	O
occurred	O	O
after	O	O
28	O	O
and	O	O
30	O	O
minutes	O	O
respectively	O	O
.	O	O

Theophylline	B_Chemical	O
concentrations	O	O
at	O	O
this	O	O
endpoint	O	O
in	O	O
serum	O	O
(	O	O
total	O	O
)	O	O
and	O	O
CSF	O	O
were	O	O
similar	O	O
but	O	O
serum	O	O
(	O	O
free	O	O
)	O	O
and	O	O
brain	O	O
concentrations	O	O
were	O	O
slightly	O	O
different	O	O
in	O	O
pregnant	O	O
rats	O	O
.	O	O

Theophylline	B_Chemical	O
serum	O	O
protein	O	O
binding	O	O
determined	O	O
by	O	O
equilibrium	O	O
dialysis	O	O
was	O	O
lower	O	O
in	O	O
pregnant	O	O
rats	O	O
.	O	O

Fetal	O	O
serum	O	O
concentrations	O	O
at	O	O
onset	O	O
of	O	O
seizures	B_Disease	O
in	O	O
the	O	O
mother	O	O
were	O	O
similar	O	O
to	O	O
maternal	O	O
brain	O	O
and	O	O
CSF	O	O
concentrations	O	O
and	O	O
correlated	O	O
significantly	O	O
with	O	O
the	O	O
former	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
advanced	O	O
pregnancy	O	O
has	O	O
a	O	O
negligible	O	O
effect	O	O
on	O	O
the	O	O
neurotoxic	B_Disease	O
response	O	O
to	O	O
theophylline	B_Chemical	O
in	O	O
rats	O	O
.	O	O

Hyperkalemia	B_Disease	O
induced	O	O
by	O	O
indomethacin	B_Chemical	O
and	O	O
naproxen	B_Chemical	O
and	O	O
reversed	O	O
by	O	O
fludrocortisone	B_Chemical	O
.	O	O

We	O	O
have	O	O
described	O	O
a	O	O
patient	O	O
with	O	O
severe	O	O
rheumatoid	B_Disease	B_Disease
arthritis	I_Disease	I_Disease
and	O	O
a	O	O
history	O	O
of	O	O
mefenamic	B_Chemical	O
acid	I_Chemical	O
nephropathy	B_Disease	O
in	O	O
whom	O	O
hyperkalemia	B_Disease	O
and	O	O
inappropriate	O	O
hypoaldosteronism	B_Disease	O
were	O	O
caused	O	O
by	O	O
both	O	O
indomethacin	B_Chemical	O
and	O	O
naproxen	B_Chemical	O
,	O	O
without	O	O
major	O	O
decline	O	O
in	O	O
renal	O	O
function	O	O
.	O	O

It	O	O
is	O	O
likely	O	O
that	O	O
preexisting	O	O
renal	B_Disease	B_Disease
disease	I_Disease	I_Disease
predisposed	O	O
this	O	O
patient	O	O
to	O	O
type	B_Disease	O
IV	I_Disease	O
renal	I_Disease	B_Disease
tubular	I_Disease	I_Disease
acidosis	I_Disease	I_Disease
with	O	O
prostaglandin	B_Chemical	O
synthetase	O	O
inhibitors	O	O
.	O	O

Because	O	O
he	O	O
was	O	O
unable	O	O
to	O	O
discontinue	O	O
nonsteroidal	O	O
anti-inflammatory	O	O
drug	O	O
therapy	O	O
,	O	O
fludrocortisone	B_Chemical	B_Chemical
was	O	O
added	O	O
,	O	O
correcting	O	O
the	O	O
hyperkalemia	B_Disease	O
and	O	O
allowing	O	O
indomethacin	B_Chemical	O
therapy	O	O
to	O	O
be	O	O
continued	O	O
safely	O	O
.	O	O

Hypotension	B_Disease	O
as	O	O
a	O	O
manifestation	O	O
of	O	O
cardiotoxicity	B_Disease	B_Disease
in	O	O
three	O	O
patients	O	O
receiving	O	O
cisplatin	B_Chemical	B_Chemical
and	O	O
5-fluorouracil	B_Chemical	B_Chemical
.	O	O

Cardiac	O	B_Disease
symptoms	O	I_Disease
,	O	O
including	O	O
hypotension	B_Disease	O
,	O	O
developed	O	O
in	O	O
three	O	O
patients	O	O
with	O	O
advanced	O	O
colorectal	B_Disease	O
carcinoma	I_Disease	O
while	O	O
being	O	O
treated	O	O
with	O	O
cisplatin	B_Chemical	B_Chemical
(	O	O
CDDP	B_Chemical	O
)	O	O
and	O	O
5-fluorouracil	B_Chemical	B_Chemical
(	O	O
5-FU	B_Chemical	B_Chemical
)	O	O
.	O	O

In	O	O
two	O	O
patients	O	O
,	O	O
hypotension	B_Disease	O
was	O	O
associated	O	O
with	O	O
severe	O	O
left	B_Disease	B_Disease
ventricular	I_Disease	I_Disease
dysfunction	I_Disease	I_Disease
.	O	O

All	O	O
three	O	O
patients	O	O
required	O	O
therapy	O	O
discontinuation	O	O
.	O	O

Cardiac	O	O
enzymes	O	O
remained	O	O
normal	O	O
despite	O	O
transient	O	O
electrocardiographic	O	O
(	O	O
EKG	O	O
)	O	O
changes	O	O
.	O	O

The	O	O
presentation	O	O
and	O	O
cardiac	O	O
evaluation	O	O
(	O	O
hemodynamic	O	O
,	O	O
echocardiographic	O	O
,	O	O
and	O	O
scintigraphic	O	O
)	O	O
of	O	O
these	O	O
patients	O	O
suggest	O	O
new	O	O
manifestations	O	O
of	O	O
5-FU	B_Chemical	O
cardiotoxicity	B_Disease	O
that	O	O
may	O	O
be	O	O
influenced	O	O
by	O	O
CDDP	B_Chemical	O
.	O	O

The	O	O
possible	O	O
pathophysiologic	O	O
mechanisms	O	O
are	O	O
discussed	O	O
.	O	O

Fatal	O	O
aplastic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
in	O	O
a	O	O
patient	O	O
treated	O	O
with	O	O
carbamazepine	B_Chemical	B_Chemical
.	O	O

A	O	O
case	O	O
of	O	O
fatal	O	O
aplastic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
due	O	O
to	O	O
carbamazepine	B_Chemical	B_Chemical
treatment	O	O
in	O	O
an	O	O
epileptic	B_Disease	O
woman	O	O
is	O	O
reported	O	O
.	O	O

Despite	O	O
concerns	O	O
of	O	O
fatal	O	O
bone	B_Disease	B_Disease
marrow	I_Disease	I_Disease
toxicity	I_Disease	I_Disease
due	O	O
to	O	O
carbamazepine	B_Chemical	B_Chemical
,	O	O
this	O	O
is	O	O
only	O	O
the	O	O
fourth	O	O
documented	O	O
and	O	O
published	O	O
report	O	O
.	O	O

Carbamazepine	B_Chemical	B_Chemical
is	O	O
a	O	O
safe	O	O
drug	O	O
,	O	O
but	O	O
physicians	O	O
and	O	O
patients	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
exceedingly	O	O
rare	O	O
but	O	O
potentially	O	O
fatal	O	O
side	O	O
effects	O	O
,	O	O
better	O	O
prevented	O	O
by	O	O
clinical	O	O
than	O	O
by	O	O
laboratory	O	O
monitoring	O	O
.	O	O

Participation	O	O
of	O	O
a	O	O
bulbospinal	O	O
serotonergic	O	O
pathway	O	O
in	O	O
the	O	O
rat	O	O
brain	O	O
in	O	O
clonidine-induced	O	O
hypotension	B_Disease	O
and	O	O
bradycardia	B_Disease	O
.	O	O

The	O	O
effects	O	O
of	O	O
microinjection	O	O
of	O	O
clonidine	B_Chemical	O
(	O	O
1	O	O
-	O	O
10	O	O
micrograms	O	O
in	O	O
1	O	O
microliter	O	O
)	O	O
into	O	O
a	O	O
region	O	O
adjacent	O	O
to	O	O
the	O	O
ventrolateral	O	O
surface	O	O
of	O	O
the	O	O
medulla	O	O
oblongata	O	O
on	O	O
cardiovascular	O	O
function	O	O
were	O	O
assessed	O	O
in	O	O
urethane-anesthetized	O	O
rats	O	O
.	O	O

Intramedullary	O	O
administration	O	O
of	O	O
clonidine	B_Chemical	O
,	O	O
but	O	O
not	O	O
saline	O	O
vehicle	O	O
,	O	O
caused	O	O
a	O	O
dose-dependent	O	O
decrease	O	O
in	O	O
both	O	O
the	O	O
mean	O	O
arterial	O	O
pressure	O	O
and	O	O
the	O	O
heart	O	O
rate	O	O
.	O	O

The	O	O
clonidine-induced	O	O
hypotension	B_Disease	O
was	O	O
antagonized	O	O
by	O	O
prior	O	O
spinal	O	O
transection	O	O
,	O	O
but	O	O
not	O	O
bilateral	O	O
vagotomy	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
clonidine-induced	O	O
bradycardia	B_Disease	O
was	O	O
antagonized	O	O
by	O	O
prior	O	O
bilateral	O	O
vagotomy	O	O
,	O	O
but	O	O
not	O	O
spinal	O	O
transection	O	O
.	O	O

Furthermore	O	O
,	O	O
selective	O	O
destruction	O	O
of	O	O
the	O	O
spinal	O	O
5-HT	B_Chemical	O
nerves	O	O
,	O	O
produced	O	O
by	O	O
bilateral	O	O
spinal	O	O
injection	O	O
of	O	O
5,7-dihydroxytryptamine	B_Chemical	B_Chemical
,	O	O
reduced	O	O
the	O	O
magnitude	O	O
of	O	O
the	O	O
vasodepressor	O	O
or	O	O
the	O	O
bradycardiac	B_Disease	B_Disease
responses	O	O
to	O	O
clonidine	B_Chemical	O
microinjected	O	O
into	O	O
the	O	O
area	O	O
near	O	O
the	O	O
ventrolateral	O	O
surface	O	O
of	O	O
the	O	O
medulla	O	O
oblongata	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
data	O	O
indicate	O	O
that	O	O
a	O	O
bulbospinal	O	O
serotonergic	O	O
pathway	O	O
is	O	O
involved	O	O
in	O	O
development	O	O
of	O	O
clonidine-induced	O	O
hypotension	B_Disease	O
and	O	O
bradycardia	B_Disease	O
.	O	O

The	O	O
induced	O	O
hypotension	B_Disease	O
is	O	O
brought	O	O
about	O	O
by	O	O
a	O	O
decrease	O	O
in	O	O
sympathetic	O	O
efferent	O	O
activity	O	O
,	O	O
whereas	O	O
the	O	O
induced	O	O
bradycardia	B_Disease	O
was	O	O
due	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
vagal	O	O
efferent	O	O
activity	O	O
.	O	O

Hypertension	B_Disease	O
in	O	O
neuroblastoma	B_Disease	O
induced	O	O
by	O	O
imipramine	B_Chemical	O
.	O	O

Hypertension	B_Disease	O
is	O	O
a	O	O
well-known	O	O
finding	O	O
in	O	O
some	O	O
patients	O	O
with	O	O
neuroblastoma	B_Disease	O
.	O	O

However	O	O
,	O	O
it	O	O
has	O	O
not	O	O
previously	O	O
been	O	O
described	O	O
in	O	O
association	O	O
with	O	O
the	O	O
use	O	O
of	O	O
Imipramine	B_Chemical	O
.	O	O

We	O	O
report	O	O
the	O	O
occurrence	O	O
of	O	O
severe	O	O
hypertension	B_Disease	O
(	O	O
blood	O	O
pressure	O	O
190/160	O	O
)	O	O
in	O	O
a	O	O
4-year-old	O	O
girl	O	O
with	O	O
neuroblastoma	B_Disease	O
who	O	O
was	O	O
given	O	O
Imipramine	B_Chemical	O
to	O	O
control	O	O
a	O	O
behavior	B_Disease	B_Disease
disorder	I_Disease	I_Disease
.	O	O

It	O	O
was	O	O
determined	O	O
later	O	O
that	O	O
this	O	O
patient	O	O
's	O	O
tumor	B_Disease	O
was	O	O
recurring	O	O
at	O	O
the	O	O
time	O	O
of	O	O
her	O	O
hypertensive	B_Disease	O
episode	O	O
.	O	O

Since	O	O
she	O	O
had	O	O
no	O	O
blood	O	O
pressure	O	O
elevation	O	O
at	O	O
initial	O	O
diagnosis	O	O
and	O	O
none	O	O
following	O	O
discontinuation	O	O
of	O	O
the	O	O
Imipramine	B_Chemical	O
(	O	O
when	O	O
she	O	O
was	O	O
in	O	O
florid	O	O
relapse	O	O
)	O	O
,	O	O
we	O	O
believe	O	O
that	O	O
this	O	O
drug	O	O
rather	O	O
than	O	O
her	O	O
underlying	O	O
disease	O	O
alone	O	O
caused	O	O
her	O	O
hypertension	B_Disease	O
.	O	O

The	O	O
mechanism	O	O
for	O	O
this	O	O
reaction	O	O
is	O	O
believed	O	O
to	O	O
be	O	O
increased	O	O
levels	O	O
of	O	O
vasoactive	O	O
catecholamines	B_Chemical	O
due	O	O
to	O	O
interference	O	O
of	O	O
their	O	O
physiologic	O	O
inactivation	O	O
by	O	O
Imipramine	B_Chemical	O
.	O	O

From	O	O
this	O	O
experience	O	O
,	O	O
we	O	O
urge	O	O
extreme	O	O
caution	O	O
in	O	O
the	O	O
use	O	O
of	O	O
tricyclic	O	O
antidepressants	O	O
in	O	O
children	O	O
with	O	O
active	O	O
neuroblastoma	B_Disease	O
.	O	O

Rechallenge	O	O
of	O	O
patients	O	O
who	O	O
developed	O	O
oral	B_Disease	O
candidiasis	I_Disease	O
or	O	O
hoarseness	B_Disease	O
with	O	O
beclomethasone	B_Chemical	B_Chemical
dipropionate	I_Chemical	I_Chemical
.	O	O

Of	O	O
158	O	O
asthmatic	B_Disease	O
patients	O	O
who	O	O
were	O	O
placed	O	O
on	O	O
inhaled	O	O
beclomethasone	B_Chemical	B_Chemical
,	O	O
15	O	O
(	O	O
9.5	O	O
%	O	O
)	O	O
developed	O	O
either	O	O
hoarseness	B_Disease	O
(	O	O
8)	O	O
,	O	O
oral	O	O
thrush	B_Disease	O
(	O	O
6	O	O
)	O	O
,	O	O
or	O	O
both	O	O
(	O	O
1	O	O
)	O	O
.	O	O

When	O	O
their	O	O
adverse	O	O
reactions	O	O
subsided	O	O
,	O	O
seven	O	O
of	O	O
these	O	O
15	O	O
patients	O	O
were	O	O
rechallenged	O	O
with	O	O
inhaled	O	O
beclomethasone	B_Chemical	B_Chemical
.	O	O

These	O	O
included	O	O
five	O	O
cases	O	O
who	O	O
developed	O	O
hoarseness	B_Disease	O
and	O	O
three	O	O
who	O	O
developed	O	O
Candidiasis	B_Disease	O
.	O	O

One	O	O
patient	O	O
had	O	O
both	O	O
.	O	O

Oral	O	O
thrush	B_Disease	O
did	O	O
not	O	O
recur	O	O
,	O	O
but	O	O
60	O	O
%	O	O
(	O	O
3/5	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
hoarseness	B_Disease	O
had	O	O
recurrence	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
patients	O	O
may	O	O
be	O	O
restarted	O	O
on	O	O
inhaled	O	O
beclomethasone	B_Chemical	B_Chemical
when	O	O
clinically	O	O
indicated	O	O
;	O	O
however	O	O
,	O	O
because	O	O
of	O	O
the	O	O
high	O	O
recurrence	O	O
rate	O	O
,	O	O
patients	O	O
who	O	O
develop	O	O
hoarseness	B_Disease	O
should	O	O
not	O	O
be	O	O
re-challenged	O	O
.	O	O

Concomitant	O	O
use	O	O
of	O	O
oral	O	O
prednisone	B_Chemical	O
and	O	O
topical	O	O
beclomethasone	B_Chemical	B_Chemical
may	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
developing	O	O
hoarseness	B_Disease	O
or	O	O
candidiasis	B_Disease	O
.	O	O

Cyclophosphamide	B_Chemical	O
cardiotoxicity	B_Disease	O
:	O	O
an	O	O
analysis	O	O
of	O	O
dosing	O	O
as	O	O
a	O	O
risk	O	O
factor	O	O
.	O	O

Patients	O	O
who	O	O
undergo	O	O
bone	O	O
marrow	O	O
transplantation	O	O
are	O	O
generally	O	O
immunosuppressed	O	O
with	O	O
a	O	O
dose	O	O
of	O	O
cyclophosphamide	B_Chemical	B_Chemical
(	O	O
CYA	B_Chemical	O
)	O	O
which	O	O
is	O	O
usually	O	O
calculated	O	O
based	O	O
on	O	O
the	O	O
patient	O	O
's	O	O
weight	O	O
.	O	O

At	O	O
these	O	O
high	O	O
doses	O	O
of	O	O
CYA	B_Chemical	O
,	O	O
serious	O	O
cardiotoxicity	B_Disease	B_Disease
may	O	O
occur	O	O
,	O	O
but	O	O
definitive	O	O
risk	O	O
factors	O	O
for	O	O
the	O	O
development	O	O
of	O	O
such	O	O
cardiotoxicity	B_Disease	B_Disease
have	O	O
not	O	O
been	O	O
described	O	O
.	O	O

Since	O	O
chemotherapeutic	O	O
agent	O	O
toxicity	B_Disease	O
generally	O	O
correlates	O	O
with	O	O
dose	O	O
per	O	O
body	O	O
surface	O	O
area	O	O
,	O	O
we	O	O
retrospectively	O	O
calculated	O	O
the	O	O
dose	O	O
of	O	O
CYA	B_Chemical	O
in	O	O
patients	O	O
transplanted	O	O
at	O	O
our	O	O
institution	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
incidence	O	O
of	O	O
CYA	B_Chemical	O
cardiotoxicity	B_Disease	B_Disease
correlated	O	O
with	O	O
the	O	O
dose	O	O
per	O	O
body	O	O
surface	O	O
area	O	O
.	O	O

Eighty	O	O
patients	O	O
who	O	O
were	O	O
to	O	O
receive	O	O
CYA	B_Chemical	O
50	O	O
mg/kg/d	O	O
for	O	O
four	O	O
days	O	O
as	O	O
preparation	O	O
for	O	O
marrow	O	O
grafting	O	O
underwent	O	O
a	O	O
total	O	O
of	O	O
84	O	O
transplants	O	O
for	O	O
aplastic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
,	O	O
Wiskott-Aldrich	B_Disease	O
syndrome	I_Disease	O
,	O	O
or	O	O
severe	B_Disease	O
combined	I_Disease	O
immunodeficiency	I_Disease	B_Disease
syndrome	I_Disease	I_Disease
.	O	O

Fourteen	O	O
of	O	O
84	O	O
(	O	O
17	O	O
%	O	O
)	O	O
patients	O	O
had	O	O
symptoms	O	O
and	O	O
signs	O	O
consistent	O	O
with	O	O
CYA	B_Chemical	O
cardiotoxicity	B_Disease	B_Disease
within	O	O
ten	O	O
days	O	O
of	O	O
receiving	O	O
1	O	O
to	O	O
4	O	O
doses	O	O
of	O	O
CYA	B_Chemical	O
.	O	O

Six	O	O
of	O	O
the	O	O
14	O	O
patients	O	O
died	O	O
with	O	O
congestive	B_Disease	B_Disease
heart	I_Disease	I_Disease
failure	I_Disease	I_Disease
.	O	O

The	O	O
dose	O	O
of	O	O
CYA	B_Chemical	O
per	O	O
body	O	O
surface	O	O
area	O	O
was	O	O
calculated	O	O
for	O	O
all	O	O
patients	O	O
and	O	O
the	O	O
patients	O	O
were	O	O
divided	O	O
into	O	O
two	O	O
groups	O	O
based	O	O
on	O	O
daily	O	O
CYA	B_Chemical	O
dose	O	O
:	O	O
Group	O	O
1	O	O
,	O	O
CYA	B_Chemical	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
1.55	O	O
g/m2/d	O	O
;	O	O
Group	O	O
2	O	O
,	O	O
CYA	B_Chemical	O
greater	O	O
than	O	O
1.55	O	O
g/m2/d	O	O
.	O	O

Cardiotoxicity	B_Disease	B_Disease
that	O	O
was	O	O
thought	O	O
to	O	O
be	O	O
related	O	O
to	O	O
CYA	B_Chemical	O
occurred	O	O
in	O	O
1/32	O	O
(	O	O
3	O	O
%	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
Group	O	O
1	O	O
and	O	O
in	O	O
13/52	O	O
(	O	O
25	O	O
%	O	O
)	O	O
patients	O	O
in	O	O
Group	O	O
2	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.025	O	O
)	O	O
.	O	O

Congestive	B_Disease	B_Disease
heart	I_Disease	I_Disease
failure	I_Disease	I_Disease
caused	O	O
or	O	O
contributed	O	O
to	O	O
death	O	O
in	O	O
0/32	O	O
patients	O	O
in	O	O
Group	O	O
1	O	O
v	O	O
6/52	O	O
(	O	O
12	O	O
%	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
Group	O	O
2	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.25	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
rate	O	O
of	O	O
engraftment	O	O
of	O	O
evaluable	O	O
patients	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
(	O	O
P	O	O
greater	O	O
than	O	O
0.5	O	O
)	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
CYA	B_Chemical	O
cardiotoxicity	B_Disease	B_Disease
correlates	O	O
with	O	O
CYA	B_Chemical	O
dosage	O	O
as	O	O
calculated	O	O
by	O	O
body	O	O
surface	O	O
area	O	O
,	O	O
and	O	O
that	O	O
patients	O	O
with	O	O
aplastic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
and	O	O
immunodeficiencies	B_Disease	O
can	O	O
be	O	O
effectively	O	O
prepared	O	O
for	O	O
bone	O	B_Disease
marrow	O	I_Disease
grafting	O	O
at	O	O
a	O	O
CYA	B_Chemical	O
dose	O	O
of	O	O
1.55	O	O
g/m2/d	O	O
for	O	O
four	O	O
days	O	O
with	O	O
a	O	O
lower	O	O
incidence	O	O
of	O	O
cardiotoxicity	B_Disease	B_Disease
than	O	O
patients	O	O
whose	O	O
CYA	B_Chemical	O
dosage	O	O
is	O	O
calculated	O	O
based	O	O
on	O	O
weight	O	O
.	O	O

This	O	O
study	O	O
reaffirms	O	O
the	O	O
principle	O	O
that	O	O
drug	O	O
toxicity	B_Disease	O
correlates	O	O
with	O	O
dose	O	O
per	O	O
body	O	O
surface	O	O
area	O	O
.	O	O

Studies	O	O
of	O	O
risk	O	O
factors	O	O
for	O	O
aminoglycoside	B_Chemical	O
nephrotoxicity	B_Disease	O
.	O	O

The	O	O
epidemiology	O	O
of	O	O
aminoglycoside-induced	O	O
nephrotoxicity	B_Disease	B_Disease
is	O	O
not	O	O
fully	O	O
understood	O	O
.	O	O

Experimental	O	O
studies	O	O
in	O	O
healthy	O	O
human	O	O
volunteers	O	O
indicate	O	O
aminoglycosides	B_Chemical	B_Chemical
cause	O	O
proximal	O	B_Disease
tubular	O	I_Disease
damage	O	I_Disease
in	O	O
most	O	O
patients	O	O
,	O	O
but	O	O
rarely	O	O
,	O	O
if	O	O
ever	O	O
,	O	O
cause	O	O
glomerular	B_Disease	O
or	I_Disease	O
tubular	I_Disease	B_Disease
dysfunction	I_Disease	I_Disease
.	O	O

Clinical	O	O
trials	O	O
of	O	O
aminoglycosides	B_Chemical	B_Chemical
in	O	O
seriously	O	O
ill	O	O
patients	O	O
indicate	O	O
that	O	O
the	O	O
relative	O	O
risk	O	O
for	O	O
developing	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
during	O	O
therapy	O	O
ranges	O	O
from	O	O
8	O	O
to	O	O
10	O	O
and	O	O
that	O	O
the	O	O
attributable	O	O
risk	O	O
is	O	O
70	O	O
%	O	O
to	O	O
80	O	O
%	O	O
.	O	O

Further	O	O
analysis	O	O
of	O	O
these	O	O
data	O	O
suggests	O	O
that	O	O
the	O	O
duration	O	O
of	O	O
therapy	O	O
,	O	O
plasma	O	O
aminoglycoside	B_Chemical	B_Chemical
levels	O	O
,	O	O
liver	B_Disease	B_Disease
disease	I_Disease	I_Disease
,	O	O
advanced	O	O
age	O	O
,	O	O
high	O	O
initial	O	O
estimated	O	O
creatinine	B_Chemical	B_Chemical
clearance	O	O
and	O	O
,	O	O
possibly	O	O
,	O	O
female	O	O
gender	O	O
all	O	O
increase	O	O
the	O	O
risk	O	O
for	O	O
nephrotoxicity	B_Disease	B_Disease
.	O	O

Other	O	O
causes	O	O
of	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
,	O	O
such	O	O
as	O	O
shock	B_Disease	O
,	O	O
appear	O	O
to	O	O
have	O	O
an	O	O
additive	O	O
effect	O	O
.	O	O

Predictive	O	O
models	O	O
have	O	O
been	O	O
developed	O	O
from	O	O
these	O	O
analyses	O	O
that	O	O
should	O	O
be	O	O
useful	O	O
for	O	O
identifying	O	O
patients	O	O
at	O	O
high	O	O
risk	O	O
.	O	O

These	O	O
models	O	O
may	O	O
also	O	O
be	O	O
useful	O	O
in	O	O
developing	O	O
insights	O	O
into	O	O
the	O	O
pathophysiology	O	O
of	O	O
aminoglycoside-induced	O	O
nephrotoxicity	B_Disease	B_Disease
.	O	O

Central	O	O
action	O	O
of	O	O
narcotic	O	O
analgesics	O	O
.	O	O

Part	O	O
IV	O	O
.	O	O

Noradrenergic	O	O
influences	O	O
on	O	O
the	O	O
activity	O	O
of	O	O
analgesics	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
clonidine	B_Chemical	O
,	O	O
naphazoline	B_Chemical	O
and	O	O
xylometazoline	B_Chemical	B_Chemical
on	O	O
analgesia	O	O
induced	O	O
by	O	O
morphine	B_Chemical	O
,	O	O
codeine	B_Chemical	O
,	O	O
fentanyl	B_Chemical	O
and	O	O
pentazocine	B_Chemical	O
,	O	O
and	O	O
on	O	O
cataleptic	B_Disease	O
effect	O	O
of	O	O
morphine	B_Chemical	O
,	O	O
codine	B_Chemical	B_Chemical
and	O	O
fentanyl	B_Chemical	O
was	O	O
studied	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
biochemical	O	O
assays	O	O
on	O	O
the	O	O
influence	O	O
of	O	O
four	O	O
analgesics	O	O
on	O	O
the	O	O
brain	O	O
concentration	O	O
and	O	O
turnover	O	O
of	O	O
noradrenaline	B_Chemical	O
(	O	O
NA	B_Chemical	O
)	O	O
were	O	O
also	O	O
performed	O	O
.	O	O

It	O	O
was	O	O
found	O	O
that	O	O
three	O	O
drugs	O	O
stimulating	O	O
central	O	O
NA	B_Chemical	O
receptors	O	O
failed	O	O
to	O	O
affect	O	O
the	O	O
analgesic	O	O
ED50	O	O
of	O	O
all	O	O
antinociceptive	O	O
agents	O	O
and	O	O
they	O	O
enhanced	O	O
catalepsy	B_Disease	O
induced	O	O
by	O	O
morphine	B_Chemical	O
and	O	O
fentanyl	B_Chemical	O
.	O	O

Codeine	B_Chemical	O
catalepsy	B_Disease	O
was	O	O
increased	O	O
by	O	O
clonidine	B_Chemical	O
and	O	O
decreased	O	O
by	O	O
naphazoline	B_Chemical	O
and	O	O
xylometazoline	B_Chemical	B_Chemical
.	O	O

The	O	O
brain	O	O
concentration	O	O
of	O	O
NA	B_Chemical	O
was	O	O
not	O	O
changed	O	O
by	O	O
morphine	B_Chemical	O
and	O	O
fentanyl	B_Chemical	O
,	O	O
but	O	O
one	O	O
of	O	O
the	O	O
doses	O	O
of	O	O
codeine	B_Chemical	O
(	O	O
45	O	O
mg/kg	O	O
)	O	O
slightly	O	O
enhanced	O	O
it	O	O
.	O	O

Pentazocine	B_Chemical	O
dose-dependently	O	O
decreased	O	O
the	O	O
brain	O	O
level	O	O
of	O	O
NA	B_Chemical	O
.	O	O

The	O	O
rate	O	O
of	O	O
NA	B_Chemical	O
turnover	O	O
was	O	O
not	O	O
altered	O	O
by	O	O
analgesics	O	O
except	O	O
for	O	O
the	O	O
higher	O	O
dose	O	O
of	O	O
fentanyl	B_Chemical	O
(	O	O
0.2	O	O
mg/kg	O	O
)	O	O
following	O	O
which	O	O
the	O	O
disappearance	O	O
of	O	O
NA	B_Chemical	O
from	O	O
the	O	O
brain	O	O
was	O	O
diminished	O	O
.	O	O

The	O	O
results	O	O
are	O	O
discussed	O	O
in	O	O
the	O	O
light	O	O
of	O	O
various	O	O
and	O	O
non-uniform	O	O
data	O	O
from	O	O
the	O	O
literature	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
in	O	O
rats	O	O
the	O	O
brain	O	O
NA	B_Chemical	O
plays	O	O
a	O	O
less	O	O
important	O	O
function	O	O
than	O	O
the	O	O
other	O	O
monoamines	B_Chemical	O
in	O	O
the	O	O
behavioural	O	O
activity	O	O
of	O	O
potent	O	O
analgesics	O	O
.	O	O

Flurothyl	B_Chemical	O
seizure	B_Disease	O
thresholds	O	O
in	O	O
mice	O	O
treated	O	O
neonatally	O	O
with	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
monosodium	B_Chemical	B_Chemical
glutamate	I_Chemical	I_Chemical
(	O	O
MSG	B_Chemical	O
):	O	O
evaluation	O	O
of	O	O
experimental	O	O
parameters	O	O
in	O	O
flurothyl	B_Chemical	O
seizure	B_Disease	O
testing	O	O
.	O	O

Monosodium	B_Chemical	B_Chemical
glutamate	I_Chemical	I_Chemical
(	O	O
MSG	B_Chemical	O
)	O	O
administration	O	O
to	O	O
neonatal	O	O
rodents	O	O
produces	O	O
convulsions	B_Disease	O
and	O	O
results	O	O
in	O	O
numerous	O	O
biochemical	O	O
and	O	O
behavioral	O	B_Disease
deficits	O	I_Disease
.	O	O

These	O	O
studies	O	O
were	O	O
undertaken	O	O
to	O	O
determine	O	O
if	O	O
neonatal	O	O
administration	O	O
of	O	O
MSG	B_Chemical	O
produced	O	O
permanent	O	O
alterations	O	O
in	O	O
seizure	B_Disease	O
susceptibility	O	O
,	O	O
since	O	O
previous	O	O
investigations	O	O
were	O	O
inconclusive	O	O
.	O	O

A	O	O
flurothyl	B_Chemical	O
ether	B_Chemical	O
seizure	B_Disease	O
screening	O	O
technique	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
seizure	B_Disease	O
susceptibility	O	O
in	O	O
adult	O	O
mice	O	O
that	O	O
received	O	O
neonatal	O	O
injections	O	O
of	O	O
MSG	B_Chemical	O
(	O	O
4	O	O
mg/g	O	O
and	O	O
1	O	O
mg/g	O	O
)	O	O
.	O	O

MSG	B_Chemical	O
treatment	O	O
resulted	O	O
in	O	O
significant	O	O
reductions	O	O
in	O	O
whole	O	O
brain	O	O
weight	O	O
but	O	O
did	O	O
not	O	O
alter	O	O
seizure	B_Disease	O
threshold	O	O
.	O	O

A	O	O
naloxone	B_Chemical	O
(	O	O
5	O	O
mg/kg	O	O
)	O	O
challenge	O	O
was	O	O
also	O	O
ineffective	O	O
in	O	O
altering	O	O
the	O	O
seizure	B_Disease	O
thresholds	O	O
of	O	O
either	O	O
control	O	O
of	O	O
MSG-treated	O	O
mice	O	O
.	O	O

Flurothyl	B_Chemical	B_Chemical
ether	B_Chemical	I_Chemical
produced	O	O
hypothermia	B_Disease	O
which	O	O
was	O	O
correlated	O	O
with	O	O
the	O	O
duration	O	O
of	O	O
flurothyl	B_Chemical	O
exposure	O	O
;	O	O
however	O	O
,	O	O
the	O	O
relationship	O	O
of	O	O
hypothermia	B_Disease	O
to	O	O
seizure	B_Disease	O
induction	O	O
was	O	O
unclear	O	O
.	O	O

Flurothyl	B_Chemical	O
seizure	B_Disease	O
testing	O	O
proved	O	O
to	O	O
be	O	O
a	O	O
rapid	O	O
and	O	O
reliable	O	O
technique	O	O
with	O	O
which	O	O
to	O	O
evaluate	O	O
seizure	B_Disease	O
susceptibility	O	O
.	O	O

Susceptibility	O	O
to	O	O
seizures	B_Disease	O
produced	O	O
by	O	O
pilocarpine	B_Chemical	O
in	O	O
rats	O	O
after	O	O
microinjection	O	O
of	O	O
isoniazid	B_Chemical	O
or	O	O
gamma-vinyl-GABA	B_Chemical	O
into	O	O
the	O	O
substantia	O	O
nigra	O	O
.	O	O

Pilocarpine	B_Chemical	O
,	O	O
given	O	O
intraperitoneally	O	O
to	O	O
rats	O	O
,	O	O
reproduces	O	O
the	O	O
neuropathological	O	O
sequelae	O	O
of	O	O
temporal	B_Disease	B_Disease
lobe	I_Disease	I_Disease
epilepsy	I_Disease	I_Disease
and	O	O
provides	O	O
a	O	O
relevant	O	O
animal	O	O
model	O	O
for	O	O
studying	O	O
mechanisms	O	O
of	O	O
buildup	O	O
of	O	O
convulsive	B_Disease	O
activity	O	O
and	O	O
pathways	O	O
operative	O	O
in	O	O
the	O	O
generalization	O	O
and	O	O
propagation	O	O
of	O	O
seizures	B_Disease	O
within	O	O
the	O	O
forebrain	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
manipulating	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
gamma-aminobutyric	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(GABA)-mediated	O	O
synaptic	O	O
inhibition	O	O
within	O	O
the	O	O
substantia	O	O
nigra	O	O
on	O	O
seizures	B_Disease	O
produced	O	O
by	O	O
pilocarpine	B_Chemical	O
in	O	O
rats	O	O
,	O	O
were	O	O
investigated	O	O
.	O	O

In	O	O
animals	O	O
pretreated	O	O
with	O	O
microinjections	O	O
of	O	O
isoniazid	B_Chemical	O
,	O	O
150	O	O
micrograms	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
activity	O	O
of	O	O
the	O	O
GABA-synthesizing	O	O
enzyme	O	O
,	O	O
L-glutamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
decarboxylase	O	O
,	O	O
into	O	O
the	O	O
substantia	O	O
nigra	O	O
pars	O	O
reticulata	O	O
(	O	O
SNR	O	O
)	O	O
,	O	O
bilaterally	O	O
,	O	O
non-convulsant	O	O
doses	O	O
of	O	O
pilocarpine	B_Chemical	O
,	O	O
100	O	O
and	O	O
200	O	O
mg/kg	O	O
,	O	O
resulted	O	O
in	O	O
severe	O	O
motor	O	O
limbic	O	O
seizures	B_Disease	O
and	O	O
status	B_Disease	O
epilepticus	I_Disease	O
.	O	O

Electroencephalographic	O	O
and	O	O
behavioral	O	O
monitoring	O	O
revealed	O	O
a	O	O
profound	O	O
reduction	O	O
of	O	O
the	O	O
threshold	O	O
for	O	O
pilocarpine-induced	O	O
convulsions	B_Disease	O
.	O	O

Morphological	O	O
analysis	O	O
of	O	O
frontal	O	O
forebrain	O	O
sections	O	O
with	O	O
light	O	O
microscopy	O	O
revealed	O	O
seizure-related	O	O
damage	O	O
to	O	O
the	O	O
hippocampal	O	O
formation	O	O
,	O	O
thalamus	O	O
,	O	O
amygdala	O	O
,	O	O
olfactory	O	O
cortex	O	O
,	O	O
substantia	O	O
nigra	O	O
and	O	O
neocortex	O	O
,	O	O
which	O	O
is	O	O
typically	O	O
observed	O	O
with	O	O
pilocarpine	B_Chemical	O
in	O	O
doses	O	O
exceeding	O	O
350	O	O
mg/kg	O	O
.	O	O

Bilateral	O	O
intrastriatal	O	O
injections	O	O
of	O	O
isoniazid	B_Chemical	O
did	O	O
not	O	O
augment	O	O
seizures	B_Disease	O
produced	O	O
by	O	O
pilocarpine	B_Chemical	O
,	O	O
200	O	O
mg/kg	O	O
.	O	O

Application	O	O
of	O	O
an	O	O
irreversible	O	O
inhibitor	O	O
of	O	O
GABA	B_Chemical	O
transaminase	O	O
,	O	O
gamma-vinyl-GABA	B_Chemical	O
(	O	O
D	B_Chemical	B_Chemical
,	I_Chemical	I_Chemical
L-4-amino-hex-5-enoic	I_Chemical	I_Chemical
acid	I_Chemical	I_Chemical
)	O	O
,	O	O
5	O	O
micrograms	O	O
,	O	O
into	O	O
the	O	O
SNR	O	O
,	O	O
bilaterally	O	O
,	O	O
suppressed	O	O
the	O	O
appearance	O	O
of	O	O
electrographic	O	O
and	O	O
behavioral	O	O
seizures	B_Disease	O
produced	O	O
by	O	O
pilocarpine	B_Chemical	O
,	O	O
380	O	O
mg/kg	O	O
.	O	O

This	O	O
treatment	O	O
was	O	O
also	O	O
sufficient	O	O
to	O	O
protect	O	O
animals	O	O
from	O	O
the	O	O
occurrence	O	O
of	O	O
brain	B_Disease	B_Disease
damage	I_Disease	I_Disease
.	O	O

Microinjections	O	O
of	O	O
gamma-vinyl-GABA	B_Chemical	O
,	O	O
5	O	O
micrograms	O	O
,	O	O
into	O	O
the	O	O
dorsal	O	O
striatum	O	O
,	O	O
bilaterally	O	O
,	O	O
failed	O	O
to	O	O
prevent	O	O
the	O	O
development	O	O
of	O	O
convulsions	B_Disease	O
produced	O	O
by	O	O
pilocarpine	B_Chemical	O
,	O	O
380	O	O
mg/kg	O	O
.	O	O

The	O	O
results	O	O
demonstrate	O	O
that	O	O
the	O	O
threshold	O	O
for	O	O
pilocarpine-induced	O	O
seizures	B_Disease	O
in	O	O
rats	O	O
is	O	O
subjected	O	O
to	O	O
the	O	O
regulation	O	O
of	O	O
the	O	O
GABA-mediated	O	O
synaptic	O	O
inhibition	O	O
within	O	O
the	O	O
substantia	O	O
nigra	O	O
.	O	O

Human	O	O
and	O	O
canine	O	O
ventricular	O	O
vasoactive	O	O
intestinal	O	O
polypeptide	O	O
:	O	O
decrease	O	O
with	O	O
heart	O	B_Disease
failure	O	I_Disease
.	O	O

Vasoactive	O	O
intestinal	O	O
polypeptide	O	O
(	O	O
VIP	O	O
)	O	O
is	O	O
a	O	O
systemic	O	O
and	O	O
coronary	O	O
vasodilator	O	O
that	O	O
may	O	O
have	O	O
positive	O	O
inotropic	O	O
properties	O	O
.	O	O

Myocardial	O	O
levels	O	O
of	O	O
VIP	O	O
were	O	O
assayed	O	O
before	O	O
and	O	O
after	O	O
the	O	O
development	O	O
of	O	O
heart	B_Disease	B_Disease
failure	I_Disease	I_Disease
in	O	O
two	O	O
canine	O	O
models	O	O
.	O	O

In	O	O
the	O	O
first	O	O
,	O	O
cobalt	B_Chemical	O
cardiomyopathy	B_Disease	O
was	O	O
induced	O	O
in	O	O
eight	O	O
dogs	O	O
;	O	O
VIP	O	O
(	O	O
by	O	O
radioimmunoassay	O	O
)	O	O
decreased	O	O
from	O	O
35	O	O
+	O	O
/-	O	O
11	O	O
pg/mg	O	O
protein	O	O
(	O	O
mean	O	O
+	O	O
/-	O	O
SD	O	O
)	O	O
to	O	O
5	O	O
+	O	O
/-	O	O
4	O	O
pg/mg	O	O
protein	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

In	O	O
six	O	O
dogs	O	O
with	O	O
doxorubicin-induced	O	O
heart	B_Disease	B_Disease
failure	I_Disease	I_Disease
,	O	O
VIP	O	O
decreased	O	O
from	O	O
31	O	O
+	O	O
/-	O	O
7	O	O
to	O	O
11	O	O
+	O	O
/-	O	O
4	O	O
pg/mg	O	O
protein	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
VIP	O	O
content	O	O
of	O	O
left	O	O
ventricular	O	O
muscle	O	O
of	O	O
resected	O	O
failing	O	O
hearts	O	O
in	O	O
10	O	O
patients	O	O
receiving	O	O
a	O	O
heart	O	O
transplant	O	O
was	O	O
compared	O	O
with	O	O
the	O	O
papillary	O	O
muscles	O	O
in	O	O
14	O	O
patients	O	O
(	O	O
five	O	O
with	O	O
rheumatic	B_Disease	B_Disease
disease	I_Disease	I_Disease
,	O	O
nine	O	O
with	O	O
myxomatous	B_Disease	B_Disease
degeneration	I_Disease	I_Disease
)	O	O
receiving	O	O
mitral	O	B_Disease
valve	O	I_Disease
prostheses	O	O
.	O	O

The	O	O
lowest	O	O
myocardial	O	O
VIP	O	O
concentration	O	O
was	O	O
found	O	O
in	O	O
the	O	O
hearts	O	O
of	O	O
patients	O	O
with	O	O
coronary	B_Disease	B_Disease
disease	I_Disease	I_Disease
(	O	O
one	O	O
patient	O	O
receiving	O	O
a	O	O
transplant	O	O
and	O	O
three	O	O
receiving	O	O
mitral	O	O
prostheses	O	O
)	O	O
(	O	O
6.3	O	O
+	O	O
/-	O	O
1.9	O	O
pg/mg	O	O
protein	O	O
)	O	O
.	O	O

The	O	O
other	O	O
patients	O	O
undergoing	O	O
transplantation	O	O
had	O	O
an	O	O
average	O	O
ejection	O	O
fraction	O	O
of	O	O
17	O	O
%	O	O
+	O	O
/-	O	O
6	O	O
%	O	O
and	O	O
a	O	O
VIP	O	O
level	O	O
of	O	O
8.8	O	O
+	O	O
/-	O	O
3.9	O	O
pg/mg	O	O
protein	O	O
.	O	O

The	O	O
hearts	O	O
without	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
(	O	O
average	O	O
ejection	O	O
fraction	O	O
of	O	O
this	O	O
group	O	O
62	O	O
%	O	O
+	O	O
/-	O	O
10	O	O
%	O	O
)	O	O
had	O	O
a	O	O
VIP	O	O
concentration	O	O
of	O	O
14.1	O	O
+	O	O
/-	O	O
7.9	O	O
pg/mg	O	O
protein	O	O
,	O	O
and	O	O
this	O	O
was	O	O
greater	O	O
than	O	O
in	O	O
hearts	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
coronary	B_Disease	B_Disease
disease	I_Disease	I_Disease
and	O	O
the	O	O
hearts	O	O
of	O	O
patients	O	O
receiving	O	O
a	O	O
transplant	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

Myocardial	O	O
catecholamines	B_Chemical	O
were	O	O
also	O	O
determined	O	O
in	O	O
14	O	O
subjects	O	O
;	O	O
a	O	O
weak	O	O
correlation	O	O
(	O	O
r	O	O
=	O	O
0.57	O	O
,	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
between	O	O
the	O	O
tissue	O	O
concentrations	O	O
of	O	O
VIP	O	O
and	O	O
norepinephrine	B_Chemical	O
was	O	O
noted.(ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O

Non-invasive	O	O
detection	O	O
of	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
by	O	O
body	O	O
surface	O	O
electrocardiographic	O	O
mapping	O	O
after	O	O
dipyridamole	B_Chemical	B_Chemical
infusion	O	O
.	O	O

Electrocardiographic	O	O
changes	O	O
after	O	O
dipyridamole	B_Chemical	B_Chemical
infusion	O	O
(	O	O
0.568	O	O
mg/kg/4	O	O
min	O	O
)	O	O
were	O	O
studied	O	O
in	O	O
41	O	O
patients	O	O
with	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
and	O	O
compared	O	O
with	O	O
those	O	O
after	O	O
submaximal	O	O
treadmill	O	O
exercise	O	O
by	O	O
use	O	O
of	O	O
the	O	O
body	O	O
surface	O	O
mapping	O	O
technique	O	O
.	O	O

Patients	O	O
were	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
;	O	O
19	O	O
patients	O	O
without	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
(	O	O
non-MI	O	O
group	O	O
)	O	O
,	O	O
14	O	O
with	O	O
anterior	B_Disease	B_Disease
infarction	I_Disease	I_Disease
(	O	O
ANT-MI	B_Disease	O
)	O	O
and	O	O
eight	O	O
with	O	O
inferior	B_Disease	B_Disease
infarction	I_Disease	I_Disease
(	O	O
INF-MI	B_Disease	O
)	O	O
.	O	O

Eighty-seven	O	O
unipolar	O	O
electrocardiograms	O	O
(	O	O
ECGs	O	O
)	O	O
distributed	O	O
over	O	O
the	O	O
entire	O	O
thoracic	O	O
surface	O	O
were	O	O
simultaneously	O	O
recorded	O	O
.	O	O

After	O	O
dipyridamole	B_Chemical	B_Chemical
,	O	O
ischemic	B_Disease	O
ST-segment	O	O
depression	B_Disease	O
(	O	O
0.05	O	O
mV	O	O
or	O	O
more	O	O
)	O	O
was	O	O
observed	O	O
in	O	O
84	O	O
%	O	O
of	O	O
the	O	O
non-MI	O	O
group	O	O
,	O	O
29	O	O
%	O	O
of	O	O
the	O	O
ANT-MI	B_Disease	O
group	O	O
,	O	O
63	O	O
%	O	O
of	O	O
the	O	O
INF-MI	B_Disease	O
group	O	O
and	O	O
61	O	O
%	O	O
of	O	O
the	O	O
total	O	O
population	O	O
.	O	O

Exercise-induced	O	O
ST	O	O
depression	B_Disease	O
was	O	O
observed	O	O
in	O	O
84	O	O
%	O	O
of	O	O
the	O	O
non-MI	O	O
group	O	O
,	O	O
43	O	O
%	O	O
of	O	O
the	O	O
ANT-MI	B_Disease	O
group	O	O
,	O	O
38	O	O
%	O	O
of	O	O
the	O	O
INF-MI	B_Disease	O
group	O	O
and	O	O
61	O	O
%	O	O
of	O	O
the	O	O
total	O	O
.	O	O

For	O	O
individual	O	O
patients	O	O
,	O	O
there	O	O
were	O	O
no	O	O
obvious	O	O
differences	O	O
between	O	O
the	O	O
body	O	O
surface	O	O
distribution	O	O
of	O	O
ST	O	O
depression	B_Disease	O
in	O	O
both	O	O
tests	O	O
.	O	O

The	O	O
increase	O	O
in	O	O
pressure	O	O
rate	O	O
product	O	O
after	O	O
dipyridamole	B_Chemical	B_Chemical
was	O	O
significantly	O	O
less	O	O
than	O	O
that	O	O
during	O	O
the	O	O
treadmill	O	O
exercise	O	O
.	O	O

The	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
dipyridamole-induced	O	O
myocardial	B_Disease	O
ischemia	I_Disease	O
is	O	O
caused	O	O
by	O	O
the	O	O
inhomogenous	O	O
distribution	O	O
of	O	O
myocardial	O	O
blood	O	O
flow	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
dipyridamole	B_Chemical	B_Chemical
ECG	O	O
test	O	O
is	O	O
as	O	O
useful	O	O
as	O	O
the	O	O
exercise	O	O
ECG	O	O
test	O	O
for	O	O
the	O	O
assessment	O	O
of	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
.	O	O

Bradycardia	B_Disease	O
after	O	O
high-dose	O	O
intravenous	O	O
methylprednisolone	B_Chemical	B_Chemical
therapy	O	O
.	O	O

In	O	O
5	O	O
consecutive	O	O
patients	O	O
with	O	O
rheumatoid	B_Disease	B_Disease
arthritis	I_Disease	I_Disease
who	O	O
received	O	O
intravenous	O	O
high-dose	O	B_Chemical
methylprednisolone	B_Chemical	I_Chemical
(	O	O
MP	B_Chemical	O
)	O	O
therapy	O	O
(	O	O
1	O	O
g	O	O
daily	O	O
for	O	O
2	O	O
or	O	O
3	O	O
consecutive	O	O
days	O	O
)	O	O
,	O	O
a	O	O
decline	O	O
in	O	O
pulse	O	O
rate	O	O
was	O	O
observed	O	O
,	O	O
most	O	O
pronounced	O	O
on	O	O
day	O	O
4	O	O
.	O	O

In	O	O
one	O	O
of	O	O
the	O	O
5	O	O
patients	O	O
the	O	O
bradycardia	B_Disease	O
was	O	O
associated	O	O
with	O	O
complaints	O	O
of	O	O
substernal	O	O
pressure	O	O
.	O	O

Reversal	O	O
to	O	O
normal	O	O
heart	O	O
rate	O	O
was	O	O
found	O	O
on	O	O
day	O	O
7	O	O
.	O	O

Electrocardiographic	O	O
registrations	O	O
showed	O	O
sinus	B_Disease	B_Disease
bradycardia	I_Disease	I_Disease
in	O	O
all	O	O
cases	O	O
.	O	O

No	O	O
significant	O	O
changes	O	O
in	O	O
plasma	O	O
concentrations	O	O
of	O	O
electrolytes	O	O
were	O	O
found	O	O
.	O	O

Careful	O	O
observation	O	O
of	O	O
patients	O	O
receiving	O	O
high-dose	O	O
MP	B_Chemical	O
is	O	O
recommended	O	O
.	O	O

High-dose	O	O
MP	B_Chemical	O
may	O	O
be	O	O
contraindicated	O	O
in	O	O
patients	O	O
with	O	O
known	O	O
heart	B_Disease	B_Disease
disease	I_Disease	I_Disease
.	O	O

Two	O	O
cases	O	O
of	O	O
downbeat	B_Disease	O
nystagmus	I_Disease	O
and	O	O
oscillopsia	B_Disease	O
associated	O	O
with	O	O
carbamazepine	B_Chemical	B_Chemical
.	O	O

Downbeat	B_Disease	O
nystagmus	I_Disease	O
is	O	O
often	O	O
associated	O	O
with	O	O
structural	O	O
lesions	O	O
at	O	O
the	O	O
craniocervical	O	O
junction	O	O
,	O	O
but	O	O
has	O	O
occasionally	O	O
been	O	O
reported	O	O
as	O	O
a	O	O
manifestation	O	O
of	O	O
metabolic	O	B_Disease
imbalance	O	I_Disease
or	O	O
drug	O	O
intoxication	O	O
.	O	O

We	O	O
recorded	O	O
the	O	O
eye	O	O
movements	O	O
of	O	O
two	O	O
patients	O	O
with	O	O
reversible	O	O
downbeat	B_Disease	O
nystagmus	I_Disease	O
related	O	O
to	O	O
carbamazepine	B_Chemical	B_Chemical
therapy	O	O
.	O	O

The	O	O
nystagmus	B_Disease	O
of	O	O
both	O	O
patients	O	O
resolved	O	O
after	O	O
reduction	O	O
of	O	O
the	O	O
serum	O	O
carbamazepine	B_Chemical	B_Chemical
levels	O	O
.	O	O

Neuroradiologic	O	O
investigations	O	O
including	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
scans	O	O
in	O	O
both	O	O
patients	O	O
showed	O	O
no	O	O
evidence	O	O
of	O	O
intracranial	O	O
abnormality	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
downbeat	B_Disease	O
nystagmus	I_Disease	O
who	O	O
are	O	O
taking	O	O
anticonvulsant	O	O
medications	O	O
,	O	O
consideration	O	O
should	O	O
be	O	O
given	O	O
to	O	O
reduction	O	O
in	O	O
dose	O	O
before	O	O
further	O	O
investigation	O	O
is	O	O
undertaken	O	O
.	O	O

Improvement	O	O
by	O	O
denopamine	B_Chemical	B_Chemical
(	O	O
TA-064	B_Chemical	O
)	O	O
of	O	O
pentobarbital-induced	O	O
cardiac	B_Disease	B_Disease
failure	I_Disease	I_Disease
in	O	O
the	O	O
dog	O	O
heart-lung	O	O
preparation	O	O
.	O	O

The	O	O
efficacy	O	O
of	O	O
denopamine	B_Chemical	B_Chemical
,	O	O
an	O	O
orally	O	O
active	O	O
beta	O	O
1-adrenoceptor	O	O
agonist	O	O
,	O	O
in	O	O
improving	O	O
cardiac	B_Disease	B_Disease
failure	I_Disease	I_Disease
was	O	O
assessed	O	O
in	O	O
dog	O	O
heart-lung	O	O
preparations	O	O
.	O	O

Cardiac	O	O
functions	O	O
depressed	O	O
by	O	O
pentobarbital	B_Chemical	O
(	O	O
118	O	O
+	O	O
/-	O	O
28	O	O
mg	O	O
;	O	O
mean	O	O
value	O	O
+	O	O
/-	O	O
SD	O	O
)	O	O
such	O	O
that	O	O
cardiac	O	O
output	O	O
and	O	O
maximum	O	O
rate	O	O
of	O	O
rise	O	O
of	O	O
left	O	O
ventricular	O	O
pressure	O	O
(	O	O
LV	O	O
dP/dt	O	O
max	O	O
)	O	O
had	O	O
been	O	O
reduced	O	O
by	O	O
about	O	O
35	O	O
%	O	O
and	O	O
26	O	O
%	O	O
of	O	O
the	O	O
respective	O	O
controls	O	O
were	O	O
improved	O	O
by	O	O
denopamine	B_Chemical	B_Chemical
(	O	O
10	O	O
-	O	O
300	O	O
micrograms	O	O
)	O	O
in	O	O
a	O	O
dose-dependent	O	O
manner	O	O
.	O	O

With	O	O
100	O	O
micrograms	O	O
denopamine	B_Chemical	B_Chemical
,	O	O
almost	O	O
complete	O	O
restoration	O	O
of	O	O
cardiac	O	O
performance	O	O
was	O	O
attained	O	O
,	O	O
associated	O	O
with	O	O
a	O	O
slight	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
.	O	O

No	O	O
arrhythmias	B_Disease	O
were	O	O
induced	O	O
by	O	O
these	O	O
doses	O	O
of	O	O
denopamine	B_Chemical	B_Chemical
.	O	O

The	O	O
results	O	O
warrant	O	O
clinical	O	O
trials	O	O
of	O	O
denopamine	B_Chemical	B_Chemical
in	O	O
the	O	O
treatment	O	O
of	O	O
cardiac	B_Disease	B_Disease
failure	I_Disease	I_Disease
.	O	O

Clonazepam	B_Chemical	B_Chemical
monotherapy	O	O
for	O	O
epilepsy	B_Disease	O
in	O	O
childhood	O	O
.	O	O

Sixty	O	O
patients	O	O
(	O	O
age-range	O	O
one	O	O
month	O	O
to	O	O
14	O	O
years	O	O
)	O	O
with	O	O
other	O	O
types	O	O
of	O	O
epilepsy	B_Disease	O
than	O	O
infantile	B_Disease	B_Disease
spasms	I_Disease	I_Disease
were	O	O
treated	O	O
with	O	O
clonazepam	B_Chemical	B_Chemical
.	O	O

Disappearance	O	O
of	O	O
seizures	B_Disease	O
and	O	O
normalization	O	O
of	O	O
abnormal	O	O
EEG	O	O
with	O	O
disappearance	O	O
of	O	O
seizures	B_Disease	O
were	O	O
recognized	O	O
in	O	O
77	O	O
%	O	O
and	O	O
50	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

Seizures	B_Disease	O
disappeared	O	O
in	O	O
71	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
generalized	O	O
seizures	B_Disease	O
and	O	O
89	O	O
%	O	O
of	O	O
partial	O	O
seizures	B_Disease	O
.	O	O

Improvement	O	O
of	O	O
abnormal	O	O
EEG	O	O
was	O	O
noticed	O	O
in	O	O
76	O	O
%	O	O
of	O	O
diffuse	O	O
paroxysms	O	O
and	O	O
in	O	O
67	O	O
%	O	O
of	O	O
focal	O	O
paroxysms	O	O
.	O	O

In	O	O
excellent	O	O
cases	O	O
,	O	O
mean	O	O
effective	O	O
dosages	O	O
were	O	O
0.086	O	O
+	O	O
/-	O	O
0.021	O	O
mg/kg/day	O	O
in	O	O
infants	O	O
and	O	O
0.057	O	O
+	O	O
/-	O	O
0.022	O	O
mg/kg/day	O	O
in	O	O
schoolchildren	O	O
,	O	O
this	O	O
difference	O	O
was	O	O
statistically	O	O
significant	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.005	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
side	O	O
effects	O	O
such	O	O
as	O	O
drowsiness	B_Disease	O
and	O	O
ataxia	B_Disease	O
was	O	O
only	O	O
5	O	O
%	O	O
.	O	O

Postmarketing	O	O
study	O	O
of	O	O
timolol-hydrochlorothiazide	O	B_Chemical
antihypertensive	O	O
therapy	O	O
.	O	O

A	O	O
postmarketing	O	O
surveillance	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
determine	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
a	O	O
fixed-ratio	O	O
combination	O	O
containing	O	O
10	O	O
mg	O	O
of	O	O
timolol	B_Chemical	B_Chemical
maleate	I_Chemical	I_Chemical
and	O	O
25	O	O
mg	O	O
of	O	O
hydrochlorothiazide	B_Chemical	O
,	O	O
administered	O	O
twice	O	O
daily	O	O
for	O	O
one	O	O
month	O	O
to	O	O
hypertensive	B_Disease	O
patients	O	O
.	O	O

Data	O	O
on	O	O
9,037	O	O
patients	O	O
were	O	O
collected	O	O
by	O	O
1,455	O	O
participating	O	O
physicians	O	O
.	O	O

Mean	O	O
systolic	O	O
blood	O	O
pressure	O	O
decreased	O	O
25	O	O
mmHg	O	O
and	O	O
mean	O	O
diastolic	O	O
blood	O	O
pressure	O	O
declined	O	O
15	O	O
mmHg	O	O
after	O	O
one	O	O
month	O	O
of	O	O
timolol-hydrochlorothiazide	O	B_Chemical
therapy	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
,	O	O
both	O	O
comparisons	O	O
)	O	O
.	O	O

Age	O	O
,	O	O
race	O	O
,	O	O
and	O	O
sex	O	O
appeared	O	O
to	O	O
have	O	O
no	O	O
influence	O	O
on	O	O
the	O	O
decrease	O	O
in	O	O
blood	O	O
pressure	O	O
.	O	O

The	O	O
antihypertensive	O	O
effect	O	O
of	O	O
the	O	O
drug	O	O
was	O	O
greater	O	O
in	O	O
patients	O	O
with	O	O
more	O	O
severe	O	O
hypertension	B_Disease	O
.	O	O

Overall	O	O
,	O	O
1,453	O	O
patients	O	O
experienced	O	O
a	O	O
total	O	O
of	O	O
2,658	O	O
adverse	O	O
events	O	O
,	O	O
the	O	O
most	O	O
common	O	O
being	O	O
fatigue	B_Disease	O
,	O	O
dizziness	B_Disease	O
,	O	O
and	O	O
weakness	B_Disease	O
.	O	O

Treatment	O	O
in	O	O
590	O	O
patients	O	O
was	O	O
discontinued	O	O
because	O	O
of	O	O
adverse	O	O
events	O	O
.	O	O

Salicylate	B_Chemical	O
nephropathy	B_Disease	O
in	O	O
the	O	O
Gunn	O	O
rat	O	O
:	O	O
potential	O	O
role	O	O
of	O	O
prostaglandins	B_Chemical	O
.	O	O

We	O	O
examined	O	O
the	O	O
potential	O	O
role	O	O
of	O	O
prostaglandins	B_Chemical	O
in	O	O
the	O	O
development	O	O
of	O	O
analgesic	O	O
nephropathy	B_Disease	O
in	O	O
the	O	O
Gunn	O	O
strain	O	O
of	O	O
rat	O	O
.	O	O

The	O	O
homozygous	O	O
Gunn	O	O
rats	O	O
have	O	O
unconjugated	O	O
hyperbilirubinemia	B_Disease	O
due	O	O
to	O	O
the	O	O
absence	O	O
of	O	O
glucuronyl	B_Chemical	O
transferase	O	O
,	O	O
leading	O	O
to	O	O
marked	O	O
bilirubin	B_Chemical	O
deposition	O	O
in	O	O
renal	O	O
medulla	O	O
and	O	O
papilla	O	O
.	O	O

These	O	O
rats	O	O
are	O	O
also	O	O
highly	O	O
susceptible	O	O
to	O	O
develop	O	O
papillary	B_Disease	B_Disease
necrosis	I_Disease	I_Disease
with	O	O
analgesic	O	O
administration	O	O
.	O	O

We	O	O
used	O	O
homozygous	O	O
(	O	O
jj	O	O
)	O	O
and	O	O
phenotypically	O	O
normal	O	O
heterozygous	O	O
(	O	O
jJ	O	O
)	O	O
animals	O	O
.	O	O

Four	O	O
groups	O	O
of	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
were	O	O
studied	O	O
:	O	O
jj	O	O
and	O	O
jJ	O	O
rats	O	O
treated	O	O
either	O	O
with	O	O
aspirin	B_Chemical	O
300	O	O
mg/kg	O	O
every	O	O
other	O	O
day	O	O
or	O	O
sham-treated	O	O
.	O	O

After	O	O
one	O	O
week	O	O
,	O	O
slices	O	O
of	O	O
cortex	O	O
,	O	O
outer	O	O
and	O	O
inner	O	O
medulla	O	O
from	O	O
one	O	O
kidney	O	O
were	O	O
incubated	O	O
in	O	O
buffer	O	O
and	O	O
prostaglandin	B_Chemical	O
synthesis	O	O
was	O	O
determined	O	O
by	O	O
radioimmunoassay	O	O
.	O	O

The	O	O
other	O	O
kidney	O	O
was	O	O
examined	O	O
histologically	O	O
.	O	O

A	O	O
marked	O	O
corticomedullary	O	O
gradient	O	O
of	O	O
prostaglandin	B_Chemical	O
synthesis	O	O
was	O	O
observed	O	O
in	O	O
all	O	O
groups	O	O
.	O	O

PGE2	B_Chemical	O
synthesis	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
outer	O	O
medulla	O	O
,	O	O
but	O	O
not	O	O
cortex	O	O
or	O	O
inner	O	O
medulla	O	O
,	O	O
of	O	O
jj	O	O
(	O	O
38	O	O
+	O	O
/-	O	O
6	O	O
ng/mg	O	O
prot	O	O
)	O	O
than	O	O
jJ	O	O
rats	O	O
(	O	O
15	O	O
+	O	O
/-	O	O
3	O	O
)	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
.	O	O

Aspirin	B_Chemical	O
treatment	O	O
reduced	O	O
PGE2	B_Chemical	O
synthesis	O	O
in	O	O
all	O	O
regions	O	O
,	O	O
but	O	O
outer	O	O
medullary	O	O
PGE2	B_Chemical	O
remained	O	O
higher	O	O
in	O	O
jj	O	O
(	O	O
18	O	O
+	O	O
/-	O	O
3	O	O
)	O	O
than	O	O
jJ	O	O
rats	O	O
(	O	O
9	O	O
+	O	O
/-	O	O
2	O	O
)	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

PGF2	B_Chemical	O
alpha	I_Chemical	O
was	O	O
also	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
outer	O	O
medulla	O	O
of	O	O
jj	O	O
rats	O	O
with	O	O
and	O	O
without	O	O
aspirin	B_Chemical	O
administration	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
changes	O	O
in	O	O
renal	O	O
prostaglandin	B_Chemical	O
synthesis	O	O
were	O	O
accompanied	O	O
by	O	O
evidence	O	O
of	O	O
renal	B_Disease	B_Disease
damage	I_Disease	I_Disease
in	O	O
aspirin-treated	O	O
jj	O	O
but	O	O
not	O	O
jJ	O	O
rats	O	O
as	O	O
evidenced	O	O
by	O	O
:	O	O
increased	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
hematuria	B_Disease	O
(	O	O
p	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
;	O	O
increased	O	O
serum	O	B_Chemical
creatinine	B_Chemical	I_Chemical
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
;	O	O
and	O	O
increase	O	O
in	O	O
outer	O	O
medullary	O	O
histopathologic	O	O
lesions	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.005	O	O
compared	O	O
to	O	O
either	O	O
sham-treated	O	O
jj	O	O
or	O	O
aspirin-treated	O	O
jJ	O	O
)	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
enhanced	O	O
prostaglandin	B_Chemical	O
synthesis	O	O
contributes	O	O
to	O	O
maintenance	O	O
of	O	O
renal	O	O
function	O	O
and	O	O
morphological	O	O
integrity	O	O
,	O	O
and	O	O
that	O	O
inhibition	O	O
of	O	O
prostaglandin	B_Chemical	O
synthesis	O	O
may	O	O
lead	O	O
to	O	O
pathological	B_Disease	O
renal	I_Disease	O
medullary	I_Disease	O
lesions	I_Disease	O
and	O	O
deterioration	B_Disease	O
of	I_Disease	O
renal	I_Disease	O
function	I_Disease	O
.	O	O

Prophylactic	O	O
lidocaine	B_Chemical	O
in	O	O
the	O	O
early	O	O
phase	O	O
of	O	O
suspected	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
.	O	O

Four	O	O
hundred	O	O
two	O	O
patients	O	O
with	O	O
suspected	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
seen	O	O
within	O	O
6	O	O
hours	O	O
of	O	O
the	O	O
onset	O	O
of	O	O
symptoms	O	O
entered	O	O
a	O	O
double-blind	O	O
randomized	O	O
trial	O	O
of	O	O
lidocaine	B_Chemical	O
vs	O	O
placebo	O	O
.	O	O

During	O	O
the	O	O
1	O	O
hour	O	O
after	O	O
administration	O	O
of	O	O
the	O	O
drug	O	O
the	O	O
incidence	O	O
of	O	O
ventricular	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
or	O	O
sustained	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
among	O	O
the	O	O
204	O	O
patients	O	O
with	O	O
acute	O	B_Disease
myocardial	B_Disease	I_Disease
infarction	I_Disease	I_Disease
was	O	O
low	O	O
,	O	O
1.5	O	O
%	O	O
.	O	O

Lidocaine	B_Chemical	O
,	O	O
given	O	O
in	O	O
a	O	O
300	O	O
mg	O	O
dose	O	O
intramuscularly	O	O
followed	O	O
by	O	O
100	O	O
mg	O	O
intravenously	O	O
,	O	O
did	O	O
not	O	O
prevent	O	O
sustained	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
,	O	O
although	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
warning	O	O
arrhythmias	B_Disease	O
between	O	O
15	O	O
and	O	O
45	O	O
minutes	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
lidocaine	B_Chemical	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

The	O	O
average	O	O
plasma	O	O
lidocaine	B_Chemical	O
level	O	O
10	O	O
minutes	O	O
after	O	O
administration	O	O
for	O	O
patients	O	O
without	O	O
a	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
was	O	O
significantly	O	O
higher	O	O
than	O	O
that	O	O
for	O	O
patients	O	O
with	O	O
an	O	O
acute	O	B_Disease
infarction	B_Disease	I_Disease
.	O	O

The	O	O
mean	O	O
plasma	O	O
lidocaine	B_Chemical	O
level	O	O
of	O	O
patients	O	O
on	O	O
beta-blocking	O	O
agents	O	O
was	O	O
no	O	O
different	O	O
from	O	O
that	O	O
in	O	O
patients	O	O
not	O	O
on	O	O
beta	O	O
blocking	O	O
agents	O	O
.	O	O

During	O	O
the	O	O
1-hour	O	O
study	O	O
period	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
central	O	O
nervous	O	O
system	O	O
side	O	O
effects	O	O
was	O	O
significantly	O	O
greater	O	O
in	O	O
the	O	O
lidocaine	B_Chemical	O
group	O	O
,	O	O
hypotension	B_Disease	O
occurred	O	O
in	O	O
11	O	O
patients	O	O
,	O	O
nine	O	O
of	O	O
whom	O	O
had	O	O
received	O	O
lidocaine	B_Chemical	O
,	O	O
and	O	O
four	O	O
patients	O	O
died	O	O
from	O	O
asystole	B_Disease	O
,	O	O
three	O	O
of	O	O
whom	O	O
had	O	O
had	O	O
lidocaine	B_Chemical	O
.	O	O

We	O	O
can	O	O
not	O	O
advocate	O	O
the	O	O
administration	O	O
of	O	O
lidocaine	B_Chemical	O
prophylactically	O	O
in	O	O
the	O	O
early	O	O
hours	O	O
of	O	O
suspected	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
.	O	O

Evidence	O	O
for	O	O
a	O	O
cholinergic	O	O
role	O	O
in	O	O
haloperidol-induced	O	O
catalepsy	B_Disease	O
.	O	O

Experiments	O	O
in	O	O
mice	O	O
tested	O	O
previous	O	O
evidence	O	O
that	O	O
activation	O	O
of	O	O
cholinergic	O	O
systems	O	O
promotes	O	O
catalepsy	B_Disease	O
and	O	O
that	O	O
cholinergic	O	O
mechanisms	O	O
need	O	O
to	O	O
be	O	O
intact	O	O
for	O	O
full	O	O
expression	O	O
of	O	O
neuroleptic-induced	O	O
catalepsy	B_Disease	O
.	O	O

Large	O	O
doses	O	O
of	O	O
the	O	O
cholinomimetic	O	O
,	O	O
pilocarpine	B_Chemical	O
,	O	O
could	O	O
induce	O	O
catalepsy	B_Disease	O
when	O	O
peripheral	O	O
cholinergic	O	O
receptors	O	O
were	O	O
blocked	O	O
.	O	O

Low	O	O
doses	O	O
of	O	O
pilocarpine	B_Chemical	O
caused	O	O
a	O	O
pronounced	O	O
enhancement	O	O
of	O	O
the	O	O
catalepsy	B_Disease	O
that	O	O
was	O	O
induced	O	O
by	O	O
the	O	O
dopaminergic	O	O
blocker	O	O
,	O	O
haloperidol	B_Chemical	O
.	O	O

A	O	O
muscarinic	O	O
receptor	O	O
blocker	O	O
,	O	O
atropine	B_Chemical	O
,	O	O
disrupted	O	O
haloperidol-induced	O	O
catalepsy	B_Disease	O
.	O	O

Intracranial	O	O
injection	O	O
of	O	O
an	O	O
acetylcholine-synthesis	O	O
inhibitor	O	O
,	O	O
hemicholinium	B_Chemical	O
,	O	O
prevented	O	O
the	O	O
catalepsy	B_Disease	O
that	O	O
is	O	O
usually	O	O
induced	O	O
by	O	O
haloperidol	B_Chemical	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
catalepsy	B_Disease	O
that	O	O
is	O	O
produced	O	O
by	O	O
neuroleptics	B_Chemical	O
such	O	O
as	O	O
haloperidol	B_Chemical	O
is	O	O
actually	O	O
mediated	O	O
by	O	O
intrinsic	O	O
central	O	O
cholinergic	O	O
systems	O	O
.	O	O

Alternatively	O	O
,	O	O
activation	O	O
of	O	O
central	O	O
cholinergic	O	O
systems	O	O
could	O	O
promote	O	O
catalepsy	B_Disease	O
by	O	O
suppression	O	O
of	O	O
dopaminergic	O	O
systems	O	O
.	O	O

Cardiovascular	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
and	O	O
hypersensitivity	B_Disease	O
to	O	O
sodium	B_Chemical	B_Chemical
pentobarbital	I_Chemical	I_Chemical
induced	O	O
by	O	O
chronic	O	O
barium	B_Chemical	B_Chemical
chloride	I_Chemical	I_Chemical
ingestion	O	O
.	O	O

Barium-supplemented	O	O
Long-Evans	O	O
hooded	O	O
rats	O	O
were	O	O
characterized	O	O
by	O	O
a	O	O
persistent	O	O
hypertension	B_Disease	O
that	O	O
was	O	O
evident	O	O
after	O	O
1	O	O
month	O	O
of	O	O
barium	B_Chemical	O
(	O	O
100	O	O
micrograms/ml	O	O
mineral	O	O
fortified	O	O
water	O	O
)	O	O
treatment	O	O
.	O	O

Analysis	O	O
of	O	O
in	O	O
vivo	O	O
myocardial	O	O
excitability	O	O
,	O	O
contractility	O	O
,	O	O
and	O	O
metabolic	O	O
characteristics	O	O
at	O	O
16	O	O
months	O	O
revealed	O	O
other	O	O
significant	O	O
barium-induced	O	O
disturbances	B_Disease	O
within	I_Disease	O
the	I_Disease	O
cardiovascular	I_Disease	O
system	I_Disease	O
.	O	O

The	O	O
most	O	O
distinctive	O	O
aspect	O	O
of	O	O
the	O	O
barium	B_Chemical	O
effect	O	O
was	O	O
a	O	O
demonstrated	O	O
hypersensitivity	B_Disease	O
of	O	O
the	O	O
cardiovascular	O	O
system	O	O
to	O	O
sodium	B_Chemical	B_Chemical
pentobarbital	I_Chemical	I_Chemical
.	O	O

Under	O	O
barbiturate	B_Chemical	O
anesthesia	O	O
,	O	O
virtually	O	O
all	O	O
of	O	O
the	O	O
myocardial	O	O
contractile	O	O
indices	O	O
were	O	O
depressed	O	O
significantly	O	O
in	O	O
barium-exposed	O	O
rats	O	O
relative	O	O
to	O	O
the	O	O
corresponding	O	O
control-fed	O	O
rats	O	O
.	O	O

The	O	O
lack	O	O
of	O	O
a	O	O
similar	O	O
response	O	O
to	O	O
ketamine	B_Chemical	O
and	O	O
xylazine	B_Chemical	B_Chemical
anesthesia	O	O
revealed	O	O
that	O	O
the	O	O
cardiovascular	O	O
actions	O	O
of	O	O
sodium	B_Chemical	B_Chemical
pentobarbital	I_Chemical	I_Chemical
in	O	O
barium-treated	O	O
rats	O	O
were	O	O
linked	O	O
specifically	O	O
to	O	O
this	O	O
anesthetic	O	O
,	O	O
and	O	O
were	O	O
not	O	O
representative	O	O
of	O	O
a	O	O
generalized	O	O
anesthetic	O	O
response	O	O
.	O	O

Other	O	O
myocardial	O	O
pathophysiologic	O	O
and	O	O
metabolic	O	O
changes	O	O
induced	O	O
by	O	O
barium	B_Chemical	O
were	O	O
manifest	O	O
,	O	O
irrespective	O	O
of	O	O
the	O	O
anesthetic	O	O
employed	O	O
.	O	O

The	O	O
contractile	O	O
element	O	O
shortening	O	O
velocity	O	O
of	O	O
the	O	O
cardiac	O	O
muscle	O	O
fibers	O	O
was	O	O
significantly	O	O
slower	O	O
in	O	O
both	O	O
groups	O	O
of	O	O
barium-treated	O	O
rats	O	O
relative	O	O
to	O	O
the	O	O
control	O	O
groups	O	O
,	O	O
irrespective	O	O
of	O	O
the	O	O
anesthetic	O	O
regimen	O	O
.	O	O

Similarly	O	O
,	O	O
significant	O	O
disturbances	O	O
in	O	O
myocardial	O	O
energy	O	O
metabolism	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
barium-exposed	O	O
rats	O	O
which	O	O
were	O	O
consistent	O	O
with	O	O
the	O	O
reduced	O	O
contractile	O	O
element	O	O
shortening	O	O
velocity	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
excitability	O	O
of	O	O
the	O	O
cardiac	O	O
conduction	O	O
system	O	O
was	O	O
depressed	O	O
preferentially	O	O
in	O	O
the	O	O
atrioventricular	O	O
nodal	O	O
region	O	O
of	O	O
hearts	O	O
from	O	O
barium-exposed	O	O
rats	O	O
.	O	O

Overall	O	O
,	O	O
the	O	O
altered	O	O
cardiac	O	O
contractility	O	O
and	O	O
excitability	O	O
characteristics	O	O
,	O	O
the	O	O
myocardial	O	O
metabolic	B_Disease	B_Disease
disturbances	I_Disease	I_Disease
,	O	O
and	O	O
the	O	O
hypersensitivity	B_Disease	O
of	O	O
the	O	O
cardiovascular	O	O
system	O	O
to	O	O
sodium	B_Chemical	B_Chemical
pentobarbital	I_Chemical	I_Chemical
suggest	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
heretofore	O	O
undescribed	O	O
cardiomyopathic	B_Disease	B_Disease
disorder	I_Disease	I_Disease
induced	O	O
by	O	O
chronic	O	O
barium	B_Chemical	O
exposure	O	O
.	O	O

These	O	O
experimental	O	O
findings	O	O
represent	O	O
the	O	O
first	O	O
indication	O	O
that	O	O
life-long	O	O
barium	B_Chemical	O
ingestion	O	O
may	O	O
have	O	O
significant	O	O
adverse	O	O
effects	O	O
on	O	O
the	O	O
mammalian	O	O
cardiovascular	O	O
system	O	O
.	O	O

Propranolol	B_Chemical	B_Chemical
antagonism	O	O
of	O	O
phenylpropanolamine-induced	O	O
hypertension	B_Disease	O
.	O	O

Phenylpropanolamine	B_Chemical	O
(	O	O
PPA	B_Chemical	O
)	O	O
overdose	B_Disease	O
can	O	O
cause	O	O
severe	O	O
hypertension	B_Disease	O
,	O	O
intracerebral	B_Disease	B_Disease
hemorrhage	I_Disease	I_Disease
,	O	O
and	O	O
death	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
propranolol	B_Chemical	B_Chemical
in	O	O
the	O	O
treatment	O	O
of	O	O
PPA-induced	O	O
hypertension	B_Disease	O
.	O	O

Subjects	O	O
received	O	O
propranolol	B_Chemical	B_Chemical
either	O	O
by	O	O
mouth	O	O
for	O	O
48	O	O
hours	O	O
before	O	O
PPA	B_Chemical	O
or	O	O
as	O	O
a	O	O
rapid	O	O
intravenous	O	O
infusion	O	O
after	O	O
PPA	B_Chemical	O
.	O	O

PPA	B_Chemical	O
,	O	O
75	O	O
mg	O	O
alone	O	O
,	O	O
increased	O	O
blood	O	O
pressure	O	O
(	O	O
31	O	O
+	O	O
/-	O	O
14	O	O
mm	O	O
Hg	O	O
systolic	O	O
,	O	O
20	O	O
+	O	O
/-	O	O
5	O	O
mm	O	O
Hg	O	O
diastolic	O	O
)	O	O
,	O	O
and	O	O
propranolol	B_Chemical	B_Chemical
pretreatment	O	O
antagonized	O	O
this	O	O
increase	O	O
(	O	O
12	O	O
+	O	O
/-	O	O
10	O	O
mm	O	O
Hg	O	O
systolic	O	O
,	O	O
10	O	O
+	O	O
/-	O	O
7	O	O
mm	O	O
Hg	O	O
diastolic	O	O
)	O	O
.	O	O

Intravenous	O	O
propranolol	B_Chemical	B_Chemical
after	O	O
PPA	B_Chemical	O
also	O	O
decreased	O	O
blood	O	O
pressure	O	O
.	O	O

Left	O	O
ventricular	O	O
function	O	O
(	O	O
assessed	O	O
by	O	O
echocardiography	O	O
)	O	O
showed	O	O
that	O	O
PPA	B_Chemical	O
increased	O	O
the	O	O
stroke	B_Disease	O
volume	O	O
30	O	O
%	O	O
(	O	O
from	O	O
62.5	O	O
+	O	O
/-	O	O
20.9	O	O
to	O	O
80.8	O	O
+	O	O
/-	O	O
22.4	O	O
ml	O	O
)	O	O
,	O	O
the	O	O
ejection	O	O
fraction	O	O
9	O	O
%	O	O
(	O	O
from	O	O
64	O	O
%	O	O
+	O	O
/-	O	O
10	O	O
%	O	O
to	O	O
70	O	O
%	O	O
+	O	O
/-	O	O
7	O	O
%	O	O
)	O	O
,	O	O
and	O	O
cardiac	O	O
output	O	O
14	O	O
%	O	O
(	O	O
from	O	O
3.6	O	O
+	O	O
/-	O	O
0.6	O	O
to	O	O
4.1	O	O
+	O	O
/-	O	O
1.0	O	O
L/min	O	O
)	O	O
.	O	O

Intravenous	O	O
propranolol	B_Chemical	B_Chemical
reversed	O	O
these	O	O
effects	O	O
.	O	O

Systemic	O	O
vascular	O	O
resistance	O	O
was	O	O
increased	O	O
by	O	O
PPA	B_Chemical	O
28	O	O
%	O	O
(	O	O
from	O	O
1710	O	O
+	O	O
/-	O	O
200	O	O
to	O	O
2190	O	O
+	O	O
/-	O	O
700	O	O
dyne	O	O
X	O	O
sec/cm5	O	O
)	O	O
and	O	O
was	O	O
further	O	O
increased	O	O
by	O	O
propranolol	B_Chemical	B_Chemical
22	O	O
%	O	O
(	O	O
to	O	O
2660	O	O
+	O	O
/-	O	O
1200	O	O
dyne	O	O
X	O	O
sec/cm5	O	O
)	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
PPA	B_Chemical	O
increases	O	O
blood	O	O
pressure	O	O
by	O	O
increasing	O	O
systemic	O	O
vascular	O	O
resistance	O	O
and	O	O
cardiac	O	O
output	O	O
,	O	O
and	O	O
that	O	O
propranolol	B_Chemical	B_Chemical
antagonizes	O	O
this	O	O
increase	O	O
by	O	O
reversing	O	O
the	O	O
effect	O	O
of	O	O
PPA	B_Chemical	O
on	O	O
cardiac	O	O
output	O	O
.	O	O

That	O	O
propranolol	B_Chemical	B_Chemical
antagonizes	O	O
the	O	O
pressor	O	O
effect	O	O
of	O	O
PPA	B_Chemical	O
is	O	O
in	O	O
contrast	O	O
to	O	O
the	O	O
interaction	O	O
in	O	O
which	O	O
propranolol	B_Chemical	B_Chemical
enhances	O	O
the	O	O
pressor	O	O
effect	O	O
of	O	O
norepinephrine	B_Chemical	O
.	O	O

This	O	O
is	O	O
probably	O	O
because	O	O
PPA	B_Chemical	O
has	O	O
less	O	O
beta	O	O
2	O	O
activity	O	O
than	O	O
does	O	O
norepinephrine	B_Chemical	O
.	O	O

Mesangial	O	O
function	O	O
and	O	O
glomerular	B_Disease	B_Disease
sclerosis	I_Disease	I_Disease
in	O	O
rats	O	O
with	O	O
aminonucleoside	B_Chemical	O
nephrosis	B_Disease	O
.	O	O

The	O	O
possible	O	O
relationship	O	O
between	O	O
mesangial	B_Disease	O
dysfunction	I_Disease	O
and	O	O
development	O	O
of	O	O
glomerular	B_Disease	B_Disease
sclerosis	I_Disease	I_Disease
was	O	O
studied	O	O
in	O	O
the	O	O
puromycin	B_Chemical	O
aminonucleoside	I_Chemical	O
(	O	O
PAN	B_Chemical	O
)	O	O
model	O	O
.	O	O

Five	O	O
male	O	O
Wistar	O	O
rats	O	O
received	O	O
repeated	O	O
subcutaneous	O	O
PAN	B_Chemical	O
injections	O	O
;	O	O
five	O	O
controls	O	O
received	O	O
saline	O	O
only	O	O
.	O	O

After	O	O
4	O	O
weeks	O	O
the	O	O
PAN	B_Chemical	O
rats	O	O
were	O	O
severely	O	O
proteinuric	B_Disease	O
(	O	O
190	O	O
+	O	O
/-	O	O
80	O	O
mg/24	O	O
hr	O	O
)	O	O
,	O	O
and	O	O
all	O	O
rats	O	O
were	O	O
given	O	O
colloidal	O	O
carbon	B_Chemical	O
(	O	O
CC	O	O
)	O	O
intravenously	O	O
.	O	O

At	O	O
5	O	O
months	O	O
glomerular	B_Disease	B_Disease
sclerosis	I_Disease	I_Disease
was	O	O
found	O	O
in	O	O
7.6	O	O
+	O	O
/-	O	O
3.4	O	O
%	O	O
of	O	O
the	O	O
glomeruli	O	O
of	O	O
PAN	B_Chemical	O
rats	O	O
;	O	O
glomeruli	O	O
of	O	O
the	O	O
controls	O	O
were	O	O
normal	O	O
.	O	O

Glomeruli	O	O
of	O	O
PAN	B_Chemical	O
rats	O	O
contained	O	O
significantly	O	O
more	O	O
CC	O	O
than	O	O
glomeruli	O	O
of	O	O
controls	O	O
.	O	O

Glomeruli	O	O
with	O	O
sclerosis	B_Disease	O
contained	O	O
significantly	O	O
more	O	O
CC	O	O
than	O	O
non-sclerotic	O	O
glomeruli	O	O
in	O	O
the	O	O
same	O	O
kidneys	O	O
.	O	O

CC	O	O
was	O	O
preferentially	O	O
localized	O	O
within	O	O
the	O	O
sclerotic	O	O
areas	O	O
of	O	O
the	O	O
affected	O	O
glomeruli	O	O
.	O	O

Since	O	O
mesangial	O	O
CC	O	O
clearance	O	O
from	O	O
the	O	O
mesangium	O	O
did	O	O
not	O	O
change	O	O
during	O	O
chronic	O	O
PAN	B_Chemical	O
treatment	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
this	O	O
preferential	O	O
CC	O	O
localization	O	O
within	O	O
the	O	O
lesions	O	O
is	O	O
caused	O	O
by	O	O
an	O	O
increased	O	O
CC	O	O
uptake	O	O
shortly	O	O
after	O	O
injection	O	O
in	O	O
apparent	O	O
vulnerable	O	O
areas	O	O
where	O	O
sclerosis	B_Disease	O
will	O	O
develop	O	O
subsequently	O	O
.	O	O

Cluster	O	O
analysis	O	O
showed	O	O
a	O	O
random	O	O
distribution	O	O
of	O	O
lesions	O	O
in	O	O
the	O	O
PAN	B_Chemical	O
glomeruli	O	O
in	O	O
concordance	O	O
with	O	O
the	O	O
random	O	O
localization	O	O
of	O	O
mesangial	O	O
areas	O	O
with	O	O
dysfunction	O	O
in	O	O
this	O	O
model	O	O
.	O	O

Similar	O	O
to	O	O
the	O	O
remnant	O	O
kidney	O	O
model	O	O
in	O	O
PAN	B_Chemical	B_Disease
nephrosis	B_Disease	I_Disease
the	O	O
development	O	O
of	O	O
glomerular	B_Disease	B_Disease
sclerosis	I_Disease	I_Disease
may	O	O
be	O	O
related	O	O
to	O	O
"	O	O
mesangial	O	O
overloading	O	O
.	O	O
"	O	O

Relationship	O	O
between	O	O
nicotine-induced	O	O
seizures	B_Disease	O
and	O	O
hippocampal	O	O
nicotinic	O	O
receptors	O	O
.	O	O

A	O	O
controversy	O	O
has	O	O
existed	O	O
for	O	O
several	O	O
years	O	O
concerning	O	O
the	O	O
physiological	O	O
relevance	O	O
of	O	O
the	O	O
nicotinic	O	O
receptor	O	O
measured	O	O
by	O	O
alpha-bungarotoxin	O	O
binding	O	O
.	O	O

Using	O	O
mice	O	O
derived	O	O
from	O	O
a	O	O
classical	O	O
F2	O	O
and	O	O
backcross	O	O
genetic	O	O
design	O	O
,	O	O
a	O	O
relationship	O	O
between	O	O
nicotine-induced	O	O
seizures	B_Disease	O
and	O	O
alpha-bungarotoxin	O	O
nicotinic	O	O
receptor	O	O
concentration	O	O
was	O	O
found	O	O
.	O	O

Mice	O	O
sensitive	O	O
to	O	O
the	O	O
convulsant	O	O
effects	O	O
of	O	O
nicotine	B_Chemical	O
had	O	O
greater	O	O
alpha-bungarotoxin	O	O
binding	O	O
in	O	O
the	O	O
hippocampus	O	O
than	O	O
seizure	B_Disease	O
insensitive	O	O
mice	O	O
.	O	O

The	O	O
binding	O	O
sites	O	O
from	O	O
seizure	B_Disease	O
sensitive	O	O
and	O	O
resistant	O	O
mice	O	O
were	O	O
equally	O	O
affected	O	O
by	O	O
treatment	O	O
with	O	O
dithiothreitol	B_Chemical	B_Chemical
,	O	O
trypsin	O	O
or	O	O
heat	O	O
.	O	O

Thus	O	O
it	O	O
appears	O	O
that	O	O
the	O	O
difference	O	O
between	O	O
seizure	B_Disease	O
sensitive	O	O
and	O	O
insensitive	O	O
animals	O	O
may	O	O
be	O	O
due	O	O
to	O	O
a	O	O
difference	O	O
in	O	O
hippocampal	O	O
nicotinic	O	O
receptor	O	O
concentration	O	O
as	O	O
measured	O	O
with	O	O
alpha-bungarotoxin	O	O
binding	O	O
.	O	O

The	O	O
role	O	O
of	O	O
p-aminophenol	B_Chemical	B_Chemical
in	O	O
acetaminophen-induced	O	O
nephrotoxicity	B_Disease	B_Disease
:	O	O
effect	O	O
of	O	O
bis(p-nitrophenyl	B_Chemical	B_Chemical
)	I_Chemical	I_Chemical
phosphate	I_Chemical	I_Chemical
on	O	O
acetaminophen	B_Chemical	O
and	O	O
p-aminophenol	B_Chemical	O
nephrotoxicity	B_Disease	O
and	O	O
metabolism	O	O
in	O	O
Fischer	O	O
344	O	O
rats	O	O
.	O	O

Acetaminophen	B_Chemical	O
(	O	O
APAP	B_Chemical	O
)	O	O
produces	O	O
proximal	O	O
tubular	B_Disease	B_Disease
necrosis	I_Disease	I_Disease
in	O	O
Fischer	O	O
344	O	O
(	O	O
F344	O	O
)	O	O
rats	O	O
.	O	O

Recently	O	O
,	O	O
p-aminophenol	B_Chemical	B_Chemical
(	O	O
PAP	B_Chemical	O
)	O	O
,	O	O
a	O	O
known	O	O
potent	O	O
nephrotoxicant	O	O
,	O	O
was	O	O
identified	O	O
as	O	O
a	O	O
metabolite	O	O
of	O	O
APAP	B_Chemical	B_Chemical
in	O	O
F344	O	O
rats	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
PAP	B_Chemical	O
formation	O	O
is	O	O
a	O	O
requisite	O	O
step	O	O
in	O	O
APAP-induced	O	O
nephrotoxicity	B_Disease	B_Disease
.	O	O

Therefore	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
bis(p-nitrophenyl	B_Chemical	B_Chemical
)	I_Chemical	O
phosphate	I_Chemical	O
(	O	O
BNPP	B_Chemical	O
)	O	O
,	O	O
an	O	O
acylamidase	O	O
inhibitor	O	O
,	O	O
on	O	O
APAP	B_Chemical	B_Chemical
and	O	O
PAP	B_Chemical	B_Disease
nephrotoxicity	B_Disease	I_Disease
and	O	O
metabolism	O	O
was	O	O
determined	O	O
.	O	O

BNPP	B_Chemical	O
(	O	O
1	O	O
to	O	O
8	O	O
mM	O	O
)	O	O
reduced	O	O
APAP	B_Chemical	O
deacetylation	O	O
and	O	O
covalent	O	O
binding	O	O
in	O	O
F344	O	O
renal	O	O
cortical	O	O
homogenates	O	O
in	O	O
a	O	O
concentration-dependent	O	O
manner	O	O
.	O	O

Pretreatment	O	O
of	O	O
animals	O	O
with	O	O
BNPP	B_Chemical	O
prior	O	O
to	O	O
APAP	B_Chemical	B_Disease
or	O	O
PAP	B_Chemical	O
administration	O	O
resulted	O	O
in	O	O
marked	O	O
reduction	O	O
of	O	O
APAP	B_Chemical	O
(	O	O
900	O	O
mg/kg	O	O
)	O	O
nephrotoxicity	B_Disease	B_Disease
but	O	O
not	O	O
PAP	B_Chemical	B_Disease
nephrotoxicity	B_Disease	I_Disease
.	O	O

This	O	O
result	O	O
was	O	O
not	O	O
due	O	O
to	O	O
altered	O	O
disposition	O	O
of	O	O
either	O	O
APAP	B_Chemical	B_Chemical
or	O	O
acetylated	O	O
metabolites	O	O
in	O	O
plasma	O	O
or	O	O
renal	O	O
cortical	O	O
and	O	O
hepatic	O	O
tissue	O	O
.	O	O

Rather	O	O
,	O	O
BNPP	B_Chemical	O
pretreatment	O	O
reduced	O	O
the	O	O
fraction	O	O
of	O	O
APAP	B_Chemical	B_Disease
excreted	O	O
as	O	O
PAP	B_Chemical	O
by	O	O
64	O	O
and	O	O
75	O	O
%	O	O
after	O	O
APAP	B_Chemical	B_Disease
doses	O	O
of	O	O
750	O	O
and	O	O
900	O	O
mg/kg	O	O
.	O	O

BNPP	B_Chemical	O
did	O	O
not	O	O
alter	O	O
the	O	O
excretion	O	O
of	O	O
APAP	B_Chemical	O
or	O	O
any	O	O
of	O	O
its	O	O
non-deacetylated	O	O
metabolites	O	O
nor	O	O
did	O	O
BNPP	B_Chemical	O
alter	O	O
excretion	O	O
of	O	O
PAP	B_Chemical	O
or	O	O
its	O	O
metabolites	O	O
after	O	O
PAP	B_Chemical	O
doses	O	O
of	O	O
150	O	O
and	O	O
300	O	O
mg/kg	O	O
.	O	O

Therefore	O	O
,	O	O
the	O	O
BNPP-induced	O	O
reduction	O	O
in	O	O
APAP-induced	O	O
nephrotoxicity	B_Disease	B_Disease
appears	O	O
to	O	O
be	O	O
due	O	O
to	O	O
inhibition	O	O
of	O	O
APAP	B_Chemical	O
deacetylation	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
PAP	B_Chemical	O
formation	O	O
,	O	O
in	O	O
vivo	O	O
,	O	O
accounts	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
,	O	O
for	O	O
APAP-induced	O	O
renal	B_Disease	B_Disease
tubular	I_Disease	I_Disease
necrosis	I_Disease	I_Disease
.	O	O

Morphine-induced	O	O
seizures	B_Disease	O
in	O	O
newborn	O	O
infants	O	O
.	O	O

Two	O	O
neonates	O	O
suffered	O	O
from	O	O
generalized	O	O
seizures	B_Disease	O
during	O	O
the	O	O
course	O	O
of	O	O
intravenous	O	O
morphine	B_Chemical	B_Chemical
sulfate	I_Chemical	I_Chemical
for	O	O
post-operative	O	O
analgesia	O	O
.	O	O

They	O	O
received	O	O
morphine	B_Chemical	O
in	O	O
doses	O	O
of	O	O
32	O	O
micrograms/kg/hr	O	O
and	O	O
40	O	O
micrograms/kg/hr	O	O
larger	O	O
than	O	O
a	O	O
group	O	O
of	O	O
10	O	O
neonates	O	O
who	O	O
received	O	O
6	O	O
-	O	O
24	O	O
micrograms/kg/hr	O	O
and	O	O
had	O	O
no	O	O
seizures	B_Disease	O
.	O	O

Plasma	O	O
concentrations	O	O
of	O	O
morphine	B_Chemical	O
in	O	O
these	O	O
neonates	O	O
was	O	O
excessive	O	O
(	O	O
60	O	O
and	O	O
90	O	O
mg/ml	O	O
)	O	O
.	O	O

Other	O	O
known	O	O
reasons	O	O
for	O	O
seizures	B_Disease	O
were	O	O
ruled	O	O
out	O	O
and	O	O
the	O	O
convulsions	B_Disease	O
stopped	O	O
a	O	O
few	O	O
hours	O	O
after	O	O
cessation	O	O
of	O	O
morphine	B_Chemical	O
and	O	O
did	O	O
not	O	O
reoccur	O	O
in	O	O
the	O	O
subsequent	O	O
8	O	O
months	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
post-operative	O	O
intravenous	O	O
morphine	B_Chemical	O
should	O	O
not	O	O
exceed	O	O
20	O	O
micrograms/kg/ml	O	O
in	O	O
neonates	O	O
.	O	O

Indomethacin	B_Chemical	O
induced	O	O
hypotension	B_Disease	O
in	O	O
sodium	B_Chemical	O
and	O	O
volume	O	O
depleted	O	O
rats	O	O
.	O	O

After	O	O
a	O	O
single	O	O
oral	O	O
dose	O	O
of	O	O
4	O	O
mg/kg	O	O
indomethacin	B_Chemical	O
(	O	O
IDM	B_Chemical	O
)	O	O
to	O	O
sodium	B_Chemical	O
and	O	O
volume	O	O
depleted	O	O
rats	O	O
plasma	O	O
renin	O	O
activity	O	O
(	O	O
PRA	O	O
)	O	O
and	O	O
systolic	O	O
blood	O	B_Disease
pressure	O	I_Disease
fell	O	O
significantly	O	O
within	O	O
four	O	O
hours	O	O
.	O	O

In	O	O
sodium	B_Chemical	O
repleted	O	O
animals	O	O
indomethacin	B_Chemical	O
did	O	O
not	O	O
change	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
although	O	O
plasma	O	O
renin	O	O
activity	O	O
was	O	O
decreased	O	O
.	O	O

Thus	O	O
,	O	O
indomethacin	B_Chemical	O
by	O	O
inhibition	O	O
of	O	O
prostaglandin	B_Chemical	O
synthesis	O	O
may	O	O
diminish	O	O
the	O	O
blood	O	O
pressure	O	O
maintaining	O	O
effect	O	O
of	O	O
the	O	O
stimulated	O	O
renin-angiotensin	O	O
system	O	O
in	O	O
sodium	B_Chemical	O
and	O	O
volume	O	O
depletion	O	O
.	O	O

On	O	O
the	O	O
antiarrhythmic	O	O
activity	O	O
of	O	O
one	O	O
N-substituted	O	B_Chemical
piperazine	B_Chemical	I_Chemical
derivative	O	O
of	O	O
trans-2-amino-3-hydroxy-1	B_Chemical	B_Chemical
,	I_Chemical	I_Chemical
2	I_Chemical	I_Chemical
,	I_Chemical	I_Chemical
3	I_Chemical	I_Chemical
,	I_Chemical	I_Chemical
4-tetrahydroanaphthalene	I_Chemical	I_Chemical
.	O	O

The	O	O
antiarrhythmic	O	O
activity	O	O
of	O	O
the	O	O
compound	O	O
N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine	B_Chemical	B_Chemical
hydrochloride	I_Chemical	I_Chemical
,	O	O
referred	O	O
to	O	O
as	O	O
P11	B_Chemical	O
,	O	O
is	O	O
studied	O	O
on	O	O
anaesthesized	O	O
cats	O	O
and	O	O
Wistar	O	O
albino	O	O
rats	O	O
,	O	O
as	O	O
well	O	O
as	O	O
on	O	O
non-anaesthesized	O	O
rabbits	O	O
.	O	O

Four	O	O
types	O	O
of	O	O
experimental	O	O
arrhythmia	B_Disease	O
are	O	O
used	O	O
--	O	O
with	O	O
BaCl2	B_Chemical	O
,	O	O
with	O	O
chloroform-adrenaline	O	O
,	O	O
with	O	O
strophantine	B_Chemical	O
G	I_Chemical	O
and	O	O
with	O	O
aconitine	B_Chemical	B_Chemical
.	O	O

The	O	O
compound	O	O
P11	B_Chemical	O
is	O	O
introduced	O	O
in	O	O
doses	O	O
of	O	O
0.25	O	O
and	O	O
0.50	O	O
mg/kg	O	O
intravenously	O	O
and	O	O
10	O	O
mg/kg	O	O
orally	O	O
.	O	O

The	O	O
compound	O	O
manifests	O	O
antiarrhythmic	O	O
activity	O	O
in	O	O
all	O	O
models	O	O
of	O	O
experimental	O	O
arrhythmia	B_Disease	O
used	O	O
,	O	O
causing	O	O
greatest	O	O
inhibition	O	O
on	O	O
the	O	O
arrhythmia	B_Disease	O
induced	O	O
by	O	O
chloroform-adrenaline	O	O
(	O	O
in	O	O
90	O	O
per	O	O
cent	O	O
)	O	O
and	O	O
with	O	O
BaCl2	B_Chemical	O
(	O	O
in	O	O
84	O	O
per	O	O
cent	O	O
)	O	O
.	O	O

The	O	O
results	O	O
obtained	O	O
are	O	O
associated	O	O
with	O	O
the	O	O
beta-adrenoblocking	O	O
and	O	O
with	O	O
the	O	O
membrane-stabilizing	O	O
action	O	O
of	O	O
the	O	O
compound	O	O
.	O	O

Recurrent	O	O
subarachnoid	B_Disease	O
hemorrhage	I_Disease	O
associated	O	O
with	O	O
aminocaproic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
therapy	O	O
and	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
artery	I_Disease	I_Disease
thrombosis	I_Disease	I_Disease
.	O	O

Case	O	O
report	O	O
.	O	O

Epsilon	B_Chemical	O
aminocaproic	I_Chemical	O
acid	I_Chemical	O
(	O	O
EACA	B_Chemical	O
)	O	O
has	O	O
been	O	O
used	O	O
to	O	O
prevent	O	O
rebleeding	O	O
in	O	O
patients	O	O
with	O	O
subarachnoid	B_Disease	O
hemorrhage	I_Disease	O
(	O	O
SAH	B_Disease	O
)	O	O
.	O	O

Although	O	O
this	O	O
agent	O	O
does	O	O
decrease	O	O
the	O	O
frequency	O	O
of	O	O
rebleeding	O	O
,	O	O
several	O	O
reports	O	O
have	O	O
described	O	O
thrombotic	B_Disease	B_Disease
complications	O	I_Disease
of	O	O
EACA	B_Chemical	O
therapy	O	O
.	O	O

These	O	O
complications	O	O
have	O	O
included	O	O
clinical	O	O
deterioration	O	O
and	O	O
intracranial	B_Disease	B_Disease
vascular	I_Disease	I_Disease
thrombosis	I_Disease	I_Disease
in	O	O
patients	O	O
with	O	O
SAH	B_Disease	O
,	O	O
arteriolar	O	O
and	O	O
capillary	O	O
fibrin	O	O
thrombi	B_Disease	O
in	O	O
patients	O	O
with	O	O
fibrinolytic	O	B_Disease
syndromes	O	I_Disease
treated	O	O
with	O	O
EACA	B_Chemical	O
,	O	O
or	O	O
other	O	O
thromboembolic	B_Disease	B_Disease
phenomena	I_Disease	I_Disease
.	O	O

Since	O	O
intravascular	O	O
fibrin	O	O
thrombi	B_Disease	O
are	O	O
often	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
fibrinolytic	O	B_Disease
disorders	O	I_Disease
,	O	O
EACA	B_Chemical	O
should	O	O
not	O	O
be	O	O
implicated	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
fibrin	O	O
thrombi	B_Disease	O
in	O	O
patients	O	O
with	O	O
disseminated	B_Disease	O
intravascular	I_Disease	B_Disease
coagulation	I_Disease	I_Disease
or	O	O
other	O	O
"	O	O
consumption	B_Disease	O
coagulopathies	I_Disease	B_Disease
.	O	O
"	O	O
This	O	O
report	O	O
describes	O	O
subtotal	O	O
infarction	B_Disease	O
of	O	O
the	O	O
kidney	O	O
due	O	O
to	O	O
thrombosis	B_Disease	O
of	I_Disease	O
a	I_Disease	O
normal	I_Disease	O
renal	I_Disease	O
artery	I_Disease	O
.	O	O

This	O	O
occlusion	O	O
occurred	O	O
after	O	O
EACA	B_Chemical	O
therapy	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
SAH	B_Disease	O
and	O	O
histopathological	O	O
documentation	O	O
of	O	O
recurrent	O	O
SAH	B_Disease	O
.	O	O

The	O	O
corresponding	O	O
clinical	O	O
event	O	O
was	O	O
characterized	O	O
by	O	O
marked	O	O
hypertension	B_Disease	O
and	O	O
abrupt	O	O
neurological	O	B_Disease
deterioration	O	I_Disease
.	O	O

Effect	O	O
of	O	O
vincristine	B_Chemical	B_Chemical
sulfate	I_Chemical	I_Chemical
on	O	O
Pseudomonas	B_Disease	O
infections	I_Disease	O
in	O	O
monkeys	O	O
.	O	O

In	O	O
rhesus	O	O
monkeys	O	O
,	O	O
intravenous	O	O
challenge	O	O
with	O	O
0.6	O	O
x	O	O
10(10	O	O
)	O	O
to	O	O
2.2	O	O
x	O	O
10(10)Pseudomonas	O	O
aeruginosa	O	O
organisms	O	O
caused	O	O
acute	O	B_Disease
illness	O	I_Disease
of	O	O
4	O	O
to	O	O
5	O	O
days	O	O
'	O	O
duration	O	O
with	O	O
spontaneous	O	O
recovery	O	O
in	O	O
13	O	O
of	O	O
15	O	O
monkeys	O	O
;	O	O
blood	O	O
cultures	O	O
became	O	O
negative	O	O
3	O	O
to	O	O
17	O	O
days	O	O
after	O	O
challenge	O	O
.	O	O

Leukocytosis	B_Disease	O
was	O	O
observed	O	O
in	O	O
all	O	O
monkeys	O	O
.	O	O

Intravenous	O	O
or	O	O
intratracheal	O	O
inoculation	O	O
of	O	O
2.0	O	O
to	O	O
2.5	O	O
mg	O	O
of	O	O
vincristine	B_Chemical	B_Chemical
sulfate	I_Chemical	I_Chemical
was	O	O
followed	O	O
by	O	O
leukopenia	B_Disease	O
in	O	O
4	O	O
to	O	O
5	O	O
days	O	O
.	O	O

Intravenous	O	O
inoculation	O	O
of	O	O
4.2	O	O
x	O	O
10(10	O	O
)	O	O
to	O	O
7.8	O	O
x	O	O
10(10	O	O
)	O	O
pyocin	O	B_Chemical
type	O	O
6	O	O
Pseudomonas	O	O
organisms	O	O
in	O	O
monkeys	O	O
given	O	O
vincristine	B_Chemical	B_Chemical
sulfate	I_Chemical	I_Chemical
4	O	O
days	O	O
previously	O	O
resulted	O	O
in	O	O
fatal	O	O
infection	B_Disease	O
in	O	O
11	O	O
of	O	O
14	O	O
monkeys	O	O
,	O	O
whereas	O	O
none	O	O
of	O	O
four	O	O
receiving	O	O
Pseudomonas	O	O
alone	O	O
died	O	O
.	O	O

These	O	O
studies	O	O
suggest	O	O
that	O	O
an	O	O
antimetabolite-induced	O	O
leukopenia	B_Disease	O
predisposes	O	O
to	O	O
severe	O	O
Pseudomonas	O	O
sepsis	B_Disease	O
and	O	O
that	O	O
such	O	O
monkeys	O	O
may	O	O
serve	O	O
as	O	O
a	O	O
biological	O	O
model	O	O
for	O	O
study	O	O
of	O	O
comparative	O	O
efficacy	O	O
of	O	O
antimicrobial	O	O
agents	O	O
.	O	O

Modification	O	O
by	O	O
propranolol	B_Chemical	B_Chemical
of	O	O
cardiovascular	O	O
effects	O	O
of	O	O
induced	O	O
hypoglycaemia	B_Disease	O
.	O	O

The	O	O
cardiovascular	O	O
effects	O	O
of	O	O
hypoglycaemia	B_Disease	O
,	O	O
with	O	O
and	O	O
without	O	O
beta-blockade	O	O
,	O	O
were	O	O
compared	O	O
in	O	O
fourteen	O	O
healthy	O	O
men	O	O
.	O	O

Eight	O	O
received	O	O
insulin	O	O
alone	O	O
,	O	O
and	O	O
eight	O	O
,	O	O
including	O	O
two	O	O
of	O	O
the	O	O
original	O	O
insulin-only	O	O
group	O	O
,	O	O
were	O	O
given	O	O
propranolol	B_Chemical	B_Chemical
and	O	O
insulin	O	O
.	O	O

In	O	O
the	O	O
insulin-group	O	O
the	O	O
period	O	O
of	O	O
hypoglycaemia	B_Disease	O
was	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
heart-rate	O	O
and	O	O
a	O	O
fall	O	O
in	O	O
diastolic	O	O
blood-pressure	O	O
.	O	O

In	O	O
the	O	O
propranolol-insulin	O	O
group	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
fall	O	O
in	O	O
heart-rate	O	O
in	O	O
most	O	O
subjects	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
diastolic	O	O
pressure	O	O
.	O	O

Typical	O	O
S-T/T	O	O
changes	O	O
occurred	O	O
in	O	O
the	O	O
insulin-group	O	O
but	O	O
in	O	O
none	O	O
of	O	O
the	O	O
propranolol-insulin	O	O
group	O	O
.	O	O

Hypertension	B_Disease	O
in	O	O
diabetics	B_Disease	O
prone	O	O
to	O	O
hypoglycaemia	B_Disease	O
attacks	O	O
should	O	O
not	O	O
be	O	O
treated	O	O
with	O	O
beta-blockers	O	O
because	O	O
these	O	O
drugs	O	O
may	O	O
cause	O	O
a	O	O
sharp	O	O
rise	O	O
in	O	O
blood-pressure	O	O
in	O	O
such	O	O
patients	O	O
.	O	O

Long-term	O	O
propranolol	O	B_Chemical
therapy	O	O
in	O	O
pregnancy	O	O
:	O	O
maternal	O	O
and	O	O
fetal	O	O
outcome	O	O
.	O	O

Propranolol	B_Chemical	B_Chemical
,	O	O
a	O	O
beta-adrenergic	O	O
blocking	O	O
agent	O	O
,	O	O
has	O	O
found	O	O
an	O	O
important	O	O
position	O	O
in	O	O
the	O	O
practice	O	O
of	O	O
medicine	O	O
.	O	O

Its	O	O
use	O	O
in	O	O
pregnancy	O	O
,	O	O
however	O	O
,	O	O
is	O	O
an	O	O
open	O	O
question	O	O
as	O	O
a	O	O
number	O	O
of	O	O
detrimental	O	O
side	O	O
effects	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
fetus	O	O
and	O	O
neonate	O	O
.	O	O

Ten	O	O
patients	O	O
and	O	O
12	O	O
pregnancies	O	O
are	O	O
reported	O	O
where	O	O
chronic	O	O
propranolol	B_Chemical	B_Chemical
has	O	O
been	O	O
administered	O	O
.	O	O

Five	O	O
patients	O	O
with	O	O
serial	O	O
pregnancies	O	O
with	O	O
and	O	O
without	O	O
propranolol	B_Chemical	B_Chemical
therapy	O	O
are	O	O
also	O	O
examined	O	O
.	O	O

Maternal	O	O
,	O	O
fetal	O	O
,	O	O
and	O	O
neonatal	O	O
complications	O	O
are	O	O
examined	O	O
.	O	O

An	O	O
attempt	O	O
is	O	O
made	O	O
to	O	O
differentiate	O	O
drug-related	O	O
complications	O	O
from	O	O
maternal	O	O
disease	O	O
--	O	O
related	O	O
complications	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
previously	O	O
reported	O	O
hypoglycemia	B_Disease	O
,	O	O
hyperbilirubinemia	B_Disease	O
,	O	O
polycythemia	B_Disease	O
,	O	O
neonatal	B_Disease	O
apnea	I_Disease	O
,	O	O
and	O	O
bradycardia	B_Disease	O
are	O	O
not	O	O
invariable	O	O
and	O	O
can	O	O
not	O	O
be	O	O
statistically	O	O
correlated	O	O
with	O	O
chronic	O	O
propranolol	B_Chemical	B_Chemical
therapy	O	O
.	O	O

Growth	B_Disease	O
retardation	I_Disease	O
,	O	O
however	O	O
,	O	O
appears	O	O
to	O	O
be	O	O
significant	O	O
in	O	O
both	O	O
of	O	O
our	O	O
series	O	O
.	O	O

Central	O	O
excitatory	O	O
actions	O	O
of	O	O
flurazepam	O	O
.	O	O

Toxic	O	O
actions	O	O
of	O	O
flurazepam	B_Chemical	O
(	O	O
FZP	B_Chemical	O
)	O	O
were	O	O
studied	O	O
in	O	O
cats	O	O
,	O	O
mice	O	O
and	O	O
rats	O	O
.	O	O

High	O	O
doses	O	O
caused	O	O
an	O	O
apparent	O	O
central	O	O
excitation	O	O
,	O	O
most	O	O
clearly	O	O
seen	O	O
as	O	O
clonic	O	O
convulsions	B_Disease	O
,	O	O
superimposed	O	O
on	O	O
general	O	O
depression	B_Disease	O
.	O	O

Following	O	O
a	O	O
lethal	O	O
dose	O	O
,	O	O
death	O	O
was	O	O
always	O	O
associated	O	O
with	O	O
convulsions	B_Disease	O
.	O	O

Comparing	O	O
the	O	O
relative	O	O
sensitivity	O	O
to	O	O
central	O	O
depression	B_Disease	O
and	O	O
excitation	O	O
revealed	O	O
that	O	O
rats	O	O
were	O	O
least	O	O
likely	O	O
to	O	O
have	O	O
convulsions	B_Disease	O
at	O	O
doses	O	O
that	O	O
did	O	O
not	O	O
first	O	O
cause	O	O
loss	B_Disease	O
of	I_Disease	O
consciousness	I_Disease	O
,	O	O
while	O	O
cats	O	O
most	O	O
clearly	O	O
showed	O	O
marked	O	O
central	O	O
excitatory	O	O
actions	O	O
.	O	O

Signs	O	O
of	O	O
FZP	B_Chemical	O
toxocity	B_Disease	O
in	O	O
cats	O	O
included	O	O
excessive	O	O
salivation	B_Disease	O
,	O	O
extreme	O	O
apprehensive	O	O
behavior	O	O
,	O	O
retching	O	O
,	O	O
muscle	B_Disease	O
tremors	I_Disease	O
and	O	O
convulsions	B_Disease	O
.	O	O

An	O	O
interaction	O	O
between	O	O
FZP	B_Chemical	O
and	O	O
pentylenetetrazol	B_Chemical	O
(	O	O
PTZ	B_Chemical	O
)	O	O
was	O	O
shown	O	O
by	O	O
pretreating	O	O
mice	O	O
with	O	O
FZP	B_Chemical	O
before	O	O
PTZ	B_Chemical	O
challenge	O	O
.	O	O

As	O	O
a	O	O
function	O	O
of	O	O
dose	O	O
,	O	O
FZP	B_Chemical	O
first	O	O
protected	O	O
against	O	O
convulsions	B_Disease	O
and	O	O
death	O	O
.	O	O

At	O	O
higher	O	O
doses	O	O
,	O	O
however	O	O
,	O	O
convulsions	B_Disease	O
again	O	O
emerged	O	O
.	O	O

These	O	O
doses	O	O
of	O	O
FZP	B_Chemical	O
were	O	O
lower	O	O
than	O	O
those	O	O
that	O	O
would	O	O
alone	O	O
cause	O	O
convulsions	B_Disease	O
.	O	O

These	O	O
results	O	O
may	O	O
be	O	O
relevant	O	O
to	O	O
the	O	O
use	O	O
of	O	O
FZP	B_Chemical	O
in	O	O
clinical	O	O
situations	O	O
in	O	O
which	O	O
there	O	O
is	O	O
increased	O	O
neural	O	O
excitability	O	O
,	O	O
such	O	O
as	O	O
epilepsy	B_Disease	O
or	O	O
sedative-hypnotic	O	O
drug	O	O
withdrawal	O	O
.	O	O

Use	O	O
of	O	O
propranolol	B_Chemical	B_Chemical
in	O	O
the	O	O
treatment	O	O
of	O	O
idiopathic	B_Disease	O
orthostatic	I_Disease	B_Disease
hypotension	I_Disease	I_Disease
.	O	O

Five	O	O
patients	O	O
with	O	O
idiopathic	B_Disease	O
orthostatic	I_Disease	B_Disease
hypotension	I_Disease	I_Disease
who	O	O
had	O	O
physiologic	O	O
and	O	O
biochemical	O	O
evidence	O	O
of	O	O
severe	O	O
autonomic	O	B_Disease
dysfunction	O	I_Disease
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

They	O	O
all	O	O
exhibited	O	O
markedly	O	O
reduced	O	O
plasma	O	O
catecholamines	B_Chemical	O
and	O	O
plasma	O	O
renin	O	O
activity	O	O
in	O	O
both	O	O
recumbent	O	O
and	O	O
upright	O	O
positions	O	O
and	O	O
had	O	O
marked	O	O
hypersensitivity	B_Disease	O
to	O	O
the	O	O
pressor	O	O
effects	O	O
of	O	O
infused	O	O
norepinephrine	B_Chemical	O
.	O	O

Treatment	O	O
with	O	O
propanolol	B_Chemical	O
administered	O	O
intravenously	O	O
(	O	O
1	O	O
-	O	O
5	O	O
mg	O	O
)	O	O
produced	O	O
increases	O	O
in	O	O
supine	O	O
and	O	O
upright	O	O
blood	O	O
pressure	O	O
in	O	O
4	O	O
of	O	O
the	O	O
5	O	O
individuals	O	O
with	O	O
rises	O	O
ranging	O	O
from	O	O
11/6	O	O
to	O	O
22/11	O	O
mmHg	O	O
.	O	O

Chronic	O	O
oral	O	O
administration	O	O
of	O	O
propranolol	B_Chemical	B_Chemical
(	O	O
40	O	O
-	O	O
160	O	O
mg/day	O	O
)	O	O
also	O	O
elevated	O	O
the	O	O
blood	O	O
pressures	O	O
of	O	O
these	O	O
individuals	O	O
with	O	O
increases	O	O
in	O	O
the	O	O
order	O	O
of	O	O
20	O	O
-	O	O
35/15	O	O
-	O	O
25	O	O
mmg	O	O
being	O	O
observed	O	O
.	O	O

In	O	O
1	O	O
patient	O	O
,	O	O
marked	O	O
hypertension	B_Disease	O
was	O	O
induced	O	O
by	O	O
propranolol	B_Chemical	B_Chemical
and	O	O
the	O	O
drug	O	O
had	O	O
to	O	O
be	O	O
withdrawn	O	O
.	O	O

It	O	O
otherwise	O	O
was	O	O
well	O	O
tolerated	O	O
and	O	O
no	O	O
important	O	O
side	O	O
effects	O	O
were	O	O
observed	O	O
.	O	O

Treatment	O	O
has	O	O
been	O	O
continued	O	O
in	O	O
3	O	O
individuals	O	O
for	O	O
6	O	O
-	O	O
13	O	O
months	O	O
with	O	O
persistence	O	O
of	O	O
the	O	O
pressor	O	O
effect	O	O
,	O	O
although	O	O
there	O	O
appears	O	O
to	O	O
have	O	O
been	O	O
some	O	O
decrease	O	O
in	O	O
the	O	O
degree	O	O
of	O	O
response	O	O
with	O	O
time	O	O
.	O	O

Hemodynamic	O	O
measurements	O	O
in	O	O
1	O	O
of	O	O
the	O	O
patients	O	O
demonstrated	O	O
an	O	O
increase	O	O
in	O	O
total	O	O
peripheral	O	O
resistance	O	O
and	O	O
essentially	O	O
no	O	O
change	O	O
in	O	O
cardiac	O	O
output	O	O
following	O	O
propranolol	B_Chemical	B_Chemical
therapy	O	O
.	O	O

The	O	O
studies	O	O
suggest	O	O
that	O	O
propranolol	B_Chemical	B_Chemical
is	O	O
a	O	O
useful	O	O
drug	O	O
in	O	O
selected	O	O
patients	O	O
with	O	O
severe	O	O
idiopathic	B_Disease	B_Disease
orthostatic	I_Disease	I_Disease
hypotension	I_Disease	I_Disease
.	O	O

Total	O	O
intravenous	O	O
anesthesia	O	O
with	O	O
etomidate	O	B_Chemical
.	O	O

III	O	O
.	O	O
Some	O	O
observations	O	O
in	O	O
adults	O	O
.	O	O

An	O	O
investigation	O	O
was	O	O
undertaken	O	O
to	O	O
determine	O	O
the	O	O
dosage	O	O
of	O	O
etomidate	B_Chemical	B_Chemical
required	O	O
to	O	O
maintain	O	O
sleep	O	O
in	O	O
adults	O	O
undergoing	O	O
surgery	O	O
under	O	O
regional	O	O
local	O	O
anesthesia	O	O
.	O	O

Premedication	O	O
of	O	O
diazepam	B_Chemical	O
10	O	O
mg	O	O
and	O	O
atropine	B_Chemical	O
0.5	O	O
mg	O	O
was	O	O
given	O	O
,	O	O
and	O	O
sleep	O	O
was	O	O
induced	O	O
and	O	O
maintained	O	O
by	O	O
intermittent	O	O
intravenous	O	O
injections	O	O
of	O	O
etomidate	B_Chemical	B_Chemical
0.1/mg/kg	O	O
,	O	O
given	O	O
whenever	O	O
the	O	O
patient	O	O
would	O	O
open	O	O
his	O	O
eyes	O	O
on	O	O
request	O	O
.	O	O

A	O	O
mean	O	O
overall	O	O
dose	O	O
of	O	O
etomidate	B_Chemical	B_Chemical
17.4	O	O
microgram/kg/min	O	O
.	O	O
was	O	O
required	O	O
to	O	O
maintain	O	O
sleep	O	O
,	O	O
but	O	O
great	O	O
individual	O	O
variation	O	O
occurred	O	O
,	O	O
with	O	O
older	O	O
patients	O	O
requiring	O	O
less	O	O
drug	O	O
.	O	O

The	O	O
investigation	O	O
was	O	O
discontinued	O	O
after	O	O
18	O	O
patients	O	O
because	O	O
of	O	O
the	O	O
frequency	O	O
and	O	O
intensity	O	O
of	O	O
side-effects	O	O
,	O	O
particularly	O	O
pain	B_Disease	O
and	O	O
myoclonia	B_Disease	B_Disease
,	O	O
which	O	O
caused	O	O
the	O	O
technique	O	O
to	O	O
be	O	O
abandoned	O	O
in	O	O
two	O	O
cases	O	O
.	O	O

It	O	O
is	O	O
considered	O	O
unlikely	O	O
that	O	O
etomidate	B_Chemical	B_Chemical
will	O	O
prove	O	O
to	O	O
be	O	O
the	O	O
hypnotic	O	O
of	O	O
choice	O	O
for	O	O
a	O	O
totally	O	O
intravenous	O	O
anesthetic	O	O
technique	O	O
in	O	O
adults	O	O
because	O	O
of	O	O
the	O	O
high	O	O
incidence	O	O
of	O	O
myoclonia	B_Disease	B_Disease
after	O	O
prolonged	O	O
administration	O	O
.	O	O

In	O	O
several	O	O
patients	O	O
uncontrollable	O	O
muscle	O	O
movements	O	O
persisted	O	O
for	O	O
many	O	O
minutes	O	O
after	O	O
complete	O	O
recovery	O	O
of	O	O
consciousness	O	O
.	O	O

Evidence	O	O
for	O	O
cardiac	O	O
beta	O	O
2-adrenoceptors	O	O
in	O	O
man	O	O
.	O	O

We	O	O
compared	O	O
the	O	O
effects	O	O
of	O	O
single	O	O
doses	O	O
of	O	O
50	O	O
mg	O	O
atenolol	B_Chemical	O
(	O	O
cardioselective	O	O
)	O	O
,	O	O
40	O	O
mg	O	O
propranolol	B_Chemical	B_Chemical
(	O	O
nonselective	O	O
)	O	O
,	O	O
and	O	O
placebo	O	O
on	O	O
both	O	O
exercise-	O	O
and	O	O
isoproterenol-induced	O	O
tachycardia	B_Disease	O
in	O	O
two	O	O
experiments	O	O
involving	O	O
nine	O	O
normal	O	O
subjects	O	O
.	O	O

Maximal	O	O
exercise	O	O
heart	O	O
rate	O	O
was	O	O
reduced	O	O
from	O	O
187	O	O
+	O	O
/-	O	O
4(SEM	O	O
)	O	O
after	O	O
placebo	O	O
to	O	O
146	O	O
+	O	O
/-	O	O
7	O	O
bpm	O	O
after	O	O
atenolol	B_Chemical	O
and	O	O
138	O	O
+	O	O
/-	O	O
6	O	O
bpm	O	O
after	O	O
propranolol	B_Chemical	B_Chemical
,	O	O
but	O	O
there	O	O
were	O	O
no	O	O
differences	O	O
between	O	O
the	O	O
drugs	O	O
.	O	O

The	O	O
effects	O	O
on	O	O
isoproterenol	B_Chemical	O
tachycardia	B_Disease	O
were	O	O
determined	O	O
before	O	O
and	O	O
after	O	O
atropine	B_Chemical	O
(	O	O
0.04	O	O
mg/kg	O	O
IV	O	O
)	O	O
.	O	O

Isoproterenol	B_Chemical	O
sensitivity	O	O
was	O	O
determined	O	O
as	O	O
the	O	O
intravenous	O	O
dose	O	O
that	O	O
increased	O	O
heart	O	O
rate	O	O
by	O	O
25	O	O
bpm	O	O
(	O	O
CD25	O	O
)	O	O
and	O	O
this	O	O
was	O	O
increased	O	O
from	O	O
1.8	O	O
+	O	O
/-	O	O
0.3	O	O
micrograms	O	O
after	O	O
placebo	O	O
to	O	O
38.9	O	O
+	O	O
/-	O	O
8.3	O	O
micrograms	O	O
after	O	O
propranolol	B_Chemical	B_Chemical
and	O	O
8.3	O	O
+	O	O
/-	O	O
1.7	O	O
micrograms	O	O
after	O	O
atenolol	B_Chemical	O
.	O	O

The	O	O
difference	O	O
in	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
two	O	O
was	O	O
significant	O	O
.	O	O

After	O	O
atropine	B_Chemical	O
the	O	O
CD25	O	O
was	O	O
unchanged	O	O
after	O	O
placebo	O	O
(	O	O
2.3	O	O
+	O	O
/-	O	O
0.3	O	O
micrograms	O	O
)	O	O
and	O	O
atenolol	B_Chemical	O
(	O	O
7.7	O	O
+	O	O
/-	O	O
1.3	O	O
micrograms	O	O
)	O	O
;	O	O
it	O	O
was	O	O
reduced	O	O
after	O	O
propranolol	B_Chemical	B_Chemical
(	O	O
24.8	O	O
+	O	O
/-	O	O
5.0	O	O
micrograms	O	O
)	O	O
,	O	O
but	O	O
remained	O	O
different	O	O
from	O	O
atenolol	B_Chemical	O
.	O	O

This	O	O
change	O	O
with	O	O
propranolol	B_Chemical	B_Chemical
sensitivity	O	O
was	O	O
calculated	O	O
as	O	O
the	O	O
apparent	O	O
Ka	O	O
,	O	O
this	O	O
was	O	O
unchanged	O	O
by	O	O
atropine	B_Chemical	O
(	O	O
11.7	O	O
+	O	O
/-	O	O
2.1	O	O
and	O	O
10.1	O	O
+	O	O
/-	O	O
2.5	O	O
ml/ng	O	O
)	O	O
.	O	O

These	O	O
data	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
hypothesis	O	O
that	O	O
exercise-induced	O	O
tachycardia	B_Disease	O
results	O	O
largely	O	O
from	O	O
beta	O	O
1-receptor	O	O
activation	O	O
that	O	O
is	O	O
blocked	O	O
by	O	O
both	O	O
cardioselective	O	O
and	O	O
nonselective	O	O
drugs	O	O
,	O	O
whereas	O	O
isoproterenol	B_Chemical	O
activates	O	O
both	O	O
beta	O	O
1-	O	O
and	O	O
beta	O	O
2-receptors	O	O
so	O	O
that	O	O
after	O	O
cardioselective	O	O
blockade	O	O
there	O	O
remains	O	O
a	O	O
beta	O	O
2-component	O	O
that	O	O
can	O	O
be	O	O
blocked	O	O
with	O	O
a	O	O
nonselective	O	O
drug	O	O
.	O	O

While	O	O
there	O	O
appear	O	O
to	O	O
be	O	O
beta	O	O
2-receptors	O	O
in	O	O
the	O	O
human	O	O
heart	O	O
,	O	O
their	O	O
physiologic	O	O
or	O	O
pathologic	O	O
roles	O	O
remain	O	O
to	O	O
be	O	O
defined	O	O
.	O	O

Hormones	O	O
and	O	O
risk	O	O
of	O	O
breast	O	B_Disease
cancer	O	I_Disease
.	O	O

This	O	O
paper	O	O
reports	O	O
the	O	O
results	O	O
of	O	O
a	O	O
study	O	O
of	O	O
50	O	O
menopausal	O	O
women	O	O
receiving	O	O
hormonal	O	O
replacement	O	O
therapy	O	O
.	O	O

The	O	O
majority	O	O
(	O	O
29	O	O
)	O	O
had	O	O
surgical	O	O
menopause	O	O
;	O	O
their	O	O
mean	O	O
age	O	O
was	O	O
45.7	O	O
years	O	O
.	O	O

It	O	O
was	O	O
hypothesized	O	O
that	O	O
progestins	B_Chemical	O
could	O	O
equilibrate	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
estrogenic	O	O
stimulation	O	O
on	O	O
the	O	O
mammary	O	O
and	O	O
endometrial	O	O
target	O	O
tissues	O	O
of	O	O
women	O	O
on	O	O
hormonal	O	O
replacement	O	O
therapy	O	O
.	O	O

The	O	O
treatment	O	O
schedule	O	O
consisted	O	O
of	O	O
conjugated	B_Chemical	O
estrogens	I_Chemical	O
(	O	O
Premarin	B_Chemical	O
)	O	O
1.25	O	O
mg/day	O	O
for	O	O
21	O	O
days	O	O
and	O	O
Medroxyprogesterone	B_Chemical	B_Chemical
acetate	I_Chemical	I_Chemical
10	O	O
mg/day	O	O
for	O	O
10	O	O
days	O	O
in	O	O
each	O	O
month	O	O
.	O	O

The	O	O
mean	O	O
treatment	O	O
period	O	O
was	O	O
18	O	O
months	O	O
.	O	O

During	O	O
the	O	O
follow-up	O	O
period	O	O
,	O	O
attention	O	O
was	O	O
paid	O	O
to	O	O
breast	O	O
modifications	O	O
as	O	O
evidenced	O	O
by	O	O
symptomatology	O	O
,	O	O
physical	O	O
examination	O	O
,	O	O
and	O	O
plate	O	O
thermography	O	O
.	O	O

Mastodynia	B_Disease	B_Disease
was	O	O
reported	O	O
by	O	O
21	O	O
patients	O	O
,	O	O
and	O	O
physical	O	O
examination	O	O
revealed	O	O
a	O	O
light	O	O
increase	O	O
in	O	O
breast	O	O
firmness	O	O
in	O	O
12	O	O
women	O	O
and	O	O
a	O	O
moderate	O	O
increase	O	O
in	O	O
breast	O	B_Disease
nodularity	O	I_Disease
in	O	O
2	O	O
women	O	O
.	O	O

Themography	O	O
confirmed	O	O
the	O	O
existence	O	O
of	O	O
an	O	O
excessive	O	O
breast	O	O
stimulation	O	O
in	O	O
1	O	O
women	O	O
who	O	O
complained	O	O
of	O	O
moderate	O	O
mastodynia	B_Disease	B_Disease
and	O	O
in	O	O
5	O	O
of	O	O
the	O	O
7	O	O
women	O	O
who	O	O
complained	O	O
of	O	O
severe	O	O
mastodynia	B_Disease	B_Disease
.	O	O

Normalization	O	O
was	O	O
obtained	O	O
by	O	O
halving	O	O
the	O	O
estrogen	B_Chemical	O
dose	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
hormonal	O	O
replacement	O	O
therapy	O	O
can	O	O
be	O	O
safely	O	O
prescribed	O	O
if	O	O
the	O	O
following	O	O
criteria	O	O
are	O	O
satisfied	O	O
:	O	O
1	O	O
)	O	O
preliminary	O	O
evaluation	O	O
of	O	O
patients	O	O
from	O	O
a	O	O
clinical	O	O
,	O	O
metabolic	O	O
,	O	O
cytologic	O	O
,	O	O
and	O	O
mammographic	O	O
perspective	O	O
;	O	O
2	O	O
)	O	O
cyclic	O	O
treatment	O	O
schedule	O	O
,	O	O
with	O	O
a	O	O
progestative	O	O
phase	O	O
of	O	O
10	O	O
days	O	O
;	O	O
and	O	O
3	O	O
)	O	O
periodic	O	O
complete	O	O
follow-up	O	O
,	O	O
with	O	O
accurate	O	O
thermographic	O	O
evaluation	O	O
of	O	O
the	O	O
breast	O	O
target	O	O
tissues	O	O
.	O	O

Early	O	O
infections	B_Disease	O
in	O	O
kidney	O	O
,	O	O
heart	O	O
,	O	O
and	O	O
liver	O	O
transplant	O	O
recipients	O	O
on	O	O
cyclosporine	B_Chemical	B_Chemical
.	O	O

Eighty-one	O	O
renal	O	O
,	O	O
seventeen	O	O
heart	O	O
,	O	O
and	O	O
twenty-four	O	O
liver	O	O
transplant	O	O
patients	O	O
were	O	O
followed	O	O
for	O	O
infection	B_Disease	O
.	O	O

Seventeen	O	O
renal	O	O
patients	O	O
received	O	O
azathioprine	B_Chemical	O
(	O	O
Aza	B_Chemical	B_Chemical
)	O	O
and	O	O
prednisone	B_Chemical	O
as	O	O
part	O	O
of	O	O
a	O	O
randomized	O	O
trial	O	O
of	O	O
immunosuppression	O	O
with	O	O
21	O	O
cyclosporine-and-prednisone-treated	O	O
renal	O	O
transplant	O	O
patients	O	O
.	O	O

All	O	O
others	O	O
received	O	O
cyclosporine	B_Chemical	B_Chemical
and	O	O
prednisone	B_Chemical	O
.	O	O

The	O	O
randomized	O	O
Aza	B_Chemical	O
patients	O	O
had	O	O
more	O	O
overall	O	O
infections	B_Disease	O
(	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
and	O	O
more	O	O
nonviral	O	O
infections	B_Disease	O
(	O	O
P	O	O
less	O	O
than	O	O
0.02	O	O
)	O	O
than	O	O
the	O	O
randomized	O	O
cyclosporine	B_Chemical	B_Chemical
patients	O	O
.	O	O

Heart	O	O
and	O	O
liver	O	O
patients	O	O
had	O	O
more	O	O
infections	B_Disease	O
than	O	O
cyclosporine	B_Chemical	O
renal	O	O
patients	O	O
but	O	O
fewer	O	O
infections	B_Disease	O
than	O	O
the	O	O
Aza	B_Chemical	O
renal	O	O
patients	O	O
.	O	O

There	O	O
were	O	O
no	O	O
infectious	O	O
deaths	O	O
in	O	O
renal	O	O
transplant	O	O
patients	O	O
on	O	O
cyclosporine	B_Chemical	B_Chemical
or	O	O
Aza	B_Chemical	B_Chemical
,	O	O
but	O	O
infection	B_Disease	O
played	O	O
a	O	O
major	O	O
role	O	O
in	O	O
3	O	O
out	O	O
of	O	O
6	O	O
cardiac	O	O
transplant	O	O
deaths	O	O
and	O	O
in	O	O
8	O	O
out	O	O
of	O	O
9	O	O
liver	O	O
transplant	O	O
deaths	O	O
.	O	O

Renal	O	O
patients	O	O
on	O	O
cyclosporine	B_Chemical	B_Chemical
had	O	O
the	O	O
fewest	O	O
bacteremias	B_Disease	O
.	O	O

Analysis	O	O
of	O	O
site	O	O
of	O	O
infection	B_Disease	O
showed	O	O
a	O	O
preponderance	O	O
of	O	O
abdominal	B_Disease	O
infections	I_Disease	O
in	O	O
liver	O	O
patients	O	O
,	O	O
intrathoracic	O	O
infections	B_Disease	O
in	O	O
heart	O	O
patients	O	O
,	O	O
and	O	O
urinary	B_Disease	B_Disease
tract	I_Disease	I_Disease
infections	I_Disease	I_Disease
in	O	O
renal	O	O
patients	O	O
.	O	O

Pulmonary	O	O
infections	B_Disease	O
were	O	O
less	O	O
common	O	O
in	O	O
cyclosporine-treated	O	O
renal	O	O
patients	O	O
than	O	O
in	O	O
Aza-treated	O	O
patients	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
.	O	O

Aza	B_Chemical	B_Chemical
patients	O	O
had	O	O
significantly	O	O
more	O	O
staphylococcal	B_Disease	O
infections	I_Disease	O
than	O	O
all	O	O
other	O	O
transplant	O	O
groups	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.005	O	O
)	O	O
,	O	O
and	O	O
systemic	O	O
fungal	B_Disease	O
infections	I_Disease	O
occurred	O	O
only	O	O
in	O	O
the	O	O
liver	O	O
transplant	O	O
group	O	O
.	O	O

Cytomegalovirus	O	O
(	O	O
CMV	O	O
)	O	O
shedding	O	O
or	O	O
serological	O	O
rises	O	O
in	O	O
antibody	O	O
titer	O	O
,	O	O
or	O	O
both	O	O
occurred	O	O
in	O	O
78	O	O
%	O	O
of	O	O
cyclosporine	B_Chemical	B_Chemical
patients	O	O
and	O	O
76	O	O
%	O	O
of	O	O
Aza	B_Chemical	B_Chemical
patients	O	O
.	O	O

Of	O	O
the	O	O
cyclosporine	B_Chemical	B_Chemical
patients	O	O
,	O	O
15	O	O
%	O	O
had	O	O
symptoms	O	O
related	O	O
to	O	O
CMV	B_Disease	O
infection	I_Disease	O
.	O	O

Serological	O	O
evidence	O	O
for	O	O
Epstein	B_Disease	O
Barr	I_Disease	O
Virus	I_Disease	O
infection	I_Disease	O
was	O	O
found	O	O
in	O	O
20	O	O
%	O	O
of	O	O
65	O	O
cyclosporine	B_Chemical	B_Chemical
patients	O	O
studied	O	O
.	O	O

Three	O	O
had	O	O
associated	O	O
symptoms	O	O
,	O	O
and	O	O
one	O	O
developed	O	O
a	O	O
lymphoma	B_Disease	O
.	O	O

Structure-activity	O	O
and	O	O
dose-effect	O	O
relationships	O	O
of	O	O
the	O	O
antagonism	O	O
of	O	O
picrotoxin-induced	O	O
seizures	B_Disease	O
by	O	O
cholecystokinin	B_Chemical	O
,	O	O
fragments	O	O
and	O	O
analogues	O	O
of	O	O
cholecystokinin	B_Chemical	O
in	O	O
mice	O	O
.	O	O

Intraperitoneal	O	O
administration	O	O
of	O	O
cholecystokinin	B_Chemical	O
octapeptide	I_Chemical	O
sulphate	O	O
ester	O	O
(	O	O
CCK-8-SE	O	O
)	O	O
and	O	O
nonsulphated	O	O
cholecystokinin	B_Chemical	B_Chemical
octapeptide	I_Chemical	I_Chemical
(	O	O
CCK-8-NS	O	O
)	O	O
enhanced	O	O
the	O	O
latency	O	O
of	O	O
seizures	B_Disease	O
induced	O	O
by	O	O
picrotoxin	B_Chemical	B_Chemical
in	O	O
mice	O	O
.	O	O

Experiments	O	O
with	O	O
N-	O	O
and	O	O
C-terminal	O	O
fragments	O	O
revealed	O	O
that	O	O
the	O	O
C-terminal	O	O
tetrapeptide	O	O
(	O	O
CCK-5	O	O
-	O	O
8)	O	O
was	O	O
the	O	O
active	O	O
centre	O	O
of	O	O
the	O	O
CCK	O	O
octapeptide	O	B_Chemical
molecule	O	O
.	O	O

The	O	O
analogues	O	O
CCK-8-SE	O	O
and	O	O
CCK-8-NS	O	O
(	O	O
dose	O	O
range	O	O
0.2	O	O
-	O	O
6.4	O	O
mumol/kg	O	O
)	O	O
and	O	O
caerulein	B_Chemical	B_Chemical
dose	O	O
range	O	O
0.1	O	O
-	O	O
0.8	O	O
mumol/kg	O	O
)	O	O
showed	O	O
bell-shaped	O	O
dose-effect	O	O
curves	O	O
,	O	O
with	O	O
the	O	O
greatest	O	O
maximum	O	O
inhibition	O	O
for	O	O
CCK-8-NS	O	O
.	O	O

The	O	O
peptide	O	O
CCK-5	O	O
-	O	O
8	O	O
had	O	O
weak	O	O
anticonvulsant	O	O
activity	O	O
in	O	O
comparison	O	O
to	O	O
the	O	O
octapeptides	O	B_Chemical
,	O	O
3.2	O	O
mumol/kg	O	O
and	O	O
larger	O	O
doses	O	O
of	O	O
the	O	O
reference	O	O
drug	O	O
,	O	O
diazepam	B_Chemical	O
,	O	O
totally	O	O
prevented	O	O
picrotoxin-induced	O	O
seizures	B_Disease	O
and	O	O
mortality	O	O
.	O	O

The	O	O
maximum	O	O
effect	O	O
of	O	O
the	O	O
peptides	O	O
tested	O	O
was	O	O
less	O	O
than	O	O
that	O	O
of	O	O
diazepam	B_Chemical	O
.	O	O

Experiments	O	O
with	O	O
analogues	O	O
and	O	O
derivatives	O	O
of	O	O
CCK-5	O	O
-	O	O
8	O	O
demonstrated	O	O
that	O	O
the	O	O
effectiveness	O	O
of	O	O
the	O	O
beta-alanyl	O	B_Chemical
derivatives	O	O
of	O	O
CCK-5	O	O
-	O	O
8	O	O
were	O	O
enhanced	O	O
and	O	O
that	O	O
they	O	O
were	O	O
equipotent	O	O
with	O	O
CCK-8-SE	O	O
.	O	O

Of	O	O
the	O	O
CCK-2	O	O
-	O	O
8	O	O
analogues	O	O
,	O	O
Ser(SO3H)7-Ac-CCK-2	O	O
-	O	O
8-SE	O	O
and	O	O
Thr(SO3H)7-Ac-CCK-2	O	O
-	O	O
8-SE	O	O
and	O	O
Hyp(SO3H)-Ac-CCK-2	O	O
-	O	O
8-SE	O	O
were	O	O
slightly	O	O
more	O	O
active	O	O
than	O	O
CCK-8-SE	O	O
.	O	O

Vasopressin	B_Chemical	O
as	O	O
a	O	O
possible	O	O
contributor	O	O
to	O	O
hypertension	B_Disease	O
.	O	O

The	O	O
role	O	O
of	O	O
vasopressin	B_Chemical	O
as	O	O
a	O	O
pressor	O	O
agent	O	O
to	O	O
the	O	O
hypertensive	B_Disease	O
process	O	O
was	O	O
examined	O	O
.	O	O

Vasopressin	B_Chemical	O
plays	O	O
a	O	O
major	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
DOCA-salt	O	O
hypertension	B_Disease	O
,	O	O
since	O	O
the	O	O
elevation	O	O
of	O	O
blood	O	O
pressure	O	O
was	O	O
not	O	O
substantial	O	O
in	O	O
the	O	O
rats	O	O
with	O	O
lithium-treated	O	O
diabetes	B_Disease	O
insipidus	I_Disease	O
after	O	O
DOCA-salt	O	O
treatment	O	O
.	O	O

Administration	O	O
of	O	O
DDAVP	B_Chemical	O
which	O	O
has	O	O
antidiuretic	O	O
action	O	O
but	O	O
minimal	O	O
vasopressor	O	O
effect	O	O
failed	O	O
to	O	O
increase	O	O
blood	O	O
pressure	O	O
to	O	O
the	O	O
levels	O	O
observed	O	O
after	O	O
administration	O	O
of	O	O
AVP	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
pressor	O	O
action	O	O
of	O	O
vasopressin	B_Chemical	O
appears	O	O
to	O	O
be	O	O
important	O	O
in	O	O
the	O	O
development	O	O
of	O	O
this	O	O
model	O	O
of	O	O
hypertension	B_Disease	O
,	O	O
since	O	O
the	O	O
enhanced	O	O
pressor	O	O
responsiveness	O	O
to	O	O
the	O	O
hormone	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
initial	O	O
stage	O	O
of	O	O
hypertension	B_Disease	O
.	O	O

Increased	O	O
secretion	O	O
of	O	O
vasopressin	B_Chemical	O
from	O	O
neurohypophysis	O	O
also	O	O
promotes	O	O
the	O	O
function	O	O
of	O	O
the	O	O
hormone	O	O
as	O	O
a	O	O
pathogenetic	O	O
factor	O	O
in	O	O
hypertension	B_Disease	O
.	O	O

An	O	O
unproportional	O	O
release	O	O
of	O	O
vasopressin	B_Chemical	O
compared	O	O
to	O	O
plasma	O	O
osmolality	O	O

may	O	O
be	O	O
induced	O	O
by	O	O
the	O	O
absence	O	O
of	O	O
an	O	O
adjusting	O	O
control	O	O
of	O	O
angiotensin	B_Chemical	O
II	O	O
forming	O	O
and	O	O
receptor	O	O
binding	O	O
capacity	O	O
for	O	O
sodium	B_Chemical	O
balance	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

However	O	O
,	O	O
the	O	O
role	O	O
of	O	O
vasopressin	B_Chemical	O
remains	O	O
to	O	O
be	O	O
determined	O	O
in	O	O
human	O	O
essential	O	O
hypertension	B_Disease	O
.	O	O

Toxic	B_Disease	O
hepatitis	I_Disease	O
induced	O	O
by	O	O
disulfiram	B_Chemical	O
in	O	O
a	O	O
non-alcoholic	O	O
.	O	O

A	O	O
reversible	O	O
toxic	B_Disease	O
liver	I_Disease	B_Disease
damage	I_Disease	I_Disease
was	O	O
observed	O	O
in	O	O
a	O	O
non-alcoholic	O	O
woman	O	O
treated	O	O
with	O	O
disulfiram	B_Chemical	O
.	O	O

The	O	O
causative	O	O
relationship	O	O
was	O	O
proven	O	O
by	O	O
challenge	O	O
.	O	O

Atrial	B_Disease	B_Disease
thrombosis	I_Disease	I_Disease
involving	O	O
the	O	O
heart	O	O
of	O	O
F-344	O	O
rats	O	O
ingesting	O	O
quinacrine	B_Chemical	B_Chemical
hydrochloride	I_Chemical	I_Chemical
.	O	O

Quinacrine	B_Chemical	B_Chemical
hydrochloride	I_Chemical	I_Chemical
is	O	O
toxic	O	O
for	O	O
the	O	O
heart	O	O
of	O	O
F-344	O	O
rats	O	O
.	O	O

Rats	O	O
treated	O	O
with	O	O
500	O	O
ppm	O	O
quinacrine	B_Chemical	B_Chemical
hydrochloride	I_Chemical	I_Chemical
in	O	O
the	O	O
diet	O	O
all	O	O
developed	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
left	O	B_Disease
atrial	B_Disease	I_Disease
thrombosis	I_Disease	I_Disease
.	O	O

The	O	O
lesion	O	O
was	O	O
associated	O	O
with	O	O
cardiac	B_Disease	B_Disease
hypertrophy	I_Disease	I_Disease
and	O	O
dilatation	O	O
and	O	O
focal	O	O
myocardial	B_Disease	B_Disease
degeneration	I_Disease	I_Disease
.	O	O

Rats	O	O
died	O	O
from	O	O
cardiac	B_Disease	B_Disease
hypertrophy	I_Disease	I_Disease
with	O	O
severe	O	O
acute	O	O
and	O	O
chronic	O	O
congestion	O	O
of	O	O
the	O	O
lungs	O	O
,	O	O
liver	O	O
,	O	O
and	O	O
other	O	O
organs	O	O
.	O	O

Seventy	O	O
percent	O	O
of	O	O
rats	O	O
given	O	O
250	O	O
ppm	O	O
quinacrine	B_Chemical	B_Chemical
hydrochloride	I_Chemical	I_Chemical
and	O	O
1,000	O	O
ppm	O	O
sodium	B_Chemical	O
nitrite	I_Chemical	O
simultaneously	O	O
in	O	O
the	O	O
diet	O	O
had	O	O
thrombosis	B_Disease	O
of	O	O
the	O	O
atria	O	O
of	O	O
the	O	O
heart	O	O
,	O	O
while	O	O
untreated	O	O
control	O	O
rats	O	O
in	O	O
this	O	O
laboratory	O	O
did	O	O
not	O	O
have	O	O
atrial	B_Disease	B_Disease
thrombosis	I_Disease	I_Disease
.	O	O

Sodium	B_Chemical	O
nitrite	I_Chemical	O
in	O	O
combination	O	O
with	O	O
quinacrine	B_Chemical	B_Chemical
hydrochloride	I_Chemical	I_Chemical
appeared	O	O
to	O	O
have	O	O
no	O	O
additional	O	O
effect	O	O
.	O	O

Alternating	B_Disease	O
sinus	I_Disease	B_Disease
rhythm	I_Disease	I_Disease
and	O	O
intermittent	O	O
sinoatrial	B_Disease	O
block	I_Disease	O
induced	O	O
by	O	O
propranolol	B_Chemical	B_Chemical
.	O	O

Alternating	B_Disease	O
sinus	I_Disease	B_Disease
rhythm	I_Disease	I_Disease
and	O	O
intermittent	O	O
sinoatrial	B_Disease	O
(	I_Disease	O
S-A	I_Disease	O
)	I_Disease	O
block	I_Disease	O
was	O	O
observed	O	O
in	O	O
a	O	O
57-year-old	O	O
woman	O	O
,	O	O
under	O	O
treatment	O	O
for	O	O
angina	B_Disease	O
with	O	O
80	O	O
mg	O	O
propranolol	B_Chemical	B_Chemical
daily	O	O
.	O	O

The	O	O
electrocardiogram	O	O
showed	O	O
alternation	O	O
of	O	O
long	O	O
and	O	O
short	O	O
P-P	O	O
intervals	O	O
and	O	O
occasional	O	O
pauses	O	O
.	O	O

These	O	O
pauses	O	O
were	O	O
always	O	O
preceded	O	O
by	O	O
the	O	O
short	O	O
P-P	O	O
intervals	O	O
and	O	O
were	O	O
usually	O	O
followed	O	O
by	O	O
one	O	O
or	O	O
two	O	O
P-P	O	O
intervals	O	O
of	O	O
0.92	O	O
-	O	O
0.95	O	O
s	O	O
representing	O	O
the	O	O
basic	O	O
sinus	O	O
cycle	O	O
.	O	O

Following	O	O
these	O	O
basic	O	O
sinus	O	O
cycles	O	O
,	O	O
alternating	B_Disease	O
rhythm	I_Disease	O
started	O	O
with	O	O
the	O	O
longer	O	O
P-P	O	O
interval	O	O
.	O	O

The	O	O
long	O	O
P-P	O	O
intervals	O	O
ranged	O	O
between	O	O
1.04	O	O
-	O	O
1.12	O	O
s	O	O
and	O	O
the	O	O
short	O	O
P-P	O	O
intervals	O	O
between	O	O
0.80	O	O
-	O	O
0.84	O	O
s	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
duration	O	O
of	O	O
the	O	O
pauses	O	O
were	O	O
equal	O	O
or	O	O
almost	O	O
equal	O	O
to	O	O
one	O	O
short	O	O
plus	O	O
one	O	O
long	O	O
P-P	O	O
interval	O	O
or	O	O
to	O	O
twice	O	O
the	O	O
basic	O	O
sinus	O	O
cycle	O	O
.	O	O

In	O	O
one	O	O
recording	O	O
a	O	O
short	O	O
period	O	O
of	O	O
regular	O	O
sinus	O	O
rhythm	O	O
with	O	O
intermittent	O	O
2/1	O	O
S-A	B_Disease	O
block	I_Disease	O
was	O	O
observed	O	O
.	O	O

This	O	O
short	O	O
period	O	O
of	O	O
sinus	O	O
rhythm	O	O
was	O	O
interrupted	O	O
by	O	O
sudden	O	O
prolongation	O	O
of	O	O
the	O	O
P-P	O	O
interval	O	O
starting	O	O
the	O	O
alternative	O	O
rhythm	O	O
.	O	O

There	O	O
were	O	O
small	O	O
changes	O	O
in	O	O
the	O	O
shape	O	O
of	O	O
the	O	O
P	O	O
waves	O	O
and	O	O
P-R	O	O
intervals	O	O
.	O	O

S-A	O	O
conduction	O	O
through	O	O
two	O	O
pathways	O	O
,	O	O
the	O	O
first	O	O
with	O	O
2/1	O	O
block	O	O
the	O	O
second	O	O
having	O	O
0.12	O	O
-	O	O
0.14	O	O
s	O	O
longer	O	O
conduction	O	O
time	O	O
and	O	O
with	O	O
occasional	O	O
2/1	O	O
block	O	O
was	O	O
proposed	O	O
for	O	O
the	O	O
explanation	O	O
of	O	O
the	O	O
alternating	O	O
P-P	O	O
interval	O	O
and	O	O
other	O	O
electrocardiographic	O	O
features	O	O
seen	O	O
.	O	O

Atropine	B_Chemical	O
1	O	O
mg	O	O
given	O	O
intravenously	O	O
resulted	O	O
in	O	O
shortening	O	O
of	O	O
all	O	O
P-P	O	O
intervals	O	O
without	O	O
changing	O	O
the	O	O
rhythm	O	O
.	O	O

The	O	O
abnormal	O	O
rhythm	O	O
disappeared	O	O
with	O	O
the	O	O
withdrawal	O	O
of	O	O
propranolol	B_Chemical	B_Chemical
and	O	O
when	O	O
the	O	O
drug	O	O
was	O	O
restarted	O	O
a	O	O
2/1	O	O
S-A	B_Disease	O
block	I_Disease	O
was	O	O
seen	O	O
.	O	O

This	O	O
was	O	O
accepted	O	O
as	O	O
evidence	O	O
for	O	O
propranolol	B_Chemical	B_Chemical
being	O	O
the	O	O
cause	O	O
of	O	O
this	O	O
conduction	B_Disease	O
disorder	I_Disease	O
.	O	O

Antitumor	O	O
effect	O	O
,	O	O
cardiotoxicity	B_Disease	B_Disease
,	O	O
and	O	O
nephrotoxicity	B_Disease	B_Disease
of	O	O
doxorubicin	B_Chemical	O
in	O	O
the	O	O
IgM	O	O
solid	O	O
immunocytoma-bearing	O	O
LOU/M/WSL	O	O
rat	O	O
.	O	O

Antitumor	O	O
activity	O	O
,	O	O
cardiotoxicity	B_Disease	B_Disease
,	O	O
and	O	O
nephrotoxicity	B_Disease	B_Disease
induced	O	O
by	O	O
doxorubicin	B_Chemical	O
were	O	O
studied	O	O
in	O	O
LOU/M/WSL	O	O
inbred	O	O
rats	O	O
each	O	O
bearing	O	O
a	O	O
transplantable	O	O
solid	O	O
IgM	O	O
immunocytoma	B_Disease	O
.	O	O

Animals	O	O
with	O	O
a	O	O
tumor	B_Disease	O
(	O	O
diameter	O	O
,	O	O
15.8	O	O
+	O	O
/-	O	O
3.3	O	O
mm	O	O
)	O	O
were	O	O
treated	O	O
with	O	O
iv	O	O
injections	O	O
of	O	O
doxorubicin	B_Chemical	O
on	O	O
5	O	O
consecutive	O	O
days	O	O
,	O	O
followed	O	O
by	O	O
1	O	O
weekly	O	O
injection	O	O
for	O	O
7	O	O
weeks	O	O
(	O	O
dose	O	O
range	O	O
,	O	O
0.015	O	O
-	O	O
4.0	O	O
mg/kg	O	O
body	O	O
wt	O	O
)	O	O
.	O	O

Tumor	B_Disease	O
regression	O	O
was	O	O
observed	O	O
with	O	O
0.5	O	O
mg	O	O
doxorubicin/kg	O	O
.	O	O

Complete	O	O
disappearance	O	O
of	O	O
the	O	O
tumor	B_Disease	O
was	O	O
induced	O	O
with	O	O
1.0	O	O
mg	O	O
doxorubicin/kg	O	O
.	O	O

Histologic	O	O
evidence	O	O
of	O	O
cardiotoxicity	B_Disease	B_Disease
scored	O	O
as	O	O
grade	O	O
III	O	O
was	O	O
only	O	O
observed	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
1.0	O	O
mg	O	O
doxorubicin/kg	O	O
.	O	O

Light	O	O
microscopic	O	O
evidence	O	O
of	O	O
renal	B_Disease	B_Disease
damage	I_Disease	I_Disease
was	O	O
seen	O	O
above	O	O
a	O	O
dose	O	O
of	O	O
0.5	O	O
mg	O	O
doxorubicin/kg	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
albuminuria	B_Disease	O
and	O	O
very	O	O
low	O	O
serum	O	O
albumin	O	O
levels	O	O
.	O	O

In	O	O
the	O	O
group	O	O
that	O	O
received	O	O
1.0	O	O
mg	O	O
doxorubicin/kg	O	O
,	O	O
the	O	O
serum	O	O
albumin	O	O
level	O	O
decreased	O	O
from	O	O
33.6	O	O
+	O	O
/-	O	O
4.1	O	O
to	O	O
1.5	O	O
+	O	O
/-	O	O
0.5	O	O
g/liter	O	O
.	O	O
Ascites	B_Disease	O
and	O	O
hydrothorax	B_Disease	O
were	O	O
observed	O	O
simultaneously	O	O
.	O	O

The	O	O
same	O	O
experiments	O	O
were	O	O
performed	O	O
with	O	O
non-tumor-bearing	O	O
rats	O	O
,	O	O
in	O	O
which	O	O
no	O	O
major	O	O
differences	O	O
were	O	O
observed	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
antitumor	O	O
activity	O	O
,	O	O
cardiotoxicity	B_Disease	B_Disease
,	O	O
and	O	O
nephrotoxicity	B_Disease	B_Disease
were	O	O
studied	O	O
simultaneously	O	O
in	O	O
the	O	O
same	O	O
LOU/M/WSL	O	O
rat	O	O
.	O	O

Albuminuria	B_Disease	O
due	O	O
to	O	O
renal	B_Disease	B_Disease
damage	I_Disease	I_Disease
led	O	O
to	O	O
extremely	O	O
low	O	O
serum	O	O
albumin	O	O
levels	O	O
,	O	O
so	O	O
ascites	B_Disease	O
and	O	O
hydrothorax	B_Disease	O
were	O	O
not	O	O
necessarily	O	O
a	O	O
consequence	O	O
of	O	O
the	O	O
observed	O	O
cardiomyopathy	B_Disease	O
.	O	O

Intraoperative	O	O
bradycardia	B_Disease	O
and	O	O
hypotension	B_Disease	O
associated	O	O
with	O	O
timolol	B_Chemical	O
and	O	O
pilocarpine	B_Chemical	O
eye	O	O
drops	O	O
.	O	O

A	O	O
69-yr-old	O	O
man	O	O
,	O	O
who	O	O
was	O	O
concurrently	O	O
being	O	O
treated	O	O
with	O	O
pilocarpine	B_Chemical	B_Chemical
nitrate	I_Chemical	I_Chemical
and	O	O
timolol	B_Chemical	B_Chemical
maleate	I_Chemical	I_Chemical
eye	O	O
drops	O	O
,	O	O
developed	O	O
a	O	O
bradycardia	B_Disease	O
and	O	O
became	O	O
hypotensive	B_Disease	O
during	O	O
halothane	B_Chemical	O
anaesthesia	O	O
.	O	O

Both	O	O
timolol	B_Chemical	O
and	O	O
pilocarpine	B_Chemical	O
were	O	O
subsequently	O	O
identified	O	O
in	O	O
a	O	O
24-h	O	O
collection	O	O
of	O	O
urine	O	O
.	O	O

Timolol	B_Chemical	O
(	O	O
but	O	O
not	O	O
pilocarpine	B_Chemical	O
)	O	O
was	O	O
detected	O	O
in	O	O
a	O	O
sample	O	O
of	O	O
plasma	O	O
removed	O	O
during	O	O
surgery	O	O
;	O	O
the	O	O
plasma	O	O
concentration	O	O
of	O	O
timolol	B_Chemical	O
(	O	O
2.6	O	O
ng	O	O
ml-1	O	O
)	O	O
was	O	O
consistent	O	O
with	O	O
partial	O	O
beta-adrenoceptor	O	O
blockade	O	O
.	O	O

It	O	O
is	O	O
postulated	O	O
that	O	O
this	O	O
action	O	O
may	O	O
have	O	O
been	O	O
enhanced	O	O
during	O	O
halothane	B_Chemical	O
anaesthesia	O	O
with	O	O
resultant	O	O
bradycardia	B_Disease	O
and	O	O
hypotension	B_Disease	O
.	O	O

Pilocarpine	B_Chemical	O
may	O	O
have	O	O
had	O	O
a	O	O
contributory	O	O
effect	O	O
.	O	O

Succinylcholine	B_Chemical	O
apnoea	B_Disease	O
:	O	O
attempted	O	O
reversal	O	O
with	O	O
anticholinesterases	O	O
.	O	O

Anticholinesterases	O	O
were	O	O
administered	O	O
in	O	O
an	O	O
attempt	O	O
to	O	O
antagonize	O	O
prolonged	O	O
neuromuscular	B_Disease	O
blockade	I_Disease	O
following	O	O
the	O	O
administration	O	O
of	O	O
succinylcholine	B_Chemical	O
in	O	O
a	O	O
patient	O	O
later	O	O
found	O	O
to	O	O
be	O	O
homozygous	O	O
for	O	O
atypical	O	O
plasma	O	O
cholinesterase	O	O
.	O	O

Edrophonium	B_Chemical	B_Chemical
10	O	O
mg	O	O
,	O	O
given	O	O
74	O	O
min	O	O
after	O	O
succinylcholine	B_Chemical	O
,	O	O
when	O	O
train-of-four	O	O
stimulation	O	O
was	O	O
characteristic	O	O
of	O	O
phase	O	O
II	O	O
block	O	O
,	O	O
produced	O	O
partial	O	O
antagonism	O	O
which	O	O
was	O	O
not	O	O
sustained	O	O
.	O	O

Repeated	O	O
doses	O	O
of	O	O
edrophonium	B_Chemical	B_Chemical
to	O	O
70	O	O
mg	O	O
and	O	O
neostigmine	B_Chemical	O
to	O	O
2.5	O	O
mg	O	O
did	O	O
not	O	O
antagonize	O	O
or	O	O
augment	O	O
the	O	O
block	O	O
.	O	O

Spontaneous	O	O
respiration	O	O
recommenced	O	O
200	O	O
min	O	O
after	O	O
succinylcholine	B_Chemical	O
administration	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
anticholinesterases	O	O
are	O	O
only	O	O
partially	O	O
effective	O	O
in	O	O
restoring	O	O
neuromuscular	O	O
function	O	O
in	O	O
succinylcholine	B_Chemical	O
apnoea	B_Disease	O
despite	O	O
muscle	O	O
twitch	O	O
activity	O	O
typical	O	O
of	O	O
phase	O	O
II	O	O
block	O	O
.	O	O

Effect	O	O
of	O	O
doxorubicin	B_Chemical	O
on	O	O
[omega-I-131]heptadecanoic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
myocardial	O	O
scintigraphy	O	O
and	O	O
echocardiography	O	O
in	O	O
dogs	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
serial	O	O
treatment	O	O
with	O	O
doxorubicin	B_Chemical	O
on	O	O
dynamic	O	O
myocardial	O	O
scintigraphy	O	O
with	O	O
[omega-I-131]heptadecanoic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(	O	O
I-131	B_Chemical	O
HA	I_Chemical	O
)	O	O
,	O	O
and	O	O
on	O	O
global	O	O
left-ventricular	O	O
function	O	O
determined	O	O
echocardiographically	O	O
,	O	O
were	O	O
studied	O	O
in	O	O
a	O	O
group	O	O
of	O	O
nine	O	O
mongrel	O	O
dogs	O	O
.	O	O

Total	O	O
extractable	O	O
myocardial	O	O
lipid	O	O
was	O	O
compared	O	O
postmortem	O	O
between	O	O
a	O	O
group	O	O
of	O	O
control	O	O
dogs	O	O
and	O	O
doxorubicin-treated	O	O
dogs	O	O
.	O	O

A	O	O
significant	O	O
and	O	O
then	O	O
progressive	O	O
fall	O	O
in	O	O
global	O	O
LV	O	O
function	O	O
was	O	O
observed	O	O
at	O	O
a	O	O
cumulative	O	O
doxorubicin	B_Chemical	O
dose	O	O
of	O	O
4	O	O
mg/kg	O	O
.	O	O

A	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
myocardial	O	O
t1/2	O	O
of	O	O
the	O	O
I-131	B_Chemical	O
HA	I_Chemical	O
was	O	O
observed	O	O
only	O	O
at	O	O
a	O	O
higher	O	O
cumulative	O	O
dose	O	O
,	O	O
10	O	O
mg/kg	O	O
.	O	O

No	O	O
significant	O	O
alteration	O	O
in	O	O
total	O	O
extractable	O	O
myocardial	O	O
lipids	O	O
was	O	O
observed	O	O
between	O	O
control	O	O
dogs	O	O
and	O	O
those	O	O
treated	O	O
with	O	O
doxorubicin	B_Chemical	O
.	O	O

Our	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
changes	O	O
leading	O	O
to	O	O
an	O	O
alteration	O	O
of	O	O
myocardial	O	O
dynamic	O	O
imaging	O	O
with	O	O
I-131	B_Chemical	O
HA	I_Chemical	O
are	O	O
not	O	O
the	O	O
initiating	O	O
factor	O	O
in	O	O
doxorubicin	B_Chemical	O
cardiotoxicity	B_Disease	O
.	O	O

Hemodynamics	O	O
and	O	O
myocardial	O	O
metabolism	O	O
under	O	O
deliberate	O	O
hypotension	O	O
.	O	O

An	O	O
experimental	O	O
study	O	O
in	O	O
dogs	O	O
.	O	O

Coronary	O	O
blood	O	O
flow	O	O
,	O	O
cardiac	O	O
work	O	O
and	O	O
metabolism	O	O
were	O	O
studied	O	O
in	O	O
dogs	O	O
under	O	O
sodium	B_Chemical	B_Chemical
nitroprusside	I_Chemical	I_Chemical
(	O	O
SNP	B_Chemical	O
)	O	O
and	O	O
trimetaphan	B_Chemical	O
(	O	O
TMP	B_Chemical	O
)	O	O
deliberate	O	O
hypotension	B_Disease	O
(	O	O
20	O	O
%	O	O
and	O	O
40	O	O
%	O	O
mean	O	O
pressure	O	O
decrease	O	O
from	O	O
baseline	O	O
)	O	O
.	O	O

Regarding	O	O
the	O	O
effects	O	O
of	O	O
drug-induced	O	O
hypotension	B_Disease	O
on	O	O
coronary	O	O
blood	O	O
flow	O	O
,	O	O
aortic	O	O
and	O	O
coronary	O	O
sinus	O	O
metabolic	O	O
data	O	O
(	O	O
pH	O	O
,	O	O
pO2	O	O
,	O	O
pCO2	O	O
)	O	O
we	O	O
could	O	O
confirm	O	O
that	O	O
nitroprusside	B_Chemical	O
hypotension	B_Disease	O
could	O	O
be	O	O
safely	O	O
used	O	O
to	O	O
30	O	O
%	O	O
mean	O	O
blood	O	O
pressure	O	O
decrease	O	O
from	O	O
control	O	O
,	O	O
trimetaphan	B_Chemical	O
hypotension	B_Disease	O
to	O	O
20	O	O
%	O	O
mean	O	O
blood	O	O
pressure	O	O
decrease	O	O
.	O	O

Cardiac	O	O
work	O	O
was	O	O
significantly	O	O
reduced	O	O
during	O	O
SNP	B_Chemical	O
hypotension	B_Disease	O
.	O	O

Myocardial	O	O
O2	B_Chemical	O
consumption	O	O
and	O	O
O2	B_Chemical	O
availability	O	O
were	O	O
directly	O	O
dependent	O	O
on	O	O
the	O	O
coronary	O	O
perfusion	O	O
.	O	O

Careful	O	O
invasive	O	O
monitoring	O	O
of	O	O
the	O	O
blood	O	O
pressure	O	O
,	O	O
blood	O	O
gases	O	O
and	O	O
of	O	O
the	O	O
ECG	O	O
ST-T	O	O
segment	O	O
is	O	O
mandatory	O	O
.	O	O

Evidence	O	O
for	O	O
a	O	O
selective	O	O
brain	O	O
noradrenergic	O	O
involvement	O	O
in	O	O
the	O	O
locomotor	O	O
stimulant	O	O
effects	O	O
of	O	O
amphetamine	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

Male	O	O
rats	O	O
received	O	O
the	O	O
noradrenaline	B_Chemical	B_Chemical
neurotoxin	O	I_Chemical
DSP4	B_Chemical	O
(	O	O
50	O	O
mg/kg	O	O
)	O	O
7	O	O
days	O	O
prior	O	O
to	O	O
injection	O	O
of	O	O
D-amphetamine	B_Chemical	B_Chemical
(	O	O
10	O	O
or	O	O
40	O	O
mumol/kg	O	O
i.p	O	O
.	O	O
)	O	O
.	O	O

The	O	O
hyperactivity	B_Disease	O
induced	O	O
by	O	O
D-amphetamine	B_Chemical	B_Chemical
(	O	O
10	O	O
mumol/kg	O	O
)	O	O
was	O	O
significantly	O	O
reduced	O	O
by	O	O
DSP4	B_Chemical	O
pretreatment	O	O
.	O	O

However	O	O
,	O	O
the	O	O
increased	O	O
rearings	O	O
and	O	O
the	O	O
amphetamine-induced	O	O
stereotypies	B_Disease	O
were	O	O
not	O	O
blocked	O	O
by	O	O
pretreatment	O	O
with	O	O
DSP4	B_Chemical	O
.	O	O

The	O	O
reduction	O	O
of	O	O
amphetamine	B_Chemical	O
hyperactivity	B_Disease	O
induced	O	O
by	O	O
DSP4	B_Chemical	O
was	O	O
blocked	O	O
by	O	O
pretreatment	O	O
with	O	O
the	O	O
noradrenaline-uptake	O	O
blocking	O	O
agent	O	O
,	O	O
desipramine	B_Chemical	O
,	O	O
which	O	O
prevents	O	O
the	O	O
neurotoxic	B_Disease	O
action	O	O
of	O	O
DSP4	B_Chemical	O
.	O	O

The	O	O
present	O	O
results	O	O
suggest	O	O
a	O	O
selective	O	O
involvement	O	O
of	O	O
central	O	O
noradrenergic	O	O
neurones	O	O
in	O	O
the	O	O
locomotor	O	O
stimulant	O	O
effect	O	O
of	O	O
amphetamine	B_Chemical	O
in	O	O
the	O	O
rat	O	O
.	O	O

Accelerated	B_Disease	O
junctional	I_Disease	O
rhythms	I_Disease	O
during	O	O
oral	O	O
verapamil	B_Chemical	O
therapy	O	O
.	O	O

This	O	O
study	O	O
examined	O	O
the	O	O
frequency	O	O
of	O	O
atrioventricular	O	O
(	O	O
AV	O	O
)	O	O
dissociation	O	O
and	O	O
accelerated	B_Disease	O
junctional	I_Disease	O
rhythms	I_Disease	O
in	O	O
59	O	O
patients	O	O
receiving	O	O
oral	O	O
verapamil	B_Chemical	O
.	O	O

Accelerated	B_Disease	O
junctional	I_Disease	O
rhythms	I_Disease	O
and	O	O
AV	O	O
dissociation	O	O
were	O	O
frequent	O	O
in	O	O
patients	O	O
with	O	O
supraventricular	B_Disease	O
tachyarrhythmias	I_Disease	O
,	O	O
particularly	O	O
AV	O	O
nodal	O	O
reentry	O	O
.	O	O

Verapamil	B_Chemical	O
administration	O	O
to	O	O
these	O	O
patients	O	O
led	O	O
to	O	O
an	O	O
asymptomatic	O	O
increase	O	O
in	O	O
activity	O	O
of	O	O
these	O	O
junctional	O	O
pacemakers	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
various	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
syndromes	O	I_Disease
,	O	O
verapamil	B_Chemical	O
neither	O	O
increased	O	O
the	O	O
frequency	O	O
of	O	O
junctional	O	O
rhythms	O	O
nor	O	O
suppressed	O	O
their	O	O
role	O	O
as	O	O
escape	O	O
rhythms	O	O
under	O	O
physiologically	O	O
appropriate	O	O
circumstances	O	O
.	O	O

Interstrain	O	O
variation	O	O
in	O	O
acute	O	O
toxic	O	O
response	O	O
to	O	O
caffeine	O	O
among	O	O
inbred	O	O
mice	O	O
.	O	O

Acute	O	O
toxic	O	O
dosage-dependent	O	O
behavioral	O	O
effects	O	O
of	O	O
caffeine	B_Chemical	O
were	O	O
compared	O	O
in	O	O
adult	O	O
males	O	O
from	O	O
seven	O	O
inbred	O	O
mouse	O	O
strains	O	O
(	O	O
A/J	O	O
,	O	O
BALB/cJ	O	O
,	O	O
CBA/J	O	O
,	O	O
C3H/HeJ	O	O
,	O	O
C57BL/6J	O	O
,	O	O
DBA/2J	O	O
,	O	O
SWR/J	O	O
)	O	O
.	O	O

C57BL/6J	O	O
,	O	O
chosen	O	O
as	O	O
a	O	O
"	O	O
prototypic	O	O
"	O	O
mouse	O	O
strain	O	O
,	O	O
was	O	O
used	O	O
to	O	O
determine	O	O
behavioral	O	O
responses	O	O
to	O	O
a	O	O
broad	O	O
range	O	O
(	O	O
5	O	O
-	O	O
500	O	O
mg/kg	O	O
)	O	O
of	O	O
caffeine	B_Chemical	O
doses	O	O
.	O	O

Five	O	O
phenotypic	O	O
characteristics	O	O
--	O	O
locomotor	O	O
activity	O	O
,	O	O
righting	O	O
ability	O	O
,	O	O
clonic	B_Disease	O
seizure	I_Disease	O
induction	O	O
,	O	O
stress-induced	O	O
lethality	O	O
,	O	O
death	O	O
without	O	O
external	O	O
stress	O	O
--	O	O
were	O	O
scored	O	O
at	O	O
various	O	O
caffeine	B_Chemical	O
doses	O	O
in	O	O
drug-naive	O	O
animals	O	O
under	O	O
empirically	O	O
optimized	O	O
,	O	O
rigidly	O	O
constant	O	O
experimental	O	O
conditions	O	O
.	O	O

Mice	O	O
(	O	O
n	O	O
=	O	O
12	O	O
for	O	O
each	O	O
point	O	O
)	O	O
received	O	O
single	O	O
IP	O	O
injections	O	O
of	O	O
a	O	O
fixed	O	O
volume/g	O	O
body	O	O
weight	O	O
of	O	O
physiological	O	O
saline	O	O
carrier	O	O
with	O	O
or	O	O
without	O	O
caffeine	B_Chemical	O
in	O	O
doses	O	O
ranging	O	O
from	O	O
125	O	O
-	O	O
500	O	O
mg/kg	O	O
.	O	O

Loss	O	O
of	O	O
righting	O	O
ability	O	O
was	O	O
scored	O	O
at	O	O
1	O	O
,	O	O
3	O	O
,	O	O
5	O	O
min	O	O
post	O	O
dosing	O	O
and	O	O
at	O	O
5	O	O
min	O	O
intervals	O	O
thereafter	O	O
for	O	O
20	O	O
min	O	O
.	O	O

In	O	O
the	O	O
same	O	O
animals	O	O
the	O	O
occurrence	O	O
of	O	O
clonic	B_Disease	O
seizures	I_Disease	O
was	O	O
scored	O	O
as	O	O
to	O	O
time	O	O
of	O	O
onset	O	O
and	O	O
severity	O	O
for	O	O
20	O	O
min	O	O
after	O	O
drug	O	O
administration	O	O
.	O	O

When	O	O
these	O	O
proceeded	O	O
to	O	O
tonic	B_Disease	O
seizures	I_Disease	O
,	O	O
death	O	O
occurred	O	O
in	O	O
less	O	O
than	O	O
20	O	O
min	O	O
.	O	O

Animals	O	O
surviving	O	O
for	O	O
20	O	O
min	O	O
were	O	O
immediately	O	O
stressed	O	O
by	O	O
a	O	O
swim	O	O
test	O	O
in	O	O
25	O	O
degrees	O	O
C	O	O
water	O	O
,	O	O
and	O	O
death-producing	O	O
tonic	B_Disease	O
seizures	I_Disease	O
were	O	O
scored	O	O
for	O	O
2	O	O
min	O	O
.	O	O

In	O	O
other	O	O
animals	O	O
locomotor	O	O
activity	O	O
was	O	O
measured	O	O
15	O	O
or	O	O
60	O	O
min	O	O
after	O	O
caffeine	B_Chemical	O
administration	O	O
.	O	O

By	O	O
any	O	O
single	O	O
behavioral	O	O
criterion	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
these	O	O
criteria	O	O
,	O	O
marked	O	O
differences	O	O
in	O	O
response	O	O
to	O	O
toxic	O	O
caffeine	B_Chemical	O
doses	O	O
were	O	O
observed	O	O
between	O	O
strains	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
behavioral	O	O
toxicity	B_Disease	O
testing	O	O
of	O	O
alkylxanthines	B_Chemical	B_Chemical
in	O	O
a	O	O
single	O	O
mouse	O	O
strain	O	O
may	O	O
be	O	O
misleading	O	O
and	O	O
suggest	O	O
that	O	O
toxic	O	O
responses	O	O
of	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
to	O	O
this	O	O
class	O	O
of	O	O
compounds	O	O
are	O	O
genetically	O	O
influenced	O	O
in	O	O
mammals	O	O
.	O	O

Treatment	O	O
of	O	O
ovarian	B_Disease	B_Disease
cancer	I_Disease	I_Disease
with	O	O
a	O	O
combination	O	O
of	O	O
cis-platinum	B_Chemical	O
,	O	O
adriamycin	B_Chemical	B_Chemical
,	O	O
cyclophosphamide	B_Chemical	B_Chemical
and	O	O
hexamethylmelamine	B_Chemical	B_Chemical
.	O	O

During	O	O
the	O	O
last	O	O
2	O	O
1/2	O	O
years	O	O
,	O	O
38	O	O
patients	O	O
with	O	O
ovarian	B_Disease	B_Disease
cancer	I_Disease	I_Disease
were	O	O
treated	O	O
with	O	O
a	O	O
combination	O	O
of	O	O
cisplatinum	B_Chemical	O
(	O	O
CPDD	B_Chemical	O
)	O	O
,	O	O
50	O	O
mg/m2	O	O
,	O	O
adriamycin	B_Chemical	B_Chemical
,	O	O
30	O	O
mg/m2	O	O
,	O	O
cyclophosphamide	B_Chemical	B_Chemical
,	O	O
300	O	O
mg/m2	O	O
,	O	O
on	O	O
day	O	O
1	O	O
;	O	O
and	O	O
hexamethylmelamine	B_Chemical	B_Chemical
(	O	O
HMM	B_Chemical	O
)	O	O
,	O	O
6	O	O
mg/kg	O	O
daily	O	O
,	O	O
for	O	O
14	O	O
days	O	O
.	O	O

Each	O	O
course	O	O
was	O	O
repeated	O	O
monthly	O	O
.	O	O

2	O	O
patients	O	O
had	O	O
stage	O	O
II	O	O
,	O	O
14	O	O
stage	O	O
III	O	O
and	O	O
22	O	O
stage	O	O
IV	O	O
disease	O	O
.	O	O

14	O	O
of	O	O
the	O	O
38	O	O
patients	O	O
were	O	O
previously	O	O
treated	O	O
with	O	O
chemotherapy	O	O
,	O	O
1	O	O
with	O	O
radiation	O	O
,	O	O
6	O	O
with	O	O
both	O	O
chemotherapy	O	O
and	O	O
radiation	O	O
,	O	O
and	O	O
17	O	O
did	O	O
not	O	O
have	O	O
any	O	O
treatment	O	O
before	O	O
CPDD	B_Chemical	O
combination	O	O
.	O	O

31	O	O
of	O	O
the	O	O
38	O	O
cases	O	O
(	O	O
81.5	O	O
%	O	O
)	O	O
demonstrated	O	O
objective	O	O
responses	O	O
lasting	O	O
for	O	O
2	O	O
months	O	O
or	O	O
more	O	O
.	O	O

These	O	O
responses	O	O
were	O	O
partial	O	O
in	O	O
19	O	O
and	O	O
complete	O	O
in	O	O
12	O	O
cases	O	O
.	O	O

Hematologic	B_Disease	O
toxicity	I_Disease	O
was	O	O
moderate	O	O
and	O	O
with	O	O
reversible	O	O
anemia	B_Disease	O
developing	O	O
in	O	O
71	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

Gastrointestinal	O	O
side	O	O
effects	O	O
from	O	O
CPDD	B_Chemical	O
were	O	O
universal	O	O
.	O	O

HMM	B_Chemical	O
gastrointestinal	B_Disease	O
toxicity	I_Disease	O
necessitated	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
in	O	O
5	O	O
patients	O	O
.	O	O

Severe	O	O
nephrotoxicity	B_Disease	B_Disease
was	O	O
observed	O	O
in	O	O
2	O	O
patients	O	O
but	O	O
was	O	O
reversible	O	O
.	O	O

There	O	O
were	O	O
no	O	O
drug-related	O	O
deaths	O	O
.	O	O

Nontraumatic	O	O
dissecting	O	O
aneurysm	O	O
of	O	O
the	O	O
basilar	O	O
artery	O	O
.	O	O

A	O	O
case	O	O
of	O	O
nontraumatic	O	O
dissecting	B_Disease	O
aneurysm	I_Disease	O
of	O	O
the	O	O
basilar	O	O
artery	O	O
in	O	O
association	O	O
with	O	O
hypertension	B_Disease	O
,	O	O
smoke	O	O
,	O	O
and	O	O
oral	B_Chemical	B_Chemical
contraceptives	I_Chemical	I_Chemical
is	O	O
reported	O	O
in	O	O
a	O	O
young	O	O
female	O	O
patient	O	O
with	O	O
a	O	O
locked-in	B_Disease	O
syndrome	I_Disease	O
.	O	O

A	O	O
method	O	O
for	O	O
the	O	O
measurement	O	O
of	O	O
tremor	O	O
,	O	O
and	O	O
a	O	O
comparison	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
tocolytic	O	O
beta-mimetics	O	O
.	O	O

A	O	O
method	O	O
permitting	O	O
measurement	O	O
of	O	O
finger	O	O
tremor	B_Disease	O
as	O	O
a	O	O
displacement-time	O	O
curve	O	O
is	O	O
described	O	O
,	O	O
using	O	O
a	O	O
test	O	O
system	O	O
with	O	O
simple	O	O
amplitude	O	O
calibration	O	O
.	O	O

The	O	O
coordinates	O	O
of	O	O
the	O	O
inversion	O	O
points	O	O
of	O	O
the	O	O
displacement-time	O	O
curves	O	O
were	O	O
transferred	O	O
through	O	O
graphical	O	O
input	O	O
equipment	O	O
to	O	O
punched	O	O
tape	O	O
.	O	O

By	O	O
means	O	O
of	O	O
a	O	O
computer	O	O
program	O	O
,	O	O
periods	O	O
and	O	O
amplitudes	O	O
of	O	O
tremor	B_Disease	O
oscillations	O	O
were	O	O
calculated	O	O
and	O	O
classified	O	O
.	O	O

The	O	O
event	O	O
frequency	O	O
for	O	O
each	O	O
class	O	O
of	O	O
periods	O	O
and	O	O
amplitudes	O	O
was	O	O
determined	O	O
.	O	O

The	O	O
actions	O	O
of	O	O
fenoterol-hydrobromide	B_Chemical	B_Chemical
,	O	O
ritodrin-HCl	B_Chemical	O
and	O	O
placebo	O	O
given	O	O
to	O	O
10	O	O
healthy	O	O
subjects	O	O
by	O	O
intravenous	O	O
infusion	O	O
in	O	O
a	O	O
double-blind	O	O
crossover	O	O
study	O	O
were	O	O
tested	O	O
by	O	O
this	O	O
method	O	O
.	O	O

At	O	O
therapeutic	O	O
doses	O	O
both	O	O
substances	O	O
raised	O	O
the	O	O
mean	O	O
tremor	B_Disease	O
amplitude	O	O
to	O	O
about	O	O
three	O	O
times	O	O
the	O	O
control	O	O
level	O	O
.	O	O

At	O	O
the	O	O
same	O	O
time	O	O
,	O	O
the	O	O
mean	O	O
period	O	O
within	O	O
each	O	O
class	O	O
of	O	O
amplitudes	O	O
shortened	O	O
by	O	O
10	O	O
-	O	O
-20	O	O
ms	O	O
,	O	O
whereas	O	O
the	O	O
mean	O	O
periods	O	O
calculated	O	O
from	O	O
all	O	O
oscillations	O	O
together	O	O
did	O	O
not	O	O
change	O	O
significantly	O	O
.	O	O

After	O	O
the	O	O
end	O	O
of	O	O
fenoterol-hydrobromide	B_Chemical	B_Chemical
infusion	O	O
,	O	O
tremor	B_Disease	O
amplitudes	O	O
decreased	O	O
significantly	O	O
faster	O	O
than	O	O
those	O	O
following	O	O
ritodrin-HCl	B_Chemical	O
infusion	O	O
.	O	O

Propylthiouracil-induced	O	O
hepatic	B_Disease	B_Disease
damage	I_Disease	I_Disease
.	O	O

Two	O	O
cases	O	O
of	O	O
propylthiouracil-induced	O	O
liver	B_Disease	B_Disease
damage	I_Disease	I_Disease
have	O	O
been	O	O
observed	O	O
.	O	O

The	O	O
first	O	O
case	O	O
is	O	O
of	O	O
an	O	O
acute	O	O
type	O	O
of	O	O
damage	O	O
,	O	O
proven	O	O
by	O	O
rechallenge	O	O
;	O	O
the	O	O
second	O	O
presents	O	O
a	O	O
clinical	O	O
and	O	O
histologic	O	O
picture	O	O
resembling	O	O
chronic	B_Disease	O
active	I_Disease	O
hepatitis	I_Disease	O
,	O	O
with	O	O
spontaneous	O	O
remission	O	O
.	O	O

Studies	O	O
on	O	O
the	O	O
bradycardia	B_Disease	O
induced	O	O
by	O	O
bepridil	B_Chemical	B_Chemical
.	O	O

Bepridil	B_Chemical	B_Chemical
,	O	O
a	O	O
novel	O	O
active	O	O
compound	O	O
for	O	O
prophylactic	O	O
treatment	O	O
of	O	O
anginal	B_Disease	B_Disease
attacks	I_Disease	I_Disease
,	O	O
induced	O	O
persistent	O	O
bradycardia	B_Disease	O
and	O	O
a	O	O
non-specific	O	O
anti-tachycardial	O	O
effect	O	O
,	O	O
the	O	O
mechanisms	O	O
of	O	O
which	O	O
were	O	O
investigated	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

In	O	O
vitro	O	O
perfusion	O	O
of	O	O
bepridil	B_Chemical	B_Chemical
in	O	O
the	O	O
life-support	O	O
medium	O	O
for	O	O
isolated	O	O
sino-atrial	O	O
tissue	O	O
from	O	O
rabbit	O	O
heart	O	O
,	O	O
caused	O	O
a	O	O
reduction	O	O
in	O	O
action	O	O
potential	O	O
(	O	O
AP	O	O
)	O	O
spike	O	O
frequency	O	O
(	O	O
recorded	O	O
by	O	O
KCl	B_Chemical	O
microelectrodes	O	O
)	O	O
starting	O	O
at	O	O
doses	O	O
of	O	O
5	O	O
X	O	O
10(-6	O	O
)	O	O
M.	O	O
This	O	O
effect	O	O
was	O	O
dose-dependent	O	O
up	O	O
to	O	O
concentrations	O	O
of	O	O
5	O	O
X	O	O
10(-5	O	O
)	O	O
M	O	O
,	O	O
whereupon	O	O
blockade	O	O
of	O	O
sinus	O	O
activity	O	O
set	O	O
in	O	O
.	O	O

Bepridil	B_Chemical	B_Chemical
at	O	O
a	O	O
dose	O	O
of	O	O
5	O	O
X	O	O
10(-6	O	O
)	O	O
M	O	O
,	O	O
induced	O	O
a	O	O
concomitant	O	O
reduction	O	O
in	O	O
AP	O	O
amplitude	O	O
(	O	O
falling	O	O
from	O	O
71	O	O
+	O	O
/-	O	O
8	O	O
mV	O	O
to	O	O
47	O	O
+	O	O
/-	O	O
6	O	O
mV	O	O
)	O	O
,	O	O
maximum	O	O
systolic	O	O
depolarization	O	O
velocity	O	O
(	O	O
phase	O	O
0	O	O
)	O	O
which	O	O
fell	O	O
from	O	O
1.85	O	O
+	O	O
/-	O	O
0.35	O	O
V/s	O	O
to	O	O
0.84	O	O
+	O	O
/-	O	O
0.28	O	O
V/s	O	O
,	O	O
together	O	O
with	O	O
maximum	O	O
diastolic	O	O
depolarization	O	O
velocity	O	O
(	O	O
phase	O	O
4	O	O
)	O	O
which	O	O
fell	O	O
from	O	O
38	O	O
+	O	O
/-	O	O
3	O	O
mV/s	O	O
to	O	O
24	O	O
+	O	O
/-	O	O
5	O	O
mV/s	O	O
.	O	O

In	O	O
vivo	O	O
injection	O	O
of	O	O
bepridil	B_Chemical	B_Chemical
at	O	O
a	O	O
dose	O	O
of	O	O
5	O	O
mg/kg	O	O
(	O	O
i.v	O	O
.	O	O
)	O	O
into	O	O
6	O	O
anaesthetized	O	O
dogs	O	O
which	O	O
had	O	O
undergone	O	O
ablation	O	O
of	O	O
all	O	O
the	O	O
extrinsic	O	O
cardiac	O	O
afferent	O	O
nerve	O	O
supply	O	O
,	O	O
together	O	O
with	O	O
a	O	O
bilateral	O	O
medullo-adrenalectomy	O	O
,	O	O
caused	O	O
a	O	O
marked	O	O
reduction	O	O
in	O	O
heart	O	O
rate	O	O
which	O	O
fell	O	O
from	O	O
98.7	O	O
+	O	O
/-	O	O
4.2	O	O
beats/min	O	O
to	O	O
76	O	O
+	O	O
/-	O	O
5.3	O	O
beats/min	O	O
sustained	O	O
for	O	O
more	O	O
than	O	O
45	O	O
min	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
bepridil	B_Chemical	B_Chemical
reduces	O	O
heart	O	O
rate	O	O
by	O	O
acting	O	O
directly	O	O
on	O	O
the	O	O
sinus	O	O
node	O	O
.	O	O

This	O	O
effect	O	O
,	O	O
which	O	O
results	O	O
in	O	O
a	O	O
flattening	O	O
of	O	O
the	O	O
phase	O	O
0	O	O
and	O	O
phase	O	O
4	O	O
slope	O	O
,	O	O
together	O	O
with	O	O
a	O	O
longer	O	O
AP	O	O
duration	O	O
,	O	O
may	O	O
be	O	O
due	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
time	O	O
constants	O	O
of	O	O
slow	O	O
inward	O	O
ionic	O	O
currents	O	O
(	O	O
already	O	O
demonstrated	O	O
elsewhere	O	O
)	O	O
,	O	O
but	O	O
also	O	O
to	O	O
an	O	O
increased	O	O
time	O	O
constant	O	O
for	O	O
deactivation	O	O
of	O	O
the	O	O
outward	O	O
potassium	B_Chemical	O
current	O	O
(	O	O
Ip	O	O
)	O	O
.	O	O

Hepatitis	B_Disease	O
and	O	O
renal	B_Disease	B_Disease
tubular	I_Disease	I_Disease
acidosis	I_Disease	I_Disease
after	O	O
anesthesia	O	O
with	O	O
methoxyflurane	B_Chemical	B_Chemical
.	O	O

A	O	O
69-year-old	O	O
man	O	O
operated	O	O
for	O	O
acute	B_Disease	B_Disease
cholecystitis	I_Disease	I_Disease
under	O	O
methoxyflurane	B_Chemical	B_Chemical
anesthesia	O	O
developed	O	O
postoperatively	O	O
a	O	O
hepatic	B_Disease	B_Disease
insufficiency	I_Disease	I_Disease
syndrome	I_Disease	I_Disease
and	O	O
renal	B_Disease	B_Disease
tubular	I_Disease	I_Disease
acidosis	I_Disease	I_Disease
.	O	O

Massive	O	O
bleeding	B_Disease	O
appeared	O	O
during	O	O
surgery	O	O
which	O	O
lasted	O	O
for	O	O
six	O	O
hours	O	O
.	O	O

Postoperative	O	O
evolution	O	O
under	O	O
supportive	O	O
therapy	O	O
was	O	O
favourable	O	O
.	O	O

Complete	O	O
recovery	O	O
was	O	O
confirmed	O	O
by	O	O
repeated	O	O
controls	O	O
performed	O	O
over	O	O
a	O	O
period	O	O
of	O	O
one	O	O
year	O	O
after	O	O
surgery	O	O
.	O	O

Pituitary	O	O
response	O	O
to	O	O
luteinizing	O	O
hormone-releasing	O	O
hormone	O	O
during	O	O
haloperidol-induced	O	O
hyperprolactinemia	B_Disease	B_Disease
.	O	O

The	O	O
effects	O	O
of	O	O
a	O	O
6-hour	O	O
infusion	O	O
with	O	O
haloperidol	B_Chemical	O
on	O	O
serum	O	B_Disease
prolactin	O	I_Disease
and	O	O
luteinizing	O	O
hormone	O	O
(	O	O
LH	O	O
)	O	O
levels	O	O
was	O	O
studied	O	O
in	O	O
a	O	O
group	O	O
of	O	O
male	O	O
subjects	O	O
.	O	O

Five	O	O
hours	O	O
after	O	O
starting	O	O
the	O	O
infusions	O	O
,	O	O
a	O	O
study	O	O
of	O	O
the	O	O
pituitary	O	O
responses	O	O
to	O	O
LH-releasing	O	O
hormone	O	O
(	O	O
LH-RH	O	O
)	O	O
was	O	O
carried	O	O
out	O	O
.	O	O

Control	O	O
patients	O	O
received	O	O
infusions	O	O
of	O	O
0.9	O	O
%	O	O
NaCl	B_Chemical	O
solution	O	O
.	O	O

During	O	O
the	O	O
course	O	O
of	O	O
haloperidol	B_Chemical	O
infusions	O	O
,	O	O
significant	O	O
hyperprolactinemia	B_Disease	B_Disease
was	O	O
found	O	O
,	O	O
together	O	O
with	O	O
an	O	O
abolished	O	O
pituitary	O	O
response	O	O
to	O	O
LH-RH	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
responses	O	O
of	O	O
control	O	O
subjects	O	O
.	O	O

Antirifampicin	O	B_Chemical
antibodies	O	O
in	O	O
acute	O	O
rifampicin-associated	O	O
renal	O	O
failure.5	O	O
patients	O	O
with	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
(	O	O
3	O	O
with	O	O
thrombopenia	B_Disease	O
and	O	O
hemolysis	B_Disease	O
)	O	O
induced	O	O
by	O	O
the	O	O
reintroduction	O	O
of	O	O
rifampicin	B_Chemical	B_Chemical
are	O	O
described	O	O
.	O	O

No	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
the	O	O
severity	O	O
of	O	O
clinical	O	O
manifestations	O	O
and	O	O
the	O	O
total	O	O
dose	O	O
taken	O	O
by	O	O
the	O	O
patients	O	O
.	O	O

In	O	O
all	O	O
but	O	O
1	O	O
patient	O	O
,	O	O
antirifampicin	O	O
antibodies	O	O
were	O	O
detected	O	O
.	O	O

Antibodies	O	O
suggested	O	O
to	O	O
be	O	O
of	O	O
the	O	O
IgM	O	O
class	O	O
were	O	O
detected	O	O
in	O	O
all	O	O
3	O	O
patients	O	O
with	O	O
hematological	B_Disease	B_Disease
disorders	I_Disease	I_Disease
.	O	O

The	O	O
pattern	O	O
of	O	O
non-specific	O	O
acute	B_Disease	B_Disease
tubular	I_Disease	I_Disease
necrosis	I_Disease	I_Disease
found	O	O
in	O	O
the	O	O
2	O	O
biopsied	O	O
patients	O	O
,	O	O
indistinguishable	O	O
from	O	O
that	O	O
of	O	O
ischemic	O	O
origin	O	O
,	O	O
raised	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
vascular-mediated	O	O
damage	O	O
.	O	O

In	O	O
3	O	O
patients	O	O
,	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
triggering	O	O
immunoallergic	O	O
mechanism	O	O
is	O	O
discussed	O	O
.	O	O

Cardiovascular	O	O
effects	O	O
of	O	O
hypotension	B_Disease	O
induced	O	O
by	O	O
adenosine	B_Chemical	B_Chemical
triphosphate	I_Chemical	I_Chemical
and	O	O
sodium	B_Chemical	B_Chemical
nitroprusside	I_Chemical	I_Chemical
on	O	O
dogs	O	O
with	O	O
denervated	O	O
hearts	O	O
.	O	O

Adenosine	B_Chemical	B_Chemical
triphosphate	I_Chemical	I_Chemical
(	O	O
ATP	B_Chemical	O
)	O	O
and	O	O
sodium	B_Chemical	B_Chemical
nitroprusside	I_Chemical	I_Chemical
(	O	O
SNP	B_Chemical	O
)	O	O
are	O	O
administered	O	O
to	O	O
patients	O	O
to	O	O
induce	O	O
and	O	O
control	O	O
hypotension	B_Disease	O
during	O	O
anesthesia	O	O
.	O	O

SNP	B_Chemical	O
is	O	O
authorized	O	O
for	O	O
clinical	O	O
use	O	O
in	O	O
USA	O	O
and	O	O
UK	O	O
,	O	O
and	O	O
ATP	B_Chemical	O
is	O	O
clinically	O	O
used	O	O
in	O	O
other	O	O
countries	O	O
such	O	O
as	O	O
Japan	O	O
.	O	O

We	O	O
investigated	O	O
how	O	O
these	O	O
two	O	O
drugs	O	O
act	O	O
on	O	O
the	O	O
cardiovascular	O	O
systems	O	O
of	O	O
20	O	O
dogs	O	O
whose	O	O
hearts	O	O
had	O	O
been	O	O
denervated	O	O
by	O	O
a	O	O
procedure	O	O
we	O	O
had	O	O
devised	O	O
.	O	O

ATP	B_Chemical	O
(	O	O
10	O	O
dogs	O	O
)	O	O
or	O	O
SNP	B_Chemical	O
(	O	O
10	O	O
dogs	O	O
)	O	O
was	O	O
administered	O	O
to	O	O
reduce	O	O
mean	O	O
arterial	O	O
pressure	O	O
by	O	O
30	O	O
%	O	O
to	O	O
70	O	O
%	O	O
of	O	O
control	O	O
.	O	O

Before	O	O
,	O	O
during	O	O
and	O	O
after	O	O
induced	O	O
hypotension	B_Disease	O
,	O	O
we	O	O
measured	O	O
major	O	O
cardiovascular	O	O
parameters	O	O
.	O	O

Hypotension	B_Disease	O
induced	O	O
by	O	O
ATP	B_Chemical	O
was	O	O
accompanied	O	O
by	O	O
significant	O	O
decreases	O	O
in	O	O
mean	O	O
pulmonary	O	O
arterial	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
,	O	O
central	O	O
venous	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
,	O	O
left	O	O
ventricular	O	O
end-diastolic	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
,	O	O
total	O	O
peripheral	O	O
resistance	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
,	O	O
rate	O	O
pressure	O	O
product	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
,	O	O
total	O	O
body	O	O
oxygen	B_Chemical	O
consumption	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
,	O	O
and	O	O
heart	O	O
rate	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
;	O	O
all	O	O
these	O	O
variables	O	O
returned	O	O
normal	O	O
within	O	O
30	O	O
min	O	O
after	O	O
ATP	B_Chemical	O
was	O	O
stopped	O	O
.	O	O

Cardiac	O	O
output	O	O
did	O	O
not	O	O
change	O	O
.	O	O

During	O	O
hypotension	B_Disease	O
produced	O	O
by	O	O
SNP	B_Chemical	O
similar	O	O
decreases	O	O
were	O	O
observed	O	O
in	O	O
mean	O	O
pulmonary	O	O
arterial	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
,	O	O
central	O	O
venous	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
,	O	O
left	O	O
ventricular	O	O
end-diastolic	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
,	O	O
total	O	O
peripheral	O	O
resistance	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
,	O	O
rate	O	O
pressure	O	O
product	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
,	O	O
and	O	O
oxygen	B_Chemical	O
content	O	O
difference	O	O
between	O	O
arterial	O	O
and	O	O
mixed	O	O
venous	O	O
blood	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
,	O	O
while	O	O
heart	O	O
rate	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
and	O	O
cardiac	O	O
output	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
were	O	O
increased	O	O
.	O	O

Recoveries	O	O
of	O	O
heart	O	O
rate	O	O
and	O	O
left	O	O
ventricular	O	O
end-diastolic	O	O
pressure	O	O
were	O	O
not	O	O
shown	O	O
within	O	O
60	O	O
min	O	O
after	O	O
SNP	B_Chemical	O
had	O	O
been	O	O
stopped	O	O
.	O	O

Both	O	O
ATP	B_Chemical	O
and	O	O
SNP	B_Chemical	O
should	O	O
act	O	O
on	O	O
the	O	O
pacemaker	O	O
tissue	O	O
of	O	O
the	O	O
heart	O	O
.	O	O

Comparative	O	O
study	O	O
:	O	O
Endografine	B_Chemical	O
(	O	O
diatrizoate	B_Chemical	B_Chemical
)	O	O
,	O	O
Vasurix	B_Chemical	B_Chemical
polyvidone	I_Chemical	I_Chemical
(	O	O
acetrizoate	B_Chemical	B_Chemical
)	O	O
,	O	O
Dimer-X	B_Chemical	O
(	O	O
iocarmate	B_Chemical	B_Chemical
)	O	O
and	O	O
Hexabrix	B_Chemical	O
(	O	O
ioxaglate	B_Chemical	B_Chemical
)	O	O
in	O	O
hysterosalpingography	O	O
.	O	O

Side	O	O
effects	O	O
of	O	O
hysterosalpingography	O	O
with	O	O
Dimer-X	B_Chemical	O
,	O	O
Hexabrix	B_Chemical	O
,	O	O
Vasurix	B_Chemical	O
polyvidone	I_Chemical	O
and	O	O
Endografine	B_Chemical	O
in	O	O
142	O	O
consecutive	O	O
patients	O	O
,	O	O
receiving	O	O
one	O	O
of	O	O
the	O	O
four	O	O
tested	O	O
media	O	O
were	O	O
evaluated	O	O
from	O	O
replies	O	O
to	O	O
postal	O	O
questionnaires	O	O
.	O	O

The	O	O
Dimer-X	B_Chemical	O
group	O	O
had	O	O
a	O	O
higher	O	O
incidence	O	O
of	O	O
nausea	B_Disease	O
and	O	O
dizziness	B_Disease	O
.	O	O

The	O	O
Endografine	B_Chemical	O
group	O	O
had	O	O
a	O	O
higher	O	O
incidence	O	O
of	O	O
abdominal	B_Disease	B_Disease
pain	I_Disease	I_Disease
.	O	O

These	O	O
differences	O	O
occur	O	O
especially	O	O
in	O	O
the	O	O
age	O	O
groups	O	O
under	O	O
30	O	O
years	O	O
.	O	O

Hexabrix	B_Chemical	O
and	O	O
Vasurix	B_Chemical	B_Chemical
polyvidone	I_Chemical	I_Chemical
are	O	O
considered	O	O
the	O	O
best	O	O
contrast	B_Chemical	O
media	I_Chemical	O
for	O	O
hysterosalpingography	O	O
and	O	O
perhaps	O	O
because	O	O
of	O	O
its	O	O
low	O	O
toxicity	B_Disease	O
Hexabrix	B_Chemical	O
should	O	O
be	O	O
preferred	O	O
.	O	O

Post-suxamethonium	O	B_Chemical
pains	B_Disease	O
in	O	O
Nigerian	O	O
surgical	O	O
patients	O	O
.	O	O

Contrary	O	O
to	O	O
an	O	O
earlier	O	O
report	O	O
by	O	O
Coxon	O	O
,	O	O
scoline	B_Chemical	O
pain	B_Disease	O
occurs	O	O
in	O	O
African	O	O
negroes	O	O
.	O	O

Its	O	O
incidence	O	O
was	O	O
determined	O	O
in	O	O
a	O	O
prospective	O	O
study	O	O
involving	O	O
a	O	O
total	O	O
of	O	O
100	O	O
Nigerian	O	O
patients	O	O
(	O	O
50	O	O
out-patients	O	O
and	O	O
50	O	O
in-patients	O	O
)	O	O
.	O	O

About	O	O
62	O	O
%	O	O
of	O	O
the	O	O
out-patients	O	O
developed	O	O
scoline	B_Chemical	O
pain	B_Disease	O
as	O	O
compared	O	O
with	O	O
about	O	O
26	O	O
%	O	O
among	O	O
the	O	O
in-patients	O	O
.	O	O

The	O	O
abolition	O	O
of	O	O
muscle	O	O
fasciculations	B_Disease	O
(	O	O
by	O	O
0.075mg/kg	O	O
dose	O	O
of	O	O
Fazadinium	B_Chemical	B_Chemical
)	O	O
did	O	O
not	O	O
influence	O	O
the	O	O
occurrence	O	O
of	O	O
scoline	B_Chemical	O
pain	B_Disease	O
.	O	O

Neither	O	O
the	O	O
type	O	O
of	O	O
induction	O	O
agent	O	O
(	O	O
Althesin	B_Chemical	O
or	O	O
Thiopentone	B_Chemical	B_Chemical
)	O	O
nor	O	O
the	O	O
salt	O	O
preparation	O	O
of	O	O
suxamethonium	B_Chemical	B_Chemical
used	O	O
(	O	O
chloride	B_Chemical	O
or	O	O
bromide	B_Chemical	O
)	O	O
,	O	O
affected	O	O
the	O	O
incidence	O	O
of	O	O
scoline	B_Chemical	O
pain	B_Disease	O
.	O	O

Invasive	O	O
carcinoma	B_Disease	O
of	I_Disease	O
the	I_Disease	O
renal	I_Disease	O
pelvis	I_Disease	O
following	O	O
cyclophosphamide	B_Chemical	B_Chemical
therapy	O	O
for	O	O
nonmalignant	O	B_Disease
disease	O	I_Disease
.	O	O

A	O	O
47-year-old	O	O
woman	O	O
with	O	O
right	O	O
hydroureteronephrosis	B_Disease	O
due	O	O
to	O	O
ureterovesical	O	O
junction	O	O
obstruction	O	O
had	O	O
gross	O	O
hematuria	B_Disease	O
after	O	O
being	O	O
treated	O	O
for	O	O
five	O	O
years	O	O
wtih	O	O
cyclophosphamide	B_Chemical	B_Chemical
for	O	O
cerebral	B_Disease	B_Disease
vasculitis	I_Disease	I_Disease
.	O	O

A	O	O
right	O	O
nephroureterectomy	O	O
was	O	O
required	O	O
for	O	O
control	O	O
of	O	O
bleeding	B_Disease	O
.	O	O

The	O	O
pathology	O	O
specimen	O	O
contained	O	O
clinically	O	O
occult	O	O
invasive	O	O
carcinoma	B_Disease	O
of	I_Disease	O
the	I_Disease	O
renal	I_Disease	O
pelvis	I_Disease	O
.	O	O

Although	O	O
the	O	O
ability	O	O
of	O	O
cyclophosphamide	B_Chemical	B_Chemical
to	O	O
cause	O	O
hemorrhagic	B_Disease	B_Disease
cystitis	B_Disease	I_Disease
and	O	O
urine	O	O
cytologic	O	O
abnormalities	O	O
indistinguishable	O	O
from	O	O
high	O	O
grade	O	O
carcinoma	B_Disease	O
is	O	O
well	O	O
known	O	O
,	O	O
it	O	O
is	O	O
less	O	O
widely	O	O
appreciated	O	O
that	O	O
it	O	O
is	O	O
also	O	O
associated	O	O
with	O	O
carcinoma	B_Disease	O
of	I_Disease	O
the	I_Disease	O
urinary	I_Disease	O
tract	I_Disease	O
.	O	O

Twenty	O	O
carcinomas	B_Disease	O
of	I_Disease	O
the	I_Disease	O
urinary	I_Disease	O
bladder	I_Disease	O
and	O	O
one	O	O
carcinoma	B_Disease	O
of	I_Disease	O
the	I_Disease	O
prostate	I_Disease	O
have	O	O
been	O	O
reported	O	O
in	O	O
association	O	O
with	O	O
its	O	O
use	O	O
.	O	O

The	O	O
present	O	O
case	O	O
is	O	O
the	O	O
first	O	O
carcinoma	B_Disease	O
of	I_Disease	O
the	I_Disease	O
renal	I_Disease	O
pelvis	I_Disease	O
reported	O	O
in	O	O
association	O	O
with	O	O
cyclophosphamide	B_Chemical	B_Chemical
treatment	O	O
.	O	O

It	O	O
is	O	O
the	O	O
third	O	O
urinary	B_Disease	B_Disease
tract	I_Disease	I_Disease
cancer	I_Disease	I_Disease
reported	O	O
in	O	O
association	O	O
with	O	O
cyclophosphamide	B_Chemical	B_Chemical
treatment	O	O
for	O	O
nonmalignant	O	B_Disease
disease	O	I_Disease
.	O	O

The	O	O
association	O	O
of	O	O
the	O	O
tumor	B_Disease	O
with	O	O
preexisting	O	O
hydroureteronephrosis	B_Disease	O
suggests	O	O
that	O	O
stasis	O	O
prolonged	O	O
and	O	O
intensified	O	O
exposure	O	O
of	O	O
upper	O	O
urinary	O	O
tract	O	O
epithelium	O	O
to	O	O
cyclophosphamide	B_Chemical	B_Chemical
.	O	O

Patients	O	O
who	O	O
are	O	O
candidates	O	O
for	O	O
long-term	O	O
cyclophosphamide	B_Chemical	B_Chemical
treatment	O	O
should	O	O
be	O	O
routinely	O	O
evaluated	O	O
for	O	O
obstructive	B_Disease	B_Disease
uropathy	I_Disease	I_Disease
.	O	O

Medial	O	O
changes	O	O
in	O	O
arterial	O	B_Disease
spasm	B_Disease	I_Disease
induced	O	O
by	O	O
L-norepinephrine	B_Chemical	B_Chemical
.	O	O

In	O	O
normal	O	O
rats	O	O
,	O	O
the	O	O
media	O	O
of	O	O
small	O	O
arteries	O	O
(	O	O
0.4	O	O
-	O	O
-0.2	O	O
mm	O	O
in	O	O
diameter	O	O
)	O	O
previously	O	O
was	O	O
shown	O	O
to	O	O
contain	O	O
intracellular	O	O
vacuoles	O	O
,	O	O
identified	O	O
ultrastructurally	O	O
as	O	O
herniations	O	O
of	O	O
one	O	O
smooth	O	O
muscle	O	O
cell	O	O
into	O	O
another	O	O
.	O	O

The	O	O
hypothesis	O	O
that	O	O
intense	O	O
vasoconstriction	O	O
would	O	O
increase	O	O
the	O	O
number	O	O
of	O	O
such	O	O
vacuoles	O	O
has	O	O
been	O	O
tested	O	O
.	O	O

In	O	O
the	O	O
media	O	O
of	O	O
the	O	O
saphenous	O	O
artery	O	O
and	O	O
its	O	O
distal	O	O
branch	O	O
,	O	O
vasoconstriction	O	O
induced	O	O
by	O	O
L-norepinephrine	B_Chemical	O
produced	O	O
many	O	O
cell-to-cell	O	O
hernias	B_Disease	O
within	O	O
15	O	O
minutes	O	O
.	O	O

At	O	O
1	O	O
day	O	O
their	O	O
number	O	O
was	O	O
reduced	O	O
to	O	O
about	O	O
1/10	O	O
of	O	O
the	O	O
original	O	O
number	O	O
.	O	O

By	O	O
7	O	O
days	O	O
the	O	O
vessel	O	O
was	O	O
almost	O	O
restored	O	O
to	O	O
normal	O	O
.	O	O

Triple	O	O
stimulation	O	O
over	O	O
1	O	O
day	O	O
induced	O	O
more	O	O
severe	O	O
changes	O	O
in	O	O
the	O	O
media	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
smooth	O	O
muscle	O	O
cells	O	O
are	O	O
susceptible	O	O
to	O	O
damage	O	O
in	O	O
the	O	O
course	O	O
of	O	O
their	O	O
specific	O	O
function	O	O
.	O	O

The	O	O
experimental	O	O
data	O	O
are	O	O
discussed	O	O
in	O	O
relation	O	O
to	O	O
medial	O	O
changes	O	O
observed	O	O
in	O	O
other	O	O
instances	O	O
of	O	O
arterial	O	B_Disease
spasm	B_Disease	I_Disease
.	O	O

Endothelial	O	O
changes	O	O
that	O	O
developed	O	O
in	O	O
the	O	O
same	O	O
experimental	O	O
model	O	O
were	O	O
described	O	O
in	O	O
a	O	O
previous	O	O
paper	O	O
.	O	O

Bilateral	O	O
retinal	B_Disease	O
artery	I_Disease	O
and	I_Disease	O
choriocapillaris	I_Disease	O
occlusion	I_Disease	O
following	O	O
the	O	O
injection	O	O
of	O	O
long-acting	O	O
corticosteroid	B_Chemical	O
suspensions	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
drugs	O	O
:	O	O
I.	O	O
Clinical	O	O
studies	O	O
.	O	O

Two	O	O
well-documented	O	O
cases	O	O
of	O	O
bilateral	O	O
retinal	B_Disease	O
artery	I_Disease	O
and	I_Disease	O
choriocapillaris	I_Disease	O
occlusions	I_Disease	O
with	O	O
blindness	B_Disease	O
following	O	O
head	O	O
and	O	O
neck	O	O
soft-tissue	O	O
injection	O	O
with	O	O
methylprednisolone	B_Chemical	B_Chemical
acetate	I_Chemical	I_Chemical
in	O	O
combination	O	O
with	O	O
lidocaine	B_Chemical	O
,	O	O
epinephrine	B_Chemical	O
,	O	O
or	O	O
penicillin	B_Chemical	O
are	O	O
reported	O	O
.	O	O

One	O	O
case	O	O
had	O	O
only	O	O
a	O	O
unilateral	O	O
injection	O	O
.	O	O

The	O	O
acute	O	O
observations	O	O
included	O	O
hazy	O	O
sensorium	O	O
,	O	O
superior	O	O
gaze	O	O
palsy	B_Disease	O
,	O	O
pupillary	B_Disease	O
abnormalities	I_Disease	O
,	O	O
and	O	O
conjunctival	O	O
hemorrhages	B_Disease	O
with	O	O
edema	B_Disease	O
.	O	O

Follow-up	O	O
changes	O	O
showed	O	O
marked	O	O
visual	B_Disease	B_Disease
loss	I_Disease	I_Disease
,	O	O
constricted	O	O
visual	O	O
fields	O	O
,	O	O
optic	O	O
nerve	O	O
pallor	O	O
,	O	O
vascular	O	O
attenuation	O	O
,	O	O
and	O	O
chorioretinal	B_Disease	O
atrophy	I_Disease	O
.	O	O

The	O	O
literature	O	O
is	O	O
reviewed	O	O
,	O	O
and	O	O
possible	O	O
causes	O	O
are	O	O
discussed	O	O
.	O	O

Abnormalities	O	O
of	O	O
the	O	O
pupil	O	O
and	O	O
visual-evoked	O	O
potential	O	O
in	O	O
quinine	B_Chemical	O
amblyopia	B_Disease	O
.	O	O

Total	O	O
blindness	B_Disease	O
with	O	O
a	O	O
transient	O	O
tonic	B_Disease	O
pupillary	I_Disease	O
response	O	O
,	O	O
denervation	O	O
supersensitivity	O	O
,	O	O
and	O	O
abnormal	O	O
visual-evoked	O	O
potentials	O	O
developed	O	O
in	O	O
a	O	O
54-year-old	O	O
man	O	O
after	O	O
the	O	O
use	O	O
of	O	O
quinine	B_Chemical	B_Chemical
sulfate	I_Chemical	I_Chemical
for	O	O
leg	B_Disease	O
cramps	I_Disease	O
.	O	O

He	O	O
later	O	O
recovered	O	O
normal	O	O
visual	O	O
acuity	O	O
.	O	O

A	O	O
transient	O	O
tonic	B_Disease	O
pupillary	I_Disease	O
response	O	O
,	O	O
denervation	O	O
supersensitivity	O	O
,	O	O
and	O	O
abnormal	O	O
visual-evoked	O	O
potentials	O	O
in	O	O
quinine	B_Chemical	O
toxicity	B_Disease	O
,	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
have	O	O
not	O	O
been	O	O
previously	O	O
reported	O	O
.	O	O

Suxamethonium-induced	O	O
jaw	B_Disease	O
stiffness	I_Disease	O
and	O	O
myalgia	B_Disease	O
associated	O	O
with	O	O
atypical	O	O
cholinesterase	O	O
:	O	O
case	O	O
report	O	O
.	O	O

An	O	O
11-year-old	O	O
boy	O	O
was	O	O
given	O	O
halothane	B_Chemical	O
,	O	O
nitrous	B_Chemical	B_Chemical
oxide	I_Chemical	I_Chemical
and	O	O
oxygen	B_Chemical	O
,	O	O
pancuronium	B_Chemical	B_Chemical
0.4	O	O
mg	O	O
and	O	O
suxamethonium	B_Chemical	B_Chemical
100	O	O
mg	O	O
for	O	O
induction	O	O
of	O	O
anaesthesia	O	O
.	O	O

In	O	O
response	O	O
to	O	O
this	O	O
a	O	O
marked	O	O
jaw	B_Disease	O
stiffness	I_Disease	O
occurred	O	O
which	O	O
lasted	O	O
for	O	O
two	O	O
minutes	O	O
and	O	O
the	O	O
anaesthesia	O	O
were	O	O
terminated	O	O
.	O	O

Four	O	O
hours	O	O
of	O	O
apnoea	B_Disease	B_Disease
ensued	O	O
and	O	O
he	O	O
suffered	O	O
generalized	O	O
severe	O	O
myalgia	B_Disease	O
lasting	O	O
for	O	O
one	O	O
week	O	O
.	O	O

He	O	O
was	O	O
found	O	O
to	O	O
have	O	O
atypical	O	O
plasma	O	O
cholinesterase	O	O
with	O	O
a	O	O
dibucaine	B_Chemical	O
number	O	O
of	O	O
12	O	O
,	O	O
indicating	O	O
homozygocity	O	B_Disease
.	O	O

This	O	O
was	O	O
verified	O	O
by	O	O
study	O	O
of	O	O
the	O	O
family	O	O
.	O	O

The	O	O
case	O	O
shows	O	O
that	O	O
prolonged	B_Disease	O
jaw	I_Disease	B_Disease
rigidity	I_Disease	I_Disease
and	O	O
myalgia	B_Disease	O
may	O	O
occur	O	O
after	O	O
suxamethonium	B_Chemical	B_Chemical
in	O	O
patients	O	O
with	O	O
atypical	O	O
cholinesterase	O	O
despite	O	O
pretreatment	O	O
with	O	O
pancuronium	B_Chemical	B_Chemical
.	O	O

Indomethacin-induced	O	O
hyperkalemia	B_Disease	O
in	O	O
three	O	O
patients	O	O
with	O	O
gouty	B_Disease	B_Disease
arthritis	I_Disease	I_Disease
.	O	O

We	O	O
describe	O	O
three	O	O
patients	O	O
in	O	O
whom	O	O
severe	O	O
,	O	O
life-threatening	O	O
hyperkalemia	B_Disease	O
and	O	O
renal	B_Disease	B_Disease
insufficiency	I_Disease	I_Disease
developed	O	O
after	O	O
treatment	O	O
of	O	O
acute	O	B_Disease
gouty	B_Disease	I_Disease
arthritis	I_Disease	I_Disease
with	O	O
indomethacin	B_Chemical	O
.	O	O

This	O	O
complication	O	O
may	O	O
result	O	O
from	O	O
an	O	O
inhibition	O	O
of	O	O
prostaglandin	B_Chemical	O
synthesis	O	O
and	O	O
consequent	O	O
hyporeninemic	B_Disease	O
hypoaidosteronism	I_Disease	O
.	O	O

Careful	O	O
attention	O	O
to	O	O
renal	O	O
function	O	O
and	O	O
potassium	B_Chemical	O
balance	O	O
in	O	O
patients	O	O
receiving	O	O
indomethacin	B_Chemical	O
or	O	O
other	O	O
nonsteroidal	O	O
anti-inflammatory	O	O
agents	O	O
,	O	O
particularly	O	O
in	O	O
those	O	O
patients	O	O
with	O	O
diabetes	B_Disease	O
mellitus	I_Disease	O
or	O	O
preexisting	O	O
renal	B_Disease	B_Disease
disease	I_Disease	I_Disease
,	O	O
will	O	O
help	O	O
prevent	O	O
this	O	O
potentially	O	O
serious	O	O
complication	O	O
.	O	O

Etomidate	O	B_Chemical
:	O	O
a	O	O
foreshortened	O	O
clinical	O	O
trial	O	O
.	O	O

A	O	O
clinical	O	O
evaluation	O	O
of	O	O
etomidate	B_Chemical	B_Chemical
for	O	O
outpatient	O	O
cystoscopy	O	O
was	O	O
embarked	O	O
upon	O	O
.	O	O

Unpremedicated	O	O
patients	O	O
were	O	O
given	O	O
fentanyl	B_Chemical	O
1	O	O
microgram/kg	O	O
followed	O	O
by	O	O
etomidate	B_Chemical	B_Chemical
0.3	O	O
mg/kg	O	O
.	O	O

Anaesthesia	O	O
was	O	O
maintained	O	O
with	O	O
intermittent	O	O
etomidate	B_Chemical	B_Chemical
in	O	O
2	O	O
-	O	O
4	O	O
mg	O	O
doses	O	O
.	O	O

Patients	O	O
were	O	O
interviewed	O	O
personally	O	O
later	O	O
the	O	O
same	O	O
day	O	O
,	O	O
and	O	O
by	O	O
questionnaire	O	O
three	O	O
to	O	O
four	O	O
weeks	O	O
later	O	O
.	O	O

The	O	O
trial	O	O
was	O	O
discontinued	O	O
after	O	O
20	O	O
cases	O	O
because	O	O
of	O	O
an	O	O
unacceptable	O	O
incidence	O	O
of	O	O
side	O	O
effects	O	O
.	O	O

Venous	O	O
pain	B_Disease	O
occurred	O	O
in	O	O
68	O	O
%	O	O
of	O	O
patients	O	O
and	O	O
50	O	O
%	O	O
had	O	O
redness	O	O
,	O	O
pain	B_Disease	O
or	O	O
swelling	B_Disease	O
related	O	O
to	O	O
the	O	O
injection	O	O
site	O	O
,	O	O
in	O	O
some	O	O
cases	O	O
lasting	O	O
up	O	O
to	O	O
three	O	O
weeks	O	O
after	O	O
anaesthesia	O	O
.	O	O

Skeletal	O	O
movements	O	O
occurred	O	O
in	O	O
50	O	O
%	O	O
of	O	O
patients	O	O
;	O	O
30	O	O
%	O	O
experienced	O	O
respiratory	B_Disease	O
upset	I_Disease	O
,	O	O
one	O	O
sufficiently	O	O
severe	O	O
to	O	O
necessitate	O	O
abandoning	O	O
the	O	O
technique	O	O
.	O	O

Nausea	B_Disease	O
and	O	O
vomiting	B_Disease	O
occurred	O	O
in	O	O
40	O	O
%	O	O
and	O	O
25	O	O
%	O	O
had	O	O
disturbing	O	O
emergence	O	O
psychoses	B_Disease	O
.	O	O

Levodopa-induced	O	O
dyskinesias	B_Disease	O
are	O	O
improved	O	O
by	O	O
fluoxetine	B_Chemical	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
severity	O	O
of	O	O
motor	B_Disease	B_Disease
disability	I_Disease	I_Disease
and	O	O
dyskinesias	B_Disease	O
in	O	O
seven	O	O
levodopa-responsive	O	O
patients	O	O
with	O	O
Parkinson	B_Disease	B_Disease
's	I_Disease	I_Disease
disease	I_Disease	I_Disease
after	O	O
an	O	O
acute	O	O
challenge	O	O
with	O	O
the	O	O
mixed	O	O
dopamine	B_Chemical	O
agonist	O	O
,	O	O
apomorphine	B_Chemical	O
,	O	O
before	O	O
and	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
fluoxetine	B_Chemical	O
(	O	O
20	O	O
mg	O	O
twice	O	O
per	O	O
day	O	O
)	O	O
for	O	O
11	O	O
+	O	O
/-	O	O
1	O	O
days	O	O
.	O	O

After	O	O
fluoxetine	B_Chemical	O
treatment	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
47	O	O
%	O	O
improvement	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
of	O	O
apomorphine-induced	O	O
dyskinesias	B_Disease	O
without	O	O
modification	O	O
of	O	O
parkinsonian	B_Disease	B_Disease
motor	B_Disease	I_Disease
disability	I_Disease	I_Disease
.	O	O

The	O	O
dyskinesias	B_Disease	O
were	O	O
reduced	O	O
predominantly	O	O
in	O	O
the	O	O
lower	O	O
limbs	O	O
during	O	O
the	O	O
onset	O	O
and	O	O
disappearance	O	O
of	O	O
dystonic	B_Disease	B_Disease
dyskinesias	B_Disease	I_Disease
(	O	O
onset-	O	O
and	O	O
end-of-dose	O	O
dyskinesias	B_Disease	O
)	O	O
and	O	O
in	O	O
the	O	O
upper	O	O
limbs	O	O
during	O	O
choreic	B_Disease	O
mid-dose	B_Disease	O
dyskinesias	I_Disease	O
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
increased	O	O
brain	O	O
serotoninergic	O	O
transmission	O	O
with	O	O
fluoxetine	B_Chemical	O
may	O	O
reduce	O	O
levodopa-	O	B_Chemical
or	O	O
dopamine	B_Chemical	O
agonist-induced	O	O
dyskinesias	B_Disease	O
without	O	O
aggravating	O	O
parkinsonian	B_Disease	B_Disease
motor	B_Disease	I_Disease
disability	I_Disease	I_Disease
.	O	O

A	O	O
large	O	O
population-based	O	O
follow-up	O	O
study	O	O
of	O	O
trimethoprim-sulfamethoxazole	B_Chemical	B_Chemical
,	O	O
trimethoprim	B_Chemical	B_Chemical
,	O	O
and	O	O
cephalexin	B_Chemical	O
for	O	O
uncommon	O	O
serious	O	O
drug	B_Disease	O
toxicity	I_Disease	O
.	O	O

We	O	O
conducted	O	O
a	O	O
population-based	O	O
45-day	O	O
follow-up	O	O
study	O	O
of	O	O
232,390	O	O
people	O	O
who	O	O
were	O	O
prescribed	O	O
trimethoprim-sulfamethoxazole	B_Chemical	B_Chemical
(	O	O
TMP-SMZ	B_Chemical	O
)	O	O
,	O	O
266,951	O	O
prescribed	O	O
trimethoprim	B_Chemical	B_Chemical
alone	O	O
,	O	O
and	O	O
196,397	O	O
prescribed	O	O
cephalexin	B_Chemical	O
,	O	O
to	O	O
estimate	O	O
the	O	O
risk	O	O
of	O	O
serious	O	O
liver	B_Disease	O
,	I_Disease	O
blood	I_Disease	O
,	I_Disease	O
skin	I_Disease	O
,	I_Disease	O
and	I_Disease	O
renal	B_Disease	B_Disease
disorders	I_Disease	I_Disease
resulting	O	O
in	O	O
referral	O	O
or	O	O
hospitalization	O	O
associated	O	O
with	O	O
these	O	O
drugs	O	O
.	O	O

The	O	O
results	O	O
were	O	O
based	O	O
on	O	O
information	O	O
recorded	O	O
on	O	O
office	O	O
computers	O	O
by	O	O
selected	O	O
general	O	O
practitioners	O	O
in	O	O
the	O	O
United	O	O
Kingdom	O	O
,	O	O
together	O	O
with	O	O
a	O	O
review	O	O
of	O	O
clinical	O	O
records	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
clinically	O	O
important	O	O
idiopathic	O	B_Disease
liver	B_Disease	I_Disease
disease	I_Disease	I_Disease
was	O	O
similar	O	O
for	O	O
persons	O	O
prescribed	O	O
TMP-SMZ	B_Chemical	O
(	O	O
5.2/100,000	O	O
)	O	O
and	O	O
those	O	O
prescribed	O	O
trimethoprim	B_Chemical	B_Chemical
alone	O	O
(	O	O
3.8/100,000	O	O
)	O	O
.	O	O

The	O	O
risk	O	O
for	O	O
those	O	O
prescribed	O	O
cephalexin	B_Chemical	O
was	O	O
somewhat	O	O
lower	O	O
(	O	O
2.0/100,000	O	O
)	O	O
.	O	O

Only	O	O
five	O	O
patients	O	O
experienced	O	O
blood	O	O
disorders	O	O
,	O	O
one	O	O
of	O	O
whom	O	O
was	O	O
exposed	O	O
to	O	O
TMP-SMZ	B_Chemical	O
;	O	O
of	O	O
seven	O	O
with	O	O
erythema	B_Disease	O
multiforme	I_Disease	O
and	O	O
Stevens-Johnson	B_Disease	O
syndrome	I_Disease	O
,	O	O
four	O	O
were	O	O
exposed	O	O
to	O	O
TMP-SMZ	B_Chemical	O
.	O	O

The	O	O
one	O	O
case	O	O
of	O	O
toxic	B_Disease	O
epidermal	I_Disease	O
necrolysis	I_Disease	O
occurred	O	O
in	O	O
a	O	O
patient	O	O
who	O	O
took	O	O
cephalexin	B_Chemical	O
.	O	O

Finally	O	O
,	O	O
only	O	O
five	O	O
cases	O	O
of	O	O
acute	O	O
parenchymal	O	O
renal	B_Disease	O
disease	I_Disease	O
occurred	O	O
,	O	O
none	O	O
likely	O	O
to	O	O
be	O	O
caused	O	O
by	O	O
a	O	O
study	O	O
drug	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
risk	O	O
of	O	O
the	O	O
serious	O	O
diseases	O	O
studied	O	O
is	O	O
small	O	O
for	O	O
the	O	O
three	O	O
agents	O	O
,	O	O
and	O	O
compares	O	O
reasonably	O	O
with	O	O
the	O	O
risk	O	O
for	O	O
many	O	O
other	O	O
antibiotics	O	O
.	O	O

Clinical	O	O
safety	O	O
of	O	O
lidocaine	B_Chemical	O
in	O	O
patients	O	O
with	O	O
cocaine-associated	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
.	O	O

STUDY	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
safety	O	O
of	O	O
lidocaine	B_Chemical	O
in	O	O
the	O	O
setting	O	O
of	O	O
cocaine-induced	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
(	O	O
MI	B_Disease	O
)	O	O
.	O	O

DESIGN	O	O
:	O	O
A	O	O
retrospective	O	O
,	O	O
multicenter	O	O
study	O	O
.	O	O

SETTING	O	O
:	O	O
Twenty-nine	O	O
university	O	O
,	O	O
university-affiliated	O	O
,	O	O
or	O	O
community	O	O
hospitals	O	O
during	O	O
a	O	O
6-year	O	O
period	O	O
(	O	O
total	O	O
of	O	O
117	O	O
cumulative	O	O
hospital-years	O	O
)	O	O
.	O	O

PARTICIPANTS	O	O
:	O	O
Patients	O	O
with	O	O
cocaine-associated	O	O
MI	B_Disease	O
who	O	O
received	O	O
lidocaine	B_Chemical	O
in	O	O
the	O	O
emergency	O	O
department	O	O
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
29	O	O
patients	O	O
who	O	O
received	O	O
lidocaine	B_Chemical	O
in	O	O
the	O	O
setting	O	O
of	O	O
cocaine-associated	O	O
MI	B_Disease	O
,	O	O
no	O	O
patient	O	O
died	O	O
;	O	O
exhibited	O	O
bradydysrhythmias	B_Disease	B_Disease
,	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
,	O	O
or	O	O
ventricular	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
;	O	O
or	O	O
experienced	O	O
seizures	B_Disease	O
after	O	O
administration	O	O
of	O	O
lidocaine	B_Chemical	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
%	O	O
to	O	O
11	O	O
%	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Despite	O	O
theoretical	O	O
concerns	O	O
that	O	O
lidocaine	B_Chemical	O
may	O	O
enhance	O	O
cocaine	B_Chemical	O
toxicity	B_Disease	O
,	O	O
the	O	O
use	O	O
of	O	O
lidocaine	B_Chemical	O
in	O	O
patients	O	O
with	O	O
cocaine-associated	O	O
MI	B_Disease	O
was	O	O
not	O	O
associated	O	O
with	O	O
significant	O	O
cardiovascular	B_Disease	O
or	I_Disease	O
central	B_Disease	B_Disease
nervous	I_Disease	I_Disease
system	I_Disease	I_Disease
toxicity	I_Disease	I_Disease
.	O	O

Experimental	O	O
progressive	O	O
muscular	O	B_Disease
dystrophy	O	I_Disease
and	O	O
its	O	O
treatment	O	O
with	O	O
high	O	O
doses	O	O
anabolizing	O	O
agents	O	O
.	O	O

We	O	O
are	O	O
still	O	O
a	O	O
long	O	O
way	O	O
from	O	O
discovering	O	O
an	O	O
unequivocal	O	O
pathogenetic	O	O
interpretation	O	O
of	O	O
progressive	O	O
muscular	B_Disease	B_Disease
dystrophy	I_Disease	I_Disease
in	O	O
man	O	O
.	O	O

Noteworthy	O	O
efforts	O	O
have	O	O
been	O	O
made	O	O
in	O	O
the	O	O
experimental	O	O
field	O	O
;	O	O
a	O	O
recessive	O	O
autosomic	O	O
form	O	O
found	O	O
in	O	O
the	O	O
mouse	O	O
seems	O	O
to	O	O
bear	O	O
the	O	O
closest	O	O
resemblance	O	O
to	O	O
the	O	O
human	O	O
form	O	O
from	O	O
the	O	O
genetic	O	O
point	O	O
of	O	O
view	O	O
.	O	O

Myopathy	B_Disease	O
due	O	O
to	O	O
lack	O	O
of	O	O
vitamin	B_Chemical	B_Chemical
E	I_Chemical	I_Chemical
and	O	O
myopathy	B_Disease	O
induced	O	O
by	O	O
certain	O	O
viruses	O	O
have	O	O
much	O	O
in	O	O
common	O	O
anatomically	O	O
and	O	O
pathologically	O	O
with	O	O
the	O	O
human	O	O
form	O	O
.	O	O

The	O	O
authors	O	O
induced	O	O
myodystrophy	B_Disease	B_Disease
in	O	O
the	O	O
rat	O	O
by	O	O
giving	O	O
it	O	O
a	O	O
diet	O	O
lacking	O	O
in	O	O
vitamin	O	O
E.	O	O
The	O	O
pharmacological	O	O
characteristics	O	O
of	O	O
vitamin	B_Chemical	B_Chemical
E	I_Chemical	I_Chemical
and	O	O
the	O	O
degenerative	O	O
changes	O	O
brought	O	O
about	O	O
by	O	O
its	O	O
deficiency	O	O
,	O	O
especially	O	O
in	O	O
the	O	O
muscles	O	O
,	O	O
are	O	O
illustrated	O	O
.	O	O

It	O	O
is	O	O
thus	O	O
confirmed	O	O
that	O	O
the	O	O
histological	O	O
characteristics	O	O
of	O	O
myopathic	B_Disease	O
rat	O	O
muscle	O	O
induced	O	O
experimentally	O	O
are	O	O
extraordinarily	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
human	O	O
myopathy	B_Disease	O
as	O	O
confirmed	O	O
during	O	O
biopsies	O	O
performed	O	O
at	O	O
the	O	O
Orthopaedic	O	O
Traumatological	O	O
Centre	O	O
,	O	O
Florence	O	O
.	O	O

The	O	O
encouraging	O	O
results	O	O
obtained	O	O
in	O	O
various	O	O
authoratative	O	O
departments	O	O
in	O	O
myopathic	B_Disease	O
patients	O	O
by	O	O
using	O	O
anabolizing	O	O
steroids	B_Chemical	O
have	O	O
encouraged	O	O
the	O	O
authors	O	O
to	O	O
investigate	O	O
the	O	O
beneficial	O	O
effects	O	O
of	O	O
one	O	O
anabolizing	O	O
agent	O	O
(	O	O
Dianabol	B_Chemical	O
,	O	O
CIBA	B_Chemical	O
)	O	O
at	O	O
high	O	O
doses	O	O
in	O	O
rats	O	O
rendered	O	O
myopathic	B_Disease	O
by	O	O
a	O	O
diet	O	O
deficient	O	O
in	O	O
vitamin	O	B_Chemical
E.	O	I_Chemical
In	O	O
this	O	O
way	O	O
they	O	O
obtained	O	O
appreciable	O	O
changes	O	O
in	O	O
body	O	O
weight	O	O
(	O	O
increased	O	O
from	O	O
50	O	O
to	O	O
70	O	O
g	O	O
after	O	O
forty	O	O
days	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
5	O	O
mg	O	O
per	O	O
day	O	O
of	O	O
anabolizing	O	O
agent	O	O
)	O	O
,	O	O
but	O	O
most	O	O
of	O	O
all	O	O
they	O	O
found	O	O
histological	O	O
changes	O	O
due	O	O
to	O	O
"	O	O
regenerative	O	O
"	O	O
changes	O	O
in	O	O
the	O	O
muscle	O	O
tissue	O	O
,	O	O
which	O	O
however	O	O
maintained	O	O
its	O	O
myopathic	B_Disease	O
characteristics	O	O
in	O	O
the	O	O
control	O	O
animals	O	O
that	O	O
were	O	O
not	O	O
treated	O	O
with	O	O
the	O	O
anabolizing	O	O
agent	O	O
.	O	O

The	O	O
authors	O	O
conclude	O	O
by	O	O
affirming	O	O
the	O	O
undoubted	O	O
efficacy	O	O
of	O	O
the	O	O
anabolizing	O	O
steroids	B_Chemical	O
in	O	O
experimental	O	O
myopathic	B_Disease	B_Disease
disease	I_Disease	I_Disease
,	O	O
but	O	O
they	O	O
have	O	O
reservations	O	O
as	O	O
to	O	O
the	O	O
transfer	O	O
of	O	O
the	O	O
results	O	O
into	O	O
the	O	O
human	O	O
field	O	O
,	O	O
where	O	O
high	O	O
dosage	O	O
can	O	O
not	O	O
be	O	O
carried	O	O
out	O	O
continuously	O	O
because	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
drug	O	O
on	O	O
virility	O	O
;	O	O
because	O	O
the	O	O
tissue	O	O
injury	O	O
too	O	O
often	O	O
occurs	O	O
at	O	O
an	O	O
irreversible	O	O
stage	O	O
vis-a-vis	O	O
the	O	O
"	O	O
regeneration	O	O
"	O	O
of	O	O
the	O	O
muscle	O	O
tissue	O	O
;	O	O
and	O	O
finally	O	O
because	O	O
the	O	O
dystrophic	O	O
injurious	O	O
agent	O	O
is	O	O
certainly	O	O
not	O	O
the	O	O
lack	O	O
of	O	O
vitamin	B_Chemical	B_Chemical
E	I_Chemical	I_Chemical
but	O	O
something	O	O
as	O	O
yet	O	O
unknown	O	O
.	O	O

Paclitaxel	B_Chemical	B_Chemical
3-hour	O	O
infusion	O	O
given	O	O
alone	O	O
and	O	O
combined	O	O
with	O	O
carboplatin	B_Chemical	B_Chemical
:	O	O
preliminary	O	O
results	O	O
of	O	O
dose-escalation	O	O
trials	O	O
.	O	O

Paclitaxel	B_Chemical	B_Chemical
(	O	O
Taxol	B_Chemical	B_Chemical
;	O	O
Bristol-Myers	O	O
Squibb	O	O
Company	O	O
,	O	O
Princeton	O	O
,	O	O
NJ	O	O
)	O	O
by	O	O
3-hour	O	O
infusion	O	O
was	O	O
combined	O	O
with	O	O
carboplatin	B_Chemical	B_Chemical
in	O	O
a	O	O
phase	O	O
I/II	O	O
study	O	O
directed	O	O
to	O	O
patients	O	O
with	O	O
non-small	B_Disease	O
cell	I_Disease	O
lung	I_Disease	B_Disease
cancer	I_Disease	I_Disease
.	O	O

Carboplatin	B_Chemical	B_Chemical
was	O	O
given	O	O
at	O	O
a	O	O
fixed	O	O
target	O	O
area	O	O
under	O	O
the	O	O
concentration-time	O	O
curve	O	O
of	O	O
6.0	O	O
by	O	O
the	O	O
Calvert	O	O
formula	O	O
,	O	O
whereas	O	O
paclitaxel	B_Chemical	B_Chemical
was	O	O
escalated	O	O
in	O	O
patient	O	O
cohorts	O	O
from	O	O
150	O	O
mg/m2	O	O
(	O	O
dose	O	O
level	O	O
I	O	O
)	O	O
to	O	O
175	O	O
,	O	O
200	O	O
,	O	O
225	O	O
,	O	O
and	O	O
250	O	O
mg/m2	O	O
.	O	O

The	O	O
225	O	O
mg/m2	O	O
level	O	O
was	O	O
expanded	O	O
for	O	O
the	O	O
phase	O	O
II	O	O
study	O	O
since	O	O
the	O	O
highest	O	O
level	O	O
achieved	O	O
(	O	O
250	O	O
mg/m2	O	O
)	O	O
required	O	O
modification	O	O
because	O	O
of	O	O
nonhematologic	O	O
toxicities	B_Disease	O
(	O	O
arthralgia	B_Disease	O
and	O	O
sensory	B_Disease	B_Disease
neuropathy	I_Disease	I_Disease
)	O	O
.	O	O

Therapeutic	O	O
effects	O	O
were	O	O
noted	O	O
at	O	O
all	O	O
dose	O	O
levels	O	O
,	O	O
with	O	O
objective	O	O
responses	O	O
in	O	O
17	O	O
(	O	O
two	O	O
complete	O	O
and	O	O
15	O	O
partial	O	O
regressions	O	O
)	O	O
of	O	O
41	O	O
previously	O	O
untreated	O	O
patients	O	O
.	O	O

Toxicities	B_Disease	O
were	O	O
compared	O	O
with	O	O
a	O	O
cohort	O	O
of	O	O
patients	O	O
in	O	O
a	O	O
phase	O	O
I	O	O
trial	O	O
of	O	O
paclitaxel	B_Chemical	B_Chemical
alone	O	O
at	O	O
identical	O	O
dose	O	O
levels	O	O
.	O	O

Carboplatin	B_Chemical	B_Chemical
did	O	O
not	O	O
appear	O	O
to	O	O
add	O	O
to	O	O
the	O	O
hematologic	B_Disease	O
toxicities	I_Disease	O
observed	O	O
,	O	O
and	O	O
the	O	O
paclitaxel/carboplatin	O	B_Chemical
combination	O	O
could	O	O
be	O	O
dosed	O	O
every	O	O
3	O	O
weeks	O	O
.	O	O

The	O	O
dose-dependent	O	O
effect	O	O
of	O	O
misoprostol	B_Chemical	B_Chemical
on	O	O
indomethacin-induced	O	O
renal	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
in	O	O
well	O	O
compensated	O	O
cirrhosis	B_Disease	O
.	O	O

Misoprostol	B_Chemical	B_Chemical
(	O	O
200	O	O
micrograms	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
acutely	O	O
counteract	O	O
the	O	O
indomethacin-induced	O	O
renal	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
in	O	O
well	O	O
compensated	O	O
cirrhotic	B_Disease	B_Disease
patients	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
the	O	O
prophylactic	O	O
value	O	O
of	O	O
misoprostol	B_Chemical	B_Chemical
was	O	O
dose-dependent	O	O
.	O	O

Parameters	O	O
of	O	O
renal	O	O
hemodynamics	O	O
and	O	O
tubular	O	O
sodium	B_Chemical	O
and	O	O
water	O	O
handling	O	O
were	O	O
assessed	O	O
by	O	O
clearance	O	O
techniques	O	O
in	O	O
26	O	O
well	O	O
compensated	O	O
cirrhotic	B_Disease	B_Disease
patients	O	O
before	O	O
and	O	O
after	O	O
an	O	O
oral	O	O
combination	O	O
of	O	O
50	O	O
mg	O	O
of	O	O
indomethacin	B_Chemical	O
and	O	O
various	O	O
doses	O	O
of	O	O
misoprostol	B_Chemical	B_Chemical
.	O	O

The	O	O
200-micrograms	O	O
dose	O	O
was	O	O
able	O	O
to	O	O
totally	O	O
abolish	O	O
the	O	O
deleterious	O	O
renal	O	O
effects	O	O
of	O	O
indomethacin	B_Chemical	O
,	O	O
whereas	O	O
the	O	O
800-micrograms	O	O
dose	O	O
resulted	O	O
in	O	O
significant	O	O
worsening	O	O
of	O	O
renal	O	O
hemodynamics	O	O
and	O	O
sodium	B_Chemical	O
retention	O	O
.	O	O

These	O	O
changes	O	O
were	O	O
maximal	O	O
in	O	O
the	O	O
hour	O	O
immediately	O	O
after	O	O
medications	O	O
and	O	O
slowly	O	O
returned	O	O
toward	O	O
base-line	O	O
levels	O	O
thereafter	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
renal	O	O
protective	O	O
effects	O	O
of	O	O
misoprostol	B_Chemical	B_Chemical
is	O	O
dose-dependent	O	O
.	O	O

However	O	O
,	O	O
until	O	O
this	O	O
apparent	O	O
ability	O	O
of	O	O
200	O	O
micrograms	O	O
of	O	O
misoprostol	B_Chemical	B_Chemical
to	O	O
prevent	O	O
the	O	O
adverse	O	O
effects	O	O
of	O	O
indomethacin	B_Chemical	O
on	O	O
renal	O	O
function	O	O
is	O	O
confirmed	O	O
with	O	O
chronic	O	O
frequent	O	O
dosing	O	O
,	O	O
it	O	O
would	O	O
be	O	O
prudent	O	O
to	O	O
avoid	O	O
nonsteroidal	O	O
anti-inflammatory	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
cirrhosis	B_Disease	O
.	O	O

Increased	O	O
frequency	O	O
and	O	O
severity	O	O
of	O	O
angio-oedema	B_Disease	O
related	O	O
to	O	O
long-term	O	O
therapy	O	O
with	O	O
angiotensin-converting	B_Chemical	O
enzyme	I_Chemical	O
inhibitor	I_Chemical	O
in	O	O
two	O	O
patients	O	O
.	O	O

Adverse	O	O
reactions	O	O
to	O	O
drugs	O	O
are	O	O
well	O	O
recognized	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
acute	O	O
or	O	O
chronic	O	B_Disease
urticaria	B_Disease	I_Disease
,	O	O
and	O	O
angio-oedema	B_Disease	O
.	O	O

Angiotensin-converting	B_Chemical	O
enzyme	I_Chemical	O
(	I_Chemical	O
ACE	I_Chemical	O
)	I_Chemical	O
inhibitors	I_Chemical	O
,	O	O
used	O	O
to	O	O
treat	O	O
hypertension	B_Disease	O
and	O	O
congestive	B_Disease	O
heart	I_Disease	O
failure	I_Disease	O
,	O	O
were	O	O
introduced	O	O
in	O	O
Europe	O	O
in	O	O
the	O	O
middle	O	O
of	O	O
the	O	O
eighties	O	O
,	O	O
and	O	O
the	O	O
use	O	O
of	O	O
these	O	O
drugs	O	O
has	O	O
increased	O	O
progressively	O	O
.	O	O

Soon	O	O
after	O	O
the	O	O
introduction	O	O
of	O	O
ACE	B_Chemical	O
inhibitors	I_Chemical	O
,	O	O
acute	O	O
bouts	O	O
of	O	O
angio-oedema	B_Disease	O
were	O	O
reported	O	O
in	O	O
association	O	O
with	O	O
the	O	O
use	O	O
of	O	O
these	O	O
drugs	O	O
.	O	O

We	O	O
wish	O	O
to	O	O
draw	O	O
attention	O	O
to	O	O
the	O	O
possibility	O	O
of	O	O
adverse	O	O
reactions	O	O
to	O	O
ACE	B_Chemical	O
inhibitors	I_Chemical	O
after	O	O
long-term	O	O
use	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
pre-existing	O	O
angio-oedema	B_Disease	O
.	O	O

Myoclonus	B_Disease	O
associated	O	O
with	O	O
lorazepam	B_Chemical	O
therapy	O	O
in	O	O
very-low-birth-weight	O	O
infants	O	O
.	O	O

Lorazepam	B_Chemical	O
is	O	O
being	O	O
used	O	O
with	O	O
increasing	O	O
frequency	O	O
as	O	O
a	O	O
sedative	O	O
in	O	O
the	O	O
newborn	O	O
and	O	O
the	O	O
young	O	O
infant	O	O
.	O	O

Concern	O	O
has	O	O
been	O	O
raised	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
safety	O	O
of	O	O
lorazepam	B_Chemical	O
in	O	O
this	O	O
age	O	O
group	O	O
,	O	O
especially	O	O
in	O	O
very-low-birth-weight	O	O
(	O	O
VLBW	O	O
;	O	O
<	O	O
1,500	O	O
g	O	O
)	O	O
infants	O	O
.	O	O

Three	O	O
young	O	O
infants	O	O
,	O	O
all	O	O
of	O	O
birth	O	O
weight	O	O
<	O	O
1,500	O	O
g	O	O
,	O	O
experienced	O	O
myoclonus	B_Disease	O
following	O	O
the	O	O
intravenous	O	O
administration	O	O
of	O	O
lorazepam	B_Chemical	O
.	O	O

The	O	O
potential	O	O
neurotoxic	B_Disease	O
effects	O	O
of	O	O
the	O	O
drug	O	O
(	O	O
and	O	O
its	O	O
vehicle	O	O
)	O	O
in	O	O
this	O	O
population	O	O
are	O	O
discussed	O	O
.	O	O

Injectable	O	O
lorazepam	B_Chemical	O
should	O	O
be	O	O
used	O	O
with	O	O
caution	O	O
in	O	O
VLBW	O	O
infants	O	O
.	O	O

Transvenous	O	O
right	O	O
ventricular	O	O
pacing	O	O
during	O	O
cardiopulmonary	O	O
resuscitation	O	O
of	O	O
pediatric	O	O
patients	O	O
with	O	O
acute	O	B_Disease
cardiomyopathy	O	I_Disease
.	O	O

We	O	O
describe	O	O
the	O	O
cardiopulmonary	O	O
resuscitation	O	O
efforts	O	O
on	O	O
five	O	O
patients	O	O
who	O	O
presented	O	O
in	O	O
acute	O	B_Disease
circulatory	B_Disease	I_Disease
failure	I_Disease	I_Disease
from	O	O
myocardial	B_Disease	B_Disease
dysfunction	I_Disease	I_Disease
.	O	O

Three	O	O
patients	O	O
had	O	O
acute	O	O
viral	O	O
myocarditis	B_Disease	O
,	O	O
one	O	O
had	O	O
a	O	O
carbamazepine-induced	O	O
acute	O	B_Disease
eosinophilic	B_Disease	I_Disease
myocarditis	B_Disease	I_Disease
,	O	O
and	O	O
one	O	O
had	O	O
cardiac	O	B_Disease
hemosiderosis	O	I_Disease
resulting	O	O
in	O	O
acute	O	B_Disease
cardiogenic	B_Disease	I_Disease
shock	I_Disease	I_Disease
.	O	O

All	O	O
patients	O	O
were	O	O
continuously	O	O
monitored	O	O
with	O	O
central	O	O
venous	O	O
and	O	O
arterial	O	O
catheters	O	O
in	O	O
addition	O	O
to	O	O
routine	O	O
noninvasive	O	O
monitoring	O	O
.	O	O

An	O	O
introducer	O	O
sheath	O	O
,	O	O
a	O	O
pacemaker	O	O
,	O	O
and	O	O
sterile	O	O
pacing	O	O
wires	O	O
were	O	O
made	O	O
readily	O	O
available	O	O
for	O	O
the	O	O
patients	O	O
,	O	O
should	O	O
the	O	O
need	O	O
arise	O	O
to	O	O
terminate	O	O
resistant	O	O
cardiac	O	B_Disease
dysrhythmias	B_Disease	I_Disease
.	O	O

All	O	O
patients	O	O
developed	O	O
cardiocirculatory	O	B_Disease
arrest	O	I_Disease
associated	O	O
with	O	O
extreme	O	O
hypotension	B_Disease	O
and	O	O
dysrhythmias	B_Disease	B_Disease
within	O	O
the	O	O
first	O	O
48	O	O
hours	O	O
of	O	O
their	O	O
admission	O	O
to	O	O
the	O	O
pediatric	O	O
intensive	O	O
care	O	O
unit	O	O
(	O	O
PICU	O	O
)	O	O
.	O	O

Right	O	O
ventricular	O	O
pacemaker	O	O
wires	O	O
were	O	O
inserted	O	O
in	O	O
all	O	O
of	O	O
them	O	O
during	O	O
cardiopulmonary	O	O
resuscitation	O	O
(	O	O
CPR	O	O
)	O	O
.	O	O

In	O	O
four	O	O
patients	O	O
,	O	O
cardiac	O	O
pacing	O	O
was	O	O
used	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
temporary	O	O
captured	O	O
rhythm	O	O
and	O	O
restoration	O	O
of	O	O
their	O	O
cardiac	O	O
output	O	O
.	O	O

These	O	O
patients	O	O
had	O	O
a	O	O
second	O	O
event	O	O
of	O	O
cardiac	B_Disease	B_Disease
arrest	I_Disease	I_Disease
,	O	O
resulting	O	O
in	O	O
death	O	O
,	O	O
within	O	O
10	O	O
to	O	O
60	O	O
minutes	O	O
.	O	O

In	O	O
one	O	O
patient	O	O
,	O	O
cardiac	O	O
pacing	O	O
was	O	O
not	O	O
used	O	O
,	O	O
because	O	O
he	O	O
converted	O	O
to	O	O
normal	O	O
sinus	O	O
rhythm	O	O
by	O	O
electrical	O	O
defibrillation	O	O
within	O	O
three	O	O
minutes	O	O
of	O	O
initiating	O	O
CPR	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
cardiac	O	O
pacing	O	O
during	O	O
resuscitative	O	O
efforts	O	O
in	O	O
pediatric	O	O
patients	O	O
suffering	O	O
from	O	O
acute	O	B_Disease
myocardial	B_Disease	I_Disease
dysfunction	I_Disease	I_Disease
may	O	O
not	O	O
have	O	O
long-term	O	O
value	O	O
in	O	O
and	O	O
of	O	O
itself	O	O
;	O	O
however	O	O
,	O	O
if	O	O
temporary	O	O
hemodynamic	O	O
stability	O	O
is	O	O
achieved	O	O
by	O	O
this	O	O
procedure	O	O
,	O	O
it	O	O
may	O	O
provide	O	O
additional	O	O
time	O	O
needed	O	O
to	O	O
institute	O	O
other	O	O
therapeutic	O	O
modalities	O	O
.	O	O

Efficacy	O	O
and	O	O
safety	O	O
of	O	O
granisetron	B_Chemical	B_Chemical
,	O	O
a	O	O
selective	O	O
5-hydroxytryptamine-3	O	B_Chemical
receptor	O	O
antagonist	O	O
,	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
nausea	B_Disease	B_Disease
and	O	I_Disease
vomiting	B_Disease	I_Disease
induced	O	O
by	O	O
high-dose	O	O
cisplatin	B_Chemical	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
assess	O	O
the	O	O
antiemetic	O	O
effects	O	O
and	O	O
safety	O	O
profile	O	O
of	O	O
four	O	O
different	O	O
doses	O	O
of	O	O
granisetron	B_Chemical	B_Chemical
(	O	O
Kytril	B_Chemical	O
;	O	O
SmithKline	O	O
Beecham	O	O
Pharmaceuticals	O	O
,	O	O
Philadelphia	O	O
,	O	O
PA	O	O
)	O	O
when	O	O
administered	O	O
as	O	O
a	O	O
single	O	O
intravenous	O	O
(	O	O
IV	O	O
)	O	O
dose	O	O
for	O	O
prophylaxis	O	O
of	O	O
cisplatin-induced	O	O
nausea	B_Disease	O
and	O	O
vomiting	B_Disease	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
One	O	O
hundred	O	O
eighty-four	O	O
chemotherapy-naive	O	O
patients	O	O
receiving	O	O
high-dose	O	O
cisplatin	B_Chemical	O
(	O	O
81	O	O
to	O	O
120	O	O
mg/m2	O	O
)	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
one	O	O
of	O	O
four	O	O
granisetron	B_Chemical	B_Chemical
doses	O	O
(	O	O
5	O	O
,	O	O
10	O	O
,	O	O
20	O	O
,	O	O
or	O	O
40	O	O
micrograms/kg	O	O
)	O	O
administered	O	O
before	O	O
chemotherapy	O	O
.	O	O

Patients	O	O
were	O	O
observed	O	O
on	O	O
an	O	O
inpatient	O	O
basis	O	O
for	O	O
18	O	O
to	O	O
24	O	O
hours	O	O
,	O	O
and	O	O
vital	O	O
signs	O	O
,	O	O
nausea	B_Disease	O
,	O	O
vomiting	B_Disease	O
,	O	O
retching	O	O
,	O	O
and	O	O
appetite	O	O
were	O	O
assessed	O	O
.	O	O

Safety	O	O
analyses	O	O
included	O	O
incidence	O	O
of	O	O
adverse	O	O
experiences	O	O
and	O	O
laboratory	O	O
parameter	O	O
changes	O	O
.	O	O

RESULTS	O	O
:	O	O
After	O	O
granisetron	B_Chemical	B_Chemical
doses	O	O
of	O	O
5	O	O
,	O	O
10	O	O
,	O	O
20	O	O
,	O	O
and	O	O
40	O	O
micrograms/kg	O	O
,	O	O
a	O	O
major	O	O
response	O	O
(	O	O
<	O	O
or	O	O
=	O	O
two	O	O
vomiting	B_Disease	O
or	O	O
retching	O	O
episodes	O	O
,	O	O
and	O	O
no	O	O
antiemetic	O	O
rescue	O	O
)	O	O
was	O	O
recorded	O	O
in	O	O
23	O	O
%	O	O
,	O	O
57	O	O
%	O	O
,	O	O
58	O	O
%	O	O
,	O	O
and	O	O
60	O	O
%	O	O
of	O	O
patients	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
a	O	O
complete	O	O
response	O	O
(	O	O
no	O	O
vomiting	B_Disease	O
or	O	O
retching	O	O
,	O	O
and	O	O
no	O	O
antiemetic	O	O
rescue	O	O
)	O	O
in	O	O
18	O	O
%	O	O
,	O	O
41	O	O
%	O	O
,	O	O
40	O	O
%	O	O
,	O	O
and	O	O
47	O	O
%	O	O
of	O	O
patients	O	O
,	O	O
respectively	O	O
.	O	O

There	O	O
was	O	O
a	O	O
statistically	O	O
longer	O	O
time	O	O
to	O	O
first	O	O
episode	O	O
of	O	O
nausea	B_Disease	O
(	O	O
P	O	O
=	O	O
.0015	O	O
)	O	O
and	O	O
vomiting	B_Disease	O
(	O	O
P	O	O
=	O	O
.0001	O	O
)	O	O
,	O	O
and	O	O
fewer	O	O
patients	O	O
were	O	O
administered	O	O
additional	O	O
antiemetic	O	O
medication	O	O
in	O	O
the	O	O
10-micrograms/kg	O	O
dosing	O	O
groups	O	O
than	O	O
in	O	O
the	O	O
5-micrograms/kg	O	O
dosing	O	O
group	O	O
.	O	O

As	O	O
granisetron	B_Chemical	B_Chemical
dose	O	O
increased	O	O
,	O	O
appetite	O	O
return	O	O
increased	O	O
(	O	O
P	O	O
=	O	O
.040	O	O
)	O	O
.	O	O

Headache	B_Disease	O
was	O	O
the	O	O
most	O	O
frequently	O	O
reported	O	O
adverse	O	O
event	O	O
(	O	O
20	O	O
%	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
A	O	O
single	O	O
10-	O	O
,	O	O
20-	O	O
,	O	O
or	O	O
40-micrograms/kg	O	O
dose	O	O
of	O	O
granisetron	B_Chemical	O
was	O	O
effective	O	O
in	O	O
controlling	O	O
vomiting	B_Disease	O
in	O	O
57	O	O
%	O	O
to	O	O
60	O	O
%	O	O
of	O	O
patients	O	O
who	O	O
received	O	O
cisplatin	B_Chemical	B_Chemical
at	O	O
doses	O	O
greater	O	O
than	O	O
81	O	O
mg/m2	O	O
and	O	O
totally	O	O
prevented	O	O
vomiting	B_Disease	O
in	O	O
40	O	O
%	O	O
to	O	O
47	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
in	O	O
efficacy	O	O
between	O	O
the	O	O
10-micrograms/kg	O	O
dose	O	O
and	O	O
the	O	O
20-	O	O
and	O	O
40-micrograms/kg	O	O
doses	O	O
.	O	O

Granisetron	B_Chemical	B_Chemical
was	O	O
well	O	O
tolerated	O	O
at	O	O
all	O	O
doses	O	O
.	O	O

Adverse	O	O
interaction	O	O
between	O	O
clonidine	B_Chemical	O
and	O	O
verapamil	B_Chemical	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
two	O	O
cases	O	O
of	O	O
a	O	O
possible	O	O
adverse	O	O
interaction	O	O
between	O	O
clonidine	B_Chemical	O
and	O	O
verapamil	B_Chemical	O
resulting	O	O
in	O	O
atrioventricular	B_Disease	O
(	I_Disease	O
AV	I_Disease	O
)	I_Disease	O
block	I_Disease	O
in	O	O
both	O	O
patients	O	O
and	O	O
severe	O	O
hypotension	B_Disease	O
in	O	O
one	O	O
patient	O	O
.	O	O

CASE	O	O
SUMMARIES	O	O
:	O	O
A	O	O
54-year-old	O	O
woman	O	O
with	O	O
hyperaldosteronism	B_Disease	O
was	O	O
treated	O	O
with	O	O
verapamil	B_Chemical	O
480	O	O
mg/d	O	O
and	O	O
spironolactone	B_Chemical	O
100	O	O
mg/d	O	O
.	O	O

After	O	O
the	O	O
addition	O	O
of	O	O
a	O	O
minimal	O	O
dose	O	O
of	O	O
clonidine	B_Chemical	O
(	O	O
0.15	O	O
mg	O	O
bid	O	O
)	O	O
,	O	O
she	O	O
developed	O	O
complete	O	O
AV	B_Disease	O
block	I_Disease	O
and	O	O
severe	O	O
hypotension	B_Disease	O
,	O	O
which	O	O
resolved	O	O
upon	O	O
cessation	O	O
of	O	O
all	O	O
medications	O	O
.	O	O

A	O	O
65-year-old	O	O
woman	O	O
was	O	O
treated	O	O
with	O	O
extended-release	O	O
verapamil	B_Chemical	O
240	O	O
mg/d	O	O
.	O	O

After	O	O
the	O	O
addition	O	O
of	O	O
clonidine	B_Chemical	O
0.15	O	O
mg	O	O
bid	O	O
she	O	O
developed	O	O
complete	O	O
AV	B_Disease	O
block	I_Disease	O
,	O	O
which	O	O
resolved	O	O
after	O	O
all	O	O
therapy	O	O
was	O	O
stopped	O	O
.	O	O

DISCUSSION	O	O
:	O	O
An	O	O
adverse	O	O
interaction	O	O
between	O	O
clonidine	B_Chemical	O
and	O	O
verapamil	B_Chemical	O
has	O	O
not	O	O
been	O	O
reported	O	O
previously	O	O
.	O	O

We	O	O
describe	O	O
two	O	O
such	O	O
cases	O	O
and	O	O
discuss	O	O
the	O	O
various	O	O
mechanisms	O	O
that	O	O
might	O	O
cause	O	O
such	O	O
an	O	O
interaction	O	O
.	O	O

Clinicians	O	O
should	O	O
be	O	O
acquainted	O	O
with	O	O
this	O	O
possibly	O	O
fatal	O	O
interaction	O	O
between	O	O
two	O	O
commonly	O	O
used	O	O
antihypertensive	O	O
drugs	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Caution	O	O
is	O	O
recommended	O	O
in	O	O
combining	O	O
clonidine	B_Chemical	O
and	O	O
verapamil	B_Chemical	O
therapy	O	O
,	O	O
even	O	O
in	O	O
patients	O	O
who	O	O
do	O	O
not	O	O
have	O	O
sinus	O	O
or	O	O
AV	O	B_Disease
node	O	I_Disease
dysfunction	O	I_Disease
.	O	O

The	O	O
two	O	O
drugs	O	O
may	O	O
act	O	O
synergistically	O	O
on	O	O
both	O	O
the	O	O
AV	O	O
node	O	O
and	O	O
the	O	O
peripheral	O	O
circulation	O	O
.	O	O

Pharmacological	O	O
studies	O	O
on	O	O
a	O	O
new	O	O
dihydrothienopyridine	B_Chemical	B_Chemical
calcium	I_Chemical	I_Chemical
antagonist	O	O
,	O	O
S-312-d	B_Chemical	O
.	O	O

5th	O	O
communication	O	O
:	O	O
anticonvulsant	O	O
effects	O	O
in	O	O
mice	O	O
.	O	O

S-312	B_Chemical	O
,	O	O
S-312-d	B_Chemical	O
,	O	O
but	O	O
not	O	O
S-312-l	B_Chemical	O
,	O	O
L-type	O	O
calcium	B_Chemical	O
channel	O	O
antagonists	O	O
,	O	O
showed	O	O
anticonvulsant	O	O
effects	O	O
on	O	O
the	O	O
audiogenic	B_Disease	O
tonic	I_Disease	O
convulsions	I_Disease	O
in	O	O
DBA/2	O	O
mice	O	O
;	O	O
and	O	O
their	O	O
ED50	O	O
values	O	O
were	O	O
18.4	O	O
(	O	O
12.8	O	O
-	O	O
27.1	O	O
)	O	O
mg/kg	O	O
,	O	O
p.o	O	O
.	O	O
and	O	O
15.0	O	O
(	O	O
10.2	O	O
-	O	O
23.7	O	O
)	O	O
mg/kg	O	O
,	O	O
p.o	O	O
.	O	O
,	O	O
respectively	O	O
,	O	O
while	O	O
that	O	O
of	O	O
flunarizine	B_Chemical	B_Chemical
was	O	O
34.0	O	O
(	O	O
26.0	O	O
-	O	O
44.8	O	O
)	O	O
mg/kg	O	O
,	O	O
p.o	O	O
.	O	O

Although	O	O
moderate	O	O
anticonvulsant	O	O
effects	O	O
of	O	O
S-312-d	B_Chemical	O
in	O	O
higher	O	O
doses	O	O
were	O	O
observed	O	O
against	O	O
the	O	O
clonic	O	O
convulsions	B_Disease	O
induced	O	O
by	O	O
pentylenetetrazole	B_Chemical	O
(	O	O
85	O	O
mg/kg	O	O
,	O	O
s.c	O	O
.	O	O
)	O	O
or	O	O
bemegride	B_Chemical	B_Chemical
(	O	O
40	O	O
mg/kg	O	O
,	O	O
s.c	O	O
.	O	O
)	O	O
,	O	O
no	O	O
effects	O	O
were	O	O
observed	O	O
in	O	O
convulsions	B_Disease	O
induced	O	O
by	O	O
N-methyl-D-aspartate	B_Chemical	B_Chemical
,	O	O
picrotoxin	B_Chemical	B_Chemical
,	O	O
or	O	O
electroshock	O	O
in	O	O
Slc	O	O
:	O	O
ddY	O	O
mice	O	O
.	O	O

S-312-d	B_Chemical	O
may	O	O
be	O	O
useful	O	O
in	O	O
the	O	O
therapy	O	O
of	O	O
certain	O	O
types	O	O
of	O	O
human	O	O
epilepsy	B_Disease	O
.	O	O

Transmural	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
with	O	O
sumatriptan	B_Chemical	B_Chemical
.	O	O

For	O	O
sumatriptan	B_Chemical	B_Chemical
,	O	O
tightness	O	O
in	O	O
the	O	O
chest	O	O
caused	O	O
by	O	O
an	O	O
unknown	O	O
mechanism	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
3	O	O
-	O	O
5	O	O
%	O	O
of	O	O
users	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
47-year-old	O	O
woman	O	O
with	O	O
an	O	O
acute	O	B_Disease
myocardial	B_Disease	I_Disease
infarction	I_Disease	I_Disease
after	O	O
administration	O	O
of	O	O
sumatriptan	B_Chemical	B_Chemical
6	O	O
mg	O	O
subcutaneously	O	O
for	O	O
cluster	B_Disease	B_Disease
headache	I_Disease	I_Disease
.	O	O

The	O	O
patient	O	O
had	O	O
no	O	O
history	O	O
of	O	O
underlying	O	O
ischaemic	B_Disease	B_Disease
heart	I_Disease	I_Disease
disease	I_Disease	I_Disease
or	O	O
Prinzmetal	B_Disease	O
's	I_Disease	O
angina	I_Disease	O
.	O	O

She	O	O
recovered	O	O
without	O	O
complications	O	O
.	O	O

Flumazenil	B_Chemical	B_Chemical
induces	O	O
seizures	B_Disease	O
and	O	O
death	O	O
in	O	O
mixed	O	O
cocaine-diazepam	O	O
intoxications	O	O
.	O	O

STUDY	O	O
HYPOTHESIS	O	O
:	O	O
Administration	O	O
of	O	O
the	O	O
benzodiazepine	B_Chemical	O
antagonist	O	O
flumazenil	B_Chemical	B_Chemical
may	O	O
unmask	O	O
seizures	B_Disease	O
in	O	O
mixed	O	O
cocaine-benzodiazepine	O	B_Chemical
intoxication	O	O
.	O	O

DESIGN	O	O
:	O	O
Male	O	O
Sprague-Dawley	O	O
rats	O	O
received	O	O
100	O	O
mg/kg	O	O
cocaine	B_Chemical	O
IP	O	O
alone	O	O
,	O	O
5	O	O
mg/kg	O	O
diazepam	B_Chemical	O
alone	O	O
,	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
diazepam	B_Chemical	O
and	O	O
cocaine	B_Chemical	O
.	O	O

Three	O	O
minutes	O	O
later	O	O
,	O	O
groups	O	O
were	O	O
challenged	O	O
with	O	O
vehicle	O	O
or	O	O
flumazenil	B_Chemical	B_Chemical
5	O	O
or	O	O
10	O	O
mg/kg	O	O
IP	O	O
.	O	O

Animal	O	O
behavior	O	O
,	O	O
seizures	B_Disease	O
(	O	O
time	O	O
to	O	O
and	O	O
incidence	O	O
)	O	O
,	O	O
death	O	O
(	O	O
time	O	O
to	O	O
and	O	O
incidence	O	O
)	O	O
,	O	O
and	O	O
cortical	O	O
EEG	O	O
tracings	O	O
were	O	O
recorded	O	O
.	O	O

INTERVENTIONS	O	O
:	O	O
Administration	O	O
of	O	O
flumazenil	B_Chemical	B_Chemical
to	O	O
animals	O	O
after	O	O
they	O	O
had	O	O
received	O	O
a	O	O
combination	O	O
dose	O	O
of	O	O
cocaine	B_Chemical	O
and	O	O
diazepam	B_Chemical	O
.	O	O

RESULTS	O	O
:	O	O
In	O	O
group	O	O
1	O	O
,	O	O
animals	O	O
received	O	O
cocaine	B_Chemical	O
followed	O	O
by	O	O
vehicle	O	O
.	O	O

This	O	O
resulted	O	O
in	O	O
100	O	O
%	O	O
developing	O	O
seizures	B_Disease	O
and	O	O
death	O	O
.	O	O

Group	O	O
2	O	O
received	O	O
diazepam	B_Chemical	O
alone	O	O
followed	O	O
by	O	O
vehicle	O	O
.	O	O

Animals	O	O
became	O	O
somnolent	O	O
and	O	O
none	O	O
died	O	O
.	O	O

Group	O	O
3	O	O
received	O	O
diazepam	B_Chemical	O
followed	O	O
by	O	O
5	O	O
mg/kg	O	O
flumazenil	B_Chemical	B_Chemical
.	O	O

Animals	O	O
became	O	O
somnolent	O	O
after	O	O
diazepam	B_Chemical	O
and	O	O
then	O	O
active	O	O
after	O	O
flumazenil	B_Chemical	B_Chemical
administration	O	O
.	O	O

In	O	O
group	O	O
4	O	O
,	O	O
a	O	O
combination	O	O
of	O	O
cocaine	B_Chemical	O
and	O	O
diazepam	B_Chemical	O
was	O	O
administered	O	O
simultaneously	O	O
.	O	O

This	O	O
resulted	O	O
in	O	O
no	O	O
overt	O	O
or	O	O
EEG-detectable	O	O
seizures	B_Disease	O
and	O	O
a	O	O
50	O	O
%	O	O
incidence	O	O
of	O	O
death	O	O
.	O	O

Group	O	O
5	O	O
received	O	O
a	O	O
similar	O	O
combination	O	O
of	O	O
cocaine	B_Chemical	O
and	O	O
diazepam	B_Chemical	O
,	O	O
followed	O	O
later	O	O
by	O	O
5	O	O
mg/kg	O	O
flumazenil	B_Chemical	B_Chemical
.	O	O

This	O	O
resulted	O	O
in	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
seizures	B_Disease	O
,	O	O
90	O	O
%	O	O
(	O	O
P	O	O
<	O	O
.01	O	O
)	O	O
,	O	O
and	O	O
death	O	O
,	O	O
100	O	O
%	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
.01	O	O
)	O	O
,	O	O
compared	O	O
with	O	O
group	O	O
4	O	O
.	O	O

Group	O	O
6	O	O
received	O	O
cocaine	B_Chemical	O
and	O	O
diazepam	B_Chemical	O
followed	O	O
by	O	O
10	O	O
mg/kg	O	O
flumazenil	B_Chemical	B_Chemical
.	O	O

This	O	O
also	O	O
resulted	O	O
in	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
seizures	B_Disease	O
,	O	O
90	O	O
%	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
.01	O	O
)	O	O
,	O	O
and	O	O
death	O	O
,	O	O
90	O	O
%	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
.05	O	O
)	O	O
,	O	O
compared	O	O
with	O	O
group	O	O
4	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Flumazenil	B_Chemical	B_Chemical
can	O	O
unmask	O	O
seizures	B_Disease	O
and	O	O
increase	O	O
the	O	O
incidence	O	O
of	O	O
death	O	O
in	O	O
a	O	O
model	O	O
of	O	O
combined	O	O
cocaine-diazepam	O	B_Chemical
intoxications	O	O
.	O	O

Mechanisms	O	O
for	O	O
protective	O	O
effects	O	O
of	O	O
free	O	O
radical	O	O
scavengers	O	O
on	O	O
gentamicin-mediated	O	O
nephropathy	B_Disease	O
in	O	O
rats	O	O
.	O	O

Studies	O	O
were	O	O
performed	O	O
to	O	O
examine	O	O
the	O	O
mechanisms	O	O
for	O	O
the	O	O
protective	O	O
effects	O	O
of	O	O
free	O	O
radical	O	O
scavengers	O	O
on	O	O
gentamicin	B_Chemical	O
(GM)-mediated	O	O
nephropathy	B_Disease	O
.	O	O

Administration	O	O
of	O	O
GM	B_Chemical	O
at	O	O
40	O	O
mg/kg	O	O
sc	O	O
for	O	O
13	O	O
days	O	O
to	O	O
rats	O	O
induced	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
renal	O	O
blood	O	O
flow	O	O
(	O	O
RBF	O	O
)	O	O
and	O	O
inulin	O	O
clearance	O	O
(	O	O
CIn	O	O
)	O	O
as	O	O
well	O	O
as	O	O
marked	O	O
tubular	B_Disease	B_Disease
damage	I_Disease	I_Disease
.	O	O

A	O	O
significant	O	O
reduction	O	O
in	O	O
urinary	O	O
guanosine	B_Chemical	B_Chemical
3',5'-cyclic	I_Chemical	I_Chemical
monophosphate	I_Chemical	I_Chemical
(	O	O
cGMP	B_Chemical	O
)	O	O
excretion	O	O
and	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
renal	O	O
cortical	O	O
renin	O	O
and	O	O
endothelin-1	O	O
contents	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
GM-mediated	O	O
nephropathy	B_Disease	O
.	O	O

Superoxide	B_Chemical	O
dismutase	O	O
(	O	O
SOD	O	O
)	O	O
or	O	O
dimethylthiourea	B_Chemical	O
(	O	O
DMTU	B_Chemical	O
)	O	O
significantly	O	O
lessened	O	O
the	O	O
GM-induced	O	O
decrement	O	O
in	O	O
CIn	O	O
.	O	O

The	O	O
SOD-induced	O	O
increase	O	O
in	O	O
glomerular	O	O
filtration	O	O
rate	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
marked	O	O
improvement	O	O
in	O	O
RBF	O	O
,	O	O
an	O	O
increase	O	O
in	O	O
urinary	O	O
cGMP	B_Chemical	O
excretion	O	O
,	O	O
and	O	O
a	O	O
decrease	O	O
in	O	O
renal	O	O
renin	O	O
and	O	O
endothelin-1	O	O
content	O	O
.	O	O

SOD	O	O
did	O	O
not	O	O
attenuate	O	O
the	O	O
tubular	B_Disease	B_Disease
damage	I_Disease	I_Disease
.	O	O

In	O	O
contrast	O	O
,	O	O
DMTU	B_Chemical	O
significantly	O	O
reduced	O	O
the	O	O
tubular	B_Disease	B_Disease
damage	I_Disease	I_Disease
and	O	O
lipid	O	O
peroxidation	O	O
,	O	O
but	O	O
it	O	O
did	O	O
not	O	O
affect	O	O
renal	O	O
hemodynamics	O	O
and	O	O
vasoactive	O	O
substances	O	O
.	O	O

Neither	O	O
SOD	O	O
nor	O	O
DMTU	B_Chemical	O
affected	O	O
the	O	O
renal	O	O
cortical	O	O
GM	B_Chemical	O
content	O	O
in	O	O
GM-treated	O	O
rats	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
1	O	O
)	O	O
both	O	O
SOD	O	O
and	O	O
DMTU	B_Chemical	O
have	O	O
protective	O	O
effects	O	O
on	O	O
GM-mediated	O	O
nephropathy	B_Disease	O
,	O	O
2	O	O
)	O	O
the	O	O
mechanisms	O	O
for	O	O
the	O	O
protective	O	O
effects	O	O
differ	O	O
for	O	O
SOD	O	O
and	O	O
DMTU	B_Chemical	O
,	O	O
and	O	O
3	O	O
)	O	O
superoxide	B_Chemical	O
anions	O	O
play	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
GM-induced	O	O
renal	O	O
vasoconstriction	O	O
.	O	O

Cephalothin-induced	O	O
immune	O	B_Disease
hemolytic	B_Disease	I_Disease
anemia	I_Disease	I_Disease
.	O	O

A	O	O
patient	O	O
with	O	O
renal	B_Disease	B_Disease
disease	I_Disease	I_Disease
developed	O	O
Coombs-positive	O	O
hemolytic	B_Disease	B_Disease
anemia	I_Disease	I_Disease
while	O	O
receiving	O	O
cephalothin	B_Chemical	O
therapy	O	O
.	O	O

An	O	O
anti-cephalothin	O	O
IgG	O	O
antibody	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
patient	O	O
's	O	O
serum	O	O
and	O	O
in	O	O
the	O	O
eluates	O	O
from	O	O
her	O	O
erythrocytes	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
nonimmunologic	O	O
binding	O	O
of	O	O
normal	O	O
and	O	O
patient	O	O
's	O	O
serum	O	O
proteins	O	O
to	O	O
her	O	O
own	O	O
and	O	O
cephalothin-coated	O	O
normal	O	O
red	O	O
cells	O	O
was	O	O
demonstrated	O	O
.	O	O

Skin	O	O
tests	O	O
and	O	O
in	O	O
vitro	O	O
lymphocyte	O	O
stimulation	O	O
revealed	O	O
that	O	O
the	O	O
patient	O	O
was	O	O
sensitized	O	O
to	O	O
cephalothin	B_Chemical	O
and	O	O
also	O	O
to	O	O
ampicillin	B_Chemical	O
.	O	O

Careful	O	O
investigation	O	O
of	O	O
drug-induced	O	O
hemolytic	B_Disease	B_Disease
anemias	I_Disease	I_Disease
reveals	O	O
the	O	O
complexity	O	O
of	O	O
the	O	O
immune	O	O
mechanisms	O	O
involved	O	O
.	O	O

Assessment	O	O
of	O	O
cardiomyocyte	O	O
DNA	O	O
synthesis	O	O
during	O	O
hypertrophy	O	O
in	O	O
adult	O	O
mice	O	O
.	O	O

The	O	O
ability	O	O
of	O	O
cardiomyocytes	O	O
to	O	O
synthesize	O	O
DNA	O	O
in	O	O
response	O	O
to	O	O
experimentally	O	O
induced	O	O
cardiac	B_Disease	B_Disease
hypertrophy	I_Disease	I_Disease
was	O	O
assessed	O	O
in	O	O
adult	O	O
mice	O	O
.	O	O

Isoproterenol	B_Chemical	O
delivered	O	O
by	O	O
osmotic	O	O
minipump	O	O
implantation	O	O
in	O	O
adult	O	O
C3Heb/FeJ	O	O
mice	O	O
resulted	O	O
in	O	O
a	O	O
46	O	O
%	O	O
increase	O	O
in	O	O
heart	O	O
weight	O	O
and	O	O
a	O	O
19.3	O	O
%	O	O
increase	O	O
in	O	O
cardiomyocyte	O	O
area	O	O
.	O	O

No	O	O
DNA	O	O
synthesis	O	O
,	O	O
as	O	O
assessed	O	O
by	O	O
autoradiographic	O	O
analysis	O	O
of	O	O
isolated	O	O
cardiomyocytes	O	O
,	O	O
was	O	O
observed	O	O
in	O	O
control	O	O
or	O	O
hypertrophic	B_Disease	O
hearts	I_Disease	O
.	O	O

A	O	O
survey	O	O
of	O	O
15	O	O
independent	O	O
inbred	O	O
strains	O	O
of	O	O
mice	O	O
revealed	O	O
that	O	O
ventricular	O	O
cardiomyocyte	O	O
nuclear	O	O
number	O	O
ranged	O	O
from	O	O
3	O	O
to	O	O
13	O	O
%	O	O
mononucleate	O	O
,	O	O
suggesting	O	O
that	O	O
cardiomyocyte	O	O
terminal	O	O
differentiation	O	O
is	O	O
influenced	O	O
directly	O	O
or	O	O
indirectly	O	O
by	O	O
genetic	O	O
background	O	O
.	O	O

To	O	O
determine	O	O
whether	O	O
the	O	O
capacity	O	O
for	O	O
reactive	O	O
DNA	O	O
synthesis	O	O
was	O	O
also	O	O
subject	O	O
to	O	O
genetic	O	O
regulation	O	O
,	O	O
cardiac	B_Disease	O
hypertrophy	I_Disease	O
was	O	O
induced	O	O
in	O	O
the	O	O
strains	O	O
of	O	O
mice	O	O
comprising	O	O
the	O	O
extremes	O	O
of	O	O
the	O	O
nuclear	O	O
number	O	O
survey	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
adult	O	O
mouse	O	O
atrial	O	O
and	O	O
ventricular	O	O
cardiomyocytes	O	O
do	O	O
not	O	O
synthesize	O	O
DNA	O	O
in	O	O
response	O	O
to	O	O
isoproterenol-induced	O	O
cardiac	B_Disease	B_Disease
hypertrophy	I_Disease	I_Disease
.	O	O

Central	O	O
cardiovascular	O	O
effects	O	O
of	O	O
AVP	B_Chemical	O
and	O	O
ANP	O	O
in	O	O
normotensive	O	O
and	O	O
spontaneously	O	O
hypertensive	B_Disease	O
rats	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
influence	O	O
of	O	O
central	O	O
arginine	B_Chemical	B_Chemical
vasopressin	I_Chemical	I_Chemical
(	O	O
AVP	B_Chemical	O
)	O	O
and	O	O
of	O	O
atrial	O	O
natriuretic	O	O
peptide	O	O
(	O	O
ANP	O	O
)	O	O
on	O	O
control	O	O
of	O	O
arterial	O	O
blood	O	O
pressure	O	O
(	O	O
MAP	O	O
)	O	O
and	O	O
heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
in	O	O
normotensive	O	O
(	O	O
WKY	O	O
)	O	O
and	O	O
spontaneously	O	O
hypertensive	B_Disease	O
(	O	O
SHR	O	O
)	O	O
rats	O	O
.	O	O

Three	O	O
series	O	O
of	O	O
experiments	O	O
were	O	O
performed	O	O
on	O	O
30	O	O
WKY	O	O
and	O	O
30	O	O
SHR	O	O
,	O	O
chronically	O	O
instrumented	O	O
with	O	O
guide	O	O
tubes	O	O
in	O	O
the	O	O
lateral	O	O
ventricle	O	O
(	O	O
LV	O	O
)	O	O
and	O	O
arterial	O	O
and	O	O
venous	O	O
catheters	O	O
.	O	O

MAP	O	O
and	O	O
HR	O	O
were	O	O
monitored	O	O
before	O	O
and	O	O
after	O	O
i.v	O	O
.	O	O

injections	O	O
of	O	O
either	O	O
vehicle	O	O
or	O	O
1	O	O
,	O	O
10	O	O
and	O	O
50	O	O
ng	O	O
of	O	O
AVP	B_Chemical	O
and	O	O
25	O	O
,	O	O
125	O	O
and	O	O
500	O	O
ng	O	O
of	O	O
ANP	O	O
.	O	O

Sensitivity	O	O
of	O	O
cardiac	O	O
component	O	O
of	O	O
baroreflex	O	O
(	O	O
CCB	O	O
)	O	O
,	O	O
expressed	O	O
as	O	O
a	O	O
slope	O	O
of	O	O
the	O	O
regression	O	O
line	O	O
was	O	O
determined	O	O
from	O	O
relationships	O	O
between	O	O
systolic	O	O
arterial	O	O
pressure	O	O
(	O	O
SAP	O	O
)	O	O
and	O	O
HR	O	O
period	O	O
(	O	O
HRp	O	O
)	O	O
during	O	O
phenylephrine	B_Chemical	O
(Phe)-induced	O	O
hypertension	B_Disease	O
and	O	O
sodium	B_Chemical	B_Chemical
nitroprusside	I_Chemical	I_Chemical
(SN)-induced	O	O
hypotension	B_Disease	O
.	O	O

CCB	O	O
was	O	O
measured	O	O
before	O	O
and	O	O
after	O	O
administration	O	O
of	O	O
either	O	O
vehicle	O	O
,	O	O
AVP	B_Chemical	O
,	O	O
ANP	O	O
,	O	O
or	O	O
both	O	O
peptides	O	O
together	O	O
.	O	O

Increases	O	O
of	O	O
MAP	O	O
occurred	O	O
after	O	O
LV	O	O
administration	O	O
of	O	O
1	O	O
,	O	O
10	O	O
and	O	O
50	O	O
ng	O	O
of	O	O
AVP	B_Chemical	O
in	O	O
WKY	O	O
and	O	O
of	O	O
10	O	O
and	O	O
50	O	O
ng	O	O
in	O	O
SHR	O	O
.	O	O

ANP	O	O
did	O	O
not	O	O
cause	O	O
significant	O	O
changes	O	O
in	O	O
MAP	O	O
in	O	O
both	O	O
strains	O	O
as	O	O
compared	O	O
to	O	O
vehicle	O	O
,	O	O
but	O	O
it	O	O
abolished	O	O
AVP-induced	O	O
MAP	O	O
increase	O	O
in	O	O
WKY	O	O
and	O	O
SHR	O	O
.	O	O

CCB	O	O
was	O	O
reduced	O	O
in	O	O
WKY	O	O
and	O	O
SHR	O	O
after	O	O
LV	O	O
administration	O	O
of	O	O
AVP	B_Chemical	O
during	O	O
SN-induced	O	O
hypotension	B_Disease	O
.	O	O

In	O	O
SHR	O	O
but	O	O
not	O	O
in	O	O
WKY	O	O
administration	O	O
of	O	O
ANP	O	O
,	O	O
AVP	B_Chemical	O
and	O	O
ANP	O	O
+	O	O
AVP	B_Chemical	O
decreased	O	O
CCB	O	O
during	O	O
Phe-induced	O	O
MAP	O	O
elevation	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
centrally	O	O
applied	O	O
AVP	B_Chemical	O
and	O	O
ANP	O	O
exert	O	O
differential	O	O
effects	O	O
on	O	O
blood	O	O
pressure	O	O
and	O	O
baroreflex	O	O
control	O	O
of	O	O
heart	O	O
rate	O	O
in	O	O
WKY	O	O
and	O	O
SHR	O	O
and	O	O
suggest	O	O
interaction	O	O
of	O	O
these	O	O
two	O	O
peptides	O	O
in	O	O
blood	O	O
pressure	O	O
regulation	O	O
at	O	O
the	O	O
level	O	O
of	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

Cutaneous	O	O
exposure	O	O
to	O	O
warfarin-like	O	O
anticoagulant	O	O
causing	O	O
an	O	O
intracerebral	B_Disease	O
hemorrhage	I_Disease	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

A	O	O
case	O	O
of	O	O
intercerebral	O	O
hematoma	B_Disease	O
due	O	O
to	O	O
warfarin-induced	O	O
coagulopathy	B_Disease	B_Disease
is	O	O
presented	O	O
.	O	O

The	O	O
39-year-old	O	O
woman	O	O
had	O	O
spread	O	O
a	O	O
warfarin-type	O	O
rat	O	O
poison	O	O
around	O	O
her	O	O
house	O	O
weekly	O	O
using	O	O
her	O	O
bare	O	O
hands	O	O
,	O	O
with	O	O
no	O	O
washing	O	O
post	O	O
application	O	O
.	O	O

Percutaneous	O	O
absorption	O	O
of	O	O
warfarin	B_Chemical	O
causing	O	O
coagulopathy	B_Disease	B_Disease
,	O	O
reported	O	O
three	O	O
times	O	O
in	O	O
the	O	O
past	O	O
,	O	O
is	O	O
a	O	O
significant	O	O
risk	O	O
if	O	O
protective	O	O
measures	O	O
,	O	O
such	O	O
as	O	O
gloves	O	O
,	O	O
are	O	O
not	O	O
used	O	O
.	O	O

An	O	O
adverse	O	O
drug	O	O
interaction	O	O
with	O	O
piroxicam	B_Chemical	O
,	O	O
which	O	O
she	O	O
took	O	O
occasionally	O	O
,	O	O
may	O	O
have	O	O
exacerbated	O	O
the	O	O
coagulopathy	B_Disease	B_Disease
.	O	O

Pediatric	O	O
heart	O	O
transplantation	O	O
without	O	O
chronic	O	O
maintenance	O	O
steroids	O	O
.	O	O

From	O	O
1986	O	O
to	O	O
February	O	O
1993	O	O
,	O	O
40	O	O
children	O	O
aged	O	O
2	O	O
months	O	O
to	O	O
18	O	O
years	O	O
(	O	O
average	O	O
age	O	O
10.4	O	O
+	O	O
/-	O	O
5.8	O	O
years	O	O
)	O	O
underwent	O	O
heart	O	O
transplantation	O	O
.	O	O

Indications	O	O
for	O	O
transplantation	O	O
were	O	O
idiopathic	B_Disease	B_Disease
cardiomyopathy	I_Disease	I_Disease
(	O	O
52	O	O
%	O	O
)	O	O
,	O	O
congenital	B_Disease	B_Disease
heart	I_Disease	I_Disease
disease	I_Disease	I_Disease
(	O	O
35	O	O
%	O	O
)	O	O
with	O	O
and	O	O
without	O	O
prior	O	O
repair	O	O
(	O	O
71	O	O
%	O	O
and	O	O
29	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
hypertrophic	B_Disease	B_Disease
cardiomyopathy	I_Disease	I_Disease
(	O	O
5	O	O
%	O	O
)	O	O
,	O	O
valvular	B_Disease	B_Disease
heart	I_Disease	I_Disease
disease	I_Disease	I_Disease
(	O	O
3	O	O
%	O	O
)	O	O
,	O	O
and	O	O
doxorubicin	B_Chemical	O
cardiomyopathy	B_Disease	O
(	O	O
5	O	O
%	O	O
)	O	O
.	O	O

Patients	O	O
were	O	O
managed	O	O
with	O	O
cyclosporine	B_Chemical	B_Chemical
and	O	O
azathioprine	B_Chemical	O
.	O	O

No	O	O
prophylaxis	O	O
with	O	O
antilymphocyte	O	O
globulin	O	O
was	O	O
used	O	O
.	O	O

Steroids	B_Chemical	O
were	O	O
given	O	O
to	O	O
39	O	O
%	O	O
of	O	O
patients	O	O
for	O	O
refractory	O	O
rejection	O	O
,	O	O
but	O	O
weaning	O	O
was	O	O
always	O	O
attempted	O	O
and	O	O
generally	O	O
successful	O	O
(	O	O
64	O	O
%	O	O
)	O	O
.	O	O

Five	O	O
patients	O	O
(	O	O
14	O	O
%	O	O
)	O	O
received	O	O
maintenance	O	O
steroids	B_Chemical	O
.	O	O

Four	O	O
patients	O	O
died	O	O
in	O	O
the	O	O
perioperative	O	O
period	O	O
and	O	O
one	O	O
died	O	O
4	O	O
months	O	O
later	O	O
.	O	O

There	O	O
have	O	O
been	O	O
no	O	O
deaths	O	O
related	O	O
to	O	O
rejection	O	O
or	O	O
infection	B_Disease	O
.	O	O

Average	O	O
follow-up	O	O
was	O	O
36	O	O
+	O	O
/-	O	O
19	O	O
months	O	O
(	O	O
range	O	O
1	O	O
to	O	O
65	O	O
months	O	O
)	O	O
.	O	O

Cumulative	O	O
survival	O	O
is	O	O
88	O	O
%	O	O
at	O	O
5	O	O
years	O	O
.	O	O

In	O	O
patients	O	O
less	O	O
than	O	O
7	O	O
years	O	O
of	O	O
age	O	O
,	O	O
rejection	O	O
was	O	O
monitored	O	O
noninvasively	O	O
.	O	O

In	O	O
the	O	O
first	O	O
postoperative	O	O
month	O	O
,	O	O
89	O	O
%	O	O
of	O	O
patients	O	O
were	O	O
treated	O	O
for	O	O
rejection	O	O
.	O	O

Freedom	O	O
from	O	O
serious	O	O
infections	B_Disease	O
was	O	O
83	O	O
%	O	O
at	O	O
1	O	O
month	O	O
and	O	O
65	O	O
%	O	O
at	O	O
1	O	O
year	O	O
.	O	O

Cytomegalovirus	B_Disease	B_Disease
infections	I_Disease	I_Disease
were	O	O
treated	O	O
successfully	O	O
with	O	O
ganciclovir	B_Chemical	B_Chemical
in	O	O
11	O	O
patients	O	O
.	O	O

No	O	O
impairment	O	O
of	O	O
growth	O	O
was	O	O
observed	O	O
in	O	O
children	O	O
who	O	O
underwent	O	O
transplantation	O	O
compared	O	O
with	O	O
a	O	O
control	O	O
population	O	O
.	O	O

Twenty-one	O	O
patients	O	O
(	O	O
60	O	O
%	O	O
)	O	O
have	O	O
undergone	O	O
annual	O	O
catheterizations	O	O
and	O	O
no	O	O
sign	O	O
of	O	O
graft	O	O
atherosclerosis	B_Disease	O
has	O	O
been	O	O
observed	O	O
.	O	O

Seizures	B_Disease	O
occurred	O	O
in	O	O
five	O	O
patients	O	O
(	O	O
14	O	O
%	O	O
)	O	O
and	O	O
hypertension	B_Disease	O
was	O	O
treated	O	O
in	O	O
10	O	O
patients	O	O
(	O	O
28	O	O
%	O	O
)	O	O
.	O	O

No	O	O
patient	O	O
was	O	O
disabled	O	O
and	O	O
no	O	O
lymphoproliferative	B_Disease	B_Disease
disorder	I_Disease	I_Disease
was	O	O
observed.(ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O

Delirium	B_Disease	O
during	O	O
fluoxetine	B_Chemical	O
treatment	O	O
.	O	O

A	O	O
case	O	O
report	O	O
.	O	O

The	O	O
correlation	O	O
between	O	O
high	O	O
serum	O	O
tricyclic	O	O
antidepressant	O	O
concentrations	O	O
and	O	O
central	O	O
nervous	O	O
system	O	O
side	O	O
effects	O	O
has	O	O
been	O	O
well	O	O
established	O	O
.	O	O

Only	O	O
a	O	O
few	O	O
reports	O	O
exist	O	O
,	O	O
however	O	O
,	O	O
on	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
serum	O	O
concentrations	O	O
of	O	O
selective	O	O
serotonin	B_Chemical	O
reuptake	O	O
inhibitors	O	O
(	O	O
SSRIs	O	O
)	O	O
and	O	O
their	O	O
toxic	O	O
effects	O	O
.	O	O

In	O	O
some	O	O
cases	O	O
,	O	O
a	O	O
high	O	O
serum	O	O
concentration	O	O
of	O	O
citalopram	B_Chemical	B_Chemical
(	O	O
>	O	O
600	O	O
nmol/L	O	O
)	O	O
in	O	O
elderly	O	O
patients	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
increased	O	O
somnolence	B_Disease	O
and	O	O
movement	B_Disease	O
difficulties	I_Disease	O
.	O	O

Widespread	O	O
cognitive	B_Disease	B_Disease
disorders	I_Disease	I_Disease
,	O	O
such	O	O
as	O	O
delirium	B_Disease	O
,	O	O
have	O	O
not	O	O
been	O	O
previously	O	O
linked	O	O
with	O	O
high	O	O
blood	O	O
levels	O	O
of	O	O
SSRIs	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
acute	O	O
hyperkinetic	B_Disease	B_Disease
delirium	B_Disease	I_Disease
connected	O	O
with	O	O
a	O	O
high	O	O
serum	O	O
total	O	O
fluoxetine	B_Chemical	O
(	O	O
fluoxetine	B_Chemical	O
plus	O	O
desmethylfluoxetine	B_Chemical	B_Chemical
)	O	O
concentration	O	O
.	O	O

Pulmonary	B_Disease	B_Disease
edema	I_Disease	I_Disease
and	O	O
shock	B_Disease	O
after	O	O
high-dose	O	O
aracytine-C	B_Chemical	O
for	O	O
lymphoma	B_Disease	O
;	O	O
possible	O	O
role	O	O
of	O	O
TNF-alpha	O	O
and	O	O
PAF.Four	O	O
out	O	O
of	O	O
23	O	O
consecutive	O	O
patients	O	O
treated	O	O
with	O	O
high-dose	O	O
Ara-C	B_Chemical	O
for	O	O
lymphomas	B_Disease	O
in	O	O
our	O	O
institution	O	O
developed	O	O
a	O	O
strikingly	O	O
similar	O	O
syndrome	O	O
during	O	O
the	O	O
perfusion	O	O
.	O	O

It	O	O
was	O	O
characterized	O	O
by	O	O
the	O	O
onset	O	O
of	O	O
fever	B_Disease	O
,	O	O
diarrhea	B_Disease	O
,	O	O
shock	B_Disease	O
,	O	O
pulmonary	B_Disease	B_Disease
edema	I_Disease	I_Disease
,	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
,	O	O
metabolic	B_Disease	B_Disease
acidosis	I_Disease	I_Disease
,	O	O
weight	B_Disease	O
gain	I_Disease	O
and	O	O
leukocytosis	B_Disease	O
.	O	O

Thorough	O	O
bacteriological	O	O
screening	O	O
failed	O	O
to	O	O
provide	O	O
evidence	O	O
of	O	O
infection	B_Disease	O
.	O	O

Sequential	O	O
biological	O	O
assays	O	O
of	O	O
IL-1	O	O
,	O	O
IL-2	O	O
,	O	O
TNF	O	O
and	O	O
PAF	O	O
were	O	O
performed	O	O
during	O	O
Ara-C	B_Chemical	O
infusion	O	O
to	O	O
ten	O	O
patients	O	O
,	O	O
including	O	O
the	O	O
four	O	O
who	O	O
developed	O	O
the	O	O
syndrome	O	O
.	O	O

TNF	O	O
and	O	O
PAF	O	O
activity	O	O
was	O	O
found	O	O
in	O	O
the	O	O
serum	O	O
of	O	O
respectively	O	O
two	O	O
and	O	O
four	O	O
of	O	O
the	O	O
cases	O	O
,	O	O
but	O	O
not	O	O
in	O	O
the	O	O
six	O	O
controls	O	O
.	O	O

As	O	O
TNF	O	O
and	O	O
PAF	O	O
are	O	O
thought	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
development	O	O
of	O	O
septic	O	B_Disease
shock	B_Disease	I_Disease
and	O	O
adult	B_Disease	B_Disease
respiratory	I_Disease	I_Disease
distress	I_Disease	I_Disease
syndrome	I_Disease	I_Disease
,	O	O
we	O	O
hypothesize	O	O
that	O	O
high-dose	O	O
Ara-C	B_Chemical	O
may	O	O
be	O	O
associated	O	O
with	O	O
cytokine	O	O
release	O	O
.	O	O

Protective	O	O
effect	O	O
of	O	O
clentiazem	B_Chemical	O
against	O	O
epinephrine-induced	O	O
cardiac	B_Disease	B_Disease
injury	I_Disease	I_Disease
in	O	O
rats	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
clentiazem	B_Chemical	O
,	O	O
a	O	O
1,5-benzothiazepine	B_Chemical	B_Chemical
calcium	B_Chemical	I_Chemical
antagonist	O	O
,	O	O
on	O	O
epinephrine-induced	O	O
cardiomyopathy	B_Disease	O
in	O	O
rats	O	O
.	O	O

With	O	O
2-week	O	O
chronic	O	O
epinephrine	B_Chemical	O
infusion	O	O
,	O	O
16	O	O
of	O	O
30	O	O
rats	O	O
died	O	O
within	O	O
4	O	O
days	O	O
,	O	O
and	O	O
severe	O	O
ischemic	B_Disease	B_Disease
lesions	I_Disease	I_Disease
and	O	O
fibrosis	B_Disease	O
of	O	O
the	O	O
left	O	O
ventricles	O	O
were	O	O
observed	O	O
.	O	O

In	O	O
epinephrine-treated	O	O
rats	O	O
,	O	O
left	O	O
atrial	O	O
and	O	O
left	O	O
ventricular	O	O
papillary	O	O
muscle	O	O
contractile	O	O
responses	O	O
to	O	O
isoproterenol	B_Chemical	O
were	O	O
reduced	O	O
,	O	O
but	O	O
responses	O	O
to	O	O
calcium	B_Chemical	O
were	O	O
normal	O	O
or	O	O
enhanced	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

Left	O	O
ventricular	O	O
alpha	O	O
and	O	O
beta	O	O
adrenoceptor	O	O
densities	O	O
were	O	O
also	O	O
reduced	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

Treatment	O	O
with	O	O
clentiazem	B_Chemical	O
prevented	O	O
epinephrine-induced	O	O
death	O	O
(	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
,	O	O
and	O	O
attenuated	O	O
the	O	O
ventricular	O	B_Disease
ischemic	B_Disease	I_Disease
lesions	I_Disease	I_Disease
and	O	O
fibrosis	B_Disease	O
,	O	O
in	O	O
a	O	O
dose-dependent	O	O
manner	O	O
.	O	O

Left	O	O
atrial	O	O
and	O	O
left	O	O
ventricular	O	O
papillary	O	O
muscle	O	O
contractile	O	O
responses	O	O
to	O	O
isoproterenol	B_Chemical	O
were	O	O
reduced	O	O
compared	O	O
to	O	O
controls	O	O
in	O	O
groups	O	O
treated	O	O
with	O	O
clentiazem	B_Chemical	O
alone	O	O
,	O	O
but	O	O
combined	O	O
with	O	O
epinephrine	B_Chemical	O
,	O	O
clentiazem	B_Chemical	O
restored	O	O
left	O	O
atrial	O	O
responses	O	O
and	O	O
enhanced	O	O
left	O	O
ventricular	O	O
papillary	O	O
responses	O	O
to	O	O
isoproterenol	B_Chemical	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
clentiazem	B_Chemical	O
did	O	O
not	O	O
prevent	O	O
epinephrine-induced	O	O
down-regulation	O	O
of	O	O
alpha	O	O
and	O	O
beta	O	O
adrenoceptors	O	O
.	O	O

Interestingly	O	O
,	O	O
clentiazem	B_Chemical	O
,	O	O
infused	O	O
alone	O	O
,	O	O
resulted	O	O
in	O	O
decreased	O	O
adrenergic	O	O
receptor	O	O
densities	O	O
in	O	O
the	O	O
left	O	O
ventricle	O	O
.	O	O

Clentiazem	B_Chemical	O
also	O	O
did	O	O
not	O	O
prevent	O	O
the	O	O
enhanced	O	O
responses	O	O
to	O	O
calcium	B_Chemical	O
seen	O	O
in	O	O
the	O	O
epinephrine-treated	O	O
animals	O	O
,	O	O
although	O	O
the	O	O
high	O	O
dose	O	O
of	O	O
clentiazem	B_Chemical	O
partially	O	O
attenuated	O	O
the	O	O
maximal	O	O
response	O	O
to	O	O
calcium	B_Chemical	O
compared	O	O
to	O	O
epinephrine-treated	O	O
animals	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
clentiazem	B_Chemical	O
attenuated	O	O
epinephrine-induced	O	O
cardiac	B_Disease	B_Disease
injury	I_Disease	I_Disease
,	O	O
possibly	O	O
through	O	O
its	O	O
effect	O	O
on	O	O
the	O	O
adrenergic	O	O
pathway	O	O
.	O	O

Kaliuretic	O	O
effect	O	O
of	O	O
L-dopa	B_Chemical	O
treatment	O	O
in	O	O
parkinsonian	B_Disease	B_Disease
patients	O	O
.	O	O

Hypokalemia	B_Disease	O
,	O	O
sometimes	O	O
severe	O	O
,	O	O
was	O	O
observed	O	O
in	O	O
some	O	O
L-dopa-treated	O	O
parkinsonian	B_Disease	B_Disease
patients	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
L-dopa	B_Chemical	O
on	O	O
the	O	O
renal	O	O
excretion	O	O
of	O	O
potassium	B_Chemical	O
was	O	O
studied	O	O
in	O	O
3	O	O
patients	O	O
with	O	O
hypokalemia	B_Disease	O
and	O	O
in	O	O
5	O	O
normokalemic	O	O
patients	O	O
by	O	O
determination	O	O
of	O	O
renal	O	O
plasma	O	O
flow	O	O
,	O	O
glomerular	O	O
filtration	O	O
rate	O	O
,	O	O
plasma	O	O
concentration	O	O
of	O	O
potassium	B_Chemical	O
and	O	O
sodium	B_Chemical	O
as	O	O
well	O	O
as	O	O
urinary	O	O
excretion	O	O
of	O	O
potassium	B_Chemical	O
,	O	O
sodium	B_Chemical	O
and	O	O
aldosterone	B_Chemical	O
.	O	O

L-Dopa	B_Chemical	O
intake	O	O
was	O	O
found	O	O
to	O	O
cause	O	O
an	O	O
increased	O	O
excretion	O	O
of	O	O
potassium	B_Chemical	O
,	O	O
and	O	O
sometimes	O	O
also	O	O
of	O	O
sodium	B_Chemical	O
,	O	O
in	O	O
the	O	O
hypokalemic	O	O
but	O	O
not	O	O
in	O	O
the	O	O
normokalemic	O	O
patients	O	O
.	O	O

This	O	O
effect	O	O
on	O	O
the	O	O
renal	O	O
function	O	O
could	O	O
be	O	O
prohibited	O	O
by	O	O
the	O	O
administration	O	O
of	O	O
a	O	O
peripheral	O	O
dopa	O	O
decarbodylase	O	O
inhibitor	O	O
.	O	O

It	O	O
is	O	O
not	O	O
known	O	O
why	O	O
this	O	O
effect	O	O
occurred	O	O
in	O	O
some	O	O
individuals	O	O
but	O	O
not	O	O
in	O	O
others	O	O
,	O	O
but	O	O
our	O	O
results	O	O
indicate	O	O
a	O	O
correlation	O	O
between	O	O
aldosterone	B_Chemical	O
production	O	O
and	O	O
this	O	O
renal	O	O
effect	O	O
of	O	O
L-dopa	B_Chemical	O
.	O	O

Cocaine	B_Chemical	O
induced	O	O
myocardial	B_Disease	B_Disease
ischemia	I_Disease	I_Disease
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
myocardial	B_Disease	B_Disease
ischemia	I_Disease	I_Disease
induced	O	O
by	O	O
cocaine	B_Chemical	O
.	O	O

The	O	O
ischemia	B_Disease	O
probably	O	O
induced	O	O
by	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
spasm	I_Disease	I_Disease
was	O	O
reversed	O	O
by	O	O
nitroglycerin	B_Chemical	O
and	O	O
calcium	B_Chemical	O
blocking	O	O
agents	O	O
.	O	O

Doxorubicin-induced	O	O
cardiotoxicity	B_Disease	B_Disease
monitored	O	O
by	O	O
ECG	O	O
in	O	O
freely	O	O
moving	O	O
mice	O	O
.	O	O

A	O	O
new	O	O
model	O	O
to	O	O
test	O	O
potential	O	O
protectors	O	O
.	O	O

In	O	O
laboratory	O	O
animals	O	O
,	O	O
histology	O	O
is	O	O
most	O	O
commonly	O	O
used	O	O
to	O	O
study	O	O
doxorubicin-induced	O	O
cardiotoxicity	B_Disease	B_Disease
.	O	O

However	O	O
,	O	O
for	O	O
monitoring	O	O
during	O	O
treatment	O	O
,	O	O
large	O	O
numbers	O	O
of	O	O
animals	O	O
are	O	O
needed	O	O
.	O	O

Recently	O	O
we	O	O
developed	O	O
a	O	O
new	O	O
method	O	O
to	O	O
measure	O	O
ECG	O	O
values	O	O
in	O	O
freely	O	O
moving	O	O
mice	O	O
by	O	O
telemetry	O	O
.	O	O

With	O	O
this	O	O
model	O	O
we	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
doxorubicin	B_Chemical	O
administration	O	O
on	O	O
the	O	O
ECG	O	O
of	O	O
freely	O	O
moving	O	O
BALB/c	O	O
mice	O	O
and	O	O
the	O	O
efficacy	O	O
of	O	O
ICRF-187	B_Chemical	O
as	O	O
a	O	O
protective	O	O
agent	O	O
.	O	O

The	O	O
ST	O	O
interval	O	O
significantly	O	O
widened	O	O
from	O	O
15.0	O	O
+	O	O
/-	O	O
1.5	O	O
to	O	O
56.8	O	O
+	O	O
/-	O	O
11.8	O	O
ms	O	O
in	O	O
week	O	O
10	O	O
(	O	O
7	O	O
weekly	O	O
doses	O	O
of	O	O
4	O	O
mg/kg	O	O
doxorubicin	B_Chemical	O
given	O	O
i.v	O	O
.	O	O
plus	O	O
3	O	O
weeks	O	O
of	O	O
observation	O	O
)	O	O
.	O	O

The	O	O
ECG	O	O
of	O	O
the	O	O
control	O	O
animals	O	O
did	O	O
not	O	O
change	O	O
during	O	O
the	O	O
entire	O	O
study	O	O
.	O	O

After	O	O
sacrifice	O	O
the	O	O
hearts	O	O
of	O	O
doxorubicin-treated	O	O
animals	O	O
were	O	O
enlarged	O	O
and	O	O
the	O	O
atria	O	O
were	O	O
hypertrophic	B_Disease	O
.	O	O

As	O	O
this	O	O
schedule	O	O
exerted	O	O
more	O	O
toxicity	B_Disease	O
than	O	O
needed	O	O
to	O	O
investigate	O	O
protective	O	O
agents	O	O
,	O	O
the	O	O
protection	O	O
of	O	O
ICRF-187	B_Chemical	O
was	O	O
determined	O	O
using	O	O
a	O	O
dose	O	O
schedule	O	O
with	O	O
lower	O	O
general	O	O
toxicity	B_Disease	O
(	O	O
6	O	O
weekly	O	O
doses	O	O
of	O	O
4	O	O
mg/kg	O	O
doxorubicin	B_Chemical	O
given	O	O
i.v	O	O
.	O	O
plus	O	O
2	O	O
weeks	O	O
of	O	O
observation	O	O
)	O	O
.	O	O

On	O	O
this	O	O
schedule	O	O
,	O	O
the	O	O
animals	O	O
'	O	O
hearts	O	O
appeared	O	O
normal	O	O
after	O	O
sacrifice	O	O
and	O	O
ICRF-187	B_Chemical	O
(	O	O
50	O	O
mg/kg	O	O
given	O	O
i.p	O	O
.	O	O

1	O	O
h	O	O
before	O	O
doxorubicin	B_Chemical	O
)	O	O
provided	O	O
almost	O	O
full	O	O
protection	O	O
.	O	O

These	O	O
data	O	O
were	O	O
confirmed	O	O
by	O	O
histology	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
this	O	O
new	O	O
model	O	O
is	O	O
very	O	O
sensitive	O	O
and	O	O
enables	O	O
monitoring	O	O
of	O	O
the	O	O
development	O	O
of	O	O
cardiotoxicity	B_Disease	B_Disease
with	O	O
time	O	O
.	O	O

These	O	O
findings	O	O
result	O	O
in	O	O
a	O	O
model	O	O
that	O	O
allows	O	O
the	O	O
testing	O	O
of	O	O
protectors	O	O
against	O	O
doxorubicin-induced	O	O
cardiotoxicity	B_Disease	B_Disease
as	O	O
demonstrated	O	O
by	O	O
the	O	O
protection	O	O
provided	O	O
by	O	O
ICRF-187	B_Chemical	O
.	O	O

Epinephrine	B_Chemical	O
dysrhythmogenicity	O	O
is	O	O
not	O	O
enhanced	O	O
by	O	O
subtoxic	O	B_Chemical
bupivacaine	B_Chemical	I_Chemical
in	O	O
dogs	O	O
.	O	O

Since	O	O
bupivacaine	B_Chemical	B_Chemical
and	O	O
epinephrine	B_Chemical	O
may	O	O
both	O	O
precipitate	O	O
dysrhythmias	B_Disease	B_Disease
,	O	O
circulating	O	O
bupivacaine	B_Chemical	B_Chemical
during	O	O
regional	O	O
anesthesia	O	O
could	O	O
potentiate	O	O
dysrhythmogenic	O	B_Disease
effects	O	O
of	O	O
epinephrine	B_Chemical	O
.	O	O

We	O	O
therefore	O	O
examined	O	O
whether	O	O
bupivacaine	B_Chemical	B_Chemical
alters	O	O
the	O	O
dysrhythmogenicity	O	B_Disease
of	O	O
subsequent	O	O
administration	O	O
of	O	O
epinephrine	B_Chemical	O
in	O	O
conscious	O	O
,	O	O
healthy	O	O
dogs	O	O
and	O	O
in	O	O
anesthetized	O	O
dogs	O	O
with	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
.	O	O

Forty-one	O	O
conscious	O	O
dogs	O	O
received	O	O
10	O	O
micrograms.kg-1.min-1	O	O
epinephrine	B_Chemical	O
.	O	O

Seventeen	O	O
animals	O	O
responded	O	O
with	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
(	O	O
VT	B_Disease	O
)	O	O
within	O	O
3	O	O
min	O	O
.	O	O

After	O	O
3	O	O
h	O	O
,	O	O
these	O	O
responders	O	O
randomly	O	O
received	O	O
1	O	O
or	O	O
2	O	O
mg/kg	O	O
bupivacaine	B_Chemical	B_Chemical
or	O	O
saline	O	O
over	O	O
5	O	O
min	O	O
,	O	O
followed	O	O
by	O	O
10	O	O
micrograms.kg-1.min-1	O	O
epinephrine	B_Chemical	O
.	O	O

In	O	O
the	O	O
bupivacaine	B_Chemical	B_Chemical
groups	O	O
,	O	O
epinephrine	B_Chemical	O
caused	O	O
fewer	O	O
prodysrhythmic	O	O
effects	O	O
than	O	O
without	O	O
bupivacaine	B_Chemical	B_Chemical
.	O	O

VT	B_Disease	O
appeared	O	O
in	O	O
fewer	O	O
dogs	O	O
and	O	O
at	O	O
a	O	O
later	O	O
time	O	O
,	O	O
and	O	O
there	O	O
were	O	O
more	O	O
sinoatrial	O	O
beats	O	O
and	O	O
less	O	O
ectopies	O	O
.	O	O

Epinephrine	B_Chemical	O
shortened	O	O
QT	O	O
less	O	O
after	O	O
bupivacaine	B_Chemical	B_Chemical
than	O	O
in	O	O
control	O	O
animals	O	O
.	O	O

One	O	O
day	O	O
after	O	O
experimental	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
,	O	O
six	O	O
additional	O	O
halothane-anesthetized	O	O
dogs	O	O
received	O	O
4	O	O
micrograms.kg-1.min-1	O	O
epinephrine	B_Chemical	O
until	O	O
VT	B_Disease	O
appeared	O	O
.	O	O

After	O	O
45	O	O
min	O	O
,	O	O
1	O	O
mg/kg	O	O
bupivacaine	B_Chemical	B_Chemical
was	O	O
injected	O	O
over	O	O
5	O	O
min	O	O
,	O	O
again	O	O
followed	O	O
by	O	O
4	O	O
micrograms.kg-1.min-1	O	O
epinephrine	B_Chemical	O
.	O	O

In	O	O
these	O	O
dogs	O	O
,	O	O
the	O	O
prodysrhythmic	O	O
response	O	O
to	O	O
epinephrine	B_Chemical	O
was	O	O
also	O	O
mitigated	O	O
by	O	O
preceding	O	O
bupivacaine	B_Chemical	B_Chemical
.	O	O

Bupivacaine	B_Chemical	B_Chemical
antagonizes	O	O
epinephrine	B_Chemical	O
dysrhythmogenicity	O	O
in	O	O
conscious	O	O
dogs	O	O
susceptible	O	O
to	O	O
VT	B_Disease	O
and	O	O
in	O	O
anesthetized	O	O
dogs	O	O
with	O	O
spontaneous	O	O
postinfarct	O	O
dysrhythmias	B_Disease	B_Disease
.	O	O

There	O	O
is	O	O
no	O	O
evidence	O	O
that	O	O
systemic	O	O
subtoxic	O	O
bupivacaine	B_Chemical	B_Chemical
administration	O	O
enhances	O	O
the	O	O
dysrhythmogenicity	O	B_Disease
of	O	O
subsequent	O	O
epinephrine	B_Chemical	O
.	O	O

Milk-alkali	B_Disease	O
syndrome	I_Disease	O
induced	O	O
by	O	O
1,25(OH)2D	B_Chemical	O
in	O	O
a	O	O
patient	O	O
with	O	O
hypoparathyroidism	B_Disease	O
.	O	O

Milk-alkali	B_Disease	O
syndrome	I_Disease	O
was	O	O
first	O	O
described	O	O
70	O	O
years	O	O
ago	O	O
in	O	O
the	O	O
context	O	O
of	O	O
the	O	O
treatment	O	O
of	O	O
peptic	B_Disease	O
ulcer	I_Disease	O
disease	I_Disease	O
with	O	O
large	O	O
amounts	O	O
of	O	O
calcium	B_Chemical	O
and	O	O
alkali	B_Chemical	O
.	O	O

Although	O	O
with	O	O
current	O	O
ulcer	B_Disease	O
therapy	O	O
(	O	O
H-2	O	O
blockers	O	O
,	O	O
omeprazole	B_Chemical	O
,	O	O
and	O	O
sucralfate	B_Chemical	O
)	O	O
,	O	O
the	O	O
frequency	O	O
of	O	O
milk-alkali	B_Disease	O
syndrome	I_Disease	O
has	O	O
decreased	O	O
significantly	O	O
,	O	O
the	O	O
classic	O	O
triad	O	O
of	O	O
hypercalcemia	B_Disease	O
,	O	O
alkalosis	B_Disease	O
,	O	O
and	O	O
renal	B_Disease	B_Disease
impairment	I_Disease	I_Disease
remains	O	O
the	O	O
hallmark	O	O
of	O	O
the	O	O
syndrome	O	O
.	O	O

Milk-alkali	B_Disease	O
syndrome	I_Disease	O
can	O	O
present	O	O
serious	O	O
and	O	O
occasionally	O	O
life-threatening	O	O
illness	O	O
unless	O	O
diagnosed	O	O
and	O	O
treated	O	O
appropriately	O	O
.	O	O

This	O	O
article	O	O
presents	O	O
a	O	O
patient	O	O
with	O	O
hypoparathyroidism	B_Disease	O
who	O	O
was	O	O
treated	O	O
with	O	O
calcium	B_Chemical	B_Chemical
carbonate	I_Chemical	I_Chemical
and	O	O
calcitriol	B_Chemical	O
resulting	O	O
in	O	O
two	O	O
admissions	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
milk-alkali	B_Disease	O
syndrome	I_Disease	O
.	O	O

The	O	O
patient	O	O
was	O	O
successfully	O	O
treated	O	O
with	O	O
intravenous	O	O
pamidronate	B_Chemical	B_Chemical
on	O	O
his	O	O
first	O	O
admission	O	O
and	O	O
with	O	O
hydrocortisone	B_Chemical	O
on	O	O
the	O	O
second	O	O
.	O	O

This	O	O
illustrates	O	O
intravenous	O	O
pamidronate	B_Chemical	B_Chemical
as	O	O
a	O	O
valuable	O	O
therapeutic	O	O
tool	O	O
when	O	O
milk-alkali	B_Disease	O
syndrome	I_Disease	O
presents	O	O
as	O	O
hypercalcemic	B_Disease	B_Disease
emergency	I_Disease	O
.	O	O

Famotidine-associated	O	O
delirium	B_Disease	O
.	O	O

A	O	O
series	O	O
of	O	O
six	O	O
cases	O	O
.	O	O

Famotidine	B_Chemical	O
is	O	O
a	O	O
histamine	O	O
H2-receptor	O	O
antagonist	O	O
used	O	O
in	O	O
inpatient	O	O
settings	O	O
for	O	O
prevention	O	O
of	O	O
stress	O	O
ulcers	B_Disease	O
and	O	O
is	O	O
showing	O	O
increasing	O	O
popularity	O	O
because	O	O
of	O	O
its	O	O
low	O	O
cost	O	O
.	O	O

Although	O	O
all	O	O
of	O	O
the	O	O
currently	O	O
available	O	O
H2-receptor	O	O
antagonists	O	O
have	O	O
shown	O	O
the	O	O
propensity	O	O
to	O	O
cause	O	O
delirium	B_Disease	O
,	O	O
only	O	O
two	O	O
previously	O	O
reported	O	O
cases	O	O
have	O	O
been	O	O
associated	O	O
with	O	O
famotidine	B_Chemical	O
.	O	O

The	O	O
authors	O	O
report	O	O
on	O	O
six	O	O
cases	O	O
of	O	O
famotidine-associated	O	O
delirium	B_Disease	O
in	O	O
hospitalized	O	O
patients	O	O
who	O	O
cleared	O	O
completely	O	O
upon	O	O
removal	O	O
of	O	O
famotidine	B_Chemical	O
.	O	O

The	O	O
pharmacokinetics	O	O
of	O	O
famotidine	B_Chemical	O
are	O	O
reviewed	O	O
,	O	O
with	O	O
no	O	O
change	O	O
in	O	O
its	O	O
metabolism	O	O
in	O	O
the	O	O
elderly	O	O
population	O	O
seen	O	O
.	O	O

The	O	O
implications	O	O
of	O	O
using	O	O
famotidine	B_Chemical	O
in	O	O
elderly	O	O
persons	O	O
are	O	O
discussed	O	O
.	O	O

Encephalopathy	B_Disease	O
during	O	O
amitriptyline	B_Chemical	O
therapy	O	O
:	O	O
are	O	O
neuroleptic	B_Disease	O
malignant	I_Disease	O
syndrome	I_Disease	O
and	O	O
serotonin	B_Disease	O
syndrome	I_Disease	O
spectrum	O	O
disorders?This	O	O
report	O	O
describes	O	O
a	O	O
case	O	O
of	O	O
encephalopathy	B_Disease	O
developed	O	O
in	O	O
the	O	O
course	O	O
of	O	O
amitriptyline	B_Chemical	O
therapy	O	O
,	O	O
during	O	O
a	O	O
remission	O	O
of	O	O
unipolar	B_Disease	B_Disease
depression	I_Disease	I_Disease
.	O	O

This	O	O
patient	O	O
could	O	O
have	O	O
been	O	O
diagnosed	O	O
as	O	O
having	O	O
either	O	O
neuroleptic	B_Disease	O
malignant	I_Disease	O
syndrome	I_Disease	O
(	O	O
NMS	B_Disease	O
)	O	O
or	O	O
serotonin	B_Disease	O
syndrome	I_Disease	O
(	O	O
SS	B_Disease	O
)	O	O
.	O	O

The	O	O
major	O	O
determinant	O	O
of	O	O
the	O	O
symptoms	O	O
may	O	O
have	O	O
been	O	O
dopamine/serotonin	O	O
imbalance	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

The	O	O
NMS-like	O	O
encephalopathy	B_Disease	O
that	O	O
develops	O	O
in	O	O
association	O	O
with	O	O
the	O	O
use	O	O
of	O	O
antidepressants	O	O
indicates	O	O
that	O	O
NMS	B_Disease	O
and	O	O
SS	B_Disease	O
are	O	O
spectrum	O	O
disorders	O	O
induced	O	O
by	O	O
drugs	O	O
with	O	O
both	O	O
antidopaminergic	O	O
and	O	O
serotonergic	O	O
effects	O	O
.	O	O

Genetic	O	O
separation	O	O
of	O	O
tumor	B_Disease	O
growth	O	O
and	O	O
hemorrhagic	B_Disease	O
phenotypes	O	O
in	O	O
an	O	O
estrogen-induced	O	O
tumor	B_Disease	O
.	O	O

Chronic	O	O
administration	O	O
of	O	O
estrogen	B_Chemical	O
to	O	O
the	O	O
Fischer	O	O
344	O	O
(	O	O
F344	O	O
)	O	O
rat	O	O
induces	O	O
growth	O	O
of	O	O
large	O	O
,	O	O
hemorrhagic	B_Disease	O
pituitary	B_Disease	O
tumors	I_Disease	O
.	O	O

Ten	O	O
weeks	O	O
of	O	O
diethylstilbestrol	B_Chemical	O
(	O	O
DES	B_Chemical	O
)	O	O
treatment	O	O
caused	O	O
female	O	O
F344	O	O
rat	O	O
pituitaries	O	O
to	O	O
grow	O	O
to	O	O
an	O	O
average	O	O
of	O	O
109.2	O	O
+	O	O
/-	O	O
6.3	O	O
mg	O	O
(	O	O
mean	O	O
+	O	O
/-	O	O
SE	O	O
)	O	O
versus	O	O
11.3	O	O
+	O	O
/-	O	O
1.4	O	O
mg	O	O
for	O	O
untreated	O	O
rats	O	O
,	O	O
and	O	O
to	O	O
become	O	O
highly	O	O
hemorrhagic	B_Disease	O
.	O	O

The	O	O
same	O	O
DES	B_Chemical	O
treatment	O	O
produced	O	O
no	O	O
significant	O	O
growth	O	O
(	O	O
8.9	O	O
+	O	O
/-	O	O
0.5	O	O
mg	O	O
for	O	O
treated	O	O
females	O	O
versus	O	O
8.7	O	O
+	O	O
/-	O	O
1.1	O	O
for	O	O
untreated	O	O
females	O	O
)	O	O
or	O	O
morphological	O	O
changes	O	O
in	O	O
Brown	O	O
Norway	O	O
(	O	O
BN	O	O
)	O	O
rat	O	O
pituitaries	O	O
.	O	O

An	O	O
F1	O	O
hybrid	O	O
of	O	O
F344	O	O
and	O	O
BN	O	O
exhibited	O	O
significant	O	O
pituitary	O	O
growth	O	O
after	O	O
10	O	O
weeks	O	O
of	O	O
DES	B_Chemical	O
treatment	O	O
with	O	O
an	O	O
average	O	O
mass	O	O
of	O	O
26.3	O	O
+	O	O
/-	O	O
0.7	O	O
mg	O	O
compared	O	O
with	O	O
8.6	O	O
+	O	O
/-	O	O
0.9	O	O
mg	O	O
for	O	O
untreated	O	O
rats	O	O
.	O	O

Surprisingly	O	O
,	O	O
the	O	O
F1	O	O
hybrid	O	O
tumors	B_Disease	O
were	O	O
not	O	O
hemorrhagic	B_Disease	O
and	O	O
had	O	O
hemoglobin	O	O
content	O	O
and	O	O
outward	O	O
appearance	O	O
identical	O	O
to	O	O
that	O	O
of	O	O
BN	O	O
.	O	O

Expression	O	O
of	O	O
both	O	O
growth	O	O
and	O	O
morphological	O	O
changes	O	O
is	O	O
due	O	O
to	O	O
multiple	O	O
genes	O	O
.	O	O

However	O	O
,	O	O
while	O	O
DES-induced	O	O
pituitary	O	O
growth	O	O
exhibited	O	O
quantitative	O	O
,	O	O
additive	O	O
inheritance	O	O
,	O	O
the	O	O
hemorrhagic	B_Disease	O
phenotype	O	O
exhibited	O	O
recessive	O	O
,	O	O
epistatic	O	O
inheritance	O	O
.	O	O

Only	O	O
5	O	O
of	O	O
the	O	O
160	O	O
F2	O	O
pituitaries	O	O
exhibited	O	O
the	O	O
hemorrhagic	B_Disease	O
phenotype	O	O
;	O	O
36	O	O
of	O	O
the	O	O
160	O	O
F2	O	O
pituitaries	O	O
were	O	O
in	O	O
the	O	O
F344	O	O
range	O	O
of	O	O
mass	O	O
,	O	O
but	O	O
31	O	O
of	O	O
these	O	O
were	O	O
not	O	O
hemorrhagic	B_Disease	O
,	O	O
indicating	O	O
that	O	O
the	O	O
hemorrhagic	B_Disease	O
phenotype	O	O
is	O	O
not	O	O
merely	O	O
a	O	O
consequence	O	O
of	O	O
extensive	O	O
growth	O	O
.	O	O

The	O	O
hemorrhagic	B_Disease	O
F2	O	O
pituitaries	O	O
were	O	O
all	O	O
among	O	O
the	O	O
most	O	O
massive	O	O
,	O	O
indicating	O	O
that	O	O
some	O	O
of	O	O
the	O	O
genes	O	O
regulate	O	O
both	O	O
phenotypes	O	O
.	O	O

Increased	O	O
expression	O	O
of	O	O
neuronal	O	O
nitric	B_Chemical	O
oxide	I_Chemical	O
synthase	O	O
in	O	O
bladder	O	O
afferent	O	O
pathways	O	O
following	O	O
chronic	O	O
bladder	B_Disease	O
irritation	I_Disease	O
.	O	O

Immunocytochemical	O	O
techniques	O	O
were	O	O
used	O	O
to	O	O
examine	O	O
alterations	O	O
in	O	O
the	O	O
expression	O	O
of	O	O
neuronal	O	O
nitric	B_Chemical	O
oxide	I_Chemical	O
synthase	O	O
(	O	O
NOS	O	O
)	O	O
in	O	O
bladder	O	O
pathways	O	O
following	O	O
acute	O	O
and	O	O
chronic	O	O
irritation	B_Disease	O
of	I_Disease	O
the	I_Disease	O
urinary	I_Disease	O
tract	I_Disease	O
of	O	O
the	O	O
rat	O	O
.	O	O

Chemical	O	O
cystitis	B_Disease	O
was	O	O
induced	O	O
by	O	O
cyclophosphamide	B_Chemical	B_Chemical
(	O	O
CYP	B_Chemical	O
)	O	O
which	O	O
is	O	O
metabolized	O	O
to	O	O
acrolein	B_Chemical	O
,	O	O
an	O	O
irritant	O	O
eliminated	O	O
in	O	O
the	O	O
urine	O	O
.	O	O

Injection	O	O
of	O	O
CYP	B_Chemical	O
(	O	O
n	O	O
=	O	O
10	O	O
,	O	O
75	O	O
mg/kg	O	O
,	O	O
i.p	O	O
.	O	O
)	O	O
2	O	O
hours	O	O
prior	O	O
to	O	O
perfusion	O	O
(	O	O
acute	O	O
treatment	O	O
)	O	O
of	O	O
the	O	O
animals	O	O
increased	O	O
Fos-immunoreactivity	O	O
(	O	O
IR	O	O
)	O	O
in	O	O
neurons	O	O
in	O	O
the	O	O
dorsal	O	O
commissure	O	O
,	O	O
dorsal	O	O
horn	O	O
,	O	O
and	O	O
autonomic	O	O
regions	O	O
of	O	O
spinal	O	O
segments	O	O
(	O	O
L1-L2	O	O
and	O	O
L6-S1	O	O
)	O	O
which	O	O
receive	O	O
afferent	O	O
inputs	O	O
from	O	O
the	O	O
bladder	O	O
,	O	O
urethra	O	O
,	O	O
and	O	O
ureter	O	O
.	O	O

Fos-IR	O	O
in	O	O
the	O	O
spinal	O	O
cord	O	O
was	O	O
not	O	O
changed	O	O
in	O	O
rats	O	O
receiving	O	O
chronic	O	O
CYP	B_Chemical	O
treatment	O	O
(	O	O
n	O	O
=	O	O
15	O	O
,	O	O
75	O	O
mg/kg	O	O
,	O	O
i.p	O	O
.	O	O
,	O	O
every	O	O
3rd	O	O
day	O	O
for	O	O
2	O	O
weeks	O	O
)	O	O
.	O	O

In	O	O
control	O	O
animals	O	O
and	O	O
in	O	O
animals	O	O
treated	O	O
acutely	O	O
with	O	O
CYP	B_Chemical	O
,	O	O
only	O	O
small	O	O
numbers	O	O
of	O	O
NOS-IR	O	O
cells	O	O
(	O	O
0.5	O	O
-	O	O
0.7	O	O
cell	O	O
profiles/sections	O	O
)	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
L6-S1	O	O
dorsal	O	O
root	O	O
ganglia	O	O
(	O	O
DRG	O	O
)	O	O
.	O	O

Chronic	O	O
CYP	B_Chemical	O
administration	O	O
significantly	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
.002	O	O
)	O	O
increased	O	O
bladder	O	O
weight	O	O
by	O	O
60	O	O
%	O	O
and	O	O
increased	O	O
(	O	O
7-	O	O
to	O	O
11-fold	O	O
)	O	O
the	O	O
numbers	O	O
of	O	O
NOS-immunoreactive	O	O
(	O	O
IR	O	O
)	O	O
afferent	O	O
neurons	O	O
in	O	O
the	O	O
L6-S1	O	O
DRG	O	O
.	O	O

A	O	O
small	O	O
increase	O	O
(	O	O
1.5-fold	O	O
)	O	O
also	O	O
occurred	O	O
in	O	O
the	O	O
L1	O	O
DRG	O	O
,	O	O
but	O	O
no	O	O
change	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
L2	O	O
and	O	O
L5	O	O
DRG	O	O
.	O	O

Bladder	O	O
afferent	O	O
cells	O	O
in	O	O
the	O	O
L6-S1	O	O
DRG	O	O
labeled	O	O
by	O	O
Fluorogold	O	O
(	O	O
40	O	O
microliters	O	O
)	O	O
injected	O	O
into	O	O
the	O	O
bladder	O	O
wall	O	O
did	O	O
not	O	O
exhibit	O	O
NOS-IR	O	O
in	O	O
control	O	O
animals	O	O
;	O	O
however	O	O
,	O	O
following	O	O
chronic	O	O
CYP	B_Chemical	O
administration	O	O
,	O	O
a	O	O
significant	O	O
percentage	O	O
of	O	O
bladder	O	O
afferent	O	O
neurons	O	O
were	O	O
NOS-IR	O	O
:	O	O
L6	O	O
(	O	O
19.8	O	O
+	O	O
/-	O	O
4.6	O	O
%	O	O
)	O	O
and	O	O
S1	O	O
(	O	O
25.3	O	O
+	O	O
/-	O	O
2.9	O	O
%	O	O
)	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
neuronal	O	O
gene	O	O
expression	O	O
in	O	O
visceral	O	O
sensory	O	O
pathways	O	O
can	O	O
be	O	O
upregulated	O	O
by	O	O
chemical	O	O
irritation	O	O
of	O	O
afferent	O	O
receptors	O	O
in	O	O
the	O	O
urinary	O	O
tract	O	O
and/or	O	O
that	O	O
pathological	O	O
changes	O	O
in	O	O
the	O	O
urinary	O	O
tract	O	O
can	O	O
initiate	O	O
chemical	O	O
signals	O	O
that	O	O
alter	O	O
the	O	O
chemical	O	O
properties	O	O
of	O	O
visceral	O	O
afferent	O	O
neurons	O	O
.	O	O

Effects	O	O
of	O	O
a	O	O
new	O	O
calcium	B_Chemical	O
antagonist	O	O
,	O	O
CD-832	B_Chemical	O
,	O	O
on	O	O
isoproterenol-induced	O	O
myocardial	B_Disease	B_Disease
ischemia	I_Disease	I_Disease
in	O	O
dogs	O	O
with	O	O
partial	O	O
coronary	B_Disease	B_Disease
stenosis	I_Disease	I_Disease
.	O	O

Effects	O	O
of	O	O
CD-832	B_Chemical	O
on	O	O
isoproterenol	B_Chemical	O
(ISO)-induced	O	O
myocardial	B_Disease	B_Disease
ischemia	I_Disease	I_Disease
were	O	O
studied	O	O
in	O	O
dogs	O	O
with	O	O
partial	O	O
coronary	B_Disease	B_Disease
stenosis	I_Disease	I_Disease
of	O	O
the	O	O
left	O	O
circumflex	O	O
coronary	O	O
artery	O	O
and	O	O
findings	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
for	O	O
nifedipine	B_Chemical	O
or	O	O
diltiazem	B_Chemical	O
.	O	O

In	O	O
the	O	O
presence	O	O
of	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
stenosis	I_Disease	I_Disease
,	O	O
3-min	O	O
periods	O	O
of	O	O
intracoronary	O	O
ISO	B_Chemical	O
infusion	O	O
(	O	O
10	O	O
ng/kg/min	O	O
)	O	O
increased	O	O
heart	O	O
rate	O	O
and	O	O
maximal	O	O
rate	O	O
of	O	O
left	O	O
ventricular	O	O
pressure	O	O
rise	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
a	O	O
decrease	O	O
in	O	O
percentage	O	O
segmental	O	O
shortening	O	O
and	O	O
ST-segment	O	O
elevation	O	O
of	O	O
the	O	O
epicardial	O	O
electrocardiogram	O	O
.	O	O

After	O	O
the	O	O
control	O	O
ISO	B_Chemical	O
infusion	O	O
with	O	O
stenosis	B_Disease	O
was	O	O
performed	O	O
,	O	O
equihypotensive	O	O
doses	O	O
of	O	O
CD-832	B_Chemical	O
(	O	O
3	O	O
and	O	O
10	O	O
micrograms/kg/min	O	O
,	O	O
n	O	O
=	O	O
7	O	O
)	O	O
,	O	O
nifedipine	B_Chemical	O
(	O	O
1	O	O
and	O	O
3	O	O
micrograms/kg/min	O	O
,	O	O
n	O	O
=	O	O
9	O	O
)	O	O
or	O	O
diltiazem	B_Chemical	O
(	O	O
10	O	O
and	O	O
30	O	O
micrograms/kg/min	O	O
,	O	O
n	O	O
=	O	O
7	O	O
)	O	O
were	O	O
infused	O	O
5	O	O
min	O	O
before	O	O
and	O	O
during	O	O
the	O	O
second	O	O
and	O	O
third	O	O
ISO	B_Chemical	O
infusion	O	O
.	O	O

Both	O	O
CD-832	B_Chemical	O
and	O	O
diltiazem	B_Chemical	O
,	O	O
but	O	O
not	O	O
nifedipine	B_Chemical	O
,	O	O
significantly	O	O
reduced	O	O
the	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
induced	O	O
by	O	O
ISO	B_Chemical	O
infusion	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
nifedipine	B_Chemical	O
,	O	O
CD-832	B_Chemical	O
(	O	O
10	O	O
micrograms/kg/min	O	O
)	O	O
prevented	O	O
the	O	O
decrease	O	O
in	O	O
percentage	O	O
segmental	O	O
shortening	O	O
from	O	O
32	O	O
+	O	O
/-	O	O
12	O	O
%	O	O
to	O	O
115	O	O
+	O	O
/-	O	O
26	O	O
%	O	O
of	O	O
the	O	O
control	O	O
value	O	O
(	O	O
P	O	O
<	O	O
.01	O	O
)	O	O
and	O	O
ST-segment	O	O
elevation	O	O
from	O	O
5.6	O	O
+	O	O
/-	O	O
1.0	O	O
mV	O	O
to	O	O
1.6	O	O
+	O	O
/-	O	O
1.3	O	O
mV	O	O
(	O	O
P	O	O
<	O	O
.01	O	O
)	O	O
at	O	O
3	O	O
min	O	O
after	O	O
ISO	B_Chemical	O
infusion	O	O
with	O	O
stenosis	B_Disease	O
.	O	O

Diltiazem	B_Chemical	O
(	O	O
30	O	O
micrograms/kg/min	O	O
)	O	O
also	O	O
prevented	O	O
the	O	O
decrease	O	O
in	O	O
percentage	O	O
segmental	O	O
shortening	O	O
from	O	O
34	O	O
+	O	O
/-	O	O
14	O	O
%	O	O
to	O	O
63	O	O
+	O	O
/-	O	O
18	O	O
%	O	O
of	O	O
the	O	O
control	O	O
value	O	O
(	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
and	O	O
ST-segment	O	O
elevation	O	O
from	O	O
4.7	O	O
+	O	O
/-	O	O
0.7	O	O
mV	O	O
to	O	O
2.1	O	O
+	O	O
/-	O	O
0.7	O	O
mV	O	O
(	O	O
P	O	O
<	O	O
.01	O	O
)	O	O
at	O	O
3	O	O
min	O	O
after	O	O
ISO	B_Chemical	O
infusion	O	O
with	O	O
stenosis	B_Disease	O
.	O	O

These	O	O
data	O	O
show	O	O
that	O	O
CD-832	B_Chemical	O
improves	O	O
myocardial	B_Disease	B_Disease
ischemia	I_Disease	I_Disease
during	O	O
ISO	B_Chemical	O
infusion	O	O
with	O	O
stenosis	B_Disease	O
and	O	O
suggest	O	O
that	O	O
the	O	O
negative	O	O
chronotropic	O	O
property	O	O
of	O	O
CD-832	B_Chemical	O
plays	O	O
a	O	O
major	O	O
role	O	O
in	O	O
the	O	O
beneficial	O	O
effects	O	O
of	O	O
CD-832	B_Chemical	O
.	O	O

The	O	O
effect	O	O
of	O	O
recombinant	O	O
human	O	O
insulin-like	O	O
growth	O	O
factor-I	O	O
on	O	O
chronic	O	O
puromycin	B_Chemical	O
aminonucleoside	I_Chemical	O
nephropathy	B_Disease	O
in	O	O
rats	O	O
.	O	O

We	O	O
recently	O	O
demonstrated	O	O
that	O	O
recombinant	O	O
hGH	O	O
exacerbates	O	O
renal	O	O
functional	O	O
and	O	O
structural	O	O
injury	O	O
in	O	O
chronic	O	O
puromycin	B_Chemical	O
aminonucleoside	I_Chemical	O
(	O	O
PAN	B_Chemical	O
)	O	O
nephropathy	B_Disease	O
,	O	O
an	O	O
experimental	O	O
model	O	O
of	O	O
glomerular	B_Disease	B_Disease
disease	I_Disease	I_Disease
.	O	O

Therefore	O	O
,	O	O
we	O	O
examined	O	O
whether	O	O
recombinant	O	O
human	O	O
(	O	O
rh	O	O
)	O	O
IGF-I	O	O
is	O	O
a	O	O
safer	O	O
alternative	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
growth	B_Disease	B_Disease
failure	I_Disease	I_Disease
in	O	O
rats	O	O
with	O	O
chronic	O	O
PAN	B_Chemical	B_Disease
nephropathy	B_Disease	I_Disease
.	O	O

The	O	O
glomerulopathy	B_Disease	B_Disease
was	O	O
induced	O	O
by	O	O
seven	O	O
serial	O	O
injections	O	O
of	O	O
PAN	B_Chemical	O
over	O	O
12	O	O
wk	O	O
.	O	O

Experimental	O	O
animals	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
received	O	O
rhIGF-I	O	O
,	O	O
400	O	O
micrograms/d	O	O
,	O	O
whereas	O	O
control	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
received	O	O
the	O	O
vehicle	O	O
.	O	O

rhIGF-I	O	O
improved	O	O
weight	O	O
gain	O	O
by	O	O
14	O	O
%	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
,	O	O
without	O	O
altering	O	O
hematocrit	O	O
or	O	O
blood	O	O
pressure	O	O
in	O	O
rats	O	O
with	O	O
renal	B_Disease	B_Disease
disease	I_Disease	I_Disease
.	O	O

Urinary	O	O
protein	O	O
excretion	O	O
was	O	O
unaltered	O	O
by	O	O
rhIGF-I	O	O
treatment	O	O
in	O	O
rats	O	O
with	O	O
chronic	O	B_Disease
PAN	B_Chemical	I_Disease
nephropathy	B_Disease	I_Disease
.	O	O

After	O	O
12	O	O
wk	O	O
,	O	O
the	O	O
inulin	O	O
clearance	O	O
was	O	O
higher	O	O
in	O	O
rhIGF-I-treated	O	O
rats	O	O
,	O	O
0.48	O	O
+	O	O
/-	O	O
0.08	O	O
versus	O	O
0.24	O	O
+	O	O
/-	O	O
0.06	O	O
mL/min/100	O	O
g	O	O
of	O	O
body	O	O
weight	O	O
in	O	O
untreated	O	O
PAN	B_Chemical	O
nephropathy	B_Disease	O
animals	O	O
,	O	O
p	O	O
<	O	O
0.05	O	O
.	O	O

The	O	O
improvement	O	O
in	O	O
GFR	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
enhanced	O	O
glomerular	B_Disease	B_Disease
hypertrophy	I_Disease	I_Disease
or	O	O
increased	O	O
segmental	O	B_Disease
glomerulosclerosis	B_Disease	I_Disease
,	O	O
tubulointerstitial	B_Disease	O
injury	I_Disease	O
,	O	O
or	O	O
renal	O	O
cortical	O	O
malondialdehyde	B_Chemical	B_Chemical
content	O	O
.	O	O

In	O	O
rats	O	O
with	O	O
PAN	B_Chemical	O
nephropathy	B_Disease	O
,	O	O
administration	O	O
of	O	O
rhIGF-I	O	O
increased	O	O
IGF-I	O	O
and	O	O
GH	O	O
receptor	O	O
gene	O	O
expression	O	O
,	O	O
without	O	O
altering	O	O
the	O	O
steady	O	O
state	O	O
level	O	O
of	O	O
IGF-I	O	O
receptor	O	O
mRNA	O	O
.	O	O

In	O	O
normal	O	O
rats	O	O
with	O	O
intact	O	O
kidneys	O	O
,	O	O
rhIGF-I	O	O
administration	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
did	O	O
not	O	O
alter	O	O
weight	O	O
gain	O	O
,	O	O
blood	O	O
pressure	O	O
,	O	O
proteinuria	B_Disease	O
,	O	O
GFR	O	O
,	O	O
glomerular	O	O
planar	O	O
area	O	O
,	O	O
renal	O	O
cortical	O	O
malondialdehyde	B_Chemical	B_Chemical
content	O	O
,	O	O
or	O	O
glomerular	O	O
or	O	O
tubulointerstitial	B_Disease	O
damage	I_Disease	O
,	O	O
compared	O	O
with	O	O
untreated	O	O
animals	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
.	O	O

rhIGF-I	O	O
treatment	O	O
reduced	O	O
the	O	O
steady	O	O
state	O	O
renal	O	O
IGF-I	O	O
mRNA	O	O
level	O	O
but	O	O
did	O	O
not	O	O
modify	O	O
gene	O	O
expression	O	O
of	O	O
the	O	O
IGF-I	O	O
or	O	O
GH	O	O
receptors	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
:	O	O
1	O	O
)	O	O
administration	O	O
of	O	O
rhIGF-I	O	O
improves	O	O
growth	O	O
and	O	O
GFR	O	O
in	O	O
rats	O	O
with	O	O
chronic	O	O
PAN	B_Chemical	O
nephropathy	B_Disease	O
and	O	O
2	O	O
)	O	O
unlike	O	O
rhGH	O	O
,	O	O
long-term	O	O
use	O	O
of	O	O
rhIGF-I	O	O
does	O	O
not	O	O
worsen	O	O
renal	O	O
functional	O	O
and	O	O
structural	O	B_Disease
injury	O	I_Disease
in	O	O
this	O	O
disease	O	O
model	O	O
.	O	O

Nefiracetam	B_Chemical	B_Chemical
(	O	O
DM-9384	B_Chemical	O
)	O	O
reverses	O	O
apomorphine-induced	O	O
amnesia	B_Disease	O
of	O	O
a	O	O
passive	O	O
avoidance	O	O
response	O	O
:	O	O
delayed	O	O
emergence	O	O
of	O	O
the	O	O
memory	O	O
retention	O	O
effects	O	O
.	O	O

Nefiracetam	B_Chemical	B_Chemical
is	O	O
a	O	O
novel	O	O
pyrrolidone	B_Chemical	B_Chemical
derivative	O	O
which	O	O
attenuates	O	O
scopolamine-induced	O	O
learning	B_Disease	O
and	I_Disease	O
post-training	I_Disease	O
consolidation	I_Disease	O
deficits	I_Disease	O
.	O	O

Given	O	O
that	O	O
apomorphine	B_Chemical	O
inhibits	O	O
passive	O	O
avoidance	O	O
retention	O	O
when	O	O
given	O	O
during	O	O
training	O	O
or	O	O
in	O	O
a	O	O
defined	O	O
10	O	O
-	O	O
12h	O	O
post-training	O	O
period	O	O
,	O	O
we	O	O
evaluated	O	O
the	O	O
ability	O	O
of	O	O
nefiracetam	B_Chemical	B_Chemical
to	O	O
attenuate	O	O
amnesia	B_Disease	O
induced	O	O
by	O	O
dopaminergic	O	O
agonism	O	O
.	O	O

A	O	O
step-down	O	O
passive	O	O
avoidance	O	O
paradigm	O	O
was	O	O
employed	O	O
and	O	O
nefiracetam	B_Chemical	B_Chemical
(	O	O
3	O	O
mg/kg	O	O
)	O	O
and	O	O
apomorphine	B_Chemical	O
(	O	O
0.5	O	O
mg/kg	O	O
)	O	O
were	O	O
given	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
during	O	O
training	O	O
and	O	O
at	O	O
the	O	O
10	O	O
-	O	O
12h	O	O
post-training	O	O
period	O	O
of	O	O
consolidation	O	O
.	O	O

Co-administration	O	O
of	O	O
nefiracetam	B_Chemical	B_Chemical
and	O	O
apomorphine	B_Chemical	O
during	O	O
training	O	O
or	O	O
10h	O	O
thereafter	O	O
produced	O	O
no	O	O
significant	O	O
anti-amnesic	O	O
effect	O	O
.	O	O

However	O	O
,	O	O
administration	O	O
of	O	O
nefiracetam	B_Chemical	B_Chemical
during	O	O
training	O	O
completely	O	O
reversed	O	O
the	O	O
amnesia	B_Disease	O
induced	O	O
by	O	O
apomorphine	B_Chemical	O
at	O	O
the	O	O
10h	O	O
post-training	O	O
time	O	O
and	O	O
the	O	O
converse	O	O
was	O	O
also	O	O
true	O	O
.	O	O

These	O	O
effects	O	O
were	O	O
not	O	O
mediated	O	O
by	O	O
a	O	O
dopaminergic	O	O
mechanism	O	O
as	O	O
nefiracetam	B_Chemical	B_Chemical
,	O	O
at	O	O
millimolar	O	O
concentrations	O	O
,	O	O
failed	O	O
to	O	O
displace	O	O
either	O	O
[3H]SCH	O	O
23390	O	O
or	O	O
[3H]spiperone	O	B_Chemical
binding	O	O
from	O	O
D1	O	O
or	O	O
D2	O	O
dopamine	B_Chemical	O
receptor	O	O
subtypes	O	O
,	O	O
respectively	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
nefiracetam	B_Chemical	B_Chemical
augments	O	O
molecular	O	O
processes	O	O
in	O	O
the	O	O
early	O	O
stages	O	O
of	O	O
events	O	O
which	O	O
ultimately	O	O
lead	O	O
to	O	O
consolidation	O	O
of	O	O
memory	O	O
.	O	O

Phenytoin	B_Chemical	O
encephalopathy	B_Disease	O
as	O	O
probable	O	O
idiosyncratic	O	O
reaction	O	O
:	O	O
case	O	O
report	O	O
.	O	O

A	O	O
case	O	O
of	O	O
phenytoin	B_Chemical	O
(	O	O
DPH	B_Chemical	O
)	O	O
encephalopathy	B_Disease	O
with	O	O
increasing	O	O
seizures	B_Disease	O
and	O	O
EEG	O	O
and	O	O
mental	O	O
changes	O	O
is	O	O
described	O	O
.	O	O

Despite	O	O
adequate	O	O
oral	O	O
dosage	O	O
of	O	O
DPH	B_Chemical	O
(	O	O
5	O	O
mg/kg/daily	O	O
)	O	O
the	O	O
plasma	O	O
level	O	O
was	O	O
very	O	O
low	O	O
(	O	O
2.8	O	O
microgramg/ml	O	O
)	O	O
.	O	O

The	O	O
encephalopathy	B_Disease	O
was	O	O
probably	O	O
an	O	O
idiosyncratic	O	O
and	O	O
not	O	O
toxic	O	O
or	O	O
allergic	O	B_Disease
reaction	O	I_Disease
.	O	O

In	O	O
fact	O	O
the	O	O
concentration	O	O
of	O	O
free	O	O
DPH	B_Chemical	O
was	O	O
normal	O	O
,	O	O
the	O	O
patient	O	O
presented	O	O
a	O	O
retarded	O	O
morbilliform	O	O
rash	B_Disease	O
during	O	O
DPH	B_Chemical	O
treatment	O	O
,	O	O
the	O	O
protidogram	O	O
was	O	O
normal	O	O
,	O	O
and	O	O
an	O	O
intradermic	O	O
DPH	B_Chemical	O
injection	O	O
had	O	O
no	O	O
local	O	O
effect	O	O
.	O	O

The	O	O
authors	O	O
conclude	O	O
that	O	O
in	O	O
a	O	O
patient	O	O
starting	O	O
DPH	B_Chemical	O
treatment	O	O
an	O	O
unexpected	O	O
increase	O	O
in	O	O
seizures	B_Disease	O
,	O	O
with	O	O
EEG	O	O
and	O	O
mental	O	O
changes	O	O
occurring	O	O
simultaneously	O	O
,	O	O
should	O	O
alert	O	O
the	O	O
physician	O	O
to	O	O
the	O	O
possible	O	O
need	O	O
for	O	O
eliminating	O	O
DPH	B_Chemical	O
from	O	O
the	O	O
therapeutic	O	O
regimen	O	O
,	O	O
even	O	O
if	O	O
plasma	O	O
concentrations	O	O
are	O	O
low	O	O
.	O	O

Prevention	O	O
and	O	O
treatment	O	O
of	O	O
endometrial	B_Disease	B_Disease
disease	I_Disease	I_Disease
in	O	O
climacteric	O	O
women	O	O
receiving	O	O
oestrogen	B_Chemical	O
therapy	O	O
.	O	O

The	O	O
treatment	O	O
regimens	O	O
are	O	O
described	O	O
in	O	O
74	O	O
patients	O	O
with	O	O
endometrial	B_Disease	B_Disease
disease	I_Disease	I_Disease
among	O	O
850	O	O
climacteric	O	O
women	O	O
receiving	O	O
oestrogen	B_Chemical	O
therapy	O	O
.	O	O

Cystic	O	B_Disease
hyperplasia	B_Disease	I_Disease
was	O	O
associated	O	O
with	O	O
unopposed	O	O
oestrogen	B_Chemical	O
therapy	O	O
without	O	O
progestagen	B_Chemical	O
.	O	O

Two	O	O
courses	O	O
of	O	O
21	O	O
days	O	O
of	O	O
5	O	O
mg	O	O
norethisterone	B_Chemical	B_Chemical
daily	O	O
caused	O	O
reversion	O	O
to	O	O
normal	O	O
in	O	O
all	O	O
57	O	O
cases	O	O
of	O	O
cystic	O	B_Disease
hyperplasia	B_Disease	I_Disease
and	O	O
6	O	O
of	O	O
the	O	O
8	O	O
cases	O	O
of	O	O
atypical	O	O
hyperplasia	B_Disease	O
.	O	O

4	O	O
cases	O	O
of	O	O
endometrial	B_Disease	O
carcinoma	I_Disease	O
referred	O	O
from	O	O
elsewhere	O	O
demonstrated	O	O
the	O	O
problems	O	O
of	O	O
inappropriate	O	O
and	O	O
unsupervised	O	O
unopposed	O	O
oestrogen	B_Chemical	O
therapy	O	O
and	O	O
the	O	O
difficulty	O	O
in	O	O
distinguishing	O	O
severe	O	O
hyperplasia	B_Disease	O
from	O	O
malignancy	B_Disease	O
.	O	O

Cyclical	O	O
low-dose	O	O
oestrogen	B_Chemical	O
therapy	O	O
with	O	O
7	O	O
-	O	O
-13	O	O
days	O	O
of	O	O
progestagen	B_Chemical	O
does	O	O
not	O	O
seem	O	O
to	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
endometrial	B_Disease	B_Disease
hyperplasia	I_Disease	I_Disease
or	O	O
carcinoma	B_Disease	O
.	O	O

Effects	O	O
of	O	O
exercise	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
isoproterenol-induced	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
.	O	O

The	O	O
effect	O	O
of	O	O
exercise	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
isoproterenol-induced	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
was	O	O
studied	O	O
in	O	O
male	O	O
rats	O	O
.	O	O

Ninety-three	O	O
rats	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
.	O	O

The	O	O
exercise-isoproterenol	O	O
(	O	O
E-1	O	O
)	O	O
and	O	O
exercise	O	O
control	O	O
(	O	O
EC	O	O
)	O	O
groups	O	O
exercised	O	O
daily	O	O
for	O	O
thirty	O	O
days	O	O
on	O	O
a	O	O
treadmill	O	O
at	O	O
1	O	O
mph	O	O
,	O	O
2	O	O
%	O	O
grade	O	O
while	O	O
animals	O	O
of	O	O
the	O	O
sedentary-isoproterenol	O	O
(	O	O
S-I	O	O
)	O	O
group	O	O
remained	O	O
sedentary	O	O
.	O	O

Eight	O	O
animals	O	O
were	O	O
assigned	O	O
to	O	O
the	O	O
sedentary	O	O
control	O	O
(	O	O
SC	O	O
)	O	O
group	O	O
which	O	O
remained	O	O
sedentary	O	O
throughout	O	O
the	O	O
experimental	O	O
period	O	O
.	O	O

Forty-eight	O	O
hours	O	O
after	O	O
the	O	O
final	O	O
exercise	O	O
period	O	O
,	O	O
S-I	O	O
and	O	O
E-I	O	O
animals	O	O
received	O	O
a	O	O
single	O	O
subcutaneous	O	O
injection	O	O
of	O	O
isoproterenol	B_Chemical	O
(	O	O
250	O	O
mg/kg	O	O
body	O	O
weight	O	O
)	O	O
.	O	O

Animals	O	O
of	O	O
the	O	O
S-I	O	O
group	O	O
exhibited	O	O
significantly	O	O
(	O	O
Pp	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
greater	O	O
mortality	O	O
from	O	O
the	O	O
effects	O	O
of	O	O
isoproterenol	B_Chemical	O
than	O	O
animals	O	O
of	O	O
the	O	O
E-I	O	O
group	O	O
.	O	O

Serum	O	O
CPK	O	O
activity	O	O
for	O	O
E-I	O	O
animals	O	O
was	O	O
significantly	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
greater	O	O
than	O	O
for	O	O
animals	O	O
in	O	O
the	O	O
S-I	O	O
and	O	O
EC	O	O
groups	O	O
twenty	O	O
hours	O	O
following	O	O
isoproterenol	B_Chemical	O
injection	O	O
.	O	O

No	O	O
statistically	O	O
significant	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
the	O	O
two	O	O
isoproterenol	B_Chemical	O
treated	O	O
groups	O	O
for	O	O
severity	O	O
of	O	O
the	O	O
induced	O	O
lesions	O	O
,	O	O
changes	O	O
in	O	O
heart	O	O
weight	O	O
,	O	O
or	O	O
heart	O	O
weight	O	O
to	O	O
body	O	O
weight	O	O
ratios	O	O
.	O	O

The	O	O
results	O	O
indicated	O	O
that	O	O
exercise	O	O
reduced	O	O
the	O	O
mortality	O	O
associated	O	O
with	O	O
the	O	O
effects	O	O
of	O	O
large	O	O
dosages	O	O
of	O	O
isoproterenol	B_Chemical	O
but	O	O
had	O	O
little	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
the	O	O
infarction	B_Disease	O
.	O	O

Human	O	O
corticotropin-releasing	O	O
hormone	O	O
and	O	O
thyrotropin-releasing	O	O
hormone	O	O
modulate	O	O
the	O	O
hypercapnic	B_Disease	O
ventilatory	O	O
response	O	O
in	O	O
humans	O	O
.	O	O

Human	O	O
corticotropin-releasing	O	O
hormone	O	O
(	O	O
hCRH	O	O
)	O	O
and	O	O
thyrotropin-releasing	O	O
hormone	O	O
(	O	O
TRH	O	O
)	O	O
are	O	O
known	O	O
to	O	O
stimulate	O	O
ventilation	O	O
after	O	O
i.v	O	O
.	O	O

administration	O	O
in	O	O
humans	O	O
.	O	O

In	O	O
a	O	O
placebo-controlled	O	O
,	O	O
single-blind	O	O
study	O	O
we	O	O
aimed	O	O
to	O	O
clarify	O	O
if	O	O
both	O	O
peptides	O	O
act	O	O
by	O	O
altering	O	O
central	O	O
chemosensitivity	O	O
.	O	O

Two	O	O
subsequent	O	O
CO2-rebreathing	O	O
tests	O	O
were	O	O
performed	O	O
in	O	O
healthy	O	O
young	O	O
volunteers	O	O
.	O	O

During	O	O
the	O	O
first	O	O
test	O	O
0.9	O	O
%	O	O
NaCl	B_Chemical	O
was	O	O
given	O	O
i.v	O	O
.	O	O
;	O	O
during	O	O
the	O	O
second	O	O
test	O	O
200	O	O
micrograms	O	O
of	O	O
hCRH	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
or	O	O
400	O	O
micrograms	O	O
of	O	O
TRH	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
was	O	O
administered	O	O
i.v	O	O
.	O	O

Nine	O	O
subjects	O	O
received	O	O
0.9	O	O
%	O	O
NaCl	B_Chemical	O
i.v	O	O
.	O	O
during	O	O
both	O	O
rebreathing	O	O
manoeuvres	O	O
.	O	O

The	O	O
CO2-response	O	O
curves	O	O
for	O	O
the	O	O
two	O	O
tests	O	O
were	O	O
compared	O	O
within	O	O
the	O	O
same	O	O
subject	O	O
.	O	O

In	O	O
the	O	O
hCRH	O	O
group	O	O
a	O	O
marked	O	O
parallel	O	O
shift	O	O
of	O	O
the	O	O
CO2-response	O	O
curve	O	O
to	O	O
the	O	O
left	O	O
was	O	O
observed	O	O
after	O	O
hCRH	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

The	O	O
same	O	O
effect	O	O
occurred	O	O
following	O	O
TRH	O	O
but	O	O
was	O	O
less	O	O
striking	O	O
(	O	O
P	O	O
=	O	O
0.05	O	O
)	O	O
.	O	O

hCRH	O	O
and	O	O
TRH	O	O
caused	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
CO2	B_Chemical	O
threshold	O	O
.	O	O

The	O	O
CO2-response	O	O
curves	O	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
nearly	O	O
identical	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
an	O	O
additive	O	O
effect	O	O
of	O	O
both	O	O
releasing	O	O
hormones	O	O
on	O	O
the	O	O
hypercapnic	B_Disease	O
ventilatory	O	O
response	O	O
in	O	O
humans	O	O
,	O	O
presumably	O	O
independent	O	O
of	O	O
central	O	O
chemosensitivity	O	O
.	O	O

Lamivudine	B_Chemical	O
is	O	O
effective	O	O
in	O	O
suppressing	O	O
hepatitis	B_Disease	O
B	I_Disease	O
virus	O	O
DNA	O	O
in	O	O
Chinese	O	O
hepatitis	B_Chemical	O
B	I_Chemical	O
surface	I_Chemical	O
antigen	I_Chemical	O
carriers	O	O
:	O	O
a	O	O
placebo-controlled	O	O
trial	O	O
.	O	O

Lamivudine	B_Chemical	O
is	O	O
a	O	O
novel	O	O
2',3'-dideoxy	B_Chemical	O
cytosine	I_Chemical	O
analogue	O	O
that	O	O
has	O	O
potent	O	O
inhibitory	O	O
effects	O	O
on	O	O
hepatitis	B_Disease	O
B	I_Disease	O
virus	O	O
replication	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
single-blind	O	O
,	O	O
placebo-controlled	O	O
study	O	O
to	O	O
assess	O	O
its	O	O
effectiveness	O	O
and	O	O
safety	O	O
in	O	O
Chinese	O	O
hepatitis	B_Chemical	O
B	I_Chemical	O
surface	I_Chemical	O
antigen	I_Chemical	O
(	O	O
HBsAg	B_Chemical	O
)	O	O
carriers	O	O
.	O	O

Forty-two	O	O
Chinese	O	O
HBsAg	B_Chemical	O
carriers	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
placebo	O	O
(	O	O
6	O	O
patients	O	O
)	O	O
or	O	O
lamivudine	B_Chemical	O
orally	O	O
in	O	O
dosages	O	O
of	O	O
25	O	O
mg	O	O
,	O	O
100	O	O
mg	O	O
,	O	O
or	O	O
300	O	O
mg	O	O
daily	O	O
(	O	O
12	O	O
patients	O	O
for	O	O
each	O	O
dosage	O	O
)	O	O
.	O	O

The	O	O
drug	O	O
was	O	O
given	O	O
for	O	O
4	O	O
weeks	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
closely	O	O
monitored	O	O
clinically	O	O
,	O	O
biochemically	O	O
,	O	O
and	O	O
serologically	O	O
up	O	O
to	O	O
4	O	O
weeks	O	O
after	O	O
drug	O	O
treatment	O	O
.	O	O

All	O	O
36	O	O
patients	O	O
receiving	O	O
lamivudine	B_Chemical	O
had	O	O
a	O	O
decrease	O	O
in	O	O
hepatitis	B_Disease	O
B	I_Disease	O
virus	O	O
(	O	O
HBV	O	O
)	O	O
DNA	O	O
values	O	O
of	O	O
>	O	O
90	O	O
%	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
compared	O	O
with	O	O
placebo	O	O
)	O	O
.	O	O

Although	O	O
25	O	O
mg	O	O
of	O	O
lamivudine	B_Chemical	O
was	O	O
slightly	O	O
less	O	O
effective	O	O
than	O	O
100	O	O
mg	O	O
(	O	O
P	O	O
=	O	O
.011	O	O
)	O	O
and	O	O
300	O	O
mg	O	O
(	O	O
P	O	O
=	O	O
.005	O	O
)	O	O
,	O	O
it	O	O
still	O	O
induced	O	O
94	O	O
%	O	O
suppression	O	O
of	O	O
HBV	O	O
DNA	O	O
after	O	O
the	O	O
fourth	O	O
week	O	O
of	O	O
therapy	O	O
.	O	O

HBV	O	O
DNA	O	O
values	O	O
returned	O	O
to	O	O
pretreatment	O	O
levels	O	O
within	O	O
4	O	O
weeks	O	O
of	O	O
cessation	O	O
of	O	O
therapy	O	O
.	O	O

There	O	O
was	O	O
no	O	O
change	O	O
in	O	O
the	O	O
hepatitis	B_Disease	O
B	I_Disease	O
e	O	O
antigen	O	O
status	O	O
or	O	O
in	O	O
aminotransferase	O	O
levels	O	O
.	O	O

No	O	O
serious	O	O
adverse	O	O
events	O	O
were	O	O
observed	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
a	O	O
4-week	O	O
course	O	O
of	O	O
lamivudine	B_Chemical	O
was	O	O
safe	O	O
and	O	O
effective	O	O
in	O	O
suppression	O	O
of	O	O
HBV	O	O
DNA	O	O
in	O	O
Chinese	O	O
HBsAg	B_Chemical	O
carriers	O	O
.	O	O

The	O	O
suppression	O	O
was	O	O
>	O	O
90	O	O
%	O	O
but	O	O
reversible	O	O
.	O	O

Studies	O	O
with	O	O
long-term	O	O
lamivudine	B_Chemical	O
administration	O	O
should	O	O
be	O	O
performed	O	O
to	O	O
determine	O	O
if	O	O
prolonged	O	O
suppression	O	O
of	O	O
HBV	O	O
DNA	O	O
can	O	O
be	O	O
achieved	O	O
.	O	O

Population-based	O	O
study	O	O
of	O	O
risk	O	O
of	O	O
venous	B_Disease	B_Disease
thromboembolism	I_Disease	I_Disease
associated	O	O
with	O	O
various	O	O
oral	B_Chemical	B_Chemical
contraceptives	I_Chemical	I_Chemical
.	O	O

BACKGROUND	O	O
:	O	O
Four	O	O
studies	O	O
published	O	O
since	O	O
December	O	O
,	O	O
1995	O	O
,	O	O
reported	O	O
that	O	O
the	O	O
incidence	O	O
of	O	O
venous	B_Disease	B_Disease
thromboembolism	I_Disease	I_Disease
(	O	O
VTE	B_Disease	O
)	O	O
was	O	O
higher	O	O
in	O	O
women	O	O
who	O	O
used	O	O
oral	B_Chemical	B_Chemical
contraceptives	I_Chemical	I_Chemical
(	O	O
OCs	B_Chemical	O
)	O	O
containing	O	O
the	O	O
third-generation	O	O
progestagens	B_Chemical	B_Chemical
gestodene	B_Chemical	I_Chemical
or	O	O
desogestrel	B_Chemical	B_Chemical
than	O	O
in	O	O
users	O	O
of	O	O
OCs	B_Chemical	O
containing	O	O
second-generation	O	O
progestagens	B_Chemical	O
.	O	O

However	O	O
,	O	O
confounding	O	O
and	O	O
bias	O	O
in	O	O
the	O	O
design	O	O
of	O	O
these	O	O
studies	O	O
may	O	O
have	O	O
affected	O	O
the	O	O
findings	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
our	O	O
study	O	O
was	O	O
to	O	O
re-examine	O	O
the	O	O
association	O	O
between	O	O
risk	O	O
of	O	O
VTE	B_Disease	O
and	O	O
OC	B_Chemical	O
use	O	O
with	O	O
a	O	O
different	O	O
study	O	O
design	O	O
and	O	O
analysis	O	O
to	O	O
avoid	O	O
some	O	O
of	O	O
the	O	O
bias	O	O
and	O	O
confounding	O	O
of	O	O
the	O	O
earlier	O	O
studies	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
used	O	O
computer	O	O
records	O	O
of	O	O
patients	O	O
from	O	O
143	O	O
general	O	O
practices	O	O
in	O	O
the	O	O
UK	O	O
.	O	O

The	O	O
study	O	O
was	O	O
based	O	O
on	O	O
the	O	O
medical	O	O
records	O	O
of	O	O
about	O	O
540,000	O	O
women	O	O
born	O	O
between	O	O
1941	O	O
and	O	O
1981	O	O
.	O	O

All	O	O
women	O	O
who	O	O
had	O	O
a	O	O
recorded	O	O
diagnosis	O	O
of	O	O
deep-vein	B_Disease	O
thrombosis	I_Disease	O
,	O	O
venous	B_Disease	B_Disease
thrombosis	I_Disease	I_Disease
not	O	O
otherwise	O	O
specified	O	O
,	O	O
or	O	O
pulmonary	O	B_Disease
embolus	O	I_Disease
during	O	O
the	O	O
study	O	O
period	O	O
,	O	O
and	O	O
who	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
an	O	O
anticoagulant	O	O
were	O	O
identified	O	O
as	O	O
potential	O	O
cases	O	O
of	O	O
VTE	B_Disease	O
.	O	O

We	O	O
did	O	O
a	O	O
cohort	O	O
analysis	O	O
to	O	O
estimate	O	O
and	O	O
compare	O	O
incidence	O	O
of	O	O
VTE	B_Disease	O
in	O	O
users	O	O
of	O	O
the	O	O
main	O	O
OC	B_Chemical	O
preparations	O	O
,	O	O
and	O	O
a	O	O
nested	O	O
case-control	O	O
study	O	O
to	O	O
calculate	O	O
the	O	O
odds	O	O
ratios	O	O
of	O	O
VTE	B_Disease	O
associated	O	O
with	O	O
use	O	O
of	O	O
different	O	O
types	O	O
of	O	O
OC	B_Chemical	O
,	O	O
after	O	O
adjustment	O	O
for	O	O
potential	O	O
confounding	O	O
factors	O	O
.	O	O

In	O	O
the	O	O
case-control	O	O
study	O	O
,	O	O
we	O	O
matched	O	O
cases	O	O
to	O	O
controls	O	O
by	O	O
exact	O	O
year	O	O
of	O	O
birth	O	O
,	O	O
practice	O	O
,	O	O
and	O	O
current	O	O
use	O	O
of	O	O
OCs	B_Chemical	O
.	O	O

We	O	O
used	O	O
a	O	O
multiple	O	O
logistic	O	O
regression	O	O
model	O	O
that	O	O
included	O	O
body-mass	O	O
index	O	O
,	O	O
number	O	O
of	O	O
cycles	O	O
,	O	O
change	O	O
in	O	O
type	O	O
of	O	O
OC	B_Chemical	O
prescribed	O	O
within	O	O
3	O	O
months	O	O
of	O	O
the	O	O
event	O	O
,	O	O
previous	O	O
pregnancy	O	O
,	O	O
and	O	O
concurrent	O	O
disease	O	O
.	O	O

FINDINGS	O	O
:	O	O
85	O	O
women	O	O
met	O	O
the	O	O
inclusion	O	O
criteria	O	O
for	O	O
VTE	B_Disease	O
,	O	O
two	O	O
of	O	O
whom	O	O
were	O	O
users	O	O
of	O	O
progestagen-only	O	O
OCs	B_Chemical	O
.	O	O

Of	O	O
the	O	O
83	O	O
cases	O	O
of	O	O
VTE	B_Disease	O
associated	O	O
with	O	O
use	O	O
of	O	O
combined	O	O
OCs	B_Chemical	O
,	O	O
43	O	O
were	O	O
recorded	O	O
as	O	O
deep-vein	B_Disease	O
thrombosis	I_Disease	O
,	O	O
35	O	O
as	O	O
pulmonary	O	B_Disease
thrombosis	B_Disease	I_Disease
,	O	O
and	O	O
five	O	O
as	O	O
venous	B_Disease	B_Disease
thrombosis	I_Disease	I_Disease
not	O	O
otherwise	O	O
specified	O	O
.	O	O

The	O	O
crude	O	O
rate	O	O
of	O	O
VTE	B_Disease	O
per	O	O
10,000	O	O
woman-years	O	O
was	O	O
4.10	O	O
in	O	O
current	O	O
users	O	O
of	O	O
any	O	O
OC	B_Chemical	O
,	O	O
3.10	O	O
in	O	O
users	O	O
of	O	O
second-generation	O	O
OCs	B_Chemical	O
,	O	O
and	O	O
4.96	O	O
in	O	O
users	O	O
of	O	O
third-generation	O	O
preparations	O	O
.	O	O

After	O	O
adjustment	O	O
for	O	O
age	O	O
,	O	O
the	O	O
rate	O	O
ratio	O	O
of	O	O
VTE	B_Disease	O
in	O	O
users	O	O
of	O	O
third-generation	O	O
relative	O	O
to	O	O
second-generation	O	O
OCs	B_Chemical	O
was	O	O
1.68	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
1.04	O	O
-	O	O
2.75	O	O
)	O	O
.	O	O

Logistic	O	O
regression	O	O
showed	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
risk	O	O
of	O	O
VTE	B_Disease	O
between	O	O
users	O	O
of	O	O
third-generation	O	O
and	O	O
second-generation	O	O
OCs	B_Chemical	O
.	O	O

Among	O	O
users	O	O
of	O	O
third-generation	O	O
progestagens	B_Chemical	O
,	O	O
the	O	O
risk	O	O
of	O	O
VTE	B_Disease	O
was	O	O
higher	O	O
in	O	O
users	O	O
of	O	O
desogestrel	B_Chemical	B_Chemical
with	O	O
20	O	O
g	O	O
ethinyloestradiol	B_Chemical	B_Chemical
than	O	O
in	O	O
users	O	O
of	O	O
gestodene	B_Chemical	B_Chemical
or	O	O
desogestrel	B_Chemical	B_Chemical
with	O	O
30	O	O
g	O	O
ethinyloestradiol	B_Chemical	B_Chemical
.	O	O

With	O	O
all	O	O
second-generation	O	O
OCs	B_Chemical	O
as	O	O
the	O	O
reference	O	O
,	O	O
the	O	O
odds	O	O
ratios	O	O
for	O	O
VTE	B_Disease	O
were	O	O
3.49	O	O
(	O	O
1.21	O	O
-	O	O
10.12	O	O
)	O	O
for	O	O
desogestrel	B_Chemical	B_Chemical
plus	O	O
20	O	O
g	O	O
ethinyloestradiol	B_Chemical	B_Chemical
and	O	O
1.18	O	O
(	O	O
0.66	O	O
-	O	O
2.17	O	O
)	O	O
for	O	O
the	O	O
other	O	O
third-generation	O	O
progestagens	B_Chemical	O
.	O	O

INTERPRETATION	O	O
:	O	O
The	O	O
previously	O	O
reported	O	O
increase	O	O
in	O	O
odds	O	O
ratio	O	O
associated	O	O
with	O	O
third-generation	O	O
OCs	B_Chemical	O
when	O	O
compared	O	O
with	O	O
second-generation	O	O
products	O	O
is	O	O
likely	O	O
to	O	O
have	O	O
been	O	O
the	O	O
result	O	O
of	O	O
residual	O	O
confounding	O	O
by	O	O
age	O	O
.	O	O

The	O	O
increased	O	O
odds	O	O
ratio	O	O
associated	O	O
with	O	O
products	O	O
containing	O	O
20	O	O
micrograms	O	O
ethinyloestradiol	B_Chemical	B_Chemical
and	O	O
desogestrel	B_Chemical	B_Chemical
compared	O	O
with	O	O
the	O	O
30	O	O
micrograms	O	O
product	O	O
is	O	O
biologically	O	O
implausible	O	O
,	O	O
and	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
the	O	O
result	O	O
of	O	O
preferential	O	O
prescribing	O	O
and	O	O
,	O	O
thus	O	O
,	O	O
confounding	O	O
.	O	O

MK-801	B_Chemical	O
augments	O	O
pilocarpine-induced	O	O
electrographic	O	O
seizure	B_Disease	O
but	O	O
protects	O	O
against	O	O
brain	B_Disease	B_Disease
damage	I_Disease	I_Disease
in	O	O
rats.1	O	O
.	O	O

The	O	O
authors	O	O
examined	O	O
the	O	O
anticonvulsant	O	O
effects	O	O
of	O	O
MK-801	B_Chemical	O
on	O	O
the	O	O
pilocarpine-induced	O	O
seizure	B_Disease	O
model	O	O
.	O	O

Intraperitoneal	O	O
injection	O	O
of	O	O
pilocarpine	B_Chemical	O
(	O	O
400	O	O
mg/kg	O	O
)	O	O
induced	O	O
tonic	B_Disease	O
and	I_Disease	O
clonic	I_Disease	O
seizure	I_Disease	O
.	O	O

Scopolamine	B_Chemical	O
(	O	O
10	O	O
mg/kg	O	O
)	O	O
and	O	O
pentobarbital	B_Chemical	O
(	O	O
5	O	O
mg/kg	O	O
)	O	O
prevented	O	O
development	O	O
of	O	O
pilocarpine-induced	O	O
behavioral	O	O
seizure	B_Disease	O
but	O	O
MK-801	B_Chemical	O
(	O	O
0.5	O	O
mg/kg	O	O
)	O	O
did	O	O
not	O	O
.	O	O

2	O	O
.	O	O
An	O	O
electrical	O	B_Disease
seizure	B_Disease	I_Disease
measured	O	O
with	O	O
hippocampal	O	O
EEG	O	O
appeared	O	O
in	O	O
the	O	O
pilocarpine-treated	O	O
group	O	O
.	O	O

Scopolamine	B_Chemical	O
and	O	O
pentobarbital	B_Chemical	O
blocked	O	O
the	O	O
pilocarpine-induced	O	O
electrographic	O	O
seizure	B_Disease	O
,	O	O
MK-801	B_Chemical	O
treatment	O	O
augmented	O	O
the	O	O
electrographic	O	O
seizure	B_Disease	O
induced	O	O
by	O	O
pilocarpine	B_Chemical	O
.	O	O

3	O	O
.	O	O
Brain	B_Disease	B_Disease
damage	I_Disease	I_Disease
was	O	O
assessed	O	O
by	O	O
examining	O	O
the	O	O
hippocampus	O	O
microscopically	O	O
.	O	O

Pilocarpine	B_Chemical	O
produced	O	O
neuronal	B_Disease	B_Disease
death	I_Disease	I_Disease
in	O	O
the	O	O
hippocampus	O	O
,	O	O
which	O	O
showed	O	O
pyknotic	O	O
changes	O	O
.	O	O

Pentobarbital	B_Chemical	O
,	O	O
scopolamine	B_Chemical	O
and	O	O
MK-801	B_Chemical	O
protected	O	O
the	O	O
brain	B_Disease	B_Disease
damage	I_Disease	I_Disease
by	O	O
pilocarpine	B_Chemical	O
,	O	O
though	O	O
in	O	O
the	O	O
MK-801-treated	O	O
group	O	O
,	O	O
the	O	O
pyramidal	O	O
cells	O	O
of	O	O
hippocampus	O	O
appeared	O	O
darker	O	O
than	O	O
normal	O	O
.	O	O

In	O	O
all	O	O
treatments	O	O
,	O	O
granule	O	O
cells	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
were	O	O
not	O	O
affected	O	O
.	O	O

4	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
status	B_Disease	O
epilepticus	I_Disease	O
induced	O	O
by	O	O
pilocarpine	B_Chemical	O
is	O	O
initiated	O	O
by	O	O
cholinergic	O	O
overstimulation	O	O
and	O	O
propagated	O	O
by	O	O
glutamatergic	O	O
transmission	O	O
,	O	O
the	O	O
elevation	O	O
of	O	O
which	O	O
may	O	O
cause	O	O
brain	B_Disease	B_Disease
damage	I_Disease	I_Disease
through	O	O
an	O	O
excitatory	O	O
NMDA	B_Chemical	O
receptor-mediated	O	O
mechanism	O	O
.	O	O

Paclitaxel	B_Chemical	B_Chemical
,	O	O
5-fluorouracil	B_Chemical	B_Chemical
,	O	O
and	O	O
folinic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
in	O	O
metastatic	O	O
breast	B_Disease	B_Disease
cancer	I_Disease	I_Disease
:	O	O
BRE-26	O	O
,	O	O
a	O	O
phase	O	O
II	O	O
trial.5-Fluorouracil	O	B_Chemical
plus	O	O
folinic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
and	O	O
paclitaxel	B_Chemical	B_Chemical
(	O	O
Taxol	B_Chemical	B_Chemical
;	O	O
Bristol-Myers	O	O
Squibb	O	O
Company	O	O
,	O	O
Princeton	O	O
,	O	O
NJ	O	O
)	O	O
are	O	O
effective	O	O
salvage	O	O
therapies	O	O
for	O	O
metastatic	O	O
breast	B_Disease	B_Disease
cancer	I_Disease	I_Disease
patients	O	O
.	O	O

Paclitaxel	B_Chemical	B_Chemical
and	O	O
5-fluorouracil	B_Chemical	B_Chemical
have	O	O
additive	O	O
cytotoxicity	B_Disease	O
in	O	O
MCF-7	O	O
cell	O	O
lines	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
phase	O	O
II	O	O
trial	O	O
of	O	O
paclitaxel	B_Chemical	B_Chemical
175	O	O
mg/m2	O	O
over	O	O
3	O	O
hours	O	O
on	O	O
day	O	O
I	O	O
followed	O	O
by	O	O
folinic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
300	O	O
mg	O	O
over	O	O
1	O	O
hour	O	O
before	O	O
5-fluorouracil	B_Chemical	B_Chemical
350	O	O
mg/m2	O	O
on	O	O
days	O	O
1	O	O
to	O	O
3	O	O
every	O	O
28	O	O
days	O	O
(	O	O
TFL	O	O
)	O	O
in	O	O
women	O	O
with	O	O
metastatic	O	O
breast	B_Disease	B_Disease
cancer	I_Disease	I_Disease
.	O	O

Analysis	O	O
is	O	O
reported	O	O
on	O	O
37	O	O
patients	O	O
with	O	O
a	O	O
minimum	O	O
of	O	O
6	O	O
months	O	O
follow-up	O	O
who	O	O
received	O	O
a	O	O
total	O	O
of	O	O
192	O	O
cycles	O	O
of	O	O
TFL	O	O
:	O	O
nine	O	O
cycles	O	O
(	O	O
5	O	O
%	O	O
)	O	O
were	O	O
associated	O	O
with	O	O
grade	O	O
3/4	O	O
neutropenia	B_Disease	O
requiring	O	O
hospitalization	O	O
;	O	O
seven	O	O
(	O	O
4	O	O
%	O	O
)	O	O
cycles	O	O
in	O	O
two	O	O
patients	O	O
required	O	O
granulocyte	B_Chemical	O
colony-stimulating	I_Chemical	O
factor	I_Chemical	O
due	O	O
to	O	O
neutropenia	B_Disease	O
;	O	O
no	O	O
patient	O	O
required	O	O
platelet	O	O
transfusions	O	O
.	O	O

Grade	O	O
3/4	O	O
nonhematologic	O	O
toxicities	B_Disease	O
were	O	O
uncommon	O	O
.	O	O

Among	O	O
the	O	O
34	O	O
patients	O	O
evaluable	O	O
for	O	O
response	O	O
,	O	O
there	O	O
were	O	O
three	O	O
complete	O	O
responses	O	O
(	O	O
9	O	O
%	O	O
)	O	O
and	O	O
18	O	O
partial	O	O
responses	O	O
(	O	O
53	O	O
%	O	O
)	O	O
for	O	O
an	O	O
overall	O	O
response	O	O
rate	O	O
of	O	O
62	O	O
%	O	O
.	O	O

Of	O	O
the	O	O
19	O	O
evaluable	O	O
patients	O	O
with	O	O
prior	O	O
doxorubicin	B_Chemical	O
exposure	O	O
,	O	O
11	O	O
(	O	O
58	O	O
%	O	O
)	O	O
responded	O	O
compared	O	O
with	O	O
nine	O	O
of	O	O
15	O	O
(	O	O
60	O	O
%	O	O
)	O	O
without	O	O
prior	O	O
doxorubicin	B_Chemical	O
.	O	O

Plasma	O	O
paclitaxel	B_Chemical	B_Chemical
concentrations	O	O
were	O	O
measured	O	O
at	O	O
the	O	O
completion	O	O
of	O	O
paclitaxel	B_Chemical	B_Chemical
infusion	O	O
and	O	O
at	O	O
24	O	O
hours	O	O
in	O	O
19	O	O
patients	O	O
.	O	O

TFL	O	B_Chemical
is	O	O
an	O	O
active	O	O
,	O	O
well-tolerated	O	O
regimen	O	O
in	O	O
metastatic	O	O
breast	B_Disease	B_Disease
cancer	I_Disease	I_Disease
.	O	O

Efficacy	O	O
and	O	O
proarrhythmia	B_Disease	O
with	O	O
the	O	O
use	O	O
of	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	O
for	O	O
sustained	O	O
ventricular	B_Disease	O
tachyarrhythmias	I_Disease	O
.	O	O

This	O	O
study	O	O
prospectively	O	O
evaluated	O	O
the	O	O
clinical	O	O
efficacy	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
torsades	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
,	O	O
and	O	O
the	O	O
presumable	O	O
risk	O	O
factors	O	O
for	O	O
torsades	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
in	O	O
patients	O	O
treated	O	O
with	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	B_Chemical
for	O	O
sustained	O	O
ventricular	B_Disease	B_Disease
tachyarrhythmias	I_Disease	I_Disease
.	O	O

Eighty-one	O	O
consecutive	O	O
patients	O	O
(	O	O
54	O	O
with	O	O
coronary	B_Disease	B_Disease
artery	I_Disease	I_Disease
disease	I_Disease	I_Disease
,	O	O
and	O	O
20	O	O
with	O	O
dilated	B_Disease	B_Disease
cardiomyopathy	I_Disease	I_Disease
)	O	O
with	O	O
inducible	O	O
sustained	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
or	O	O
ventricular	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
received	O	O
oral	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	O
to	O	O
prevent	O	O
induction	O	O
of	O	O
the	O	O
ventricular	B_Disease	B_Disease
tachyarrhythmia	I_Disease	I_Disease
.	O	O

During	O	O
oral	O	O
loading	O	O
with	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	O
,	O	O
continuous	O	O
electrocardiographic	O	O
(	O	O
ECG	O	O
)	O	O
monitoring	O	O
was	O	O
performed	O	O
.	O	O

Those	O	O
patients	O	O
in	O	O
whom	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	B_Chemical
prevented	O	O
induction	O	O
of	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
or	O	O
ventricular	B_Disease	B_Disease
fibrillation	I_Disease	I_Disease
were	O	O
discharged	O	O
with	O	O
the	O	O
drug	O	O
and	O	O
followed	O	O
up	O	O
on	O	O
an	O	O
outpatient	O	O
basis	O	O
for	O	O
21	O	O
+	O	O
/-	O	O
18	O	O
months	O	O
.	O	O

Induction	O	O
of	O	O
the	O	O
ventricular	B_Disease	O
tachyarrhythmia	I_Disease	O
was	O	O
prevented	O	O
by	O	O
oral	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	B_Chemical
in	O	O
35	O	O
(	O	O
43	O	O
%	O	O
)	O	O
patients	O	O
;	O	O
the	O	O
ventricular	B_Disease	B_Disease
tachyarrhythmia	I_Disease	I_Disease
remained	O	O
inducible	O	O
in	O	O
40	O	O
(	O	O
49	O	O
%	O	O
)	O	O
patients	O	O
;	O	O
and	O	O
two	O	O
(	O	O
2.5	O	O
%	O	O
)	O	O
patients	O	O
did	O	O
not	O	O
tolerate	O	O
even	O	O
40	O	O
mg	O	O
of	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	B_Chemical
once	O	O
daily	O	O
.	O	O

Four	O	O
(	O	O
5	O	O
%	O	O
)	O	O
patients	O	O
had	O	O
from	O	O
torsades	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
during	O	O
the	O	O
initial	O	O
oral	O	O
treatment	O	O
with	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	O
.	O	O

Neither	O	O
ECG	O	O
[	O	O
sinus-cycle	O	O
length	O	O
(	O	O
SCL	O	O
)	O	O
,	O	O
QT	O	O
or	O	O
QTc	O	O
interval	O	O
,	O	O
or	O	O
U	O	O
wave	O	O
]	O	O
nor	O	O
clinical	O	O
parameters	O	O
identified	O	O
patients	O	O
at	O	O
risk	O	O
for	O	O
torsades	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
.	O	O

However	O	O
,	O	O
the	O	O
oral	O	O
dose	O	O
of	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
patients	O	O
with	O	O
torsades	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
(	O	O
200	O	O
+	O	O
/-	O	O
46	O	O
vs.	O	O
328	O	O
+	O	O
/-	O	O
53	O	O
mg/day	O	O
;	O	O
p	O	O
=	O	O
0.0017	O	O
)	O	O
.	O	O

Risk	O	O
factors	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
torsades	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
were	O	O
the	O	O
appearance	O	O
of	O	O
an	O	O
U	O	O
wave	O	O
(	O	O
p	O	O
=	O	O
0.049	O	O
)	O	O
,	O	O
female	O	O
gender	O	O
(	O	O
p	O	O
=	O	O
0.015	O	O
)	O	O
,	O	O
and	O	O
significant	O	O
dose-corrected	O	O
changes	O	O
of	O	O
SCL	O	O
,	O	O
QT	O	O
interval	O	O
,	O	O
and	O	O
QTc	O	O
interval	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

During	O	O
follow-up	O	O
,	O	O
seven	O	O
(	O	O
20	O	O
%	O	O
)	O	O
patients	O	O
had	O	O
a	O	O
nonfatal	O	O
ventricular	B_Disease	B_Disease
tachycardia	I_Disease	I_Disease
recurrence	O	O
,	O	O
and	O	O
two	O	O
(	O	O
6	O	O
%	O	O
)	O	O
patients	O	O
died	O	O
suddenly	O	O
.	O	O

One	O	O
female	O	O
patient	O	O
with	O	O
stable	O	O
cardiac	B_Disease	B_Disease
disease	I_Disease	I_Disease
had	O	O
recurrent	O	O
torsades	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
after	O	O
2	O	O
years	O	O
of	O	O
successful	O	O
treatment	O	O
with	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	O
.	O	O

Torsades	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
occurred	O	O
early	O	O
during	O	O
treatment	O	O
even	O	O
with	O	O
low	O	O
doses	O	O
of	O	O
oral	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	B_Chemical
.	O	O

Pronounced	O	O
changes	O	O
in	O	O
the	O	O
surface	O	O
ECG	O	O
(	O	O
cycle	O	O
length	O	O
,	O	O
QT	O	O
,	O	O
and	O	O
QTc	O	O
)	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
dose	O	O
of	O	O
oral	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	B_Chemical
might	O	O
identify	O	O
a	O	O
subgroup	O	O
of	O	O
patients	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
for	O	O
torsades	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
.	O	O

Other	O	O
ECG	O	O
parameters	O	O
before	O	O
the	O	O
application	O	O
of	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	O
did	O	O
not	O	O
identify	O	O
patients	O	O
at	O	O
increased	O	O
risk	O	O
for	O	O
torsades	B_Disease	O
de	I_Disease	O
pointes	I_Disease	O
.	O	O

Recurrence	O	O
rates	O	O
of	O	O
ventricular	B_Disease	O
tachyarrhythmias	I_Disease	O
are	O	O
high	O	O
despite	O	O
complete	O	O
suppression	O	O
of	O	O
the	O	O
arrhythmia	B_Disease	O
during	O	O
programmed	O	O
stimulation	O	O
.	O	O

Therefore	O	O
programmed	O	O
electrical	O	O
stimulation	O	O
in	O	O
the	O	O
case	O	O
of	O	O
d	B_Chemical	O
,	I_Chemical	O
l-sotalol	I_Chemical	O
seems	O	O
to	O	O
be	O	O
of	O	O
limited	O	O
prognostic	O	O
value	O	O
.	O	O

Chronic	O	O
hyperprolactinemia	B_Disease	B_Disease
and	O	O
changes	O	O
in	O	O
dopamine	B_Chemical	O
neurons	O	O
.	O	O

The	O	O
tuberoinfundibular	O	O
dopaminergic	O	O
(	O	O
TIDA	O	O
)	O	O
system	O	O
is	O	O
known	O	O
to	O	O
inhibit	O	O
prolactin	O	O
(	O	O
PRL	O	O
)	O	O
secretion	O	O
.	O	O

In	O	O
young	O	O
animals	O	O
this	O	O
system	O	O
responds	O	O
to	O	O
acute	O	O
elevations	O	O
in	O	O
serum	O	O
PRL	O	O
by	O	O
increasing	O	O
its	O	O
activity	O	O
.	O	O

However	O	O
,	O	O
this	O	O
responsiveness	O	O
is	O	O
lost	O	O
in	O	O
aging	O	O
rats	O	O
with	O	O
chronically	O	O
high	O	O
serum	O	O
PRL	O	O
levels	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
induce	O	O
hyperprolactinemia	B_Disease	B_Disease
in	O	O
rats	O	O
for	O	O
extended	O	O
periods	O	O
of	O	O
time	O	O
and	O	O
examine	O	O
its	O	O
effects	O	O
on	O	O
dopaminergic	O	O
systems	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

Hyperprolactinemia	B_Disease	B_Disease
was	O	O
induced	O	O
by	O	O
treatment	O	O
with	O	O
haloperidol	B_Chemical	O
,	O	O
a	O	O
dopamine	B_Chemical	O
receptor	O	O
antagonist	O	O
,	O	O
and	O	O
Palkovits	O	O
'	O	O
microdissection	O	O
technique	O	O
in	O	O
combination	O	O
with	O	O
high-performance	O	O
liquid	O	O
chromatography	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
neurotransmitter	O	O
concentrations	O	O
in	O	O
several	O	O
areas	O	O
of	O	O
the	O	O
brain	O	O
.	O	O

After	O	O
6	O	O
months	O	O
of	O	O
hyperprolactinemia	B_Disease	B_Disease
,	O	O
dopamine	B_Chemical	O
(	O	O
DA	B_Chemical	O
)	O	O
concentrations	O	O
in	O	O
the	O	O
median	O	O
eminence	O	O
(	O	O
ME	O	O
)	O	O
increased	O	O
by	O	O
84	O	O
%	O	O
over	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Nine	O	O
months	O	O
of	O	O
hyperprolactinemia	B_Disease	B_Disease
produced	O	O
a	O	O
50	O	O
%	O	O
increase	O	O
in	O	O
DA	B_Chemical	O
concentrations	O	O
in	O	O
the	O	O
ME	O	O
over	O	O
the	O	O
control	O	O
group	O	O
.	O	O

However	O	O
,	O	O
DA	B_Chemical	O
response	O	O
was	O	O
lost	O	O
if	O	O
a	O	O
9-month	O	O
long	O	O
haloperidol-induced	O	O
hyperprolactinemia	B_Disease	B_Disease
was	O	O
followed	O	O
by	O	O
a	O	O
1	O	O
1/2	O	O
month-long	O	O
extremely	O	O
high	O	O
increase	O	O
in	O	O
serum	O	O
PRL	O	O
levels	O	O
produced	O	O
by	O	O
implantation	O	O
of	O	O
MMQ	O	O
cells	O	O
under	O	O
the	O	O
kidney	O	O
capsule	O	O
.	O	O

There	O	O
was	O	O
no	O	O
change	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
DA	B_Chemical	O
,	O	O
norepinephrine	B_Chemical	O
(	O	O
NE	B_Chemical	O
)	O	O
,	O	O
serotonin	B_Chemical	O
(	O	O
5-HT	B_Chemical	O
)	O	O
,	O	O
or	O	O
their	O	O
metabolites	O	O
in	O	O
the	O	O
arcuate	O	O
nucleus	O	O
(	O	O
AN	O	O
)	O	O
,	O	O
medial	O	O
preoptic	O	O
area	O	O
(	O	O
MPA	O	O
)	O	O
,	O	O
caudate	O	O
putamen	O	O
(	O	O
CP	O	O
)	O	O
,	O	O
substantia	O	O
nigra	O	O
(	O	O
SN	O	O
)	O	O
,	O	O
and	O	O
zona	O	O
incerta	O	O
(	O	O
ZI	O	O
)	O	O
,	O	O
except	O	O
for	O	O
a	O	O
decrease	O	O
in	O	O
5-hydroxyindoleacetic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(	O	O
5-HIAA	B_Chemical	O
)	O	O
in	O	O
the	O	O
AN	O	O
after	O	O
6-months	O	O
of	O	O
hyperprolactinemia	B_Disease	B_Disease
and	O	O
an	O	O
increase	O	O
in	O	O
DA	B_Chemical	O
concentrations	O	O
in	O	O
the	O	O
AN	O	O
after	O	O
9-months	O	O
of	O	O
hyperprolactinemia	B_Disease	B_Disease
.	O	O

These	O	O
results	O	O
demonstrate	O	O
that	O	O
hyperprolactinemia	B_Disease	B_Disease
specifically	O	O
affects	O	O
TIDA	O	O
neurons	O	O
and	O	O
these	O	O
effects	O	O
vary	O	O
,	O	O
depending	O	O
on	O	O
the	O	O
duration	O	O
and	O	O
intensity	O	O
of	O	O
hyperprolactinemia	B_Disease	B_Disease
.	O	O

The	O	O
age-related	O	O
decrease	O	O
in	O	O
hypothalamic	O	O
dopamine	B_Chemical	O
function	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
increases	O	O
in	O	O
PRL	O	O
secretion	O	O
.	O	O

Treatment-related	O	O
disseminated	O	O
necrotizing	O	O
leukoencephalopathy	O	B_Disease
with	O	O
characteristic	O	O
contrast	O	O
enhancement	O	O
of	O	O
the	O	O
white	O	O
matter	O	O
.	O	O

This	O	O
report	O	O
describes	O	O
unique	O	O
contrast	O	O
enhancement	O	O
of	O	O
the	O	O
white	O	O
matter	O	O
on	O	O
T1-weighted	O	O
magnetic	O	O
resonance	O	O
images	O	O
of	O	O
two	O	O
patients	O	O
with	O	O
disseminated	O	O
necrotizing	O	O
leukoencephalopathy	B_Disease	B_Disease
,	O	O
which	O	O
developed	O	O
from	O	O
acute	B_Disease	B_Disease
lymphoblastic	I_Disease	I_Disease
leukemia	I_Disease	I_Disease
treated	O	O
with	O	O
high-dose	O	B_Chemical
methotrexate	B_Chemical	I_Chemical
.	O	O

In	O	O
both	O	O
patients	O	O
,	O	O
the	O	O
enhancement	O	O
was	O	O
more	O	O
pronounced	O	O
near	O	O
the	O	O
base	O	O
of	O	O
the	O	O
brain	O	O
than	O	O
at	O	O
the	O	O
vertex	O	O
.	O	O

Necropsy	O	O
of	O	O
the	O	O
first	O	O
case	O	O
revealed	O	O
loss	B_Disease	O
of	I_Disease	O
myelination	I_Disease	O
and	O	O
necrosis	B_Disease	O
of	O	O
the	O	O
white	O	O
matter	O	O
.	O	O

Possible	O	O
mechanisms	O	O
causing	O	O
such	O	O
a	O	O
leukoencephalopathy	B_Disease	B_Disease
are	O	O
discussed	O	O
.	O	O

Thrombotic	B_Disease	B_Disease
complications	O	I_Disease
in	O	O
acute	B_Disease	B_Disease
promyelocytic	I_Disease	I_Disease
leukemia	I_Disease	I_Disease
during	O	O
all-trans-retinoic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
therapy	O	O
.	O	O

A	O	O
case	O	O
of	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
,	O	O
due	O	O
to	O	O
occlusion	B_Disease	O
of	I_Disease	O
renal	I_Disease	O
vessels	I_Disease	O
in	O	O
a	O	O
patient	O	O
with	O	O
acute	B_Disease	B_Disease
promyelocytic	I_Disease	I_Disease
leukemia	I_Disease	I_Disease
(	O	O
APL	B_Disease	O
)	O	O
treated	O	O
with	O	O
all-trans-retinoic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
(	O	O
ATRA	B_Chemical	O
)	O	O
and	O	O
tranexamic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
has	O	O
been	O	O
described	O	O
recently	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
in	O	O
an	O	O
APL	B_Disease	O
patient	O	O
treated	O	O
with	O	O
ATRA	B_Chemical	O
alone	O	O
.	O	O

This	O	O
case	O	O
further	O	O
supports	O	O
the	O	O
concern	O	O
about	O	O
thromboembolic	B_Disease	B_Disease
complications	O	I_Disease
associated	O	O
with	O	O
ATRA	B_Chemical	O
therapy	O	O
in	O	O
APL	B_Disease	O
patients	O	O
.	O	O

The	O	O
patients	O	O
,	O	O
a	O	O
43-year-old	O	O
man	O	O
,	O	O
presented	O	O
all	O	O
the	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
APL	B_Disease	O
and	O	O
was	O	O
included	O	O
in	O	O
a	O	O
treatment	O	O
protocol	O	O
with	O	O
ATRA	B_Chemical	O
.	O	O

After	O	O
10	O	O
days	O	O
of	O	O
treatment	O	O
,	O	O
he	O	O
developed	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
that	O	O
was	O	O
completely	O	O
reversible	O	O
after	O	O
complete	O	O
remission	O	O
of	O	O
APL	B_Disease	O
was	O	O
achieved	O	O
and	O	O
therapy	O	O
discontinued	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
ATRA	B_Chemical	O
is	O	O
a	O	O
valid	O	O
therapeutic	O	O
choice	O	O
for	O	O
patients	O	O
with	O	O
APL	B_Disease	B_Chemical
,	O	O
although	O	O
the	O	O
procoagulant	O	O
tendency	O	O
is	O	O
not	O	O
completely	O	O
corrected	O	O
.	O	O

Thrombotic	B_Disease	B_Disease
events	O	I_Disease
,	O	O
however	O	O
,	O	O
could	O	O
be	O	O
avoided	O	O
by	O	O
using	O	O
low-dose	O	O
heparin	B_Chemical	O
.	O	O

Pupillary	O	O
changes	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
stimulant-induced	O	O
mania	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

A	O	O
30-year-old	O	O
cocaine-dependent	O	O
man	O	O
who	O	O
was	O	O
a	O	O
subject	O	O
in	O	O
a	O	O
study	O	O
evaluating	O	O
the	O	O
anticraving	O	O
efficacy	O	O
of	O	O
the	O	O
stimulant	O	O
medication	O	O
diethylpropion	B_Chemical	B_Chemical
(	O	O
DEP	B_Chemical	O
)	O	O
became	O	O
manic	B_Disease	O
during	O	O
his	O	O
second	O	O
week	O	O
on	O	O
the	O	O
study	O	O
drug	O	O
.	O	O

Pupillometric	O	O
changes	O	O
while	O	O
on	O	O
DEP	B_Chemical	O
,	O	O
especially	O	O
changes	O	O
in	O	O
the	O	O
total	O	O
power	O	O
of	O	O
pupillary	B_Disease	O
oscillation	I_Disease	O
,	O	O
were	O	O
dramatically	O	O
different	O	O
than	O	O
those	O	O
observed	O	O
in	O	O
the	O	O
eight	O	O
other	O	O
study	O	O
subjects	O	O
who	O	O
did	O	O
not	O	O
become	O	O
manic	B_Disease	O
.	O	O

The	O	O
large	O	O
changes	O	O
in	O	O
total	O	O
power	O	O
of	O	O
pupillary	B_Disease	O
oscillation	I_Disease	O
occurred	O	O
a	O	O
few	O	O
days	O	O
before	O	O
the	O	O
patient	O	O
became	O	O
fully	O	O
manic	B_Disease	O
.	O	O

Such	O	O
medication-associated	O	O
changes	O	O
in	O	O
the	O	O
total	O	O
power	O	O
of	O	O
pupillary	B_Disease	O
oscillation	I_Disease	O
might	O	O
be	O	O
of	O	O
utility	O	O
in	O	O
identifying	O	O
persons	O	O
at	O	O
risk	O	O
for	O	O
manic-like	O	O
adverse	O	O
effects	O	O
during	O	O
the	O	O
medical	O	O
use	O	O
of	O	O
psychomotor	O	O
stimulants	O	O
or	O	O
sympathomimetic	O	O
agents	O	O
.	O	O

Fetal	O	O
risks	O	O
due	O	O
to	O	O
warfarin	O	O
therapy	O	O
during	O	O
pregnancy	O	O
.	O	O

Two	O	O
mothers	O	O
with	O	O
heart	O	B_Disease
valve	O	I_Disease
prosthesis	O	I_Disease
were	O	O
treated	O	O
with	O	O
warfarin	B_Chemical	O
during	O	O
pregnancy	O	O
.	O	O

In	O	O
the	O	O
first	O	O
case	O	O
a	O	O
caesarean	O	O
section	O	O
was	O	O
done	O	O
one	O	O
week	O	O
after	O	O
replacement	O	O
of	O	O
warfarin	B_Chemical	O
with	O	O
heparin	B_Chemical	O
.	O	O

The	O	O
baby	O	O
died	O	O
of	O	O
cerebral	B_Disease	O
and	I_Disease	O
pulmonary	B_Disease	B_Disease
hemorrhage	B_Disease	I_Disease
.	O	O

The	O	O
second	O	O
mother	O	O
had	O	O
a	O	O
male	O	O
infant	O	O
by	O	O
caesarean	O	O
section	O	O
.	O	O

The	O	O
baby	O	O
showed	O	O
warfarin-induced	O	O
embryopathy	B_Disease	O
with	O	O
nasal	B_Disease	O
hypoplasia	I_Disease	O
and	O	O
stippled	B_Disease	O
epiphyses	I_Disease	O
(	O	O
chondrodysplasia	B_Disease	O
punctata	I_Disease	O
)	O	O
.	O	O

Nasal	B_Disease	O
hypoplasia	I_Disease	O
with	O	O
or	O	O
without	O	O
stippled	B_Disease	O
epiphyses	I_Disease	O
has	O	O
now	O	O
been	O	O
reported	O	O
in	O	O
11	O	O
infants	O	O
born	O	O
to	O	O
mothers	O	O
treated	O	O
with	O	O
warfarin	B_Chemical	O
during	O	O
the	O	O
first	O	O
trimester	O	O
,	O	O
and	O	O
a	O	O
causal	O	O
association	O	O
is	O	O
probable	O	O
.	O	O

In	O	O
view	O	O
of	O	O
the	O	O
risks	O	O
to	O	O
both	O	O
mother	O	O
and	O	O
fetus	O	O
in	O	O
women	O	O
with	O	O
prosthetic	O	O
cardiac	O	O
valves	O	O
it	O	O
is	O	O
recommended	O	O
that	O	O
therapeutic	O	O
abortion	O	O
be	O	O
advised	O	O
as	O	O
the	O	O
first	O	O
alternative	O	O
.	O	O

The	O	O
negative	O	O
mucosal	O	O
potential	O	O
:	O	O
separating	O	O
central	O	O
and	O	O
peripheral	O	O
effects	O	O
of	O	O
NSAIDs	O	O
in	O	O
man	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
We	O	O
wanted	O	O
to	O	O
test	O	O
whether	O	O
assessment	O	O
of	O	O
both	O	O
a	O	O
central	O	O
pain-related	O	O
signal	O	O
(	O	O
chemo-somatosensory	O	O
evoked	O	O
potential	O	O
,	O	O
CSSEP	O	O
)	O	O
and	O	O
a	O	O
concomitantly	O	O
recorded	O	O
peripheral	O	O
signal	O	O
(	O	O
negative	O	O
mucosal	O	O
potential	O	O
,	O	O
NMP	O	O
)	O	O
allows	O	O
for	O	O
separation	O	O
of	O	O
central	O	O
and	O	O
peripheral	O	O
effects	O	O
of	O	O
NSAIDs	O	O
.	O	O

For	O	O
this	O	O
purpose	O	O
,	O	O
experimental	O	O
conditions	O	O
were	O	O
created	O	O
in	O	O
which	O	O
NSAIDs	O	O
had	O	O
previously	O	O
been	O	O
observed	O	O
to	O	O
produce	O	O
effects	O	O
on	O	O
phasic	O	O
and	O	O
tonic	O	O
pain	B_Disease	O
by	O	O
either	O	O
central	O	O
or	O	O
peripheral	O	O
mechanisms	O	O
.	O	O

METHODS	O	O
:	O	O
According	O	O
to	O	O
a	O	O
double-blind	O	O
,	O	O
randomised	O	O
,	O	O
controlled	O	O
,	O	O
threefold	O	O
cross-over	O	O
design	O	O
,	O	O
18	O	O
healthy	O	O
subjects	O	O
(	O	O
11	O	O
males	O	O
,	O	O
7	O	O
females	O	O
;	O	O
mean	O	O
age	O	O
26	O	O
years	O	O
)	O	O
received	O	O
either	O	O
placebo	O	O
,	O	O
400	O	O
mg	O	O
ibuprofen	B_Chemical	O
,	O	O
or	O	O
800	O	O
mg	O	O
ibuprofen	B_Chemical	O
.	O	O

Phasic	O	O
pain	B_Disease	O
was	O	O
applied	O	O
by	O	O
means	O	O
of	O	O
short	O	O
pulses	O	O
of	O	O
CO2	B_Chemical	O
to	O	O
the	O	O
nasal	O	O
mucosa	O	O
(	O	O
stimulus	O	O
duration	O	O
500	O	O
ms	O	O
,	O	O
interval	O	O
approximately	O	O
60	O	O
s	O	O
)	O	O
,	O	O
and	O	O
tonic	O	O
pain	B_Disease	O
was	O	O
induced	O	O
in	O	O
the	O	O
nasal	O	O
cavity	O	O
by	O	O
means	O	O
of	O	O
dry	O	O
air	O	O
of	O	O
controlled	O	O
temperature	O	O
,	O	O
humidity	O	O
and	O	O
flow	O	O
rate	O	O
(	O	O
22	O	O
degrees	O	O
C	O	O
,	O	O
0	O	O
%	O	O
relative	O	O
humidity	O	O
,	O	O
145	O	O
ml.s-1	O	O
)	O	O
.	O	O

Both	O	O
CSSEPs	O	O
as	O	O
central	O	O
and	O	O
NMPs	O	O
as	O	O
peripheral	O	O
correlates	O	O
of	O	O
pain	B_Disease	O
were	O	O
obtained	O	O
in	O	O
response	O	O
to	O	O
the	O	O
CO2	B_Chemical	O
stimuli	O	O
.	O	O

Additionally	O	O
,	O	O
the	O	O
subjects	O	O
rated	O	O
the	O	O
intensity	O	O
of	O	O
both	O	O
phasic	O	O
and	O	O
tonic	O	O
pain	B_Disease	O
by	O	O
means	O	O
of	O	O
visual	O	O
analogue	O	O
scales	O	O
.	O	O

RESULTS	O	O
:	O	O
As	O	O
described	O	O
earlier	O	O
,	O	O
administration	O	O
of	O	O
ibuprofen	B_Chemical	O
was	O	O
followed	O	O
by	O	O
a	O	O
decrease	O	O
in	O	O
tonic	O	O
pain	B_Disease	O
but-relative	O	O
to	O	O
placebo-an	O	O
increase	O	O
in	O	O
correlates	O	O
of	O	O
phasic	O	O
pain	B_Disease	O
,	O	O
indicating	O	O
a	O	O
specific	O	O
effect	O	O
of	O	O
ibuprofen	B_Chemical	O
on	O	O
the	O	O
interaction	O	O
between	O	O
the	O	O
pain	B_Disease	O
stimuli	O	O
under	O	O
these	O	O
special	O	O
experimental	O	O
conditions	O	O
.	O	O

Based	O	O
on	O	O
the	O	O
similar	O	O
behaviour	O	O
of	O	O
CSSEP	O	O
and	O	O
NMP	O	O
,	O	O
it	O	O
was	O	O
concluded	O	O
that	O	O
the	O	O
pharmacological	O	O
process	O	O
underlying	O	O
this	O	O
phenomenon	O	O
was	O	O
localised	O	O
in	O	O
the	O	O
periphery	O	O
.	O	O

By	O	O
means	O	O
of	O	O
the	O	O
simultaneous	O	O
recording	O	O
of	O	O
interrelated	O	O
peripheral	O	O
and	O	O
central	O	O
electrophysiologic	O	O
correlates	O	O
of	O	O
nociception	O	O
,	O	O
it	O	O
was	O	O
possible	O	O
to	O	O
separate	O	O
central	O	O
and	O	O
peripheral	O	O
effects	O	O
of	O	O
an	O	O
NSAID	O	O
.	O	O

The	O	O
major	O	O
advantage	O	O
of	O	O
this	O	O
pain	B_Disease	O
model	O	O
is	O	O
the	O	O
possibility	O	O
of	O	O
obtaining	O	O
peripheral	O	O
pain-related	O	O
activity	O	O
directly	O	O
using	O	O
a	O	O
non-invasive	O	O
technique	O	O
in	O	O
humans	O	O
.	O	O

Effect	O	O
of	O	O
D-Glucarates	B_Chemical	O
on	O	O
basic	O	O
antibiotic-induced	O	O
renal	B_Disease	B_Disease
damage	I_Disease	I_Disease
in	O	O
rats	O	O
.	O	O

Dehydrated	B_Disease	O
rats	O	O
regularly	O	O
develop	O	O
acute	B_Disease	B_Disease
renal	I_Disease	I_Disease
failure	I_Disease	I_Disease
following	O	O
single	O	O
injection	O	O
of	O	O
aminoglycoside	B_Chemical	B_Chemical
antibiotics	O	O
combined	O	O
with	O	O
dextran	O	B_Chemical
or	O	O
of	O	O
antibiotics	O	O
only	O	O
.	O	O

Oral	O	O
administration	O	O
of	O	O
2,5-di-O-acetyl-D-glucaro-1,4	B_Chemical	B_Chemical
-	I_Chemical	I_Chemical
6,3-dilactone	I_Chemical	I_Chemical
protected	O	O
rats	O	O
against	O	O
renal	B_Disease	B_Disease
failure	I_Disease	I_Disease
induced	O	O
by	O	O
kanamycin-dextran	O	B_Chemical
.	O	O

The	O	O
protective	O	O
effect	O	O
was	O	O
prevalent	O	O
among	O	O
D-glucarates	B_Chemical	O
,	O	O
and	O	O
also	O	O
to	O	O
other	O	O
saccharic	B_Chemical	B_Chemical
acid	I_Chemical	I_Chemical
,	O	O
hexauronic	B_Chemical	B_Chemical
acids	I_Chemical	I_Chemical
and	O	O
hexaaldonic	B_Chemical	B_Chemical
acids	I_Chemical	I_Chemical
,	O	O
although	O	O
to	O	O
a	O	O
lesser	O	O
degree	O	O
,	O	O
but	O	O
not	O	O
to	O	O
a	O	O
hexaaldose	O	B_Chemical
,	O	O
sugar	B_Chemical	O
alcohols	I_Chemical	O
,	O	O
substances	O	O
inthe	O	O
TCA	B_Chemical	O
cycle	O	O
and	O	O
other	O	O
acidic	O	O
compounds	O	O
.	O	O

D-Glucarates	B_Chemical	O
were	O	O
effective	O	O
against	O	O
renal	B_Disease	B_Disease
damage	I_Disease	I_Disease
induced	O	O
by	O	O
peptide	O	O
antibiotics	O	O
as	O	O
well	O	O
as	O	O
various	O	O
aminoglycoside	B_Chemical	O
antibitocis	O	O
.	O	O

Dose-responses	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
protective	O	O
effect	O	O
of	O	O
D-Glucarates	B_Chemical	B_Chemical
.	O	O

With	O	O
a	O	O
D-glucarate	B_Chemical	B_Chemical
of	O	O
a	O	O
fixed	O	O
size	O	O
of	O	O
dose	O	O
,	O	O
approximately	O	O
the	O	O
same	O	O
degree	O	O
of	O	O
protection	O	O
was	O	O
obtained	O	O
against	O	O
renal	B_Disease	B_Disease
damages	I_Disease	I_Disease
induced	O	O
by	O	O
different	O	O
basic	O	O
antibiotics	O	O
despite	O	O
large	O	O
disparities	O	O
in	O	O
administration	O	O
doses	O	O
of	O	O
different	O	O
antibiotics	O	O
.	O	O

D-Glucarates	B_Chemical	O
had	O	O
the	O	O
ability	O	O
to	O	O
prevent	O	O
renal	B_Disease	B_Disease
damage	I_Disease	I_Disease
but	O	O
not	O	O
to	O	O
cure	O	O
it	O	O
.	O	O

Rats	O	O
excreted	O	O
acidic	O	O
urine	O	O
when	O	O
they	O	O
were	O	O
spared	O	O
from	O	O
renal	B_Disease	B_Disease
lesions	I_Disease	I_Disease
by	O	O
monosaccharides	B_Chemical	O
.	O	O

The	O	O
reduction	O	O
effect	O	O
of	O	O
D-glucarates	B_Chemical	O
against	O	O
nephrotoxicity	B_Disease	B_Disease
of	O	O
basic	O	O
antibiotics	O	O
was	O	O
discussed	O	O
.	O	O

Acute	O	O
severe	O	O
depression	B_Disease	O
following	O	O
peri-operative	O	O
ondansetron	B_Chemical	B_Chemical
.	O	O

A	O	O
41-year-old	O	O
woman	O	O
with	O	O
a	O	O
strong	O	O
history	O	O
of	O	O
postoperative	B_Disease	O
nausea	I_Disease	O
and	I_Disease	O
vomiting	I_Disease	O
presented	O	O
for	O	O
abdominal	O	O
hysterectomy	O	O
3	O	O
months	O	O
after	O	O
a	O	O
previous	O	O
anaesthetic	O	O
where	O	O
ondansetron	B_Chemical	B_Chemical
prophylaxis	O	O
had	O	O
been	O	O
used	O	O
.	O	O

She	O	O
had	O	O
developed	O	O
a	O	O
severe	O	O
acute	O	O
major	B_Disease	B_Disease
depression	I_Disease	I_Disease
disorder	I_Disease	I_Disease
almost	O	O
immediately	O	O
thereafter	O	O
,	O	O
possibly	O	O
related	O	O
to	O	O
the	O	O
use	O	O
of	O	O
a	O	O
serotonin	B_Chemical	O
antagonist	O	O
.	O	O

Nine	O	O
years	O	O
before	O	O
she	O	O
had	O	O
experienced	O	O
a	O	O
self-limited	O	O
puerperal	O	O
depressive	B_Disease	O
episode	I_Disease	O
.	O	O

Anaesthesia	O	O
with	O	O
a	O	O
propofol	B_Chemical	B_Chemical
infusion	O	O
and	O	O
avoidance	O	O
of	O	O
serotonin	B_Chemical	O
antagonists	O	O
provided	O	O
a	O	O
nausea-free	O	O
postoperative	O	O
course	O	O
without	O	O
exacerbation	O	O
of	O	O
the	O	O
depression	B_Disease	O
disorder	I_Disease	O
.	O	O

Hypertensive	B_Disease	O
response	O	O
during	O	O
dobutamine	B_Chemical	B_Chemical
stress	O	O
echocardiography	O	O
.	O	O

Among	O	O
3,129	O	O
dobutamine	B_Chemical	B_Chemical
stress	O	O
echocardiographic	O	O
studies	O	O
,	O	O
a	O	O
hypertensive	B_Disease	O
response	O	O
,	O	O
defined	O	O
as	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
>	O	O
or	O	O
=	O	O
220	O	O
mm	O	O
Hg	O	O
and/or	O	O
diastolic	O	O
BP	O	O
>	O	O
or	O	O
=	O	O
110	O	O
mm	O	O
Hg	O	O
,	O	O
occurred	O	O
in	O	O
30	O	O
patients	O	O
(	O	O
1	O	O
%	O	O
)	O	O
.	O	O

Patients	O	O
with	O	O
this	O	O
response	O	O
more	O	O
often	O	O
had	O	O
a	O	O
history	O	O
of	O	O
hypertension	B_Disease	O
and	O	O
had	O	O
higher	O	O
resting	O	O
systolic	O	O
and	O	O
diastolic	O	O
BP	O	O
before	O	O
dobutamine	B_Chemical	B_Chemical
infusion	O	O
.	O	O

Continuously	O	O
nebulized	O	O
albuterol	B_Chemical	O
in	O	O
severe	O	O
exacerbations	O	O
of	O	O
asthma	B_Disease	O
in	O	O
adults	O	O
:	O	O
a	O	O
case-controlled	O	O
study	O	O
.	O	O

A	O	O
retrospective	O	O
,	O	O
case-controlled	O	O
analysis	O	O
comparing	O	O
patients	O	O
admitted	O	O
to	O	O
a	O	O
medical	O	O
intensive	O	O
care	O	O
unit	O	O
with	O	O
severe	O	O
exacerbations	O	O
of	O	O
asthma	B_Disease	O
who	O	O
received	O	O
continuously	O	O
nebulized	O	O
albuterol	B_Chemical	O
(	O	O
CNA	O	O
)	O	O
versus	O	O
intermittent	O	O
albuterol	B_Chemical	O
(	O	O
INA	O	O
)	O	O
treatments	O	O
is	O	O
reported	O	O
.	O	O

Forty	O	O
matched	O	O
pairs	O	O
of	O	O
patients	O	O
with	O	O
asthma	B_Disease	O
are	O	O
compared	O	O
.	O	O

CNA	O	O
was	O	O
administered	O	O
for	O	O
a	O	O
mean	O	O
of	O	O
11	O	O
+	O	O
/-	O	O
10	O	O
hr	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
cardiac	B_Disease	B_Disease
dysrhythmias	I_Disease	I_Disease
was	O	O
similar	O	O
between	O	O
groups	O	O
.	O	O

Symptomatic	O	O
hypokalemia	B_Disease	O
did	O	O
not	O	O
occur	O	O
.	O	O

CNA	O	O
patients	O	O
had	O	O
higher	O	O
heart	O	O
rates	O	O
during	O	O
treatment	O	O
,	O	O
which	O	O
may	O	O
reflect	O	O
severity	O	O
of	O	O
illness	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
intubation	O	O
was	O	O
similar	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
CNA	O	O
and	O	O
INA	O	O
demonstrated	O	O
similar	O	O
profiles	O	O
with	O	O
regard	O	O
to	O	O
safety	O	O
,	O	O
morbidity	O	O
,	O	O
and	O	O
mortality	O	O
.	O	O

Paraplegia	B_Disease	O
following	O	O
intrathecal	O	O
methotrexate	B_Chemical	O
:	O	O
report	O	O
of	O	O
a	O	O
case	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O

A	O	O
patient	O	O
who	O	O
developed	O	O
paraplegia	B_Disease	O
following	O	O
the	O	O
intrathecal	O	O
instillation	O	O
of	O	O
methotrexate	B_Chemical	O
is	O	O
discribed	O	O
.	O	O

The	O	O
ten	O	O
previously	O	O
reported	O	O
cases	O	O
of	O	O
this	O	O
unusual	O	O
complication	O	O
are	O	O
reviewed	O	O
.	O	O

The	O	O
following	O	O
factors	O	O
appear	O	O
to	O	O
predispose	O	O
to	O	O
the	O	O
development	O	O
of	O	O
this	O	O
complication	O	O
:	O	O
abnormal	O	O
cerebrospinal	O	O
dynamics	O	O
related	O	O
to	O	O
the	O	O
presence	O	O
of	O	O
central	B_Disease	O
nervous	I_Disease	O
system	I_Disease	O
leukemia	I_Disease	O
,	O	O
and	O	O
epidural	O	O
cerebrospinal	O	O
leakage	O	O
;	O	O
elevated	O	O
cerebrospinal	O	O
fluid	O	O
methothexate	B_Chemical	B_Chemical
concentration	O	O
related	O	O
to	O	O
abnormal	O	O
cerebrospinal	O	O
fluid	O	O
dynamics	O	O
and	O	O
to	O	O
inappropriately	O	O
high	O	O
methotrexate	B_Chemical	O
doses	O	O
based	O	O
on	O	O
body	O	O
surface	O	O
area	O	O
calculations	O	O
in	O	O
older	O	O
children	O	O
and	O	O
adults	O	O
;	O	O
the	O	O
presence	O	O
of	O	O
neurotoxic	B_Disease	O
preservatives	O	O
in	O	O
commercially	O	O
available	O	O
methotrexate	B_Chemical	O
preparations	O	O
and	O	O
diluents	O	O
;	O	O
and	O	O
the	O	O
use	O	O
of	O	O
methotrexate	B_Chemical	O
diluents	O	O
of	O	O
unphysiologic	O	O
pH	O	O
,	O	O
ionic	O	O
content	O	O
and	O	O
osmolarity	O	O
.	O	O

The	O	O
role	O	O
of	O	O
methotrexate	B_Chemical	O
contaminants	O	O
,	O	O
local	O	O
folate	B_Disease	O
deficiency	I_Disease	O
,	O	O
and	O	O
cranial	O	O
irradiation	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
intrathecal	O	O
methotrexate	B_Chemical	O
toxicity	B_Disease	O
is	O	O
unclear	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
neurotoxicity	B_Disease	B_Disease
may	O	O
be	O	O
reduced	O	O
by	O	O
employing	O	O
lower	O	O
doses	O	O
of	O	O
methotrexate	B_Chemical	O
in	O	O
the	O	O
presence	O	O
of	O	O
central	B_Disease	O
nervous	I_Disease	O
system	I_Disease	O
leukemia	I_Disease	O
,	O	O
in	O	O
older	O	O
children	O	O
and	O	O
adults	O	O
,	O	O
and	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
epidural	O	O
leakage	O	O
.	O	O

Only	O	O
preservative-free	O	O
methotrexate	B_Chemical	O
in	O	O
Elliott	O	O
's	O	O
B	O	O
Solution	O	O
at	O	O
a	O	O
concentration	O	O
of	O	O
not	O	O
more	O	O
than	O	O
1	O	O
mg/ml	O	O
should	O	O
be	O	O
used	O	O
for	O	O
intrathecal	O	O
administration	O	O
.	O	O

Periodic	O	O
monitoring	O	O
of	O	O
cerebruspinal	O	O
fluid	O	O
methotrexate	B_Chemical	O
levels	O	O
may	O	O
be	O	O
predictive	O	O
of	O	O
the	O	O
development	O	O
of	O	O
serious	O	O
neurotoxicity	B_Disease	B_Disease
.	O	O

Hyperosmolar	B_Disease	O
nonketotic	I_Disease	O
coma	I_Disease	O
precipitated	O	O
by	O	O
lithium-induced	O	O
nephrogenic	B_Disease	O
diabetes	I_Disease	O
insipidus	I_Disease	O
.	O	O

A	O	O
45-year-old	O	O
man	O	O
,	O	O
with	O	O
a	O	O
10-year	O	O
history	O	O
of	O	O
manic	B_Disease	B_Disease
depression	I_Disease	I_Disease
treated	O	O
with	O	O
lithium	B_Chemical	O
,	O	O
was	O	O
admitted	O	O
with	O	O
hyperosmolar	B_Disease	O
,	I_Disease	O
nonketotic	I_Disease	O
coma	I_Disease	O
.	O	O

He	O	O
gave	O	O
a	O	O
five-year	O	O
history	O	O
of	O	O
polyuria	B_Disease	O
and	O	O
polydipsia	B_Disease	O
,	O	O
during	O	O
which	O	O
time	O	O
urinalysis	O	O
had	O	O
been	O	O
negative	O	O
for	O	O
glucose	B_Chemical	O
.	O	O

After	O	O
recovery	O	O
from	O	O
hyperglycaemia	B_Disease	O
,	O	O
he	O	O
remained	O	O
polyuric	B_Disease	O
despite	O	O
normal	O	O
blood	O	O
glucose	B_Chemical	O
concentrations	O	O
;	O	O
water	O	O
deprivation	O	O
testing	O	O
indicated	O	O
nephrogenic	B_Disease	O
diabetes	I_Disease	O
insipidus	I_Disease	O
,	O	O
likely	O	O
to	O	O
be	O	O
lithium-induced	O	O
.	O	O

We	O	O
hypothesize	O	O
that	O	O
when	O	O
this	O	O
man	O	O
developed	O	O
type	B_Disease	O
2	I_Disease	O
diabetes	I_Disease	O
,	O	O
chronic	O	O
polyuria	B_Disease	O
due	O	O
to	O	O
nephrogenic	B_Disease	O
diabetes	I_Disease	O
insipidus	I_Disease	O
was	O	O
sufficient	O	O
to	O	O
precipitate	O	O
hyperosmolar	O	O
dehydration	B_Disease	O
.	O	O

Effects	O	O
of	O	O
the	O	O
intracoronary	O	O
infusion	O	O
of	O	O
cocaine	O	O
on	O	O
left	O	B_Disease
ventricular	O	I_Disease
systolic	O	I_Disease
and	O	O
diastolic	O	O
function	O	O
in	O	O
humans	O	O
.	O	O

BACKGROUND	O	O
:	O	O
In	O	O
dogs	O	O
,	O	O
a	O	O
large	O	O
amount	O	O
of	O	O
intravenous	O	O
cocaine	B_Chemical	O
causes	O	O
a	O	O
profound	O	O
deterioration	B_Disease	O
of	I_Disease	O
left	I_Disease	O
ventricular	I_Disease	O
(	I_Disease	O
LV	I_Disease	O
)	I_Disease	O
systolic	I_Disease	O
function	I_Disease	O
and	O	O
an	O	O
increase	O	O
in	O	O
LV	O	O
end-diastolic	O	O
pressure	O	O
.	O	O

This	O	O
study	O	O
was	O	O
done	O	O
to	O	O
assess	O	O
the	O	O
influence	O	O
of	O	O
a	O	O
high	O	O
intracoronary	O	O
cocaine	B_Chemical	O
concentration	O	O
on	O	O
LV	O	O
systolic	O	O
and	O	O
diastolic	O	O
function	O	O
in	O	O
humans	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
In	O	O
20	O	O
patients	O	O
(	O	O
14	O	O
men	O	O
and	O	O
6	O	O
women	O	O
aged	O	O
39	O	O
to	O	O
72	O	O
years	O	O
)	O	O
referred	O	O
for	O	O
cardiac	O	O
catheterization	O	O
for	O	O
the	O	O
evaluation	O	O
of	O	O
chest	B_Disease	B_Disease
pain	I_Disease	I_Disease
,	O	O
we	O	O
measured	O	O
heart	O	O
rate	O	O
,	O	O
systemic	O	O
arterial	O	O
pressure	O	O
,	O	O
LV	O	O
pressure	O	O
and	O	O
its	O	O
first	O	O
derivative	O	O
(	O	O
dP/dt	O	O
)	O	O
,	O	O
and	O	O
LV	O	O
volumes	O	O
and	O	O
ejection	O	O
fraction	O	O
before	O	O
and	O	O
during	O	O
the	O	O
final	O	O
2	O	O
to	O	O
3	O	O
minutes	O	O
of	O	O
a	O	O
15-minute	O	O
intracoronary	O	O
infusion	O	O
of	O	O
saline	O	O
(	O	O
n=10	O	O
,	O	O
control	O	O
subjects	O	O
)	O	O
or	O	O
cocaine	B_Chemical	B_Chemical
hydrochloride	I_Chemical	I_Chemical
1	O	O
mg/min	O	O
(	O	O
n=10	O	O
)	O	O
.	O	O

No	O	O
variable	O	O
changed	O	O
with	O	O
saline	O	O
.	O	O

With	O	O
cocaine	B_Chemical	O
,	O	O
the	O	O
drug	O	O
concentration	O	O
in	O	O
blood	O	O
obtained	O	O
from	O	O
the	O	O
coronary	O	O
sinus	O	O
was	O	O
3.0+/-0.4	O	O
(	O	O
mean+/-SD	O	O
)	O	O
mg/L	O	O
,	O	O
similar	O	O
in	O	O
magnitude	O	O
to	O	O
the	O	O
blood	O	O
cocaine	B_Chemical	O
concentration	O	O
reported	O	O
in	O	O
abusers	O	O
dying	O	O
of	O	O
cocaine	B_Chemical	O
intoxication	O	O
.	O	O

Cocaine	B_Chemical	O
induced	O	O
no	O	O
significant	O	O
change	O	O
in	O	O
heart	O	O
rate	O	O
,	O	O
LV	O	O
dP/dt	O	O
(	O	O
positive	O	O
or	O	O
negative	O	O
)	O	O
,	O	O
or	O	O
LV	O	O
end-diastolic	O	O
volume	O	O
,	O	O
but	O	O
it	O	O
caused	O	O
an	O	O
increase	O	O
in	O	O
systolic	O	O
and	O	O
mean	O	O
arterial	O	O
pressures	O	O
,	O	O
LV	O	O
end-diastolic	O	O
pressure	O	O
,	O	O
and	O	O
LV	O	O
end-systolic	O	O
volume	O	O
,	O	O
as	O	O
well	O	O
as	O	O
a	O	O
decrease	O	O
in	O	O
LV	O	O
ejection	O	O
fraction	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
humans	O	O
,	O	O
the	O	O
intracoronary	O	O
infusion	O	O
of	O	O
cocaine	B_Chemical	O
sufficient	O	O
in	O	O
amount	O	O
to	O	O
achieve	O	O
a	O	O
high	O	O
drug	O	O
concentration	O	O
in	O	O
coronary	O	O
sinus	O	O
blood	O	O
causes	O	O
a	O	O
deterioration	B_Disease	O
of	I_Disease	O
LV	I_Disease	O
systolic	I_Disease	O
and	I_Disease	O
diastolic	I_Disease	O
performance	I_Disease	O
.	O	O

Ascending	O	O
dose	O	O
tolerance	O	O
study	O	O
of	O	O
intramuscular	O	O
carbetocin	O	B_Chemical
administered	O	O
after	O	O
normal	O	O
vaginal	O	O
birth	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
maximum	O	O
tolerated	O	O
dose	O	O
(	O	O
MTD	O	O
)	O	O
of	O	O
carbetocin	B_Chemical	B_Chemical
(	O	O
a	O	O
long-acting	O	O
synthetic	O	O
analogue	O	O
of	O	O
oxytocin	B_Chemical	O
)	O	O
,	O	O
when	O	O
administered	O	O
immediately	O	O
after	O	O
vaginal	O	O
delivery	O	O
at	O	O
term	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
Carbetocin	B_Chemical	B_Chemical
was	O	O
given	O	O
as	O	O
an	O	O
intramuscular	O	O
injection	O	O
immediately	O	O
after	O	O
the	O	O
birth	O	O
of	O	O
the	O	O
infant	O	O
in	O	O
45	O	O
healthy	O	O
women	O	O
with	O	O
normal	O	O
singleton	O	O
pregnancies	O	O
who	O	O
delivered	O	O
vaginally	O	O
at	O	O
term	O	O
.	O	O

Dosage	O	O
groups	O	O
of	O	O
15	O	O
,	O	O
30	O	O
,	O	O
50	O	O
,	O	O
75	O	O
,	O	O
100	O	O
,	O	O
125	O	O
,	O	O
150	O	O
,	O	O
175	O	O
or	O	O
200	O	O
microg	O	O
carbetocin	B_Chemical	B_Chemical
were	O	O
assigned	O	O
to	O	O
blocks	O	O
of	O	O
three	O	O
women	O	O
according	O	O
to	O	O
the	O	O
continual	O	O
reassessment	O	O
method	O	O
(	O	O
CRM	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
All	O	O
dosage	O	O
groups	O	O
consisted	O	O
of	O	O
three	O	O
women	O	O
,	O	O
except	O	O
those	O	O
with	O	O
100	O	O
microg	O	O
(	O	O
n=6	O	O
)	O	O
and	O	O
200	O	O
microg	O	O
(	O	O
n=18	O	O
)	O	O
.	O	O

Recorded	O	O
were	O	O
dose-limiting	O	O
adverse	O	O
events	O	O
:	O	O
hyper-	B_Disease	B_Chemical
or	I_Disease	O
hypotension	I_Disease	O
(	O	O
three	O	O
)	O	O
,	O	O
severe	O	O
abdominal	B_Disease	B_Disease
pain	I_Disease	I_Disease
(	O	O
0	O	O
)	O	O
,	O	O
vomiting	B_Disease	O
(	O	O
0	O	O
)	O	O
and	O	O
retained	B_Disease	O
placenta	I_Disease	O
(	O	O
four	O	O
)	O	O
.	O	O

Serious	O	O
adverse	O	O
events	O	O
occurred	O	O
in	O	O
seven	O	O
women	O	O
:	O	O
six	O	O
cases	O	O
with	O	O
blood	B_Disease	B_Disease
loss	I_Disease	I_Disease
>	O	O
or	O	O
=	O	O
1000	O	O
ml	O	O
,	O	O
four	O	O
cases	O	O
of	O	O
manual	O	O
placenta	O	O
removal	O	O
,	O	O
five	O	O
cases	O	O
of	O	O
additional	O	O
oxytocics	O	O
administration	O	O
and	O	O
five	O	O
cases	O	O
of	O	O
blood	O	O
transfusion	O	O
.	O	O

Maximum	O	O
blood	B_Disease	B_Disease
loss	I_Disease	I_Disease
was	O	O
greatest	O	O
at	O	O
the	O	O
upper	O	O
and	O	O
lower	O	O
dose	O	O
levels	O	O
,	O	O
and	O	O
lowest	O	O
in	O	O
the	O	O
70	O	O
-	O	O
125	O	O
microg	O	O
dose	O	O
range	O	O
.	O	O

Four	O	O
out	O	O
of	O	O
six	O	O
cases	O	O
with	O	O
blood	B_Disease	B_Disease
loss	I_Disease	I_Disease
>	O	O
or	O	O
=	O	O
1000	O	O
ml	O	O
occurred	O	O
in	O	O
the	O	O
200	O	O
microg	O	O
group	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
additional	O	O
administration	O	O
of	O	O
oxytocics	O	O
(	O	O
4/5	O	O
)	O	O
and	O	O
blood	O	O
transfusion	O	O
(	O	O
3/5	O	O
)	O	O
occurred	O	O
in	O	O
the	O	O
dose	O	O
groups	O	O
of	O	O
200	O	O
microg	O	O
.	O	O

All	O	O
retained	O	O
placentae	O	O
were	O	O
found	O	O
in	O	O
the	O	O
group	O	O
of	O	O
200	O	O
microg	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
MTD	O	O
was	O	O
calculated	O	O
to	O	O
be	O	O
at	O	O
200	O	O
microg	O	O
carbetocin	B_Chemical	B_Chemical
.	O	O

Heparin-induced	O	O
thrombocytopenia	B_Disease	O
,	O	O
paradoxical	O	O
thromboembolism	B_Disease	O
,	O	O
and	O	O
other	O	O
side	O	O
effects	O	O
of	O	O
heparin	B_Chemical	O
therapy	O	O
.	O	O

Although	O	O
several	O	O
new	O	O
anticoagulant	O	O
drugs	O	O
are	O	O
in	O	O
development	O	O
,	O	O
heparin	B_Chemical	O
remains	O	O
the	O	O
drug	O	O
of	O	O
choice	O	O
for	O	O
most	O	O
anticoagulation	O	O
needs	O	O
.	O	O

The	O	O
clinical	O	O
effects	O	O
of	O	O
heparin	B_Chemical	O
are	O	O
meritorious	O	O
,	O	O
but	O	O
side	O	O
effects	O	O
do	O	O
exist	O	O
.	O	O

Important	O	O
untoward	O	O
effects	O	O
of	O	O
heparin	B_Chemical	O
therapy	O	O
including	O	O
heparin-induced	O	O
thrombocytopenia	B_Disease	O
,	O	O
heparin-associated	O	O
osteoporosis	B_Disease	O
,	O	O
eosinophilia	B_Disease	O
,	O	O
skin	B_Disease	B_Disease
reactions	I_Disease	I_Disease
,	O	O
allergic	B_Disease	B_Disease
reactions	I_Disease	I_Disease
other	O	O
than	O	O
thrombocytopenia	B_Disease	O
and	O	O
alopecia	B_Disease	O
will	O	O
be	O	O
discussed	O	O
in	O	O
this	O	O
article	O	O
.	O	O

Nonopaque	O	O
crystal	O	O
deposition	O	O
causing	O	O
ureteric	B_Disease	B_Disease
obstruction	I_Disease	I_Disease
in	O	O
patients	O	O
with	O	O
HIV	O	O
undergoing	O	O
indinavir	B_Chemical	O
therapy	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
We	O	O
describe	O	O
the	O	O
unique	O	O
CT	O	O
features	O	O
of	O	O
ureteric	B_Disease	O
calculi	I_Disease	O
in	O	O
six	O	O
HIV-infected	B_Disease	O
patients	O	O
receiving	O	O
indinavir	B_Chemical	O
,	O	O
the	O	O
most	O	O
commonly	O	O
used	O	O
HIV	O	O
protease	O	O
inhibitor	O	O
,	O	O
which	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
urolithiasis	B_Disease	B_Disease
.	O	O

CONCLUSION	O	O
:	O	O
Ureteric	B_Disease	B_Disease
obstruction	I_Disease	I_Disease
caused	O	O
by	O	O
precipitated	O	O
indinavir	B_Chemical	O
crystals	O	O
may	O	O
be	O	O
difficult	O	O
to	O	O
diagnose	O	O
with	O	O
unenhanced	O	O
CT	O	O
.	O	O

The	O	O
calculi	O	O
are	O	O
not	O	O
opaque	O	O
,	O	O
and	O	O
secondary	O	O
signs	O	O
of	O	O
obstruction	O	O
may	O	O
be	O	O
absent	O	O
or	O	O
minimal	O	O
and	O	O
should	O	O
be	O	O
sought	O	O
carefully	O	O
.	O	O

Images	O	O
may	O	O
need	O	O
to	O	O
be	O	O
obtained	O	O
using	O	O
i.v	O	O
.	O	O

contrast	O	O
material	O	O
to	O	O
enable	O	O
diagnosis	O	O
of	O	O
ureteric	B_Disease	B_Chemical
stones	I_Disease	I_Chemical
or	I_Disease	O
obstruction	I_Disease	O
in	O	O
patients	O	O
with	O	O
HIV	B_Disease	O
infection	I_Disease	O
who	O	O
receive	O	O
indinavir	B_Chemical	O
therapy	O	O
.	O	O

Ischemic	B_Disease	B_Disease
colitis	I_Disease	I_Disease
and	O	O
sumatriptan	B_Chemical	B_Chemical
use	O	O
.	O	O

Sumatriptan	B_Chemical	B_Chemical
succinate	I_Chemical	I_Chemical
,	O	O
a	O	O
serotonin-1	O	B_Chemical
(	O	I_Chemical
5-hydroxytryptamine-1	O	I_Chemical
)	O	O
receptor	O	O
agonist	O	O
,	O	O
is	O	O
an	O	O
antimigraine	O	O
drug	O	O
that	O	O
is	O	O
reported	O	O
to	O	O
act	O	O
by	O	O
selectively	O	O
constricting	O	O
intracranial	O	O
arteries	O	O
.	O	O

Recently	O	O
,	O	O
vasopressor	O	O
responses	O	O
that	O	O
are	O	O
distinct	O	O
from	O	O
the	O	O
cranial	O	O
circulation	O	O
have	O	O
been	O	O
demonstrated	O	O
to	O	O
occur	O	O
in	O	O
the	O	O
systemic	O	O
,	O	O
pulmonary	O	O
,	O	O
and	O	O
coronary	O	O
circulations	O	O
.	O	O

Cases	O	O
have	O	O
been	O	O
published	O	O
of	O	O
coronary	B_Disease	B_Disease
vasospasm	I_Disease	I_Disease
,	O	O
myocardial	B_Disease	B_Disease
ischemia	I_Disease	I_Disease
,	O	O
and	O	O
myocardial	B_Disease	B_Disease
infarction	I_Disease	I_Disease
occurring	O	O
after	O	O
sumatriptan	B_Chemical	B_Chemical
use	O	O
.	O	O

We	O	O
report	O	O
on	O	O
the	O	O
development	O	O
of	O	O
8	O	O
serious	O	O
cases	O	O
of	O	O
ischemic	B_Disease	B_Disease
colitis	I_Disease	I_Disease
in	O	O
patients	O	O
with	O	O
migraine	B_Disease	O
treated	O	O
with	O	O
sumatriptan	B_Chemical	B_Chemical
.	O	O

Pallidotomy	O	O
with	O	O
the	O	O
gamma	O	O
knife	O	O
:	O	O
a	O	O
positive	O	O
experience.51	O	O
patients	O	O
with	O	O
medically	O	O
refractory	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
underwent	O	O
stereotactic	O	O
posteromedial	O	O
pallidotomy	O	O
between	O	O
August	O	O
1993	O	O
and	O	O
February	O	O
1997	O	O
for	O	O
treatment	O	O
of	O	O
bradykinesia	B_Disease	B_Chemical
,	O	O
rigidity	B_Disease	O
,	O	O
and	O	O
L-DOPA-induced	O	O
dyskinesias	B_Disease	O
.	O	O

In	O	O
29	O	O
patients	O	O
,	O	O
the	O	O
pallidotomies	O	O
were	O	O
performed	O	O
with	O	O
the	O	O
Leksell	O	O
Gamma	O	O
Knife	O	O
and	O	O
in	O	O
22	O	O
they	O	O
were	O	O
performed	O	O
with	O	O
the	O	O
standard	O	O
radiofrequency	O	O
(	O	O
RF	O	O
)	O	O
method	O	O
.	O	O

Clinical	O	O
assessment	O	O
as	O	O
well	O	O
as	O	O
blinded	O	O
ratings	O	O
of	O	O
Unified	O	O
Parkinson	B_Disease	O
's	I_Disease	O
Disease	I_Disease	O
Rating	O	O
Scale	O	O
(	O	O
UPDRS	O	O
)	O	O
scores	O	O
were	O	O
carried	O	O
out	O	O
pre-	O	O
and	O	O
postoperatively	O	O
.	O	O

Mean	O	O
follow-up	O	O
time	O	O
is	O	O
20.6	O	O
months	O	O
(	O	O
range	O	O
6	O	O
-	O	O
48	O	O
)	O	O
and	O	O
all	O	O
except	O	O
4	O	O
patients	O	O
have	O	O
been	O	O
followed	O	O
more	O	O
than	O	O
one	O	O
year	O	O
.	O	O

85	O	O
percent	O	O
of	O	O
patients	O	O
with	O	O
dyskinesias	B_Disease	O
were	O	O
relieved	O	O
of	O	O
symptoms	O	O
,	O	O
regardless	O	O
of	O	O
whether	O	O
the	O	O
pallidotomies	O	O
were	O	O
performed	O	O
with	O	O
the	O	O
Gamma	O	O
Knife	O	O
or	O	O
radiofrequency	O	O
methods	O	O
.	O	O

About	O	O
2/3	O	O
of	O	O
the	O	O
patients	O	O
in	O	O
both	O	O
Gamma	O	O
Knife	O	O
and	O	O
radiofrequency	O	O
groups	O	O
showed	O	O
improvements	O	O
in	O	O
bradykinesia	B_Disease	O
and	O	O
rigidity	B_Disease	O
,	O	O
although	O	O
when	O	O
considered	O	O
as	O	O
a	O	O
group	O	O
neither	O	O
the	O	O
Gamma	O	O
Knife	O	O
nor	O	O
the	O	O
radiofrequency	O	O
group	O	O
showed	O	O
statistically	O	O
significant	O	O
improvements	O	O
in	O	O
UPDRS	O	O
scores	O	O
.	O	O

One	O	O
patient	O	O
in	O	O
the	O	O
Gamma	O	O
Knife	O	O
group	O	O
(	O	O
3.4	O	O
%	O	O
)	O	O
developed	O	O
a	O	O
homonymous	B_Disease	B_Disease
hemianopsia	I_Disease	I_Disease
9	O	O
months	O	O
following	O	O
treatment	O	O
and	O	O
5	O	O
patients	O	O
(	O	O
27.7	O	O
%	O	O
)	O	O
in	O	O
the	O	O
radiofrequency	O	O
group	O	O
became	O	O
transiently	O	O
confused	O	O
postoperatively	O	O
.	O	O

No	O	O
other	O	O
complications	O	O
were	O	O
seen	O	O
.	O	O

Gamma	O	O
Knife	O	O
pallidotomy	O	O
is	O	O
as	O	O
effective	O	O
as	O	O
radiofrequency	O	O
pallidotomy	O	O
in	O	O
controlling	O	O
certain	O	O
of	O	O
the	O	O
symptoms	O	O
of	O	O
Parkinson	B_Disease	O
's	I_Disease	O
disease	I_Disease	O
.	O	O

It	O	O
may	O	O
be	O	O
the	O	O
only	O	O
practical	O	O
technique	O	O
available	O	O
in	O	O
certain	O	O
patients	O	O
,	O	O
such	O	O
as	O	O
those	O	O
who	O	O
take	O	O
anticoagulants	O	O
,	O	O
have	O	O
bleeding	B_Disease	O
diatheses	O	O
or	O	O
serious	O	O
systemic	O	O
medical	O	O
illnesses	O	O
.	O	O

It	O	O
is	O	O
a	O	O
viable	O	O
option	O	O
for	O	O
other	O	O
patients	O	O
as	O	O
well	O	O
.	O	O

Centrally	O	O
mediated	O	O
cardiovascular	O	O
effects	O	O
of	O	O
intracisternal	O	O
application	O	O
of	O	O
carbachol	O	B_Chemical
in	O	O
anesthetized	O	O
rats	O	O
.	O	O

The	O	O
pressor	O	O
response	O	O
to	O	O
the	O	O
intracisternal	O	O
(	O	O
i.c	O	O
.	O	O
)	O	O
injection	O	O
of	O	O
carbachol	B_Chemical	B_Chemical
(	O	O
1	O	O
mug	O	O
)	O	O
in	O	O
anesthetized	O	O
rats	O	O
was	O	O
analyzed	O	O
.	O	O

This	O	O
response	O	O
was	O	O
significantly	O	O
reduced	O	O
by	O	O
the	O	O
intravenous	O	O
(	O	O
i.v	O	O
.	O	O
)	O	O
injection	O	O
of	O	O
guanethidine	B_Chemical	B_Chemical
(	O	O
5	O	O
mg	O	O
)	O	O
,	O	O
hexamethonium	B_Chemical	B_Chemical
(	O	O
10	O	O
mg	O	O
)	O	O
or	O	O
phentolamine	B_Chemical	O
(	O	O
5	O	O
mg	O	O
)	O	O
,	O	O
and	O	O
conversely	O	O
,	O	O
potentiated	O	O
by	O	O
i.v	O	O
.	O	O

desmethylimipramine	B_Chemical	B_Chemical
(	O	O
0.3	O	O
mg	O	O
)	O	O
,	O	O
while	O	O
propranolol	B_Chemical	B_Chemical
(	O	O
0.5	O	O
mg	O	O
)	O	O
i.v	O	O
.	O	O
selectively	O	O
inhibited	O	O
the	O	O
enlargement	B_Disease	O
of	I_Disease	O
pulse	I_Disease	O
pressure	I_Disease	O
and	O	O
the	O	O
tachycardia	B_Disease	O
following	O	O
i.c	O	O
.	O	O

carbachol	B_Chemical	B_Chemical
(	O	O
1	O	O
mug	O	O
)	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
pressor	O	O
response	O	O
to	O	O
i.c	O	O
.	O	O
carbachol	B_Chemical	B_Chemical
(	O	O
1	O	O
mug	O	O
)	O	O
was	O	O
almost	O	O
completely	O	O
blocked	O	O
by	O	O
i.c	O	O
.	O	O

atropine	B_Chemical	O
(	O	O
3	O	O
mug	O	O
)	O	O
or	O	O
hexamethonium	B_Chemical	B_Chemical
(	O	O
500	O	O
mug	O	O
)	O	O
,	O	O
and	O	O
significantly	O	O
reduced	O	O
by	O	O
i.c	O	O
.	O	O

chlorpromazine	B_Chemical	O
(	O	O
50	O	O
mug	O	O
)	O	O
but	O	O
significantly	O	O
potentiated	O	O
by	O	O
i.c	O	O
.	O	O

desmethylimipramine	B_Chemical	B_Chemical
(	O	O
30	O	O
mug	O	O
)	O	O
.	O	O

The	O	O
pressor	O	O
response	O	O
to	O	O
i.c	O	O
.	O	O

carbachol	B_Chemical	B_Chemical
(	O	O
1	O	O
mug	O	O
)	O	O
remained	O	O
unchanged	O	O
after	O	O
sectioning	O	O
of	O	O
the	O	O
bilateral	O	O
cervical	O	O
vagal	O	O
nerves	O	O
but	O	O
disappeared	O	O
after	O	O
sectioning	O	O
of	O	O
the	O	O
spinal	O	O
cord	O	O
(	O	O
C7-C8	O	O
)	O	O
.	O	O

From	O	O
the	O	O
above	O	O
result	O	O
it	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
pressor	O	O
response	O	O
to	O	O
i.c	O	O
.	O	O
carbachol	B_Chemical	B_Chemical
ortral	O	O
and	O	O
peripheral	O	O
adrenergic	O	O
mechanisms	O	O
,	O	O
and	O	O
that	O	O
the	O	O
sympathetic	O	O
trunk	O	O
is	O	O
the	O	O
main	O	O
pathway	O	O
.	O	O

Neuroleptic	B_Disease	O
malignant	I_Disease	O
syndrome	I_Disease	O
and	O	O
methylphenidate	B_Chemical	O
.	O	O

A	O	O
1-year-old	O	O
female	O	O
presented	O	O
with	O	O
neuroleptic	B_Disease	O
malignant	I_Disease	O
syndrome	I_Disease	O
probably	O	O
caused	O	O
by	O	O
methylphenidate	B_Chemical	O
.	O	O

She	O	O
had	O	O
defects	O	O
in	O	O
the	O	O
supratentorial	O	O
brain	O	O
including	O	O
the	O	O
basal	O	O
ganglia	O	O
and	O	O
the	O	O
striatum	O	O
(	O	O
multicystic	B_Disease	O
encephalomalacia	I_Disease	O
)	O	O
due	O	O
to	O	O
severe	O	O
perinatal	O	O
hypoxic-ischemic	B_Disease	O
encephalopathy	I_Disease	O
,	O	O
which	O	O
was	O	O
considered	O	O
to	O	O
be	O	O
a	O	O
possible	O	O
predisposing	O	O
factor	O	O
causing	O	O
neuroleptic	B_Disease	O
malignant	I_Disease	O
syndrome	I_Disease	O
.	O	O

A	O	O
dopaminergic	O	O
blockade	O	O
mechanism	O	O
generally	O	O
is	O	O
accepted	O	O
as	O	O
the	O	O
pathogenesis	O	O
of	O	O
this	O	O
syndrome	O	O
.	O	O

However	O	O
,	O	O
methylphenidate	B_Chemical	O
is	O	O
a	O	O
dopamine	B_Chemical	O
agonist	O	O
via	O	O
the	O	O
inhibition	O	O
of	O	O
uptake	O	O
of	O	O
dopamine	B_Chemical	O
,	O	O
and	O	O
therefore	O	O
dopaminergic	O	O
systems	O	O
in	O	O
the	O	O
brainstem	O	O
(	O	O
mainly	O	O
the	O	O
midbrain	O	O
)	O	O
and	O	O
the	O	O
spinal	O	O
cord	O	O
were	O	O
unlikely	O	O
to	O	O
participate	O	O
in	O	O
the	O	O
onset	O	O
of	O	O
this	O	O
syndrome	O	O
.	O	O

A	O	O
relative	O	O
gamma-aminobutyric	O	O
acid-ergic	O	O
deficiency	O	O
might	O	O
occur	O	O
because	O	O
diazepam	B_Chemical	O
,	O	O
a	O	O
gamma-aminobutyric	O	O
acid-mimetic	O	O
agent	O	O
,	O	O
was	O	O
strikingly	O	O
effective	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
patient	O	O
with	O	O
neuroleptic	B_Disease	O
malignant	I_Disease	O
syndrome	I_Disease	O
probably	O	O
caused	O	O
by	O	O
methylphenidate	B_Chemical	O
.	O	O

Differential	O	O
effects	O	O
of	O	O
17alpha-ethinylestradiol	B_Chemical	B_Chemical
on	O	O
the	O	O
neutral	O	O
and	O	O
acidic	O	O
pathways	O	O
of	O	O
bile	B_Chemical	O
salt	I_Chemical	O
synthesis	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

Effects	O	O
of	O	O
17alpha-ethinylestradiol	B_Chemical	B_Chemical
(	O	O
EE	B_Chemical	O
)	O	O
on	O	O
the	O	O
neutral	O	O
and	O	O
acidic	O	O
biosynthetic	O	O
pathways	O	O
of	O	O
bile	B_Chemical	O
salt	I_Chemical	O
(	O	O
BS	B_Chemical	O
)	O	O
synthesis	O	O
were	O	O
evaluated	O	O
in	O	O
rats	O	O
with	O	O
an	O	O
intact	O	O
enterohepatic	O	O
circulation	O	O
and	O	O
in	O	O
rats	O	O
with	O	O
long-term	O	O
bile	O	O
diversion	O	O
to	O	O
induce	O	O
BS	B_Chemical	O
synthesis	O	O
.	O	O

For	O	O
this	O	O
purpose	O	O
,	O	O
bile	B_Chemical	O
salt	I_Chemical	O
pool	O	O
composition	O	O
,	O	O
synthesis	O	O
of	O	O
individual	O	O
BS	B_Chemical	O
in	O	O
vivo	O	O
,	O	O
hepatic	O	O
activities	O	O
,	O	O
and	O	O
expression	O	O
levels	O	O
of	O	O
cholesterol	B_Chemical	O
7alpha-hydroxylase	O	O
(	O	O
CYP7A	O	O
)	O	O
,	O	O
and	O	O
sterol	B_Chemical	O
27-hydroxylase	O	O
(	O	O
CYP27	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
of	O	O
other	O	O
enzymes	O	O
involved	O	O
in	O	O
BS	B_Chemical	O
synthesis	O	O
,	O	O
were	O	O
analyzed	O	O
in	O	O
rats	O	O
treated	O	O
with	O	O
EE	B_Chemical	O
(	O	O
5	O	O
mg/kg	O	O
,	O	O
3	O	O
days	O	O
)	O	O
or	O	O
its	O	O
vehicle	O	O
.	O	O

BS	B_Chemical	O
pool	O	O
size	O	O
was	O	O
decreased	O	O
by	O	O
27	O	O
%	O	O
but	O	O
total	O	O
BS	B_Chemical	O
synthesis	O	O
was	O	O
not	O	O
affected	O	O
by	O	O
EE	B_Chemical	O
in	O	O
intact	O	O
rats	O	O
.	O	O

Synthesis	O	O
of	O	O
cholate	B_Chemical	B_Chemical
was	O	O
reduced	O	O
by	O	O
68	O	O
%	O	O
in	O	O
EE-treated	O	O
rats	O	O
,	O	O
while	O	O
that	O	O
of	O	O
chenodeoxycholate	B_Chemical	B_Chemical
was	O	O
increased	O	O
by	O	O
60	O	O
%	O	O
.	O	O

The	O	O
recently	O	O
identified	O	O
Delta22-isomer	O	O
of	O	O
beta-muricholate	O	B_Chemical
contributed	O	O
for	O	O
5.4	O	O
%	O	O
and	O	O
18.3	O	O
%	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
to	O	O
the	O	O
pool	O	O
in	O	O
control	O	O
and	O	O
EE-treated	O	O
rats	O	O
,	O	O
respectively	O	O
,	O	O
but	O	O
could	O	O
not	O	O
be	O	O
detected	O	O
in	O	O
bile	O	O
after	O	O
exhaustion	O	O
of	O	O
the	O	O
pool	O	O
.	O	O

A	O	O
clear	O	O
reduction	O	O
of	O	O
BS	B_Chemical	O
synthesis	O	O
was	O	O
found	O	O
in	O	O
bile-diverted	O	O
rats	O	O
treated	O	O
with	O	O
EE	B_Chemical	O
,	O	O
yet	O	O
biliary	O	O
BS	B_Chemical	O
composition	O	O
was	O	O
only	O	O
minimally	O	O
affected	O	O
.	O	O

Activity	O	O
of	O	O
CYP7A	O	O
was	O	O
decreased	O	O
by	O	O
EE	B_Chemical	O
in	O	O
both	O	O
intact	O	O
and	O	O
bile-diverted	O	O
rats	O	O
,	O	O
whereas	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
CYP27	O	O
was	O	O
not	O	O
affected	O	O
.	O	O

Hepatic	O	O
mRNA	O	O
levels	O	O
of	O	O
CYP7A	O	O
were	O	O
significantly	O	O
reduced	O	O
by	O	O
EE	B_Chemical	O
in	O	O
bile-diverted	O	O
rats	O	O
only	O	O
;	O	O
CYP27	O	O
mRNA	O	O
levels	O	O
were	O	O
not	O	O
affected	O	O
by	O	O
EE	B_Chemical	O
.	O	O

In	O	O
addition	O	O
,	O	O
mRNA	O	O
levels	O	O
of	O	O
sterol	B_Chemical	O
12alpha-hydroxylase	O	O
and	O	O
lithocholate	O	B_Chemical
6beta-hydroxylase	O	O
were	O	O
increased	O	O
by	O	O
bile	O	O
diversion	O	O
and	O	O
suppressed	O	O
by	O	O
EE	B_Chemical	O
.	O	O

This	O	O
study	O	O
shows	O	O
that	O	O
17alpha-ethinylestradiol	B_Chemical	B_Chemical
(EE)-induced	O	O
intrahepatic	B_Disease	O
cholestasis	I_Disease	O
in	O	O
rats	O	O
is	O	O
associated	O	O
with	O	O
selective	O	O
inhibition	O	O
of	O	O
the	O	O
neutral	O	O
pathway	O	O
of	O	O
bile	B_Chemical	O
salt	I_Chemical	O
(	O	O
BS	B_Chemical	O
)	O	O
synthesis	O	O
.	O	O

Simultaneous	O	O
impairment	O	O
of	O	O
other	O	O
enzymes	O	O
in	O	O
the	O	O
BS	B_Chemical	O
biosynthetic	O	O
pathways	O	O
may	O	O
contribute	O	O
to	O	O
overall	O	O
effects	O	O
of	O	O
EE	B_Chemical	O
on	O	O
BS	B_Chemical	O
synthesis	O	O
.	O	O

Glibenclamide-sensitive	O	O
hypotension	B_Disease	O
produced	O	O
by	O	O
helodermin	B_Chemical	O
assessed	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
helodermin	B_Chemical	O
,	O	O
a	O	O
basic	O	O
35-amino	O	B_Chemical
acid	O	I_Chemical
peptide	O	O
isolated	O	O
from	O	O
the	O	O
venom	O	O
of	O	O
a	O	O
lizard	O	O
salivary	O	O
gland	O	O
,	O	O
on	O	O
arterial	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
were	O	O
examined	O	O
in	O	O
the	O	O
rat	O	O
,	O	O
focusing	O	O
on	O	O
the	O	O
possibility	O	O
that	O	O
activation	O	O
of	O	O
ATP	B_Chemical	O
sensitive	O	O
K+	O	O
(	O	O
K(ATP	O	O
)	O	O
)	O	O
channels	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
responses	O	O
.	O	O

The	O	O
results	O	O
were	O	O
also	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
vasoactive	O	O
intestinal	O	O
polypeptide	O	O
(	O	O
VIP	O	O
)	O	O
.	O	O

Helodermin	B_Chemical	B_Chemical
produced	O	O
hypotension	B_Disease	O
in	O	O
a	O	O
dose-dependent	O	O
manner	O	O
with	O	O
approximately	O	O
similar	O	O
potency	O	O
and	O	O
duration	O	O
to	O	O
VIP	O	O
.	O	O

Hypotension	B_Disease	O
induced	O	O
by	O	O
both	O	O
peptides	O	O
was	O	O
significantly	O	O
attenuated	O	O
by	O	O
glibenclamide	B_Chemical	B_Chemical
,	O	O
which	O	O
abolished	O	O
a	O	O
levcromakalim-produced	O	O
decrease	O	O
in	O	O
arterial	O	O
blood	O	O
pressure	O	O
.	O	O

Oxyhemoglobin	O	O
did	O	O
not	O	O
affect	O	O
helodermin-induced	O	O
hypotension	B_Disease	O
,	O	O
whereas	O	O
it	O	O
shortened	O	O
the	O	O
duration	O	O
of	O	O
acetylcholine	B_Chemical	O
(ACh)-produced	O	O
hypotension	B_Disease	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
helodermin-produced	O	O
hypotension	B_Disease	O
is	O	O
partly	O	O
attributable	O	O
to	O	O
the	O	O
activation	O	O
of	O	O
glibenclamide-sensitive	O	O
K+	O	O
channels	O	O
(	O	O
K(ATP	O	O
)	O	O
channels	O	O
)	O	O
,	O	O
which	O	O
presumably	O	O
exist	O	O
on	O	O
arterial	O	O
smooth	O	O
muscle	O	O
cells	O	O
.	O	O

EDRF	O	O
(	O	O
endothelium-derived	O	O
relaxing	O	O
factor)/nitric	O	O
oxide	O	O
does	O	O
not	O	O
seem	O	O
to	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
peptide-produced	O	O
hypotension	B_Disease	O
.	O	O

Long-term	O	O
efficacy	O	O
and	O	O
adverse	O	O
event	O	O
of	O	O
nifedipine	B_Chemical	O
sustained-release	O	O
tablets	O	O
for	O	O
cyclosporin	O	O
A-induced	O	O
hypertension	B_Disease	O
in	O	O
patients	O	O
with	O	O
psoriasis	B_Disease	O
.	O	O

Thirteen	O	O
psoriatic	B_Disease	O
patients	O	O
with	O	O
hypertension	B_Disease	O
during	O	O
the	O	O
course	O	O
of	O	O
cyclosporin	B_Chemical	O
A	I_Chemical	O
therapy	O	O
were	O	O
treated	O	O
for	O	O
25	O	O
months	O	O
with	O	O
a	O	O
calcium	B_Chemical	O
channel	O	O
blocker	O	O
,	O	O
sustained-release	O	O
nifedipine	B_Chemical	O
,	O	O
to	O	O
study	O	O
the	O	O
clinical	O	O
antihypertensive	O	O
effects	O	O
and	O	O
adverse	O	O
events	O	O
during	O	O
treatment	O	O
with	O	O
both	O	O
drugs	O	O
.	O	O

Seven	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
had	O	O
exhibited	O	O
a	O	O
subclinical	O	O
hypertensive	B_Disease	O
state	O	O
before	O	O
cyclosporin	B_Chemical	O
A	I_Chemical	O
therapy	O	O
.	O	O

Both	O	O
systolic	O	O
and	O	O
diastolic	O	O
blood	O	O
pressures	O	O
of	O	O
these	O	O
13	O	O
patients	O	O
were	O	O
decreased	O	O
significantly	O	O
after	O	O
4	O	O
weeks	O	O
of	O	O
nifedipine	B_Chemical	O
therapy	O	O
,	O	O
and	O	O
blood	O	O
pressure	O	O
was	O	O
maintained	O	O
within	O	O
the	O	O
normal	O	O
range	O	O
thereafter	O	O
for	O	O
25	O	O
months	O	O
.	O	O

The	O	O
adverse	O	O
events	O	O
during	O	O
combined	O	O
therapy	O	O
with	O	O
cyclosporin	B_Chemical	B_Chemical
A	I_Chemical	I_Chemical
and	O	O
nifedipine	B_Chemical	O
included	O	O
an	O	O
increase	O	O
in	O	O
blood	B_Chemical	B_Chemical
urea	I_Chemical	I_Chemical
nitrogen	I_Chemical	I_Chemical
levels	O	O
in	O	O
9	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
and	O	O
development	O	O
of	O	O
gingival	B_Disease	B_Disease
hyperplasia	I_Disease	I_Disease
in	O	O
2	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
.	O	O

Our	O	O
findings	O	O
indicate	O	O
that	O	O
sustained-release	O	O
nifedipine	B_Chemical	O
is	O	O
useful	O	O
for	O	O
hypertensive	B_Disease	B_Disease
psoriatic	B_Disease	I_Disease
patients	O	O
under	O	O
long-term	O	O
treatment	O	O
with	O	O
cyclosporin	B_Chemical	B_Chemical
A	I_Chemical	I_Chemical
,	O	O
but	O	O
that	O	O
these	O	O
patients	O	O
should	O	O
be	O	O
monitored	O	O
for	O	O
gingival	B_Disease	B_Disease
hyperplasia	I_Disease	I_Disease
.	O	O

